isoniazid has been researched along with Koch's Disease in 5538 studies
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.
hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe." | 9.69 | Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023) |
| "Our findings suggest that twice-daily dolutegravir might be unnecessary in people with HIV-associated tuberculosis." | 9.69 | Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. ( Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y, 2023) |
| " Of 749 infants, 694 (93%) received Bacille Calmette-Guérin (BCG) vaccination, 675 (90%) were born to mothers who had completed isoniazid treatment, 20 (3%) were exposed to tuberculosis, seven (1%) became HIV positive, and one (<1%) developed probable tuberculosis." | 9.69 | Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. ( Aaron, L; Bradford, S; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Golner, A; Gupta, A; Jean-Phillippe, P; Kabugho, E; Kulkarni, V; Masheto, G; Montepiedra, G; Mutambanengwe, M; Raesi, M; Shayo, A; Singh, P; Sterling, TR; Stranix-Chibanda, L; Theron, G; Vhembo, T; Weinberg, A, 2023) |
| "Alcohol use is common among people with HIV and is a risk factor for tuberculosis disease and non-adherence to isoniazid preventive therapy (IPT)." | 9.69 | Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial. ( Adong, J; Beesiga, B; Bryant, K; Chamie, G; Emenyonu, NI; Fatch, R; Gandhi, M; Hahn, JA; Havlir, DV; Kamya, MR; Kekibiina, A; Lodi, S; Marson, K; McDonell, MG; Muyindike, WR; Thirumurthy, H, 2023) |
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 9.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| " Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention." | 9.51 | Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ( Bradford, S; Britto, P; Chakhtoura, N; Chalermchockcharoentkit, A; Chipato, T; Dooley, KE; Gupta, A; Jayachandran, P; Kamthunzi, P; Langat, D; Mathad, JS; Montepiedra, G; Norman, J; Patil, S; Popson, S; Rouzier, V; Savic, R; Townley, E; Wiesner, L; Zhang, N, 2022) |
| "In AIDS Clinical Trials Group study A5338, concomitant rifampicin, isoniazid, and efavirenz was associated with more rapid plasma medroxyprogesterone acetate (MPA) clearance compared to historical controls without tuberculosis or HIV therapy." | 9.51 | Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. ( Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP, 2022) |
| "Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid-rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization's (WHO) END TB Strategy." | 9.41 | Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. ( Akello, L; Belknap, R; Berger, CA; Bishop, O; Cattamanchi, A; Dowdy, DW; Handley, MA; Kadota, JL; Kamya, MR; Katahoire, A; Katamba, A; Kiwanuka, N; Musinguzi, A; Nabunje, J; Nahid, P; Nakitende, A; Patel, D; Phillips, PPJ; Sammann, A; Semitala, FC; Welishe, F, 2021) |
| "The aim of this study was to systematically assess the efficacy, safety, and tolerability of isoniazid preventive therapy (IPT) for tuberculosis (TB) in people with HIV (PWH)." | 9.41 | Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV. ( Gudi, SK; Jagi, JL; Thomas, C; Undela, K, 2023) |
| "3 months of weekly rifapentine plus isoniazid (3HP) and 4 months of daily rifampicin (4R) are recommended for tuberculosis preventive treatment." | 9.41 | Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. ( Belknap, R; Benedetti, A; Borisov, A; Campbell, JR; Chaisson, RE; Chan, PC; Martinson, N; Menzies, D; Nahid, P; Scott, NA; Sizemore, E; Sterling, TR; Villarino, ME; Wang, JY; Winters, N, 2023) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes." | 9.41 | Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021) |
| "Pyrazinamide is a potent sterilising agent that shortens the treatment duration needed to cure tuberculosis." | 9.41 | Optimising pyrazinamide for the treatment of tuberculosis. ( Aarnoutse, R; Bliven-Sizemore, E; Boeree, MJ; Dooley, KE; Heinrich, N; Hoelscher, M; Mac Kenzie, W; Morlock, G; Peloquin, CA; Phillips, PPJ; Posey, J; Savic, RM; Stout, JE; Weiner, M; Whitworth, W; Zhang, N, 2021) |
| "Tuberculosis patients "resistant to isoniazid and susceptible to rifampicin (Hr-TB)" remain neglected, despite a high burden and poor outcomes." | 9.41 | Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018. ( Alaverdyan, S; Gadoev, J; Kumar, A; Nabirova, D; Parpieva, N; Sayfutdinov, Z; Sultanov, S; Turaev, L, 2021) |
| "Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV." | 9.34 | Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. ( Beattie, T; Chaisson, RE; Churchyard, GJ; Dooley, KE; Edward, VA; Fyvie, MJ; Gupte, A; Likoti, M; Marzinke, MA; Savic, R; Sebe, M; Shibambo, I; Wolf, L; Zhang, N, 2020) |
| "Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial two days of tuberculosis treatment but that isoniazid's activity declines significantly after day three." | 9.34 | Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. ( Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M, 2020) |
| "We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection." | 9.30 | One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. ( Andersen, J; Banda, P; Benson, CA; Chaisson, RE; da Silva Escada, RO; Fletcher, CV; Gupta, A; Hakim, J; Jean Juste, MA; Kanyama, C; Lama, JR; Langat, D; Leon-Cruz, J; Masheto, G; Mawlana, S; Mohapi, L; Moran, L; Mwelase, N; Nuermberger, E; Omoz-Oarhe, A; Ramchandani, R; Severe, P; Supparatpinyo, K; Swindells, S; Valencia, J, 2019) |
| "Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV." | 9.27 | Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018) |
| "The present study is designed to conduct, the analysis on the curative effect of Lamivudine in treating liver function lesion caused by hepatitis B combined anti-TB drugs." | 9.27 | Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with Anti-TB drugs. ( Han, Y; Xia, S; Zhou, J, 2018) |
| "We did a multicountry open-label randomised clinical trial comparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients initiating antiretroviral therapy with CD4 cell counts of less than 50 cells per μL." | 9.22 | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. ( Alave, J; Badal-Faesen, S; Bao, J; Bisson, GP; Gupta, A; Hakim, J; Henostroza, G; Hogg, E; Hosseinipour, MC; Jones, L; Kirui, FK; Kumarasamy, N; Kumwenda, J; Lagat, D; Lama, JR; Leger, PD; Mave, V; Miyahara, S; Mohapi, L; Moses, A; Mugyenyi, P; Naidoo, K; Nyirenda, M; Pillay, S; Riviere, C; Sun, X; Veloso, VG; Zolopa, A, 2016) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 9.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "Thirty-six months of isoniazid preventive therapy (36IPT) was superior to 6 months of IPT (6IPT) in preventing tuberculosis (TB) among HIV-infected adults in Botswana." | 9.20 | Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. ( Agizew, TB; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Rose, CE; Samandari, T; Shang, N; Shepherd, J; Sibanda, T; Tedla, Z, 2015) |
| "A recent major cluster randomized trial of screening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among South African gold miners showed reduced individual-level tuberculosis incidence but no detectable population-level impact." | 9.20 | Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. ( Churchyard, GJ; Corbett, EL; Cox, AP; Fielding, KL; Grant, AD; Hayes, RJ; Lewis, JJ; Sumner, T; Vynnycky, E; White, RG, 2015) |
| "In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST." | 9.20 | Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. ( Abimbola, T; Marston, B; Samandari, T; Sangrujee, N; Smith, T, 2015) |
| "We investigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunodeficiency virus and tuberculosis and included in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia." | 9.19 | Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. ( Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C, 2014) |
| "Mass screening and treatment for latent tuberculosis had no significant effect on tuberculosis control in South African gold mines, despite the successful use of isoniazid in preventing tuberculosis during treatment." | 9.19 | A trial of mass isoniazid preventive therapy for tuberculosis control. ( Chaisson, RE; Churchyard, GJ; Coetzee, L; Corbett, EL; Fielding, KL; Godfrey-Faussett, P; Grant, AD; Hayes, RJ; Lewis, JJ, 2014) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 9.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "To evaluate the efficacy and safety of a 6-month intermittent regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB) in human immunodeficiency virus (HIV) negative patients with culture-confirmed pulmonary or extra-pulmonary tuberculosis and either isoniazid (INH) resistance or INH intolerance." | 9.19 | Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. ( Bock, N; Bozeman, L; Goldberg, SV; Hamilton, CD; Heilig, CM; Hershfield, E; Kyle, RP; Narita, M; Reves, R; Tapy, JM; Wing, D, 2014) |
| "Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily." | 9.19 | Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ( Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014) |
| "While 6- to 12-month courses of isoniazid for tuberculosis prevention are considered safe in pregnant women, the effects of longer-term isoniazid prophylaxis or isoniazid in combination with antiretroviral therapy (ART) are not established in human-immunodeficiency-virus-(HIV-) infected women who experience pregnancy during the course of therapy." | 9.17 | Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. ( Mathebula, U; Mathoma, A; Moathlodi, R; Mosimaneotsile, B; Samandari, T; Taylor, AW; Theebetsile, I, 2013) |
| " Clinic staff were trained in tuberculosis screening, use of tuberculin skin tests, and use of isoniazid preventive therapy." | 9.17 | Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Efron, A; Golub, JE; King, BS; Moulton, LH; Pacheco, AG; Saraceni, V, 2013) |
| "This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis." | 9.17 | NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. ( Azuma, J; Fujio, Y; Kamimura, S; Kawase, I; Kubota, R; Nagai, T; Ohno, M; Okuda, Y; Takashima, T; Tsuyuguchi, K; Yokota, S, 2013) |
| "In accordance with WHO guidelines, people with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin skin test, but duration of prophylaxis is restricted to 6 months." | 9.15 | 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. ( Agizew, TB; Bozeman, L; Castro, KG; Davis, MK; Kilmarx, PH; Moeti, TL; Moffat, HJ; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Shang, N; Sibanda, T; Talbot, EA; Tedla, Z; Wells, CD, 2011) |
| "To compare the risk to household contacts of isoniazid (INH) susceptible and INH-resistant cases of tuberculosis (TB) in a rural community in South India." | 9.15 | Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases. ( , 2011) |
| "Primary isoniazid prophylaxis did not improve tuberculosis-disease-free survival among HIV-infected children or tuberculosis-infection-free survival among HIV-uninfected children immunized with BCG vaccine." | 9.15 | Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. ( Bobat, R; Cotton, MF; Jean-Philippe, P; Kim, S; Madhi, SA; McSherry, G; Mitchell, C; Nachman, S; Violari, A, 2011) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 9.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis." | 9.15 | Three months of rifapentine and isoniazid for latent tuberculosis infection. ( Bliven-Sizemore, E; Borisov, AS; Bozeman, L; Chaisson, RE; Conde, MB; Gordin, F; Hackman, J; Hamilton, CD; Horsburgh, CR; Kerrigan, A; Menzies, D; Shang, N; Sterling, TR; Villarino, ME; Weiner, M; Weis, SE; Wing, D, 2011) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy." | 9.14 | Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. ( Chaisson, RE; Golub, JE; Gray, GE; Martinson, NA; McIntyre, JA; Mohapi, L; Moshabela, M; Pronyk, P; Struthers, H; Thsabangu, N, 2009) |
| "To describe reasons for exclusion from isoniazid tuberculosis preventive therapy (IPT) and outcomes of persons living with HIV (PLWH) during 6 months of IPT." | 9.14 | Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. ( Agizew, TB; Chengeta, B; Kilmarx, PH; Mathoma, A; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Tedla, Z; Wells, CD, 2010) |
| "Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity." | 9.13 | Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. ( Al Jahdali, H; Benedetti, A; Dion, MJ; Gardam, M; Hoeppner, V; Khan, K; Long, R; Memish, Z; Menzies, D; Schwartzman, K; Trajman, A; Yang, J, 2008) |
| "Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality." | 9.12 | Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. ( Anglaret, X; Badje, A; Barnabas, RV; Boulle, A; Eholie, S; Ford, N; Gabillard, D; Golub, JE; Maartens, G; Rangaka, MX; Ross, JM; Shapiro, AE; Thomas, KK; Walker, AS; Wilkinson, RJ; Williams, BG, 2021) |
| "In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNFalpha) for the treatment of their rheumatologic diseases." | 9.12 | Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. ( Hanta, I; Kocabas, A; Kuleci, S; Ozbek, S; Sert, M, 2007) |
| "In the treatment of latent tuberculosis infection, a 3-month course of isoniazid plus rifampin resulted in better adherence and a lower percentage of discontinued treatments than a 6-month isoniazid course." | 9.12 | [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. ( Dimas, JF; García, AJ; García, M; Geijo, MP; Herranz, CR; Vaño, D, 2007) |
| "To characterize the bidirectional interaction between twice-daily nelfinavir and twice-weekly rifabutin and isoniazid in patients with tuberculosis and human immunodeficiency virus (HIV) infection." | 9.12 | Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. ( Becker, MI; Benator, DA; Burman, WJ; Engle, M; Hsyu, PH; Jones, BE; Khan, AE; Peloquin, CA; Sandman, L; Silva-Trigo, C; Vernon, AA; Weiner, MH; Zhao, ZA, 2007) |
| "A 9-month course of isoniazid monotherapy is currently recommended for the treatment of latent tuberculosis infection (LTBI) and has been shown to be effective in both children and adults." | 9.12 | The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. ( Gelesme, A; Gourgiotis, D; Metsou, F; Spyridis, NP; Spyridis, PG; Sypsa, V; Tsolia, MN; Valianatou, M, 2007) |
| "Two months of treatment with rifampin-pyrazinamide (RZ) and 9 months of treatment with isoniazid are both recommended for treatment of latent tuberculosis infection in adults without human immunodeficiency virus infection, but the relative cost-effectiveness of these 2 treatments is unknown." | 9.11 | Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. ( Bernardo, J; Daley, CL; Hopewell, PC; Jasmer, RM; Kawamura, LM; King, MD; Saukkonen, JJ; Snyder, DC, 2004) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 9.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "Lower plasma concentrations of rifabutin and, perhaps, isoniazid were associated with ARR failure or relapse in patients with tuberculosis and HIV infection treated with twice-weekly therapy." | 9.11 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ( Benator, D; Burman, W; Hodge, T; Jones, B; Khan, A; Peloquin, CA; Silva-Trigo, C; Vernon, A; Weiner, M; Zhao, Z, 2005) |
| "To determine the effect on tuberculosis incidence of a clinic providing isoniazid preventive therapy to HIV-infected adults under routine conditions." | 9.11 | Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. ( Chaisson, RE; Charalambous, S; Churchyard, GJ; Corbett, EL; Day, JH; De Cock, KM; Fielding, KL; Grant, AD; Hayes, RJ, 2005) |
| "To evaluate the role of isoniazid prophylaxis in prevention of tuberculosis among allogeneic stem cell transplant recipients." | 9.11 | Role of isoniazid prophylaxis for prevention of tuberculosis in haemopoietic stem cell transplant recipients. ( Ahmed, P; Altaf, C; Anwar, M; Hussain, I; Khan, B; Raza, S; Ullah, K, 2005) |
| "A higher incidence of hepatotoxicity was associated with rifampin plus pyrazinamide than isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong." | 9.10 | Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. ( Chan, CK; Chang, KC; Law, WS; Leung, CC; Tam, CM; Wong, MY; Yew, WW, 2003) |
| "Once-weekly rifapentine 600 mg plus isoniazid (INH) during the continuation phase treatment of tuberculosis is associated with a relapse rate higher than that of twice-weekly rifampin plus INH." | 9.10 | A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. ( Bock, NN; Conwell, DS; Hamilton, CD; Mosher, A; Pachucki, C; Samuels, M; Sterling, TR; Vernon, A; Wang, YC, 2002) |
| "To evaluate the efficacy of isoniazid for the prevention of tuberculosis in tuberculin skin test-positive and negative individuals with HIV infection." | 9.09 | Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. ( Battegay, M; Bucher, HC; Griffith, LE; Guyatt, GH; Naef, M; Sendi, P; Sudre, P, 1999) |
| "The tolerability of and adherence to intermittent short-term rifabutin-isoniazid preventive treatment was assessed in subjects dually infected with Mycobacterium tuberculosis and the human immunodeficiency virus (HIV)." | 9.09 | Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. ( Bonazzi, L; Cadeo, G; Caligaris, S; Carosi, G; Matteelli, A; Olliaro, P; Scalzini, A; Signorini, L; Tebaldi, A; Tomasoni, L, 1999) |
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 9.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "Patients older than 18 years who were diagnosed with a first episode of tuberculosis at the national HIV testing centre in Haiti, and who successfully completed a 6-month rifampicin-containing regimen for active pulmonary tuberculosis, were randomly assigned 1 year of post-treatment isoniazid prophylaxis or placebo." | 9.09 | Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. ( Desvarieux, M; Fitzgerald, DW; Johnson, WD; Joseph, P; Pape, JW; Severe, P, 2000) |
| "Mycobacterium tuberculosis antigen 85 is induced in vitro by isoniazid (INH); its sustained induction in sputum during tuberculosis (TB) therapy predicts relapse." | 9.09 | Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. ( Dietze, R; Eisenach, K; Ellner, JJ; Johnson, JL; Maciel, E; Palaci, M; Phillips, M; Rocha, LM; Rose, L; Teixeira, L; Wallis, RS; Wells, C, 2001) |
| "We conducted a randomized trial with a factorial design comparing strategies for improving adherence to isoniazid preventive therapy in 300 injection drug users with reactive tuberculin tests and no evidence of active tuberculosis." | 9.09 | A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. ( Barnes, GL; Cavalcante, S; Chaisson, RE; Hackman, J; Kimbrough , L; Metha, S; Moore, RD; Watkinson, L, 2001) |
| "A prospective comparative study was conducted to determine the effect of isoniazid prophylaxis on the incidence of active tuberculosis among Thai HIV-infected patients for 1 year." | 9.08 | Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals. ( Saenghirunvattana, S, 1996) |
| "To determine the efficacy of isoniazid 300 mg daily for 6 months in the prevention of tuberculosis in HIV-1-infected adults and to determine whether tuberculosis preventive therapy prolongs survival in HIV-1-infected adults." | 9.08 | Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. ( Bwayo, JJ; Chakaya, JM; Elliott, LC; Gilks, CF; Githui, WA; Hawken, MP; Juma, ES; Kimari, JN; McAdam, KP; Meme, HK; Morris, JS; Ngugi, EN; Nunn, PP; Odhiambo, JA; Plummer, FA; Porter, JD; Thiong'o, LN, 1997) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 9.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| "Screening for active tuberculosis (TB) and providing isoniazid (INH) preventive therapy in jails are important control measures." | 9.08 | A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. ( Goldenson, J; Hoynes, TM; McIntosh, HW; Reilly, P; Tulsky, JP; White, MC, 1998) |
| "Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today." | 9.07 | [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide]. ( Brändli, O; Dreher, D; Morger, D, 1993) |
| " Isoniazid preventive therapy (IPT) has been used globally for this purpose for many years, including in pregnancy." | 9.05 | The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis. ( Falzon, D; Figueroa, C; Hamada, Y; Kanchar, A; Martín-Sánchez, M, 2020) |
| "Isoniazid preventive therapy is one of the key interventions in reducing the risk of active disease among children exposed to tuberculosis." | 9.01 | Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review. ( Grace, SG, 2019) |
| "Isoniazid (INH) was the first synthesized drug that mediated bactericidal killing of the bacterium Mycobacterium tuberculosis, a major clinical breakthrough." | 9.01 | The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis. ( Jacobs, WR; Vilchèze, C, 2019) |
| " Thus, scaling up the isoniazid preventive therapy program and its strict compliance is necessary to avert HIV fueled tuberculosis." | 9.01 | The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. ( Endalamaw, A; Eshetie, S; Geremew, D; Negash, M; Tessema, B, 2019) |
| "Isoniazid is recommended for prevention of tuberculosis (TB) in HIV-infected adults, but its efficacy in children living with HIV (CLHIV) is not known." | 8.98 | Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018) |
| "The drug isoniazid (INH) is a key component of global tuberculosis (TB) control programmes." | 8.95 | Isoniazid-resistant tuberculosis: a cause for concern? ( Jenkins, HE; Lipman, MC; McHugh, TD; Stagg, HR, 2017) |
| "Isoniazid (INH) is one of the most potent anti-tuberculosis (TB) agents." | 8.93 | Isoniazid-resistant tuberculosis in Iran: A systematic review. ( Amin, M; Chirani, AS; Halabian, R; Imani Fooladi, AA; Javad Nasiri, M, 2016) |
| "Isoniazid (INH) is one of the most active compounds used to treat tuberculosis (TB) worldwide." | 8.93 | Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. ( Hanna, LE; Selvakumar, N; Subbian, S; Unissa, AN, 2016) |
| "To systematically identify from qualitative data in the published literature the main barriers to adherence to isoniazid preventive therapy (IPT) for tuberculosis (TB) among people living with HIV/AIDS (PLWHA)." | 8.90 | Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. ( Booth, A; Makanjuola, T; Taddese, HB, 2014) |
| " Upon combining data from all eight studies, isoniazid prophylaxis was found to be efficacious in preventing development of tuberculosis, with a pooled RR of 0." | 8.90 | Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. ( Abuogi, L; Ayieko, J; Bukusi, EA; Reingold, A; Simchowitz, B; Smith, AH, 2014) |
| "Isoniazid resistance is an obstacle to the treatment of tuberculosis disease and latent tuberculosis infection in children." | 8.89 | Isoniazid-resistant tuberculosis in children: a systematic review. ( Becerra, MC; Cohen, T; Keshavjee, S; Parr, JB; Tolman, AW; Yuen, CM, 2013) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 8.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| "Isoniazid (INH) is one of the most important drugs for the treatment of tuberculosis (TB)." | 8.86 | Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. ( Detjen, AA; Magdorf, K; Thee, S; Wahn, U, 2010) |
| "One-third of the world's population is infected with tuberculosis, and 9 months of isoniazid monotherapy is the treatment of choice for latent tuberculosis infection." | 8.85 | 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. ( Mylonakis, E; Ziakas, PD, 2009) |
| "For rifampicin, the majority of the studies that applied NRA to isolates had a sensitivity and specificity >94% and for isoniazid, >92%." | 8.84 | The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. ( Angeby, K; Hoffner, S; Martin, A; Palomino, JC; Panaiotov, S; Portaels, F, 2008) |
| "In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation." | 8.83 | Isoniazid preventive therapy and risk for resistant tuberculosis. ( Balcells, ME; Godfrey-Faussett, P; Grant, AD; Thomas, SL, 2006) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 8.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "A major difficulty associated with the use of standard therapy with isoniazid for latent tuberculosis infection is poor patient adherence to therapy because of the prolonged course required." | 8.82 | Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. ( Ena, J; Valls, V, 2005) |
| "Scaling up a shorter preventive regimen such as weekly isoniazid and rifapentine (3HP) for 3 months is a priority for tuberculosis (TB) preventive treatment (TPT)." | 8.31 | Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment. ( Amanullah, F; Becerra, MC; Dahri, AA; Farooq, S; Hussain, H; Islam, Z; Jaswal, M; Keshavjee, S; Khan, AJ; Khowaja, S; Madhani, F; Malik, AA; Manzar, S; Noorani, S; Safdar, N; Salahuddin, N; Shah, JA; Shahbaz, SS; Shahzad, M, 2023) |
| "Cisatracurium besylate was identified to be highly protective for the viability of macrophages during Mycobacterium tuberculosis infection via inhibiting necroptosis." | 8.31 | Cisatracurium besylate rescues Mycobacterium Tuberculosis-infected macrophages from necroptosis and enhances the bactericidal effect of isoniazid. ( Chen, L; Chen, Y; Han, Z; Hu, S; Liu, H; Liu, J; Ma, L; Sai, N; Wang, K; Wen, Q; Zhang, J; Zhang, Z; Zhou, C; Zhou, X, 2023) |
| "Isoniazid (INH) preventive therapy is recommended to prevent tuberculosis (TB) disease for persons with HIV (PWH), except for those with regular and heavy alcohol consumption, due to hepatotoxicity concerns." | 8.31 | Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. ( Adong, J; Cheng, DM; Emenyonu, NI; Fatch, R; Hahn, JA; Jacobson, KR; Linas, BP; Muyindike, WR; Ngabirano, C; Terrault, NA; Tumwegamire, A, 2023) |
| "Cisgender women receiving efavirenz- or dolutegravir-based HIV therapy, or on isoniazid-rifampin for tuberculosis, were followed after a single oral dose of levonorgestrel." | 8.31 | Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. ( Agyemang, N; Badal-Faesen, S; Baker, P; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Haas, DW; Jalil, EM; Kayama, C; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Van Schalkwyk, M; Woolley, E, 2023) |
| "No population pharmacokinetics (PK) model of isoniazid (INH) has been reported for the Indonesian population with tuberculosis (TB)." | 8.12 | Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis. ( Charisma, AN; Cho, YS; Choi, YK; Hoa, PQ; Hoa, PV; Indrawanto, DW; Jayanti, RP; Kusmiati, T; Long, NP; Mertaniasih, NM; Permatasari, A; Shin, JG; Soedarsono, S; Yuliwulandari, R, 2022) |
| " Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen." | 8.12 | Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022) |
| "The chemotherapeutic regimens of patients with drug-susceptible (DS)- tuberculosis (TB) comprise four primary anti-TB drugs: rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA), administered for six-to-nine months." | 8.12 | Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro. ( Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022) |
| "Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 8.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
| "Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect." | 8.12 | Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022) |
| "Isoniazid preventive therapy (IPT) is effective in treating tuberculosis (TB) infection and hence limiting progression to active disease." | 8.12 | Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study. ( Alinga, SB; Biraro, IA; Etukoit, MB; Kagimu, D; Kakumba, K; Kateeba Tusiime, A; Kato, D; Kazibwe, A; Kirenga, B; Mafabi, CG; Miya, Y; Mugenyi, L; Nkabala, R; Ochwo, M; Odoi, C; Oluka, AI; Opito, R; Oryokot, B; Ouma, S; Tayebwakushaba, E; Tusiimire, W, 2022) |
| "Isoniazid-monoresistant tuberculosis (HR-TB) requires early diagnosis and adapted treatment to achieve optimal outcomes." | 8.12 | Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. ( Bachir, M; Billard-Pomares, T; Chiesi, S; Guglielmetti, L; Jaffré, J; Langris, H; Lemaître, N; Pourcher, V; Robert, J; Schramm, F; Tunesi, S, 2022) |
| "To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV." | 8.12 | Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV. ( Barnabas, RV; Cangelosi, GA; Gersh, JK; Hatherill, M; Hawn, TR; Horne, DJ; Joudeh, LL; Kinuthia, J; Matemo, D; Mendelsohn, SC; Scriba, TJ; Valinetz, ED; Wald, A, 2022) |
| "A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI)." | 8.12 | Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs. ( Cole, J; Day, CL; Dick, EJ; Foreman, TW; Ganatra, SR; Gandhi, NR; Gonzalez, O; Hall-Ursone, S; Kaushal, D; Mehra, S; Peloquin, CA; Rengarajan, J; Schlesinger, LS; Sharan, R; Shivanna, V; Singh, DK; Thippeshappa, R, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 8.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Tuberculosis (TB) is major public health concern and Isoniazid Preventive Therapy (IPT) helps to prevent TB development among patients living with human immune deficiency virus (PLWHIV)." | 8.12 | Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia. ( Damtew, Y; Endawkie, A; Mebratu, W; Mohammed, S; Wedajo, S, 2022) |
| "Isoniazid and its metabolites are potentially associated with hepatotoxicity and treatment outcomes in patients who receive antituberculosis (TB) therapy." | 8.12 | Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS. ( Cho, YS; Kim, DH; Kim, MJ; Ky Anh, N; My Tung, P; Phuoc Long, N; Shin, JG, 2022) |
| "We aimed to assess the coverage of tuberculosis screening and isoniazid preventive therapy (IPT) among people living with human immunodeficiency virus (PLHIV) at Gambella Hospital, southwest Ethiopia." | 8.02 | Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, southwest Ethiopia: a retrospective study design. ( Aboma, M; Dida, N, 2021) |
| "Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV." | 8.02 | Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021) |
| "The in vivo release segregation of rifampicin (RIF) and isoniazid (INH) has been proposed as a strategy to avoid RIF acid degradation, which is known as one of the main factors for reduced RIF bioavailability and can result in drug-resistant tuberculosis." | 8.02 | Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid. ( Litterio, NJ; Lorenzutti, AM; Luciani-Giacobbe, LC; Olivera, ME; Ramírez-Rigo, MV, 2021) |
| " We compared the cost per completed course of preventive treatment with either 6 months of daily isoniazid (6H) or 3 months of weekly isoniazid and rifapentine (3HP), delivered by the Indus Health Network tuberculosis program in Karachi, Pakistan, between October 2016 and February 2018." | 8.02 | Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. ( Becerra, MC; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Lu, C; Majidulla, A; Malik, AA; Safdar, N; Yuen, CM, 2021) |
| "A limited sampling strategy (LSS) to estimate the exposure to isoniazid was developed considering N-acetyltransferase 2 (NAT2) genotypes in Korean patients with tuberculosis." | 8.02 | Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis. ( Choi, G; Ha, JE; Kim, ES; Lee, J; Lee, JH; Lee, JI; Lee, K; Park, JS; Song, J; Yang, S, 2021) |
| "This study aimed to develop a population pharmacokinetic model using full pharmacokinetic (PK) profiles of isoniazid (INH) taking into account demographic and genetic covariates and to develop Bayesian estimators for predicting INH area under the curve (AUC) in Tunisian tuberculosis patients." | 8.02 | Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients. ( Alshaikheid, M; Aouam, K; Ben Fadhel, N; Ben Fredj, N; Ben Romdhane, H; Chaabane, A; Chadli, Z; Hannachi, I; Kerkeni, E; Kolsi, N; Koubaa, J, 2021) |
| "Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)." | 8.02 | Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021) |
| "Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB)." | 8.02 | Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. ( Bachir, M; Billard-Pomares, T; Chiesi, S; Guglielmetti, L; Jaffré, J; Langris, H; Lemaître, N; Pourcher, V; Robert, J; Schramm, F; Tunesi, S, 2021) |
| "Depot medroxyprogesterone acetate is an injectable hormonal contraceptive, widely used by women of childbearing potential living with HIV and/or tuberculosis." | 8.02 | A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. ( Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021) |
| "Niacin or tryptophan deficiency causes pellagra." | 8.02 | A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021) |
| "We constructed a decision tree model to project lifetime costs and benefits of isoniazid PGT for drug-susceptible tuberculosis in Brazil, South Africa, and India." | 7.96 | Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. ( Andrews, JR; Croda, J; Goldhaber-Fiebert, JD; Rens, NE; Uyl-de Groot, CA, 2020) |
| "Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis." | 7.96 | Isoniazid-resistant tuberculosis: A problem we can no longer ignore. ( Pai, M; Sulis, G, 2020) |
| "Isoniazid resistant Mycobacterium tuberculosis (Hr-TB) is the most frequently encountered TB resistance phenotype in North America but limited data exist on the effectiveness of current therapeutic regimens." | 7.96 | Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017. ( Cooper, R; Edwards, BD; Edwards, J; Fisher, D; Kunimoto, D; Somayaji, R, 2020) |
| "Antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) are known to have a tuberculosis (TB) protective effect at the individual level among people living with HIV (PLHIV)." | 7.96 | Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018. ( Choto, RC; Harries, AD; Mabaya, S; Mbito, C; Mutasa-Apollo, T; Sandy, C; Takarinda, KC; Timire, C, 2020) |
| "Background The standardized doses of isoniazid in therapy against tuberculosis are determined based on total body weight, without considering genetic polymorphisms of the metabolic enzyme N-acetyltransferase-2 that contribute to the wide pharmacokinetic variability of isoniazid." | 7.96 | Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. ( Huerta-García, AP; Magaña-Aquino, M; Medellín-Garibay, SE; Milán-Segovia, RDC; Ortiz-Álvarez, A; Portales-Pérez, DP; Rodríguez-Pinal, CJ; Romano-Moreno, S, 2020) |
| "Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes." | 7.96 | Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study. ( Chang, J; Choi, JS; Chung, KS; Jung, JY; Kang, YA; Kim, EY; Kim, SY; Kim, YS; Kwak, SH; Lee, EH; Lee, SH; Leem, AY; Park, MS, 2020) |
| "To investigate the incidence of tuberculosis (TB) in patients with rheumatic diseases receiving high-dose glucocorticoids and to evaluate the preventive effect of isoniazid (INH)." | 7.96 | Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. ( Curtis, JR; Lee, EB; Lee, H; Lee, JK; Park, JW; Song, YW, 2020) |
| "A multicentre, prospective pilot study was initiated among adults living with HIV on isoniazid 300 mg with pyridoxine 50 mg after ruling out active tuberculosis (TB)." | 7.96 | Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. ( Agarwal, U; Bhavani, PK; Chitra, A; Maheshmanisha, J; Mothi, SN; Nandagopal, K; Padmapriyadarsini, C; Poornagangadevi, N; Reddy, D; Rewari, BB; Sekar, L; Selvaraj, M; Swaminathan, S; Tamizhselvan, M; Vennila, S, 2020) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for people living with HIV (PLHIV) to prevent tuberculosis (TB), including pregnant women." | 7.91 | Brief Report: High Programmatic Isoniazid Preventive Therapy (IPT) Use in Pregnancy Among HIV-Infected Women. ( Copeland, A; Cranmer, LM; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Richardson, BA; Wagner, AD, 2019) |
| "Isoniazid resistant tuberculosis is the most prevalent type of resistance in Swaziland and over two-thirds of the isoniazid resistant tuberculosis patients are tuberculosis and human immunodeficiency virus co-infected." | 7.91 | Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study. ( Chien, LY; Dlamini, NC; Ji, DD, 2019) |
| " The research method applied was comparative analysis of the results of own study and studies by other researchers, concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS when treated with isoniazid." | 7.91 | Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid. ( Głowacka, M; Jarosz, MJ; Juszkiewicz, K; Włoszczak-Szubzda, A, 2019) |
| "Isoniazid (INH) is a first-line antituberculosis (TB) agent with a pharmacokinetic profile characterized by high interindividual variation; however, population pharmacokinetic studies in patients with TB are scarce." | 7.91 | Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis. ( Agudelo, Y; Morales-Gutierrez, J; Naranjo, TW; Neely, MN; Rodriguez, CA; Sierra, Y; Zapata, J; Zapata, JD; Zuluaga, AF, 2019) |
| "Clinical relevance of the effects of genetic variation on isoniazid concentrations and low first-line tuberculosis drug exposures observed require further investigation." | 7.91 | Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. ( Adamson, J; Chirehwa, M; Denti, P; Govender, K; McIlleron, H; Naidoo, A; Naidoo, K; Ncgapu, S; Padayatchi, N; Ramsuran, V; Singh, R; Yende-Zuma, N, 2019) |
| "Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment." | 7.91 | Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014. ( Duarte, R; Fiebig, L; Hollo, V; Jackson, S; Karo, B; Kearns, C; Ködmön, C; Kohlenberg, A; Korzeniewska-Kosela, M; Papaventsis, D; Solovic, I; van der Werf, MJ; van Soolingen, D, 2019) |
| "Isoniazid (INH) represents the cornerstone for the treatment of cases infected with Mycobacterium tuberculosis (MTB) strains." | 7.91 | Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China. ( Dong, L; Huang, H; Huo, F; Jing, W; Lu, J; Ma, Y; Pang, Y; Shi, J; Wang, Y; Zhao, L; Zong, Z, 2019) |
| "Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear." | 7.88 | Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014. ( DiMiceli, L; Kempker, RR; Magee, MJ; Sales, RF; Salindri, AD; Schechter, MC, 2018) |
| "The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG." | 7.88 | Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. ( de Jong, BC; de Rijk, P; Fissette, K; Lempens, P; Meehan, CJ; Rigouts, L; Van Deun, A; Vandelannoote, K, 2018) |
| "The classic fixed-dose combination (FDC) of 4 tuberculosis drugs, namely rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol dihydrochloride (EDH) has the twin issues of physical stability and RIF cross-reaction in the 4-FDC." | 7.88 | Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal. ( Battini, S; Mannava, MKC; Nangia, A, 2018) |
| " tuberculosis H37Rv cultures were exposed to VPA or SAHA over 6 days, in the presence or absence of isoniazid (INH) and rifampicin (RIF)." | 7.88 | Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. ( Maeurer, M; Rao, M; Valentini, D; Zumla, A, 2018) |
| "A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB)." | 7.88 | Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. ( Churchyard, GJ; Dowdy, DW; Johnson, KT; Sohn, H, 2018) |
| "We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage." | 7.88 | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. ( Bendavid, E; Feldman, MW; Rhines, AS, 2018) |
| "To describe outcomes associated with the implementation of isoniazid preventive therapy (IPT) in a cohort of tuberculosis (TB) treatment-experienced human immunodeficiency virus (HIV) infected patients on antiretroviral therapy (ART)." | 7.85 | Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. ( Gengiah, S; Gengiah, TN; Maharaj, B; Naidoo, A; Naidoo, K; Yende-Zuma, N, 2017) |
| "One of the reasons why Isoniazid preventive therapy (IPT) for Tuberculosis (TB) is not widely used in low income countries is concerns on cost of excluding active TB." | 7.85 | Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. ( Aboud, S; Bakari, M; Chitama, D; Moshiro, C; Mugusi, F; Shayo, GA, 2017) |
| "Every year, over 1 million people develop isoniazid (INH) resistant tuberculosis (TB)." | 7.85 | Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada. ( Chiang, LY; Cook, VJ; Johnston, JC; Krajden, M; Romanowski, K; Roth, DZ; Tang, P, 2017) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 7.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Tuberculosis (TB) screening affords clinicians the opportunity to diagnose or exclude TB disease and initiate isoniazid preventive therapy (IPT) for people living with HIV (PLHIV)." | 7.85 | Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam. ( Cowger, TL; Danyuttapolchai, J; Duong, BD; Khanh, VT; Kittimunkong, S; Monkongdee, P; Nateniyom, S; Ngoc, DV; Nhan, DT; Nhung, NV; Pevzner, ES; Thai, LH; Thinh, T; Thoa, CK; Whitehead, S; Yen, NTB, 2017) |
| "To understand the impact of efflux pump genes such as mmpL3 and mmpL7 on isoniazid (INH) resistance and to correlate with presence or absence of mutations in essential genes of INH resistance (katG, inhA, and nat) in clinical isolates of Mycobacterium tuberculosis (M." | 7.85 | Variants of katG, inhA and nat genes are not associated with mutations in efflux pump genes (mmpL3 and mmpL7) in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India. ( Dusthackeer, VNA; Hanna, LE; Kumar, MP; Kumari, VI; Lakshmi, AR; Nagarajan, P; Sukumar, S; Unissa, AN, 2017) |
| "We measured hair and plasma concentrations of isoniazid among sixteen children with tuberculosis who underwent personal or video-assisted directly observed therapy and thus had 100% adherence." | 7.85 | Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. ( Bacchetti, P; Bharadwaj, R; Dooley, KE; Gandhi, M; Gerona, R; Gupta, A; Gupte, N; Kagal, A; Khwaja, S; Kinikar, A; Koli, H; Kumar, H; Mave, V; Nimkar, S; Ramachandran, G; Wen, A, 2017) |
| "We assessed uptake of isoniazid preventive therapy (IPT) among child contacts of smear-positive tuberculosis (TB) patients and its implementation challenges from healthcare providers' and parents' perspectives in Bhopal, India." | 7.85 | Isoniazid Preventive Therapy among Children Living with Tuberculosis Patients: Is It Working? A Mixed-Method Study from Bhopal, India. ( Bali, S; Bhat, P; Kharate, A; Kokane, AM; Kumar, AM; Nagar, M; Sahu, S; Singh, AR; Verma, M, 2017) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 7.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 7.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "In HIV-uninfected individuals, isoniazid preventive therapy (IPT) has been associated with long-term protection against tuberculosis (TB)." | 7.83 | Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. ( Boulle, A; Houben, RM; Maartens, G; Rangaka, MX; Sumner, T; White, RG; Wilkinson, RJ, 2016) |
| "The durability of isoniazid preventive therapy (IPT) in preventing tuberculosis (TB) is limited in high-prevalence settings." | 7.83 | The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. ( Chihota, V; Churchyard, GJ; Fielding, KL; Grant, AD; Hermans, SM; Lewis, JJ; Vynnycky, E, 2016) |
| "To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens." | 7.83 | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016) |
| "Increasing evidence indicates an increased risk of tuberculosis (TB) for rheumatoid arthritis (RA) patients receiving biologic therapy, and the effectiveness of isoniazid prophylaxis (INHP) in TB prevention." | 7.83 | Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan. ( Chang, CL; Chen, DY; Chen, HH; Chen, YM; Liao, TL; Lin, CH, 2016) |
| "World Health Organization advocates for integration of HIV-tuberculosis (TB) services and recommends intensive case finding (ICF), isoniazid preventive therapy (IPT), and infection control ("Three I's") for TB prevention and control among persons living with HIV." | 7.83 | Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. ( Avit-Edi, D; Ballif, M; Blevins, M; Castelnuovo, B; Charles, MK; Cortes, CP; Dung, NT; Durier, N; Dusingize, JC; Fenner, L; Lindegren, ML; Nakigozi, G; Sterling, TR; Wester, CW, 2016) |
| " tuberculosis Uganda II family as the main causative agent of tuberculosis in Uganda is not attributed to its susceptibility behavior to Isoniazid and Rifampicin." | 7.83 | Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families. ( Joloba, ML; Kasule, GW; Kateete, DP, 2016) |
| "Patients treated for tuberculosis (TB) who had rifampicin (RMP) or isoniazid (INH) concentrations measured between 1 January 2005 and 31 December 2012 were studied retrospectively." | 7.83 | Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand. ( Chiu, W; Hu, R; Lewis, C; Maze, MJ; Nisbet, M; Paynter, J, 2016) |
| " High-payload (40-50% w/w) inhalable particles containing NTZ alone or in combination with antituberculosis (TB) agents isoniazid (INH) and rifabutin (RFB) were prepared with high incorporation efficiency of 92%." | 7.83 | Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis. ( Gupta, A; Gupta, P; Gupta, UD; Kumar, S; Meena, J; Misra, A; Panda, AK; Sharma, D; Sharma, S, 2016) |
| "To study the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) in adult tuberculosis (TB) patients and examine factors that influence drug pharmacokinetics." | 7.83 | Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. ( Chandrasekaran, V; Hemanth Kumar, AK; Kannan, T; Lavanya, J; Ramachandran, G; Ramesh, K; Sudha, V; Swaminathan, S; Vijayakumar, A, 2016) |
| "The largest outbreak of isoniazid-resistant (INH-R) Mycobacterium tuberculosis in Western Europe is centred in North London, with over 400 cases diagnosed since 1995." | 7.83 | Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance. ( Karlikowska, M; Lipman, M; McHugh, TD; Satta, G; Shorten, RJ; Witney, AA, 2016) |
| "To study the proteomic and morphological changes in Mycobacterium tuberculosis H37Rv exposed to subinhibitory concentration of isoniazid (INH)." | 7.83 | Proteomic and morphological changes produced by subinhibitory concentration of isoniazid in Mycobacterium tuberculosis. ( Campanerut-Sá, PA; Cardoso, RF; Donatti, L; Evaristo, GP; Fiorini, A; Ghiraldi-Lopes, LD; Meneguello, JE; Patussi, EV; Scodro, RB; Siqueira, VL; Souza, EM, 2016) |
| "Resistance to isoniazid (INH-R) in Mycobacterium tuberculosis is mainly due to mutations at position 315 (S315T) of the catalase-peroxidase KatG." | 7.83 | Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. ( Boudinet, M; Brossier, F; Jarlier, V; Petrella, S; Sougakoff, W, 2016) |
| " tuberculosis complex that confer resistance to isoniazid and rifampicin has potentiated the knowledge of their distribution, given the geographical variability." | 7.83 | The genotypic study of Mycobacterium tuberculosis complex resistant to isoniazid: Galicia, Spain (2008-2013). ( Alonso, P; Barbeito-Castiñeiras, G; Fernández, A; González-Mediero, G; Mejuto, B; Pérez Del Molino, ML, 2016) |
| "This report describes the pharmacokinetic profiles of chronically administered oral isoniazid and rifampin in one adult male and one adult female Asian elephant ( Elephas maximus ) that were asymptomatically infected with Mycobacterium tuberculosis ." | 7.83 | ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS. ( Alsultan, A; Egelund, EF; Isaza, R; Peloquin, CA, 2016) |
| "A large isoniazid-resistant tuberculosis outbreak centred on London, United Kingdom, has been ongoing since 1995." | 7.83 | Whole Genome Sequence Analysis of a Large Isoniazid-Resistant Tuberculosis Outbreak in London: A Retrospective Observational Study. ( Broda, A; Brown, T; Casali, N; Drobniewski, F; Harris, SR; Parkhill, J, 2016) |
| "Extending the duration of isoniazid preventive therapy (IPT) among people living with HIV (PLHIV) may improve its effectiveness at both individual and population levels, but could also increase selective pressure in favor of isoniazid-resistant tuberculosis (TB) strains." | 7.83 | Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. ( Cohen, T; Crawford, FW; Kunkel, A; Shepherd, J, 2016) |
| "Drug susceptibility testing using molecular techniques can enhance the identification of drug-resistant Mycobacterium tuberculosis Two multiplex real-time polymerase chain reaction (qPCR) assays were developed to detect the most common resistance-associated mutations to isoniazid (katGS315T, inhA-15C → T), and rifampicin (rpoBH526Y and rpoBS531L)." | 7.83 | Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis. ( Collantes, J; Rigouts, L; Solari, FB, 2016) |
| "The duration of protection against tuberculosis provided by isoniazid preventive therapy is not known for human immunodeficiency virus (HIV)-infected individuals living in settings of medium tuberculosis incidence." | 7.81 | Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Golub, JE; Moulton, LH; Pacheco, AG; Saraceni, V, 2015) |
| "Rifampin, together with isoniazid, has been the backbone of the current first-line treatment of tuberculosis (TB)." | 7.81 | Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. ( Aarnoutse, RE; Alffenaar, JW; de Jager, A; de Lange, WC; Kosterink, JG; Mulder, LW; Proost, JH; Sturkenboom, MG; van Altena, R; van der Werf, TS, 2015) |
| "We report the discovery and confirmation of 23 novel mutations with previously undocumented role in isoniazid (INH) drug resistance, in catalase-peroxidase (katG) gene of Mycobacterium tuberculosis (Mtb) isolates." | 7.81 | Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. ( Amallraja, AM; Catanzaro, A; Catanzaro, D; Chawla, A; Crudu, V; Elghraoui, A; Gler, MT; Goodmanson, AP; Paul, LV; Ramirez-Busby, SM; Rodrigues, C; Rodwell, TC; Sirgel, FA; Streicher, EM; Torres, JN; Valafar, F; Victor, TC; Zadorozhny, V, 2015) |
| "The risk of developing tuberculosis (TB) disease in HIV-uninfected children after isoniazid preventive therapy (IPT) for a positive QuantiFERON-TB Gold In-Tube test (QFT-GIT) is unknown." | 7.81 | Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. ( Geldenhuys, HD; Hanekom, WA; Hatherill, M; Hughes, EJ; Hussey, G; Landry, B; Luabeya, KK; Mahomed, H; McShane, H; Mulenga, H; Scriba, TJ; Tameris, MD; Toefey, A; Van Schalkwyk, A, 2015) |
| "Isoniazid-filled Fe2 O3 hollow nanospheres (INH@Fe2 O3 , diameter <30 nm, 48 wt % INH-load) are prepared for the first time and suggested for tuberculosis therapy." | 7.81 | Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria. ( Dittmar, KE; Eich, J; Feldmann, C; Goldmann, O; Hagens, K; Leidinger, P; Lünsdorf, H; Oehlmann, W; Schaible, UE; Schwudke, D; Treptow, J; Zehethofer, N, 2015) |
| "Development of polyneuropathy (PNP) under treatment for tuberculosis (TB), including isoniazid (INH), is a highly relevant adverse drug effect." | 7.81 | Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? ( Hartmann, CJ; Hartung, HP; Kieseier, BC; Konta, L; Pabst, T; Steinberger, D; Stettner, M, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 7.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| " Horwitz, and co-workers use confocal microscopy to demonstrate the avid uptake of RITC-labeled mesoporous silica nanoparticles loaded with the anti-tuberculosis drug isoniazid (shown here in red) by human macrophages (nuclei stained blue with DAPI) infected with GFP-expressing Mycobacterium tuberculosis (shown here in green)." | 7.81 | Tuberculosis: pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice (Small 38/2015). ( Clemens, DL; Dillon, BJ; Horwitz, MA; Hwang, AA; Lee, BY; Zink, JI, 2015) |
| "Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment." | 7.81 | A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. ( Choi, R; Jeon, K; Jeong, BH; Jung, JA; Kim, TE; Ko, JW; Koh, WJ; Kwon, OJ; Lee, H; Lee, SY; Park, HY; Woo, HI, 2015) |
| "Isoniazid (INH) is one of the effective antituberculosis (TB) drugs used for TB treatment." | 7.81 | Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach. ( Deshmukh, S; Harinath, BC; Jena, L; Kumar, S; Waghmare, P, 2015) |
| "In the present paper, we report the synthesis via catalytic Michael reaction and biological results of a series of 3-heteryl substituted pyrrolidine-2,5-dione derivatives as moderate inhibitors against Mycobacterium tuberculosis H37Rv growth." | 7.80 | Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis. ( Baltas, M; Gorichko, M; Guidetti, B; Lherbet, C; Matviiuk, T; Mori, G; Pasca, MR; Rodriguez, F; Voitenko, Z, 2014) |
| " We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction." | 7.80 | A patient with HIV and tuberculosis with diminished clopidogrel response. ( Metzger, NL; Momary, KM, 2014) |
| "Isoniazid (INH) resistance is now the most common type of tuberculosis (TB) infection resistance worldwide." | 7.80 | Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. ( Chang, PJ; Chou, PC; Chung, FT; Huang, CD; Kuo, CH; Kuo, HP; Lin, SM; Shie, SS; Wang, TY, 2014) |
| "We used previously published data for 76 South African children with tuberculosis to describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid." | 7.80 | Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ( Denti, P; Donald, PR; McIlleron, HM; Schaaf, HS; Seddon, JA; Seifart, HI; Simonsson, US; Smith, PJ; Thee, S; Zvada, SP, 2014) |
| "Genetic variants in NAT2 are associated with pharmacokinetic variation of isoniazid, the cornerstone of antituberculosis treatment." | 7.80 | Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. ( Aarnoutse, RE; Coenen, MJ; de Waard, JH; García, JF; Hermans, PW; López, D; Schijvenaars, MM; Verhagen, LM, 2014) |
| "The MeltPro TB/INH assay, recently approved by the Chinese Food and Drug Administration, is a closed-tube, dual-color, melting curve analysis-based, real-time PCR test specially designed to detect 30 isoniazid (INH) resistance mutations in katG position 315 (katG 315), the inhA promoter (positions -17 to -8), inhA position 94, and the ahpC promoter (positions -44 to -30 and -15 to 3) of Mycobacterium tuberculosis." | 7.80 | Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis. ( Hu, S; Li, G; Li, H; Li, Q; Liu, X; Niu, J; Quan, S; Wang, F; Wen, H; Xu, Y, 2014) |
| "Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis complex (MTBC) are defined by resistance to at least rifampin (RMP) and isoniazid (INH)." | 7.80 | Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. ( Driscoll, J; Hartline, D; Lentz, AJ; Metchock, B; Sikes, D; Starks, AM; Yakrus, MA, 2014) |
| "The Lesotho Ministry of Health issued guidelines on active case finding (ACF) for tuberculosis (TB) and isoniazid preventive therapy (IPT) in April 2011." | 7.80 | Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy. ( Ahimbisibwe, A; Barnes, GL; Chaisson, RE; Gounder, CR; Guay, L; Isavwa, A; Kassaye, S; Maama-Maime, LB; Machekano, R; Mokone, M; Ntene-Sealiete, K; Oyebanji, O; Sahu, M; Tiam, A, 2014) |
| "The resazurin microtiter assay (classic REMA), a colorimetric liquid culture-based drug susceptibility assay for Mycobacterium tuberculosis (MTB), has been endorsed by the World Health Organization." | 7.80 | Evaluation of the modified colorimetric resazurin microtiter plate-based antibacterial assay for rapid and reliable tuberculosis drug susceptibility testing. ( Boum, Y; Katawera, V; Siedner, M, 2014) |
| " in a recent issue of this Journal address one of the current debates regarding the potential role of thioridazine in the treatment of tuberculosis." | 7.80 | Thioridazine for treatment of tuberculosis: promises and pitfalls. ( Dutta, NK; Karakousis, PC, 2014) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 7.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| "The data suggest isoniazid could be considered for use in ALBC for musculoskeletal tuberculosis if used with systemic treatment." | 7.79 | Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study. ( Cho, SN; Han, CD; Oh, T; Park, KK; Yang, JH, 2013) |
| "The expected increase in drug-resistant tuberculosis due to large-scale preventive treatment in people living with HIV calls for reconsidering the "double use" of isoniazid for prophylaxis and curative treatment (Mills et al." | 7.79 | For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance. ( Cobelens, FG, 2013) |
| " The main barriers as reported by 144 HCWs working in hospitals without IPT programme, were: (1) unclear direction of national policy (60%), (2) fear of emerging Isoniazid resistant tuberculosis (52%), and (3) fear of poor adherence (30%)." | 7.79 | Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. ( Kaewkungwal, J; Lawpoolsri, S; Moolphate, S; Pungrassami, P; Sanguanwongse, N; Yamada, N, 2013) |
| "To elaborate optimal anti-tuberculosis regimens following drug susceptibility testing (DST) to isoniazid (H) and rifampicin (R)." | 7.79 | [Proposal of anti-tuberculosis regimens based on susceptibility to isoniazid and rifampicin]. ( Alarcón, V; Mendoza-Ticona, A; Moore, DA; Samalvides, F; Seas, C, 2013) |
| "Our modeling work suggests that isoniazid preventive therapy (IPT) can be effective in reducing drug-sensitive tuberculosis (TB) and that the risk of IPT driving resistance can be reduced by improving the detection and rapid treatment of individuals with drug-resistant disease and by limiting IPT to those in whom the intervention will have the largest benefit." | 7.79 | Response to comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis". ( Cohen, T; Colijn, C; Mills, HL, 2013) |
| "The World Health Organization (WHO) recommends active tuberculosis (TB) case finding among people living with human immunodeficiency virus (HIV) in resource-limited settings using a symptom-based algorithm; those without active TB disease should be offered isoniazid preventive therapy (IPT)." | 7.79 | Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. ( Blumberg, HM; Kempker, R; Ofotokun, I; Stenehjem, E; Temesgen, O; Tenna, A; Zaeh, S, 2013) |
| "Peroxidatic activation of the anti-tuberculosis pro-drug isoniazid by Mycobacterium tuberculosis catalase-peroxidase (KatG) is regulated by gating residues of a heme access channel." | 7.79 | Access channel residues Ser315 and Asp137 in Mycobacterium tuberculosis catalase-peroxidase (KatG) control peroxidatic activation of the pro-drug isoniazid. ( Andersson, KK; Hersleth, HP; Magliozzo, RS; Zhao, X; Zhu, J, 2013) |
| "The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months." | 7.79 | Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection. ( Clotet, L; Domínguez, A; Ferrer, A; Garrido, P; Pina, JM; Sala, MR; Salleras, L, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 7.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "To describe the characteristics and outcomes of incident tuberculosis (TB) cases in human immunodeficiency virus (HIV) infected adults exposed to isoniazid preventive therapy (IPT) with access to antiretroviral and anti-tuberculosis treatment." | 7.79 | Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana. ( Agizew, T; Johnson, JL; Marape, M; Miranda, AG; Nyirenda, S; Reuter, H; Samandari, T; Sibanda, T; Tedla, Z, 2013) |
| " A tuberculin skin test was positive, we started anti-tuberculosis (TB) chemoprophylaxis with isoniazid (INH)." | 7.78 | Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis. ( Ito, M; Izumi, Y; Kakugawa, T; Kinoshita, A; Migita, K; Miyagawa, K; Miyashita, T; Sasaki, E; Umeno, T, 2012) |
| "Data on the genetic variation of isolates of Mycobacterium tuberculosis and spectrum of mutations determining resistance to principal anti-tuberculosis drugs isoniazid (INH) and rifampicin (RIF) have not yet been studied in Saudi Arabia." | 7.78 | New insight into the molecular characterization of isoniazid and rifampicin resistant Mycobacterium tuberculosis strains from Saudi Arabia. ( Al-Hajoj, S; Al-Omari, R; Al-rabiah, F; Hillemann, A; Shoukri, M; Varghese, B; Wijayanti, DR, 2012) |
| "Mutations at codons 526 and 531 in the rpoB gene and at 315 in the katG gene are considered diagnostic markers for resistance to rifampin and isoniazid in tuberculosis." | 7.78 | Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México. ( Cuellar, A; Cuevas-Cordoba, B; Enciso, A; Enciso, L; Zenteno-Cuevas, R, 2012) |
| "The optimal management strategy for patients with isoniazid (INH) monoresistant forms of tuberculosis (TB) has been widely debated." | 7.78 | Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. ( Cohen, T; Furin, J; Gegia, M; Kalandadze, I; Vashakidze, L, 2012) |
| "Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0." | 7.78 | Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. ( Arias, F; Barrera, L; Boulahbal, F; Cavanaugh, JS; Cegielski, JP; Coulter, C; Drobniewski, F; Kim, H; Kurbatova, EV; Lumb, R; Martín-Casabona, N; Metchock, B; Richter, E; Santos Silva, A; Shah, NS; Van Deun, A; Wright, A; Zemanova, I, 2012) |
| "Specific isoniazid (INH) resistance conferring mutations have been shown to impact the likelihood of tuberculosis (TB) transmission." | 7.78 | Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. ( Cattamanchi, A; Dantes, R; Hopewell, PC; Kato-Maeda, M; Kawamura, M; Kim, E; Metcalfe, J; Nahid, P, 2012) |
| "Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance." | 7.78 | Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012) |
| "This study evaluated the feasibility of using 2 multiplex allele-specific polymerase chain reaction (MAS-PCR) assays targeting 2 mutations (codon 315 of the katG gene and the 15th nucleotide preceding the mabA-inhA operon) to directly detect isoniazid (INH)-resistant Mycobacterium tuberculosis in cultured isolates and respiratory specimens." | 7.77 | Direct detection of isoniazid-resistant Mycobacterium tuberculosis in respiratory specimens by multiplex allele-specific polymerase chain reaction. ( Cheng, VC; Ho, PL; Lam, JT; Lee, AS; Que, TL; Siu, GK; Tam, YH; Tse, CW; Yam, WC; Yip, KT; Yuen, KY, 2011) |
| "Isoniazid (INH) is a key agent in the treatment of tuberculosis." | 7.77 | Downregulation of katG expression is associated with isoniazid resistance in Mycobacterium tuberculosis. ( Ando, H; Kato, S; Kirikae, T; Kitao, T; Miyoshi-Akiyama, T; Mori, T, 2011) |
| "In molecular epidemiological studies of drug resistant Mycobacterium tuberculosis (TB) in Sweden a large outbreak of an isoniazid resistant strain was identified, involving 115 patients, mainly from the Horn of Africa." | 7.77 | Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden. ( Advani, A; Bruchfeld, J; Castro, E; Ghebremichael, S; Groenheit, R; Hoffner, S; Källenius, G; Kan, B; Koivula, T; Mazurek, J; Melefors, Ö; Pawlowski, A; Pennhag, A; Sandegren, L, 2011) |
| "Limited data exist about the clinical characteristics of Mycobacterium tuberculosis (TB) isolates with resistance to isoniazid (IZN)." | 7.77 | Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. ( Fox, L; Haim, I; Kramer, MR; Metvachuk, A; Priess, R; Shitrit, D, 2011) |
| "We conducted a case–control study to examine risk factors for isoniazid-monoresistant Mycobacterium tuberculosis in an ongoing outbreak in London." | 7.77 | Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. ( Altass, L; Anaraki, S; Bothamley, G; Brailsford, S; Carless, J; Charlett, A; Lipman, M; Lozewicz, S; Maguire, H; Yates, M; Yates, S, 2011) |
| "We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa." | 7.77 | Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. ( Jacobson, KR; Murray, MB; Streicher, EM; Theron, D; Victor, TC; Warren, RM, 2011) |
| "Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)." | 7.77 | Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011) |
| "A series of 27 salicylanilide-based carbamates was prepared as a part of our ongoing search for new antituberculosis drugs." | 7.76 | Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains. ( Férriz, JM; Imramovský, A; Kunc, F; Stolaríková, J; Vavríková, E; Vávrová, K; Vinsová, J, 2010) |
| "The aim of this study was to evaluate a simple, rapid, and inexpensive colorimetric nitrate reductase assay (NRA) for direct drug susceptibility testing (DST) of Mycobacterium tuberculosis against rifampicin (RIF) and isoniazid (INH)." | 7.76 | Evaluation of direct method of drug susceptibility testing of Mycobacterium tuberculosis to rifampicin and isoniazid by nitrate reductase assay in a national reference laboratory. ( Behera, D; Meharwal, SK; Myneedu, VP; Visalakshi, P, 2010) |
| "Reports have shown that oleanolic acid (OA), a triterpenoid, exists widely in food, medicinal herbs and other plants, and that it has antimycobacterial activity against the Mycobacterium tuberculosis strain H37Rv (ATCC 27294)." | 7.76 | In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis. ( Deng, X; Fan, J; Ge, F; Guo, N; Jin, Q; Liu, S; Song, Y; Wang, X; Wu, X; Ye, H; Yu, L; Zeng, F, 2010) |
| "Active tuberculosis (TB) must be excluded before initiating isoniazid preventive therapy (IPT) in persons infected with human immunodeficiency virus (HIV), but currently used screening strategies have poor sensitivity and specificity and high patient attrition rates." | 7.76 | Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. ( Benites, C; Brady, MF; Chavez, G; Coronel, J; Friedland, JS; Gilman, RH; Moore, DA; Navincopa, M; Pinedo, Y; Reddy, KP; Rojas, C; Sánchez, E; Solari, L; Ticona, E; Valencia, J, 2010) |
| "Despite World Health Organization recommendations, concerns about promoting resistance have impeded implementation of isoniazid preventive therapy (IPT) for tuberculosis (TB)." | 7.76 | Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. ( Chihota, VN; Churchyard, GJ; Fielding, KL; Grant, AD; Lewis, JJ; Russell, EC; van Halsema, CL, 2010) |
| "A retrospective study on isoniazid-resistant tuberculosis (TB) was conducted in the low-burden country, Denmark (DK)." | 7.76 | Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. ( Andersen, AB; Andersen, PH; Bang, D; Thomsen, VØ, 2010) |
| "BACKGROUND/SETTING: Treatment for 3 months with rifampicin (R) and isoniazid (H) (3RH) for latent tuberculosis infection (LTBI), defined as an inappropriately positive tuberculin skin test with no clinical or x-ray evidence of disease, has been used locally since 1989." | 7.76 | Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. ( Bright-Thomas, R; Morris, JA; Nandwani, S; Ormerod, LP; Smith, J, 2010) |
| "Antiretroviral therapy and isoniazid preventive therapy (IPT) are both effective interventions to prevent HIV-associated tuberculosis, but work via different mechanisms." | 7.76 | Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. ( Churchyard, GJ; De Cock, KM; Kranzer, K; Lawn, SD; Lewis, JJ; Wood, R, 2010) |
| "In this study, we designed a simple and rapid colorimetric detection method, a one-tube loop-mediated isothermal amplification (LAMP)-PCR-hybridization-restriction endonuclease-ELISA [one-tube LAMP-PCR-HY-RE-ELISA] system, to detect resistance to isoniazid, ethambutol and streptomycin in strains of Mycobacterium tuberculosis isolated from clinical specimens." | 7.76 | One-tube loop-mediated isothermal amplification combined with restriction endonuclease digestion and ELISA for colorimetric detection of resistance to isoniazid, ethambutol and streptomycin in Mycobacterium tuberculosis isolates. ( Chen, YH; Hsu, HJ; Lee, MF; Peng, CF, 2010) |
| "The spoligotyping-based population structure of multidrug-resistant (MDR) Mycobacterium tuberculosis strains isolated in Poland (n = 46), representing all culture-positive MDR tuberculosis (MDR-TB) cases, was compared to that of isoniazid (INH)-monoresistant strains (n = 71) isolated in 2004." | 7.76 | Spoligotype-based comparative population structure analysis of multidrug-resistant and isoniazid-monoresistant Mycobacterium tuberculosis complex clinical isolates in Poland. ( Augustynowicz-Kopec, E; Jagielski, T; Rastogi, N; Zozio, T; Zwolska, Z, 2010) |
| "We evaluated high-resolution melting (HRM) curve analysis as a tool for detecting rifampin (RIF) and isoniazid (INH) resistance in Mycobacterium tuberculosis in an accurate, affordable, and rapid manner." | 7.76 | High-resolution melting curve analysis for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates. ( Chang, CL; Cho, EH; Choi, GE; Hwang, SH; Kim, HH; Kim, HJ; Kim, JH; Lee, EY; Lee, SM; Yi, J, 2010) |
| "To design and standardize an in-house reverse line blot hybridization (RLBH) assay for the accurate identification of 15 clinically relevant species of mycobacteria and for the detection of drug resistance to rifampin (RIF), isoniazid (INH), and streptomycin (STR) in Mycobacterium tuberculosis complex (MTB)." | 7.75 | Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex. ( Mehta, A; Rodrigues, C; Shenai, S, 2009) |
| "Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described." | 7.75 | Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. ( Cattamanchi, A; Dantes, RB; Grinsdale, J; Hopewell, PC; Jarlsberg, LG; Kawamura, LM; Metcalfe, JZ; Nahid, P; Osmond, D, 2009) |
| " tuberculosis strains were resistant to EMB alone and EMB together with additional resistance to rifampicin and isoniazid (9 of 50, 18% and 11 of 50, 22%, respectively)." | 7.75 | Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. ( Ahmad, S; Jaber, AA; Mokaddas, E, 2009) |
| "In most countries with a high burden of tuberculosis, children with tuberculosis are prescribed isoniazid at dosages of 4-6 mg/kg/day, as recommended by international authorities." | 7.75 | Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. ( Donald, PR; Hussey, GD; McIlleron, H; Schaaf, HS; Smith, PJ; Werely, CJ; Willemse, M, 2009) |
| "The marked reduction in the potent early bactericidal activity of isoniazid during the initial phase of antituberculosis (anti-TB) therapy has been attributed not only to the depletion of logarithmically growing bacilli but also to the emergence of isoniazid resistance." | 7.75 | Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. ( Ahmad, Z; Bishai, WR; Fraig, MM; Grosset, JH; Karakousis, PC; Klinkenberg, LG; Nuermberger, EL; Peloquin, CA; Pinn, ML, 2009) |
| "To evaluate the frequency and nature of mutations in genes associated with resistance to rifampicin and isoniazid in Mycobacterium tuberculosis isolates collected from Yangon, Myanmar." | 7.75 | Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. ( Grewal, HM; Kross, M; Phyu, S; Stavrum, R; Syre, H; Ti, T; Valvatne, H, 2009) |
| "For the purpose of a side-effect monitoring of isoniazid (INH), we investigated the relationship between the genotypes of drug-metabolizing enzymes involved in INH metabolism and the serum concentrations of INH and its metabolites in 129 tuberculosis patients hospitalizing in the National Hospital Organization Chiba-East Hospital." | 7.74 | Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. ( Fukino, K; Hashimoto, M; Hirai, S; Nakamura, T; Sasaki, Y; Ueno, K; Yamagishi, F, 2008) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 7.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "The purpose of this study was to evaluate the GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) for its ability to detect resistance to rifampin (RIF) and isoniazid (INH) in Mycobacterium tuberculosis clinical strains and directly in clinical samples." | 7.74 | GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. ( Domínguez, J; Garcia-Sierra, N; Haba, L; Lacoma, A; Maldonado, J; Prat, C; Rosés, S; Ruiz-Manzano, J, 2008) |
| "The genetic compositions of 71 isoniazid-resistant Mycobacterium tuberculosis strains from Poland were determined by spoligotyping." | 7.74 | Genetic diversity of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Poland and assessed by spoligotyping. ( Augustynowicz-Kopec, E; Jagielski, T; Zwolska, Z, 2008) |
| "Seven percent of tuberculosis (TB) cases reported to the US National Tuberculosis Surveillance System in 2005 had Mycobacterium tuberculosis isolates with resistance to at least isoniazid." | 7.74 | Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. ( Armstrong, LR; Harrington, TA; Hoopes, AJ; Ijaz, K; Kammerer, JS, 2008) |
| "Considering the significant increase of isoniazid (INH) resistance in Iranian Mycobacterium tuberculosis isolates in the last few years and to investigate the prevalence and diagnostic potential of the most commonly reported mutations associated with INH resistance in Iran, we analyzed parts of the katG gene and fabG1-inhA and oxyR-ahpC regulatory regions in a sample of 48 INH-resistant and 25 INH-sensitive isolates." | 7.74 | Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran. ( Doustdar, F; Farnia, P; Khosravi, AD; Masjedi, MR; Velayati, AA, 2008) |
| "It is believed that the cessation of isoniazid's early bactericidal activity during the initial phase of antituberculosis therapy is due to the depletion of Mycobacterium tuberculosis in the exponential phase of growth." | 7.74 | Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. ( Ambrose, PG; Bhavnani, SM; Brown, D; Drusano, GL; Gumbo, T; Liu, W; Louie, A, 2007) |
| "The aim of the study presented here was to determine the minimal inhibitory concentration of isoniazid for strains of isoniazid-resistant or multidrug-resistant Mycobacterium tuberculosis isolated from children in the Western Cape Province of South Africa." | 7.74 | Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. ( Brittle, W; Donald, PR; Engelke, E; Hesseling, AC; Marais, BJ; Schaaf, HS; van Helden, PD; Victor, TC, 2007) |
| "To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases." | 7.74 | [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. ( Aono, A; Ito, K; Ogata, H; Wada, M; Yoshiyama, T, 2007) |
| "Three Mycobacterium tuberculosis genetic loci--rpoB and katG genes and the fabG1(mabA)-inhA operon promoter region--were studied to reveal the mutations associated with rifampicin and isoniazid resistance." | 7.74 | Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. ( Afanas'ev, MV; Cherednichenko, AG; Chernousova, LN; Govorun, VM; Ikryannikova, LN; Il'ina, EN; Kamaev, EY; Kinsht, VN; Kuz'min, AV; Larionova, EE; Sidorenko, SV; Skorniakov, SN; Smirnova, TG, 2007) |
| "The new GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) was tested with 125 clinical isolates and directly with 72 smear-positive sputum specimens for its ability to detect rifampin (RMP) and isoniazid (INH) resistance in Mycobacterium tuberculosis complex (MTBC) strains." | 7.74 | Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. ( Hillemann, D; Richter, E; Rüsch-Gerdes, S, 2007) |
| "Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis." | 7.74 | Gatifloxacin in combination with rifampicin in a murine tuberculosis model. ( Cynamon, M; Shoen, C; Sklaney, MR, 2007) |
| " tuberculosis strains, which were selected from the collection of RYOKEN drug resistance survey in 2002, were selected and subjected to the susceptibility testing to isoniazid using MGIT AST and 1% Ogawa standard methods." | 7.74 | [Comparative study of bactec MGIT 960 AST and conventional proportion method using Ogawa medium for the drug susceptibility testing of Mycobacterium tuberculosis to isoniazid]. ( Abe, C; Fujii, S; Kamada, A; Kawabe, Y; Kawashiro, T; Kobayashi, I; Machida, K; Mitarai, S; Mori, K; Ogata, H; Shigetoh, E; Suyama, H; Suzuki, K; Takashima, T; Takigawa, S; Tano, M; Wada, M; Yano, S, 2007) |
| "Isoniazid (INH) therapy for tuberculosis carries a known risk for hepatoxicity, and leads to hepatic failure in a small subset of patients." | 7.74 | Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. ( Ament, ME; Chao, CS; Martín, MG; McDiarmid, SV; Sharp, HL; Sinatra, FR; Vargas, JH; Wu, SS, 2007) |
| "Seventy-four Mycobacterium tuberculosis clinical isolates from China were subjected to drug susceptibility testing using ethambutol, isoniazid, rifampin, and ofloxacin." | 7.74 | Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China. ( Otomo, K; Shi, R; Sugawara, I; Zhang, G; Zhang, J, 2007) |
| "The presence of mutations in specific regions of katG, inhA, oxyR-ahpC and kasA associated with isoniazid (INH)-resistant clinical isolates of Mycobacterium tuberculosis from India were analysed by DNA sequencing." | 7.74 | Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India. ( Narayanan, PR; Narayanan, S; Nusrath Unissa, A; Selvakumar, N, 2008) |
| "Isoniazid (INH, isonicotinic acid hydrazine) is one of only two therapeutic agents effective in treating tuberculosis." | 7.74 | The tuberculosis prodrug isoniazid bound to activating peroxidases. ( Brown, KA; Macdonald, IK; Metcalfe, C; Moody, PC; Murphy, EJ; Raven, EL, 2008) |
| "Isoniazid is the most widely used first line antituberculosis drug." | 7.74 | Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis. ( Golani, A; Maitra, A; Patel, Z; Singh, N, 2008) |
| "Despite having potent activity against actively replicating Mycobacterium tuberculosis, isoniazid has very limited activity against dormant bacilli." | 7.74 | Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. ( Bishai, WR; Karakousis, PC; Williams, EP, 2008) |
| "The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial." | 7.73 | Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005) |
| "To determine the overall incidence of isoniazid (INH) hepatotoxicity in a public health tuberculosis clinic over a 7-year period, and to determine if systematic, limited aspartate aminotransferase (AST) monitoring would be of benefit in detecting INH hepatotoxicity." | 7.73 | Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. ( Chrisman, CR; Fountain, FF; Self, TH; Tolley, E, 2005) |
| "Elucidation of the molecular basis of isoniazid (INH) resistance in Mycobacterium tuberculosis has led to the development of different genotypic approaches for the rapid detection of INH resistance in clinical isolates." | 7.73 | Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. ( Billman-Jacobe, H; Fyfe, J; Globan, M; Lavender, C; Sievers, A, 2005) |
| "To report a case of optic neuritis associated with concurrent etanercept and isoniazid therapy." | 7.73 | Optic neuritis with concurrent etanercept and isoniazid therapy. ( Antón-Torres, R; Borrás-Blasco, J; González-Ferrandez, JA; Navarro-Ruiz, A; Noguera-Pons, R; Romero-Crespo, I, 2005) |
| "Since the introduction of new recommendations for the treatment of latent tuberculosis infection (LTB1) disregarding age as a limitation, increasing numbers of older individuals are expected to undergo treatment with isoniazid for the prevention of tuberculosis, raising the potential for an increase in isoniazid hepatotoxicity." | 7.73 | Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection. ( Aziz, H; Debari, VA; Ismail, M; Khan, MA; Shubair, M, 2006) |
| "A new, fast 'low cost and density' DNA microarray (LCD array), designed for the detection of mutations that confer isoniazid or rifampicin resistance in Mycobacterium tuberculosis isolates, has been developed and was evaluated using 46 resistant clinical isolates from Barcelona." | 7.73 | Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. ( Aragón, LM; Coll, P; Español, M; Garrigó, M; Heiser, V; Navarro, F, 2006) |
| "A novel PCR-based reverse hybridization method Genotype MTBDR assay (Hain Lifescience GmbH, Nehren, Germany) was evaluated for rapid detection of rifampin (RIF) and isoniazid (INH) resistance in Turkish Mycobacterium tuberculosis isolates." | 7.73 | Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. ( Akinci, P; Cavusoglu, C; Soyler, I; Turhan, A, 2006) |
| "Nucleotide changes in catalase peroxidase (Kat G) gene and gene encoding the beta subunit of RNA polymerase (rpo B), responsible for isoniazid and rifampicin drug resistance were determined in the clinical isolates of Mycobacterium tuberculosis by PCR-RFLP, Line probe assay and DNA sequencing." | 7.73 | Molecular characterization of mutation associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis isolates. ( Anand, R; Basir, SF; Gupta, S; Khare, S; Lal, S; Negi, SS; Pasha, ST, 2006) |
| "Treatment of latent tuberculosis infection (LTBI) is an important aspect of tuberculosis control in the United States, but the effectiveness of this strategy is compromised by poor adherence to the recommended 9-month isoniazid regimen." | 7.73 | Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. ( Adelakun, A; Baruch, N; Bur, S; Cronin, WA; Doherty, MC; Dorman, SE; Federline, L; Karney, W; Milman, J; Montes de Oca, R; Page, KR; Sifakis, F; Walsh, T, 2006) |
| "Isoniazid (INH) and rifampin (RIF) are two of the most important antituberculosis drugs, and resistance to both of these drugs can often result in treatment failure and fatal clinical outcome." | 7.73 | Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. ( Dormandy, J; Mitsani, D; Rivenburg, J; Salfinger, M; Somoskovi, A, 2006) |
| "To apply the Arkansas color method in order to evaluate drug compliance and factors that can predict treatment adherence in patients being treated for latent tuberculosis infection (LTBI) with a single daily dose of isoniazid (INH)." | 7.72 | Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection. ( Amir, J; Baum, G; Eidlitz-Markus, T; Mimouni, M; Zeharia, A, 2003) |
| "7%) isoniazid-resistant Mycobacterium tuberculosis isolates." | 7.72 | Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. ( Bakonyte, D; Baranauskaite, A; Cicenaite, J; Sosnovskaja, A; Stakenas, P, 2003) |
| "To assess the impact of iron loading on the activity of isoniazid and ethambutol in the treatment of murine tuberculosis." | 7.72 | Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. ( Boelaert, RJ; Grosset, J; Lounis, N; Maslo, C; Truffot-Pernot, C, 2003) |
| "Isoniazid is one of the most useful drugs for the treatment of tuberculosis." | 7.72 | Current interest of isoniazid in the chemotherapy of tuberculosis in the light of its in vitro activity. ( Casal, M; Rodríguez-Cano, F; Ruiz, P; Zerolo, FJ, 2003) |
| "Mutations in the katG locus of catalase peroxidase in Mycobacterium tuberculosis (MTB) account for major isoniazid (INH) resistance." | 7.72 | Detection of katG Ser315Thr substitution in respiratory specimens from patients with isoniazid-resistant Mycobacterium tuberculosis using PCR-RFLP. ( Chiu, A; Ho, PL; Kam, KM; Leung, ET; Seto, WH; Yam, WC; Yuen, KY, 2003) |
| "To determine the prevalence of isoniazid resistance by year of birth among previously treated and untreated tuberculosis patients by country of birth." | 7.72 | Isoniazid resistance among tuberculosis patients by birth cohort in Germany. ( Forssbohm, M; Loddenkemper, R; Rieder, HL, 2003) |
| " tuberculosis to isoniazid (INH) and rifampin (RIF) based on incorporation of nitrate in broth cultures containing growth supplements." | 7.72 | Rapid colorimetric method for testing susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin in liquid cultures. ( Bjorvatn, B; Grewal, HM; Phyu, S; Sandven, P; Syre, H, 2003) |
| "The absorption of rifampin, isoniazid, and D-xylose in patients with human immunodeficiency virus (HIV) infection and diarrhea, in patients with HIV infection and tuberculosis (TB), in patients with pulmonary TB alone, and in healthy subjects was studied." | 7.72 | Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. ( Gurumurthy, P; Hemanth Kumar, AK; Krishnarajasekhar, OR; Kumar, S; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "We have identified a potential quality control strain of Mycobacterium tuberculosis to monitor isoniazid susceptibility testing." | 7.72 | Identification of a Mycobacterium tuberculosis strain with stable, low-level resistance to isoniazid. ( Gross, W; Heifets, L; Higgins, M; Madison, BM; Morlock, G; Ridderhof, JC; Siddiqi, SH; Thompson, A; Warren, N, 2004) |
| "The presence of ACC and other mutations at codon 315 in the katG gene was detected by PCR amplification followed by restriction fragment length polymorphism (PCR-RFLP) generated with restriction enzymes Msp I and MspA1 I in 37 isoniazid-resistant and 22-susceptible Mycobacterium tuberculosis isolates from Kuwait obtained in 2001." | 7.72 | Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. ( Ahmad, S; Mokaddas, E, 2004) |
| "To characterize the treatment of latent tuberculosis infection and the impact on treatment completion of the 2-month rifampin and pyrazinamide regimen as compared to the traditional 6- to 12-month isoniazid regimen among persons incarcerated at a county correctional facility." | 7.72 | Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. ( Brannan, GL; Clancey, T; Conklin, TJ; Lincoln, T; Lynch, V; Rose, DN; Tuthill, RJ, 2004) |
| "The prevalence of mutations in the katG, inhA and oxyR-ahpC genes of isoniazid (INH)-resistant Mycobacterium tuberculosis isolates in the Philippines were determined." | 7.72 | Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical strains isolated in the Philippines. ( Herrera, L; Jiménez, MS; Portero, JL; Sáez-Nieto, JA; Saiz, P; Valverde, A, 2004) |
| "We investigated mutations in the genes katG, inhA (regulatory and structural regions), and kasA and the oxyR-ahpC intergenic region of 97 isoniazid (INH)-resistant and 60 INH-susceptible Mycobacterium tuberculosis isolates obtained in two states in Brazil: São Paulo and Paraná." | 7.72 | Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. ( Barco, P; Cardoso, RF; Cecon, L; Cooksey, RC; Forestiero, F; Hirata, MH; Hirata, RD; Leite, CQ; Mamizuka, EM; Morlock, GP; Sato, DN; Shikama, Mde L, 2004) |
| "Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide." | 7.72 | Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 7.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "Sixty-eight BALB/c mice were infected with the intravenous injections of Mycobacterium tuberculosis (MBT), a clinical strain resistant to streptomycin, isoniazid, rifampicin, and kanamycin." | 7.72 | [Use of dissolved ozone in the treatment of experimental tuberculosis in mice]. ( Belianin, II; Martynova, LP; Nikonenko, BV; Shmelev, EI, 2004) |
| "The worldwide threat of drug-resistant tuberculosis (TB) to human health has led to the development of molecular methods for rapidly determining the resistance of clinical Mycobacterium tuberculosis isolates to the two front-line antituberculous drugs, isoniazid and rifampin." | 7.71 | Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. ( Abal, AT; Ahmad, S; Mokaddas, E, 2002) |
| "A method for detecting multidrug-resistant Mycobacterium tuberculosis by using a reduction of resazurin is described." | 7.71 | Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. ( Camacho, M; Guerra, H; Martin, A; Palomino, JC; Portaels, F; Swings, J, 2002) |
| "Twenty patients with urinary tuberculosis were treated with ofloxacin (200 mg/day, 6 months), rifampin (600 mg/day, 3 months) and isoniazid (300 mg/day, 3 months) between 1989 and 1990." | 7.71 | Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study. ( Castiñeiras, AA; Della-Latta, P; Herreras, A; Pérez-Pascual, P; Zarranz, JE, 2002) |
| "We retrospectively evaluated the use of disulfiram among alcoholic patients being treated for active tuberculosis." | 7.71 | Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis. ( Breese, P; Burman, WJ; Cohn, D; Reves, R; Terra, M, 2002) |
| "To determine the prevalence of S315T mutation within the katG gene that confers clinically significant resistance to isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from tuberculosis patients in Dubai and Beirut." | 7.71 | Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut. ( Ahmad, S; Araj, GF; Chugh, TD; Fares, E; Mustafa, AS, 2002) |
| "We report a male infant with congenital tuberculosis who developed cerebral hemorrhage associated with vitamin K deficiency during treatment with isoniazid and rifampin." | 7.71 | Cerebral hemorrhage associated with vitamin K deficiency in congenital tuberculosis treated with isoniazid and rifampin. ( Haruta, T; Kobayashi, K; Kubota, M; Maeda, H; Nishio, T, 2002) |
| "Isoniazid (INH) chemoprophylaxis has a positive impact on the development of clinical tuberculosis." | 7.71 | Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis. ( Alaei, A; Alaei, K; Mansouri, D, 2002) |
| "National tuberculosis treatment guidelines suggest a regimen of 2RZE/10RE for the treatment of isoniazid resistant organisms." | 7.71 | Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? ( Green, RM; Horsfield, N; Ormerod, LP, 2001) |
| "A mutation (CCG-->CTG [Arg-->Leu]) in codon 463 of katG (catalase peroxidase) of Mycobacterium tuberculosis has been found in isoniazid (INH)-resistant strains." | 7.71 | The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg-->Leu mutation at codon 463 of katG are not associated. ( Dankert, J; de Haas, PE; Kuijper, EJ; van der Ende, A; van Doorn, HR; van Soolingen, D; Welten, AG, 2001) |
| "Previously, we reported on the use of rifampin-loaded microspheres to effectively treat Mycobacterium tuberculosis-infected macrophages and mice." | 7.71 | Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. ( Barrow, EL; Barrow, WW; Quenelle, DC; Staas, JK; Winchester, GA, 2001) |
| "Mycobacterium tuberculosis has two genes for ferric uptake regulator orthologues, one of which, furA, is situated immediately upstream of katG encoding catalase-peroxidase, a major virulence factor that also activates the prodrug isoniazid." | 7.71 | Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. ( Cole, ST; Deretic, V; Domenech, P; Honoré, N; Pym, AS; Song, J, 2001) |
| "6 x 10(7) CFU of Mycobacterium tuberculosis were treated 14 days later for 6 months with a regimen of once-weekly 10 mg of rifapentine and 75 mg of isoniazid per kg of body weight supplemented with either 150 mg of streptomycin per kg or 100 mg of moxifloxacin per kg during either both the 2-week daily initial and once-weekly continuation phases or only in the daily 2-week initial phase." | 7.71 | Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. ( Bentoucha, A; Grosset, J; Ji, B; Lounis, N; O'Brien, RJ; Roscigno, G; Truffot-Pernot, C; Vernon, A, 2001) |
| "Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis." | 7.71 | In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. ( Alvirez-Freites, EJ; Carter, JL; Cynamon, MH, 2002) |
| "To determine the acceptability, compliance and side effects of isoniazid (INH) prophylaxis against tuberculosis among HIV infected police officers (PO) in Dar es Salaam." | 7.70 | Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam. ( Aris, EA; Bakari, M; Biberfeld, G; Chale, S; Josiah, R; Magao, P; Mhalu, F; Moshi, A; Mugusi, F; Pallangyo, K; Pallangyo, N; Sandström, E, 2000) |
| "Prophylaxis of tuberculosis in children with four month (n = 53) and three month regimens (n = 213) of rifampicin and isoniazid from 1987 to 1996 were tolerated without any toxicity." | 7.70 | Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. ( Ormerod, LP, 1998) |
| "Although isoniazid (isonicotinic acid hydrazide, INH) is widely used for the treatment of tuberculosis, its molecular target has remained elusive." | 7.70 | Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. ( Barry, CE; Crane, DD; Mdluli, K; Mead, D; Musser, JM; Pan, X; Ramaswamy, S; Slayden, RA; Zhu, Y, 1998) |
| "Mutants in the structural gene of the inhA-encoded NADH-dependent 2-trans enoyl-acyl carrier protein reductase were identified from isoniazid-resistant clinical isolates of Mycobacterium tuberculosis." | 7.70 | Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. ( Basso, LA; Blanchard, JS; Jacobs, WR; Musser, JM; Zheng, R, 1998) |
| "To determine the value of ahpC promoter mutations for the rapid prediction of isoniazid resistance, this genomic region was characterized in 50 isoniazid-resistant and 12 isoniazid-sensitive Mycobacterium tuberculosis isolates." | 7.70 | Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. ( Bretzel, G; Feldmann, K; Löscher, T; Rifai, M; Rinder, H; Rüsch-Gerdes, S; Thomschke, A, 1998) |
| "Once-weekly therapy with combinations of isoniazid plus a rifamycin was tested in the mouse low-dose aerosol infection model against two strains of Mycobacterium tuberculosis." | 7.70 | Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. ( Brooks, JV; Orme, IM, 1998) |
| "To study the activity of metronidazole on persisting tubercle bacilli, BALB/c mice were infected with Mycobacterium tuberculosis and, after 14 days, treated with isoniazid (H) or rifampicin (R) or isoniazid + rifampicin (HR) for 2 months." | 7.70 | Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. ( Herbert, D; Kubendiran, G; Paramasivan, CN, 1998) |
| "Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated because of the risk of hepatotoxicity." | 7.70 | Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. ( Buskin, SE; Goldberg, SV; Nolan, CM, 1999) |
| "To compare the strategy of TB vaccination with that of tuberculin skin-testing in conjunction with isoniazid (INH) in preventing tuberculosis in HIV-infected persons." | 7.70 | Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. ( Brehm, WT; Chaisson, RE; Moore, RD; Sterling, TR, 1999) |
| "To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis." | 7.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| "The molecular prediction of isoniazid (INH) resistance in Mycobacterium tuberculosis is hampered by the need for specialized equipment, expertise, high costs, a limited range of detectable mutations, or several of these factors." | 7.70 | Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples. ( Cambau, E; Casal, M; Feldmann, K; Grosset, J; Gutierrez, J; Jarlier, V; Löscher, T; Richter, E; Rifai, M; Rinder, H; Rüsch-Gerdes, S; Tortoli, E; Vaquero, M, 1999) |
| "Rifapentine is a long-acting rifamycin which may be useful for intermittent drug therapy against tuberculosis." | 7.70 | Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. ( Bishai, WR; Chaisson, RE; Miyazaki, E, 1999) |
| " In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model." | 7.70 | Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999) |
| "New rapid phenotypic assays for the detection of rifampin resistance in Mycobacterium tuberculosis have recently been described, but most of these require liquid cultures, which reduces the utility of many tests in terms of turnaround times." | 7.70 | Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of Mycobacterium tuberculosis. ( Butcher, PD; Drobniewski, FA; Eltringham, IJ; Mangan, JA; Wilson, SM, 1999) |
| "Annual skin testing for tuberculosis infection and anergy was performed, and eligible patients were offered daily isoniazid for 12 months and followed prospectively." | 7.70 | Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. ( Gourevitch, MN; Hartel, D; Klein, RS; Schoenbaum, EE; Selwyn, PA, 1999) |
| "The use of isoniazid (INH) for the treatment of INH-resistant Mycobacterium tuberculosis infection has been controversial." | 7.70 | High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. ( Cheng, S; Cynamon, MH; DeStefano, MS; Harpster, T; Zhang, Y, 1999) |
| "To evaluate an approach to enhancing compliance with tuberculosis chemoprophylaxis in drug users enrolled on methadone maintenance utilizing an isoniazid (INH)-methadone admixture." | 7.70 | Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance. ( Durante, AJ; Friedman, L; Henry, S; O'Connor, PG; Selwyn, PA; Shi, JM, 1999) |
| "The effectiveness of various once-weekly 10 mg/kg rifapentine (P)- containing regimens for treatment of tuberculosis was assessed in mice infected intravenously with 4." | 7.70 | Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. ( Daniel, N; Geiter, LJ; Grosset, J; Hejblum, G; Ji, B; Lounis, N; O'Brien, RJ; Szpytma, M; Truffot-Pernot, C; Vernon, A, 2000) |
| "The prevalence of mutations at amino acid (aa) position 315 in the katG gene of isoniazid (INH)-resistant Mycobacterium tuberculosis isolates in The Netherlands and the mutation's association with the level of INH resistance, multidrug resistance, and transmission were determined." | 7.70 | Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. ( Borgdorff, MW; de Haas, PE; Kuijper, E; Rinder, H; van Doorn, HR; van Soolingen, D, 2000) |
| "The target for isoniazid preventive therapy against tuberculosis in Japan has been contact persons of tuberculosis patients with the age of less than 30." | 7.70 | [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings]. ( Yoshiyama, T, 2000) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 7.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "In tests with 18 drug-susceptible strains of Mycobacterium tuberculosis, the MIC at which 50% of the strains are inhibited by levofloxacin (LVFX) was one dilution less than that at which 50% of the strains are inhibited by ofloxacin (OFLO), but the MICs at which 90% of the strains are inhibited were similar." | 7.69 | In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. ( Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C, 1995) |
| "A retrospective study of tuberculosis patients treated with isoniazid was undertaken in order to establish the prevalence and specificity of antibodies against histones, chromatin and denatured DNA." | 7.69 | IgA antihistone antibodies in isoniazid-treated tuberculosis patients. ( Casiano, CA; Rubin, RL; Vázquez-Del Mercado, M, 1995) |
| "The ever-increasing incidence of tuberculosis calls for the implementation of control measures, including new efficient, short-term preventive therapies to replace 6 to 12 months of isoniazid therapy." | 7.69 | Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. ( Della Bruna, C; Jabès, D; Olliaro, P; Rossi, R, 1994) |
| "The effectiveness of intermittent administration of rifapentine (RPT), with or without isoniazid (INH), for preventive therapy of tuberculosis was evaluated in immunocompetent (normal) and nude mice." | 7.69 | Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. ( Chapuis, L; Grosset, JH; Ji, B; O'Brien, RJ; Raviglione, MC; Truffot-Pernot, C, 1994) |
| "The catalase-peroxidase gene (katG) and a two-gene locus (inhA) containing mutations associated with resistance to isoniazid in Mycobacterium tuberculosis were sequenced in 34 resistant and 12 susceptible strains." | 7.69 | Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. ( Kapur, V; Kreiswirth, BN; Musser, JM; van Embden, JD; van Soolingen, D; Williams, DL, 1996) |
| "Resistance to isoniazid in Mycobacterium tuberculosis has been associated with mutations in genes encoding the mycobacterial catalase-peroxidase (katG) and the InhA protein (inhA)." | 7.69 | Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. ( Bai, GH; Li, Z; Morris, SL; Rouse, DA, 1995) |
| "Antituberculosis activity of clarithromycin (CLA), a macrolide antibiotic, was investigated in vitro, in macrophages, and in C57BL/6 mice, CLA showed high in vitro MICs (4 to > 16 micrograms/ml) for several strains of Mycobacterium tuberculosis and caused slight enhancement of activity of rifampin (RIF) against H37Rv but failed to increase the activity of either RIF or isoniazid (INH) against other strains." | 7.69 | Antituberculosis activity of clarithromycin. ( Daneluzzi, D; Gangadharam, PR; Luna-Herrera, J; Reddy, VM, 1995) |
| "One of the mechanisms of isoniazid resistance to Mycobacterium tuberculosis has been proved to be the chromosomal deletion of katG." | 7.69 | KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates. ( Abe, C; Goto, M; Kimura, S; Kitada, K; Oka, S; Shimada, K; Tachikawa, N; Wada, M, 1995) |
| "The activity of KRM-1648, alone and in combination with isoniazid, was compared with those of isoniazid, rifampin, and the combination of rifampin plus isoniazid in a murine model of tuberculosis." | 7.69 | Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. ( Cynamon, MH; Klemens, SP, 1996) |
| "The efficacies of rifampin-containing preventive regimens were measured in Cornell model mice in which an initially severe infection with Mycobacterium tuberculosis H37Rv was first treated for 7 weeks with 25 mg of isoniazid and 1,000 mg of pyrazinamide per kg of body weight in the diet and then with one of four test regimens given by daily oral gavage for 6 weeks." | 7.69 | Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. ( Dhillon, J; Dickinson, JM; Mitchison, DA; Sole, K, 1996) |
| "In our efforts to develop new drugs for the treatment of tuberculosis, especially that caused by multidrug-resistant strains, we investigated clofazimine (CFM) and two of its analogs, B4154 and B4157, for their antituberculosis activities." | 7.69 | Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. ( Daneluzzi, D; Gangadharam, PR; Nadadhur, G; O'Sullivan, JF; Reddy, VM, 1996) |
| "Prolonged therapy with rifampicin and isoniazid can cause vitamin D deficiency or osteomalacia, particularly in patients with marginal vitamin D stores." | 7.69 | Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong. ( Chan, TY, 1996) |
| "The present case report describes a 10-year-old boy with clinical history of steroid-dependent asthma who developed severe exacerbation of his respiratory symptoms upon isoniazid administration." | 7.69 | A case of acute deterioration in asthma symptoms induced by isoniazid prophylaxis. ( Cacciola, R; Colombrita, R; Polosa, R; Prosperini, G, 1997) |
| "Isoniazid resistance in Mycobacterium tuberculosis is associated with lack of catalase-peroxidase activity." | 7.68 | Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. ( Guan, L; Kornblum, J; Kreiswirth, B; Laraque, F; Riegler, N; Riley, LW; Stoeckle, MY; Weitzman, I, 1993) |
| "In a case-control study of 92 Indian patients, 46 with active tuberculosis (cases) and 46 tuberculin reactors without the disease (control subjects), significantly more control subjects than patients had prior adequate isoniazid chemoprophylaxis." | 7.68 | The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians. ( Leonardson, G; Mori, MA; Welty, TK, 1992) |
| "A 33-year-old man with AIDS and pleuro-pulmonary tuberculosis was treated with a combination of antituberculous medications for 12 months and with continuation of isoniazid." | 7.68 | Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. ( Jones, WD; Shafer, RW, 1991) |
| "In a retrospective study to evaluate the efficacy of isoniazid (INH) for the prevention of tuberculosis, we studied 1760 patients with hematological malignancies over a twenty-year period (1970-1989)." | 7.68 | [Infection prophylaxis in patients with hematological malignancies (II)--Successful prophylaxis of tuberculosis with isoniazid]. ( Atogami, S; Kamihira, S; Maeda, T; Miyazaki, Y; Moriuchi, Y; Murata, K; Nagai, K; Satoh, T; Tokunaga, S; Yanagisako, T, 1991) |
| "In a first experiment, the efficacy of a 6-month course of isoniazid (INH) alone in comparison with 2-month courses of rifampin (RMP) alone, RMP + pyrazinamide (PZA), or RMP + PZA + INH as preventive therapy of tuberculosis was evaluated in the mouse." | 7.67 | Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. ( Grosset, JH; Lecoeur, HF; Truffot-Pernot, C, 1989) |
| "A single dose kinetics of isoniazid and rifampicin alone, and combination was studied in well-nourished and malnourished patients of tuberculosis." | 7.67 | Single dose kinetics of rifampicin and isoniazid in well-nourished and malnourished patients of tuberculosis. ( Dhand, R; Garg, SK; Gupta, PH; Jha, VK; Kalra, S; Lal, R; Malik, SK; Shukla, VK, 1988) |
| "The bioavailability of isoniazid, rifampin, and pyrazinamide in 2 combined formulations of the 3 drugs (Rifater) for use primarily in the short-course chemotherapy of tuberculosis has been studied in Chinese patients in Singapore and Hong Kong." | 7.67 | The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. ( Allen, BW; Chan, SL; Ellard, DR; Ellard, GA; Girling, DJ; Ng, HK; Nunn, AJ; Tan, TH; Teo, SK, 1986) |
| "Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 7.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
| "The outcome of isoniazid chemoprophylaxis for tuberculosis was assessed in refugees from Southeast Asia." | 7.67 | Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. ( Aitken, ML; Anderson, KM; Elarth, AM; Miller, WT; Nolan, CM, 1986) |
| "Drug susceptibility studies on strains of Mycobacterium tuberculosis isolated from widely different populations of patients and tested by two different techniques indicated that all 55 strains resistant to rifampicin were also resistant to isoniazid, while many strains resistant to isoniazid were found to be susceptible to rifampicin." | 7.66 | Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis. ( Aziz, A; Middlebrook, G; Reggiardo, Z; Siddiqi, SH, 1981) |
| "Calcium metabolism was studied in 83 patients during eighteen months' rifampicin and isoniazid therapy for tuberculosis by measurements including calcium, alkaline phosphatase and 25-hydroxycholecalciferol (25-HCC)." | 7.66 | Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis. ( Brown, J; Erooga, MA; Perry, W; Stamp, TC, 1982) |
| "41 226 isoniazid exposed and 22 811 non-exposed patients admitted to Canadian institutions for the treatment of tuberculosis from 1952 to 1960 were followed to 1973 by computerised record linkage to the National Death Index and, for 1969 to 1973, to the National Cancer Incidence Reporting System; The mortality for the total cohort compared to that expected from the mortality in the Canadian population, was greater than expected for tuberculosis, other chest diseases and certain cancer sites associated with cigarette smoking (except bladder cancer)." | 7.66 | Isoniazid exposure in relation to cancer incidence and mortality in a cohort of tuberculosis patients. ( Coppock, E; Howe, GR; Lindsay, J; Miller, AB, 1979) |
| "Three cases of histamine reaction occuring in tuberculosis patients on ingestion of a species of tropical fish, Sardinella (Amblygaster) sirm are reported." | 7.66 | Histamine poisoning in tuberculosis patients on ingestion of tropical fish. ( Uragoda, CG, 1978) |
| "Tests of sensitivity to rifampin of over 2,200 strains of Mycobacterium tuberculosis demonstrated a progressive increase in the number of rifampin-resistant isolates during the past four years in Massachusetts." | 7.65 | Emergence of rifampin-resistant Mycobacterium tuberculosis in Massachusetts. ( Stottmeier, KD, 1976) |
| " The acetylator phenotype of over 600 pulmonary tuberculosis patients treated with intermittent isoniazid-containing regimens in two controlled clinical trials was determined using either sulphadimidine or a slow-release isoniazid formulation." | 7.65 | Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. ( Ellard, GA; Gammon, PT, 1977) |
| "Five children with tuberculosis were treated with isoniazid (20 mg." | 7.65 | [Toxic hepatitis caused by rifampin and isoniazid in treatment of tuberculosis (author's transl)]. ( Abeledo Mezquita, G; Otero Reigada, MC, 1977) |
| "The effect of streptomycin used alone and in combination with tubazid on the brain electric activity was studied in chronic experiments on rabbits with tuberculosis." | 7.65 | [Effect of the prolonged use of streptomycin as well as streptomycin in combination with tubazid on the bioelectrical activity of the brain in experimental tuberculosis]. ( Aksel'rod, LB; Bogun, OI; Kniazheva, VN; Sukolovskaia, DM, 1976) |
| "Black male tuberculosis patients (106) were phenotyped into 59% fast and 41% slow acetylators with isoniazid (NH) plasma half-lives." | 7.65 | Isoniazid acetylator status of Black South African tuberculosis patients. ( Bach, PH; Bima, B; Higgins-Opitz, SB; Leary, WP, 1976) |
| "A major step toward the eradication of tuberculosis in the United States has been the use of isoniazid for chemoprophylaxis in certain persons who have positive tuberculin skin tests but no other evidence of active infection." | 7.65 | Isoniazid chemoprophylaxis of tuberculosis. ( Davidson, FF; Jenkins, D, 1972) |
| "It is well known that in the treatment of tuberculosis with isoniazid the complication of peripheral neuritis may arise." | 7.64 | Peripheral neuritis due to isoniazid. ( ANDREWS, RH; DEVADATTA, S; FOX, W; GANGADHARAM, PR; RAMAKRISHNAN, CV; SELKON, JB; VELU, S, 1960) |
| "Since isoniazid is metabolized in man to several derivatives with little or no specific activity against the tubercle bacillus, its rate of inactivation in the body may have an important bearing on its efficacy as an antituberculosis drug." | 7.64 | Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. ( BHATIA, AL; GANGADHARAM, PR; RADHAKRISHNA, S; SELKON, JB, 1961) |
| "A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tuberculosis in a 1-year comparison of four domiciliary chemotherapeutic regimens-three of isoniazid alone, either in moderate (HI-1 and HI-2 regimens) or in low (H regimen) dosage, and one of isoniazid in low dosage plus p-aminosalicylic acid (PAS) (PH regimen) -has recently been undertaken by the Tuberculosis Chemotherapy Centre, Madras." | 7.64 | Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS. ( DEVADATTA, S; FOX, W; GANGADHARAM, PR; NAIR, CN; SELKON, JB, 1961) |
| "The authors present a report from the Tuberculosis Chemotherapy Centre, Madras, on the prevalence and attack rate of tuberculosis among close family contacts of tuberculous patients in South India undergoing domiciliary chemotherapy either with isoniazid plus PAS or with one of three regimens of isoniazid alone." | 7.64 | Prevalence and early attack rate of tuberculosis among close family contacts of tuberculous patients in South India under domiciliary treatment with isoniazid plus PAS or isoniazid alone. ( ANDREWS, RH; DEVADATTA, S; FOX, W; RADHAKRISHNA, S; RAMAKRISHNAN, CV; SOMASUNDARAM, PR; VELU, S, 1961) |
| "This study from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress during the second year of the patients in a concurrent comparison of four domiciliary chemotherapeutic regimens (isoniazid plus PAS and three regimens of isoniazid alone) who had bacteriologically active or bacteriologically relapsed pulmonary tuberculosis, with isoniazid-resistant organisms, at the end of the first year of treatment." | 7.64 | The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance. Response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS. ( BHATIA, AL; DEVADATTA, S; FOX, W; NARAYANA, AS; RAMAKRISHNAN, CV; SELKON, JB; VELU, S, 1962) |
| "Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8." | 7.11 | Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022) |
| "Pharmacokinetic studies in the past have shown inadequate antituberculosis drug levels in children with the currently available dosing regimens." | 6.90 | Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. ( Aruldhas, BW; Bose, A; Hoglund, RM; Mathew, BS; Mathew, SK; Ranjalkar, J; Tarning, J; Verghese, VP, 2019) |
| "Isoniazid disposition was described using a two-compartment model with first-order absorption and linear elimination in most of the studies." | 6.82 | Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. ( Banerjee, M; M, SS; Mallayasamy, S; Raju, AP; Rao, M; Saravu, K; Sv, CS; Thomas, L; Varma, M, 2022) |
| "Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy." | 6.80 | Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. ( Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S, 2015) |
| " The serum INH concentrations were higher in the undernourished group but the pharmacokinetic parameters were comparable with those in the normal nutrition group." | 6.75 | Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis. ( Gupta, D; Gupta, P; Mishra, TK; Roy, V; Sethi, GR, 2010) |
| " This study compared completion rates for isoniazid (INH) preventive therapy for injection drug users (IDUs) randomly assigned to methadone treatment combined with directly observed preventive treatment (DOPT) versus those assigned to routine TB clinic referral without methadone treatment." | 6.70 | A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. ( Batki, SL; Bradley, JM; Bradley, M; Delucchi, K; Gruber, VA, 2002) |
| "There was a significant difference in the Cmax between free and RIF combined with INH (6." | 6.69 | Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis. ( Chitemerere, C; Gumbo, J; Ndudzo, P; Nyazema, NZ; Rabvukwa, P, 1999) |
| " It is evident that guidelines established for the prevention and treatment of this problem differ between industrialised and developing countries, and that further research is needed to define the optimum dosing of pyridoxine supplementation in populations where there is a significant burden of TB and HIV." | 6.47 | Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. ( Benatar, M; Harrison, TB; Heckmann, JM; van der Watt, JJ, 2011) |
| "Isoniazid-induced pancreatitis is potentially reversible; early recognition and drug withdrawal are warranted in the appropriate clinical setting." | 6.42 | Recurrent acute pancreatitis after isoniazid. ( Chow, KM; Leung, CB; Li, PK; Szeto, CC, 2004) |
| "Isoniazid is a first-line pro-drug that requires activation through an enzyme called catalase peroxidase, but is subject to widespread resistance, driven by mutations in katG and inhA genes and other loci with compensatory effects (e." | 5.91 | Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. ( Ahmad, S; Alam, J; Ali, S; Campino, S; Clark, TG; Khan, AS; Khan, MT; Khan, TA; Khattak, B; Mohammad, N; Napier, G; Phelan, JE; Qasim, M, 2023) |
| " To address this knowledge gap, we used physiologically based pharmacokinetic (PBPK) modeling to evaluate NAT2 phenotype-specific effects of pregnancy on INH disposition." | 5.91 | Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy. ( Amaeze, OU; Isoherranen, N, 2023) |
| "Mycobacterium tuberculosis is exposed to diverse stresses inside the host during dormancy." | 5.91 | Rv1255c, a dormancy-related transcriptional regulator of TetR family in Mycobacterium tuberculosis, enhances isoniazid tolerance in Mycobacterium smegmatis. ( Ajay Kumar, R; Gopi Reji, J; K Edison, L; Kurthkoti, K; Pushparajan, AR; Raghunandanan, S, 2023) |
| "Children with drug-susceptible tuberculosis in Malawi and South Africa underwent pharmacokinetic sampling while receiving first-line tuberculosis drugs as single formulations according the 2010 WHO recommended doses." | 5.72 | Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. ( Bekker, A; Davies, G; Denti, P; Gonzalez-Martinez, C; Hesseling, AC; McIlleron, HM; Rabie, H; Svensson, EM; van der Laan, LE; van Rie, A; Wasmann, RE; Wiesner, L; Winckler, J; Zar, HJ, 2022) |
| " The findings of the present study indicate the need to periodically assess adherence and persistence to IPT in the child TB contacts as high intermittent missed dosing rates can undermine the effectiveness of IPT in preventing incident disease." | 5.72 | Adherence to Isoniazid Preventive Therapy among children living with tuberculosis patients in Delhi, India: An exploratory prospective study. ( Basu, S; Chandra, S; Chopra, KK; Khanna, A; Sharma, N; Sharma, P, 2022) |
| " Simulations were performed to assess INH exposure and optimal dosing regimens, using 2 targets: Cmax at 3-6 mg/L and area under the curve (AUC) ≥ 10." | 5.72 | Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022) |
| " Moreover, acetylation phenotype-based INH dosing has been shown to be cost-effective as well as successful in terms of treatment outcomes and the increase in the quality of life of the patients." | 5.72 | Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India. ( Das, A; Khan, N, 2022) |
| " Nonlinear mixed-effects models were developed to describe the pharmacokinetic data." | 5.72 | Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Sundell, J, 2022) |
| "Pyrazinamide resistance was found in 6/80 (7." | 5.72 | Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022) |
| "tuberculosis) is usually treated by oral antimycobacterial agents, including rifampicin, ethambutol, and pyrazinamide, but the treatment regimen with intravenous and/or intramuscular antimycobacterial agents for patients who cannot take medications orally remains unclear." | 5.72 | A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen. ( Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N, 2022) |
| "In people with HIV-associated DS-PTB with CD4+ counts ≥100 cells/μL on efavirenz-based ART, the 4-month daily rifapentine-moxifloxacin regimen was noninferior to the 6-month control regimen and was safe." | 5.69 | Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). ( Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z, 2023) |
| "Our findings suggest that twice-daily dolutegravir might be unnecessary in people with HIV-associated tuberculosis." | 5.69 | Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial. ( Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y, 2023) |
| " Of 749 infants, 694 (93%) received Bacille Calmette-Guérin (BCG) vaccination, 675 (90%) were born to mothers who had completed isoniazid treatment, 20 (3%) were exposed to tuberculosis, seven (1%) became HIV positive, and one (<1%) developed probable tuberculosis." | 5.69 | Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial. ( Aaron, L; Bradford, S; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Golner, A; Gupta, A; Jean-Phillippe, P; Kabugho, E; Kulkarni, V; Masheto, G; Montepiedra, G; Mutambanengwe, M; Raesi, M; Shayo, A; Singh, P; Sterling, TR; Stranix-Chibanda, L; Theron, G; Vhembo, T; Weinberg, A, 2023) |
| "Alcohol use is common among people with HIV and is a risk factor for tuberculosis disease and non-adherence to isoniazid preventive therapy (IPT)." | 5.69 | Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial. ( Adong, J; Beesiga, B; Bryant, K; Chamie, G; Emenyonu, NI; Fatch, R; Gandhi, M; Hahn, JA; Havlir, DV; Kamya, MR; Kekibiina, A; Lodi, S; Marson, K; McDonell, MG; Muyindike, WR; Thirumurthy, H, 2023) |
| "To develop a pharmacokinetic model of isoniazid (INH) concentration taking into account demographic factors and genetic variables [N-acetyltransferase 2 (NAT2) genotype], and to propose an initial INH dosage that could maximize the probability of achieving the desired INH concentration." | 5.62 | Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia. ( Aouam, K; Boughattas, N; Chaabane, A; Chadly, Z; Chickaid, M; Fadhel, NB; Fredj, NB; Romdhane, HB; Woillard, JB, 2021) |
| "Isoniazid was later substituted with rifabutin in 2 patients with isoniazid-resistant tuberculosis." | 5.62 | Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients. ( Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS, 2021) |
| "Isoniazid was administered as 100 mg or 300 mg oral tablets and rifapentine was administered as 150 mg oral tablets." | 5.62 | Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. ( Amanullah, F; Becerra, MC; Fareed, U; Farooq, S; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Khan, H; Malik, AA; Nasir, K; Safdar, N; Shahbaz, S, 2021) |
| " Therefore, we aimed to provide insight into the optimal dosing of INH for each NAT2 acetylator phenotype with respect to the probability of achieving a pharmacokinetic (PK)/pharmacodynamic target." | 5.62 | Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis. ( Cho, YS; Choi, YK; Ghim, JL; Jang, TW; Kim, HJ; Lee, HK; Long, NP; Oh, JY; Park, HK; Park, Y; Phuong, NTT; Shin, JG, 2021) |
| "Tuberculosis is a leading cause of death worldwide." | 5.56 | Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection. ( Almeida, AJ; Alves, AD; Gaspar, MM; Grenha, A; Guerreiro, F; Pinho, J; Simões, S, 2020) |
| " Both sex and CD4 cell count affected the bioavailability of isoniazid." | 5.56 | Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020) |
| "Increased dosing of rifampicin and pyrazinamide seems a viable strategy to shorten treatment and prevent relapse of drug-susceptible tuberculosis (TB), but safety and efficacy remains to be confirmed." | 5.51 | Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP). ( Alffenaar, JC; Augustinsson, D; Bornefall, A; Carlsson, B; Ekqvist, D; Fredrikson, M; Niward, K; Nordvall, MJ; Paues, J; Sandstedt, M; Simonsson, USH; Sönnerbrandt, M, 2022) |
| "We report pregnancy outcomes among South African women with HIV enrolled in a randomized trial of 4 TPT regimens (two 3-month regimens, rifapentine/isoniazid [3HP] or rifampin/isoniazid [3HR], isoniazid for 6 months, or isoniazid continuously)." | 5.51 | Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial. ( Barnes, GL; Chaisson, RE; Gupta, A; Martinson, NA; Moulton, LH; Msandiwa, R; Singh, P, 2022) |
| " Rifapentine clearance is higher among women with HIV, but all women achieved exposures of rifapentine and isoniazid associated with successful tuberculosis prevention." | 5.51 | Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women. ( Bradford, S; Britto, P; Chakhtoura, N; Chalermchockcharoentkit, A; Chipato, T; Dooley, KE; Gupta, A; Jayachandran, P; Kamthunzi, P; Langat, D; Mathad, JS; Montepiedra, G; Norman, J; Patil, S; Popson, S; Rouzier, V; Savic, R; Townley, E; Wiesner, L; Zhang, N, 2022) |
| "In AIDS Clinical Trials Group study A5338, concomitant rifampicin, isoniazid, and efavirenz was associated with more rapid plasma medroxyprogesterone acetate (MPA) clearance compared to historical controls without tuberculosis or HIV therapy." | 5.51 | Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. ( Angira, F; Badal-Faesen, S; Baker, P; Cohn, SE; Denti, P; Francis, J; Haas, DW; Kendall, MA; Mawlana, S; McIlleron, H; Mngqibisa, R; Omoz-Oarhe, A; Robinson, JA; Samaneka, WP, 2022) |
| "The aim of the present work was to produce 3D-printed oral dosage forms with a sufficient drug dose displaying various release profiles." | 5.51 | 3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release. ( Öblom, H; Pimparade, M; Preis, M; Repka, M; Sandler, N; Speer, I; Zhang, J, 2019) |
| "Metformin (MET) is a potential combination drug to elevate anti-TB efficacy." | 5.51 | Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study. ( Ali, M; Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2019) |
| "Anthropometric, genetic, and dosage characteristics of Mexican patients with TB are an important source of risk for subtherapeutic plasma concentrations of anti-TB drugs." | 5.51 | Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis. ( Huerta-García, AP; Magaña-Aquino, M; Medellín-Garibay, SE; Milán-Segovia, RDC; Ortiz-Álvarez, A; Portales-Pérez, DP; Rodríguez-Pinal, CJ; Romano-Moreno, S; Salazar-González, RA, 2019) |
| "Drug resistant tuberculosis is increasing world-wide." | 5.48 | Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. ( Kirschner, DE; Linderman, JJ; Pienaar, E, 2018) |
| " The aim of this study was to evaluate the anti-Mycobacterium tuberculosis activity of nine naphthoimidazoles, alone and combined with isoniazid (INH) and rifampicin (RIF)." | 5.48 | Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin. ( Carvalho, TDSC; Corrêa Barros, LP; da Silva, PEA; de Moura, KCG; Del Rio, KP; Halicki, PCB; Pinto, MDCFR; Ramos, DF, 2018) |
| " Eighty children with TBI received a 12-dose once-weekly isoniazid/rifapentine regimen; 79 (99%) completed therapy, 94% reported no adverse events, 1 child had mildly elevated transaminases but 1 adolescent later developed pulmonary TB." | 5.43 | Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection. ( Cruz, AT; Starke, JR, 2016) |
| "A few cases of drug-induced autoimmune hepatitis or the drug reaction with eosinophilia and systemic symptom (DRESS) syndrome by anti-tuberculosis medications have been reported." | 5.43 | [Concomitant Drug Reaction with Eosinophilia and Systemic Symptom Syndrome from Ethambutol and Autoimmune Hepatitis from Isoniazid]. ( Choi, JH; Heo, NY; Jo, KM; Kim, WG; Nam, KH; Park, CS; Park, SH, 2016) |
| "We identified significant gaps in the treatment for M." | 5.43 | Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California. ( Bolan, R; Chang, AH; Dubé, MP; Ghosh, JK; Kerndt, PR; Shin, SS; Yang, OO, 2016) |
| "Ursolic acid (UA) has immunomodulatory function and exhibits antimycobacterial activity." | 5.42 | Ursolic Acid Activates Intracellular Killing Effect of Macrophages During Mycobacterium tuberculosis Infection. ( Jang, WS; Lee, BE; Nam, KW; Podder, B; Song, HY, 2015) |
| "Tuberculosis is a major global health problem for which improved therapeutics are needed to shorten the course of treatment and combat emergence of drug resistance." | 5.42 | pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice. ( Clemens, DL; Dillon, BJ; Horwitz, MA; Hwang, AA; Lee, BY; Zink, JI, 2015) |
| "tuberculosis have been developed." | 5.42 | Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. ( Awasthi, D; Carreau, A; Goullieux, L; Knudson, SE; Kumar, K; Lagrange, S; Ojima, I; Slayden, RA; Vermet, H, 2015) |
| "Scaling up shorter regimens for tuberculosis (TB) prevention such as once weekly isoniazid-rifapentine (3HP) taken for 3 months is a key priority for achieving targets set forth in the World Health Organization's (WHO) END TB Strategy." | 5.41 | Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial. ( Akello, L; Belknap, R; Berger, CA; Bishop, O; Cattamanchi, A; Dowdy, DW; Handley, MA; Kadota, JL; Kamya, MR; Katahoire, A; Katamba, A; Kiwanuka, N; Musinguzi, A; Nabunje, J; Nahid, P; Nakitende, A; Patel, D; Phillips, PPJ; Sammann, A; Semitala, FC; Welishe, F, 2021) |
| "The aim of this study was to systematically assess the efficacy, safety, and tolerability of isoniazid preventive therapy (IPT) for tuberculosis (TB) in people with HIV (PWH)." | 5.41 | Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV. ( Gudi, SK; Jagi, JL; Thomas, C; Undela, K, 2023) |
| " We included studies in children aged <18 years being treated for drug-susceptible tuberculosis with rifampicin (RIF), pyrazinamide, isoniazid, and ethambutol." | 5.41 | Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis. ( Béranger, A; Gegia, M; Linh, NN; Mirzayev, F; Mohamed, A; Nahid, P; Radtke, K; Savic, RM; Schumacher, SG; Solans, BP, 2023) |
| "3 months of weekly rifapentine plus isoniazid (3HP) and 4 months of daily rifampicin (4R) are recommended for tuberculosis preventive treatment." | 5.41 | Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis. ( Belknap, R; Benedetti, A; Borisov, A; Campbell, JR; Chaisson, RE; Chan, PC; Martinson, N; Menzies, D; Nahid, P; Scott, NA; Sizemore, E; Sterling, TR; Villarino, ME; Wang, JY; Winters, N, 2023) |
| "International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1078, a randomized noninferiority study designed to compare the safety of starting isoniazid preventive therapy (IPT) in women living with human immunodeficiency virus (HIV) either during pregnancy or after delivery, showed that IPT during pregnancy increased the risk of composite adverse pregnancy outcomes, but not individual outcomes." | 5.41 | Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus. ( Aaron, L; Chakhtoura, N; Chipato, T; Gupta, A; Jean-Philippe, P; Lespinasse, D; Loftis, AJ; Masheto, G; McCarthy, K; Montepiedra, G; Nematadzira, T; Ngocho, J; Nyati, M; Onyango-Makumbi, C; Patil, S; Theron, G; Tongprasert, F; Weinberg, A; Zimmer, B, 2021) |
| "Pyrazinamide is a potent sterilising agent that shortens the treatment duration needed to cure tuberculosis." | 5.41 | Optimising pyrazinamide for the treatment of tuberculosis. ( Aarnoutse, R; Bliven-Sizemore, E; Boeree, MJ; Dooley, KE; Heinrich, N; Hoelscher, M; Mac Kenzie, W; Morlock, G; Peloquin, CA; Phillips, PPJ; Posey, J; Savic, RM; Stout, JE; Weiner, M; Whitworth, W; Zhang, N, 2021) |
| "Tuberculosis patients "resistant to isoniazid and susceptible to rifampicin (Hr-TB)" remain neglected, despite a high burden and poor outcomes." | 5.41 | Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018. ( Alaverdyan, S; Gadoev, J; Kumar, A; Nabirova, D; Parpieva, N; Sayfutdinov, Z; Sultanov, S; Turaev, L, 2021) |
| "Isoniazid therapy was started with marked improvement of psoriatic lesions before biologic treatment could be initiated." | 5.40 | Improvement in severe psoriasis associated with isoniazid treatment. ( Brzezinski, P; Chiriac, A; Feldman, SR; Ferariu, D; Solovan, C, 2014) |
| " However, further studies to identify the optimal statin and dosing are required." | 5.40 | Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014) |
| "The granuloma is treated with isoniazid (INH), a drug that inhibits the synthesis of mycolic acids (MA)." | 5.40 | A model of isoniazid treatment of tuberculosis. ( Grobler, A; Lemmer, Y; Moody, C; Viljoen, H, 2014) |
| "Tuberculosis has re-emerged as a worldwide threat, which has motivated the development of new drugs." | 5.40 | [Fe(CN)5(isoniazid)](3-): an iron isoniazid complex with redox behavior implicated in tuberculosis therapy. ( Basso, LA; Butler, JS; de Mesquita Vieira, FG; Diógenes, IC; Lopes, LG; Sadler, PJ; Santiago, DS; Sousa, EH, 2014) |
| " Daily dosing of rifapentine (P), a potent rifamycin with high intracellular accumulation, in place of rifampin (R) in the standard antitubercular regimen significantly shortens the duration of treatment needed to prevent relapse in a murine model of active TB." | 5.38 | Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. ( Dutta, NK; Grosset, JH; Illei, PB; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML, 2012) |
| "Tuberculosis is a growing international health concern." | 5.35 | Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial. ( Abdelaal, A; Badran, E; El Mashad, N; El-Ghaffar, HA; Fathy, A; Zaghloul, MH, 2009) |
| " Safety studies showed that inoculation of RUTI caused a temporary increase of rectal temperature (1-2 degrees C) and local swelling, both adverse effects being well tolerated." | 5.35 | Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats. ( Cáceres, N; Cardona, PJ; Domingo, M; Gil, O; Grassa, M; Guirado, E; Nofrarias, M; Pérez, B; Serrano, E; Vilaplana, C, 2009) |
| "Drug-resistant tuberculosis is a major problem worldwide." | 5.35 | Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco. ( Akrim, M; Chaoui, I; El Mzibri, M; Elouad, R; Jordaan, AM; Kourout, M; Lahlou, O; Sabouni, R; Victor, TC, 2009) |
| "Chemotherapy for Mycobacterium tuberculosis infection may decrease interferon (IFN)-gamma responses to early secretory antigenic target 6 and culture filtrate protein (CFP)-10; a reaction that could be useful to monitor the success of treatment." | 5.35 | Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. ( Harada, N; Higuchi, K; Mori, T, 2008) |
| "Short-course preventive therapy with 12 doses of once-weekly rifapentine (900 mg) plus isoniazid (900 mg) could greatly improve tuberculosis control, especially in areas with high co-endemicity with HIV." | 5.34 | Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial. ( Beattie, T; Chaisson, RE; Churchyard, GJ; Dooley, KE; Edward, VA; Fyvie, MJ; Gupte, A; Likoti, M; Marzinke, MA; Savic, R; Sebe, M; Shibambo, I; Wolf, L; Zhang, N, 2020) |
| " Its use in combination with rifapentine (RPT), an antituberculosis (TB) antibiotic, may reduce the exposure of DOR compromising viral suppression in those living with HIV-1 co-infected with TB." | 5.34 | Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers. ( Kraft, WK; Lam, E; Schaefer, J; Zhan, T; Zheng, R, 2020) |
| " We provide inferential tools for SCQE and its first application, examining whether isoniazid preventive therapy (IPT) reduced tuberculosis (TB) incidence among 26 715 HIV patients in Tanzania." | 5.34 | Inference without randomization or ignorability: A stability-controlled quasi-experiment on the prevention of tuberculosis. ( Hazlett, C; Maokola, W; Wulf, DA, 2020) |
| "Clinical studies suggest that isoniazid contributes rapid bacterial killing during the initial two days of tuberculosis treatment but that isoniazid's activity declines significantly after day three." | 5.34 | Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial. ( Bishai, W; Dawson, R; De Jager, V; Diacon, A; Donahue, K; Fletcher, CV; Hafner, R; Hogg, E; Miyahara, S; Sun, X; Swindells, S; Urbanowski, M, 2020) |
| "Existing data on the effect of treatment of latent tuberculosis infection (LTBI) on T-cell responses to Mycobacterium tuberculosis (MTB)-specific antigens are contradictory." | 5.34 | Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. ( Anzidei, G; Bizzoni, F; Butera, O; Casetti, R; Dainotto, D; Girardi, E; Goletti, D; Ippolito, G; Nisii, C; Parracino, MP; Poccia, F, 2007) |
| "Tuberculosis is a common complication and leading cause of death in HIV infection." | 5.34 | The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. ( Cavalcante, SC; Chaisson, RE; Durovni, B; Efron, A; Golub, JE; King, BS; Moore, RD; Moulton, LH; Pacheco, AG; Saraceni, V, 2007) |
| "Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens." | 5.34 | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007) |
| " When INH was concomitantly given as an admixture over food, Tmax was delayed and variability in drug absorption was significantly increased." | 5.33 | Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana). ( Dunker, F; Isaza, R; Maslow, JN; Mikota, SK; Peddie, J; Peddie, LR; Peloquin, CA; Riddle, H; Zhu, M, 2005) |
| "This level of sensitivity and specificity is concordant with that from the determination of M." | 5.33 | Evaluation of the CombiChip Mycobacteria Drug-Resistance detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis. ( Jang, H; Kang, SJ; Kim, C; Kim, SY; Park, YJ; Song, E; Yoo, J, 2006) |
| "Evaluation of sources of pharmacokinetic variation can facilitate optimization of tuberculosis treatment regimens by identification of avoidable sources of variation and of risk factors for low or high drug concentrations in patients." | 5.33 | Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. ( Burger, A; Folb, PI; McIlleron, H; Norman, J; Smith, P; Wash, P, 2006) |
| "Mycobacterium tuberculosis is one of the leading causes of death worldwide, and multidrug-resistant tuberculosis (MDR-TB) is associated with a high case fatality rate." | 5.33 | Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. ( Canducci, F; Cirillo, DM; Migliori, GB; Miotto, P; Penati, V; Piana, F, 2006) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 5.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| " We sought to determine whether isoniazid prophylaxis administered during liver transplant candidacy was safe and effective for the prevention of posttransplantation tuberculosis." | 5.31 | Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. ( Gayowski, T; Singh, N; Wagener, MM, 2002) |
| "Drug delivery strategies to achieve a sustained drug release and increased bioavailability involve the use of biodegradable polymeric drug carriers." | 5.31 | Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. ( Dutt, M; Khuller, GK, 2001) |
| "In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 28 weeks, initiated either during pregnancy (immediate group) or at week 12 after delivery (deferred group)." | 5.30 | Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women. ( Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Chakhtoura, N; Chipato, T; Costello, D; Gupta, A; Hesseling, A; Jean-Philippe, P; Masheto, GR; Mave, V; McCarthy, K; Mmbaga, BT; Montepiedra, G; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Vhembo, T; Violari, A; Weinberg, A; Zimmer, B, 2019) |
| "We evaluated WOT in persons with active Mycobacterium tuberculosis complex disease using IS-enabled combination isoniazid 150 mg/rifampin 300 mg (IS-Rifamate)." | 5.30 | Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial. ( Benson, CA; Blaschke, T; Browne, SH; Gonzalez Garcia, J; Low, J; Moser, K; Peloquin, CA; Tucker, AJ; Umlauf, A; Vaida, F, 2019) |
| "We conducted a randomized, open-label, phase 3 noninferiority trial comparing the efficacy and safety of a 1-month regimen of daily rifapentine plus isoniazid (1-month group) with 9 months of isoniazid alone (9-month group) in HIV-infected patients who were living in areas of high tuberculosis prevalence or who had evidence of latent tuberculosis infection." | 5.30 | One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. ( Andersen, J; Banda, P; Benson, CA; Chaisson, RE; da Silva Escada, RO; Fletcher, CV; Gupta, A; Hakim, J; Jean Juste, MA; Kanyama, C; Lama, JR; Langat, D; Leon-Cruz, J; Masheto, G; Mawlana, S; Mohapi, L; Moran, L; Mwelase, N; Nuermberger, E; Omoz-Oarhe, A; Ramchandani, R; Severe, P; Supparatpinyo, K; Swindells, S; Valencia, J, 2019) |
| " The chemotherapeutic data essentially confirmed the bioavailability data." | 5.29 | Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. ( Gangadharam, PR; Kailasam, S; Srinivasan, S; Wise, DL, 1994) |
| "6% of these had blood levels in the toxic range." | 5.29 | Phenytoin toxicity due to concomitant antituberculosis therapy. ( Aboo, A; Walubo, A, 1995) |
| "Hepatotoxicity associated with isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) has not been well studied in severely immunosuppressed people with HIV." | 5.27 | Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. ( Bisson, GP; Gupta, A; Hosseinipour, MC; Hughes, MD; Kidonge, KK; Kumwenda, J; Lavenberg, JA; Miyahara, S; Ngongondo, M; Nyirenda, M; Sun, X; Torres, TS, 2018) |
| "To reduce the risk of tuberculosis (TB) among individuals with human immunodeficiency virus (HIV) infection, the World Health Organization recommends at least 6 months of isoniazid preventive therapy (IPT)." | 5.27 | Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi. ( Barnes, GL; Chaisson, RE; Corbett, EL; Dowdy, DW; Khundi, M; Little, KM; Makombe, S; Ngwira, LG; Nkhoma, A, 2018) |
| "Using data from the Tuberculosis Trials Consortium Study 22 (development cohort), we assessed relapse and cure isolates to determine the MIC values of isoniazid and rifampin that were below the standard resistance breakpoint (0." | 5.27 | Bacterial Factors That Predict Relapse after Tuberculosis Therapy. ( Alland, D; Boom, WH; Chakravorty, S; Chippada Venkata, UD; Colangeli, R; Connell, R; Diem, L; Dietze, R; Gupta, A; Jedrey, H; Johnson, JL; Kim, S; Ma, S; Mac Kenzie, WR; Okwera, A; Sherman, DR; Sizemore, EE, 2018) |
| "The present study is designed to conduct, the analysis on the curative effect of Lamivudine in treating liver function lesion caused by hepatitis B combined anti-TB drugs." | 5.27 | Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with Anti-TB drugs. ( Han, Y; Xia, S; Zhou, J, 2018) |
| "Isoniazid was added to the drinking water quarantined and given streptomycin and isoniazid by intramuscular injection." | 5.27 | Use of streptomycin and isoniazid during a tuberculosis epizootic in a rhesus and cynomolgus breeding colony. ( Elwell, MR; Pomsdhit, J; Tingpalapong, M; Ward, GS, 1985) |
| "The aim of the study was to compare plasma concentrations of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between tuberculosis (TB) patients with and without diabetes mellitus (DM)." | 5.24 | Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus. ( Chandrasekaran, V; Kannan, T; Kumar, AK; Lavanya, J; Murali, AL; Ramachandran, G; Sudha, V; Swaminathan, S, 2017) |
| "We did a multicountry open-label randomised clinical trial comparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients initiating antiretroviral therapy with CD4 cell counts of less than 50 cells per μL." | 5.22 | Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial. ( Alave, J; Badal-Faesen, S; Bao, J; Bisson, GP; Gupta, A; Hakim, J; Henostroza, G; Hogg, E; Hosseinipour, MC; Jones, L; Kirui, FK; Kumarasamy, N; Kumwenda, J; Lagat, D; Lama, JR; Leger, PD; Mave, V; Miyahara, S; Mohapi, L; Moses, A; Mugyenyi, P; Naidoo, K; Nyirenda, M; Pillay, S; Riviere, C; Sun, X; Veloso, VG; Zolopa, A, 2016) |
| "We developed a Markov model of anti-tuberculosis treatment to compare two regimens for treating TB: a 6-month standard (rifampin-based) treatment and a 4-month regimen using high-dose RPT." | 5.22 | Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis. ( Hamilton, CD; Holland, DP; Stout, JE, 2016) |
| "The objective of this report was to study the pharmacokinetics of rifampin (RMP), isoniazid (INH), and pyrazinamide (PZA) in HIV-infected children with tuberculosis (TB) treated with a thrice-weekly anti-TB regimen in the government program in India." | 5.20 | Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India. ( Banurekha, VV; Bhavani, PK; Dayal, R; Gangadevi, NP; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sekar, L; Swaminathan, S, 2015) |
| "RIN(®)-150 is a fixed-dose combination (FDC) tablet containing rifampicin (RMP, 150 mg) and isoniazid (INH, 75 mg) developed for the treatment of tuberculosis." | 5.20 | Bioequivalence of fixed-dose combination RIN®-150 to each reference drug in loose combination. ( Crownover, P; Damle, B; O'Gorman, M; Wang, HF; Wang, R, 2015) |
| "Thirty-six months of isoniazid preventive therapy (36IPT) was superior to 6 months of IPT (6IPT) in preventing tuberculosis (TB) among HIV-infected adults in Botswana." | 5.20 | Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis. ( Agizew, TB; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Rose, CE; Samandari, T; Shang, N; Shepherd, J; Sibanda, T; Tedla, Z, 2015) |
| "A recent major cluster randomized trial of screening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-2011 among South African gold miners showed reduced individual-level tuberculosis incidence but no detectable population-level impact." | 5.20 | Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy. ( Churchyard, GJ; Corbett, EL; Cox, AP; Fielding, KL; Grant, AD; Hayes, RJ; Lewis, JJ; Sumner, T; Vynnycky, E; White, RG, 2015) |
| "In Botswana, a 36-month course of isoniazid treatment of latent tuberculosis (TB) infection [isoniazid preventive therapy (IPT)] was superior to 6-month IPT in reducing TB and death in persons living with HIV (PLHIV), having positive tuberculin skin tests (TSTs) but not in those with negative TST." | 5.20 | Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana. ( Abimbola, T; Marston, B; Samandari, T; Sangrujee, N; Smith, T, 2015) |
| "We investigated the population pharmacokinetics and pharmacogenetics of efavirenz in 307 patients coinfected with human immunodeficiency virus and tuberculosis and included in the Cambodian Early vs Late Initiation of Antiretrovirals trial (CAMELIA) in Cambodia." | 5.19 | Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia. ( Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C, 2014) |
| "Mass screening and treatment for latent tuberculosis had no significant effect on tuberculosis control in South African gold mines, despite the successful use of isoniazid in preventing tuberculosis during treatment." | 5.19 | A trial of mass isoniazid preventive therapy for tuberculosis control. ( Chaisson, RE; Churchyard, GJ; Coetzee, L; Corbett, EL; Fielding, KL; Godfrey-Faussett, P; Grant, AD; Hayes, RJ; Lewis, JJ, 2014) |
| "This is a substudy of the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS) Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146-CARINEMO) trial, which assessed the pharmacokinetics of rifampin or isoniazid with or without the coadministration of nonnucleoside reverse transcriptase inhibitor-based HIV antiretroviral therapy in HIV-tuberculosis-coinfected patients in Mozambique." | 5.19 | Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment. ( Amin, A; Barau, C; Barrail-Tran, A; Baudin, E; Bhatt, NB; Bonnet, M; Furlan, V; Grinsztejn, B; Meggi, B; Silva, C; Taburet, AM, 2014) |
| "To evaluate the efficacy and safety of a 6-month intermittent regimen of rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB) in human immunodeficiency virus (HIV) negative patients with culture-confirmed pulmonary or extra-pulmonary tuberculosis and either isoniazid (INH) resistance or INH intolerance." | 5.19 | Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance. ( Bock, N; Bozeman, L; Goldberg, SV; Hamilton, CD; Heilig, CM; Hershfield, E; Kyle, RP; Narita, M; Reves, R; Tapy, JM; Wing, D, 2014) |
| "To assess the performance of QuantiFERON-TB Gold In-Tube (QFT-GIT) test for active tuberculosis (TB) in HIV adults, and its variation over time in patients on antiretroviral therapy (ART) and/or isoniazide preventive therapy (IPT)." | 5.19 | Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa. ( Anglaret, X; Badje, A; Danel, C; Deschamps, N; Eholie, S; Gabillard, D; Herrmann, JL; Inwoley, A; Kabran, M; Lecarrou, J; Moh, R; Ntakpe, JB; Ouattara, E; Perronne, C, 2014) |
| "Sixteen patients with TB-HIV co-infection received rifabutin 300 mg QD in combination with tuberculosis chemotherapy (initially pyrazinamide, isoniazid and ethambutol then only isoniazid), and were then randomized to receive isoniazid and LPV/r based ART with rifabutin 150 mg tiw or rifabutin 150 mg daily." | 5.19 | Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy. ( Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L, 2014) |
| "While 6- to 12-month courses of isoniazid for tuberculosis prevention are considered safe in pregnant women, the effects of longer-term isoniazid prophylaxis or isoniazid in combination with antiretroviral therapy (ART) are not established in human-immunodeficiency-virus-(HIV-) infected women who experience pregnancy during the course of therapy." | 5.17 | Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy. ( Mathebula, U; Mathoma, A; Moathlodi, R; Mosimaneotsile, B; Samandari, T; Taylor, AW; Theebetsile, I, 2013) |
| " Clinic staff were trained in tuberculosis screening, use of tuberculin skin tests, and use of isoniazid preventive therapy." | 5.17 | Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Efron, A; Golub, JE; King, BS; Moulton, LH; Pacheco, AG; Saraceni, V, 2013) |
| "This study is a pharmacogenetic clinical trial designed to clarify whether the N-acetyltransferase 2 gene (NAT2) genotype-guided dosing of isoniazid improves the tolerability and efficacy of the 6-month four-drug standard regimen for newly diagnosed pulmonary tuberculosis." | 5.17 | NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. ( Azuma, J; Fujio, Y; Kamimura, S; Kawase, I; Kubota, R; Nagai, T; Ohno, M; Okuda, Y; Takashima, T; Tsuyuguchi, K; Yokota, S, 2013) |
| "The roles of the NAT2 genotype and enzyme maturation on isoniazid pharmacokinetics were investigated in South African infants with perinatal HIV exposure enrolled in a randomized, double-blind, controlled trial of isoniazid for prevention of tuberculosis disease and latent infection." | 5.16 | The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. ( D'Argenio, DZ; Fletcher, CV; Kiser, JJ; Mitchell, CD; Seifart, HI; Werely, CJ; Zhu, R, 2012) |
| "In accordance with WHO guidelines, people with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin skin test, but duration of prophylaxis is restricted to 6 months." | 5.15 | 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. ( Agizew, TB; Bozeman, L; Castro, KG; Davis, MK; Kilmarx, PH; Moeti, TL; Moffat, HJ; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Shang, N; Sibanda, T; Talbot, EA; Tedla, Z; Wells, CD, 2011) |
| "To compare the risk to household contacts of isoniazid (INH) susceptible and INH-resistant cases of tuberculosis (TB) in a rural community in South India." | 5.15 | Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases. ( , 2011) |
| "Primary isoniazid prophylaxis did not improve tuberculosis-disease-free survival among HIV-infected children or tuberculosis-infection-free survival among HIV-uninfected children immunized with BCG vaccine." | 5.15 | Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. ( Bobat, R; Cotton, MF; Jean-Philippe, P; Kim, S; Madhi, SA; McSherry, G; Mitchell, C; Nachman, S; Violari, A, 2011) |
| " The aim of the study was to document the pharmacokinetics of the first-line anti-TB agents in children <2 years of age comparing previous and revised WHO dosages of isoniazid (INH; 5 versus 10 mg/kg/day), rifampin (RMP; 10 versus 15 mg/kg/day), and pyrazinamide (PZA; 25 versus 35 mg/kg/day) and to investigate the effects of clinical covariates, including HIV coinfection, nutritional status, age, gender, and type of tuberculosis (TB), and the effect of NAT2 acetylator status." | 5.15 | Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. ( Donald, PR; Hesseling, AC; Magdorf, K; Roll, S; Rosenkranz, B; Schaaf, HS; Seddon, JA; Seifart, HI; Thee, S; Werely, CJ, 2011) |
| "We conducted an open-label, randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine (900 mg) plus isoniazid (900 mg) (combination-therapy group) with 9 months of self-administered daily isoniazid (300 mg) (isoniazid-only group) in subjects at high risk for tuberculosis." | 5.15 | Three months of rifapentine and isoniazid for latent tuberculosis infection. ( Bliven-Sizemore, E; Borisov, AS; Bozeman, L; Chaisson, RE; Conde, MB; Gordin, F; Hackman, J; Hamilton, CD; Horsburgh, CR; Kerrigan, A; Menzies, D; Shang, N; Sterling, TR; Villarino, ME; Weiner, M; Weis, SE; Wing, D, 2011) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for preventing tuberculosis in HIV-infected adults, although few countries have instituted this policy." | 5.14 | Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. ( Chaisson, RE; Golub, JE; Gray, GE; Martinson, NA; McIntyre, JA; Mohapi, L; Moshabela, M; Pronyk, P; Struthers, H; Thsabangu, N, 2009) |
| "The clinical and epidemiological characteristics, adverse events, treatment adherence and effectiveness of isoniazid chemoprophylaxis were analyzed in a cohort of 138 tuberculosis/HIV-coinfected patients." | 5.14 | Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. ( Hökerberg, YH; Pacheco, SJ; Passos, SR; Rolla, VC; Souza, CT, 2009) |
| "The use of isoniazid (INH) as chemoprophylaxis for tuberculosis (TB) in renal transplant recipients has not been widely studied or reported from a country where TB is endemic." | 5.14 | Use of isoniazid chemoprophylaxis in renal transplant recipients. ( Ahmed, E; Akhtar, F; Akhtar, S; Naqvi, A; Naqvi, R; Noor, H; Rizvi, A; Saeed, T, 2010) |
| "To describe reasons for exclusion from isoniazid tuberculosis preventive therapy (IPT) and outcomes of persons living with HIV (PLWH) during 6 months of IPT." | 5.14 | Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006. ( Agizew, TB; Chengeta, B; Kilmarx, PH; Mathoma, A; Mosimaneotsile, B; Motsamai, OI; Nyirenda, S; Samandari, T; Tedla, Z; Wells, CD, 2010) |
| "To compare the efficacy of an intermittent 6-month regimen (Reg6M: 2EHRZ(3)/4HR(3) [ethambutol, 1,200 mg; isoniazid, 600 mg; rifampicin, 450 or 600 mg depending on body weight <60 or > or =60 kg; and pyrazinamide, 1,500 mg for 2 mo; followed by 4 mo of isoniazid and rifampicin at the same doses]) versus a 9-month regimen (Reg9M: 2EHRZ(3)/7HR(3)) in HIV/tuberculosis (TB)." | 5.14 | Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial. ( Chinnaiyan, P; Iliayas, S; Menon, PA; Narayanan, PR; Narendran, G; Padmapriyadarsini, C; Ramachandran, R; Sakthivel, R; Santhanakrishnan, R; Suhadev, M; Swaminathan, S; Venkatesan, P, 2010) |
| " According to the findings of the present study, all 3 of the potentially hepatotoxic drugs (isoniazid, rifampicin, and pyrazinamide) can be reintroduced simultaneously at full dosage safely from day 1, especially for patients with bilateral extensive pulmonary tuberculosis, to halt disease transmission or to treat patients with life-threatening tuberculosis." | 5.14 | Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. ( Jayaswal, A; Makharia, G; Mohan, A; Sarda, P; Sharma, SK; Singh, S; Singla, R; Sreenivas, V, 2010) |
| "Consenting employees were screened prior to IPT for active tuberculosis and increased risk of isoniazid toxicity using a questionnaire and chest radiograph." | 5.14 | Adverse events with isoniazid preventive therapy: experience from a large trial. ( Churchyard, GJ; Fielding, KL; Grant, AD; Luttig, MM; Mngadi, KT; van Halsema, CL, 2010) |
| "Treatment of latent tuberculosis infection with isoniazid for 9 months is complicated by poor patient adherence and the need for close follow-up of side effects, especially hepatotoxicity." | 5.13 | Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. ( Al Jahdali, H; Benedetti, A; Dion, MJ; Gardam, M; Hoeppner, V; Khan, K; Long, R; Memish, Z; Menzies, D; Schwartzman, K; Trajman, A; Yang, J, 2008) |
| "Isoniazid preventive therapy prevents active tuberculosis in people with HIV, but previous studies have found no evidence of benefit in people with HIV who had a negative tuberculin skin test, and a non-significant effect on mortality." | 5.12 | Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data. ( Anglaret, X; Badje, A; Barnabas, RV; Boulle, A; Eholie, S; Ford, N; Gabillard, D; Golub, JE; Maartens, G; Rangaka, MX; Ross, JM; Shapiro, AE; Thomas, KK; Walker, AS; Wilkinson, RJ; Williams, BG, 2021) |
| "The efficacy of isoniazid (INH) prophylaxis in renal allograft recipients who are on long-term immunosuppression in a region highly prevalent for tuberculosis (TB) was studied." | 5.12 | Efficacy of isoniazid prophylaxis in renal allograft recipients. ( Ahmed, E; Akhtar, F; Akhtar, S; Bhatti, S; Naqvi, A; Naqvi, R; Noor, H; Rizvi, A; Saeed, T; Sheikh, R, 2006) |
| "In this study, we investigated the safety and toxicity of isoniazid (INH) intervention therapy to the patients with latent tuberculosis who were given tumor necrosis factor alpha (TNFalpha) for the treatment of their rheumatologic diseases." | 5.12 | Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha. ( Hanta, I; Kocabas, A; Kuleci, S; Ozbek, S; Sert, M, 2007) |
| "In the treatment of latent tuberculosis infection, a 3-month course of isoniazid plus rifampin resulted in better adherence and a lower percentage of discontinued treatments than a 6-month isoniazid course." | 5.12 | [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. ( Dimas, JF; García, AJ; García, M; Geijo, MP; Herranz, CR; Vaño, D, 2007) |
| "To characterize the bidirectional interaction between twice-daily nelfinavir and twice-weekly rifabutin and isoniazid in patients with tuberculosis and human immunodeficiency virus (HIV) infection." | 5.12 | Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection. ( Becker, MI; Benator, DA; Burman, WJ; Engle, M; Hsyu, PH; Jones, BE; Khan, AE; Peloquin, CA; Sandman, L; Silva-Trigo, C; Vernon, AA; Weiner, MH; Zhao, ZA, 2007) |
| "A 9-month course of isoniazid monotherapy is currently recommended for the treatment of latent tuberculosis infection (LTBI) and has been shown to be effective in both children and adults." | 5.12 | The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. ( Gelesme, A; Gourgiotis, D; Metsou, F; Spyridis, NP; Spyridis, PG; Sypsa, V; Tsolia, MN; Valianatou, M, 2007) |
| "Two months of treatment with rifampin-pyrazinamide (RZ) and 9 months of treatment with isoniazid are both recommended for treatment of latent tuberculosis infection in adults without human immunodeficiency virus infection, but the relative cost-effectiveness of these 2 treatments is unknown." | 5.11 | Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial. ( Bernardo, J; Daley, CL; Hopewell, PC; Jasmer, RM; Kawamura, LM; King, MD; Saukkonen, JJ; Snyder, DC, 2004) |
| "There is little published information regarding treatment completion, safety, and efficacy of rifampin administered daily for 4 months-a recommended alternative to 9 months of isoniazid for therapy of latent tuberculosis infection." | 5.11 | Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. ( Brassard, P; Dion, MJ; Mannix, S; Menzies, D; Rabinovitch, B; Schwartzman, K, 2004) |
| "We evaluated the effects of human immunodeficiency virus (HIV) disease on pharmacokinetics of antituberculosis medications by measuring concentrations of isoniazid and rifampin in blood and of pyrazinamide and ethambutol in urine." | 5.11 | Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease. ( Bhagavathy, S; Gurumurthy, P; Hemanth Kumar, AK; Mahilmaran, A; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Ravichandran, N; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "Although isoniazid (INH) preventive therapy (IPT) can reduce the risk of active TB among HIV-infected individuals, preventive therapy is rarely used in developing countries." | 5.11 | INH preventive therapy among adult HIV-infected patients in Thailand. ( Hiransuthikul, N; Hiransuthikul, P; Nelson, KE; Paewplot, R; Vorayingyong, A, 2005) |
| "Lower plasma concentrations of rifabutin and, perhaps, isoniazid were associated with ARR failure or relapse in patients with tuberculosis and HIV infection treated with twice-weekly therapy." | 5.11 | Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. ( Benator, D; Burman, W; Hodge, T; Jones, B; Khan, A; Peloquin, CA; Silva-Trigo, C; Vernon, A; Weiner, M; Zhao, Z, 2005) |
| "To determine the effect on tuberculosis incidence of a clinic providing isoniazid preventive therapy to HIV-infected adults under routine conditions." | 5.11 | Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. ( Chaisson, RE; Charalambous, S; Churchyard, GJ; Corbett, EL; Day, JH; De Cock, KM; Fielding, KL; Grant, AD; Hayes, RJ, 2005) |
| "To evaluate the role of isoniazid prophylaxis in prevention of tuberculosis among allogeneic stem cell transplant recipients." | 5.11 | Role of isoniazid prophylaxis for prevention of tuberculosis in haemopoietic stem cell transplant recipients. ( Ahmed, P; Altaf, C; Anwar, M; Hussain, I; Khan, B; Raza, S; Ullah, K, 2005) |
| "We sought to determine the efficacy of coaching Latino adolescents with latent tuberculosis infection to adhere to isoniazid treatment." | 5.10 | Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial. ( Blumberg, EJ; Friedman, L; Hofstetter, CR; Hovell, MF; Kelley, NJ; Moser, K; Sipan, CL; Slymen, D; Vera, AY, 2003) |
| "A higher incidence of hepatotoxicity was associated with rifampin plus pyrazinamide than isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong." | 5.10 | Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. ( Chan, CK; Chang, KC; Law, WS; Leung, CC; Tam, CM; Wong, MY; Yew, WW, 2003) |
| "Once-weekly rifapentine 600 mg plus isoniazid (INH) during the continuation phase treatment of tuberculosis is associated with a relapse rate higher than that of twice-weekly rifampin plus INH." | 5.10 | A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. ( Bock, NN; Conwell, DS; Hamilton, CD; Mosher, A; Pachucki, C; Samuels, M; Sterling, TR; Vernon, A; Wang, YC, 2002) |
| "To evaluate the efficacy of isoniazid for the prevention of tuberculosis in tuberculin skin test-positive and negative individuals with HIV infection." | 5.09 | Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. ( Battegay, M; Bucher, HC; Griffith, LE; Guyatt, GH; Naef, M; Sendi, P; Sudre, P, 1999) |
| "The tolerability of and adherence to intermittent short-term rifabutin-isoniazid preventive treatment was assessed in subjects dually infected with Mycobacterium tuberculosis and the human immunodeficiency virus (HIV)." | 5.09 | Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study. ( Bonazzi, L; Cadeo, G; Caligaris, S; Carosi, G; Matteelli, A; Olliaro, P; Scalzini, A; Signorini, L; Tebaldi, A; Tomasoni, L, 1999) |
| "To compare a 2-month regimen of daily rifampin and pyrazinamide with a 12-month regimen of daily isoniazid in preventing tuberculosis in persons with human immunodeficiency virus (HIV) infection." | 5.09 | Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O ( Barry, MA; Chaisson, RE; Coberly, J; de Lourdes Garcia, M; Gordin, F; Hafner, R; Klukowicz, AJ; Matts, JP; Miller, C; O'Brien, RJ; Schechter, M; Valdespino, JL, 2000) |
| "To assess the compliance, tolerance and efficacy of a short chemoprophylaxis regimen (IR) for tuberculosis using isoniazid (INH) plus rifampin (RIF) during 3 months versus a standard regimen (I) of isoniazid during 12 months in HIV positive patients." | 5.09 | [Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group]. ( Blanch, JJ; Cuadra, F; Espinosa, A; Geijo, P; Largo, J; Maciá, MA; Martínez Alfaro, EM; Mateos, F; Rodríguez Zapata, M; Rosa, C; Sánchez Martínez, PA; Sánchez, L; Sepúlveda, MA; Solera, J, 2000) |
| "Patients older than 18 years who were diagnosed with a first episode of tuberculosis at the national HIV testing centre in Haiti, and who successfully completed a 6-month rifampicin-containing regimen for active pulmonary tuberculosis, were randomly assigned 1 year of post-treatment isoniazid prophylaxis or placebo." | 5.09 | Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial. ( Desvarieux, M; Fitzgerald, DW; Johnson, WD; Joseph, P; Pape, JW; Severe, P, 2000) |
| "We prospectively evaluated the effectiveness of desensitization therapy for cases showing side-effects to antituberculous drugs (Isoniazid and Rifampicin) according to the guideline proposed by the Treatment Committee of the Japanese Society for Tuberculosis." | 5.09 | [Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis]. ( Abe, T; Kawahara, S; Kobashi, Y; Kuraoka, T; Matsushima, T; Nishimura, K; Okimoto, N; Shigeto, E; Shishido, S; Takeyama, H, 2000) |
| "Transplant recipients are predisposed to develop opportunistic infections such as tuberculosis, and isoniazid (INH) is used in most antitubercular therapeutic and prophylactic protocols." | 5.09 | Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients. ( Garg, SK; Gupta, KL; Jha, V; Kohli, HS; Muthukumar, T; Sakhuja, V; Singh, B; Sud, K, 2000) |
| "Mycobacterium tuberculosis antigen 85 is induced in vitro by isoniazid (INH); its sustained induction in sputum during tuberculosis (TB) therapy predicts relapse." | 5.09 | Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials. ( Dietze, R; Eisenach, K; Ellner, JJ; Johnson, JL; Maciel, E; Palaci, M; Phillips, M; Rocha, LM; Rose, L; Teixeira, L; Wallis, RS; Wells, C, 2001) |
| "We conducted a randomized trial with a factorial design comparing strategies for improving adherence to isoniazid preventive therapy in 300 injection drug users with reactive tuberculin tests and no evidence of active tuberculosis." | 5.09 | A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users. ( Barnes, GL; Cavalcante, S; Chaisson, RE; Hackman, J; Kimbrough , L; Metha, S; Moore, RD; Watkinson, L, 2001) |
| "A prospective comparative study was conducted to determine the effect of isoniazid prophylaxis on the incidence of active tuberculosis among Thai HIV-infected patients for 1 year." | 5.08 | Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals. ( Saenghirunvattana, S, 1996) |
| "The aims of this study were to (1) identify trends and risk factors for mycobacterial disease and (2) determine the effect of expanded access to isoniazid chemoprophylaxis on tuberculosis incidence." | 5.08 | Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease. ( Astemborski, J; Bonds, M; Galai, N; Graham, NM; Nelson, KE; Rizzo, RT; Sheeley, L; Vlahov, D, 1996) |
| "To determine the efficacy of isoniazid 300 mg daily for 6 months in the prevention of tuberculosis in HIV-1-infected adults and to determine whether tuberculosis preventive therapy prolongs survival in HIV-1-infected adults." | 5.08 | Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. ( Bwayo, JJ; Chakaya, JM; Elliott, LC; Gilks, CF; Githui, WA; Hawken, MP; Juma, ES; Kimari, JN; McAdam, KP; Meme, HK; Morris, JS; Ngugi, EN; Nunn, PP; Odhiambo, JA; Plummer, FA; Porter, JD; Thiong'o, LN, 1997) |
| "To test the hypothesis that antituberculous drug disposition is altered in patients with AIDS, we studied the steady-state pharmacokinetics of isoniazid (300 mg/d), rifampin (600 mg/d), and pyrazinamide (1,500 mg/d) in 29 adults (14 patients infected with human immunodeficiency virus [HIV] and 15 non-HIV-infected patients) with tuberculosis in Nairobi, Kenya." | 5.08 | Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea. ( Aoki, FY; Choudhri, SH; Gathua, S; Hawken, M; Long, R; Minyiri, GO; Sahai, J; Sitar, DS; Watkins, W, 1997) |
| "To characterize the susceptibility to levofloxacin of clinical isolates of Mycobacterium tuberculosis (MTB) obtained from patients with HIV-related tuberculosis and to characterize the molecular genetics of levofloxacin resistance." | 5.08 | Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica ( Chirgwin, K; El Sadr, WM; Hafner, R; Heifets, LB; Klein, O; Kreiswirth, BN; Matts, JP; Musser, JM; Nelson, ET; Perlman, DC; Salomon, N; Telzak, EE, 1997) |
| "Screening for active tuberculosis (TB) and providing isoniazid (INH) preventive therapy in jails are important control measures." | 5.08 | A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail. ( Goldenson, J; Hoynes, TM; McIntosh, HW; Reilly, P; Tulsky, JP; White, MC, 1998) |
| "Compliance with tuberculosis preventive therapy in a randomized placebo-controlled trial in 2736 HIV-infected Ugandans was measured using urinary isoniazid metabolite testing, clinic attendance, and self-report." | 5.08 | Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration. ( Ellner, J; Johnson, J; Mayanja, H; Mugerwa, R; Nsubuga, P; Okwera, A; Pekovic, V; Vjecha, M; Whalen, C, 1998) |
| "To evaluate compliance, side effects and the efficacy of a short course of chemoprophylaxis for tuberculosis with isoniazid plus rifampin during 3 months, compared with the classic course of isoniazid for 9 months." | 5.08 | [Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis]. ( Castillejos, ML; Cuenca, D; Espinosa, A; Martínez Alfaro, E; Sáez, L; Serna, E; Solera, J, 1998) |
| " Adults in the Cape Town municipal area with a first episode of pulmonary tuberculosis were treated either with Rifater or a regimen consisting of isoniazid, rifampicin, pyrazinamide and ethambutol." | 5.07 | Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. ( Bohmer, PD; Macnab, MF; Seager, JR, 1994) |
| "Short-course chemotherapy of six-month duration with an initial combination of three drugs (isoniazid [H], rifampin [R] and pyrazinamide [Z]) is recommended as the treatment of choice in tuberculosis today." | 5.07 | [Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide]. ( Brändli, O; Dreher, D; Morger, D, 1993) |
| "Chemoprophylaxis against tuberculosis with isoniazid for 1 year is very useful, but patient compliance is very low." | 5.07 | Evaluation of the efficacy of health education on the compliance with antituberculosis chemoprophylaxis in school children. A randomized clinical trial. ( Alcaide Megias, J; Altet Gomez, MN; Canela Soler, J; Navas Alcala, E; Salleras Sanmarti, L; Serra Majem, L; Suñe Puigbo, MR, 1993) |
| "This article reports the findings from a clinical study that examined the impact of health education and counseling on the decision of a patient infected with tuberculosis (TB) to complete a regimen of isoniazid (INH) chemoprophylaxis for 6 months to prevent TB." | 5.07 | Tuberculosis prevention project. ( Barnwell, MD; Chitkara, R; Lamberta, F, 1992) |
| "In a study in Singapore, patients of Chinese, Malay, or Indian ethnic origin with sputum-smear-positive pulmonary tuberculosis received 2 months of daily treatment with streptomycin, isoniazid, rifampin, and pyrazinamide followed by daily isoniazid and rifampin, either with or without pyrazinamide, allocated at random." | 5.06 | Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council. ( , 1986) |
| " Isoniazid preventive therapy (IPT) has been used globally for this purpose for many years, including in pregnancy." | 5.05 | The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis. ( Falzon, D; Figueroa, C; Hamada, Y; Kanchar, A; Martín-Sánchez, M, 2020) |
| "In patients with newly diagnosed tuberculosis, diabetes is associated with isoniazid resistance." | 5.05 | The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis. ( Huang, D; Liang, Z; Wang, Y, 2020) |
| " Our experience with a multinational trial of isoniazid (INH) preventive therapy for tuberculosis revealed marked variation among the seven participating countries in the amount of tuberculosis screening prior to the trial; this variation contributed to the observed differences in the risk of tuberculosis among the countries." | 5.05 | Variations in national health care practices and behaviours and their influence on international research. ( Farer, LS; Snider, DE; Thompson, NJ, 1985) |
| "The known mode of action of isoniazid (INH) is to inhibit bacterial cell wall synthesis following activation by the bacterial catalase-peroxidase enzyme KatG in Mycobacterium tuberculosis (Mtb)." | 5.01 | Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action. ( Khan, SR; Manialawy, Y; Siraki, AG, 2019) |
| "Isoniazid preventive therapy is one of the key interventions in reducing the risk of active disease among children exposed to tuberculosis." | 5.01 | Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review. ( Grace, SG, 2019) |
| "Isoniazid (INH) was the first synthesized drug that mediated bactericidal killing of the bacterium Mycobacterium tuberculosis, a major clinical breakthrough." | 5.01 | The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis. ( Jacobs, WR; Vilchèze, C, 2019) |
| "Although isoniazid (INH) has been successful in treating Tuberculosis (TB) since its introduction in 1952, there has been continual reports of drug-associated hepatotoxicity in TB patients." | 5.01 | Pharmacokinetics of isoniazid: The good, the bad, and the alternatives. ( Addison, AP; Erwin, ER; John, SF; Olaleye, OA; Rosell, RC, 2019) |
| " Thus, scaling up the isoniazid preventive therapy program and its strict compliance is necessary to avert HIV fueled tuberculosis." | 5.01 | The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis. ( Endalamaw, A; Eshetie, S; Geremew, D; Negash, M; Tessema, B, 2019) |
| "Isoniazid is recommended for prevention of tuberculosis (TB) in HIV-infected adults, but its efficacy in children living with HIV (CLHIV) is not known." | 4.98 | Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis. ( Charan, J; Emmanuel, P; Goyal, JP; Kumar, A; Patel, A; Reljic, T, 2018) |
| "Efavirenz (EFV) and rifampicin-isoniazid (RH) are cornerstone drugs in human immunodeficiency virus (HIV)-tuberculosis (TB) coinfection treatment but with complex drug interactions, efficacy and safety challenges." | 4.98 | Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review. ( Atwine, D; Bonnet, M; Taburet, AM, 2018) |
| "The drug isoniazid (INH) is a key component of global tuberculosis (TB) control programmes." | 4.95 | Isoniazid-resistant tuberculosis: a cause for concern? ( Jenkins, HE; Lipman, MC; McHugh, TD; Stagg, HR, 2017) |
| "Isoniazid (INH) is one of the most potent anti-tuberculosis (TB) agents." | 4.93 | Isoniazid-resistant tuberculosis in Iran: A systematic review. ( Amin, M; Chirani, AS; Halabian, R; Imani Fooladi, AA; Javad Nasiri, M, 2016) |
| "Isoniazid (INH) is one of the most active compounds used to treat tuberculosis (TB) worldwide." | 4.93 | Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. ( Hanna, LE; Selvakumar, N; Subbian, S; Unissa, AN, 2016) |
| "To systematically identify from qualitative data in the published literature the main barriers to adherence to isoniazid preventive therapy (IPT) for tuberculosis (TB) among people living with HIV/AIDS (PLWHA)." | 4.90 | Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data. ( Booth, A; Makanjuola, T; Taddese, HB, 2014) |
| " Upon combining data from all eight studies, isoniazid prophylaxis was found to be efficacious in preventing development of tuberculosis, with a pooled RR of 0." | 4.90 | Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. ( Abuogi, L; Ayieko, J; Bukusi, EA; Reingold, A; Simchowitz, B; Smith, AH, 2014) |
| "Uptake of isoniazid preventive therapy (IPT) to prevent tuberculosis has been poor, particularly in the highest risk populations." | 4.90 | Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews. ( Adams, LV; Blunt, H; Odato, K; Steingart, KR; Talbot, EA, 2014) |
| "After the introduction of isoniazid and rifampicin, the second one discovered in the Lepetit Research Laboratories (Milan, Italy), under the supervision of Professor Piero Sensi, tuberculosis (TB) was considered an illness of the past." | 4.90 | Trends in discovery of new drugs for tuberculosis therapy. ( Pasca, MR; Riccardi, G, 2014) |
| "Because treatment can only be initiated when infection is detected, and is guided by the results of antimicrobial susceptibility testing, there recently has been a marked increase in the development and testing of novel assays designed to detect Mycobacterium tuberculosis complex, with or without simultaneous detection of resistance to isoniazid and/or rifampin." | 4.89 | Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing. ( Wilson, ML, 2013) |
| "Isoniazid (INH) is one of the most commonly used drugs in treatment of human tuberculosis and the most efficient." | 4.89 | Isoniazid: an update on the multiple mechanisms for a singular action. ( Bernadou, J; Bernardes-Génisson, V; Chollet, A; Deraeve, C; Pratviel, G, 2013) |
| "Isoniazid preventive therapy (IPT) prevents tuberculosis (TB) in immunocompetent children <5 years of age after exposure to an infectious TB source case." | 4.89 | Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years). ( Boon, GP; Cotton, MF; Jeena, PM; Schaaf, HS, 2013) |
| "Isoniazid resistance is an obstacle to the treatment of tuberculosis disease and latent tuberculosis infection in children." | 4.89 | Isoniazid-resistant tuberculosis in children: a systematic review. ( Becerra, MC; Cohen, T; Keshavjee, S; Parr, JB; Tolman, AW; Yuen, CM, 2013) |
| " Key recent developments to address HIV-related TB among PWIDs include the use of simplified symptom-based algorithm to provide isoniazid-preventive therapy, molecular DNA detection methods for Mycobacterium tuberculosis and the immediate provision of antiretroviral therapy within the first 2 weeks of initiation of anti-TB treatment." | 4.88 | Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. ( Getahun, H; Gunneberg, C; Raviglione, M; Sculier, D; Verster, A, 2012) |
| "In this systematic review, we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months, adding rifampicin to isoniazid regimens, benefits of different regimens, chemotherapy for <6 months, daily chemotherapy, direct observation treatment, intermittent chemotherapy for 6 months or longer, isoniazid, low-level laser therapy for pulmonary tuberculosis, regimens containing quinolones, rifampicin plus isoniazid, substituting rifampicin with ethambutol in the continuous phase, and support mechanisms for directly observed treatment." | 4.87 | Tuberculosis (HIV-negative people). ( Eisenhut, M; Ziganshina, LE, 2011) |
| "To compare the incidence of severe hepatitis in HIV-infected patients receiving rifampicin plus pyrazinamide (RZ) for antituberculosis prophylaxis with that of patients receiving a conventional isoniazid-based regime for 6 to 12 months (6-12H)." | 4.86 | [Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials]. ( Camacho, A; Castón, JJ; Gallo, M; García-Lázaro, M; Kindelán, JM; Natera, C; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J, 2010) |
| "Isoniazid (INH) is one of the most important drugs for the treatment of tuberculosis (TB)." | 4.86 | Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis. ( Detjen, AA; Magdorf, K; Thee, S; Wahn, U, 2010) |
| "In this systematic review we present information relating to the effectiveness and safety of the following interventions: adding pyrazinamide in chemotherapy regimens lasting up to 6 months; adding rifampicin to isoniazid regimens; benefits of different regimens; chemotherapy for less than 6 months; daily chemotherapy; direct observation treatment; intermittent chemotherapy for 6 months or longer; isoniazid; low-level laser therapy for pulmonary tuberculosis; regimens containing quinolones; rifampicin plus isoniazid; substituting rifampicin with ethambutol in the continuous phase; and support mechanisms for directly observed treatment." | 4.85 | Tuberculosis (HIV-negative people). ( Garner, P; Ziganshina, LE, 2009) |
| "One-third of the world's population is infected with tuberculosis, and 9 months of isoniazid monotherapy is the treatment of choice for latent tuberculosis infection." | 4.85 | 4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. ( Mylonakis, E; Ziakas, PD, 2009) |
| "The cornerstone of tuberculosis management is a 6-month course of isoniazid, rifampicin, pyrazinamide and ethambutol." | 4.84 | Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. ( Aarnoutse, RE; Boeree, MJ; de Lange, WC; Dekhuijzen, R; Tostmann, A; van der Ven, AJ, 2008) |
| " The purpose of this article is to describe the use of the Medication Event Monitoring System (MEMS) in a study of patients receiving isoniazid for latent tuberculosis infection." | 4.84 | Use of electronic monitoring in clinical nursing research. ( Ailinger, RL; Black, PL; Lima-Garcia, N, 2008) |
| "For rifampicin, the majority of the studies that applied NRA to isolates had a sensitivity and specificity >94% and for isoniazid, >92%." | 4.84 | The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. ( Angeby, K; Hoffner, S; Martin, A; Palomino, JC; Panaiotov, S; Portaels, F, 2008) |
| "In the context of tuberculosis (TB) resurgence, isoniazid preventive therapy (IPT) is increasingly promoted, but concerns about the risk for development of isoniazid-resistant tuberculosis may hinder its widespread implementation." | 4.83 | Isoniazid preventive therapy and risk for resistant tuberculosis. ( Balcells, ME; Godfrey-Faussett, P; Grant, AD; Thomas, SL, 2006) |
| " isoniazid (INH) for the prevention of tuberculosis (TB) among persons with or without human immunodeficiency virus (HIV) infection." | 4.83 | Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis. ( Gao, XF; Li, YP; Liu, GJ; Sun, X; Wang, L; Wen, J; Xie, Y, 2006) |
| "Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such reactions during antituberculosis chemotherapy." | 4.83 | Antituberculosis drugs and hepatotoxicity. ( Leung, CC; Yew, WW, 2006) |
| "A major difficulty associated with the use of standard therapy with isoniazid for latent tuberculosis infection is poor patient adherence to therapy because of the prolonged course required." | 4.82 | Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. ( Ena, J; Valls, V, 2005) |
| "The administration of isoniazid (INH) has been proposed, evaluated and implemented to prevent tuberculosis (TB) disease among patients who are infected with the human immunodeficiency virus (HIV)." | 4.82 | Review editorial: prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment. ( Apers, L; Colebunders, R; Lynen, L; Worodria, W, 2005) |
| "The identification of the target of isoniazid in the mycobacterial tuberculosis pathogen opens the way for the developoment of new drugs and diagnostic tests to combat drug-resistant pathogen strains." | 4.79 | Tuberculosis. Beating the bacillus. ( Young, DB, 1994) |
| " Prophylactic pyridoxine supplementation during short-course chemotherapy for tuberculosis is not generally necessary in the daily 'A' regimen, but should be maintained in the twice-weekly (high-dose isoniazid) 'B' regimen for adults and children over 20 kg." | 4.77 | Acetylator phenotype and short-course chemotherapy for tuberculosis in Papua New Guinea. ( Currie, B; Hudson, B; Krause, V; Mondia, P, 1989) |
| "Resistance to isoniazid (INH) and rifampicin (RIF) first-line drugs in Mycobacterium tuberculosis (Mtb), together called multi-drug resistance, threatens tuberculosis control." | 4.31 | Large-scale genomic analysis of Mycobacterium tuberculosis reveals extent of target and compensatory mutations linked to multi-drug resistant tuberculosis. ( Campino, S; Clark, TG; Napier, G; Phelan, JE, 2023) |
| "Scaling up a shorter preventive regimen such as weekly isoniazid and rifapentine (3HP) for 3 months is a priority for tuberculosis (TB) preventive treatment (TPT)." | 4.31 | Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment. ( Amanullah, F; Becerra, MC; Dahri, AA; Farooq, S; Hussain, H; Islam, Z; Jaswal, M; Keshavjee, S; Khan, AJ; Khowaja, S; Madhani, F; Malik, AA; Manzar, S; Noorani, S; Safdar, N; Salahuddin, N; Shah, JA; Shahbaz, SS; Shahzad, M, 2023) |
| "Cisatracurium besylate was identified to be highly protective for the viability of macrophages during Mycobacterium tuberculosis infection via inhibiting necroptosis." | 4.31 | Cisatracurium besylate rescues Mycobacterium Tuberculosis-infected macrophages from necroptosis and enhances the bactericidal effect of isoniazid. ( Chen, L; Chen, Y; Han, Z; Hu, S; Liu, H; Liu, J; Ma, L; Sai, N; Wang, K; Wen, Q; Zhang, J; Zhang, Z; Zhou, C; Zhou, X, 2023) |
| "Isoniazid (INH) preventive therapy is recommended to prevent tuberculosis (TB) disease for persons with HIV (PWH), except for those with regular and heavy alcohol consumption, due to hepatotoxicity concerns." | 4.31 | Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use. ( Adong, J; Cheng, DM; Emenyonu, NI; Fatch, R; Hahn, JA; Jacobson, KR; Linas, BP; Muyindike, WR; Ngabirano, C; Terrault, NA; Tumwegamire, A, 2023) |
| "Cisgender women receiving efavirenz- or dolutegravir-based HIV therapy, or on isoniazid-rifampin for tuberculosis, were followed after a single oral dose of levonorgestrel." | 4.31 | Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis. ( Agyemang, N; Badal-Faesen, S; Baker, P; Barr, E; Belaunzaran-Zamudio, PF; Cohn, SE; Gadama, L; Gatechompol, S; Godfrey, C; Haas, DW; Jalil, EM; Kayama, C; Mawlana, S; Mngqibisa, R; Olefsky, M; Pham, M; Podany, AT; Scarsi, KK; Smeaton, LM; Supparatpinyo, K; Van Schalkwyk, M; Woolley, E, 2023) |
| "Data on protein binding are incomplete for first-line antituberculosis drugs, and lacking for second-line antituberculosis drugs that are used extensively for multi-drug-resistant tuberculosis (levofloxacin, linezolid and moxifloxacin)." | 4.31 | Protein binding investigation of first-line and second-line antituberculosis drugs. ( Aalhoul, F; Cotton, F; Fage, D, 2023) |
| " Of the patients taking isoniazid (INH) for tuberculosis prophylaxis, 47." | 4.31 | Compliance level to Tuberculosis prophylaxis in patients undergoing therapy with tumor necrosis factor-alpha inhibitors: a cross-sectional study. ( Aytac, S; Dogru, S; Ovayolu, O, 2023) |
| "We used nonlinear mixed-effects modeling to characterize the pharmacokinetics of rifampicin, isoniazid, and pyrazinamide, and investigated the association of human immunodeficiency virus (HIV), antiretroviral therapy (ART), drug formulation, age, and body size with their pharmacokinetics." | 4.31 | Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis. ( Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H, 2023) |
| "No population pharmacokinetics (PK) model of isoniazid (INH) has been reported for the Indonesian population with tuberculosis (TB)." | 4.12 | Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis. ( Charisma, AN; Cho, YS; Choi, YK; Hoa, PQ; Hoa, PV; Indrawanto, DW; Jayanti, RP; Kusmiati, T; Long, NP; Mertaniasih, NM; Permatasari, A; Shin, JG; Soedarsono, S; Yuliwulandari, R, 2022) |
| "Isoniazid(INH, H) has been a key drug for treating drug-susceptible tuberculosis (TB) for nearly seventy years." | 4.12 | [Association between isoniazid induced hepatotoxicity and host N-acetyltransferase 2 polymorphisms]. ( Guo, JQ; Tang, S; Yan, XF; Yang, S, 2022) |
| " Here, two murine models of tuberculosis were used to test whether novel regimens replacing rifapentine and isoniazid with bedaquiline and another drug would maintain or increase the sterilizing activity of the regimen." | 4.12 | Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models. ( Carr, W; Converse, PJ; Dartois, V; Dooley, KE; Garcia, A; Kurbatova, E; Nuermberger, EL; Stout, JE; Tasneen, R; Vernon, AA; Zimmerman, MD, 2022) |
| "The chemotherapeutic regimens of patients with drug-susceptible (DS)- tuberculosis (TB) comprise four primary anti-TB drugs: rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA), administered for six-to-nine months." | 4.12 | Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro. ( Anderson, R; Cholo, MC; Mashele, SA; Matjokotja, MT; Rasehlo, SSM; Steel, HC, 2022) |
| "Pellagra is caused by niacin (vitamin B3) deficiency and patients with pellagra present with a characteristic rash." | 4.12 | Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study. ( Auld, AF; Buono, N; Chilikutali, L; Chisuwo, L; Chiwaula, MJ; da Silva, R; Girma, B; Gunde, LJ; Gutreuter, S; Jahn, A; Kalua, T; Kaunda, E; Kim, EJ; Kumwenda, T; Maida, A; Maphosa, T; Marshall, RE; Mbewe, K; Mekonnen, TF; Melgar, M; Mhango, V; Moffitt, A; Mponda, K; Mtoto, F; Muula, AS; Mwamale, S; Mwenyeheri, G; Nabity, SA; Nagoli, E; Ngongonda, D; Nyirenda, R; Odo, M; Oeltmann, JE; Sharma, AJ; Sunguti, J; Surie, D; Williams, AM; Woelk, G; Zimba, SB, 2022) |
| "Although antiretroviral therapy (ART) can avert tuberculosis (TB) incidence among human immunodeficiency virus (HIV) infected patients, the concomitant use of ART with isoniazid (INH) has a paramount effect." | 4.12 | Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia. ( Adem, M; Bayleyegn, B; Geremew, D; Geremew, H; Tamir, M; Tegene, B, 2022) |
| "Isoniazid preventive therapy (IPT) is effective in treating tuberculosis (TB) infection and hence limiting progression to active disease." | 4.12 | Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study. ( Alinga, SB; Biraro, IA; Etukoit, MB; Kagimu, D; Kakumba, K; Kateeba Tusiime, A; Kato, D; Kazibwe, A; Kirenga, B; Mafabi, CG; Miya, Y; Mugenyi, L; Nkabala, R; Ochwo, M; Odoi, C; Oluka, AI; Opito, R; Oryokot, B; Ouma, S; Tayebwakushaba, E; Tusiimire, W, 2022) |
| "Isoniazid-monoresistant tuberculosis (HR-TB) requires early diagnosis and adapted treatment to achieve optimal outcomes." | 4.12 | Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France. ( Bachir, M; Billard-Pomares, T; Chiesi, S; Guglielmetti, L; Jaffré, J; Langris, H; Lemaître, N; Pourcher, V; Robert, J; Schramm, F; Tunesi, S, 2022) |
| "To examine the association between isoniazid preventive therapy (IPT) or nontuberculous mycobacteria (NTM) sputum culture positivity and tuberculosis (TB) transcriptional signatures in people with HIV." | 4.12 | Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV. ( Barnabas, RV; Cangelosi, GA; Gersh, JK; Hatherill, M; Hawn, TR; Horne, DJ; Joudeh, LL; Kinuthia, J; Matemo, D; Mendelsohn, SC; Scriba, TJ; Valinetz, ED; Wald, A, 2022) |
| " To support tuberculosis diagnosis, the same strategy was applied to simultaneously probe in Mycobacterium tuberculosis for rifampicin-resistance mutations occurring within one 81-bp region and one 48-bp region in the rpoB gene, plus five isoniazid-resistance mutations in the inhA and katG genes." | 4.12 | High-Throughput Variant Detection Using a Color-Mixing Strategy. ( Li, R; Luo, J; Song, P; Xie, NG; Zhang, DY; Zhang, K, 2022) |
| "Isoniazid is a cornerstone of modern tuberculosis (TB) therapy and targets the enoyl ACP reductase InhA, a key enzyme in mycolic acid biosynthesis." | 4.12 | Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis. ( Alcaraz, M; Biet, F; Cochard, T; Conde, C; Kremer, L; Kumar, V; Roquet-Banères, F; Sharma, B, 2022) |
| "A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI)." | 4.12 | Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs. ( Cole, J; Day, CL; Dick, EJ; Foreman, TW; Ganatra, SR; Gandhi, NR; Gonzalez, O; Hall-Ursone, S; Kaushal, D; Mehra, S; Peloquin, CA; Rengarajan, J; Schlesinger, LS; Sharan, R; Shivanna, V; Singh, DK; Thippeshappa, R, 2022) |
| "To quantify the South African adult tuberculosis (TB) incidence and mortality attributable to HIV between 1990 and 2019 and to estimate the reduction in TB incidence due to directly observed therapy, antiretroviral therapy (ART), isoniazid preventive therapy, increased TB screening, and Xpert MTB/RIF." | 4.12 | The impact of HIV and tuberculosis interventions on South African adult tuberculosis trends, 1990-2019: a mathematical modeling analysis. ( Boulle, A; Johnson, LF; Kubjane, M; Osman, M, 2022) |
| "TBI-166, derived from riminophenazine analogues, shows more potent anti-TB activity than clofazimine and is being assessed against tuberculosis (TB) in a phase IIa clinical trial in China." | 4.12 | Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis. ( Chen, X; Ding, Y; Fu, L; Guo, S; Liu, H; Lu, Y; Wang, B; Wang, N; Zhang, W; Zhu, H, 2022) |
| "Isoniazid preventive therapy (IPT) can reduce the risk of tuberculosis (TB) in children living with HIV (CLHIV), but data on the outcomes of the IPT cascade in CLHIV are limited." | 4.12 | Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019. ( John-Stewart, G; Kinuthia, J; LaCourse, SM; Matemo, D; Mecha, J; Oele, E; Onyango, DO; van der Sande, MAB; Yuen, CM, 2022) |
| "Tuberculosis (TB) is major public health concern and Isoniazid Preventive Therapy (IPT) helps to prevent TB development among patients living with human immune deficiency virus (PLWHIV)." | 4.12 | Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia. ( Damtew, Y; Endawkie, A; Mebratu, W; Mohammed, S; Wedajo, S, 2022) |
| "We estimated costs of managing different forms of tuberculosis (TB) across Canada by conducting a retrospective chart review and cost assessment of patients treated for TB infection, drug-susceptible TB (DS TB), isoniazid-resistant TB, or multidrug-resistant TB (MDR TB) at 3 treatment centers." | 4.12 | Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016. ( Brode, SK; Campbell, JR; Chiang, LY; Jamieson, F; Johnston, JC; Khadawardi, H; Mah, HK; Nsengiyumva, P; Oxlade, O; Rasberry, H; Rea, E; Romanowski, K; Sabur, NF; Sander, B; Schwartzman, K; Uppal, A, 2022) |
| "Isoniazid preventive therapy (IPT) can prevent tuberculosis among people receiving antiretroviral therapy (ART)." | 4.12 | Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. ( Chisonjela, F; Cohen, T; Kiravu, A; Lyatuu, G; Machumi, L; Menzies, NA; Minde, J; Sando, D; Sudfeld, CR; Zhu, J, 2022) |
| "Isoniazid and its metabolites are potentially associated with hepatotoxicity and treatment outcomes in patients who receive antituberculosis (TB) therapy." | 4.12 | Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS. ( Cho, YS; Kim, DH; Kim, MJ; Ky Anh, N; My Tung, P; Phuoc Long, N; Shin, JG, 2022) |
| "Isoniazid (INH) is prescribed both for the prophylaxis as well as the treatment of tuberculosis." | 4.02 | PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid. ( Balhara, A; Singh, S, 2021) |
| "We aimed to assess the coverage of tuberculosis screening and isoniazid preventive therapy (IPT) among people living with human immunodeficiency virus (PLHIV) at Gambella Hospital, southwest Ethiopia." | 4.02 | Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, southwest Ethiopia: a retrospective study design. ( Aboma, M; Dida, N, 2021) |
| "HIV-infected persons are at increased risk of developing tuberculosis and Isoniazid preventive therapy has been shown to reduce the occurrence of tuberculosis among this group of persons." | 4.02 | Effect of mobile-phone messaging on patient and health-worker knowledge and adherence to the isoniazid preventive therapy guideline in HIV clinics in Southeast, Nigeria. ( Agu, AP; Akamike, IC; Alo, C; Ogbonnaya, LU; Okedo-Alex, IN; Uneke, CJ, 2021) |
| " Therefore, to satisfy the need for comprehensive monitoring of anti-tuberculosis drugs in human plasma, a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for simultaneous quantification of first-line anti-tuberculosis drugs (ethambutol, isoniazid, pyrazinamide, and rifampicin) along with their six primary metabolites." | 4.02 | LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring. ( Bandere, D; Cirule, A; Grinberga, S; Igumnova, V; Kivrane, A; Krams, A; Pole, I; Pugovics, O; Ranka, R; Sevostjanovs, E; Viksna, A, 2021) |
| "Rifampin appears to be safe and as effective as isoniazid across many populations with health conditions, including HIV." | 4.02 | Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials. ( Al-Jahdali, H; Bah, B; Belo, M; Campbell, JR; Cook, VJ; Long, R; Menzies, D; Schwartzman, K; Trajman, A, 2021) |
| "The in vivo release segregation of rifampicin (RIF) and isoniazid (INH) has been proposed as a strategy to avoid RIF acid degradation, which is known as one of the main factors for reduced RIF bioavailability and can result in drug-resistant tuberculosis." | 4.02 | Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid. ( Litterio, NJ; Lorenzutti, AM; Luciani-Giacobbe, LC; Olivera, ME; Ramírez-Rigo, MV, 2021) |
| "We assessed adherence in an infant tuberculosis prevention trial in Kenya with a urine isoniazid metabolite-detecting dipstick." | 4.02 | Urine Biomarker Assessment of Infant Adherence to Isoniazid Prophylaxis. ( Escudero, JN; John-Stewart, G; Kinuthia, J; LaCourse, SM; Leon, D; Lutz, B; Maleche-Obimbo, E; Matemo, D; Mecha, J; Panpradist, N; Richardson, BA, 2021) |
| "Isoniazid Preventive Therapy (IPT) is a proven public health tool to reduce Tuberculosis (TB) among people living with HIV." | 4.02 | Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016). ( Lawson, L; Mahande, M; Maokola, W; Msuya, S; Ngowi, B; Robert, M; Todd, J, 2021) |
| " We compared the cost per completed course of preventive treatment with either 6 months of daily isoniazid (6H) or 3 months of weekly isoniazid and rifapentine (3HP), delivered by the Indus Health Network tuberculosis program in Karachi, Pakistan, between October 2016 and February 2018." | 4.02 | Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. ( Becerra, MC; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Lu, C; Majidulla, A; Malik, AA; Safdar, N; Yuen, CM, 2021) |
| "Rifampicin (RIF) and isoniazid (INH) are the two most effective first-line antibiotic drugs for the treatment of tuberculosis (TB)." | 4.02 | Detection of Mycobacterium tuberculosis complex in pulmonary and extrapulmonary samples with the FluoroType MTBDR assay. ( Folkvardsen, DB; Lillebaek, T; Rasmussen, EM; Svensson, E, 2021) |
| "A limited sampling strategy (LSS) to estimate the exposure to isoniazid was developed considering N-acetyltransferase 2 (NAT2) genotypes in Korean patients with tuberculosis." | 4.02 | Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis. ( Choi, G; Ha, JE; Kim, ES; Lee, J; Lee, JH; Lee, JI; Lee, K; Park, JS; Song, J; Yang, S, 2021) |
| "This study aimed to develop a population pharmacokinetic model using full pharmacokinetic (PK) profiles of isoniazid (INH) taking into account demographic and genetic covariates and to develop Bayesian estimators for predicting INH area under the curve (AUC) in Tunisian tuberculosis patients." | 4.02 | Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients. ( Alshaikheid, M; Aouam, K; Ben Fadhel, N; Ben Fredj, N; Ben Romdhane, H; Chaabane, A; Chadli, Z; Hannachi, I; Kerkeni, E; Kolsi, N; Koubaa, J, 2021) |
| "Isoniazid preventive therapy (IPT) against tuberculosis (TB) is a life-saving intervention for people living with HIV (PLHIV)." | 4.02 | Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017). ( Auld, AF; Gunde, LJ; Jahn, A; Kirking, HL; Maida, A; Nabity, SA; Nyirenda, RK; Odo, M; Oeltmann, JE; Shiraishi, RW; Surie, D, 2021) |
| "Isoniazid-monoresistant tuberculosis (HR-TB) is the most prevalent form of drug-resistant TB worldwide and in France and is associated with poorer treatment outcomes compared with drug-susceptible TB (DS-TB)." | 4.02 | Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. ( Bachir, M; Billard-Pomares, T; Chiesi, S; Guglielmetti, L; Jaffré, J; Langris, H; Lemaître, N; Pourcher, V; Robert, J; Schramm, F; Tunesi, S, 2021) |
| "isoniazid preventive therapy for people living with HIV is an essential public health intervention in low-income countries with high tuberculosis and HIV burden." | 4.02 | Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania. ( Frumence, G; Komba, FF, 2021) |
| "Depot medroxyprogesterone acetate is an injectable hormonal contraceptive, widely used by women of childbearing potential living with HIV and/or tuberculosis." | 4.02 | A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment. ( Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X, 2021) |
| "Secondary analysis of the stepped-wedge, cluster-randomized THRio trial for isoniazid preventive therapy (IPT) to prevent tuberculosis (TB)." | 4.02 | Brief Report: Yield of Repeat Tuberculin Skin Testing for People Living With HIV in Brazil. ( Cavalcante, SC; Chaisson, LH; Chaisson, RE; Cohn, S; Durovni, B; Golub, JE; Saraceni, V, 2021) |
| "Niacin or tryptophan deficiency causes pellagra." | 4.02 | A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report. ( Kabengele, C; M'hango, H; Malumani, M; Mweemba, D, 2021) |
| "Isoniazid preventive therapy (IPT) reduces the risk of active tuberculosis among people living with HIV, but implementation of IPT in South Africa and elsewhere remains slow." | 3.96 | Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics. ( Golub, JE; Hanrahan, CF; Jarrett, BA; Martinson, NA; Motlhaoleng, K; Mpungose, N; Tilchin, C; Woznica, DM, 2020) |
| "We constructed a decision tree model to project lifetime costs and benefits of isoniazid PGT for drug-susceptible tuberculosis in Brazil, South Africa, and India." | 3.96 | Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis. ( Andrews, JR; Croda, J; Goldhaber-Fiebert, JD; Rens, NE; Uyl-de Groot, CA, 2020) |
| "Giorgia Sulis and Madhukar Pai discuss the global distribution, and approaches to diagnosis and treatment, of isoniazid-resistant tuberculosis." | 3.96 | Isoniazid-resistant tuberculosis: A problem we can no longer ignore. ( Pai, M; Sulis, G, 2020) |
| "Isoniazid resistant Mycobacterium tuberculosis (Hr-TB) is the most frequently encountered TB resistance phenotype in North America but limited data exist on the effectiveness of current therapeutic regimens." | 3.96 | Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017. ( Cooper, R; Edwards, BD; Edwards, J; Fisher, D; Kunimoto, D; Somayaji, R, 2020) |
| "31) were associated with increased risk of tuberculosis whereas taking Isoniazid Preventive Therapy (IPT) (AHR = 0." | 3.96 | Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study. ( Aemro, A; Anlay, DZ; Jember, A, 2020) |
| "Antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) are known to have a tuberculosis (TB) protective effect at the individual level among people living with HIV (PLHIV)." | 3.96 | Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018. ( Choto, RC; Harries, AD; Mabaya, S; Mbito, C; Mutasa-Apollo, T; Sandy, C; Takarinda, KC; Timire, C, 2020) |
| "276 rifampin-resistance tuberculosis (RR-TB) and 30 rifampicin-sensitive clinical isolates were randomly selected from patients with tuberculosis in Shanghai Pulmonary Hospital (SPH)." | 3.96 | Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Shanghai, China. ( Gao, R; Guo, Y; Shen, X; Tan, G; Wang, H; Wu, X; Wu, Z; Yang, J; Yu, F, 2020) |
| "Background The standardized doses of isoniazid in therapy against tuberculosis are determined based on total body weight, without considering genetic polymorphisms of the metabolic enzyme N-acetyltransferase-2 that contribute to the wide pharmacokinetic variability of isoniazid." | 3.96 | Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis. ( Huerta-García, AP; Magaña-Aquino, M; Medellín-Garibay, SE; Milán-Segovia, RDC; Ortiz-Álvarez, A; Portales-Pérez, DP; Rodríguez-Pinal, CJ; Romano-Moreno, S, 2020) |
| " Since 25% of the drug resistance was attributable to sanctuary EPTB sites notorious for poor rifampin penetration, we hypothesize that poor anti-tuberculosis drug dosing might have a role in the development of resistance." | 3.96 | Machine learning reveals that Mycobacterium tuberculosis genotypes and anatomic disease site impacts drug resistance and disease transmission among patients with proven extra-pulmonary tuberculosis. ( Magazi, BT; Malinga, LA; Maningi, NE; Mbelle, NN; Pasipanodya, JG; Shey, BA; Sibandze, DB, 2020) |
| "In accordance with international guidance for tuberculosis (TB) prevention, the Tanzanian Ministry of Health recommends isoniazid preventive therapy (IPT) for children aged 12 months and older who are living with HIV." | 3.96 | Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania. ( Adams, LV; Ahluwalia, AK; Daffé, ZN; Hunter, OF; Kyesi, F; Munseri, P; von Reyn, CF, 2020) |
| " Here, we describe the case of a 3-year-old immunocompetent girl who developed BCG-associated cervical spondylitis and was successfully treated by prompt surgical drainage of the abscess and administration of isoniazid and rifampicin for 9 months without sequelae." | 3.96 | Bacillus Calmette-GuÉrin-Associated Cervical Spondylitis in a 3-Year-Old Immunocompetent Girl. ( Imakiire, R; Imuta, N; Kawano, Y; Koriyama, T; Nishi, J; Nishikawa, T; Taniguchi, N; Tawaratsumida, H; Tominaga, H, 2020) |
| "Isoniazid (INH) mono-resistant tuberculosis (Hr-TB) is a highly prevalent type of drug-resistant TB, possibly associated with unfavorable treatment outcomes." | 3.96 | Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study. ( Chang, J; Choi, JS; Chung, KS; Jung, JY; Kang, YA; Kim, EY; Kim, SY; Kim, YS; Kwak, SH; Lee, EH; Lee, SH; Leem, AY; Park, MS, 2020) |
| "Isoniazid preventive therapy (IPT) taken by People Living with HIV (PLHIV) protects against active tuberculosis (TB)." | 3.96 | Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data. ( Karanja, M; Kingwara, L; Kiplimo, R; Kirui, E; Maina, M; Masini, E; Ngari, F; Ngugi, C; Onyango, E; Owiti, P, 2020) |
| "Here, we present how UISS accurately simulates tuberculosis dynamics and its interaction within the immune system, and how it predicts the efficacy of the combined action of isoniazid and RUTI vaccine in a specific digital population cohort." | 3.96 | Moving forward through the in silico modeling of tuberculosis: a further step with UISS-TB. ( Cardona, PJ; Fichera, E; Juarez, MA; Motta, S; Pappalardo, F; Parasiliti Palumbo, GA; Pennisi, M; Russo, G; Sgroi, G; Viceconti, M; Walker, KB, 2020) |
| "To investigate the incidence of tuberculosis (TB) in patients with rheumatic diseases receiving high-dose glucocorticoids and to evaluate the preventive effect of isoniazid (INH)." | 3.96 | Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids. ( Curtis, JR; Lee, EB; Lee, H; Lee, JK; Park, JW; Song, YW, 2020) |
| "A multicentre, prospective pilot study was initiated among adults living with HIV on isoniazid 300 mg with pyridoxine 50 mg after ruling out active tuberculosis (TB)." | 3.96 | Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting. ( Agarwal, U; Bhavani, PK; Chitra, A; Maheshmanisha, J; Mothi, SN; Nandagopal, K; Padmapriyadarsini, C; Poornagangadevi, N; Reddy, D; Rewari, BB; Sekar, L; Selvaraj, M; Swaminathan, S; Tamizhselvan, M; Vennila, S, 2020) |
| " Most of the compounds with alkoxyimino groups attached to the piperazine or cyclohexyl ring of PBTZ169, exhibit excellent in vitro activity against both drug-sensitive and clinically isolated multidrug-resistant Mycobacterium tuberculosis (MTB) strains (MIC: < 0." | 3.91 | Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents. ( Franzblau, SG; Fu, L; Gu, J; Han, B; Liu, M; Lu, Y; Lv, K; Ma, C; Ma, X; Tao, Z; Wan, B; Wang, A; Xu, S, 2019) |
| "The World Health Organization recommends isoniazid preventive therapy (IPT) for people living with HIV (PLHIV) to prevent tuberculosis (TB), including pregnant women." | 3.91 | Brief Report: High Programmatic Isoniazid Preventive Therapy (IPT) Use in Pregnancy Among HIV-Infected Women. ( Copeland, A; Cranmer, LM; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Richardson, BA; Wagner, AD, 2019) |
| "Isoniazid resistant tuberculosis is the most prevalent type of resistance in Swaziland and over two-thirds of the isoniazid resistant tuberculosis patients are tuberculosis and human immunodeficiency virus co-infected." | 3.91 | Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study. ( Chien, LY; Dlamini, NC; Ji, DD, 2019) |
| " The research method applied was comparative analysis of the results of own study and studies by other researchers, concerning the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS when treated with isoniazid." | 3.91 | Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid. ( Głowacka, M; Jarosz, MJ; Juszkiewicz, K; Włoszczak-Szubzda, A, 2019) |
| " Though atonic seizures were observed during the treatment, it disappeared after isoniazid discontinuation and pyridoxal phosphate administration." | 3.91 | Clinical findings and treatment of disseminated 'Mycobacterium avium subspecies hominissuis' infection in a domestic cat. ( Hatoya, S; Hirai, K; Kanegi, R; Nabetani, T; Sugiura, K; Tanaka, T; Wada, Y; Yasugi, M, 2019) |
| "Isoniazid (INH) is a first-line antituberculosis (TB) agent with a pharmacokinetic profile characterized by high interindividual variation; however, population pharmacokinetic studies in patients with TB are scarce." | 3.91 | Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis. ( Agudelo, Y; Morales-Gutierrez, J; Naranjo, TW; Neely, MN; Rodriguez, CA; Sierra, Y; Zapata, J; Zapata, JD; Zuluaga, AF, 2019) |
| "Both isoniazid preventive therapy (IPT) and antiretroviral therapy (ART) reduce tuberculosis risk in individuals living with HIV." | 3.91 | Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting. ( Azman, AS; Boulle, A; Dowdy, DW; Kendall, EA; Maartens, G; Rangaka, MX; Wilkinson, RJ, 2019) |
| " The secondary objective was to determine the overall incidence of hepatitis in children on Anti tubercular treatment (ATT) and isoniazid prophylactic therapy (IPT)." | 3.91 | Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children. ( Indumathi, CK; Jain, S; Krishnamurthy, S; Sethuraman, A, 2019) |
| "The AdvanSure MDR-TB GenoBlot Assay detects isoniazid- and rifampin-resistant tuberculosis using mutation-specific probes, including probes to disputed rpoB mutations." | 3.91 | Advantages of the AdvanSure MDR-TB GenoBlot assay containing disputed rpoB mutation-specific probes in a routine clinical laboratory setting. ( Huh, HJ; Jhun, BW; Kang, OK; Koh, WJ; Lee, NY; Yoo, IY, 2019) |
| " Subjects who experienced hypersensitivity reactions, including maculopapular exanthema (MPE) and drug reaction with eosinophilia and systemic symptoms (DRESS), to first-line anti-tuberculosis medications (isoniazid [INH], ethambutol [EMB], rifampin [RFP], and pyrazinamide [PZA]) were enrolled." | 3.91 | Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications. ( Ban, GY; Jeong, YJ; Kim, SH; Lee, SH; Park, HS; Shin, SS; Shin, YS; Ye, YM, 2019) |
| "Isoniazid preventive therapy (IPT) is a proven means to prevent tuberculosis (TB) disease among people living with HIV (PLHIV)." | 3.91 | Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study. ( Mamuye, AT; Teklu, AM; Yirdaw, KD; Zewdu, S, 2019) |
| "Clinical relevance of the effects of genetic variation on isoniazid concentrations and low first-line tuberculosis drug exposures observed require further investigation." | 3.91 | Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis. ( Adamson, J; Chirehwa, M; Denti, P; Govender, K; McIlleron, H; Naidoo, A; Naidoo, K; Ncgapu, S; Padayatchi, N; Ramsuran, V; Singh, R; Yende-Zuma, N, 2019) |
| "Isoniazid (INH) is an essential drug for tuberculosis (TB) treatment." | 3.91 | Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014. ( Duarte, R; Fiebig, L; Hollo, V; Jackson, S; Karo, B; Kearns, C; Ködmön, C; Kohlenberg, A; Korzeniewska-Kosela, M; Papaventsis, D; Solovic, I; van der Werf, MJ; van Soolingen, D, 2019) |
| "Isoniazid (INH) prophylaxis is recommended for the prevention of tuberculosis (TB) reactivation before or/and during initiation of treatment with tumour necrosis factor antagonists (anti-TNF agents)." | 3.91 | Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy? ( Akyuz, F; Besisik, F; Cagatay, T; Cavus, B; Demir, K; Evirgen, S; Gulluoglu, M; Iliaz, R; Karaca, C; Kaymakoglu, S; Keskin, M; Koksalan, K; Onder, S; Ormeci, A; Soyer, OM, 2019) |
| " In this study, a TetR family transcriptional factor (OxiR), encoded by Rv0067c in Mycobacterium tuberculosis, was found to be an isoniazid (INH) resistance regulator." | 3.91 | OxiR specifically responds to isoniazid and regulates isoniazid susceptibility in mycobacteria. ( Gao, CH; Hu, LH; Jia, WZ; Lou, ZZ; Sun, YC; Tao, HL; Yang, M; Zhang, L, 2019) |
| "To evaluate performance of thin layer agar (TLA) 7H11 method for detection of ofloxacin (OFX) and kanamycin (KM) resistance in smear positive clinical specimens of patients with tuberculosis comparing the results with gold standard MGIT 960 system." | 3.91 | Evaluation of Thin Layer Agar 7H11 for Direct Susceptibility Testing of Mycobacterium Tuberculosis Complex against Second Line Anti Tuberculosis Drugs on Smear Positive Specimens. ( Gardezi, AH; Hussain, A; Ikram, A; Khadim, MT; Satti, L; Zaman, G, 2019) |
| "Isoniazid preventive therapy (IPT), for people living with HIV (PLHIV) is the proven and recommended intervention to avert tuberculosis (TB)." | 3.91 | Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. ( Bhatta, U; Chinnakali, P; Dhungana, GP; Pandey, B; Thekkur, P; Zhang, WH, 2019) |
| " We estimated tuberculosis treatment outcomes in children younger than 5 years following WHO guidelines (children are dosed by weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: one based on a proposed algorithm that uses age, weight, and available formulations, in which underweight children would receive the same drug doses as would normal weight children of the same age; and another based on an individualised algorithm without dose limitations, in which derived doses results in target exposure attainment for the typical child." | 3.91 | Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study. ( Dodd, PJ; Dooley, KE; Garcia-Prats, AJ; Hesseling, AC; McKenna, L; Radtke, KK; Savic, RM, 2019) |
| "We aim to optimize the paediatric dosing regimen of isoniazid, rifampicin and pyrazinamide for the first-line treatment of tuberculosis, based on a fixed dose combination (FDC) mini-tablet using simulations." | 3.91 | Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis. ( Dokoumetzidis, A; Nalda-Molina, R; Sfouni, M; Tsiligiannis, A, 2019) |
| "Isoniazid (INH) represents the cornerstone for the treatment of cases infected with Mycobacterium tuberculosis (MTB) strains." | 3.91 | Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China. ( Dong, L; Huang, H; Huo, F; Jing, W; Lu, J; Ma, Y; Pang, Y; Shi, J; Wang, Y; Zhao, L; Zong, Z, 2019) |
| "Despite the high proportion of isoniazid prophylaxis, the incidence of tuberculosis in our patients receiving TNF-α antagonist was higher than the literature." | 3.88 | Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk. ( Arseven, O; Bingol, Z; Cagatay, P; Cagatay, T; Ece, T; Erelel, M; Erkan, F; Gulbaran, Z; Kılıçaslan, Z; Kıyan, E; Okumus, G; Yegin, Z, 2018) |
| "Isoniazid-monoresistant tuberculosis (INH-monoresistant TB) is the most common drug-resistant TB type in the United States; however, its impact on TB treatment outcomes is not clear." | 3.88 | Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014. ( DiMiceli, L; Kempker, RR; Magee, MJ; Sales, RF; Salindri, AD; Schechter, MC, 2018) |
| "Isoniazid preventive therapy (IPT) reduces mortality among people living with HIV (PLHIV) and is recommended for those without active tuberculosis (TB) symptoms." | 3.88 | Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis. ( Ellner, JJ; Freiman, JM; Hahn, JA; Horsburgh, CR; Jacobson, KR; Linas, BP; Muyindike, WR, 2018) |
| "The traditional treatment of tuberculosis (TB) infection (9 months of daily isoniazid [9H]) is safe but completion rates of <50% are reported." | 3.88 | Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens. ( Cruz, AT; Starke, JR, 2018) |
| "The majority of Mycobacterium tuberculosis isolates resistant to isoniazid harbour a mutation in katG." | 3.88 | Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. ( de Jong, BC; de Rijk, P; Fissette, K; Lempens, P; Meehan, CJ; Rigouts, L; Van Deun, A; Vandelannoote, K, 2018) |
| "The classic fixed-dose combination (FDC) of 4 tuberculosis drugs, namely rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol dihydrochloride (EDH) has the twin issues of physical stability and RIF cross-reaction in the 4-FDC." | 3.88 | Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal. ( Battini, S; Mannava, MKC; Nangia, A, 2018) |
| "In this high-incidence setting, the use of targeted active case finding in combination with secondary isoniazid preventive therapy in previously treated individuals could accelerate decreases in tuberculosis morbidity and mortality." | 3.88 | Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. ( Beyers, N; Bilinski, A; Cohen, T; Marx, FM; Menzies, NA; Salomon, JA; Yaesoubi, R, 2018) |
| " tuberculosis H37Rv cultures were exposed to VPA or SAHA over 6 days, in the presence or absence of isoniazid (INH) and rifampicin (RIF)." | 3.88 | Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis. ( Maeurer, M; Rao, M; Valentini, D; Zumla, A, 2018) |
| "To compare daily exposure to tuberculosis (TB) patients between HIV-infected and non-HIV-infected health care workers (HCWs), and examine the uptake of antiretroviral therapy (ART) and isoniazid preventive therapy (IPT) among HIV-infected HCWs in Botswana." | 3.88 | High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana. ( Ho-Foster, A; Kestler, M; Modongo, C; Phologolo, T; Shin, SS; Wang, Q; Zetola, NM, 2018) |
| "A short-course regimen of 3 months of weekly rifapentine and isoniazid (3HP) has recently been recommended by the World Health Organization as an alternative to at least 6 months of daily isoniazid (isoniazid preventive therapy [IPT]) for prevention of tuberculosis (TB)." | 3.88 | Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings. ( Churchyard, GJ; Dowdy, DW; Johnson, KT; Sohn, H, 2018) |
| "The 4-drug regimen of rifampin, isoniazid, pyrazinamide, and ethambutol is an inexpensive, reliable option for treating patients with drug-susceptible tuberculosis (TB)." | 3.88 | Protein Binding of First-Line Antituberculosis Drugs. ( Al-Shaer, MH; Alghamdi, WA; Peloquin, CA, 2018) |
| "We model the epidemiological impact of providing isoniazid preventive therapy (IPT) to South African adolescents, among whom HIV prevalence is low, latent tuberculosis (TB) prevalence is high, and school-based programs may enable population-level coverage." | 3.88 | Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. ( Bendavid, E; Feldman, MW; Rhines, AS, 2018) |
| "We obtained whole-genome sequences and associated phenotypes of resistance or susceptibility to the first-line antituberculosis drugs isoniazid, rifampin, ethambutol, and pyrazinamide for isolates from 16 countries across six continents." | 3.88 | Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. ( Allix-Béguec, C; Arandjelovic, I; Beckert, P; Bi, L; Bonnet, M; Bradley, P; Cabibbe, AM; Cancino-Muñoz, I; Caulfield, MJ; Chaiprasert, A; Cirillo, DM; Clifton, DA; Comas, I; Crook, DW; De Filippo, MR; de Neeling, H; Diel, R; Drobniewski, FA; Faksri, K; Farhat, MR; Fleming, J; Fowler, P; Fowler, TA; Gao, Q; Gardy, J; Gascoyne-Binzi, D; Gibertoni-Cruz, AL; Gil-Brusola, A; Golubchik, T; Gonzalo, X; Grandjean, L; Guthrie, JL; He, G; Hoosdally, S; Hunt, M; Iqbal, Z; Ismail, N; Johnston, J; Khanzada, FM; Khor, CC; Kohl, TA; Kong, C; Lipworth, S; Liu, Q; Maphalala, G; Martinez, E; Mathys, V; Merker, M; Miotto, P; Mistry, N; Moore, DAJ; Murray, M; Niemann, S; Omar, SV; Ong, RT; Peto, TEA; Posey, JE; Prammananan, T; Pym, A; Rodrigues, C; Rodrigues, M; Rodwell, T; Rossolini, GM; Sánchez Padilla, E; Schito, M; Shen, X; Shendure, J; Sintchenko, V; Sloutsky, A; Smith, EG; Snyder, M; Soetaert, K; Starks, AM; Supply, P; Suriyapol, P; Tahseen, S; Tang, P; Teo, YY; Thuong, TNT; Thwaites, G; Tortoli, E; van Soolingen, D; Walker, AS; Walker, TM; Wilcox, M; Wilson, DJ; Wyllie, D; Yang, Y; Zhang, H; Zhao, Y; Zhu, B, 2018) |
| "Despite being globally recommended as an effective intervention in tuberculosis (TB) prevention among people living with HIV, isoniazid preventive therapy (IPT) implementation remains suboptimal, especially in sub-Saharan Africa." | 3.88 | Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study. ( Atela, M; Eboreime, E; Ibisomi, L; Wambiya, EOA, 2018) |
| "The approval of bedaquiline to treat tuberculosis has validated adenosine triphosphate (ATP) synthase as an attractive target to kill Mycobacterium tuberculosis (Mtb)." | 3.85 | Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis. ( Alcock, P; Ambady, A; Ashton, H; Balakrishnan, G; Balasubramanian, V; Bharath, S; Bhat, J; Collier, M; Cooper, CB; Dinesh, N; Gupta, AK; Guptha, S; Hameed P, S; Hosagrahara, VP; Iyer, P; Kandaswamy, K; Kaur, P; Kavanagh, S; Kedari, C; Mallya, M; Markad, SD; McLaughlin, RE; Mdluli, K; Mudugal, NV; Mukherjee, K; Murray, D; Nanduri, R; Narayan, A; Narayanan, S; Naveen Kumar, CN; Naylor, K; Panda, M; Panduga, V; Plant, D; Plant, H; Prabhakar, KR; Preston, M; Raichurkar, A; Ramachandran, V; Ravishankar, S; Reddy, J; Rich, K; Rubin, H; Rudrapatna, S; Sambandamurthy, VK; Saralaya, R; Shandil, R; Sharma, S; Shinde, V; Solapure, S; Tantry, SJ; Walsh, J; Whiteaker, J; Yano, T, 2017) |
| "To describe outcomes associated with the implementation of isoniazid preventive therapy (IPT) in a cohort of tuberculosis (TB) treatment-experienced human immunodeficiency virus (HIV) infected patients on antiretroviral therapy (ART)." | 3.85 | Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART. ( Gengiah, S; Gengiah, TN; Maharaj, B; Naidoo, A; Naidoo, K; Yende-Zuma, N, 2017) |
| "To determine the prevalence of resistance to amikacin, capreomycin and ofloxacin in cases of tuberculosis resistant to isoniazid and/or rifampin during 2012-2013." | 3.85 | [Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013]. ( Llerena, C; Murcia, M; Valbuena, A; Zabaleta, A, 2017) |
| "One of the reasons why Isoniazid preventive therapy (IPT) for Tuberculosis (TB) is not widely used in low income countries is concerns on cost of excluding active TB." | 3.85 | Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study. ( Aboud, S; Bakari, M; Chitama, D; Moshiro, C; Mugusi, F; Shayo, GA, 2017) |
| "Every year, over 1 million people develop isoniazid (INH) resistant tuberculosis (TB)." | 3.85 | Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada. ( Chiang, LY; Cook, VJ; Johnston, JC; Krajden, M; Romanowski, K; Roth, DZ; Tang, P, 2017) |
| "Rifampin (RIF) mono-resistant tuberculosis (RMR-TB) is a rare disease." | 3.85 | Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis. ( Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS, 2017) |
| "Treatment of people living with HIV (PLHIV) with latent tuberculosis (TB) infection using isoniazid preventive therapy (IPT) can reduce the risk of TB disease, however, the scale-up of IPT among PLHIV in Thailand and worldwide has been slow." | 3.85 | Implementing an isoniazid preventive therapy program for people living with HIV in Thailand. ( Danyuttapolchai, J; Kanphukiew, A; Kittimunkong, S; Klinbuayaem, V; Maipanich, N; Maokamnerd, Y; Martin, M; Monkongdee, P; Nateniyom, S; Painujit, S; Pevzner, E; Whitehead, S, 2017) |
| "The enzymes responsible for biotin biosynthesis in mycobacteria have been considered as potential drug targets owing to the important role in infection and cell survival that the biotin synthetic pathway plays in Mycobacterium tuberculosis." | 3.85 | Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening. ( Aoki, S; Baba, H; Kawashima, S; Komatsu, H; Maruoka, T; Morita, K; Sacchettini, JC; Sakamoto, H; Taira, J; Umei, T, 2017) |
| "Tuberculosis (TB) screening affords clinicians the opportunity to diagnose or exclude TB disease and initiate isoniazid preventive therapy (IPT) for people living with HIV (PLHIV)." | 3.85 | Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam. ( Cowger, TL; Danyuttapolchai, J; Duong, BD; Khanh, VT; Kittimunkong, S; Monkongdee, P; Nateniyom, S; Ngoc, DV; Nhan, DT; Nhung, NV; Pevzner, ES; Thai, LH; Thinh, T; Thoa, CK; Whitehead, S; Yen, NTB, 2017) |
| "Isoniazid (INH) is part of the first-line-therapy for tuberculosis (TB) but can cause drug-induced liver injury (DILI)." | 3.85 | Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients. ( Aminkeng, F; Brunham, LR; Chan, SL; Chee, CBE; Chua, APG; Gan, SH; Jin, S; Loh, M; Wang, YT, 2017) |
| "To understand the impact of efflux pump genes such as mmpL3 and mmpL7 on isoniazid (INH) resistance and to correlate with presence or absence of mutations in essential genes of INH resistance (katG, inhA, and nat) in clinical isolates of Mycobacterium tuberculosis (M." | 3.85 | Variants of katG, inhA and nat genes are not associated with mutations in efflux pump genes (mmpL3 and mmpL7) in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India. ( Dusthackeer, VNA; Hanna, LE; Kumar, MP; Kumari, VI; Lakshmi, AR; Nagarajan, P; Sukumar, S; Unissa, AN, 2017) |
| "We measured hair and plasma concentrations of isoniazid among sixteen children with tuberculosis who underwent personal or video-assisted directly observed therapy and thus had 100% adherence." | 3.85 | Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis. ( Bacchetti, P; Bharadwaj, R; Dooley, KE; Gandhi, M; Gerona, R; Gupta, A; Gupte, N; Kagal, A; Khwaja, S; Kinikar, A; Koli, H; Kumar, H; Mave, V; Nimkar, S; Ramachandran, G; Wen, A, 2017) |
| " In 2014, we evaluated patient acceptability toward IVR as part of the ENRICH Study, aimed to enhance adherence to isoniazid preventive therapy for tuberculosis prevention among HIV-positive adults in Ethiopia." | 3.85 | A Qualitative Evaluation of the Acceptability of an Interactive Voice Response System to Enhance Adherence to Isoniazid Preventive Therapy Among People Living with HIV in Ethiopia. ( Daftary, A; Gadisa, T; Hirsch-Moverman, Y; Howard, AA; Kassie, GM; Melaku, Z; Saito, S, 2017) |
| "The prevalence of tuberculosis among HIV positive patients in Xinjiang was higher than in China taken as a whole, and HIV was diagnosed late, with underuse of isoniazid preventive therapy." | 3.85 | High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China. ( Andersson, R; Maimaiti, R; Mijiti, P; Musa, M; Pan, K; Wubili, M; Zhang, Y, 2017) |
| "We assessed uptake of isoniazid preventive therapy (IPT) among child contacts of smear-positive tuberculosis (TB) patients and its implementation challenges from healthcare providers' and parents' perspectives in Bhopal, India." | 3.85 | Isoniazid Preventive Therapy among Children Living with Tuberculosis Patients: Is It Working? A Mixed-Method Study from Bhopal, India. ( Bali, S; Bhat, P; Kharate, A; Kokane, AM; Kumar, AM; Nagar, M; Sahu, S; Singh, AR; Verma, M, 2017) |
| "Combination of isoniazid (INH) and rifampicin (RFP) causes liver injury frequently among tuberculosis patients." | 3.85 | Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin. ( Deng, Y; Guo, Y; He, L; Li, C; Peng, W; Zuo, C, 2017) |
| "Isoniazid preventive therapy (IPT) is effective for preventing active tuberculosis (TB), although its mechanism of action is poorly understood and the optimal disease burden for IPT use has not been defined." | 3.85 | Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact. ( Denholm, JT; Handel, A; Houben, RM; McBryde, ES; Ragonnet, R; Sumner, T; Trauer, JM, 2017) |
| "A series of indole and pyridine based 1,3,4-oxadiazole derivatives 5a-t were synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Ra (MTB) and Mycobacterium bovis BCG both in active and dormant state." | 3.83 | Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents. ( Bhatt, K; Desai, NC; Jha, PC; Khedkar, VM; Nawale, L; Sarkar, D; Somani, H; Trivedi, A, 2016) |
| "Hepatotoxicity due to anti tuberculosis drugs, rifampin and isoniazid, is a major problem in tuberculosis patients." | 3.83 | Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains. ( Amani, A; Fazly Bazzaz, BS; Khameneh, B; Rostami, J; Vahdati-Mashhadian, N, 2016) |
| "Intensified tuberculosis (TB) case finding and isoniazid preventive therapy (IPT) are strongly recommended for children who are HIV infected." | 3.83 | Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience. ( Alowo, A; Bilardi, D; Costenaro, P; Cotton, MF; Fregonese, F; Giaquinto, C; Kizito, S; Lundin, R; Massavon, W; Mazza, A; Morelli, E; Nabachwa, SM; Namisi, CP; Nannyonga Musoke, M; Penazzato, M, 2016) |
| "To compare the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) between HIV-infected and HIV-uninfected children with tuberculosis (TB) and correlate it with TB treatment outcome." | 3.83 | Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status. ( Agarwal, D; Banurekha, VV; Bhavani, PK; Gangadevi, NP; Kalpana, S; Kannan, T; Kumar, AK; Kumar, SR; Mathevan, G; Ramachandran, G; Ravichandran, N; Sanjeeva, GN; Sudha, V; Swaminathan, S; Venkatesh, S, 2016) |
| "Experimental and clinical studies have indicated that the antileprosy drug clofazimine may contribute treatment-shortening activity when included in tuberculosis treatment regimens." | 3.83 | Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy. ( Adamson, J; Almeida, DV; Ammerman, NC; Bester, LA; Dorasamy, A; Grosset, JH; Mgaga, Z; Moodley, C; Moodley, S; Ngcobo, B; Singh, SD; Swanson, RV, 2016) |
| "In HIV-uninfected individuals, isoniazid preventive therapy (IPT) has been associated with long-term protection against tuberculosis (TB)." | 3.83 | Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. ( Boulle, A; Houben, RM; Maartens, G; Rangaka, MX; Sumner, T; White, RG; Wilkinson, RJ, 2016) |
| "The durability of isoniazid preventive therapy (IPT) in preventing tuberculosis (TB) is limited in high-prevalence settings." | 3.83 | The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study. ( Chihota, V; Churchyard, GJ; Fielding, KL; Grant, AD; Hermans, SM; Lewis, JJ; Vynnycky, E, 2016) |
| "To investigate the clinical characteristics, adverse drug reactions, and outcomes of the oldest old patients (aged ≥80 years) with tuberculosis (TB) treated with rifampicin, isoniazid, and pyrazinamide (RIP)-containing regimens." | 3.83 | The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. ( Chang, PJ; Cheng, CW; Chou, YL; Lin, HS; Lin, JC; Lin, MS; Ye, JJ, 2016) |
| "Increasing evidence indicates an increased risk of tuberculosis (TB) for rheumatoid arthritis (RA) patients receiving biologic therapy, and the effectiveness of isoniazid prophylaxis (INHP) in TB prevention." | 3.83 | Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan. ( Chang, CL; Chen, DY; Chen, HH; Chen, YM; Liao, TL; Lin, CH, 2016) |
| "World Health Organization advocates for integration of HIV-tuberculosis (TB) services and recommends intensive case finding (ICF), isoniazid preventive therapy (IPT), and infection control ("Three I's") for TB prevention and control among persons living with HIV." | 3.83 | Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. ( Avit-Edi, D; Ballif, M; Blevins, M; Castelnuovo, B; Charles, MK; Cortes, CP; Dung, NT; Durier, N; Dusingize, JC; Fenner, L; Lindegren, ML; Nakigozi, G; Sterling, TR; Wester, CW, 2016) |
| " tuberculosis Uganda II family as the main causative agent of tuberculosis in Uganda is not attributed to its susceptibility behavior to Isoniazid and Rifampicin." | 3.83 | Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families. ( Joloba, ML; Kasule, GW; Kateete, DP, 2016) |
| "A child's risk of developing tuberculosis (TB) can be reduced by nearly 60% with administration of 6 months course of isoniazid preventive therapy (IPT)." | 3.83 | Uptake of Isoniazid Preventive Therapy among Under-Five Children: TB Contact Investigation as an Entry Point. ( Daba, S; G Suarez, P; Gashu, Z; Gebre, N; Habte, D; Hiruy, N; Jerene, D; K Haile, Y; Kassie, Y; Melese, M; Melkieneh, K; Negash, S; Tadesse, Y, 2016) |
| "Patients treated for tuberculosis (TB) who had rifampicin (RMP) or isoniazid (INH) concentrations measured between 1 January 2005 and 31 December 2012 were studied retrospectively." | 3.83 | Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand. ( Chiu, W; Hu, R; Lewis, C; Maze, MJ; Nisbet, M; Paynter, J, 2016) |
| "NAT2 genotype is an indicator for isoniazid dosage adjusting for tuberculosis treatment." | 3.83 | Rapid identification of the NAT2 genotype in tuberculosis patients by multicolor melting curve analysis. ( Chen, S; Dai, G; Dong, L; Hu, Y; Huang, H; Li, Y; Yu, X; Zhao, L, 2016) |
| " High-payload (40-50% w/w) inhalable particles containing NTZ alone or in combination with antituberculosis (TB) agents isoniazid (INH) and rifabutin (RFB) were prepared with high incorporation efficiency of 92%." | 3.83 | Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis. ( Gupta, A; Gupta, P; Gupta, UD; Kumar, S; Meena, J; Misra, A; Panda, AK; Sharma, D; Sharma, S, 2016) |
| "To study the pharmacokinetics of rifampicin (RMP), isoniazid (INH) and pyrazinamide (PZA) in adult tuberculosis (TB) patients and examine factors that influence drug pharmacokinetics." | 3.83 | Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India. ( Chandrasekaran, V; Hemanth Kumar, AK; Kannan, T; Lavanya, J; Ramachandran, G; Ramesh, K; Sudha, V; Swaminathan, S; Vijayakumar, A, 2016) |
| "The largest outbreak of isoniazid-resistant (INH-R) Mycobacterium tuberculosis in Western Europe is centred in North London, with over 400 cases diagnosed since 1995." | 3.83 | Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance. ( Karlikowska, M; Lipman, M; McHugh, TD; Satta, G; Shorten, RJ; Witney, AA, 2016) |
| "Isoniazid (INH) is the most effective drug used as a first-line tuberculosis (TB) treatment besides rifampicin, pyrazinamide, and ethambutol." | 3.83 | NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs. ( Bencheikh, RS; Bourkadi, JE; El Bouazzi, O; Guaoua, S; Hammi, S; Ratbi, I; Sefiani, A; Tebaa, A, 2016) |
| "Isoniazid preventive therapy is a key public health intervention for the prevention of tuberculosis disease among people living with HIV." | 3.83 | Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study. ( Klinkenberg, E; Legesse, B; Tedla, K; Teklay, G; Teklu, T, 2016) |
| "To study the proteomic and morphological changes in Mycobacterium tuberculosis H37Rv exposed to subinhibitory concentration of isoniazid (INH)." | 3.83 | Proteomic and morphological changes produced by subinhibitory concentration of isoniazid in Mycobacterium tuberculosis. ( Campanerut-Sá, PA; Cardoso, RF; Donatti, L; Evaristo, GP; Fiorini, A; Ghiraldi-Lopes, LD; Meneguello, JE; Patussi, EV; Scodro, RB; Siqueira, VL; Souza, EM, 2016) |
| "Resistance to isoniazid (INH-R) in Mycobacterium tuberculosis is mainly due to mutations at position 315 (S315T) of the catalase-peroxidase KatG." | 3.83 | Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. ( Boudinet, M; Brossier, F; Jarlier, V; Petrella, S; Sougakoff, W, 2016) |
| " tuberculosis complex that confer resistance to isoniazid and rifampicin has potentiated the knowledge of their distribution, given the geographical variability." | 3.83 | The genotypic study of Mycobacterium tuberculosis complex resistant to isoniazid: Galicia, Spain (2008-2013). ( Alonso, P; Barbeito-Castiñeiras, G; Fernández, A; González-Mediero, G; Mejuto, B; Pérez Del Molino, ML, 2016) |
| "This report describes the pharmacokinetic profiles of chronically administered oral isoniazid and rifampin in one adult male and one adult female Asian elephant ( Elephas maximus ) that were asymptomatically infected with Mycobacterium tuberculosis ." | 3.83 | ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS. ( Alsultan, A; Egelund, EF; Isaza, R; Peloquin, CA, 2016) |
| "A large isoniazid-resistant tuberculosis outbreak centred on London, United Kingdom, has been ongoing since 1995." | 3.83 | Whole Genome Sequence Analysis of a Large Isoniazid-Resistant Tuberculosis Outbreak in London: A Retrospective Observational Study. ( Broda, A; Brown, T; Casali, N; Drobniewski, F; Harris, SR; Parkhill, J, 2016) |
| " However, the models projected that, in the South Africa national tuberculosis programme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretroviral therapy, expanded facility-based screening for symptoms of tuberculosis at health centres, and improved tuberculosis care could achieve a 55% reduction in incidence (range 31-62%) and a 72% reduction in mortality (range 64-82%) compared with 2015 levels." | 3.83 | Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. ( Arinaminpathy, N; Azman, AS; Bacaër, N; Bendavid, E; Boccia, D; Chadha, VK; Chang, ST; Charalambous, S; Chin, DP; Churchyard, G; Cohen, T; Daniels, C; Denholm, JT; Dewan, P; Ditiu, L; Dowdy, DW; Eaton, JW; Eckhoff, PA; Feldman, MW; Goldhaber-Fiebert, JD; Gomez, GB; Grant, AD; Handel, A; Hippner, P; Hosseini, M; Houben, RMGJ; Huynh, GH; Kimerling, ME; Lalli, M; Lin, HH; Mametja, LD; Mandal, S; McBryde, ES; Menzies, NA; Pandey, S; Pillay, Y; Pretorius, C; Rade, K; Rhines, AS; Sahu, S; Salomon, JA; Suen, SC; Sumner, T; Trauer, JM; Vassall, A; Wagner, BG; Wang, L; Whalen, CC; White, RG; Wu, CY, 2016) |
| "Although isoniazid preventive therapy (IPT) is effective in the prevention of tuberculosis (TB) in people living with the human immunodeficiency virus (PLHIV), patient adherence to this strategy is suboptimal." | 3.83 | Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia. ( Ayele, HT; Bonten, MJ; van Mourik, MS, 2016) |
| "Extending the duration of isoniazid preventive therapy (IPT) among people living with HIV (PLHIV) may improve its effectiveness at both individual and population levels, but could also increase selective pressure in favor of isoniazid-resistant tuberculosis (TB) strains." | 3.83 | Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic. ( Cohen, T; Crawford, FW; Kunkel, A; Shepherd, J, 2016) |
| "A switch of continuation phase tuberculosis (TB) treatment regimen from Ethambutol (E) and Isoniazid (H) combination for 6 months (6EH) to Rifampicin (R) and Isoniazid (H) combination for 4 months (4RH) was recommended." | 3.83 | Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study. ( Asres, A; Deressa, W; Jerene, D, 2016) |
| " We conducted this study to evaluate the association between polymorphisms of CYP2E1, Isoniazid (INH) concentration and the acetylator status of INH in cases of Indonesian tuberculosis patients with drug-induced liver disease (DILI)." | 3.83 | CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients. ( Atthobari, J; Darmawan, E; Irham, LM; Mulyani, UA; Perwitasari, DA, 2016) |
| "Drug susceptibility testing using molecular techniques can enhance the identification of drug-resistant Mycobacterium tuberculosis Two multiplex real-time polymerase chain reaction (qPCR) assays were developed to detect the most common resistance-associated mutations to isoniazid (katGS315T, inhA-15C → T), and rifampicin (rpoBH526Y and rpoBS531L)." | 3.83 | Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis. ( Collantes, J; Rigouts, L; Solari, FB, 2016) |
| "We prospectively examined the incidence of drug-induced hepatitis in 2070 patients treated for TB with the standard regimen based on 6 months of rifampicin (R, RMP) and isoniazid (H, INH), with 2 months of initial pyrazinamide (Z, PZA) and ethambutol (E, EMB), over a 30-year period from 1981 to 2010, in Blackburn, UK." | 3.83 | Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period. ( Bright-Thomas, RJ; Gondker, AR; Morris, J; Ormerod, LP, 2016) |
| "Seven polycharged species, incorporating 1, 2, 3, 4 and 6 guanidine arms organized around a benzene core were synthesized and assayed as anti-mycobacterial agents against Mycobacterium tuberculosis." | 3.81 | Guanidinium compounds with sub-micromolar activities against Mycobacterium tuberculosis. Synthesis, characterization and biological evaluations. ( Constant, P; Daffé, M; Massimba-Dibama, H; Mourer, M; Regnouf-de-Vains, JB, 2015) |
| "A series of novel pyrazole linked triazolo-pyrimidine hybrids were synthesized and evaluated for their anti-tuberculosis activity against M." | 3.81 | Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study. ( Bhatt, JD; Chudasama, CJ; Patel, KD, 2015) |
| "The objective of this study was to evaluate the association between the use of anti-tuberculosis (anti-TB) agents, isoniazid (INH), rifampicin (RIF), and their combination (INH + RIF), and the risk of hepatocellular carcinoma (HCC) in cirrhotic patients." | 3.81 | Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case-control study. ( Hung, DZ; Kao, CH; Lim, YP; Lin, CL; Lin, YN, 2015) |
| "The duration of protection against tuberculosis provided by isoniazid preventive therapy is not known for human immunodeficiency virus (HIV)-infected individuals living in settings of medium tuberculosis incidence." | 3.81 | Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study. ( Cavalcante, SC; Chaisson, RE; Cohn, S; Durovni, B; Golub, JE; Moulton, LH; Pacheco, AG; Saraceni, V, 2015) |
| "Despite the resistance developed by the Mycobacterium tuberculosis (MTb) strains, isoniazid (INH) has been recognized as one of the best drug for treatment of Tuberculosis (Tb)." | 3.81 | Antitubercular activity of Ru (II) isoniazid complexes. ( Aguiar, Id; da Silva, AC; Franco, DW; Lopes, ÉO; Lopes, LG; Marino, LB; Pavan, FR; Roveda, AC; Tavares, A, 2015) |
| "Mycobacterium tuberculosis-infected mice in the chronic phase of the disease (day 30) received: (i) isoniazid and rifampicin (drugs) daily for 30 days; (ii) DNA immunotherapy (DNA), consisting of four 100 μg injections at 10 day intervals; (iii) both therapies (DNA + drugs); or (iv) saline." | 3.81 | Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis. ( Arnoldi, FG; Brandão, IT; Cagnard, N; Chiocchia, G; Jacques, S; Letourneur, F; Masson, AP; Ramos, SG; Rios, WM; Rodrigues, RF; Silva, CL; Soares, LS; Souza, PR; Zárate-Bladés, CR, 2015) |
| "In pregnant women who have been exposed to tuberculosis (TB), primary isoniazid prophylaxis is only recommended in cases of immunosuppression, chronic medical conditions or obstetric risk factors, and close and sustained contact with a patient with infectious TB." | 3.81 | [Spanish Society for Pediatric Infectious Diseases guidelines on tuberculosis in pregnant women and neonates (ii): Prophylaxis and treatment]. ( Baquero-Artigao, F; de la Calle Fernández-Miranda, M; del Rosal Rabes, T; Goncé Mellgren, A; Mellado Peña, MJ; Navarro Gómez, ML; Noguera Julián, A, 2015) |
| "The World Health Organization recommends for tuberculosis retreatment a regimen of isoniazid (H), rifampicin (R), ethambutol (E), pyrazinamide (Z), and streptomycin (S) for 2 months, followed by H, R, E, and Z for 1 month and H, R, and E for 5 months." | 3.81 | High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study. ( Acuña-Villaorduña, C; Ayakaka, I; Dryden-Peterson, S; Fennelly, KP; Hosford, J; Jones-López, EC; Nakubulwa, S; Okwera, A; Reilly, N; Worodria, W, 2015) |
| "Rifampin, together with isoniazid, has been the backbone of the current first-line treatment of tuberculosis (TB)." | 3.81 | Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis. ( Aarnoutse, RE; Alffenaar, JW; de Jager, A; de Lange, WC; Kosterink, JG; Mulder, LW; Proost, JH; Sturkenboom, MG; van Altena, R; van der Werf, TS, 2015) |
| " tuberculosis isolates, twenty paired isolates with disputed drug susceptibilities to isoniazid (INH) were selected according to the MGIT960 testing and Löwenstein-Jensen (L-J) proportion methods." | 3.81 | Discrepancies in Drug Susceptibility Test for Tuberculosis Patients Resulted from the Mixed Infection and the Testing System. ( Bai, D; Huang, H; Li, C; Li, L; Li, Z; Mei, Z; Sun, Z; Xu, S; Xu, Y, 2015) |
| "Progressive liver failure is rarely seen in tuberculosis chemoprophylaxis with isoniazid." | 3.81 | Successful living donor liver transplantation of fulminant liver failure due to isoniazid prophylaxis. ( Ara, C; Çakır, T; Koc, S; Soyer, HV, 2015) |
| "We report the discovery and confirmation of 23 novel mutations with previously undocumented role in isoniazid (INH) drug resistance, in catalase-peroxidase (katG) gene of Mycobacterium tuberculosis (Mtb) isolates." | 3.81 | Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates. ( Amallraja, AM; Catanzaro, A; Catanzaro, D; Chawla, A; Crudu, V; Elghraoui, A; Gler, MT; Goodmanson, AP; Paul, LV; Ramirez-Busby, SM; Rodrigues, C; Rodwell, TC; Sirgel, FA; Streicher, EM; Torres, JN; Valafar, F; Victor, TC; Zadorozhny, V, 2015) |
| "The risk of developing tuberculosis (TB) disease in HIV-uninfected children after isoniazid preventive therapy (IPT) for a positive QuantiFERON-TB Gold In-Tube test (QFT-GIT) is unknown." | 3.81 | Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children. ( Geldenhuys, HD; Hanekom, WA; Hatherill, M; Hughes, EJ; Hussey, G; Landry, B; Luabeya, KK; Mahomed, H; McShane, H; Mulenga, H; Scriba, TJ; Tameris, MD; Toefey, A; Van Schalkwyk, A, 2015) |
| "Isoniazid-filled Fe2 O3 hollow nanospheres (INH@Fe2 O3 , diameter <30 nm, 48 wt % INH-load) are prepared for the first time and suggested for tuberculosis therapy." | 3.81 | Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria. ( Dittmar, KE; Eich, J; Feldmann, C; Goldmann, O; Hagens, K; Leidinger, P; Lünsdorf, H; Oehlmann, W; Schaible, UE; Schwudke, D; Treptow, J; Zehethofer, N, 2015) |
| "Development of polyneuropathy (PNP) under treatment for tuberculosis (TB), including isoniazid (INH), is a highly relevant adverse drug effect." | 3.81 | Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping? ( Hartmann, CJ; Hartung, HP; Kieseier, BC; Konta, L; Pabst, T; Steinberger, D; Stettner, M, 2015) |
| "Data on feasibility and completion rates of isoniazid preventive therapy (IPT) in HIV-infected patient in Asia are limited." | 3.81 | Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy. ( Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J, 2015) |
| " Horwitz, and co-workers use confocal microscopy to demonstrate the avid uptake of RITC-labeled mesoporous silica nanoparticles loaded with the anti-tuberculosis drug isoniazid (shown here in red) by human macrophages (nuclei stained blue with DAPI) infected with GFP-expressing Mycobacterium tuberculosis (shown here in green)." | 3.81 | Tuberculosis: pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice (Small 38/2015). ( Clemens, DL; Dillon, BJ; Horwitz, MA; Hwang, AA; Lee, BY; Zink, JI, 2015) |
| "Isoniazid (INH) is an essential component of first-line anti-tuberculosis (TB) treatment." | 3.81 | A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis. ( Choi, R; Jeon, K; Jeong, BH; Jung, JA; Kim, TE; Ko, JW; Koh, WJ; Kwon, OJ; Lee, H; Lee, SY; Park, HY; Woo, HI, 2015) |
| " The major revision was to increase isoniazid, rifampicin and pyrazinamide dosages according to body weight in children." | 3.81 | The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. ( Gie, RP; Graham, SM; Grzemska, M, 2015) |
| "Isoniazid (INH) is one of the effective antituberculosis (TB) drugs used for TB treatment." | 3.81 | Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach. ( Deshmukh, S; Harinath, BC; Jena, L; Kumar, S; Waghmare, P, 2015) |
| "In the present paper, we report the synthesis via catalytic Michael reaction and biological results of a series of 3-heteryl substituted pyrrolidine-2,5-dione derivatives as moderate inhibitors against Mycobacterium tuberculosis H37Rv growth." | 3.80 | Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis. ( Baltas, M; Gorichko, M; Guidetti, B; Lherbet, C; Matviiuk, T; Mori, G; Pasca, MR; Rodriguez, F; Voitenko, Z, 2014) |
| "Symptom-based tuberculosis screening identifies less than one-third of eligible HIV-infected patients as candidates for isoniazid preventive therapy (IPT)." | 3.80 | Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV. ( Bangsberg, DR; Byakwaga, H; Cattamanchi, A; Davis, JL; Huang, L; Hunt, PW; Martin, JN; Muzoora, C; Nahid, P; Scibetta, C; Semitala, FC; Yoon, C, 2014) |
| " We report a case of clopidogrel non-responsiveness in a patient with HIV, latent tuberculosis and cardiovascular disease with a history of myocardial infarction." | 3.80 | A patient with HIV and tuberculosis with diminished clopidogrel response. ( Metzger, NL; Momary, KM, 2014) |
| "Coadministration of rifampicin (RIF)/isoniazid (INH) is clinically recommended to improve the treatment of tuberculosis." | 3.80 | Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid. ( Hocht, C; Moretton, MA; Sosnik, A; Taira, C, 2014) |
| "To compare the free and total plasma drug concentrations of rifampicin (RMP), isoniazid and pyrazinamide in subjects with or without anti-tuberculosis drug-induced hepatotoxicity (DIH)." | 3.80 | Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. ( Biswas, A; Makharia, GK; Satyaraddi, A; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Sirohiwal, A; Velpandian, T; Vishnubhatla, S, 2014) |
| "Isoniazid (INH) resistance is now the most common type of tuberculosis (TB) infection resistance worldwide." | 3.80 | Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis. ( Chang, PJ; Chou, PC; Chung, FT; Huang, CD; Kuo, CH; Kuo, HP; Lin, SM; Shie, SS; Wang, TY, 2014) |
| "We used previously published data for 76 South African children with tuberculosis to describe the population pharmacokinetics of rifampicin, pyrazinamide and isoniazid." | 3.80 | Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. ( Denti, P; Donald, PR; McIlleron, HM; Schaaf, HS; Seddon, JA; Seifart, HI; Simonsson, US; Smith, PJ; Thee, S; Zvada, SP, 2014) |
| "Isoniazid (INH) is recommended for use as posttuberculosis exposure preventive therapy in children." | 3.80 | Pharmacokinetics of isoniazid in low-birth-weight and premature infants. ( Bekker, A; Cotton, MF; Draper, HR; Hesseling, AC; Schaaf, HS; Seifart, HI; Werely, CJ, 2014) |
| "Genetic variants in NAT2 are associated with pharmacokinetic variation of isoniazid, the cornerstone of antituberculosis treatment." | 3.80 | Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis. ( Aarnoutse, RE; Coenen, MJ; de Waard, JH; García, JF; Hermans, PW; López, D; Schijvenaars, MM; Verhagen, LM, 2014) |
| "The MeltPro TB/INH assay, recently approved by the Chinese Food and Drug Administration, is a closed-tube, dual-color, melting curve analysis-based, real-time PCR test specially designed to detect 30 isoniazid (INH) resistance mutations in katG position 315 (katG 315), the inhA promoter (positions -17 to -8), inhA position 94, and the ahpC promoter (positions -44 to -30 and -15 to 3) of Mycobacterium tuberculosis." | 3.80 | Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis. ( Hu, S; Li, G; Li, H; Li, Q; Liu, X; Niu, J; Quan, S; Wang, F; Wen, H; Xu, Y, 2014) |
| "Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis complex (MTBC) are defined by resistance to at least rifampin (RMP) and isoniazid (INH)." | 3.80 | Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States. ( Driscoll, J; Hartline, D; Lentz, AJ; Metchock, B; Sikes, D; Starks, AM; Yakrus, MA, 2014) |
| "Isoniazid preventive therapy (IPT) with antiretroviral therapy (ART) reduces incident tuberculosis among patients infected with the human immunodeficiency virus." | 3.80 | Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity. ( Charalambous, S; Chihota, VN; Churchyard, GJ; Kufa, T, 2014) |
| " TB-exposed newborns requiring isoniazid preventive therapy (IPT) or anti-tuberculosis treatment were followed to 6 months of age." | 3.80 | Determinants of tuberculosis treatment completion among newborns in a high-burden setting. ( Bekker, A; Du Preez, K; Hesseling, AC; Schaaf, HS; Slogrove, AL, 2014) |
| "This study aims to assess whether NAT2 genotype affects susceptibility to moderate to severe liver injury in patients undergoing drug treatment for tuberculosis with isoniazid-containing regimens." | 3.80 | N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. ( Ahmed, MU; Aithal, GP; Al Maruf, A; Daly, AK; Day, CP; Hasnat, A; Ng, CS; Pirmohamed, M, 2014) |
| " tuberculosis isolates from 104 TB patients attending a tertiary referral hospital of north India were screened for susceptibility to isoniazid (INH), rifampicin (RIF), ethambutol (EMB) and streptomycin (STR) by proportion method and multiplex-allele-specific-polymerase chain reaction (MAS-PCR)." | 3.80 | A study of Mycobacterium tuberculosis genotypic diversity & drug resistance mutations in Varanasi, north India. ( Anupurba, S; Gupta, A; Kulkarni, S; Rastogi, N, 2014) |
| "The Lesotho Ministry of Health issued guidelines on active case finding (ACF) for tuberculosis (TB) and isoniazid preventive therapy (IPT) in April 2011." | 3.80 | Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy. ( Ahimbisibwe, A; Barnes, GL; Chaisson, RE; Gounder, CR; Guay, L; Isavwa, A; Kassaye, S; Maama-Maime, LB; Machekano, R; Mokone, M; Ntene-Sealiete, K; Oyebanji, O; Sahu, M; Tiam, A, 2014) |
| "To determine the proportion of household contacts aged <6 years of patients with tuberculosis (TB) with positive sputum microscopy results who initiated and completed isoniazid preventive treatment (IPT), and to determine reasons for non-initiation and non-completion of IPT." | 3.80 | Isoniazid preventive treatment in children in two districts of South India: does practice follow policy? ( Frederick, A; Kumar, AM; Moonan, PK; Murali, L; Nair, SA; Satyanarayana, S; Shazia, A; Shivaramakrishna, HR, 2014) |
| "To evaluate the cost-effectiveness of the Three I's for HIV/TB (human immunodeficiency virus/tuberculosis): antiretroviral therapy (ART), intensified TB case finding (ICF), isoniazid preventive treatment (IPT), and TB infection control (IC)." | 3.80 | Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. ( Abimbola, T; Bennett, R; Date, A; Granich, R; Gupta, S; Sangrujee, N; Suthar, AB, 2014) |
| "The resazurin microtiter assay (classic REMA), a colorimetric liquid culture-based drug susceptibility assay for Mycobacterium tuberculosis (MTB), has been endorsed by the World Health Organization." | 3.80 | Evaluation of the modified colorimetric resazurin microtiter plate-based antibacterial assay for rapid and reliable tuberculosis drug susceptibility testing. ( Boum, Y; Katawera, V; Siedner, M, 2014) |
| " in a recent issue of this Journal address one of the current debates regarding the potential role of thioridazine in the treatment of tuberculosis." | 3.80 | Thioridazine for treatment of tuberculosis: promises and pitfalls. ( Dutta, NK; Karakousis, PC, 2014) |
| "Assessment of the activity of thioridazine towards Mycobacterium tuberculosis (Mtb), in vitro and in vivo as a single drug and in combination with tuberculosis (TB) drugs." | 3.80 | Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy. ( Aarnoutse, R; Bakker-Woudenberg, IA; Boeree, MJ; de Knegt, GJ; de Steenwinkel, JE; ten Kate, MT; van Soolingen, D, 2014) |
| "The data suggest isoniazid could be considered for use in ALBC for musculoskeletal tuberculosis if used with systemic treatment." | 3.79 | Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study. ( Cho, SN; Han, CD; Oh, T; Park, KK; Yang, JH, 2013) |
| " In a tuberculosis-endemic country like India, it was traditionally believed that the occurrence of tuberculosis in lupus was due to the chronic immunosuppression caused by lupus or because of the use of steroids or isoniazid-induced lupus." | 3.79 | Exacerbation of latent lupus: is the culprit acid-fast bacilli or antitubercular therapy? ( Arya, S; Ghangas, N; Gupta, V; Kaur, M; Kumar, H; Mathur, R; Ray, S; Singh, H; Talapatra, P, 2013) |
| "The expected increase in drug-resistant tuberculosis due to large-scale preventive treatment in people living with HIV calls for reconsidering the "double use" of isoniazid for prophylaxis and curative treatment (Mills et al." | 3.79 | For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance. ( Cobelens, FG, 2013) |
| " The main barriers as reported by 144 HCWs working in hospitals without IPT programme, were: (1) unclear direction of national policy (60%), (2) fear of emerging Isoniazid resistant tuberculosis (52%), and (3) fear of poor adherence (30%)." | 3.79 | Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand. ( Kaewkungwal, J; Lawpoolsri, S; Moolphate, S; Pungrassami, P; Sanguanwongse, N; Yamada, N, 2013) |
| " Minimal inhibitory concentrations (MICs) of isoniazid (INH), rifampicin (RMP) and levofloxacin (LVX) from 169 DR tuberculosis (TB) isolates, 78 of them monoresistant to INH, 13 to RMP, 7 to LVX, and 71 MDR-TB, were determined." | 3.79 | Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs. ( Cataldi, AA; Di Giulio, AB; Imperiale, BR; Morcillo, NS; Zumárraga, MJ, 2013) |
| "To elaborate optimal anti-tuberculosis regimens following drug susceptibility testing (DST) to isoniazid (H) and rifampicin (R)." | 3.79 | [Proposal of anti-tuberculosis regimens based on susceptibility to isoniazid and rifampicin]. ( Alarcón, V; Mendoza-Ticona, A; Moore, DA; Samalvides, F; Seas, C, 2013) |
| "Our modeling work suggests that isoniazid preventive therapy (IPT) can be effective in reducing drug-sensitive tuberculosis (TB) and that the risk of IPT driving resistance can be reduced by improving the detection and rapid treatment of individuals with drug-resistant disease and by limiting IPT to those in whom the intervention will have the largest benefit." | 3.79 | Response to comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis". ( Cohen, T; Colijn, C; Mills, HL, 2013) |
| "The World Health Organization (WHO) recommends active tuberculosis (TB) case finding among people living with human immunodeficiency virus (HIV) in resource-limited settings using a symptom-based algorithm; those without active TB disease should be offered isoniazid preventive therapy (IPT)." | 3.79 | Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. ( Blumberg, HM; Kempker, R; Ofotokun, I; Stenehjem, E; Temesgen, O; Tenna, A; Zaeh, S, 2013) |
| "Peroxidatic activation of the anti-tuberculosis pro-drug isoniazid by Mycobacterium tuberculosis catalase-peroxidase (KatG) is regulated by gating residues of a heme access channel." | 3.79 | Access channel residues Ser315 and Asp137 in Mycobacterium tuberculosis catalase-peroxidase (KatG) control peroxidatic activation of the pro-drug isoniazid. ( Andersson, KK; Hersleth, HP; Magliozzo, RS; Zhao, X; Zhu, J, 2013) |
| "The "Thibela TB" cluster randomised trial of community-wide isoniazid preventive therapy (IPT) to reduce tuberculosis incidence in the South African gold mines." | 3.79 | Eligibility for isoniazid preventive therapy in South African gold mines. ( Chihota, VN; Churchyard, GJ; Coetzee, L; Fielding, KL; Grant, AD; Lewis, JJ; Luttig, M; Muller, D; Popane, F, 2013) |
| "To study the evolutionary relationship of Mycobacterium tuberculosis isolates from 13 patients in a large outbreak of isoniazid-resistant tuberculosis in London." | 3.79 | When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak. ( Charalambous, BM; Gillespie, SH; Jenkins, C; Lipman, MC; McGregor, AC; McHugh, TD; Platt, S; Shorten, RJ, 2013) |
| "The purpose of this study was to evaluate the cost-effectiveness of the strategy of controlling the contacts of tuberculosis patients with latent tuberculosis infection by means of treatment with rifampin for 4 months or isoniazid for 9 months." | 3.79 | Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection. ( Clotet, L; Domínguez, A; Ferrer, A; Garrido, P; Pina, JM; Sala, MR; Salleras, L, 2013) |
| "Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6) polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in HIV/tuberculosis-coinfected (HIV/TB) patients is unavailable." | 3.79 | Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients. ( Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S, 2013) |
| "To describe the characteristics and outcomes of incident tuberculosis (TB) cases in human immunodeficiency virus (HIV) infected adults exposed to isoniazid preventive therapy (IPT) with access to antiretroviral and anti-tuberculosis treatment." | 3.79 | Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana. ( Agizew, T; Johnson, JL; Marape, M; Miranda, AG; Nyirenda, S; Reuter, H; Samandari, T; Sibanda, T; Tedla, Z, 2013) |
| " A tuberculin skin test was positive, we started anti-tuberculosis (TB) chemoprophylaxis with isoniazid (INH)." | 3.78 | Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis. ( Ito, M; Izumi, Y; Kakugawa, T; Kinoshita, A; Migita, K; Miyagawa, K; Miyashita, T; Sasaki, E; Umeno, T, 2012) |
| "Clinical algorithms for evaluating HIV-infected individuals for tuberculosis (TB) prior to isoniazid preventive therapy (IPT) perform poorly, and interferon-γ release assays (IGRAs) have moderate accuracy for active TB." | 3.78 | Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms. ( Boulle, A; Fielding, K; Gideon, HP; Glynn, JR; Goliath, R; Maartens, G; Mathee, S; Mwansa-Kambafwile, J; Pai, M; Rangaka, MX; Titus, R; Wilkinson, KA; Wilkinson, RJ, 2012) |
| "Antituberculosis drug-induced hepatitis attributed to isoniazide (INH) is one of the most prevalent drug-induced liver injuries." | 3.78 | Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis. ( Ben Mahmoud, L; Ghozzi, H; Hachicha, H; Hakim, A; Hammami, S; Kamoun, A; Makni, H; Sahnoun, Z; Zalila, N; Zeghal, K, 2012) |
| "Data on the genetic variation of isolates of Mycobacterium tuberculosis and spectrum of mutations determining resistance to principal anti-tuberculosis drugs isoniazid (INH) and rifampicin (RIF) have not yet been studied in Saudi Arabia." | 3.78 | New insight into the molecular characterization of isoniazid and rifampicin resistant Mycobacterium tuberculosis strains from Saudi Arabia. ( Al-Hajoj, S; Al-Omari, R; Al-rabiah, F; Hillemann, A; Shoukri, M; Varghese, B; Wijayanti, DR, 2012) |
| "The investigation of the binding between isoniazid (or isonicotinic acid hydrazide, INH) and serum albumin is of crucial importance to reveal the reason of resistant Mycobacterium tuberculosis strains towards INH and to increase the anti-tuberculous activity of INH." | 3.78 | Study on the interaction between isoniazid and bovine serum albumin by fluorescence spectroscopy: the effect of dimethylsulfoxide. ( Aznauryan, MG; Markarian, SA, 2012) |
| "Mutations at codons 526 and 531 in the rpoB gene and at 315 in the katG gene are considered diagnostic markers for resistance to rifampin and isoniazid in tuberculosis." | 3.78 | Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México. ( Cuellar, A; Cuevas-Cordoba, B; Enciso, A; Enciso, L; Zenteno-Cuevas, R, 2012) |
| "The optimal management strategy for patients with isoniazid (INH) monoresistant forms of tuberculosis (TB) has been widely debated." | 3.78 | Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009. ( Cohen, T; Furin, J; Gegia, M; Kalandadze, I; Vashakidze, L, 2012) |
| "Regimens for isoniazid-based preventive therapy (IPT) for tuberculosis (TB) in HIV-infected individuals have not been widely adopted given concerns regarding efficacy, adherence and drug resistance." | 3.78 | The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis. ( Freedberg, KA; Kumarasamy, N; Losina, E; Mayer, KH; Pho, MT; Ponnuraja, C; Scott, CA; Swaminathan, S; Uhler, LM; Walensky, RP, 2012) |
| "Chemoprophylaxis with isoniazid and rifampicin generally decreased IFN-γ levels among tuberculosis contacts." | 3.78 | Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort. ( Lee, SH; Lee, SW; Yim, JJ, 2012) |
| "Based on data from 14 Supranational Tuberculosis (TB) Reference Laboratories worldwide, the proportion of rifampicin (RMP) resistant isolates that were isoniazid (INH) susceptible by phenotypic drug susceptibility testing varied widely (0." | 3.78 | Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs. ( Arias, F; Barrera, L; Boulahbal, F; Cavanaugh, JS; Cegielski, JP; Coulter, C; Drobniewski, F; Kim, H; Kurbatova, EV; Lumb, R; Martín-Casabona, N; Metchock, B; Richter, E; Santos Silva, A; Shah, NS; Van Deun, A; Wright, A; Zemanova, I, 2012) |
| "Specific isoniazid (INH) resistance conferring mutations have been shown to impact the likelihood of tuberculosis (TB) transmission." | 3.78 | Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis. ( Cattamanchi, A; Dantes, R; Hopewell, PC; Kato-Maeda, M; Kawamura, M; Kim, E; Metcalfe, J; Nahid, P, 2012) |
| "In Uganda, isoniazid plus ethambutol is used for 6 months (6HE) during the continuation treatment phase of new tuberculosis (TB) cases." | 3.78 | Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis. ( Castelnuovo, B; Hermans, SM; Kuznik, A; Lamorde, M; Manabe, YC; Mullins, CD, 2012) |
| "We have previously demonstrated a potent in vitro inhibitory activity for two pentacyano(isoniazid)ferrate(II) compounds, namely IQG-607 and IQG-639, against the Mycobacterium tuberculosis enoyl-acyl carrier protein reductase enzyme." | 3.78 | Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection. ( Basso, LA; Calixto, JB; Campos, MM; de França Lopes, LG; Dos Santos Junior, A; Dos Santos, AJ; Rodrigues-Junior, VS; Santos, DS; Schneider, CZ; Sousa, EH; Souto, AA, 2012) |
| "InhA, the NADH-dependent enoyl-acyl carrier protein reductase from Mycobacterium tuberculosis (Mtb) is the proposed main target of the first-line antituberculosis drug isoniazid (INH)." | 3.78 | Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations. ( Bernadou, J; Bernardes-Génisson, V; Pratviel, G; Stigliani, JL, 2012) |
| " Further, we determined the concordance between DST results for isoniazid and rifampin for Mycobacterium tuberculosis isolates obtained using the MGIT 960 system and the absolute concentration method, which was conducted at the Korean Institute of Tuberculosis." | 3.78 | Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system. ( Kim, CK; Ko, Y; Koh, WJ; Lee, NY; Park, KS, 2012) |
| " In a study of tuberculosis patients, who were in prison, no relation was found between PGG and resistance to isoniazid, but most of the identified isolates belonged to PGG 1 (45." | 3.78 | Determination of principal genotypic groups among susceptible, MDR and XDR clinical isolates of Mycobacterium tuberculosis in Belarus and Iran. ( Ahmadi, A; Arjomandzadegan, M; Eshghinejad, A; Eshrati, M; Farazi, AA; Farnia, P; Kahbazi, M; Owlia, P; Sheikholeslami, F; Shojapur, M; Surkova, LK; Titov, LP, 2012) |
| "To explain why the efficacies of isoniazid (INH) and rifamycins during the treatment of tuberculosis (TB) are related not to the area under the curve (AUC)/minimum inhibitory concentration (MIC), but to peak drug concentrations." | 3.78 | Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins. ( Mitchison, DA, 2012) |
| "Standard tuberculosis (TB) treatment includes an initial regimen containing drugs that are both rapidly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help prevent the emergence of drug resistance." | 3.78 | Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. ( Almeida, D; Ammerman, NC; Bishai, WR; Converse, PJ; Grosset, J; Hafner, R; Lalloo, U; Li, SY; Pym, AS; Swindells, S; Tyagi, S; Wallengren, K, 2012) |
| "To study the efficacy and safety of Category III DOTS treatment (intermittent thrice-weekly rifampicin [RMP], isoniazid [INH] and pyrazinamide for 2 months, followed by RMP and INH for 4 months) under India's Revised National Tuberculosis Control Programme in patients with uncomplicated small unilateral pleural effusion (<1500 ml)." | 3.78 | Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion. ( Chauhan, LS; Jain, NK; Mohan, A; Sharma, SK; Solanki, R, 2012) |
| " The patient received antituberculosis regimen, including isoniazid, rifampin, ethambutol, and ofloxacin." | 3.78 | Postoperative spondylodiscitis caused by Mycobacterium bovis BCG: a case study. ( Rätsep, T, 2012) |
| "On November 16, 2012, the Illinois State tuberculosis (TB) program notified CDC's Division of Tuberculosis Elimination of a national shortage of 300 mg tablets of the antituberculosis medication isoniazid (INH)." | 3.78 | Notes from the field: national shortage of isoniazid 300 mg tablets. ( , 2012) |
| "Moxifloxacin (MFX) is reported to have promising antimycobacterial activity, and has a potential to shorten tuberculosis (TB) treatment." | 3.78 | Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin. ( Geetharani, A; Hemanth Kumar, AK; Nandhakumar, B; Nandini, R; Ramachandran, G; Srinivasan, R; Sugirda, P; Tharani, CB, 2012) |
| " The synthesised compounds were evaluated for their antimycobacterial activity against Mycobacterium tuberculosis H(37)Rv and isoniazid (INH) resistant M." | 3.77 | Bis dihydropyrimidine: synthesis and antimycobacterial activity. ( Ali, MA; Govindasamy, J; Manogaran, E; Pandian, S; Sellappan, V, 2011) |
| "This study evaluated the feasibility of using 2 multiplex allele-specific polymerase chain reaction (MAS-PCR) assays targeting 2 mutations (codon 315 of the katG gene and the 15th nucleotide preceding the mabA-inhA operon) to directly detect isoniazid (INH)-resistant Mycobacterium tuberculosis in cultured isolates and respiratory specimens." | 3.77 | Direct detection of isoniazid-resistant Mycobacterium tuberculosis in respiratory specimens by multiplex allele-specific polymerase chain reaction. ( Cheng, VC; Ho, PL; Lam, JT; Lee, AS; Que, TL; Siu, GK; Tam, YH; Tse, CW; Yam, WC; Yip, KT; Yuen, KY, 2011) |
| "Isoniazid (INH) is a key agent in the treatment of tuberculosis." | 3.77 | Downregulation of katG expression is associated with isoniazid resistance in Mycobacterium tuberculosis. ( Ando, H; Kato, S; Kirikae, T; Kitao, T; Miyoshi-Akiyama, T; Mori, T, 2011) |
| "In molecular epidemiological studies of drug resistant Mycobacterium tuberculosis (TB) in Sweden a large outbreak of an isoniazid resistant strain was identified, involving 115 patients, mainly from the Horn of Africa." | 3.77 | Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden. ( Advani, A; Bruchfeld, J; Castro, E; Ghebremichael, S; Groenheit, R; Hoffner, S; Källenius, G; Kan, B; Koivula, T; Mazurek, J; Melefors, Ö; Pawlowski, A; Pennhag, A; Sandegren, L, 2011) |
| "The aim of this study was to investigate isoniazid, rifampicin, streptomycin and ethambutol resistance rates of Mycobacterium tuberculosis complex strains isolated from clinical specimens in the Mycobacteriology Laboratories of Karadeniz Technical University Hospital between January 2005-March 2010." | 3.77 | [Resistance rates of Mycobacterium tuberculosis complex strains isolated from clinical specimens]. ( Aydın, F; Bayramoğlu, G; Buruk, K; Dede, R; Dinç, U; Kaklıkkaya, N; Köse, T; Ozkul, G, 2011) |
| "Limited data exist about the clinical characteristics of Mycobacterium tuberculosis (TB) isolates with resistance to isoniazid (IZN)." | 3.77 | Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis. ( Fox, L; Haim, I; Kramer, MR; Metvachuk, A; Priess, R; Shitrit, D, 2011) |
| " Between day 52 and 5 mo after infection, 10 of the 170 mice infected according to this protocol developed torticollis, including mice in treatment groups that received combination antibiotic therapy of rifampin-pyrazinamide or moxifloxacin-rifampin-pyrazinamide." | 3.77 | Torticollis in mice intravenously infected with Mycobacterium tuberculosis. ( DeGroote, MA; Gilliland, JC; Kendall, LV; Lenaerts, AJ; Magden, ER; Weiner, CM, 2011) |
| "We conducted a case–control study to examine risk factors for isoniazid-monoresistant Mycobacterium tuberculosis in an ongoing outbreak in London." | 3.77 | Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: case-control study and recommendations. ( Altass, L; Anaraki, S; Bothamley, G; Brailsford, S; Carless, J; Charlett, A; Lipman, M; Lozewicz, S; Maguire, H; Yates, M; Yates, S, 2011) |
| "This study focused on evaluating four emulsion-based processing strategies for polymeric nanoparticle synthesis to explicate the mechanisms of nanoparticle formation and the influence on achieving sustained-release of two anti-tuberculosis drugs, isoniazid and rifampicin." | 3.77 | Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers. ( Choonara, YE; du Toit, LC; Jarvis, DL; Khan, RA; Kumar, P; Murphy, CS; Ndesendo, VM; Pillay, V, 2011) |
| "Our data confirm the usefulness of moxifloxacin in the treatment of tuberculosis and suggest that levofloxacin may be used as an alternative drug in the treatment of latent tuberculosis when it is not possible to use isoniazid." | 3.77 | Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model. ( Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M, 2011) |
| "We report treatment outcomes from a retrospective cohort of patients with isoniazid-monoresistant tuberculosis in rural South Africa." | 3.77 | Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. ( Jacobson, KR; Murray, MB; Streicher, EM; Theron, D; Victor, TC; Warren, RM, 2011) |
| "Quantifying isoniazid resistant (INH-R) tuberculosis (TB) is important because isoniazid resistance reduces the probability of treatment success, may facilitate the spread of multidrug resistance, and may reduce the effectiveness of isoniazid preventive therapy (IPT)." | 3.77 | Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009. ( Cohen, T; Jenkins, HE; Zignol, M, 2011) |
| "Isoniazide preventive therapy (IPT) is given to individuals with latent infection of tuberculosis (TB) to prevent the progression to active disease." | 3.77 | Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. ( Biadgilign, S; Deribew, A; Mindachew, M; Tessema, F, 2011) |
| "A case-control study including Caucasian patients with tuberculosis (TB) treated with isoniazid, rifampicin and pyrazinamide." | 3.77 | N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. ( Agúndez, JA; Botana-Rial, M; Constenla, L; Fernández-Villar, A; Leiro-Fernandez, V; Valverde, D; Vázquez-Gallardo, R, 2011) |
| " Unfortunately, the emergence of multiple drug-resistant tuberculosis in many parts of the world is leading to a diversification of drug regimens and to the use of drugs that are more toxic per se and more likely to interact with others." | 3.77 | Clinically significant drug interactions with antituberculosis agents. ( Davies, PD; Grange, JM; Winstanley, PA, 1994) |
| "A series of 27 salicylanilide-based carbamates was prepared as a part of our ongoing search for new antituberculosis drugs." | 3.76 | Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains. ( Férriz, JM; Imramovský, A; Kunc, F; Stolaríková, J; Vavríková, E; Vávrová, K; Vinsová, J, 2010) |
" In this study, ACH-702 was found to have promising in vitro antibacterial activity against Mycobacterium tuberculosis, with MICs of | 3.76 | In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates. ( Ackerman, M; Cynamon, MH; Pucci, MJ; Shoen, CM; Thanassi, JA, 2010) | |
| "Isoniazid-NAD truncated adducts embedding a lipophilic fragment were designed, synthesized and evaluated as inhibitors of the enoyl-acyl carrier protein (ACP) reductase (InhA) of Mycobacterium tuberculosis and as antimycobacterial agents." | 3.76 | Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents. ( Bernadou, J; Bernardes-Génisson, V; Constant, P; Delaine, T; Meunier, B; Quémard, A, 2010) |
| "In this study, a pyrosequencing method for monitoring two genes related to isoniazid (INH)-resistance and a region of the rpoB gene linked to rifampin (RMP)-resistance in Mycobacterium tuberculosis was developed and evaluated." | 3.76 | A pyrosequencing method for molecular monitoring of regions in the inhA, ahpC and rpoB genes of Mycobacterium tuberculosis. ( Bocanegra-García, V; Cruz-Pulido, W; Garza-González, E; González, GM; Rentería, A; Rivera, G, 2010) |
| "The aim of this study was to evaluate a simple, rapid, and inexpensive colorimetric nitrate reductase assay (NRA) for direct drug susceptibility testing (DST) of Mycobacterium tuberculosis against rifampicin (RIF) and isoniazid (INH)." | 3.76 | Evaluation of direct method of drug susceptibility testing of Mycobacterium tuberculosis to rifampicin and isoniazid by nitrate reductase assay in a national reference laboratory. ( Behera, D; Meharwal, SK; Myneedu, VP; Visalakshi, P, 2010) |
| "Isoniazid preventive therapy (IPT) prevents tuberculosis (TB) in people living with HIV (human immunodeficiency virus, PLWH)." | 3.76 | Tuberculosis in asymptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention. ( Agizew, TB; Arwady, MA; Kilmarx, PH; Mosimaneotsile, B; Motsamai, O; Nyirenda, S; Samandari, T; Tedla, Z; Wells, CD; Yoon, JC, 2010) |
| "Reports have shown that oleanolic acid (OA), a triterpenoid, exists widely in food, medicinal herbs and other plants, and that it has antimycobacterial activity against the Mycobacterium tuberculosis strain H37Rv (ATCC 27294)." | 3.76 | In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis. ( Deng, X; Fan, J; Ge, F; Guo, N; Jin, Q; Liu, S; Song, Y; Wang, X; Wu, X; Ye, H; Yu, L; Zeng, F, 2010) |
| "Chest radiography is used to screen for tuberculosis (TB) in asymptomatic persons living with the human immunodeficiency virus (PLWH) seeking isoniazid preventive therapy (IPT)." | 3.76 | Association of chest radiographic abnormalities with tuberculosis disease in asymptomatic HIV-infected adults. ( Agizew, T; Bachhuber, MA; Makwaruzi, VZ; Mboya, JJ; Nyirenda, S; Parker, JE; Samandari, T; Tallaksen, RJ; Tedla, Z, 2010) |
| "Active tuberculosis (TB) must be excluded before initiating isoniazid preventive therapy (IPT) in persons infected with human immunodeficiency virus (HIV), but currently used screening strategies have poor sensitivity and specificity and high patient attrition rates." | 3.76 | Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons. ( Benites, C; Brady, MF; Chavez, G; Coronel, J; Friedland, JS; Gilman, RH; Moore, DA; Navincopa, M; Pinedo, Y; Reddy, KP; Rojas, C; Sánchez, E; Solari, L; Ticona, E; Valencia, J, 2010) |
| "Despite World Health Organization recommendations, concerns about promoting resistance have impeded implementation of isoniazid preventive therapy (IPT) for tuberculosis (TB)." | 3.76 | Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. ( Chihota, VN; Churchyard, GJ; Fielding, KL; Grant, AD; Lewis, JJ; Russell, EC; van Halsema, CL, 2010) |
| "A retrospective study on isoniazid-resistant tuberculosis (TB) was conducted in the low-burden country, Denmark (DK)." | 3.76 | Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome. ( Andersen, AB; Andersen, PH; Bang, D; Thomsen, VØ, 2010) |
| "Despite recommendations to provide isoniazid preventive therapy (IPT) to eligible children aged <5 years who are in close contact with an infectious tuberculosis (TB) case, IPT delivery in high-burden settings remains poor." | 3.76 | Recording isoniazid preventive therapy delivery to children: operational challenges. ( Beyers, N; Enarson, DA; Hamade, H; Hesseling, AC; Mandalakas, AM; Van Wyk, SS, 2010) |
| "BACKGROUND/SETTING: Treatment for 3 months with rifampicin (R) and isoniazid (H) (3RH) for latent tuberculosis infection (LTBI), defined as an inappropriately positive tuberculin skin test with no clinical or x-ray evidence of disease, has been used locally since 1989." | 3.76 | Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children. ( Bright-Thomas, R; Morris, JA; Nandwani, S; Ormerod, LP; Smith, J, 2010) |
| "Isoniazid (INH) and rifampicin (RMP) resistance in Mycobacterium tuberculosis complex (MTC) isolates are mainly based on mutations in a limited number of genes." | 3.76 | Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana. ( Adjei, O; Browne, EN; Chinbuah, A; Gyapong, J; Hillemann, D; Homolka, S; Horstmann, RD; Kubica, T; Meyer, CG; Niemann, S; Osei, I; Owusu-Dabo, E; Ruesch-Gerdes, S, 2010) |
| " Latent tuberculosis was diagnosed at baseline and the patient was treated with isoniazid for 9 months." | 3.76 | Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis. ( Ferguglia, G; Laria, G; Prestinari, F, 2010) |
| "Antiretroviral therapy and isoniazid preventive therapy (IPT) are both effective interventions to prevent HIV-associated tuberculosis, but work via different mechanisms." | 3.76 | Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. ( Churchyard, GJ; De Cock, KM; Kranzer, K; Lawn, SD; Lewis, JJ; Wood, R, 2010) |
| "In this study, we designed a simple and rapid colorimetric detection method, a one-tube loop-mediated isothermal amplification (LAMP)-PCR-hybridization-restriction endonuclease-ELISA [one-tube LAMP-PCR-HY-RE-ELISA] system, to detect resistance to isoniazid, ethambutol and streptomycin in strains of Mycobacterium tuberculosis isolated from clinical specimens." | 3.76 | One-tube loop-mediated isothermal amplification combined with restriction endonuclease digestion and ELISA for colorimetric detection of resistance to isoniazid, ethambutol and streptomycin in Mycobacterium tuberculosis isolates. ( Chen, YH; Hsu, HJ; Lee, MF; Peng, CF, 2010) |
| "The spoligotyping-based population structure of multidrug-resistant (MDR) Mycobacterium tuberculosis strains isolated in Poland (n = 46), representing all culture-positive MDR tuberculosis (MDR-TB) cases, was compared to that of isoniazid (INH)-monoresistant strains (n = 71) isolated in 2004." | 3.76 | Spoligotype-based comparative population structure analysis of multidrug-resistant and isoniazid-monoresistant Mycobacterium tuberculosis complex clinical isolates in Poland. ( Augustynowicz-Kopec, E; Jagielski, T; Rastogi, N; Zozio, T; Zwolska, Z, 2010) |
| "We evaluated high-resolution melting (HRM) curve analysis as a tool for detecting rifampin (RIF) and isoniazid (INH) resistance in Mycobacterium tuberculosis in an accurate, affordable, and rapid manner." | 3.76 | High-resolution melting curve analysis for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates. ( Chang, CL; Cho, EH; Choi, GE; Hwang, SH; Kim, HH; Kim, HJ; Kim, JH; Lee, EY; Lee, SM; Yi, J, 2010) |
| "The standard antitubercular treatment (ATT), which consists of isoniazid (INH), rifampicin (RIF), ethambutol, and pyrazinamide (PZA), is the best available treatment for tuberculosis (TB)." | 3.76 | Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation. ( Antonini, TM; Antoun, F; Azoulay, D; Castaing, D; Delvart, V; Escaut, L; Ichai, P; Saliba, F; Samuel, D; Sebagh, M, 2010) |
| "Despite good evidence that isoniazid preventive therapy (IPT) reduces incidence of tuberculosis among people with HIV infection, implementation of IPT is low." | 3.76 | Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. ( Chandler, C; Charalambous, S; Churchyard, GJ; Dwadwa, T; Grant, AD; Hamilton, R; Lester, R, 2010) |
| "To describe the association between isoniazid preventive therapy (IPT) and mortality among individuals starting antiretroviral therapy (ART) in a workplace programme in South Africa where tuberculosis (TB) incidence is very high." | 3.76 | Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. ( Charalambous, S; Churchyard, GJ; Dowdeswell, R; Fielding, KL; Grant, AD; Hoffmann, CJ; Innes, C; Pienaar, J, 2010) |
| "The objective of this study was to evaluate the resistance to isoniazid (INH), rifampicin (RIF), streptomycin (STR) and ethambutol (EMB), with the Canetti's proportions method (PM) and the nitrate reductase assay (NRA) of 59 clinical strains of Mycobacterium tuberculosis, isolated in the period of august 2005 to december 2006, in Sucre state, Venezuela." | 3.76 | [Susceptibility of M. tuberculosis to antituberculosis drugs as determined by two methods, in Sucre state, Venezuela]. ( Bello, T; Chirinos, G; De Donato, M; de Waard, JH; Mendoza, R; Takiff, H, 2010) |
| "22 microM) and was 3 times more active than standard isoniazid (INH) and equally active as rifampicin (RIF) in log-phase culture of Mycobacterium tuberculosis H37Rv." | 3.75 | 5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species. ( Banerjee, D; Dhakla, P; Manjashetty, TH; Senthilkumar, P; Sriram, D; Yogeeswari, P, 2009) |
| "To design and standardize an in-house reverse line blot hybridization (RLBH) assay for the accurate identification of 15 clinically relevant species of mycobacteria and for the detection of drug resistance to rifampin (RIF), isoniazid (INH), and streptomycin (STR) in Mycobacterium tuberculosis complex (MTB)." | 3.75 | Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex. ( Mehta, A; Rodrigues, C; Shenai, S, 2009) |
| "Risk factors and treatment outcomes under program conditions for isoniazid (INH)-monoresistant tuberculosis have not been well described." | 3.75 | Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. ( Cattamanchi, A; Dantes, RB; Grinsdale, J; Hopewell, PC; Jarlsberg, LG; Kawamura, LM; Metcalfe, JZ; Nahid, P; Osmond, D, 2009) |
| " tuberculosis strains were resistant to EMB alone and EMB together with additional resistance to rifampicin and isoniazid (9 of 50, 18% and 11 of 50, 22%, respectively)." | 3.75 | Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. ( Ahmad, S; Jaber, AA; Mokaddas, E, 2009) |
| "To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy." | 3.75 | Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results. ( Campos-Neto, A; Guillet, J; Joshi, S; Kashino, SS; Napolitano, DR; Nardell, E; Pollock, NR; Sloutsky, A; Wong, M, 2009) |
| "Isoniazid given daily for 9 months is the standard treatment for latent tuberculosis infection (LTBI), but its effectiveness is limited by poor completion rates." | 3.75 | Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. ( Hamilton, CD; Holland, DP; Sanders, GD; Stout, JE, 2009) |
| "In most countries with a high burden of tuberculosis, children with tuberculosis are prescribed isoniazid at dosages of 4-6 mg/kg/day, as recommended by international authorities." | 3.75 | Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines. ( Donald, PR; Hussey, GD; McIlleron, H; Schaaf, HS; Smith, PJ; Werely, CJ; Willemse, M, 2009) |
| " In the present study, various well-known PDF inhibitors, such as BB-3497, actinonin, 1,10-phenanthroline, hydroxylamine hydrochloride and galardin, were selected to evaluate their inhibitory activity against Mycobacterium tuberculosis." | 3.75 | In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv. ( Kanwar, AJ; Khuller, GK; Sharma, A; Sharma, S, 2009) |
| " We describe a candidate for kidney transplantation who was treated with isoniazid because of active tuberculosis." | 3.75 | Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test. ( Brambilla, C; Cagni, N; Colombo, MB; Crespiatico, L; Innocente, A; Poli, F; Scalamogna, M, 2009) |
| "Completion rates, total cost, and adverse effects were compared for patients in central Massachusetts treated for latent tuberculosis infection with 9 months of isoniazid or 4 months of rifampin." | 3.75 | A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts. ( Daly, JS; Ellis, J; Kaminski, M; Wessolossky, M; Young, H, 2009) |
| "Macrophage responses to infection with Mycobacterium tuberculosis (MTB) and treatment with soluble isoniazid (INH) plus rifabutin (RFB) versus microparticles containing equivalent amounts of drugs were compared." | 3.75 | Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy. ( Misra, A; Mohan, M; Muttil, P; Patel, SK; Sharma, R; Singh, AK; Verma, RK; Yadav, AB, 2009) |
| "The marked reduction in the potent early bactericidal activity of isoniazid during the initial phase of antituberculosis (anti-TB) therapy has been attributed not only to the depletion of logarithmically growing bacilli but also to the emergence of isoniazid resistance." | 3.75 | Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. ( Ahmad, Z; Bishai, WR; Fraig, MM; Grosset, JH; Karakousis, PC; Klinkenberg, LG; Nuermberger, EL; Peloquin, CA; Pinn, ML, 2009) |
| "To evaluate the frequency and nature of mutations in genes associated with resistance to rifampicin and isoniazid in Mycobacterium tuberculosis isolates collected from Yangon, Myanmar." | 3.75 | Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing. ( Grewal, HM; Kross, M; Phyu, S; Stavrum, R; Syre, H; Ti, T; Valvatne, H, 2009) |
| "Isoniazid preventive therapy (IPT) is recognised as an important component of collaborative tuberculosis (TB) and human immunodeficiency virus (HIV) activities to reduce the burden of TB in people living with HIV (PLHIV)." | 3.75 | Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. ( Aït-Khaled, N; Alarcon, E; Bissell, K; Boillot, F; Caminero, JA; Chiang, CY; Clevenbergh, P; Dlodlo, R; Enarson, DA; Enarson, P; Ferroussier, O; Fujiwara, PI; Harries, AD; Heldal, E; Hinderaker, SG; Kim, SJ; Lienhardt, C; Rieder, HL; Rusen, ID; Trébucq, A; Van Deun, A; Wilson, N, 2009) |
| "A meta-analysis of isoniazid preventive therapy (IPT) in human immunodeficiency virus-positive individuals failed to show a mortality benefit even though tuberculosis is a leading cause of death in this group." | 3.75 | Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study. ( Bachhuber, MA; Gross, R, 2009) |
| "The mutation in KatG315 is found in the majority of isoniazid resistant strains worldwide, especially in areas with a high incidence of tuberculosis." | 3.75 | High level association of mutation in KatG315 with MDR and XDR clinical isolates of Mycobacterium tuberculosis in Belarus. ( Setareh, M; Surkova, LK; Titov, LP, 2009) |
| "For the purpose of a side-effect monitoring of isoniazid (INH), we investigated the relationship between the genotypes of drug-metabolizing enzymes involved in INH metabolism and the serum concentrations of INH and its metabolites in 129 tuberculosis patients hospitalizing in the National Hospital Organization Chiba-East Hospital." | 3.74 | Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. ( Fukino, K; Hashimoto, M; Hirai, S; Nakamura, T; Sasaki, Y; Ueno, K; Yamagishi, F, 2008) |
| "These results suggest that regimens consisting of isoniazid or moxifloxacin plus rifapentine and pyrazinamide may dramatically shorten the duration of treatment needed to cure human tuberculosis." | 3.74 | Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? ( Almeida, D; Grosset, JH; Nuermberger, EL; Rosenthal, IM; Zhang, M, 2008) |
| "The purpose of this study was to evaluate the GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) for its ability to detect resistance to rifampin (RIF) and isoniazid (INH) in Mycobacterium tuberculosis clinical strains and directly in clinical samples." | 3.74 | GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. ( Domínguez, J; Garcia-Sierra, N; Haba, L; Lacoma, A; Maldonado, J; Prat, C; Rosés, S; Ruiz-Manzano, J, 2008) |
| "The genetic compositions of 71 isoniazid-resistant Mycobacterium tuberculosis strains from Poland were determined by spoligotyping." | 3.74 | Genetic diversity of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Poland and assessed by spoligotyping. ( Augustynowicz-Kopec, E; Jagielski, T; Zwolska, Z, 2008) |
| "Seven percent of tuberculosis (TB) cases reported to the US National Tuberculosis Surveillance System in 2005 had Mycobacterium tuberculosis isolates with resistance to at least isoniazid." | 3.74 | Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003. ( Armstrong, LR; Harrington, TA; Hoopes, AJ; Ijaz, K; Kammerer, JS, 2008) |
| "Considering the significant increase of isoniazid (INH) resistance in Iranian Mycobacterium tuberculosis isolates in the last few years and to investigate the prevalence and diagnostic potential of the most commonly reported mutations associated with INH resistance in Iran, we analyzed parts of the katG gene and fabG1-inhA and oxyR-ahpC regulatory regions in a sample of 48 INH-resistant and 25 INH-sensitive isolates." | 3.74 | Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran. ( Doustdar, F; Farnia, P; Khosravi, AD; Masjedi, MR; Velayati, AA, 2008) |
| "It is believed that the cessation of isoniazid's early bactericidal activity during the initial phase of antituberculosis therapy is due to the depletion of Mycobacterium tuberculosis in the exponential phase of growth." | 3.74 | Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. ( Ambrose, PG; Bhavnani, SM; Brown, D; Drusano, GL; Gumbo, T; Liu, W; Louie, A, 2007) |
| "The aim of the study presented here was to determine the minimal inhibitory concentration of isoniazid for strains of isoniazid-resistant or multidrug-resistant Mycobacterium tuberculosis isolated from children in the Western Cape Province of South Africa." | 3.74 | Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. ( Brittle, W; Donald, PR; Engelke, E; Hesseling, AC; Marais, BJ; Schaaf, HS; van Helden, PD; Victor, TC, 2007) |
| "To evaluate treatment results of Rifampicin (R) resistant Isoniazid (H) susceptible tuberculosis cases." | 3.74 | [Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study]. ( Aono, A; Ito, K; Ogata, H; Wada, M; Yoshiyama, T, 2007) |
| "Three Mycobacterium tuberculosis genetic loci--rpoB and katG genes and the fabG1(mabA)-inhA operon promoter region--were studied to reveal the mutations associated with rifampicin and isoniazid resistance." | 3.74 | Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation. ( Afanas'ev, MV; Cherednichenko, AG; Chernousova, LN; Govorun, VM; Ikryannikova, LN; Il'ina, EN; Kamaev, EY; Kinsht, VN; Kuz'min, AV; Larionova, EE; Sidorenko, SV; Skorniakov, SN; Smirnova, TG, 2007) |
| "The preliminary study was performed to determine the frequency of tuberculin skin test (TST) positivity among 26 patients and their donors screened by TST to investigate whether tuberculin positivity of a recipient or donor influenced the rate of tuberculosis disease, transplant-related events, and to evaluate the effectiveness of isoniazide (INAH) prophylaxis administered to those with positive TST." | 3.74 | Tuberculin skin test positivity in pediatric allogeneic BMT recipients and donors in Turkey. ( Cetin, M; Gulhan, B; Ozcelik, U; Tavil, B; Tezcan, I; Tuncer, M; Uckan, D, 2007) |
| "The new GenoType MTBDRplus assay (Hain Lifescience GmbH, Nehren, Germany) was tested with 125 clinical isolates and directly with 72 smear-positive sputum specimens for its ability to detect rifampin (RMP) and isoniazid (INH) resistance in Mycobacterium tuberculosis complex (MTBC) strains." | 3.74 | Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. ( Hillemann, D; Richter, E; Rüsch-Gerdes, S, 2007) |
| "Gatifloxacin previously demonstrated good in vitro and in vivo activities against Mycobacterium tuberculosis." | 3.74 | Gatifloxacin in combination with rifampicin in a murine tuberculosis model. ( Cynamon, M; Shoen, C; Sklaney, MR, 2007) |
| " tuberculosis strains, which were selected from the collection of RYOKEN drug resistance survey in 2002, were selected and subjected to the susceptibility testing to isoniazid using MGIT AST and 1% Ogawa standard methods." | 3.74 | [Comparative study of bactec MGIT 960 AST and conventional proportion method using Ogawa medium for the drug susceptibility testing of Mycobacterium tuberculosis to isoniazid]. ( Abe, C; Fujii, S; Kamada, A; Kawabe, Y; Kawashiro, T; Kobayashi, I; Machida, K; Mitarai, S; Mori, K; Ogata, H; Shigetoh, E; Suyama, H; Suzuki, K; Takashima, T; Takigawa, S; Tano, M; Wada, M; Yano, S, 2007) |
| "Treatment of latent tuberculosis infection with isoniazid (INH) or rifampin (RIF) is controversial in liver transplant candidates due to potential hepatotoxicity." | 3.74 | Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. ( Bui, L; Jahng, AW; Joyner, JL; Tran, T, 2007) |
| "The aim of the present study was to compare the effect of patient choice on completion rates and adverse drug reactions for patients treated for latent tuberculosis infection (LTBI) using 3-month rifampicin and isoniazid treatment (3RH) or 6-month isoniazid treatment (6H)." | 3.74 | Patient choice promotes adherence in preventive treatment for latent tuberculosis. ( Bates, IP; Bothamley, GH; Engova, D; Rennie, TW, 2007) |
| "Isoniazid (INH) therapy for tuberculosis carries a known risk for hepatoxicity, and leads to hepatic failure in a small subset of patients." | 3.74 | Isoniazid-related hepatic failure in children: a survey of liver transplantation centers. ( Ament, ME; Chao, CS; Martín, MG; McDiarmid, SV; Sharp, HL; Sinatra, FR; Vargas, JH; Wu, SS, 2007) |
| "Standard treatment of active tuberculosis (TB) consists of isoniazid (INH), rifampin (RMP), pyrazinamide (PZA) and ethambutol (EMB)." | 3.74 | Adverse drug reactions associated with first-line anti-tuberculosis drug regimens. ( Bruchet, N; Elwood, RK; Fitzgerald, JM; Marra, CA; Marra, F; Moadebi, S; Richardson, K, 2007) |
| "Seventy-four Mycobacterium tuberculosis clinical isolates from China were subjected to drug susceptibility testing using ethambutol, isoniazid, rifampin, and ofloxacin." | 3.74 | Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China. ( Otomo, K; Shi, R; Sugawara, I; Zhang, G; Zhang, J, 2007) |
| "To determine the sensitivity and specificity of the Arkansas method for detecting isoniazid (INH) metabolites among South African adults and to examine the effect of smoking status on positive results." | 3.74 | Evaluation of the Arkansas method of urine testing for isoniazid in South Africa. ( Churchyard, G; Fielding, K; Grant, AD; Hanifa, Y; Lewis, J; Mngadi, K, 2007) |
| "In a prospective study conducted by laboratory technologists in a diagnostic laboratory in Cape Town, South Africa, a semi-automated phage-based antibiotic susceptibility assay was implemented and the performance of the luciferase reporter mycobacteriophage (LRP) system for susceptibility testing of clinical Mycobacterium tuberculosis complex (MTC) isolates against rifampin and isoniazid was evaluated." | 3.74 | Evaluation of a semi-automated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa. ( Banaiee, N; Barthus, C; Behr, MA; Jacobs, WR; January, V; Lambrick, M; Roditi, D; Steyn, LM, 2008) |
| "The presence of mutations in specific regions of katG, inhA, oxyR-ahpC and kasA associated with isoniazid (INH)-resistant clinical isolates of Mycobacterium tuberculosis from India were analysed by DNA sequencing." | 3.74 | Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India. ( Narayanan, PR; Narayanan, S; Nusrath Unissa, A; Selvakumar, N, 2008) |
| " We report the case of a 45-year-old man who had ankylosing spondylitis and was receiving infliximab and isoniazid for latent tuberculosis." | 3.74 | Severe sporotrichoid fish tank granuloma following infliximab therapy. ( Chatziolou, E; Frangoulis, E; Katsambas, A; Koumantaki-Mathioudaki, E; Rallis, E, 2007) |
| "Isoniazid (INH, isonicotinic acid hydrazine) is one of only two therapeutic agents effective in treating tuberculosis." | 3.74 | The tuberculosis prodrug isoniazid bound to activating peroxidases. ( Brown, KA; Macdonald, IK; Metcalfe, C; Moody, PC; Murphy, EJ; Raven, EL, 2008) |
| "Isoniazid is the most widely used first line antituberculosis drug." | 3.74 | Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis. ( Golani, A; Maitra, A; Patel, Z; Singh, N, 2008) |
| "Despite having potent activity against actively replicating Mycobacterium tuberculosis, isoniazid has very limited activity against dormant bacilli." | 3.74 | Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. ( Bishai, WR; Karakousis, PC; Williams, EP, 2008) |
| "To investigate retrospectively the incidence of drug-induced hepatitis (DIH) caused by antituberculosis drugs including isoniazid (INH), rifampicin (RFP), with and without pyrazinamide (PZA), and to evaluate risk factors for DIH in tuberculosis patients complicated with chronic hepatitis (CH)." | 3.74 | [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis]. ( Akagawa, S; Ariga, H; Kaneko, Y; Kawabe, Y; Kawashima, M; Kunogi, M; Kurashima, A; Machida, K; Masuda, K; Matsui, H; Matsui, Y; Nagai, H; Nagayama, N; Oshima, N; Shimada, M; Suzuki, J; Tamura, A; Toyoda, E; Yotsumoto, H, 2008) |
| "Tuberculosis is treated with a group of drugs that need to be used over a long period of time and isoniazid is the major drug in this group." | 3.74 | Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. ( Aktoğu, S; Bozok Cetintaş, V; Erer, OF; Eroğlu, Z; Kosova, B; Ozdemir, I; Topçuoğlu, N, 2008) |
| "Reduction of colony forming units by rifampicin-isoniazid therapy given 9-17 weeks post-infection was made more pronounced by immunotherapy with a vaccine made of fragmented Mycobacterium tuberculosis cells detoxified and liposomed (RUTI), given on weeks 17, 19 and 21 post-infection, in the murine model of tuberculosis in C57BL/6 and DBA/2 inbred strains." | 3.73 | Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis. ( Amat, I; Arcos, V; Ausina, V; Cardona, PJ; Díaz, J; Gordillo, S; Guirado, E; Tapia, G; Vilaplana, C, 2005) |
| "The efficacy of isoniazid (INAH) prophylaxis against tuberculosis (TB) in patients taking corticosteroid remains controversial." | 3.73 | Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy. ( Chan, TM; Lau, CS; Lo, Y; Mok, MY; Wong, WS, 2005) |
| "To investigate the prognosis of isoniazid (H) resistant rifampicin (R) susceptible tuberculosis cases with emphasis on the risk factors of developing MDR." | 3.73 | [Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis]. ( Aono, A; Ito, K; Ogata, H; Wada, M; Yoshiyama, T, 2005) |
| "To test the reliability and validity of 8-day and 30-day self-report measures of adherence to daily isoniazid (INH) for treatment of latent tuberculosis infection (LTBI)." | 3.73 | Self-report INH adherence measures were reliable and valid in Latino adolescents with latent tuberculosis infection. ( Berg, JP; Blumberg, EJ; Hovell, MF; Kelley, NJ; Sipan, CL; Vera, AY, 2005) |
| "The present study was planned to evaluate the chemotherapeutic potential of nebulized solid lipid particles (SLPs) incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis." | 3.73 | Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. ( Khuller, GK; Pandey, R, 2005) |
| "To determine the overall incidence of isoniazid (INH) hepatotoxicity in a public health tuberculosis clinic over a 7-year period, and to determine if systematic, limited aspartate aminotransferase (AST) monitoring would be of benefit in detecting INH hepatotoxicity." | 3.73 | Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. ( Chrisman, CR; Fountain, FF; Self, TH; Tolley, E, 2005) |
| "Elucidation of the molecular basis of isoniazid (INH) resistance in Mycobacterium tuberculosis has led to the development of different genotypic approaches for the rapid detection of INH resistance in clinical isolates." | 3.73 | Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia. ( Billman-Jacobe, H; Fyfe, J; Globan, M; Lavender, C; Sievers, A, 2005) |
| "To report a case of optic neuritis associated with concurrent etanercept and isoniazid therapy." | 3.73 | Optic neuritis with concurrent etanercept and isoniazid therapy. ( Antón-Torres, R; Borrás-Blasco, J; González-Ferrandez, JA; Navarro-Ruiz, A; Noguera-Pons, R; Romero-Crespo, I, 2005) |
| "M tuberculosis resistance to isoniazid showed a decreased rate over the study period from 20 to 5." | 3.73 | Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003. ( Abed, MS; Al-Muraikhy, AA; Al-Tawfiq, JA, 2005) |
| "Since the introduction of new recommendations for the treatment of latent tuberculosis infection (LTB1) disregarding age as a limitation, increasing numbers of older individuals are expected to undergo treatment with isoniazid for the prevention of tuberculosis, raising the potential for an increase in isoniazid hepatotoxicity." | 3.73 | Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection. ( Aziz, H; Debari, VA; Ismail, M; Khan, MA; Shubair, M, 2006) |
| "Isoniazid preventive therapy (IPT) has been shown to reduce the risk of active tuberculosis in tuberculin skin test (TST) positive human immunodeficiency virus (HIV) infected individuals." | 3.73 | Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand. ( Hiransuthikul, N; Hiransuthikul, P; Jirawisit, M; Kasak, S; Nelson, KE; Paewplot, R, 2005) |
| "The purpose of this study was to evaluate whether non-US-born pregnant women receiving prenatal care are targeted for treatment of latent tuberculosis (TB) infection (LTBI) with isoniazid (INH) to prevent active TB." | 3.73 | Tuberculosis prevention for non-US-born pregnant women. ( DeHovitz, JA; Driver, CR; Munsiff, SS; Pfeiffer, MR; Sackoff, JE; Streett, LS, 2006) |
| "A new, fast 'low cost and density' DNA microarray (LCD array), designed for the detection of mutations that confer isoniazid or rifampicin resistance in Mycobacterium tuberculosis isolates, has been developed and was evaluated using 46 resistant clinical isolates from Barcelona." | 3.73 | Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. ( Aragón, LM; Coll, P; Español, M; Garrigó, M; Heiser, V; Navarro, F, 2006) |
| "Isoniazid is the antituberculosis drug that causes psychiatric manifestations most often." | 3.73 | [Isoniazid-induced visual hallucinosis]. ( Ben Kheder, A; Ben Mefteh, R; Bourguiba, M; Drira, I; Fennira, H; Maâlej, S, 2006) |
| "A novel PCR-based reverse hybridization method Genotype MTBDR assay (Hain Lifescience GmbH, Nehren, Germany) was evaluated for rapid detection of rifampin (RIF) and isoniazid (INH) resistance in Turkish Mycobacterium tuberculosis isolates." | 3.73 | Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. ( Akinci, P; Cavusoglu, C; Soyler, I; Turhan, A, 2006) |
| "Nucleotide changes in catalase peroxidase (Kat G) gene and gene encoding the beta subunit of RNA polymerase (rpo B), responsible for isoniazid and rifampicin drug resistance were determined in the clinical isolates of Mycobacterium tuberculosis by PCR-RFLP, Line probe assay and DNA sequencing." | 3.73 | Molecular characterization of mutation associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis isolates. ( Anand, R; Basir, SF; Gupta, S; Khare, S; Lal, S; Negi, SS; Pasha, ST, 2006) |
| "Treatment of latent tuberculosis infection (LTBI) is an important aspect of tuberculosis control in the United States, but the effectiveness of this strategy is compromised by poor adherence to the recommended 9-month isoniazid regimen." | 3.73 | Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. ( Adelakun, A; Baruch, N; Bur, S; Cronin, WA; Doherty, MC; Dorman, SE; Federline, L; Karney, W; Milman, J; Montes de Oca, R; Page, KR; Sifakis, F; Walsh, T, 2006) |
| "Isoniazid (INH) and rifampin (RIF) are two of the most important antituberculosis drugs, and resistance to both of these drugs can often result in treatment failure and fatal clinical outcome." | 3.73 | Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. ( Dormandy, J; Mitsani, D; Rivenburg, J; Salfinger, M; Somoskovi, A, 2006) |
| "To apply the Arkansas color method in order to evaluate drug compliance and factors that can predict treatment adherence in patients being treated for latent tuberculosis infection (LTBI) with a single daily dose of isoniazid (INH)." | 3.72 | Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection. ( Amir, J; Baum, G; Eidlitz-Markus, T; Mimouni, M; Zeharia, A, 2003) |
| "To optimise an anti-tuberculosis extemporaneous powder formulation for suspension in order to develop a fixed combination of rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride as a powder to be reconstituted with water by the patient prior to administration." | 3.72 | Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination. ( Danckwerts, MP; Ebrahim, S; Pillay, V, 2003) |
| " Specimens were cultured for Mycobacterium tuberculosis and tested for resistance to isoniazid, rifampicin, ethambutol, and streptomycin." | 3.72 | Control of anti-tuberculosis drug resistance in Botswana. ( Binkin, NJ; Kenyon, TA; Mallon, V; Moeti, TL; Mwasekaga, MJ; Talbot, EA, 2003) |
| "7%) isoniazid-resistant Mycobacterium tuberculosis isolates." | 3.72 | Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania. ( Bakonyte, D; Baranauskaite, A; Cicenaite, J; Sosnovskaja, A; Stakenas, P, 2003) |
| "To assess the impact of iron loading on the activity of isoniazid and ethambutol in the treatment of murine tuberculosis." | 3.72 | Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis. ( Boelaert, RJ; Grosset, J; Lounis, N; Maslo, C; Truffot-Pernot, C, 2003) |
| "Isoniazid is one of the most useful drugs for the treatment of tuberculosis." | 3.72 | Current interest of isoniazid in the chemotherapy of tuberculosis in the light of its in vitro activity. ( Casal, M; Rodríguez-Cano, F; Ruiz, P; Zerolo, FJ, 2003) |
| "To determine the efficacy of secondary preventive therapy against tuberculosis (TB) among gold miners working in South Africa." | 3.72 | Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy? ( Chaisson, RE; Charalambous, S; Churchyard, GJ; Corbett, EL; Day, JH; De Cock, KM; Fielding, K; Grant, AD; Hayes, RJ; Samb, B, 2003) |
| "Mutations in the katG locus of catalase peroxidase in Mycobacterium tuberculosis (MTB) account for major isoniazid (INH) resistance." | 3.72 | Detection of katG Ser315Thr substitution in respiratory specimens from patients with isoniazid-resistant Mycobacterium tuberculosis using PCR-RFLP. ( Chiu, A; Ho, PL; Kam, KM; Leung, ET; Seto, WH; Yam, WC; Yuen, KY, 2003) |
| "To determine the prevalence of isoniazid resistance by year of birth among previously treated and untreated tuberculosis patients by country of birth." | 3.72 | Isoniazid resistance among tuberculosis patients by birth cohort in Germany. ( Forssbohm, M; Loddenkemper, R; Rieder, HL, 2003) |
| " tuberculosis to isoniazid (INH) and rifampin (RIF) based on incorporation of nitrate in broth cultures containing growth supplements." | 3.72 | Rapid colorimetric method for testing susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin in liquid cultures. ( Bjorvatn, B; Grewal, HM; Phyu, S; Sandven, P; Syre, H, 2003) |
| "The capacity to generate a chronic and persistent infection in the experimental murine model of tuberculosis induced aerogenically by a low-dose inoculum was determined in eight isoniazid-resistant clinical strains of Mycobacterium tuberculosis showing different catalase-peroxidase (C-P) activities." | 3.72 | Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. ( Amat, I; Ariza, A; Ausina, V; Cardona, PJ; Díaz, J; Gordillo, S; Llatjós, R; Lonca, J; Pallarés, A; Vilaplana, C, 2003) |
| "The results of animal studies suggest that isoniazid-resistant strains of Mycobacterium tuberculosis are less pathogenic than isoniazid-susceptible strains." | 3.72 | Effect of drug resistance on the generation of secondary cases of tuberculosis. ( Burgos, M; Daley, CL; DeRiemer, K; Hopewell, PC; Small, PM, 2003) |
| "The absorption of rifampin, isoniazid, and D-xylose in patients with human immunodeficiency virus (HIV) infection and diarrhea, in patients with HIV infection and tuberculosis (TB), in patients with pulmonary TB alone, and in healthy subjects was studied." | 3.72 | Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis. ( Gurumurthy, P; Hemanth Kumar, AK; Krishnarajasekhar, OR; Kumar, S; Padmapriyadarsini, C; Paramesh, P; Rajasekaran, S; Ramachandran, G; Sekar, L; Swaminathan, S; Venkatesan, P, 2004) |
| "The accuracy of the Bactec MGIT 960 system for susceptibility testing of 177 clinical isolates of Mycobacterium tuberculosis to first line drugs (isoniazid, rifampicin, ethambutol and streptomycin) was compared with the agar reference method." | 3.72 | Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study. ( Anagnostou, S; Costopoulos, C; Gitti, Z; Kontos, F; Maniati, M; Maniatis, AN; Nicolaou, S; Petinaki, E; Tselentis, I, 2004) |
| "To study the probability of acquiring drug resistance to isoniazid (H) and rifampicin (R) on recurrence after treatment success, default and failure, among sputum smear-positive pulmonary tuberculosis (TB) patients treated with standardised short-course chemotherapy." | 3.72 | Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. ( Mori, T; Nampaisan, O; Palittapongarnpim, P; Rhiengtong, D; Supawitkul, S; Uthaivorawit, W; Yanai, H; Yoshiyama, T, 2004) |
| "We have identified a potential quality control strain of Mycobacterium tuberculosis to monitor isoniazid susceptibility testing." | 3.72 | Identification of a Mycobacterium tuberculosis strain with stable, low-level resistance to isoniazid. ( Gross, W; Heifets, L; Higgins, M; Madison, BM; Morlock, G; Ridderhof, JC; Siddiqi, SH; Thompson, A; Warren, N, 2004) |
| "The presence of ACC and other mutations at codon 315 in the katG gene was detected by PCR amplification followed by restriction fragment length polymorphism (PCR-RFLP) generated with restriction enzymes Msp I and MspA1 I in 37 isoniazid-resistant and 22-susceptible Mycobacterium tuberculosis isolates from Kuwait obtained in 2001." | 3.72 | Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East. ( Ahmad, S; Mokaddas, E, 2004) |
| "To characterize the treatment of latent tuberculosis infection and the impact on treatment completion of the 2-month rifampin and pyrazinamide regimen as compared to the traditional 6- to 12-month isoniazid regimen among persons incarcerated at a county correctional facility." | 3.72 | Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens. ( Brannan, GL; Clancey, T; Conklin, TJ; Lincoln, T; Lynch, V; Rose, DN; Tuthill, RJ, 2004) |
| "National mycobacteriology reference laboratory in Peru conducting routine testing of susceptibility to isoniazid, rifampin, ethambutol, pyrazinamide, and streptomycin, in Mycobacterium tuberculosis isolates from previously treated patients." | 3.72 | Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001. ( Asencios-Solis, L; Bayona, J; Becerra, MC; Leo-Hurtado, E; Quispe-Torres, N; Salazar-Lindo, E; Vásquez-Campos, L, 2004) |
| "The prevalence of mutations in the katG, inhA and oxyR-ahpC genes of isoniazid (INH)-resistant Mycobacterium tuberculosis isolates in the Philippines were determined." | 3.72 | Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical strains isolated in the Philippines. ( Herrera, L; Jiménez, MS; Portero, JL; Sáez-Nieto, JA; Saiz, P; Valverde, A, 2004) |
| "Isoniazid, a first-line antibiotic used for the treatment of tuberculosis, is a prodrug that requires activation by the Mycobacterium tuberculosis enzyme KatG." | 3.72 | Purification and characterization of Mycobacterium tuberculosis KatG, KatG(S315T), and Mycobacterium bovis KatG(R463L). ( Belisle, JT; Brennan, PJ; Cockerill, FR; Hall, L; Hill, PJ; Lane, BD; Lukat-Rodgers, GS; Roberts, GD; Rodgers, KR; Rusnak, F; Uhl, JR; Wengenack, NL, 2004) |
| " The infant was born to a woman with active tuberculosis, and she was on prophylactic isoniazid." | 3.72 | Isoniazid and hypoglycaemia in a premature infant. ( Dağoğlu, T; Ovali, F; Samanci, N; Sevinç, E, 2004) |
| "We investigated mutations in the genes katG, inhA (regulatory and structural regions), and kasA and the oxyR-ahpC intergenic region of 97 isoniazid (INH)-resistant and 60 INH-susceptible Mycobacterium tuberculosis isolates obtained in two states in Brazil: São Paulo and Paraná." | 3.72 | Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. ( Barco, P; Cardoso, RF; Cecon, L; Cooksey, RC; Forestiero, F; Hirata, MH; Hirata, RD; Leite, CQ; Mamizuka, EM; Morlock, GP; Sato, DN; Shikama, Mde L, 2004) |
| "Severe liver injury has been attributed to preventive treatment of latent tuberculosis infection with a 2-month course of rifampin-pyrazinamide." | 3.72 | Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment. ( Baars, H; Borgdorff, M; Cobelens, F; Kalisvaart, N; Keizer, S; Kik, S; Mensen, M; Trompenaars, MC; van Gerven, P; van Hest, R, 2004) |
| "In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)-infected individuals with latent tuberculosis infection (LTBI)." | 3.72 | Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? ( Chaisson, RE; Cohn, DL; Gordin, FM; Matts, JP; O'Brien, RJ, 2004) |
| "Sixty-eight BALB/c mice were infected with the intravenous injections of Mycobacterium tuberculosis (MBT), a clinical strain resistant to streptomycin, isoniazid, rifampicin, and kanamycin." | 3.72 | [Use of dissolved ozone in the treatment of experimental tuberculosis in mice]. ( Belianin, II; Martynova, LP; Nikonenko, BV; Shmelev, EI, 2004) |
| "Treatment of initial reactors with isoniazid in all three risk groups was associated with a net savings of $14,800 to $15,700 for each tuberculosis case prevented." | 3.72 | Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis. ( Salpeter, EE; Salpeter, SR, 2004) |
| "The worldwide threat of drug-resistant tuberculosis (TB) to human health has led to the development of molecular methods for rapidly determining the resistance of clinical Mycobacterium tuberculosis isolates to the two front-line antituberculous drugs, isoniazid and rifampin." | 3.71 | Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait. ( Abal, AT; Ahmad, S; Mokaddas, E, 2002) |
| "A method for detecting multidrug-resistant Mycobacterium tuberculosis by using a reduction of resazurin is described." | 3.71 | Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. ( Camacho, M; Guerra, H; Martin, A; Palomino, JC; Portaels, F; Swings, J, 2002) |
| "The usefulness of isoniazid (INH), a key component of short-course chemotherapy of tuberculosis, is threatened by the emergence of drug-resistant strains of Mycobacterium tuberculosis with mutations in the katG gene." | 3.71 | Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. ( Cole, ST; Pym, AS; Saint-Joanis, B, 2002) |
| "Twenty patients with urinary tuberculosis were treated with ofloxacin (200 mg/day, 6 months), rifampin (600 mg/day, 3 months) and isoniazid (300 mg/day, 3 months) between 1989 and 1990." | 3.71 | Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study. ( Castiñeiras, AA; Della-Latta, P; Herreras, A; Pérez-Pascual, P; Zarranz, JE, 2002) |
| "We retrospectively evaluated the use of disulfiram among alcoholic patients being treated for active tuberculosis." | 3.71 | Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis. ( Breese, P; Burman, WJ; Cohn, D; Reves, R; Terra, M, 2002) |
| "To determine the prevalence of S315T mutation within the katG gene that confers clinically significant resistance to isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates recovered from tuberculosis patients in Dubai and Beirut." | 3.71 | Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut. ( Ahmad, S; Araj, GF; Chugh, TD; Fares, E; Mustafa, AS, 2002) |
| "Exposure to tuberculosis was treated with isoniazid." | 3.71 | Congenital tuberculosis and management of exposures in a neonatal intensive care unit. ( Holt, D; Laartz, BW; Larkin, JA; Narvarte, HJ; Pomputius, WF, 2002) |
| "Treatment of latent tuberculosis infection (LTBI) with isoniazid is recommended for transplant recipients with positive tuberculin skin test (TST)." | 3.71 | Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. ( Benito, N; González, J; Horcajada, JP; Moreno, A; Navasa, M; Rimola, A; Sued, O, 2002) |
| "We report a male infant with congenital tuberculosis who developed cerebral hemorrhage associated with vitamin K deficiency during treatment with isoniazid and rifampin." | 3.71 | Cerebral hemorrhage associated with vitamin K deficiency in congenital tuberculosis treated with isoniazid and rifampin. ( Haruta, T; Kobayashi, K; Kubota, M; Maeda, H; Nishio, T, 2002) |
| "After clinical illness, treatment, and death of a captive male bongo antelope (Tragelaphus eurycerus isaaci) caused by tuberculosis involving Mycobacterium bovis, four tuberculin test reactive captive bongos were treated for 6 mo with isoniazid (INH) and rifampin (RIF) and intermittent single doses of other medications before being euthanized." | 3.71 | Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci). ( Aguilar, R; Auclair, B; Maslow, JN; Mikota, SK; Peloquin, CA, 2002) |
| "Isoniazid (INH) chemoprophylaxis has a positive impact on the development of clinical tuberculosis." | 3.71 | Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis. ( Alaei, A; Alaei, K; Mansouri, D, 2002) |
| "National tuberculosis treatment guidelines suggest a regimen of 2RZE/10RE for the treatment of isoniazid resistant organisms." | 3.71 | Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started? ( Green, RM; Horsfield, N; Ormerod, LP, 2001) |
| "To evaluate tuberculosis (TB) prevention in HIV clinics based on the prevalence and incidence of TB and the efficacy of preventive therapy with isoniazid (INH)." | 3.71 | TB prevention in HIV clinics in New York City. ( Frieden, TR; Sackoff, JE; Torian, LV, 2001) |
| "A mutation (CCG-->CTG [Arg-->Leu]) in codon 463 of katG (catalase peroxidase) of Mycobacterium tuberculosis has been found in isoniazid (INH)-resistant strains." | 3.71 | The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg-->Leu mutation at codon 463 of katG are not associated. ( Dankert, J; de Haas, PE; Kuijper, EJ; van der Ende, A; van Doorn, HR; van Soolingen, D; Welten, AG, 2001) |
| "Previously, we reported on the use of rifampin-loaded microspheres to effectively treat Mycobacterium tuberculosis-infected macrophages and mice." | 3.71 | Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid. ( Barrow, EL; Barrow, WW; Quenelle, DC; Staas, JK; Winchester, GA, 2001) |
| "Mycobacterium tuberculosis has two genes for ferric uptake regulator orthologues, one of which, furA, is situated immediately upstream of katG encoding catalase-peroxidase, a major virulence factor that also activates the prodrug isoniazid." | 3.71 | Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis. ( Cole, ST; Deretic, V; Domenech, P; Honoré, N; Pym, AS; Song, J, 2001) |
| "6 x 10(7) CFU of Mycobacterium tuberculosis were treated 14 days later for 6 months with a regimen of once-weekly 10 mg of rifapentine and 75 mg of isoniazid per kg of body weight supplemented with either 150 mg of streptomycin per kg or 100 mg of moxifloxacin per kg during either both the 2-week daily initial and once-weekly continuation phases or only in the daily 2-week initial phase." | 3.71 | Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. ( Bentoucha, A; Grosset, J; Ji, B; Lounis, N; O'Brien, RJ; Roscigno, G; Truffot-Pernot, C; Vernon, A, 2001) |
| "Standard drug susceptibility testing by the proportion method against streptomycin (S), isoniazid (H), rifampicin (R), and ethambutol (E) was performed with Mycobacterium tuberculosis isolated from 916 new cases and 456 previously treated cases." | 3.71 | Sample survey of drug-resistant tuberculosis in Henan, China, 1996. ( Ding, D; Duanmu, HJ; Li, D; Peng, YL; Song, H; Wang, G; Wang, L; Xing, J; Zhang, G; Zhang, L; Zhang, Z, 2002) |
| "Gatifloxacin (GAT) and moxifloxacin (MXF) were evaluated in vitro to determine their activities against Mycobacterium tuberculosis." | 3.71 | In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. ( Alvirez-Freites, EJ; Carter, JL; Cynamon, MH, 2002) |
| "Isoniazid therapy was shown to be 70% effective at preventing tuberculosis in HIV-infected, PPD-positive Ugandan adults, but the feasibility of implementation outside an efficacy trial has not been established." | 3.71 | Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda. ( Antivelink, L; Brink, A; Elliott, A; French, N; Gilks, C; Lugada, ES; Nakiyingi, J; Nanyunja, M; Watera, C; Whitworth, J, 2002) |
| "To determine the acceptability, compliance and side effects of isoniazid (INH) prophylaxis against tuberculosis among HIV infected police officers (PO) in Dar es Salaam." | 3.70 | Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam. ( Aris, EA; Bakari, M; Biberfeld, G; Chale, S; Josiah, R; Magao, P; Mhalu, F; Moshi, A; Mugusi, F; Pallangyo, K; Pallangyo, N; Sandström, E, 2000) |
| "A colorimetric, microplate-based Alamar Blue assay (MABA) method was used to determine the MICs of isoniazid (INH), rifampin, streptomycin (SM), and ethambutol (EMB) for 34 Peruvian Mycobacterium tuberculosis isolates (including both pansensitive and multidrug-resistant strains) and the H37Rv strain by using bacterial suspensions prepared directly from solid media." | 3.70 | Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. ( Cook, MB; Degnan, MT; Ferguson, RM; Franzblau, SG; Gilman, RH; Hernandez, A; Madico, G; McLaughlin, JC; Quenzer, VK; Torres, P; Witzig, RS, 1998) |
| "Prophylaxis of tuberculosis in children with four month (n = 53) and three month regimens (n = 213) of rifampicin and isoniazid from 1987 to 1996 were tolerated without any toxicity." | 3.70 | Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. ( Ormerod, LP, 1998) |
| " Most children (64%) did not have cultures done; however, among culture-proved cases isoniazid-resistant Mycobacterium tuberculosis was isolated in 7%." | 3.70 | Tuberculosis in children and adolescents: California, 1985 to 1995. ( Cummings, K; Lobato, MN; Royce, S; Will, D, 1998) |
| "9 percent of Mycobacterium tuberculosis strains were resistant to at least one drug (range, 2 to 41 percent); resistance to isoniazid (7." | 3.70 | Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. ( Binkin, N; Bustreo, F; Chaulet, P; Cohn, DL; Kim, SJ; Lambregts-van Weezenbeek, CS; Laszlo, A; Nunn, P; Pablos-Méndez, A; Raviglione, MC; Rieder, HL, 1998) |
| "Although isoniazid (isonicotinic acid hydrazide, INH) is widely used for the treatment of tuberculosis, its molecular target has remained elusive." | 3.70 | Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. ( Barry, CE; Crane, DD; Mdluli, K; Mead, D; Musser, JM; Pan, X; Ramaswamy, S; Slayden, RA; Zhu, Y, 1998) |
| " Assuming 65% isoniazid effectiveness, and incorporating costs of screening, observed chemoprophylaxis and clinical monitoring, a net savings in tuberculosis-related hospital costs of $285,284 ($563 per person screened) was associated with DOPT ($10,274 per case prevented)." | 3.70 | Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis. ( Alcabes, P; Arno, PS; Gourevitch, MN; Wasserman, WC, 1998) |
| "Mutants in the structural gene of the inhA-encoded NADH-dependent 2-trans enoyl-acyl carrier protein reductase were identified from isoniazid-resistant clinical isolates of Mycobacterium tuberculosis." | 3.70 | Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. ( Basso, LA; Blanchard, JS; Jacobs, WR; Musser, JM; Zheng, R, 1998) |
| "To determine the value of ahpC promoter mutations for the rapid prediction of isoniazid resistance, this genomic region was characterized in 50 isoniazid-resistant and 12 isoniazid-sensitive Mycobacterium tuberculosis isolates." | 3.70 | Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis. ( Bretzel, G; Feldmann, K; Löscher, T; Rifai, M; Rinder, H; Rüsch-Gerdes, S; Thomschke, A, 1998) |
| "Once-weekly therapy with combinations of isoniazid plus a rifamycin was tested in the mouse low-dose aerosol infection model against two strains of Mycobacterium tuberculosis." | 3.70 | Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model. ( Brooks, JV; Orme, IM, 1998) |
| " It was used to determine if ahpC, a gene that is involved in defence against oxidative stress and isoniazid (INH) resistance, is important for virulence of Mycobacterium bovis, a member of the Mycobacterium tuberculosis complex." | 3.70 | Antisense RNA to ahpC, an oxidative stress defence gene involved in isoniazid resistance, indicates that AhpC of Mycobacterium bovis has virulence properties. ( Blanchardand, JS; Collins, DM; de Lisle, GW; Marcinkeviciene, JA; Wilson, T, 1998) |
| "To study the activity of metronidazole on persisting tubercle bacilli, BALB/c mice were infected with Mycobacterium tuberculosis and, after 14 days, treated with isoniazid (H) or rifampicin (R) or isoniazid + rifampicin (HR) for 2 months." | 3.70 | Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis. ( Herbert, D; Kubendiran, G; Paramasivan, CN, 1998) |
| "Isoniazid prophylaxis for 12 months effectively prevents tuberculosis in HIV-infected persons and may decrease the incidence of other HIV-related disease and mortality." | 3.70 | Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis. ( Rose, DN, 1998) |
| " - The LTT was performed with isoniazid and rifampicin in 15 tuberculosis and 2 MOTT (Mycobacteria other than tuberculosis)-infection patients who suffered drug reactions, in 23 patients without any adverse reactions, in 7 controls previously exposed to antituberculous drugs, and in 14 controls who had never been exposed." | 3.70 | Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs. ( Greinert, U; Müller-Quernheim, J; Schlaak, M; Schreiber, J; Zissel, G, 1999) |
| "Isoniazid preventive therapy for latent tuberculosis (TB) infection has been debated because of the risk of hepatotoxicity." | 3.70 | Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. ( Buskin, SE; Goldberg, SV; Nolan, CM, 1999) |
| "To compare the strategy of TB vaccination with that of tuberculin skin-testing in conjunction with isoniazid (INH) in preventing tuberculosis in HIV-infected persons." | 3.70 | Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world. ( Brehm, WT; Chaisson, RE; Moore, RD; Sterling, TR, 1999) |
| "To establish the chemotherapeutic value of a depot drug preparation of isoniazid and pyrazinamide against experimental tuberculosis." | 3.70 | Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. ( Gangadharam, PR; Geeta, N; Hsu, YY; Wise, DL, 1999) |
| "The molecular prediction of isoniazid (INH) resistance in Mycobacterium tuberculosis is hampered by the need for specialized equipment, expertise, high costs, a limited range of detectable mutations, or several of these factors." | 3.70 | Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples. ( Cambau, E; Casal, M; Feldmann, K; Grosset, J; Gutierrez, J; Jarlier, V; Löscher, T; Richter, E; Rifai, M; Rinder, H; Rüsch-Gerdes, S; Tortoli, E; Vaquero, M, 1999) |
| "Rifapentine is a long-acting rifamycin which may be useful for intermittent drug therapy against tuberculosis." | 3.70 | Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis. ( Bishai, WR; Chaisson, RE; Miyazaki, E, 1999) |
| " In this study, we evaluated the ability of rifapentine (RFP), in monotherapy and combination therapy, to completely eradicate a Mycobacterium tuberculosis infection and to prevent relapse posttreatment in a Swiss mouse model." | 3.70 | Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice. ( Chase, SE; Chmielewski, AJ; Cynamon, MH; Lenaerts, AM, 1999) |
| "New rapid phenotypic assays for the detection of rifampin resistance in Mycobacterium tuberculosis have recently been described, but most of these require liquid cultures, which reduces the utility of many tests in terms of turnaround times." | 3.70 | Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of Mycobacterium tuberculosis. ( Butcher, PD; Drobniewski, FA; Eltringham, IJ; Mangan, JA; Wilson, SM, 1999) |
| "Annual skin testing for tuberculosis infection and anergy was performed, and eligible patients were offered daily isoniazid for 12 months and followed prospectively." | 3.70 | Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis. ( Gourevitch, MN; Hartel, D; Klein, RS; Schoenbaum, EE; Selwyn, PA, 1999) |
| "These data show that tuberculosis has a high prevalence in transplant recipients, that it can effectively be treated using rifampin-containing antituberculosis drugs with a close follow-up of serum cyclosporine levels, and that INH prophylaxis is safe but more experience is needed to define the target population." | 3.70 | Tuberculosis in renal transplant recipients. ( Duman, S; Ece, T; Kiliçaslan, Z; Ozkahya, M; Sayiner, A; Tokat, Y; Yildiz, A, 1999) |
| "The use of isoniazid (INH) for the treatment of INH-resistant Mycobacterium tuberculosis infection has been controversial." | 3.70 | High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection. ( Cheng, S; Cynamon, MH; DeStefano, MS; Harpster, T; Zhang, Y, 1999) |
| "To evaluate an approach to enhancing compliance with tuberculosis chemoprophylaxis in drug users enrolled on methadone maintenance utilizing an isoniazid (INH)-methadone admixture." | 3.70 | Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance. ( Durante, AJ; Friedman, L; Henry, S; O'Connor, PG; Selwyn, PA; Shi, JM, 1999) |
| "A 14-yr old previously healthy girl receiving preventive isoniazid therapy who suddenly developed generalized tonic-clonic seizures and coma." | 3.70 | Acute isoniazid neurotoxicity during preventive therapy. ( Gorjup, V; Horvat, M; Martinjak-Dvorsek, I; Noc, M, 2000) |
| "The effectiveness of various once-weekly 10 mg/kg rifapentine (P)- containing regimens for treatment of tuberculosis was assessed in mice infected intravenously with 4." | 3.70 | Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens. ( Daniel, N; Geiter, LJ; Grosset, J; Hejblum, G; Ji, B; Lounis, N; O'Brien, RJ; Szpytma, M; Truffot-Pernot, C; Vernon, A, 2000) |
| "(1) The recommended treatment protocol for the vast majority of cases of tuberculosis is a 6-month course of isoniazid and rifampicin, plus pyrazinamide and ethambutol for the first two months." | 3.70 | Treatment of tuberculosis: a well-standardised protocol. ( , 2000) |
| "The prevalence of mutations at amino acid (aa) position 315 in the katG gene of isoniazid (INH)-resistant Mycobacterium tuberculosis isolates in The Netherlands and the mutation's association with the level of INH resistance, multidrug resistance, and transmission were determined." | 3.70 | Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands. ( Borgdorff, MW; de Haas, PE; Kuijper, E; Rinder, H; van Doorn, HR; van Soolingen, D, 2000) |
| "The target for isoniazid preventive therapy against tuberculosis in Japan has been contact persons of tuberculosis patients with the age of less than 30." | 3.70 | [Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings]. ( Yoshiyama, T, 2000) |
| " All patients were given rifampicin, ethambutol, and isoniazid, and the three who had tuberculosis of other organs were also treated with streptomycin." | 3.69 | Tuberculosis of the breast. ( Düren, M; Durgun, V; Göksoy, E; Uygun, N, 1995) |
| "We report three patients who experienced hepatotoxic reactions in association with acetaminophen ingestion while undergoing treatment for active tuberculosis with isoniazid, rifampin, and other agents." | 3.69 | Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. ( Nelson, SD; Nolan, CM; Sandblom, RE; Slattery, JT; Thummel, KE, 1994) |
| "In tests with 18 drug-susceptible strains of Mycobacterium tuberculosis, the MIC at which 50% of the strains are inhibited by levofloxacin (LVFX) was one dilution less than that at which 50% of the strains are inhibited by ofloxacin (OFLO), but the MICs at which 90% of the strains are inhibited were similar." | 3.69 | In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. ( Grosset, J; JI, B; Lounis, N; Truffot-Pernot, C, 1995) |
| "A retrospective study of tuberculosis patients treated with isoniazid was undertaken in order to establish the prevalence and specificity of antibodies against histones, chromatin and denatured DNA." | 3.69 | IgA antihistone antibodies in isoniazid-treated tuberculosis patients. ( Casiano, CA; Rubin, RL; Vázquez-Del Mercado, M, 1995) |
| "Isoniazid (INH) resistance of the Mycobacterium tuberculosis Complex (MtbC) is associated with both loss of catalase activity and mutation of the inhA gene." | 3.69 | Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. ( Collins, DM; de Lisle, GW; Wilson, TM, 1995) |
| "To assess the operational aspects of isoniazid preventive chemotherapy (IPT) for tuberculosis in persons dually infected with HIV and Mycobacterium tuberculosis identified at an independent HIV voluntary counselling and testing centre in Kampala, Uganda." | 3.69 | Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre. ( Aisu, T; Barugahare, L; Engwau, FA; Eriki, P; McFarland, D; Narain, JP; Raviglione, MC; Tembo, G; van Praag, E, 1995) |
| "The ever-increasing incidence of tuberculosis calls for the implementation of control measures, including new efficient, short-term preventive therapies to replace 6 to 12 months of isoniazid therapy." | 3.69 | Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis. ( Della Bruna, C; Jabès, D; Olliaro, P; Rossi, R, 1994) |
| "This study was designed to provide a preliminary assessment of the occurrence of tuberculosis exposure, infection and disease within a national sample of infants and children with human immunodeficiency virus (HIV) exposure or infection, and to determine the prevalence of Mycobacterium tuberculosis isolates resistant both to isoniazid and rifampin in these patients or their adult source contacts." | 3.69 | Tuberculosis in human immunodeficiency virus-exposed or -infected United States children. ( Gutman, LT; Moye, J; Tian, C; Zimmer, B, 1994) |
| "Twenty patients, 1 through 13 years of age from Pediatric Tuberculosis Clinic of All India Institute of Medical Sciences, New Delhi, suffering from pulmonary primary complex (PPC) were investigated for serum and urine concentrations of isoniazid (INH) and acetylisoniazid (AcINH)." | 3.69 | Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen. ( Beotra, A; D'monty, V; Mukhopadhya, S; Semwal, OP; Seth, SD; Seth, V, 1994) |
| "The effectiveness of intermittent administration of rifapentine (RPT), with or without isoniazid (INH), for preventive therapy of tuberculosis was evaluated in immunocompetent (normal) and nude mice." | 3.69 | Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice. ( Chapuis, L; Grosset, JH; Ji, B; O'Brien, RJ; Raviglione, MC; Truffot-Pernot, C, 1994) |
| "The catalase-peroxidase gene (katG) and a two-gene locus (inhA) containing mutations associated with resistance to isoniazid in Mycobacterium tuberculosis were sequenced in 34 resistant and 12 susceptible strains." | 3.69 | Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. ( Kapur, V; Kreiswirth, BN; Musser, JM; van Embden, JD; van Soolingen, D; Williams, DL, 1996) |
| "Resistance to isoniazid in Mycobacterium tuberculosis has been associated with mutations in genes encoding the mycobacterial catalase-peroxidase (katG) and the InhA protein (inhA)." | 3.69 | Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis. ( Bai, GH; Li, Z; Morris, SL; Rouse, DA, 1995) |
| "Antituberculosis activity of clarithromycin (CLA), a macrolide antibiotic, was investigated in vitro, in macrophages, and in C57BL/6 mice, CLA showed high in vitro MICs (4 to > 16 micrograms/ml) for several strains of Mycobacterium tuberculosis and caused slight enhancement of activity of rifampin (RIF) against H37Rv but failed to increase the activity of either RIF or isoniazid (INH) against other strains." | 3.69 | Antituberculosis activity of clarithromycin. ( Daneluzzi, D; Gangadharam, PR; Luna-Herrera, J; Reddy, VM, 1995) |
| "108 guinea pigs were infected with M-tuberculosis 2 weeks later 36 of them were put on treatment with rifampicin and isoniazid, the rest served as untreated control." | 3.69 | [Oxidative metabolism changes in respiratory tract cells of guinea pigs during natural development of experimental tuberculosis and under specific chemotherapy]. ( Abdullaev, RIu; Kaminskaia, GO, 1996) |
| "Mice with experimental tuberculosis were given isoniazid, rifampicin, erythromycin, cefotaxime, ofloxacin." | 3.69 | [Immunotropic activity of antimicrobial agents used in tuberculosis]. ( Aleksandrova, AE; Vinogradova, TI, 1996) |
| "To describe the clinical and demographic characteristics of fatal hepatitis due to single-drug isoniazid preventive therapy for tuberculosis, we did a survey of cases from state health departments, published case reports, and reports to the Centers for Disease Control and Prevention from 1970 to 1992." | 3.69 | Isoniazid-related fatal hepatitis. ( Millard, PS; Reade-Christopher, SJ; Weber, DJ; Wilcosky, TC, 1996) |
| "One of the mechanisms of isoniazid resistance to Mycobacterium tuberculosis has been proved to be the chromosomal deletion of katG." | 3.69 | KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates. ( Abe, C; Goto, M; Kimura, S; Kitada, K; Oka, S; Shimada, K; Tachikawa, N; Wada, M, 1995) |
| "The activity of KRM-1648, alone and in combination with isoniazid, was compared with those of isoniazid, rifampin, and the combination of rifampin plus isoniazid in a murine model of tuberculosis." | 3.69 | Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model. ( Cynamon, MH; Klemens, SP, 1996) |
| "The in vitro and in vivo activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis H37Rv were compared with those of rifampin." | 3.69 | In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis. ( Amitani, R; Kuze, F; Murayama, T; Suzuki, K; Tanaka, E; Yamamoto, T, 1996) |
| "The efficacies of rifampin-containing preventive regimens were measured in Cornell model mice in which an initially severe infection with Mycobacterium tuberculosis H37Rv was first treated for 7 weeks with 25 mg of isoniazid and 1,000 mg of pyrazinamide per kg of body weight in the diet and then with one of four test regimens given by daily oral gavage for 6 weeks." | 3.69 | Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. ( Dhillon, J; Dickinson, JM; Mitchison, DA; Sole, K, 1996) |
| "In our efforts to develop new drugs for the treatment of tuberculosis, especially that caused by multidrug-resistant strains, we investigated clofazimine (CFM) and two of its analogs, B4154 and B4157, for their antituberculosis activities." | 3.69 | Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. ( Daneluzzi, D; Gangadharam, PR; Nadadhur, G; O'Sullivan, JF; Reddy, VM, 1996) |
| "It has been reported recently that isoniazid resistant strains of Mycobacterium tuberculosis have lost the katG gene which encodes the catalase-peroxidase enzyme." | 3.69 | Presence of katG gene in resistant Mycobacterium tuberculosis. ( Jaber, M; Kumar, R; Rattan, A, 1996) |
| "We evaluated a patient who developed a psychotic disorder after 4 months of isoniazid prophylaxis for a positive tuberculosis tine test." | 3.69 | Psychotic disorder associated with isoniazid. ( Bourgeois, JA; Waraich, BS; Zelenko, M, 1996) |
| " The objectives of this research were thus to describe the use and the results of TST among patients with HIV infection in Switzerland and to measure the usefulness of isoniazid preventive chemotherapy and the incidence of tuberculosis (TB) relative to TST and CD4 cell count at the time of TST." | 3.69 | [HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study]. ( Bassetti, S; Hirschel, BJ; Ledergerber, B; Malvy, D; Rieder, H; Sudre, P, 1996) |
| "Prolonged therapy with rifampicin and isoniazid can cause vitamin D deficiency or osteomalacia, particularly in patients with marginal vitamin D stores." | 3.69 | Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong. ( Chan, TY, 1996) |
| "The effect of lomefloxacin was studied on mice with experimental infection due to Mycobacterium tuberculosis." | 3.69 | [Antitubercular activity of lomefloxacin in an experiment]. ( Makarova, OV; Mikhaĭlova, LP; Mozhokina, GN; Sokolova, GB, 1996) |
| "To assess the economic benefits and costs of providing isoniazid preventive therapy for tuberculosis (TB) in HIV-infected persons in Zambia." | 3.69 | Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia. ( Foster, S; Godfrey-Faussett, P; Porter, J, 1997) |
| "The present case report describes a 10-year-old boy with clinical history of steroid-dependent asthma who developed severe exacerbation of his respiratory symptoms upon isoniazid administration." | 3.69 | A case of acute deterioration in asthma symptoms induced by isoniazid prophylaxis. ( Cacciola, R; Colombrita, R; Polosa, R; Prosperini, G, 1997) |
| "Isoniazid chemoprophylaxis effectively prevents the development of active infectious tuberculosis." | 3.69 | Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis. ( Owens, DK; Salpeter, EE; Salpeter, SR; Sanders, GD, 1997) |
| "In spring 1993, four students in a high school were diagnosed with tuberculosis resistant to isoniazid, streptomycin, and ethionamide." | 3.69 | Outbreak of drug-resistant tuberculosis with second-generation transmission in a high school in California. ( Elcock, M; Kent, JH; Maxwell, R; Meador, J; Onorato, I; Ridzon, R; Royce, S; Shefer, A; Smith, P; Valway, S; Weismuller, P; Woodley, C, 1997) |
| "Isoniazid prophylaxis in HIV-positive injecting drug users has been shown to significantly reduce the incidence of tuberculosis (TB)." | 3.69 | Isoniazid TB prophylaxis effective in drug users with HIV. ( , 1996) |
| " The risk for active tuberculosis to develop in patients not receiving isoniazid chemoprophylaxis was similar in patients with a positive PPD test result (10." | 3.68 | Risk for developing tuberculosis among anergic patients infected with HIV. ( Alberdi, JC; Baraia-Etxaburu, J; Bouza, E; Cosín, J; López-Gay, D; Miralles, P; Moreno, S; Parras, F; Pérez-Tascón, M; Vicente, T, 1993) |
| "From January 1990 to December 1991, 16 patients with multidrug-resistant tuberculosis (MDR-TB) caused by Mycobacterium tuberculosis resistant to isoniazid, rifampin, and streptomycin were diagnosed at Elmhurst Hospital." | 3.68 | Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. ( Beck-Sague, CM; Coronado, VG; Crawford, JT; Davis, BJ; Frieden, TR; Hutton, MD; Kilburn, JO; Nicholas, P; Villareal, C; Woodley, CL, 1993) |
| "2 weeks after infection with Mycobacterium tuberculosis H37Rv, groups of mice were treated with rifampicin (R) 15 mg/kg, isoniazid (H) 25 mg/kg, pyrazinamide (Z) 300 mg/kg, ethambutol (E) 100 mg/kg three times weekly (RHZE3); RH/ZE, an alternating regimen of RH on days 1, 3 and 5 of the week and ZE on days 2, 4 and 6, RZ/HE or RE/HZ." | 3.68 | Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis. ( Dickinson, JM; Guy, A; Mitchison, DA, 1993) |
| " The development of isoniazid for the prevention of tuberculosis is reviewed." | 3.68 | Prevention of infections in patients with neoplastic disease: use of a historical model for developmental strategies. ( White, MH, 1993) |
| "Three dialysis patients with extrapulmonary tuberculosis developed confusion 4-14 days after commencement of treatment with anti-tuberculosis drugs, despite the use of prophylactic pyridoxine." | 3.68 | Isoniazid induced encephalopathy in dialysis patients. ( Cheng, IK; Cheung, WC; Ip, M; Lo, CY; Lo, WK, 1993) |
| " tuberculosis strains isolated from patients with pulmonary tuberculosis treated in the Institute of Tuberculosis and Lung Diseases and in Pediatric Clinic of Medical Academy in Warsaw in 1982-1991 years was performed for isoniazid (INH), streptomycin (SM), rifampicin (RMP) and ethambutol (EMB)." | 3.68 | [Analysis of drug sensitivity of M. tuberculosis strains isolated from patients treated for tuberculosis in 1982-1991]. ( Jezierska-Anczuków, A; Zalewska-Schöntaler, N, 1993) |
| "Isoniazid resistance in Mycobacterium tuberculosis is associated with lack of catalase-peroxidase activity." | 3.68 | Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. ( Guan, L; Kornblum, J; Kreiswirth, B; Laraque, F; Riegler, N; Riley, LW; Stoeckle, MY; Weitzman, I, 1993) |
| " Overall, 33 percent of these patients had isolates resistant to one or more antituberculosis drugs, 26 percent had isolates resistant to at least isoniazid, and 19 percent had isolates resistant to both isoniazid and rifampin." | 3.68 | The emergence of drug-resistant tuberculosis in New York City. ( Cauthen, GM; Dooley, SW; Frieden, TR; Kilburn, JO; Pablos-Mendez, A; Sterling, T, 1993) |
| " tuberculosis, reactivation of the disease may be prevented by chemoprophylaxis with isoniazid or rifampicin." | 3.68 | [Indications for chemoprophylaxis of tuberculosis. Arguments for]. ( Nicod, LP, 1993) |
| "We compared exposures among 18 patients with AIDS in whom tuberculosis resistant to isoniazid and streptomycin was diagnosed from January 1989 through April 1990 (the case patients) with exposures among 30 control patients who had AIDS and tuberculosis susceptible to isoniazid, streptomycin, or both." | 3.68 | An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. ( Castro, KG; Crawford, JT; Dooley, SW; Edlin, BR; Grieco, MH; Kilburn, JO; Ong, KR; Sordillo, EM; Tokars, JI; Williams, J, 1992) |
| "Twelve children who developed active tuberculosis even after receiving isoniazid (INH) chemoprophylaxis were seen at Tokyo Metropolitan Children's Hospital from 1982 through 1991." | 3.68 | [Active tuberculosis in children who received INH chemoprophylaxis]. ( Ikeda, K; Kawasaki, K; Kijimoto, C; Kurokawa, H; Sugimori, M, 1992) |
| "In a case-control study of 92 Indian patients, 46 with active tuberculosis (cases) and 46 tuberculin reactors without the disease (control subjects), significantly more control subjects than patients had prior adequate isoniazid chemoprophylaxis." | 3.68 | The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians. ( Leonardson, G; Mori, MA; Welty, TK, 1992) |
| "Serologic markers for hepatitis viruses were studied in 40 children who developed acute hepatitis during antituberculosis therapy with rifampin and isoniazid, with the aim of assessing the contributory role of these viruses toward producing hepatic injury." | 3.68 | Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis? ( Govil, YC; Kumar, A; Mehotra, R; Misra, PK; Rana, GS, 1991) |
| "Maryland data substantiate the safety of isoniazid therapy in preventing tuberculosis." | 3.68 | Preventive therapy for tuberculosis in Maryland. ( Flynn, J; Highsmith, H; Israel, E; Matuszak, DL; Rabindran, E; Woodall, H, 1991) |
| "A 33-year-old man with AIDS and pleuro-pulmonary tuberculosis was treated with a combination of antituberculous medications for 12 months and with continuation of isoniazid." | 3.68 | Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid. ( Jones, WD; Shafer, RW, 1991) |
| "In a retrospective study to evaluate the efficacy of isoniazid (INH) for the prevention of tuberculosis, we studied 1760 patients with hematological malignancies over a twenty-year period (1970-1989)." | 3.68 | [Infection prophylaxis in patients with hematological malignancies (II)--Successful prophylaxis of tuberculosis with isoniazid]. ( Atogami, S; Kamihira, S; Maeda, T; Miyazaki, Y; Moriuchi, Y; Murata, K; Nagai, K; Satoh, T; Tokunaga, S; Yanagisako, T, 1991) |
| "Treatment of tuberculosis in a hemodialysis patient with isoniazid, rifampin, and pyrazinamide resulted in the development of acute cerebellar dysfunction." | 3.68 | Cerebellar syndrome caused by isoniazid. ( Blumberg, EA; Gil, RA, 1990) |
| " Cholestyramine therapy for hypercholesterolemia, the treatment of mild hypertension, isoniazid therapy for inactive tuberculosis and carotid endarterectomy in patients with mild stroke formed the final cluster." | 3.68 | Therapeutic priorities of Canadian internists. ( Laupacis, A; Roberts, RS; Sackett, DL, 1990) |
| "Concentrations of isoniazid and rifampicin were determined in time-matched samples of saliva and serum from 30 tuberculous patients (18 with pulmonary tuberculosis and 12 with intestinal tuberculosis), comprising 18 slow and 12 rapid acetylators of isoniazid, following administration of isoniazid 300 mg and rifampicin 12 mg/kg." | 3.68 | Salivary levels of isoniazid and rifampicin in tuberculous patients. ( Gurumurthy, P; Narayana, AS; Rahman, F; Sarma, GR, 1990) |
| "The cost effectiveness of short tuberculosis treatment regimes using rifampicin (R) or ethambutol (E) is calculated and compared to long regimes based on thiacetazone and isoniazid (TH)." | 3.67 | Cost savings from alternative treatments for tuberculosis. ( Barnum, HN, 1986) |
| "This study shows that memory immune T lymphocytes, harvested from young (3-month-old) mice infected intravenously with Mycobacterium tuberculosis and then exposed to protracted chemotherapy with isoniazid, are capable of adoptively protecting old (24 month) mice from a subsequent fatal challenge infection." | 3.67 | Aging and immunity to tuberculosis: prolonged survival of old mice infected with Mycobacterium tuberculosis by adoptive immunization with memory-immune T lymphocytes. ( Orme, IM, 1989) |
| "In a first experiment, the efficacy of a 6-month course of isoniazid (INH) alone in comparison with 2-month courses of rifampin (RMP) alone, RMP + pyrazinamide (PZA), or RMP + PZA + INH as preventive therapy of tuberculosis was evaluated in the mouse." | 3.67 | Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide. ( Grosset, JH; Lecoeur, HF; Truffot-Pernot, C, 1989) |
| "Over a 2-year period, all patients with incipient tuberculosis seen in a hospital unit were given a 6-month treatment consisting of rifampicine, isoniazide, pyrazinamide and ethambutol." | 3.67 | [Routine use of 6-month antitubercular treatment in 300 patients]. ( Aeberhardt, G; Bernheim, J; Dautzenberg, B; Gallinari, C; Grosset, J; Lévy, A; Sors, C, 1986) |
| "Daily administration of isoniazid for one year to persons infected with Mycobacterium tuberculosis is effective in considerably reducing the risk of disease." | 3.67 | Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy. ( Caras, GJ; Koplan, JP; Snider, DE, 1986) |
| "The results herein show that mice infected with Mycobacterium tuberculosis and then exposed to a protracted course of isoniazid chemotherapy possess a heightened state of acquired resistance to subsequent challenge with the homologous organism." | 3.67 | Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection. ( Orme, IM, 1988) |
| "A single dose kinetics of isoniazid and rifampicin alone, and combination was studied in well-nourished and malnourished patients of tuberculosis." | 3.67 | Single dose kinetics of rifampicin and isoniazid in well-nourished and malnourished patients of tuberculosis. ( Dhand, R; Garg, SK; Gupta, PH; Jha, VK; Kalra, S; Lal, R; Malik, SK; Shukla, VK, 1988) |
| "The in vitro activity of dihydromycoplanecin A (DHMP A), a new cyclic peptide antibiotic, was compared with those of antimycobacterial drugs such as streptomycin, isoniazid (INH), rifampin, and ofloxacin against several clinically isolated species of mycobacteria, including Mycobacterium tuberculosis, M." | 3.67 | Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A. ( Aoyagi, T; Arai, M; Arai, T; Haneishi, T; Katayama, T; Kawahara, Y; Kurihara, K; Nakajima, M; Shiraishi, A; Torikata, A, 1988) |
| "Treatment of tuberculosis: A 6-month regimen consisting of isoniazid, rifampin, and pyrazinamide given for 2 months followed by isoniazid and rifampin for 4 months is effective treatment in patients with fully susceptible organisms who comply with the treatment regimen." | 3.67 | American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. ( , 1986) |
| "The introduction of chemoprophylaxis with rifampicin and isoniazid in 1981 significantly reduced the incidence of tuberculosis." | 3.67 | Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects showing strong reactions to tuberculin testing. ( Ormerod, LP, 1987) |
| "4 years) who have been treated with isoniazid for prevention of tuberculosis, data from 1935 were suitable for analysis." | 3.67 | Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons. ( Abraham, JH; Harrison, RW; Stead, WW; To, T, 1987) |
| "The bioavailability of isoniazid, rifampin, and pyrazinamide in 2 combined formulations of the 3 drugs (Rifater) for use primarily in the short-course chemotherapy of tuberculosis has been studied in Chinese patients in Singapore and Hong Kong." | 3.67 | The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. ( Allen, BW; Chan, SL; Ellard, DR; Ellard, GA; Girling, DJ; Ng, HK; Nunn, AJ; Tan, TH; Teo, SK, 1986) |
| "To determine the effect of rifampicin therapy on hepatic oxidase activity in animal protein deficient patients antipyrine and quinine t 1/2 and 6B-hydroxycortisol (6B-OHF) excretion was studied in 8 Indian vegetarians during treatment for tuberculosis." | 3.67 | Hepatic mixed function oxidase induction during rifampicin/isoniazid therapy in Indian vegetarians. ( Jenkins, MV; Perry, W, 1986) |
| "Results are presented of the incidence of hepatitis, nearly always with jaundice, among 1686 patients in clinical trials of the treatment of spinal tuberculosis, of tuberculosis meningitis and of pulmonary tuberculosis with short-course regimens containing rifampicin, isoniazid, streptomycin and pyrazinamide." | 3.67 | Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide. ( Janardhanam, B; Parthasarathy, R; Ramachandran, P; Santha, T; Sarma, GR; Sivasubramanian, S; Somasundaram, PR; Tripathy, SP, 1986) |
| "Short-course chemotherapy with isoniazid and rifampin is well established for pulmonary tuberculosis but not yet for extrapulmonary disease." | 3.67 | Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience. ( Dutt, AK; Moers, D; Stead, WW, 1986) |
| "The outcome of isoniazid chemoprophylaxis for tuberculosis was assessed in refugees from Southeast Asia." | 3.67 | Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. ( Aitken, ML; Anderson, KM; Elarth, AM; Miller, WT; Nolan, CM, 1986) |
| "Twenty-one patients with pleural effusion and 27 patients with lymphadenitis, both tubercular in origin, were administered isoniazid, rifampicin and ethambutol in a daily single dose for 9 months." | 3.67 | Clinical experience with short-course chemotherapy in patients with tubercular pleural effusion and lymphadenitis. ( Behera, D; Malik, SK, 1985) |
| " tuberculosis to Streptomycin (SM), Isoniazid (INH), Ethambutol (EMB) and Rifampicin (RMP) in the department of the Bas-Rhin from 1971 to 1978." | 3.66 | [Resistance of the Koch bacillus to antibacillary agents in the Department of the Lower Rhine]. ( Burghard, G; Cooreman, J; Grosset, J, 1983) |
| "The course of infection with Mycobacterium tuberculosis strains H37Rv, H37Ra and their isoniazid-resistant, hydrogen peroxide-susceptible mutants in guinea-pig spleen and lung were assessed by measuring changes in number of viable bacteria during the first and second 3-day intervals after i." | 3.66 | The contribution of hydrogen peroxide resistance to virulence of Mycobacterium tuberculosis during the first six days after intravenous infection of normal and BCG-vaccinated guinea-pigs. ( Aber, VR; Jackett, PS; Lowrie, DB; Mitchison, DA, 1981) |
| "Drug susceptibility studies on strains of Mycobacterium tuberculosis isolated from widely different populations of patients and tested by two different techniques indicated that all 55 strains resistant to rifampicin were also resistant to isoniazid, while many strains resistant to isoniazid were found to be susceptible to rifampicin." | 3.66 | Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis. ( Aziz, A; Middlebrook, G; Reggiardo, Z; Siddiqi, SH, 1981) |
| "In a first experiment mice infected intravenously with 10(6) Mycobacterium tuberculosis were randomly treated either with isoniazid (INH) + rifampicin (RMP) 25 mg/kg or with INH + RMP + pyrazinamide (PZA) or with INH + RMP + PZA + streptomycin (SM)." | 3.66 | [Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]. ( Fermanian, J; Grosset, J; Lecoeur, H; Truffot, C, 1982) |
| "Calcium metabolism was studied in 83 patients during eighteen months' rifampicin and isoniazid therapy for tuberculosis by measurements including calcium, alkaline phosphatase and 25-hydroxycholecalciferol (25-HCC)." | 3.66 | Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis. ( Brown, J; Erooga, MA; Perry, W; Stamp, TC, 1982) |
| "7 female patients between ages 18-42 who were receiving treatment with rifampicin (450-600 mg daily) for tuberculosis were given a single dose of Minovlar (50 mg ethynlestradiol (EE) and 1 mg norethindrone acetate) and given a dose 1 month after stopping rifampicin." | 3.66 | The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ( Back, DJ; Breckenridge, AM; Crawford, FE; Hall, JM; MacIver, M; Orme, ML; Rowe, PH; Smith, E; Watts, MJ, 1980) |
| "We used decision analysis to determine the benefits and risks of preventive therapy with isoniazid for young adults whose only risk factor for the development of active tuberculosis was a positive tuberculin skin test." | 3.66 | Should young adults with a positive tuberculin test take isoniazid? ( Aronson, MD; Delbanco, TL; Taylor, WC, 1981) |
| "In a series of 1,212 tuberculosis patients treated on a regime of streptomycin/isoniazid/thiacetazone (S/INH/thiacetazone) over a period of 10 years in Nigeria there were 171 cases considered to have toxic reactions to thiacetazone (14%)." | 3.66 | Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria. ( Pearson, CA, 1978) |
| " The Author concludes the paper, affirming that chemoprophylaxis with isoniazid, after 20 years of application, has obtained the official chrism and can furnish, besides the BCG vaccine, a remarkable contribution to the control of tuberculosis in all countries of the world." | 3.66 | [Antitubercular chemoprophylaxis after 20 years of its world-wide application]. ( Zorini, AO, 1979) |
| "41 226 isoniazid exposed and 22 811 non-exposed patients admitted to Canadian institutions for the treatment of tuberculosis from 1952 to 1960 were followed to 1973 by computerised record linkage to the National Death Index and, for 1969 to 1973, to the National Cancer Incidence Reporting System; The mortality for the total cohort compared to that expected from the mortality in the Canadian population, was greater than expected for tuberculosis, other chest diseases and certain cancer sites associated with cigarette smoking (except bladder cancer)." | 3.66 | Isoniazid exposure in relation to cancer incidence and mortality in a cohort of tuberculosis patients. ( Coppock, E; Howe, GR; Lindsay, J; Miller, AB, 1979) |
| "Modern tuberculosis treatment suggests the intermittent regimens of isoniazid twice or once weekly." | 3.66 | [The importance of estimating the individual acetylation rate in modern tuberculosis treatment]. ( Duru, S, 1979) |
| "Three cases of histamine reaction occuring in tuberculosis patients on ingestion of a species of tropical fish, Sardinella (Amblygaster) sirm are reported." | 3.66 | Histamine poisoning in tuberculosis patients on ingestion of tropical fish. ( Uragoda, CG, 1978) |
| "On eating preparations of a particular variety of fish, the skipjack (bonito), patients with tuberculosis on isoniazid repeatedly developed symptoms very similar to those of histamine poisoning." | 3.65 | Adverse reactions to isoniazid on ingestion of fish with a high histamine content. ( Kottegoda, SR; Uragoda, CG, 1977) |
| "Tests of sensitivity to rifampin of over 2,200 strains of Mycobacterium tuberculosis demonstrated a progressive increase in the number of rifampin-resistant isolates during the past four years in Massachusetts." | 3.65 | Emergence of rifampin-resistant Mycobacterium tuberculosis in Massachusetts. ( Stottmeier, KD, 1976) |
| "Serial viable counts on Mycobacterium tuberculosis exposed in vitro to isoniazid, rifampicin and ethambutol in Tween-albumin liquid medium showed no bactericidal synergism between isoniazid and rifampicin and no influence of ethambutol on the bactericidal activity of isoniazid or isoniazid plus rifampicin." | 3.65 | Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol. ( Dickinson, JM; Mitchison, DA, 1976) |
| " The acetylator phenotype of over 600 pulmonary tuberculosis patients treated with intermittent isoniazid-containing regimens in two controlled clinical trials was determined using either sulphadimidine or a slow-release isoniazid formulation." | 3.65 | Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens. ( Ellard, GA; Gammon, PT, 1977) |
| "Five children with tuberculosis were treated with isoniazid (20 mg." | 3.65 | [Toxic hepatitis caused by rifampin and isoniazid in treatment of tuberculosis (author's transl)]. ( Abeledo Mezquita, G; Otero Reigada, MC, 1977) |
| " The authors report here a case where despite an adjusted initial dose there was a decrease in the rate of acetylation during treatment with INH-rifampicin and ethambutol, without hepatic involvement but accompanied by retrobulbar optic neuritis." | 3.65 | [Modification during treatment of the rate of acetylation of isoniazide clinically or biologically detectable hepatic damage (author's transl)]. ( Albengres, E; Breau, JL; Chrétien, J; Hirsch, A; Houin, G; Saltiel, JC; Tillement, JP, 1977) |
| "The effect of streptomycin used alone and in combination with tubazid on the brain electric activity was studied in chronic experiments on rabbits with tuberculosis." | 3.65 | [Effect of the prolonged use of streptomycin as well as streptomycin in combination with tubazid on the bioelectrical activity of the brain in experimental tuberculosis]. ( Aksel'rod, LB; Bogun, OI; Kniazheva, VN; Sukolovskaia, DM, 1976) |
| "Black male tuberculosis patients (106) were phenotyped into 59% fast and 41% slow acetylators with isoniazid (NH) plasma half-lives." | 3.65 | Isoniazid acetylator status of Black South African tuberculosis patients. ( Bach, PH; Bima, B; Higgins-Opitz, SB; Leary, WP, 1976) |
| "The introduction of ethambutol and rifampicin has modified the therapy of tuberculosis." | 3.65 | [New aspects of tuberculosis therapy]. ( Haegi, V, 1975) |
| "Analysis of the overt hepatic disease that developed in 114 patients while taking isoniazid for chemoprophylaxis of tuberculosis showed it to be mainly hepatocellular." | 3.65 | Isoniazid-associated hepatitis in 114 patients. ( Black, M; Epler, GR; Ishak, KG; Mitchell, JR; Zimmerman, HJ, 1975) |
| "Two groups of tuberculosis patients, phenotyped as either slow or fast inactivators of isoniazid, participated in a preliminary bioavailability study of a new INH-matrix preparation with sustained action." | 3.65 | Comparative blood levels and metabolism of INH and an INH-matrix preparation in fast and slow inactivators. ( Eidus, L; Jeanes, CW; Schaefer, O, 1973) |
| "A major step toward the eradication of tuberculosis in the United States has been the use of isoniazid for chemoprophylaxis in certain persons who have positive tuberculin skin tests but no other evidence of active infection." | 3.65 | Isoniazid chemoprophylaxis of tuberculosis. ( Davidson, FF; Jenkins, D, 1972) |
| "A controlled comparison by the Tuberculosis Chemotherapy Centre, Madras, of the merits of home as compared with sanatorium treatment for pulmonary tuberculosis showed that, at the end of a year of chemotherapy with isoniazid plus p-aminosalicylic acid (PAS), the response of the home patients closely approached that of the sanatorium patients." | 3.64 | Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate. ( ANDREWS, RH; ANGEL, JH; BHATIA, AL; DEVADATTA, S; FOX, W; JANARDHANAM, B; RADHAKRISHNA, S; RAMAKRISHNAN, CV; SUBBAIAH, TV; VELU, S, 1961) |
| "It is well known that in the treatment of tuberculosis with isoniazid the complication of peripheral neuritis may arise." | 3.64 | Peripheral neuritis due to isoniazid. ( ANDREWS, RH; DEVADATTA, S; FOX, W; GANGADHARAM, PR; RAMAKRISHNAN, CV; SELKON, JB; VELU, S, 1960) |
| "A recent report by the Tuberculosis Chemotherapy Centre, Madras, showed that the response of patients to a year's domiciliary treatment for pulmonary tuberculosis with isoniazid plus p-aminosalicylic acid closely approached that of patients to a year's sanatorium treatment with the same combination of drugs." | 3.64 | Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate. ( ANDREWS, RH; DEVADATTA, S; FOX, W; RADHAKRISHNA, S; RAMAKRISHNAN, CV; SELKON, JB; SOMASUNDARAM, PR; SUBBAIAH, TV; VELU, S, 1960) |
| "This study from the Tuberculosis Chemotherapy Centre, Madras, compares patients infected with isoniazid-resistant tubercle bacilli ("R" patients) with those infected with isoniazid-sensitive tubercle bacilli ("S" patients) as regards, first, their pretreatment status and, secondly, their response to a year's chemotherapy, either with isoniazid plus p-aminosalicylic acid (PAS) or with isoniazid alone." | 3.64 | Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone. ( ANDREWS, RH; BHATIA, AL; DEVADATTA, S; FOX, W; MITCHISON, DA; RADHAKRISHNA, S; RAMAKRISHNAN, CV; SELKON, JB; VELU, S, 1961) |
| "Since isoniazid is metabolized in man to several derivatives with little or no specific activity against the tubercle bacillus, its rate of inactivation in the body may have an important bearing on its efficacy as an antituberculosis drug." | 3.64 | Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. ( BHATIA, AL; GANGADHARAM, PR; RADHAKRISHNA, S; SELKON, JB, 1961) |
| "A series of studies on the rate of inactivation of isoniazid in Indian patients with pulmonary tuberculosis in a 1-year comparison of four domiciliary chemotherapeutic regimens-three of isoniazid alone, either in moderate (HI-1 and HI-2 regimens) or in low (H regimen) dosage, and one of isoniazid in low dosage plus p-aminosalicylic acid (PAS) (PH regimen) -has recently been undertaken by the Tuberculosis Chemotherapy Centre, Madras." | 3.64 | Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS. ( DEVADATTA, S; FOX, W; GANGADHARAM, PR; NAIR, CN; SELKON, JB, 1961) |
| "This study from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress during the second year of those patients in a 1-year comparison of four domiciliary chemotherapeutic regimens (isoniazid plus PAS and three regimens of isoniazid alone) whose pulmonary tuberculosis had attained bacteriological quiescence at the end of the year of chemotherapy." | 3.64 | Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate. ( ANDREWS, RH; ANGEL, JH; DEVADATTA, S; FOX, W; GANGADHARAM, PR; NARAYANA, AS; RAMAKRISHNAN, CV; SELKON, JB; SOMASUNDARAM, PR; VELU, S, 1961) |
| "The authors present a report from the Tuberculosis Chemotherapy Centre, Madras, on the prevalence and attack rate of tuberculosis among close family contacts of tuberculous patients in South India undergoing domiciliary chemotherapy either with isoniazid plus PAS or with one of three regimens of isoniazid alone." | 3.64 | Prevalence and early attack rate of tuberculosis among close family contacts of tuberculous patients in South India under domiciliary treatment with isoniazid plus PAS or isoniazid alone. ( ANDREWS, RH; DEVADATTA, S; FOX, W; RADHAKRISHNA, S; RAMAKRISHNAN, CV; SOMASUNDARAM, PR; VELU, S, 1961) |
| "Recent work carried out at the Tuberculosis Chemotherapy Centre, Madras, and at the Postgraduate Medical School of London has shown that isoniazid-sensitive cultures of tubercle bacilli obtained before the start of chemotherapy from South Indian patients with pulmonary tuberculosis are of lower average virulence than corresponding cultures from British patients." | 3.64 | A COMPARISON OF THE VIRULENCE IN THE GUINEA-PIG OF TUBERCLE BACILLI FROM THAI AND BRITISH PATIENTS. ( BHATIA, AL; HITZE, KL; JACOB, CV; RAMACHANDRAN, K; SELKON, JB, 1963) |
| "This study from the Tuberculosis Chemotherapy Centre, Madras, summarizes the progress during the second year of the patients in a concurrent comparison of four domiciliary chemotherapeutic regimens (isoniazid plus PAS and three regimens of isoniazid alone) who had bacteriologically active or bacteriologically relapsed pulmonary tuberculosis, with isoniazid-resistant organisms, at the end of the first year of treatment." | 3.64 | The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance. Response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS. ( BHATIA, AL; DEVADATTA, S; FOX, W; NARAYANA, AS; RAMAKRISHNAN, CV; SELKON, JB; VELU, S, 1962) |
| "Cumulative 24-month Mycobacterium tuberculosis infection incidence (measured primarily by tuberculin skin test [TST]) was high among human immunodeficiency virus exposed but uninfected infants (8." | 3.11 | Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial. ( Carimo, N; Cranmer, LM; Escudero, JN; Hawn, TR; John-Stewart, G; Kinuthia, J; LaCourse, SM; Maleche-Obimbo, E; Matemo, D; Mecha, J; Richardson, BA; Warr, AJ, 2022) |
| " However, the occurrence of potentially serious adverse events (AE) is a limitation of TPT regimens." | 3.01 | A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events. ( Lisboa Bastos, M; Melnychuk, L; Menzies, D; Perlman-Arrow, S, 2023) |
| "The duration of the standard treatment for tuberculosis can be shortened to four months but this treatment regimen is also based on rifapentine, in addition to isoniazid, pyrazinamide, and moxifloxacin." | 3.01 | [Treatment of tuberculosis: what is new?] ( Brehm, TT; Friesen, I; Heyckendorf, J; Kalsdorf, B; Kandulla, J; Köhler, N; Kuhns, M; Lange, C; Martensen, J; Schmiedel, S; Terhalle, E, 2023) |
| "Additionally, treating tuberculosis with antibiotics also poses a serious risk of hepatotoxicity in the patient's body." | 3.01 | Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. ( Ahmad, W; Alharbi, JN; Alomary, MN; Alyahya, SA; Ansari, MA; Ansari, SMA; Ather, H; Hani, U; Imran, MA; Islam, N; Jamous, YF; Shoaib, S; Wahab, S, 2023) |
| "People with radiographic evidence for pulmonary tuberculosis (TB), but negative sputum cultures, have increased risk of developing culture-positive TB." | 3.01 | Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review and meta-analysis. ( Carlin, F; Esmail, H; Gray, AT; Houben, RMGJ; Kik, SV; Macpherson, L; MacPherson, P; Quartagno, M; Richards, AS; Rogozińska, E; Sossen, B, 2023) |
| " We investigated pregnancy-induced and pharmacogenetic-associated pharmacokinetic changes and drug-drug interactions between isoniazid and efavirenz in pregnant women." | 3.01 | Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. ( Aaron, L; Aurpibul, L; Bhosale, R; Bradford, S; Browning, R; Chakhtoura, N; Chanaiwa, V; Chipato, T; Costello, D; Denti, P; Gausi, K; Gupta, A; Haas, DW; Hesseling, A; Jean-Philippe, P; Kabugho, E; Masheto, GR; McCarthy, K; Mhembere, T; Mmbaga, BT; Montepiedra, G; Mutambanengwe, M; Nevrekhar, N; Norman, J; Nyati, M; Onyango-Makumbi, C; Rouzier, V; Shin, K; Sterling, TR; Stranix-Chibanda, L; Theron, G; Tongprasert, F; Vhembo, T; Violari, A; Wallis, CL; Weinberg, A; Wiesner, L; Zimmer, B, 2021) |
| "To describe the pharmacokinetics of isoniazid and acetyl-isoniazid in TB/HIV-coinfected patients, and assess the effects of efavirenz co-administration and a 50% increase in the dose of rifampicin on the pharmacokinetic parameters of isoniazid and acetyl-isoniazid." | 2.90 | Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid. ( Affolabi, D; Bah-Sow, O; Chirehwa, MT; Denti, P; McIlleron, H; Merle, C; Wiesner, L, 2019) |
| "Pharmacokinetic studies in the past have shown inadequate antituberculosis drug levels in children with the currently available dosing regimens." | 2.90 | Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India. ( Aruldhas, BW; Bose, A; Hoglund, RM; Mathew, BS; Mathew, SK; Ranjalkar, J; Tarning, J; Verghese, VP, 2019) |
| "Isoniazid disposition was described using a two-compartment model with first-order absorption and linear elimination in most of the studies." | 2.82 | Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models. ( Banerjee, M; M, SS; Mallayasamy, S; Raju, AP; Rao, M; Saravu, K; Sv, CS; Thomas, L; Varma, M, 2022) |
| "Tuberculosis was one of the most frequent HIV associated diseases, although screening tests were not performed in almost 18%, depending on the concurrence of social risk factors." | 2.82 | [Tuberculosis and socioeconomic factors in spanish population: a systematic review.] ( Ruiz-Tornero, AM; Sánchez-Recio, R, 2022) |
| " The pharmacokinetic parameters of rifampin, isoniazid, ethambutol, and pyrazinamide were determined for each patient." | 2.80 | Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis. ( Chigutsa, E; Gumbo, T; McIlleron, H; Pasipanodya, JG; Sirgel, FA; Smith, PJ; van Helden, PD; Visser, ME, 2015) |
| "Participants receiving daily rifapentine and isoniazid with efavirenz had pharmacokinetic evaluations at baseline and weeks 2 and 4 of concomitant therapy." | 2.80 | Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention. ( Andersen, JW; Bao, Y; Benson, CA; Chaisson, RE; Fletcher, CV; Gupta, A; Kim, P; Mohapi, L; Mwelase, T; Podany, AT; Supparatpinyo, K; Swindells, S, 2015) |
| " INH pharmacokinetic parameters were characterized using a population pharmacokinetic approach." | 2.77 | Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants. ( Bobat, R; Carey, VJ; Cotton, MF; DʼArgenio, DZ; Fletcher, CV; Kiser, JJ; Madhi, SA; McSherry, GD; Seifart, HI; Werely, CJ; Zhu, R, 2012) |
| "The front line antitubercular drugs rifampicin (RMP) and isoniazid (INH), when co-administered, face the problem of reduced bioavailability of RMP." | 2.76 | Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin. ( Avachat, AM; Bhise, SB, 2011) |
| " The serum INH concentrations were higher in the undernourished group but the pharmacokinetic parameters were comparable with those in the normal nutrition group." | 2.75 | Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis. ( Gupta, D; Gupta, P; Mishra, TK; Roy, V; Sethi, GR, 2010) |
| "We investigated adherence to study medication in a two centre, randomized trial comparing daily to three times a week dosing of isoniazid." | 2.74 | Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. ( Cotton, MF; Golub, JE; le Roux, DM; le Roux, SM; Workman, L; Zar, HJ, 2009) |
| "Prophylaxis against tuberculosis has been recognized as important for preventing clinical forms of tuberculosis, mainly in HIV positive patients." | 2.73 | [Effectiveness of prophylaxis against tuberculosis in patients infected with HIV]. ( Arbeláez, A; Arbeláez, MP; Arias, SL; Betancourt, G; Gómez, RD; Nagles, J; Peláez, LM; Rojas, C; Velásquez, G; Vélez, L, 2007) |
| " The purpose of this study was to demonstrate utility of a physiologically-based pharmacokinetic modeling approach to predict plasma and lung concentrations of 11 compounds used or under development as TB therapies (bedaquiline [and N-desmethyl bedaquiline], clofazimine, cycloserine, ethambutol, ethionamide, isoniazid, kanamycin, linezolid, pyrazinamide, rifampicin, and rifapentine)." | 2.72 | Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs. ( Almond, L; Berg, A; Gardner, I; Hatley, O; Humphries, H; Jamei, M; Pan, X; Romero, K; Small, B; Zhang, M, 2021) |
| "Tuberculosis is a common cause of phlyctenular keratoconjunctivitis, especially for patients who live in a high endemic area of tuberculosis." | 2.72 | A rare case of primary sinonasal tuberculosis presented with phlyctenular keratoconjunctivitis in a pediatric patient: A case report and literature review. ( Apiwattanakul, N; Assawawiroonhakarn, S; Boonsathorn, S; Wiriyachai, T, 2021) |
| " Moreover, we include available data to support therapeutic drug monitoring of these drugs and known pharmacokinetic and pharmacodynamic targets that can be used for optimization of therapy." | 2.72 | Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs. ( Aarnoutse, RE; Alffenaar, JC; Denti, P; Dooley, KE; Märtson, AG; Peloquin, CA; Sloan, DJ; Sturkenboom, MGG; Svensson, EM; van den Elsen, SHJ, 2021) |
| "Among persons who were underweight at diagnosis, weight gain of 5% or less between diagnosis and completion of 2-mo intensive phase therapy was moderately associated with an increased relapse risk (18." | 2.72 | Lack of weight gain and relapse risk in a large tuberculosis treatment trial. ( Horsburgh, CR; Khan, A; Reves, R; Sterling, TR; Vernon, A, 2006) |
| "The incidence of tuberculosis has been increasing substantially on a worldwide basis over the past decade, but no tuberculosis-specific drugs have been discovered in 40 years." | 2.71 | A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. ( Andries, K; Cambau, E; de Chaffoy, D; Göhlmann, HW; Guillemont, J; Hoffner, S; Huitric, E; Jarlier, V; Lee, E; Lounis, N; Neefs, JM; Timmerman, P; Truffot-Pernot, C; Van Gestel, J; Verhasselt, P; Williams, P; Winkler, H; Zhu, M, 2005) |
| "Patients of end stage renal disease (ESRD) taken for RT formed the subjects of study." | 2.71 | Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient. ( Agarwal, SK; Bhowmik, D; Dash, SC; Gupta, S; Tiwari, SC, 2004) |
| " In this study, the relative bioavailability of rifampicin, isoniazid and pyrazinamide was assessed in a group of 14 healthy male subjects using the FDC tablet containing 4 drugs versus separate formulations at the same dose levels." | 2.70 | Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations. ( Agrawal, S; Bhade, SR; Kaul, CL; Kaur, KJ; Panchagnula, R; Singh, I, 2002) |
| "Tuberculosis was associated with an increased mortality (adjusted rate ratio 1." | 2.70 | Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. ( Fuchs, D; Godfrey-Faussett, P; Hosp, M; Lisse, I; Mwinga, A; Quigley, MA, 2001) |
| "The perceived need for simple, non-invasive methods of assessing the relative bioavailability of rifampicin in fixed-dose combination (FDC) anti-tuberculosis formulations." | 2.70 | The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations. ( Ellard, GA; Fourie, PB; Pillai, G; Smith, PJ, 2001) |
| " This study compared completion rates for isoniazid (INH) preventive therapy for injection drug users (IDUs) randomly assigned to methadone treatment combined with directly observed preventive treatment (DOPT) versus those assigned to routine TB clinic referral without methadone treatment." | 2.70 | A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. ( Batki, SL; Bradley, JM; Bradley, M; Delucchi, K; Gruber, VA, 2002) |
| " Steroid dosage varied according to diagnosis and severity." | 2.69 | Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids? ( Andonopoulos, AP; Bounas, A; Karokis, D; Safridi, C, 1998) |
| "There was a significant difference in the Cmax between free and RIF combined with INH (6." | 2.69 | Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis. ( Chitemerere, C; Gumbo, J; Ndudzo, P; Nyazema, NZ; Rabvukwa, P, 1999) |
| " Thirty-four HCWs (41%) developed an adverse event; in 26 (76%), toxicity was sufficiently severe to require cessation of treatment." | 2.69 | Isoniazid toxicity in health care workers. ( Grayson, ML; Stuart, RL; Wilson, J, 1999) |
| "Management of latent tuberculosis infection (LTBI) is a critical element in the elimination of tuberculosis (TB)." | 2.66 | Latent tuberculosis infection: recent progress and challenges in South Korea. ( Jeon, D, 2020) |
| " New data on optimal drug selection and dosing are emerging with the inclusion of children in clinical trials and ongoing research on age-related pharmacokinetics and pharmacodynamics." | 2.66 | Tuberculosis treatment in children: The changing landscape. ( Huynh, J; Marais, BJ; Schaaf, HS; Thwaites, G, 2020) |
| "Isoniazid was measured by spectrophotometry and Ketoconazole by the microbiologic method with Candida albicans as test microorganism." | 2.66 | [Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin]. ( Acevedo, C; De Salvo, MC; Galati, MR; García Fernández, JC; Masana, M; Mingolla, L; Negroni, R; Pilheu, JA; Rubio, MC; Yunis, AS, 1989) |
| "No trend toward an increasing cancer rate in the isoniazid group was observed with the passage of time." | 2.65 | The incidence of cancer among participants in controlled, randomized isoniazid preventive therapy trial. ( Costello, HD; Snider, DE, 1980) |
| "Tuberculosis has been one of the greatest global health challenges of all time." | 2.61 | Marine natural products as potential anti-tubercular agents. ( Gerwick, WH; Hou, XM; Shao, CL; Wang, CY, 2019) |
| " Inter-individual pharmacokinetic variability and the effect of age, nutritional status, Human immunodeficiency virus (HIV) infection, acetylator genotype may need to be accounted for in striving for the dosages best suited for an individual." | 2.61 | Pharmacokinetics of First-Line Anti-Tubercular Drugs. ( Kabra, SK; Lodha, R; Mukherjee, A, 2019) |
| " Pharmacokinetic and pharmacogenetic studies are increasingly performed and might confirm their potential role in optimizing treatment outcome in specific settings and populations." | 2.58 | Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization? ( Bonora, S; Calcagno, A; Motta, I, 2018) |
| "GB tuberculosis is a difficult diagnosis preoperatively." | 2.58 | A comprehensive review on Primary gallbladder tuberculosis. ( Agrawal, S; Anjum, R; Gupta, A; Mallik, D, 2018) |
| "Tuberculous liver abscess is a rare disease entity even in endemic areas of Mycobacterium tuberculosis." | 2.53 | Isolated tuberculous liver abscess in an immunocompetent adult patient: A case report and literature review. ( Chen, TC; Chou, LT; Huang, CC; Lai, AB; Wang, JH, 2016) |
| " We pooled data by study quality, design, region, dosing modality and patient characteristics." | 2.53 | Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. ( Al-Efraij, K; Campbell, JR; Cook, VJ; Johnston, J; Marra, F; Mota, L, 2016) |
| "The first-line of treatment for tuberculosis includes the drugs Isoniazid (INH) and Rifampicin (RIF) metabolized in the liver." | 2.52 | [The role of pharmacogenomics in the tuberculosis treatment regime]. ( Guio, H; Levano, KS; Sánchez, C; Tarazona, D, 2015) |
| "HIV is the top and tuberculosis is the second leading cause of death from infectious disease worldwide, with an estimated 8." | 2.50 | Tuberculosis and HIV co-infection in children. ( Chiappini, E; de Martino, M; Galli, L; Thorne, C; Turkova, A; Venturini, E, 2014) |
| "This review will introduce pharmacokinetic parameters for key anti-TB drugs, as well as the indications and limitations of measuring these parameters in clinical practice." | 2.50 | Understanding pharmacokinetics to improve tuberculosis treatment outcome. ( Heysell, SK; Reynolds, J, 2014) |
| "Congenital tuberculosis is diagnosed by Cantwell criteria and treatment includes three or four anti-tubercular drug regimen." | 2.50 | Management of newborn infant born to mother suffering from tuberculosis: current recommendations & gaps in knowledge. ( Das, S; Faridi, MM; Mittal, H, 2014) |
| "Tuberculosis is a bacterial disease that predominantly affects the lungs and results in extensive tissue pathology." | 2.49 | A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis. ( Barry, CE; Dartois, V, 2013) |
| "Treatment of latent tuberculosis (TB) infection is an important component of TB control programs in both high- and low-prevalence countries." | 2.49 | Treatment of latent tuberculosis infection. ( Parekh, MJ; Schluger, NW, 2013) |
| "Tuberculosis is a major disease causing every year 1." | 2.48 | Tuberculosis: the drug development pipeline at a glance. ( Baulard, AR; Crauste, C; Déprez, B; Flipo, M; Villemagne, B; Willand, N, 2012) |
| "It is essential to identify and treat contacts of tuberculosis patients with active disease." | 2.48 | Contacts of infectious tuberculosis patients: monitor those at highest risk of developing tuberculosis. ( , 2012) |
| " PubMed, Ovid MEDLINE and EMBASE were systematically searched for publications in English to evaluate the evidence about dosing schedules and treatment efficacy." | 2.47 | Treatment of tuberculosis and optimal dosing schedules. ( Chang, KC; Grosset, J; Leung, CC; Yew, WW, 2011) |
| " It is evident that guidelines established for the prevention and treatment of this problem differ between industrialised and developing countries, and that further research is needed to define the optimum dosing of pyridoxine supplementation in populations where there is a significant burden of TB and HIV." | 2.47 | Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. ( Benatar, M; Harrison, TB; Heckmann, JM; van der Watt, JJ, 2011) |
| "Intracranial tubercular subdural empyema in the pediatric age group is an extremely rare but curable entity." | 2.46 | Pediatric intracranial subdural empyema caused by Mycobacterium tuberculosis--a case report and review of literature. ( Ambekar, S; Banerjee, AD; Chandramouli, BA; Pandey, P, 2010) |
| "Treatment of MDR tuberculosis is difficult and has been based for twenty years on the use of fluoroquinolones and injectable antibiotics such as amikacin, kanamycin and capreomycin." | 2.46 | [Anti-tuberculosis drug resistance and therapeutic dead end]. ( Robert, J; Veziris, N, 2010) |
| "Isoniazid LTBI treatment was associated with reduced MTB reactivation in transplant patients with latent MTB risk factors (0." | 2.45 | Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. ( Gould, MK; Holty, JE; Keeffe, EB; Meinke, L; Ruoss, SJ, 2009) |
| " However, they are associated to a high rate of adverse effects that can lead to therapeutic failure." | 2.44 | [Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management]. ( Aouam, K; Ben Romdhane, F; Boughattas, NA; Chaabane, A; Chakroun, M; Loussaïef, C, 2007) |
| "Chemotherapy for tuberculosis is indicated in case of disease as well as in latent tuberculosis infection." | 2.42 | [Tuberculosis-current therapeutic principles]. ( Greinert, U; Zabel, P, 2003) |
| "tuberculosis is 5-10 % and highest during the first two years after infection." | 2.42 | [Latent tuberculosis infection: recommendations for preventive therapy in adults in Germany]. ( Haas, WH; Hauer, B; Hohlfeld, J; Kropp, R; Loddenkemper, R; Loytved, G; Magdorf, K; Rieder, HL; Sagebiel, D; Schaberg, T, 2004) |
| "Isoniazid-induced pancreatitis is potentially reversible; early recognition and drug withdrawal are warranted in the appropriate clinical setting." | 2.42 | Recurrent acute pancreatitis after isoniazid. ( Chow, KM; Leung, CB; Li, PK; Szeto, CC, 2004) |
| "tuberculosis were rather difficult in Japan, by using tuberculin skin test." | 2.41 | [Hospital infection control practice for tuberculosis]. ( Suzuki, K, 2002) |
| "Tuberculosis is the commonest opportunistic infection in HIV-infected patients in developing countries including India." | 2.41 | Tuberculosis with human immunodeficiency virus infection. ( Cherian, T; Verghese, VP, 2000) |
| "Isoniazid (INH) has been the mainstay of preventive therapy for 40 years, but its use is limited by concerns about toxicity and poor adherence." | 2.41 | New developments in the treatment of latent tuberculosis. ( Chaisson, RE, 2000) |
| "Congenital tuberculosis is rare, and the clinical presentation of tuberculosis during pregnancy and infancy is often non-specific, making recognition difficult." | 2.41 | Congenital tuberculosis: a rare manifestation of a common infection. ( Smith, KC, 2002) |
| "Treatment of tuberculosis has three major goals: healing the patient, preventing selection of resistant strains and control transmission of tuberculosis." | 2.40 | [Antitubercular chemotherapy]. ( Dautzenberg, B; Jouveshomme, S, 1997) |
| "To determine whether preventive treatment for tuberculosis in adults infected with HIV reduces the frequency of tuberculosis and overall mortality." | 2.40 | Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials. ( Garner, P; Squire, SB; Wilkinson, D, 1998) |
| "Pharyngeal tuberculosis is an uncommon condition." | 2.40 | [Pharyngeal tuberculosis: an analytical study and report of 10 cases]. ( Kharoubi, S, 1998) |
| "Isoniazid has been the accepted drug for use as prophylaxis for TB in immunocompetent patients, and there is evidence that isoniazid is also effective in HIV-positive, PPD-positive patients." | 2.39 | Prophylaxis for tuberculosis in Europe--ongoing research. ( Carosi, G; Matteelli, A, 1996) |
| "Optimum treatment of tuberculosis in persons with human immunodeficiency virus (HIV) infection is still being defined." | 2.38 | Failure of therapy for tuberculosis in human immunodeficiency virus infection. ( Nolan, CM, 1992) |
| "Tuberculosis is on the increase in the United States, so physicians would be prudent to renew familiarity with the disease." | 2.38 | Tuberculosis makes a comeback. Giving and interpreting the Mantoux test. ( Dickensheets, DL, 1989) |
| "Pyrazinamide, an antituberculous drug discovered in 1952, was first considered as a toxic drug." | 2.36 | [Toxicity of pyrazinamide in antituberculous treatments (author's transl)]. ( Perdrizet, S; Pretet, S, 1980) |
| "Drug treatment of tuberculosis is reviewed." | 2.35 | Chemotherapy of tuberculosis. ( Koerner, SK; Pinsker, KL, 1976) |
| "Mycobacterium kansasii pulmonary disease is frequently misdiagnosed and treated as tuberculosis, especially in countries with high tuberculosis burden." | 1.91 | Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment. ( Jiang, Y; Li, J; Shen, X; Wang, L; Xu, B; Yu, C; Zhang, Y; Zheng, X, 2023) |
| "Isoniazid is a first-line pro-drug that requires activation through an enzyme called catalase peroxidase, but is subject to widespread resistance, driven by mutations in katG and inhA genes and other loci with compensatory effects (e." | 1.91 | Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan. ( Ahmad, S; Alam, J; Ali, S; Campino, S; Clark, TG; Khan, AS; Khan, MT; Khan, TA; Khattak, B; Mohammad, N; Napier, G; Phelan, JE; Qasim, M, 2023) |
| " To address this issue, we utilized a murine model of antibiotic-induced dysbiosis to assay the bioavailability of rifampicin, moxifloxacin, pyrazinamide, and isoniazid in mouse plasma over a period of 12 h following individual oral administration." | 1.91 | The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability. ( Dartois, V; Mittereder, LR; Namasivayam, S; Oland, S; Sher, A; Wang, H; Zimmerman, M, 2023) |
| "Tuberculosis is a serious contagious disease mainly affecting the lungs and is common in the developing countries." | 1.91 | Anti-tubercular therapy (ATT) induced exfoliative dermatitis-A case series. ( Balijepalli, MK; Butti, L; Kandra, N; Masapogu, S; Somarouthu, VS; Uppala, PK; Uttaravalli, U; Vangoori, Y; Varghese, AM, 2023) |
| "Tuberculosis is the number one killer of infectious diseases caused by a single microbe, namely Mycobacterium tuberculosis (Mtb)." | 1.91 | Antimycobacterial pyridine carboxamides: From design to in vivo activity. ( Bárta, P; Bouz, G; Doležal, M; Forbak, M; Janďourek, O; Konečná, K; Korduláková, J; Kubíčková, P; Kučera, R; Nawrot, DE; Novák, M; Paterová, P; Pavliš, O; Zemanová, J; Zitko, J, 2023) |
| " To address this gap, we formulate a whole-body physiologically-based pharmacokinetic (PBPK) model for EPTB that for the first time includes the ability to simulate drug concentrations in the pleura and lymph node, the most commonly affected sites of EPTB." | 1.91 | A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites. ( Gadgil, CJ; Ramachandran, A, 2023) |
| " To address this knowledge gap, we used physiologically based pharmacokinetic (PBPK) modeling to evaluate NAT2 phenotype-specific effects of pregnancy on INH disposition." | 1.91 | Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy. ( Amaeze, OU; Isoherranen, N, 2023) |
| "Directly observed treatment (DOT) for tuberculosis (TB) is recommended by the World Health Organization." | 1.91 | Community-supported self-administered tuberculosis treatment combined with active tuberculosis screening: a pilot experience in Conakry, Guinea. ( Camara, LM; Cherif, GF; de Jong, BC; Decroo, T; Delamou, A; Gils, T; Hassane-Harouna, S; Ortuño-Gutiérrez, N; Rigouts, L, 2023) |
| "Mycobacterium tuberculosis is exposed to diverse stresses inside the host during dormancy." | 1.91 | Rv1255c, a dormancy-related transcriptional regulator of TetR family in Mycobacterium tuberculosis, enhances isoniazid tolerance in Mycobacterium smegmatis. ( Ajay Kumar, R; Gopi Reji, J; K Edison, L; Kurthkoti, K; Pushparajan, AR; Raghunandanan, S, 2023) |
| " para-Aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant Mycobacterium tuberculosis, has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day, which in turn causes severe gastrointestinal disturbances presumably by disruption of gut microbiota and host epithelial cells." | 1.72 | Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS). ( Aldrich, CC; Baughn, AD; Boshoff, HIM; Dartois, V; Hegde, PV; Howe, MD; Jia, Z; Pan, Y; Remache, B; Sharma, S; Zimmerman, MD, 2022) |
| "Children with drug-susceptible tuberculosis in Malawi and South Africa underwent pharmacokinetic sampling while receiving first-line tuberculosis drugs as single formulations according the 2010 WHO recommended doses." | 1.72 | Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study. ( Bekker, A; Davies, G; Denti, P; Gonzalez-Martinez, C; Hesseling, AC; McIlleron, HM; Rabie, H; Svensson, EM; van der Laan, LE; van Rie, A; Wasmann, RE; Wiesner, L; Winckler, J; Zar, HJ, 2022) |
| " Adverse drug events were more frequent in the older age group (22." | 1.72 | Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases. ( Chung, C; Jo, KW; Kim, YJ; Shim, TS, 2022) |
| "Tuberculosis is an ancient disease of mankind, and its causative bacterium is Mycobacterium tuberculosis." | 1.72 | Thermodynamic integration combined with molecular dynamic simulations to explore the cross-resistance mechanism of isoniazid and ethionamide. ( Gong, X; Liu, H; Yang, Y; Zhang, Q; Zhang, Y; Zhao, N, 2022) |
| " The findings of the present study indicate the need to periodically assess adherence and persistence to IPT in the child TB contacts as high intermittent missed dosing rates can undermine the effectiveness of IPT in preventing incident disease." | 1.72 | Adherence to Isoniazid Preventive Therapy among children living with tuberculosis patients in Delhi, India: An exploratory prospective study. ( Basu, S; Chandra, S; Chopra, KK; Khanna, A; Sharma, N; Sharma, P, 2022) |
| " Simulations were performed to assess INH exposure and optimal dosing regimens, using 2 targets: Cmax at 3-6 mg/L and area under the curve (AUC) ≥ 10." | 1.72 | Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure. ( Bekker, A; Béranger, A; Browning, R; Cababasay, M; Capparelli, EV; Cotton, MF; Mirochnick, M; Moye, J; Savic, RM; Solans, BP; Violari, A; Wang, J; Wiesner, L, 2022) |
| "Isoniazid resistance was detected in 13% of the patients and rifampicin resistance was detected in 8%." | 1.72 | Evaluation of diagnostic components and management of childhood pulmonary tuberculosis: a prospective study from Istanbul, Turkey. ( Cakin, ZE; Cakir, E; Cakir, FB; Collak, A; Dogan Demir, A; Erenberk, U; Kut, A; Nursoy, M; Ozaydin, E; Ustabas Kahraman, F; Uzuner, S, 2022) |
| " Often antitubercular human dose selection is derived from pharmacokinetic data in plasma." | 1.72 | Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection. ( Della Pasqua, O; Ferrer, S; Muliaditan, M; Ortega-Muro, F; Teutonico, D, 2022) |
| " Moreover, acetylation phenotype-based INH dosing has been shown to be cost-effective as well as successful in terms of treatment outcomes and the increase in the quality of life of the patients." | 1.72 | Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India. ( Das, A; Khan, N, 2022) |
| "Isoniazid resistance was significantly associated with the Beijing genotype of Lineage 2 (19." | 1.72 | Association between Mycobacterium tuberculosis genotype and diabetes mellitus/hypertension: a molecular study. ( Chaiprasert, A; Chen, H; Chongsuvivatwong, V; Guo, S; Lei, S; Li, J; Luo, R; McNeil, E; Ou, W; Palittapongarnpim, P; Qin, W; Surachat, K; Zhang, S, 2022) |
| "Primary psoas tuberculosis is the presence of "Koch's bacillus'' within the iliopsoas muscle caused by hematogenous or lymphatic seeding from a distant site." | 1.72 | Primary psoas tuberculosis abscess with an iliac bone lytic lesion: a case report. ( Abouhareb, R; Alasadi, L; Alrstom, A; Alsuliman, T; Daher, N; Karam, B; Mohandes, AF; Rajab Bek, MW, 2022) |
| "58 children were assessed for eligibilty and enrolled between June 25, 2016, and Feb 6, 2018; 44 had complete stool testing and serum pharmacokinetic data, and they were included in the analyses." | 1.72 | Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study. ( Alshaer, MH; Gratz, J; Heysell, SK; Houpt, ER; Justine, M; Kosek, M; Liu, J; Maro, A; Mduma, E; Mpagama, SG; Mujaga, B; Peloquin, CA; Rogawski McQuade, ET; Thomas, TA; Van Aartsen, D, 2022) |
| "Fluoxetine also has an additive effect on the effect of isoniazid, and their concomitant use in the delivery system can have significant effects in treating infection of all clinical strains of Mtb." | 1.72 | An effective nano drug delivery and combination therapy for the treatment of Tuberculosis. ( Amiri, V; Delorme, V; Ebrahimzadeh, N; Kasaeian, A; Maleki, M; Masoumi, M; Pourazar, S; Sadeghinia, M; Sheikhpour, M, 2022) |
| "Isoniazid prophylaxis treatment period is long and can cause liver damage." | 1.72 | Effectiveness and safety of available preventive tuberculosis treatment regimens for children and adolescents: protocol for a systematic review and network meta-analysis. ( Acosta-Reyes, J; Benjumea-Bedoya, D; Estupiñán-Bohorquez, AF; Florez, ID; Hoyos Mendez, Y; Sabella-Jiménez, V, 2022) |
| " Nonlinear mixed-effects models were developed to describe the pharmacokinetic data." | 1.72 | Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Sundell, J, 2022) |
| "Tuberculosis (TB), caused by Mycobacterium tuberculosis infection, remains a leading cause of death from an infectious agent, resulting in more than a million deaths per year." | 1.72 | A world without tuberculosis: moving from imagination to reality. ( Jacobs, WR, 2022) |
| "Pyrazinamide resistance was found in 6/80 (7." | 1.72 | Pyrazinamide resistance in rifampicin discordant tuberculosis. ( Mlisana, KP; Mvelase, NR; Singh, R; Swe Swe-Han, K, 2022) |
| "Nearly half of the patients were non-adherent to the daily dosing regimen." | 1.72 | Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis patients on a newly introduced daily dose regimen in South India: A cross-sectional study. ( Chenniah, J; Ganesan, RM; Mahalingam, VT; Meka, G; Munagala, AK; Peraman, R; Thamineni, R, 2022) |
| "tuberculosis) is usually treated by oral antimycobacterial agents, including rifampicin, ethambutol, and pyrazinamide, but the treatment regimen with intravenous and/or intramuscular antimycobacterial agents for patients who cannot take medications orally remains unclear." | 1.72 | A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen. ( Kamoshita, F; Karaushi, H; Mitsutake, K; Miyawaki, Y; Seki, M; Watanabe, N, 2022) |
| "Drug products used for treating tuberculosis are one of the most widely reported medicines to be classified as falsified or substandard in low- and middle-income countries, representing a major hazard to health." | 1.72 | Development and Optimization of a New UPLC-UV/MS Method through DoE and MLR for Detecting Substandard Drug Products to Treat Tuberculosis. ( Cáceres-Pérez, AR; Fariña, JB; Oliva, A; Santoveña-Estévez, A; Suárez-González, J, 2022) |
| "Bacille Calmette-Guérin (BCG) adenitis is an uncommon complication following BCG vaccination." | 1.72 | Clinical, Microbiological Profile and Treatment Outcomes of Infants with BCG Adenitis: A Retrospective Study. ( Chacko, A; Dash, N; Michael, JS; Rebekah, G; Rose, W; Venkatesan, M; Verghese, VP, 2022) |
| "Tuberculosis has remained a leading cause of death among people living with HIV (PLHIV) globally." | 1.72 | Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania. ( Jacobs, C; Maritim, P; Mdoe, P; Nyarubamba, RF; Silumbwe, A; Zulu, JM, 2022) |
| "Mycobacterium tuberculosis is one of the hardest to treat bacterial pathogens with a high capacity to develop antibiotic resistance by mutations." | 1.72 | Dynamics of Extensive Drug Resistance Evolution of Mycobacterium tuberculosis in a Single Patient During 9 Years of Disease and Treatment. ( Andersson, DI; Hjort, K; Hoffner, S; Jurén, P; Sandegren, L; Toro, JC, 2022) |
| "Pyrazinamide exposures were similar to those in adults." | 1.72 | Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations. ( Aarnoutse, R; Chabala, C; Chirehwa, M; Choo, L; Gibb, D; Hesseling, AC; Hissar, S; Kapasa, M; Kinikar, A; LeBeau, K; Mave, V; McIlleron, H; Mulenga, V; Palmer, M; Turkova, A; van der Zalm, M; Wiesner, L; Wobudeya, E; Zimba, KM, 2022) |
| "Tuberculosis was the predominant comorbidity (15." | 1.62 | Low prevalence of isoniazid preventive therapy uptake among HIV-infected patients attending tertiary health facility in Lagos, Southwest Nigeria. ( Adejumo, IA; Badru, WA; Busari, AA; Olanrewaju, OA; Olayemi, SO; Oreagba, IA; Oshikoya, KA; Usman, SO, 2021) |
| " Population pharmacokinetic modeling generated estimates of drug exposure (Cmax and AUC) from individual-level post hoc Bayesian estimates of plasma and intrapulmonary pharmacokinetics." | 1.62 | Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis. ( Chasweka, M; Chirambo, AP; Chitani, A; Davies, GR; Dilly-Penchala, S; Else, LJ; Gordon, SB; Khoo, SH; Malamba, RD; McCallum, AD; Meghji, JZ; Mwandumba, HC; Pertinez, HE; Sheha, I; Sloan, DJ, 2021) |
| " For some, weekly dosing was perceived as being easier to remember and less disruptive, leading to a preference for 3 months isoniazid and rifapentine, which is dosed weekly." | 1.62 | Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru. ( Becerra, MC; Galea, JT; Jimenez, J; Keshavjee, S; Lecca, L; Millones, AK; Puma, D; Yuen, CM, 2021) |
| "To develop a pharmacokinetic model of isoniazid (INH) concentration taking into account demographic factors and genetic variables [N-acetyltransferase 2 (NAT2) genotype], and to propose an initial INH dosage that could maximize the probability of achieving the desired INH concentration." | 1.62 | Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia. ( Aouam, K; Boughattas, N; Chaabane, A; Chadly, Z; Chickaid, M; Fadhel, NB; Fredj, NB; Romdhane, HB; Woillard, JB, 2021) |
| "Isoniazid was later substituted with rifabutin in 2 patients with isoniazid-resistant tuberculosis." | 1.62 | Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients. ( Alameer, R; Almaghrabi, RS; Almohaizeie, A; Alrajhi, AA; Alshehri, N; Nizami, I; Omrani, AS, 2021) |
| "Tuberculosis is a devastating and a deadly disease despite the novel advances in its diagnostic tools and drug therapy." | 1.62 | Phenotypic and genotypic drug sensitivity profiles of Mycobacterium tuberculosis infection and associated factors in northeastern Ethiopia. ( Amare, M; Ameni, G; Erko, B; Gashaw, F; Gumi, B; Mekonnen, Y; Yenew, B, 2021) |
| "Although latent tuberculosis infection (LTBI) treatment is given before anti-tumor necrosis factor (TNF) treatment, tuberculosis (TB) still develops in these patients and the risk factors are not well known." | 1.62 | Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy. ( Aksu, K; Kaptan, Y; Oksel, F; Sayiner, A; Suner, A; Taş, MN, 2021) |
| "Isoniazid was administered as 100 mg or 300 mg oral tablets and rifapentine was administered as 150 mg oral tablets." | 1.62 | Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study. ( Amanullah, F; Becerra, MC; Fareed, U; Farooq, S; Hussain, H; Jaswal, M; Keshavjee, S; Khan, AJ; Khan, H; Malik, AA; Nasir, K; Safdar, N; Shahbaz, S, 2021) |
| "Isoniazid treatment had an adequate tolerance and adherence." | 1.62 | Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City. ( García-Tirado, J; Martin-Onraet, A; Osorio-López, EA; Vilar-Compte, D, 2021) |
| " Therefore, we aimed to provide insight into the optimal dosing of INH for each NAT2 acetylator phenotype with respect to the probability of achieving a pharmacokinetic (PK)/pharmacodynamic target." | 1.62 | Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis. ( Cho, YS; Choi, YK; Ghim, JL; Jang, TW; Kim, HJ; Lee, HK; Long, NP; Oh, JY; Park, HK; Park, Y; Phuong, NTT; Shin, JG, 2021) |
| "Mycobacterium tuberculosis is a causative organism of tuberculosis, which is the most deadly disease after cancer in the current decade." | 1.56 | Development of 'S', 'N' Heterocycles as Antimycobacterials Targeting Fatty Acid Biosynthesis. ( Choudhari, PB; Dahiwade, LK; Dhavale, RP; More, HN; Rochlani, SP, 2020) |
| "Although rare, tuberculosis has been reported with biologic treatment against psoriasis in Japan, a tuberculosis medium-burden country." | 1.56 | Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities. ( Furue, M; Hayashi, H; Higashi, Y; Hino, R; Imafuku, S; Kaneko, S; Kikuchi, S; Koike, Y; Matsuzaka, Y; Mitoma, C; Miyagi, T; Morizane, S; Nakahara, T; Nakamura, M; Nomura, H; Ohata, C; Ohyama, B; Okazaki, F; Sawada, Y; Sugita, K; Takahashi, K; Tsuruta, N; Yamaguchi, K; Yamaguchi, M; Yanase, T; Yonekura, K, 2020) |
| "Among over 8000 patients treated for latent tuberculosis we found no evidence of acquired drug resistance, underscoring the safety of rifampin monotherapy for latent tuberculosis." | 1.56 | Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection. ( Aiona, K; Belknap, R; Flynn, AG; Haas, MK; Reves, R, 2020) |
| "Tuberculosis is a leading cause of death worldwide." | 1.56 | Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection. ( Almeida, AJ; Alves, AD; Gaspar, MM; Grenha, A; Guerreiro, F; Pinho, J; Simões, S, 2020) |
| "New effective compounds to treat tuberculosis are urgently needed." | 1.56 | Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy. ( Abbadi, BL; Basso, LA; Bizarro, CV; Bondan da Silva, J; Machado, P; Picada, JN; Pissinate, K; Rodrigues-Junior, VS; Sperotto, NDM; Villela, AD, 2020) |
| " Both sex and CD4 cell count affected the bioavailability of isoniazid." | 1.56 | Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy. ( Äbelö, A; Ashton, M; Bienvenu, E; Birgersson, S; Janzén, D; Sundell, J, 2020) |
| "Active tuberculosis was diagnosed in three of the 196 TST-positive patients who adhered to PTI (1." | 1.56 | Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil. ( Avelino-Silva, VI; Freitas, AC; Gutierrez, EB; Picone, CM, 2020) |
| " In this work, we developed a translational approach which can allow for forward translation to predict efficacy of drug combination in EBA studies using the Multistate Tuberculosis Pharmacometric (MTP) and the General Pharmacodynamic Interaction (GPDI) models informed by in vitro static time-kill data." | 1.56 | Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development. ( Coates, ARM; Hu, Y; Simonsson, USH; Susanto, BO; Wicha, SG, 2020) |
| " The prospective cohort were HIV patients without TB disease initiated on a dosage of Isoniazid 300 mg/day for adults and 150 mg/day for children for a period of 6 months." | 1.56 | A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda. ( Calnan, J; Kadama, H; Karungi Karamagi Nkolo, E; Katureebe, C; Kiragga, D; Lawino, A; Muhire, M; Musinguzi, J; Nabwire, J; Namuwenge, P; Sensalire, S; Seyoum, D, 2020) |
| "Ethambutol was stopped in all these 8 patients." | 1.56 | Ocular adverse events in drug sensitive TB patients on daily fixed dose combination anti-TB drugs: A record review study from Kerala, India. ( Balakrishnan, S; Das, M; Manu, MS; Mehta, K; Neena, PS; Rakesh, PS; Satyanarayana, S; Sindhu, MP; Sunil Kumar, M; Valamparampil, MJ, 2020) |
| " Low bioavailability due to the active substances' incompatibility in acidic medium was reported for some of these FDC forms." | 1.56 | Compatibility investigation for a new antituberculotic fixed dose combination with an adequate drug delivery. ( Lasić, K; Mornar, A; Petruševska, V, 2020) |
| " Similarly, orally disintegrating tablets (ODTs) are an increasingly popular dosage form that aid compliance since they do not require swallowing." | 1.56 | Formulation and Bioequivalence Testing of Fixed-Dose Combination Orally Disintegrating Tablets for the Treatment of Tuberculosis in the Paediatric Population. ( Badhan, RKS; Dennison, TJ; Mohammed, AR; Smith, JC, 2020) |
| "Tuberculosis-related hemophagocytic syndrome (HPS) is reported, but not HPS caused by Mycobacterium bovis in children." | 1.56 | Hemophagocytic syndrome associated with Mycobacterium bovis in a patient with X-SCID: a case report. ( Chen, M; Cheng, Y; Huang, C; Huang, T; Li, Y; Qin, C; Shi, B; Tang, W; Xia, Z; Xiao, S; Xu, H, 2020) |
| "Postoperative spondylodiscitis (PSD) and postoperative osteomyelitis (POM) are known complications of lumbar disc surgery." | 1.56 | Tuberculous Spondylodiscitis after Lumbar Microdiscectomy. ( Kaplan, N; Ozger, O, 2020) |
| "tuberculosis have evolved mutations in a previously uncharacterized DnaA pathway that quantitatively increases resistance to the key first-line antibiotic isoniazid." | 1.56 | Mutations in dnaA and a cryptic interaction site increase drug resistance in Mycobacterium tuberculosis. ( Brown, J; Chao, MC; Culviner, PH; Dulberger, CL; Fortune, SM; Giffen, SR; Hicks, ND; Liu, Q; Sixsmith, J; Stanley, S; Wolf, ID, 2020) |
| "Dosing recommendations for treating childhood tuberculosis (TB) were revised by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated these changes are relatively limited." | 1.56 | Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania. ( Augustino, D; Gratz, J; Heysell, SK; Houpt, ER; Justine, M; Kibiki, GS; Kivuyo, S; Mduma, E; Mfinanga, S; Mmbaga, B; Nicodemu, I; Peloquin, CA; Thomas, TA; Yeconia, A; Zagurski, T, 2020) |
| " Higher or more frequent dosing is needed to improve TB treatment outcomes in India." | 1.56 | Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes. ( Agibothu Kupparam, HK; Balasubramanian, U; Chandrasekaran, P; Dhanasekaran, K; Dooley, KE; Gaikwad, S; Golub, J; Gupta, A; Gupte, A; Gupte, N; Hanna, LE; Kadam, D; Kagal, A; Kulkarni, V; Mave, V; Murali, L; Paradkar, M; Pradhan, N; Ramachandran, G; Shivakumar, SVBY; Sivaramakrishnan, GN; Swaminathan, S; Thiruvengadam, K; Thomas, B, 2020) |
| "Isoniazid resistance was observed in 40% (23/58 tested) and rifampin resistance in 19." | 1.51 | High mortality during tuberculosis retreatment at a Ghanaian tertiary center: a retrospective cohort study. ( Bamfo, TD; Bouton, TC; Carter, J; Forson, A; Jacobson, K; Jenkins, H; Kudzawu, S; Kwara, A; Zigah, F, 2019) |
| "Ethambutol concentration was associated with creatinine clearance (Ccr, P = ." | 1.51 | Determinants of serum concentration of first-line anti-tuberculosis drugs from China. ( Dang, L; Lei, Q; Lv, X; Wang, H; Zhao, Y; Zhou, J; Zhu, C, 2019) |
| "Tuberculosis is a bacterial infectious disease that is usually transmitted by inhalation of droplets containing the bacteria." | 1.51 | [Tuberculosis]. ( Heyckendorf, J; Kalsdorf, B; Lange, C; Maurer, FP, 2019) |
| "The aim of the present work was to produce 3D-printed oral dosage forms with a sufficient drug dose displaying various release profiles." | 1.51 | 3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release. ( Öblom, H; Pimparade, M; Preis, M; Repka, M; Sandler, N; Speer, I; Zhang, J, 2019) |
| "Metformin (MET) is a potential combination drug to elevate anti-TB efficacy." | 1.51 | Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study. ( Ali, M; Mertaniasih, NM; Novita, BD; Pranoto, A; Soediono, EI, 2019) |
| " The nanohybrids were aimed to improve oral drug bioavailability and reduce physicochemical incompatibility of INH with other concomitantly administered tuberculostatic agents." | 1.51 | Halloysite nanotubes as tools to improve the actual challenge of fixed doses combinations in tuberculosis treatment. ( Aguzzi, C; Bonferoni, C; Carazo, E; Cerezo, P; Ferrari, F; Lanni, C; Sandri, G; Viseras, C, 2019) |
| " Patients with severe illness received high-dose rifampicin immediately, the others had a higher dosage guided by therapeutic drug monitoring." | 1.51 | High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre. ( Aarnoutse, R; Bergsma-de Guchteneire, I; Boeree, M; Hoefsloot, W; Kuipers, S; Magis-Escurra, C; Seijger, C; Te Brake, L; van Crevel, R; van Ingen, J, 2019) |
| "Anthropometric, genetic, and dosage characteristics of Mexican patients with TB are an important source of risk for subtherapeutic plasma concentrations of anti-TB drugs." | 1.51 | Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis. ( Huerta-García, AP; Magaña-Aquino, M; Medellín-Garibay, SE; Milán-Segovia, RDC; Ortiz-Álvarez, A; Portales-Pérez, DP; Rodríguez-Pinal, CJ; Romano-Moreno, S; Salazar-González, RA, 2019) |
| " Thus, our modified drug delivery nanocomposites afforded higher drug bioavailability with large potential for fabrication as long-acting drug delivery nanocomposites, especially with hydrophobic drugs inducing the growth of osteoblastic bone cells." | 1.51 | Fabrication of bioactive rifampicin loaded κ-Car-MA-INH/Nano hydroxyapatite composite for tuberculosis osteomyelitis infected tissue regeneration. ( Amarnath Praphakar, R; Rajan, M; Sam Ebenezer, R; Shakila, H; Sumathra, M; Vignesh, S, 2019) |
| "Pulmonary tuberculosis was bacteriologically confirmed in 4 057 subjects." | 1.51 | Tuberculosis in Poland in 2017 ( Korzeniewska- Koseła, M, 2019) |
| "Tuberculosis is the leading cause of death worldwide from infectious diseases." | 1.48 | Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors. ( Argyrou, A; Augustyns, K; Balabon, O; Ballell, L; Barros, D; Bates, RH; Blanco-Ruano, D; Cacho, M; Cunningham, F; Huss, S; Lopez-Roman, EM; Pitta, E; Rogacki, MK; Van der Veken, P; Vande Velde, CML, 2018) |
| "In the treatment of murine tuberculosis, a rifampicin dose of 30 mg/kg was sufficient to eradicate persistent M." | 1.48 | Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria. ( Alameda-Martin, L; Coates, A; Davies, G; Harrison, T; Hu, Y; Liu, Y; Ortega-Muro, F; Pertinez, H, 2018) |
| " Isoniazid, rifampin, and pyrazinamide concentration-time profiles and treatment outcome were obtained from 161 Indian children with drug-sensitive tuberculosis undergoing thrice-weekly dosing as per previous Indian pediatric guidelines." | 1.48 | Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications. ( Bhavani, PK; Dooley, KE; Gangadevi, NP; Guiastrennec, B; Gupta, A; Karlsson, MO; Kumar, AKH; Ramachandran, G; Savic, RM; Swaminathan, S, 2018) |
| "Tuberculosis, pneumonia, and severe bacterial infections are the main causes of hospital admission in HIV-infected children." | 1.48 | Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease. ( Archary, M; Ford, N; Frigati, L; Penazzato, M; Rabie, H, 2018) |
| "Drug resistant tuberculosis is increasing world-wide." | 1.48 | Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas. ( Kirschner, DE; Linderman, JJ; Pienaar, E, 2018) |
| "People with HIV infection with latent tuberculosis (TB) infection (LTBI) are at a 10-fold greater risk of developing active disease." | 1.48 | New and Noteworthy in Tuberculosis Diagnostics and Treatment. ( Swindells, S, 2018) |
| " The aim of this study was to evaluate the anti-Mycobacterium tuberculosis activity of nine naphthoimidazoles, alone and combined with isoniazid (INH) and rifampicin (RIF)." | 1.48 | Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin. ( Carvalho, TDSC; Corrêa Barros, LP; da Silva, PEA; de Moura, KCG; Del Rio, KP; Halicki, PCB; Pinto, MDCFR; Ramos, DF, 2018) |
| "WHO information note indicates that isoniazid preventive therapy (IPT) is generally safe with little risk of hepatotoxicity." | 1.48 | Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea. ( Berhane, A; Debesai, M; Russom, M; Tekeste, T; Teklesenbet, T; Zeregabr, M, 2018) |
| "Ensuring adherence and support during treatment of tuberculosis (TB) is a major public health challenge." | 1.48 | Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support. ( Bastos, M; Falzon, D; Mappin-Kasirer, B; Nsengiyumva, NP; Oxlade, O; Schwartzman, K; Trajman, A, 2018) |
| "Tuberculosis is one of the infectious diseases with the greatest global burden, affecting millions of people." | 1.46 | A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis. ( Flint, L; Manning, AJ; McGillivray, A; Ovechkina, Y; Parish, T; Roberts, DM, 2017) |
| "Suppurative lymphadenitis is one of the severe complication after BCG vaccination, but its diagnostic criteria and treatment guidelines have not yet been established." | 1.46 | BCG vaccination-induced suppurative lymphadenitis: four signs to pay attention to. ( Baek, SO; Han, HH; Ko, HS, 2017) |
| "Psoriatic patients with latent tuberculosis infection (LTBI) need a prophylaxis before starting a treatment with biological drugs." | 1.46 | Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting. ( Conti, A; Galdo, G; Gisondi, P; Lasagni, C; Odorici, G; Pellacani, G; Piaserico, S, 2017) |
| " There is a need for more research on optimization of dosing to maximize efficacy and safety of currently used drugs." | 1.46 | Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs. ( Chandrasekaran, V; Kawaskar, M; Kumar, AK; Kumar, AKH; Lavanya, J; Ramachandran, G; Swaminathan, S, 2017) |
| "Four main treatment barriers emerged from the data: 1) dosing errors, 2) time- and labor-intensive preparation and administration of medications, 3) provider concern that isoniazid preventive therapy (IPT) generates isoniazid resistance, and 4) poor adherence to IPT." | 1.46 | Barriers to the treatment of childhood tuberculous infection and tuberculosis disease: a qualitative study. ( Becerra, MC; Canales, P; Chiang, SS; Contreras, C; Del Castillo, H; Jimenez, J; Lecca, L; Roche, S; Tintaya, K, 2017) |
| " Compound 10a also displayed good pharmacokinetic profiles with oral bioavailability (F) of 41." | 1.43 | Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis. ( Ding, K; Li, M; Liu, Z; Lu, X; Tang, J; Zhang, T; Zhang, X, 2016) |
| " Monte Carlo simulation was performed with the intent of identifying the probability of achieving an AUC24 greater than the identified threshold of hepatotoxicity with different dosing regimens (2." | 1.43 | Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB? ( Baraldo, M; Bassetti, M; Cojutti, P; Duranti, S; Isola, M; Pea, F; Viale, P, 2016) |
| "Targeted diagnosis and treatment of latent tuberculosis (TB) infection (LTBI) among persons with a high risk of exposure to TB or of developing TB when infected has been performed and monitored routinely in the Netherlands since 1993." | 1.43 | Monitoring latent tuberculosis infection diagnosis and management in the Netherlands. ( Cobelens, F; de Vries, G; Erkens, CG; Schimmel, H; Slump, E; van den Hof, S; Verhagen, M, 2016) |
| "New compounds with antituberculosis activity and their combination with classic drugs have been evaluated to determine possible interactions and antagonism." | 1.43 | Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium tuberculosis. ( Barbosa, AR; Caleffi-Ferracioli, KR; Cardoso, RF; García-Ramos, JC; Leite, CQ; Pavan, FR; Ruiz-Azuara, L; Siqueira, VL; Toledano-Magaña, Y, 2016) |
| "Screening for and treating tuberculosis (TB) infection in children and adolescents is an effective way of decreasing future TB cases." | 1.43 | School-based Study to Identify and Treat Adolescent Students at Risk for Tuberculosis Infection. ( Cruz, AT; Graviss, EA; Hatzenbuehler, LA; Smith, EO; Starke, JR, 2016) |
| "HIV-infected adults with substance abuse (tobacco smoking, khat chewing and alcohol) should be prioritised for TB screening." | 1.43 | Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study. ( Alemu, YM; Awoke, W; Wilder-Smith, A, 2016) |
| " Eighty children with TBI received a 12-dose once-weekly isoniazid/rifapentine regimen; 79 (99%) completed therapy, 94% reported no adverse events, 1 child had mildly elevated transaminases but 1 adolescent later developed pulmonary TB." | 1.43 | Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection. ( Cruz, AT; Starke, JR, 2016) |
| "A few cases of drug-induced autoimmune hepatitis or the drug reaction with eosinophilia and systemic symptom (DRESS) syndrome by anti-tuberculosis medications have been reported." | 1.43 | [Concomitant Drug Reaction with Eosinophilia and Systemic Symptom Syndrome from Ethambutol and Autoimmune Hepatitis from Isoniazid]. ( Choi, JH; Heo, NY; Jo, KM; Kim, WG; Nam, KH; Park, CS; Park, SH, 2016) |
| "We identified significant gaps in the treatment for M." | 1.43 | Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California. ( Bolan, R; Chang, AH; Dubé, MP; Ghosh, JK; Kerndt, PR; Shin, SS; Yang, OO, 2016) |
| "2h) and low absolute bioavailability (1." | 1.42 | Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis. ( Chaturvedi, V; Dasgupta, A; Gupta, AD; Jaiswal, S; Kashyap, VK; Khan, SR; Krishnan, MY; Lal, J; Roy, KK; Saxena, AK; Sharma, A; Sharma, SK; Singh, S; Sinha, S; Srivastava, R, 2015) |
| "Recurrent tuberculosis is a major health burden and may be due to relapse with the original strain or reinfection with a new strain." | 1.42 | Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up. ( Banda, L; Chiwaya, A; Clark, TG; Coll, F; Crampin, AC; Glynn, JR; Guerra-Assunção, JA; Harris, D; Houben, RM; Khan, P; Mallard, K; McNerney, R; Mzembe, T; Parkhill, J; Pereira, RP, 2015) |
| "Ursolic acid (UA) has immunomodulatory function and exhibits antimycobacterial activity." | 1.42 | Ursolic Acid Activates Intracellular Killing Effect of Macrophages During Mycobacterium tuberculosis Infection. ( Jang, WS; Lee, BE; Nam, KW; Podder, B; Song, HY, 2015) |
| " Adequacy of SDC was based on the maximum concentration (Cmax) achieved in serum, with rifampicin (RMP) values <8 μg/ml and isoniazid (INH) values <3 μg/ml for daily dosing and <9 μg/ml for intermittent dosing considered inadequate." | 1.42 | Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients. ( Ahmed, R; Cooper, R; Der, E; Gao, Z; Hansen, E; Kharrat, H; Kunimoto, D; Long, R; Mah, A, 2015) |
| "Despite efforts to detect and treat active tuberculosis (TB) at the border, 75% of all active TB cases diagnosed in our hospital were illegal migrants." | 1.42 | Preventing tuberculosis transmission at a maternity hospital by targeted screening radiography of migrants. ( Abu-Hanna, J; Aviram, G; Braun, T; Carmeli, Y; Grisaru-Soen, G; Lessing, JB; Schechner, V, 2015) |
| "Tuberculosis is a major global health problem for which improved therapeutics are needed to shorten the course of treatment and combat emergence of drug resistance." | 1.42 | pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice. ( Clemens, DL; Dillon, BJ; Horwitz, MA; Hwang, AA; Lee, BY; Zink, JI, 2015) |
| "tuberculosis have been developed." | 1.42 | Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model. ( Awasthi, D; Carreau, A; Goullieux, L; Knudson, SE; Kumar, K; Lagrange, S; Ojima, I; Slayden, RA; Vermet, H, 2015) |
| "Improvement in tuberculosis treatment regimens requires selection of antibiotics and dosing schedules from a large design space of possibilities." | 1.42 | In silico evaluation and exploration of antibiotic tuberculosis treatment regimens. ( Dartois, V; Kirschner, DE; Linderman, JJ; Pienaar, E, 2015) |
| "Isoniazid neurotoxicity has never been reported to cause bilateral dentate hyperintensities, for which the differentials are few and include metronidazole toxicity." | 1.40 | Isoniazid-induced cerebellitis: a disguised presentation. ( John, M; Peter, P, 2014) |
| "Primary glans penis tuberculosis is a rare disease, but we must consider it (both primary and secondary forms) to try to avoid diagnostic delays that may cause prejudice for the patient." | 1.40 | Primary tuberculosis of the glans penis. ( Alvarez Bandres, S; Garcia Garcia, D; Jimenez Calvo, J; Jimenez Parra, JD; Sotil Arrieta, A; Torres Varas, L, 2014) |
| "Isoniazid therapy was started with marked improvement of psoriatic lesions before biologic treatment could be initiated." | 1.40 | Improvement in severe psoriasis associated with isoniazid treatment. ( Brzezinski, P; Chiriac, A; Feldman, SR; Ferariu, D; Solovan, C, 2014) |
| " However, further studies to identify the optimal statin and dosing are required." | 1.40 | Simvastatin increases the in vivo activity of the first-line tuberculosis regimen. ( Bruiners, N; Gennaro, ML; Karakousis, PC; Pine, R; Pinn, ML; Skerry, C, 2014) |
| "The granuloma is treated with isoniazid (INH), a drug that inhibits the synthesis of mycolic acids (MA)." | 1.40 | A model of isoniazid treatment of tuberculosis. ( Grobler, A; Lemmer, Y; Moody, C; Viljoen, H, 2014) |
| "tuberculosis were obtained from the Novosibirsk Research Institute of Tuberculosis, Russia." | 1.40 | Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia. ( Alkhovik, OI; Cherednichenko, AG; Dymova, MA; Filipenko, ML; Khrapov, EA; Petrenko, TI, 2014) |
| "Tuberculosis has re-emerged as a worldwide threat, which has motivated the development of new drugs." | 1.40 | [Fe(CN)5(isoniazid)](3-): an iron isoniazid complex with redox behavior implicated in tuberculosis therapy. ( Basso, LA; Butler, JS; de Mesquita Vieira, FG; Diógenes, IC; Lopes, LG; Sadler, PJ; Santiago, DS; Sousa, EH, 2014) |
| "During 2007-2011, a total of 203 systemic lupus erythematosus (SLE) patients with high-risk active TB, such as a history of TB infection, TB family member and strong positive purified protein derivative (PPD) skin test or hypoalbuminemia and hyperglycemia were enrolled." | 1.40 | [Preventive therapy for iatrogenic active tuberculosis in systemic lupus erythematosus patients]. ( Li, G; Lin, B; Ma, L; Wang, D; Wang, G; Wang, L, 2014) |
| " In addition, compound 8o was nontoxic to Vero cells and orally bioavailable in a preliminary pharmacokinetics study." | 1.39 | Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents. ( Gao, C; Peng, CT; Wang, NY; Wei, Y; Xia, Y; Xiong, Y; Xu, Y; Ye, TH; You, XY; Yu, LT; Zeng, XX; Zhang, LD; Zuo, WQ, 2013) |
| " Moreover, the rs1495741 genotypes showed an association with the isoniazid dosage required for induction of hepatotoxicity." | 1.39 | The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity. ( Ho, HT; Hsiong, CH; Hu, OY; Huang, TY; Jong, YJ; Lu, PL; Perng, WC; Wang, NC; Wang, TH, 2013) |
| "To evaluate IPT feasibility, treatment completion and adverse events (AE) and their determinants under field conditions." | 1.39 | Isoniazid preventive treatment: predictors of adverse events and treatment completion. ( Besozzi, G; Casali, L; Codecasa, LR; Delmastro, M; Ferrara, G; Ferrarese, M; Murgia, N; Raviglione, MC; Repossi, AC, 2013) |
| "The currently recommended dosages of rifampicin (RMP), isoniazid (INH), pyrazinamide (PZA) and ethambutol in children are extrapolated from adult pharmacokinetic studies, and have not been adequately evaluated in children." | 1.39 | Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children. ( Banu Rekha, VV; Bhavani, PK; Hemanth Kumar, AK; Mathevan, G; Poorana Gangadevi, N; Ramachandran, G; Ramesh Kumar, S; Ravichandran, N; Sekar, L; Swaminathan, S; Vijayasekaran, D, 2013) |
| "Isoniazid is a widely used frontline drug against tuberculosis." | 1.39 | High throughput screening of 7-methylpicene-1,2-diol as arylamine N-acetyltransferase (NAT) inhibitor to establish a isoniazid supplement in anti-tubercular therapy. ( Choudhury, MD; Chowdhury, A; Paul, P, 2013) |
| "The standard treatment for tuberculosis (TB) is the key to its control." | 1.39 | [Tuberculosis annual report 2010--(9) Treatment of tuberculosis-2]. ( , 2013) |
| "Tuberculosis is still a global health problem all over the world despite its mortality has been decreased with effective treatment regimens." | 1.39 | Unfinished battle with childhood tuberculosis: is it curable with less drugs and shorter duration? ( Cinel, G; Çobanoğlu, N; Doğru, D; Göçmen, A; Kiper, N; Köse, M; Koyun, M; Özçelik, U; Pekcan, S; Tana Aslan, A; Yalçın, E, 2013) |
| "Active tuberculosis is common among human immunodeficiency virus (HIV)-infected persons living in tuberculosis-endemic areas, but the hazard of subsequent tuberculosis disease has not been quantified in a single prospective cohort." | 1.39 | Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis. ( Arbeit, RD; Bakari, M; Horsburgh, CR; Lahey, T; Mackenzie, T; Maro, I; Matee, M; Mtei, L; Pallangyo, K; von Reyn, CF, 2013) |
| " Rifampicin concentrations during the dosing interval were determined by HPLC at three different timepoints: (i) after 2 weeks of TB therapy and before starting HIV therapy (T0); (ii) after 4 weeks of combined therapy (T1); and (iii) after 10 weeks of combined therapy (T2)." | 1.38 | Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso. ( Bonkoungou, V; Carvalho, AC; Comelli, M; Cusato, M; Dembélé, SM; Kouanda, S; Matteelli, A; Nacanabo, R; Regazzi, M; Saleri, N; Villani, P, 2012) |
| " In this article, a case series is presented to illustrate the value of individualized TB drug dosing in four patients with low TB drug concentrations." | 1.38 | Therapeutic drug monitoring in the treatment of tuberculosis patients. ( Aarnoutse, R; Boeree, M; Ijdema, D; Magis-Escurra, C; van den Boogaard, J, 2012) |
| " Drug therapy either alone or in combination with BCG, was more effective at lessening clinical disease and lesion severity compared to control animals or those receiving BCG alone." | 1.38 | Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis. ( Ackart, D; Basaraba, RJ; Caraway, ML; Hascall-Dove, L; Henao-Tamayo, M; Ordway, DJ; Orme, EA; Orme, IM; Shang, S; Shanley, CA, 2012) |
| "Contacts with latent tuberculosis infection (LTBI) are offered chemoprophylaxis to prevent active disease; however, the effectiveness of this intervention is unclear as treatment completion is generally low." | 1.38 | Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. ( Ahuja, SD; Anger, HA; Harris, TG; Kreiswirth, BN; Li, J; Proops, D; Shashkina, E, 2012) |
| " Daily dosing of rifapentine (P), a potent rifamycin with high intracellular accumulation, in place of rifampin (R) in the standard antitubercular regimen significantly shortens the duration of treatment needed to prevent relapse in a murine model of active TB." | 1.38 | Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. ( Dutta, NK; Grosset, JH; Illei, PB; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML, 2012) |
| "Infection in cancer patients with TB was significantly more often recorded among elderly patients and those suffering from poverty." | 1.38 | Characterization of Mycobacterium tuberculosis isolated from cancer patients with suspected tuberculosis infection in Egypt: identification, prevalence, risk factors and resistance pattern. ( Afifi, S; Eissa, S; El-Dahshan, R; El-Sharif, A; Rafeh, N, 2012) |
| "Half the recurrences occurred in the first year since completing treatment." | 1.38 | The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting. ( Crampin, AC; French, N; Glynn, JR; Houben, RM; Mboma, S; Mpunga, J; Mwaungulu, L; Mwaungulu, NJ; Mwenibabu, M; Mzemba, T, 2012) |
| "5% of tuberculosis (TB) cases reported in 2003 in Taipei City had no recorded pre-treatment body weight and that among those who had, inconsistent dosing of anti-TB drugs was frequent." | 1.38 | Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan. ( Bai, KJ; Chiang, CY; Hsu, YL; Lin, TP; Shih, HC; Yang, SL; Yen, MY; Yu, MC, 2012) |
| " No pharmacokinetic data are available from South American children." | 1.38 | Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations. ( Aarnoutse, RE; de Groot, R; de Waard, JH; García, JF; Hermans, PW; López, D; Verhagen, LM; Warris, A, 2012) |
| " The cytotoxic effects against mouse fibroblasts (NIH 3T3) in vitro were evaluated for 5c and 5d, which displayed no toxic effects (IC(50) > 1000 μM) against the mouse fibroblast cell line NIH 3T3." | 1.37 | Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies. ( Chitra, S; Manisankar, P; Muthusubramanian, S; Paul, N; Sriram, D; Yogeeswari, P, 2011) |
| "Incomplete transverse myelitis (ITM) of unknown origin is associated with high rates of morbidity and mortality." | 1.37 | Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study. ( Chen, X; Feng, Y; Guo, N; Huang, F; Lai, R; Liu, J; Sun, Q, 2011) |
| "tuberculosis is growing steadily; however, data on the genetic variation of isolates of M." | 1.37 | Genetic variation of Mycobacterium tuberculosis circulating in Kharkiv Oblast, Ukraine. ( Dymova, MA; Filipenko, ML; Khrapov, EA; Krutko, VS; Liashenko, OO; Poteiko, PI, 2011) |
| "tuberculosis was identified by microscopic observation and Ziehl-Neelsen staining." | 1.37 | Drug susceptibility pattern of Mycobacterium tuberculosis isolates against conventional anti-tuberculosis drugs in Dhaka, Bangladesh. ( Hossain, A; Hossain, M; Islam, S; Khalil, I; Mottalib, A, 2011) |
| "Mycobacterium tuberculosis is the causative agent of a pulmonary epidemic that is estimated to infect one-third of the world's population and that has an increased incidence of multidrug resistance." | 1.37 | T cell monitoring of chemotherapy in experimental rat tuberculosis. ( Bifani, P; Camacho, L; Dartois, V; Foo, DG; Hervé, M; Siew, JY; Singhal, A; Tay, HC, 2011) |
| "Isoniazid (INH) was given to those patients with positive TST or clinical risk factors for latent TB infection (LTBI)." | 1.37 | A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. ( Choi, SH; Han, DJ; Jeong, JY; Jung, JH; Kim, SC; Kim, SH; Kim, YH; Kim, YS; Lee, SO; Park, IA; Park, JB; Park, JS; Park, SJ; Park, SK; Woo, JH; Yun, SC, 2011) |
| " Population pharmacokinetic parameters and their variability encountered in tuberculosis patients were utilized in Monte Carlo simulations to determine the probability that particular daily doses of the drugs would achieve or exceed the EC(90) in the epithelial lining fluid of 10,000 tuberculosis patients." | 1.36 | New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. ( Gumbo, T, 2010) |
| " For the first 2 weeks of therapy, the dosing frequency was 5 days/week, and for the remaining period, twice weekly." | 1.36 | Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. ( Ahmad, Z; Grosset, JH; Karakousis, PC; Nuermberger, EL; Peloquin, CA; Pinn, ML; Tasneen, R; Williams, KN, 2010) |
| " Of 506 patients prescribed a three-drug fixed-dose combination (FDC), the dosage was adequate in 374 (73." | 1.36 | Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan. ( Bai, KJ; Chiang, CY; Enarson, DA; Lee, CN; Luh, KT; Suo, J, 2010) |
| "Isoniazide was conjugated to peptide (91)SEFAYGSFVRTVSLPV(106), a functional T-cell epitope of the immunodominant 16 kDa protein of Mycobacterium tuberculosis." | 1.36 | Characterisation of the membrane affinity of an isoniazide peptide conjugate by tensiometry, atomic force microscopy and sum-frequency vibrational spectroscopy, using a phospholipid Langmuir monolayer model. ( Bosze, S; Hill, K; Horváti, K; Hudecz, F; Keszthelyi, T; Kiss, E; Pénzes, CB; Schnöller, D, 2010) |
| "Isoniazid resistance has been described before in those who are immunocompromised." | 1.36 | Human bovine tuberculosis - remains in the differential. ( Bilal, S; Iqbal, M; Murphy, P; Power, J, 2010) |
| "Of 250 cases started on Category II retreatment, 209 were relapse cases; of these, 18 were INH-resistant RMP-susceptible, 18 were INH+RMP-resistant and nine were culture-negative." | 1.36 | Risk of relapse and failure after retreatment with the Category II regimen in Nepal. ( Maharjan, B; Shrestha, B; Yoshiyama, T, 2010) |
| "Tuberculosis is a major cause of mortality among patients with HIV and poses a risk throughout the course of HIV disease, even after successful initiation of antiretroviral therapy (ART)." | 1.35 | Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. ( Getahun, H; Havlir, DV; Nunn, P; Sanne, I, 2008) |
| "When active tuberculosis is identified, combination therapy with isoniazid, rifampin, pyrazinamide, and ethambutol should be promptly initiated for a two-month "intensive phase," and in most cases, followed by isoniazid and a rifamycin product for a four- to seven-month "continuation phase." | 1.35 | Update on the treatment of tuberculosis. ( Inge, LD; Wilson, JW, 2008) |
| "To study the effect of treatment of latent tuberculosis infection (LTBI) on QuantiFERON TB-2G (QFT-2G) test results." | 1.35 | [Effects of prophylaxis on QuantiFERON TB-2G responses among children]. ( Harada, N; Higuchi, K; Mori, T; Okada, K, 2008) |
| "Isoniazid treatment was initiated in those patients with a latent infection, and they were followed up at 2-month intervals." | 1.35 | Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. ( Aydin, N; Bayram, H; Bayram, N; Börekçi, S; Dikensoy, O; Elbek, O; Uyar, M, 2009) |
| "Tuberculosis is a growing international health concern." | 1.35 | Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial. ( Abdelaal, A; Badran, E; El Mashad, N; El-Ghaffar, HA; Fathy, A; Zaghloul, MH, 2009) |
| "Liver diseases are common in patients with HIV due to viral hepatitis B and C co-infections, opportunistic infections or malignancies, antiretroviral drugs and drugs for opportunistic infections." | 1.35 | The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. ( Colebunders, R; Feld, J; Kambugu, A; Katabira, E; Katwere, M; Ocama, P; Opio, KC; Piloya, T; Ronald, A; Thomas, D, 2008) |
| " The median number of dosage adjustments to attain normal concentrations was 1 (range 0-4 adjustments)." | 1.35 | Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. ( Engemann, JJ; Fortenberry, ER; Hamilton, CD; Holland, DP; Peloquin, CA; Stout, JE; Weintrob, AC, 2009) |
| " Safety studies showed that inoculation of RUTI caused a temporary increase of rectal temperature (1-2 degrees C) and local swelling, both adverse effects being well tolerated." | 1.35 | Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats. ( Cáceres, N; Cardona, PJ; Domingo, M; Gil, O; Grassa, M; Guirado, E; Nofrarias, M; Pérez, B; Serrano, E; Vilaplana, C, 2009) |
| "Mycobacterium tuberculosis infection has been shown to result in increased HIV replication and disease progression in HIV-infected individuals through increased immune activation." | 1.35 | Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis. ( Hanna, LE; Narayanan, PR; Nayak, K; Subramanyam, S; Swaminathan, S; Venkatesan, P, 2009) |
| " Thus, we developed a novel simple in vitro pharmacokinetic/pharmacodynamic (PK/PD) model for establishing time-kill curves and applied it for evaluating the antimicrobial activity of different dosing regimens of isoniazid (INH) against Mycobacterium bovis BCG as a surrogate for virulent M." | 1.35 | A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria. ( Budha, NR; Hurdle, JG; Lee, RB; Lee, RE; Meibohm, B, 2009) |
| "Drug-resistant tuberculosis is a major problem worldwide." | 1.35 | Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco. ( Akrim, M; Chaoui, I; El Mzibri, M; Elouad, R; Jordaan, AM; Kourout, M; Lahlou, O; Sabouni, R; Victor, TC, 2009) |
| "Chemotherapy for Mycobacterium tuberculosis infection may decrease interferon (IFN)-gamma responses to early secretory antigenic target 6 and culture filtrate protein (CFP)-10; a reaction that could be useful to monitor the success of treatment." | 1.35 | Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis. ( Harada, N; Higuchi, K; Mori, T, 2008) |
| " ChP is safe in IBD patients even in those taking concomitant, potentially hepatotoxic drugs." | 1.35 | Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. ( Araméndiz, R; Beltrán, B; Cabré, E; Cabriada, JL; Domènech, E; Gassull, MA; Ginard, D; Gisbert, JP; Hinojosa, J; Mañosa, M; San Román, AL; Saro, C; Zabana, Y, 2008) |
| "Existing data on the effect of treatment of latent tuberculosis infection (LTBI) on T-cell responses to Mycobacterium tuberculosis (MTB)-specific antigens are contradictory." | 1.34 | Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study. ( Anzidei, G; Bizzoni, F; Butera, O; Casetti, R; Dainotto, D; Girardi, E; Goletti, D; Ippolito, G; Nisii, C; Parracino, MP; Poccia, F, 2007) |
| "To study the frequency and degree of adverse effect, other than liver dysfunction, of isoniazid (INH) preventive therapy in Japanese people." | 1.34 | [Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid]. ( Hoshino, H; Ito, K; Kato, S; Masuyama, H; Nakazono, T; Sugita, H; Yoshiyama, T, 2007) |
| "tuberculosis have striking similarities, such as necrosis, mineralization, and hypoxia, to natural infections in humans." | 1.34 | Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. ( Aly, S; Andries, K; Basaraba, RJ; Cantarero, L; Ehlers, S; Hoff, D; Lenaerts, AJ; Orme, IM, 2007) |
| "Tuberculosis is a common complication and leading cause of death in HIV infection." | 1.34 | The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. ( Cavalcante, SC; Chaisson, RE; Durovni, B; Efron, A; Golub, JE; King, BS; Moore, RD; Moulton, LH; Pacheco, AG; Saraceni, V, 2007) |
| "Moxifloxacin is an 8-methoxyfluoroquinolone currently used in second-line regimens." | 1.34 | Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. ( Bishai, WR; Chaisson, RE; Grosset, JH; Nuermberger, EL; Peloquin, CA; Rosenthal, IM; Tyagi, S; Vernon, AA; Williams, KN; Zhang, M, 2007) |
| "Tuberculosis is the leading cause of infectious disease mortality in the world by a bacterial pathogen." | 1.33 | Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain. ( Aldrich, CC; Barry, CE; Beck, BJ; Bennett, EM; Boshoff, HI; Celia, L; Somu, RV; Wilson, DJ, 2006) |
| " Pharmacokinetic profiles of SQ109 in mice following a single administration showed its C(max) as 1038 (intravenous (i." | 1.33 | Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. ( Coward, L; Gorman, G; Hanrahan, C; Jia, L; Nikonenko, B; Noker, P; Protopopova, M; Tomaszewski, JE, 2005) |
| " When INH was concomitantly given as an admixture over food, Tmax was delayed and variability in drug absorption was significantly increased." | 1.33 | Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana). ( Dunker, F; Isaza, R; Maslow, JN; Mikota, SK; Peddie, J; Peddie, LR; Peloquin, CA; Riddle, H; Zhu, M, 2005) |
| "Tuberculosis is a leading cause of morbidity and mortality worldwide." | 1.33 | Susceptibility testing of Mycobacterium tuberculosis: comparison of the BACTEC TB-460 method and flow cytometric assay with the proportion method. ( Callister, SM; DeCoster, DJ; Schell, RF; Vena, RM, 2005) |
| "We speculated that those allergy-like symptoms were due to both the increased histamine in the food made with the saury under poor storage conditions and the patients' reduced histaminase activities due to INH." | 1.33 | An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in tuberculous ward. ( Ishikawa, T; Miki, M; Okayama, H, 2005) |
| "This level of sensitivity and specificity is concordant with that from the determination of M." | 1.33 | Evaluation of the CombiChip Mycobacteria Drug-Resistance detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis. ( Jang, H; Kang, SJ; Kim, C; Kim, SY; Park, YJ; Song, E; Yoo, J, 2006) |
| "Evaluation of sources of pharmacokinetic variation can facilitate optimization of tuberculosis treatment regimens by identification of avoidable sources of variation and of risk factors for low or high drug concentrations in patients." | 1.33 | Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. ( Burger, A; Folb, PI; McIlleron, H; Norman, J; Smith, P; Wash, P, 2006) |
| "Mycobacterium tuberculosis is one of the leading causes of death worldwide, and multidrug-resistant tuberculosis (MDR-TB) is associated with a high case fatality rate." | 1.33 | Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. ( Canducci, F; Cirillo, DM; Migliori, GB; Miotto, P; Penati, V; Piana, F, 2006) |
| "Tuberculosis has claimed its victims throughout much of known human history." | 1.33 | The history of tuberculosis. ( Daniel, TM, 2006) |
| "To improve the bioavailability of antitubercular drugs (ATDs) as well as to assess the feasibility of administering ATDs via the respiratory route, this study reports the formulation of three frontline ATDs, i." | 1.32 | Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. ( Khuller, GK; Pandey, R; Prasad, B; Sharma, A; Sharma, S; Zahoor, A, 2003) |
| "Patient non-compliance is the major drawback associated with the long-duration chemotherapy of tuberculosis (TB); hence, reduction in dosing frequency forms an important therapeutic strategy." | 1.32 | Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. ( Khuller, GK; Pandey, R; Sharma, S; Zahoor, A, 2003) |
| "Treatment with isoniazid was beneficial in HIV-infected, tuberculin-positive IDUs." | 1.32 | Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs. ( Amofa, J; Driver, CR; Fujiwara, PI; Gourevitch, MN; Highley, E; Kaye, K; Munsiff, SS; Rubino, MA; Scholten, JN; Seewald, R; Trim, C, 2003) |
| " The mean residence time and absolute bioavailability were increased several-fold as compared with unencapsulated drugs." | 1.32 | Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. ( Khuller, GK; Pandey, R, 2004) |
| "The emphasis on treatment of latent tuberculosis (TB) infection highlights the tradeoff between short-term decrements in health status from 'preventive' therapy, and long-term gains related to fewer cases of active TB." | 1.32 | Feasibility and reliability of health-related quality of life measurements among tuberculosis patients. ( Bourbeau, J; Dion, MJ; Menzies, D; Schwartzman, K; Tousignant, P, 2004) |
| " The relative bioavailability (as compared to oral free drugs) was increased by 5." | 1.32 | Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs. ( Khuller, GK; Pandey, R; Sharma, S, 2004) |
| " The effective therapeutic dosage of drugs could be reduced to half by supplementing HNP-1 in the therapeutic schedule." | 1.32 | Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy. ( Kalita, A; Khuller, GK; Verma, I, 2004) |
| "tuberculosis were resistant to at least one of the standard anti-tuberculosis agents." | 1.32 | Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2002: a report of the Australian Mycobacterium Reference Laboratory Network. ( Bastian, I; Chew, W; Gilpin, C; Haverkort, F; James, G; Lumb, R; Sievers, A, 2003) |
| "Tuberculosis is a major cause of childhood morbidity and mortality in high-burden settings, particularly in the third-world settings." | 1.32 | Childhood turberculosis: reflections from the front line. ( Marais, BJ, 2004) |
| "tuberculosis have reaffirmed tuberculosis as a primary public health threat." | 1.31 | A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. ( Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y, 2000) |
| " We sought to determine whether isoniazid prophylaxis administered during liver transplant candidacy was safe and effective for the prevention of posttransplantation tuberculosis." | 1.31 | Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. ( Gayowski, T; Singh, N; Wagener, MM, 2002) |
| "Isoniazid for 6-12 mo has been the mainstay of treatment for LTBI in the United States for more than 30 yr." | 1.31 | Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. ( , 2000) |
| "Isoniazid (INH) treatment for latent TB infection (LTBI) reduces the riskfor developing active TB by 41%-92% (1)." | 1.31 | Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997. ( , 2000) |
| "tuberculosis was also detected on direct microscopy and polymerase chain reaction." | 1.31 | Mycobacterium tuberculosis infections after renal transplantation. ( Altiparmak, MR; Apaydin, S; Ataman, R; Erek, E; Oztürk, R; Serdengeçti, K, 2000) |
| "Drug delivery strategies to achieve a sustained drug release and increased bioavailability involve the use of biodegradable polymeric drug carriers." | 1.31 | Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. ( Dutt, M; Khuller, GK, 2001) |
| "Connatal tuberculosis was confirmed at 48 days of age by isolation of Mycobacterium tuberculosis from the infant's tracheal aspirate and the mother's menstrual discharge." | 1.31 | Connatal tuberculosis in an extremely low birth weight infant: case report and management of exposure to tuberculosis in a neonatal intensive care unit. ( Fujioka, H; Ichiba, H; Saitoh, M; Shintaku, H; Yamano, T, 2001) |
| "Tuberculosis was found in seven children with a positive test, five of whom were from Ethiopia." | 1.31 | Compliance to treatment of latent tuberculosis infection in a region of Israel. ( Arbelli, Y; Bibi, H; Chemtob, D; Feigin, I; Shoseyov, D; Weiler-Ravell, D, 2002) |
| "Sensitivity and specificity were estimated." | 1.31 | Urine testing to monitor adherence to TB preventive therapy. ( Berg, J; Blumberg, E; Catanzaro, A; Friedman, L; Hovell, MF; Kelley, N; Moser, K; Perry, S; Sipan, C; Vera, A, 2002) |
| " Isoniazid and rifampicin encapsulated in liposomes were less toxic to peritoneal macrophages as compared to free drugs." | 1.30 | Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. ( Deol, P; Khuller, GK, 1997) |
| "This retrospective analysis was designed to evaluate the inactivation index (I3) method used to adjust the isoniazid dose during long-term administration in a pediatric population." | 1.30 | Isoniazid dose adjustment in a pediatric population. ( Badoual, J; Crémier, O; d'Athis, P; Gendrel, D; Olive, G; Pariente-Khayat, A; Pons, G; Rey, E; Vauzelle-Kervroëdan, F, 1998) |
| "Tuberculosis is one of the major public health problems that WHO has tackled throughout the last 50 years." | 1.30 | Commentary: making tuberculosis treatment available for all. ( Maher, D; Nunn, P, 1998) |
| "Tuberculosis is a common infection of renal transplant recipients in developing countries." | 1.30 | Tuberculosis after renal transplantation: experience of one Turkish centre. ( Ark, E; Beşişik, F; Ecder, T; Ece, T; Kiliçarslan, I; Sever, MS; Tabak, L; Türkmen, A; Yildiz, A, 1998) |
| "To test whether the bioavailability of antituberculosis drugs is altered in HIV-infected patients with tuberculosis." | 1.30 | Does AIDS impair the absorption of antituberculosis agents? ( Smith, PJ; Taylor, B, 1998) |
| "Tuberculosis is a serious opportunistic infection in transplant recipients." | 1.30 | Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. ( Paterson, DL; Singh, N, 1998) |
| "Tuberculosis is an endemic disease in our countries." | 1.30 | [Tuberculosis among hemodialysis patients in Dakar, apropos of 2 cases]. ( Bao, O; Diouf, B; Diouf, ML; Ka, MM; Mbengue, M; Moreira-Diop, T; Niang, A; Pouye, A, 1998) |
| "tuberculosis are treated with antibiotics (isoniazid and pyrazinamide), resulting in no detectable bacilli by organ culture." | 1.30 | Reactivation of latent tuberculosis: variations on the Cornell murine model. ( Chan, J; Flynn, JL; Joseph, H; Mohan, VP; Scanga, CA; Yu, K, 1999) |
| " Results show that RIF/PZA, dosed either daily or twice weekly, is as effective in preventing tuberculosis in dually-infected adults, as INH/pyridoxine given for 6-12 months." | 1.30 | Short course preventive therapy for tuberculosis is successful in HIV-infected patients. ( Chaisson, RE, 1998) |
| "Acute dacryocystitis is uncommon later and tuberculosis is exceptionally responsible for it." | 1.29 | [Tuberculous dacryocystitis]. ( Bureau, E; Chetail, N; Cotton, JB; Durra, A; Grenier, JL; Ligeon-Ligeonnet, P; Sartre, J, 1995) |
| "Tuberculosis has been increasing especially in urban areas and in immunosuppressed patients; however, the incidence and factors associated with tuberculosis in OLT patients are unknown." | 1.29 | Tuberculosis in liver transplant patients. ( Halpern, M; Mendelson, MH; Meyers, BR; Miller, C; Neibart, E; Sheiner, P, 1994) |
| " The chemotherapeutic data essentially confirmed the bioavailability data." | 1.29 | Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers. ( Gangadharam, PR; Kailasam, S; Srinivasan, S; Wise, DL, 1994) |
| "The authors made an attempt to treat experimental tuberculosis with sodium glutamate and isoniazide under chronic exposure to PAH dust." | 1.29 | [Morphological features of tissue reactions in combined treatment of experimental tuberculosis induced by xenobiotics]. ( Kazak, TI; Kleĭn, AV; Nosova, NA; Pavlov, VA, 1995) |
| "6% of these had blood levels in the toxic range." | 1.29 | Phenytoin toxicity due to concomitant antituberculosis therapy. ( Aboo, A; Walubo, A, 1995) |
| "Treatment with isoniazid and rifampicin for 9 months is adequate for patients with localized pleuropulmonary disease." | 1.29 | The high incidence of tuberculosis among renal transplant recipients in India. ( Chugh, KS; Jha, V; Joshi, K; Sakhuja, V; Varma, PP, 1996) |
| "Nasal tuberculosis is a rare entity since it early diagnosis and the improvements in treatment." | 1.29 | [Primary nasal tuberculosis]. ( Echeverría Zabalza, ME; Grijalba Uche, M; Medina Solá, JJ, 1996) |
| "Isoniazid prophylaxis is a major part of the U." | 1.29 | Impact on USAF tuberculosis detection and control program given a low facility tuberculosis prevalence rate. ( Hebrink, ST; Popper, SE; Smith, DA; Stewart, TB, 1996) |
| "Tuberculosis is increasing in Siberia." | 1.29 | Tuberculosis in Siberia: 2. Diagnosis, chemoprophylaxis and treatment. ( Besse, C; Connolly, M; Drobniewski, F; Ignatenko, N; Lyagoshina, T; Nye, P; Paul, J; Tayler, E, 1996) |
| "The prophylaxis of tuberculosis is cost-effective in that it prevents hospitalizations and eliminates the need for multidrug treatment of active disease." | 1.29 | Prophylaxis of mycobacterial infections in immunocompromised patients. ( Fisher, MA; Krance, MB, 1996) |
| "Forty-one of our patients had pulmonary tuberculosis, 38 had extra pulmonary and in 61 it was disseminated." | 1.28 | AIDS and tuberculosis in Spain. A report of 140 cases. ( Adrados, M; Díaz, F; García Aguado, C; González Lahoz, JM; Laguna, F; Martínez, R; Puente, S, 1991) |
| "Seven patients received no treatment because tuberculosis was first diagnosed after death." | 1.28 | Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. ( Chaisson, RE; Goodman, PC; Hopewell, PC; Sande, MA; Schecter, GF; Small, PM, 1991) |
| "The memory T cell immune response to Mycobacterium tuberculosis infection was examined in strains of mice which vary in their natural susceptibility to Mycobacterium bovis BCG infection." | 1.28 | Memory T cell-mediated resistance to Mycobacterium tuberculosis infection in innately susceptible and resistant mice. ( Collins, FM; Flory, CM; Hubbard, RD, 1991) |
| "In order to solve the problem of poor patient compliance, attempts were made to prolong the bioavailability of antimycobacterial drugs after a single administration." | 1.28 | Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer. ( Ashtekar, DR; Farhi, DC; Gangadharam, PR; Wise, DL, 1991) |
| "The decision was analyzed for an intravenous drug abuser who may have been anergic, while tuberculin test status, race, and gender were varied." | 1.28 | Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis. ( Jordan, TJ; Lewit, EM; Montgomery, RL; Reichman, LB, 1991) |
| "Hydrocephalus was demonstrated by cranial computerized tomography in all 30 patients (100%)." | 1.28 | Central nervous system tuberculosis in children: a review of 30 cases. ( Connor, JD; Waecker, NJ, 1990) |
| "Tuberculosis is a significant public health problem in developing countries, despite the fact that the means for effective control have been available for more than 35 yr." | 1.27 | Tuberculosis in Cuba. ( Pedraza, RO; Pérez-Stable, EJ, 1984) |
| " The adjustment of Isoniazid dosage according to acetylator status has not resulted in any statistically significant benefit in those patients studied." | 1.27 | [Adjusting or not adjusting isoniazid dosage?]. ( Boval, C; Gaillard, JP; Grosset, J; Parrot, R, 1983) |
| "Mean duration of treatment for tuberculosis decreased from 20." | 1.27 | Tuberculosis control practices in major metropolitan health departments in the United States. 3. Standard of practice in 1984. ( Leff, AR; Leff, DR, 1985) |
| "Isoniazid was added to the drinking water quarantined and given streptomycin and isoniazid by intramuscular injection." | 1.27 | Use of streptomycin and isoniazid during a tuberculosis epizootic in a rhesus and cynomolgus breeding colony. ( Elwell, MR; Pomsdhit, J; Tingpalapong, M; Ward, GS, 1985) |
| "Of the 191 patients with extra-pulmonary tuberculosis, 39% had lymph node involvement, 26% bone or joint disease and 19% a pleural effusion." | 1.27 | Tuberculosis in Tanzania--a national survey of newly notified cases. Tanzanian/British Medical Research Council Collaborative Study. ( , 1985) |
| "Sarcoidosis is a multisystem disease of unknown etiology characterized by non-caseating granulomatous inflammation of various organs, but most frequently involving the lungs of young adults." | 1.27 | Sarcoidosis of the larynx in a child. ( deSa, D; Leahy, F; Mina, M, 1985) |
| "When dosing isoniazid in patients' serum after ingestion, the authors find a difference in the isoniazid levels when isoniazid is used alone, then, when isoniazid is used simultaneously with rifampicin." | 1.26 | [Antibacterian activity modifications of serum isoniazid when using it with rifampicin (author's transl)]. ( Bergogne-Berezin, E; Lafaix, C; Nouhouayi, A, 1982) |
| "We treated five isoniazid-overdosed patients each with a single dose of pyridoxine hydrochloride equivalent to the gram amount of isoniazid ingested and compared their outcome with that of 41 patients from the literature who received little or no pyridoxine." | 1.26 | Single high-dose pyridoxine treatment for isoniazid overdose. ( Lacouture, PG; Lovejoy, FH; Wason, S, 1981) |
| "Of 1490 patients, 88." | 1.26 | Tuberculosis in Kenya: a second national sampling survey of drug resistance and other factors, and a comparison with the prevalence data from the first national sampling survey. An East African and British Medical Research Council Co-operative Investigati ( , 1978) |
| " As compared to INH the lower toxicity permits a higher dosage of gluronazide." | 1.26 | [Experimental comparison of the tuberculostatic activities of INH, INHG and INHG-Na (author's transl)]. ( Orlowski, EH; Rosenfeld, M; Schunk, R; Wolter, H, 1976) |
| "tuberculosis were isolated from patients with pulmonary disease, no catalase-negative strains were isolated from patients with extrapulmonary disease, suggesting limited pathogenic potentialities of catalase-negative strains for man." | 1.26 | Some bacteriologic aspects of the epidemiology of pulmonary and extrapulmonary tuberculosis. ( Ali, MA; Middlebrook, G; Siddiqi, SH; Stauffer, JC, 1976) |
| "Of 1694 patients with pulmonary tuberculosis with or without extra-pulmonary tuberculosis, 96." | 1.25 | Tuberculosis in Tanzania: a national sampling survey of drug resistance and other factors. ( , 1975) |
| "Four had developed serious pulmonary tuberculosis and one tuberculous meningitis, all within the three months which followed a post-contact negative tuberculin test." | 1.25 | Preventive treatment of tuberculin-negative contacts. ( Beaudry, PH; Brickman, HF, 1973) |
| "of isoniazid." | 1.24 | Unclassified mycobacteria isolated from human suspect tuberculosis cases in New-foundland: preliminary studies on fifteen strains. ( BUTLER, RW; JOSEPHSON, JE, 1963) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3448 (62.26) | 18.7374 |
| 1990's | 377 (6.81) | 18.2507 |
| 2000's | 466 (8.41) | 29.6817 |
| 2010's | 844 (15.24) | 24.3611 |
| 2020's | 403 (7.28) | 2.80 |
| Authors | Studies |
|---|---|
| Stover, CK | 1 |
| Warrener, P | 1 |
| VanDevanter, DR | 1 |
| Sherman, DR | 3 |
| Arain, TM | 1 |
| Langhorne, MH | 1 |
| Anderson, SW | 1 |
| Towell, JA | 1 |
| Yuan, Y | 2 |
| McMurray, DN | 1 |
| Kreiswirth, BN | 4 |
| Barry, CE | 6 |
| Baker, WR | 1 |
| Andries, K | 5 |
| Verhasselt, P | 1 |
| Guillemont, J | 1 |
| Göhlmann, HW | 1 |
| Neefs, JM | 1 |
| Winkler, H | 1 |
| Van Gestel, J | 1 |
| Timmerman, P | 1 |
| Zhu, M | 2 |
| Lee, E | 1 |
| Williams, P | 1 |
| de Chaffoy, D | 1 |
| Huitric, E | 1 |
| Hoffner, S | 6 |
| Cambau, E | 2 |
| Truffot-Pernot, C | 14 |
| Lounis, N | 6 |
| Jarlier, V | 6 |
| Matsumoto, M | 2 |
| Hashizume, H | 2 |
| Tomishige, T | 2 |
| Kawasaki, M | 2 |
| Tsubouchi, H | 2 |
| Sasaki, H | 2 |
| Shimokawa, Y | 1 |
| Komatsu, M | 2 |
| Byrne, ST | 1 |
| Denkin, SM | 1 |
| Zhang, Y | 15 |
| Somu, RV | 1 |
| Wilson, DJ | 2 |
| Bennett, EM | 1 |
| Boshoff, HI | 1 |
| Celia, L | 1 |
| Beck, BJ | 1 |
| Aldrich, CC | 2 |
| Sriram, D | 17 |
| Yogeeswari, P | 14 |
| Dhakla, P | 1 |
| Senthilkumar, P | 3 |
| Banerjee, D | 2 |
| Manjashetty, TH | 1 |
| Upadhayaya, RS | 1 |
| Kulkarni, GM | 1 |
| Vasireddy, NR | 1 |
| Vandavasi, JK | 1 |
| Dixit, SS | 1 |
| Sharma, V | 3 |
| Chattopadhyaya, J | 1 |
| Raparti, V | 1 |
| Chitre, T | 1 |
| Bothara, K | 1 |
| Kumar, V | 4 |
| Dangre, S | 1 |
| Khachane, C | 1 |
| Gore, S | 1 |
| Deshmane, B | 1 |
| Zampieri, D | 1 |
| Mamolo, MG | 1 |
| Laurini, E | 1 |
| Fermeglia, M | 1 |
| Posocco, P | 1 |
| Pricl, S | 1 |
| Banfi, E | 1 |
| Scialino, G | 1 |
| Vio, L | 1 |
| Hearn, MJ | 2 |
| Cynamon, MH | 11 |
| Chen, MF | 1 |
| Coppins, R | 1 |
| Davis, J | 1 |
| Joo-On Kang, H | 1 |
| Noble, A | 1 |
| Tu-Sekine, B | 1 |
| Terrot, MS | 1 |
| Trombino, D | 1 |
| Thai, M | 1 |
| Webster, ER | 1 |
| Wilson, R | 1 |
| Ranjith Kumar, R | 1 |
| Perumal, S | 1 |
| Férriz, JM | 1 |
| Vávrová, K | 1 |
| Kunc, F | 1 |
| Imramovský, A | 2 |
| Stolaríková, J | 6 |
| Vavríková, E | 2 |
| Vinsová, J | 6 |
| Pucci, MJ | 1 |
| Ackerman, M | 1 |
| Thanassi, JA | 1 |
| Shoen, CM | 2 |
| Naidu, G | 1 |
| Bhat, P | 3 |
| Changtam, C | 1 |
| Hongmanee, P | 1 |
| Suksamrarn, A | 1 |
| Aboul-Fadl, T | 1 |
| Bin-Jubair, FA | 1 |
| Aboul-Wafa, O | 1 |
| Delaine, T | 1 |
| Bernardes-Génisson, V | 4 |
| Quémard, A | 1 |
| Constant, P | 4 |
| Meunier, B | 2 |
| Bernadou, J | 4 |
| Srivastav, NC | 1 |
| Rai, D | 1 |
| Tse, C | 1 |
| Agrawal, B | 1 |
| Kunimoto, DY | 1 |
| Kumar, R | 4 |
| Trivedi, AR | 1 |
| Bhuva, VR | 1 |
| Dholariya, BH | 1 |
| Dodiya, DK | 1 |
| Kataria, VB | 1 |
| Shah, VH | 1 |
| Thomas, A | 2 |
| Srividya, M | 1 |
| Izumizono, Y | 1 |
| Arevalo, S | 1 |
| Koseki, Y | 2 |
| Kuroki, M | 1 |
| Aoki, S | 2 |
| Kantevari, S | 2 |
| Yempala, T | 2 |
| Surineni, G | 1 |
| Sridhar, B | 1 |
| Chitra, S | 1 |
| Paul, N | 1 |
| Muthusubramanian, S | 1 |
| Manisankar, P | 1 |
| Thomas, KD | 1 |
| Adhikari, AV | 1 |
| Chowdhury, IH | 1 |
| Sandeep, T | 1 |
| Mahmood, R | 1 |
| Bhattacharya, B | 1 |
| Sumesh, E | 1 |
| Jin, Y | 1 |
| Gill, SK | 1 |
| Kirchhoff, PD | 1 |
| Wan, B | 5 |
| Franzblau, SG | 7 |
| Garcia, GA | 1 |
| Showalter, HD | 1 |
| Li, YB | 1 |
| Xie, YY | 1 |
| Du, NN | 1 |
| Lu, Y | 7 |
| Xu, HZ | 1 |
| Wang, B | 4 |
| Yu, Y | 1 |
| Liu, YX | 1 |
| Song, DQ | 1 |
| Chen, RX | 1 |
| Polanc, S | 1 |
| Kočevar, M | 1 |
| Košmrlj, J | 1 |
| Horváti, K | 5 |
| Bosze, S | 8 |
| Telvekar, VN | 3 |
| Bairwa, VK | 1 |
| Satardekar, K | 1 |
| Bellubi, A | 1 |
| Lu, X | 3 |
| Liu, X | 5 |
| Chen, L | 3 |
| Zhou, C | 2 |
| You, Q | 1 |
| Karuvalam, RP | 1 |
| Haridas, KR | 1 |
| Nayak, SK | 1 |
| Row, TN | 1 |
| Rajeesh, P | 1 |
| Rishikesan, R | 1 |
| Kumari, NS | 1 |
| Forge, D | 1 |
| Cappoen, D | 2 |
| Laurent, J | 1 |
| Stanicki, D | 1 |
| Mayence, A | 1 |
| Huang, TL | 1 |
| Verschaeve, L | 2 |
| Huygen, K | 2 |
| Vanden Eynde, JJ | 1 |
| Alegaon, SG | 1 |
| Alagawadi, KR | 1 |
| Sonkusare, PV | 1 |
| Chaudhary, SM | 1 |
| Dadwe, DH | 1 |
| Shah, AS | 1 |
| Mourer, M | 2 |
| Massimba Dibama, H | 1 |
| Daffé, M | 3 |
| Regnouf-de-Vains, JB | 2 |
| Villemagne, B | 1 |
| Crauste, C | 1 |
| Flipo, M | 1 |
| Baulard, AR | 1 |
| Déprez, B | 1 |
| Willand, N | 1 |
| Chopra, S | 2 |
| Koolpe, GA | 1 |
| Tambo-Ong, AA | 1 |
| Matsuyama, KN | 1 |
| Ryan, KJ | 1 |
| Tran, TB | 1 |
| Doppalapudi, RS | 1 |
| Riccio, ES | 1 |
| Iyer, LV | 1 |
| Green, CE | 1 |
| Madrid, PB | 1 |
| Shelke, SN | 1 |
| Mhaske, GR | 1 |
| Bonifácio, VD | 1 |
| Gawande, MB | 1 |
| Jardosh, HH | 1 |
| Patel, MP | 1 |
| Gao, C | 4 |
| Ye, TH | 1 |
| Wang, NY | 1 |
| Zeng, XX | 1 |
| Zhang, LD | 1 |
| Xiong, Y | 1 |
| You, XY | 1 |
| Xia, Y | 1 |
| Xu, Y | 4 |
| Peng, CT | 1 |
| Zuo, WQ | 1 |
| Wei, Y | 1 |
| Yu, LT | 1 |
| Dartois, V | 10 |
| Maurya, HK | 1 |
| Verma, R | 2 |
| Alam, S | 1 |
| Pandey, S | 2 |
| Pathak, V | 1 |
| Sharma, S | 19 |
| Srivastava, KK | 1 |
| Negi, AS | 1 |
| Gupta, A | 29 |
| Kale, MG | 1 |
| Raichurkar, A | 2 |
| P, SH | 1 |
| Waterson, D | 1 |
| McKinney, D | 1 |
| Manjunatha, MR | 1 |
| Kranthi, U | 1 |
| Koushik, K | 1 |
| Jena, Lk | 1 |
| Shinde, V | 2 |
| Rudrapatna, S | 2 |
| Barde, S | 1 |
| Humnabadkar, V | 1 |
| Madhavapeddi, P | 1 |
| Basavarajappa, H | 1 |
| Ghosh, A | 1 |
| Ramya, VK | 1 |
| Guptha, S | 2 |
| Vachaspati, P | 1 |
| Kumar, KN | 1 |
| Giridhar, J | 1 |
| Reddy, J | 3 |
| Panduga, V | 3 |
| Ganguly, S | 1 |
| Ahuja, V | 2 |
| Gaonkar, S | 2 |
| Kumar, CN | 1 |
| Ogg, D | 1 |
| Tucker, JA | 1 |
| Boriack-Sjodin, PA | 1 |
| de Sousa, SM | 1 |
| Sambandamurthy, VK | 2 |
| Ghorpade, SR | 1 |
| Kondreddi, RR | 1 |
| Jiricek, J | 1 |
| Rao, SP | 1 |
| Lakshminarayana, SB | 1 |
| Camacho, LR | 1 |
| Rao, R | 1 |
| Herve, M | 2 |
| Bifani, P | 2 |
| Ma, NL | 1 |
| Kuhen, K | 1 |
| Goh, A | 1 |
| Chatterjee, AK | 1 |
| Dick, T | 2 |
| Diagana, TT | 1 |
| Manjunatha, UH | 1 |
| Smith, PW | 1 |
| Matviiuk, T | 1 |
| Mori, G | 2 |
| Lherbet, C | 1 |
| Rodriguez, F | 1 |
| Pasca, MR | 2 |
| Gorichko, M | 1 |
| Guidetti, B | 1 |
| Voitenko, Z | 1 |
| Baltas, M | 1 |
| Sridevi, JP | 3 |
| More, UA | 1 |
| Joshi, SD | 1 |
| Aminabhavi, TM | 1 |
| Gadad, AK | 1 |
| Nadagouda, MN | 1 |
| Kulkarni, VH | 1 |
| Pieroni, M | 1 |
| Cho, S | 1 |
| Costantino, G | 1 |
| Patel, KN | 1 |
| Claes, P | 1 |
| Jacobs, J | 1 |
| Anthonissen, R | 1 |
| Mathys, V | 2 |
| De Kimpe, N | 1 |
| Poce, G | 2 |
| Cocozza, M | 2 |
| Consalvi, S | 2 |
| Biava, M | 2 |
| Pedgaonkar, GS | 2 |
| Jeankumar, VU | 2 |
| Saxena, S | 2 |
| Devi, PB | 2 |
| Renuka, J | 2 |
| Naidu, KM | 1 |
| Suresh, A | 1 |
| Subbalakshmi, J | 1 |
| Raghavaiah, P | 1 |
| Chandra Sekhar, KV | 1 |
| Zitko, J | 2 |
| Servusová, B | 1 |
| Janoutová, A | 1 |
| Paterová, P | 2 |
| Mandíková, J | 1 |
| Garaj, V | 1 |
| Vejsová, M | 1 |
| Marek, J | 1 |
| Doležal, M | 2 |
| Tonelli, M | 1 |
| Novelli, F | 1 |
| Tasso, B | 1 |
| Sparatore, A | 1 |
| Boido, V | 1 |
| Sparatore, F | 1 |
| Cannas, S | 1 |
| Molicotti, P | 1 |
| Zanetti, S | 1 |
| Parapini, S | 1 |
| Loddo, R | 1 |
| Krátký, M | 4 |
| Baranyai, Z | 2 |
| Szabó, I | 2 |
| Paraskevopoulos, G | 1 |
| Singh, S | 9 |
| Roy, KK | 1 |
| Khan, SR | 2 |
| Kashyap, VK | 1 |
| Sharma, A | 8 |
| Jaiswal, S | 1 |
| Sharma, SK | 6 |
| Krishnan, MY | 1 |
| Chaturvedi, V | 2 |
| Lal, J | 1 |
| Sinha, S | 2 |
| Dasgupta, A | 3 |
| Gupta, AD | 1 |
| Srivastava, R | 1 |
| Saxena, AK | 1 |
| Ramprasad, J | 1 |
| Nayak, N | 1 |
| Dalimba, U | 1 |
| Peethambar, SK | 1 |
| Achur, R | 1 |
| Kumar, HS | 1 |
| Massimba-Dibama, H | 1 |
| Bhatt, JD | 1 |
| Chudasama, CJ | 1 |
| Patel, KD | 1 |
| Jain, PP | 1 |
| Degani, MS | 1 |
| Raju, A | 1 |
| Anantram, A | 1 |
| Seervi, M | 1 |
| Sathaye, S | 1 |
| Ray, M | 1 |
| Rajan, MGR | 1 |
| Pajk, S | 1 |
| Živec, M | 1 |
| Šink, R | 1 |
| Sosič, I | 1 |
| Neu, M | 1 |
| Chung, CW | 1 |
| Martínez-Hoyos, M | 1 |
| Pérez-Herrán, E | 3 |
| Álvarez-Gómez, D | 1 |
| Álvarez-Ruíz, E | 1 |
| Mendoza-Losana, A | 2 |
| Castro-Pichel, J | 1 |
| Barros, D | 2 |
| Ballell-Pages, L | 1 |
| Young, RJ | 1 |
| Convery, MA | 1 |
| Encinas, L | 2 |
| Gobec, S | 1 |
| Karad, SC | 1 |
| Purohit, VB | 1 |
| Thakor, P | 1 |
| Thakkar, VR | 1 |
| Raval, DK | 1 |
| Desai, NC | 1 |
| Somani, H | 1 |
| Trivedi, A | 1 |
| Bhatt, K | 1 |
| Nawale, L | 1 |
| Khedkar, VM | 1 |
| Jha, PC | 1 |
| Sarkar, D | 2 |
| Subhedar, DD | 1 |
| Shaikh, MH | 1 |
| Arkile, MA | 1 |
| Yeware, A | 1 |
| Shingate, BB | 1 |
| Garg, G | 1 |
| Pande, M | 1 |
| Agrawal, A | 1 |
| Li, J | 7 |
| Stec, J | 1 |
| Onajole, OK | 1 |
| Lun, S | 2 |
| Guo, H | 4 |
| Merenbloom, B | 1 |
| Vistoli, G | 2 |
| Bishai, WR | 10 |
| Kozikowski, AP | 1 |
| Tanwar, B | 1 |
| Kumar, A | 5 |
| Chakraborti, AK | 2 |
| Tang, J | 1 |
| Liu, Z | 2 |
| Li, M | 1 |
| Zhang, T | 2 |
| Zhang, X | 1 |
| Ding, K | 1 |
| Tantry, SJ | 1 |
| Markad, SD | 1 |
| Bhat, J | 1 |
| Balakrishnan, G | 1 |
| Gupta, AK | 1 |
| Ambady, A | 1 |
| Kedari, C | 1 |
| Mudugal, NV | 1 |
| Narayan, A | 1 |
| Naveen Kumar, CN | 1 |
| Nanduri, R | 2 |
| Bharath, S | 2 |
| Prabhakar, KR | 2 |
| Kandaswamy, K | 1 |
| Saralaya, R | 2 |
| Kaur, P | 2 |
| Dinesh, N | 1 |
| Rich, K | 1 |
| Murray, D | 1 |
| Plant, H | 1 |
| Preston, M | 1 |
| Ashton, H | 1 |
| Plant, D | 1 |
| Walsh, J | 1 |
| Alcock, P | 1 |
| Naylor, K | 1 |
| Collier, M | 1 |
| Whiteaker, J | 1 |
| McLaughlin, RE | 1 |
| Mallya, M | 1 |
| Panda, M | 1 |
| Ramachandran, V | 2 |
| Shandil, R | 2 |
| Mdluli, K | 2 |
| Cooper, CB | 1 |
| Rubin, H | 2 |
| Yano, T | 1 |
| Iyer, P | 1 |
| Narayanan, S | 3 |
| Kavanagh, S | 1 |
| Mukherjee, K | 1 |
| Balasubramanian, V | 3 |
| Hosagrahara, VP | 1 |
| Solapure, S | 2 |
| Ravishankar, S | 1 |
| Hameed P, S | 1 |
| Saharan, VD | 1 |
| Mahajan, SS | 1 |
| Yang, T | 1 |
| Moreira, W | 1 |
| Nyantakyi, SA | 1 |
| Chen, H | 2 |
| Aziz, DB | 1 |
| Go, ML | 1 |
| Hu, YQ | 1 |
| Zhang, S | 5 |
| Zhao, F | 1 |
| Feng, LS | 5 |
| Lv, ZS | 3 |
| Xu, Z | 4 |
| Wu, X | 5 |
| Ren, QC | 2 |
| Chang, L | 1 |
| Song, XF | 1 |
| Alfonso, S | 1 |
| Venditti, G | 1 |
| Fernandez-Menendez, R | 1 |
| Bates, RH | 2 |
| Barros Aguirre, D | 1 |
| Ballell, L | 2 |
| De Logu, A | 1 |
| Fan, YL | 2 |
| Wu, JB | 1 |
| Cheng, XW | 1 |
| Zhang, FZ | 1 |
| Jin, XH | 1 |
| Huang, ZP | 1 |
| Yu, HF | 1 |
| Zeng, ZG | 1 |
| Gao, T | 1 |
| Lv, K | 2 |
| Tao, Z | 2 |
| Liu, Q | 3 |
| Yang, L | 1 |
| Wu, S | 1 |
| Wang, A | 3 |
| Huang, M | 1 |
| Liu, M | 2 |
| Vosátka, R | 1 |
| Švarcová, M | 1 |
| Janoušek, J | 1 |
| Madacki, J | 1 |
| Huszár, S | 1 |
| Mikušová, K | 1 |
| Korduláková, J | 3 |
| Trejtnar, F | 1 |
| Chikhale, RV | 1 |
| Barmade, MA | 1 |
| Murumkar, PR | 1 |
| Yadav, MR | 1 |
| Kumar, G | 1 |
| Krishna, VS | 1 |
| Jachak, SM | 1 |
| Guardia, A | 1 |
| Baiget, J | 1 |
| Cacho, M | 2 |
| Pérez, A | 1 |
| Ortega-Guerra, M | 1 |
| Nxumalo, W | 1 |
| Khanye, SD | 1 |
| Rullas, J | 1 |
| Ortega, F | 1 |
| Jiménez, E | 1 |
| Fraile-Gabaldón, MT | 1 |
| Esquivias, J | 1 |
| Fernández, R | 1 |
| Porras-De Francisco, E | 2 |
| Alonso, M | 1 |
| Giordano, I | 1 |
| Rivero, C | 1 |
| Miguel-Siles, J | 1 |
| Osende, JG | 1 |
| Badiola, KA | 1 |
| Rutledge, PJ | 1 |
| Todd, MH | 1 |
| Remuiñán, M | 1 |
| Alemparte, C | 1 |
| Rogacki, MK | 1 |
| Pitta, E | 1 |
| Balabon, O | 1 |
| Huss, S | 1 |
| Lopez-Roman, EM | 1 |
| Argyrou, A | 1 |
| Blanco-Ruano, D | 1 |
| Vande Velde, CML | 1 |
| Augustyns, K | 1 |
| Cunningham, F | 1 |
| Van der Veken, P | 1 |
| Hou, XM | 1 |
| Wang, CY | 1 |
| Gerwick, WH | 1 |
| Shao, CL | 1 |
| Janďourek, O | 2 |
| Novotná, E | 1 |
| Gu, J | 2 |
| Fu, L | 2 |
| Ma, C | 1 |
| Ma, X | 1 |
| Han, B | 1 |
| Xu, S | 2 |
| Sutar, YB | 1 |
| Mali, JK | 1 |
| Rajmani, RS | 1 |
| Singh, A | 6 |
| Borsoi, AF | 1 |
| Paz, JD | 1 |
| Abbadi, BL | 3 |
| Macchi, FS | 1 |
| Sperotto, N | 2 |
| Pissinate, K | 2 |
| Rambo, RS | 2 |
| Ramos, AS | 1 |
| Machado, D | 1 |
| Viveiros, M | 1 |
| Bizarro, CV | 3 |
| Basso, LA | 9 |
| Machado, P | 4 |
| Ramesh, D | 1 |
| Joji, A | 1 |
| Vijayakumar, BG | 1 |
| Sethumadhavan, A | 1 |
| Mani, M | 1 |
| Kannan, T | 8 |
| Maaliki, C | 1 |
| Fu, J | 1 |
| Villaume, S | 1 |
| Viljoen, A | 2 |
| Raynaud, C | 1 |
| Hammoud, S | 1 |
| Thibonnet, J | 1 |
| Kremer, L | 2 |
| Vincent, SP | 1 |
| Thiery, E | 1 |
| Ribeiro, RCB | 1 |
| de Marins, DB | 1 |
| Di Leo, I | 1 |
| da Silva Gomes, L | 1 |
| de Moraes, MG | 1 |
| Villela, AD | 2 |
| da Silva, WF | 1 |
| da Silva, LCRP | 1 |
| Cristina de Moraes, M | 1 |
| Ferreira, VF | 1 |
| da Silva, FC | 1 |
| Nascimento, V | 1 |
| Verma, SK | 1 |
| Verma, S | 2 |
| Vaishnav, Y | 1 |
| Tiwari, SP | 1 |
| Rakesh, KP | 1 |
| Cavalier, JF | 1 |
| Spilling, CD | 1 |
| Durand, T | 1 |
| Camoin, L | 1 |
| Canaan, S | 1 |
| Cordeiro, R | 1 |
| Kachroo, M | 1 |
| Girase, PS | 1 |
| Dhawan, S | 1 |
| Shinde, SR | 1 |
| Palkar, MB | 1 |
| Karpoormath, R | 1 |
| Pflégr, V | 1 |
| Horváth, L | 1 |
| Pál, A | 1 |
| Shyam, M | 1 |
| Verma, H | 1 |
| Bhattacharje, G | 1 |
| Mukherjee, P | 1 |
| Kamilya, S | 1 |
| Jalani, P | 1 |
| Das, S | 2 |
| Mondal, A | 1 |
| Das, AK | 1 |
| Brucoli, F | 1 |
| Bagnéris, C | 1 |
| Dickman, R | 1 |
| Basavanakatti, VN | 1 |
| Naresh Babu, P | 1 |
| Sankaran, V | 1 |
| Dev, A | 1 |
| Sinha, BN | 1 |
| Bhakta, S | 1 |
| Jayaprakash, V | 1 |
| Hegde, PV | 1 |
| Howe, MD | 1 |
| Zimmerman, MD | 3 |
| Boshoff, HIM | 1 |
| Remache, B | 1 |
| Jia, Z | 1 |
| Pan, Y | 1 |
| Baughn, AD | 1 |
| Alelaiwi, SH | 1 |
| Heindl, JE | 1 |
| Sivaganesh, V | 1 |
| Peethambaran, B | 1 |
| McKee, JR | 1 |
| Kumar Sahoo, S | 1 |
| Maddipatla, S | 1 |
| Nageswara Rao Gajula, S | 1 |
| Naiyaz Ahmad, M | 1 |
| Kaul, G | 1 |
| Nanduri, S | 1 |
| Sonti, R | 1 |
| Madhavi Yaddanapudi, V | 1 |
| Agrahari, AK | 1 |
| Rajkhowa, S | 1 |
| Tiwari, VK | 1 |
| Fernandes, GFS | 1 |
| Thompson, AM | 1 |
| Castagnolo, D | 1 |
| Denny, WA | 1 |
| Dos Santos, JL | 1 |
| Le, NH | 1 |
| Tranier, S | 1 |
| Nahoum, V | 1 |
| Guillet, V | 1 |
| Maveyraud, L | 1 |
| Mourey, L | 1 |
| Verhaeghe, P | 1 |
| Marrakchi, H | 1 |
| Ang, CW | 1 |
| Lee, BM | 1 |
| Jackson, CJ | 1 |
| Wang, Y | 6 |
| Francisco, AF | 1 |
| Kelly, JM | 1 |
| Bernhardt, PV | 1 |
| Tan, L | 1 |
| West, NP | 1 |
| Sykes, ML | 1 |
| Hinton, AO | 1 |
| Bolisetti, R | 1 |
| Avery, VM | 1 |
| Cooper, MA | 1 |
| Blaskovich, MAT | 1 |
| Cheng, S | 2 |
| Wang, Q | 4 |
| Chen, X | 5 |
| Chen, J | 1 |
| Chen, D | 1 |
| Shen, D | 1 |
| Tian, J | 1 |
| Ye, F | 1 |
| Huang, H | 4 |
| Zhang, D | 1 |
| Gengiah, S | 4 |
| Barker, PM | 3 |
| Yende-Zuma, N | 5 |
| Mbatha, M | 1 |
| Naidoo, S | 1 |
| Taylor, M | 3 |
| Loveday, M | 3 |
| Mhlongo, M | 1 |
| Jackson, C | 1 |
| Nunn, AJ | 7 |
| Padayatchi, N | 6 |
| Karim, SSA | 1 |
| Naidoo, K | 9 |
| Olomi, W | 1 |
| Andia Biraro, I | 1 |
| Kilonzo, K | 1 |
| Te Brake, L | 2 |
| Kibirige, D | 1 |
| Chamba, N | 1 |
| Elias Ntinginya, N | 1 |
| Sabi, I | 1 |
| Critchley, J | 1 |
| Sharples, K | 1 |
| Hill, PC | 3 |
| Van Crevel, R | 3 |
| Balhara, A | 1 |
| Oxlade, O | 5 |
| Rochon, H | 1 |
| Campbell, JR | 7 |
| Menzies, D | 13 |
| Yanes-Lane, M | 1 |
| Ortiz-Brizuela, E | 1 |
| Benedetti, A | 4 |
| Churchyard, G | 8 |
| Busari, AA | 1 |
| Oshikoya, KA | 1 |
| Adejumo, IA | 1 |
| Olanrewaju, OA | 1 |
| Usman, SO | 1 |
| Badru, WA | 1 |
| Oreagba, IA | 1 |
| Olayemi, SO | 1 |
| Makanda-Charambira, PD | 1 |
| Nourse, P | 1 |
| Luyckx, VA | 1 |
| Coetzee, A | 1 |
| McCulloch, MI | 1 |
| Connolly, C | 3 |
| Schluger, NW | 2 |
| Barr, DA | 1 |
| Omollo, C | 1 |
| Mason, M | 1 |
| Koch, A | 1 |
| Wilkinson, RJ | 11 |
| Lalloo, DG | 1 |
| Meintjes, G | 6 |
| Mizrahi, V | 1 |
| Warner, DF | 1 |
| Davies, G | 3 |
| Aboma, M | 1 |
| Dida, N | 1 |
| Saavedra, B | 1 |
| Mambuque, E | 1 |
| Gomes, N | 1 |
| Nguenha, D | 1 |
| Mabunda, R | 1 |
| Faife, L | 1 |
| Langa, R | 1 |
| Munguambe, S | 1 |
| Manjate, F | 1 |
| Cossa, A | 1 |
| Scott, L | 3 |
| García-Basteiro, AL | 1 |
| Mlobeli, R | 1 |
| Tshabalala, MF | 1 |
| Humphries, H | 1 |
| Almond, L | 1 |
| Berg, A | 1 |
| Gardner, I | 1 |
| Hatley, O | 1 |
| Pan, X | 3 |
| Small, B | 1 |
| Zhang, M | 3 |
| Jamei, M | 1 |
| Romero, K | 1 |
| Penn-Nicholson, A | 2 |
| Georghiou, SB | 2 |
| Ciobanu, N | 1 |
| Kazi, M | 1 |
| Bhalla, M | 1 |
| David, A | 2 |
| Conradie, F | 2 |
| Ruhwald, M | 3 |
| Crudu, V | 3 |
| Rodrigues, C | 5 |
| Myneedu, VP | 2 |
| Denkinger, CM | 2 |
| Schumacher, SG | 3 |
| Amer, S | 1 |
| El Hefnawy, A | 1 |
| Baz, A | 1 |
| Okasha, H | 1 |
| Thwe, EP | 1 |
| Namwat, W | 1 |
| Pinlaor, P | 1 |
| Rueangsak, K | 1 |
| Sangka, A | 1 |
| Ye, M | 1 |
| Yuan, W | 1 |
| Molaeipour, L | 1 |
| Azizian, K | 1 |
| Ahmadi, A | 2 |
| Kouhsari, E | 1 |
| Finnegan, R | 1 |
| Stanzelova, A | 1 |
| Verbruggen, T | 1 |
| Fahey, D | 1 |
| Harte, J | 1 |
| Smyth, B | 1 |
| Moylett, E | 1 |
| Narh-Bana, SA | 1 |
| Chirwa, TF | 1 |
| Chirwa, ED | 1 |
| Bonsu, F | 1 |
| Ibisomi, L | 2 |
| Kawonga, M | 1 |
| Denti, P | 12 |
| Wasmann, RE | 2 |
| van Rie, A | 3 |
| Winckler, J | 1 |
| Bekker, A | 4 |
| Rabie, H | 4 |
| Hesseling, AC | 14 |
| van der Laan, LE | 1 |
| Gonzalez-Martinez, C | 1 |
| Zar, HJ | 6 |
| Wiesner, L | 11 |
| Svensson, EM | 2 |
| McIlleron, HM | 2 |
| Akamike, IC | 2 |
| Okedo-Alex, IN | 2 |
| Alo, C | 2 |
| Agu, AP | 2 |
| Uneke, CJ | 1 |
| Ogbonnaya, LU | 2 |
| Nardotto, GHB | 1 |
| Bollela, VR | 1 |
| Rocha, A | 1 |
| Della Pasqua, O | 2 |
| Lanchote, VL | 1 |
| Tersigni, C | 1 |
| Boiardi, G | 1 |
| Tofani, L | 1 |
| Venturini, E | 2 |
| Montagnani, C | 1 |
| Bortone, B | 1 |
| Bianchi, L | 1 |
| Chiappini, E | 2 |
| Cassetta, MI | 1 |
| Fallani, S | 1 |
| Novelli, A | 1 |
| Galli, L | 3 |
| Sharma, N | 4 |
| Basu, S | 2 |
| Khanna, A | 3 |
| Sharma, P | 2 |
| Chandra, S | 2 |
| Kivrane, A | 1 |
| Grinberga, S | 1 |
| Sevostjanovs, E | 1 |
| Igumnova, V | 2 |
| Pole, I | 2 |
| Viksna, A | 2 |
| Bandere, D | 2 |
| Krams, A | 2 |
| Cirule, A | 2 |
| Pugovics, O | 1 |
| Ranka, R | 3 |
| Chung, C | 1 |
| Kim, YJ | 1 |
| Jo, KW | 3 |
| Shim, TS | 3 |
| Sumner, T | 6 |
| Mendelsohn, SC | 3 |
| Scriba, TJ | 5 |
| Hatherill, M | 6 |
| White, RG | 6 |
| Fodor, K | 2 |
| Pályi, B | 1 |
| Henczkó, J | 1 |
| Balka, G | 2 |
| Gyulai, G | 2 |
| Kiss, É | 4 |
| Biri-Kovács, B | 2 |
| Senoner, Z | 1 |
| Kendall, EA | 3 |
| Hussain, H | 6 |
| Kunkel, A | 2 |
| Kubiak, RW | 1 |
| Trajman, A | 5 |
| Menzies, R | 2 |
| Drain, PK | 1 |
| Torres Ortiz, A | 1 |
| Coronel, J | 4 |
| Vidal, JR | 1 |
| Bonilla, C | 1 |
| Moore, DAJ | 2 |
| Gilman, RH | 6 |
| Balloux, F | 1 |
| Kon, OM | 2 |
| Didelot, X | 1 |
| Grandjean, L | 4 |
| Semitala, FC | 2 |
| Kadota, JL | 1 |
| Musinguzi, A | 1 |
| Nabunje, J | 1 |
| Welishe, F | 1 |
| Nakitende, A | 1 |
| Akello, L | 1 |
| Bishop, O | 1 |
| Patel, D | 1 |
| Sammann, A | 1 |
| Nahid, P | 9 |
| Belknap, R | 4 |
| Kamya, MR | 5 |
| Handley, MA | 1 |
| Phillips, PPJ | 4 |
| Katahoire, A | 1 |
| Berger, CA | 1 |
| Kiwanuka, N | 2 |
| Katamba, A | 1 |
| Dowdy, DW | 9 |
| Cattamanchi, A | 5 |
| Zhang, Q | 1 |
| Yang, Y | 4 |
| Gong, X | 1 |
| Zhao, N | 1 |
| Liu, H | 4 |
| Soedarsono, S | 1 |
| Jayanti, RP | 1 |
| Mertaniasih, NM | 2 |
| Kusmiati, T | 1 |
| Permatasari, A | 1 |
| Indrawanto, DW | 1 |
| Charisma, AN | 1 |
| Yuliwulandari, R | 2 |
| Long, NP | 2 |
| Choi, YK | 2 |
| Hoa, PQ | 1 |
| Hoa, PV | 1 |
| Cho, YS | 4 |
| Shin, JG | 5 |
| Karmakar, M | 1 |
| Ragonnet, R | 2 |
| Ascher, DB | 1 |
| Trauer, JM | 3 |
| Denholm, JT | 3 |
| Chopra, KK | 1 |
| Béranger, A | 2 |
| Solans, BP | 2 |
| Cotton, MF | 15 |
| Mirochnick, M | 1 |
| Violari, A | 7 |
| Wang, J | 3 |
| Cababasay, M | 1 |
| Browning, R | 2 |
| Moye, J | 2 |
| Capparelli, EV | 1 |
| Savic, RM | 6 |
| Yang, S | 2 |
| Guo, JQ | 1 |
| Yan, XF | 1 |
| Tang, S | 1 |
| Dogan Demir, A | 1 |
| Kut, A | 1 |
| Ozaydin, E | 1 |
| Nursoy, M | 1 |
| Cakir, FB | 1 |
| Ustabas Kahraman, F | 1 |
| Erenberk, U | 1 |
| Uzuner, S | 1 |
| Collak, A | 1 |
| Cakin, ZE | 1 |
| Cakir, E | 1 |
| Malik, AA | 5 |
| Muliaditan, M | 1 |
| Teutonico, D | 1 |
| Ortega-Muro, F | 2 |
| Ferrer, S | 1 |
| Soltobekova, N | 1 |
| Kozukeev, T | 1 |
| Yiehdego, G | 1 |
| Labib, F | 1 |
| Hovhannesyan, A | 1 |
| Rossi, R | 3 |
| Turkova, A | 4 |
| Wills, GH | 1 |
| Wobudeya, E | 2 |
| Chabala, C | 4 |
| Palmer, M | 2 |
| Kinikar, A | 4 |
| Hissar, S | 2 |
| Choo, L | 2 |
| Musoke, P | 2 |
| Mulenga, V | 2 |
| Mave, V | 7 |
| Joseph, B | 1 |
| LeBeau, K | 2 |
| Thomason, MJ | 1 |
| Mboizi, RB | 1 |
| Kapasa, M | 2 |
| van der Zalm, MM | 1 |
| Raichur, P | 1 |
| Bhavani, PK | 6 |
| McIlleron, H | 15 |
| Demers, AM | 1 |
| Aarnoutse, R | 7 |
| Love-Koh, J | 1 |
| Seddon, JA | 3 |
| Welch, SB | 1 |
| Graham, SM | 7 |
| Gibb, DM | 1 |
| Crook, AM | 1 |
| Ekqvist, D | 1 |
| Bornefall, A | 1 |
| Augustinsson, D | 1 |
| Sönnerbrandt, M | 1 |
| Nordvall, MJ | 1 |
| Fredrikson, M | 1 |
| Carlsson, B | 1 |
| Sandstedt, M | 1 |
| Simonsson, USH | 3 |
| Alffenaar, JC | 7 |
| Paues, J | 1 |
| Niward, K | 1 |
| Thirumalaisamy, R | 1 |
| Aroulmoji, V | 1 |
| Iqbal, MN | 1 |
| Saride, S | 1 |
| Bhuvaneswari, M | 1 |
| Deepa, M | 1 |
| Sivasankar, C | 1 |
| Khan, R | 1 |
| Tasneen, R | 2 |
| Garcia, A | 1 |
| Converse, PJ | 2 |
| Kurbatova, E | 2 |
| Vernon, AA | 3 |
| Carr, W | 1 |
| Stout, JE | 6 |
| Dooley, KE | 14 |
| Nuermberger, EL | 8 |
| Mashele, SA | 1 |
| Steel, HC | 1 |
| Matjokotja, MT | 1 |
| Rasehlo, SSM | 1 |
| Anderson, R | 1 |
| Cholo, MC | 1 |
| Khan, N | 1 |
| Das, A | 3 |
| Xia, Z | 2 |
| Tan, Y | 1 |
| Crabtree-Ramirez, B | 1 |
| Jenkins, CA | 1 |
| Shepherd, BE | 2 |
| Jayathilake, K | 1 |
| Veloso, VG | 2 |
| Carriquiry, G | 1 |
| Gotuzzo, E | 1 |
| Cortes, CP | 2 |
| Padgett, D | 1 |
| McGowan, C | 1 |
| Sierra-Madero, J | 1 |
| Koenig, S | 1 |
| Pape, JW | 3 |
| Sterling, TR | 19 |
| Megna, M | 1 |
| Patruno, C | 1 |
| Bongiorno, MR | 1 |
| Gambardella, A | 1 |
| Guarneri, C | 1 |
| Foti, C | 1 |
| Lembo, S | 1 |
| Loconsole, F | 1 |
| Fabbrocini, G | 1 |
| Benoit Vásquez, GI | 1 |
| Morrobel, AL | 1 |
| Benjumea-Bedoya, D | 3 |
| Del Corral-Londoño, H | 1 |
| Nabity, SA | 2 |
| Mponda, K | 1 |
| Gutreuter, S | 1 |
| Surie, D | 2 |
| Zimba, SB | 1 |
| Chisuwo, L | 1 |
| Moffitt, A | 1 |
| Williams, AM | 1 |
| Sharma, AJ | 1 |
| Marshall, RE | 1 |
| Chiwaula, MJ | 1 |
| da Silva, R | 1 |
| Kumwenda, T | 1 |
| Chilikutali, L | 1 |
| Mwamale, S | 1 |
| Nagoli, E | 1 |
| Mwenyeheri, G | 1 |
| Ngongonda, D | 1 |
| Kaunda, E | 1 |
| Mtoto, F | 1 |
| Mhango, V | 1 |
| Mbewe, K | 1 |
| Melgar, M | 1 |
| Odo, M | 2 |
| Jahn, A | 2 |
| Buono, N | 1 |
| Maida, A | 2 |
| Girma, B | 2 |
| Kalua, T | 2 |
| Nyirenda, R | 1 |
| Sunguti, J | 1 |
| Woelk, G | 1 |
| Gunde, LJ | 2 |
| Mekonnen, TF | 1 |
| Maphosa, T | 2 |
| Kim, EJ | 1 |
| Auld, AF | 2 |
| Muula, AS | 1 |
| Oeltmann, JE | 2 |
| Geremew, D | 2 |
| Geremew, H | 1 |
| Tamir, M | 1 |
| Adem, M | 1 |
| Tegene, B | 1 |
| Bayleyegn, B | 1 |
| Grams, ES | 1 |
| Silva Ramos, A | 1 |
| Neves Muniz, M | 1 |
| Alberton Perelló, M | 1 |
| Calle González, L | 1 |
| Duarte, LS | 1 |
| Galina, L | 1 |
| Silva Dadda, A | 1 |
| Arraché Gonçalves, G | 1 |
| Valim Bizarro, C | 1 |
| Guo, S | 2 |
| Lei, S | 1 |
| Palittapongarnpim, P | 2 |
| McNeil, E | 1 |
| Chaiprasert, A | 2 |
| Ou, W | 1 |
| Surachat, K | 1 |
| Qin, W | 1 |
| Luo, R | 1 |
| Chongsuvivatwong, V | 1 |
| Dohál, M | 1 |
| Dvořáková, V | 1 |
| Šperková, M | 1 |
| Pinková, M | 1 |
| Spitaleri, A | 1 |
| Norman, A | 1 |
| Cabibbe, AM | 2 |
| Rasmussen, EM | 2 |
| Porvazník, I | 2 |
| Škereňová, M | 1 |
| Solovič, I | 3 |
| Cirillo, DM | 3 |
| Mokrý, J | 2 |
| Acuña-Villaorduña, C | 2 |
| Jones-López, EC | 2 |
| Marques-Rodrigues, P | 1 |
| Fregona, G | 1 |
| Gaeddert, M | 1 |
| Ribeiro-Rodrigues, R | 1 |
| Vinhas, S | 1 |
| Palaci, M | 4 |
| Salgame, P | 3 |
| Dietze, R | 3 |
| Ellner, J | 2 |
| Warr, AJ | 4 |
| Anterasian, C | 1 |
| Shah, JA | 2 |
| De Rosa, SC | 1 |
| Nguyen, FK | 1 |
| Maleche-Obimbo, E | 6 |
| Cranmer, LM | 8 |
| Matemo, D | 8 |
| Mecha, J | 5 |
| Kinuthia, J | 9 |
| LaCourse, SM | 11 |
| John-Stewart, GC | 3 |
| Hawn, TR | 5 |
| Kazibwe, A | 1 |
| Oryokot, B | 1 |
| Mugenyi, L | 1 |
| Kagimu, D | 1 |
| Oluka, AI | 1 |
| Kato, D | 1 |
| Ouma, S | 1 |
| Tayebwakushaba, E | 1 |
| Odoi, C | 1 |
| Kakumba, K | 1 |
| Opito, R | 1 |
| Mafabi, CG | 1 |
| Ochwo, M | 1 |
| Nkabala, R | 1 |
| Tusiimire, W | 1 |
| Kateeba Tusiime, A | 1 |
| Alinga, SB | 1 |
| Miya, Y | 1 |
| Etukoit, MB | 1 |
| Biraro, IA | 1 |
| Kirenga, B | 1 |
| Mohandes, AF | 1 |
| Karam, B | 1 |
| Alrstom, A | 1 |
| Alasadi, L | 1 |
| Rajab Bek, MW | 1 |
| Daher, N | 1 |
| Alsuliman, T | 1 |
| Abouhareb, R | 1 |
| Anderson, G | 1 |
| Vinnard, C | 3 |
| Bachir, M | 2 |
| Guglielmetti, L | 4 |
| Tunesi, S | 2 |
| Billard-Pomares, T | 2 |
| Chiesi, S | 2 |
| Jaffré, J | 2 |
| Langris, H | 2 |
| Pourcher, V | 2 |
| Schramm, F | 2 |
| Lemaître, N | 2 |
| Robert, J | 3 |
| Wen, Z | 1 |
| Li, T | 1 |
| Zhu, W | 1 |
| Chen, W | 3 |
| Zhang, H | 3 |
| Wang, W | 1 |
| Escudero, JN | 4 |
| Richardson, BA | 5 |
| Carimo, N | 1 |
| John-Stewart, G | 6 |
| Valinetz, ED | 1 |
| Gersh, JK | 1 |
| Joudeh, LL | 1 |
| Wald, A | 1 |
| Cangelosi, GA | 2 |
| Barnabas, RV | 3 |
| Horne, DJ | 1 |
| Jiang, Y | 3 |
| Zhao, X | 2 |
| Fan, Z | 1 |
| Bhosale, D | 1 |
| Mali, SN | 1 |
| Thorat, BR | 1 |
| Wavhal, SS | 1 |
| Bhagat, DS | 1 |
| Borade, RM | 1 |
| Van Aartsen, D | 1 |
| Justine, M | 2 |
| Mduma, E | 2 |
| Mpagama, SG | 3 |
| Alshaer, MH | 2 |
| Peloquin, CA | 22 |
| Mujaga, B | 1 |
| Maro, A | 1 |
| Gratz, J | 3 |
| Kosek, M | 1 |
| Liu, J | 6 |
| Rogawski McQuade, ET | 1 |
| Houpt, ER | 3 |
| Thomas, TA | 2 |
| Heysell, SK | 6 |
| Mohammed, KAS | 1 |
| Khudhair, GS | 1 |
| Al-Rabeai, DB | 1 |
| Sheikhpour, M | 2 |
| Delorme, V | 1 |
| Kasaeian, A | 1 |
| Amiri, V | 1 |
| Masoumi, M | 1 |
| Sadeghinia, M | 1 |
| Ebrahimzadeh, N | 1 |
| Maleki, M | 1 |
| Pourazar, S | 1 |
| Xie, NG | 1 |
| Zhang, K | 1 |
| Song, P | 1 |
| Li, R | 2 |
| Luo, J | 2 |
| Zhang, DY | 1 |
| Alcaraz, M | 1 |
| Sharma, B | 2 |
| Roquet-Banères, F | 1 |
| Conde, C | 1 |
| Cochard, T | 1 |
| Biet, F | 1 |
| Dejprapasorn, S | 1 |
| Kantachuvesiri, S | 1 |
| Pornsuriyasak, P | 1 |
| Sakulchairungrueng, B | 1 |
| Gesprasert, G | 1 |
| Bruminhent, J | 1 |
| Masini, T | 1 |
| Kanchar, A | 2 |
| Mirzayev, F | 2 |
| Viney, K | 1 |
| Yedilbayev, A | 1 |
| Zignol, M | 3 |
| Falzon, D | 3 |
| Sharma, K | 1 |
| Sharma, M | 1 |
| Dhillon, MS | 1 |
| Pillay, S | 2 |
| de Vos, M | 3 |
| Derendinger, B | 2 |
| Streicher, EM | 3 |
| Dolby, T | 2 |
| Scott, LA | 1 |
| Steinhobel, AD | 1 |
| Warren, RM | 3 |
| Theron, G | 7 |
| Thomas, L | 1 |
| Raju, AP | 1 |
| M, SS | 1 |
| Varma, M | 1 |
| Saravu, K | 1 |
| Banerjee, M | 1 |
| Sv, CS | 1 |
| Mallayasamy, S | 1 |
| Rao, M | 3 |
| Sharan, R | 1 |
| Ganatra, SR | 1 |
| Singh, DK | 2 |
| Cole, J | 1 |
| Foreman, TW | 2 |
| Thippeshappa, R | 1 |
| Shivanna, V | 1 |
| Gonzalez, O | 1 |
| Day, CL | 2 |
| Gandhi, NR | 2 |
| Dick, EJ | 1 |
| Hall-Ursone, S | 1 |
| Mehra, S | 2 |
| Schlesinger, LS | 1 |
| Rengarajan, J | 2 |
| Kaushal, D | 2 |
| Kubjane, M | 1 |
| Osman, M | 1 |
| Boulle, A | 7 |
| Johnson, LF | 1 |
| Perumal, R | 2 |
| Arodola-Oladoyinbo, O | 1 |
| Naidoo, A | 4 |
| Kawuma, AN | 1 |
| Gengiah, TN | 2 |
| Chirehwa, M | 4 |
| Onyango, D | 2 |
| Ding, Y | 1 |
| Zhu, H | 1 |
| Zhang, W | 5 |
| Wang, N | 1 |
| Onyango, DO | 1 |
| van der Sande, MAB | 1 |
| Yuen, CM | 6 |
| Oele, E | 1 |
| Mebratu, W | 1 |
| Wedajo, S | 1 |
| Mohammed, S | 1 |
| Endawkie, A | 1 |
| Damtew, Y | 1 |
| Sumaila, M | 1 |
| Kumar, P | 3 |
| Ubanako, P | 1 |
| Adeyemi, SA | 1 |
| Choonara, YE | 2 |
| Sintayehu, K | 1 |
| Zeleke, ED | 2 |
| Temesgen, B | 1 |
| Kifle, M | 1 |
| Assefa, DG | 2 |
| Zenebe, K | 1 |
| Kassahun, A | 1 |
| Yimer, BT | 1 |
| Shumail, S | 1 |
| Jaswal, M | 4 |
| Farooq, S | 3 |
| Maniar, R | 1 |
| Khowaja, S | 2 |
| Safdar, N | 4 |
| Khan, AJ | 4 |
| Nsengiyumva, P | 1 |
| Chiang, LY | 2 |
| Jamieson, F | 1 |
| Khadawardi, H | 1 |
| Mah, HK | 1 |
| Rasberry, H | 1 |
| Rea, E | 1 |
| Romanowski, K | 2 |
| Sabur, NF | 1 |
| Sander, B | 1 |
| Uppal, A | 1 |
| Johnston, JC | 2 |
| Schwartzman, K | 9 |
| Brode, SK | 1 |
| Singh, P | 2 |
| Moulton, LH | 8 |
| Barnes, GL | 5 |
| Msandiwa, R | 4 |
| Chaisson, RE | 45 |
| Martinson, NA | 9 |
| Makova, NC | 1 |
| Muchekeza, M | 1 |
| Chirenda, J | 1 |
| Chadambuka, A | 1 |
| Govha, E | 1 |
| Juru, TP | 1 |
| Gombe, NT | 2 |
| Tshimanga, M | 2 |
| Pettit, AC | 1 |
| Vernon, A | 7 |
| Dawson, R | 2 |
| Sanne, I | 2 |
| Waja, Z | 1 |
| Mohapi, L | 5 |
| Podany, AT | 3 |
| Samaneka, W | 1 |
| Johnson, JL | 6 |
| Muzanyi, G | 1 |
| Lalloo, UG | 1 |
| Bryant, K | 2 |
| Sizemore, E | 2 |
| Scott, N | 1 |
| Dorman, SE | 2 |
| Swindells, S | 9 |
| Wang, H | 5 |
| Bi, J | 1 |
| Pan, M | 1 |
| Guo, Q | 2 |
| Xiao, G | 1 |
| Cui, Y | 1 |
| Hu, S | 3 |
| Chan, CK | 3 |
| Kaneko, T | 2 |
| Zhang, G | 4 |
| Chen, S | 2 |
| Sabella-Jiménez, V | 1 |
| Hoyos Mendez, Y | 1 |
| Estupiñán-Bohorquez, AF | 1 |
| Acosta-Reyes, J | 1 |
| Florez, ID | 1 |
| Sundell, J | 2 |
| Bienvenu, E | 2 |
| Birgersson, S | 2 |
| Äbelö, A | 2 |
| Ashton, M | 2 |
| Kaswaswa, K | 1 |
| MacPherson, P | 4 |
| Kumwenda, M | 1 |
| Mpunga, J | 2 |
| Thindwa, D | 2 |
| Nliwasa, M | 1 |
| Mwapasa, M | 1 |
| Odland, J | 1 |
| Tomoka, T | 1 |
| Chipungu, G | 1 |
| Mukaka, M | 1 |
| Corbett, EL | 8 |
| Dhameliya, TM | 1 |
| Tiwari, R | 1 |
| Patel, KI | 1 |
| Vagolu, SK | 1 |
| Panda, D | 1 |
| Jacobs, WR | 8 |
| Hartman-Adams, H | 1 |
| Gerbo, RM | 1 |
| George, S | 2 |
| Mvelase, NR | 1 |
| Singh, R | 3 |
| Swe Swe-Han, K | 1 |
| Mlisana, KP | 1 |
| Manyazewal, T | 2 |
| Woldeamanuel, Y | 1 |
| Holland, DP | 4 |
| Fekadu, A | 1 |
| Marconi, VC | 1 |
| Thamineni, R | 1 |
| Peraman, R | 1 |
| Chenniah, J | 1 |
| Meka, G | 1 |
| Munagala, AK | 1 |
| Mahalingam, VT | 1 |
| Ganesan, RM | 1 |
| Grasa Lozano, CD | 1 |
| Baro-Fernández, M | 1 |
| Rubio-San-Simón, A | 1 |
| Blázquez-Gamero, D | 1 |
| López-Roa, P | 1 |
| Liébana, C | 1 |
| Guerra-García, P | 1 |
| Moraleda, C | 1 |
| Epalza, C | 1 |
| Ridahunlang, N | 1 |
| Bisht, R | 1 |
| Rishanlang, N | 1 |
| Yu, C | 1 |
| Zheng, X | 2 |
| Wang, L | 8 |
| Shen, X | 4 |
| Xu, B | 1 |
| Karaushi, H | 1 |
| Seki, M | 2 |
| Miyawaki, Y | 1 |
| Watanabe, N | 1 |
| Kamoshita, F | 1 |
| Mitsutake, K | 1 |
| Srichana, T | 1 |
| Eze, FN | 1 |
| Thawithong, E | 1 |
| Garg, S | 1 |
| Kunimoto, D | 3 |
| Rayat, GR | 1 |
| Vojnov, L | 1 |
| Venter, WDF | 1 |
| Zhu, J | 3 |
| Lyatuu, G | 1 |
| Sudfeld, CR | 1 |
| Kiravu, A | 1 |
| Sando, D | 1 |
| Machumi, L | 1 |
| Minde, J | 1 |
| Chisonjela, F | 1 |
| Cohen, T | 10 |
| Menzies, NA | 3 |
| da Silva, P | 1 |
| Trollip, A | 1 |
| Schumacher, S | 1 |
| Stevens, W | 1 |
| McVeigh, LG | 1 |
| Zaazoue, MA | 1 |
| Lane, BC | 1 |
| Voorhies, JM | 1 |
| Bradbury, J | 1 |
| Furin, J | 2 |
| Reuter, A | 1 |
| Eyde, L | 1 |
| Cox, H | 1 |
| Fortún, J | 4 |
| Navas, E | 3 |
| Suárez-González, J | 1 |
| Cáceres-Pérez, AR | 1 |
| Oliva, A | 1 |
| Santoveña-Estévez, A | 1 |
| Fariña, JB | 1 |
| Bletsis, PP | 1 |
| Al Moujahid, A | 1 |
| Wink, FR | 1 |
| van den Elskamp, IJ | 1 |
| de Jong, T | 1 |
| Moh, DR | 1 |
| Badjé, A | 5 |
| Kassi, AN | 1 |
| Ntakpé, JB | 3 |
| Kouame, GM | 3 |
| Ouassa, T | 3 |
| Danel, C | 4 |
| Domoua, SK | 2 |
| Anglaret, X | 7 |
| Eholié, SP | 2 |
| Pršo, K | 1 |
| Žideková, N | 1 |
| Kertys, M | 1 |
| Dash, N | 1 |
| Verghese, VP | 3 |
| Rose, W | 1 |
| Michael, JS | 1 |
| Rebekah, G | 1 |
| Venkatesan, M | 1 |
| Chacko, A | 1 |
| Jagi, JL | 3 |
| Thomas, C | 3 |
| Gudi, SK | 3 |
| Undela, K | 3 |
| Nyarubamba, RF | 3 |
| Silumbwe, A | 3 |
| Jacobs, C | 3 |
| Maritim, P | 3 |
| Mdoe, P | 3 |
| Zulu, JM | 3 |
| Walker, WL | 3 |
| Schmit, KM | 3 |
| Welch, EC | 3 |
| Vonnahme, LA | 3 |
| Talwar, A | 3 |
| Nguyen, M | 3 |
| Stojanovic, D | 3 |
| Langer, AJ | 3 |
| Cocoros, NM | 3 |
| Ruiz-Tornero, AM | 3 |
| Sánchez-Recio, R | 3 |
| Khan, AS | 3 |
| Phelan, JE | 4 |
| Khan, MT | 3 |
| Ali, S | 3 |
| Qasim, M | 3 |
| Mohammad, N | 3 |
| Napier, G | 4 |
| Ahmad, S | 7 |
| Alam, J | 3 |
| Khattak, B | 3 |
| Campino, S | 4 |
| Clark, TG | 5 |
| Khan, TA | 3 |
| Ky Anh, N | 2 |
| My Tung, P | 2 |
| Kim, MJ | 2 |
| Phuoc Long, N | 2 |
| Kim, DH | 3 |
| Radisic, MV | 2 |
| Pujato, NR | 2 |
| Bravo, PM | 2 |
| Del Grosso, RC | 2 |
| Hunter, M | 2 |
| Beltramino, S | 2 |
| Linares González, L | 2 |
| Cornet, ML | 2 |
| Del Carmen Rial, M | 2 |
| Franzini, RL | 2 |
| Dotta, AC | 2 |
| León, LR | 2 |
| Walther, J | 2 |
| Uva, PD | 2 |
| Werber, G | 2 |
| Leitao, RCF | 2 |
| Silva, F | 2 |
| Ribeiro, GH | 2 |
| Santos, IC | 2 |
| Guerreiro, JF | 2 |
| Mendes, F | 3 |
| Batista, AA | 2 |
| Pavan, FR | 4 |
| da S Maia, PI | 2 |
| Paulo, A | 2 |
| Deflon, VM | 2 |
| Ou, X | 1 |
| Zhang, Z | 4 |
| Zhao, B | 1 |
| Song, Z | 1 |
| Wang, S | 4 |
| He, W | 1 |
| Pei, S | 1 |
| Liu, D | 2 |
| Xing, R | 1 |
| Xia, H | 2 |
| Zhao, Y | 5 |
| Narang, A | 1 |
| Marras, SAE | 1 |
| Kurepina, N | 1 |
| Chauhan, V | 1 |
| Shashkina, E | 2 |
| Kreiswirth, B | 2 |
| Varma-Basil, M | 1 |
| Subbian, S | 5 |
| Sparks, IL | 1 |
| Derbyshire, KM | 1 |
| Morita, YS | 1 |
| Radtke, K | 1 |
| Mohamed, A | 1 |
| Gegia, M | 2 |
| Linh, NN | 1 |
| Bekele, D | 1 |
| Ejigu, DA | 1 |
| Molla, W | 1 |
| Woldesenbet, TT | 1 |
| Aynalem, A | 1 |
| Abebe, M | 2 |
| Mebratu, A | 1 |
| Kim, N | 1 |
| Seok, KH | 1 |
| Shin, S | 3 |
| Kim, B | 1 |
| Park, H | 1 |
| Roh, EY | 1 |
| Yoon, JH | 1 |
| Xin, H | 1 |
| Du, Y | 1 |
| Cao, X | 1 |
| Pan, S | 1 |
| Guan, L | 2 |
| Shen, F | 1 |
| Zhang, B | 2 |
| Wang, D | 3 |
| Feng, B | 1 |
| Du, J | 1 |
| Guan, X | 1 |
| He, Y | 3 |
| Yan, J | 1 |
| Jin, Q | 2 |
| Gao, L | 1 |
| Mandima, P | 1 |
| Baltrusaitis, K | 1 |
| Montepiedra, G | 8 |
| Aaron, L | 5 |
| Mathad, J | 1 |
| Onyango-Makumbi, C | 4 |
| Nyati, M | 3 |
| Ngocho, J | 2 |
| Chareka, G | 1 |
| Ponatshego, P | 1 |
| Masheto, G | 4 |
| McCarthy, K | 4 |
| Jean-Philippe, P | 7 |
| Stranix-Chibanda, L | 4 |
| Villegas Arbeláez, E | 1 |
| Martínez-Peñaloza, D | 1 |
| Beltrán-Arroyave, CP | 1 |
| Restrepo Gouzy, AV | 1 |
| Marín, D | 1 |
| Cadavid Álvarez, LM | 1 |
| Molinares, B | 1 |
| Montes Zuluaga, FN | 1 |
| Pulido Duarte, H | 1 |
| Suárez Parra, PM | 1 |
| Alzate Ángel, JC | 1 |
| Vélez-Parra, G | 1 |
| Realpe, T | 1 |
| Vásquez Villa, M | 1 |
| Ríos Buitrago, SY | 1 |
| Puerta Zapata, J | 1 |
| Arango García, LM | 1 |
| Perea Torres, Y | 1 |
| Pérez Doncel, N | 1 |
| Arbeláez Montoya, MP | 1 |
| Robledo, J | 1 |
| Blumenfeld, A | 1 |
| Rubinstein, F | 1 |
| Mancini, P | 5 |
| Knopoff, EG | 1 |
| Otero, L | 2 |
| Zetola, N | 1 |
| Campos, M | 1 |
| Zunt, J | 1 |
| Bayer, A | 1 |
| Curisinche, M | 1 |
| Ochoa, T | 1 |
| Reyes, M | 1 |
| Vega, V | 1 |
| Van der Stuyft, P | 1 |
| Mary Rebecca, Y | 1 |
| Sudha, V | 5 |
| Bharathiraja, T | 1 |
| Lavanya, J | 6 |
| Hemanth Kumar, AK | 9 |
| Samukawa, N | 1 |
| Yamaguchi, T | 1 |
| Ozeki, Y | 1 |
| Matsumoto, S | 1 |
| Igarashi, M | 1 |
| Kinoshita, N | 1 |
| Hatano, M | 1 |
| Tokudome, K | 1 |
| Matsunaga, S | 1 |
| Tomita, S | 1 |
| Madamarandawala, P | 1 |
| Rajapakse, S | 1 |
| Gunasena, B | 1 |
| Madegedara, D | 1 |
| Magana-Arachchi, D | 1 |
| Nilgiriwala, K | 2 |
| Rabodoarivelo, MS | 1 |
| Hall, MB | 1 |
| Patel, G | 1 |
| Mandal, A | 1 |
| Mishra, S | 1 |
| Andrianomanana, FR | 1 |
| Dingle, K | 1 |
| Rodger, G | 1 |
| Crook, DW | 3 |
| Hoosdally, S | 2 |
| Mistry, N | 3 |
| Rakotosamimanana, N | 1 |
| Iqbal, Z | 3 |
| Grandjean Lapierre, S | 1 |
| Walker, TM | 2 |
| Gui, X | 1 |
| Yao, L | 1 |
| Ma, J | 1 |
| Lou, H | 1 |
| Ying, R | 1 |
| Sun, Q | 3 |
| Liu, Y | 4 |
| Ho, CM | 1 |
| Lee, BY | 3 |
| Clemens, DL | 3 |
| Horwitz, MA | 3 |
| Ding, X | 1 |
| Hao, X | 1 |
| Yang, H | 3 |
| Sha, W | 1 |
| Namasivayam, S | 1 |
| Zimmerman, M | 2 |
| Oland, S | 1 |
| Mittereder, LR | 1 |
| Sher, A | 1 |
| Allard-Gray, A | 1 |
| Boakye, I | 1 |
| Camara, A | 1 |
| Eisenbeis, L | 1 |
| Guimarães-Teixeira, E | 1 |
| Sow, O | 1 |
| Zielinski, D | 1 |
| Winters, N | 1 |
| Borisov, A | 1 |
| Chan, PC | 2 |
| Martinson, N | 3 |
| Scott, NA | 2 |
| Villarino, ME | 3 |
| Wang, JY | 1 |
| Adepoju, VA | 1 |
| Adelekan, A | 1 |
| Adepoju, OE | 1 |
| Onyezue, OI | 1 |
| Imoyera, W | 1 |
| Nkeiruka, A | 1 |
| Olofinbiyi, AB | 1 |
| Malhotra, S | 2 |
| Dasgupta-Tsinikas, S | 1 |
| Yumul, J | 1 |
| Kaneta, K | 1 |
| Lenz, A | 1 |
| Kizzee, R | 1 |
| Bihm, D | 1 |
| Jung, C | 1 |
| Neely, M | 1 |
| Guevara, RE | 1 |
| Higashi, J | 1 |
| Bender, JM | 1 |
| Özgür, D | 1 |
| Ersoy, L | 1 |
| Ülger, M | 1 |
| Tezcan Ülger, S | 1 |
| Aslan, G | 2 |
| Gupta, S | 5 |
| Bhagavathula, M | 1 |
| Biswas, A | 2 |
| Palacios, A | 1 |
| Salgueiro, V | 1 |
| Lavín, JL | 1 |
| Dogra, N | 1 |
| Prados-Rosales, R | 1 |
| Rodríguez, GM | 1 |
| Madhani, F | 1 |
| Noorani, S | 1 |
| Shahbaz, SS | 1 |
| Salahuddin, N | 1 |
| Amanullah, F | 2 |
| Manzar, S | 1 |
| Islam, Z | 1 |
| Dahri, AA | 1 |
| Shahzad, M | 1 |
| Keshavjee, S | 5 |
| Becerra, MC | 8 |
| Bao, Z | 1 |
| Cao, H | 1 |
| Li, X | 2 |
| Ning, Z | 1 |
| Hu, Y | 5 |
| Davies Forsman, L | 2 |
| Varghese, AM | 1 |
| Kandra, N | 1 |
| Uppala, PK | 1 |
| Vangoori, Y | 1 |
| Butti, L | 1 |
| Masapogu, S | 1 |
| Uttaravalli, U | 1 |
| Somarouthu, VS | 1 |
| Balijepalli, MK | 1 |
| Melnychuk, L | 1 |
| Perlman-Arrow, S | 1 |
| Lisboa Bastos, M | 1 |
| Gafar, F | 1 |
| Feng, Z | 1 |
| Miao, Y | 1 |
| Peng, Y | 1 |
| Sun, F | 1 |
| Ge, S | 1 |
| Song, L | 1 |
| Li, Y | 6 |
| Wang, X | 4 |
| Motlhaoleng, K | 2 |
| Moropeng, L | 1 |
| Abraham, P | 1 |
| Moloantoa, T | 1 |
| Wen, Q | 1 |
| Zhang, J | 3 |
| Han, Z | 1 |
| Chen, Y | 2 |
| Wang, K | 1 |
| Sai, N | 1 |
| Zhou, X | 1 |
| Ma, L | 2 |
| Yildirim, K | 1 |
| Atas, C | 1 |
| Simsek, E | 1 |
| Coban, AY | 2 |
| Griesel, R | 1 |
| Simmons, B | 1 |
| Omar, Z | 1 |
| Keene, CM | 1 |
| Hill, AM | 1 |
| Maartens, G | 9 |
| Bakshi, S | 1 |
| Kaur, M | 2 |
| Verma, A | 2 |
| Hahn, JA | 4 |
| Ngabirano, C | 1 |
| Fatch, R | 3 |
| Emenyonu, NI | 3 |
| Cheng, DM | 2 |
| Adong, J | 2 |
| Tumwegamire, A | 1 |
| Terrault, NA | 1 |
| Linas, BP | 2 |
| Jacobson, KR | 4 |
| Muyindike, WR | 4 |
| Agyemang, N | 1 |
| Scarsi, KK | 1 |
| Baker, P | 2 |
| Smeaton, LM | 1 |
| Olefsky, M | 1 |
| Woolley, E | 1 |
| Barr, E | 1 |
| Pham, M | 1 |
| Mawlana, S | 3 |
| Supparatpinyo, K | 3 |
| Gatechompol, S | 1 |
| Jalil, EM | 1 |
| Gadama, L | 1 |
| Badal-Faesen, S | 3 |
| Van Schalkwyk, M | 1 |
| Kayama, C | 1 |
| Belaunzaran-Zamudio, PF | 1 |
| Godfrey, C | 2 |
| Cohn, SE | 3 |
| Mngqibisa, R | 3 |
| Haas, DW | 4 |
| Sampiron, EG | 2 |
| Calsavara, LL | 1 |
| Baldin, VP | 1 |
| Montaholi, DC | 1 |
| Leme, ALD | 1 |
| Namba, DY | 1 |
| Alves Olher, VG | 1 |
| Caleffi-Ferraciolli, KR | 1 |
| Cardoso, RF | 6 |
| Siqueira, VLD | 1 |
| Vandresen, F | 1 |
| Scodro, RBL | 2 |
| Brehm, TT | 1 |
| Köhler, N | 1 |
| Schmiedel, S | 1 |
| Terhalle, E | 1 |
| Martensen, J | 1 |
| Kalsdorf, B | 2 |
| Kandulla, J | 1 |
| Heyckendorf, J | 2 |
| Kuhns, M | 1 |
| Friesen, I | 1 |
| Lange, C | 3 |
| Tanoglu, A | 1 |
| Erdem, H | 1 |
| Friedland, JS | 4 |
| Ankaralı, H | 1 |
| Garcia-Goez, JF | 1 |
| Albayrak, A | 1 |
| El-Kholy, A | 1 |
| Ceviker, SA | 1 |
| Amer, F | 1 |
| Erol, S | 1 |
| Darazam, IA | 1 |
| Rabiei, MM | 1 |
| Sarwar, MZ | 1 |
| Zeb, M | 1 |
| Nawaz, H | 1 |
| Ceylan, MR | 1 |
| Cernat, R | 1 |
| Tasbakan, M | 1 |
| Ayoade, F | 1 |
| Ruch, Y | 1 |
| Tigen, ET | 1 |
| Angioni, G | 1 |
| Rajani, DP | 1 |
| Akhtar, N | 1 |
| Surme, S | 1 |
| Sengoz, G | 1 |
| Karlıdag, GE | 1 |
| Marino, A | 1 |
| Ripon, RK | 1 |
| Çağ, Y | 1 |
| Aydın, Ö | 2 |
| Akkoyunlu, Y | 1 |
| Seyman, D | 1 |
| Angamuthu, K | 1 |
| Cascio, A | 1 |
| Popescu, CP | 1 |
| Sirmatel, F | 1 |
| Eren, E | 1 |
| Dar, RE | 1 |
| Munu, FU | 1 |
| Tanoglu, EG | 1 |
| Echeverry, E | 1 |
| Velez, JD | 1 |
| Artuk, C | 1 |
| Balin, SO | 1 |
| Pandya, N | 1 |
| Erdem, A | 1 |
| Demiray, EKD | 1 |
| Aypak, A | 1 |
| Mapingure, MP | 1 |
| Zech, JM | 1 |
| Hirsch-Moverman, Y | 5 |
| Msukwa, M | 1 |
| Howard, AA | 4 |
| Makoni, T | 1 |
| Gwanzura, C | 1 |
| Apollo, T | 1 |
| Sandy, C | 3 |
| Musuka, GN | 1 |
| Rabkin, M | 1 |
| Nawrot, DE | 1 |
| Bouz, G | 1 |
| Konečná, K | 1 |
| Bárta, P | 1 |
| Novák, M | 3 |
| Kučera, R | 1 |
| Zemanová, J | 1 |
| Forbak, M | 1 |
| Pavliš, O | 1 |
| Kubíčková, P | 1 |
| Ramachandran, A | 1 |
| Gadgil, CJ | 1 |
| Tabernero, P | 1 |
| Newton, PN | 1 |
| Herrera-Pérez, IG | 1 |
| Rodríguez-Báez, AS | 1 |
| Ortiz-Álvarez, A | 3 |
| Velarde-Salcedo, R | 1 |
| Arriaga-García, FJ | 1 |
| Rodríguez-Pinal, CJ | 4 |
| Romano-Moreno, S | 5 |
| Milán-Segovia, RDC | 4 |
| Medellín-Garibay, SE | 4 |
| Ansari, MA | 1 |
| Shoaib, S | 1 |
| Alomary, MN | 1 |
| Ather, H | 1 |
| Ansari, SMA | 1 |
| Hani, U | 1 |
| Jamous, YF | 1 |
| Alyahya, SA | 1 |
| Alharbi, JN | 1 |
| Imran, MA | 1 |
| Wahab, S | 1 |
| Ahmad, W | 1 |
| Islam, N | 2 |
| Diel, R | 7 |
| Breuer, C | 2 |
| Bös, L | 2 |
| Geerdes-Fenge, H | 2 |
| Günther, A | 2 |
| Häcker, B | 2 |
| Hannemann, J | 2 |
| Nienhaus, A | 4 |
| Priwitzer, M | 2 |
| Witte, P | 2 |
| Bauer, T | 3 |
| Shibutani, K | 1 |
| Ishikawa, K | 1 |
| Mori, N | 1 |
| Rajendran, P | 1 |
| Padmapriyadarsini, C | 6 |
| Nair, S | 1 |
| Sivakumar, S | 2 |
| Gupta, PK | 1 |
| Jahagirdar, P | 1 |
| Tripathi, D | 1 |
| Devarajan, PV | 1 |
| Kulkarni, S | 2 |
| Chipato, T | 5 |
| Chanaiwa, V | 2 |
| Vhembo, T | 3 |
| Mutambanengwe, M | 2 |
| Raesi, M | 1 |
| Bradford, S | 4 |
| Golner, A | 1 |
| Costello, D | 3 |
| Kulkarni, V | 2 |
| Shayo, A | 1 |
| Kabugho, E | 2 |
| Jean-Phillippe, P | 1 |
| Chakhtoura, N | 5 |
| Weinberg, A | 4 |
| Amaeze, OU | 1 |
| Isoherranen, N | 1 |
| Wondmeneh, TG | 1 |
| Mekonnen, AT | 1 |
| Sadovska, D | 1 |
| Berge, I | 1 |
| Bogdanova, I | 1 |
| Vaivode, A | 1 |
| Freimane, L | 1 |
| Norvaiša, I | 1 |
| Ozere, I | 1 |
| Hassane-Harouna, S | 1 |
| Gils, T | 1 |
| Decroo, T | 2 |
| Ortuño-Gutiérrez, N | 1 |
| Delamou, A | 1 |
| Cherif, GF | 1 |
| Camara, LM | 1 |
| Rigouts, L | 5 |
| de Jong, BC | 3 |
| Gopi Reji, J | 1 |
| K Edison, L | 1 |
| Raghunandanan, S | 1 |
| Pushparajan, AR | 1 |
| Kurthkoti, K | 1 |
| Ajay Kumar, R | 1 |
| Fage, D | 1 |
| Aalhoul, F | 1 |
| Cotton, F | 1 |
| Aytac, S | 1 |
| Ovayolu, O | 1 |
| Dogru, S | 1 |
| Sekayi, W | 1 |
| Namyalo, E | 1 |
| Namayanja, J | 1 |
| Kungu, JM | 1 |
| Gray, AT | 1 |
| Macpherson, L | 1 |
| Carlin, F | 1 |
| Sossen, B | 1 |
| Richards, AS | 1 |
| Kik, SV | 1 |
| Houben, RMGJ | 2 |
| Quartagno, M | 1 |
| Rogozińska, E | 1 |
| Esmail, H | 1 |
| Chamie, G | 4 |
| Kekibiina, A | 1 |
| Beesiga, B | 1 |
| Marson, K | 2 |
| Lodi, S | 2 |
| Thirumurthy, H | 2 |
| McDonell, MG | 2 |
| Gandhi, M | 4 |
| Havlir, DV | 5 |
| Galileya, LT | 1 |
| Lee, J | 2 |
| Njahira Mukui, I | 1 |
| Hesseling, A | 3 |
| Zar, H | 1 |
| Gibb, D | 2 |
| Trivedi, P | 1 |
| Quincer, EM | 1 |
| Lyland, A | 1 |
| Figueroa, J | 1 |
| Antwi, S | 1 |
| Maranchick, N | 1 |
| Dompreh, A | 1 |
| Amissah, AK | 1 |
| Sly-Moore, E | 1 |
| Martyn-Dickens, C | 1 |
| Opoku, T | 1 |
| Enimil, A | 1 |
| Bosomtwe, D | 1 |
| Ojewale, O | 1 |
| Sarfo, AD | 1 |
| Appiah, AF | 1 |
| Kusi-Amponsah, I | 1 |
| Dong, SK | 1 |
| Osei Kuffour, B | 1 |
| Morgan, R | 1 |
| Kwara, A | 3 |
| Nkanga, CI | 1 |
| Krause, RWM | 1 |
| Wagner, AD | 1 |
| Copeland, A | 1 |
| Miyahara, S | 5 |
| Ramchandani, R | 3 |
| Kim, S | 9 |
| Evans, SR | 1 |
| Montiel Quezel-Guerraz, N | 1 |
| Sánchez-Porto, A | 1 |
| Ortega Torres, M | 1 |
| Pérez Santos, MJ | 1 |
| Acosta, F | 1 |
| Guzman, A | 1 |
| Correa Ruiz, A | 1 |
| Bérmudez Ruiz, P | 1 |
| Dlamini, NC | 1 |
| Ji, DD | 1 |
| Chien, LY | 1 |
| Bouton, TC | 1 |
| Forson, A | 1 |
| Kudzawu, S | 1 |
| Zigah, F | 1 |
| Jenkins, H | 1 |
| Bamfo, TD | 1 |
| Carter, J | 1 |
| Jacobson, K | 1 |
| Mukherjee, TI | 1 |
| Saito, S | 2 |
| Gadisa, T | 2 |
| Melaku, Z | 2 |
| Romain, AS | 1 |
| Mornand, P | 1 |
| Chaput, U | 1 |
| Guedj, R | 1 |
| Grimprel, E | 1 |
| McCaw, ZR | 1 |
| Meng, Z | 1 |
| Wei, LJ | 1 |
| Tornheim, JA | 1 |
| Udwadia, ZF | 1 |
| Horsburgh, CR | 9 |
| Manialawy, Y | 1 |
| Siraki, AG | 1 |
| Jarrett, BA | 1 |
| Woznica, DM | 1 |
| Tilchin, C | 1 |
| Mpungose, N | 1 |
| Golub, JE | 15 |
| Hanrahan, CF | 3 |
| Juszkiewicz, K | 1 |
| Jarosz, MJ | 1 |
| Włoszczak-Szubzda, A | 1 |
| Głowacka, M | 1 |
| Durovni, B | 12 |
| Cavalacante, S | 1 |
| Masonoke, K | 1 |
| Saraceni, V | 9 |
| Lebina, L | 2 |
| Efron, A | 4 |
| Cohn, S | 8 |
| Chon, S | 1 |
| Masheto, GR | 2 |
| Mmbaga, BT | 2 |
| Aurpibul, L | 2 |
| Bhosale, R | 2 |
| Rouzier, V | 3 |
| Shin, K | 2 |
| Zimmer, B | 4 |
| Nyathi, S | 1 |
| Dlodlo, RA | 3 |
| Satyanarayana, S | 6 |
| Takarinda, KC | 2 |
| Tweya, H | 1 |
| Hove, S | 1 |
| Matambo, R | 1 |
| Mandewo, W | 1 |
| Nyathi, K | 1 |
| Sibanda, E | 1 |
| Harries, AD | 10 |
| Browne, SH | 1 |
| Umlauf, A | 1 |
| Tucker, AJ | 1 |
| Low, J | 1 |
| Moser, K | 4 |
| Gonzalez Garcia, J | 1 |
| Blaschke, T | 1 |
| Vaida, F | 1 |
| Benson, CA | 4 |
| Lei, Q | 1 |
| Dang, L | 1 |
| Zhu, C | 3 |
| Lv, X | 1 |
| Zhou, J | 3 |
| Hameed, S | 2 |
| Mahmood, N | 2 |
| Chaudhry, MN | 1 |
| Ahmad, SR | 1 |
| Aqeel Ur Rahman, M | 1 |
| Dahiwade, LK | 1 |
| Rochlani, SP | 1 |
| Choudhari, PB | 1 |
| Dhavale, RP | 1 |
| More, HN | 1 |
| Chaisson, LH | 2 |
| Seabrook, D | 1 |
| Cavalcante, SC | 9 |
| Kagujje, M | 1 |
| Mubiana, ML | 1 |
| Mwamba, E | 1 |
| Muyoyeta, M | 2 |
| Maurer, FP | 1 |
| Bucşan, AN | 1 |
| Peloquin, C | 1 |
| Doyle, LA | 1 |
| Russell-Lodrigue, K | 1 |
| Altman, J | 1 |
| Ernst, JD | 1 |
| Blumberg, HM | 6 |
| Batalha, IL | 1 |
| Bernut, A | 1 |
| Schiebler, M | 1 |
| Ouberai, MM | 1 |
| Passemar, C | 1 |
| Klapholz, C | 1 |
| Kinna, S | 1 |
| Michel, S | 1 |
| Sader, K | 1 |
| Castro-Hartmann, P | 1 |
| Renshaw, SA | 1 |
| Welland, ME | 1 |
| Floto, RA | 1 |
| Bai, H | 1 |
| Wu, T | 1 |
| Jiao, L | 1 |
| Wu, Q | 2 |
| Zhao, Z | 4 |
| Song, J | 6 |
| Liu, T | 2 |
| Lv, Y | 1 |
| Ying, B | 3 |
| Kanegi, R | 1 |
| Yasugi, M | 1 |
| Nabetani, T | 1 |
| Tanaka, T | 1 |
| Wada, Y | 1 |
| Hirai, K | 1 |
| Sugiura, K | 1 |
| Hatoya, S | 1 |
| Prayuni, K | 1 |
| Susilowati, RW | 1 |
| M Sofro, AS | 1 |
| Tokunaga, K | 2 |
| Rodriguez, CA | 2 |
| Zuluaga, AF | 1 |
| Neely, MN | 1 |
| Sierra, Y | 1 |
| Morales-Gutierrez, J | 1 |
| Zapata, J | 1 |
| Zapata, JD | 1 |
| Naranjo, TW | 1 |
| Agudelo, Y | 1 |
| Velasco-Arnaiz, E | 1 |
| Soriano-Arandes, A | 1 |
| Espiau, M | 1 |
| Altet, N | 1 |
| Fortuny, C | 1 |
| Monsonís, M | 1 |
| Tebruegge, M | 1 |
| Noguera-Julian, A | 1 |
| Mir, SA | 1 |
| Pi, J | 1 |
| Shen, L | 1 |
| Yang, E | 1 |
| Shen, H | 1 |
| Huang, D | 2 |
| Wang, R | 2 |
| Hu, C | 1 |
| Jin, H | 1 |
| Cai, H | 1 |
| Cai, J | 1 |
| Zeng, G | 1 |
| Chen, ZW | 1 |
| Kaneko, S | 1 |
| Tsuruta, N | 1 |
| Yamaguchi, K | 1 |
| Miyagi, T | 1 |
| Takahashi, K | 1 |
| Higashi, Y | 1 |
| Morizane, S | 1 |
| Nomura, H | 1 |
| Yamaguchi, M | 1 |
| Hino, R | 1 |
| Sawada, Y | 1 |
| Nakamura, M | 1 |
| Ohyama, B | 1 |
| Ohata, C | 1 |
| Yonekura, K | 1 |
| Hayashi, H | 2 |
| Yanase, T | 1 |
| Matsuzaka, Y | 1 |
| Sugita, K | 1 |
| Kikuchi, S | 1 |
| Mitoma, C | 1 |
| Nakahara, T | 1 |
| Furue, M | 1 |
| Okazaki, F | 1 |
| Koike, Y | 1 |
| Imafuku, S | 1 |
| Yang, Q | 2 |
| Ruan, Q | 1 |
| Shen, Y | 1 |
| Jiang, T | 2 |
| Wu, J | 1 |
| Cai, L | 1 |
| Pan, K | 2 |
| Lin, M | 1 |
| Huang, X | 1 |
| Shao, L | 2 |
| Flynn, AG | 1 |
| Aiona, K | 1 |
| Haas, MK | 1 |
| Reves, R | 5 |
| Grenha, A | 2 |
| Alves, AD | 2 |
| Guerreiro, F | 2 |
| Pinho, J | 1 |
| Simões, S | 1 |
| Almeida, AJ | 1 |
| Gaspar, MM | 1 |
| Barcellos, RB | 1 |
| de Almeida, IN | 1 |
| da Silva, EC | 1 |
| Gomes, HM | 2 |
| de Assis Figueredo, LJ | 1 |
| Halon, ML | 2 |
| Dalla Costa, ER | 3 |
| Dos Santos, ÍR | 1 |
| Vater, MC | 1 |
| Alves, S | 1 |
| da Silva Carvalho, W | 1 |
| Suffys, P | 1 |
| Sola, C | 2 |
| de Miranda, SS | 1 |
| Rossetti, ML | 2 |
| Kritski, A | 2 |
| Rodrigues-Junior, VS | 2 |
| Sperotto, NDM | 1 |
| Picada, JN | 1 |
| Bondan da Silva, J | 1 |
| Wu, L | 1 |
| Ye, Z | 2 |
| Lin, J | 1 |
| Zheng, L | 1 |
| Chu, N | 1 |
| Rens, NE | 1 |
| Uyl-de Groot, CA | 1 |
| Goldhaber-Fiebert, JD | 2 |
| Croda, J | 1 |
| Andrews, JR | 1 |
| Schutz, C | 1 |
| Barr, D | 1 |
| Ward, A | 1 |
| Janssen, S | 1 |
| Burton, R | 1 |
| Shey, M | 1 |
| Reddy, MM | 1 |
| Thekkur, P | 2 |
| Ramya, N | 1 |
| Kamath, PBT | 1 |
| Shastri, SG | 1 |
| Kumar, RBN | 1 |
| Chinnakali, P | 2 |
| Nirgude, AS | 1 |
| Rangaraju, C | 1 |
| Somashekar, N | 1 |
| Kumar, AMV | 4 |
| Sulis, G | 1 |
| Pai, M | 6 |
| Panwar, P | 1 |
| Maurya, SC | 1 |
| Nag, RK | 1 |
| Srivastava, SK | 1 |
| Chowdhary, S | 1 |
| Seminari, E | 1 |
| Monzillo, V | 1 |
| Lombardi, A | 1 |
| Barbarini, D | 1 |
| Scudeller, L | 1 |
| Schimmenti, A | 1 |
| Muzzi, A | 1 |
| Marone, P | 1 |
| Ramachandran, G | 18 |
| Requena-Mendez, A | 1 |
| Sekaggya-Wiltshire, C | 4 |
| Matteelli, A | 4 |
| Fehr, J | 4 |
| Janzén, D | 1 |
| Picone, CM | 2 |
| Freitas, AC | 1 |
| Gutierrez, EB | 2 |
| Avelino-Silva, VI | 1 |
| Santos, NCS | 1 |
| Leal, DC | 1 |
| do Prado, SM | 1 |
| Micheletti, DF | 1 |
| Costacurta, GF | 1 |
| de Almeida, AL | 1 |
| da Silva, LA | 1 |
| Ieque, AL | 1 |
| Ghiraldi Lopes, LD | 1 |
| de Pádua, RA | 1 |
| Siqueira, VL | 4 |
| Caleffi-Ferracioli, KR | 3 |
| Ciesielczuk, H | 1 |
| Kouvas, N | 1 |
| North, N | 1 |
| Buchanan, R | 1 |
| Tiberi, S | 3 |
| Susanto, BO | 1 |
| Wicha, SG | 1 |
| Coates, ARM | 1 |
| Aksenova, VA | 2 |
| Vasilyeva, IA | 1 |
| Kasaeva, TC | 1 |
| Samoilova, AG | 1 |
| Pshenichnaya, NY | 1 |
| Tyulkova, TE | 1 |
| Boffa, JM | 1 |
| Fisher, DA | 1 |
| Mayan, MJ | 1 |
| Sauve, RS | 1 |
| Williamson, TS | 1 |
| Alemu, A | 1 |
| Yesuf, A | 1 |
| Zerihun, B | 1 |
| Getu, M | 1 |
| Worku, T | 1 |
| Bitew, ZW | 1 |
| Piubello, A | 2 |
| Souleymane, MB | 1 |
| Lynen, L | 3 |
| Van Deun, A | 5 |
| von Groote-Bidlingmaier, F | 1 |
| Sun, X | 5 |
| Hafner, R | 5 |
| Rosenkranz, SL | 1 |
| Ignatius, EH | 1 |
| Moran, L | 2 |
| Donahue, K | 2 |
| Vanker, N | 1 |
| Diacon, AH | 1 |
| Jeon, D | 1 |
| Zhao, H | 2 |
| Xie, W | 1 |
| Edwards, BD | 1 |
| Edwards, J | 1 |
| Cooper, R | 2 |
| Somayaji, R | 1 |
| Fisher, D | 2 |
| Al Abri, S | 1 |
| Kowada, A | 1 |
| Yaqoubi, F | 1 |
| Al Khalili, S | 1 |
| Ndunda, N | 1 |
| Petersen, E | 1 |
| Ogunsola, OO | 1 |
| Ajayi, O | 1 |
| Ojo, O | 1 |
| Adeyeye, O | 1 |
| Akinro, Y | 1 |
| Oke, O | 1 |
| Adurogbola, AA | 1 |
| Olajide, O | 1 |
| Tiendrebeogo, T | 1 |
| Becquet, R | 1 |
| Niranjan Prabhu, SS | 1 |
| Dibu, J | 1 |
| Wilfred, P | 1 |
| Chaudhary, DK | 1 |
| Jeyaraj, C | 1 |
| Shanthi, M | 1 |
| Aemro, A | 1 |
| Jember, A | 1 |
| Anlay, DZ | 1 |
| Hamada, Y | 1 |
| Figueroa, C | 1 |
| Martín-Sánchez, M | 1 |
| Thomas, BE | 1 |
| Kumar, JV | 1 |
| Chiranjeevi, M | 1 |
| Shah, D | 1 |
| Khandewale, A | 1 |
| Thiruvengadam, K | 2 |
| Haberer, JE | 1 |
| Mayer, KH | 2 |
| Subbaraman, R | 1 |
| Pári, E | 1 |
| Szeder, B | 1 |
| Zsila, F | 1 |
| Swain, SS | 1 |
| Paidesetty, SK | 1 |
| Padhy, RN | 1 |
| Hussain, T | 2 |
| Mayanja-Kizza, H | 3 |
| Savic, R | 2 |
| Gupte, A | 2 |
| Marzinke, MA | 1 |
| Zhang, N | 3 |
| Edward, VA | 1 |
| Wolf, L | 1 |
| Sebe, M | 1 |
| Likoti, M | 1 |
| Fyvie, MJ | 1 |
| Shibambo, I | 1 |
| Beattie, T | 1 |
| Churchyard, GJ | 19 |
| Huynh, J | 1 |
| Thwaites, G | 2 |
| Marais, BJ | 4 |
| Schaaf, HS | 13 |
| Shkurupy, VA | 2 |
| Cherdantseva, LA | 1 |
| Kovner, AV | 1 |
| Troitskii, AV | 2 |
| Bystrova, TN | 1 |
| Starostenko, AA | 1 |
| Mutasa-Apollo, T | 1 |
| Choto, RC | 1 |
| Mabaya, S | 1 |
| Mbito, C | 1 |
| Timire, C | 1 |
| Liang, Z | 1 |
| Robert, M | 3 |
| Todd, J | 3 |
| Ngowi, BJ | 2 |
| Msuya, SE | 2 |
| Ramadhani, A | 3 |
| Sambu, V | 1 |
| Jerry, I | 1 |
| Mujuni, MR | 1 |
| Mahande, MJ | 3 |
| Ngocho, JS | 1 |
| Maokola, W | 3 |
| Wan, L | 1 |
| Wei, JH | 1 |
| Liu, HC | 1 |
| Li, MC | 1 |
| Zhao, LL | 1 |
| Zhao, XQ | 1 |
| Liu, ZG | 1 |
| Wan, KL | 1 |
| Li, GL | 1 |
| Guan, CX | 1 |
| Kim, HY | 2 |
| Bridges, JFP | 2 |
| Schwoebel, V | 2 |
| Koura, KG | 2 |
| Adjobimey, M | 1 |
| Gnanou, S | 1 |
| Wandji, AG | 1 |
| Gody, JC | 1 |
| Delacourt, C | 1 |
| Detjen, A | 1 |
| Masserey, E | 1 |
| Mselatti, P | 1 |
| Roggi, A | 2 |
| Trébucq, A | 3 |
| Gao, R | 1 |
| Guo, Y | 3 |
| Yang, J | 2 |
| Wu, Z | 1 |
| Tan, G | 1 |
| Yu, F | 1 |
| Pieterman, ED | 1 |
| Sarink, MJ | 1 |
| Sala, C | 1 |
| Cole, ST | 4 |
| de Steenwinkel, JEM | 1 |
| Bax, HI | 1 |
| van den Elsen, SHJ | 2 |
| Akkerman, OW | 3 |
| Wessels, M | 1 |
| Jongedijk, EM | 1 |
| Ghimire, S | 1 |
| van der Werf, TS | 3 |
| Bolhuis, MS | 1 |
| Touw, DJ | 2 |
| Galvão, FES | 1 |
| Fonseca, AAD | 1 |
| Pinto, ACG | 1 |
| da Paixão, TP | 1 |
| Albério, CAA | 1 |
| Vieira, JLF | 1 |
| Lam, E | 1 |
| Schaefer, J | 1 |
| Zheng, R | 3 |
| Zhan, T | 1 |
| Kraft, WK | 1 |
| Kort, F | 1 |
| Fournier Le Ray, L | 1 |
| Chauffour, A | 1 |
| Aubry, A | 2 |
| Veziris, N | 5 |
| Mantell, JE | 1 |
| Lebelo, L | 1 |
| Nachman, S | 7 |
| Frederix, K | 1 |
| Maama, LB | 1 |
| El-Sadr, WM | 1 |
| Brown, AK | 1 |
| Aljohani, AKB | 1 |
| Alsalem, FMA | 1 |
| Broadhead, JL | 1 |
| Gill, JH | 1 |
| Sellars, JD | 1 |
| Sensalire, S | 1 |
| Karungi Karamagi Nkolo, E | 1 |
| Nabwire, J | 1 |
| Lawino, A | 1 |
| Kiragga, D | 1 |
| Muhire, M | 1 |
| Kadama, H | 1 |
| Katureebe, C | 1 |
| Namuwenge, P | 1 |
| Musinguzi, J | 1 |
| Calnan, J | 1 |
| Seyoum, D | 1 |
| Grande, SW | 1 |
| Adams, LV | 5 |
| Maseko, TSB | 1 |
| Talbot, EA | 6 |
| deGijsel, D | 1 |
| Mikal, J | 1 |
| Simelane, ZZ | 1 |
| Achili, A | 1 |
| Mkhontfo, M | 1 |
| Haumba, SM | 1 |
| Lyu, M | 1 |
| Zhao, J | 1 |
| Yang, Z | 1 |
| Chong, W | 1 |
| Ming, L | 1 |
| Reisinger, AC | 1 |
| Hermann, J | 1 |
| Vagena, FR | 1 |
| Hackl, G | 1 |
| Eller, P | 1 |
| Jain, N | 1 |
| Kalam, H | 1 |
| Singh, L | 1 |
| Kedia, S | 1 |
| Das, P | 1 |
| Kumar, D | 2 |
| Manu, MS | 1 |
| Mehta, K | 1 |
| Das, M | 1 |
| Balakrishnan, S | 1 |
| Sunil Kumar, M | 1 |
| Rakesh, PS | 1 |
| Sindhu, MP | 1 |
| Valamparampil, MJ | 1 |
| Neena, PS | 1 |
| Desai, U | 1 |
| Doshi, K | 1 |
| Joshi, JM | 1 |
| Singh, VK | 1 |
| Mishra, A | 1 |
| Bark, S | 1 |
| Mani, A | 1 |
| Hunter, RL | 1 |
| Jagannath, C | 1 |
| Khan, A | 3 |
| Petruševska, V | 1 |
| Lasić, K | 1 |
| Mornar, A | 1 |
| Laurent, S | 1 |
| Zakham, F | 1 |
| Bertelli, C | 1 |
| Merz, L | 1 |
| Nicod, L | 1 |
| Mazza-Stalder, J | 1 |
| Greub, G | 1 |
| Jaton, K | 1 |
| Opota, O | 1 |
| Huerta-García, AP | 2 |
| Magaña-Aquino, M | 3 |
| Portales-Pérez, DP | 4 |
| Volynets, GP | 1 |
| Tukalo, MA | 1 |
| Bdzhola, VG | 1 |
| Derkach, NM | 1 |
| Gumeniuk, MI | 1 |
| Tarnavskiy, SS | 1 |
| Yarmoluk, SM | 1 |
| Negi, S | 1 |
| Pahari, S | 1 |
| Bashir, H | 1 |
| Agrewala, JN | 1 |
| Bhaskar, A | 4 |
| Kumari, A | 1 |
| Singh, M | 1 |
| Kumar, S | 6 |
| Dabla, A | 1 |
| Chaturvedi, S | 1 |
| Yadav, V | 1 |
| Chattopadhyay, D | 1 |
| Prakash Dwivedi, V | 1 |
| Khan, MZ | 1 |
| Dwivedi, VP | 2 |
| Nandicoori, VK | 1 |
| Xiao, K | 1 |
| Zhong, L | 3 |
| Dennison, TJ | 1 |
| Smith, JC | 1 |
| Badhan, RKS | 1 |
| Mohammed, AR | 1 |
| Sibandze, DB | 1 |
| Magazi, BT | 1 |
| Malinga, LA | 1 |
| Maningi, NE | 1 |
| Shey, BA | 1 |
| Pasipanodya, JG | 6 |
| Mbelle, NN | 1 |
| Ryu, BH | 1 |
| Baek, EH | 1 |
| Kim, SE | 1 |
| Kim, HJ | 3 |
| Cho, OH | 1 |
| Hong, SI | 1 |
| Do, HJ | 1 |
| Park, CH | 2 |
| Al-Jahdali, H | 1 |
| Bah, B | 1 |
| Belo, M | 1 |
| Cook, VJ | 3 |
| Long, R | 6 |
| Kohli, M | 1 |
| MacLean, E | 1 |
| McCallum, AD | 1 |
| Pertinez, HE | 1 |
| Else, LJ | 1 |
| Dilly-Penchala, S | 1 |
| Chirambo, AP | 1 |
| Sheha, I | 1 |
| Chasweka, M | 1 |
| Chitani, A | 1 |
| Malamba, RD | 1 |
| Meghji, JZ | 1 |
| Gordon, SB | 1 |
| Davies, GR | 4 |
| Khoo, SH | 2 |
| Sloan, DJ | 2 |
| Mwandumba, HC | 1 |
| van Wijk, RC | 1 |
| Hu, W | 1 |
| Dijkema, SM | 1 |
| van den Berg, DJ | 1 |
| Bahi, R | 1 |
| Verbeek, FJ | 1 |
| Spaink, HP | 1 |
| van der Graaf, PH | 1 |
| Krekels, EHJ | 1 |
| Zomorodbakhsh, S | 1 |
| Abbasian, Y | 1 |
| Naghinejad, M | 1 |
| Hazlett, C | 1 |
| Wulf, DA | 1 |
| Luciani-Giacobbe, LC | 1 |
| Lorenzutti, AM | 1 |
| Litterio, NJ | 1 |
| Ramírez-Rigo, MV | 1 |
| Olivera, ME | 1 |
| Gausi, K | 1 |
| Norman, J | 3 |
| Wallis, CL | 1 |
| Nevrekhar, N | 1 |
| Mhembere, T | 1 |
| Tongprasert, F | 2 |
| Hernandez, J | 1 |
| Ashley, D | 1 |
| Cao, R | 2 |
| Abrahem, R | 2 |
| Nguyen, T | 1 |
| To, K | 1 |
| Yegiazaryan, A | 1 |
| Akinwale David, A | 1 |
| Kumar Tiwari, R | 1 |
| Venketaraman, V | 2 |
| Korayem, GB | 1 |
| Alissa, DA | 1 |
| AlSuhaibani, NI | 1 |
| AlSwailem, GS | 1 |
| AlShammari, MA | 1 |
| Yaqoob, I | 1 |
| Aljasser, DS | 1 |
| Almaghrabi, RS | 2 |
| Shi, B | 1 |
| Chen, M | 1 |
| Xiao, S | 1 |
| Tang, W | 1 |
| Qin, C | 1 |
| Cheng, Y | 1 |
| Huang, T | 1 |
| Huang, C | 2 |
| Xu, H | 1 |
| Gonlugur, T | 1 |
| Basol, G | 1 |
| Gonlugur, U | 1 |
| Loftis, AJ | 2 |
| Nematadzira, T | 1 |
| Patil, S | 2 |
| Lespinasse, D | 1 |
| Hunter, OF | 1 |
| Kyesi, F | 1 |
| Ahluwalia, AK | 1 |
| Daffé, ZN | 1 |
| Munseri, P | 1 |
| von Reyn, CF | 5 |
| Sayedi, SM | 1 |
| Seddiq, MK | 2 |
| Rashidi, MK | 1 |
| Qader, G | 2 |
| Ikram, N | 2 |
| Melese, M | 3 |
| Suarez, PG | 4 |
| Ozger, O | 1 |
| Kaplan, N | 1 |
| Hjort, K | 2 |
| Jurén, P | 1 |
| Toro, JC | 1 |
| Andersson, DI | 2 |
| Sandegren, L | 2 |
| Leon, D | 1 |
| Panpradist, N | 1 |
| Lutz, B | 1 |
| Ferguson, O | 1 |
| Jo, Y | 1 |
| Pennington, J | 1 |
| Johnson, K | 1 |
| Dowdy, D | 1 |
| Mukhtar, M | 1 |
| Pallagi, E | 1 |
| Csóka, I | 1 |
| Benke, E | 1 |
| Farkas, Á | 1 |
| Zeeshan, M | 1 |
| Burián, K | 1 |
| Kókai, D | 1 |
| Ambrus, R | 1 |
| Mandalakas, AM | 7 |
| Kay, A | 1 |
| Du Preez, K | 4 |
| Martinez, L | 1 |
| Ronge, L | 1 |
| DiNardo, A | 1 |
| Kirchner, HL | 1 |
| Anton, C | 1 |
| Lemos, CX | 1 |
| Machado, FD | 1 |
| Bernardi, RM | 1 |
| Freitas, AA | 1 |
| Silva, DR | 1 |
| Hernández-González, O | 1 |
| Zarazúa, S | 1 |
| Veytia-Bucheli, JI | 1 |
| González-Chávez, MM | 1 |
| Uresti-Rivera, EE | 1 |
| Pérez-Vázquez, FJ | 1 |
| Ketema, L | 1 |
| Dememew, ZG | 1 |
| Assefa, D | 2 |
| Gudina, T | 1 |
| Kassa, A | 1 |
| Letta, T | 1 |
| Ayele, B | 1 |
| Tadesse, Y | 2 |
| Tegegn, B | 1 |
| Datiko, DG | 1 |
| Negeri, C | 1 |
| Bedru, A | 1 |
| Klinkenberg, E | 3 |
| Imakiire, R | 1 |
| Nishikawa, T | 1 |
| Tominaga, H | 1 |
| Tawaratsumida, H | 1 |
| Imuta, N | 1 |
| Koriyama, T | 1 |
| Nishi, J | 1 |
| Taniguchi, N | 1 |
| Kawano, Y | 1 |
| Lin, X | 1 |
| Fu, Y | 1 |
| Bai, J | 1 |
| Kwak, SH | 1 |
| Choi, JS | 1 |
| Lee, EH | 3 |
| Lee, SH | 5 |
| Leem, AY | 2 |
| Kim, SY | 4 |
| Chung, KS | 1 |
| Kim, EY | 1 |
| Jung, JY | 1 |
| Park, MS | 2 |
| Kim, YS | 4 |
| Chang, J | 2 |
| Kang, YA | 2 |
| Hicks, ND | 1 |
| Giffen, SR | 1 |
| Culviner, PH | 1 |
| Chao, MC | 1 |
| Dulberger, CL | 1 |
| Stanley, S | 1 |
| Brown, J | 2 |
| Sixsmith, J | 1 |
| Wolf, ID | 1 |
| Fortune, SM | 2 |
| Roscoe, C | 1 |
| Lockhart, C | 1 |
| de Klerk, M | 1 |
| Baughman, A | 1 |
| Agolory, S | 1 |
| Gawanab, M | 1 |
| Menzies, H | 1 |
| Jonas, A | 1 |
| Salomo, N | 1 |
| Taffa, N | 1 |
| Lowrance, D | 1 |
| Robsky, K | 1 |
| Tollefson, D | 1 |
| Pevzner, E | 2 |
| Hamunime, N | 1 |
| Mavhunga, F | 1 |
| Mungunda, H | 1 |
| Karanja, M | 2 |
| Kingwara, L | 1 |
| Owiti, P | 2 |
| Kirui, E | 1 |
| Ngari, F | 1 |
| Kiplimo, R | 1 |
| Maina, M | 1 |
| Masini, E | 3 |
| Onyango, E | 2 |
| Ngugi, C | 1 |
| Shrivastava, P | 1 |
| Gautam, L | 1 |
| Sharma, R | 4 |
| Dube, D | 1 |
| Vyas, S | 1 |
| Vyas, SP | 1 |
| Sinyavskaya, AM | 1 |
| Kovner, AM | 1 |
| Einbeck, CO | 1 |
| Hunter, CJ | 1 |
| Yasukawa, K | 1 |
| Ngowi, B | 1 |
| Lawson, L | 1 |
| Mahande, M | 1 |
| Msuya, S | 1 |
| Majidulla, A | 1 |
| Lu, C | 1 |
| Russo, G | 1 |
| Sgroi, G | 1 |
| Parasiliti Palumbo, GA | 1 |
| Pennisi, M | 1 |
| Juarez, MA | 1 |
| Cardona, PJ | 8 |
| Motta, S | 1 |
| Walker, KB | 1 |
| Fichera, E | 1 |
| Viceconti, M | 1 |
| Pappalardo, F | 1 |
| Kay, AW | 2 |
| Thivalapill, N | 1 |
| Skinner, D | 1 |
| Dube, GS | 2 |
| Dlamini, N | 1 |
| Mzileni, B | 1 |
| Fuentes, P | 1 |
| Ustero, P | 1 |
| Park, JW | 1 |
| Curtis, JR | 1 |
| Lee, H | 2 |
| Lee, JK | 1 |
| Song, YW | 1 |
| Lee, EB | 1 |
| Nabisere, R | 1 |
| Arinaitwe, A | 1 |
| Muyise, R | 1 |
| Asienzo, J | 1 |
| Anguzu, G | 1 |
| Owarwo, N | 1 |
| Lwanga, I | 1 |
| Lamorde, M | 4 |
| Laker, E | 1 |
| Ross, JM | 1 |
| Rangaka, MX | 5 |
| Walker, AS | 3 |
| Shapiro, AE | 2 |
| Thomas, KK | 1 |
| Eholie, S | 3 |
| Gabillard, D | 4 |
| Ford, N | 2 |
| Williams, BG | 2 |
| Gil, H | 1 |
| Margaryan, H | 1 |
| Azamat, I | 1 |
| Ziba, B | 1 |
| Bayram, H | 2 |
| Nazirov, P | 1 |
| Gomez, D | 1 |
| Singh, J | 1 |
| Zayniddin, S | 1 |
| Parpieva, N | 2 |
| Achar, J | 1 |
| Svensson, E | 1 |
| Folkvardsen, DB | 1 |
| Lillebaek, T | 2 |
| Buck, WC | 1 |
| Nguyen, H | 1 |
| Siapka, M | 1 |
| Basu, L | 1 |
| Greenberg Cowan, J | 2 |
| De Deus, MI | 1 |
| Gleason, M | 1 |
| Ferreira, F | 1 |
| Xavier, C | 1 |
| Jose, B | 1 |
| Muthemba, C | 1 |
| Simione, B | 1 |
| Kerndt, P | 1 |
| Millones, AK | 1 |
| Galea, JT | 1 |
| Puma, D | 1 |
| Jimenez, J | 2 |
| Lecca, L | 2 |
| Tükenmez, H | 1 |
| Sarkar, S | 1 |
| Anoosheh, S | 1 |
| Kruchanova, A | 1 |
| Edström, I | 1 |
| Harrison, GA | 1 |
| Stallings, CL | 1 |
| Almqvist, F | 1 |
| Larsson, C | 1 |
| Greybe, L | 1 |
| Morrison, JL | 1 |
| Fredj, NB | 1 |
| Romdhane, HB | 1 |
| Woillard, JB | 1 |
| Chickaid, M | 1 |
| Fadhel, NB | 1 |
| Chadly, Z | 1 |
| Chaabane, A | 3 |
| Boughattas, N | 1 |
| Aouam, K | 3 |
| Fiore-Gartland, A | 1 |
| Mulenga, H | 3 |
| Kimbung Mbandi, S | 1 |
| Borate, B | 1 |
| Hadley, K | 1 |
| Hikuam, C | 1 |
| Kaskar, M | 1 |
| Musvosvi, M | 1 |
| Bilek, N | 1 |
| Self, S | 1 |
| Erasmus, M | 1 |
| Jaxa, L | 1 |
| Raphela, R | 1 |
| Innes, C | 2 |
| Brumskine, W | 1 |
| Hiemstra, A | 1 |
| Malherbe, ST | 1 |
| Hassan-Moosa, R | 1 |
| Tameris, M | 2 |
| Walzl, G | 2 |
| Nizami, I | 1 |
| Alameer, R | 1 |
| Alshehri, N | 1 |
| Almohaizeie, A | 1 |
| Alrajhi, AA | 2 |
| Omrani, AS | 1 |
| Boeree, MJ | 3 |
| Weiner, M | 3 |
| Heinrich, N | 2 |
| Bliven-Sizemore, E | 2 |
| Hoelscher, M | 2 |
| Whitworth, W | 1 |
| Morlock, G | 2 |
| Posey, J | 1 |
| Mac Kenzie, W | 1 |
| Choi, G | 1 |
| Ha, JE | 1 |
| Kim, ES | 1 |
| Park, JS | 3 |
| Lee, K | 1 |
| Lee, JH | 3 |
| Lee, JI | 1 |
| Rao, KU | 1 |
| Henderson, DI | 1 |
| Krishnan, N | 1 |
| Puthia, M | 1 |
| Glegola-Madejska, I | 1 |
| Brive, L | 1 |
| Bjarnemark, F | 1 |
| Millqvist Fureby, A | 1 |
| Tenland, E | 1 |
| Sturegård, E | 2 |
| Robertson, BD | 1 |
| Godaly, G | 1 |
| Wiriyachai, T | 1 |
| Boonsathorn, S | 1 |
| Apiwattanakul, N | 1 |
| Assawawiroonhakarn, S | 1 |
| Amisi, JA | 1 |
| Carter, EJ | 3 |
| Szkwarko, D | 2 |
| Alshaikheid, M | 1 |
| Ben Fredj, N | 1 |
| Hannachi, I | 1 |
| Kolsi, N | 1 |
| Ben Fadhel, N | 1 |
| Kerkeni, E | 1 |
| Ben Romdhane, H | 1 |
| Koubaa, J | 1 |
| Chadli, Z | 1 |
| Sturkenboom, MGG | 1 |
| Märtson, AG | 1 |
| Aarnoutse, RE | 7 |
| Orazulike, N | 1 |
| Sharma, JB | 1 |
| Umeora, OUJ | 1 |
| Gashaw, F | 1 |
| Erko, B | 1 |
| Mekonnen, Y | 1 |
| Yenew, B | 1 |
| Amare, M | 1 |
| Gumi, B | 1 |
| Ameni, G | 2 |
| Kaptan, Y | 1 |
| Suner, A | 1 |
| Taş, MN | 1 |
| Oksel, F | 1 |
| Aksu, K | 1 |
| Sayiner, A | 2 |
| Khan, H | 1 |
| Nasir, K | 1 |
| Fareed, U | 1 |
| Shahbaz, S | 1 |
| Shiraishi, RW | 1 |
| Kirking, HL | 1 |
| Nyirenda, RK | 1 |
| Sayfutdinov, Z | 1 |
| Nabirova, D | 1 |
| Gadoev, J | 1 |
| Turaev, L | 2 |
| Sultanov, S | 1 |
| Alaverdyan, S | 1 |
| Teng, TL | 1 |
| Huang, HR | 2 |
| Chu, NH | 1 |
| Diacon, A | 1 |
| Hogg, E | 2 |
| Urbanowski, M | 1 |
| De Jager, V | 1 |
| Fletcher, CV | 5 |
| Bishai, W | 2 |
| Singh, AK | 4 |
| Verma, RK | 3 |
| Mukker, JK | 1 |
| Yadav, AB | 4 |
| Muttil, P | 2 |
| Mohan, M | 3 |
| Agrawal, AK | 2 |
| Dwivedi, AK | 1 |
| Gupta, P | 8 |
| Gupta, UD | 6 |
| Mani, U | 1 |
| Chaudhari, BP | 1 |
| Murthy, RC | 1 |
| Bhadauria, S | 1 |
| Rath, SK | 1 |
| Misra, A | 6 |
| Dippenaar, A | 1 |
| Beylis, N | 1 |
| van Helden, PD | 5 |
| Zegarra-Chapoñan, R | 1 |
| Bonadonna, LV | 1 |
| Martina-Chávez, MB | 1 |
| Zeladita-Huaman, J | 1 |
| Weyenga, H | 1 |
| Katana, AK | 1 |
| Ng Ang A, LW | 1 |
| Sirengo, M | 1 |
| Ondondo, RO | 1 |
| Wambugu, C | 1 |
| Waruingi, RN | 1 |
| Muthee, RW | 1 |
| Ngugi, EW | 1 |
| Shah, NS | 8 |
| Pathmanathan, I | 1 |
| Maloney, S | 1 |
| De Cock, KM | 6 |
| Takamiya, M | 1 |
| Takarinda, K | 1 |
| Balachandra, S | 1 |
| Godfrey, M | 1 |
| Radin, E | 1 |
| Hakim, A | 2 |
| Pearson, ML | 1 |
| Choto, R | 1 |
| Rogers, JH | 1 |
| Komba, FF | 1 |
| Frumence, G | 1 |
| Mao, L | 1 |
| Liu, C | 1 |
| Ning, B | 1 |
| Bao, D | 1 |
| Fan, J | 2 |
| Lyon, CJ | 1 |
| Sun, Z | 2 |
| Mitchell, CD | 2 |
| Hu, TY | 1 |
| Kwarisiima, D | 2 |
| Camlin, CS | 1 |
| Nikonenko, BV | 4 |
| Bocharova, IV | 2 |
| Lepekha, LN | 1 |
| Osorio-López, EA | 1 |
| Vilar-Compte, D | 1 |
| García-Tirado, J | 1 |
| Martin-Onraet, A | 1 |
| Binkhamis, KM | 1 |
| Bahatheg, MA | 1 |
| Altahan, FA | 1 |
| Alwakeel, SS | 1 |
| Almutairi, KA | 1 |
| Alsaeed, AF | 1 |
| Alkadi, DA | 1 |
| Alshafai, HA | 1 |
| Almajid, FM | 1 |
| Barry, MA | 3 |
| Norouzi, F | 1 |
| Moghim, S | 1 |
| Farzaneh, S | 1 |
| Fazeli, H | 1 |
| Salehi, M | 1 |
| Nasr Esfahani, B | 1 |
| Kalsum, S | 1 |
| Andersson, B | 1 |
| Das, J | 1 |
| Schön, T | 2 |
| Lerm, M | 1 |
| Belay, M | 1 |
| Tulu, B | 1 |
| Younis, S | 1 |
| Jolliffe, DA | 1 |
| Tayachew, D | 1 |
| Manwandu, H | 1 |
| Abozen, T | 1 |
| Tirfie, EA | 1 |
| Tegegn, M | 1 |
| Zewude, A | 1 |
| Forrest, S | 1 |
| Mayito, J | 1 |
| Huggett, JF | 1 |
| Jones, GM | 1 |
| O'Sullivan, DM | 1 |
| Martineau, HM | 1 |
| Noursadeghi, M | 1 |
| Chandran, A | 1 |
| Harris, KA | 1 |
| Nikolayevskyy, V | 4 |
| Demaret, J | 1 |
| Berg, S | 1 |
| Vordermeier, M | 1 |
| Balcha, TT | 1 |
| Aseffa, A | 1 |
| Reece, ST | 1 |
| Martineau, AR | 1 |
| Mollan, KR | 1 |
| Eron, JJ | 1 |
| Krajewski, TJ | 1 |
| Painter, W | 1 |
| Duke, ER | 1 |
| Morse, CG | 1 |
| Goecker, EA | 1 |
| Premkumar, L | 1 |
| Wolfe, CR | 1 |
| Szewczyk, LJ | 1 |
| Alabanza, PL | 1 |
| Degli-Angeli, EJ | 1 |
| Brown, AJ | 1 |
| Dragavon, JA | 1 |
| Won, JJ | 1 |
| Keys, J | 1 |
| Hudgens, MG | 1 |
| Fang, L | 1 |
| Wohl, DA | 1 |
| Cohen, MS | 1 |
| Baric, RS | 1 |
| Coombs, RW | 1 |
| Sheahan, TP | 1 |
| Fischer, WA | 1 |
| Li, B | 1 |
| Hong, S | 1 |
| Li, L | 2 |
| Eltayeb, O | 1 |
| Dong, C | 1 |
| Shuang, S | 1 |
| He, H | 1 |
| Li, Q | 3 |
| Shu, C | 1 |
| Sekar, L | 5 |
| Reddy, D | 1 |
| Chitra, A | 1 |
| Poornagangadevi, N | 1 |
| Selvaraj, M | 1 |
| Mothi, SN | 1 |
| Nandagopal, K | 1 |
| Vennila, S | 1 |
| Tamizhselvan, M | 1 |
| Maheshmanisha, J | 1 |
| Agarwal, U | 1 |
| Rewari, BB | 1 |
| Swaminathan, S | 21 |
| Francis, J | 2 |
| Kendall, MA | 2 |
| Firnhaber, C | 1 |
| Jang, TW | 1 |
| Oh, JY | 1 |
| Lee, HK | 3 |
| Park, HK | 1 |
| Ghim, JL | 1 |
| Park, Y | 1 |
| Phuong, NTT | 1 |
| Golub, J | 3 |
| Peetluk, LS | 1 |
| Rebeiro, PF | 1 |
| Ridolfi, FM | 1 |
| Andrade, BB | 1 |
| Cordeiro-Santos, M | 1 |
| Calvacante, S | 1 |
| Figueiredo, MC | 1 |
| Rolla, VC | 2 |
| Polat, E | 1 |
| Senel, S | 1 |
| Kim, HW | 1 |
| Shin, AY | 1 |
| Ha, JH | 1 |
| Ahn, JH | 1 |
| Kang, HS | 1 |
| Kim, JS | 1 |
| Maokola, WM | 1 |
| Sandoval, M | 1 |
| Mtetwa, G | 1 |
| Mkhabela, M | 1 |
| Ndlovu, B | 1 |
| Devezin, T | 1 |
| Sikhondze, W | 1 |
| Vambe, D | 1 |
| Sibanda, J | 1 |
| Stevens, RH | 1 |
| Lukhele, B | 1 |
| Mathad, JS | 1 |
| Britto, P | 1 |
| Jayachandran, P | 1 |
| Townley, E | 1 |
| Popson, S | 1 |
| Langat, D | 2 |
| Chalermchockcharoentkit, A | 1 |
| Kamthunzi, P | 1 |
| Dodani, SK | 1 |
| Nasim, A | 1 |
| Aziz, T | 1 |
| Naqvi, A | 3 |
| Lunn, AM | 1 |
| Unnikrishnan, M | 1 |
| Perrier, S | 1 |
| Robinson, JA | 1 |
| Angira, F | 1 |
| Omoz-Oarhe, A | 2 |
| Samaneka, WP | 1 |
| Tousif, S | 1 |
| Devi, A | 1 |
| Negi, K | 1 |
| Moitra, B | 1 |
| Ranganathan, A | 1 |
| Das, G | 1 |
| Zimba, KM | 1 |
| van der Zalm, M | 1 |
| Kabengele, C | 1 |
| M'hango, H | 1 |
| Mweemba, D | 1 |
| Malumani, M | 1 |
| Berhanu, RH | 1 |
| Sgarabotto, D | 1 |
| Fasolato, S | 1 |
| Vianello, F | 1 |
| Vittadello, F | 1 |
| Boccagni, P | 1 |
| Ferrarese, A | 1 |
| Burra, P | 2 |
| Angeli, P | 1 |
| Cillo, U | 2 |
| Villegas, L | 1 |
| Huamán, M | 1 |
| Sterling, T | 2 |
| Seas, C | 2 |
| Manning, AJ | 1 |
| Ovechkina, Y | 1 |
| McGillivray, A | 1 |
| Flint, L | 1 |
| Roberts, DM | 1 |
| Parish, T | 1 |
| Bahi, GA | 1 |
| Boyvin, L | 1 |
| Méité, S | 1 |
| M'Boh, GM | 1 |
| Yeo, K | 1 |
| N'Guessan, KR | 2 |
| Bidié, AD | 1 |
| Djaman, AJ | 1 |
| Maharaj, B | 1 |
| Arscott-Mills, T | 1 |
| Masole, L | 1 |
| Ncube, R | 1 |
| Steenhoff, AP | 1 |
| Ruíz de Zárate, B | 1 |
| Gomez-Pastrana, D | 1 |
| Pérez-Escolano, E | 1 |
| Aragón Fernández, C | 1 |
| López Prieto, MD | 1 |
| Mashabela, F | 1 |
| Hoffmann, JD | 1 |
| Shembe, S | 1 |
| Velaphi, S | 2 |
| Lala, SG | 1 |
| Baek, SO | 1 |
| Ko, HS | 1 |
| Han, HH | 1 |
| van der Heijden, YF | 1 |
| Karim, F | 2 |
| Mufamadi, G | 1 |
| Zako, L | 1 |
| Chinappa, T | 1 |
| Maruri, F | 1 |
| Moosa, MS | 1 |
| Pym, AS | 4 |
| Llerena, C | 2 |
| Zabaleta, A | 2 |
| Valbuena, A | 1 |
| Murcia, M | 1 |
| Castro, C | 1 |
| Ricardo, A | 1 |
| Puerto, G | 1 |
| Conti, A | 2 |
| Piaserico, S | 1 |
| Gisondi, P | 1 |
| Odorici, G | 1 |
| Galdo, G | 1 |
| Lasagni, C | 1 |
| Pellacani, G | 1 |
| Saito, K | 1 |
| Warrier, T | 1 |
| Somersan-Karakaya, S | 1 |
| Kaminski, L | 1 |
| Mi, J | 1 |
| Jiang, X | 1 |
| Park, S | 2 |
| Shigyo, K | 1 |
| Gold, B | 1 |
| Roberts, J | 1 |
| Weber, E | 1 |
| Nathan, CF | 1 |
| Hamim, A | 1 |
| Sayedi, M | 1 |
| Rashidi, M | 1 |
| Manzoor, L | 1 |
| Ramesh, K | 2 |
| Haribabu, H | 1 |
| Omar, SM | 1 |
| Maziad, NA | 1 |
| El-Tantawy, NM | 1 |
| Bunyasi, EW | 1 |
| Luabeya, AKK | 1 |
| Geldenhuys, H | 2 |
| Landry, BS | 1 |
| Schmidt, BM | 1 |
| Hanekom, WA | 2 |
| Mahomed, H | 2 |
| McShane, H | 3 |
| Rodrigues, S | 1 |
| Cavaco, JS | 1 |
| Pontes, JF | 1 |
| Rosa da Costa, AM | 1 |
| Buttini, F | 1 |
| Shayo, GA | 1 |
| Chitama, D | 1 |
| Moshiro, C | 1 |
| Aboud, S | 2 |
| Bakari, M | 6 |
| Mugusi, F | 3 |
| Larson, A | 1 |
| Gleeson, F | 1 |
| Rajan, E | 1 |
| Huang, SF | 1 |
| Chen, MH | 1 |
| Wang, FD | 1 |
| Tsai, CY | 1 |
| Fung, CP | 1 |
| Su, WJ | 1 |
| Kim, SK | 1 |
| Du Plessis, L | 2 |
| Carr, C | 1 |
| Sasse, S | 1 |
| Yuengling, KA | 1 |
| Azzawi, S | 1 |
| Deya, RW | 1 |
| Masese, LN | 1 |
| Jaoko, W | 1 |
| Mandaliya, KN | 1 |
| Overbaugh, J | 1 |
| McClelland, RS | 1 |
| Sampaio, PCM | 1 |
| Lira, YG | 1 |
| Ribeiro, HYU | 1 |
| de Paula Moreira, F | 1 |
| Gadelha, MSM | 1 |
| da Cruz, SFS | 1 |
| Pal, SK | 1 |
| Pandey, D | 1 |
| Fakir, NA | 1 |
| Rathod, S | 1 |
| Sinha, D | 1 |
| Sinha, P | 1 |
| Periera, M | 1 |
| Balgam, S | 1 |
| Sekar, G | 1 |
| UmaDevi, KR | 1 |
| Anupurba, S | 3 |
| Nema, V | 1 |
| Havlicek, J | 1 |
| Rivera-Milla, E | 1 |
| Slickers, P | 1 |
| Andres, S | 1 |
| Feuerriegel, S | 1 |
| Niemann, S | 3 |
| Merker, M | 2 |
| Labugger, I | 1 |
| Saikia, UN | 1 |
| Verma, I | 2 |
| Kumar, AKH | 3 |
| Chandrasekaran, V | 6 |
| Kumar, AK | 4 |
| Kawaskar, M | 1 |
| Roth, DZ | 1 |
| Krajden, M | 1 |
| Tang, P | 2 |
| Tram, KH | 2 |
| Mwangwa, F | 2 |
| Atukunda, M | 2 |
| Owaraganise, A | 2 |
| Ayieko, J | 3 |
| Plenty, A | 1 |
| Kwariisima, D | 1 |
| Clark, TD | 2 |
| Petersen, ML | 2 |
| Charlebois, ED | 2 |
| Marquez, C | 2 |
| Zhang, ZG | 1 |
| Wu, JF | 1 |
| Wang, LQ | 1 |
| Han, L | 1 |
| Ma, SB | 1 |
| Gao, TJ | 1 |
| Mahlalela, N | 1 |
| Pasipamire, M | 1 |
| Ginindza, S | 1 |
| Calnan, M | 1 |
| Haumba, S | 1 |
| Okwara, FN | 1 |
| Oyore, JP | 1 |
| Were, FN | 1 |
| Gwer, S | 1 |
| Lee, SD | 1 |
| Kim, WS | 1 |
| Danyuttapolchai, J | 2 |
| Kittimunkong, S | 2 |
| Nateniyom, S | 2 |
| Painujit, S | 1 |
| Klinbuayaem, V | 1 |
| Maipanich, N | 1 |
| Maokamnerd, Y | 1 |
| Whitehead, S | 3 |
| Kanphukiew, A | 1 |
| Monkongdee, P | 2 |
| Martin, M | 1 |
| Taira, J | 1 |
| Morita, K | 1 |
| Kawashima, S | 1 |
| Umei, T | 1 |
| Baba, H | 2 |
| Maruoka, T | 1 |
| Komatsu, H | 1 |
| Sakamoto, H | 1 |
| Sacchettini, JC | 1 |
| Cowger, TL | 1 |
| Thai, LH | 1 |
| Duong, BD | 1 |
| Nhung, NV | 2 |
| Nhan, DT | 1 |
| Thoa, CK | 1 |
| Khanh, VT | 1 |
| Yen, NTB | 1 |
| Ngoc, DV | 1 |
| Thinh, T | 1 |
| Pevzner, ES | 1 |
| Cagatay, T | 3 |
| Bingol, Z | 1 |
| Kıyan, E | 1 |
| Yegin, Z | 1 |
| Okumus, G | 1 |
| Arseven, O | 1 |
| Erkan, F | 1 |
| Gulbaran, Z | 2 |
| Erelel, M | 2 |
| Ece, T | 3 |
| Cagatay, P | 2 |
| Kılıçaslan, Z | 3 |
| Chan, SL | 2 |
| Chua, APG | 1 |
| Aminkeng, F | 1 |
| Chee, CBE | 1 |
| Jin, S | 1 |
| Loh, M | 1 |
| Gan, SH | 1 |
| Wang, YT | 1 |
| Brunham, LR | 1 |
| Unissa, AN | 3 |
| Dusthackeer, VNA | 1 |
| Kumar, MP | 1 |
| Nagarajan, P | 1 |
| Sukumar, S | 2 |
| Kumari, VI | 1 |
| Lakshmi, AR | 2 |
| Hanna, LE | 5 |
| Zhang, ZT | 1 |
| Wang, DB | 1 |
| Li, CY | 1 |
| Deng, JY | 1 |
| Zhang, JB | 1 |
| Bi, LJ | 1 |
| Zhang, XE | 1 |
| Famewo, EB | 1 |
| Clarke, AM | 1 |
| Wiid, I | 2 |
| Ngwane, A | 1 |
| van Helden, P | 2 |
| Afolayan, AJ | 1 |
| Salindri, AD | 1 |
| Sales, RF | 1 |
| DiMiceli, L | 1 |
| Schechter, MC | 1 |
| Kempker, RR | 1 |
| Magee, MJ | 2 |
| Sriraman, K | 1 |
| Saranath, D | 1 |
| Chatterjee, A | 1 |
| Quan, TP | 1 |
| Bawa, Z | 1 |
| Foster, D | 1 |
| Walker, T | 1 |
| Del Ojo Elias, C | 1 |
| Rathod, P | 1 |
| Bradley, P | 2 |
| Mowbray, J | 1 |
| Wyllie, DH | 1 |
| Peto, TEA | 2 |
| Smith, EG | 2 |
| Sellami, M | 1 |
| Mnejja, M | 1 |
| Charfi, S | 1 |
| Ghorbel, A | 1 |
| Addo, KK | 1 |
| Addo, SO | 1 |
| Mensah, GI | 1 |
| Mosi, L | 1 |
| Bonsu, FA | 1 |
| Kagal, A | 3 |
| Nimkar, S | 2 |
| Koli, H | 2 |
| Khwaja, S | 2 |
| Bharadwaj, R | 2 |
| Gerona, R | 1 |
| Wen, A | 1 |
| Kumar, H | 2 |
| Bacchetti, P | 1 |
| Gupte, N | 3 |
| Motta, I | 2 |
| Calcagno, A | 2 |
| Bonora, S | 1 |
| Freiman, JM | 1 |
| Ellner, JJ | 3 |
| Pertinez, H | 1 |
| Alameda-Martin, L | 1 |
| Harrison, T | 1 |
| Coates, A | 1 |
| Starke, J | 1 |
| Guiastrennec, B | 1 |
| Karlsson, MO | 1 |
| Gangadevi, NP | 3 |
| Charan, J | 1 |
| Goyal, JP | 1 |
| Reljic, T | 1 |
| Emmanuel, P | 1 |
| Patel, A | 1 |
| Moh, R | 3 |
| N'takpé, JB | 1 |
| Ouattara, E | 3 |
| Le Carrou, J | 2 |
| Bohoussou, F | 1 |
| Messou, E | 2 |
| Cruz, AT | 4 |
| Starke, JR | 5 |
| van Heerden, A | 1 |
| Schaafsma, TT | 1 |
| Hughes, JP | 1 |
| Baeten, JM | 1 |
| van Rooyen, H | 1 |
| Tumwesigye, E | 1 |
| Celum, CL | 1 |
| Ngongondo, M | 1 |
| Hughes, MD | 1 |
| Bisson, GP | 3 |
| Kumwenda, J | 2 |
| Lavenberg, JA | 1 |
| Torres, TS | 1 |
| Nyirenda, M | 2 |
| Kidonge, KK | 1 |
| Hosseinipour, MC | 2 |
| Sikri, K | 1 |
| Duggal, P | 1 |
| Kumar, C | 1 |
| Batra, SD | 1 |
| Vashist, A | 1 |
| Tripathi, K | 1 |
| Sethi, T | 1 |
| Tyagi, JS | 1 |
| Martin, IW | 1 |
| Dionne, K | 1 |
| Deml, SM | 1 |
| Wengenack, NL | 2 |
| Parrish, NM | 1 |
| Ahmed, A | 1 |
| Mekonnen, D | 1 |
| Shiferaw, AM | 1 |
| Belayneh, F | 1 |
| Yenit, MK | 1 |
| Cao, J | 1 |
| Mi, Y | 1 |
| Shi, C | 2 |
| Bian, Y | 1 |
| Liu, L | 1 |
| Miao, L | 1 |
| Lempens, P | 1 |
| Meehan, CJ | 1 |
| Vandelannoote, K | 1 |
| Fissette, K | 1 |
| de Rijk, P | 2 |
| Draper, HR | 2 |
| McSherry, G | 4 |
| Krezinski, E | 1 |
| Coetzee, J | 2 |
| Mitchell, C | 4 |
| van der Linde, M | 2 |
| Battini, S | 1 |
| Mannava, MKC | 1 |
| Nangia, A | 1 |
| Adane, K | 1 |
| Spigt, M | 1 |
| Dinant, GJ | 1 |
| Alvarez-Uria, G | 1 |
| Midde, M | 1 |
| Choko, AT | 1 |
| Khundi, M | 2 |
| Sambakunsi, R | 1 |
| Ngwira, LG | 2 |
| Webb, EL | 1 |
| Marx, FM | 1 |
| Yaesoubi, R | 1 |
| Salomon, JA | 2 |
| Bilinski, A | 1 |
| Beyers, N | 4 |
| AlMatar, M | 1 |
| Makky, EA | 1 |
| Var, I | 1 |
| Kayar, B | 1 |
| Köksal, F | 1 |
| O'Donnell, M | 1 |
| Page-Shipp, L | 1 |
| Lewis, JJ | 8 |
| Velen, K | 1 |
| Senoge, S | 1 |
| Zishiri, E | 1 |
| Popane, F | 3 |
| Chihota, VN | 4 |
| Clark, D | 1 |
| Charalambous, S | 8 |
| Valentini, D | 1 |
| Zumla, A | 5 |
| Maeurer, M | 2 |
| Boffa, J | 1 |
| Mayan, M | 1 |
| Ndlovu, S | 1 |
| Mhlaba, T | 1 |
| Williamson, T | 1 |
| Sauve, R | 1 |
| Gumbo, T | 8 |
| Frigati, L | 1 |
| Archary, M | 1 |
| Penazzato, M | 2 |
| Gao, S | 1 |
| Wang, Z | 2 |
| Xie, X | 1 |
| You, C | 1 |
| Xi, Y | 1 |
| Baker, BJ | 1 |
| Shin, SS | 3 |
| Modongo, C | 2 |
| Zetola, NM | 2 |
| Phologolo, T | 1 |
| Kestler, M | 2 |
| Ho-Foster, A | 1 |
| Little, KM | 1 |
| Nkhoma, A | 1 |
| Makombe, S | 1 |
| Migliori, GB | 7 |
| Sotgiu, G | 3 |
| Johnson, KT | 1 |
| Sohn, H | 2 |
| Atwine, D | 1 |
| Bonnet, M | 6 |
| Taburet, AM | 3 |
| Jung, BH | 1 |
| Park, JI | 1 |
| Lee, SG | 1 |
| Chen, KY | 1 |
| Huang, L | 2 |
| Fu, DJ | 1 |
| Kaya, F | 1 |
| Rakhilin, N | 1 |
| Nazarova, EV | 1 |
| Bu, P | 1 |
| Russell, DG | 2 |
| Alghamdi, WA | 1 |
| Al-Shaer, MH | 1 |
| Pienaar, E | 3 |
| Linderman, JJ | 3 |
| Kirschner, DE | 3 |
| Das, SK | 2 |
| Anjum, R | 1 |
| Agrawal, S | 2 |
| Mallik, D | 1 |
| Esteves, LS | 1 |
| Vasconcellos, SEG | 1 |
| Vargas, A | 1 |
| Ferreira Junior, SLM | 1 |
| Ribeiro, MO | 2 |
| Rodenbusch, R | 1 |
| Suffys, PN | 2 |
| Rossetti, MLR | 1 |
| Weldegebreal, T | 1 |
| Ahmed, I | 1 |
| Muhiye, A | 1 |
| Belete, S | 1 |
| Bekele, A | 1 |
| Kaba, M | 1 |
| Doss C, GP | 1 |
| Kumar, T | 1 |
| Corrêa Barros, LP | 1 |
| Del Rio, KP | 1 |
| Carvalho, TDSC | 1 |
| Pinto, MDCFR | 1 |
| de Moura, KCG | 1 |
| Halicki, PCB | 1 |
| Ramos, DF | 1 |
| da Silva, PEA | 1 |
| Genestet, C | 1 |
| Bernard-Barret, F | 1 |
| Hodille, E | 1 |
| Ginevra, C | 1 |
| Ader, F | 1 |
| Goutelle, S | 2 |
| Lina, G | 1 |
| Dumitrescu, O | 1 |
| Russom, M | 1 |
| Debesai, M | 1 |
| Zeregabr, M | 1 |
| Berhane, A | 1 |
| Tekeste, T | 1 |
| Teklesenbet, T | 1 |
| Atta, A | 1 |
| Fahmy, S | 1 |
| Rizk, O | 1 |
| Mahran, MA | 1 |
| Labouta, IM | 1 |
| Hakkimane, SS | 1 |
| Shenoy, VP | 1 |
| Gaonkar, SL | 1 |
| Bairy, I | 1 |
| Guru, BR | 1 |
| Zuur, MA | 2 |
| van Asselt, ADI | 1 |
| van 't Boveneind-Vrubleuskaya, N | 1 |
| Aleksa, A | 1 |
| Postma, MJ | 1 |
| Alffenaar, JWC | 1 |
| O'Connell, N | 1 |
| Rhines, AS | 2 |
| Feldman, MW | 2 |
| Bendavid, E | 2 |
| Teskey, G | 1 |
| Islamoglu, H | 1 |
| Munjal, S | 1 |
| Gyurjian, K | 1 |
| Colangeli, R | 1 |
| Jedrey, H | 1 |
| Connell, R | 1 |
| Ma, S | 2 |
| Chippada Venkata, UD | 1 |
| Chakravorty, S | 1 |
| Sizemore, EE | 1 |
| Diem, L | 1 |
| Okwera, A | 4 |
| Boom, WH | 4 |
| Mac Kenzie, WR | 1 |
| Alland, D | 2 |
| Nsengiyumva, NP | 1 |
| Mappin-Kasirer, B | 1 |
| Bastos, M | 1 |
| Hu, L | 1 |
| Yang, M | 2 |
| He, ZG | 1 |
| Han, Y | 1 |
| Xia, S | 1 |
| Lin, Y | 2 |
| Zachariah, R | 2 |
| Cohen, DB | 1 |
| Meghji, J | 1 |
| Squire, SB | 3 |
| Chirehwa, MT | 1 |
| Affolabi, D | 1 |
| Bah-Sow, O | 1 |
| Merle, C | 1 |
| Allix-Béguec, C | 1 |
| Arandjelovic, I | 1 |
| Bi, L | 1 |
| Beckert, P | 1 |
| Cancino-Muñoz, I | 1 |
| Caulfield, MJ | 1 |
| Clifton, DA | 1 |
| Comas, I | 1 |
| De Filippo, MR | 1 |
| de Neeling, H | 2 |
| Drobniewski, FA | 4 |
| Faksri, K | 1 |
| Farhat, MR | 1 |
| Fleming, J | 1 |
| Fowler, P | 1 |
| Fowler, TA | 1 |
| Gao, Q | 1 |
| Gardy, J | 1 |
| Gascoyne-Binzi, D | 1 |
| Gibertoni-Cruz, AL | 1 |
| Gil-Brusola, A | 1 |
| Golubchik, T | 1 |
| Gonzalo, X | 1 |
| He, G | 1 |
| Guthrie, JL | 1 |
| Hunt, M | 1 |
| Ismail, N | 2 |
| Johnston, J | 2 |
| Khanzada, FM | 1 |
| Khor, CC | 1 |
| Kohl, TA | 1 |
| Kong, C | 1 |
| Lipworth, S | 1 |
| Maphalala, G | 1 |
| Martinez, E | 1 |
| Miotto, P | 2 |
| Murray, M | 1 |
| Omar, SV | 2 |
| Ong, RT | 1 |
| Posey, JE | 1 |
| Prammananan, T | 1 |
| Pym, A | 2 |
| Rodrigues, M | 1 |
| Rodwell, T | 1 |
| Rossolini, GM | 1 |
| Sánchez Padilla, E | 1 |
| Schito, M | 1 |
| Shendure, J | 1 |
| Sintchenko, V | 1 |
| Sloutsky, A | 2 |
| Snyder, M | 1 |
| Soetaert, K | 1 |
| Starks, AM | 2 |
| Supply, P | 2 |
| Suriyapol, P | 1 |
| Tahseen, S | 1 |
| Teo, YY | 1 |
| Thuong, TNT | 1 |
| Tortoli, E | 2 |
| van Soolingen, D | 10 |
| Wilcox, M | 1 |
| Wyllie, D | 1 |
| Zhu, B | 1 |
| Azman, AS | 2 |
| Yew, WW | 5 |
| Chang, KC | 6 |
| Leung, CC | 7 |
| Chan, DP | 1 |
| Vilchèze, C | 2 |
| Yeconia, A | 1 |
| Nicodemu, I | 1 |
| Augustino, D | 1 |
| Kivuyo, S | 1 |
| Mfinanga, S | 1 |
| Zagurski, T | 1 |
| Kibiki, GS | 2 |
| Mmbaga, B | 1 |
| Magombedze, G | 1 |
| Srivastava, S | 2 |
| Deshpande, D | 1 |
| Visser, ME | 2 |
| Chigutsa, E | 2 |
| Porter, BW | 1 |
| Venkatappa, TK | 1 |
| Indumathi, CK | 1 |
| Sethuraman, A | 1 |
| Jain, S | 1 |
| Krishnamurthy, S | 1 |
| Capodagli, GC | 1 |
| Awasthi, D | 2 |
| Shrestha, R | 1 |
| Maharaja, K | 1 |
| Sukheja, P | 1 |
| Li, SG | 1 |
| Inoyama, D | 1 |
| Ho Liang, HP | 1 |
| Sarathy, J | 1 |
| Mina, M | 2 |
| Rasic, G | 1 |
| Russo, R | 1 |
| Perryman, AL | 1 |
| Richmann, T | 1 |
| Singleton, E | 1 |
| Husain, S | 1 |
| Soteropoulos, P | 1 |
| Morris, R | 1 |
| Porter, G | 1 |
| Agnihotri, G | 1 |
| Ekins, S | 1 |
| Rhee, KY | 2 |
| Connell, N | 1 |
| Neiditch, MB | 1 |
| Freundlich, JS | 1 |
| Wambiya, EOA | 1 |
| Atela, M | 1 |
| Eboreime, E | 1 |
| Aruldhas, BW | 1 |
| Hoglund, RM | 1 |
| Ranjalkar, J | 1 |
| Tarning, J | 1 |
| Mathew, SK | 1 |
| Bose, A | 1 |
| Mathew, BS | 1 |
| Grace, SG | 1 |
| Öblom, H | 1 |
| Pimparade, M | 1 |
| Speer, I | 1 |
| Preis, M | 1 |
| Repka, M | 1 |
| Sandler, N | 1 |
| Vaghasiya, K | 1 |
| Ray, E | 1 |
| Kumar Singh, A | 1 |
| Datta Gupta, U | 1 |
| Kumar Verma, R | 1 |
| Sabasaba, A | 1 |
| Mwambi, H | 1 |
| Somi, G | 1 |
| Yoo, IY | 1 |
| Huh, HJ | 1 |
| Kang, OK | 1 |
| Jhun, BW | 1 |
| Koh, WJ | 4 |
| Lee, NY | 2 |
| Ban, GY | 1 |
| Jeong, YJ | 1 |
| Shin, YS | 1 |
| Park, HS | 1 |
| Kim, SH | 3 |
| Ye, YM | 1 |
| Yirdaw, KD | 2 |
| Teklu, AM | 3 |
| Mamuye, AT | 1 |
| Zewdu, S | 2 |
| Gezae, KE | 1 |
| Abebe, HT | 1 |
| Gebretsadik, LG | 1 |
| Van Ginderdeuren, E | 1 |
| Bassett, J | 1 |
| Hanrahan, C | 2 |
| Mutunga, L | 1 |
| Ramsuran, V | 1 |
| Ncgapu, S | 1 |
| Adamson, J | 3 |
| Govender, K | 1 |
| Cusato, J | 1 |
| von Braun, A | 3 |
| Turyasingura, G | 1 |
| Castelnuovo, B | 4 |
| Di Perri, G | 2 |
| Lung, T | 1 |
| Marks, GB | 2 |
| Anh, NT | 1 |
| Hoa, NLP | 1 |
| Anh, LTN | 1 |
| Hoa, NB | 1 |
| Britton, WJ | 1 |
| Bestrashniy, J | 1 |
| Jan, S | 1 |
| Fox, GJ | 1 |
| Novita, BD | 1 |
| Ali, M | 1 |
| Pranoto, A | 1 |
| Soediono, EI | 1 |
| Luo, M | 1 |
| Yu, J | 1 |
| Yi, X | 1 |
| Wei, H | 1 |
| Monedero-Recuero, I | 1 |
| Aung, TK | 3 |
| Chadha, S | 1 |
| Chiang, CY | 5 |
| Dongo, JP | 1 |
| Heldal, E | 2 |
| Jensen, P | 1 |
| Nyengele, JPK | 1 |
| Mlilo, N | 1 |
| Nakanwagi-Mukwaya, A | 1 |
| Ncube, RT | 1 |
| Nyinoburyo, R | 1 |
| Oo, NL | 1 |
| Patel, LN | 1 |
| Rusen, ID | 2 |
| Sanda, T | 1 |
| Syed, I | 1 |
| Thu, AS | 1 |
| Tonsing, J | 1 |
| Zamora, V | 1 |
| Zishiri, C | 1 |
| Hinderaker, SG | 2 |
| Aït-Khaled, N | 2 |
| Caminero Luna, J | 1 |
| Fujiwara, PI | 3 |
| Carazo, E | 1 |
| Sandri, G | 1 |
| Cerezo, P | 1 |
| Lanni, C | 1 |
| Ferrari, F | 1 |
| Bonferoni, C | 1 |
| Viseras, C | 1 |
| Aguzzi, C | 1 |
| Leon-Cruz, J | 1 |
| Mwelase, N | 1 |
| Jean Juste, MA | 1 |
| Lama, JR | 2 |
| Valencia, J | 2 |
| da Silva Escada, RO | 1 |
| Banda, P | 1 |
| Severe, P | 3 |
| Hakim, J | 3 |
| Kanyama, C | 1 |
| Andersen, J | 1 |
| Nuermberger, E | 1 |
| Saunders, MJ | 1 |
| Evans, CA | 1 |
| Seijger, C | 1 |
| Hoefsloot, W | 1 |
| Bergsma-de Guchteneire, I | 1 |
| van Ingen, J | 2 |
| Kuipers, S | 1 |
| Boeree, M | 2 |
| Magis-Escurra, C | 2 |
| Kyaw, NTT | 1 |
| Kyaw, KWY | 1 |
| Min, AC | 2 |
| Moe, J | 2 |
| Aung, ZZ | 1 |
| Oo, MM | 2 |
| Soe, KT | 1 |
| Oo, HN | 2 |
| Aung, ST | 2 |
| Phyo, KH | 1 |
| Saw, S | 1 |
| Thuya, SS | 1 |
| Mon, YY | 1 |
| Naing, NN | 1 |
| Kyi, MS | 1 |
| Lai, J | 1 |
| Dememew, Z | 1 |
| Jerene, D | 6 |
| Abashawl, A | 1 |
| Feleke, B | 3 |
| Ruff, A | 2 |
| Dutta, NK | 3 |
| Klinkenberg, LG | 2 |
| Vazquez, MJ | 1 |
| Segura-Carro, D | 1 |
| Colmenarejo, G | 1 |
| Ramon, F | 1 |
| Rodriguez-Miquel, B | 1 |
| Mata-Cantero, L | 1 |
| Chuang, YM | 2 |
| Lee, JJ | 1 |
| Eoh, H | 1 |
| Bader, JS | 1 |
| Karakousis, PC | 8 |
| Karo, B | 1 |
| Kohlenberg, A | 1 |
| Hollo, V | 1 |
| Duarte, R | 1 |
| Fiebig, L | 1 |
| Jackson, S | 1 |
| Kearns, C | 1 |
| Ködmön, C | 1 |
| Korzeniewska-Kosela, M | 1 |
| Papaventsis, D | 2 |
| van der Werf, MJ | 2 |
| Mukherjee, A | 3 |
| Lodha, R | 3 |
| Kabra, SK | 3 |
| Hu, X | 1 |
| Peng, W | 2 |
| Salazar-González, RA | 1 |
| Akyuz, F | 1 |
| Cavus, B | 1 |
| Iliaz, R | 1 |
| Soyer, OM | 1 |
| Ormeci, A | 1 |
| Evirgen, S | 1 |
| Onder, S | 1 |
| Koksalan, K | 1 |
| Keskin, M | 1 |
| Karaca, C | 1 |
| Demir, K | 1 |
| Gulluoglu, M | 1 |
| Besisik, F | 2 |
| Kaymakoglu, S | 1 |
| Goodell, AJ | 1 |
| Shete, PB | 1 |
| Vreman, R | 1 |
| McCabe, D | 1 |
| Porco, TC | 1 |
| Barry, PM | 1 |
| Flood, J | 1 |
| Marks, SM | 2 |
| Hill, A | 1 |
| Kahn, JG | 1 |
| Iacobino, A | 1 |
| Giannoni, F | 1 |
| Pardini, M | 1 |
| Piccaro, G | 1 |
| Fattorini, L | 2 |
| Chandrasekaran, P | 3 |
| Gaikwad, S | 1 |
| Agibothu Kupparam, HK | 1 |
| Paradkar, M | 1 |
| Dhanasekaran, K | 1 |
| Sivaramakrishnan, GN | 1 |
| Thomas, B | 1 |
| Pradhan, N | 1 |
| Kadam, D | 1 |
| Balasubramanian, U | 1 |
| Murali, L | 2 |
| Shivakumar, SVBY | 1 |
| Erwin, ER | 1 |
| Addison, AP | 1 |
| John, SF | 2 |
| Olaleye, OA | 2 |
| Rosell, RC | 1 |
| Endalamaw, A | 1 |
| Negash, M | 1 |
| Eshetie, S | 1 |
| Tessema, B | 2 |
| Amarnath Praphakar, R | 1 |
| Sumathra, M | 1 |
| Sam Ebenezer, R | 1 |
| Vignesh, S | 1 |
| Shakila, H | 1 |
| Rajan, M | 1 |
| Thee, S | 4 |
| Krüger, R | 1 |
| von Bernuth, H | 1 |
| Meisel, C | 1 |
| Kölsch, U | 1 |
| Kirchberger, V | 1 |
| Feiterna-Sperling, C | 1 |
| Zhang, L | 4 |
| Tao, HL | 1 |
| Sun, YC | 1 |
| Lou, ZZ | 1 |
| Jia, WZ | 1 |
| Hu, LH | 1 |
| Gao, CH | 1 |
| Hussain, A | 1 |
| Zaman, G | 1 |
| Satti, L | 1 |
| Ikram, A | 1 |
| Gardezi, AH | 1 |
| Khadim, MT | 1 |
| Rienksma, RA | 1 |
| Schaap, PJ | 1 |
| Martins Dos Santos, VAP | 1 |
| Suarez-Diez, M | 1 |
| Dhungana, GP | 1 |
| Bhatta, U | 1 |
| Pandey, B | 1 |
| Zhang, WH | 1 |
| Jain, V | 1 |
| Hill, WC | 1 |
| Paruolo, JB | 1 |
| Giovino, AC | 1 |
| Dye, C | 2 |
| Sharling, L | 1 |
| Goodman, M | 1 |
| Chorba, T | 1 |
| Mase, S | 1 |
| Qureshi, S | 1 |
| Ahmad, K | 1 |
| Fatima, P | 1 |
| Hassan, RM | 1 |
| Sherali, F | 1 |
| Lalani, N | 1 |
| Jehan, F | 1 |
| Ali, SA | 2 |
| Qamar, FN | 1 |
| Dharra, R | 1 |
| Radhakrishnan, VS | 1 |
| Prasad, T | 1 |
| Thakur, Z | 1 |
| Cirillo, JD | 1 |
| Sheoran, A | 1 |
| Pandey, AK | 1 |
| Kulharia, M | 1 |
| Mehta, PK | 1 |
| Munir, A | 1 |
| Kumar, N | 2 |
| Ramalingam, SB | 1 |
| Tamilzhalagan, S | 1 |
| Shanmugam, SK | 1 |
| Palaniappan, AN | 1 |
| Nair, D | 1 |
| Priyadarshini, P | 1 |
| Natarajan, M | 1 |
| Tripathy, S | 1 |
| Ranganathan, UD | 1 |
| Peacock, SJ | 1 |
| Parkhill, J | 3 |
| Blundell, TL | 1 |
| Beshir, MT | 1 |
| Beyene, AH | 1 |
| Tlaye, KG | 1 |
| Demelew, TM | 1 |
| Radtke, KK | 1 |
| Dodd, PJ | 2 |
| Garcia-Prats, AJ | 1 |
| McKenna, L | 1 |
| Tsiligiannis, A | 1 |
| Sfouni, M | 1 |
| Nalda-Molina, R | 1 |
| Dokoumetzidis, A | 1 |
| Huo, F | 1 |
| Lu, J | 2 |
| Zong, Z | 1 |
| Jing, W | 1 |
| Shi, J | 1 |
| Ma, Y | 1 |
| Dong, L | 2 |
| Zhao, L | 2 |
| Pang, Y | 2 |
| Korzeniewska- Koseła, M | 1 |
| Ho, HT | 1 |
| Wang, TH | 1 |
| Hsiong, CH | 1 |
| Perng, WC | 1 |
| Wang, NC | 1 |
| Huang, TY | 1 |
| Jong, YJ | 1 |
| Lu, PL | 1 |
| Hu, OY | 1 |
| Eisenhut, M | 2 |
| Bouchentouf, R | 2 |
| Bouaity, B | 2 |
| Touati, M | 2 |
| Benjelloun, A | 1 |
| Ali Aitbenasser, M | 1 |
| Han, CD | 1 |
| Oh, T | 1 |
| Cho, SN | 1 |
| Yang, JH | 1 |
| Park, KK | 1 |
| Taylor, AW | 1 |
| Mosimaneotsile, B | 5 |
| Mathebula, U | 1 |
| Mathoma, A | 2 |
| Moathlodi, R | 1 |
| Theebetsile, I | 1 |
| Samandari, T | 11 |
| He, D | 1 |
| Bai, F | 1 |
| Shen, J | 1 |
| Zhu, Q | 1 |
| Yue, T | 1 |
| Gao, Y | 1 |
| Feng, Y | 2 |
| Weng, X | 1 |
| Zou, H | 1 |
| Garg, R | 1 |
| Bose, M | 1 |
| Aljalil, A | 1 |
| Chihani, M | 1 |
| Ammar, H | 1 |
| Braga, JU | 1 |
| da Conceição, DA | 1 |
| Singh, H | 2 |
| Ray, S | 2 |
| Gupta, V | 1 |
| Talapatra, P | 1 |
| Mathur, R | 1 |
| Arya, S | 1 |
| Ghangas, N | 1 |
| Cobelens, FG | 2 |
| Mills, HL | 3 |
| Colijn, C | 3 |
| Codecasa, LR | 1 |
| Murgia, N | 1 |
| Ferrarese, M | 1 |
| Delmastro, M | 1 |
| Repossi, AC | 1 |
| Casali, L | 1 |
| Besozzi, G | 1 |
| Ferrara, G | 1 |
| Raviglione, MC | 6 |
| Poorana Gangadevi, N | 1 |
| Vijayasekaran, D | 1 |
| Banu Rekha, VV | 1 |
| Ramesh Kumar, S | 1 |
| Ravichandran, N | 4 |
| Mathevan, G | 3 |
| Velayati, AA | 4 |
| Farnia, P | 6 |
| Masjedi, MR | 4 |
| Huyen, MN | 1 |
| Buu, TN | 1 |
| Lan, NT | 2 |
| Dung, NH | 1 |
| Kremer, K | 3 |
| Tiemersma, EW | 1 |
| Belchis, DA | 1 |
| Chowdhury, A | 1 |
| Paul, P | 1 |
| Choudhury, MD | 1 |
| Zhou, Z | 1 |
| Wei, Q | 1 |
| Liu, P | 1 |
| Ma, A | 1 |
| Zou, F | 1 |
| Wilson, ML | 2 |
| Cowan, J | 1 |
| Barnhart, S | 1 |
| Demamu, S | 1 |
| Fiseha, D | 1 |
| Graham, W | 1 |
| Melese, E | 1 |
| Reason, L | 1 |
| Tefera Asfaw, F | 1 |
| Feleke, G | 1 |
| Law, S | 1 |
| Moolphate, S | 1 |
| Lawpoolsri, S | 1 |
| Pungrassami, P | 1 |
| Sanguanwongse, N | 1 |
| Yamada, N | 1 |
| Kaewkungwal, J | 1 |
| Sheen, P | 2 |
| Couvin, D | 1 |
| Zimic, M | 1 |
| Dominguez, M | 1 |
| Luna, G | 2 |
| Rastogi, N | 4 |
| Moore, DA | 5 |
| Sanchez-Padilla, E | 1 |
| Ardizzoni, E | 1 |
| Sauvageot, D | 1 |
| Ahoua, L | 1 |
| Martin, A | 4 |
| Varaine, F | 3 |
| Adatu-Engwau, F | 1 |
| Akeche, G | 1 |
| Salaniponi, F | 2 |
| Imperiale, BR | 2 |
| Zumárraga, MJ | 1 |
| Di Giulio, AB | 2 |
| Cataldi, AA | 1 |
| Morcillo, NS | 2 |
| Muñoz Aguilar, G | 1 |
| Alcón Sáez, JJ | 1 |
| Gómez Zafra, R | 1 |
| Domingo Triadó, I | 1 |
| Lee, SM | 2 |
| Yim, JJ | 2 |
| Yoo, CG | 1 |
| Kim, YW | 1 |
| Han, SK | 1 |
| Yang, SC | 1 |
| Manca, ML | 1 |
| Cassano, R | 2 |
| Valenti, D | 1 |
| Trombino, S | 2 |
| Ferrarelli, T | 2 |
| Picci, N | 2 |
| Fadda, AM | 2 |
| Manconi, M | 2 |
| Deraeve, C | 1 |
| Chollet, A | 1 |
| Pratviel, G | 2 |
| Dewan, P | 2 |
| Mendoza-Ticona, A | 1 |
| Alarcón, V | 1 |
| Samalvides, F | 1 |
| Pacheco, AG | 6 |
| King, BS | 3 |
| Wang, P | 1 |
| Bai, Y | 1 |
| Kang, J | 1 |
| Hao, Y | 1 |
| Luo, T | 1 |
| Bertrand, J | 2 |
| Verstuyft, C | 1 |
| Chou, M | 1 |
| Borand, L | 1 |
| Chea, P | 1 |
| Nay, KH | 1 |
| Blanc, FX | 1 |
| Mentré, F | 1 |
| Hutke, V | 1 |
| Wankhade, G | 1 |
| Waghmare, PJ | 1 |
| Harinath, BC | 3 |
| Lapphra, K | 1 |
| Sutthipong, C | 1 |
| Foongladda, S | 1 |
| Vanprapar, N | 1 |
| Phongsamart, W | 1 |
| Wittawatmongkol, O | 1 |
| Saksawad, R | 1 |
| Chokephaibulkit, K | 2 |
| Parekh, MJ | 1 |
| Ukwaja, KN | 3 |
| Boon, GP | 1 |
| Jeena, PM | 2 |
| Maltempe, FG | 1 |
| de Lemos, AS | 1 |
| Vieira, MA | 1 |
| Halpern, M | 3 |
| Quaresma, RG | 1 |
| Borchardt, AC | 1 |
| Santos, MA | 1 |
| Gonçalves, RT | 1 |
| Santoro-Lopes, G | 1 |
| Zaeh, S | 1 |
| Kempker, R | 1 |
| Stenehjem, E | 1 |
| Temesgen, O | 1 |
| Ofotokun, I | 1 |
| Tenna, A | 1 |
| Thiel, BA | 1 |
| Toefy, A | 1 |
| Suliman, S | 1 |
| Pienaar, B | 1 |
| Chheng, P | 2 |
| Scriba, T | 1 |
| Hanekom, W | 1 |
| Hersleth, HP | 1 |
| Andersson, KK | 1 |
| Magliozzo, RS | 1 |
| Chen, TC | 1 |
| Chou, LT | 1 |
| Huang, CC | 1 |
| Lai, AB | 1 |
| Wang, JH | 1 |
| Fielding, KL | 13 |
| Grant, AD | 18 |
| Luttig, M | 1 |
| Muller, D | 4 |
| Coetzee, L | 3 |
| Shinn-Forng Peng, S | 1 |
| Chiou, MY | 1 |
| Ling, DL | 1 |
| Chang, LY | 1 |
| Wang, KF | 1 |
| Fang, CT | 1 |
| Huang, LM | 1 |
| Lin, PL | 2 |
| Ford, CB | 1 |
| Coleman, MT | 1 |
| Myers, AJ | 1 |
| Gawande, R | 1 |
| Ioerger, T | 1 |
| Sacchettini, J | 1 |
| Flynn, JL | 3 |
| Yoon, C | 1 |
| Davis, JL | 1 |
| Muzoora, C | 1 |
| Byakwaga, H | 1 |
| Scibetta, C | 1 |
| Bangsberg, DR | 2 |
| Hunt, PW | 1 |
| Martin, JN | 1 |
| Metzger, NL | 1 |
| Momary, KM | 1 |
| Ando, H | 2 |
| Miyoshi-Akiyama, T | 2 |
| Watanabe, S | 1 |
| Kirikae, T | 2 |
| Moretton, MA | 1 |
| Hocht, C | 1 |
| Taira, C | 1 |
| Sosnik, A | 1 |
| Satyaraddi, A | 1 |
| Velpandian, T | 2 |
| Vishnubhatla, S | 1 |
| Sirohiwal, A | 1 |
| Makharia, GK | 1 |
| Soobratty, MR | 1 |
| Whitfield, R | 2 |
| Subramaniam, K | 1 |
| Grove, G | 1 |
| Carver, A | 1 |
| O'Donovan, GV | 1 |
| Wu, HH | 1 |
| Lee, OY | 1 |
| Swaminathan, R | 1 |
| Cope, GF | 2 |
| Milburn, HJ | 1 |
| Denegetu, AW | 1 |
| Dolamo, BL | 1 |
| Godfrey-Faussett, P | 7 |
| Hayes, RJ | 4 |
| Rubin, EJ | 2 |
| Peter, P | 1 |
| John, M | 1 |
| Wang, TY | 1 |
| Lin, SM | 1 |
| Shie, SS | 1 |
| Chou, PC | 1 |
| Huang, CD | 1 |
| Chung, FT | 1 |
| Kuo, CH | 1 |
| Chang, PJ | 2 |
| Kuo, HP | 1 |
| Zvada, SP | 1 |
| Donald, PR | 6 |
| Seifart, HI | 7 |
| Smith, PJ | 5 |
| Simonsson, US | 1 |
| Werely, CJ | 6 |
| Makanjuola, T | 1 |
| Taddese, HB | 1 |
| Booth, A | 1 |
| Cinel, G | 1 |
| Kiper, N | 1 |
| Pekcan, S | 1 |
| Koyun, M | 1 |
| Köse, M | 1 |
| Çobanoğlu, N | 1 |
| Tana Aslan, A | 1 |
| Yalçın, E | 1 |
| Doğru, D | 1 |
| Özçelik, U | 2 |
| Göçmen, A | 1 |
| Verhagen, LM | 2 |
| Coenen, MJ | 1 |
| López, D | 2 |
| García, JF | 2 |
| de Waard, JH | 3 |
| Schijvenaars, MM | 1 |
| Hermans, PW | 2 |
| FUSILLO, MH | 2 |
| WAGNER, BM | 2 |
| KUHNS, DM | 2 |
| DUCA, CJ | 1 |
| TURNER, FJ | 1 |
| MEYERS, E | 1 |
| ROTHLAUF, MV | 1 |
| FLORIANI, C | 1 |
| ESPINAL, BR | 1 |
| FEBBRARO, EE | 1 |
| Abuogi, L | 1 |
| Simchowitz, B | 1 |
| Bukusi, EA | 1 |
| Smith, AH | 1 |
| Reingold, A | 1 |
| de Martino, M | 1 |
| Thorne, C | 1 |
| Adamu, B | 1 |
| Abdu, A | 1 |
| Abba, AA | 1 |
| Borodo, MM | 1 |
| Tleyjeh, IM | 1 |
| Ahmed, W | 1 |
| Menon, S | 1 |
| Godbole, AA | 1 |
| Karthik, PV | 1 |
| Nagaraja, V | 1 |
| Reynolds, J | 1 |
| Li, G | 2 |
| Li, H | 1 |
| Niu, J | 1 |
| Quan, S | 1 |
| Wang, F | 1 |
| Wen, H | 1 |
| Sheng, YJ | 1 |
| Wu, G | 1 |
| He, HY | 1 |
| Zou, YS | 1 |
| Huang, YM | 1 |
| Deng, CL | 1 |
| Yakrus, MA | 1 |
| Driscoll, J | 1 |
| Lentz, AJ | 1 |
| Sikes, D | 1 |
| Hartline, D | 1 |
| Metchock, B | 2 |
| Bhatt, NB | 1 |
| Barau, C | 1 |
| Amin, A | 1 |
| Baudin, E | 1 |
| Meggi, B | 1 |
| Silva, C | 1 |
| Furlan, V | 1 |
| Grinsztejn, B | 1 |
| Barrail-Tran, A | 1 |
| Kufa, T | 1 |
| Slogrove, AL | 1 |
| Ruesen, C | 1 |
| van Gageldonk-Lafeber, AB | 1 |
| de Vries, G | 2 |
| Erkens, CG | 2 |
| van Rest, J | 1 |
| Korthals Altes, H | 1 |
| Kamst, M | 1 |
| Jimenez Parra, JD | 1 |
| Alvarez Bandres, S | 1 |
| Garcia Garcia, D | 1 |
| Torres Varas, L | 1 |
| Sotil Arrieta, A | 1 |
| Jimenez Calvo, J | 1 |
| Lombardi, G | 1 |
| Dal Monte, P | 1 |
| Denicolò, A | 1 |
| Tadolini, M | 3 |
| Martelli, G | 2 |
| Bacchi Reggiani, ML | 1 |
| Viale, P | 4 |
| Landini, MP | 1 |
| Yaqub, F | 1 |
| Abimbola, S | 1 |
| Richardson, ET | 1 |
| Wood, R | 8 |
| Olithselvan, A | 1 |
| Rajagopala, S | 1 |
| Vij, M | 1 |
| Shanmugam, V | 1 |
| Shanmugam, N | 1 |
| Rela, M | 2 |
| Soborg, C | 1 |
| Andersen, PH | 2 |
| Ravn, P | 1 |
| Johnson, DF | 2 |
| Malone, LL | 1 |
| Zalwango, S | 1 |
| Mukisa Oketcho, J | 1 |
| Chervenak, KA | 2 |
| Thiel, B | 1 |
| Stein, CM | 1 |
| Lancioni, CL | 1 |
| Pal, P | 1 |
| Patra, SK | 1 |
| Gomathi, NS | 1 |
| Scrivo, R | 1 |
| Sauzullo, I | 1 |
| Mengoni, F | 1 |
| Riccieri, V | 1 |
| Altieri, AM | 1 |
| Cantoro, L | 1 |
| Vullo, V | 1 |
| Mastroianni, CM | 1 |
| Valesini, G | 1 |
| Pandit, S | 1 |
| Choudhury, S | 1 |
| Bhattacharya, S | 1 |
| Chiriac, A | 1 |
| Ferariu, D | 1 |
| Solovan, C | 1 |
| Brzezinski, P | 1 |
| Feldman, SR | 1 |
| Skerry, C | 1 |
| Pinn, ML | 4 |
| Bruiners, N | 1 |
| Pine, R | 1 |
| Gennaro, ML | 1 |
| Kaur, R | 1 |
| Garg, T | 3 |
| Malik, B | 1 |
| Rath, G | 3 |
| Goyal, AK | 3 |
| Odato, K | 1 |
| Blunt, H | 1 |
| Steingart, KR | 1 |
| Ng, CS | 1 |
| Hasnat, A | 1 |
| Al Maruf, A | 1 |
| Ahmed, MU | 1 |
| Pirmohamed, M | 1 |
| Day, CP | 1 |
| Aithal, GP | 1 |
| Daly, AK | 1 |
| Adrián Cataldi, A | 1 |
| Bekker, LG | 2 |
| Amlabu, V | 1 |
| Mulligan, C | 1 |
| Jele, N | 1 |
| Evans, A | 1 |
| Gray, D | 1 |
| Smith, P | 3 |
| Heilig, CM | 1 |
| Tapy, JM | 2 |
| Bozeman, L | 3 |
| Kyle, RP | 1 |
| Hamilton, CD | 6 |
| Bock, N | 2 |
| Narita, M | 2 |
| Wing, D | 2 |
| Hershfield, E | 1 |
| Goldberg, SV | 2 |
| Lemus, D | 1 |
| Echemendía, M | 1 |
| Díaz, R | 1 |
| Llop, A | 1 |
| Llanes, MJ | 1 |
| Chen, FC | 1 |
| Liao, YC | 1 |
| Huang, JM | 1 |
| Lin, CH | 2 |
| Chen, YY | 1 |
| Dou, HY | 1 |
| Hsiung, CA | 1 |
| Naranbhai, V | 1 |
| Fletcher, H | 1 |
| Hill, AV | 1 |
| Madhi, SA | 4 |
| Schopfer, K | 1 |
| Rieder, HL | 9 |
| Steinlin-Schopfer, JF | 1 |
| Bodmer, T | 1 |
| Chantana, Y | 1 |
| Studer, P | 1 |
| Laurent, D | 1 |
| Zwahlen, M | 1 |
| Richner, B | 1 |
| Lemmer, Y | 1 |
| Grobler, A | 1 |
| Moody, C | 1 |
| Viljoen, H | 1 |
| Riccardi, G | 1 |
| Gashu, Z | 2 |
| Edginton, ME | 1 |
| Kumar, AM | 3 |
| Letamo, Y | 1 |
| Weiss, B | 1 |
| Tiam, A | 1 |
| Machekano, R | 1 |
| Gounder, CR | 1 |
| Maama-Maime, LB | 1 |
| Ntene-Sealiete, K | 1 |
| Sahu, M | 1 |
| Isavwa, A | 1 |
| Oyebanji, O | 1 |
| Ahimbisibwe, A | 1 |
| Mokone, M | 1 |
| Guay, L | 1 |
| Kassaye, S | 1 |
| Tieu, HV | 1 |
| Suntarattiwong, P | 1 |
| Puthanakit, T | 1 |
| Chotpitayasunondh, T | 1 |
| Sirivichayakul, S | 1 |
| Buranapraditkun, S | 1 |
| Rungrojrat, P | 1 |
| Chomchey, N | 1 |
| Tsiouris, S | 1 |
| Hammer, S | 1 |
| Nandi, V | 2 |
| Ananworanich, J | 1 |
| Salazar-González, R | 1 |
| Gómez, R | 1 |
| Medellín-Garibay, S | 1 |
| Núñez-Ruíz, A | 1 |
| Milán-Segovia, RC | 1 |
| Dymova, MA | 2 |
| Cherednichenko, AG | 3 |
| Alkhovik, OI | 1 |
| Khrapov, EA | 2 |
| Petrenko, TI | 1 |
| Filipenko, ML | 3 |
| Sousa, EH | 3 |
| de Mesquita Vieira, FG | 1 |
| Butler, JS | 1 |
| Santiago, DS | 1 |
| Diógenes, IC | 2 |
| Lopes, LG | 3 |
| Sadler, PJ | 1 |
| Shivaramakrishna, HR | 1 |
| Frederick, A | 1 |
| Shazia, A | 1 |
| Nair, SA | 1 |
| Moonan, PK | 1 |
| McLeod, KE | 1 |
| Milovanovic, M | 1 |
| Getahun, H | 8 |
| Granich, R | 5 |
| Date, A | 4 |
| Lepere, P | 1 |
| Hersh, B | 1 |
| Gouws, E | 1 |
| Samb, B | 2 |
| Abimbola, T | 2 |
| Suthar, AB | 2 |
| Bennett, R | 2 |
| Sangrujee, N | 2 |
| Mittal, H | 1 |
| Faridi, MM | 1 |
| Martin, L | 1 |
| Faulx, D | 1 |
| Valdez, M | 1 |
| Metzler, M | 1 |
| Crudder, C | 1 |
| Castillo, E | 2 |
| Caviedes, L | 2 |
| Rodriguez, M | 1 |
| Sukumar, N | 1 |
| Tan, S | 1 |
| Aldridge, BB | 1 |
| Choi, SW | 1 |
| Maiga, M | 1 |
| Maiga, MC | 1 |
| Atudorei, V | 1 |
| Sharp, ZD | 1 |
| Timmins, GS | 1 |
| Lim, YP | 1 |
| Lin, CL | 1 |
| Hung, DZ | 1 |
| Lin, YN | 1 |
| Kao, CH | 1 |
| Baytunca, MB | 1 |
| Erermis, S | 1 |
| Bildik, T | 1 |
| Kayahan, B | 1 |
| Katawera, V | 1 |
| Siedner, M | 1 |
| Boum, Y | 1 |
| Supervía, A | 1 |
| Pallàs, O | 1 |
| Piccari, L | 1 |
| Herrera Fernández, S | 1 |
| Domínguez Álvarez, M | 1 |
| Cirera, I | 1 |
| del Baño, F | 1 |
| Sirgel, FA | 2 |
| Kabran, M | 2 |
| Inwoley, A | 2 |
| Herrmann, JL | 1 |
| Lecarrou, J | 1 |
| Deschamps, N | 2 |
| Perronne, C | 3 |
| Singh, V | 1 |
| Friis, H | 1 |
| Faurholt-Jepsen, D | 1 |
| Bhatnagar, S | 1 |
| Saini, S | 1 |
| Grewal, HM | 3 |
| Guerra-Assunção, JA | 1 |
| Houben, RM | 4 |
| Crampin, AC | 2 |
| Mzembe, T | 1 |
| Mallard, K | 1 |
| Coll, F | 1 |
| Khan, P | 1 |
| Banda, L | 1 |
| Chiwaya, A | 1 |
| Pereira, RP | 1 |
| McNerney, R | 1 |
| Harris, D | 1 |
| Glynn, JR | 4 |
| Tedla, Z | 8 |
| Nguyen, ML | 1 |
| Sibanda, T | 5 |
| Nyirenda, S | 8 |
| Agizew, TB | 5 |
| Girde, S | 1 |
| Rose, CE | 2 |
| Oshi, SN | 1 |
| Alobu, I | 1 |
| Oshi, DC | 1 |
| Rustad, TR | 1 |
| Minch, KJ | 1 |
| Winkler, JK | 1 |
| Hobbs, S | 1 |
| Hickey, M | 1 |
| Brabant, W | 1 |
| Turkarslan, S | 1 |
| Price, ND | 1 |
| Baliga, NS | 1 |
| Bacsa, B | 1 |
| Rusvai, M | 1 |
| Szabó, E | 1 |
| Hudecz, F | 2 |
| Podder, B | 1 |
| Jang, WS | 1 |
| Nam, KW | 1 |
| Lee, BE | 1 |
| Song, HY | 1 |
| Naiker, S | 1 |
| Kellerman, T | 1 |
| Reddy, T | 1 |
| Harries, A | 2 |
| Lienhardt, C | 2 |
| Bonura, C | 1 |
| Gomgnimbou, MK | 1 |
| Refrégier, G | 1 |
| Aleo, A | 1 |
| Fasciana, T | 1 |
| Giammanco, A | 1 |
| Mammina, C | 1 |
| Beamer, G | 1 |
| Major, S | 1 |
| Das, B | 1 |
| Campos-Neto, A | 2 |
| Kumar, SR | 2 |
| Banurekha, VV | 2 |
| Sanjeeva, GN | 2 |
| Dayal, R | 1 |
| Cilfone, NA | 1 |
| Mattila, JT | 1 |
| Butler, JR | 1 |
| Riahi, F | 1 |
| Derakhshan, M | 1 |
| Mosavat, A | 1 |
| Soleimanpour, S | 1 |
| Rezaee, SA | 1 |
| Atikan, BY | 1 |
| Cavusoglu, C | 2 |
| Dortkardesler, M | 1 |
| Sozeri, B | 1 |
| Manina, G | 1 |
| Dhar, N | 2 |
| McKinney, JD | 2 |
| Hall, J | 1 |
| Elliott, C | 1 |
| Mah, A | 1 |
| Kharrat, H | 1 |
| Ahmed, R | 1 |
| Gao, Z | 1 |
| Der, E | 1 |
| Hansen, E | 1 |
| Lee, SO | 2 |
| Park, IA | 2 |
| Kim, SM | 2 |
| Park, SJ | 2 |
| Yun, SC | 2 |
| Jung, JH | 2 |
| Kim, YH | 2 |
| Choi, SH | 2 |
| Woo, JH | 2 |
| Park, SK | 2 |
| Han, DJ | 2 |
| Leeb, S | 1 |
| Buxbaum, C | 1 |
| Fischler, B | 1 |
| de Knegt, GJ | 1 |
| ten Kate, MT | 1 |
| Bakker-Woudenberg, IA | 1 |
| de Steenwinkel, JE | 1 |
| Lin, B | 1 |
| Wang, G | 2 |
| Aguiar, Id | 1 |
| Tavares, A | 1 |
| Roveda, AC | 1 |
| da Silva, AC | 1 |
| Marino, LB | 1 |
| Lopes, ÉO | 1 |
| Franco, DW | 1 |
| Ricks, PM | 1 |
| Hershow, RC | 1 |
| Rahimian, A | 1 |
| Huo, D | 1 |
| Johnson, W | 1 |
| Prachand, N | 1 |
| Jimenez, A | 1 |
| Wiebel, W | 1 |
| Paul, W | 1 |
| Wang, HF | 1 |
| O'Gorman, M | 1 |
| Crownover, P | 1 |
| Damle, B | 1 |
| Motsamai, OI | 3 |
| Shang, N | 3 |
| Shepherd, J | 2 |
| Rodrigues, RF | 1 |
| Zárate-Bladés, CR | 1 |
| Rios, WM | 1 |
| Soares, LS | 1 |
| Souza, PR | 1 |
| Brandão, IT | 1 |
| Masson, AP | 1 |
| Arnoldi, FG | 1 |
| Ramos, SG | 1 |
| Letourneur, F | 1 |
| Jacques, S | 1 |
| Cagnard, N | 1 |
| Chiocchia, G | 1 |
| Silva, CL | 2 |
| Flores-Suárez, LF | 1 |
| Saldarriaga Rivera, LM | 1 |
| Rivera Rosales, RM | 1 |
| Ruiz, N | 1 |
| Báez Saldaña, R | 1 |
| Baquero-Artigao, F | 1 |
| Mellado Peña, MJ | 1 |
| del Rosal Rabes, T | 1 |
| Noguera Julián, A | 1 |
| Goncé Mellgren, A | 1 |
| de la Calle Fernández-Miranda, M | 1 |
| Navarro Gómez, ML | 1 |
| Modi, S | 2 |
| Briggs, MA | 1 |
| Emerson, C | 1 |
| Taylor, NK | 1 |
| Vynnycky, E | 2 |
| Cox, AP | 1 |
| Knight, GM | 1 |
| Phillips, PP | 1 |
| Lipman, MC | 4 |
| Reves, RR | 1 |
| Chakraborty, S | 1 |
| Sturkenboom, MG | 3 |
| Robijns, K | 1 |
| Harteveld, AR | 1 |
| Greijdanus, B | 1 |
| Uges, DR | 1 |
| Alffenaar, JW | 2 |
| Green, EP | 1 |
| Catalani, C | 1 |
| Diero, L | 1 |
| Gardner, A | 1 |
| Ndwiga, C | 1 |
| Keny, A | 1 |
| Israelski, D | 1 |
| Biondich, P | 1 |
| Assebe, LF | 1 |
| Reda, HL | 1 |
| Wubeneh, AD | 1 |
| Lerebo, WT | 1 |
| Lambert, SM | 1 |
| Nguyen, LT | 2 |
| Sullivan, CT | 1 |
| Makam, AN | 1 |
| Ayakaka, I | 1 |
| Dryden-Peterson, S | 1 |
| Nakubulwa, S | 1 |
| Worodria, W | 3 |
| Reilly, N | 1 |
| Hosford, J | 1 |
| Fennelly, KP | 1 |
| Accinelli, RA | 1 |
| Romero, LR | 1 |
| García, RF | 1 |
| Sánchez, R | 1 |
| Schechner, V | 1 |
| Lessing, JB | 1 |
| Grisaru-Soen, G | 1 |
| Braun, T | 1 |
| Abu-Hanna, J | 1 |
| Carmeli, Y | 1 |
| Aviram, G | 1 |
| Cheng, JM | 1 |
| Hiscoe, L | 1 |
| Pollock, SL | 1 |
| Hasselback, P | 1 |
| Gardy, JL | 1 |
| Parker, R | 1 |
| Gillini, L | 1 |
| Centis, R | 1 |
| D'Ambrosio, L | 2 |
| Fedele, A | 1 |
| Aprile, V | 1 |
| Pasanisi, G | 1 |
| Donateo, L | 1 |
| Costa, D | 1 |
| Tundo, P | 1 |
| Wasserman, S | 1 |
| Mulder, LW | 1 |
| de Jager, A | 1 |
| van Altena, R | 2 |
| de Lange, WC | 3 |
| Proost, JH | 1 |
| Kosterink, JG | 2 |
| Mei, Z | 1 |
| Bai, D | 2 |
| Li, Z | 3 |
| Li, C | 2 |
| Bao, Y | 1 |
| Andersen, JW | 1 |
| Mwelase, T | 1 |
| Kim, P | 1 |
| Çakır, T | 1 |
| Ara, C | 1 |
| Soyer, HV | 1 |
| Koc, S | 1 |
| Strydom, K | 1 |
| Ismail, F | 1 |
| Matabane, MM | 1 |
| Onwuegbuna, O | 1 |
| Khandelwal, S | 1 |
| Karmarkar, M | 1 |
| Rajagopalan, S | 1 |
| Rao, N | 1 |
| Anandkumar, A | 1 |
| Datta, S | 1 |
| Kassie, Y | 2 |
| Alem, G | 1 |
| Daba, SH | 1 |
| Hiruye, N | 1 |
| Law, WS | 2 |
| Lee, SN | 1 |
| Tai, LB | 1 |
| Leung, EC | 1 |
| Tam, CM | 3 |
| Abdool Karim, SS | 1 |
| Anzian, A | 1 |
| Minga, A | 1 |
| Bouhoussou, F | 1 |
| Emieme, A | 1 |
| Kouamé, A | 2 |
| Toni, TD | 1 |
| Ahiboh, H | 1 |
| Rabe, C | 1 |
| Sidibé, B | 1 |
| Nzunetu, G | 1 |
| Konan, R | 1 |
| Gnokoro, J | 1 |
| Gouesse, P | 1 |
| Dohoun, L | 1 |
| Kamagate, S | 1 |
| Yao, A | 1 |
| Amon, S | 1 |
| Kouame, AB | 1 |
| Koua, A | 1 |
| Kouamé, E | 1 |
| Ndri, Y | 1 |
| Ba-Gomis, O | 1 |
| Daligou, M | 1 |
| Ackoundzé, S | 1 |
| Hawerlander, D | 1 |
| Ani, A | 1 |
| Dembélé, F | 1 |
| Koné, F | 1 |
| Guéhi, C | 1 |
| Kanga, C | 1 |
| Koule, S | 1 |
| Séri, J | 1 |
| Oyebi, M | 1 |
| Mbakop, N | 1 |
| Makaila, O | 1 |
| Babatunde, C | 1 |
| Babatounde, N | 1 |
| Bleoué, G | 1 |
| Tchoutedjem, M | 1 |
| Kouadio, AC | 1 |
| Sena, G | 1 |
| Yededji, SY | 1 |
| Assi, R | 1 |
| Bakayoko, A | 1 |
| Mahassadi, A | 1 |
| Attia, A | 1 |
| Oussou, A | 1 |
| Mobio, M | 1 |
| Bamba, D | 1 |
| Koman, M | 1 |
| Horo, A | 1 |
| Chenal, H | 1 |
| Sassan-Morokro, M | 1 |
| Konate, S | 1 |
| Aka, K | 1 |
| Aoussi, E | 1 |
| Journot, V | 1 |
| Nchot, C | 1 |
| Karcher, S | 1 |
| Chaix, ML | 1 |
| Rouzioux, C | 1 |
| Sow, PS | 2 |
| Girard, PM | 1 |
| Menan, H | 1 |
| Bissagnene, E | 1 |
| Kadio, A | 1 |
| Ettiegne-Traore, V | 1 |
| Moh-Semdé, C | 1 |
| Massumbuko, JM | 1 |
| Chêne, G | 1 |
| Dosso, M | 2 |
| N'Dri-Yoman, T | 1 |
| Salamon, R | 1 |
| Hwang, AA | 2 |
| Dillon, BJ | 2 |
| Zink, JI | 2 |
| Inoue, S | 1 |
| Lee, HB | 1 |
| Becker, AL | 1 |
| Weigel, KM | 1 |
| Kim, JH | 2 |
| Lee, KH | 1 |
| Chung, JH | 1 |
| Knudson, SE | 1 |
| Kumar, K | 1 |
| Carreau, A | 1 |
| Goullieux, L | 1 |
| Lagrange, S | 1 |
| Vermet, H | 1 |
| Ojima, I | 1 |
| Slayden, RA | 2 |
| Torres, JN | 1 |
| Paul, LV | 1 |
| Rodwell, TC | 2 |
| Victor, TC | 5 |
| Amallraja, AM | 1 |
| Elghraoui, A | 1 |
| Goodmanson, AP | 1 |
| Ramirez-Busby, SM | 1 |
| Chawla, A | 1 |
| Zadorozhny, V | 1 |
| Catanzaro, D | 2 |
| Gler, MT | 1 |
| Catanzaro, A | 5 |
| Valafar, F | 2 |
| Luabeya, KK | 1 |
| Tameris, MD | 1 |
| Geldenhuys, HD | 1 |
| Van Schalkwyk, A | 1 |
| Hughes, EJ | 1 |
| Toefey, A | 1 |
| Hussey, G | 2 |
| Landry, B | 1 |
| Smith, T | 1 |
| Marston, B | 1 |
| Lisdawati, V | 1 |
| Puspandari, N | 1 |
| Rif'ati, L | 1 |
| Soekarno, T | 1 |
| M, M | 1 |
| K, S | 1 |
| Ratnasari, L | 1 |
| Izzatun, N | 1 |
| Parwati, I | 1 |
| Sedgwick, P | 1 |
| Joekes, K | 1 |
| Leidinger, P | 1 |
| Treptow, J | 1 |
| Hagens, K | 1 |
| Eich, J | 1 |
| Zehethofer, N | 1 |
| Schwudke, D | 1 |
| Oehlmann, W | 1 |
| Lünsdorf, H | 1 |
| Goldmann, O | 1 |
| Schaible, UE | 1 |
| Dittmar, KE | 1 |
| Feldmann, C | 1 |
| Murthy, RS | 1 |
| Edessa, D | 1 |
| Likisa, J | 1 |
| Yotebieng, M | 1 |
| Edmonds, A | 1 |
| Lelo, P | 1 |
| Wenzi, LK | 1 |
| Ndjibu, PT | 1 |
| Lusiama, J | 1 |
| Kabuayi, JP | 1 |
| Behets, F | 1 |
| Stettner, M | 1 |
| Steinberger, D | 1 |
| Hartmann, CJ | 1 |
| Pabst, T | 1 |
| Konta, L | 1 |
| Hartung, HP | 1 |
| Kieseier, BC | 1 |
| Trinh, TT | 1 |
| Han, DT | 1 |
| Bloss, E | 1 |
| Le, TH | 1 |
| Vu, TT | 1 |
| Mai, AH | 1 |
| Nguyen, NV | 1 |
| Dinh, SN | 1 |
| Rockwood, N | 1 |
| Abdullahi, LH | 1 |
| Makoni, A | 1 |
| Chemhuru, M | 1 |
| Mungati, M | 1 |
| Bangure, D | 1 |
| van Griensven, J | 1 |
| Choun, K | 1 |
| Chim, B | 1 |
| Thai, S | 1 |
| Lorent, N | 1 |
| Fan, L | 1 |
| Yang, X | 1 |
| Yao, J | 1 |
| Yi, L | 1 |
| van der Watt, JJ | 2 |
| Benatar, MG | 1 |
| Harrison, TB | 2 |
| Carrara, H | 1 |
| Heckmann, JM | 2 |
| Hatsuda, K | 1 |
| Takeuchi, M | 1 |
| Ogata, K | 1 |
| Sasaki, Y | 3 |
| Kagawa, T | 1 |
| Nakatsuji, H | 1 |
| Ibaraki, M | 1 |
| Sakaguchi, M | 1 |
| Kurata, M | 1 |
| Hayashi, S | 1 |
| Jung, JA | 1 |
| Kim, TE | 1 |
| Jeong, BH | 1 |
| Park, HY | 2 |
| Jeon, K | 2 |
| Kwon, OJ | 2 |
| Ko, JW | 1 |
| Choi, R | 1 |
| Woo, HI | 2 |
| Lee, SY | 2 |
| Ayele, HT | 2 |
| Mourik, MS | 1 |
| Debray, TP | 1 |
| Bonten, MJ | 2 |
| Grzemska, M | 1 |
| Gie, RP | 2 |
| Martinez, BJ | 1 |
| Khameneh, B | 1 |
| Fazly Bazzaz, BS | 1 |
| Amani, A | 1 |
| Rostami, J | 1 |
| Vahdati-Mashhadian, N | 1 |
| Principi, N | 1 |
| Lancella, L | 1 |
| Villani, A | 1 |
| Esposito, S | 1 |
| Meloni, M | 1 |
| Corti, N | 2 |
| Henning, L | 1 |
| Gutteck, U | 2 |
| Weber, R | 1 |
| Guio, H | 1 |
| Levano, KS | 1 |
| Sánchez, C | 1 |
| Tarazona, D | 1 |
| Costenaro, P | 1 |
| Massavon, W | 1 |
| Lundin, R | 1 |
| Nabachwa, SM | 1 |
| Fregonese, F | 1 |
| Morelli, E | 4 |
| Alowo, A | 1 |
| Nannyonga Musoke, M | 1 |
| Namisi, CP | 1 |
| Kizito, S | 1 |
| Bilardi, D | 1 |
| Mazza, A | 1 |
| Giaquinto, C | 1 |
| Okumura, M | 1 |
| Yoshiyama, T | 8 |
| Matsuda, S | 1 |
| Osawa, T | 1 |
| Morimoto, K | 1 |
| Yanai, H | 4 |
| Kurasima, A | 1 |
| Ogata, H | 5 |
| Gotoh, H | 1 |
| Venkatesh, S | 1 |
| Kalpana, S | 1 |
| Agarwal, D | 1 |
| Cojutti, P | 1 |
| Duranti, S | 1 |
| Isola, M | 1 |
| Baraldo, M | 1 |
| Bassetti, M | 1 |
| Pea, F | 1 |
| Hamadah, AM | 1 |
| Beaulieu, LM | 1 |
| Wilson, JW | 2 |
| Aksamit, TR | 1 |
| Gregoire, JR | 1 |
| Williams, AW | 1 |
| Dillon, JJ | 1 |
| Albright, RC | 1 |
| Onuigbo, M | 1 |
| Iyer, VK | 1 |
| Hickson, LJ | 1 |
| Huerga, H | 2 |
| Mueller, Y | 1 |
| Ferlazzo, G | 1 |
| Mpala, Q | 1 |
| Bevilacqua, P | 1 |
| Vasquez, B | 1 |
| Noël Mekiedje, C | 1 |
| Ouattara, A | 1 |
| Mchunu, G | 1 |
| Weyenga, HO | 1 |
| Slump, E | 1 |
| Verhagen, M | 1 |
| Schimmel, H | 1 |
| Cobelens, F | 3 |
| van den Hof, S | 2 |
| Swanson, RV | 1 |
| Ammerman, NC | 3 |
| Ngcobo, B | 1 |
| Moodley, C | 1 |
| Dorasamy, A | 1 |
| Moodley, S | 1 |
| Mgaga, Z | 1 |
| Bester, LA | 1 |
| Singh, SD | 1 |
| Almeida, DV | 1 |
| Grosset, JH | 9 |
| Barbosa, AR | 1 |
| Leite, CQ | 2 |
| García-Ramos, JC | 1 |
| Toledano-Magaña, Y | 1 |
| Ruiz-Azuara, L | 1 |
| Garcia, MJ | 1 |
| Lopez, MR | 1 |
| Jena, L | 2 |
| Deshmukh, S | 1 |
| Waghmare, P | 1 |
| Hermans, SM | 2 |
| Chihota, V | 1 |
| Ayles, H | 2 |
| Moses, A | 1 |
| Riviere, C | 1 |
| Kirui, FK | 1 |
| Lagat, D | 1 |
| Mugyenyi, P | 1 |
| Henostroza, G | 1 |
| Leger, PD | 1 |
| Alave, J | 1 |
| Kumarasamy, N | 3 |
| Bao, J | 1 |
| Jones, L | 1 |
| Zolopa, A | 1 |
| Lin, HS | 1 |
| Cheng, CW | 1 |
| Lin, MS | 1 |
| Chou, YL | 1 |
| Lin, JC | 1 |
| Ye, JJ | 1 |
| Yu, X | 2 |
| Ma, YF | 1 |
| Jiang, GL | 2 |
| Chen, ST | 1 |
| Wang, GR | 1 |
| Lalande, L | 1 |
| Bourguignon, L | 1 |
| Maire, P | 1 |
| Liao, TL | 1 |
| Chen, YM | 1 |
| Chang, CL | 2 |
| Chen, HH | 1 |
| Chen, DY | 1 |
| Charles, MK | 1 |
| Lindegren, ML | 1 |
| Wester, CW | 1 |
| Blevins, M | 1 |
| Dung, NT | 1 |
| Dusingize, JC | 1 |
| Avit-Edi, D | 1 |
| Durier, N | 1 |
| Nakigozi, G | 1 |
| Ballif, M | 1 |
| Fenner, L | 3 |
| Hatzenbuehler, LA | 1 |
| Graviss, EA | 2 |
| Smith, EO | 1 |
| Alemu, YM | 1 |
| Awoke, W | 1 |
| Wilder-Smith, A | 1 |
| Singla, M | 1 |
| Kanhiya, K | 1 |
| Seifert, M | 1 |
| Garfein, RS | 1 |
| Kasule, GW | 1 |
| Kateete, DP | 1 |
| Joloba, ML | 2 |
| Dobler, CC | 1 |
| Moin, A | 1 |
| Raizaday, A | 1 |
| Nagshubha, B | 1 |
| Mota, L | 1 |
| Al-Efraij, K | 1 |
| Marra, F | 2 |
| Chandanwale, A | 1 |
| Khadse, S | 1 |
| Suryavanshi, N | 1 |
| Joshi, S | 2 |
| Horng, H | 1 |
| Benet, LZ | 1 |
| Datta, G | 1 |
| Nieto, LM | 1 |
| Davidson, RM | 1 |
| Mehaffy, C | 2 |
| Pederson, C | 1 |
| Dobos, KM | 2 |
| Strong, M | 1 |
| Javad Nasiri, M | 1 |
| Chirani, AS | 1 |
| Amin, M | 1 |
| Halabian, R | 1 |
| Imani Fooladi, AA | 1 |
| Behrens, RH | 1 |
| Gebre, N | 1 |
| Daba, S | 1 |
| Habte, D | 1 |
| Hiruy, N | 1 |
| Negash, S | 1 |
| Melkieneh, K | 1 |
| K Haile, Y | 1 |
| G Suarez, P | 1 |
| Choi, JH | 1 |
| Heo, NY | 1 |
| Park, SH | 1 |
| Park, CS | 1 |
| Jo, KM | 1 |
| Kim, WG | 1 |
| Nam, KH | 1 |
| Daftary, A | 1 |
| Kassie, GM | 1 |
| Yamashiro, LH | 1 |
| Eto, C | 1 |
| Soncini, M | 1 |
| Horewicz, V | 1 |
| Garcia, M | 2 |
| Schlindwein, AD | 1 |
| Grisard, EC | 1 |
| Rovaris, DB | 1 |
| Báfica, A | 1 |
| Klein, DJ | 1 |
| Boukouvala, S | 1 |
| McDonagh, EM | 1 |
| Shuldiner, SR | 1 |
| Laurieri, N | 1 |
| Thorn, CF | 1 |
| Altman, RB | 1 |
| Klein, TE | 1 |
| Capligina, V | 1 |
| Elferts, D | 1 |
| Jansone, I | 1 |
| Miro, JM | 2 |
| Calvet, G | 1 |
| La Rosa, A | 1 |
| Infante, R | 2 |
| Chen, MP | 1 |
| Benator, DA | 2 |
| Gordin, F | 4 |
| Maze, MJ | 1 |
| Paynter, J | 1 |
| Chiu, W | 1 |
| Hu, R | 1 |
| Nisbet, M | 1 |
| Lewis, C | 1 |
| Chang, AH | 1 |
| Ghosh, JK | 1 |
| Dubé, MP | 1 |
| Bolan, R | 1 |
| Yang, OO | 1 |
| Kerndt, PR | 1 |
| Stagg, HR | 2 |
| Harris, RJ | 1 |
| Hatherell, HA | 1 |
| Obach, D | 1 |
| Tsuchiya, N | 1 |
| Kranzer, K | 4 |
| Kim, J | 1 |
| Abubakar, I | 2 |
| Verbeeck, RK | 1 |
| Günther, G | 1 |
| Kibuule, D | 1 |
| Hunter, C | 1 |
| Rennie, TW | 2 |
| Ngwane, AH | 1 |
| Panayides, JL | 1 |
| Chouteau, F | 1 |
| Macingwana, L | 1 |
| Baker, B | 1 |
| Madikane, E | 1 |
| de Kock, C | 1 |
| Chibale, K | 1 |
| Parkinson, CJ | 1 |
| Mmutlane, EM | 1 |
| Dai, G | 1 |
| Post, FA | 1 |
| Baghaei, P | 1 |
| Tabarsi, P | 2 |
| Javanmard, P | 1 |
| Marjani, M | 2 |
| Moniri, A | 1 |
| Mathivha, KT | 1 |
| Meena, J | 1 |
| Sharma, D | 1 |
| Panda, AK | 1 |
| Oloo, SA | 1 |
| Vijayakumar, A | 1 |
| Otto-Knapp, R | 1 |
| Vesenbeckh, S | 1 |
| Schönfeld, N | 1 |
| Bettermann, G | 1 |
| Roth, A | 1 |
| Rüssmann, H | 1 |
| Mauch, H | 2 |
| Rogers, Z | 1 |
| Hiruy, H | 1 |
| Mbowane, C | 1 |
| Ngotho, L | 1 |
| Jeena, P | 1 |
| Satta, G | 1 |
| Witney, AA | 1 |
| Shorten, RJ | 2 |
| Karlikowska, M | 1 |
| Lipman, M | 2 |
| McHugh, TD | 3 |
| Guaoua, S | 1 |
| Ratbi, I | 1 |
| El Bouazzi, O | 1 |
| Hammi, S | 2 |
| Tebaa, A | 2 |
| Bourkadi, JE | 2 |
| Bencheikh, RS | 1 |
| Sefiani, A | 1 |
| Teklay, G | 1 |
| Teklu, T | 1 |
| Legesse, B | 1 |
| Tedla, K | 1 |
| Campanerut-Sá, PA | 1 |
| Ghiraldi-Lopes, LD | 1 |
| Meneguello, JE | 1 |
| Fiorini, A | 1 |
| Evaristo, GP | 1 |
| Scodro, RB | 1 |
| Patussi, EV | 1 |
| Donatti, L | 1 |
| Souza, EM | 1 |
| Brossier, F | 1 |
| Boudinet, M | 1 |
| Petrella, S | 1 |
| Sougakoff, W | 2 |
| Pérez Del Molino, ML | 1 |
| Barbeito-Castiñeiras, G | 1 |
| Mejuto, B | 1 |
| Alonso, P | 1 |
| Fernández, A | 1 |
| González-Mediero, G | 1 |
| Bruchfeld, J | 2 |
| Golka, K | 1 |
| Selinski, S | 1 |
| Selvakumar, N | 2 |
| Murali, AL | 1 |
| Gupta-Wright, A | 1 |
| van Oosterhout, JJ | 1 |
| Wilson, DK | 1 |
| Flach, C | 1 |
| Reddy, KP | 2 |
| Walensky, RP | 2 |
| Peters, JA | 1 |
| Alufandika-Moyo, M | 1 |
| Lawn, SD | 5 |
| Egelund, EF | 1 |
| Isaza, R | 2 |
| Alsultan, A | 2 |
| Casali, N | 1 |
| Broda, A | 1 |
| Harris, SR | 1 |
| Brown, T | 2 |
| Drobniewski, F | 8 |
| Huynh, GH | 1 |
| Arinaminpathy, N | 1 |
| Lin, HH | 1 |
| Wu, CY | 1 |
| Mandal, S | 1 |
| Suen, SC | 1 |
| Bacaër, N | 2 |
| Handel, A | 2 |
| Whalen, CC | 3 |
| Chang, ST | 1 |
| Wagner, BG | 1 |
| Eckhoff, PA | 1 |
| McBryde, ES | 2 |
| Pretorius, C | 2 |
| Lalli, M | 1 |
| Eaton, JW | 1 |
| Boccia, D | 1 |
| Hosseini, M | 1 |
| Gomez, GB | 1 |
| Sahu, S | 2 |
| Daniels, C | 2 |
| Ditiu, L | 1 |
| Chin, DP | 1 |
| Chadha, VK | 1 |
| Rade, K | 1 |
| Hippner, P | 1 |
| Pillay, Y | 1 |
| Mametja, LD | 1 |
| Kimerling, ME | 2 |
| Vassall, A | 1 |
| van Mourik, MS | 1 |
| Wattanapokayakit, S | 1 |
| Mushiroda, T | 1 |
| Wichukchinda, N | 1 |
| Chuchottawon, C | 1 |
| Nedsuwan, S | 1 |
| Rojanawiwat, A | 1 |
| Denjanta, S | 1 |
| Kantima, T | 1 |
| Wongyai, J | 1 |
| Suwankesawong, W | 1 |
| Rungapiromnan, W | 1 |
| Kidkeukarun, R | 1 |
| Bamrungram, W | 1 |
| Chaiwong, A | 1 |
| Suvichapanich, S | 1 |
| Mahasirimongkol, S | 1 |
| Padiadpu, J | 1 |
| Baloni, P | 1 |
| Anand, K | 1 |
| Munshi, M | 1 |
| Thakur, C | 1 |
| Mohan, A | 3 |
| Chandra, N | 1 |
| Lopez, AL | 1 |
| Aldaba, JG | 1 |
| Ama, CG | 1 |
| Sylim, PG | 1 |
| Geraldino, XD | 1 |
| Sarol, JN | 1 |
| Salonga, AM | 1 |
| Crawford, FW | 1 |
| Ravimohan, S | 1 |
| Tamuhla, N | 1 |
| Ivaturi, V | 1 |
| Pasipanodya, J | 1 |
| Weissman, D | 1 |
| Asres, A | 1 |
| Deressa, W | 1 |
| Okoli, EI | 1 |
| Roets, L | 1 |
| Baghban, A | 1 |
| Azar, MM | 1 |
| Bernardo, RM | 1 |
| Malinis, M | 1 |
| Aniemeke, E | 1 |
| Ha, NP | 1 |
| Chong, CR | 1 |
| Gu, P | 1 |
| Liu, JO | 1 |
| Perwitasari, DA | 1 |
| Irham, LM | 1 |
| Darmawan, E | 1 |
| Mulyani, UA | 1 |
| Atthobari, J | 1 |
| Kotecha, D | 1 |
| Sardar, M | 1 |
| Latimer, MD | 1 |
| Ruiz-García, MM | 1 |
| Grau Delgado, J | 1 |
| Andrés Franch, MI | 1 |
| Prats Sánchez, I | 1 |
| Nieto R, LM | 1 |
| Creissen, E | 1 |
| Troudt, J | 1 |
| Troy, A | 1 |
| Bielefeldt-Ohmann, H | 1 |
| Burgos, M | 2 |
| Izzo, A | 2 |
| Collantes, J | 1 |
| Solari, FB | 1 |
| Bright-Thomas, RJ | 1 |
| Gondker, AR | 1 |
| Morris, J | 2 |
| Ormerod, LP | 7 |
| Yeo, Y | 1 |
| Sung, H | 1 |
| Kim, MN | 1 |
| Nagu, TJ | 1 |
| Matee, MI | 2 |
| Maeurer, MJ | 1 |
| Fawzi, WW | 1 |
| Yun, YM | 1 |
| Chae, HJ | 1 |
| Cho, HJ | 1 |
| Ji, M | 1 |
| Kim, IS | 1 |
| Wee, KA | 1 |
| Lee, W | 1 |
| Song, SH | 1 |
| Chun, S | 1 |
| Semu, M | 1 |
| Fenta, TG | 1 |
| Medhin, G | 1 |
| Bartoletti, M | 1 |
| Tedeschi, S | 1 |
| Morelli, M | 1 |
| Bertuzzo, V | 1 |
| Pianta, P | 1 |
| Cristini, F | 1 |
| Giannella, M | 1 |
| Lewis, RE | 1 |
| Pinna, AD | 1 |
| Maimaiti, R | 1 |
| Mijiti, P | 1 |
| Wubili, M | 1 |
| Musa, M | 1 |
| Andersson, R | 1 |
| Singh, AR | 1 |
| Kharate, A | 1 |
| Kokane, AM | 1 |
| Bali, S | 1 |
| Verma, M | 1 |
| Nagar, M | 1 |
| Scherrer, AU | 1 |
| Manabe, YC | 3 |
| Buzibye, A | 1 |
| Ledergerber, B | 2 |
| Kambugu, A | 2 |
| Byakika-Kibwika, P | 1 |
| He, L | 1 |
| Deng, Y | 1 |
| Zuo, C | 1 |
| Jacobson, KB | 1 |
| Niccolai, L | 1 |
| Mtungwa, N | 1 |
| Moll, AP | 1 |
| Shenoi, SV | 1 |
| Abebe, W | 1 |
| Taye, K | 1 |
| Feleke, Y | 1 |
| Hallström, I | 1 |
| Ruff, AJ | 1 |
| Zeldow, B | 2 |
| Bobat, R | 4 |
| Mofenson, LM | 1 |
| Egere, U | 1 |
| Togun, T | 1 |
| Sillah, A | 1 |
| Mendy, F | 1 |
| Otu, J | 1 |
| Kampmann, B | 1 |
| Chongwe, G | 1 |
| Jumbe-Marsden, E | 1 |
| Somwe, SW | 1 |
| Reichman, LB | 8 |
| Langat, A | 1 |
| Ronen, K | 1 |
| McGrath, CJ | 1 |
| LaCourse, S | 1 |
| Pintye, J | 1 |
| Odeny, B | 1 |
| Singa, B | 1 |
| Katana, A | 1 |
| Nganga, L | 1 |
| Jenkins, HE | 2 |
| Chiang, SS | 1 |
| Roche, S | 1 |
| Contreras, C | 1 |
| Del Castillo, H | 1 |
| Canales, P | 1 |
| Tintaya, K | 1 |
| Aung, NM | 1 |
| Hanson, J | 1 |
| Kyi, TT | 1 |
| Htet, ZW | 1 |
| Cooper, DA | 1 |
| Boyd, MA | 1 |
| Kyi, MM | 1 |
| Saw, HA | 1 |
| Bouazzi, OE | 1 |
| Tanani, DS | 1 |
| Soulaymani-Bencheikh, R | 1 |
| Badrane, N | 1 |
| Bengueddour, R | 1 |
| Abe, C | 3 |
| Kobayashi, I | 2 |
| Mitarai, S | 3 |
| Wada, M | 5 |
| Kawabe, Y | 3 |
| Takashima, T | 3 |
| Suzuki, K | 5 |
| Sng, LH | 1 |
| Htay, HH | 1 |
| Fukino, K | 1 |
| Hirai, S | 1 |
| Nakamura, T | 1 |
| Hashimoto, M | 1 |
| Yamagishi, F | 2 |
| Ueno, K | 2 |
| Shenai, S | 1 |
| Mehta, A | 1 |
| Suzuki, Y | 1 |
| Miwa, S | 1 |
| Shirai, M | 1 |
| Ohba, H | 1 |
| Murakami, M | 1 |
| Fujita, K | 1 |
| Suda, T | 1 |
| Nakamura, H | 1 |
| Hayakawa, H | 1 |
| Chida, K | 1 |
| Ling, DI | 2 |
| Zwerling, AA | 1 |
| Nunn, P | 5 |
| Akpaka, PE | 1 |
| Baboolal, S | 1 |
| Clarke, D | 1 |
| Francis, L | 1 |
| Munseri, PJ | 1 |
| Mtei, L | 4 |
| Fordham von Reyn, C | 1 |
| Adhvaryu, MR | 1 |
| Reddy, N | 1 |
| Vakharia, BC | 1 |
| Rosenthal, IM | 2 |
| Almeida, D | 2 |
| Inge, LD | 1 |
| Lacoma, A | 1 |
| Garcia-Sierra, N | 1 |
| Prat, C | 1 |
| Ruiz-Manzano, J | 2 |
| Haba, L | 1 |
| Rosés, S | 1 |
| Maldonado, J | 1 |
| Domínguez, J | 1 |
| Hofmann-Thiel, S | 1 |
| Feldmann, K | 4 |
| Uzakova, GT | 1 |
| Murmusaeva, G | 1 |
| Hoffmann, H | 1 |
| Augustynowicz-Kopec, E | 2 |
| Jagielski, T | 2 |
| Zwolska, Z | 2 |
| Hoopes, AJ | 1 |
| Kammerer, JS | 1 |
| Harrington, TA | 1 |
| Ijaz, K | 2 |
| Armstrong, LR | 1 |
| Franken, WP | 1 |
| Arend, SM | 1 |
| Thijsen, SF | 1 |
| Bouwman, JJ | 1 |
| Koster, BF | 1 |
| van Dissel, JT | 1 |
| Bossink, AW | 1 |
| Bakir, M | 1 |
| Millington, KA | 1 |
| Soysal, A | 1 |
| Deeks, JJ | 1 |
| Efee, S | 1 |
| Aslan, Y | 1 |
| Dosanjh, DP | 1 |
| Lalvani, A | 1 |
| Higuchi, K | 2 |
| Okada, K | 1 |
| Harada, N | 2 |
| Mori, T | 4 |
| Dion, MJ | 4 |
| Al Jahdali, H | 1 |
| Memish, Z | 2 |
| Khan, K | 1 |
| Gardam, M | 1 |
| Hoeppner, V | 1 |
| Zhou, ZM | 1 |
| Zhao, DY | 1 |
| Zhao, WJ | 1 |
| Yang, MM | 1 |
| Elbek, O | 1 |
| Uyar, M | 1 |
| Aydin, N | 1 |
| Börekçi, S | 1 |
| Bayram, N | 1 |
| Dikensoy, O | 1 |
| He, GX | 1 |
| Zhao, YL | 1 |
| Liu, YH | 1 |
| Wang, SF | 1 |
| Wang, LX | 1 |
| Borgdorff, MW | 4 |
| Dantes, RB | 1 |
| Metcalfe, JZ | 1 |
| Jarlsberg, LG | 1 |
| Grinsdale, J | 1 |
| Kawamura, LM | 3 |
| Osmond, D | 1 |
| Hopewell, PC | 9 |
| Doustdar, F | 1 |
| Khosravi, AD | 1 |
| Breen, R | 1 |
| Perti, T | 1 |
| Girardi, E | 3 |
| Sahni, R | 1 |
| Miranda, C | 1 |
| Yen-Lieberman, B | 1 |
| Tomford, JW | 1 |
| Terpeluk, P | 1 |
| Quartey, P | 1 |
| Johnson, LT | 1 |
| Gordon, SM | 1 |
| Jaber, AA | 1 |
| Mokaddas, E | 3 |
| Abdelaal, A | 1 |
| El-Ghaffar, HA | 1 |
| Zaghloul, MH | 1 |
| El Mashad, N | 1 |
| Badran, E | 1 |
| Fathy, A | 1 |
| van-der-Werf, MJ | 1 |
| Au, BK | 1 |
| Anh, DD | 1 |
| Kam, KM | 2 |
| van-Doorn, HR | 1 |
| van-Soolingen, D | 1 |
| Kamal, A | 1 |
| Azeeza, S | 1 |
| Malik, MS | 1 |
| Shaik, AA | 1 |
| Rao, MV | 1 |
| Silva, MS | 1 |
| Arnold, LS | 1 |
| Rostirolla, DC | 1 |
| Cafrune, PI | 1 |
| Espinoza, RC | 1 |
| Telles, MA | 1 |
| Ritacco, V | 1 |
| Lopes, ML | 1 |
| Campelo, CL | 1 |
| Miranda, SS | 1 |
| da Silva, PE | 1 |
| Fonseca, Lde S | 1 |
| Ho, JL | 1 |
| Kritski, AL | 3 |
| Pollock, NR | 1 |
| Kashino, SS | 1 |
| Napolitano, DR | 1 |
| Guillet, J | 1 |
| Wong, M | 1 |
| Nardell, E | 2 |
| Kurosu, M | 1 |
| Crick, DC | 1 |
| Shamaei, M | 1 |
| Chitsaz, E | 1 |
| Kazempour, M | 1 |
| Esmaeili, M | 1 |
| Amiri, MV | 1 |
| Mirsaeidi, M | 2 |
| Mansouri, D | 2 |
| Sanders, GD | 2 |
| Ocama, P | 1 |
| Katwere, M | 1 |
| Piloya, T | 1 |
| Feld, J | 1 |
| Opio, KC | 1 |
| Katabira, E | 1 |
| Thomas, D | 1 |
| Colebunders, R | 4 |
| Ronald, A | 1 |
| Willemse, M | 2 |
| Hussey, GD | 1 |
| Weintrob, AC | 1 |
| Engemann, JJ | 1 |
| Fortenberry, ER | 1 |
| Domingo, M | 2 |
| Gil, O | 3 |
| Serrano, E | 1 |
| Guirado, E | 3 |
| Nofrarias, M | 1 |
| Grassa, M | 1 |
| Cáceres, N | 3 |
| Pérez, B | 1 |
| Vilaplana, C | 4 |
| Benmansour, N | 1 |
| El hord, S | 1 |
| Oudidi, A | 1 |
| Benjelloun, MC | 1 |
| El alami, MN | 1 |
| Ziganshina, LE | 2 |
| Garner, P | 2 |
| Sutton, BS | 1 |
| Arias, MS | 1 |
| Eang, MT | 1 |
| Anuradha, CM | 1 |
| Mulakayala, C | 1 |
| Babajan, B | 1 |
| Naveen, M | 1 |
| Rajasekhar, C | 1 |
| Kumar, CS | 1 |
| Khuller, GK | 15 |
| Kanwar, AJ | 2 |
| Angelini, MC | 1 |
| MacCormack-Gagnon, J | 1 |
| Dizio, S | 1 |
| Pronyk, P | 1 |
| Thsabangu, N | 1 |
| Moshabela, M | 1 |
| Struthers, H | 1 |
| Gray, GE | 2 |
| McIntyre, JA | 2 |
| Poli, F | 1 |
| Innocente, A | 1 |
| Cagni, N | 1 |
| Brambilla, C | 1 |
| Crespiatico, L | 1 |
| Colombo, MB | 1 |
| Scalamogna, M | 1 |
| Souza, CT | 1 |
| Hökerberg, YH | 1 |
| Pacheco, SJ | 1 |
| Passos, SR | 1 |
| Young, H | 1 |
| Wessolossky, M | 1 |
| Ellis, J | 1 |
| Kaminski, M | 1 |
| Daly, JS | 1 |
| El Kabbaj, D | 1 |
| Aatif, M | 1 |
| Moussa, LA | 1 |
| Khassouani, CE | 1 |
| Oualim, Z | 1 |
| Ibrahim, M | 1 |
| Tezcan, S | 1 |
| Emekdaş, G | 1 |
| Kittisupamongkol, W | 1 |
| Juréen, P | 1 |
| Giske, CG | 1 |
| Chryssanthou, E | 1 |
| Werngren, J | 1 |
| Kahlmeter, G | 1 |
| Hoffner, SE | 1 |
| Angeby, KA | 1 |
| Patel, SK | 1 |
| Holty, JE | 1 |
| Gould, MK | 1 |
| Meinke, L | 1 |
| Keeffe, EB | 1 |
| Ruoss, SJ | 1 |
| Camacho, A | 1 |
| Pérez-Camacho, I | 1 |
| Rivero, A | 2 |
| Natera, C | 1 |
| García-Lázaro, M | 1 |
| Castón, JJ | 1 |
| Gallo, M | 1 |
| Kindelán, JM | 2 |
| Torre-Cisneros, J | 2 |
| Garza-González, E | 1 |
| González, GM | 1 |
| Rentería, A | 1 |
| Cruz-Pulido, W | 1 |
| Rivera, G | 1 |
| Bocanegra-García, V | 1 |
| Nayak, K | 1 |
| Subramanyam, S | 1 |
| Venkatesan, P | 5 |
| Narayanan, PR | 3 |
| Heuts, F | 1 |
| Carow, B | 1 |
| Wigzell, H | 1 |
| Rottenberg, ME | 1 |
| Ahmad, Z | 3 |
| Fraig, MM | 1 |
| Valvatne, H | 1 |
| Syre, H | 2 |
| Kross, M | 1 |
| Stavrum, R | 1 |
| Ti, T | 1 |
| Phyu, S | 2 |
| Last, JP | 1 |
| Kozakiewicz, JM | 1 |
| Reid, A | 1 |
| Raviglione, M | 4 |
| Alarcon, E | 1 |
| Bissell, K | 2 |
| Boillot, F | 1 |
| Caminero, JA | 2 |
| Clevenbergh, P | 1 |
| Dlodlo, R | 1 |
| Enarson, DA | 5 |
| Enarson, P | 1 |
| Ferroussier, O | 1 |
| Kim, SJ | 3 |
| Wilson, N | 1 |
| Bachhuber, MA | 2 |
| Gross, R | 1 |
| Ekochin, LH | 1 |
| Manadan, AM | 1 |
| Aggarwal, R | 1 |
| Sequeira, W | 1 |
| Block, JA | 1 |
| Budha, NR | 1 |
| Lee, RB | 1 |
| Hurdle, JG | 1 |
| Lee, RE | 2 |
| Meibohm, B | 1 |
| Eley, B | 1 |
| Chaoui, I | 1 |
| Sabouni, R | 1 |
| Kourout, M | 1 |
| Jordaan, AM | 1 |
| Lahlou, O | 1 |
| Elouad, R | 1 |
| Akrim, M | 1 |
| El Mzibri, M | 1 |
| Balabanova, Y | 2 |
| Kruuner, A | 1 |
| Malomanova, N | 1 |
| Simak, T | 1 |
| Ilyina, N | 1 |
| Zakharova, S | 2 |
| Lebedeva, N | 1 |
| Alexander, HL | 1 |
| O'Brien, R | 1 |
| Shakhmistova, A | 1 |
| Fedorin, I | 2 |
| Naqvi, R | 2 |
| Akhtar, S | 2 |
| Ahmed, E | 2 |
| Noor, H | 2 |
| Saeed, T | 2 |
| Akhtar, F | 2 |
| Rizvi, A | 2 |
| Gomes, V | 1 |
| Suga, H | 1 |
| Atomiya, AN | 1 |
| Visalakshi, P | 1 |
| Meharwal, SK | 1 |
| Behera, D | 2 |
| Aydin, M | 1 |
| Sunmez, S | 1 |
| Gul, A | 1 |
| Artim, B | 1 |
| le Roux, SM | 2 |
| le Roux, DM | 2 |
| Workman, L | 1 |
| Ziakas, PD | 1 |
| Mylonakis, E | 1 |
| Chengeta, B | 1 |
| Kilmarx, PH | 3 |
| Wells, CD | 4 |
| Narendran, G | 1 |
| Iliayas, S | 2 |
| Santhanakrishnan, R | 1 |
| Menon, PA | 2 |
| Ramachandran, R | 2 |
| Chinnaiyan, P | 2 |
| Suhadev, M | 1 |
| Sakthivel, R | 1 |
| Arwady, MA | 1 |
| Yoon, JC | 1 |
| Motsamai, O | 2 |
| Egwaga, S | 2 |
| Mkopi, A | 1 |
| Range, N | 1 |
| Haag-Arbenz, V | 1 |
| Baraka, A | 1 |
| Grewal, P | 1 |
| Mshinda, H | 1 |
| Lwilla, F | 1 |
| van Leth, F | 2 |
| Setareh, M | 1 |
| Titov, LP | 2 |
| Surkova, LK | 2 |
| Tijink, BM | 1 |
| de Bree, R | 1 |
| Ge, F | 1 |
| Zeng, F | 1 |
| Liu, S | 1 |
| Guo, N | 2 |
| Ye, H | 1 |
| Song, Y | 2 |
| Deng, X | 1 |
| Yu, L | 1 |
| Detjen, AA | 1 |
| Wahn, U | 1 |
| Magdorf, K | 3 |
| Avachat, AM | 1 |
| Bhise, SB | 1 |
| Williams, KN | 2 |
| Agizew, T | 3 |
| Makwaruzi, VZ | 1 |
| Tallaksen, RJ | 1 |
| Parker, JE | 1 |
| Mboya, JJ | 1 |
| Roy, V | 1 |
| Gupta, D | 1 |
| Sethi, GR | 1 |
| Mishra, TK | 1 |
| Cilliers, K | 1 |
| Labadarios, D | 1 |
| Maritz, JS | 1 |
| Singla, R | 1 |
| Sarda, P | 1 |
| Makharia, G | 1 |
| Jayaswal, A | 1 |
| Sreenivas, V | 1 |
| Mahan, CS | 1 |
| Walusimbi, M | 1 |
| Lancioni, C | 1 |
| Charlebois, E | 1 |
| Baseke, J | 1 |
| Mugerwa, RD | 2 |
| Khalili, H | 1 |
| Dashti-Khavidaki, S | 1 |
| Amini, M | 1 |
| Mahjub, R | 1 |
| Hajiabdolbaghi, M | 1 |
| Minion, J | 1 |
| Brady, MF | 1 |
| Navincopa, M | 1 |
| Ticona, E | 1 |
| Chavez, G | 1 |
| Sánchez, E | 1 |
| Rojas, C | 2 |
| Solari, L | 1 |
| Pinedo, Y | 1 |
| Benites, C | 1 |
| Green, E | 2 |
| Obi, CL | 1 |
| Nchabeleng, M | 1 |
| de Villiers, BE | 1 |
| Sein, PP | 1 |
| Letsoalo, T | 1 |
| Hoosen, AA | 1 |
| Bessong, PO | 1 |
| Ndip, RN | 2 |
| Anderson, C | 1 |
| Story, A | 1 |
| Yoshikawa, K | 1 |
| Yano, S | 2 |
| van Halsema, CL | 2 |
| Russell, EC | 1 |
| Cansü, E | 1 |
| Erdogan, F | 1 |
| Ulusam, AO | 1 |
| Ahmad, R | 1 |
| Bang, D | 1 |
| Andersen, AB | 1 |
| Thomsen, VØ | 1 |
| Migita, K | 1 |
| Umeno, T | 1 |
| Miyagawa, K | 1 |
| Izumi, Y | 1 |
| Sasaki, E | 1 |
| Kakugawa, T | 1 |
| Ito, M | 2 |
| Kinoshita, A | 1 |
| Miyashita, T | 1 |
| Peeler, C | 1 |
| Díaz, I | 1 |
| Tapia, G | 2 |
| Díaz, J | 4 |
| Fort, M | 1 |
| Pinto, S | 1 |
| Caylà, J | 1 |
| Corner, L | 1 |
| Van Wyk, SS | 2 |
| Hamade, H | 1 |
| Banerjee, AD | 1 |
| Pandey, P | 1 |
| Ambekar, S | 1 |
| Chandramouli, BA | 1 |
| Uçar, E | 1 |
| Kiliç, A | 1 |
| Ceyhan, I | 1 |
| Yilmaz, S | 1 |
| Kiliç, S | 1 |
| Tarhan, G | 1 |
| Simşek, H | 1 |
| Güllü, U | 1 |
| Başustaoğlu, AC | 1 |
| Yao, C | 1 |
| Zhu, T | 1 |
| Huang, J | 1 |
| Fu, W | 1 |
| Bright-Thomas, R | 1 |
| Nandwani, S | 1 |
| Smith, J | 1 |
| Morris, JA | 1 |
| Homolka, S | 1 |
| Meyer, CG | 1 |
| Hillemann, D | 2 |
| Owusu-Dabo, E | 1 |
| Adjei, O | 1 |
| Horstmann, RD | 1 |
| Browne, EN | 1 |
| Chinbuah, A | 1 |
| Osei, I | 1 |
| Gyapong, J | 1 |
| Kubica, T | 1 |
| Ruesch-Gerdes, S | 1 |
| Saraogi, GK | 1 |
| Joshi, B | 1 |
| Jain, NK | 2 |
| Agrawal, GP | 1 |
| Bai, KJ | 2 |
| Lee, CN | 1 |
| Suo, J | 2 |
| Luh, KT | 1 |
| Altet Gómez, N | 1 |
| Ali, MA | 2 |
| Manogaran, E | 1 |
| Govindasamy, J | 1 |
| Sellappan, V | 1 |
| Pandian, S | 1 |
| Prestinari, F | 1 |
| Ferguglia, G | 1 |
| Laria, G | 1 |
| Currie, AC | 1 |
| Knight, SR | 1 |
| Morris, PJ | 1 |
| Nikolaou, S | 1 |
| Karabela, S | 1 |
| Ioannidis, P | 1 |
| Konstantinidou, E | 1 |
| Marinou, I | 1 |
| Sainti, A | 1 |
| Kanavaki, S | 1 |
| Lee, MF | 1 |
| Chen, YH | 1 |
| Hsu, HJ | 1 |
| Peng, CF | 1 |
| Hill, K | 1 |
| Pénzes, CB | 1 |
| Schnöller, D | 1 |
| Keszthelyi, T | 1 |
| Bilal, S | 1 |
| Iqbal, M | 1 |
| Murphy, P | 1 |
| Power, J | 1 |
| Boussetta, K | 1 |
| Tinsa, F | 1 |
| Ghaffari, H | 1 |
| Brini, I | 1 |
| Aloui, N | 1 |
| Jaubert, F | 1 |
| Bousnina, S | 1 |
| Zozio, T | 1 |
| Choi, GE | 1 |
| Yi, J | 1 |
| Hwang, SH | 1 |
| Kim, HH | 1 |
| Lee, EY | 1 |
| Cho, EH | 1 |
| Dubrulle, S | 1 |
| Vervel, C | 1 |
| Boutignon, H | 1 |
| Romeo, B | 1 |
| Lahey, T | 3 |
| Arbeit, RD | 4 |
| Matee, M | 3 |
| Waddell, R | 2 |
| Vuola, JM | 1 |
| Pallangyo, K | 4 |
| Ichai, P | 1 |
| Saliba, F | 1 |
| Antoun, F | 1 |
| Azoulay, D | 1 |
| Sebagh, M | 1 |
| Antonini, TM | 1 |
| Escaut, L | 1 |
| Delvart, V | 1 |
| Castaing, D | 1 |
| Samuel, D | 1 |
| Hashida, N | 1 |
| Terubayashi, A | 1 |
| Ohguro, N | 1 |
| Chevalier, B | 1 |
| Margery, J | 1 |
| Sane, M | 1 |
| Camara, P | 1 |
| Lefebvre, N | 1 |
| Gueye, M | 1 |
| Thiam, M | 1 |
| Perrier-Gros-Claude, JD | 1 |
| Simon, F | 1 |
| Fabre, M | 3 |
| Soler, C | 2 |
| Herve, V | 1 |
| Mbaye, PS | 1 |
| Debonne, JM | 1 |
| Suh, GY | 1 |
| Chung, DR | 1 |
| Yoonchang, SW | 1 |
| Kang, ES | 1 |
| Shrestha, B | 1 |
| Maharjan, B | 1 |
| Roper, M | 1 |
| Mitchell, S | 1 |
| Gamarra, N | 1 |
| Mendoza, A | 1 |
| Hauck, Y | 1 |
| Pourcel, C | 1 |
| Vergnaud, G | 1 |
| Vong, R | 1 |
| Eldred, LJ | 1 |
| Mngadi, KT | 2 |
| Luttig, MM | 2 |
| Ntshele, S | 1 |
| Mdluli, J | 1 |
| Mngadi, N | 1 |
| Sefuthi, C | 1 |
| Clark, DA | 1 |
| Lester, R | 1 |
| Hamilton, R | 1 |
| Dwadwa, T | 1 |
| Chandler, C | 1 |
| Vellozo, V | 1 |
| Israel, G | 1 |
| Sculier, D | 2 |
| Gunneberg, C | 3 |
| Blanc, L | 1 |
| Hoffmann, CJ | 2 |
| Dowdeswell, R | 1 |
| Pienaar, J | 1 |
| De Groote, MA | 1 |
| Gilliland, JC | 2 |
| Wells, CL | 1 |
| Brooks, EJ | 1 |
| Woolhiser, LK | 1 |
| Gruppo, V | 1 |
| Orme, IM | 6 |
| Lenaerts, AJ | 3 |
| Bark, CM | 1 |
| Morrison, CS | 1 |
| Salata, RA | 1 |
| Byamugisha, JK | 1 |
| Katalemwa, NH | 1 |
| Mukasa, JB | 1 |
| Musoke, RN | 1 |
| Nankya-Mutyoba, J | 1 |
| Rwambuya, S | 1 |
| Walker, CJ | 1 |
| Siu, GK | 1 |
| Tam, YH | 1 |
| Ho, PL | 2 |
| Lee, AS | 2 |
| Que, TL | 1 |
| Tse, CW | 1 |
| Yip, KT | 1 |
| Lam, JT | 1 |
| Cheng, VC | 1 |
| Yuen, KY | 2 |
| Yam, WC | 2 |
| Grosset, J | 27 |
| Köser, CU | 1 |
| Summers, DK | 1 |
| Archer, JA | 1 |
| Kitao, T | 1 |
| Kato, S | 3 |
| Coulter, JB | 3 |
| Groenheit, R | 1 |
| Koivula, T | 1 |
| Ghebremichael, S | 1 |
| Advani, A | 1 |
| Castro, E | 1 |
| Pennhag, A | 1 |
| Mazurek, J | 2 |
| Pawlowski, A | 1 |
| Kan, B | 1 |
| Melefors, Ö | 1 |
| Källenius, G | 2 |
| Lai, R | 1 |
| Huang, F | 1 |
| Aydın, F | 1 |
| Kaklıkkaya, N | 1 |
| Bayramoğlu, G | 1 |
| Ozkul, G | 1 |
| Buruk, K | 1 |
| Dinç, U | 1 |
| Köse, T | 1 |
| Dede, R | 1 |
| Koo, MS | 2 |
| Manca, C | 1 |
| Yang, G | 2 |
| O'Brien, P | 2 |
| Sung, N | 1 |
| Tsenova, L | 2 |
| Fallows, D | 2 |
| Muller, G | 2 |
| Ehrt, S | 1 |
| Kaplan, G | 2 |
| Mendoza, R | 1 |
| De Donato, M | 1 |
| Takiff, H | 1 |
| Bello, T | 1 |
| Chirinos, G | 1 |
| Ivanyi, J | 3 |
| Tudó, G | 1 |
| Laing, K | 1 |
| Mitchison, DA | 32 |
| Butcher, PD | 2 |
| Waddell, SJ | 1 |
| Fox, L | 1 |
| Kramer, MR | 2 |
| Haim, I | 1 |
| Priess, R | 1 |
| Metvachuk, A | 1 |
| Shitrit, D | 1 |
| Liashenko, OO | 1 |
| Poteiko, PI | 1 |
| Krutko, VS | 1 |
| Magden, ER | 1 |
| Weiner, CM | 1 |
| DeGroote, MA | 1 |
| Kendall, LV | 1 |
| Bazira, J | 1 |
| Asiimwe, BB | 1 |
| Bwanga, F | 1 |
| Frigati, LJ | 1 |
| Lombard, CJ | 4 |
| Benatar, M | 1 |
| Maguire, H | 1 |
| Brailsford, S | 1 |
| Carless, J | 1 |
| Yates, M | 2 |
| Altass, L | 1 |
| Yates, S | 1 |
| Anaraki, S | 1 |
| Charlett, A | 1 |
| Lozewicz, S | 1 |
| Bothamley, G | 1 |
| Davis, MK | 1 |
| Moeti, TL | 2 |
| Moffat, HJ | 1 |
| Castro, KG | 3 |
| Dodd, LE | 1 |
| Zirbs, M | 1 |
| Kigitsidou, E | 1 |
| Seifert, F | 1 |
| Ring, J | 1 |
| Brockow, K | 1 |
| Kolibab, K | 1 |
| Derrick, SC | 1 |
| Morris, SL | 2 |
| Abes, GT | 1 |
| Abes, FL | 1 |
| Jamir, JC | 1 |
| Mottalib, A | 1 |
| Hossain, M | 1 |
| Khalil, I | 1 |
| Islam, S | 1 |
| Hossain, A | 1 |
| Zhu, R | 2 |
| Kiser, JJ | 2 |
| D'Argenio, DZ | 1 |
| Maurya, DP | 1 |
| Sultana, Y | 1 |
| Aqil, M | 1 |
| Chuttani, K | 2 |
| Ali, A | 1 |
| Mishra, AK | 2 |
| Foo, DG | 1 |
| Tay, HC | 1 |
| Siew, JY | 1 |
| Singhal, A | 1 |
| Camacho, L | 1 |
| de Oliveira, JL | 1 |
| da Silva Junior, GB | 1 |
| Daher, Ede F | 1 |
| Pillay, V | 2 |
| Ndesendo, VM | 1 |
| du Toit, LC | 1 |
| Khan, RA | 1 |
| Murphy, CS | 1 |
| Jarvis, DL | 1 |
| Bateman, C | 1 |
| Hoza, AS | 1 |
| Torrea, G | 1 |
| Chonde, TM | 1 |
| Basra, D | 1 |
| Egwaga, SM | 1 |
| Gideon, HP | 1 |
| Wilkinson, KA | 3 |
| Mwansa-Kambafwile, J | 1 |
| Fielding, K | 3 |
| Goliath, R | 1 |
| Titus, R | 1 |
| Mathee, S | 1 |
| Martín-Dávila, P | 1 |
| López-Vélez, R | 1 |
| Pintado, V | 2 |
| Cobo, J | 1 |
| González, A | 1 |
| Bonilla, M | 1 |
| Aneiros, V | 1 |
| Gómez-Mampaso, E | 1 |
| Moreno, S | 3 |
| Hausler, H | 1 |
| Ram, M | 1 |
| Cremades, R | 1 |
| Rodríguez, JC | 1 |
| García-Pachón, E | 1 |
| Galiana, A | 1 |
| Ruiz-García, M | 1 |
| López, P | 1 |
| Royo, G | 1 |
| Reid, AJ | 1 |
| Morrison, J | 1 |
| Park, JB | 2 |
| Kim, SC | 1 |
| Jeong, JY | 1 |
| Forster, M | 1 |
| Phiri, S | 1 |
| Braitstein, P | 1 |
| Lewden, C | 1 |
| Schechter, M | 2 |
| Pascoe, M | 1 |
| Sprinz, E | 1 |
| Dickinson, D | 1 |
| Fox, MP | 1 |
| McIntyre, J | 1 |
| Khongphatthanayothin, M | 1 |
| Dabis, F | 1 |
| Brinkhof, MW | 1 |
| Egger, M | 1 |
| Lerra, S | 1 |
| Nazir, T | 1 |
| Mir Qadri, S | 1 |
| Kirmani, M | 1 |
| Theron, D | 1 |
| Murray, MB | 1 |
| Kuwabara, K | 1 |
| Ben Mahmoud, L | 1 |
| Ghozzi, H | 1 |
| Kamoun, A | 1 |
| Hachicha, H | 1 |
| Hammami, S | 1 |
| Sahnoun, Z | 1 |
| Zalila, N | 1 |
| Makni, H | 1 |
| Zeghal, K | 1 |
| Kielland, LG | 1 |
| Vage, RA | 1 |
| Eide, GE | 1 |
| Sørnes, S | 1 |
| Naess, A | 1 |
| Burkett, EA | 1 |
| Bradshaw, WT | 1 |
| Tiwari, P | 1 |
| Soneja, M | 1 |
| Peixoto, B | 1 |
| Santos, DS | 3 |
| Longhinotti, E | 1 |
| Moreira, Ide S | 1 |
| Dutt, N | 1 |
| Rosenkranz, B | 1 |
| Roll, S | 1 |
| Mtabho, C | 1 |
| Mpagama, S | 1 |
| Mwaigwisya, S | 1 |
| Pholwat, S | 1 |
| Ndusilo, N | 1 |
| Kabali, C | 1 |
| Brooks, DR | 1 |
| Lombard, C | 1 |
| Saleri, N | 1 |
| Dembélé, SM | 1 |
| Villani, P | 1 |
| Carvalho, AC | 1 |
| Cusato, M | 1 |
| Bonkoungou, V | 1 |
| Nacanabo, R | 1 |
| Kouanda, S | 1 |
| Comelli, M | 1 |
| Regazzi, M | 1 |
| Mojahedi, MJ | 1 |
| Feizzadeh, B | 1 |
| Aghdam, B | 1 |
| Hekmat, R | 1 |
| Görl, N | 1 |
| Kneitz, C | 1 |
| Borisov, AS | 1 |
| Hackman, J | 2 |
| Kerrigan, A | 1 |
| Weis, SE | 1 |
| Conde, MB | 1 |
| Mindachew, M | 1 |
| Deribew, A | 1 |
| Tessema, F | 1 |
| Biadgilign, S | 1 |
| Namuwenge, PM | 1 |
| Mukonzo, JK | 1 |
| Wanyenze, R | 1 |
| Byaruhanga, R | 1 |
| Mauro, MV | 1 |
| Giraldi, C | 1 |
| van den Boogaard, J | 1 |
| Ijdema, D | 1 |
| Kiziltaş, Ş | 1 |
| Çolak, Y | 1 |
| Ulaşoğlu, C | 1 |
| Öztürk, O | 1 |
| Yorulmaz, E | 1 |
| Adali, G | 1 |
| Enç, F | 1 |
| Tuncer, İ | 1 |
| Shang, S | 1 |
| Shanley, CA | 1 |
| Caraway, ML | 1 |
| Orme, EA | 1 |
| Henao-Tamayo, M | 1 |
| Hascall-Dove, L | 1 |
| Ackart, D | 1 |
| Ordway, DJ | 1 |
| Basaraba, RJ | 2 |
| Leiro-Fernandez, V | 1 |
| Valverde, D | 1 |
| Vázquez-Gallardo, R | 1 |
| Botana-Rial, M | 1 |
| Constenla, L | 1 |
| Agúndez, JA | 1 |
| Fernández-Villar, A | 2 |
| Maheswaran, H | 1 |
| Barton, P | 1 |
| Field, M | 1 |
| Clarke, A | 1 |
| Kelleher, M | 1 |
| Hamsho, A | 1 |
| Mellor, S | 1 |
| Ready, A | 1 |
| Inston, N | 1 |
| van Dellen, D | 1 |
| Beer, J | 1 |
| Emmrich, F | 1 |
| Sack, U | 1 |
| Rodloff, AC | 1 |
| Varghese, B | 1 |
| Hillemann, A | 1 |
| Wijayanti, DR | 1 |
| Shoukri, M | 1 |
| Al-rabiah, F | 1 |
| Al-Omari, R | 1 |
| Al-Hajoj, S | 1 |
| Markarian, SA | 1 |
| Aznauryan, MG | 1 |
| Zenteno-Cuevas, R | 1 |
| Cuevas-Cordoba, B | 1 |
| Enciso, A | 1 |
| Enciso, L | 1 |
| Cuellar, A | 1 |
| Al-Darraji, HA | 1 |
| Kamarulzaman, A | 1 |
| Altice, FL | 1 |
| Anger, HA | 1 |
| Proops, D | 1 |
| Harris, TG | 1 |
| Ahuja, SD | 1 |
| Nackers, F | 1 |
| Espié, E | 1 |
| Aloo, AO | 1 |
| Bastard, M | 1 |
| Etard, JF | 1 |
| Sitienei, J | 2 |
| Chakaya, J | 1 |
| Nolan, S | 1 |
| Geiman, DE | 1 |
| Akhtar, MF | 1 |
| Rabbani, M | 1 |
| Sharif, A | 1 |
| Akhtar, B | 1 |
| Saleem, A | 1 |
| Murtaza, G | 1 |
| Williams, K | 1 |
| Minkowski, A | 1 |
| Amoabeng, O | 1 |
| Taylor, D | 1 |
| Wallis, RS | 3 |
| Mdluli, KE | 2 |
| Grundmann, K | 1 |
| Friedrich, C | 1 |
| Hasiloglu, ZI | 1 |
| Albayram, S | 1 |
| Asik, M | 1 |
| Kilic, O | 1 |
| Unver, O | 1 |
| Erdemli, HE | 1 |
| Kocer, N | 1 |
| Johnson, JR | 1 |
| Kalandadze, I | 1 |
| Vashakidze, L | 1 |
| Kakkar, D | 1 |
| Tiwari, AK | 1 |
| Datta, A | 1 |
| Illei, PB | 1 |
| Pho, MT | 2 |
| Losina, E | 1 |
| Ponnuraja, C | 1 |
| Uhler, LM | 1 |
| Scott, CA | 1 |
| Freedberg, KA | 1 |
| Boyles, TH | 1 |
| Chehab, JC | 1 |
| Vilakazi-Nhlapo, K | 1 |
| Vranken, P | 1 |
| Peters, A | 1 |
| Klausner, JD | 2 |
| Lee, SW | 2 |
| Kurbatova, EV | 2 |
| Cavanaugh, JS | 1 |
| Wright, A | 1 |
| Kim, H | 1 |
| Barrera, L | 1 |
| Boulahbal, F | 3 |
| Richter, E | 3 |
| Martín-Casabona, N | 1 |
| Arias, F | 1 |
| Zemanova, I | 1 |
| Santos Silva, A | 1 |
| Coulter, C | 1 |
| Lumb, R | 3 |
| Cegielski, JP | 2 |
| Ramsay, A | 1 |
| Garg, N | 1 |
| Towle, M | 1 |
| Smyth, C | 1 |
| Baggaley, R | 1 |
| Williams, B | 2 |
| van Gorkom, J | 2 |
| Granich, RM | 1 |
| Castell, S | 1 |
| Lattuada, E | 1 |
| Lanzafame, M | 1 |
| Vento, S | 2 |
| Dantes, R | 1 |
| Metcalfe, J | 1 |
| Kim, E | 1 |
| Kato-Maeda, M | 1 |
| Kawamura, M | 2 |
| Bristow, CC | 1 |
| Larson, E | 1 |
| Vilakazi-Nhlapo, AK | 1 |
| Wilson, M | 2 |
| Verster, A | 1 |
| Hirnschall, G | 1 |
| DʼArgenio, DZ | 1 |
| McSherry, GD | 1 |
| Carey, VJ | 1 |
| Navascués, A | 1 |
| Gil-Setas, A | 1 |
| Tordoya, IJ | 1 |
| Jiménez-Pajares, MS | 1 |
| Mullins, CD | 1 |
| Kuznik, A | 1 |
| Dos Santos Junior, A | 1 |
| Dos Santos, AJ | 1 |
| Schneider, CZ | 1 |
| Calixto, JB | 1 |
| de França Lopes, LG | 1 |
| Souto, AA | 1 |
| Campos, MM | 1 |
| Stigliani, JL | 1 |
| McLaughlin, AM | 1 |
| Gibbons, N | 1 |
| Fitzgibbon, M | 1 |
| Power, JT | 1 |
| Foley, SC | 1 |
| Hayes, JP | 1 |
| Rogers, T | 1 |
| Keane, J | 1 |
| Ko, Y | 1 |
| Kim, CK | 1 |
| Park, KS | 1 |
| Arjomandzadegan, M | 1 |
| Sheikholeslami, F | 1 |
| Owlia, P | 1 |
| Eshghinejad, A | 1 |
| Farazi, AA | 1 |
| Eshrati, M | 1 |
| Kahbazi, M | 1 |
| Shojapur, M | 1 |
| Nau, JY | 1 |
| Ruiz-Moreno, JL | 1 |
| Peña-Santos, G | 1 |
| Crépeau, CA | 1 |
| Dufresne, M | 1 |
| Khan, S | 1 |
| Quach, C | 1 |
| Dendukuri, N | 1 |
| Lands, LC | 1 |
| Silaigwana, B | 1 |
| El-Sharif, A | 1 |
| Afifi, S | 1 |
| El-Dahshan, R | 1 |
| Rafeh, N | 1 |
| Eissa, S | 1 |
| Rutherford, ME | 1 |
| Triasih, R | 1 |
| Sinfield, R | 1 |
| Tyagi, S | 2 |
| Li, SY | 1 |
| Wallengren, K | 1 |
| Lalloo, U | 1 |
| Mboma, S | 1 |
| Mzemba, T | 1 |
| Mwaungulu, NJ | 1 |
| Mwaungulu, L | 1 |
| Mwenibabu, M | 1 |
| French, N | 2 |
| Yu, MC | 1 |
| Shih, HC | 1 |
| Yen, MY | 1 |
| Hsu, YL | 1 |
| Yang, SL | 1 |
| Lin, TP | 2 |
| Mackenzie, T | 1 |
| Maro, I | 1 |
| Solanki, R | 1 |
| Chauhan, LS | 1 |
| Gulec, SG | 1 |
| Telhan, L | 1 |
| Koçkaya, T | 1 |
| Erdem, E | 1 |
| Bayraktar, B | 1 |
| Palanduz, A | 1 |
| Byers, P | 1 |
| Warris, A | 1 |
| de Groot, R | 1 |
| Chen, TH | 1 |
| Mtika, C | 1 |
| McGregor, AC | 1 |
| Platt, S | 1 |
| Jenkins, C | 1 |
| Gillespie, SH | 2 |
| Charalambous, BM | 1 |
| Taylor, AB | 1 |
| Myer, L | 2 |
| Azuma, J | 1 |
| Ohno, M | 1 |
| Kubota, R | 1 |
| Yokota, S | 1 |
| Nagai, T | 1 |
| Tsuyuguchi, K | 1 |
| Okuda, Y | 1 |
| Kamimura, S | 1 |
| Fujio, Y | 1 |
| Kawase, I | 1 |
| Rätsep, T | 1 |
| Lytras, T | 1 |
| Spala, G | 1 |
| Bonovas, S | 1 |
| Panagiotopoulos, T | 1 |
| Kerkhoff, AD | 1 |
| Nakiyingi-Miiro, J | 1 |
| Loddenkemper, R | 4 |
| Beneri, CA | 1 |
| Pillay, E | 1 |
| Dittmer, S | 1 |
| Hawkins, E | 1 |
| Pina, JM | 1 |
| Clotet, L | 1 |
| Ferrer, A | 1 |
| Sala, MR | 1 |
| Garrido, P | 1 |
| Salleras, L | 1 |
| Domínguez, A | 1 |
| Gopalan, N | 1 |
| Perumal, V | 1 |
| Santhanakrishnan, RK | 1 |
| Navaneethapandian, PD | 1 |
| Elangovan, T | 1 |
| Wares, F | 2 |
| Paranji Ramaiyengar, N | 1 |
| Manosuthi, W | 1 |
| Sukasem, C | 1 |
| Lueangniyomkul, A | 1 |
| Mankatitham, W | 1 |
| Thongyen, S | 1 |
| Nilkamhang, S | 1 |
| Manosuthi, S | 1 |
| Sungkanuparph, S | 1 |
| Rekha, B | 1 |
| Jagarajamma, K | 1 |
| Sivanandham, R | 1 |
| Marape, M | 1 |
| Miranda, AG | 1 |
| Reuter, H | 1 |
| Sumenkova, DV | 1 |
| Poliakov, LM | 1 |
| Panin, LE | 1 |
| Prakash, P | 1 |
| Singh, SK | 1 |
| Tolman, AW | 1 |
| Parr, JB | 1 |
| Chiosea, S | 1 |
| Srinivasan, R | 1 |
| Geetharani, A | 1 |
| Sugirda, P | 1 |
| Nandhakumar, B | 1 |
| Nandini, R | 1 |
| Tharani, CB | 2 |
| Abal, AT | 1 |
| Palomino, JC | 2 |
| Camacho, M | 1 |
| Guerra, H | 1 |
| Swings, J | 1 |
| Portaels, F | 3 |
| Wanchu, A | 1 |
| Bhatnagar, A | 1 |
| Khullar, M | 1 |
| Sud, A | 1 |
| Bambery, P | 1 |
| Chan, KC | 1 |
| Tang, HW | 1 |
| Wong, K | 1 |
| Saint-Joanis, B | 2 |
| Castiñeiras, AA | 1 |
| Pérez-Pascual, P | 1 |
| Zarranz, JE | 1 |
| Della-Latta, P | 1 |
| Herreras, A | 1 |
| Altíparmak, MR | 2 |
| Pamuk, ON | 1 |
| Pamuk, GE | 1 |
| Ataman, R | 2 |
| Serdengeçti, K | 2 |
| Burman, WJ | 3 |
| Terra, M | 1 |
| Breese, P | 1 |
| Cohn, D | 1 |
| Singh, N | 3 |
| Wagener, MM | 1 |
| Gayowski, T | 1 |
| Meissner, PE | 2 |
| Bunn, JE | 1 |
| Fares, E | 1 |
| Araj, GF | 1 |
| Chugh, TD | 1 |
| Mustafa, AS | 1 |
| Labana, S | 1 |
| Pandey, R | 6 |
| Singh, I | 2 |
| Kaur, KJ | 2 |
| Bhade, SR | 2 |
| Kaul, CL | 2 |
| Panchagnula, R | 2 |
| Laartz, BW | 1 |
| Narvarte, HJ | 1 |
| Holt, D | 1 |
| Larkin, JA | 1 |
| Pomputius, WF | 1 |
| Benito, N | 1 |
| Sued, O | 1 |
| Moreno, A | 3 |
| Horcajada, JP | 1 |
| González, J | 3 |
| Navasa, M | 1 |
| Rimola, A | 1 |
| Kobayashi, K | 1 |
| Haruta, T | 1 |
| Maeda, H | 1 |
| Kubota, M | 1 |
| Nishio, T | 1 |
| Auclair, B | 1 |
| Mikota, SK | 2 |
| Aguilar, R | 1 |
| Maslow, JN | 2 |
| Jasmer, RM | 3 |
| Riska, PF | 1 |
| Carleton, S | 1 |
| Curley, C | 1 |
| Bonnaud, F | 1 |
| Zigani, A | 1 |
| Hollender, ES | 1 |
| Ashkin, D | 1 |
| Eidlitz-Markus, T | 1 |
| Zeharia, A | 1 |
| Baum, G | 1 |
| Mimouni, M | 1 |
| Amir, J | 1 |
| Hovell, M | 1 |
| Blumberg, E | 2 |
| Gil-Trejo, L | 1 |
| Vera, A | 2 |
| Kelley, N | 2 |
| Sipan, C | 2 |
| Hofstetter, CR | 2 |
| Marshall, S | 1 |
| Berg, J | 2 |
| Friedman, L | 4 |
| Furuta, I | 1 |
| Yamazumi, T | 1 |
| Barton, LL | 1 |
| Lepage, P | 1 |
| Dekker, TG | 1 |
| Lötter, AP | 1 |
| Danckwerts, MP | 1 |
| Ebrahim, S | 1 |
| Mohan, B | 1 |
| Benito González, JJ | 1 |
| Benito González, F | 1 |
| Santa Cruz Ruiz, S | 1 |
| Gómez González, JL | 1 |
| Coscarón Blanco, E | 1 |
| Cordero Sánchez, M | 1 |
| del Cañizo Alvarez, A | 1 |
| Kenyon, TA | 2 |
| Mwasekaga, MJ | 1 |
| Mallon, V | 1 |
| Binkin, NJ | 2 |
| Gibson, A | 1 |
| Ruddy, M | 1 |
| Yates, MD | 1 |
| Zevallos, M | 1 |
| Justman, JE | 1 |
| Hurtado, AM | 1 |
| Hill, KR | 1 |
| Rosenblatt, W | 1 |
| Bender, J | 1 |
| Scharmen, T | 1 |
| Bakonyte, D | 1 |
| Baranauskaite, A | 1 |
| Cicenaite, J | 1 |
| Sosnovskaja, A | 1 |
| Stakenas, P | 1 |
| Maslo, C | 1 |
| Boelaert, RJ | 1 |
| Bergeron, KG | 1 |
| Bonebrake, RG | 1 |
| Allen, C | 1 |
| Gray, CJ | 1 |
| Moshi, A | 1 |
| Aris, EA | 1 |
| Chale, S | 1 |
| Josiah, R | 1 |
| Magao, P | 1 |
| Pallangyo, N | 1 |
| Sandström, E | 1 |
| Biberfeld, G | 1 |
| Mhalu, F | 1 |
| Chimzizi, RB | 1 |
| Nyirenda, TE | 1 |
| Salaniponi, FM | 2 |
| Ruiz, P | 1 |
| Rodríguez-Cano, F | 1 |
| Zerolo, FJ | 1 |
| Casal, M | 3 |
| SAMITIER AZPARREN, J | 1 |
| BURNAND, R | 1 |
| SCHUYKER, SA | 1 |
| DE CARVALHO, P | 2 |
| GOMEZ, FD | 2 |
| CANCELA FREIJO, J | 1 |
| BREA, RJ | 1 |
| TRENCHI, A | 2 |
| BURGOS, R | 1 |
| MALLUCHE, H | 1 |
| GEMMI, A | 1 |
| GRUTZ, O | 2 |
| HEILMEYER, L | 3 |
| SCHAICH, W | 1 |
| BUCHEGGER, G | 1 |
| KILCHLING, H | 1 |
| SCHMIDT, F | 2 |
| WALTER, AM | 2 |
| TUCZEK, H | 3 |
| SAUPE, M | 2 |
| PERKINS, JE | 3 |
| MARONCELLI, P | 3 |
| SALVATORI, GC | 1 |
| COUVELAIRE, R | 2 |
| DEBRAY, JR | 2 |
| DESMONTS-CROS-DECAM, A | 1 |
| BATTIGELLI, G | 2 |
| ALMANSA DE CARA, S | 2 |
| UEHLINGER, E | 2 |
| SIEBENMANN, R | 2 |
| FREI, H | 2 |
| WIESMANN, E | 1 |
| WANNER, J | 2 |
| TANNER, E | 3 |
| RAYBAUD, A | 2 |
| TEBROCK, HE | 3 |
| FISHER, MM | 3 |
| MAMLOK, ER | 2 |
| CLARK, CM | 2 |
| ELMENDORF, DF | 2 |
| CAWTHON, WU | 2 |
| MUSCHENHEIM, C | 11 |
| MCDERMOTT, W | 13 |
| KARLSON, AG | 6 |
| FELDMAN, WH | 3 |
| FETTERHOFF, KI | 1 |
| HOLMES, CX | 2 |
| MARTIN, GE | 3 |
| MOUNT, FW | 11 |
| FEREBEE, SH | 19 |
| LEVADITI, C | 4 |
| VAISMAN, A | 4 |
| CHAIGNEAUERHARD, H | 1 |
| NAWROCKI, G | 2 |
| BLAUROCK, G | 1 |
| LATTIMER, JK | 6 |
| JOINER, CL | 2 |
| MACLEAN, KS | 2 |
| PRITCHARD, EK | 1 |
| ANDERSON, K | 1 |
| KING, MB | 1 |
| COLLARD, P | 2 |
| KNOX, R | 4 |
| GOULDING, R | 1 |
| ROBSON, JM | 6 |
| RENTCHNICK, P | 1 |
| DE PRADA Y FERNANDEZ MESONES, J | 1 |
| ALARCON, DG | 2 |
| RIVAS, A | 2 |
| BRAMBILLA, G | 1 |
| PORCELLI, T | 2 |
| JORG, ME | 1 |
| GONDONI, G | 1 |
| GUERRA SANZ, FJ | 3 |
| TOVAR MARTIN, E | 3 |
| OMODEI ZORINI, A | 8 |
| ENGEL, M | 2 |
| GSELL, O | 2 |
| BERGEL, M | 1 |
| KONIECZNY, S | 1 |
| BRUNA, F | 1 |
| PROUST, AJ | 2 |
| BEACHAM, EG | 2 |
| RIST, N | 8 |
| GRUMBACH, F | 15 |
| SIVRIERE, E | 3 |
| ROBITZEK, EH | 3 |
| SELIKOFF, IJ | 3 |
| MAMLOK, E | 1 |
| TENDLAU, A | 4 |
| WITKIND, E | 1 |
| WILLNER, I | 2 |
| KRIESER, AE | 1 |
| SANDERSON, AG | 1 |
| VIK, M | 1 |
| MYERS, JA | 1 |
| DADDI, G | 6 |
| OMODEI-ZORINI, A | 11 |
| D'AMBROSIO, R | 1 |
| CUTILLO, E | 1 |
| MONACO, A | 5 |
| ORICCHIO, D | 10 |
| SCIACCA, F | 1 |
| RAMOS, R | 1 |
| BALLABRIGA, A | 1 |
| SECRETAN, M | 3 |
| KUHLMANN, F | 1 |
| PURSELL MENGUEZ, A | 2 |
| GUERRA, RB | 1 |
| PALERMO, G | 1 |
| SCARPA, A | 1 |
| MELIS, A | 1 |
| GIURA, F | 1 |
| IZAR, G | 2 |
| CLARK, C | 1 |
| BOWEN, DA | 2 |
| COLLINS, DM | 4 |
| SITA LUMSDEN, EG | 1 |
| SWOBODA, JA | 1 |
| RADENBACH, KL | 7 |
| TREMBLAY, JN | 1 |
| PITTS, FW | 2 |
| MILLER, FL | 3 |
| DYE, WE | 3 |
| TEMPEL, CW | 5 |
| FITZPATRICK, MJ | 2 |
| LASCH, F | 1 |
| AMSCHLER, H | 1 |
| STAHLMANN, W | 2 |
| BETHGE, W | 2 |
| LYNCH, HP | 1 |
| BREES, AG | 1 |
| INGRAO, F | 1 |
| FERRETTI, R | 2 |
| ROSSETTI, D | 1 |
| BORIO, G | 1 |
| LAPP, AD | 2 |
| BLACK, GA | 2 |
| O'RAFFERTY, JN | 2 |
| ORLANDELLI, M | 5 |
| NICOLAJ, P | 3 |
| DEGLI ESPOSTI, A | 8 |
| CHAIGNEAU-ERHARD, H | 2 |
| LOPEZ SENDON, M | 2 |
| BETETTO, D | 1 |
| DIAS, O | 1 |
| FARRELL, FP | 1 |
| HORAK, J | 2 |
| DE CANCELLA, LC | 1 |
| DE LACERDA, V | 1 |
| CARDOSO, M | 1 |
| HEINRICH, K | 1 |
| NAGORNY, S | 2 |
| POGGIO, G | 2 |
| NANNINGA, HS | 1 |
| DI BENEDETTO, V | 1 |
| AZZARELLO, L | 1 |
| MATERA, AB | 1 |
| CARABELLI, ET | 1 |
| BESTA, B | 14 |
| DE SIMONI, G | 6 |
| TADDEI, M | 1 |
| SPIEGELMAN, AR | 1 |
| QUIGLEY, TJ | 1 |
| ROMANO, S | 2 |
| CARUSELLI, M | 1 |
| THOREN, M | 1 |
| HINSHAW, HC | 1 |
| PURRIEL, P | 5 |
| MURAS, O | 5 |
| MARTISCHNIG, KM | 1 |
| WARD, PM | 1 |
| PATSCH, J | 1 |
| RIEBEL, J | 1 |
| GALLAND, R | 1 |
| MAILLET, J | 1 |
| MONALDI, V | 5 |
| PACINI, D | 1 |
| BLASI, A | 4 |
| CURCI, G | 8 |
| TROPEANO, L | 1 |
| BONFIGLIO, V | 1 |
| BRUSTOLON, A | 3 |
| GANGEMI, G | 4 |
| BONAVOLONTA, G | 2 |
| DE BERARDINIS, E | 1 |
| PERITI, P | 3 |
| FOWST, G | 2 |
| CASCIO, G | 2 |
| PURPURA, R | 2 |
| LA GRUTTA, A | 1 |
| REALE, V | 1 |
| BEVILOTTI, V | 1 |
| LATTE, B | 1 |
| VENTURI, G | 1 |
| BAZZICALUPO, C | 1 |
| PORTELLA, A | 1 |
| CONTIERI, M | 1 |
| GYSELEN, A | 5 |
| REGINSTER, A | 5 |
| THYS, F | 2 |
| WINS, J | 2 |
| BRAY, G | 2 |
| MORIN, J | 3 |
| HAIZMANN, R | 2 |
| TORLONE, M | 1 |
| LOFFLER, W | 2 |
| BASSET, A | 1 |
| PULLING, FB | 1 |
| COUNIHAN, HE | 1 |
| ABRAHAMSON, ML | 1 |
| O'CONNOR, MH | 1 |
| DICKENSON, J | 1 |
| COOPER, DL | 1 |
| MUGRDITCHIAN, PS | 1 |
| BAROUKY, E | 1 |
| KHOURY, MB | 1 |
| HATEM, JM | 1 |
| GOKCE, T | 1 |
| SEBETY, AM | 1 |
| GRECO, RA | 1 |
| FORD, RA | 1 |
| HAWKINS, GK | 1 |
| BRANDSCHWEDE, S | 2 |
| WILDE, W | 2 |
| MAURIZIO, E | 1 |
| BOLOGNESI, M | 2 |
| BOCCONI, VL | 1 |
| RATNER, B | 2 |
| D'ARCANGELO, D | 1 |
| BERTACCINI, S | 1 |
| RUSSO, V | 1 |
| BARBAGIANNI, A | 1 |
| MORGAGNI, W | 1 |
| BOLONDI, O | 3 |
| SOSSI, O | 2 |
| ZOPPINI, A | 1 |
| TOSI, B | 1 |
| MARANGONI, P | 2 |
| VALENTI, S | 6 |
| LENTI, R | 1 |
| CONFORTO, S | 1 |
| LUCENTINI, L | 1 |
| BALDUCCI, R | 1 |
| LESINSKI, J | 1 |
| WEHRLIN, H | 2 |
| MAGNI, L | 3 |
| CUENOT, M | 1 |
| SUPNIEWSKI, J | 1 |
| JONSCHER, K | 1 |
| FOJUDZKI, E | 1 |
| NOWAK, S | 1 |
| SZCZEPSKI, O | 1 |
| ELISEO, V | 1 |
| FICO, D | 1 |
| PEREZ HERVADA, E | 1 |
| WACKER, T | 1 |
| BONARD, EC | 1 |
| GASTESI, A | 1 |
| BELLUZZI, V | 1 |
| LINTON, WS | 1 |
| RABINOVITZ, E | 1 |
| OLIE, M | 1 |
| TEMPLE, AD | 1 |
| ALLARIA, A | 1 |
| BRANCIFORTI, S | 1 |
| ZANASI, R | 1 |
| LUCIUS, K | 2 |
| HEIN, J | 3 |
| STECHER, W | 2 |
| BERNSTEIN, J | 2 |
| JAMBOR, WP | 2 |
| LOTT, WA | 2 |
| PANSY, F | 2 |
| STEINBERG, BA | 2 |
| YALE, HL | 2 |
| GRAMAZIO, V | 2 |
| OCCHIALINI, B | 1 |
| GALZERANO, G | 2 |
| NITTI, V | 6 |
| BRAVO ORTEGA, A | 1 |
| PUEYO GARCIA, A | 1 |
| ROURERA FARRE, A | 1 |
| GRUNDLAND, I | 1 |
| BRETT, R | 1 |
| BRAUN-FALCO, O | 1 |
| PRINKE, H | 1 |
| BARCLAY, WR | 3 |
| EBERT, RH | 3 |
| LE ROY, GV | 1 |
| MANTHEI, RW | 3 |
| ROTH, LJ | 3 |
| RANDOLPH, H | 1 |
| JOSEPH, S | 1 |
| COHEN, SS | 2 |
| DICK, JC | 3 |
| BARNS, T | 1 |
| SMITH, HG | 1 |
| SNAITH, LM | 1 |
| ALLEN, HS | 1 |
| MORETTI, E | 3 |
| KOCZKA, I | 1 |
| NYIREDY, G | 1 |
| KOVACS, M | 1 |
| HUNYADI, G | 1 |
| ROKA, J | 1 |
| RENYI, L | 2 |
| SZUCS, S | 1 |
| ZEBROWSKI, T | 9 |
| HERBERT-ZEBROWSKA, H | 1 |
| HAAPANEN, J | 2 |
| CAPORALETTI, I | 1 |
| PONZETTA, G | 1 |
| STEENKEN, W | 6 |
| WOLINSKY, E | 10 |
| MCLEAN, RL | 1 |
| ANDERSON, RJ | 1 |
| FINKELDEY, W | 1 |
| STEFANI, H | 1 |
| MORERE, P | 6 |
| ALBERTINI, G | 4 |
| PIETRI, A | 4 |
| LEVI-VALENSI, A | 6 |
| MOLINA, C | 5 |
| RAVINA, A | 6 |
| PESTEL, M | 6 |
| LE JOUBIOUX, E | 2 |
| BUCHMAN, J | 1 |
| FENTON, R | 1 |
| LECOCQ, E | 1 |
| LINZ, R | 3 |
| SCHMID, F | 1 |
| KUCZBORSKI, S | 2 |
| GROB, W | 1 |
| WISSLER, H | 4 |
| FANCONI, G | 1 |
| CHOREMIS, C | 2 |
| PADIATELLIS, K | 1 |
| PRIFTIS, N | 2 |
| ALAMANIS, J | 1 |
| DANELATOU, C | 2 |
| DESMONT-CROS-DECAM, A | 1 |
| JONES, WA | 1 |
| JONES, GP | 1 |
| MARTONI, L | 1 |
| STEFANINI, S | 1 |
| ROSSINI, A | 2 |
| FATTORI, A | 2 |
| GABALLO, S | 2 |
| CHIARI, G | 1 |
| PAINI, R | 1 |
| MAZZEO, G | 1 |
| FERRARO, F | 1 |
| MALASPINA, M | 2 |
| ORIOL ANGUERA, J | 1 |
| GUALLAR SEGARRA, J | 1 |
| POMARES RIQUELME, A | 1 |
| ALTAVA, V | 1 |
| BARRERA, M | 1 |
| PENA, J | 1 |
| PERIS CEBOLLA, M | 1 |
| BULGARELLI, R | 2 |
| BUFFONI, L | 4 |
| GIUBILEO, A | 1 |
| BEKIERKUNST, A | 5 |
| SZULGA, T | 3 |
| DUFOURT, A | 2 |
| OLLAGNIER, C | 1 |
| LAMBERT, R | 1 |
| NECHCOVITCH, P | 2 |
| RADOYTCHITCH, V | 2 |
| Gebala, A | 2 |
| Małeski, K | 1 |
| Michałowicz, Z | 1 |
| Sekułowa, J | 1 |
| Studnicka, K | 1 |
| CANTORE, B | 2 |
| ZUCCONI, C | 1 |
| MELILLO, G | 1 |
| KAKAVIAS, S | 1 |
| MAZZI, A | 1 |
| SANVICO, A | 1 |
| PINERO, MR | 1 |
| ZAPATERO, J | 2 |
| CALDERON, J | 2 |
| GARCIA-MORENO PEREGRIN, A | 1 |
| AGURTO, MA | 1 |
| RODRIGUEZ JOHNSON, ME | 1 |
| DE QUEIROZ, R | 2 |
| REGO, G | 1 |
| PELEGATTI, W | 1 |
| DE PASSOS, JA | 1 |
| BITTENCOURT, C | 1 |
| DE SOUSA, HV | 1 |
| CATTINI, S | 2 |
| FUST, B | 7 |
| ANAN'EV, PN | 1 |
| JUDET, R | 1 |
| JUDET, J | 1 |
| RENE, L | 1 |
| LAGRANGE, J | 1 |
| TAVAT, S | 1 |
| YEGINSU, N | 1 |
| ARPACIOGLU, H | 1 |
| TURNAOGLU, F | 1 |
| CHU, J | 1 |
| GEISSBERGER, M | 1 |
| POINTILLART, J | 1 |
| CONARD, V | 1 |
| MERCADAL PEYRI, J | 2 |
| TARGA GIMENEZ, M | 2 |
| KLARNET, JA | 1 |
| GUGELOT, A | 1 |
| BAUD, P | 1 |
| CHEVALIER, R | 1 |
| SANDS, JH | 1 |
| WEISER, O | 1 |
| DESMEULES, R | 2 |
| DORVAL, CH | 1 |
| LESSARD, C | 1 |
| MONTMINY, L | 1 |
| DION, R | 2 |
| GAREAU, PE | 1 |
| SEGA, A | 1 |
| VRSCAJ, B | 1 |
| LARMOLA, E | 1 |
| BRUCKNER, R | 1 |
| STUDER, A | 2 |
| Wesołowski, S | 3 |
| Bulinski, W | 2 |
| TCHERTKOFF, IG | 1 |
| ASISIAN, M | 1 |
| NENASHEV, P | 1 |
| DAVIDSON, LR | 1 |
| BEAULIEU, M | 1 |
| ALTMAN, V | 1 |
| SHIN, E | 1 |
| CASATI, G | 1 |
| COGO, L | 1 |
| GEMELLI, D | 1 |
| BLANCO RODRIGUEZ, F | 2 |
| BARIETY, M | 4 |
| CHOUBRAC, P | 3 |
| GUERIN, C | 1 |
| THIBAUT, P | 1 |
| QUATTROCCHI, G | 1 |
| LA ROSA, G | 1 |
| GAMMON, GC | 1 |
| BURGE, FW | 2 |
| KING, G | 2 |
| CHATONNIER, F | 2 |
| CHATONNIER-ROQUELAURE, MT | 1 |
| LABORDE, J | 1 |
| MIGUERES, J | 2 |
| ASSERAF, W | 1 |
| ALBUQUERQUE, A | 1 |
| PARRELLA, M | 2 |
| TANZI, PL | 3 |
| D'ALFONSO, G | 2 |
| NEGRI, B | 1 |
| GUNELLA, G | 3 |
| CETRANGOLO, R | 2 |
| SURI, JC | 1 |
| BHATIA, AL | 8 |
| JUNQUERA VILLA, JM | 1 |
| LERMAN, F | 1 |
| LERMAN, P | 1 |
| SPIVACK, LL | 1 |
| GRUN, H | 2 |
| CID PALACIOS, J | 1 |
| FILLA, E | 4 |
| SAVASTANO, D | 1 |
| PACI, A | 4 |
| ERTUG, C | 2 |
| EASOM, HF | 2 |
| WILLIS, HS | 1 |
| GORGENYI-GOTTCHE, O | 4 |
| SIRALY, F | 4 |
| SZATMARY, M | 1 |
| KOWALCZYK, J | 2 |
| KRASNITZ, A | 1 |
| JENKINS, BE | 1 |
| GRUNBERG, E | 2 |
| SCHNITZER, RJ | 4 |
| MARK, HJ | 3 |
| HARROWER, JR | 1 |
| BROWN, WB | 1 |
| HOBBY, GL | 8 |
| LENERT, TF | 5 |
| BIEHL, JP | 3 |
| SKLAVEM, JH | 1 |
| HIRSCH, E | 1 |
| DUGGELI, O | 4 |
| TRENDELENBURG, F | 4 |
| SCHETTINO, S | 1 |
| SALVIOLI, G | 1 |
| HARING, W | 1 |
| HENNIG, K | 1 |
| TIEDEMANN, IL | 1 |
| PATZELT, O | 1 |
| KLEE, P | 3 |
| WEISS, HJ | 1 |
| ZIERSKI, M | 6 |
| DOBRZYNSKI, Z | 2 |
| GRABOWSKI, L | 1 |
| SAJEWICZ, A | 1 |
| Bilinski, W | 1 |
| RIEHL, G | 2 |
| DA SILVEIRA, AG | 1 |
| MENEZES, J | 1 |
| CASTRO, LM | 1 |
| MANTA, MC | 1 |
| DE LIMA, JQ | 1 |
| FELIX, S | 1 |
| VIEIRA, TG | 1 |
| TAVARES, W | 1 |
| AGUIAR, A | 1 |
| MAGARAO, MF | 1 |
| SOARES, DP | 1 |
| DE CORTES, VC | 1 |
| O'BRIEN, B | 1 |
| CONALTY, ML | 4 |
| LEIDER, M | 1 |
| SAWICKY, HH | 1 |
| STEWART, JF | 1 |
| GAUTHIER, H | 1 |
| THIERS, H | 1 |
| COLOMB, D | 1 |
| BAGUENA CANDELA, R | 3 |
| WOLF, HJ | 1 |
| DZIUBA, K | 2 |
| BLAHA, H | 1 |
| NOBILI, L | 1 |
| MOGGIAN, G | 1 |
| PRATS, GF | 1 |
| DONGHI, A | 2 |
| DE LAVIN, JD | 2 |
| ASTALDI, G | 2 |
| GORINI, P | 2 |
| GALDI, G | 2 |
| RICCI, G | 4 |
| RAVAZZONI, L | 1 |
| CAVEZZALI, A | 1 |
| LEVI, R | 1 |
| BARONI, V | 1 |
| MAGISTRETTI, M | 1 |
| CASPANI, R | 1 |
| SADA, E | 3 |
| DE MARTINI, A | 1 |
| LOSANO, G | 1 |
| PALENZONA, C | 2 |
| RONA, G | 1 |
| PAUTASSI, G | 1 |
| BIANCO, T | 1 |
| VOARINO, EL | 1 |
| ROLLA, G | 1 |
| ROSSINI, G | 3 |
| SPADA, E | 1 |
| CAPELLO, M | 1 |
| CERESA, C | 1 |
| DE BLASIIS, M | 1 |
| NOBILE, F | 1 |
| RAZZABONI, G | 1 |
| SETTI, L | 1 |
| BRUSA, P | 1 |
| CARLETTI, B | 2 |
| MESSMER, E | 1 |
| ZEICHNER, J | 1 |
| CHILDRESS, WG | 1 |
| CZYZEWSKA, J | 1 |
| PANCOTTO, L | 1 |
| PIENIAZEK, J | 7 |
| PLEWIK, W | 2 |
| Godlewski, J | 1 |
| Zogała, E | 1 |
| BRUEL, R | 1 |
| AMOUROUX, P | 1 |
| BRIONES, E | 1 |
| ROMERO SAN LUCAS, E | 1 |
| LUNA RUILOVA, M | 1 |
| CORDERO, AA | 1 |
| CORTI, RN | 1 |
| MAGNIN, PH | 1 |
| URSI, CF | 1 |
| CATTA, J | 1 |
| ALBERTI, H | 1 |
| LEYS, A | 1 |
| AGIUS, J | 1 |
| DUMON, G | 8 |
| SOULAYROL, R | 1 |
| BERNARD, E | 10 |
| KREIS, B | 11 |
| LOTTE, A | 6 |
| AUBIN, H | 1 |
| DANIELS, M | 1 |
| FOX, W | 20 |
| DA SILVA, OD | 1 |
| DE ALDA CALLEJA, M | 1 |
| RODRIGUEZ ADRADOS, J | 1 |
| BAYO CABANA, E | 1 |
| AGUILERA MAS, J | 1 |
| VENDRELL VILA, D | 1 |
| LIANAS COLOMINAS, A | 1 |
| SORIANO, M | 1 |
| GONZALEZ RIBAS, M | 1 |
| CASANOVAS, P | 1 |
| TRUJOLS, A | 1 |
| VINTRO, P | 1 |
| DJOURICHITCH, M | 1 |
| POUSSIER, J | 1 |
| FOUQUET, J | 6 |
| HEIMANN, V | 2 |
| TEYSSIER, L | 6 |
| BRETON, A | 4 |
| COLETSOS, PJ | 1 |
| DUROUX, A | 2 |
| MASSON, P | 2 |
| MARTY, J | 2 |
| LACRAMPE, H | 1 |
| JARNIOU, A | 2 |
| DAVY, PE | 1 |
| VERAN, P | 7 |
| BERNOU, A | 1 |
| TRICOIRE, J | 1 |
| COANT, F | 1 |
| LANOE, JF | 1 |
| JULLIEN, W | 1 |
| GERAUD, J | 1 |
| FABRE, P | 1 |
| FREOUR, P | 7 |
| WONE, C | 3 |
| GERNEZ-RIEUX, C | 6 |
| BEERENS, H | 3 |
| FOURNIER, P | 2 |
| TACQUET, A | 6 |
| BUTTARO, CA | 1 |
| RAGAZZINI, F | 1 |
| GIUSTI, M | 1 |
| COCCHI, R | 2 |
| VERROTTI, M | 1 |
| BARDELLI, N | 1 |
| PADIATELLIS, C | 1 |
| ALLAMANIS, N | 1 |
| ROY, A | 3 |
| DE GRACIANSKY, P | 1 |
| BOULLE, S | 1 |
| BOULLE, M | 1 |
| DALION, J | 1 |
| MAGRO, G | 1 |
| JACOBSSON, E | 1 |
| EHRNER, L | 1 |
| MIDDLETON, JW | 1 |
| LONGFIELD, AN | 1 |
| BARAT, I | 3 |
| PAPP, A | 2 |
| RECKNAGEL, K | 1 |
| FIEGEL, G | 1 |
| REYMANN, F | 1 |
| SPATH, F | 1 |
| KOLE, W | 1 |
| TEICHMANN, W | 2 |
| FORSTER, E | 1 |
| ZELLER, F | 3 |
| DOLCET, L | 1 |
| MACCONE, V | 1 |
| ROMUALDI, A | 1 |
| TORRIANI, S | 1 |
| MERCADAL, J | 1 |
| TARGA, M | 1 |
| KUSKE, FA | 1 |
| SIEBENMANN, CO | 2 |
| LUBING, HN | 1 |
| CUTLER, SS | 1 |
| BURBANK, B | 1 |
| BATTAGLIA, B | 2 |
| CORNU, P | 4 |
| FREESE, H | 1 |
| PANNARALE, MR | 1 |
| LEONARDI, F | 1 |
| BORIONI, D | 1 |
| CHAKROBORITY, AN | 1 |
| BANERJEE, AK | 1 |
| GHOSH, S | 2 |
| BOYD, G | 1 |
| ROY, TE | 1 |
| JOSIUKAS, A | 1 |
| KONN, G | 1 |
| THELEN, A | 1 |
| VERGELIN, ME | 1 |
| GARRE, O | 1 |
| COHEN RUA, RA | 1 |
| VERNA, JF | 2 |
| SCHECHTMANN, MR | 1 |
| SUMBATOV, GA | 2 |
| UMEZAWA, H | 1 |
| OIKAWA, K | 1 |
| SUZUKI, M | 1 |
| HANNA, M | 1 |
| SHEHATA, AH | 1 |
| HANNA, AZ | 1 |
| FLETCHER, AG | 1 |
| PAUL, M | 1 |
| RANBHISE, MP | 1 |
| GRAF, R | 1 |
| RITCHIE, GM | 1 |
| TAYLOR, RM | 1 |
| DESPIERRES, G | 3 |
| CHARLEUX, P | 1 |
| REVOL, L | 1 |
| RUBIN, EH | 1 |
| CHEIFETZ, I | 1 |
| KATZEV, H | 1 |
| EIDINGER, SL | 1 |
| BRIEF, C | 1 |
| BOSCO, I | 1 |
| COTTINI, GB | 1 |
| CENSI, G | 1 |
| BAROZZI, R | 1 |
| CABITZA, A | 1 |
| SCHWENKENBECKER, D | 1 |
| SCHLEPCKOW, D | 1 |
| FRANK, P | 1 |
| KOVACS, P | 1 |
| FABO, F | 1 |
| VARGHA, G | 1 |
| HUTAS, I | 1 |
| BOGGIAN, B | 1 |
| BROUET, G | 3 |
| HALPERN, BN | 1 |
| MARCHE, J | 2 |
| MALLET, J | 2 |
| PEREDA, A | 1 |
| BRUN, O | 1 |
| CALVET, J | 1 |
| RIBET, A | 1 |
| COLL, J | 1 |
| MASSON, H | 1 |
| SPINOIT, C | 1 |
| KLURFELD, G | 1 |
| NIGOGHOSSIAN, GA | 1 |
| DJURISIC, M | 5 |
| RADOJCIC, V | 2 |
| NESKOVIC, P | 2 |
| MATHIEU DE FOSSEY, B | 1 |
| BARTH, F | 1 |
| MEYER-ROHN, J | 3 |
| NIXDORF, H | 1 |
| CORMIA, FE | 1 |
| COSTELLO, MJ | 1 |
| BARKER, LP | 1 |
| NELSON, CT | 1 |
| WILSON, EW | 1 |
| CRAMER, JA | 1 |
| MARIQUE, P | 1 |
| SIMON, K | 2 |
| ARRIGONI, G | 1 |
| LOVATI, G | 1 |
| SCOLES, E | 2 |
| DE LUCA, V | 1 |
| CANTONNET, P | 1 |
| NEGRO, RC | 2 |
| PEREZ SCREMINI, A | 1 |
| BARSUMIAN, M | 1 |
| DISSMANN, E | 2 |
| IGLAUER, E | 2 |
| KAPL, R | 1 |
| OBRECHT, V | 2 |
| RENOVANZ, HD | 3 |
| SCHETTLER, U | 1 |
| GAASE, A | 1 |
| GISELEN, A | 1 |
| SCHWANDER, R | 1 |
| SEHM, G | 1 |
| FERNANDEZ BUA, H | 2 |
| INCHAURREGUI, GA | 1 |
| ROJAS, PA | 1 |
| GOROSTIAGUE, J | 1 |
| MELLO AGUERRE, M | 1 |
| PINTOS FUENTES, RJ | 1 |
| AUBERTIN, E | 1 |
| DULONG DE ROSNAY, C | 1 |
| LABADIE, P | 1 |
| DUPUY, JK | 1 |
| BERLIN, II | 1 |
| ANDERSON, T | 1 |
| KERR, MR | 1 |
| LANDSMAN, JB | 1 |
| TORRES-GOST, J | 1 |
| FLETCHER, AP | 1 |
| GIRARD, M | 1 |
| FRAISSE, H | 1 |
| FORD, RM | 1 |
| MICHEL, W | 3 |
| COCOZZA, G | 1 |
| FEROLA, R | 1 |
| KAMINSKY, A | 1 |
| SEVINSKY, B | 1 |
| KAPLAN, A | 1 |
| SCOLLO, A | 1 |
| SALA, L | 1 |
| ALEMAN, E | 2 |
| BURGOS DE PABLO, A | 1 |
| FERNANDEZ CAMARA, J | 1 |
| PIECHAUD, F | 1 |
| JACOB, P | 1 |
| CHAUVEAU, J | 1 |
| CARTIER, R | 1 |
| VIVERET, J | 1 |
| GAGLIO, M | 1 |
| CONSOLO, F | 1 |
| VERRIENTI, G | 1 |
| BELSANTI, R | 1 |
| NUGEL, A | 1 |
| BELLINGI, J | 1 |
| FOSSATI, C | 3 |
| GUILLONES, NO | 1 |
| SCHWEID, C | 1 |
| BUTZENGEIGER, KH | 1 |
| KRUMBHOLZ, J | 1 |
| WESSING, L | 1 |
| UNVERRICHT, W | 1 |
| SCHATTMANN, K | 1 |
| LORENZ, TH | 1 |
| CALDEN, G | 1 |
| OUSLEY, JL | 1 |
| MURPHY, JD | 1 |
| OKANO, T | 1 |
| BLOCH, H | 3 |
| WIDELOCK, D | 7 |
| PEIZER, LR | 7 |
| BULKELEY, WC | 1 |
| SUAREZ PALACIOS, F | 1 |
| GIRARDI, VC | 2 |
| BOTTARO CANTALUPPI, LR | 1 |
| OECONOMOPOULOS, N | 1 |
| STEPHANOPOULOS, C | 1 |
| LIACACOS, D | 1 |
| COSTELETOS, E | 1 |
| POLYCHRONIDIS, A | 1 |
| TSIMONOS, T | 1 |
| NASAINAS, A | 1 |
| AILIANOS, T | 1 |
| SHARMA, OD | 1 |
| BLUNDI, E | 1 |
| BREATHNACH, CS | 1 |
| CHILDRESS, ME | 1 |
| THOREN, ME | 1 |
| DANIELS, AC | 1 |
| LORENZO VELAZQUEZ, B | 1 |
| CARINENA, J | 1 |
| ADAN, A | 1 |
| CERVERO ALCANIZ, R | 1 |
| KOTTGEN, HU | 1 |
| HARTUNG, K | 3 |
| IZZO, G | 1 |
| GENTILI, A | 3 |
| PERI, T | 2 |
| CRAVOS, G | 1 |
| HUNT, B | 1 |
| WASSERSUG, JD | 1 |
| ATTILI, L | 1 |
| GUARNERIO, GC | 1 |
| BRUN, J | 2 |
| VIALLIER, J | 4 |
| SERRE, H | 2 |
| DANZER, R | 1 |
| LANDOLT, R | 1 |
| DE TONI, G | 2 |
| BACIALLI, L | 2 |
| BERNARDINI, M | 1 |
| TRABUCCO, G | 1 |
| RENEDO FORNOS, JA | 1 |
| ROMEO, JL | 1 |
| DE PARTEARROYO, FR | 2 |
| AYERBE VALLES, SA | 2 |
| RAGNO, I | 2 |
| PREZIOSI, P | 2 |
| PORCELLATI, G | 2 |
| CIAMILLO, E | 1 |
| FRONGIA, L | 1 |
| CHRETIEN, J | 3 |
| POLI, M | 1 |
| ENGLER, M | 1 |
| SPIES, HW | 2 |
| LEPPER, MH | 2 |
| BLATT, NH | 1 |
| DOWLING, HF | 2 |
| CAPON, AW | 1 |
| KOSTKA, Z | 1 |
| BROZ, O | 1 |
| AURITI, G | 1 |
| D'AGOSTINO, S | 1 |
| ESPOSTI, AD | 1 |
| ABBA, GC | 1 |
| PEREGO, C | 1 |
| LIBERO, M | 1 |
| BONA, F | 1 |
| HENNING, H | 1 |
| FOTZSCH, A | 1 |
| BAUFELD, H | 1 |
| CHECINSKI, T | 1 |
| HOLSINGER, RE | 1 |
| DALTON, JE | 1 |
| D'AGOSTINO, N | 1 |
| GARCIA-MORENO, F | 1 |
| BOLLOLI, D | 1 |
| PANA, C | 7 |
| DI MARIA, G | 1 |
| COSTANTINI, E | 1 |
| DOUGLAS, RS | 1 |
| SANSOTTA, V | 1 |
| MANAI, G | 1 |
| ROVESCALLI, A | 1 |
| CANESI, MT | 1 |
| VIDAL, J | 5 |
| VIDAL, F | 1 |
| HUSSON, M | 1 |
| GAILLARD, C | 1 |
| PASZKOWSKA, A | 2 |
| MODZELEWSKA, I | 1 |
| KOWALCZYKOWA, J | 2 |
| PLATA RUEDA, E | 1 |
| BENDA, R | 4 |
| URQUIA, DA | 1 |
| LA TORRE, C | 1 |
| PENA, A | 1 |
| AGOS DE PASTORE, C | 1 |
| HARTUNG, A | 1 |
| WOODS, AC | 2 |
| BECKER, B | 2 |
| WOOD, RM | 2 |
| HELWEG-LARSEN, P | 3 |
| RASMUSSEN, KN | 6 |
| DALET, R | 2 |
| MOATTI, G | 1 |
| CAYRE, RM | 1 |
| FERREIRA, C | 1 |
| FERREIRA, NC | 1 |
| VALDES RUIZ, M | 1 |
| JUANES GONZALEZ, A | 1 |
| GRANADO, MA | 1 |
| JUANES GONZALEZ, M | 2 |
| TOMPSETT, R | 5 |
| McCUNE, R | 3 |
| ORMOND, LH | 1 |
| DEUSCHLE, K | 11 |
| BRUCHMANN, I | 1 |
| HASCHE, E | 1 |
| LINK, R | 1 |
| NIEDERMOWE, W | 1 |
| BOURIMBORDE, AO | 1 |
| MORGANTI, RA | 1 |
| MIGLIOLI, S | 3 |
| CORONA, A | 1 |
| DI LUZIO, G | 1 |
| CHAROCOPOS, S | 1 |
| INGLESSI, E | 1 |
| SEGAL, J | 1 |
| CHAKRAVARTY, SC | 1 |
| MIYAMOTO, Y | 2 |
| MIURA, K | 1 |
| YAMAZAKI, H | 1 |
| INCZE, JS | 1 |
| GANCZARSKI, A | 1 |
| DUNIN-HORKAWICZ, H | 1 |
| HOROSZEWICZ, J | 1 |
| KASPEROWICZ, J | 1 |
| ORŁOWSKA, I | 1 |
| STEMPIEN, R | 1 |
| TUROWSKA, I | 1 |
| WISNIEWSKA, A | 1 |
| PAULY, W | 1 |
| GLAUBITZ, E | 1 |
| PETENYI, G | 1 |
| FONO, R | 1 |
| BUJKO, K | 1 |
| JAROSZEWICZ, W | 1 |
| MARTIN-LALANDE, J | 1 |
| LAFORGE, S | 1 |
| PINETTI, P | 1 |
| NOUVION, H | 1 |
| PELLIER, G | 1 |
| GUILBAUD, P | 1 |
| CHOVELON, R | 1 |
| PLACE-VERGHNES, A | 1 |
| AZORIN, D | 1 |
| PARAF, J | 1 |
| ZIVY, P | 1 |
| PARAF, M | 1 |
| RAPAUD, G | 1 |
| ROSENBERG, E | 1 |
| LABRE, J | 1 |
| BOULLET, M | 1 |
| CUCINOTTA, U | 1 |
| BEHRENS, W | 1 |
| ROSENMUND, H | 1 |
| KUMAGAI, T | 2 |
| KUMAGAI, H | 1 |
| ASHINO, Y | 1 |
| AIZAWA, S | 1 |
| KANAYA, A | 2 |
| SUGAWARA, T | 2 |
| KAWAMORITA, K | 1 |
| OIKAWA, Y | 1 |
| DRNDARSKI, K | 3 |
| HEUNER, W | 1 |
| ABEE, H | 1 |
| BLOCH, RG | 2 |
| DOONEIEF, AS | 2 |
| BUCHBERG, AS | 2 |
| SPELLMAN, S | 2 |
| LICHTENSTEIN, MR | 2 |
| MIZENBERG, E | 2 |
| GIERSON, HW | 1 |
| CHAMBERLAIN, PM | 1 |
| BUNN, PA | 1 |
| ROBINSON, F | 2 |
| CHAPMAN, PT | 3 |
| TEPE, J | 1 |
| FIRZLAFF, HU | 1 |
| WIESE, O | 1 |
| EWERBECK, H | 1 |
| WECHSELBERG, K | 2 |
| HORLEIN, H | 2 |
| JAHNKE, K | 1 |
| EIDUS, L | 8 |
| LANYI, MR | 1 |
| COATES, EO | 2 |
| BRICKMAN, GL | 1 |
| MEADE, GM | 2 |
| SCHLAEGEL, TF | 2 |
| HUNGERFORD, LN | 1 |
| ORMOND, L | 4 |
| McCUNE, RM | 4 |
| CAMPAGNA, M | 3 |
| CALIX, A | 1 |
| HAUSER, G | 1 |
| ADAR, H | 1 |
| FREERKSEN, E | 7 |
| KLEINSCHMIDT, H | 1 |
| WEICKSEL, P | 3 |
| NIEMSCH, H | 1 |
| SITT, W | 1 |
| MULLER, E | 1 |
| POPPENDIECK, K | 1 |
| BADE, G | 1 |
| CHAIGNEAU-EHRARD, H | 1 |
| SCHOCH, A | 2 |
| MAGGI, R | 2 |
| GARCIA DIAZ, CJ | 2 |
| WINFIELD, DL | 2 |
| SPARER, PJ | 1 |
| PHILLIPS, S | 6 |
| DI VIRGILIO, A | 1 |
| GARBINSKI, T | 3 |
| DERUBSKA, B | 2 |
| SZLENKIER, E | 2 |
| NIEWIADOMSKA, S | 2 |
| EIGNER, J | 1 |
| CZANIK, P | 2 |
| KERTES, I | 1 |
| KRATOCHWIL, L | 1 |
| WOJCIECHOWSKI, Z | 1 |
| STARKIEWICZOWA, J | 2 |
| MOESCHLIN, S | 3 |
| AUSTRIAN, H | 2 |
| SONNENBERG, H | 1 |
| BUDISAVLJEVIC, M | 1 |
| VUCKOVIC, Lj | 1 |
| GRUJIC, M | 1 |
| ILIC, Lj | 1 |
| LABAN, M | 1 |
| MILETIC, V | 1 |
| POPOVIC, J | 1 |
| PUTNIK, Dj | 1 |
| MINCHEV, S | 1 |
| DRAGIEV, M | 1 |
| IANEV, N | 1 |
| JORDE, R | 1 |
| SLAVIN, P | 2 |
| FALKENFLETH, G | 1 |
| BRAVO, A | 1 |
| PUEYO, A | 1 |
| SIMON, R | 1 |
| HEWELL, B | 1 |
| SUYEMOTO, D | 1 |
| POROT, M | 3 |
| GANDON, J | 1 |
| VEST, M | 1 |
| DEZYNA, M | 1 |
| GRYBOS, J | 1 |
| BLOEDORN, H | 2 |
| SWEANY, HC | 2 |
| PEREZ, JA | 4 |
| VICENTE-MASTELLARI, A | 1 |
| YOUNG, RV | 1 |
| DE LIMA, SO | 1 |
| BARRY, VC | 2 |
| DENNEY, JM | 1 |
| GAFFNEY, EE | 2 |
| WINDER, F | 2 |
| DENNENY, JM | 1 |
| JUZWA, J | 1 |
| POMPE, K | 1 |
| LOUBRY, MP | 1 |
| LUNTZ, G | 1 |
| ROSENOW, H | 2 |
| EISENBLATTER, J | 2 |
| TODOROFF, T | 2 |
| BOMBARDELLI, E | 1 |
| MARCHESI, C | 1 |
| REALE, M | 4 |
| PAOLI, G | 2 |
| MERLO, P | 1 |
| NELLO, RP | 1 |
| VERGANI, F | 3 |
| VALERI, FM | 1 |
| MULARGIA, A | 1 |
| TAPIA SANZ, J | 1 |
| BELENGUER RIPOLLES, P | 1 |
| PEDRAZA PALOMO, M | 1 |
| VALLEDOR, T | 3 |
| HERNANDEZ MIYARES, C | 1 |
| COSTALES, F | 3 |
| BORBOLLA, L | 3 |
| SATANOSWSKY, C | 1 |
| GARCIA PALACIOS, A | 2 |
| LATAPI, F | 1 |
| ESCALONA, E | 1 |
| RODRIGUEZ, O | 1 |
| CASTRO ESTRADA, S | 1 |
| DURISIC, M | 4 |
| BUNN, P | 1 |
| JOHNSEN, L | 1 |
| HEWITT, WC | 1 |
| DICKIE, HA | 2 |
| LARSON, FC | 2 |
| OLSON, DE | 1 |
| SCHULZ, KH | 1 |
| TERRUZZI, B | 1 |
| PLUCKTHUN, H | 1 |
| BOHNKE, H | 1 |
| TRAUTWEIN, H | 3 |
| BOHLKE, E | 2 |
| ELGUETA, H | 1 |
| PENA, G | 1 |
| MUDIE, IS | 1 |
| HORNE, NW | 6 |
| CROFTON, JW | 5 |
| GRIFFITHS, DL | 1 |
| QUINLAN, AG | 1 |
| RICHARDS, HJ | 1 |
| PAYNE, HM | 1 |
| HACKNEY, RL | 2 |
| CLARK, EA | 1 |
| JOHNSON, PC | 1 |
| COHEN, S | 1 |
| ANG, E | 1 |
| ROTHSTEIN, E | 1 |
| BRUCE, TH | 1 |
| LORBER, J | 2 |
| MONNET, P | 3 |
| GALLOIS, P | 1 |
| LUISETTI, GL | 1 |
| GARAVENTA, M | 1 |
| GHIONE, M | 3 |
| MIOTTI, T | 1 |
| TOENNIESSEN, E | 1 |
| MACLEOD, EK | 1 |
| CONESE, G | 1 |
| COLONNA, L | 1 |
| EDER, J | 1 |
| WARM, I | 1 |
| BOROWIECKA, A | 6 |
| THIELEN, R | 1 |
| DES AUTELS, EJ | 1 |
| PFUETZKE, KH | 1 |
| JUAREZ PEINADO, R | 1 |
| SALMAREGGI, A | 1 |
| INGRASSIA, L | 1 |
| MIDGLEY, RL | 1 |
| MOORE, B | 1 |
| VON GERZANITS, P | 1 |
| WALTHER, G | 1 |
| WINTER, KA | 1 |
| FRANK, F | 2 |
| CARON, M | 3 |
| POPP, O | 1 |
| KLINGHARDT, GW | 1 |
| MROWKA, S | 1 |
| MITFESSEL, M | 1 |
| ALIOTTA, N | 2 |
| CANITANO, PF | 1 |
| MEISSNER, G | 14 |
| ALLEN, AR | 4 |
| MARCY, GE | 2 |
| YU, JK | 2 |
| SAENZ, A | 2 |
| PATUREL, G | 1 |
| SUSINI, R | 1 |
| DALLET, R | 1 |
| EL-AYDOUNI, MD | 1 |
| WEISS, M | 1 |
| SALZMAN, L | 1 |
| STURA, L | 1 |
| MANNARI, M | 1 |
| CLEMENTI, E | 1 |
| LONGARATO, FJ | 2 |
| GONZALEZ, M | 2 |
| COSTA, A | 1 |
| PEREZ, O | 1 |
| IBANEZ, S | 2 |
| LEGARRETA, J | 1 |
| DIAZ, E | 1 |
| GERVOIS, M | 1 |
| ZORINI, AO | 7 |
| PIOVANO, S | 1 |
| CASAMAYOU, E | 1 |
| GAMMON, GD | 1 |
| WALLACE, AT | 1 |
| STEWART, SM | 5 |
| TURNBULL, FA | 1 |
| KITTEL, H | 1 |
| KENDIG, EL | 4 |
| TREVATHAN, GE | 1 |
| OWNBY, R | 1 |
| KNAPP, P | 1 |
| VON SALLMANN, L | 1 |
| BUNDY, M | 1 |
| ALEXANDER, IH | 1 |
| KUEHN, CC | 1 |
| HUGHES, HB | 1 |
| JONES, AP | 1 |
| SCHMIDT, LH | 3 |
| ELMENDORF, D | 1 |
| DANGLER, G | 3 |
| CANTARELLA, R | 1 |
| DE MARCO, F | 1 |
| VIRGILIO, R | 1 |
| ANGULO-ORTEGA, A | 1 |
| LIENER, A | 1 |
| BERG, G | 3 |
| PELLEGRINO, ED | 1 |
| PETRIK, FG | 1 |
| HORTON, R | 1 |
| SCHERER, IW | 1 |
| WINNE, JF | 1 |
| PENA, CD | 1 |
| CARTER, FS | 1 |
| PREGOWSKI, W | 4 |
| BRODA, Z | 3 |
| FRYCZ, L | 1 |
| MALINOWSKI, J | 1 |
| KOŁSUT, H | 1 |
| KOZŁOWSKI, H | 1 |
| EL-MOFTY, AM | 1 |
| EL-ZAWAHRY, M | 1 |
| SCHULLER, A | 1 |
| BUEZAS, V | 1 |
| LORENZETTI, L | 1 |
| SHEBANOV, FV | 1 |
| MADAR, E | 1 |
| SANTESSON, G | 1 |
| SCHWARTZ, WS | 2 |
| MOYER, RE | 1 |
| NIMITZ, HJ | 1 |
| PATIALA, J | 3 |
| ADDINGTON, MC | 1 |
| OESTREICHER, R | 2 |
| DRESSLER, SH | 3 |
| MIDDLEBROOK, G | 14 |
| AUERBACH, O | 1 |
| SWEETNAM, WP | 2 |
| MURPHY, EF | 2 |
| MUSOTTO, G | 1 |
| LAURO, S | 1 |
| GOLDMAN, SE | 1 |
| EIBEL, P | 1 |
| CIANCAGLINI, E | 1 |
| BEHR, W | 1 |
| STEINHOFF, H | 1 |
| SALKIN, D | 2 |
| SCHWARTZ, JA | 2 |
| DE MOURA, C | 1 |
| MELI, G | 2 |
| GAMMARROTA, V | 1 |
| MARENZI, AD | 1 |
| BARRERA, LA | 1 |
| GRIS, MR | 1 |
| ALEMANY, RE | 1 |
| GOMEZ, CJ | 1 |
| BONFIGLIOLI, H | 1 |
| PRADO, JM | 1 |
| PILORGE MORA, EA | 1 |
| KRONIK, P | 1 |
| PASIECZNY, T | 1 |
| PLEASURE, H | 1 |
| WIEDORN, WS | 1 |
| ERVIN, F | 1 |
| PRATT, P | 1 |
| SALERNO, G | 1 |
| COSTA, F | 1 |
| OGILVIE, CM | 2 |
| LAWSON, JH | 1 |
| LEES, AW | 4 |
| ALLAN, GW | 1 |
| McKENZIE, P | 1 |
| SAMPIRISI, F | 1 |
| CATASTA, L | 1 |
| CAZZANIGA, G | 1 |
| APPELBAUM, E | 2 |
| ANDERSON, TA | 1 |
| GERGOVICH, H | 1 |
| SZANTROCH-MISZKE, A | 1 |
| CHRZANOWSKA-SRZEDNICKA, K | 1 |
| CARROLL, JD | 1 |
| MARSH, K | 1 |
| VIALA, JJ | 1 |
| ZORINI, O | 1 |
| DE ALMEIDA, EB | 1 |
| DE BRITO, AA | 1 |
| FERRARI, B | 1 |
| D'ANGELO, G | 1 |
| BONOMI, F | 1 |
| ABBO, F | 1 |
| SALOMONE, C | 1 |
| SCHNEIDT, W | 1 |
| CROCCO, G | 1 |
| SINIECKI, B | 1 |
| BABICH, S | 1 |
| BENNARI, B | 1 |
| LEGNANI, F | 1 |
| MARCHIO', B | 1 |
| SEGOVINI, A | 1 |
| SPANGHERO, L | 1 |
| ZMAJEVICICH, G | 1 |
| LOUBRY, P | 1 |
| COBY, J | 1 |
| KASTARLAK, N | 1 |
| ONEN, K | 1 |
| GORPE, A | 1 |
| DALOUS, A | 1 |
| KALBIAN, VV | 1 |
| FRAWLEY, TF | 1 |
| ROSCH, PJ | 1 |
| KATZ, S | 5 |
| STOREY, PB | 3 |
| McCORMICK, GF | 1 |
| LAHESMAA, R | 1 |
| LUCCHESI, M | 27 |
| MARINO, T | 1 |
| GIANANDREA, G | 1 |
| MONACO, U | 1 |
| CAIONE, C | 1 |
| RUGGIERI, F | 1 |
| VOLTERRA, G | 1 |
| SCHLICHT, K | 1 |
| ORLOWSKI, EH | 4 |
| CLAUS, H | 1 |
| TURNBULL, FW | 1 |
| LUKAVSKY, J | 1 |
| PETROVICKY, O | 2 |
| PRESCOTT, B | 1 |
| KAUFFMAN, G | 1 |
| SATO, N | 2 |
| HOFFMANN, I | 2 |
| TELEGDI, I | 2 |
| ORBAN, S | 3 |
| POZSONYI, J | 2 |
| SCHWEIG, G | 1 |
| STREBELY, G | 2 |
| WOHL, V | 2 |
| ROMEO, F | 3 |
| WIER, JA | 2 |
| GREGORY, LJ | 2 |
| STEAD, W | 1 |
| MAYOCK, RL | 2 |
| WEISER, OL | 2 |
| BERGSMANN, O | 1 |
| KESZTELE, V | 2 |
| KLINGE, A | 1 |
| KOSTRZEWA, J | 2 |
| PICHULA, K | 2 |
| TUSZYNSKA, B | 5 |
| COPAITICH, T | 2 |
| DONNO, L | 1 |
| HUMBERT, R | 2 |
| TROJANOWSKI, S | 2 |
| ZEBROWSKI, L | 1 |
| PACZKOWSKI, A | 1 |
| MONTALBINE, V | 1 |
| RODRIGUEZ-PINERO Y JIMENEZ, M | 1 |
| PEREL'MAN, EI | 1 |
| MALM, E | 1 |
| SAVI, C | 1 |
| MORICHI, G | 3 |
| ANGELI, G | 1 |
| BUSANI, L | 1 |
| TEDESCHI, G | 1 |
| IRSKENS, KJ | 1 |
| OVERBY, HT | 1 |
| WOLIUNG, RW | 1 |
| ORNSTEIN, GG | 1 |
| MORA, FB | 1 |
| LLAMEDO, LP | 1 |
| LOMBOS, O | 3 |
| STEINLIN, H | 1 |
| CHAVES, AD | 9 |
| ROBINS, AB | 2 |
| ABELES, H | 3 |
| TAJIMA, M | 1 |
| HARVEY, G | 1 |
| LESLIE, G | 1 |
| DODSON, LF | 1 |
| SANDERS, AG | 1 |
| FLOREY, HW | 1 |
| BOHNI, F | 1 |
| CORACH, L | 1 |
| DE PIFFARETTI, MM | 1 |
| MOLINA, MA | 1 |
| BARRIE, J | 1 |
| ROULET, A | 1 |
| DOUVRES, PA | 1 |
| CELLERINO, RJ | 1 |
| CAMPOS, RM | 1 |
| WEISBERG, MM | 1 |
| BURGHARD, G | 2 |
| RYDE, C | 1 |
| MISKOVITS, G | 1 |
| GREGERSEN, M | 1 |
| KRATKA, WH | 1 |
| JESPERSEN, A | 2 |
| SPINA, G | 13 |
| MARCHIONINI, A | 1 |
| ROCKL, H | 1 |
| KOCH, F | 1 |
| BLENNERHASSETT, GH | 1 |
| STRADAIOLI, G | 1 |
| KLOTT, M | 1 |
| VENULET, F | 1 |
| CZERSKI, K | 1 |
| SEGAGNI, E | 2 |
| LIND, A | 1 |
| MITCHELL, RS | 4 |
| ANDERSON, L | 1 |
| OHR, I | 1 |
| Delay, J | 1 |
| Bourguignon, A | 1 |
| Buisson, J | 1 |
| Henne, M | 1 |
| MACASKILL, J | 1 |
| SOMNER, AR | 1 |
| CLEGG, JW | 1 |
| GELLIS, SN | 1 |
| MURPHY, RV | 1 |
| SCHWERMA, KB | 1 |
| LAWRENCE, PJ | 1 |
| ABRIC, J | 1 |
| GIROULLE, H | 1 |
| BONICKE, R | 2 |
| CARDINALI, G | 1 |
| MAJ, A | 1 |
| POMPANIO, N | 1 |
| BACHMANN, KD | 1 |
| SATANOWSKY, C | 1 |
| LAMERENS, S | 1 |
| ROUCO, JM | 1 |
| MACCAGNANI, G | 1 |
| ORGANICK, A | 1 |
| BATTEN, J | 4 |
| SZNURA, J | 1 |
| NAGUIB, M | 1 |
| MAJEWSKA, Z | 1 |
| PRATS, F | 1 |
| PALMER, CE | 7 |
| PAYRAU, P | 1 |
| GUYARD, M | 1 |
| PERDRIEL, G | 1 |
| PETRONELLI, A | 1 |
| DA COL, A | 1 |
| ZAIDI, SH | 2 |
| HARRISON, CV | 2 |
| KING, EJ | 2 |
| GAUTHIER, M | 1 |
| SPLAWINSKI, J | 1 |
| KOPEC, H | 2 |
| PIASECKI, W | 1 |
| DUBEY, VD | 1 |
| THIEL, JC | 1 |
| PILHEU, JA | 5 |
| MASANTI, J | 1 |
| PERREAU, P | 1 |
| FRESNEAU, M | 1 |
| BOUMARD, B | 1 |
| LE BRIZAUT, Y | 1 |
| CARBAJO MARTIN, JJ | 1 |
| PFISTER, FC | 1 |
| DIETZSCH, HJ | 1 |
| TIBURTIUS, HF | 2 |
| WECHSLER, H | 3 |
| SPIRITO, AL | 1 |
| WHITTLE, GT | 1 |
| PAGANI, E | 1 |
| LUPACCHINI, A | 1 |
| SHUL'GINA, ZL | 1 |
| BUNGER, P | 2 |
| SCHUTZE, G | 1 |
| MEESE, T | 2 |
| BLITTERSDORF, F | 1 |
| SCHRODTER, S | 1 |
| YENER, MS | 1 |
| GAZIOGLU, K | 1 |
| COSKUN, N | 1 |
| BROZ, J | 1 |
| RACINE, R | 1 |
| MELLO-AGUERRE, M | 2 |
| GANCHEV, N | 1 |
| KONSTANTINOV, N | 1 |
| FON-IUNG, Ie | 1 |
| CANETTI, G | 13 |
| GEORGOPOULOS, G | 1 |
| BOIKOV, B | 1 |
| NAIDENOVA, S | 1 |
| HIRANO, N | 2 |
| NAKANISHI, K | 1 |
| FUKUNAGA, K | 1 |
| SONNECK, HJ | 1 |
| FLESCH, I | 1 |
| PINTARER, G | 1 |
| SZOKE, G | 1 |
| TOTH, E | 1 |
| SCHWEIG, GM | 1 |
| ORBAN, A | 1 |
| WEILER, P | 1 |
| FINN, OA | 1 |
| ROGERS, J | 1 |
| DE PALMA, M | 1 |
| CENTNER, J | 1 |
| MODAVE, J | 1 |
| BULSKA, M | 1 |
| PLYWACZEWSKA, I | 1 |
| BOUDOURESQUES, J | 1 |
| MASSAD, L | 1 |
| PICCIONE, A | 1 |
| RADEK, ML | 1 |
| SZONYI, L | 2 |
| KMITA, S | 1 |
| KOLBOW, H | 3 |
| SARROUY, C | 1 |
| GILLOT, F | 1 |
| SENDRA, L | 1 |
| VENEZIA, R | 1 |
| PHELIP, H | 1 |
| CAJGFINGER, H | 1 |
| WEILLER, P | 2 |
| PEREGO, MA | 1 |
| CARBAJO, JJ | 1 |
| SZANTO, S | 1 |
| HANKOVSZKY, M | 1 |
| PETIT, A | 1 |
| LACROIX, AC | 1 |
| SAYAG, A | 1 |
| DOUARD, T | 1 |
| DENST, J | 1 |
| RUSSELL, WF | 8 |
| HORTON, GE | 1 |
| MEADOW, PM | 1 |
| WORSSAM, AR | 1 |
| YOUMANS, AS | 1 |
| YOUMANS, GP | 1 |
| LINCOLN, EM | 3 |
| LYTHCOTT, GI | 1 |
| STACHOWSKY, L | 1 |
| GRABOWSKI, W | 1 |
| SOROKO, J | 1 |
| TAS, J | 1 |
| SHMUSHKOVITZ, J | 1 |
| ZITRIN, A | 1 |
| THOMPSON, DS | 1 |
| MEADOW, P | 1 |
| WOLOSKER, N | 4 |
| CIVIL INGLES, J | 2 |
| MELNOTTE, P | 2 |
| SENAULT, R | 2 |
| HUTTIN, R | 2 |
| SADOUL, P | 1 |
| SCHMID, PC | 2 |
| SCHOPPHOVEN, G | 1 |
| LUGOSI, L | 1 |
| BUTLER, K | 1 |
| STORNIELLO, G | 7 |
| SCHOEPS, U | 1 |
| DIDCOCK, KA | 1 |
| TRUC, E | 1 |
| SCHILLIRO, R | 1 |
| DUTARTE, JP | 1 |
| SILORATA, AB | 1 |
| CALDERATO, V | 1 |
| BOUR, H | 1 |
| DUCOMET, JC | 1 |
| TOSTI, U | 1 |
| OKA, S | 5 |
| SUZUKI, C | 1 |
| KUROBANE, T | 1 |
| KANNO, I | 3 |
| SATO, S | 1 |
| NIITU, Y | 1 |
| AWATAGUCHI, S | 1 |
| UEDA, H | 1 |
| YAMADA, S | 2 |
| YAKUWA, E | 1 |
| SHOJI, M | 1 |
| KOMATSUDA, K | 1 |
| BENMUSSA, S | 1 |
| DIDIER, R | 1 |
| ZANA, R | 1 |
| GHILEB, H | 1 |
| SAMAMA, M | 1 |
| BIRK, G | 1 |
| HEINE, F | 1 |
| STROBEL, W | 1 |
| FILOGRANA, V | 2 |
| BARTMANN, K | 20 |
| VILLNOW, J | 8 |
| SCHWARZ, C | 9 |
| KLEMM, E | 1 |
| BARTNICKA, J | 1 |
| BALDAMUS, U | 4 |
| PONICK, U | 3 |
| KOSTER, K | 1 |
| DICKSON, I | 1 |
| CORCOS, A | 5 |
| CORCOS, S | 2 |
| GAUDIER, B | 2 |
| PIERRET, R | 2 |
| BACIGALUPI, RG | 2 |
| GARCIA AUSTT, E | 2 |
| GOMENSORO, JB | 2 |
| MASSERA, MJ | 2 |
| MATTEO, AL | 2 |
| PORTILLO, JM | 2 |
| SALDUN DE RODRIGUEZ, ML | 2 |
| SOTO, JA | 2 |
| KRACHT, J | 4 |
| LUTZ, A | 4 |
| SICHEL, D | 2 |
| DE MORO, ER | 2 |
| MARTINEZ MARCHETTI, A | 2 |
| DIXON, GJ | 2 |
| ROBERTS, GB | 2 |
| TYRRELL, WF | 2 |
| BRESCIA, D | 2 |
| SILANOS, G | 3 |
| ROGNATO, C | 3 |
| BELLOMO, G | 2 |
| LOMBARDO, G | 2 |
| ALEXANIAN, DA | 2 |
| FUSCO, G | 2 |
| TOZZI, M | 2 |
| GAIDA, A | 2 |
| STEVENSON, AW | 2 |
| ABRAM-DOSSA, D | 2 |
| CAMPO, C | 2 |
| CHAPTAL, J | 3 |
| JEAN, R | 3 |
| LIVINGSTONE, JL | 2 |
| DEBRE, R | 7 |
| FOUSSEREAU, S | 3 |
| NOUFFLARD, H | 8 |
| DOBROWOLSKI, B | 3 |
| GRUMBACH, R | 3 |
| KAPLAN, M | 3 |
| BENSOUSSAN, C | 2 |
| ABELLO, J | 2 |
| PHILBERT, M | 2 |
| SCHWOB, RA | 2 |
| HANDLEY, AE | 2 |
| ALKEN, CE | 2 |
| FISCHBECK, W | 2 |
| GLOGOWSKI, G | 3 |
| LANGE, M | 2 |
| COHN, ML | 5 |
| MANDEL, W | 4 |
| BAGNOLI, F | 2 |
| BONOLI, P | 2 |
| PRALORAN, L | 7 |
| NEUMANN, K | 2 |
| BASU, UP | 2 |
| BHADRA, NC | 2 |
| GUHA, P | 2 |
| CARVALHO DA SILVA, N | 2 |
| TEICHHOLZ, M | 3 |
| BECKER, SW | 2 |
| MOUNCE, SH | 2 |
| VERBEKE, R | 2 |
| BEKAERT, J | 2 |
| DE BRABANDERE, R | 2 |
| STEYAERT, J | 2 |
| SHER, BC | 2 |
| CZAJA, ZG | 1 |
| TAKIMURA, Y | 2 |
| POPPER, H | 1 |
| LAGER, S | 1 |
| WITZ, MA | 2 |
| YUSAWA, K | 1 |
| SHINKAI, N | 1 |
| HIRASAWA, I | 1 |
| HASHIMOTO, Y | 1 |
| IWASAKI, T | 2 |
| NICK, J | 1 |
| BASTOS-MORA, F | 1 |
| PORTAL-LLAMEDO, L | 1 |
| STEINHAEUSER, F | 1 |
| VELTMAN, G | 1 |
| GROTH-PETERSEN, E | 3 |
| EPSTEIN, IG | 2 |
| NAIR, KG | 2 |
| BOYD, LJ | 2 |
| MORALES, SM | 1 |
| JORDAHL, C | 5 |
| DES PREZ, R | 4 |
| MURDOCH, JM | 1 |
| HAY, D | 2 |
| SASSO, C | 1 |
| SARNO, A | 1 |
| CURBELO DE MALET, S | 1 |
| KASK, E | 1 |
| FUJIOKA, K | 1 |
| YOSHIDA, F | 3 |
| SUGIURA, A | 1 |
| KAI, Y | 1 |
| KASAI, T | 1 |
| NISHIYAMA, K | 1 |
| HIRASHIMA, N | 1 |
| YOSHIDA, N | 1 |
| SHIMODA, T | 1 |
| MIKHAILOV, FA | 2 |
| SMOLIANSKAIA, AZ | 1 |
| LOWYS, P | 1 |
| IVASHCHENKO, EA | 1 |
| DA SILVA, NC | 1 |
| WAREMBOURG, H | 1 |
| VOISIN, C | 1 |
| PAUCHANT, M | 1 |
| VON OLDERSHAUSEN, HF | 1 |
| VON OLDERSHAUSEN, R | 1 |
| MORELLINI, M | 1 |
| FERRARI, S | 1 |
| MALAGUZZI-VALERI, F | 2 |
| ZUBIANI, M | 4 |
| KIMMIG, J | 1 |
| KRUGER, F | 1 |
| VON ARNIM, HH | 1 |
| KOANG, NK | 1 |
| HU, TC | 1 |
| TCH'EN, CL | 1 |
| CHU, TH | 1 |
| MUTTI, E | 1 |
| PETRONE, R | 1 |
| BERENCSI, G | 4 |
| SIMON, N | 1 |
| FURUTA, M | 1 |
| DUBOIS-VERLIERE, T | 1 |
| SAVEL, J | 1 |
| DU PLESSIS, JJ | 1 |
| DE SOUSA, MA | 1 |
| DE ALEMQUER, M | 4 |
| CAEIRO, A | 2 |
| DEMOULIN-BRAHY, L | 1 |
| DENYS-DE TEMMERMAN, A | 1 |
| DONNERBERG, RL | 1 |
| ATWELL, RJ | 2 |
| BROWNING, RH | 1 |
| FENG, CH | 1 |
| T'ANG, CM | 1 |
| MENG, CM | 1 |
| FAVEZ, G | 6 |
| AGUET, F | 1 |
| SOURDAT, P | 1 |
| MAGNENAT, P | 1 |
| BRINSMADE, A | 1 |
| HSU, KH | 3 |
| SASAKI, M | 2 |
| YAMORI, T | 1 |
| OIFEBAKH, MI | 1 |
| PUZIK, VI | 2 |
| ROZENFEL'D, RM | 1 |
| BELL, JC | 2 |
| RIEMENSNIDER, DK | 1 |
| GERARD, A | 2 |
| GARAVENTA, A | 2 |
| COSTA, G | 1 |
| GUNELLA, S | 1 |
| LANGER, R | 1 |
| CORCOS, V | 1 |
| UTKIN, VV | 3 |
| AGAPKIN, IN | 2 |
| BAGAEVA, MI | 2 |
| JANKOV, M | 1 |
| MOIGNETEAU, C | 2 |
| DURIEZ, J | 1 |
| DEBEAUMONT, A | 1 |
| CAUCHOIX, J | 1 |
| RUBBO, SD | 4 |
| EDGAR, J | 1 |
| VAUGHAN, G | 2 |
| REISS, J | 1 |
| TOWNSEND, SM | 1 |
| FELDMAN, S | 1 |
| BEHAR, AJ | 1 |
| WEBER, D | 1 |
| MEYERHOFF, WK | 1 |
| LEONCINI, G | 2 |
| MAZZINI, C | 1 |
| MIGLIORI, V | 1 |
| GRASSI, A | 1 |
| DOS NEVES, JS | 1 |
| ESPINDOLA, N | 1 |
| HAUDUROY, P | 2 |
| WACHSMUTH, C | 1 |
| ABLER, C | 1 |
| MATL, Z | 1 |
| GOCIAR, F | 1 |
| HERDEGEN, L | 1 |
| JALUVKA, A | 1 |
| KLADIVOVA, L | 1 |
| NEUMANN, R | 1 |
| SYKORA, F | 1 |
| KIRSHNER, JJ | 2 |
| STOTT, H | 3 |
| CRISSEY, JT | 1 |
| OSBORNE, ED | 1 |
| JORDON, JW | 1 |
| PRICE, JM | 1 |
| BROWN, RR | 1 |
| ABRAHAM, K | 1 |
| POPPE DE FIGUEIREDO, F | 1 |
| DE PAOLA, D | 2 |
| IWASHITA, I | 1 |
| HOOFT, C | 1 |
| VAN WINCKEL, H | 1 |
| VAN ZEBEN, W | 1 |
| VERBIEST, H | 1 |
| WRUBL, A | 1 |
| ROMEO, G | 1 |
| SEREMBE, M | 2 |
| GOTI, F | 1 |
| VERCELLINO, A | 1 |
| RABINO, A | 1 |
| TORREGROSSA, O | 1 |
| CHRISTENSEN, O | 1 |
| HOLM, S | 1 |
| RASMUSSEN, KH | 1 |
| HALAMA, F | 1 |
| KLIMKIEWICZ, GR | 1 |
| ELLIS, WC | 1 |
| MALONE, HJ | 1 |
| DOLGIN, J | 1 |
| ABDURASHITOVA, MV | 1 |
| CHERTKOVA, EI | 3 |
| FEREBEE, S | 1 |
| ANASTASIADES, A | 1 |
| SCOZIA, A | 2 |
| ALIPERTA, A | 2 |
| DAVIES, GE | 1 |
| DRIVER, GW | 1 |
| STRUBE, RE | 1 |
| STERN, KF | 1 |
| SHIMOMURA, Y | 1 |
| ROTTINI, E | 1 |
| PICCHIO, E | 1 |
| FIORENTINI, M | 1 |
| SUDA, J | 1 |
| DI LAURO, E | 1 |
| WYSS, A | 1 |
| JOOS, H | 1 |
| DESSAUER, P | 1 |
| ALTMANN, A | 1 |
| MOREAU, F | 1 |
| MOTIWALE, AG | 1 |
| NASTA, M | 4 |
| NEGULESCU, V | 1 |
| ALGEORGE, G | 6 |
| ARHIRI, M | 4 |
| SACCO, F | 1 |
| GUALA, B | 1 |
| GUERRA, P | 1 |
| ZUCCHETTI, B | 1 |
| BORSELLA, C | 2 |
| MERELLI, B | 1 |
| SOSNOWSKI, K | 2 |
| TOKAREVA, BA | 1 |
| LIMA FILHO, MT | 1 |
| CARRIJO, LN | 2 |
| ABUCHALLA, D | 2 |
| ALTMANN, V | 1 |
| DIAZ, RM | 1 |
| DUNBAR, FP | 3 |
| DAVIS, R | 1 |
| JEFFERIES, MB | 2 |
| PERELLI, A | 2 |
| ZILIOTTO, G | 1 |
| ROYE, WE | 1 |
| EWART, GE | 1 |
| AUSPITZ, P | 1 |
| SISTI, MA | 2 |
| SCODITTI, G | 2 |
| BARILLI, L | 1 |
| COPPARI, V | 1 |
| KOURILSKY, R | 1 |
| KOURILSKY, S | 1 |
| THUILLIER, Y | 1 |
| SELKON, JB | 13 |
| ROSENFELD, M | 7 |
| WALSH, A | 1 |
| O'FLYNN, JD | 1 |
| GOFRON, W | 1 |
| JANSSEN, G | 2 |
| STAEMMLER, HG | 1 |
| POTHMANN, FJ | 1 |
| TRIGUB, NI | 3 |
| LESOBRE, R | 4 |
| OURY, M | 1 |
| CROZAFON, C | 1 |
| BARBEITO, AM | 1 |
| HERBST, R | 1 |
| PUXKANDL, H | 1 |
| NACHTIGALL, C | 1 |
| BUCHWALD, G | 1 |
| PICKROTH, G | 2 |
| HALL, HE | 1 |
| SCHERAGO, M | 1 |
| CROFTON, J | 1 |
| VAN VLIERBERGHE, RG | 1 |
| PATTYN, S | 1 |
| VANBREUSEGHEM, R | 1 |
| GUPTA, SK | 2 |
| MATHUR, IS | 2 |
| MUKERJI, B | 3 |
| GUGLIELMETTI, P | 2 |
| SIGNORINI, LF | 2 |
| FISSI-MARRACCINI, G | 1 |
| DIETEL, K | 1 |
| AIAZZI MANCINI, P | 1 |
| WU, SC | 1 |
| KU, CY | 1 |
| CHENG, TY | 2 |
| TS'UI, HP | 1 |
| MA, KC | 1 |
| CH'EN, JP | 1 |
| BOMPY, S | 1 |
| MACHON, Z | 1 |
| FOYE, WO | 1 |
| DUVALL, RN | 1 |
| CRAMBLETT, HG | 1 |
| BRYAN, GT | 1 |
| MACQUEEN, JC | 1 |
| NISHIMURA, H | 1 |
| ROSATI, T | 3 |
| BADIALI, L | 4 |
| LUCCIOLI, F | 1 |
| MARINO, E | 1 |
| KROBER, KH | 1 |
| ROBEL, G | 1 |
| DEL PRINCIPE, A | 1 |
| DE LIMA FILHO, MT | 1 |
| SIEGEL, D | 3 |
| EDWARD, DW | 1 |
| GIOVA, C | 1 |
| DI RUGGIERO, A | 1 |
| MARINELLI, N | 1 |
| CANIGLIA, M | 1 |
| ZIERZ, P | 1 |
| PAETZOLD, OH | 1 |
| MIYOSHI, H | 1 |
| OKANO, G | 1 |
| LANIER, VS | 1 |
| RUSSEL, WF | 1 |
| HEATON, A | 1 |
| ROBINSON, A | 2 |
| POZZI, G | 1 |
| SCOCCIA, S | 1 |
| LEONARDI, G | 1 |
| PERSHIN, GN | 6 |
| MAKEEVA, OO | 9 |
| IAKOVLEVA, AI | 2 |
| KLEBANOVA, AA | 2 |
| MYSKIN, VS | 1 |
| ABRAMSON, ES | 2 |
| FEIREISS, D | 1 |
| ROUCH, LC | 1 |
| EGAN, JB | 1 |
| WADDINGTON, AL | 1 |
| TELLESSON, WG | 1 |
| RENKIN, A | 1 |
| SMART, J | 1 |
| GOUGH, J | 1 |
| KUO, TL | 1 |
| CHANG, JC | 1 |
| CHU, TY | 1 |
| KORYCKA, A | 1 |
| SLIWINSKA, H | 1 |
| SUTHERLAND, AM | 1 |
| KAMEYAMA, Y | 2 |
| HIRASHIKI, Y | 1 |
| KUNIGOSHI, U | 1 |
| LINATI, A | 1 |
| HANSSON, CG | 1 |
| ROSS, JD | 1 |
| SPASOV, A | 1 |
| ROBEV, S | 1 |
| HARE, EH | 1 |
| WALSH, JJ | 1 |
| LINN, RH | 1 |
| JACOBS, S | 2 |
| MARTINS, J | 1 |
| IANNELLO, JA | 1 |
| OTTO, H | 2 |
| EVANDER, LC | 2 |
| ROSE, NR | 1 |
| BEUTNER, EH | 2 |
| TASHIRO, K | 1 |
| DOYLE, W | 1 |
| BRIDGE, EV | 2 |
| CARR, DT | 2 |
| BERTE, SJ | 4 |
| DEWLETT, HJ | 3 |
| SCHMIDT, HW | 2 |
| YOUATT, J | 1 |
| MASCHERPA, A | 1 |
| MILANI, C | 1 |
| KANAI, K | 10 |
| NAKAJIMA, M | 2 |
| YANAGISAWA, K | 1 |
| ITO, Y | 1 |
| KARLHUBER, F | 1 |
| TARSHIS, MS | 2 |
| MESCOLINI, G | 1 |
| DE DIMONI, G | 1 |
| DELANK, HW | 1 |
| FIEBRAND, H | 1 |
| WAGNER, WH | 1 |
| MAEDA, M | 2 |
| HARASAWA, M | 1 |
| KOYAMA, K | 1 |
| NAKAMOTO, T | 1 |
| MASSOLA, U | 1 |
| JENEY, E | 1 |
| ZSOLNAI, T | 1 |
| HAHN, J | 2 |
| PORTARSKI, G | 1 |
| VERSE, H | 1 |
| BIERSCHENK, H | 1 |
| PFAFFENBERG, R | 4 |
| JAHLER, H | 2 |
| BACHMAN, H | 1 |
| FREUND, J | 1 |
| ALLISON, ST | 1 |
| SERI, I | 7 |
| ZEMANEK, J | 1 |
| MASSA, B | 1 |
| MANZONE, P | 1 |
| SARTORIO, E | 1 |
| OSEGLIA, G | 1 |
| CARTA, Q | 1 |
| NAGATA, S | 2 |
| CETRANGOLO, A | 6 |
| LAPENA, D | 1 |
| DE DIAZ, LS | 1 |
| CAMERINI, G | 1 |
| MAZUREK, LJ | 1 |
| JASINSKI, Z | 1 |
| KOROSSY, S | 1 |
| GOZONY, M | 1 |
| GENAZZANI, E | 1 |
| PAOLETTI, A | 1 |
| NEVES, S | 1 |
| ESPINDULA, N | 1 |
| JANCIK, E | 8 |
| MORAVEK, J | 1 |
| BASTARRACHEA, F | 1 |
| GONZALEZ-MENDOZA, A | 1 |
| PEREZ-TAMAYO, R | 1 |
| BOJALIL, LF | 1 |
| MANNION, RA | 1 |
| COTTRELL, TL | 1 |
| LLOYD, FA | 1 |
| SUSEBACH, HD | 1 |
| FEDORCHENKO, PM | 1 |
| LESPAGNOL, A | 1 |
| MACLEOD, HM | 1 |
| NOWAK, K | 1 |
| TREPPINGER, K | 1 |
| BAHRS, G | 2 |
| DOY, CH | 1 |
| DIXSON, S | 1 |
| LYON, RH | 1 |
| HALL, WH | 1 |
| McALISTER, E | 1 |
| ORGANICK, AB | 1 |
| CARACCIOLO, M | 1 |
| TIBERI, GF | 1 |
| MATSUZAKI, Y | 1 |
| BOTTINO, D | 1 |
| MAGGIORA, L | 1 |
| SANTOPADRE, I | 1 |
| CIBERT, J | 1 |
| BARBIER, J | 1 |
| SUSHIDA, K | 1 |
| FRIEDMAN, E | 1 |
| SULLIVAN, FM | 1 |
| RAVAZZONI, C | 1 |
| SCARPONI, F | 1 |
| BARBERA, L | 2 |
| MAGGIONI, L | 1 |
| LEITES, V | 1 |
| HEATON, AD | 1 |
| SITNOVA, VK | 1 |
| ACETO, JN | 1 |
| COVERT, DF | 1 |
| ACHESON, RM | 1 |
| MYNORS, L | 1 |
| TAYLOR, KB | 1 |
| ACRED, P | 1 |
| BROWN, DM | 1 |
| WRIGHT, D | 1 |
| ADACHI, I | 3 |
| TAKAHASHI, C | 1 |
| SHIMADA, H | 3 |
| OKAI, T | 3 |
| TAKAHASI, T | 2 |
| DAVID, H | 3 |
| ALIMOV, ShA | 1 |
| AZARNYKH, MA | 1 |
| ALONSO LOMAS, L | 1 |
| ARIAS MARTINEZ, J | 1 |
| AGOTE POVEDA, IP | 1 |
| ANNEAR, TD | 1 |
| BAKER, GP | 1 |
| BARBOLINI, G | 2 |
| LOSCHI, GC | 1 |
| KAUFMAN, I | 1 |
| LYONS, HA | 3 |
| MARSH, W | 1 |
| BURNETT, PC | 1 |
| BRODIE, D | 1 |
| CATTANEO, C | 5 |
| IPATA, PL | 1 |
| MAGGINI, P | 1 |
| CRASTES DE PAULET, A | 1 |
| BONNET, H | 1 |
| PETIT, M | 1 |
| GUILLAUMOT, R | 1 |
| COMSTOCK, GW | 13 |
| MOUNTH, FW | 1 |
| COVACEV, L | 1 |
| FROLOVA, VM | 1 |
| GOLDSHTEIN, VD | 1 |
| GREBENNIK, LI | 4 |
| PASHCHENKO, NI | 1 |
| GILL, R | 1 |
| KASS, I | 2 |
| HAWARD, LR | 1 |
| HERTWIG, B | 1 |
| VIRCHOW, C | 2 |
| IURKINA, AI | 1 |
| IWAINSKY, H | 5 |
| GERLOFF, W | 3 |
| SCHMIEDEL, A | 3 |
| DAHLSTROM, AW | 1 |
| WILSON, JL | 3 |
| SEDLACEK, BB | 1 |
| DEVADATTA, S | 9 |
| ANDREWS, RH | 6 |
| ANGEL, JH | 2 |
| JANARDHANAM, B | 2 |
| RADHAKRISHNA, S | 10 |
| RAMAKRISHNAN, CV | 10 |
| SUBBAIAH, TV | 4 |
| VELU, S | 9 |
| GANGADHARAM, PR | 10 |
| DORMER, BA | 4 |
| MARTINAGLIA, G | 1 |
| HOBBS, WB | 1 |
| WOOD, MM | 1 |
| DVOIRIN, MS | 2 |
| ZAMDBORG, LIa | 1 |
| MOISEEVA, DN | 1 |
| ECKLEY, GM | 1 |
| NAGASHIMA, M | 1 |
| NAITO, M | 4 |
| MAEKAWA, N | 2 |
| KUBO, T | 1 |
| HAMADA, K | 2 |
| TSUJINO, H | 1 |
| NAKAYAMA, S | 1 |
| BERTEAUX, S | 1 |
| OHSATO, T | 1 |
| PARENTI, G | 1 |
| PASQUIER, J | 1 |
| MAURO, B | 4 |
| PECORA, DV | 1 |
| JAEHLER, H | 1 |
| PINAMONTI, F | 1 |
| CANE, P | 1 |
| ZUKOWSKA, H | 1 |
| PRZEWORSKA-KANIEWICZ, D | 1 |
| RAMAGLIA, M | 1 |
| NINNI, A | 7 |
| MONTELLA, A | 1 |
| REI, TS | 1 |
| SMITH, JT | 2 |
| THOMAS, CG | 1 |
| SALIBA, A | 3 |
| BEATTY, OA | 3 |
| PACINI, L | 1 |
| DOWDEN, CW | 1 |
| SALVETTI, F | 1 |
| BILLIA, P | 1 |
| SCHIFFRIN, D | 1 |
| REPETTI, L | 1 |
| UCERO, G | 1 |
| SELLMER, A | 1 |
| KAKINOKI, H | 1 |
| KASSOWITZ, KE | 1 |
| KRAKAUER, R | 1 |
| KUR'IANOVA, EN | 1 |
| DAVYDOVA, NK | 1 |
| KUROIWA, K | 1 |
| KOGI, Y | 1 |
| KOL'NIKOVA, NM | 1 |
| LAMBERT, HP | 1 |
| LEMBERSKII, IG | 1 |
| ITKINA, RE | 1 |
| LEMENAGER, J | 2 |
| MOREL, C | 1 |
| LIBERMAN, SS | 1 |
| MAKSIMENKO, NT | 1 |
| THODE, P | 1 |
| MASSALSKI, W | 1 |
| MIGDALSKA, B | 1 |
| ODRZYWOLSKA, A | 1 |
| SZYMANSKA, D | 1 |
| URBANSKA-DABROWSKA, H | 1 |
| PASQUIER, JF | 4 |
| EPIFANIO, C | 1 |
| MIRZOIAN, EZ | 3 |
| KAMINSKAIA, AA | 1 |
| ANASTASIADES, AA | 1 |
| SCHNACK, GA | 1 |
| TAI, FH | 1 |
| JEN, TM | 1 |
| CHU, BY | 1 |
| HAN, SH | 1 |
| TITCHE, LL | 1 |
| STEIN, HF | 1 |
| MEETZ, SP | 1 |
| TSUKAMURA, M | 6 |
| TUENNERHOFF, FK | 3 |
| SCHWABE, HK | 5 |
| URBANCIK, R | 5 |
| SIMANE, Z | 3 |
| KRAUS, P | 1 |
| REIL, I | 1 |
| URBANSKI, T | 1 |
| SERAFINOWA, B | 1 |
| GUSTOWSKI, W | 1 |
| VENULET, J | 5 |
| JAKIMOWSKA, K | 2 |
| JANOWIEC, M | 8 |
| SOMASUNDARAM, PR | 4 |
| MOUNEY, M | 1 |
| VYAS, KJ | 1 |
| WEISS, W | 2 |
| CHUN, HH | 1 |
| FLIPPIN, HF | 2 |
| YASHIRO, A | 1 |
| ZITRIN, CM | 1 |
| JANSSEN, EG | 2 |
| JIMENEZ, M | 1 |
| MUSCHENHELM, C | 1 |
| ALBORES, JM | 1 |
| COSIN, A | 1 |
| ROZEMBAUM, S | 1 |
| GOYA, E | 1 |
| MALACALZA, N | 1 |
| ARMSTRONG, AR | 1 |
| PEART, HE | 1 |
| BELL, WJ | 3 |
| BROWN, PP | 2 |
| JARNIOU, AP | 1 |
| ISRAEL, L | 2 |
| ENJALBERT, M | 1 |
| FABRE, C | 1 |
| BOWEN, CD | 1 |
| BERUMEN, LB | 1 |
| BLOMQUIST, ET | 2 |
| BURACZEWSKA, M | 3 |
| CARLI, R | 1 |
| CATENA, E | 3 |
| PIAZZA, R | 1 |
| DAVID, JD | 1 |
| LEAHY, DJ | 1 |
| DE CECCO, L | 1 |
| BRISSAUD, HE | 2 |
| GERBEAUX, J | 3 |
| MOISAN, F | 1 |
| TURMEL, C | 1 |
| DEUSCHLE, KW | 2 |
| DONOHOE, RF | 2 |
| DUKE, CJ | 1 |
| ROMANSKY, MJ | 1 |
| HARRISON, I | 2 |
| SWART, JA | 1 |
| VIDOR, SR | 1 |
| FUKUI, A | 1 |
| FYFE, WM | 1 |
| GARCIA PASTOR, R | 1 |
| GREUEL, H | 1 |
| SCHAEFER, EL | 1 |
| GROBLI, CW | 1 |
| LERNER, S | 2 |
| GAD, U | 2 |
| OSTERGAARD, F | 1 |
| GUGLIEMETTI, P | 1 |
| MARRACCINI, GF | 1 |
| GUILLEMAN, P | 1 |
| KAR, K | 1 |
| CHATTERJEE, J | 1 |
| TAKAHASHI, H | 1 |
| TAN, TH | 2 |
| WIDODO, S | 1 |
| THOMAS, HE | 1 |
| TURLETTI TOLA, A | 1 |
| URBANSKA, A | 1 |
| GUIN, JJ | 2 |
| VINCZE, E | 2 |
| SCHWEIGER, O | 5 |
| VANDRA, E | 1 |
| WEINGAERTNER, L | 2 |
| WOJEWSKI, A | 1 |
| KAPUR, VN | 1 |
| GILLIS, S | 1 |
| TEXLER, K | 1 |
| GODDEN, JF | 1 |
| IGNATAVICHUTE, BK | 1 |
| IL'INA, TB | 5 |
| ALBRECHT, KF | 2 |
| BHARUCHA, PE | 1 |
| TALWALKER, YB | 1 |
| BJERKEDAL, T | 4 |
| BOUCOT, KR | 1 |
| POINGT, O | 1 |
| DEZEUSTRE, J | 1 |
| CAPELLI, F | 1 |
| DAVIS, CL | 1 |
| DAIROV, D | 1 |
| DEUSCHLE, HW | 1 |
| NAIR, CN | 1 |
| GIANNICE, C | 1 |
| NOTARBARTOLO DI VILLAROSA, R | 1 |
| GOOSSENS, M | 1 |
| GROUNDS, JG | 3 |
| RASPI, E | 3 |
| HAGIHARA, K | 1 |
| ITO, N | 1 |
| TAKEUCHI, K | 1 |
| KAJIMA, H | 1 |
| DEGUCHI, T | 1 |
| FETERHOFF, KI | 1 |
| KAISER, JC | 1 |
| HUETTL, C | 1 |
| SHCHEPETIL'NIKOVA, OG | 1 |
| SHENOY, MA | 1 |
| SHIMOIDE, H | 3 |
| TOYOHARA, M | 3 |
| SHMELEV, NA | 2 |
| KOZULITSYNA, TI | 3 |
| SHORT, EI | 1 |
| SIEFERT, G | 1 |
| SPIESS, H | 2 |
| GERAGHTY, E | 1 |
| SUGIMOTO, H | 3 |
| MIYAJIMA, T | 1 |
| TEREKHOVA, NIa | 1 |
| TRNKA, L | 2 |
| NARAYANA, AS | 4 |
| VILARINHO, E | 1 |
| LEPEUPLE, A | 2 |
| THIBIER, R | 4 |
| VIVIEN, JN | 3 |
| AUGUSTI, G | 1 |
| LEVI-VALENSI, P | 1 |
| KESPI, JM | 1 |
| MARCUS, H | 1 |
| YOO, OH | 1 |
| AKYOL, T | 1 |
| WILLIAMS, MH | 2 |
| NAGASAWA, S | 2 |
| OHKOSHI, M | 1 |
| OMORI, Y | 1 |
| OSATO, T | 1 |
| KINO, C | 1 |
| PASTOR, MF | 1 |
| HERRERO, JJ | 2 |
| LOPEZ MEDRANO, CM | 1 |
| FARIAS, CE | 4 |
| PERNOD, J | 2 |
| CHAMBATTE, C | 2 |
| BATIME, J | 2 |
| KERMAREC, J | 1 |
| MASTROLORENZO, HC | 1 |
| PINES, A | 3 |
| DI CARLO, FC | 1 |
| CAFIRE, N | 1 |
| FERNANDEZ, H | 1 |
| GAJEWSKA, E | 1 |
| KULEJEWSKA, M | 1 |
| KWILER, S | 1 |
| MASZCZYK, Z | 2 |
| PIEKARNIAK, K | 2 |
| TYSAROWSKI, W | 1 |
| SUKHANOVSKII, VP | 1 |
| SULITSKII, VA | 1 |
| GUTNIK, EP | 1 |
| HANSEN, OH | 1 |
| HELGAKER, J | 1 |
| HEYMER, A | 2 |
| GRANT, IW | 1 |
| HORNUNG, S | 2 |
| POLONCZYK, M | 2 |
| DRAJKA-KROPACZEK, L | 1 |
| RAPF, T | 1 |
| HOTTER, GJ | 1 |
| HUEMPFNER, HR | 1 |
| ZAPOLSKY, I | 1 |
| KENNEDY, JA | 1 |
| IIZUKA, Y | 1 |
| ARIGA, H | 2 |
| IWAZAKI, T | 1 |
| FRADKIN, VA | 1 |
| KAMEDA, K | 1 |
| FELSCH, G | 1 |
| JORKE, D | 1 |
| GEL'BERG, IS | 1 |
| BOGOSLOV, EM | 1 |
| HODGSON, AR | 1 |
| COURY, C | 2 |
| STORA, C | 2 |
| FRANCHEL, F | 1 |
| ORINSTEIN, E | 1 |
| DELAVILLE, MR | 1 |
| PARIENTE, D | 1 |
| PIERON, R | 4 |
| PRETET, S | 2 |
| BERTI, R | 2 |
| ROBINSON, E | 1 |
| SIMPSON, DG | 3 |
| HUBAYTAR, RT | 1 |
| TERAMATSU, T | 2 |
| LACALMONTIE, J | 2 |
| REY, JC | 1 |
| DUBRA, FA | 2 |
| RIEBE, J | 1 |
| RUCHELMAN, HH | 1 |
| CHOFNAS, I | 2 |
| FRANZOSI, P | 1 |
| SOKLAKOVA, VS | 1 |
| SCHILLING, I | 1 |
| SILVEIRA, J | 2 |
| MEDEIROS, S | 2 |
| SMIRNOV, GA | 6 |
| TURNER, PP | 1 |
| TUXEN, A | 1 |
| UEDA, C | 1 |
| TAO, TT | 1 |
| KUMASHIRO, Y | 1 |
| UEMURA, T | 1 |
| VAGUE, J | 1 |
| CODACCIONI, JL | 1 |
| SIMONIN, R | 1 |
| FAVIER, G | 2 |
| TEITELBAUM, M | 1 |
| MILLER, G | 1 |
| BERNARD, PJ | 1 |
| VARGA, J | 1 |
| VISCHER, WA | 2 |
| ROULET, FC | 1 |
| WASSERFALLEN, M | 1 |
| WERNER, E | 2 |
| DROBNY, H | 1 |
| ZIECHE, K | 1 |
| WILHELMI, E | 1 |
| YAD, MI | 1 |
| ALVAREZ-SIERRA OVIEDO, J | 1 |
| BOSZORMENYI, M | 4 |
| FAUSZT, I | 3 |
| BARABAS, M | 1 |
| JAKAB, Z | 1 |
| MAJZIK, G | 1 |
| SAGODI, R | 1 |
| BUTLER, RW | 1 |
| JOSEPHSON, JE | 1 |
| BYUN, HW | 1 |
| CUCCIA, D | 1 |
| D'ESOPO, ND | 1 |
| EL-DEWI, T | 1 |
| BONSTEIN, H | 1 |
| KOMAR, TV | 1 |
| DIMOND, AH | 2 |
| MURRAY, FJ | 1 |
| LIVESAY, VT | 1 |
| CANBY, JP | 1 |
| GLEASON, DM | 1 |
| GIRGIS, AS | 1 |
| SHIGEMATSU, T | 1 |
| KONDO, K | 2 |
| MUELLER, F | 1 |
| KRULIK, R | 3 |
| KOHOUT, M | 2 |
| PONGOR, F | 2 |
| OMODEIZORINI, A | 2 |
| MARIANI, B | 3 |
| DESIMONI, G | 2 |
| CHENEBAULT, J | 3 |
| BENNIS, M | 1 |
| NOVAK, JB | 1 |
| ALIMOV, RSh | 1 |
| BASTAROLI, JC | 1 |
| BUTT, H | 1 |
| LITMAN, GI | 1 |
| CANEVARI, M | 1 |
| ROCCO, V | 1 |
| OKAMOTO, K | 1 |
| FUJINAGA, R | 1 |
| YAMAUCHI, H | 1 |
| BENIANS, RG | 1 |
| SABLJICA, B | 1 |
| RAJCEVIC, V | 1 |
| HAHN, D | 1 |
| BOESZOERMENYI, M | 2 |
| KANITZ, E | 1 |
| MAJUMDAR, AC | 2 |
| SEN, R | 2 |
| MATHUR, PD | 2 |
| OSEWSKI, T | 2 |
| DELOFF, L | 2 |
| GRZESKOWSKI, J | 2 |
| MICHALIK, M | 2 |
| OKLEK, K | 2 |
| STRUPCZEWSKA-JANUSZOWA, H | 1 |
| KOCHNOWSKI, G | 1 |
| ROSENBERG, S | 1 |
| SAITO, T | 2 |
| PUGACHEV, VS | 1 |
| MARCHENKO, MA | 1 |
| SOSNOWSKI, W | 2 |
| MALINOWSKA, B | 1 |
| SZCZURKIEWICZ, W | 1 |
| KAZANEK, I | 1 |
| HANLEY, HG | 2 |
| LLOYD, J | 2 |
| VOITEK, V | 1 |
| EROSHINA, NV | 1 |
| VERMA, BN | 1 |
| VASSERMAN, ME | 1 |
| SCHRADI, A | 1 |
| OSVATH, S | 1 |
| GERGELY, I | 1 |
| TANI, P | 5 |
| POPPIUS, H | 2 |
| ARIZTIA, A | 1 |
| BASU, SK | 1 |
| MAHASAYA, DR | 1 |
| REDONDA, M | 1 |
| HAGEMAN, JH | 1 |
| D ESOPO, ND | 1 |
| GLENN, WW | 1 |
| VISHNEVSKY-VYSNIAUSKAS, C | 1 |
| DOYLE, WM | 1 |
| KALLIO, E | 1 |
| FRANZAS, F | 1 |
| STUPENENGO, RH | 1 |
| WENDY, CD | 1 |
| JESSAMINE, AG | 2 |
| HAMILTON, EJ | 2 |
| HALASZ, S | 1 |
| LEVENDEL, L | 1 |
| VARADY, T | 1 |
| BEDE, L | 1 |
| KAROLYI, A | 1 |
| KAERKELAE, A | 1 |
| MIETTINEN, P | 1 |
| TUOVINEN, E | 1 |
| ASTERIADOU-SAMARTZE, E | 1 |
| STARR, S | 2 |
| BERKOVICH, S | 2 |
| PARFENOVA, IP | 1 |
| SHMUKLER, BA | 1 |
| COLLINS, TF | 4 |
| RUSEV, LR | 1 |
| NIKOLOV, GS | 1 |
| BROIDE, L | 1 |
| ORSI, A | 1 |
| CHANDLER, AC | 1 |
| LOCATCHER-KHORAZO, D | 2 |
| RABUKHIN, AE | 1 |
| ACCARD, R | 1 |
| TOURAINE, J | 1 |
| FODOR, T | 2 |
| TARNOK, I | 1 |
| SOMI KOVACS, T | 1 |
| NEMETH, T | 1 |
| HORVATH, B | 1 |
| MAROTI, A | 1 |
| WABROSCH, G | 1 |
| KRACT, J | 1 |
| RUHE, AF | 1 |
| OKAWA, H | 1 |
| ITO, T | 2 |
| KAMESAKI, H | 1 |
| SUGIYAMA, I | 1 |
| ICHIOKA, M | 1 |
| OKAMOTO, S | 1 |
| MUROHASHI, T | 3 |
| GEISLER, F | 1 |
| PFUETZE, KH | 1 |
| PYLE, MM | 2 |
| ASAI, S | 1 |
| TSUKADA, K | 1 |
| MURANYI, J | 1 |
| HORVATH, J | 1 |
| GAT, L | 1 |
| MANDI, L | 1 |
| PINTER, L | 1 |
| ZECHNER, E | 1 |
| MUELLER, RW | 1 |
| AOKI, K | 1 |
| TOKIWA, T | 1 |
| YAMAMOTO, T | 2 |
| SZACSURY, J | 1 |
| LOUGHEED, JC | 1 |
| SAPORTA, J | 1 |
| HOLMES, J | 1 |
| JACOB, CV | 1 |
| HITZE, KL | 2 |
| RAMACHANDRAN, K | 1 |
| DEBRAY, C | 1 |
| SPRYSZAK, A | 2 |
| ZORAWSKI, C | 2 |
| WAGNER, J | 1 |
| VEINEROV, IB | 2 |
| VELTMAN, RP | 1 |
| COTTE, J | 1 |
| ROULLET, A | 1 |
| MATSUDA, M | 2 |
| SASA, M | 1 |
| SUGIYAMA, K | 1 |
| TOUSEK, J | 2 |
| MAKOVA, M | 2 |
| ZELENKA, M | 2 |
| DICKINSON, JM | 13 |
| LEFFORD, MJ | 4 |
| RAMSAY, JH | 1 |
| MORRIS, D | 1 |
| FROMAN, S | 1 |
| LANGEROVA, M | 1 |
| MAHLER, HT | 1 |
| SULA, L | 1 |
| LETACON, J | 1 |
| PRADO-TORTEROLO, JM | 1 |
| VICECONTI, G | 1 |
| BAMBOV, L | 1 |
| GRUCA, A | 1 |
| SERAFIN, R | 1 |
| HIEROWSKI, M | 1 |
| WESTFAL, I | 2 |
| MICHETTI, F | 1 |
| LAVAL, P | 1 |
| CHARPIN, J | 1 |
| DUMON-LEGRE, M | 1 |
| BALOZET, P | 1 |
| XAU, F | 1 |
| GOUVITSOS, A | 1 |
| PARREL, L | 1 |
| FABRE, A | 1 |
| LEMERCIER, MJ | 1 |
| KHERSONSKII, GR | 1 |
| LACHINIAN, SR | 1 |
| EVDOKIMOVA, AD | 1 |
| ROZANOVA, MD | 1 |
| KUZMINA, VS | 1 |
| EREMICHEVA, TI | 1 |
| GUSEV, VA | 1 |
| LOPATNIKOVA, IV | 1 |
| BOGDANOVA, VV | 1 |
| TERENTEVA, GM | 1 |
| TARANGER, JH | 1 |
| DUMON LEGRE, M | 1 |
| PRESTON, DF | 1 |
| KRUML, J | 1 |
| POLENSKA, H | 1 |
| JUHASZ, P | 1 |
| VALYI NAGY, T | 1 |
| KULCSAR, G | 1 |
| NORRIS, FH | 1 |
| GARVEY, PH | 1 |
| SWALBACH, GW | 1 |
| KOWALCZYLKOWA, J | 1 |
| KULIG, A | 1 |
| ROKITA, Z | 1 |
| SMACZNA, D | 1 |
| MATERNOWSKA, W | 2 |
| JASIELSKARUDNICKA, M | 1 |
| ALIABINA, MG | 1 |
| STUKALOVA, BI | 1 |
| MAMOLAT, AS | 1 |
| KANTARBAEVA, ZK | 1 |
| BLONSKAIA, LI | 1 |
| KRIVTSOVA, AI | 1 |
| DARGEVICH, VK | 1 |
| BELOGUROVA, VP | 6 |
| DRABKINA, RO | 1 |
| UVAROVA, OA | 2 |
| ZEMSKOVA, ZS | 6 |
| KUZNETSOVA, KV | 1 |
| CHERNIGOVSKAIA, NN | 1 |
| UDILOVA, NN | 2 |
| SHMALII, KV | 1 |
| MELNIKOV, EL | 1 |
| BINSTOCK, A | 1 |
| GARCIAVELLOSO, MA | 1 |
| MARCHESE, MJ | 1 |
| BERTORELLO, MC | 1 |
| CARDOZO, E | 1 |
| MASSARO, D | 2 |
| BROCARD, H | 1 |
| LOYGUE, AM | 1 |
| HOUSSET, H | 1 |
| COHEN, A | 1 |
| BEAUREPAIRE, Y | 1 |
| MACHADOFILHO, J | 3 |
| BARUFFI, W | 1 |
| FADEL, JC | 1 |
| KOGA, K | 1 |
| MONTENEGRO, W | 1 |
| CAPALDO, G | 1 |
| ETTORRE, D | 1 |
| GAGLIARDI, L | 1 |
| GARCIAHERRERA, E | 1 |
| PUECH, P | 1 |
| ABELOOS, D | 1 |
| BARRAT, L | 1 |
| VITOLO, A | 1 |
| LUSZCZEWSKA-TOMASZEWSKA, D | 1 |
| KOLOSOWSKA, J | 1 |
| MERGEL-MADEY, B | 1 |
| MONDESHKI, M | 1 |
| PASHMAKOV, I | 1 |
| DUNCAN, JT | 1 |
| CONN, HO | 3 |
| SINGH, B | 3 |
| BARBARA, C | 1 |
| SACHS, M | 1 |
| HEINRICH, F | 1 |
| KELLER, L | 1 |
| MITCHELL, JH | 1 |
| RUIZ, RC | 1 |
| PROCHAZKA, J | 1 |
| PASSOSJDE, A | 1 |
| RIOSSDA, C | 1 |
| SPROVIERI, JW | 1 |
| PADOVAN, JA | 1 |
| HARBERT, F | 1 |
| RIORDAN, D | 1 |
| DARZINS, E | 1 |
| PUKITE, A | 1 |
| LOWE, CR | 1 |
| SCHOENE, W | 1 |
| MAYO, P | 1 |
| WOJCIK, RA | 1 |
| OMODEI-ZORONI, A | 1 |
| HAGER-MALECKA, B | 1 |
| WANAT-KONDRATOWICZ, W | 1 |
| GREGER, J | 1 |
| WITKOWSKI, W | 1 |
| SNAJDR, V | 1 |
| KRAKORA, P | 1 |
| FISER, F | 1 |
| CHODOUNSKA, V | 1 |
| STERNLIEB, I | 1 |
| SENKEVICH, NA | 1 |
| KALITEEVSKAIA, TN | 1 |
| SOSNINA, GK | 1 |
| DEGARCIA FONTES, RB | 1 |
| GAJER, M | 1 |
| GENTILE RAMOS, I | 1 |
| THOMAS, JR | 1 |
| BOHANNAN, JC | 1 |
| SCHOLES, VE | 1 |
| COHEN, I | 1 |
| RUBIOPALACIOS, H | 1 |
| RODRIGUEZ, J | 1 |
| FREIJEIRO, R | 1 |
| OSORIO, HS | 1 |
| FERNANDEZLIRA, D | 1 |
| RODRIGUEZ, HM | 1 |
| GONZALEZCRUZ, E | 1 |
| SABAR, IR | 1 |
| BAYGIN, R | 1 |
| RAO, KR | 1 |
| RAJAGOPALAN, CR | 1 |
| REDDY, DJ | 1 |
| TODD, RM | 3 |
| ZDUNCZYNK PAWELEK, H | 1 |
| BLITEK GOLC, D | 1 |
| KOSTRZEWSKA, K | 1 |
| KOSTRZENSKI, W | 2 |
| RICCHETTI, C | 2 |
| CRISCI, J | 1 |
| LARKIN, JC | 2 |
| HALL, ZM | 1 |
| ZORAB, PA | 1 |
| JEFFERSON, KE | 1 |
| JOHNSON, PM | 4 |
| CRAWFORD GALIARDI, L | 1 |
| GREETHAM, L | 3 |
| IVASKA, T | 1 |
| LAPIN, A | 1 |
| MAIER, J | 1 |
| O'MALLEY, P | 1 |
| TREMBLEY, C | 1 |
| TOMCSANYI, A | 1 |
| LOEW, B | 1 |
| BOWER, G | 1 |
| TARANGER, J | 3 |
| LAUGIER, J | 2 |
| RALEIGH, JW | 1 |
| SMITH, MM | 1 |
| ROY, AD | 1 |
| ALLAN, J | 1 |
| ACCARD, JL | 1 |
| BERMAN-ROBERT, D | 1 |
| NESTADT, A | 1 |
| LEASK, E | 1 |
| GIBB, RC | 1 |
| LAIDLAW, JP | 1 |
| ZHUKOVA, MP | 1 |
| LAUGERI, S | 1 |
| LAMI, L | 1 |
| NAGAISHI, C | 1 |
| NAGASAWA, J | 1 |
| SANCHEZYLLADES, L | 1 |
| DEENSTRA, H | 1 |
| PRIGNOT, J | 1 |
| VASILENKO, OS | 1 |
| BEREZINA, EK | 1 |
| CORPE, RF | 3 |
| ZAJACZKOWSKA, J | 2 |
| KRAKOWKA, P | 1 |
| JANCZY, S | 1 |
| KORLAKOWSKI, J | 1 |
| ZYCH, D | 1 |
| KRYCHNIAK, W | 1 |
| BEK, E | 1 |
| SIWINSKA, I | 1 |
| WOZNIAK, S | 1 |
| LAUROC, DE | 1 |
| GINZBURG, EA | 1 |
| SHKLOVSKAIA, IG | 1 |
| DUBRA, F | 1 |
| EDUARDOGARAY, C | 1 |
| NYUL TOTH, P | 1 |
| RISKO, T | 1 |
| BORSAY, J | 1 |
| CUCCHIANIACEVEDO, RA | 1 |
| FIORINO, A | 1 |
| NIKOLAJUKDEIRURZUN, R | 1 |
| MANDE, R | 2 |
| HERRAULT, A | 1 |
| GOMAA, TM | 1 |
| NOCETTIFASOLINO, J | 1 |
| BIAGIOLI, ER | 1 |
| IZQUIERDO, G | 1 |
| REICHEL, G | 1 |
| ZIESCHE, K | 1 |
| WALCZAK, H | 1 |
| BARASH, LI | 1 |
| IARKHO, MI | 1 |
| DONADIO, V | 1 |
| CIRILLO, R | 1 |
| CANDAU, MG | 3 |
| GALE, GL | 1 |
| KERR, WK | 1 |
| LAUSTELA, EV | 1 |
| KYLLOENEN, KE | 1 |
| SZUNGYI, Z | 1 |
| PENKOVSKAJA, A | 1 |
| DEBENEST, P | 1 |
| LAMPE, WT | 1 |
| PELUSO, E | 1 |
| CHARCOSSET, F | 1 |
| GABRIEL, MT | 1 |
| WAARDENBURG, HA | 1 |
| GOW, JG | 4 |
| LISIN, N | 1 |
| JOHNSTON, RN | 1 |
| SMITH, DH | 1 |
| RITCHIE, RT | 1 |
| LOCKHART, W | 1 |
| VILDERMAN, AM | 2 |
| EVGRAFOVA, ZA | 3 |
| REZNIK, SE | 2 |
| FINN, ER | 3 |
| AKOPIAN, IM | 1 |
| SIMEONOV, MN | 1 |
| GANAGO, FM | 1 |
| SHMURUN, RI | 1 |
| SILNITSKII, PA | 1 |
| PERMSKAIA, VA | 1 |
| ZVANTSEVA, VA | 1 |
| IZVEKOV, AT | 1 |
| KUZTSENOK, IaB | 1 |
| KHARAKTER, Zh | 1 |
| LAMY, R | 1 |
| MENEGAZZO, C | 1 |
| MAGNITSKII, VA | 1 |
| LAVRENTEVA, LL | 1 |
| SOLERCANTO, J | 1 |
| SZENDROEI, Z | 1 |
| CSERNUS, A | 1 |
| HUETTL, T | 1 |
| LANYI, M | 1 |
| KADAR, A | 1 |
| MARCATILI, S | 1 |
| EISSNER, H | 1 |
| FUCHS, G | 1 |
| YAMAMURA, Y | 1 |
| HUTCHIN, P | 1 |
| LINDSKOG, GE | 1 |
| MORIYAMA, E | 2 |
| NAKAMURA, RM | 1 |
| ACEVEDO, RC | 1 |
| PILHEU, J | 1 |
| RODRIGUEZ, E | 1 |
| CASTELLARIERA, J | 1 |
| GRANENAFUGUET, P | 1 |
| COLLCOLOME, F | 1 |
| MORGAN, WK | 1 |
| NORMAN, JO | 1 |
| WILLIAMS, RP | 1 |
| MONTEROJARAMILLO, SC | 1 |
| KILLEN, DA | 1 |
| FOSTER, JH | 1 |
| RHEA, WG | 1 |
| MCCRACKEN, RC | 1 |
| DIVELEY, WL | 1 |
| HUBBARD, WW | 1 |
| GUILFOIL, PH | 1 |
| LORIAN, V | 1 |
| ZANON, U | 1 |
| NAGRATH, SP | 1 |
| SANTOS, JC | 1 |
| BUSCH, HG | 1 |
| EVANS, DA | 2 |
| DAWSON, JJ | 1 |
| KULKARNI, KG | 1 |
| MOHAN, K | 1 |
| SURANYI, S | 1 |
| SIMARSZKY, J | 1 |
| ENGBAEK, HC | 3 |
| MAGNUSSON, M | 1 |
| PETRAGNANI, G | 1 |
| SPAZIANTE, G | 1 |
| VILARDO, S | 1 |
| JENSEN, KA | 1 |
| KLAER, I | 1 |
| ZORZOLI, P | 1 |
| BRANDER, L | 1 |
| PELTOKALLIO, P | 1 |
| PELTOKALLIO, V | 1 |
| COTTIN, S | 2 |
| COZAN, R | 2 |
| REY, J | 1 |
| JIMENEZHERRERO, J | 1 |
| MAEKIPAJA, J | 1 |
| HENRY, C | 1 |
| LEHUNSEC, J | 1 |
| FONTAN, P | 1 |
| LESTON, JM | 2 |
| GONZALEZMONTANER, LJ | 1 |
| SARTORIS, L | 1 |
| CUNARRODEGIMENO, G | 1 |
| NEVILLE, JG | 1 |
| DUBOWITZ, LM | 1 |
| DUBOWITZ, V | 1 |
| BLACK, BG | 1 |
| CHAPMAN, JS | 1 |
| TSUI, HP | 1 |
| TUNG, C | 1 |
| CHEN, TM | 1 |
| CHANG, KS | 1 |
| LI, TS | 1 |
| ASSELIN, J | 1 |
| HORI, M | 2 |
| SHOJI, K | 1 |
| YAMANOUCHI, T | 2 |
| SAWAI, A | 2 |
| JONES, WC | 1 |
| MILLER, WE | 1 |
| NOZAKI, T | 1 |
| GAVRILENKO, VS | 1 |
| REPNITSKAIA, ZD | 1 |
| SERGEEV, VV | 2 |
| TIURI, EI | 1 |
| SILD, ME | 1 |
| MELKUMOV, GA | 1 |
| MATUSIS, TI | 1 |
| VAVILIN, GI | 7 |
| FUNSHTEIN, LV | 2 |
| SHCHERBAN, EI | 2 |
| GRISHCHENKO, VV | 1 |
| KHAIKIN, AIa | 1 |
| OKREMA, VIa | 1 |
| SORKIN, Ie | 1 |
| LABRAM, C | 1 |
| CIMINO, A | 1 |
| MATHUR, JB | 1 |
| KHANNA, BK | 1 |
| KASAI, E | 1 |
| TSUKAMURA, S | 1 |
| TAYLOR, RG | 1 |
| BOOTH, DF | 1 |
| TUOVINEN, PI | 1 |
| SUTINEN, S | 1 |
| THOMAS, CP | 1 |
| LAPERUTA, AM | 1 |
| EQUIOIZ, LP | 1 |
| SILVA, GA | 1 |
| GARBULSKY, R | 1 |
| BERTOGLIO, O | 1 |
| DIFRANCO, G | 1 |
| MAZINA, EG | 1 |
| OSINTSEVA, VP | 1 |
| GRIGORIAN, VG | 1 |
| LECNAIA, AA | 1 |
| FRANCIS, RS | 1 |
| CURWEN, MP | 1 |
| TYRAKOWSKA, J | 1 |
| GWOZDZIEWICZ, T | 1 |
| ANKIEWICZ, J | 1 |
| ZAJAC, J | 1 |
| HORVATH, G | 1 |
| KRAAN, JK | 1 |
| AMADIO, G | 2 |
| CAFURE, N | 1 |
| GRAZIA, G | 1 |
| STEVENSON, FH | 1 |
| KATONA, L | 1 |
| LAKITS, E | 1 |
| PALOS, F | 1 |
| MUNROE, WD | 1 |
| LAWSON, WJ | 1 |
| HOLCOMB, TH | 1 |
| BARASZ, Z | 1 |
| UNGAR, I | 1 |
| ENTZ, A | 1 |
| WATSON, PG | 1 |
| ILLES, I | 1 |
| VIZER, K | 1 |
| VAMOS, G | 1 |
| ASPINALL, DL | 1 |
| MONTES, O | 1 |
| COMENALE, D | 1 |
| ROSSI, F | 1 |
| CHEVALLIER, J | 1 |
| COMENALEPINTO, D | 1 |
| MATTEI, AF | 1 |
| CLIMESCO, V | 1 |
| CRISAN, E | 1 |
| ANTONESCO, D | 1 |
| KOSMALA, U | 1 |
| DUDEK, Z | 1 |
| KNAPIKOWA, D | 1 |
| KAZAK, TI | 2 |
| KRZHIVITSKAIA, VP | 1 |
| NAZAROVA, IB | 1 |
| KULIK, NM | 1 |
| KERTSELLI, IuS | 1 |
| LISITSINA, LP | 1 |
| BUDESINSKY, Z | 1 |
| BYDZOVSKY, V | 1 |
| SLUKA, J | 1 |
| STUHL, L | 1 |
| FREY, N | 2 |
| LEHIR, M | 1 |
| CHICOU, J | 1 |
| HETRICK, G | 3 |
| MERCIER, A | 1 |
| NEEL, R | 1 |
| OHRI, BB | 1 |
| AGARWAL, VK | 1 |
| SAEED, AH | 1 |
| IAROSLAVSKII, VE | 1 |
| BLALOCK, FA | 2 |
| OLLERODELAROSA, E | 1 |
| DIAZROMERO, A | 1 |
| LIEBERMAN, A | 1 |
| CAFIERO, F | 1 |
| VALLON, C | 1 |
| KAWAGUCHI, M | 1 |
| AOJI, I | 1 |
| KINUGASA, S | 1 |
| SANO, Y | 1 |
| ROSA, E | 1 |
| GREENBERG, HB | 4 |
| PAUS, B | 1 |
| VARPELA, E | 1 |
| MCCLEMENT, JH | 2 |
| SUN, TN | 1 |
| TENG, WW | 1 |
| YUE, CJ | 1 |
| REILLY, RJ | 2 |
| SEGAWA, A | 2 |
| SIEGEL, J | 2 |
| GIRGIS, A | 2 |
| GLEASON, D | 2 |
| QUERE, MA | 1 |
| SERAFINO, X | 1 |
| CAYRET, A | 1 |
| CHANDRA, RK | 1 |
| LARSON, CL | 1 |
| WICHT, WC | 1 |
| ASEEV, DD | 1 |
| SERGEEV, IS | 1 |
| LAPTEVA, NV | 1 |
| SELLERS, RD | 1 |
| SCOTT, WR | 1 |
| ROOT, HD | 1 |
| PERRY, JF | 1 |
| LEDWITH, JW | 1 |
| BINDER, HJ | 1 |
| ORR, HD | 1 |
| SYKES, BJ | 1 |
| VULLIEMOZ, P | 1 |
| SEN, NN | 1 |
| GIUNIO, N | 1 |
| DEVI, PK | 1 |
| MUJUMDAR, SS | 1 |
| MOKADAM, NG | 1 |
| MENON, CR | 1 |
| GAWAI, TB | 1 |
| BECH, AO | 1 |
| TAI, AR | 1 |
| EMERSON, PA | 2 |
| KUPER, SW | 1 |
| KOZULITSINA, TI | 2 |
| ANGAWA, JO | 1 |
| SURRETT, NE | 1 |
| SEVERN, HD | 1 |
| GROSS, JH | 1 |
| GOLDHAMMER, EJ | 1 |
| RAUNIO, O | 1 |
| ELO, O | 1 |
| SMITH, AE | 1 |
| ASPEVIK, E | 1 |
| EVENSTAD, E | 1 |
| HAUKENES, G | 1 |
| LOCKS, MO | 1 |
| GOODMAN, SB | 1 |
| BLOCK, MH | 1 |
| LARGE, SE | 3 |
| DRENDARSKI, K | 1 |
| SCEPAN, V | 1 |
| PUCHKOV, VV | 1 |
| CHERNITSKII, GI | 1 |
| SOLOVEV, VN | 1 |
| ZUEVA, VS | 3 |
| DOLZHANSKII, VM | 1 |
| KORNIENKO, VT | 1 |
| GALLOWAY, RK | 1 |
| VERWILGHEN, R | 1 |
| REYBROUCK, G | 1 |
| CALLENS, L | 1 |
| COSEMANS, J | 1 |
| MAURO, G | 1 |
| PAMPLONA, PA | 2 |
| BURACZEWSKI, O | 1 |
| OSINSKI, J | 1 |
| KRZYSZKOWSKA, A | 1 |
| PHILIP, RN | 1 |
| CRAWFORD-GAGLIARDI, L | 3 |
| HATTON, F | 1 |
| PERDRIZET, S | 2 |
| ROUILLON, A | 1 |
| MATHUR, KS | 1 |
| MATHUR, JS | 1 |
| SAPRU, RP | 1 |
| SAID AKHMEDOV, AA | 1 |
| ELKONINA, VA | 1 |
| LIUBETSKAIA, MZ | 1 |
| DIUSHIKIAN, AKh | 1 |
| NIKIFOROVA, VL | 1 |
| BONDAREV, IM | 3 |
| REZNIK, BIa | 1 |
| ISRAEL-ASSELAIN, L | 1 |
| SORS, C | 2 |
| PEQUIGNOT, H | 1 |
| ADAMS, P | 1 |
| WHITE, C | 1 |
| VOLINI, F | 1 |
| COLTON, R | 1 |
| LESTER, W | 1 |
| DARRAS, T | 1 |
| FALK, A | 2 |
| MEDINA, G | 1 |
| JENNE, JW | 1 |
| BOLAR, SS | 1 |
| KATZ, J | 2 |
| KUNOFSKY, S | 2 |
| DAMIJONAITIS, V | 2 |
| LAFLEUR, A | 2 |
| CARON, T | 2 |
| NESET, G | 1 |
| HAYASHI, TT | 1 |
| OLMSTED, PS | 1 |
| SCHMIDT, PG | 1 |
| NEVESJDOS, S | 1 |
| WILBEK, E | 2 |
| VERGARAOLIVAS, A | 1 |
| ALIMOV, CA | 1 |
| GOEKCE, TL | 1 |
| LAUCKNER, JR | 1 |
| BALL, JD | 1 |
| CHAKLEINE, IA | 1 |
| JARRY, JJ | 1 |
| BALGAIRIES, E | 1 |
| SCHMELEV, NA | 2 |
| CHIBA, Y | 1 |
| TAKAHARA, T | 1 |
| NAGASHIMA, A | 1 |
| CLAICIU, I | 1 |
| DEVOE, AG | 1 |
| FEIWEL, M | 1 |
| MUNRO, DD | 1 |
| PURTSKHVENIDZE, ChG | 1 |
| TAGA, M | 1 |
| SITZMANN, FC | 1 |
| HATTORI, S | 1 |
| KALICH, R | 1 |
| KREBS, A | 4 |
| REGNIERS, P | 1 |
| BROUILLET-GABRIEL, MT | 2 |
| MESDJIAN, E | 2 |
| DEUTICKE, P | 1 |
| HASCHEK, H | 1 |
| SEEDAT, YK | 1 |
| WOLPERT, SM | 1 |
| MARTIN, FR | 1 |
| FARKOUH, EF | 1 |
| AMSON, KM | 1 |
| WILLIAMS, JL | 1 |
| SCHLESS, JM | 1 |
| ALLISON, RF | 1 |
| INGLIS, RM | 1 |
| WHITE, EF | 1 |
| TOPPERMAN, S | 1 |
| DECOR, Y | 1 |
| KRUCHAKOVA, FA | 1 |
| CHERKASSKAIA, EI | 1 |
| ROE, FJ | 1 |
| BOYLAND, E | 1 |
| HADDOW, A | 1 |
| FOURNAUD, S | 1 |
| SPENCER, IW | 1 |
| COSTER, ME | 1 |
| MCPHAIL, AV | 1 |
| RICHTER, M | 1 |
| HANN, ES | 1 |
| GRACEY, L | 1 |
| BROSBE, EA | 1 |
| SUGIHARA, PT | 1 |
| ADAMS, JM | 1 |
| KIMURA, H | 1 |
| GERMOUTY, J | 2 |
| MINGASSON, F | 1 |
| CORNEA, P | 1 |
| KOEHLER, R | 1 |
| PAWLOWSKA, I | 1 |
| BRAUNER, J | 1 |
| KNAPP, A | 1 |
| TRUSKETT, I | 1 |
| PFANNER, D | 1 |
| SILBERGLEIT, A | 1 |
| ARBULU, A | 1 |
| DEFEVER, BA | 1 |
| NEDWICKI, EG | 1 |
| GLOWACKA, M | 1 |
| GRZYBOWSKA, J | 1 |
| SIGAL, LD | 1 |
| HAMNER, JE | 1 |
| SUSLOVA, AL | 1 |
| OLEJNICEK, M | 1 |
| WEBEROVA, M | 1 |
| REIMANN, HA | 2 |
| MA, PP | 1 |
| CHEUNG, OT | 1 |
| GOPINATHAN, KP | 1 |
| SIRSI, M | 1 |
| VAIDYANATHAN, CS | 1 |
| BEYER, A | 1 |
| PEPLAU, G | 1 |
| WEIDMANN, R | 1 |
| DE FIGUEIREDO, FP | 1 |
| GROW, JB | 1 |
| SAKAMOTO, T | 1 |
| SUTTON, PH | 1 |
| BEATTIE, PH | 1 |
| JEUNE, M | 1 |
| DECHAVANNE, D | 1 |
| VIALTEL, M | 1 |
| BALLY, E | 1 |
| CROXATTO, OC | 2 |
| PEREIRA, A | 1 |
| DIAS, C | 1 |
| KAPLAN, SA | 1 |
| RAYNAUD, J | 1 |
| NAVEAU, M | 1 |
| SANCHEZ PEREZ, F | 1 |
| SANCHEZ CUESTA, E | 1 |
| MEYER, L | 1 |
| DURAND, M | 1 |
| KAHN, M | 1 |
| LEFEVRE, JP | 1 |
| MORELEC, R | 1 |
| LEJOUBIOUX, E | 1 |
| JULLIEN, JL | 1 |
| CHANAS, P | 1 |
| WIESNER, E | 1 |
| GRACE, EJ | 2 |
| SCHAEFFER, JH | 1 |
| BUSSINELLO, E | 1 |
| BAJOCCHI, E | 1 |
| CALOV, WL | 1 |
| JOHNSTON, GA | 1 |
| RITCHIE, FL | 1 |
| WHYTE, HM | 1 |
| SIFONTES, JE | 3 |
| BERIO, CL | 1 |
| RIVERA, KR | 1 |
| GRANA, J | 1 |
| DIAZ DE GARAU, P | 1 |
| VICENS, CN | 1 |
| ACOSTA, R | 1 |
| CORRIGAN, C | 1 |
| MATAS, M | 1 |
| FREIER, N | 1 |
| KESLER, H | 1 |
| PLETTENBERG, W | 1 |
| DIECKHOFF, J | 1 |
| GRUNDER, G | 1 |
| PICCOLI, P | 1 |
| MEYER, M | 1 |
| LINDGREN, G | 1 |
| RACHWAŁ, J | 1 |
| TOMAN, K | 1 |
| COMINELLI, E | 1 |
| UNGER, H | 1 |
| PROSSER, M | 1 |
| HEKELE, K | 1 |
| LASS, A | 2 |
| SCHWADERER, A | 1 |
| SZATHMARY, M | 1 |
| REHBERG, W | 1 |
| SHUKRY, H | 1 |
| AWWAAD, S | 1 |
| REISNER, D | 1 |
| RAGO, T | 1 |
| RAVNAY, T | 1 |
| GARAZSI, M | 1 |
| MEDKOVA, L | 1 |
| MEDEK, B | 1 |
| BENTIVIGLIO, GC | 1 |
| VELICKY, J | 1 |
| RADEK, M | 1 |
| MILLANES MARCOS, S | 1 |
| BOSWORTH, DM | 1 |
| FIELDING, JW | 1 |
| WILSON, H | 1 |
| GUZMAN-ACOSTA, M | 1 |
| DEMAREST, LM | 1 |
| VASILEV, VN | 2 |
| TRICHEREAU, R | 1 |
| GEFFRIAUD, M | 1 |
| ROBIN, C | 1 |
| NURIT, Y | 1 |
| BOURGEOIS, J | 1 |
| LOPEZ-BELIO, M | 1 |
| FONTAN, A | 1 |
| VERIN, M | 1 |
| LARTIGAUT, D | 1 |
| AMORATI, A | 1 |
| GALLETTI, F | 1 |
| GELLI, G | 1 |
| LOLI-PICCOLOMINI, M | 1 |
| ROVERSI, L | 1 |
| OGIER, E | 1 |
| GERLAND, W | 1 |
| RITOSSA, P | 1 |
| LATO, M | 1 |
| TOMALINO, D | 1 |
| TEPE, HJ | 1 |
| WUNDERLICH, K | 1 |
| FERABOLI, M | 1 |
| RAMOS, A | 1 |
| TORRES-MARTY, L | 1 |
| SUTHERLAND, I | 1 |
| KAUFFMANN, GW | 1 |
| GERISCHER, C | 1 |
| JACOBI, F | 1 |
| HUDGENS, RO | 2 |
| KIRCHHOFF, HW | 1 |
| KIRCHNER, JJ | 1 |
| KLUGH, GA | 1 |
| PRATT, PC | 1 |
| PLIQUETT, R | 1 |
| KROEGER, K | 1 |
| KUESTER, F | 1 |
| LAZAROU, P | 1 |
| LEVY, D | 1 |
| NATHAN, A | 1 |
| OLSEN, PZ | 1 |
| TORNING, K | 3 |
| JONES, GR | 1 |
| PATEL, CV | 1 |
| PEPYS, J | 1 |
| KINSLEY, BJ | 1 |
| PISZCZEK, EA | 1 |
| RENTH, M | 1 |
| SCANDROGLIO, JJ | 1 |
| SAIM, A | 1 |
| SCOUREI, E | 1 |
| FIERBINZIANOU-FILIMON, M | 1 |
| FRULING, M | 1 |
| NETEDOU, NS | 1 |
| RADOVITCH, P | 1 |
| SCHLOSS, J | 1 |
| ISMAIL, Z | 1 |
| SCHWARTZ, I | 1 |
| SMALL, MJ | 1 |
| SEGARRA, FO | 1 |
| SHERMAN, DS | 1 |
| SERAFINI, L | 1 |
| SHEEHY, TF | 1 |
| FERGUS, EM | 1 |
| LEE, JR | 1 |
| SHIMADA, F | 1 |
| SIMPSON, JM | 1 |
| ASHIZAWA, H | 1 |
| HYDE, L | 1 |
| JUHLIN, I | 1 |
| JUVARA, I | 1 |
| SIMIONESCU, N | 1 |
| REDULESCU, D | 1 |
| KASZA, L | 1 |
| KOBAYASHI, H | 1 |
| KAWADA, Y | 1 |
| TERAMURA, F | 1 |
| KOHN, R | 1 |
| CLOTTEN, R | 1 |
| KOIKE, S | 1 |
| MURASE, S | 1 |
| OOMI, A | 1 |
| KOIZUMI, K | 1 |
| OKAMOTO, R | 1 |
| KOZAKIEWICZ, J | 1 |
| ROTTER, Z | 1 |
| KAWAI, M | 1 |
| NAKAI, J | 1 |
| KUSUNODA, F | 1 |
| MORI, K | 2 |
| MAGALIF, NI | 1 |
| UPNER, TK | 1 |
| MASSE, NP | 1 |
| MATHEY, J | 1 |
| LORO MARCHESE, JH | 1 |
| MATSUURA, M | 1 |
| LUCEL, Y | 1 |
| MAYOBRE, RA | 1 |
| MIKUNI, M | 1 |
| OISHI, M | 2 |
| NIKITOVA, AN | 1 |
| OATWAY, WH | 1 |
| OFUJI, M | 1 |
| NAKAYA, T | 1 |
| AIDANI, K | 1 |
| WALLACE, JG | 1 |
| RAJENDRAN, K | 1 |
| JACOB, PG | 1 |
| RIUMINA, TF | 1 |
| RODRIGUES, F | 2 |
| ROMEO, V | 1 |
| STAFFIERI, P | 1 |
| RUDOI, NM | 3 |
| SAHEKI, T | 1 |
| ARAI, K | 1 |
| ASAKURA, H | 1 |
| NOZOE, N | 1 |
| SCHMIDT, B | 1 |
| MENNE, WR | 1 |
| MODDE, H | 1 |
| Day, JH | 2 |
| Wald, E | 1 |
| Leung, ET | 1 |
| Chiu, A | 1 |
| Seto, WH | 1 |
| Forssbohm, M | 1 |
| Butt, T | 1 |
| Kazmi, SY | 1 |
| Ahmad, RN | 1 |
| Mahmood, A | 1 |
| Karamat, KA | 1 |
| Anwar, M | 2 |
| Hovell, MF | 3 |
| Sipan, CL | 2 |
| Blumberg, EJ | 2 |
| Slymen, D | 1 |
| Kelley, NJ | 2 |
| Vera, AY | 2 |
| Sandven, P | 1 |
| Bjorvatn, B | 1 |
| Zahoor, A | 3 |
| Prasad, B | 1 |
| Gordillo, S | 2 |
| Amat, I | 3 |
| Lonca, J | 1 |
| Pallarés, A | 1 |
| Llatjós, R | 1 |
| Ariza, A | 1 |
| Ausina, V | 3 |
| Vanhoof, J | 1 |
| Landewe, S | 1 |
| Van Wijngaerden, E | 1 |
| Geusens, P | 1 |
| Kerridge, I | 1 |
| Ethell, M | 1 |
| Potter, M | 1 |
| Prentice, HG | 1 |
| Wong, MY | 1 |
| Skotnikova, OI | 1 |
| Nosova, EY | 1 |
| Markova, OV | 1 |
| Irtuganova, OA | 1 |
| Krudu, VN | 1 |
| Ginda, SS | 1 |
| Golishcheva, OV | 1 |
| Biryukova, MN | 1 |
| Strel'tsova, EN | 1 |
| Kalyanina, OV | 1 |
| Litvinov, VI | 1 |
| Moroz, AM | 1 |
| Lapa, SA | 1 |
| Gryadunov, DA | 1 |
| Mikhailovich, VM | 1 |
| DeRiemer, K | 2 |
| Small, PM | 3 |
| Daley, CL | 3 |
| Greinert, U | 2 |
| Zabel, P | 1 |
| Scholten, JN | 1 |
| Driver, CR | 2 |
| Munsiff, SS | 2 |
| Kaye, K | 1 |
| Rubino, MA | 1 |
| Gourevitch, MN | 4 |
| Trim, C | 1 |
| Amofa, J | 1 |
| Seewald, R | 1 |
| Highley, E | 1 |
| Gurumurthy, P | 3 |
| Rajasekaran, S | 2 |
| Krishnarajasekhar, OR | 1 |
| Paramesh, P | 2 |
| Brown, MO | 1 |
| Howard, E | 1 |
| DeAlleaume, L | 1 |
| Snyder, DC | 1 |
| Saukkonen, JJ | 2 |
| Bernardo, J | 4 |
| King, MD | 1 |
| Sánchez-Arcilla, I | 1 |
| Vílchez, JM | 1 |
| García de la Torre, M | 1 |
| Fernández, X | 1 |
| Noguerado, A | 1 |
| Kontos, F | 1 |
| Maniati, M | 1 |
| Costopoulos, C | 1 |
| Gitti, Z | 1 |
| Nicolaou, S | 1 |
| Petinaki, E | 1 |
| Anagnostou, S | 1 |
| Tselentis, I | 1 |
| Maniatis, AN | 1 |
| Schuh, A | 1 |
| Zeiler, G | 1 |
| Jain, D | 1 |
| Dash, S | 1 |
| BUCK, M | 1 |
| GREENBERGER, ME | 2 |
| GREENBERGER, AJ | 1 |
| KLEIN, M | 2 |
| TURELL, M | 2 |
| CLOUGH, PW | 1 |
| BRYSON, V | 1 |
| SZYBALSKI, W | 1 |
| DEMEREC, M | 1 |
| PAYNE, RF | 1 |
| MAMMLOK, ER | 1 |
| DRUMM, AE | 1 |
| SPIEGELMAN, A | 2 |
| DETAR, M | 1 |
| KETTLITZ, V | 2 |
| HERNANDEZ DIAZ, A | 1 |
| PATALANO, A | 1 |
| TORRES-ACERO FERNANDEZ, JM | 1 |
| SPROVIERI, L | 1 |
| THOMSON, WA | 1 |
| GEMMI, M | 1 |
| BANCALE, A | 1 |
| SARTI, A | 1 |
| CINAGLIA, S | 1 |
| GUIDERI, R | 1 |
| BONELLI, M | 1 |
| SANGUIGNO, N | 1 |
| MOLESE, A | 1 |
| GUNELLA, P | 1 |
| MAZZETTA, A | 1 |
| VIALE, L | 1 |
| GIOBBI, A | 1 |
| LUPI, C | 1 |
| ROSSI, B | 1 |
| VAGO, A | 1 |
| LEPRI, G | 1 |
| CAPALBI, S | 1 |
| MASERA, N | 1 |
| BALLERINI, G | 1 |
| DI NOLA, F | 1 |
| ANGELA, G | 1 |
| FEGIZ, G | 1 |
| NAGLESIO, E | 1 |
| OLIARO, T | 1 |
| BIJLSMA, UG | 1 |
| VACCAREZZA, RF | 1 |
| IKEMI, Y | 1 |
| RAMER, Z | 1 |
| TØRNING, K | 1 |
| HAARHØJ, J | 1 |
| DeStefano, MS | 2 |
| Sklaney, MR | 2 |
| Monica, BJ | 1 |
| Slee, AM | 1 |
| Rhiengtong, D | 1 |
| Nampaisan, O | 1 |
| Supawitkul, S | 1 |
| Uthaivorawit, W | 1 |
| Ogimoto, A | 1 |
| Hamada, M | 1 |
| Shigematsu, Y | 1 |
| Hara, Y | 1 |
| Saeki, H | 1 |
| Katayama, H | 1 |
| Hamada, H | 1 |
| Higaki, J | 1 |
| Madison, BM | 1 |
| Siddiqi, SH | 4 |
| Heifets, L | 1 |
| Gross, W | 1 |
| Higgins, M | 1 |
| Warren, N | 1 |
| Thompson, A | 1 |
| Ridderhof, JC | 1 |
| Davies, PD | 2 |
| Sorokoumova, GM | 1 |
| Selishcheva, AA | 1 |
| Malikova, NM | 1 |
| Minina, AS | 1 |
| Shvets, VI | 1 |
| Schaberg, T | 3 |
| Hauer, B | 1 |
| Haas, WH | 1 |
| Hohlfeld, J | 1 |
| Kropp, R | 1 |
| Loytved, G | 1 |
| Sagebiel, D | 1 |
| Tousignant, P | 1 |
| Bourbeau, J | 1 |
| Lincoln, T | 1 |
| Brannan, GL | 1 |
| Lynch, V | 1 |
| Conklin, TJ | 1 |
| Clancey, T | 1 |
| Rose, DN | 5 |
| Tuthill, RJ | 1 |
| Vásquez-Campos, L | 1 |
| Asencios-Solis, L | 1 |
| Leo-Hurtado, E | 1 |
| Quispe-Torres, N | 1 |
| Salazar-Lindo, E | 1 |
| Bayona, J | 1 |
| Gunawardana, SS | 1 |
| Earley, AR | 1 |
| Pollard, AJ | 1 |
| Bethell, D | 1 |
| Rabinovitch, B | 1 |
| Mannix, S | 2 |
| Brassard, P | 1 |
| Tornero Saltó, J | 1 |
| Nogués Orpí, JJ | 1 |
| González Compta, X | 1 |
| Cisa Lluís, E | 1 |
| Doménech Juan, I | 1 |
| Dicenta Sousa, M | 1 |
| Herrera, L | 1 |
| Valverde, A | 1 |
| Saiz, P | 1 |
| Sáez-Nieto, JA | 1 |
| Portero, JL | 1 |
| Jiménez, MS | 1 |
| Lui, SL | 1 |
| Li, FK | 1 |
| Choy, BY | 1 |
| Chan, TM | 2 |
| Lo, WK | 2 |
| Lai, KN | 1 |
| Lane, BD | 1 |
| Hill, PJ | 1 |
| Uhl, JR | 1 |
| Lukat-Rodgers, GS | 1 |
| Hall, L | 1 |
| Roberts, GD | 1 |
| Cockerill, FR | 1 |
| Brennan, PJ | 2 |
| Rodgers, KR | 1 |
| Belisle, JT | 1 |
| Rusnak, F | 1 |
| Ovali, F | 1 |
| Samanci, N | 1 |
| Sevinç, E | 1 |
| Dağoğlu, T | 1 |
| Jayaram, R | 1 |
| Shandil, RK | 1 |
| Suresh, BL | 1 |
| Mahesh, BN | 1 |
| Jayashree, R | 1 |
| Kantharaj, E | 1 |
| Lardizabal, A | 1 |
| Hayden, CH | 2 |
| Cooksey, RC | 1 |
| Morlock, GP | 1 |
| Barco, P | 1 |
| Cecon, L | 1 |
| Forestiero, F | 1 |
| Sato, DN | 1 |
| Shikama, Mde L | 1 |
| Mamizuka, EM | 1 |
| Hirata, RD | 1 |
| Hirata, MH | 1 |
| Gosling, R | 1 |
| Gillespie, S | 1 |
| Smirnova, TG | 3 |
| Chernousova, LN | 3 |
| Andreevskaia, SN | 1 |
| Nikolaeva, GM | 1 |
| van Hest, R | 1 |
| Baars, H | 1 |
| Kik, S | 1 |
| van Gerven, P | 1 |
| Trompenaars, MC | 1 |
| Kalisvaart, N | 1 |
| Keizer, S | 1 |
| Borgdorff, M | 1 |
| Mensen, M | 1 |
| Gordin, FM | 1 |
| Cohn, DL | 5 |
| Matts, JP | 3 |
| O'Brien, RJ | 5 |
| Chow, KM | 1 |
| Szeto, CC | 1 |
| Leung, CB | 1 |
| Li, PK | 1 |
| Kalita, A | 1 |
| Itskowitz, MS | 1 |
| Nelson, LJ | 1 |
| Jereb, JA | 1 |
| Raffetto, JD | 1 |
| Menzoían, JO | 1 |
| Güneri, S | 1 |
| Unsal, I | 1 |
| Oztop, A | 1 |
| Erkut, M | 1 |
| Avkan Oğuz, V | 1 |
| Ozgü, A | 1 |
| Cakmak, R | 1 |
| Marín, M | 1 |
| García de Viedma, D | 1 |
| Ruíz-Serrano, MJ | 1 |
| Bouza, E | 2 |
| Bhagavathy, S | 1 |
| Mahilmaran, A | 1 |
| Bastian, I | 1 |
| Chew, W | 1 |
| Gilpin, C | 1 |
| Haverkort, F | 1 |
| James, G | 1 |
| Sievers, A | 2 |
| Samala, R | 1 |
| Einck, L | 1 |
| Nacy, CA | 1 |
| Belianin, II | 1 |
| Shmelev, EI | 1 |
| Martynova, LP | 1 |
| Alaei, K | 1 |
| Alaei, A | 1 |
| Jou, R | 1 |
| Huang, WL | 1 |
| Salpeter, SR | 4 |
| Salpeter, EE | 2 |
| Jia, L | 1 |
| Tomaszewski, JE | 1 |
| Coward, L | 1 |
| Noker, P | 1 |
| Gorman, G | 1 |
| Nikonenko, B | 1 |
| Protopopova, M | 1 |
| Arcos, V | 2 |
| Broussy, S | 1 |
| Gornitzka, H | 1 |
| Ena, J | 1 |
| Valls, V | 1 |
| Bassanello, M | 1 |
| Vitale, A | 1 |
| D'Antiga, L | 1 |
| Zanus, G | 1 |
| Brolese, A | 1 |
| Ciarleglio, FA | 1 |
| Guariso, G | 1 |
| Zancan, L | 1 |
| Guido, M | 1 |
| D'Amico, DF | 1 |
| Peddie, LR | 1 |
| Dunker, F | 1 |
| Peddie, J | 1 |
| Riddle, H | 1 |
| Lambert, LA | 1 |
| Navin, TR | 1 |
| Agarwal, SK | 1 |
| Dash, SC | 1 |
| Bhowmik, D | 1 |
| Tiwari, SC | 1 |
| Ridzon, R | 2 |
| Hiransuthikul, N | 2 |
| Nelson, KE | 3 |
| Hiransuthikul, P | 2 |
| Vorayingyong, A | 1 |
| Paewplot, R | 2 |
| Tomono, K | 1 |
| Hashimoto, S | 1 |
| Mok, MY | 1 |
| Lo, Y | 1 |
| Wong, WS | 1 |
| Lau, CS | 1 |
| DeCoster, DJ | 1 |
| Vena, RM | 1 |
| Callister, SM | 1 |
| Schell, RF | 1 |
| Ito, K | 5 |
| Aono, A | 2 |
| Benator, D | 1 |
| Burman, W | 1 |
| Jones, B | 1 |
| Silva-Trigo, C | 2 |
| Hodge, T | 1 |
| Berg, JP | 1 |
| Cranswick, N | 1 |
| Mulholland, K | 1 |
| Valencia Ortega, ME | 1 |
| Fountain, FF | 1 |
| Tolley, E | 1 |
| Chrisman, CR | 1 |
| Self, TH | 2 |
| Ashokraj, Y | 1 |
| Kohli, G | 1 |
| Varma, MV | 1 |
| Tat'kov, SI | 1 |
| Norkina, OV | 1 |
| Sivkov, AIu | 1 |
| Boldyrev, AN | 1 |
| Azaev, MSh | 1 |
| Kinsht, VN | 3 |
| Kurunov, IuN | 3 |
| Krasnov, VA | 1 |
| Medvedeva, EV | 1 |
| Baranova, OI | 1 |
| Ivlev-Duntau, AP | 1 |
| Bodnev, SA | 1 |
| Blinova, LN | 1 |
| Pasechnikov, AD | 1 |
| Fyfe, AJ | 1 |
| Soutar, RL | 1 |
| Tong, X | 1 |
| Zheng, Z | 1 |
| Geng, Z | 1 |
| Bhusal, Y | 1 |
| Shiohira, CM | 1 |
| Yamane, N | 1 |
| Lavender, C | 1 |
| Globan, M | 1 |
| Billman-Jacobe, H | 1 |
| Fyfe, J | 1 |
| Barcena, R | 1 |
| Oton, E | 1 |
| Angeles Moreno, M | 1 |
| Garcia-Gonzalez, M | 1 |
| de Vicente, E | 1 |
| White, MC | 5 |
| Tulsky, JP | 4 |
| Menendez, E | 2 |
| Goldenson, J | 4 |
| Noguera-Pons, R | 1 |
| Borrás-Blasco, J | 1 |
| Romero-Crespo, I | 1 |
| Antón-Torres, R | 1 |
| Navarro-Ruiz, A | 1 |
| González-Ferrandez, JA | 1 |
| Yoon, Y | 1 |
| Curry, K | 1 |
| Ahmed, P | 1 |
| Khan, B | 1 |
| Altaf, C | 1 |
| Ullah, K | 1 |
| Raza, S | 1 |
| Hussain, I | 2 |
| Al-Tawfiq, JA | 1 |
| Al-Muraikhy, AA | 1 |
| Abed, MS | 1 |
| Bachmann, MO | 1 |
| Ishigatsubo, Y | 1 |
| Miki, M | 1 |
| Ishikawa, T | 1 |
| Okayama, H | 1 |
| Apers, L | 2 |
| Newton, SM | 1 |
| Davidson, RN | 1 |
| Pasvol, G | 3 |
| Aziz, H | 1 |
| Shubair, M | 1 |
| Debari, VA | 1 |
| Ismail, M | 1 |
| Khan, MA | 2 |
| Hernández-Hernández, E | 1 |
| Alberú, J | 1 |
| González-Michaca, L | 1 |
| Bobadilla-del Valle, M | 1 |
| Quiroz-Mejía, RA | 1 |
| Baizabal-Olarte, R | 1 |
| Correa-Rotter, R | 1 |
| Sifuentes-Osornio, J | 1 |
| Jirawisit, M | 1 |
| Kasak, S | 1 |
| Park, YJ | 1 |
| Song, E | 1 |
| Jang, H | 1 |
| Kim, C | 1 |
| Yoo, J | 1 |
| Kang, SJ | 1 |
| Sackoff, JE | 3 |
| Pfeiffer, MR | 1 |
| Streett, LS | 1 |
| DeHovitz, JA | 1 |
| Francis, D | 1 |
| Parisien, I | 1 |
| Rocher, I | 1 |
| Dhingra, VK | 1 |
| Rajpal, S | 1 |
| Aggarwal, N | 1 |
| Aggarwaln, JK | 1 |
| Shadab, K | 1 |
| Jain, SK | 1 |
| Ovsiankina, ES | 1 |
| Kasimtseva, OV | 1 |
| Vasil'eva, IA | 1 |
| Aragón, LM | 1 |
| Navarro, F | 1 |
| Heiser, V | 1 |
| Garrigó, M | 2 |
| Español, M | 1 |
| Coll, P | 2 |
| Maâlej, S | 1 |
| Drira, I | 1 |
| Ben Mefteh, R | 1 |
| Fennira, H | 1 |
| Bourguiba, M | 1 |
| Ben Kheder, A | 1 |
| Atun, R | 1 |
| Coker, R | 1 |
| Wash, P | 1 |
| Burger, A | 1 |
| Folb, PI | 1 |
| Balcells, ME | 1 |
| Thomas, SL | 1 |
| Berkowitz, FE | 1 |
| Severens, JL | 1 |
| Shieh, FK | 1 |
| Snyder, G | 1 |
| Murphy, C | 1 |
| Turhan, A | 1 |
| Akinci, P | 1 |
| Soyler, I | 1 |
| Caws, M | 1 |
| Duy, PM | 1 |
| Tho, DQ | 1 |
| Hoa, DV | 1 |
| Farrar, J | 1 |
| Piana, F | 1 |
| Penati, V | 1 |
| Canducci, F | 1 |
| Oliveira, JS | 1 |
| de Sousa, EH | 1 |
| de Souza, ON | 1 |
| Moreira, IS | 1 |
| Shamputa, IC | 1 |
| Jugheli, L | 1 |
| Sadradze, N | 1 |
| Willery, E | 1 |
| Nyamathi, AM | 1 |
| Christiani, A | 1 |
| Gregerson, P | 1 |
| Leake, B | 1 |
| Negi, SS | 1 |
| Anand, R | 1 |
| Pasha, ST | 1 |
| Basir, SF | 1 |
| Khare, S | 1 |
| Lal, S | 1 |
| Veenstra, H | 1 |
| Baumann, R | 1 |
| Carroll, NM | 1 |
| Lukey, PT | 1 |
| Kidd, M | 1 |
| Bolliger, CT | 1 |
| Senaratne, WV | 1 |
| Pinidiyapathirage, MJ | 1 |
| Perera, GA | 1 |
| Wickremasinghe, AR | 1 |
| Daniel, TM | 4 |
| Bhatti, S | 1 |
| Sheikh, R | 1 |
| Page, KR | 1 |
| Sifakis, F | 1 |
| Montes de Oca, R | 1 |
| Cronin, WA | 1 |
| Doherty, MC | 1 |
| Federline, L | 1 |
| Bur, S | 1 |
| Walsh, T | 1 |
| Karney, W | 1 |
| Milman, J | 1 |
| Baruch, N | 1 |
| Adelakun, A | 1 |
| Ignatova, A | 1 |
| Dubiley, S | 1 |
| Stepanshina, V | 1 |
| Shemyakin, I | 1 |
| Seet, Q | 1 |
| Denkin, S | 1 |
| Parsons, L | 1 |
| Somoskovi, A | 1 |
| Dormandy, J | 1 |
| Mitsani, D | 1 |
| Rivenburg, J | 1 |
| Salfinger, M | 1 |
| Gao, XF | 1 |
| Liu, GJ | 1 |
| Wen, J | 1 |
| Xie, Y | 1 |
| Li, YP | 1 |
| Sichletidis, L | 1 |
| Settas, L | 1 |
| Spyratos, D | 1 |
| Chloros, D | 1 |
| Patakas, D | 1 |
| Mohammadzadeh, A | 1 |
| Ghazvini, K | 1 |
| Behdani, M | 1 |
| Rashed, T | 1 |
| Ghanaat, J | 1 |
| Bal, AM | 1 |
| Hoshino, H | 2 |
| Nakazono, T | 2 |
| Masuyama, H | 2 |
| Sugita, H | 2 |
| Kocabay, G | 1 |
| Tutkun, IT | 1 |
| Ecder, T | 2 |
| Kominski, GF | 1 |
| Varon, SF | 1 |
| Morisky, DE | 1 |
| Malotte, CK | 2 |
| Ebin, VJ | 1 |
| Coly, A | 1 |
| Chiao, C | 1 |
| Louie, A | 1 |
| Liu, W | 1 |
| Ambrose, PG | 1 |
| Bhavnani, SM | 1 |
| Brown, D | 1 |
| Drusano, GL | 1 |
| Nyamathi, A | 1 |
| Stein, JA | 1 |
| Schumann, A | 1 |
| Tyler, D | 1 |
| Dieltiens, G | 1 |
| Goletti, D | 1 |
| Parracino, MP | 1 |
| Butera, O | 1 |
| Bizzoni, F | 1 |
| Casetti, R | 1 |
| Dainotto, D | 1 |
| Anzidei, G | 1 |
| Nisii, C | 1 |
| Ippolito, G | 2 |
| Poccia, F | 1 |
| Hartkoorn, RC | 1 |
| Chandler, B | 1 |
| Owen, A | 1 |
| Ward, SA | 1 |
| Bertel Squire, S | 1 |
| Back, DJ | 2 |
| Engelke, E | 1 |
| Brittle, W | 1 |
| Hanta, I | 1 |
| Ozbek, S | 1 |
| Kuleci, S | 1 |
| Sert, M | 1 |
| Kocabas, A | 1 |
| Loussaïef, C | 1 |
| Ben Romdhane, F | 1 |
| Boughattas, NA | 1 |
| Chakroun, M | 1 |
| Itotani, M | 1 |
| Kuroda, H | 1 |
| Bowerman, RJ | 1 |
| Bakir Ozbey, S | 1 |
| Kasapoğlu, F | 1 |
| Helvaci, S | 1 |
| Afanas'ev, MV | 2 |
| Ikryannikova, LN | 1 |
| Il'ina, EN | 2 |
| Sidorenko, SV | 1 |
| Kuz'min, AV | 2 |
| Larionova, EE | 2 |
| Kamaev, EY | 1 |
| Skorniakov, SN | 2 |
| Govorun, VM | 2 |
| Dinakaran, M | 1 |
| Thirumurugan, R | 1 |
| King, B | 1 |
| Eisenach, K | 2 |
| Jindani, A | 1 |
| Sirgel, F | 2 |
| Tavil, B | 1 |
| Gulhan, B | 1 |
| Cetin, M | 1 |
| Tezcan, I | 1 |
| Tuncer, M | 1 |
| Uckan, D | 1 |
| Geijo, MP | 1 |
| Herranz, CR | 1 |
| Vaño, D | 1 |
| García, AJ | 1 |
| Dimas, JF | 1 |
| López-Cortés, L | 1 |
| Castillo, R | 1 |
| Verdejo, J | 2 |
| García, MA | 1 |
| Martínez-Marcos, FJ | 1 |
| Díez, F | 1 |
| Escribano, JC | 1 |
| Canueto, J | 1 |
| Lozano, F | 1 |
| Pasquau, J | 1 |
| Hernández, JJ | 1 |
| Márquez, M | 1 |
| Hoff, D | 1 |
| Aly, S | 1 |
| Ehlers, S | 1 |
| Cantarero, L | 1 |
| Ebrahim, GJ | 1 |
| Rüsch-Gerdes, S | 3 |
| Weiner, MH | 1 |
| Zhao, ZA | 1 |
| Khan, AE | 1 |
| Jones, BE | 1 |
| Sandman, L | 1 |
| Engle, M | 1 |
| Hsyu, PH | 1 |
| Becker, MI | 1 |
| Cynamon, M | 1 |
| Shoen, C | 1 |
| Machida, K | 2 |
| Tano, M | 1 |
| Takigawa, S | 1 |
| Kamada, A | 1 |
| Shigetoh, E | 1 |
| Fujii, S | 1 |
| Suyama, H | 1 |
| Kawashiro, T | 1 |
| Moore, RD | 3 |
| Jahng, AW | 1 |
| Tran, T | 1 |
| Bui, L | 1 |
| Joyner, JL | 1 |
| Bothamley, GH | 1 |
| Engova, D | 1 |
| Bates, IP | 1 |
| Ailinger, RL | 2 |
| Black, P | 1 |
| Nguyen, N | 1 |
| Lasus, H | 1 |
| Wu, SS | 1 |
| Chao, CS | 1 |
| Vargas, JH | 1 |
| Sharp, HL | 1 |
| Martín, MG | 1 |
| McDiarmid, SV | 1 |
| Sinatra, FR | 1 |
| Ament, ME | 1 |
| Xia, YY | 1 |
| Zhan, SY | 1 |
| Leiro, V | 1 |
| Botana, M | 1 |
| Sopeña, B | 1 |
| Sarala, K | 1 |
| Anitha, S | 1 |
| Kumaraswami, V | 1 |
| Marra, CA | 1 |
| Bruchet, N | 1 |
| Richardson, K | 1 |
| Moadebi, S | 1 |
| Elwood, RK | 1 |
| Fitzgerald, JM | 1 |
| Um, SW | 1 |
| Kwon, SY | 1 |
| Yoon, HI | 1 |
| Park, KU | 1 |
| Lee, CT | 1 |
| Mor, A | 1 |
| Bingham, CO | 1 |
| Kishimoto, M | 1 |
| Izmirly, PM | 1 |
| Greenberg, JD | 1 |
| Reddy, S | 1 |
| Rosenthal, PB | 1 |
| Spyridis, NP | 1 |
| Spyridis, PG | 1 |
| Gelesme, A | 1 |
| Sypsa, V | 1 |
| Valianatou, M | 1 |
| Metsou, F | 1 |
| Gourgiotis, D | 1 |
| Tsolia, MN | 1 |
| Luzi, G | 1 |
| Diamanti, AP | 1 |
| Germano, V | 1 |
| Laganà, B | 1 |
| Di Rosa, R | 1 |
| Salemi, S | 1 |
| Stoppacciaro, A | 1 |
| D'Amelio, R | 1 |
| Ikriannikova, LN | 1 |
| Kamaev, EIu | 1 |
| Shi, R | 1 |
| Otomo, K | 2 |
| Sugawara, I | 1 |
| Falagas, ME | 1 |
| Voidonikola, PT | 1 |
| Angelousi, AG | 1 |
| Mohammed, A | 1 |
| Ehrlich, R | 1 |
| Cilliers, F | 1 |
| Hanifa, Y | 1 |
| Mngadi, K | 1 |
| Lewis, J | 1 |
| Banaiee, N | 1 |
| January, V | 1 |
| Barthus, C | 1 |
| Lambrick, M | 1 |
| Roditi, D | 1 |
| Behr, MA | 1 |
| Steyn, LM | 1 |
| Tostmann, A | 1 |
| van der Ven, AJ | 1 |
| Dekhuijzen, R | 1 |
| Nusrath Unissa, A | 1 |
| Shishido, Y | 1 |
| Sato, A | 1 |
| Yano, I | 1 |
| Koyama, A | 1 |
| Hattori, T | 1 |
| Rallis, E | 1 |
| Koumantaki-Mathioudaki, E | 1 |
| Frangoulis, E | 1 |
| Chatziolou, E | 1 |
| Katsambas, A | 1 |
| Metcalfe, C | 1 |
| Macdonald, IK | 1 |
| Murphy, EJ | 1 |
| Brown, KA | 1 |
| Raven, EL | 1 |
| Moody, PC | 1 |
| Herold, JS | 1 |
| Machan, JT | 1 |
| Jaeger, T | 1 |
| DiMase, JD | 1 |
| Agrawal, D | 1 |
| Golani, A | 1 |
| Patel, Z | 1 |
| Maitra, A | 1 |
| Williams, EP | 1 |
| Loulergue, P | 1 |
| Mir, O | 1 |
| Dhote, R | 1 |
| Kaneko, Y | 1 |
| Nagayama, N | 1 |
| Shimada, M | 1 |
| Suzuki, J | 2 |
| Kunogi, M | 1 |
| Matsui, Y | 1 |
| Kawashima, M | 1 |
| Oshima, N | 1 |
| Masuda, K | 1 |
| Matsui, H | 1 |
| Nagai, H | 1 |
| Tamura, A | 1 |
| Akagawa, S | 1 |
| Toyoda, E | 1 |
| Kurashima, A | 1 |
| Yotsumoto, H | 1 |
| Ekaza, E | 1 |
| Kouakou, J | 1 |
| Arbeláez, MP | 1 |
| Arbeláez, A | 1 |
| Gómez, RD | 1 |
| Vélez, L | 1 |
| Arias, SL | 1 |
| Nagles, J | 1 |
| Peláez, LM | 1 |
| Betancourt, G | 1 |
| Velásquez, G | 1 |
| Bozok Cetintaş, V | 1 |
| Erer, OF | 1 |
| Kosova, B | 1 |
| Ozdemir, I | 1 |
| Topçuoğlu, N | 1 |
| Aktoğu, S | 1 |
| Eroğlu, Z | 1 |
| Fernández López, E | 1 |
| de Unamuno Pérez, P | 1 |
| Yelamanchili Priya, D | 1 |
| Black, PL | 1 |
| Lima-Garcia, N | 1 |
| Lau, TY | 1 |
| Kornfeld, H | 1 |
| Panaiotov, S | 1 |
| Angeby, K | 1 |
| Ouifki, R | 1 |
| Zabana, Y | 1 |
| Domènech, E | 1 |
| San Román, AL | 1 |
| Beltrán, B | 1 |
| Cabriada, JL | 1 |
| Saro, C | 1 |
| Araméndiz, R | 1 |
| Ginard, D | 1 |
| Hinojosa, J | 1 |
| Gisbert, JP | 1 |
| Mañosa, M | 1 |
| Cabré, E | 1 |
| Gassull, MA | 1 |
| Moodie, AS | 2 |
| Bowerfind, ES | 1 |
| Steinfeld, LI | 1 |
| Cohen, SC | 1 |
| Hammes, LM | 1 |
| Hammond, EC | 1 |
| Mathur, PP | 2 |
| Edwards, WT | 1 |
| Fox, LE | 3 |
| Martin, SP | 4 |
| Dunavant, BG | 1 |
| le Lirzin, M | 4 |
| Barrie, JD | 1 |
| Bruce, LG | 1 |
| Curry, FJ | 2 |
| Paklerska-Pobratyn, H | 1 |
| Preizler, J | 1 |
| Smith, DT | 4 |
| Yerushalmy, J | 1 |
| Davis, SD | 1 |
| Wedgwood, RJ | 1 |
| Björnesjö, KB | 1 |
| Jarnulf, B | 1 |
| Burkholder, CR | 1 |
| Hirsh, DC | 1 |
| Hickman, RL | 1 |
| Soave, OA | 1 |
| Myles, RK | 1 |
| Brock, PG | 1 |
| Roach, M | 1 |
| Peters, W | 1 |
| Lainson, R | 1 |
| Shaw, JJ | 1 |
| Robinson, BL | 1 |
| Leão, AF | 1 |
| Jenkins, P | 1 |
| Michelson, R | 1 |
| Ahuja, YR | 2 |
| Jaju, M | 4 |
| Kaminskaia, GO | 3 |
| Gedymin, LE | 1 |
| de Kantor, IN | 1 |
| Lázaro, L | 1 |
| Aparicio, G | 1 |
| Blancarte, L | 1 |
| Da Costa Santiago, A | 1 |
| Kuffo, D | 1 |
| Laszlo, A | 2 |
| Masó Domínguez, J | 1 |
| Reyes Gutiérrez, JH | 1 |
| George, RH | 1 |
| Snider, DE | 10 |
| Lecoeur, H | 3 |
| Guelpa-Lauras, CC | 1 |
| Aleksandrova, AE | 7 |
| Moldaver, BL | 1 |
| Borisova, OA | 1 |
| Vishnevskiĭ, BI | 5 |
| Solov'eva, IP | 1 |
| Makinskiĭ, AI | 1 |
| Maliuk, VI | 3 |
| Rubin, DH | 1 |
| Carbone, J | 1 |
| Fong, B | 1 |
| Borowitz, D | 1 |
| Leven, R | 1 |
| Grossman, M | 1 |
| Haanaes, OC | 1 |
| Gulsvik, A | 1 |
| Wood, M | 1 |
| Wallin, JD | 1 |
| O'Neill, W | 1 |
| Cooreman, J | 1 |
| Valenzuela, MT | 1 |
| Scheel, G | 1 |
| Ponce, J | 1 |
| Lepe, R | 1 |
| Velasco, M | 1 |
| Valenzuela, P | 1 |
| Jones, WD | 2 |
| Good, RC | 1 |
| Collins, FM | 2 |
| Watson, SR | 1 |
| Farer, LS | 7 |
| Pérez-Stable, EJ | 1 |
| Pedraza, RO | 1 |
| Bakir, F | 1 |
| Sabri, G | 1 |
| Walker, PF | 1 |
| Nagami, P | 1 |
| Yoshikawa, TT | 2 |
| Doyle, RM | 1 |
| Foley, HT | 1 |
| Priĭmak, AA | 1 |
| Suvorova, VI | 2 |
| Sokolova, GB | 3 |
| Braude, VI | 2 |
| Antipov, IuP | 1 |
| Parrot, R | 2 |
| Boval, C | 1 |
| Gaillard, JP | 1 |
| Bismuth, R | 1 |
| Humarau, H | 1 |
| Tamura, N | 1 |
| Jones, FL | 1 |
| von Haacke, N | 1 |
| Stafford, N | 1 |
| Coleman, DL | 1 |
| Slutkin, G | 2 |
| Möller, E | 1 |
| Ringdén, O | 1 |
| Strandvik, B | 1 |
| Sundelin, P | 1 |
| Dolgaia, TM | 1 |
| Koplan, JP | 2 |
| Jackett, PS | 1 |
| Aber, VR | 2 |
| Lowrie, DB | 3 |
| Sbarbaro, JA | 5 |
| Iseman, MD | 6 |
| Straus, E | 1 |
| Wu, N | 1 |
| Quraishi, MA | 1 |
| Levine, S | 1 |
| Aziz, A | 2 |
| Reggiardo, Z | 1 |
| Dutt, AK | 7 |
| Stead, WW | 12 |
| Steinbrück, P | 1 |
| Pitchenik, AE | 2 |
| Russell, BW | 1 |
| Cleary, T | 1 |
| Pejovic, I | 1 |
| Cole, C | 1 |
| Truffot, C | 1 |
| Fermanian, J | 1 |
| Van Scoy, RE | 3 |
| Wilkowske, CJ | 2 |
| Penketh, RJ | 1 |
| Gibney, SF | 1 |
| Nurse, GT | 1 |
| Hopkinson, DA | 1 |
| de Souza, GR | 1 |
| Sant'Anna, CC | 1 |
| Lapa e Silva, JR | 1 |
| Mano, DB | 1 |
| Bethlem, NM | 1 |
| Perry, W | 3 |
| Ziia, AV | 1 |
| Glik, MS | 1 |
| Simon, JA | 1 |
| McVicker, SJ | 1 |
| Ferrell, CR | 1 |
| Payne, CB | 1 |
| Armstrong, EM | 1 |
| Le, CT | 1 |
| Broquié, G | 2 |
| Jovanović, M | 1 |
| Vlahović, M | 1 |
| Tiliakos, N | 1 |
| Morales, AR | 1 |
| Tsoukalas, S | 1 |
| Johnson, NM | 1 |
| McNicol, MW | 1 |
| Burton-Kee, EJ | 1 |
| Mowbray, JF | 1 |
| Costello, HD | 1 |
| Glassroth, J | 1 |
| Robins, AG | 1 |
| Rusby, NL | 1 |
| Mann, PC | 1 |
| Bush, M | 1 |
| Janssen, DL | 1 |
| Frank, ES | 1 |
| Montali, RJ | 1 |
| Heckscher, T | 1 |
| Højgaard, C | 1 |
| Larsen, SO | 2 |
| Vergmann, B | 2 |
| Nouhouayi, A | 1 |
| Bergogne-Berezin, E | 1 |
| Lafaix, C | 1 |
| Gsellman, RM | 1 |
| Bonifazi, F | 1 |
| Sanguinetti, CM | 1 |
| Gasparini, S | 1 |
| Nagami, PH | 1 |
| Erooga, MA | 1 |
| Stamp, TC | 1 |
| Musch, E | 1 |
| Eichelbaum, M | 1 |
| Wang, JK | 1 |
| von Sassen, W | 1 |
| Ochs, HR | 1 |
| Castro-Parra, M | 1 |
| Dengler, HJ | 1 |
| Atkins, JN | 1 |
| Brodie, MJ | 1 |
| Hillyard, CJ | 1 |
| Nikolin, VP | 1 |
| Kaledin, VI | 1 |
| Matienko, NA | 1 |
| Budker, VG | 1 |
| Breckenridge, AM | 1 |
| Crawford, FE | 1 |
| Hall, JM | 1 |
| MacIver, M | 1 |
| Orme, ML | 1 |
| Rowe, PH | 1 |
| Smith, E | 1 |
| Watts, MJ | 1 |
| Miceli, JN | 1 |
| Olson, WA | 1 |
| Cohen, SN | 2 |
| Diktaban, T | 1 |
| Lucente, FE | 1 |
| Taylor, WC | 4 |
| Aronson, MD | 1 |
| Delbanco, TL | 1 |
| Jain, VK | 1 |
| Mathur, KC | 1 |
| Wason, S | 1 |
| Lacouture, PG | 1 |
| Lovejoy, FH | 1 |
| Passes, HI | 1 |
| Bonora, G | 1 |
| De La Pierre, L | 1 |
| Perletti, L | 1 |
| Zabolotnykh, NV | 3 |
| Chumak, AA | 1 |
| Kostromin, AP | 1 |
| Arioli, V | 2 |
| Berti, M | 1 |
| Carniti, G | 1 |
| Randisi, E | 1 |
| Rossi, E | 1 |
| Scotti, R | 1 |
| Castillo, J | 1 |
| Lema, M | 1 |
| Cameselle, L | 1 |
| Al-Shaban, W | 1 |
| Cerviño, L | 1 |
| Salgueiro, M | 1 |
| Noya, M | 1 |
| Maddrey, WC | 2 |
| Andrew, OT | 1 |
| Schoenfeld, PY | 1 |
| Humphreys, MH | 1 |
| Gomoliako, IV | 1 |
| Bal'tseva, LB | 1 |
| Klimenko, MT | 2 |
| DeHoff, JB | 1 |
| Mulvaney, DM | 1 |
| Albert, R | 1 |
| Locks, M | 1 |
| Raleigh, J | 1 |
| Sutton, F | 1 |
| Wall, MA | 1 |
| Göksoy, E | 1 |
| Düren, M | 1 |
| Durgun, V | 1 |
| Uygun, N | 1 |
| de la Mata, M | 1 |
| Rufian, S | 1 |
| Villanueva Marcos, JL | 1 |
| Gutierrez Aroca, J | 1 |
| Miño, G | 1 |
| Pera, C | 1 |
| Nolan, CM | 8 |
| Sandblom, RE | 1 |
| Thummel, KE | 1 |
| Slattery, JT | 1 |
| Nelson, SD | 1 |
| JI, B | 5 |
| Vázquez-Del Mercado, M | 1 |
| Casiano, CA | 1 |
| Rubin, RL | 1 |
| Masobe, P | 1 |
| Lee, T | 1 |
| Price, M | 1 |
| Decrey, PH | 1 |
| Pécoud, A | 1 |
| Raeber, PA | 1 |
| Zellweger, JP | 4 |
| Saunderson, PR | 1 |
| Wilson, TM | 1 |
| de Lisle, GW | 2 |
| Ristow, M | 1 |
| Möhlig, M | 1 |
| Rifai, M | 3 |
| Schatz, H | 2 |
| Pfeiffer, A | 1 |
| Weyer, K | 2 |
| Groenewald, P | 1 |
| Zwarenstein, M | 2 |
| Hawken, M | 2 |
| Gathua, S | 2 |
| Brindle, R | 1 |
| Githui, W | 1 |
| Odhiambo, J | 1 |
| Batchelor, B | 1 |
| Gilks, C | 2 |
| Chintu, C | 1 |
| Bhat, G | 1 |
| Luo, C | 1 |
| Diwan, V | 1 |
| Dupont, HL | 1 |
| Trautmann, M | 1 |
| Ruhnke, M | 1 |
| Held, T | 2 |
| Weinke, T | 1 |
| Cotton, JB | 1 |
| Ligeon-Ligeonnet, P | 1 |
| Durra, A | 1 |
| Sartre, J | 1 |
| Bureau, E | 1 |
| Chetail, N | 1 |
| Grenier, JL | 1 |
| Macnab, MF | 2 |
| Bohmer, PD | 1 |
| Seager, JR | 2 |
| Koukol, SC | 1 |
| DeHaven, JI | 1 |
| Riggs, DR | 1 |
| Lamm, DL | 1 |
| Mulder, D | 1 |
| Hayes, R | 1 |
| Palusci, VJ | 1 |
| O'Hare, D | 1 |
| Lawrence, RM | 1 |
| Aisu, T | 1 |
| van Praag, E | 1 |
| Eriki, P | 1 |
| Narain, JP | 2 |
| Barugahare, L | 1 |
| Tembo, G | 1 |
| McFarland, D | 1 |
| Engwau, FA | 1 |
| Pickwell, SM | 1 |
| Walley, J | 1 |
| Porter, J | 2 |
| Klemens, SP | 2 |
| Grossi, MA | 1 |
| Jabès, D | 1 |
| Della Bruna, C | 1 |
| Olliaro, P | 2 |
| Saba, J | 1 |
| Lacassin, F | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Vildé, JL | 1 |
| Gutman, LT | 1 |
| Tian, C | 1 |
| Grange, JM | 2 |
| Winstanley, PA | 1 |
| Ibrahim, ZY | 1 |
| Menke, JJ | 1 |
| Teira, R | 1 |
| Seth, V | 1 |
| Seth, SD | 1 |
| Beotra, A | 1 |
| Semwal, OP | 1 |
| D'monty, V | 1 |
| Mukhopadhya, S | 1 |
| Grant, A | 1 |
| Porter, JD | 3 |
| Reeve, P | 1 |
| Young, DB | 1 |
| Chapuis, L | 1 |
| Kennedy, N | 1 |
| Krylov, VA | 1 |
| Titov, VF | 1 |
| Tereshin, VS | 1 |
| Moreno Guillén, S | 1 |
| Sánchez Fuentes, D | 1 |
| Barragán Casas, JM | 1 |
| Garcinuño Jiménez, MA | 1 |
| Martín Casado, M | 1 |
| Martín Marcos, M | 1 |
| John, GT | 1 |
| Thomas, PP | 1 |
| Thomas, M | 1 |
| Jeyaseelan, L | 1 |
| Jacob, CK | 1 |
| Shastry, JC | 1 |
| Nightingale, SL | 1 |
| Hortoneda Giménez, M | 1 |
| Alfonso Sánchez, JL | 1 |
| Cortés Vizcaíno, C | 1 |
| Sabater Pons, A | 1 |
| Meyers, BR | 2 |
| Sheiner, P | 2 |
| Mendelson, MH | 2 |
| Neibart, E | 1 |
| Miller, C | 3 |
| Schwartz, M | 1 |
| Mor, E | 1 |
| Rabassa, AA | 1 |
| Trey, G | 1 |
| Shukla, U | 1 |
| Samo, T | 1 |
| Anand, BS | 1 |
| Wallace, RJ | 1 |
| Dunbar, D | 1 |
| Brown, BA | 1 |
| Onyi, G | 1 |
| Dunlap, R | 1 |
| Ahn, CH | 1 |
| Murphy, DT | 1 |
| Barrio, E | 1 |
| Carballo, E | 1 |
| Cabarcos, A | 1 |
| Baraia-Etxaburu, J | 1 |
| Parras, F | 1 |
| Pérez-Tascón, M | 1 |
| Miralles, P | 1 |
| Vicente, T | 1 |
| Alberdi, JC | 1 |
| Cosín, J | 1 |
| López-Gay, D | 1 |
| Malone, JL | 1 |
| Paparello, SF | 1 |
| Malone, JD | 1 |
| Hill, HE | 1 |
| Myers, JW | 1 |
| Weiss, P | 1 |
| Coronado, VG | 1 |
| Beck-Sague, CM | 1 |
| Hutton, MD | 1 |
| Davis, BJ | 1 |
| Nicholas, P | 1 |
| Villareal, C | 1 |
| Woodley, CL | 1 |
| Kilburn, JO | 3 |
| Crawford, JT | 2 |
| Frieden, TR | 4 |
| Sirenko, IA | 1 |
| Grechanina, EIa | 1 |
| Ozerova, LS | 1 |
| Vinogradova, TI | 2 |
| Tschegoleva, RA | 1 |
| Padmini, R | 1 |
| Srinivasan, S | 2 |
| Nalini, P | 1 |
| Mahadevan, S | 1 |
| Wang, ZX | 1 |
| Rideout, M | 1 |
| Scharman, EJ | 1 |
| Rosencrane, JG | 1 |
| Kailasam, S | 3 |
| Wise, DL | 3 |
| Nardini, S | 1 |
| Fraser, VJ | 1 |
| Kilo, CM | 1 |
| Bailey, TC | 1 |
| Medoff, G | 1 |
| Dunagan, WC | 1 |
| Racine-Perreaud, E | 1 |
| Esteban Sánchez, T | 1 |
| Redondo Luciáñez, ER | 1 |
| Pérez Martínez, F | 1 |
| Rodríguez Herrero, D | 1 |
| Galindo León, A | 1 |
| Calero del Castillo, JB | 1 |
| Collins, CM | 1 |
| Altman, C | 1 |
| Biour, M | 1 |
| Grangé, JD | 1 |
| Guy, A | 1 |
| Guelar, A | 1 |
| Gatell, JM | 1 |
| Podzamczer, D | 1 |
| Lozano, L | 1 |
| Aznar, E | 1 |
| Mallolas, J | 1 |
| Zamora, L | 1 |
| White, MH | 1 |
| Travis, J | 1 |
| Chandra, RS | 1 |
| Dalvi, SS | 1 |
| Powar, HS | 1 |
| Karnad, PD | 1 |
| Kshirsagar, NA | 1 |
| Mitinskaia, LA | 2 |
| Ivanova, ES | 1 |
| Kufakova, GA | 1 |
| Cheung, WC | 1 |
| Lo, CY | 1 |
| Ip, M | 1 |
| Cheng, IK | 1 |
| Wilson, BA | 1 |
| Kochi, A | 1 |
| Vareldzis, B | 1 |
| Styblo, K | 1 |
| Hayashi, A | 1 |
| Shimura, A | 1 |
| Uchiyama, H | 1 |
| Nagao, K | 1 |
| Kuriyama, T | 1 |
| Brändli, O | 1 |
| Dreher, D | 1 |
| Morger, D | 1 |
| Zalewska-Schöntaler, N | 1 |
| Jezierska-Anczuków, A | 1 |
| Hinman, AR | 1 |
| Dooley, SW | 3 |
| Fischl, MA | 1 |
| Sepkowitz, KA | 1 |
| Goldberger, MJ | 1 |
| Shinnick, TM | 1 |
| Dunphy, CA | 1 |
| Krueger, LE | 1 |
| Goldbaum, GM | 1 |
| Wood, RW | 1 |
| Woods, GL | 1 |
| Witebsky, FG | 1 |
| Stoeckle, MY | 1 |
| Riegler, N | 1 |
| Weitzman, I | 1 |
| Kornblum, J | 1 |
| Laraque, F | 1 |
| Riley, LW | 1 |
| Pablos-Mendez, A | 2 |
| Cauthen, GM | 2 |
| Blum, RN | 1 |
| Polish, LB | 1 |
| Catlin, BJ | 2 |
| Nicod, LP | 1 |
| Medici, TC | 1 |
| Khan, J | 1 |
| Ajanee, N | 1 |
| Jafri, W | 1 |
| Schürmann, D | 1 |
| Bergmann, F | 1 |
| Jautzke, G | 1 |
| Fehrenbach, J | 1 |
| Ruf, B | 1 |
| Radermecker, M | 1 |
| Salleras Sanmarti, L | 2 |
| Alcaide Megias, J | 2 |
| Altet Gomez, MN | 2 |
| Canela Soler, J | 2 |
| Navas Alcala, E | 2 |
| Suñe Puigbo, MR | 2 |
| Serra Majem, L | 1 |
| Israel, HL | 3 |
| Barrasa Villar, JI | 1 |
| Guimbao Bescós, J | 1 |
| Gotor Lázaro, G | 1 |
| Aspíroz Sancho, C | 1 |
| Pavlov, VA | 1 |
| Kleĭn, AV | 1 |
| Nosova, NA | 1 |
| Musser, JM | 5 |
| Kapur, V | 1 |
| Williams, DL | 1 |
| van Embden, JD | 1 |
| Rouse, DA | 1 |
| Bai, GH | 1 |
| Luna-Herrera, J | 1 |
| Reddy, VM | 2 |
| Daneluzzi, D | 2 |
| Bruins, J | 1 |
| Gribnau, JH | 1 |
| Bwire, R | 1 |
| Camins, BC | 1 |
| Watkins, DL | 1 |
| Walubo, A | 1 |
| Aboo, A | 1 |
| Sakhuja, V | 2 |
| Jha, V | 2 |
| Varma, PP | 1 |
| Joshi, K | 2 |
| Chugh, KS | 1 |
| Rubinstien, EM | 1 |
| Madden, GM | 1 |
| Lyons, RW | 1 |
| Hsu, HS | 1 |
| Wang, LS | 1 |
| Wu, YC | 1 |
| Fahn, HJ | 1 |
| Huang, MH | 1 |
| Sanklecha, MU | 1 |
| Raghavan, K | 1 |
| Mehta, MN | 1 |
| Beller, M | 1 |
| Gunn-Moore, DA | 1 |
| Jenkins, PA | 2 |
| Lucke, VM | 1 |
| Aguilar, X | 1 |
| Ruiz, J | 1 |
| Fernández-Muixí, J | 1 |
| Teixidó, A | 1 |
| Gallego, M | 1 |
| Ribas, J | 1 |
| Richart, C | 1 |
| Morera, J | 1 |
| Sane, SV | 1 |
| Sane, NS | 1 |
| Thakker, SV | 1 |
| Ali, J | 1 |
| Trehan, AK | 1 |
| Abdullaev, RIu | 1 |
| Park, SB | 1 |
| Joo, I | 1 |
| Park, YI | 1 |
| Suk, J | 1 |
| Cho, WH | 1 |
| Kim, HC | 1 |
| Martinez, ME | 1 |
| Sanchez-Cabezudo, MJ | 1 |
| Peña, JM | 1 |
| Vazquez, JJ | 2 |
| Cárdenas Rodríguez, M | 1 |
| Pérez Gómez, P | 1 |
| Lozano Mera, L | 1 |
| Kohn, MR | 1 |
| Arden, MR | 1 |
| Vasilakis, J | 1 |
| Shenker, IR | 1 |
| O'Brien, KL | 1 |
| Dietz, HC | 1 |
| Romagnoli, M | 1 |
| Eiden, J | 1 |
| Gibson, J | 2 |
| McConville, JH | 2 |
| Brook, MG | 1 |
| Miller, RF | 1 |
| Suwanagool, S | 1 |
| Chuenarom, V | 1 |
| Pechthanon, L | 1 |
| Sonjai, A | 1 |
| Leelarasamee, A | 1 |
| Pathrakom, C | 1 |
| Saenghirunvattana, S | 1 |
| Grijalba Uche, M | 1 |
| Echeverría Zabalza, ME | 1 |
| Medina Solá, JJ | 1 |
| Woo, J | 1 |
| Chan, C | 1 |
| Chan, R | 1 |
| Cheung, W | 1 |
| Or, K | 1 |
| Chan, K | 1 |
| Shkurupiĭ, VA | 2 |
| Chernova, TG | 1 |
| Popper, SE | 1 |
| Hebrink, ST | 1 |
| Smith, DA | 1 |
| Stewart, TB | 1 |
| Millard, PS | 1 |
| Wilcosky, TC | 1 |
| Reade-Christopher, SJ | 1 |
| Weber, DJ | 1 |
| Regnard, PJ | 1 |
| Barry, P | 1 |
| Isselin, J | 1 |
| Graham, NM | 2 |
| Galai, N | 1 |
| Astemborski, J | 1 |
| Bonds, M | 1 |
| Rizzo, RT | 1 |
| Sheeley, L | 1 |
| Vlahov, D | 1 |
| Carosi, G | 2 |
| Tayler, E | 1 |
| Ignatenko, N | 1 |
| Paul, J | 1 |
| Connolly, M | 1 |
| Nye, P | 1 |
| Lyagoshina, T | 1 |
| Besse, C | 1 |
| Alperstein, G | 2 |
| Morgan, KR | 2 |
| Fett, MJ | 1 |
| Nossar, V | 1 |
| Stewart, GJ | 1 |
| Goto, M | 1 |
| Tachikawa, N | 1 |
| Kitada, K | 1 |
| Shimada, K | 2 |
| Kimura, S | 2 |
| Amitani, R | 1 |
| Tanaka, E | 1 |
| Murayama, T | 1 |
| Kuze, F | 2 |
| Dhillon, J | 2 |
| Sole, K | 1 |
| Nadadhur, G | 1 |
| O'Sullivan, JF | 1 |
| Benedetti, MS | 1 |
| Brmbolić, BJ | 1 |
| Boricić, I | 1 |
| Salemović, DR | 1 |
| Jevtović, DL | 1 |
| Ranin, JT | 1 |
| Begić-Janeva, A | 1 |
| Krance, MB | 1 |
| Fisher, MA | 1 |
| Prokop'eva, ED | 1 |
| Pigareva, NV | 1 |
| Cho, KH | 1 |
| Lee, DY | 1 |
| Kim, CW | 1 |
| MacGregor, RR | 2 |
| Taboada Lopez, G | 1 |
| Navarro de Claure, ML | 1 |
| Nixon, GM | 1 |
| Stanley, TV | 1 |
| Jaber, M | 1 |
| Rattan, A | 1 |
| Durrheim, DN | 1 |
| Belt, EL | 1 |
| Bourgeois, JA | 1 |
| Zelenko, M | 1 |
| Waraich, BS | 1 |
| Kiuchi, T | 1 |
| Tanaka, K | 1 |
| Inomata, Y | 1 |
| Uemoto, S | 1 |
| Satomura, K | 1 |
| Egawa, H | 1 |
| Uyama, S | 1 |
| Sano, K | 1 |
| Okajima, H | 1 |
| Yamaoka, Y | 1 |
| Zaragoza, RM | 1 |
| Hernandez, A | 2 |
| Treviño, M | 1 |
| Diliz, HS | 1 |
| Alvarez, L | 1 |
| Malek-Ahmadi, P | 1 |
| Chavez, M | 1 |
| Contreras, SA | 1 |
| Sudre, P | 2 |
| Rieder, H | 1 |
| Bassetti, S | 1 |
| Hirschel, BJ | 1 |
| Malvy, D | 1 |
| Rana, F | 1 |
| Hawken, MP | 3 |
| Meme, HK | 2 |
| Chakaya, JM | 2 |
| Githui, WA | 2 |
| Odhiambo, JA | 2 |
| McAdam, KP | 3 |
| Lucas, SJ | 1 |
| Chan, TY | 1 |
| Schütte, W | 1 |
| Berghaus, A | 1 |
| Schütte, A | 1 |
| Mozhokina, GN | 1 |
| Makarova, OV | 1 |
| Mikhaĭlova, LP | 1 |
| Sreevatsan, S | 1 |
| Deretic, V | 3 |
| Antony, SJ | 1 |
| Ynares, C | 1 |
| Dummer, JS | 1 |
| Deol, P | 2 |
| Ngamvithayapong, J | 1 |
| Uthaivoravit, W | 1 |
| Akarasewi, P | 1 |
| Sawanpanyalert, P | 1 |
| Thomas, RE | 1 |
| Elliott, LC | 1 |
| Morris, JS | 1 |
| Juma, ES | 1 |
| Thiong'o, LN | 1 |
| Kimari, JN | 1 |
| Ngugi, EN | 1 |
| Bwayo, JJ | 1 |
| Gilks, CF | 1 |
| Plummer, FA | 1 |
| Nunn, PP | 1 |
| Foster, S | 1 |
| MacIntyre, CR | 2 |
| Kendig, N | 1 |
| Kummer, L | 1 |
| Birago, S | 1 |
| Hengster, P | 1 |
| Sölder, B | 1 |
| Fille, M | 1 |
| Menardi, G | 1 |
| Evans, ME | 1 |
| Finger, R | 1 |
| Colmenero, JD | 1 |
| García-Ordoñez, MA | 1 |
| Sebastián, MD | 1 |
| Pérez-Ruiz, E | 1 |
| Sánchez-Lora, J | 1 |
| Sánchez-González, J | 1 |
| Bentabol, G | 1 |
| Juárez, C | 1 |
| Firsova, VA | 1 |
| Gubkina, MF | 1 |
| Efimova, LN | 1 |
| Kurunov, IN | 1 |
| Arkhipov, SA | 1 |
| Choudhri, SH | 1 |
| Minyiri, GO | 1 |
| Watkins, W | 1 |
| Sahai, J | 1 |
| Sitar, DS | 1 |
| Aoki, FY | 1 |
| Pagán-Ramos, E | 1 |
| Banerjee, A | 2 |
| Polosa, R | 1 |
| Colombrita, R | 1 |
| Prosperini, G | 1 |
| Cacciola, R | 1 |
| Tang, LL | 1 |
| Lim, IH | 1 |
| Ling, ML | 1 |
| Tay, L | 1 |
| Wong, SY | 1 |
| Perlman, DC | 2 |
| El Sadr, WM | 1 |
| Heifets, LB | 2 |
| Nelson, ET | 1 |
| Chirgwin, K | 1 |
| Salomon, N | 2 |
| Telzak, EE | 1 |
| Klein, O | 1 |
| Koreeda, Y | 1 |
| Hirotsu, Y | 1 |
| Fukunaga, H | 1 |
| Mizuno, K | 1 |
| Tomiyama, Y | 1 |
| Niina, K | 1 |
| Higashimoto, I | 1 |
| Jounsono, M | 1 |
| Kawabata, M | 1 |
| Osame, M | 1 |
| March, F | 1 |
| Garriga, X | 1 |
| Rodríguez, P | 1 |
| Moreno, C | 2 |
| Prats, G | 1 |
| Owens, DK | 2 |
| Kent, JH | 1 |
| Valway, S | 1 |
| Weismuller, P | 1 |
| Maxwell, R | 1 |
| Elcock, M | 1 |
| Meador, J | 1 |
| Royce, S | 2 |
| Shefer, A | 1 |
| Woodley, C | 1 |
| Onorato, I | 1 |
| Hoeppner, VH | 1 |
| Witzig, RS | 1 |
| McLaughlin, JC | 1 |
| Torres, P | 1 |
| Madico, G | 1 |
| Degnan, MT | 1 |
| Cook, MB | 1 |
| Quenzer, VK | 1 |
| Ferguson, RM | 1 |
| Khaĭdukov, SV | 1 |
| Mezhlumova, MB | 1 |
| Litvinov, IS | 1 |
| Iakhin, RT | 1 |
| Leleu, O | 1 |
| Aubry, P | 1 |
| Verhoest, P | 1 |
| Jounieaux, V | 1 |
| Rey, E | 1 |
| Pons, G | 1 |
| Crémier, O | 1 |
| Vauzelle-Kervroëdan, F | 1 |
| Pariente-Khayat, A | 1 |
| d'Athis, P | 1 |
| Badoual, J | 1 |
| Olive, G | 1 |
| Gendrel, D | 1 |
| Dawson, C | 1 |
| Hoynes, TM | 2 |
| Schecter, G | 1 |
| Zahiri, K | 1 |
| Ramdani, B | 1 |
| Hachim, K | 1 |
| Benghanem, MG | 1 |
| Fatihi, E | 1 |
| Zaid, D | 1 |
| Jouveshomme, S | 1 |
| Dautzenberg, B | 2 |
| Spike, J | 1 |
| Barhoumi, C | 1 |
| Masmoudi, AS | 1 |
| Gritli, N | 1 |
| Hamza, M | 1 |
| Nsiri, B | 1 |
| Amor, A | 1 |
| Mechghoul, S | 1 |
| Belhadj, O | 1 |
| Xiao, Y | 1 |
| Mattei, M | 1 |
| Iona, E | 1 |
| Ricci, ML | 1 |
| Thoresen, OF | 1 |
| Creti, R | 1 |
| Orefici, G | 1 |
| Arif, K | 1 |
| Amanullah, S | 1 |
| Siddiqui, I | 1 |
| Khan, JA | 1 |
| Nayani, P | 1 |
| Kelley, C | 1 |
| Collins, F | 1 |
| Rouse, D | 1 |
| Morris, S | 1 |
| LoBue, PA | 1 |
| Lobato, MN | 1 |
| Cummings, K | 1 |
| Will, D | 1 |
| Binkin, N | 1 |
| Bustreo, F | 1 |
| Lambregts-van Weezenbeek, CS | 1 |
| Chaulet, P | 2 |
| Zhu, Y | 1 |
| Ramaswamy, S | 1 |
| Mead, D | 1 |
| Crane, DD | 1 |
| Moulding, T | 4 |
| Reilly, P | 1 |
| McIntosh, HW | 1 |
| Florence, E | 1 |
| Maher, D | 1 |
| Elizaga, J | 1 |
| Fallab-Stubi, CL | 1 |
| Sauty, A | 1 |
| Uldry, C | 1 |
| Iorillo, D | 1 |
| Burnier, M | 1 |
| Alcabes, P | 2 |
| Wasserman, WC | 1 |
| Arno, PS | 1 |
| Pekovic, V | 1 |
| Mayanja, H | 1 |
| Vjecha, M | 1 |
| Johnson, J | 1 |
| Nsubuga, P | 1 |
| Mugerwa, R | 1 |
| Whalen, C | 1 |
| Yildiz, A | 2 |
| Sever, MS | 1 |
| Türkmen, A | 1 |
| Tabak, L | 1 |
| Kiliçarslan, I | 1 |
| Ark, E | 1 |
| Andonopoulos, AP | 1 |
| Safridi, C | 1 |
| Karokis, D | 1 |
| Bounas, A | 1 |
| Taylor, B | 1 |
| Griggs, H | 1 |
| Cammarata, SK | 1 |
| Wilkinson, D | 2 |
| Vordermeier, HM | 1 |
| Sjölund, A | 1 |
| Blanchard, JS | 1 |
| Halsey, NA | 1 |
| Coberly, J | 2 |
| Chaisson, R | 1 |
| Mills, K | 1 |
| Daniels, L | 1 |
| Kurylak, D | 1 |
| Smukalska, E | 1 |
| Dylewska, K | 1 |
| Staszak-Kowalska, R | 1 |
| Rinder, H | 3 |
| Thomschke, A | 1 |
| Bretzel, G | 1 |
| Löscher, T | 2 |
| Kharoubi, S | 1 |
| Brooks, JV | 1 |
| Sawert, H | 1 |
| Antonucci, G | 1 |
| Wilson, T | 1 |
| Marcinkeviciene, JA | 1 |
| Blanchardand, JS | 1 |
| Paramasivan, CN | 1 |
| Kubendiran, G | 1 |
| Herbert, D | 1 |
| Torian, LV | 2 |
| Brudney, KF | 1 |
| Menzies, IB | 1 |
| Paterson, DL | 1 |
| Martínez Alfaro, E | 1 |
| Solera, J | 2 |
| Serna, E | 1 |
| Cuenca, D | 1 |
| Castillejos, ML | 1 |
| Espinosa, A | 2 |
| Sáez, L | 1 |
| Domoua, K | 1 |
| N'Dhatz, M | 1 |
| Coulibaly, G | 1 |
| Traore, F | 1 |
| Koffi, J | 1 |
| Achi, V | 1 |
| Daix, T | 1 |
| Ouattara, Y | 1 |
| Ouedraogo, M | 1 |
| Beugre, LK | 1 |
| Konan, JB | 1 |
| Coulibaly, V | 1 |
| Coulibaly, IM | 1 |
| Yapi, A | 1 |
| Goyal, A | 1 |
| Nagarkar, NM | 1 |
| Uppal, KS | 1 |
| Mohan, H | 1 |
| Dass, A | 1 |
| Bock, NN | 2 |
| Metzger, BS | 1 |
| Tapia, JR | 1 |
| Diouf, B | 1 |
| Niang, A | 1 |
| Pouye, A | 1 |
| Diouf, ML | 1 |
| Mbengue, M | 1 |
| Ka, MM | 1 |
| Moreira-Diop, T | 1 |
| Bao, O | 1 |
| Corrigan, D | 1 |
| Paton, J | 1 |
| Schreiber, J | 1 |
| Zissel, G | 1 |
| Schlaak, M | 1 |
| Müller-Quernheim, J | 1 |
| Novaro, GM | 1 |
| Buskin, SE | 1 |
| Reingold, AL | 1 |
| Brehm, WT | 1 |
| McGuigan, MA | 1 |
| Yamada, J | 1 |
| Bucher, HC | 1 |
| Griffith, LE | 1 |
| Guyatt, GH | 1 |
| Naef, M | 1 |
| Sendi, P | 1 |
| Battegay, M | 1 |
| Ronge, R | 1 |
| Amdekar, YK | 1 |
| Mwaba, P | 1 |
| Sturm, AW | 1 |
| Geeta, N | 1 |
| Hsu, YY | 1 |
| White, AJ | 1 |
| Robinson-White, CM | 1 |
| Luitel, H | 1 |
| Tascon, RE | 1 |
| Bonato, VL | 1 |
| Lima, VM | 1 |
| Faccioli, LH | 1 |
| Stavropoulos, E | 1 |
| Colston, MJ | 1 |
| Hewinson, RG | 1 |
| Moelling, K | 1 |
| Pozniak, AL | 1 |
| Miller, R | 1 |
| Scanga, CA | 1 |
| Mohan, VP | 1 |
| Joseph, H | 1 |
| Yu, K | 1 |
| Chan, J | 1 |
| Starr, M | 2 |
| Sawyer, S | 2 |
| Carlin, J | 1 |
| Powell, C | 1 |
| Newman, R | 1 |
| Johnson, P | 1 |
| Muhindi, DW | 1 |
| Vaquero, M | 1 |
| Gutierrez, J | 1 |
| Miyazaki, E | 1 |
| Lenaerts, AM | 2 |
| Chase, SE | 2 |
| Chmielewski, AJ | 1 |
| Alwood, K | 1 |
| Gachuhi, R | 1 |
| Coggin, W | 1 |
| Blazes, D | 1 |
| Eltringham, IJ | 2 |
| Mangan, JA | 1 |
| Wilson, SM | 2 |
| Hartel, D | 1 |
| Selwyn, PA | 2 |
| Schoenbaum, EE | 1 |
| Klein, RS | 1 |
| Pérez, J | 1 |
| Alicea, E | 1 |
| Casal, J | 1 |
| Rodríguez, W | 1 |
| Takamatsu, I | 1 |
| Korzets, A | 1 |
| Gafter, U | 1 |
| Duman, S | 1 |
| Ozkahya, M | 1 |
| Tokat, Y | 1 |
| Harpster, T | 1 |
| Signorini, L | 1 |
| Cadeo, G | 1 |
| Scalzini, A | 1 |
| Bonazzi, L | 1 |
| Caligaris, S | 1 |
| Tomasoni, L | 1 |
| Tebaldi, A | 1 |
| del Castillo Otero, D | 1 |
| Peñafiel Colás, M | 1 |
| Alvarez Gutiérrez, F | 1 |
| Soto Campos, JG | 1 |
| Calderón Osuna, E | 1 |
| Toral Marín, J | 1 |
| Sánchez Gómez, J | 1 |
| Oner-Eyüboglu, AF | 1 |
| Kalpaklioglu, AF | 1 |
| Moray, G | 1 |
| Haberal, M | 1 |
| Yue, Y | 1 |
| Heym, B | 1 |
| Nyazema, NZ | 1 |
| Rabvukwa, P | 1 |
| Gumbo, J | 1 |
| Ndudzo, P | 1 |
| Chitemerere, C | 1 |
| Lee, TS | 1 |
| Spellman, E | 1 |
| Berg, DE | 1 |
| Montenegro-James, S | 1 |
| O'Connor, PG | 1 |
| Shi, JM | 1 |
| Henry, S | 1 |
| Durante, AJ | 1 |
| Martinjak-Dvorsek, I | 1 |
| Gorjup, V | 1 |
| Horvat, M | 1 |
| Noc, M | 1 |
| Anderson, D | 1 |
| Anderson, V | 1 |
| Pentland, L | 1 |
| Johnson, PD | 1 |
| de Lourdes Garcia, M | 1 |
| Valdespino, JL | 1 |
| Klukowicz, AJ | 1 |
| Stepanshina, VN | 1 |
| Panfertsev, EA | 1 |
| Mitrofanova, GN | 1 |
| Korobova, OV | 1 |
| Stepanshin, IuG | 1 |
| Shemiakin, IG | 1 |
| Medvedeva, IM | 1 |
| Ollé-Goig, JE | 1 |
| Mani, MK | 1 |
| Daniel, N | 1 |
| Geiter, LJ | 1 |
| Szpytma, M | 1 |
| Hejblum, G | 1 |
| Jerant, AF | 1 |
| Bannon, M | 1 |
| Rittenhouse, S | 1 |
| Stuart, RL | 3 |
| Wilson, J | 1 |
| Grayson, ML | 3 |
| Schoeman, JH | 1 |
| Vundule, C | 1 |
| Tatley, M | 1 |
| Plant, AJ | 1 |
| Hendrie, D | 1 |
| Dhawan, A | 1 |
| Wade, JJ | 1 |
| Lim, WH | 1 |
| Ruiz, G | 1 |
| Price, JF | 1 |
| Hadzic, N | 1 |
| Baker, AJ | 1 |
| Heaton, ND | 1 |
| Mieli-Vergani, G | 1 |
| Warndorff, DK | 1 |
| Ngwira, B | 1 |
| Chagaluka, S | 1 |
| Pönnighaus, JM | 1 |
| Fine, PE | 1 |
| Thomsen, VO | 1 |
| Bauer, J | 1 |
| Glismann, S | 1 |
| Mathew, R | 1 |
| Santha, T | 2 |
| Scalcini, M | 2 |
| Amaya-Tapia, G | 1 |
| Martín-Del Campo, L | 1 |
| Aguirre-Avalos, G | 1 |
| Portillo-Gómez, L | 1 |
| Covarrubias-Pinedo, A | 1 |
| Aguilar-Benavides, S | 1 |
| Martínez Alfaro, EM | 1 |
| Cuadra, F | 1 |
| Maciá, MA | 1 |
| Geijo, P | 1 |
| Sánchez Martínez, PA | 1 |
| Rodríguez Zapata, M | 1 |
| Largo, J | 1 |
| Sepúlveda, MA | 1 |
| Rosa, C | 1 |
| Sánchez, L | 1 |
| Mateos, F | 1 |
| Blanch, JJ | 1 |
| Apaydin, S | 1 |
| Oztürk, R | 1 |
| Erek, E | 1 |
| Kobashi, Y | 2 |
| Okimoto, N | 2 |
| Matsushima, T | 2 |
| Abe, T | 2 |
| Nishimura, K | 2 |
| Shishido, S | 2 |
| Kawahara, S | 2 |
| Shigeto, E | 2 |
| Takeyama, H | 2 |
| Kuraoka, T | 2 |
| de Haas, PE | 2 |
| van Doorn, HR | 2 |
| Kuijper, E | 1 |
| Fitzgerald, DW | 2 |
| Desvarieux, M | 1 |
| Joseph, P | 2 |
| Johnson, WD | 2 |
| Choi, IS | 1 |
| Joh, JW | 1 |
| Lee, SK | 1 |
| Huh, WS | 1 |
| Oh, HY | 1 |
| Peck, KR | 1 |
| Song, JH | 1 |
| Kim, MK | 1 |
| Ko, YH | 1 |
| Lee, BB | 1 |
| Sharma, AK | 1 |
| Tolani, SL | 1 |
| Rathi, GL | 1 |
| Gupta, HP | 1 |
| Gupta, R | 1 |
| Dutt, M | 3 |
| Cherian, T | 1 |
| Iinuma, Y | 1 |
| Lee, R | 1 |
| Schoolnik, GK | 1 |
| Venter, A | 1 |
| Mitchison, D | 1 |
| Hollingshead, JR | 1 |
| Larro, M | 1 |
| Puri, MM | 1 |
| Arora, VK | 1 |
| Quigley, MA | 1 |
| Mwinga, A | 2 |
| Hosp, M | 2 |
| Lisse, I | 1 |
| Fuchs, D | 1 |
| Balakrishnan, C | 1 |
| Mangat, G | 1 |
| Mittal, G | 1 |
| Joshi, VR | 1 |
| Horsfield, N | 1 |
| Green, RM | 1 |
| Sud, K | 1 |
| Muthukumar, T | 1 |
| Garg, SK | 2 |
| Kohli, HS | 1 |
| Gupta, KL | 1 |
| Phillips, M | 1 |
| Teixeira, L | 1 |
| Rocha, LM | 1 |
| Maciel, E | 1 |
| Rose, L | 1 |
| Wells, C | 1 |
| Saitoh, M | 1 |
| Ichiba, H | 1 |
| Fujioka, H | 1 |
| Shintaku, H | 1 |
| Yamano, T | 1 |
| Kuijper, EJ | 1 |
| van der Ende, A | 1 |
| Welten, AG | 1 |
| Dankert, J | 1 |
| Cui, D | 1 |
| Laserson, KF | 1 |
| Kenyon, AS | 1 |
| Layloff, T | 1 |
| Khan, MY | 1 |
| Kinsara, AJ | 1 |
| Osoba, AO | 1 |
| Wali, S | 1 |
| Samman, Y | 1 |
| Quenelle, DC | 1 |
| Winchester, GA | 1 |
| Staas, JK | 1 |
| Barrow, EL | 1 |
| Barrow, WW | 1 |
| Nist, A | 1 |
| Bowersox, J | 1 |
| James, JS | 1 |
| Kita, T | 1 |
| Tanigawara, Y | 1 |
| Chikazawa, S | 1 |
| Hatanaka, H | 1 |
| Sakaeda, T | 1 |
| Komada, F | 1 |
| Iwakawa, S | 1 |
| Okumura, K | 1 |
| Watkinson, L | 1 |
| Kimbrough , L | 1 |
| Metha, S | 1 |
| Cavalcante, S | 1 |
| Domenech, P | 1 |
| Honoré, N | 1 |
| Stephenson, I | 1 |
| Wiselka, MJ | 1 |
| Qualie, MJ | 1 |
| Bhalla, RK | 1 |
| Jones, TM | 1 |
| Rothburn, MM | 1 |
| Swift, AC | 1 |
| Pillai, G | 1 |
| Ellard, GA | 7 |
| Fourie, PB | 1 |
| Bruña-Romero, O | 1 |
| González-Aseguinolaza, G | 1 |
| Hafalla, JC | 1 |
| Tsuji, M | 1 |
| Nussenzweig, RS | 1 |
| Trinh, C | 1 |
| Horn, L | 1 |
| Des Jarlais, DC | 1 |
| Manders, AJ | 1 |
| van den Borne, HW | 1 |
| Kok, GJ | 1 |
| Ollé-Goig, J | 1 |
| Kingston, M | 1 |
| Childs, K | 1 |
| Carlin, E | 1 |
| Perel'man, MI | 1 |
| Khomiakov, IuN | 1 |
| Kiselev, VI | 1 |
| Severin, ES | 1 |
| Pal'tsev, MA | 1 |
| Kura, MM | 1 |
| Hira, SK | 1 |
| Mellon, LR | 1 |
| Noel, E | 1 |
| Bentoucha, A | 1 |
| Roscigno, G | 1 |
| Casado, JL | 1 |
| Antela, A | 1 |
| Quereda, C | 1 |
| Dronda, F | 1 |
| Bibi, H | 1 |
| Weiler-Ravell, D | 1 |
| Shoseyov, D | 1 |
| Feigin, I | 1 |
| Arbelli, Y | 1 |
| Chemtob, D | 1 |
| Steinmann, RA | 1 |
| Rickel, MK | 1 |
| Spedini, P | 1 |
| Iannaccone, R | 1 |
| Sue, YJ | 1 |
| Avner, JR | 1 |
| Perry, S | 1 |
| Peng, YL | 1 |
| Xing, J | 1 |
| Li, D | 1 |
| Song, H | 1 |
| Ding, D | 1 |
| Duanmu, HJ | 1 |
| Alvirez-Freites, EJ | 1 |
| Carter, JL | 1 |
| Lugada, ES | 1 |
| Watera, C | 1 |
| Nakiyingi, J | 1 |
| Elliott, A | 1 |
| Brink, A | 1 |
| Nanyunja, M | 1 |
| Antivelink, L | 1 |
| Whitworth, J | 1 |
| Bendayan, D | 1 |
| Raz, M | 1 |
| Zulu, I | 1 |
| Farthing, MJ | 1 |
| Mulambo, S | 1 |
| Kelly, P | 1 |
| Rabahi, MF | 1 |
| Rodrigues, AB | 1 |
| Queiroz de Mello, F | 1 |
| de Almeida Netto, JC | 1 |
| Portillo, CJ | 1 |
| Patel, PA | 1 |
| Voigt, MD | 1 |
| Smith, KC | 1 |
| Pachucki, C | 1 |
| Wang, YC | 1 |
| Conwell, DS | 1 |
| Mosher, A | 1 |
| Samuels, M | 1 |
| Batki, SL | 1 |
| Gruber, VA | 1 |
| Bradley, JM | 1 |
| Bradley, M | 1 |
| Delucchi, K | 1 |
| Riaz, AA | 1 |
| Robshaw, P | 1 |
| Isla, AM | 1 |
| Jin, CF | 1 |
| Sable, R | 1 |
| Martin, PD | 1 |
| Bates, JH | 1 |
| Anah, CO | 1 |
| Newton, RW | 1 |
| Ziegler, HK | 1 |
| Sinazadeh, M | 1 |
| Springett, VH | 2 |
| Diop, S | 1 |
| de Medeiros, D | 1 |
| Baylet, R | 1 |
| Sankalé, M | 1 |
| Clarke, PD | 1 |
| Bilyk, MA | 1 |
| Dudchik, GKh | 1 |
| Barthel, E | 1 |
| Pearson, CA | 1 |
| Subbammal, S | 1 |
| Nair, NG | 1 |
| Tripathy, SP | 3 |
| Harris, AA | 1 |
| Karakusis, P | 1 |
| Schwenk, R | 1 |
| Kelly, K | 1 |
| Tse, KS | 1 |
| Sehon, AH | 1 |
| Sahn, SA | 2 |
| Lakshminarayan, S | 2 |
| Duroux, P | 1 |
| Glassroth, JL | 4 |
| Byrd, RB | 2 |
| Horn, BR | 1 |
| Griggs, GA | 1 |
| Solomon, DA | 1 |
| van Geuns, HA | 1 |
| Kuntz, HD | 1 |
| Rausch, V | 1 |
| Conge, G | 2 |
| Freedman, J | 1 |
| Lim, FC | 1 |
| Habedank, M | 1 |
| Uragoda, CG | 3 |
| Kottegoda, SR | 1 |
| Edsall, JR | 2 |
| Awe, RJ | 1 |
| Bunyan, SB | 1 |
| Reagan, WP | 1 |
| Efremova, IIa | 2 |
| Schiffman, PL | 1 |
| Ashkar, B | 1 |
| Bishop, M | 1 |
| Cleary, MG | 1 |
| Kondo, E | 6 |
| Felton, CP | 2 |
| Johnson, AO | 1 |
| Aderele, WI | 1 |
| Jentgens, H | 2 |
| Lebeau, B | 1 |
| Rochemaure, J | 1 |
| Papadimitriou, M | 1 |
| Memmos, D | 1 |
| Metaxas, P | 1 |
| Africanov, II | 1 |
| Howe, GR | 1 |
| Lindsay, J | 1 |
| Coppock, E | 1 |
| Miller, AB | 1 |
| Teklu, B | 1 |
| Brickman, HF | 2 |
| Beaudry, PH | 2 |
| Duru, S | 1 |
| Rosenthal, AR | 1 |
| Baker, ED | 1 |
| Linden, RA | 1 |
| Azuma, Y | 1 |
| Salinger, PL | 1 |
| Bailey, WC | 6 |
| Sellers, CA | 1 |
| Sutton, FD | 1 |
| Sheehy, TW | 1 |
| Maetz, HM | 1 |
| Brown, RC | 2 |
| Seaton, A | 1 |
| Reissmann, K | 1 |
| Kerner, U | 1 |
| Robinson, D | 1 |
| Rosenberg, SA | 1 |
| Seipp, C | 1 |
| Sears, HF | 1 |
| Röhrborn, G | 1 |
| Miltenburger, HG | 1 |
| Blaha, HM | 1 |
| Girling, DJ | 2 |
| Krakowska, M | 1 |
| Kamińska, M | 1 |
| González Montaner, LJ | 1 |
| Palma Beltran, O | 1 |
| Abbate, E | 1 |
| Gini, G | 1 |
| Berim, MG | 1 |
| Gozman, EA | 1 |
| Kalugina, NM | 1 |
| Choulot, JJ | 1 |
| Beaufils, F | 1 |
| Aujard, Y | 1 |
| Labrune, B | 1 |
| Barrett-Connor, E | 1 |
| McNicol, M | 1 |
| Pinsker, KL | 1 |
| Koerner, SK | 1 |
| Sumaya, CV | 1 |
| Simek, M | 1 |
| Smith, MH | 2 |
| Seidemann, MF | 1 |
| Ferriss, GS | 1 |
| Rubin, W | 1 |
| Stottmeier, KD | 2 |
| Epler, GR | 2 |
| Chrostowski, K | 1 |
| Kanabus, P | 1 |
| Weichselbaumer, W | 1 |
| Gorz, E | 1 |
| Shimizu, T | 1 |
| Yokoyama, M | 1 |
| Yoshida, U | 1 |
| Onuma, H | 1 |
| Narita, A | 1 |
| Gammon, PT | 2 |
| Deppe, JT | 1 |
| Rosenzweig, DY | 1 |
| Abeledo Mezquita, G | 1 |
| Otero Reigada, MC | 1 |
| Davis, RS | 1 |
| Stoler, BS | 1 |
| Kader, MM | 1 |
| Soliman, KM | 1 |
| Shouab, S | 1 |
| El-Moursi, BA | 1 |
| Peltier, G | 1 |
| Legrand, M | 1 |
| Albengres, E | 1 |
| Houin, G | 1 |
| Breau, JL | 1 |
| Hirsch, A | 1 |
| Saltiel, JC | 1 |
| Tillement, JP | 1 |
| Gongaware, T | 1 |
| Krafft, W | 1 |
| Rapoport, MI | 1 |
| Sievers, ML | 2 |
| Herrier, RN | 1 |
| Aksel'rod, LB | 1 |
| Sukolovskaia, DM | 1 |
| Kniazheva, VN | 1 |
| Bogun, OI | 1 |
| Sodikov, ES | 3 |
| Gapon'ko, LA | 3 |
| Bach, PH | 3 |
| Higgins-Opitz, SB | 2 |
| Bima, B | 1 |
| Leary, WP | 3 |
| Wolter, H | 1 |
| Schunk, R | 1 |
| Deck, KA | 1 |
| Gehrhardt, A | 1 |
| Klein, HO | 1 |
| Ludes, H | 1 |
| Novak, RA | 1 |
| Burgher, LW | 2 |
| Polansky, F | 2 |
| Viznerova, S | 1 |
| Vodrazkova, A | 1 |
| Ogasawara, FR | 1 |
| Turbiner, S | 1 |
| Giunta, J | 1 |
| Maloney, PL | 1 |
| Mitchell, JR | 2 |
| Long, MW | 1 |
| Thorgeirsson, UP | 1 |
| Jollow, DJ | 1 |
| Tala, E | 1 |
| Thomas, PA | 1 |
| Manko, MA | 1 |
| Edwards, PQ | 3 |
| von Wichert, P | 1 |
| Haegi, V | 1 |
| Bittker, TE | 1 |
| Ovreberg, K | 1 |
| Black, M | 1 |
| Zimmerman, HJ | 1 |
| Ishak, KG | 1 |
| Sidor, K | 1 |
| Kleeberg, H | 1 |
| Gärtig, D | 1 |
| Glatthaar, E | 1 |
| Nel, E | 1 |
| Stander, M | 1 |
| Flynn, JP | 1 |
| Bentley, SE | 1 |
| Prasad, TR | 1 |
| Heffernan, JF | 1 |
| Kehler, E | 1 |
| Moulding, TS | 2 |
| Morrison-Smith, J | 1 |
| Hoose, C | 1 |
| Vale, JR | 1 |
| Afrikanov, II | 1 |
| Il'inykh, AP | 1 |
| Stauffer, JC | 1 |
| Barbera, A | 1 |
| Borja, H | 1 |
| Masoli, P | 1 |
| Offerhaus, L | 1 |
| Kumar, L | 2 |
| Barnwell, MD | 1 |
| Chitkara, R | 1 |
| Lamberta, F | 1 |
| Edlin, BR | 1 |
| Tokars, JI | 1 |
| Grieco, MH | 1 |
| Williams, J | 1 |
| Sordillo, EM | 1 |
| Ong, KR | 1 |
| Veeken, H | 1 |
| Bermejo, A | 1 |
| Oyelami, OA | 1 |
| Kumaresan, JA | 1 |
| Maganu, ET | 1 |
| Naqvi, SA | 1 |
| Hussain, M | 1 |
| Askari, H | 1 |
| Hashmi, A | 1 |
| Hussain, Z | 1 |
| Hafiz, S | 1 |
| Yazdani, I | 1 |
| Rizvi, SA | 1 |
| Ikeda, K | 1 |
| Sugimori, M | 1 |
| Kawasaki, K | 1 |
| Kurokawa, H | 1 |
| Kijimoto, C | 1 |
| Gottlieb, JE | 1 |
| Tsakalidis, D | 1 |
| Pratsidou, P | 1 |
| Hitoglou-Makedou, A | 1 |
| Tzouvelekis, G | 1 |
| Sofroniadis, I | 1 |
| Salpeter, S | 1 |
| Dwyer, B | 1 |
| Kikuchi, Y | 1 |
| Mitamura, K | 1 |
| Pang, SC | 1 |
| Clayton, AS | 1 |
| Harrison, RH | 1 |
| Mori, MA | 1 |
| Leonardson, G | 1 |
| Welty, TK | 1 |
| Cruciani, M | 1 |
| Marocco, S | 1 |
| Mazzi, R | 1 |
| Concia, E | 1 |
| Bassetti, D | 1 |
| Valles, H | 1 |
| Garcia Guzman, A | 1 |
| Blanc, JM | 1 |
| Fumanal, L | 1 |
| de Francisco, JE | 1 |
| Hernández García, P | 1 |
| Martínez Cruz, F | 1 |
| Cayuelas Martínez, T | 1 |
| Oliven, A | 1 |
| Odeh, M | 1 |
| Bassan, H | 1 |
| O'Donoghue, DJ | 1 |
| Short, CD | 1 |
| Gokal, R | 1 |
| Johnson, RW | 1 |
| Vidal López, ML | 1 |
| Aparicio Rodrigo, M | 1 |
| Martín Peinador, Y | 1 |
| Rodríguez López, C | 1 |
| García de Miguel, MJ | 1 |
| García Hortelano, J | 1 |
| Kovaleva, SI | 2 |
| Pust, RE | 1 |
| Lacroix, C | 1 |
| Kleeberg, HH | 2 |
| Shafer, RW | 2 |
| Chirgwin, KD | 1 |
| Glatt, AE | 1 |
| Dahdouh, MA | 1 |
| Landesman, SH | 1 |
| Suster, B | 1 |
| Van den Hombergh, J | 1 |
| Gebhard, AC | 1 |
| Voorhoeve, HW | 1 |
| Kutteh, WH | 1 |
| Hatch, KD | 1 |
| Carlen, R | 1 |
| Shaw, D | 1 |
| Berger, R | 1 |
| Rehm, S | 1 |
| Parkin, DP | 1 |
| Laguna, F | 1 |
| Adrados, M | 1 |
| Díaz, F | 1 |
| Martínez, R | 1 |
| García Aguado, C | 1 |
| Puente, S | 1 |
| González Lahoz, JM | 1 |
| Khodzitskaia, VK | 1 |
| Zosimov, AN | 1 |
| Maheshwari, RK | 1 |
| Gupta, BD | 1 |
| Steele, MA | 1 |
| Burk, RF | 1 |
| DesPrez, RM | 1 |
| Rössler, W | 1 |
| Reichelt, A | 1 |
| Mielke, M | 1 |
| Alexander, M | 1 |
| Schecter, GF | 1 |
| Goodman, PC | 1 |
| Sande, MA | 1 |
| Hubbard, RD | 1 |
| Flory, CM | 1 |
| Misra, PK | 1 |
| Mehotra, R | 1 |
| Govil, YC | 1 |
| Rana, GS | 1 |
| Zhang, YS | 1 |
| Rabindran, E | 1 |
| Matuszak, DL | 1 |
| Israel, E | 1 |
| Woodall, H | 1 |
| Highsmith, H | 1 |
| Flynn, J | 1 |
| Tsevat, J | 3 |
| Wong, JB | 3 |
| Pauker, SG | 3 |
| Ferlinz, R | 1 |
| Ashtekar, DR | 1 |
| Farhi, DC | 1 |
| Susmano, SB | 1 |
| Jordan, TJ | 1 |
| Lewit, EM | 1 |
| Montgomery, RL | 1 |
| Moriuchi, Y | 1 |
| Kamihira, S | 1 |
| Satoh, T | 1 |
| Yanagisako, T | 1 |
| Miyazaki, Y | 1 |
| Murata, K | 1 |
| Nagai, K | 1 |
| Tokunaga, S | 1 |
| Maeda, T | 1 |
| Atogami, S | 1 |
| Peterson, KL | 1 |
| Judson, FN | 1 |
| Serra Majen, L | 1 |
| Garrido Morales, P | 1 |
| Harrison, JM | 1 |
| Wright, PA | 1 |
| Stazi, C | 1 |
| Stazi, F | 1 |
| Lode, H | 1 |
| Waecker, NJ | 1 |
| Connor, JD | 1 |
| Blumberg, EA | 1 |
| Gil, RA | 1 |
| Dhand, R | 4 |
| Singhi, PD | 1 |
| Rao, KL | 1 |
| Katariya, S | 1 |
| Aoyagi, T | 2 |
| Toyoda, T | 1 |
| Laupacis, A | 1 |
| Sackett, DL | 1 |
| Roberts, RS | 1 |
| Shirley, L | 1 |
| Grady, MT | 1 |
| Etkind, SW | 1 |
| Almeida, C | 1 |
| Lamb, GA | 1 |
| Anthoine, D | 1 |
| Derelle, J | 1 |
| Leuenberger, P | 1 |
| Michaud, PA | 1 |
| Creditor, MC | 1 |
| Rahman, F | 1 |
| Sarma, GR | 3 |
| Dylewski, J | 1 |
| Thibert, L | 1 |
| Barnum, HN | 1 |
| Aziz, K | 1 |
| Ishaq, M | 1 |
| Jittinandana, A | 1 |
| Lecoeur, HF | 2 |
| Lagrange, PH | 1 |
| Gheorghiu, M | 1 |
| Raad, I | 1 |
| Cusick, J | 1 |
| Sherertz, RJ | 1 |
| Sabbagh, M | 1 |
| Howell, N | 1 |
| Beliakova, OI | 1 |
| Sibirnaia, RI | 2 |
| Snitinskaia, Os | 1 |
| Elghoul, MT | 1 |
| Joshi, RM | 1 |
| Rizghalla, T | 1 |
| Currie, B | 1 |
| Krause, V | 1 |
| Mondia, P | 1 |
| Hudson, B | 1 |
| Upadhyaya, MP | 1 |
| Chaturvedi, SK | 1 |
| Chadwick, M | 1 |
| Nicholson, G | 1 |
| Gaya, H | 1 |
| Tournier, G | 1 |
| Nakajo, MM | 1 |
| Steiner, P | 2 |
| Ladron de Guevara, R | 1 |
| Dickensheets, DL | 1 |
| Gallet, S | 1 |
| Bellon, G | 1 |
| Galati, MR | 1 |
| Yunis, AS | 1 |
| De Salvo, MC | 1 |
| Negroni, R | 1 |
| García Fernández, JC | 1 |
| Mingolla, L | 1 |
| Rubio, MC | 1 |
| Masana, M | 1 |
| Acevedo, C | 1 |
| Matinskaia, LA | 1 |
| Firsovaia, VA | 1 |
| Rudyĭ, NM | 1 |
| Dzhokhadze, VA | 1 |
| Steg, A | 1 |
| Leleu, C | 1 |
| Debré, B | 1 |
| Boccon-Gibod, L | 1 |
| Sicard, D | 1 |
| Merkel, S | 1 |
| Fischer, P | 1 |
| Weinecke, W | 1 |
| Vossenas, P | 1 |
| Cohen, R | 1 |
| Braslow, C | 1 |
| Michaels, D | 1 |
| Zoloth, S | 1 |
| Dockweiler, U | 1 |
| Gallinari, C | 1 |
| Aeberhardt, G | 1 |
| Lévy, A | 1 |
| Bernheim, J | 1 |
| Cox, JH | 1 |
| Haponik, EF | 1 |
| Sox, HC | 1 |
| Lillington, G | 1 |
| Gottlieb, J | 1 |
| Reichman, L | 1 |
| Jordan, T | 1 |
| Colice, G | 1 |
| Caras, GJ | 1 |
| Khor, M | 1 |
| Coates, AR | 1 |
| Krespine, C | 1 |
| Helsens, C | 1 |
| Haddad, NM | 1 |
| Zaytoun, GM | 1 |
| Hadi, U | 1 |
| Smith, LS | 1 |
| Schillaci, RF | 1 |
| Baohong, J | 1 |
| Chang, CE | 1 |
| Khaled, S | 1 |
| Boldina, IG | 1 |
| Boldysheva, AV | 1 |
| Shchegoleva, RA | 1 |
| Malik, SK | 4 |
| Kalra, S | 1 |
| Gupta, PH | 1 |
| Jha, VK | 1 |
| Shukla, VK | 1 |
| Lal, R | 1 |
| Wolf, RH | 1 |
| Gibson, SV | 1 |
| Watson, EA | 1 |
| Baskin, GB | 1 |
| Steensma, JT | 1 |
| Haneishi, T | 1 |
| Shiraishi, A | 1 |
| Katayama, T | 1 |
| Torikata, A | 1 |
| Kawahara, Y | 1 |
| Kurihara, K | 1 |
| Arai, M | 1 |
| Arai, T | 1 |
| Elarth, AM | 3 |
| Barr, HW | 1 |
| Ivaniuta, OM | 1 |
| Sokirko, TA | 2 |
| Suslov, EI | 1 |
| Ioannou, PC | 1 |
| Gilhotra, R | 1 |
| Sehgal, S | 2 |
| Rao, RV | 1 |
| Raghunandharao, D | 1 |
| Davidson, PT | 2 |
| Hanh, LQ | 1 |
| Alvarenga, AE | 1 |
| Gao, DZ | 1 |
| Aguado, AG | 1 |
| Lavilla, P | 1 |
| Puig, JG | 1 |
| Barbado, J | 1 |
| Valencia, E | 1 |
| Schechter, CB | 2 |
| Silver, AL | 2 |
| Leperchey, F | 1 |
| Vicaut, E | 1 |
| Deplus, S | 1 |
| Gervais, P | 1 |
| To, T | 1 |
| Harrison, RW | 1 |
| Abraham, JH | 1 |
| Young, TK | 1 |
| Hershfield, ES | 1 |
| Immanuel, C | 1 |
| Ellard, DR | 1 |
| Allen, BW | 1 |
| Teo, SK | 1 |
| Ng, HK | 1 |
| Jenkins, MV | 1 |
| Sullam, PM | 1 |
| Parthasarathy, R | 1 |
| Ramachandran, P | 1 |
| Sivasubramanian, S | 1 |
| Tofte, RW | 1 |
| Thompson, NJ | 1 |
| Claiborne, RA | 1 |
| Nolan, RJ | 1 |
| Moers, D | 1 |
| Grzybowski, S | 2 |
| Aitken, ML | 1 |
| Anderson, KM | 1 |
| Miller, WT | 1 |
| Leff, DR | 1 |
| Leff, AR | 1 |
| Blom, WA | 1 |
| Zeedijk, N | 1 |
| Lofgren, JP | 1 |
| Warren, E | 1 |
| Pillans, PI | 1 |
| Yernault, JC | 1 |
| Lenke, RR | 1 |
| Turkel, SB | 1 |
| Monsen, R | 1 |
| Chan, JC | 1 |
| Tabak, JI | 1 |
| Ward, GS | 1 |
| Elwell, MR | 1 |
| Tingpalapong, M | 1 |
| Pomsdhit, J | 1 |
| Podusovskiĭ, VF | 1 |
| Manastyrskaia, OS | 1 |
| Leahy, F | 1 |
| deSa, D | 1 |
| Zykov, MP | 2 |
| Patel, RI | 1 |
| Nyka, W | 1 |
| O'Neill, EF | 1 |
| Mathur, AK | 1 |
| Vil'derman, AM | 3 |
| Alarcón-Segovia, D | 2 |
| Fishbein, E | 2 |
| Reyes, PA | 1 |
| Díes, H | 1 |
| Shwadsky, S | 1 |
| Citron, KM | 2 |
| Dhar, S | 1 |
| Kennedy, I | 1 |
| Halper, AR | 1 |
| Mkutu, MP | 1 |
| Halper, S | 1 |
| Sen, PK | 2 |
| Chatterjee, R | 2 |
| Saha, JR | 2 |
| Eule, H | 2 |
| Kromberg, M | 1 |
| Maisey, DN | 1 |
| Day, JL | 1 |
| Boman, G | 4 |
| Ringberger, VA | 1 |
| Good, AE | 2 |
| Green, RA | 1 |
| Zarafonetis, CJ | 1 |
| Cannat, A | 1 |
| Seligmann, M | 1 |
| Bansal, OP | 1 |
| Wahal, PK | 1 |
| Atal, PR | 1 |
| Lequesne, M | 1 |
| Shefer, LB | 1 |
| Rodríguez, A | 1 |
| Fernández, E | 1 |
| Fendall, R | 1 |
| Aquinas, M | 1 |
| Radenac, H | 1 |
| Burzoni, FJ | 2 |
| Chicou, FJ | 2 |
| Leonelli, C | 1 |
| Papillon, FH | 1 |
| Pawczyński, C | 3 |
| Girshov, BD | 1 |
| Glushachenko, GI | 1 |
| Benhassine, M | 1 |
| Förström, L | 1 |
| Hannuksela, M | 1 |
| Pejovic, H | 1 |
| Cacciatore, R | 1 |
| Valdez, H | 1 |
| Sanders, WE | 1 |
| Kekhaiov, IR | 1 |
| Radner, DB | 1 |
| Abbott, MR | 1 |
| Pierson, DJ | 1 |
| Petty, TL | 1 |
| Jones, JM | 1 |
| Wahlen, A | 1 |
| Stollenwerk, M | 1 |
| Swinburn, PD | 1 |
| McGregor, DD | 2 |
| Kaupas, V | 2 |
| Regli, J | 1 |
| Ziegler, WJ | 1 |
| Burkes, J | 1 |
| Ursov, IG | 1 |
| L'vova, KD | 1 |
| Deshayes, P | 1 |
| Houdent, G | 1 |
| Lemercier, JP | 1 |
| Desseauve, P | 1 |
| Simonin, JL | 1 |
| Radanov, R | 1 |
| Spasova, N | 1 |
| Kalfin, E | 1 |
| Degtiarev, VP | 1 |
| Charachon, R | 1 |
| Junien-Lavillauroy, C | 1 |
| Roux, O | 1 |
| Faivre, A | 1 |
| Monroe, JF | 1 |
| Meyer, A | 1 |
| Hokama, S | 3 |
| Toida, I | 1 |
| Ando, F | 1 |
| Yamamoto, S | 1 |
| Ruffino, J | 2 |
| Tubiana, M | 1 |
| Serizay, B | 1 |
| Demonet, B | 1 |
| Charles, A | 1 |
| Matsumiya, T | 2 |
| Marien, C | 1 |
| Jagueux, M | 1 |
| Makarevich, NM | 1 |
| Bethge, H | 1 |
| Manning, PJ | 1 |
| Clarkson, TB | 1 |
| Zaki, MH | 2 |
| Hudson, LD | 1 |
| Decroix, G | 2 |
| Pujet, JC | 2 |
| Mafart, Y | 1 |
| Barranger, C | 1 |
| Houdard, C | 1 |
| Boury, G | 1 |
| Favre, M | 1 |
| Lancastre, F | 1 |
| Le Fichoux, Y | 1 |
| Blanchon, P | 1 |
| Paillas, J | 1 |
| Holler, A | 1 |
| Groseille, Y | 1 |
| Blanchon, B | 1 |
| Blanchon, F | 1 |
| Viteau, JM | 1 |
| Toulet, J | 1 |
| Plonteux, G | 1 |
| Abiven, M | 1 |
| Bonfante, N | 1 |
| Nielsen, E | 1 |
| Härö, AS | 1 |
| Hjaltested, OP | 1 |
| Levin, ML | 1 |
| Vella, EE | 1 |
| Peters, U | 1 |
| Hausamen, TU | 1 |
| Grosse-Brockhoff, F | 1 |
| Buechner, HA | 1 |
| Cornet, A | 1 |
| Dubrisay, J | 1 |
| Barbier, JP | 1 |
| Hirsch, JF | 1 |
| Carnot, F | 1 |
| Sharov, GI | 1 |
| Gel'berg, SI | 1 |
| Peschanskiĭ, VS | 1 |
| Geering, JM | 1 |
| Ruch, W | 1 |
| Dettli, L | 1 |
| Allan, WG | 1 |
| Perel'man, AE | 2 |
| Ashmarin, IP | 1 |
| Gaber, IE | 2 |
| Goriukhina, OA | 1 |
| Bayliss, CG | 1 |
| Miller, CT | 1 |
| Larbaoui, D | 1 |
| Lewis, JH | 1 |
| Gregg, DB | 1 |
| Johnson, MW | 1 |
| Anttolainen, I | 1 |
| Runyon, EH | 1 |
| Varughese, P | 1 |
| Hodgkin, MM | 3 |
| Hsu, AH | 1 |
| McRae, KB | 1 |
| Woolpert, SF | 1 |
| Feldmann, G | 1 |
| Boivin, P | 1 |
| Troube, H | 1 |
| Boucherot, J | 1 |
| Penaud, J | 1 |
| Guibout, P | 1 |
| Hubaytar, R | 1 |
| Rudescu, D | 1 |
| Petre, A | 1 |
| Gould, DB | 1 |
| Falcao, H | 1 |
| Galdabini, J | 1 |
| Hurwitz, A | 1 |
| Schlozman, DL | 1 |
| Brummer, DL | 2 |
| Ozgen, ZS | 1 |
| Neumann, G | 1 |
| Ashba, JK | 1 |
| Boyce, JM | 1 |
| Telejko, Z | 1 |
| Aach, R | 1 |
| Kissane, J | 1 |
| Cappucci, DT | 1 |
| O'Shea, JL | 1 |
| Smith, GD | 1 |
| Davidson, FF | 2 |
| Dürr, DK | 1 |
| Chaves-Carballo, E | 1 |
| Sanchez, GA | 1 |
| Douma, J | 2 |
| Moss, JD | 1 |
| Lewis, JE | 1 |
| Knauer, CM | 1 |
| Proust, A | 1 |
| Evans, C | 1 |
| Kisielewicz, J | 1 |
| Dobrzyński, W | 1 |
| Joblonowski, Z | 1 |
| Kociecka, I | 1 |
| Turczynowski, R | 1 |
| Schmidt, W | 1 |
| Nagy, E | 1 |
| Mészáros, C | 1 |
| Somlyói, I | 1 |
| Frank, GL | 1 |
| Roulet, H | 1 |
| Poti, SJ | 1 |
| Wilson, EA | 1 |
| Thelin, TJ | 1 |
| Dilts, PV | 1 |
| Wiza, J | 1 |
| Rudnicka, M | 1 |
| Szymaczek-Meyer, L | 1 |
| Russell, SL | 1 |
| Russell, DW | 2 |
| Taylor, SL | 2 |
| Dascomb, HE | 2 |
| Ziskind, MM | 3 |
| Samuels, MS | 1 |
| Ziskind, M | 1 |
| DeRouen, TA | 2 |
| Wolf, FS | 2 |
| Bowersox, DW | 1 |
| Wintebauer, RH | 1 |
| Stewart, GL | 1 |
| Orme, B | 1 |
| Barron, E | 1 |
| Thompson, DH | 1 |
| Carson, B | 1 |
| Ellinoy, BJ | 1 |
| Mays, JF | 1 |
| McSherry, PV | 1 |
| Rosenthal, LC | 1 |
| Lallemant, Y | 1 |
| Gehanno, P | 1 |
| Flieder, J | 1 |
| Texter, EC | 1 |
| Boitnott, JK | 1 |
| Westley, TA | 1 |
| Baugh, DO | 1 |
| Randa, D | 1 |
| Rabinovich, S | 1 |
| Jeanes, CW | 1 |
| Schaefer, O | 1 |
| Mikkelson, MK | 1 |
| Snoke, AT | 1 |
| Sharp, C | 1 |
| Westley, T | 1 |
| Vall-Spinosa, A | 2 |
| Savula, MM | 1 |
| Mattson, K | 1 |
| Víznerová, A | 2 |
| Havlík, I | 1 |
| Slavíková, Z | 1 |
| Schmidt, H | 1 |
| Dimov, D | 1 |
| Dahlström, G | 1 |
| Hanngren, A | 3 |
| Stavenow, S | 1 |
| Wiman, LG | 1 |
| Arkhipova, OP | 1 |
| Gross, NJ | 1 |
| Frenkel, LD | 1 |
| Lynch, JM | 1 |
| Quigley, CF | 1 |
| Cox, E | 1 |
| Grzybowshi, S | 1 |
| Rohwedder, JJ | 1 |
| Postlethwaite, AE | 1 |
| Bartel, AG | 1 |
| Kelley, WN | 1 |
| Homberg, JC | 1 |
| Plomteux, G | 1 |
| Heusghem, C | 1 |
| Ferdinande, R | 1 |
| Lecoq, A | 1 |
| Winandy, A | 1 |
| Parmentier, JC | 1 |
| Nebout, T | 1 |
| Dhumeaux, D | 1 |
| Berthelot, P | 1 |
| Pollak, B | 1 |
| Karagoz, A | 1 |
| Weill, H | 1 |
| Jackson, HA | 1 |
| Saraux, H | 1 |
| Bechetoille, A | 1 |
| Nou, B | 1 |
| Page, JR | 1 |
| Jash, DK | 1 |
| Levaditi, JC | 1 |
| Kosloff-Sénéchal, F | 1 |
| Balouet, G | 1 |
| Augier, J | 2 |
| Belzer, IS | 1 |
| Weber, JC | 1 |
| Kok-Jensen, A | 1 |
| Protivinsky, R | 1 |
| Gadebusch, HH | 1 |
| Donovick, R | 1 |
| Spada, S | 1 |
| Kazakov, KS | 1 |
| Chernogradskiĭ, IP | 1 |
| Kalow, W | 1 |
| El'nik, VI | 1 |
| Coudray, P | 1 |
| Boytar, V | 1 |
| Johnson, GE | 1 |
| Heaf, F | 1 |
| Posner, E | 1 |
| Yoshida, K | 1 |
| Bibik, NF | 1 |
| Motomiya, M | 1 |
| Sato, H | 1 |
| Fujimoto, M | 1 |
| Sugi, H | 1 |
| Vinnik, LA | 1 |
| Mauss, H | 1 |
| Di Filippo, A | 1 |
| Woodruff, CE | 1 |
| Howard, WL | 1 |
| Klopfenstein, MD | 1 |
| Steininger, WJ | 1 |
| Giza, T | 1 |
| Hanicka, M | 1 |
| Herman, T | 1 |
| Jelonek, A | 1 |
| Kurdzielewicz, J | 1 |
| Rembiesowa, H | 1 |
| Rudnik, J | 1 |
| Wójciak, W | 1 |
| Esipovich, EI | 1 |
| Ivanitskaia, NN | 3 |
| Markovic, J | 1 |
| Termine, A | 1 |
| Natali, P | 1 |
| Sarrat, H | 1 |
| Solov'ev, VN | 2 |
| Beck, AD | 1 |
| Clarke, GL | 1 |
| Schmidt, JP | 1 |
| Erhard, G | 1 |
| Lubenson, AS | 1 |
| Iodice, F | 1 |
| Razza, I | 1 |
| Verbist, L | 1 |
| Gillet, P | 1 |
| Rozniecki, J | 1 |
| Tomaszkiewicz, L | 1 |
| Bechcińska, B | 1 |
| Cyperling, I | 1 |
| Fabbrocini, V | 1 |
| Tizes, R | 2 |
| Godinez, F | 1 |
| Seeliger, HP | 1 |
| Ahiaku-Brew, C | 1 |
| Bercea, O | 1 |
| Bonciocat, N | 1 |
| Shaw, NM | 1 |
| Basu, AK | 1 |
| Kartseva, TM | 1 |
| Douady, D | 1 |
| Jeanguyot, MT | 1 |
| Rosembaum, SB | 1 |
| Sibilla, S | 2 |
| Steiner, M | 2 |
| Portugaleza, C | 1 |
| Lafont, J | 1 |
| Lafont, P | 1 |
| Havel, A | 2 |
| Stadler, ET | 1 |
| Bonforte, RJ | 1 |
| Gribetz, I | 1 |
| Lester, TW | 1 |
| Chorba, RW | 1 |
| Sanders, JL | 1 |
| Gorislavets, II | 1 |
| Kessler, R | 1 |
| Adámek, L | 1 |
| Simonová, S | 1 |
| Smirnov, VD | 1 |
| Ota, Y | 1 |
| Nemsadze, MN | 1 |
| Yamaguchi, J | 1 |
| Ariji, F | 1 |
| Madokoro, K | 1 |
| Kumano, N | 1 |
| de Beco, O | 1 |
| Polascik, M | 1 |
| Golden, B | 1 |
| Slagel, WA | 1 |
| Noble, J | 2 |
| Clayton, LB | 1 |
| Jenkins, D | 1 |
| Rosenblatt, WF | 1 |
| Longstreth, GF | 1 |
| Newcomer, AD | 1 |
| Westbrook, PR | 1 |
| Mordasini, ER | 1 |
| Dantzker, DR | 1 |
| Steinberg, HN | 1 |
| Kmiecik, JE | 1 |
| Abdullina, ZR | 1 |
| Poffenbarger, PL | 1 |
| Byrd, CB | 1 |
| Nelson, R | 1 |
| Elliott, RC | 1 |
| Garibaldi, RA | 1 |
| Drusin, RE | 1 |
| Gregg, MB | 1 |
| Dove, JT | 1 |
| Chaparas, SD | 1 |
| Hedrick, SR | 1 |
| Refshauge, WD | 1 |
| Ward, AS | 1 |
| Narain, R | 3 |
| Mayurnath, S | 3 |
| Rao, MS | 2 |
| Murthy, SS | 2 |
| Sharma, OP | 1 |
| Kester, NM | 1 |
| Midholm, A | 2 |
| Brahe-Pedersen, C | 1 |
| Ogawa, T | 1 |
| Motomura, K | 1 |
| Shub, C | 1 |
| Salmonsen, PC | 1 |
| Jordan, JE | 1 |
| Hofmann, MA | 1 |
| Alexander, BB | 1 |
| Pedersen, CB | 1 |
| Ashmarin, IN | 1 |
| Strandgaard, E | 1 |
| Dettlaff, Z | 1 |
| Zettler, H | 1 |
| Knebel, B | 1 |
| Venho, VM | 1 |
| Koskinen, R | 1 |
| Poole, G | 1 |
| Stradling, P | 1 |
| Worlledge, S | 1 |
| Young, RC | 1 |
| Griffith, PA | 1 |
| Perrin, P | 1 |
| DiPalma, JR | 1 |
| Bauer, H | 1 |
| Meijer, J | 2 |
| Bignall, JR | 1 |
| Lehmann, J | 1 |
| Taylor, LL | 1 |
| Pastor, JR | 1 |
| Bjartveit, K | 1 |
| Gemperli, R | 1 |
| Kováts, F | 1 |
| Riska, N | 2 |
| Vivenzio, L | 1 |
| Avery, ME | 1 |
| Wolfsdorf, J | 1 |
| Weber, WW | 1 |
| Khoury, SA | 1 |
| Theodore, A | 1 |
| Platte, VJ | 1 |
| Durfee, ML | 1 |
| Nemir, RL | 1 |
| Sewell, EM | 1 |
| Warren, BJ | 1 |
| Timoshenko, AS | 1 |
| Bagga, AS | 1 |
| Naganna, K | 1 |
| Lebedeva, LV | 2 |
| Kanevskaia, SS | 1 |
| Grebenkina, AI | 1 |
| Mason, E | 1 |
| Rao, KV | 1 |
| Menon, NK | 1 |
| Bush, OB | 1 |
| Sugimoto, M | 1 |
| Fujii, Y | 1 |
| Brown, FA | 1 |
| Horwitz, O | 1 |
| Payne, PG | 1 |
| Dixon, FR | 1 |
| Feldman, J | 1 |
| Korotaev, GA | 2 |
| Betancourt, VM | 1 |
| Lukjan, Z | 1 |
| Rogowski, F | 1 |
| Oleński, J | 1 |
| Howells, G | 1 |
| Koviazina, AI | 1 |
| Butkina, TK | 1 |
| Thompson, JE | 1 |
| Batiashvili, OG | 1 |
| Gogebashvili, NV | 1 |
| Mattila, MJ | 1 |
| Nieminen, E | 1 |
| Tiitinen, H | 1 |
| Uçak, D | 1 |
| Uçak, A | 1 |
| Durante, C | 1 |
| Ras, R | 1 |
| Powell, SM | 1 |
| Tyler, JM | 2 |
| Kutt, H | 2 |
| Brennan, R | 1 |
| Dehejia, H | 1 |
| Verebely, K | 1 |
| Sunahara, S | 2 |
| Griesbach, R | 1 |
| Gottwald, W | 1 |
| Katz, GA | 1 |
| Jobin, GC | 1 |
| Ashley, MJ | 1 |
| Koch-Weser, D | 1 |
| Chodosh, PL | 1 |
| Willis, W | 1 |
| Mair, IW | 1 |
| Johannessen, TA | 1 |
| Borgå, O | 2 |
| Sjöqvist, F | 2 |
| Hanzel, GD | 1 |
| Rosenthal, SR | 1 |
| Unholtz, K | 1 |
| Malmborg, AS | 1 |
| Efremova, ZR | 1 |
| Galkeeva, TN | 1 |
| Semenov, AD | 1 |
| Migulina, VM | 1 |
| Zlatkina, TI | 1 |
| Hanoteau, J | 1 |
| Rudesco, D | 1 |
| Sachs, JM | 1 |
| Miller, CH | 1 |
| Bagchi, AK | 1 |
| Pain, HP | 1 |
| Repo, K | 1 |
| Azhipa, IaI | 1 |
| Cherednichenko, LP | 2 |
| Strang, EJ | 1 |
| Hollins, PJ | 1 |
| Simmons, AV | 1 |
| Zhoglo, SI | 1 |
| Drutel, P | 1 |
| Bréfort, G | 1 |
| Rajtar-Leontiew, Z | 2 |
| Wernsdorfer, G | 1 |
| Wernsdorfer, WH | 1 |
| Kradolfer, F | 4 |
| Rudaĭtene, AP | 1 |
| Nickling, HG | 1 |
| Fukuhara, T | 1 |
| Sasaoka, A | 1 |
| Mitsui, M | 1 |
| Tveit, J | 1 |
| Schnell, R | 1 |
| Line, DH | 1 |
| Seitanidis, B | 1 |
| Morgan, JO | 1 |
| Hoffbrand, AV | 1 |
| Derrlaff, Z | 1 |
| Blisse, A | 1 |
| Rao, PN | 1 |
| Bhat, KS | 1 |
| Leal, F | 1 |
| Guillermand, J | 1 |
| Morilleau, R | 1 |
| Fremond, Y | 1 |
| Vaccon, G | 1 |
| Lesnaia, AA | 1 |
| Kalb, JC | 1 |
| Pujol, M | 1 |
| Pallanza, R | 1 |
| Furesz, S | 1 |
| Bolzoni, G | 1 |
| Blattner, RJ | 1 |
| Govindaraj, M | 1 |
| Grant, LJ | 1 |
| Jerde, OM | 1 |
| Batten, JC | 1 |
| Woźniak, W | 1 |
| Szepietowska, B | 1 |
| Werakso, B | 1 |
| Duboczy, BO | 1 |
| Reid, LR | 1 |
| Rabinovich, IM | 1 |
| Kropachev, VA | 1 |
| Trukhmanova, LB | 1 |
| Markelova, TM | 1 |
| Heyworth, F | 1 |
| Reimann, U | 1 |
| Matzeu, M | 1 |
| Edmond, E | 1 |
| Keay, AJ | 1 |
| Wallace, A | 1 |
| Nazarenko, GG | 1 |
| Marschke, G | 1 |
| Whittington, HG | 1 |
| Grey, L | 1 |
| Cugell, DW | 1 |
| Hepper, NG | 1 |
| Pierce, AK | 1 |
| Erdélyi, B | 1 |
| Fenyvesi, E | 1 |
| Robinson, MG | 1 |
| Foadi, M | 1 |
| Brummer, DI | 1 |
| Busygina, RN | 1 |
| Draganiuk, KA | 1 |
| Ezerskiĭ, VF | 1 |
| Kandt, D | 1 |
| Flach, W | 1 |
| Strakhova, VM | 1 |
| Titel'man, KM | 1 |
| Ebina, T | 1 |
| Kayaba, K | 1 |
| Kudo, S | 1 |
| Tanno, S | 1 |
| Eskenasy, A | 1 |
| Glass, F | 1 |
| Mallach, HJ | 1 |
| Simsch, A | 1 |
| Yue, WY | 1 |
| Haapanen, JH | 1 |
| Wiśniewski, K | 1 |
| Granda, J | 1 |
| Winters, W | 1 |
| McDowell, FH | 1 |
| Tsuji, K | 1 |
| Smith, JM | 1 |
| Markkanen, T | 1 |
| Levanto, A | 1 |
| Sallinen, V | 1 |
| Salmela, E | 1 |
| Seki, S | 2 |
| Bigman, O | 1 |
| Berger, ME | 1 |
| Belinskiĭ, AN | 1 |
| Palleschi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Addressing Challenges in Scaling up TB and HIV Treatment Integration in Public Health Settings in South Africa[NCT02654613] | 8,000 participants (Actual) | Interventional | 2015-06-01 | Completed | |||
| A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People With Diabetes[NCT04600167] | Phase 3 | 3,000 participants (Anticipated) | Interventional | 2022-06-17 | Recruiting | ||
| Multicentre Clinical Trial to Assess the Performance of the Xpert MTB/XDR Assay for INH- and Second-line Resistance Detection[NCT03728725] | 710 participants (Actual) | Observational | 2019-07-11 | Completed | |||
| Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention: the 3HP Options Implementation Trial[NCT03934931] | 1,656 participants (Actual) | Interventional | 2020-07-13 | Active, not recruiting | |||
| A Prospective Multicenter Phase II-study: Pharmacokinetics and Safety of High-Dose Rifampicin and Pyrazinamide in a Shorter Tuberculosis Treatment Compared With Standardized Treatment in Patients With Mild to Moderate Pulmonary TB[NCT04694586] | Phase 2 | 40 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Preventing Mycobacterium Tuberculosis Infection in HIV-Exposed Infants[NCT02613169] | Phase 2 | 300 participants (Actual) | Interventional | 2016-08-31 | Completed | ||
| Novel TB Prevention Regimens for HIV-Infected Adults[NCT00057122] | Phase 3 | 1,148 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Electronic Pillbox-enabled Self-administered Therapy Versus Standard Directly Observed Therapy for Tuberculosis Medication Adherence and Treatment Outcomes in Ethiopia: a Multicenter Randomized Controlled Trial[NCT04216420] | 114 participants (Actual) | Interventional | 2020-06-01 | Completed | |||
| Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection[NCT01404312] | Phase 3 | 3,000 participants (Actual) | Interventional | 2012-05-23 | Completed | ||
| A Phase IV Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Safety of Immediate (Antepartum-Initiated) Versus Deferred (Postpartum-Initiated) Isoniazid Preventive Therapy Among HIV-Infected Women in High Tuberculosis (TB) Incidence Setting[NCT01494038] | Phase 4 | 956 participants (Actual) | Interventional | 2014-08-19 | Completed | ||
| TB Screening Improves Preventive Therapy Uptake Trial[NCT04557176] | 1,719 participants (Actual) | Interventional | 2020-11-16 | Active, not recruiting | |||
| A Pilot Clinical Trial Characterizing Use of Ingestion Sensor Enabled Rifamate in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis[NCT01960257] | Phase 4 | 92 participants (Actual) | Interventional | 2013-10-25 | Completed | ||
| Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months for Tuberculosis Preventive Treatment: A Randomized Controlled Study in China[NCT02430259] | Phase 3 | 566 participants (Anticipated) | Interventional | 2015-03-31 | Completed | ||
| Safety, Tolerability, and Drug-drug Interactions of Short-course Treatment of Latent Tuberculosis Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventative Therapy Among HIV-infected Patients Taking Dolutegravir-based Antiretro[NCT03435146] | Phase 1/Phase 2 | 135 participants (Actual) | Interventional | 2018-01-18 | Completed | ||
| An Observational Study of Salivary Versus Blood Concentrations of Various Anti-Tuberculosis Drugs in Tuberculosis Patients[NCT03080012] | 24 participants (Actual) | Observational | 2017-03-07 | Completed | |||
| A Randomized Trial to Compare Effectiveness of 4 Months Rifampin (4 RIF) With 9 Months Isoniazid (9 INH) in the Prevention of Active TB in Children: The P4v9 Trial[NCT00170209] | Phase 3 | 844 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Randomized Clinical Trial of 4 Months of Rifampin vs. 9 Months of Isoniazid for Latent Tuberculosis Infection. Part 3 - Effectiveness[NCT00931736] | Phase 3 | 6,031 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| A Randomized, Partially-blinded, Clinical Trial of Isoniazid and Rifapentine (3HP) Therapy to Prevent Pulmonary Tuberculosis in High-risk Individuals Identified by a Transcriptomic Correlate of Risk[NCT02735590] | Phase 2/Phase 3 | 2,927 participants (Actual) | Interventional | 2016-09-20 | Active, not recruiting | ||
| TBTC Study 28: Evaluation of a Moxifloxacin-based, Isoniazid-sparing Regimen for Tuberculosis Treatment[NCT00144417] | Phase 2 | 433 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| TBTC Study 27: An Evaluation of the Activity and Tolerability of Moxifloxacin During the First Two Months of Treatment for Pulmonary Tuberculosis--A Double-Blind, Randomized, Multicenter Study by the Tuberculosis Trials Consortium[NCT00140309] | Phase 2 | 350 participants | Interventional | 2003-07-31 | Completed | ||
| A Multiple Arm, Multiple Stage, Phase 2, OL, Randomized, Controlled Trial to Evaluate 4 Treatment Regimens of SQ109, Increased Doses of Rifampicin, and Moxifloxacin in Adults With Newly Diagnosed, Smear-positive Pulmonary Tuberculosis[NCT01785186] | Phase 2 | 365 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Essentiality of Isoniazid in Tuberculosis Therapy[NCT01589497] | Phase 2 | 69 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Drinkers' Intervention to Prevent Tuberculosis (DIPT Study)[NCT03492216] | 680 participants (Actual) | Interventional | 2018-04-16 | Completed | |||
| A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women With Latent Tuberculosis Infection[NCT02651259] | Phase 1/Phase 2 | 50 participants (Actual) | Interventional | 2017-03-13 | Completed | ||
| An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz (EFV) in Women Co-infected With Human Immunodeficiency Virus (HIV) and Tuberculosis (TB)[NCT02412436] | Phase 2 | 62 participants (Actual) | Interventional | 2015-11-03 | Completed | ||
| Community Intervention for Tuberculosis Active Contact Tracing and Preventive Therapy - a Cluster Randomized Study (CONTACT)[NCT03832023] | 1,400 participants (Actual) | Interventional | 2019-10-14 | Completed | |||
| Sustainable East Africa Research in Community Health[NCT01864603] | 150,395 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| A Phase II Trial to Describe the Pharmacokinetics, Safety and Efficacy of Pharmacogenetics-guided Dosing of Isoniazid in Patients With HIV-associated TB[NCT05124678] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-12-07 | Recruiting | ||
| Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)[NCT00495651] | Phase 3 | 2,073 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Leveraging mHealth to Enable and Adapt Community Health Worker Strategies to Improve TB/HIV Patient Outcomes in South Africa (LEAP-TB-SA) Trial[NCT04298905] | 200 participants (Anticipated) | Interventional | 2022-03-10 | Recruiting | |||
| A Prospective Study of Shortening the Duration of Standard Short Course Chemotherapy From 6 Months to 4 Months in HIV-non-infected Patients With Fully Drug-Susceptible, Non-cavitary Pulmonary Tuberculosis With Negative Sputum Cultures After 2 Months of An[NCT00130247] | Phase 3 | 394 participants (Actual) | Interventional | 2002-04-08 | Completed | ||
| An Open Label Randomized Controlled Clinical Trial Comparing a 24Week Oral Regimen Containing Moxifloxacin With a 24 Week Standard Drug Regimen for the Treatment of Smear-positive Pulmonary Tuberculosis in Patients Previously Treated for TB[NCT02114684] | Phase 1/Phase 2 | 197 participants (Actual) | Interventional | 2013-11-30 | Completed | ||
| Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial[NCT05215990] | Phase 1/Phase 2 | 80 participants (Anticipated) | Interventional | 2022-01-15 | Recruiting | ||
| One-month Latent Tuberculosis Treatment for Renal Transplant Candidates[NCT05411744] | Phase 4 | 25 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| 2R2: Higher Dose Rifampin for 2 Months vs Standard Dose Rifampin for Latent TB: a 3-arm Randomized Trial.[NCT03988933] | Phase 2 | 1,368 participants (Actual) | Interventional | 2019-09-20 | Active, not recruiting | ||
| Early Risk Assessment in TB contactS by New Diagnostic tEsts[NCT04781257] | 2,100 participants (Anticipated) | Observational | 2021-03-01 | Active, not recruiting | |||
| Safety of Rifampicin at High Dose for the Treatment of Adult Subjects With Complex Drug Susceptible Pulmonary and Extrapulmonary Tuberculosis[NCT04768231] | Phase 2 | 130 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| A Randomized, Placebo-Controlled Study of Limited vs. Continuous Isoniazid Tuberculosis Preventive Therapy in HIV-infected Persons in Botswana[NCT00164281] | Phase 4 | 2,000 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Impact of TB Preventive Therapy for HIV/TB Co-infected Patients With Access to Highly Active Antiretroviral Therapy in Rio de Janeiro, Brazil: A Phased Implementation Trial[NCT00107887] | Phase 4 | 17,415 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| PROvide MIner-friendly SErvices for Integrated TB/HIV Care in Lesotho Study (PROMISE Study)[NCT03537872] | 248 participants (Actual) | Interventional | 2018-03-13 | Completed | |||
| URBAN ARCH (3/5) Uganda Cohort TB Preventive Therapy for HIV-infected Alcohol Users in Uganda: an Evaluation of Safety Tolerability and Adherence[NCT03302299] | Phase 4 | 302 participants (Actual) | Interventional | 2017-04-07 | Completed | ||
| Phase I Study of Whether Preclearance of Latent M. Tuberculosis (MTB) Infection With Isoniazid (INH) Enhances Specific Immune Responses to MTB Following Subsequent BCG Revaccination in Healthy, HIV-Uninfected, Tuberculin Skin Test Positive Adults[NCT01119521] | Phase 1 | 82 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Randomized, Four-arm Open Label Phase Two-b Clinical Trial to Evaluate the Pharmacokinetics, Safety/Tolerability and Efficacy of High Dose Rifampicin in TB-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy[NCT03982277] | Phase 2 | 130 participants (Actual) | Interventional | 2019-04-30 | Completed | ||
| Estimation of Plasma Free and Total Drug Levels of Rifampicin, Isoniazid and Pyrazinamide in Patients on Antituberculosis Therapy and Its Correlation With Development of Drug Induced Hepatotoxicity[NCT01456845] | 110 participants (Actual) | Observational | 2010-08-31 | Completed | |||
| TB Treatment Support Tools: Refinement and Evaluation of an Interactive Mobile App and Direct Adherence Monitoring on TB Treatment Outcomes[NCT04221789] | 555 participants (Actual) | Interventional | 2020-11-17 | Active, not recruiting | |||
| Randomized Non-inferiority Trial Comparing the Nevirapine-based Antiretroviral Therapy Versus the Standard Efavirenz-based ART for the Treatment of HIV-TB Co-infected Patients on Rifampicin-based Therapy (ANRS 12146 CARINEMO)[NCT00495326] | Phase 2/Phase 3 | 570 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents[NCT03230409] | 359 participants (Actual) | Interventional | 2014-01-01 | Completed | |||
| Long Term Study of 2 Isoniazid (INH) Prophylactic Regimens With Concomitant Cotrimoxazole (CTX) in HIV-infected Children - Impact on Morbidity, Mortality, Bacterial Resistance and Incidence of Tuberculosis[NCT00330304] | Phase 3 | 450 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| TBTC Study 24: A Non-Comparative Study of the Efficacy of a Largely-Intermittent, Six-Month Tuberculosis Treatment Regimen Among Patients Who Will Not Receive Isoniazid Due to Initial Isoniazid Resistance or Intolerance[NCT00023374] | 98 participants (Actual) | Interventional | 2000-08-31 | Completed | |||
| A Randomized Double Blind Placebo Controlled Trial of Adjunctive Dexamethasone for the Treatment of HIV-infected Adults With Tuberculous Meningitis[NCT03092817] | Phase 3 | 520 participants (Actual) | Interventional | 2017-05-25 | Active, not recruiting | ||
| A Randomized Double Blind Placebo Controlled Non-inferiority Trial of Adjunctive Dexamethasone for the Treatment of HIV-uninfected Adults With Tuberculous Meningitis Stratified by Leukotriene A4 Hydrolase Genotype[NCT03100786] | Phase 3 | 640 participants (Anticipated) | Interventional | 2018-02-08 | Recruiting | ||
| Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study[NCT02816931] | 37 participants (Actual) | Observational | 2016-03-31 | Completed | |||
| An Open Label, Randomized Controlled Trial to Establish the Efficacy and Safety of a Study Strategy Consisting of 6 Months of Bedaquiline (BDQ), Delamanid (DLM), and Linezolid (LNZ), With Levofloxacin (LVX) and Clofazimine (CFZ) Compared to the Current So[NCT04062201] | Phase 3 | 402 participants (Actual) | Interventional | 2019-08-22 | Active, not recruiting | ||
| Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis[NCT03827811] | 625 participants (Anticipated) | Observational | 2020-01-30 | Recruiting | |||
| Micronutrient Supplementation in Conjunction With Standard Anti-Tuberculosis Therapy in Paediatric (6 Months-15 Years) New Pulmonary Tuberculosis Patients[NCT00801606] | Phase 3 | 403 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Pharmacokinetics of Rifabutin Combined With Antiretroviral Therapy in the Treatment of Tuberculosis Patient With HIV Infection in South Africa: A Phase II Trial[NCT00640887] | Phase 2 | 48 participants (Anticipated) | Interventional | 2009-02-28 | Completed | ||
| The Prophylaxis of Tuberculosis According to TSPOT Results After Kidney Transplantation (PTTKT):Protocol for an Open-label, Prospective, Randomized, 3-arm, Controlled Trial[NCT05249699] | 303 participants (Anticipated) | Interventional | 2022-04-01 | Not yet recruiting | |||
| A Prospective, Randomized Controlled Study for the Efficacy and Safety of the Substitution of Pyrazinamide and Ethambutol With Moxifloxacin During the Intensive Phase of Treatment of Pulmonary Tuberculosis[NCT04187469] | 286 participants (Anticipated) | Interventional | 2020-03-01 | Not yet recruiting | |||
| Does Providing Medical Personnel in the AMPATH Network With Patient-specific Reminders Regarding TB That Are Generated From a Patient's EMR Improve the Prevalence of IPT Initiation and Decrease the Time From Screening to Treatment?[NCT01934309] | 3,782 participants (Actual) | Interventional | 2013-09-30 | Completed | |||
| A Multicenter Clinical Trial to Evaluate the Feasibility and Outcome of Same-day Antiretroviral Therapy With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) Among Patients Testing Positive by HIV Confirmatory Tests[NCT04712058] | 200 participants (Anticipated) | Interventional | 2021-01-20 | Recruiting | |||
| Same Day Community-based ART Initiation Versus Clinic-based Pre-ART Assessment and Counselling for Individuals Newly Tested HIV-positive During Community-based HIV Testing in Rural Lesotho - a Randomized Controlled Trial[NCT02692027] | Phase 3 | 276 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Phase II Double-blinded Randomized Controlled Evaluation of MVA85A/AERAS-485 for Safety, Immunogenicity and Prevention of Tuberculosis in BCG-vaccinated, HIV-negative Infants[NCT00953927] | Phase 2 | 2,797 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Reducing Early Mortality and Early Morbidity by Empiric Tuberculosis Treatment Regimens (REMEMBER)[NCT01380080] | Phase 4 | 851 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Global Consortium for Drug-resistant Tuberculosis Diagnostics[NCT02170441] | 1,128 participants (Actual) | Observational | 2012-04-30 | Completed | |||
| TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection[NCT00023452] | Phase 3 | 8,053 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
| Efficacy of Risk-Targeted Video Based Directly on Observed Therapy for Latent TB[NCT03783728] | 0 participants (Actual) | Observational | 2019-06-30 | Withdrawn (stopped due to Investigator is leaving the University) | |||
| Feasibility, Accuracy, and Effect of Point-of-care Xpert MTB/RIF Ultra and Xpert MTB/RIF Ultra Testing in Patients Suspected of Having TB: a Randomised Controlled Trial[NCT03356925] | 1,549 participants (Actual) | Interventional | 2018-02-06 | Completed | |||
| Multi Center Clinical Research and Evaluation of Melting Technology for Rapid Detection of Drug Resistant Tuberculosis[NCT02776150] | 3,100 participants (Anticipated) | Observational | 2016-05-31 | Not yet recruiting | |||
| DARDAR Health Project (Disseminated Tuberculosis and HIV Infection)[NCT00052195] | Phase 2/Phase 3 | 1,975 participants (Actual) | Interventional | 2001-09-30 | Completed | ||
| A Natural History Study of Tuberculosis in China; Correlates of a Successful Response to Treatment[NCT01071603] | 199 participants (Actual) | Observational | 2010-02-02 | Completed | |||
| Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI® Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Inf[NCT01136161] | Phase 2 | 95 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Demonstration of the Dynamic Hypothesis of Latent Tuberculosis Infection[NCT00905970] | 105 participants (Anticipated) | Observational | 2009-05-31 | Recruiting | |||
| Study of Latent Tuberculosis Infection (LTBI) by High Resolution Scanner[NCT00904956] | 12 participants (Anticipated) | Observational | 2009-11-30 | Recruiting | |||
| A Pharmacokinetics Study Comparing Lopinavir Plasma Exposure When Given as Lopinavir/Ritonavir (1:1) in the Presence of Rifampicin and Lopinavir/Ritonavir (4:1) Without Rifampicin in HIV and TB Co-infected Children in South Africa.[NCT02348177] | Phase 4 | 96 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Randomized Clinical Trial to Assess the Efficacy of Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis[NCT00376012] | Phase 3 | 300 participants (Actual) | Interventional | 2001-02-28 | Active, not recruiting | ||
| A Nurse Case Management Intervention to Improve MDR-TB/HIV Co-Infection Outcomes[NCT02129244] | 3,600 participants (Anticipated) | Interventional | 2014-10-31 | Active, not recruiting | |||
| Study of Safety and Efficacy of Different Regimes of Reintroduction of Anti-TB Drugs in Antituberculosis Treatment Induced Hepatotoxicity[NCT00405301] | Phase 4 | 175 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers[NCT02771249] | Phase 1 | 37 participants (Actual) | Interventional | 2016-06-03 | Completed | ||
| A Randomised, Pragmatic, Open-Label Trial To Evaluate The Effect Of Three Months Of High Dose Rifapentine Plus Isoniazid Administered As A Single Round Or Given Annually In HIV-Positive Individuals[NCT02980016] | Phase 3 | 4,027 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Primary Prophylaxis for Prevention of TB in Prison's Populations[NCT03028129] | Phase 4 | 467 participants (Actual) | Interventional | 2017-09-04 | Terminated (stopped due to Interim analysis showed efficacy less than 2.5%.) | ||
| A Randomized, Double Blind, Placebo Controlled Trial to Determine the Efficacy of Isoniazid (INH) in Preventing Tuberculosis Disease and Latent Tuberculosis Infection Among Infants With Perinatal Exposure to HIV[NCT00080119] | Phase 2/Phase 3 | 1,354 participants (Actual) | Interventional | 2004-02-29 | Terminated (stopped due to Data Safety Monitoring Board (DSMB) recommended stopping study due to futility) | ||
| A Prospective Observational Study of Usefulness of a T Cell-based Assay for Latent Tuberculosis Infection in Renal Transplant Recipients[NCT00682045] | 240 participants (Anticipated) | Observational | 2008-06-30 | Completed | |||
| DNA Sequencing of MDR TB in Eastern Siberia[NCT02508610] | 630 participants (Anticipated) | Observational | 2013-11-30 | Recruiting | |||
| A Randomized Clinical Trial of Early Empiric Anti-Mycobacterium Tuberculosis Therapy for Sepsis in Sub-Saharan Africa[NCT04618198] | Phase 3 | 436 participants (Anticipated) | Interventional | 2021-12-10 | Recruiting | ||
| Acceptability and Completion Rates of a New 12 Dose Treatment (3 Month) Compared to the Standard Treatment for Latent TB Infection Treatment[NCT02689089] | Phase 4 | 182 participants (Actual) | Interventional | 2016-11-28 | Completed | ||
| TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.[NCT01582711] | Phase 3 | 1,002 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [NCT00298870] | Phase 4 | 172 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Evaluation of Two Different Preventive Therapy Regimens for Tuberculosis in HIV Infected Persons[NCT00351702] | Phase 3 | 650 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| Comparison of Quantiferon-TB Gold Assay With Tuberculin Skin Testing for Detecting Latent Mycobacterium Tuberculosis Infection in Patients With Chronic Liver Disease Awaiting Liver Transplantation[NCT00402402] | Phase 4 | 300 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| Immune Activation and Drug Absorption in HIV-Infected Patients[NCT01845298] | 7 participants (Actual) | Interventional | 2014-06-30 | Completed | |||
| Evaluation of the Pharmacokinetics of Antituberculosis Drugs and Tuberculosis Treatment Outcomes in HIV-tuberculosis Co-infected Ugandan Adults[NCT01782950] | Phase 4 | 400 participants (Anticipated) | Interventional | 2013-02-28 | Recruiting | ||
| Double-Blind, Randomized, Placebo-Controlled Phase I Study, to Study the Tolerability and Immunogenicity of 4 RUTI Antituberculous Vaccine Different Doses (5, 25, 100 y 200µg of FCMtb) in Healthy Volunteers[NCT00546273] | Phase 1 | 24 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen[NCT00023361] | 215 participants | Interventional | 1999-02-28 | Completed | |||
| TBTC Study 23A: Pharmacokinetics of Intermittent Isoniazid and Rifabutin in USPHS Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen[NCT00023348] | Phase 2/Phase 3 | 150 participants | Interventional | 1999-07-31 | Completed | ||
| Role of Pseudomonas Aeruginosa Biofilms in Exacerbations in Patients With Bronchiectasis With and Without Chronic Obstructive Pulmonary Disease[NCT04803695] | 96 participants (Anticipated) | Observational | 2018-03-01 | Recruiting | |||
| Drugs for Treatment of Latent Tuberculosis Infection Objective 4: Identify Biomarkers for Clinical Trials of Drugs Active Against Latent TB[NCT00293228] | Phase 4 | 200 participants (Anticipated) | Interventional | 2007-02-28 | Completed | ||
| A Single-blind Stepped Wedge Cluster Randomized Controlled Behaviour Change Trial to Determine Effectiveness of Prevention Programme of Melioidosis in Diabetics in Ubon Ratchathani, Northeast Thailand[NCT02089152] | 9,075 participants (Actual) | Interventional | 2014-04-01 | Completed | |||
| Short-Course Isoniazid and Rifampin Compared With Isoniazid for Latent Tuberculosis Infection: A Randomized Clinical Trial.[NCT00397709] | Phase 4 | 228 participants | Interventional | 1996-03-31 | Terminated | ||
| The Importance of Exogenous Reinfection in the Tuberculosis Endemic of Taiwan[NCT00173433] | 150 participants (Anticipated) | Observational | 2005-08-31 | Completed | |||
| The Treatment of Pulmonary Mycobacterium Tuberculosis in HIV Infection[NCT00001033] | Phase 3 | 650 participants | Interventional | Completed | |||
| Nine Months' Short Course Regimen Protocol for the Treatment of Multidrug Resistance-tuberculosis (MDR-TB) Patients in Gabon[NCT03057756] | 23 participants (Anticipated) | Observational [Patient Registry] | 2015-09-11 | Recruiting | |||
| Diagnosis of Active Tuberculosis in Endemic Area by Using Enzyme-Linked Immunospot Assay for Gamma-Interferon[NCT00174083] | 200 participants | Observational | 2005-08-31 | Recruiting | |||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000638] | 2,000 participants | Interventional | Completed | ||||
| Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection[NCT00000636] | 2,000 participants | Interventional | Completed | ||||
| Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.[NCT00760149] | Phase 2 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase Ib Safety and Immunogenicity Clinical Trial of Heterologous Prime-boost Immunisation With ChAd3-EBO Z and MVA-EBO Z in Healthy Senegalese Adult Volunteers Aged 18-50 Years.[NCT02485912] | Phase 1 | 40 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| TBTC Study 25:A Prospective, Randomized, Double-Blind Study of the Tolerability of Higher Doses of Rifapentine[NCT00023426] | Phase 2 | 150 participants | Interventional | 1999-07-31 | Completed | ||
| Prophylactic Use of Entecavir to Reduce Hepatitis Flare in Highly Viremic HBV Patients With Active Tuberculosis Receiving Anti-tuberculous Treatment[NCT01724723] | Phase 4 | 50 participants (Anticipated) | Interventional | 2012-12-31 | Not yet recruiting | ||
| Efficacy of Simultaneous Versus Sequential Antiretroviral Therapy and Antituberculosis Treatment in Patients With AIDS and Active Tuberculosis. Open, Randomized and Controlled, Multisite Clinical Trial.[NCT00737724] | 63 participants (Actual) | Interventional | 2008-03-31 | Terminated (stopped due to Other published trials showed definitive expected superiority of Group 1) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The count of eligible people living with HIV (PLHIV) offered 3HP who accept to initiate treatment (by age, gender, CD4 stratum, viral load suppression) divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.998 |
| Facilitated Self-Administered Therapy (SAT) | 1.00 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.995 |
The count of eligible participants who accept treatment and take at least 11 of 12 once weekly doses of rifapentine (RPT)/isoniazid (INH) within 16 weeks of treatment initiation divided by the count of those randomized. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.946 |
| Facilitated Self-Administered Therapy (SAT) | 0.922 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.944 |
Count of participants who take at least 11 of 12 doses within 16 weeks of treatment initiation divided by the count those who take at least one dose of 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.947 |
| Facilitated Self-Administered Therapy (SAT) | 0.922 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.949 |
Count of participants for whom treatment is discontinued due to adverse events or intolerance divided by the count of those who initiated 3HP. (NCT03934931)
Timeframe: Within 16 weeks of treatment initiation
| Intervention | proportion of participants (Number) |
|---|---|
| Facilitated Directly Observed Therapy (DOT) | 0.0054 |
| Facilitated Self-Administered Therapy (SAT) | 0.013 |
| Patient Choice Between Facilitated DOT and Facilitated SAT | 0.0073 |
"Number of infants with a combined endpoint of MTB infection, TB disease, and death~MTB infection as measured by IGRA or tuberculin skin test at 12 months post-enrollment~TB disease including microbiologically confirmed (culture or Xpert positive), or probable TB (clinical diagnosis).~Death of infant" (NCT02613169)
Timeframe: Over 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Isoniazid | 11 |
| No Isoniazid | 19 |
Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization
| Intervention | participants (Number) |
|---|---|
| Isoniazid | 10 |
| No Isoniazid | 18 |
Among HEU infants enrolled at approximately 6 weeks of age, compare the risk of acquiring MTB infection during 1 year of follow-up in infants randomized to receive INH vs. no INH using an interferon-gamma release (IGRA) QuantiFERON-TB Gold Plus (QFT-Plus) assay or tuberculin skin test as part of a composite endpoint to determine MTB infection status (NCT02613169)
Timeframe: at 12 months post randomization
| Intervention | TB infections/100 person years (Number) |
|---|---|
| Isoniazid | 7.0 |
| No Isoniazid | 13.4 |
Number of infants with grade 3 or higher treatment-related adverse events as assessed by DAIDS Table for the Grading Severity of Pediatric Adverse Experiences (NCT02613169)
Timeframe: Over 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Isoniazid | 21 |
| No Isoniazid | 16 |
Incidence rate (events per 100 person-years) was estimated, and 95.1% confidence interval used to account for interim analysis of primary efficacy outcome. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | Events per 100 person-years (Number) |
|---|---|
| RPT Plus INH Regimen (Arm A) | 0.6506 |
| INH Regimen (Arm B) | 0.6736 |
Cumulative incidence function estimated nonparametrically, treating TB-related deaths as competing risks. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| Cumulative incidence by 1 year post-randomization | Cumulative incidence by 2 years post-randomization | Cumulative incidence by 3 years post-randomization | Cumulative incidence by 4 years post-randomization | |
| INH Regimen (Arm B) | 0.5 | 1.0 | 1.5 | 2.0 |
| RPT Plus INH Regimen (Arm A) | 0.3 | 0.4 | 0.9 | 1.6 |
Data table estimates for percentage who died by each time point were estimated using Kaplan-Meier at 1, 2, 3, and 4 years post-entry. (NCT01404312)
Timeframe: From entry to occurrence of event, up to end of follow-up 3 years after last participant enrolled (median follow-up time: 3.3 years)
| Intervention | events per 100 participants (Number) | |||
|---|---|---|---|---|
| 1 year post-entry | 2 years post-entry | 3 years post-entry | 4 years post-entry | |
| INH Regimen (Arm B) | 0.63 | 1.15 | 1.62 | 2.29 |
| RPT Plus INH Regimen (Arm A) | 0.35 | 0.49 | 1.05 | 2.00 |
"Mean and standard deviation.~Week 16 samples have not yet been analyzed because the metabolite assay is being validated, and requires submission for approval by the Clinical Pharmacology Quality Assurance Program. Analysis of week 16 samples are anticipated to be available in September 2019." (NCT01404312)
Timeframe: Measured at Weeks 0, 2, 4, and 16
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week 0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 3787 | 3870 | 4082 |
Mean and standard deviation (NCT01404312)
Timeframe: Measured at Weeks 0, 2, and 4
| Intervention | nanograms per mL (Mean) | ||
|---|---|---|---|
| Week0 | Week 2 | Week 4 | |
| RPT Plus INH Regimen (Arm A) | 7573 | 6234 | 5797 |
Among MTB-diagnosed participants who underwent drug-susceptibility testing, the number who had any resistance to a particular drug. (NCT01404312)
Timeframe: After TB diagnosis
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifampin72268104 | Rifampin72268105 | Isoniazid72268104 | Isoniazid72268105 | Ethambutol72268104 | Ethambutol72268105 | Pyrazinamide72268104 | Pyrazinamide72268105 | |||||||||
| Developed Resistance | Did not Develop Resistance | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 1 | |||||||||||||||
| INH Regimen (Arm B) | 1 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 14 | |||||||||||||||
| INH Regimen (Arm B) | 11 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 2 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 12 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 7 | |||||||||||||||
| INH Regimen (Arm B) | 0 | |||||||||||||||
| RPT Plus INH Regimen (Arm A) | 6 | |||||||||||||||
| INH Regimen (Arm B) | 6 | |||||||||||||||
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 15.93 |
| Arm B (Deferred INH Treatment) | 13.79 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 16.98 |
| Arm B (Deferred INH Treatment) | 10.09 |
Incidence rate, calculated by Mantel-Haenszel (MH), weighted by gestational age strata 1) gestational age at entry less than 24 weeks or 2) gestational age at entry greater than or equal to 24 weeks. AE's include laboratory results, signs/symptoms, or diagnoses; graded as per Division of AIDS (DAIDS) or by protocol-defined hepatotoxicity measures. Related to treatment indicates possibly, probably, or definitely related to INH or Placebo for INH as judged by Independent Endpoint Review Committee. Discontinuation refers to permanent discontinuation of study treatment. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 15.03 |
| Arm B (Deferred INH Treatment) | 14.93 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 2.99 |
| Arm B (Deferred INH Treatment) | 4.68 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.00 |
| Arm B (Deferred INH Treatment) | 1.38 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 3.42 |
| Arm B (Deferred INH Treatment) | 4.72 |
Incidence rate was calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 2.99 |
| Arm B (Deferred INH Treatment) | 4.42 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through Week 48 postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.40 |
| Arm B (Deferred INH Treatment) | 0.78 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB infection, as judged by Secondary Endpoint Review Committee (NCT01494038)
Timeframe: Measured from study entry to Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.60 |
| Arm B (Deferred INH Treatment) | 0.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Probable or confirmed TB, or congenital TB as defined using the Cantwell criteria (see reference), judged by the Secondary Endpoint Review Committee. Includes an infant death due to unknown cause. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 0.54 |
| Arm B (Deferred INH Treatment) | 0.52 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 56.36 |
| Arm B (Deferred INH Treatment) | 50.88 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. Hepatotoxicity definition as defined by DAIDS AE grading criteria 1.0. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. Protocol-specific definition of hepatotoxicity: Any one of the following: 1) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 5 times the upper limit of normal (ULN), where ULN is specified by the clinic physician; 2) Total bilirubin > 3 X ULN; 3) ALT greater than 3 X ULN and total bilirubin greater than 2 X ULN; or 4) ALT > 3 X ULN and persistent symptomatic clinical hepatitis (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through delivery
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 1.77 |
| Arm B (Deferred INH Treatment) | 2.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 8.37 |
| Arm B (Deferred INH Treatment) | 4.98 |
Incidence rate calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 7.91 |
| Arm B (Deferred INH Treatment) | 4.52 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study entry through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 56.48 |
| Arm B (Deferred INH Treatment) | 40.59 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata. (NCT01494038)
Timeframe: Measured from study start through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 8.37 |
| Arm B (Deferred INH Treatment) | 4.98 |
Incidence rates calculated by Mantel-Haenszel, weighted by gestational age strata (NCT01494038)
Timeframe: Measured from study start through 12 weeks postpartum
| Intervention | events per 100 person-years (Number) |
|---|---|
| Arm A (Immediate INH Treatment) | 7.91 |
| Arm B (Deferred INH Treatment) | 4.52 |
Hospitalization due to reasons other than birth (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 73 |
| Arm B (Deferred INH Treatment) | 75 |
Laboratory, sign/symptom, or diagnoses graded as 3 or higher by DAIDS criteria. (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 193 |
| Arm B (Deferred INH Treatment) | 196 |
As before, but AE is judged to be possibly, probably, or definitely related to INH or Placebo for INH, by clinic medical staff (NCT01494038)
Timeframe: Measured from study entry through Week 48 after birth
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 5 |
| Arm B (Deferred INH Treatment) | 6 |
Fetal deaths include both stillbirths and spontaneous abortions; in case of a multiple birth, mothers who had at least one fetal death (NCT01494038)
Timeframe: Measured from study entry through end of pregnancy
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 17 |
| Arm B (Deferred INH Treatment) | 9 |
Premature birth is defined as gestational age of < 37 weeks at delivery. (NCT01494038)
Timeframe: Measured at delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 48 |
| Arm B (Deferred INH Treatment) | 40 |
Resistance to INH from isolates of Mycobacterium tuberculosis, as a percentage of mothers who develop culture-confirmed TB (NCT01494038)
Timeframe: Measured from study entry through Week 48 postpartum
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A (Immediate INH Treatment) | 1 |
| Arm B (Deferred INH Treatment) | 0 |
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used, (NCT01494038)
Timeframe: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| Third trimester of pregnancy | Week 16 postpartum | |
| Fast Metabolizers | 38.5 | 46.9 |
| Intermediate Metabolizers | 62.5 | 76.2 |
| Slow Metabolizers | 153.02 | 186 |
Pharmacokinetic parameter was estimated from population PK modeling fitted to the intensive PK data. AUC0-24h was predicted using population pharmacokinetic model using the NONMEM software program. A 2-compartment model with first-order absorption with transit compartment and first-order elimination with well-stirred liver model to capture hepatic clearance and first-pass extraction with 1 parameter (hepatic intrinsic clearance) was used, (NCT01494038)
Timeframe: Measured at antepartum (third trimester and >= 2 weeks after starting study drug) and week 16 postpartum (+/-) 4 weeks) while on active INH; blood samples were drawn pre-dose and at 1, 2, 4, 6, 8, and 12 hours post-dosing.
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| Third trimester of pregnancy | Week 16 postpartum | |
| Fast Metabolizers | 3.63 | 4.25 |
| Intermediate Metabolizers | 6.55 | 7.67 |
| Slow Metabolizers | 21.6 | 25.3 |
"Subject responses regarding satisfaction with the DHFS were reported on post study questionnaires regarding their experience with the DHFS and the usability of the system, using summary statistics. Areas evaluated may include ease of use, time needed to use the system, negative impressions, and changes to quality of life. Analyses of individual questions as well as summary metrics across questions were explored.~Percentage of participants who reported being comfortable replacing the patch on their own" (NCT01960257)
Timeframe: 2-3 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Stage 1: DHFS With IS-RM Plus SOC DOT | 75.3 |
| Stage 2: DHFS With IS-RM | 92.8 |
Determine positive detection accuracy (PDA, direct confirmation of TB medication ingestion) of the DHFS when compared to a healthcare worker witnessing actual TB medication ingestion. (NCT01960257)
Timeframe: 2 weeks
| Intervention | percentage of DHFS detected doses (Number) |
|---|---|
| DHFS With IS-RM Plus SOC DOT | 99.3 |
Determine the percentage of witnessed doses by DHFS and standard of care (SOC), respectively. (NCT01960257)
Timeframe: 16 weeks
| Intervention | percentage of witnessed doses (Number) |
|---|---|
| Wirelessly Observed Therapy (WOT) | 92.9 |
| SOC DOT | 63.1 |
"Pharmacokinetic parameters will be assessed for rifampicin, moxifloxacin and SQ109:~area under the plasma concentration curve from dosing to the end of the dosing interval (AUC 0-24) (in h*ng/mL)~the observed maximum concentration (Cmax( (in ng/mL)~time to reach Cmax (Tmax)(in hours)~the minimum observed plasma concentration 24 hours following the last dose (Cmin) (in hours),~clearance (Cl) (in mL/minute),~volume of distribution (Vd) (in L),~elimination half-life (T1/2,) (in hours)~free (protein-unbound) fraction (for rifampicin only) (in percent)." (NCT01785186)
Timeframe: 0 - 12 weeks
| Intervention | Rifampicin AUC(mg*h/l) (Geometric Mean) |
|---|---|
| HRZQ | 17.4 |
| Arm 1 (R35) | 170 |
| HR20ZQ | 68.3 |
| HR20ZM | 57.8 |
| HRZE | 24.2 |
From enrollment, the time to stable culture conversion (2 consecutive negative weekly cultures) in liquid media. (NCT01785186)
Timeframe: 0 - 12 weeks
| Intervention | days (Median) |
|---|---|
| Arm 1 (R35) | 48 |
| HRZQ | 63 |
| HR20ZQ | 66 |
| HR20ZM | 55 |
| HRZE | 62 |
All Adverse Events (AE), and AEs considered to be drug-related will coded using standard AE dictionaries. (NCT01785186)
Timeframe: 0 - 12 weeks
| Intervention | participants (Number) | |
|---|---|---|
| Number of Patients with at least 1 AE | Number of patients with at least 1 SAE | |
| Arm 1 (R35) | 53 | 4 |
| HR20ZM | 49 | 4 |
| HR20ZQ | 42 | 5 |
| HRZE | 92 | 6 |
| HRZQ | 49 | 4 |
PK AUCs of Isoniazid (INH) from 0 to 24 hours obtained at Day 1 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | h*ng/mL (Median) |
|---|---|
| RHZE-RHZE | 10725.8 |
| RHZE-RZE | 7970.6 |
| RHZE-RMZE | 7165.1 |
PK AUCs of Isoniazid from 0 to 24 hours obtained at Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | h*ng/mL (Median) |
|---|---|
| RHZE-RHZE | 9797.2 |
PK AUCs of Moxiflozacin (Mox) from 0 to 24 hours obtained at Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | h*ng/mL (Median) |
|---|---|
| RHZE-RMZE | 22498.4 |
Pearson correlation coefficient was used to examine the correlation between TTP and log10 CFU among all qualified samples obtained on study (NCT01589497)
Timeframe: Pre-entry, Day 0, Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11 and Day 14
| Intervention | correlation coefficient (Number) |
|---|---|
| Overall | -0.75 |
"The daily change in log10 CFU/mL sputum was calculated as follows:~EBA2-14(CFU) = (log10 CFU/mL at day 2 - log10 CFU/mL at day 14)/12.~For a CFU/mL count of 0, the log10 CFU/mL was set to 0." (NCT01589497)
Timeframe: Day 2 and day 14
| Intervention | log10 CFU/ mL (Median) |
|---|---|
| RHZE-RHZE | 0.143 |
| RHZE-RZE | 0.093 |
| RHZE-RMZE | 0.123 |
| RZE-RZE | 0.104 |
"The daily change in log10 CFU/mL sputum was calculated as follows:~EBA0-2(CFU) = (baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 2)/2.~For a CFU/mL count of 0, the log10 CFU/mL was set to 0." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 2
| Intervention | log10 CFU/ mL (Median) |
|---|---|
| RHZE-RHZE | 0.255 |
| RHZE-RZE | 0.385 |
| RHZE-RMZE | 0.111 |
| RZE-RZE | 0.034 |
"The daily change in TTP was calculated as follows:~EBA0-14(TTP) = [baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 14]/14." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 14
| Intervention | hours (Median) |
|---|---|
| RHZE-RHZE | -12 |
| RHZE-RZE | -12 |
| RHZE-RMZE | -13 |
| RZE-RZE | -11 |
"The daily change in TTP was calculated as follows:~EBA0-2(TTP) = (baseline TTP (mean of TTP at pre-entry and day 0) - TTP at day 2)/2." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 2
| Intervention | hours (Median) |
|---|---|
| RHZE-RHZE | -31 |
| RHZE-RZE | -30 |
| RHZE-RMZE | -29 |
| RZE-RZE | -25 |
"The daily change in TTP was calculated as follows:~EBA2-14(TTP) = (TTP at day 2 - TTP at day 14)/12." (NCT01589497)
Timeframe: Day 2 and Day 14
| Intervention | hours (Median) |
|---|---|
| RHZE-RHZE | -9 |
| RHZE-RZE | -9 |
| RHZE-RMZE | -12 |
| RZE-RZE | -9 |
"The daily decrease was calculated as follows:~EBA0-14(CFU)= [baseline log10 CFU/mL sputum (mean of log10 CFU/mL at pre-entry and day 0) - log10 CFU/mL at day 14]/14. For a CFU/ml count of 0, the log10 CFU/mL was set to 0.~No formal statistical testing was conducted to compare the arms. Please refer to the explanation in the Protocol Section." (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 14
| Intervention | log10 CFU/ mL (Median) |
|---|---|
| RHZE-RHZE | 0.134 |
| RHZE-RZE | 0.096 |
| RHZE-RMZE | 0.136 |
| RZE-RZE | 0.119 |
Isoniazid PK parameter CL/F obtained Day 1 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | L/hour (Median) |
|---|---|
| RHZE-RHZE | 28.0 |
| RHZE-RZE | 37.6 |
| RHZE-RMZE | 41.9 |
Isoniazid PK parameter CL/F obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | L/hour (Median) |
|---|---|
| RHZE-RHZE | 30.6 |
Isoniazid (INH) PK parameter CLast obtained Day 1. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL. (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 50 |
| RHZE-RZE | 50 |
| RHZE-RMZE | 50 |
Isoniazid (INH) PK parameter CLast obtained Day 14. The lower limit of quantification of the assay (LLOQ) for INH was 100 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 50 ng/mL. (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 50 |
Isoniazid PK parameter Cmax obtained Day 1 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 1
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 3165 |
| RHZE-RZE | 2920 |
| RHZE-RMZE | 2760 |
Isoniazid PK parameter Cmax obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Isoniazid dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RHZE | 3130 |
Moxifloxacin PK parameter CL/F obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | L/hour (Median) |
|---|---|
| RHZE-RMZE | 17.8 |
Moxifloxacin PK parameter CLast obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RMZE | 178 |
Moxifloxacin PK parameter Cmax obtained Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Moxifloxacin dosing at Day 14
| Intervention | ng/mL (Median) |
|---|---|
| RHZE-RMZE | 3010 |
PK AUCs of Ethambutol (EMB) from 0 to 24 hours obtained at Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | h*ng/mL (Median) | |
|---|---|---|
| EMB AUC0-24hour at Day 1 | EMB AUC0-24hour at Day 14 | |
| RHZE-RHZE | 11918.8 | 16414.9 |
| RHZE-RMZE | 11322.4 | 15181.2 |
| RHZE-RZE | 11145.8 | 16675.9 |
| RZE-RZE | 10716.8 | 16574.6 |
PK AUCs of Pyrazinamide (PZA) from 0 to 24 hours obtained at Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | h*ng/mL (Median) | |
|---|---|---|
| PZA AUC0-24hour at Day 1 | PZA AUC0-24hour at Day 14 | |
| RHZE-RHZE | 301214.5 | 249879.1 |
| RHZE-RMZE | 292078.2 | 280071.0 |
| RHZE-RZE | 255283.0 | 201389.7 |
| RZE-RZE | 272853.9 | 252276.8 |
Ethambutol PK parameter CL/F obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | L/hour (Median) | |
|---|---|---|
| EMB CL/F Day 1 | EMB CL/F Day 14 | |
| RHZE-RHZE | 93.6 | 57.9 |
| RHZE-RMZE | 83.8 | 56.8 |
| RHZE-RZE | 85.4 | 63.5 |
| RZE-RZE | 76.5 | 60.1 |
Ethambutol PK parameter CLast obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| EMB CLast at Day 1 | EMB CLast at Day 14 | |
| RHZE-RHZE | 86.5 | 205.0 |
| RHZE-RMZE | 40 | 164 |
| RHZE-RZE | 85 | 176 |
| RZE-RZE | 86 | 159 |
Ethambutol PK parameter Cmax obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Ethambutol dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| EMB Cmax at Day 1 | EMB Cmax at Day 14 | |
| RHZE-RHZE | 2650 | 2980 |
| RHZE-RMZE | 2470 | 2780 |
| RHZE-RZE | 2040 | 3090 |
| RZE-RZE | 2220 | 2920 |
The log10 CFU count per mL from sputum samples processed by standard method or decontaminated method. (NCT01589497)
Timeframe: Pre-entry, Day 0 and Day 14
| Intervention | log10 CFU/ mL (Median) | ||
|---|---|---|---|
| Pre-entry | Day 0 | Day 14 | |
| Decontaminated Processing Method | 5.89 | 5.58 | 3.74 |
| Standard Processing Method | 5.80 | 5.68 | 4.01 |
Pharmacokinetic Parameter Area Under the Concentration-time Curve (AUCs) of Rifampicin from 0 to 24 hours obtained at Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | h*ng/mL (Median) | |
|---|---|---|
| RIF AUC0-24hour at Day 1 | RIF AUC0-24hour at Day 14 | |
| RHZE-RHZE | 37358.8 | 31361.4 |
| RHZE-RMZE | 51434.1 | 26751.2 |
| RHZE-RZE | 42062.6 | 27161.7 |
| RZE-RZE | 39294.0 | 30521.0 |
Pyrazinamide PK parameter CL/F obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | L/hour (Median) | |
|---|---|---|
| PZA CL/F Day 1 | PZA CL/F Day 14 | |
| RHZE-RHZE | 4.1 | 4.5 |
| RHZE-RMZE | 4.7 | 4.7 |
| RHZE-RZE | 4.8 | 5.4 |
| RZE-RZE | 4.2 | 4.7 |
Pyrazinamide PK parameter CLast obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| PZA CLast at Day 1 | PZA CLast at Day 14 | |
| RHZE-RHZE | 3370 | 1955.0 |
| RHZE-RMZE | 3130 | 1790 |
| RHZE-RZE | 2850 | 1280 |
| RZE-RZE | 2710 | 1770 |
Pyrazinamide PK parameter Cmax obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Pyrazinamide dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| PZA Cmax at Day 1 | PZA Cmax at Day 14 | |
| RHZE-RHZE | 27650 | 29300 |
| RHZE-RMZE | 28800 | 29300 |
| RHZE-RZE | 27000 | 27000 |
| RZE-RZE | 25800 | 28000 |
Rifampicin PK parameter Clearance (CL/F) obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | L/hour (Median) | |
|---|---|---|
| RIF CL/F Day 1 | RIF CL/F Day 14 | |
| RHZE-RHZE | 14.0 | 18.0 |
| RHZE-RMZE | 10.5 | 21.5 |
| RHZE-RZE | 12.5 | 22.1 |
| RZE-RZE | 14.3 | 17.0 |
Rifampicin (RIF) PK parameter Last Concentration (CLast) obtained Day 1 and Day 14. The lower limit of quantification of the assay (LLOQ) for RIF was 40 ng/mL. The results below the lower limit of quantification were assigned as one-half the value of the LLOQ, which was 20 ng/mL. (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| RIF CLast at Day 1 | RIF CLast at Day 14 | |
| RHZE-RHZE | 74.5 | 20 |
| RHZE-RMZE | 133 | 20 |
| RHZE-RZE | 20 | 20 |
| RZE-RZE | 20 | 20 |
Rifampicin PK parameter Parameter Maximum Plasma Concentration (Cmax) obtained Day 1 and Day 14 (NCT01589497)
Timeframe: -0.5 hour (pre-dose), 1, 2, 3, 5, 7, 10, 12 and 24 hours after Rifampicin dosing at Day 1 and Day 14
| Intervention | ng/mL (Median) | |
|---|---|---|
| RIF Cmax at Day 1 | RIF Cmax at Day 14 | |
| RHZE-RHZE | 5565 | 7145 |
| RHZE-RMZE | 8660 | 7370 |
| RHZE-RZE | 6060 | 6960 |
| RZE-RZE | 4880 | 8350 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~• Estimated a single absorption rate constant (ka) for the whole population" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hr-1 (Mean) |
|---|---|
| All Cohorts | 1.74 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Estimated the transit compartment rate constant (ktr), which is synonymous with the absorption constant (ka), for the whole population Note that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hr-1 (Mean) |
|---|---|
| All Cohorts | 1.43 |
"PK parameters from postpartum women were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Calculated an average CL for all post-partum individuals" (NCT02651259)
Timeframe: Data used in the population PK analysis for postpartum women included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| All Cohorts | 1.64 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Calculated an average CL for all women in the 2nd trimester (cohort I) and all women in the 3rd trimester (cohort II)" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 1.4 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 1.50 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption and a separate compartment for metabolite formation~Estimated a single des-RPT CLmet/F for the whole population Note: that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate with the relative standard error" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) |
|---|---|
| All Cohorts | 2.82 |
Cord blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 3.24 |
Cord blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants)
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 2.97 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
Based on site-specified confirmatory TB test. If women and infants were diagnosed with active TB during study they would be referred to local care for TB management and treatment. (NCT02651259)
Timeframe: Measured from birth through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1(Infants Born to Women Enrolled in Second Trimester) | 0 |
| Cohort 2 (Infants Born to Women Enrolled in Third Trimester) | 0 |
Based on site-specified confirmatory TB test. If women and infants were diagnosed with active TB during study they would be referred to local care for TB management and treatment. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses will be recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that result in discontinuation of study drug regimen, and that meet criteria for EAE reporting will be further evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study treatment dispensation (approximately for 12 weeks)
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 0 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 20 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 16 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 8 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 12 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) and were used. (NCT02651259)
Timeframe: Measured from study entry through participants' last study visit at 24 weeks after delivery
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 4 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 0 |
At entry and follow-up, all lab results, sign and symptoms, and diagnoses were recorded. Also, during follow-up grade 2 events related to pregnancy complications, hepatotoxicity, hemorrhage, or peripheral neuropathy, and all grade 3 or events that resulted in discontinuation of study drug regimen, and that met criteria for EAE reporting would further be evaluated and recorded. The DAIDS Table for Grading Adult and Pediatric Adverse Events (V 2.0) and Expedited AE Manual (V 2.0) were used. (NCT02651259)
Timeframe: Measured from birth through infants' last study visit at 24 weeks after birth
| Intervention | percent of participants (Number) |
|---|---|
| Cohort 1 (Infants Born to Women Enrolled in Second Trimester) | 0 |
| Cohort 2 (Infants Born to Women Enrolled in Third Trimester) | 0 |
Plasma blood concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 5.31 |
Plasma concentrations were summarized using using R (version 3.5.1). (NCT02651259)
Timeframe: at delivery - (within 3 days of life for infants).
| Intervention | mcg/mL (Mean) |
|---|---|
| All Cohorts | 2.47 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~• Estimated a single INH Vc/F for the whole population" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L (Mean) |
|---|---|
| All Cohorts | 107 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Estimated a single RPT Vc/F for for the whole population Note: that the mean stated below is actually the value that is obtained from a population analysis and represents a population estimate with the relative standard error" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L (Mean) |
|---|---|
| All Cohorts | 30.1 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained AUC by model-based integration" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | hour*mg/L (Mean) | |
|---|---|---|
| AUC (0-24) for RPT | AUC (0-24) for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 424.7 | 158.7 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 406.8 | 153.7 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with 2 mixtures to characterize subpopulations based on acetylation status~Estimated a separate INH CL/F based on acetylation status (fast, slow)" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | L/hr (Mean) | |
|---|---|---|
| CL/F (slow acetylators) | CL/F (fast acetylators) | |
| All Cohorts | 8.98 | 32.7 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained Cmax by model-based estimation" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | mg/L (Mean) | |
|---|---|---|
| Cmax for RPT | Cmax for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 30.2 | 8.76 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 28.6 | 8.50 |
"PK parameters were determined from plasma concentration-time profiles using a nonlinear mixed effects model (version 7.4; ICON PLC, Dublin, Ireland).~Developed a 1 compartment PK model with transit compartments for oral absorption~Obtained Cmin by model-based estimation" (NCT02651259)
Timeframe: Data used in the population PK analysis included the intensive PK visit (pre-dose (t0) and 0.5, 1, 2. 4, 5, 8, 12, 24, 48, 72 hours post-dose) and sparse PK visit (1, 4, 24, 48 hours post-dose).
| Intervention | mg/L (Mean) | |
|---|---|---|
| Cmin for RPT | Cmin for des-RPT | |
| Cohort 1 (Pregnant Women Enrolled in the Second Trimester) | 1.45 | 1.06 |
| Cohort 2 (Pregnant Women Enrolled in the Third Trimester) | 1.58 | 1.20 |
The cumulative percentage of participants having a DMPA concentration less than 0.1 ng/mL at week 12 was calculated using a Kaplan-Meier estimator with an associated standard error. The confidence interval was calculated using a log-log transformation. Suppression of ovulation generally occurs as long as the DMPA level is => 0.1 ng/mL. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | cumulative percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 11.9 |
Describe the DMPA plasma area under the curve (AUC) between 0 and 12 weeks, where AUC(0-12wks) was calculated using non-compartmental methods.The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | ng*week/mL (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 7.63 |
Describe the apparent DMPA clearance (CL/F) between 0 and 12 weeks. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | L/week (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 19681 |
Describe the DMPA maximum observed concentration (Cmax) between 0 and 12 weeks. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | ng/mL (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 1.04 |
Describe the DMPA minimum observed concentration (Cmin) between 0 and 12 weeks. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | ng/mL (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 0.33 |
Describe the terminal elimination half-life of DMPA (t½) between 0 and 12 weeks, where t½ was calculated using nonlinear mixed-effects (NLME) modelling. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | hours (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 55 |
The percent of participants who experienced a grade 3 (severe) or higher sign/symptom or laboratory abnormality were calculated with an exact Clopper-Pearson 95% confidence interval. Events were graded (1=mild, 2=moderate, 3=severe, 4=life-threatening, 5=death) according to the DAIDS AE Grading Table (V1.0). (NCT02412436)
Timeframe: Weeks 2, 4, 6, 8, 10, and 12
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 12.9 |
The percent of participants with plasma DMPA concentrations below 0.1 ng/mL was calculated with an exact Clopper-Pearson 95% confidence interval. Suppression of ovulation generally occurs as long as the DMPA level is => 0.1 ng/mL. (NCT02412436)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 11.9 |
The percent of participants with plasma progesterone levels above 1 ng/mL was calculated with an exact Clopper-Pearson 95% confidence interval. Ovulation generally occurs when the progesterone level is > 5 ng/mL. If there were participants with plasma progesterone levels > 1 ng/mL, then the percent of participants with plasma progesterone levels > 5 ng/mL would have been calculated by study week. (NCT02412436)
Timeframe: Week 12
| Intervention | percentage of participants (Number) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 0.0 |
Describe the time at which DMPA levels drop below the threshold of 0.1 ng/mL, based on participant-specific estimated elimination slopes from nonlinear mixed-effects (NLME) models. The Week 0 time point was drawn prior to DMPA injection. (NCT02412436)
Timeframe: Weeks 0, 2, 4, 6, 8, 10, and 12
| Intervention | days (Median) |
|---|---|
| Arm A: Depot Medroxyprogesterone Acetate | 74.2 |
The percents of participants with plasma DMPA concentrations below 0.1 ng/mL at weeks 2, 4, 6, 8, and 10 were calculated with exact Clopper-Pearson 95% confidence intervals. Suppression of ovulation generally occurs as long as the DMPA level is => 0.1 ng/mL. (NCT02412436)
Timeframe: Weeks 2, 4, 6, 8, and 10
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Week 2 DMPA < 0.1 ng/mL | Week 4 DMPA < 0.1 ng/mL | Week 6 DMPA < 0.1 ng/mL | Week 8 DMPA < 0.1 ng/mL | Week 10 DMPA < 0.1 ng/mL | |
| Arm A: Depot Medroxyprogesterone Acetate | 0.0 | 0.0 | 0.0 | 0.0 | 2.4 |
Number of patients with adherence to PrEP treatment (self reported adherence at >=1 visit) (NCT01864603)
Timeframe: 3 years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 3282 |
HIV+ adults with on- and off-farm employment (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 85.5 |
| Control | 82.4 |
"Cumulative 3 year HIV incidence in men and women ages ≥15 years after the start of Phase I intervention.~Mean was calculated as the average across clusters of the cluster-level cumulative incidence." (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 0.77 |
| Control | 0.81 |
Proportion of baseline HIV+ ART-naive persons who initiate ART Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 83 |
| Control | 50 |
HIV incidence rate in men and women ages ≥15 years after the start of Phase II intervention (started after 3 years of Phase I). (NCT01864603)
Timeframe: 3 years follow up
| Intervention | Incident HIV per 100 person-year (Number) |
|---|---|
| Intervention | 0.35 |
| Control | 0.92 |
HIV incidence rates during the first and third year of follow up; Results from the Control arm are not provided because annual HIV incidence was not measured in the control arm (annual HIV testing was only conducted in the intervention arm). (NCT01864603)
Timeframe: 3 years follow up
| Intervention | per 100 person-years (Number) |
|---|---|
| Intervention Year 1 | 0.43 |
| Intervention Year 3 | 0.31 |
"Probability of an infant born to an HIV+ mother remaining alive and HIV uninfected.~Mean was calculated as the average across clusters of the cluster-level cumulative incidence." (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 96.7 |
| Control | 93.6 |
"hypertension control (greater than or equal to 140 mg Hg systolic or 90 mg Hg diastolic after 3 repeated readings) at year 3 among adults aged >= 30 years with hypertension.~Mean was calculated as the average across clusters of the cluster-level cumulative incidence." (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 47 |
| Control | 37 |
Cumulative incidence of TB or death due to illness among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 3.7 |
| Control | 4.6 |
Proportion of Persons Attending an HIV Clinic Visit by 30 Days After HIV Test Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 30 days after HIV test
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 41 |
| Control | 24 |
Mortality risk among HIV+ population. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 3.0 |
| Control | 3.9 |
Percent of HIV+ adults with HIV RNA <=500 c/mL. Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 79 |
| Control | 68 |
Percentage of participants with chronic kidney disease (CKD) (NCT01864603)
Timeframe: 3 years follow up
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 361 |
| Control | 248 |
HIV NNRTI drug-resistance mutations found at baseline (NCT01864603)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| Intervention | 8 |
| Control | 11 |
Percent of time spent actively engaged in HIV care among HIV+ adults with baseline viremia (NCT01864603)
Timeframe: 3 years follow up
| Intervention | percentage of days (Mean) |
|---|---|
| Intervention | 81 |
| Control | 73 |
Cost of ART streamlined care delivery amount HIV+ persons (NCT01864603)
Timeframe: Follow up year 3
| Intervention | USD per person year (Mean) |
|---|---|
| Intervention | 291 |
| Control | 221 |
Plasma HIV RNA <400 cps/ml Mean was calculated as the average across clusters of the cluster-level cumulative incidence. (NCT01864603)
Timeframe: 3 years follow up
| Intervention | cumulative events per 100 persons (Mean) |
|---|---|
| Intervention | 67 |
| Control | 47 |
(NCT00130247)
Timeframe: 2 years
| Intervention | Participants (Number) |
|---|---|
| 4-Month Arm | 0 |
| 6-Month Arm | 0 |
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months
| Intervention | Participants (Number) |
|---|---|
| 4-Month Arm | 13 |
| 6-Month Arm | 3 |
Patients who presented with TB after completion of study phase treatment but before the end of follow-up were classified as relapses. A bacteriologic relapse was defined as a patient who became consistently culture-positive [defined as at least 1 of the following]: (a) at least 1 sputum mycobacterial culture growing at least 10 colonies of MTB on solid medium; (b) 2 or more respiratory secretion cultures that are positive for MTB in liquid media; or (c) any culture from an extrapulmonary site that is positive for MTB during follow-up after successful completion of initial anti-TB treatment. (NCT00130247)
Timeframe: 30 months
| Intervention | Participants (Number) |
|---|---|
| 4-Month Arm | 13 |
| 6-Month Arm | 3 |
(NCT00130247)
Timeframe: 1 and 2 years after successful completion of initial anti-TB treatment
| Intervention | Participants (Number) | |
|---|---|---|
| Relapses at 1 year | Relapses at 2 years | |
| 4-Month Arm | 10 | 13 |
| 6-Month Arm | 3 | 3 |
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years
| Intervention | Participants (Number) | |
|---|---|---|
| Treatment Failures | Relapses | |
| 4-Month Arm | 0 | 13 |
| 6-Month Arm | 0 | 3 |
A culture-positive treatment failure was defined as initial culture conversion but subsequent reversion to culture positivity. A clinical treatment failure was defined as a patient with clinical and/or radiographic evidence of progressive tuberculosis not confirmed by a positive culture after 4 or more months of anti-TB treatment while still receiving treatment. Patients who defaulted before completing study treatment and returned later with culture-positive tuberculosis were termed failures after non-adherence. (NCT00130247)
Timeframe: 2 years
| Intervention | Participants (Number) | |
|---|---|---|
| Treatment Failures | Relapses | |
| 4-Month Arm | 0 | 13 |
| 6-Month Arm | 0 | 3 |
To compare the proportion of patients with any Grade 3 or 4 adverse reactions in the two study arms. Outcome measured in terms of number of participants with at least one grade 3 or 4 events, and not in number of events. (NCT02114684)
Timeframe: Up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Moxifloxacin | 43 |
| Control | 25 |
A patient was defined as having an unfavourable outcome if he/she was not cured at the end of treatment or did not successfully complete treatment. Recurrence after completion of treatment was defined as two positive cultures within a period of four months without an intervening negative culture. (NCT02114684)
Timeframe: up to 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Moxifloxacin | 13 |
| Control | 6 |
To determine the time to culture-conversion of the moxifloxacin regimen and the ethambutol regimen. (NCT02114684)
Timeframe: Up to 2 years
| Intervention | weeks (Median) |
|---|---|
| Moxifloxacin | 6.0 |
| Control | 7.9 |
To compare adverse events and 8-week culture conversion rates among HIV-infected patients vs. HIV-uninfected patients. The proportion of participants with at least one grade 3 or 4 adverse event was measured. (NCT02114684)
Timeframe: up to 2 years for adverse events and 8 weeks for culture conversion rates
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| participants with grade 3/4 adverse events | participants culture negative at 8 weeks | |
| HIV Negative, Control | 6 | 22 |
| HIV Negative, Moxifloxacin | 13 | 21 |
| HIV Positive, Control | 19 | 51 |
| HIV Positive, Moxifloxacin | 30 | 57 |
The proportion of patients with negative sputum cultures at the end of the intensive phase (8 weeks) and the proportion of patients with negative sputum cultures at 6 months were compared between the two study arms. All participants with sputum culture results at week 8 and month 6 were included in the analysis. (NCT02114684)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| culture negative at 8 weeks | culture negative at 6 months | |
| Control | 73 | 92 |
| Moxifloxacin | 78 | 84 |
Safety will be assessed by the occurrence of a Grade 3/4 hepatotoxicity at any time during the assigned treatment period. (NCT03302299)
Timeframe: Hepatotoxicity occurring during the six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | percent (Number) |
|---|---|
| INH and Vitamin B6 | 8.3 |
Lack of tolerability will be defined as any isoniazid (INH) treatment discontinuation prior to completion of the prescribed course (6 months of INH taken over a maximum period of 9 months) due to side effects or alanine transaminase (ALT)/aspartate transaminase (AST) elevations. (NCT03302299)
Timeframe: Six month course (180 pills) of isoniazid (INH), which may be taken over a maximum of 9 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| INH and Vitamin B6 | 32 |
Alanine transaminase (ALT) or aspartate transaminase (AST) elevations (>2x the upper limit of normal) at study screening (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 80 |
Latent tuberculosis assessed at screening via tuberculin skin testing (TST). A TST induration >=5mm was considered positive for latent tuberculosis. (NCT03302299)
Timeframe: Study screening visit
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Screening | 308 |
INH concentration in hair (pmol/mg) will be measured at 3- and 6- months during INH therapy. (NCT03302299)
Timeframe: Measured at 3- and 6- months after INH initiation
| Intervention | pmol/mg (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 36.0 | 37.8 |
Suboptimal INH adherence was defined as <90% of days with at least 1 electronic medication management (EMM) pill cap opening in the previous 90 days, at 3- and 6-months. (NCT03302299)
Timeframe: Adherence will be measured over the 6 months on INH or until INH discontinuation (whichever is shorter)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 31.3 | 43.9 |
"Participants were asked In the past 30 days, how many days in total have you not taken your pill? and were presented with a visual analog scale (VAS) to indicate the percentage of INH taken in the past 30 days. We converted the VAS percentage into number of days out of 30 to match the first question. Our final self-report measure was the minimum number of the 2 self-reported measurements." (NCT03302299)
Timeframe: Self-reported INH medication adherence via VAS will be measured 3- and 6- months after starting INH
| Intervention | days (Median) | |
|---|---|---|
| at 3 months | at 6 months | |
| INH and Vitamin B6 | 30 | 30 |
The Self Rating Single Item (SRSI) adherence scale asks participants to rate their ability to take their medications as prescribed over the past 30 days. Participants reporting INH use in the prior 30 days at the 3- or 6-month interview are included here, and reported their INH adherence in the prior 30 days as excellent, very good, good, fair, poor, or very poor. (NCT03302299)
Timeframe: Self-reported INH medication adherence via SRSI will be measured 3- and 6- months after starting INH
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| At 3 months72558043 | At 6 months72558043 | |||||||||||
| Excellent | Very good | Good | Fair | Poor | Very poor | |||||||
| INH and Vitamin B6 | 160 | |||||||||||
| INH and Vitamin B6 | 79 | |||||||||||
| INH and Vitamin B6 | 38 | |||||||||||
| INH and Vitamin B6 | 2 | |||||||||||
| INH and Vitamin B6 | 124 | |||||||||||
| INH and Vitamin B6 | 90 | |||||||||||
| INH and Vitamin B6 | 41 | |||||||||||
| INH and Vitamin B6 | 4 | |||||||||||
| INH and Vitamin B6 | 0 | |||||||||||
| INH and Vitamin B6 | 1 | |||||||||||
The number (percentage) of subjects with a diagnosis of tuberculosis based on clinically-derived tuberculosis (TB) diagnostic criteria were summarized by treatment group for all subjects. (NCT00953927)
Timeframe: 15 to 36 months post-vaccination
| Intervention | participants with a diagnosis of TB (Number) |
|---|---|
| Investigational Vaccine | 32 |
| Control Group | 39 |
An ex vivo IFN-γ ELISPOT assay was used to assess specific T cell responses to an Ag85A peptide pool for a subset of infants. (NCT00953927)
Timeframe: 7 days post-vaccination
| Intervention | SFC per million PBMCs (Median) |
|---|---|
| Investigational Vaccine | 143.000 |
| Control Group | 1.000 |
The number (percentage) of infants with QuantiFERON conversions at any time on the study were summarized by treatment group. (NCT00953927)
Timeframe: 15 to 36 months post-vaccination
| Intervention | participants (Number) |
|---|---|
| Investigational Vaccine | 178 |
| Control Group | 171 |
Adverse events (AE) were collected for 28 days after vaccination. The subject's parent or guardian recorded information regarding occurrences of solicited adverse events in diary cards through 7 days after vaccination. Serious adverse events (SAE) were collected from the time of study vaccine dosing throughout the entire study. A safety cohort (the first 330 infants enrolled) also had serum chemistry and hematology testing up to 28 days post-vaccination. (NCT00953927)
Timeframe: AEs recorded 28 days post-vaccination; SAEs recorded for entire study period.
| Intervention | percentage of all subjects vaccinated (Number) |
|---|---|
| Investigational Vaccine | 95.9 |
| Control Group | 83.7 |
Intracellular cytokine staining (ICS) assay immune response was expressed as the percentage of cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T cells producing any one of three cytokines (IFN-γ, TNF-α, or IL-2) or any combination of the three cytokines simultaneously after stimulation with an Ag85A peptide pool on a subset of infants. (NCT00953927)
Timeframe: 28 days post-vaccination
| Intervention | percentage of cytokine expressing cells (Median) | |
|---|---|---|
| Percent cytokine expressing CD4 cells | Percent cytokine expressing CD8 cells | |
| Control Group | 0.003 | 0.000 |
| Investigational Vaccine | 0.012 | 0.007 |
Frequencies of CD4 and CD8 T cells expressing cytokines (IFN-γ, IL-2 and TNF-α) following stimulation of whole blood with an Ag85A peptide pool were also measured by flow cytometry for a subset of infants. (NCT00953927)
Timeframe: 28 days post-vaccination
| Intervention | percentage of cytokine expressing cells (Median) | |
|---|---|---|
| Percent IL2/IFN-gamma/TNF expressing CD4 cells | Percent IL2/IFN-gamma/ TNF expressing CD8 cells | |
| Control Group | 0.001 | 0.000 |
| Investigational Vaccine | 0.030 | 0.000 |
The Kaplan-Meier estimate of cumulative probability of death by week 24 (NCT01380080)
Timeframe: From study entry to week 24
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 4.8 |
| Arm B: IPT | 5.2 |
The Kaplan-Meier estimate of the cumulative probability of death or AIDS progression by week 24. AIDS progression was defined as new WHO stage 3 or 4 conditions occurred after study entry. (NCT01380080)
Timeframe: From study entry to week 24
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 17.1 |
| Arm B: IPT | 12.5 |
The Kaplan-Meier estimate of the cumulative probability of death or AIDS progression by week 48. AIDS progression was defined as new WHO stage 3 or 4 conditions occurred after study entry. (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 19.3 |
| Arm B: IPT | 15.3 |
"The Kaplan-Meier estimate of the cumulative probability of death or unknown vital status by week 24.~The vital status was considered unknown at week 24 if a participant prematurely discontinued from the study before week 24 and no vital status was obtained at week 48." (NCT01380080)
Timeframe: From study entry to week 24
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 5.2 |
| Arm B: IPT | 5.2 |
The Kaplan-Meier estimate of the cumulative probability of first AIDS progression which was defined as the identification of a new World Health Organization (WHO) stage 3 or 4 condition (NCT01380080)
Timeframe: From study entry to week 96
| Intervention | Cumulative probability per 100 persons (Number) |
|---|---|
| Arm A: Empiric | 16.6 |
| Arm B: IPT | 11.3 |
Proportion of participants with premature discontinuation of antiretroviral therapy (ART) by Week 48 (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.19 |
| Arm B: IPT | 0.21 |
Proportion of participants with premature discontinuation of any component of TB treatment by Week 48 (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.13 |
| Arm B: IPT | 0.05 |
Proportion of participants with at least one new Grade 3 or 4 laboratory or sign or symptom that is at least a one-grade increase from baseline by Week 48. Grade 3=Severe, Grade 4=Life-Threatening according to DAIDS AE Grading Table (see references). (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.32 |
| Arm B: IPT | 0.30 |
"Proportion of participants with at least one new Grade 3 or 4 that is at least a one-grade increase from baseline for the following targeted laboratory values by Week 48~The targeted laboratory events include hemoglobin, serum creatinine, ALT and AST" (NCT01380080)
Timeframe: From study entry to week 48. The lab events were collected at study entry, weeks 2, 4, 8, 12, 16, 20, 24, and 48.
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.11 |
| Arm B: IPT | 0.13 |
Proportion of participants with IRIS (using current ACTG definition Appendix 60, see References) by Week 48. IRIS in participants with TB and other opportunistic infections may occur shortly after the initiation of potent combination ART, particularly in participants with advanced HIV disease. (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.04 |
| Arm B: IPT | 0.05 |
Proportion of participants with reportable hospitalization reported by Week 48 (NCT01380080)
Timeframe: From study entry to week 48
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.10 |
| Arm B: IPT | 0.12 |
Proportion of participants with TB diagnosis per current ACTG Diagnosis Appendix 60 by week 96 (NCT01380080)
Timeframe: From study entry to week 96
| Intervention | Proportion of participants (Number) |
|---|---|
| Arm A: Empiric | 0.08 |
| Arm B: IPT | 0.05 |
Median time to TB treatment initiation since study entry (NCT01380080)
Timeframe: From study entry to week 96
| Intervention | Days (Median) |
|---|---|
| Arm A: Empiric | 0 |
| Arm B: IPT | 0 |
The absolute levels of CD4+ T-cell counts (cells/mm^3) (NCT01380080)
Timeframe: At weeks 0, 4, 24, and 48
| Intervention | cells/ mm^3 (Median) | |||
|---|---|---|---|---|
| Week 0 | Week 4 | Week 24 | Week 48 | |
| Arm A: Empiric | 18 | 74 | 121 | 176 |
| Arm B: IPT | 19 | 76 | 121 | 172 |
Change was calculated as the CD4+ T-cell count at the later weeks (4, 24 and 48) minus the baseline (week 0) CD4+ T-cell count. (NCT01380080)
Timeframe: Weeks 0, 4, 24 and 48
| Intervention | cells/ mm^3 (Median) | ||
|---|---|---|---|
| Week 4 | Week 24 | Week 48 | |
| Arm A: Empiric | 49 | 96 | 158 |
| Arm B: IPT | 54 | 102 | 146 |
Proportion of participants with HIV-1 RNA level <400 copies/mL. (NCT01380080)
Timeframe: At weeks 0, 4, 24, and 48
| Intervention | Proportion of participants (Number) | |||
|---|---|---|---|---|
| Week 0 | Week 4 | Week 24 | Week 48 | |
| Arm A: Empiric | 0 | 0.46 | 0.84 | 0.87 |
| Arm B: IPT | 0.01 | 0.49 | 0.85 | 0.89 |
Cumulative TB disease rate was defined as number of participants (regardless of age) with culture-confirmed TB disease (defined as positive culture for MTB]) or probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB, or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to 33 Months
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.49 |
| 3RPT/INH | 0.24 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 33 months after enrollment (for those who completed therapy within 33 months) per 100 participants w/33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.11 |
| 3RPT/INH | 0.05 |
Cumulative TB disease rate was defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for MTB) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, CT scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for AFB], or caseating granulomata at autopsy or biopsy) between enrollment and 24 months after completion of study therapy per 100 participants with up to 33 months of follow-up and was calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 27 (3RPT/INH) or Month 33 (9INH)
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.37 |
| 3RPT/INH | 0.16 |
Cumulative TB disease rate defined as number of participants ≥18 years old with culture-confirmed TB disease (defined as positive culture for Mycobacterium tuberculosis [MTB]) and those <18 years old with probable (clinical) TB disease (defined as objective evidence of clinical TB disease [cough, fever, night sweats, weight loss, or hemoptysis] based on history or physical exam plus radiograph, computed tomography [CT] scan, other diagnostic tests PLUS response to antituberculosis therapy AND objective improvement of radiograph or other diagnostic tests; OR evidence of granuloma with organism positive for acid-fast bacilli [AFB], or caseating granulomata at autopsy or biopsy) between enrollment and the 990th Day of the Trial (33 months after enrollment, or end of the trial) per 100 participants with (w/)33 months of follow-up calculated using survival analysis methods (Kaplan-Meier approach). (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | TB cases per 100 participants w/followup (Number) |
|---|---|
| 9INH | 0.43 |
| 3RPT/INH | 0.19 |
Completion in the 3RPT/INH arm was defined as: received 12 doses of RPT/INH within 16 weeks (12 weeks optimal). However, participants were considered to have completed therapy if at least 11 doses of RPT/INH had been received (~90%) during the 16-week time period. Completion in the 9INH arm was defined as: received 270 doses of INH within 52 weeks (39 weeks optimal). However, participants were considered to have completed therapy if at least 240 doses of INH were received (~90%) during the 52-week period. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 69.0 |
| 3RPT/INH | 82.1 |
(NCT00023452)
Timeframe: Baseline up to Month 35
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 1.0 |
| 3RPT/INH | 0.8 |
Discontinuation of study drug due to an adverse drug reaction associated with either 3RPT/INH or 9INH was defined as discontinuing treatment and/or study due to a treatment-related adverse event (AE) (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 3.8 |
| 3RPT/INH | 4.9 |
Drug discontinuations for any reason associated with 3RPT/INH or 9INH included all reasons for discontinuation from study treatment, regardless of relationship to treatment. (NCT00023452)
Timeframe: Baseline up to Month 3 (3RPT/INH) or Month 9 (9INH)
| Intervention | percentage of participants (Number) |
|---|---|
| 9INH | 31.0 |
| 3RPT/INH | 17.9 |
Drug-susceptibility testing (DST) was performed on isolates of MTB obtained from participants who developed signs and symptoms of active TB disease (including sputum specimens or specimens from appropriate body site for extrapulmonary TB disease). DST was performed at site's local laboratory and sent to Sponsor for confirmatory susceptibility testing. DST included all drugs currently used to treat TB disease, including pyrazinamide (PZA) and fluoroquinolones. Susceptibility was tested for other drugs at the Sponsor laboratory at the following concentrations: INH, 0.02, 1.0, and 5.0 micrograms per milliliter (µg/mL) and rifampin (RIF), 1.0 µg/mL. Isolates resistant to RIF were assumed to be resistant to RPT. (NCT00023452)
Timeframe: Baseline up to Month 33
| Intervention | percentage of participants (Number) | |
|---|---|---|
| INH monoresistance | RIF and PZA resistant | |
| 3RPT/INH | 0 | 14 |
| 9INH | 15 | 0 |
Drug toxicities (or AEs) were graded using Common Toxicity Criteria (CTC version 2.0, Publish Date April 30, 1999, Cancer Therapy Evaluation Program). Grade 3 and 4 drug toxicities associated with 3RPT/INH or 9INH were defined as treatment-related Grade 3 or 4 AEs (considered either possibly, probably, or definitely related to the study drug by the investigator). (NCT00023452)
Timeframe: Baseline up to 60 days after the last dose of study drug (Month 5 [3RPT/INH] or Month 11 [9INH])
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Grade 3 | Grade 4 | |
| 3RPT/INH | 2.7 | 0.4 |
| 9INH | 2.2 | 0.4 |
Number of participants who had a Quantiferon TB Gold Plus (QIAGEN®) score greater than or equal to 0.35 international units per milliliter, at the time of the premature exclusion visit, on all participants in the group. (NCT03028129)
Timeframe: up to 6 months
| Intervention | participants (Number) |
|---|---|
| Treatment | 49 |
| Control | 77 |
Deaths from any cause were included. Results report percent of participants dying by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 0.8 |
| HIVneg/PL | 0.8 |
| HIVpos/INH | 11.6 |
| HIVpos/PL | 7.2 |
Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 7.8 |
| HIVneg/PL | 8.5 |
| HIVpos/INH | 20.3 |
| HIVpos/PL | 23.7 |
Criteria for diagnosis with TB disease were: Definite-isolation of M.tb or positive stain on CSF; Probable-positive AFB stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of PTB and either a +ve TST or minimum score on algorithm to diagnose clinical TB. All records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB disease. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 8.3 |
| HIVneg/PL | 9.1 |
Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 10.4 |
| HIVneg/PL | 12.1 |
| HIVpos/INH | 22.4 |
| HIVpos/PL | 27.9 |
Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive TST based on a PPD performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVpos/INH | 29.4 |
| HIVpos/PL | 32.8 |
Criteria for diagnosis with TB infection were outlined in the protocol. TB infection included TB disease (see primary outcome measure 1 for definition) and latent TB infection. Latent TB infection was diagnosed by a positive tuberculin skin test (TST) based on a purified protein derivative (PPD) performed at week 96. Participant records were reviewed by an Endpoint Review Group to verify that participants had met the criteria for TB infection. Results report percent of participants reaching TB infection or death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVneg/INH | 10.9 |
| HIVneg/PL | 12.6 |
HIV disease progression was defined as any advancement in Centers for Disease Control (CDC) disease category from entry or death. If a participant was CDC disease category C at entry progression was defined as death. Results report percent of participants with HIV progression or death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVpos/INH | 30.6 |
| HIVpos/PL | 22.5 |
Criteria for diagnosis with TB disease: Definite-isolation of Mycobacterium TB (M.tb) or +ve stain on cerebrospinal fluid (CSF); Probable- +ve acid fast bacilli (AFB) stain on fluids/tissues other than CSF and sufficient clinical criteria/radiographic evidence suggestive of TB; Possible-abnormal chest radiograph suggestive of pulmonary TB (PTB) and either a +ve tuberculin skin test (TST) or minimum score on algorithm for clinical TB. Records reviewed by Endpoint Review Group. Results report percent of participants reaching TB disease/death by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) |
|---|---|
| HIVpos/INH | 27.4 |
| HIVpos/PL | 28.9 |
Signs, symptoms and laboratory values were graded according to the Division of AIDS Adverse Event Grading System. Any event of grade 3 or higher not present at entry that occurred after randomization was classified as a new event. Results report percent of participants with a new event by week 96 calculated using the Kaplan-Meier method. (NCT00080119)
Timeframe: Through to week 96
| Intervention | Percent of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| New >=grade 3 sign/symptom | New >= grade 3 peripheral neuropathy | New >=grade 3 lab abnormality | New >=grade 3 hemoglobin | New >=grade 3 ANC | New >=grade 3 platelets | New >=grade 3 SGOT | New >=grade 3 SGPT | |
| HIVneg/INH | 5.0 | 1.1 | 4.9 | 0.0 | 1.7 | 0.3 | 1.0 | 2.8 |
| HIVneg/PL | 4.2 | 0.3 | 4.6 | 0.0 | 0.3 | 0.0 | 2.8 | 4.4 |
| HIVpos/INH | 16.8 | 2.4 | 11.3 | 1.8 | 1.6 | 1.7 | 0.4 | 5.9 |
| HIVpos/PL | 11.7 | 0.8 | 10.1 | 1.2 | 3.5 | 0.9 | 2.5 | 4.0 |
haematological and biochemical laboratory tests (NCT00546273)
Timeframe: at protocol defined timepoints: days 0, 7, 21, 28, 35, 56, 112 & 156
| Intervention | number of abnormalities (Number) |
|---|---|
| RUTI 5 Micrograms of FCMtb | 0 |
| RUTI 25 Micrograms of FCMtb | 0 |
| RUTI 100 Micrograms of FCMtb | 0 |
| RUTI 200 Micrograms of FCMtb | 0 |
| Placebo | 0 |
"The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.~The following parameters will be assessed for both groups:~Occurrence of solicited local reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination~Occurrence of unsolicited adverse events for 28 days following the vaccination~Change from baseline for safety laboratory measures~Occurrence of serious adverse events during the whole study duration" (NCT02485912)
Timeframe: 26 weeks
| Intervention | participants (Number) |
|---|---|
| Group 1 | 20 |
| Group 2 | 20 |
"Ebolavirus specific immunogenicity will be assessed by a variety of immunological assays. The primary immunogenicity outcome measures are ELISA and neutralization antigen-specific assays for antibody responses and intracellular cytokine staining (ICS) assay for T cell responses.~Exploratory outcome measures will include ex-vivo ELISPOT, plasma blast assays and flow cytometry performed with research samples collected at different study timepoints as well as other immunogenicity assays throughout the study. An evaluation of genetic factors associated with immune responses may be performed as exploratory evaluation. Vaccine-induced mRNA expression profiles during 1 week after vaccination may also be performed as an exploratory evaluation." (NCT02485912)
Timeframe: 26 weeks
| Intervention | participants (Number) |
|---|---|
| Group 1 | 20 |
| Group 2 | 20 |
261 reviews available for isoniazid and Koch's Disease
| Article | Year |
|---|---|
Tuberculosis: the drug development pipeline at a glance.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Humans; Tuberculosis | 2012 |
A medicinal chemists' guide to the unique difficulties of lead optimization for tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Lung; Mycobacterium tuberculosis; Tuberculos | 2013 |
SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Structure-Activity Relationship; | 2014 |
Isoniazid derivatives and their anti-tubercular activity.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Isoniazid; Mycobacterium tuberculosis; Tuber | 2017 |
Triazole derivatives and their anti-tubercular activity.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Molecu | 2017 |
Recent advances of pyrazole-containing derivatives as anti-tubercular agents.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Molecular Structure; Mycobacterium | 2017 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecula | 2018 |
Recent advances of imidazole-containing derivatives as anti-tubercular agents.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Imidazoles; Microbial Sens | 2018 |
Marine natural products as potential anti-tubercular agents.
Topics: Animals; Antitubercular Agents; Aquatic Organisms; Biological Products; Humans; Tuberculosis | 2019 |
Anti-tuberculosis activity and its structure-activity relationship (SAR) studies of oxadiazole derivatives: A key review.
Topics: Animals; Antitubercular Agents; Drug Discovery; Humans; Models, Molecular; Mycobacterium tuberculosi | 2021 |
Lipolytic enzymes inhibitors: A new way for antibacterial drugs discovery.
Topics: Antitubercular Agents; Carboxylic Ester Hydrolases; Drug Design; Enzyme Inhibitors; Humans; Lactones | 2021 |
An appraisal of anti-mycobacterial activity with structure-activity relationship of piperazine and its analogues: A review.
Topics: Animals; Antitubercular Agents; Drug Design; Drug Discovery; Humans; Mycobacterium tuberculosis; Pip | 2021 |
Emerging impact of triazoles as anti-tubercular agent.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Structure-Ac | 2022 |
Tuberculosis Drug Discovery: Challenges and New Horizons.
Topics: Antitubercular Agents; COVID-19 Drug Treatment; Drug Discovery; Humans; Mycobacterium tuberculosis; | 2022 |
Tuberculosis preventive therapy for people living with HIV: A systematic review and network meta-analysis.
Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coi | 2021 |
Development of physiologically-based pharmacokinetic models for standard of care and newer tuberculosis drugs.
Topics: Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Standard of Care; Tuberculosis | 2021 |
Antibiotic heteroresistance in Mycobacterium tuberculosis isolates: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Mycobacteriu | 2021 |
Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Genotype; Humans; Isoniazi | 2022 |
Isoniazid Derivatives as Anti-Tubercular Agents: From Structural Design to Clinical Investigations.
Topics: Antitubercular Agents; Humans; Isoniazid; Models, Molecular; Mycobacterium tuberculosis; Tuberculosi | 2023 |
Management and outcomes of surgical site tuberculosis infection due to infected bone graft in spine surgery: a single-institution experience and 1-year postoperative follow-up.
Topics: COVID-19; Follow-Up Studies; Humans; Isoniazid; Retrospective Studies; Rifampin; Surgical Wound Infe | 2023 |
Latent tuberculosis infection: approach and therapeutic schemes.
Topics: Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Rifamycins; Tuberculosis | 2022 |
[Primary isoniazid preventive therapy : A strategy still relevant in the era of test and treat ; literature review].
Topics: Anti-Retroviral Agents; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Randomized Control | 2022 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Longitudinal Studies; Tuberculosis | 2023 |
[Tuberculosis and socioeconomic factors in spanish population: a systematic review.]
Topics: Delayed Diagnosis; Humans; Isoniazid; Male; Socioeconomic Factors; Spain; Tuberculosis | 2022 |
[Tuberculosis and socioeconomic factors in spanish population: a systematic review.]
Topics: Delayed Diagnosis; Humans; Isoniazid; Male; Socioeconomic Factors; Spain; Tuberculosis | 2022 |
[Tuberculosis and socioeconomic factors in spanish population: a systematic review.]
Topics: Delayed Diagnosis; Humans; Isoniazid; Male; Socioeconomic Factors; Spain; Tuberculosis | 2022 |
[Tuberculosis and socioeconomic factors in spanish population: a systematic review.]
Topics: Delayed Diagnosis; Humans; Isoniazid; Male; Socioeconomic Factors; Spain; Tuberculosis | 2022 |
Mycobacterium smegmatis: The Vanguard of Mycobacterial Research.
Topics: Escherichia coli; Humans; Isoniazid; Mycobacterium smegmatis; Mycobacterium tuberculosis; Tuberculos | 2023 |
Effectiveness and Pharmacokinetic Exposures of First-Line Drugs Used to Treat Drug-Susceptible Tuberculosis in Children: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Ethambutol; HIV; HIV Infections; Humans; Isoniazid; | 2023 |
Isoniazid Preventive Therapy for Prevention of Tuberculosis among People Living with HIV in Ethiopia: A Systematic Review of Implementation and Impacts.
Topics: Antitubercular Agents; Child; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Tuberculosis | 2022 |
Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Network Me | 2023 |
Barriers and Facilitators of Isoniazid Preventive Therapy Implementation among People Living with HIV in Nigeria: A Scoping Review of the Literature.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Nigeria; Tuberculosis | 2023 |
A Systematic Review and Meta-Analysis of Tuberculous Preventative Therapy Adverse Events.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Therapy, Combinati | 2023 |
[Treatment of tuberculosis: what is new?]
Topics: Antitubercular Agents; Humans; Isoniazid; Moxifloxacin; Pyrazinamide; Tuberculosis; Tuberculosis, Mu | 2023 |
Integrating 3HP-based tuberculosis preventive treatment into Zimbabwe's Fast Track HIV treatment model: experiences from a pilot study.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Pilot Projects; Tuber | 2023 |
Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage.
Topics: Antitubercular Agents; Bacterial Proteins; Chemical and Drug Induced Liver Injury; Drug Resistance, | 2023 |
The incidence rate of tuberculosis and its associated factors among HIV-positive persons in Sub-Saharan Africa: a systematic review and meta-analysis.
Topics: Adult; Africa South of the Sahara; Child; HIV Infections; Humans; Incidence; Isoniazid; Male; Trimet | 2023 |
Treatment for radiographically active, sputum culture-negative pulmonary tuberculosis: A systematic review and meta-analysis.
Topics: Adult; Antitubercular Agents; Child; Humans; Isoniazid; Prospective Studies; Sputum; Tuberculosis; T | 2023 |
Isoniazid and host immune system interactions: A proposal for a novel comprehensive mode of action.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Host Microbial Interactions; Humans; Isoniazid; | 2019 |
A systematic review and meta-analysis of first-line tuberculosis drug concentrations and treatment outcomes.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Humans; Isoniazid; Observational Studies as Topi | 2020 |
Latent tuberculosis infection: recent progress and challenges in South Korea.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Republic of Korea; Tuberculosis | 2020 |
The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis.
Topics: Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Isoniazid; Postpartum Period; Pregnancy; | 2020 |
Isoniazid-phytochemical conjugation: A new approach for potent and less toxic anti-TB drug development.
Topics: Antitubercular Agents; Benzaldehydes; Drug Development; Glycosides; Humans; Indoles; Isoniazid; Mole | 2020 |
Tuberculosis treatment in children: The changing landscape.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Humans; Is | 2020 |
The impact of diabetes mellitus on drug resistance in patients with newly diagnosed tuberculosis: a systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Comorbidity; Dia | 2020 |
A novel risk factor for predicting anti-tuberculosis drug resistance in patients with tuberculosis complicated with type 2 diabetes mellitus.
Topics: Adult; Aged; Antitubercular Agents; Diabetes Mellitus, Type 2; Drug Resistance, Bacterial; Drug Resi | 2020 |
Tuberculosis in 2019.
Topics: Antitubercular Agents; Ethambutol; Health Policy; Humans; India; Isoniazid; Molecular Diagnostic Tec | 2020 |
Diagnostic accuracy of centralised assays for TB detection and detection of resistance to rifampicin and isoniazid: a systematic review and meta-analysis.
Topics: Antibiotics, Antitubercular; Cross-Sectional Studies; Drug Resistance, Bacterial; Humans; Isoniazid; | 2021 |
Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.
Topics: Adult; Anti-Retroviral Agents; Antibiotic Prophylaxis; Antitubercular Agents; CD4 Lymphocyte Count; | 2021 |
A rare case of primary sinonasal tuberculosis presented with phlyctenular keratoconjunctivitis in a pediatric patient: A case report and literature review.
Topics: Antibiotics, Antitubercular; Child; Child, Preschool; Female; Humans; Isoniazid; Keratoconjunctiviti | 2021 |
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs.
Topics: Antitubercular Agents; Bayes Theorem; Humans; Isoniazid; Pharmaceutical Preparations; Tuberculosis | 2021 |
Tuberculosis (TB) in pregnancy - A review.
Topics: Antitubercular Agents; Female; Humans; Infant, Newborn; Isoniazid; Pregnancy; Tuberculosis; Tubercul | 2021 |
The Treatment of Tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Monitoring; Drug Therapy, Combination; Humans; Isoniazid; Levof | 2021 |
Child contact management in high tuberculosis burden countries: A mixed-methods systematic review.
Topics: Adolescent; Attitude; Child; Child, Preschool; Communicable Disease Control; Contact Tracing; Health | 2017 |
A systematic review of national policies for the management of persons exposed to tuberculosis.
Topics: Antitubercular Agents; Contact Tracing; Health Policy; Humans; Isoniazid; National Health Programs; | 2017 |
Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, | 2018 |
Isoniazid for the Prevention of Tuberculosis in HIV-Infected Children: A Systematic Review and Meta-Analysis.
Topics: Antitubercular Agents; Child; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials a | 2018 |
Novel compounds targeting InhA for TB therapy.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Inhibins; Isoniazid; Tuberculosis | 2018 |
Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: A systematic review.
Topics: Africa; Anti-HIV Agents; Antitubercular Agents; Asia; Body Weight; Central Nervous System Diseases; | 2018 |
A comprehensive review on Primary gallbladder tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Female; Gallbladder Diseases; Humans; Isoniazid; Ma | 2018 |
How can integrated care and research assist in achieving the SDG targets for diabetes, tuberculosis and HIV/AIDS?
Topics: Anti-Retroviral Agents; Antitubercular Agents; Biomedical Research; Delivery of Health Care, Integra | 2018 |
A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Microbial Sensitivity Tests; Recurrence; R | 2018 |
Uncloaking an ancient adversary: Can pathogen biomarker elicitors play a role in confirming extrapulmonary TB and latent TB infection?
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Bacteriological Techniques; Biomarkers; DNA, Bac | 2018 |
Barriers to the implementation of isoniazid preventive therapy for tuberculosis in children in endemic settings: A review.
Topics: Antitubercular Agents; Child; Endemic Diseases; Humans; Isoniazid; Preventive Medicine; Tuberculosis | 2019 |
The Isoniazid Paradigm of Killing, Resistance, and Persistence in Mycobacterium tuberculosis.
Topics: Acetylcysteine; Animals; Ascorbic Acid; Bacterial Proteins; Catalase; Drug Discovery; Drug Resistanc | 2019 |
Pharmacokinetics of First-Line Anti-Tubercular Drugs.
Topics: Age Factors; Antitubercular Agents; Child; Drug Overdose; Ethambutol; Food; Genotype; HIV Infections | 2019 |
Pharmacokinetics of isoniazid: The good, the bad, and the alternatives.
Topics: Animals; Antitubercular Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Clinical | 2019 |
The protective effect of isoniazid preventive therapy on tuberculosis incidence among HIV positive patients receiving ART in Ethiopian settings: a meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Cohort Studies; Ethiopia; Health Resou | 2019 |
[Pseudotumor form of primary nasopharyngeal tuberculosis: apropos of 2 new cases and review of the literature].
Topics: Antitubercular Agents; Biopsy; Diagnosis, Differential; Drug Therapy, Combination; Humans; Isoniazid | 2013 |
Rapid diagnosis of Mycobacterium tuberculosis infection and drug susceptibility testing.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; Coinfection; | 2013 |
Isoniazid: an update on the multiple mechanisms for a singular action.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Isoniazid; Molecular Structure; Mycobacte | 2013 |
Treatment of latent tuberculosis infection.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Iso | 2013 |
Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years).
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; HIV Infections; Humans; Infant; Infant, | 2013 |
Isolated tuberculous liver abscess in an immunocompetent adult patient: A case report and literature review.
Topics: Aged; Antitubercular Agents; Biopsy; Blood Chemical Analysis; Drug Combinations; Ethambutol; Humans; | 2016 |
Factors associated with adherence to treatment with isoniazid for the prevention of tuberculosis amongst people living with HIV/AIDS: a systematic review of qualitative data.
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Coinfection; Developing Countries; HIV In | 2014 |
Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; HIV Infections; Humans; Infant; Isoniazi | 2014 |
Tuberculosis and HIV co-infection in children.
Topics: Child; Coinfection; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Incidence; | 2014 |
Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hepatitis B; | 2014 |
Understanding pharmacokinetics to improve tuberculosis treatment outcome.
Topics: Antitubercular Agents; Diabetes Mellitus; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoni | 2014 |
The association between CYP2E1 polymorphisms and hepatotoxicity due to anti-tuberculosis drugs: a meta-analysis.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 CYP2E1; Gene Frequency; Genet | 2014 |
The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.
Topics: Adalimumab; Adult; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Crohn Disease | 2016 |
Interventions to improve delivery of isoniazid preventive therapy: an overview of systematic reviews.
Topics: Antitubercular Agents; Health Personnel; HIV Infections; Humans; Isoniazid; Medication Adherence; Tu | 2014 |
Isoniazid preventive therapy for tuberculosis in South Africa: an assessment of the local evidence base.
Topics: Humans; Isoniazid; Randomized Controlled Trials as Topic; South Africa; Tuberculosis | 2014 |
Trends in discovery of new drugs for tuberculosis therapy.
Topics: Alcohol Oxidoreductases; Animals; Antitubercular Agents; Bacterial Proteins; Drug Discovery; Extensi | 2014 |
Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control.
Topics: Antitubercular Agents; Humans; Incidence; Isoniazid; Risk Reduction Behavior; South Africa; Tubercul | 2014 |
Review of policy and status of implementation of collaborative HIV-TB activities in 23 high-burden countries.
Topics: Antitubercular Agents; CD4 Lymphocyte Count; Guidelines as Topic; HIV Infections; Humans; Internatio | 2014 |
Management of newborn infant born to mother suffering from tuberculosis: current recommendations & gaps in knowledge.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; BCG Vaccine; Female; Humans; Infant, Newborn; | 2014 |
TB screening among people living with HIV/AIDS in resource-limited settings.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Health Resources | 2015 |
Use of isoniazid preventive therapy for tuberculosis prophylaxis among people living with HIV/AIDS: a review of the literature.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Developing Countries; Health Resources; HIV Infe | 2015 |
Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.
Topics: Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Bacterial; Drug Therapy, Comb | 2015 |
The diagnosis, management and prevention of HIV-associated tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Disease Progre | 2014 |
Risk Factors for Acquired Rifamycin and Isoniazid Resistance: A Systematic Review and Meta-Analysis.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Bacterial; Humans; Is | 2015 |
Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials.
Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Isoniazid; Randomized Controlled Trials as Topic | 2015 |
Recommendations Concerning the First-Line Treatment of Children with Tuberculosis.
Topics: Antitubercular Agents; Child; Drug Resistance, Microbial; Humans; Isoniazid; Medication Adherence; T | 2016 |
[The role of pharmacogenomics in the tuberculosis treatment regime].
Topics: Antitubercular Agents; Humans; Isoniazid; Peru; Pharmacogenetics; Polymorphism, Genetic; Tuberculosi | 2015 |
Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis.
Topics: Antitubercular Agents; Databases, Factual; Dose-Response Relationship, Drug; Drug Monitoring; Ethamb | 2016 |
Isoniazid-resistant tuberculosis in Iran: A systematic review.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Iran; Isoniazid; Mycobacterium tuberculos | 2016 |
What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Isoniazid; Myc | 2016 |
Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Topics: Antitubercular Agents; Drug Monitoring; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tests; | 2016 |
Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Humans; Isoniazid; Mutation; | 2016 |
Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Female; Humans; Immunos | 2016 |
Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment.
Topics: Adolescent; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Ethambutol; Feasibility Studies; Fe | 2017 |
Isoniazid-resistant tuberculosis: a cause for concern?
Topics: Antitubercular Agents; Genotype; Global Health; Humans; Isoniazid; Mycobacterium tuberculosis; Natio | 2017 |
GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Humans; Isoniazid; Microbial | 2008 |
New approaches to the treatment of latent tuberculosis.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; M | 2008 |
Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy.
Topics: Adult; Animals; Anti-Retroviral Agents; Antigens, Bacterial; Antitubercular Agents; CD4 Lymphocyte C | 2009 |
Pacemaker wire infection with Mycobacterium tuberculosis: a case report and literature review.
Topics: Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Iso | 2009 |
Efforts towards the development of new antitubercular agents: potential for thiolactomycin based compounds.
Topics: Animals; Antitubercular Agents; Drug Design; Ethambutol; Isoniazid; Microbial Sensitivity Tests; Mol | 2008 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
A dynamic reinfection hypothesis of latent tuberculosis infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Recurrence; Tuberculosis | 2009 |
Tuberculosis (HIV-negative people).
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Low-Level Light Thera | 2009 |
Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Liver Diseases; Liver Transplantation; Male | 2009 |
[Use of rifampicin plus pyrazinamide for antituberculosis prophylaxis does not increase the risk of severe hepatotoxicity in HIV patients: meta-analysis of randomized controlled clinical trials].
Topics: Anti-HIV Agents; Antibiotic Prophylaxis; Antitubercular Agents; Chemical and Drug Induced Liver Inju | 2010 |
4 months of rifampin compared with 9 months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Health Care Costs; Humans; Isoniazid; Liver; Medicatio | 2009 |
Isoniazid pharmacokinetic studies of the 1960s: considering a higher isoniazid dose in childhood tuberculosis.
Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Humans; Inf | 2010 |
Pediatric intracranial subdural empyema caused by Mycobacterium tuberculosis--a case report and review of literature.
Topics: Adolescent; Antibiotics, Antitubercular; Craniotomy; Dura Mater; Empyema, Subdural; Humans; Isoniazi | 2010 |
Tuberculosis in renal transplant recipients: the evidence for prophylaxis.
Topics: Antitubercular Agents; Demography; Humans; Isoniazid; Kidney Transplantation; Mycobacterium tubercul | 2010 |
Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple; Ethambutol; Extensively Dru | 2010 |
[Anti-tuberculosis drug resistance and therapeutic dead end].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Capreomycin; Drug Resistance, Bacterial; Drug Resistan | 2010 |
Treatment of tuberculosis and optimal dosing schedules.
Topics: AIDS-Related Opportunistic Infections; Animals; Antitubercular Agents; Child; Disease Models, Animal | 2011 |
Tuberculosis (HIV-negative people).
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Low-Level Light Therapy; Tuberculosis; Tub | 2011 |
The secret trumps, impelling the pathogenicity of tubercle bacilli.
Topics: Aerosols; Antigen Presentation; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Cyto | 2011 |
Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Polyneuropathies; Practice Guidelines as T | 2011 |
Clinical practice. Latent tuberculosis infection in the United States.
Topics: Adult; Antigens, Bacterial; Antitubercular Agents; Drug Therapy, Combination; Female; Global Health; | 2011 |
Recent advances in the laboratory detection of Mycobacterium tuberculosis complex and drug resistance.
Topics: Antitubercular Agents; Bacteriological Techniques; Drug Resistance, Bacterial; Humans; Isoniazid; Mo | 2011 |
Epidemiology of tuberculosis and HIV: recent advances in understanding and responses.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antigens, Bacterial; Antitubercular A | 2011 |
Neonatal tuberculosis: neonatal intensive care unit considerations in the United States.
Topics: Emigration and Immigration; Humans; Infant; Infant, Newborn; Intensive Care, Neonatal; Isoniazid; My | 2011 |
Intensive case finding and isoniazid preventative therapy in HIV infected individuals in Africa: economic model and value of information analysis.
Topics: Adult; Africa; Antitubercular Agents; Chemoprevention; Cost-Benefit Analysis; Data Interpretation, S | 2012 |
Isoniazid preventive therapy in correctional facilities: a systematic review.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; | 2012 |
[Not just a success story. On the history of tuberculosis treatment].
Topics: Antitubercular Agents; Ethambutol; History, 17th Century; History, 18th Century; History, 19th Centu | 2012 |
New vaccines for the prevention of tuberculosis in human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte | 2012 |
Scale-up of isoniazid preventive therapy in PEPFAR-assisted clinical sites in South Africa.
Topics: Antitubercular Agents; Communicable Disease Control; Epidemics; Guideline Adherence; HIV Infections; | 2012 |
Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services.
Topics: Antitubercular Agents; Chemoprevention; Comorbidity; Harm Reduction; Hepatitis B; Hepatitis C; HIV I | 2012 |
Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions.
Topics: Antitubercular Agents; Attitude of Health Personnel; Child; Drug Resistance; Endemic Diseases; Guide | 2012 |
Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; CD4 Lymphocyte Count; Developing Countries; HIV Infec | 2012 |
Contacts of infectious tuberculosis patients: monitor those at highest risk of developing tuberculosis.
Topics: Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Rifampin; Risk Factors; Tuberculosi | 2012 |
Isoniazid-resistant tuberculosis in children: a systematic review.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Humans; Infa | 2013 |
[Hospital infection control practice for tuberculosis].
Topics: Chemoprevention; Cross Infection; Humans; Infection Control; Infectious Disease Transmission, Patien | 2002 |
Clinical practice. Latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Male; Practice Guideline | 2002 |
Latent tuberculosis: models, mechanisms, and novel prospects for eradication.
Topics: Animals; Antitubercular Agents; BCG Vaccine; Culture Media; Disease Models, Animal; Genes, Bacterial | 2002 |
New guidelines: what to do about an unexpected positive tuberculin skin test.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Guideline Adherence; Humans; Isoniazid; Practice | 2003 |
[Tuberculosis].
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; BCG Vacci | 2002 |
[Diagnosed tuberculosis using specific DNA probe hybridization methods].
Topics: Bacterial Proteins; DNA Probes; DNA-Directed RNA Polymerases; Drug Resistance; Humans; Isoniazid; Mo | 2002 |
Tuberculosis in the elderly.
Topics: Aged; Antitubercular Agents; Comorbidity; Humans; Incidence; Isoniazid; Tuberculin Test; Tuberculosi | 2003 |
Latent tuberculosis in pregnancy: screening and treatment.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury, Chronic; | 2003 |
THE CHEMOPROPHYLAXIS OF TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Chemoprevention; Child | 1963 |
[PREVENTION OF TUBERCULOSIS].
Topics: Adolescent; BCG Vaccine; Child; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Myco | 1964 |
[UROGENITAL TUBERCULOSIS: PATHOGENESIS, DIAGNOSIS AND THERAPY. SURVEY OF THE MOST IMPORTANT PUBLICATIONS OF THE LAST YEARS].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri | 1964 |
[Tuberculosis-current therapeutic principles].
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combi | 2003 |
Clinical inquiries. Are liver function tests required for patients taking isoniazid for latent TB?
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Liver Function Tes | 2004 |
[Latent tuberculosis infection: recommendations for preventive therapy in adults in Germany].
Topics: Adult; Antitubercular Agents; Germany; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 2004 |
Considering the role of four months of rifampin in the treatment of latent tuberculosis infection.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; | 2004 |
Recurrent acute pancreatitis after isoniazid.
Topics: Acute Disease; Adult; Antitubercular Agents; Humans; Isoniazid; Male; Pancreatitis; Recurrence; Tube | 2004 |
Drugs for tuberculosis.
Topics: Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Drug Resi | 2004 |
Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; R | 2005 |
[Adverse effects of biologic agents in treatment of rheumatoid arthritis--prevention of tuberculosis].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antitub | 2005 |
Isoniazid treatment of children: can genetics help guide treatment?
Topics: Age Factors; Antitubercular Agents; Child; Drug Administration Schedule; Genotype; Humans; Isoniazid | 2005 |
[Chemoprophylaxis for tuberculosis].
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antirheumatic Agents; Antitubercular Agents; Child; | 2005 |
Review editorial: prevention of tuberculosis in resource-poor countries with increasing access to highly active antiretroviral treatment.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly A | 2005 |
Isoniazid to prevent first and recurrent episodes of TB.
Topics: Antitubercular Agents; Humans; Isoniazid; Practice Guidelines as Topic; Recurrence; Tuberculosis | 2006 |
Isoniazid preventive therapy and risk for resistant tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Incidence; Isoniazid; Mycobacterium tuber | 2006 |
Slow-onset inhibition of 2-trans-enoyl-ACP (CoA) reductase from Mycobacterium tuberculosis by an inorganic complex.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Design; Humans; Isoniazid; Kinetics; Mycobacterium t | 2006 |
Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Comorbidity; Drug Therapy, Combination; HIV Infe | 2006 |
Antituberculosis drugs and hepatotoxicity.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Dru | 2006 |
[Modern diagnosis of tuberculosis].
Topics: Adenosine Deaminase; Antibiotics, Antitubercular; Antitubercular Agents; Bacteriological Techniques; | 2006 |
[Trends in tuberculosis treatment duration].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Resistance | 2006 |
[Adverse effects of antitubercular drugs: epidemiology, mechanisms, and patient management].
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 2007 |
Screening for novel antituberculosis agents that are effective against multidrug resistant tuberculosis.
Topics: Antitubercular Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Humans; | 2007 |
[Systematic review of anti-tuberculosis drug induced adverse reactions in China].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; China; Drug-Related Side Effects and | 2007 |
Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glucocorticosteroids and the preventive role of isoniazid: a review of the available evidence.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Cohort Studies; Female; Humans; Incidence; | 2007 |
Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; In | 2008 |
Peroxiredoxin systems in mycobacteria.
Topics: Amino Acid Motifs; Animals; Antioxidants; Antitubercular Agents; Bacterial Proteins; Catalase; Drug | 2007 |
Use of electronic monitoring in clinical nursing research.
Topics: Adult; Antitubercular Agents; Bias; Clinical Nursing Research; Data Collection; Drug Monitoring; Dru | 2008 |
The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; N | 2008 |
Isoniazid.
Topics: Animals; Antitubercular Agents; Humans; Isoniazid; Treatment Outcome; Tuberculosis | 2008 |
Pyridoxine supplementation during isoniazid therapy.
Topics: Humans; Isoniazid; Peripheral Nervous System Diseases; Pyridoxine; Tuberculosis; Vitamin B 6 Deficie | 1980 |
[New findings concerning the biochemical mechanisms of the tuberculous process and the correction of biochemical abnormalities using etiopathogenetic preparations].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethionamide; Fatty Acids; Humans; Isoniazid; Liver | 1984 |
[Toxicity of pyrazinamide in antituberculous treatments (author's transl)].
Topics: Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Gout; Humans; Isoniazid; Nausea; P | 1980 |
Chemotherapy of tuberculosis for the 1980's.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1980 |
Tuberculosis in the 1980s.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Chemical and Drug Induced Liver Injury; Drug Resistance; | 1980 |
Complicated tuberculosis and residual disease.
Topics: HIV Seropositivity; Humans; Isoniazid; Recurrence; Risk Factors; Tuberculosis; Tuberculosis, Pulmona | 1994 |
Hepatotoxicity and transaminase measurement during isoniazid chemoprophylaxis in children.
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Humans; Inciden | 1995 |
Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy.
Topics: Clinical Protocols; Disease Outbreaks; Humans; Infectious Disease Transmission, Professional-to-Pati | 1995 |
Positive PPD and chemoprophylaxis for tuberculosis infection.
Topics: Adult; Antitubercular Agents; BCG Vaccine; HIV Infections; Humans; Isoniazid; Middle Aged; Tuberculi | 1995 |
Clinically significant drug interactions with antituberculosis agents.
Topics: Absorption; Antitubercular Agents; Biotransformation; Cytochrome P-450 Enzyme System; Drug Interacti | 1994 |
Preventive therapy for tuberculosis in HIV-infected persons: international recommendations, research, and practice.
Topics: AIDS Serodiagnosis; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administratio | 1995 |
Tuberculosis. Beating the bacillus.
Topics: Animals; Drug Resistance, Microbial; Genes, Bacterial; Humans; Isoniazid; Models, Biological; Mutati | 1994 |
[Advances in the prevention of tuberculosis].
Topics: Animals; BCG Vaccine; Humans; Isoniazid; Tuberculosis; Vaccination | 1993 |
Isoniazid prophylaxis of tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Humans; Isoniazid; Tuberculosis | 1994 |
Fatal isoniazid-induced hepatitis. Its risk during chemoprophylaxis.
Topics: Adult; Age Factors; Aged; Cause of Death; Chemical and Drug Induced Liver Injury; Drug Combinations; | 1993 |
Multidrug-resistant tuberculosis and its control.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Drug Resistance, Microbial; Drug | 1993 |
Tuberculosis symposium: emerging problems and promise.
Topics: Drug Resistance, Microbial; HIV Infections; Humans; Isoniazid; Mycobacterium tuberculosis; New York | 1993 |
[Chemoprophylaxis for children exposed to tuberculosis].
Topics: Antitubercular Agents; Child; Humans; Isoniazid; Time Factors; Tuberculin Test; Tuberculosis | 1993 |
Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual mycobacterial variant.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Cat Diseases; Cats; Diagnosis, Differential; | 1996 |
Primary esophageal tuberculosis: a case report and 1996 update.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Esophageal Diseases; Female; Humans; Isonia | 1996 |
Prevention and management of tuberculosis in HIV positive patients living in countries with a low prevalence of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Cross Infection; Emigration and Immigration; Ethambutol; HIV Seropositivity; | 1996 |
Prophylaxis for tuberculosis in Europe--ongoing research.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Clinical | 1996 |
Inducing properties of rifabutin, and effects on the pharmacokinetics and metabolism of concomitant drugs.
Topics: Acquired Immunodeficiency Syndrome; Humans; Isoniazid; Rifabutin; Tuberculosis | 1995 |
Mantoux (tuberculosis) testing. Evaluation of guidelines for testing in Canadian institutions.
Topics: Antitubercular Agents; Canada; Humans; Isoniazid; Mass Screening; Practice Guidelines as Topic; Rese | 1997 |
Loss of oxyR in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Base Sequence; DNA-Binding Proteins; Drug Resistance, Microbial; Gene Express | 1997 |
New horizons in the treatment of tuberculosis.
Topics: Animals; Drug Design; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Mycolic Acids; Pyra | 1997 |
[Antitubercular chemotherapy].
Topics: Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Protocols; Drug | 1997 |
Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of randomised placebo controlled trials.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Humans; Isoniazid; Randomized C | 1998 |
[Pharyngeal tuberculosis: an analytical study and report of 10 cases].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Pharyn | 1998 |
The tuberculosis pandemic--which way now?
Topics: Adult; Animals; Antibiotics, Antitubercular; Antitubercular Agents; Cattle; Child; Disease Outbreaks | 1999 |
Tuberculosis preventive therapy in HIV-infected persons: feasibility issues in developing countries.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Developing Countries; HIV Infections; Humans; Isoniazi | 1999 |
[Factors for the onset of and the exacerbation of tuberculosis. 3. Clinical factors for the development and the exacerbation of active tuberculosis. a. Children, young adult].
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Disease | 1999 |
Community-wide implementation of targeted testing for and treatment of latent tuberculosis infection.
Topics: Emigration and Immigration; Humans; Ill-Housed Persons; Isoniazid; Managed Care Programs; Prisons; S | 1999 |
[Prevention and treatment of pregnancy-complicated tuberculosis].
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Pregnancy; Pregnancy Complications, Infectious; Tu | 1998 |
Tuberculosis preventive therapy for HIV-infected persons in less developed countries.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Communicable Disease Control; Cost-Ben | 2000 |
The molecular basis of isoniazid resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Drug Resistance; Humans; Isoniazid; Mycobacteri | 1999 |
A review of isoniazid-related hepatotoxicity during chemoprophylaxis.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Decision Support Techniques; Humans; | 1999 |
Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Rifampin; Tuberculin Test; Tu | 2000 |
Mycobacterium tuberculosis infection in pediatric liver transplant recipients.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child, Preschool; Hemorrh | 2000 |
A current approach to the management of tuberculosis infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; BCG Vaccine; Ethambutol; Forecasting; | 2000 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Role of individual drugs in the chemotherapy of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug Resistance; D | 2000 |
Tuberculosis with human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; BCG Vaccine; Child; HIV Infections; Humans; Isoniazid; Risk F | 2000 |
[Tuberculosis].
Topics: Antitubercular Agents; BCG Vaccine; Cross Infection; Humans; Infectious Disease Transmission, Patien | 2000 |
New developments in the treatment of latent tuberculosis.
Topics: Antitubercular Agents; Global Health; Guidelines as Topic; HIV Infections; Humans; Isoniazid; Mass S | 2000 |
DNA microarrays and combinatorial chemical libraries: tools for the drug discovery pipeline.
Topics: Antitubercular Agents; Drug Design; Ethambutol; Gene Expression; Humans; Isoniazid; Mycobacterium tu | 2000 |
[Antitubercular drug-induced liver injuries].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Rifampin; Tubercul | 1998 |
Congenital tuberculosis: a rare manifestation of a common infection.
Topics: BCG Vaccine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Isoniazid; Pregnancy; Pregn | 2002 |
Treatment of tuberculosis.
Topics: Adult; Aminosalicylic Acids; Capreomycin; Child; Cycloserine; Drug Resistance, Microbial; Drug Thera | 1975 |
Advances in the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Pyrazinamide | 1976 |
Diagnosis and management of tuberculosis.
Topics: Adrenal Cortex Hormones; Ambulatory Care; Aminosalicylic Acid; Antitubercular Agents; BCG Vaccine; D | 1979 |
[Current problems of BCG innoculation of newborns and children].
Topics: BCG Vaccine; Child, Preschool; Humans; Infant; Isoniazid; Lymphadenitis; Pyridoxine; Tuberculosis; V | 1979 |
Chemotherapy of tuberculosis.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Ethambutol; Follow-Up Studies; Humans; Isoniazid; Ri | 1976 |
Diagnosis, prevention and early therapy of tuberculosis.
Topics: Aminosalicylic Acids; Ethambutol; Female; Humans; Hypersensitivity, Delayed; Isoniazid; Male; Mycoba | 1976 |
The impact of the HIV epidemic on tuberculosis control programmes in developing countries.
Topics: Acquired Immunodeficiency Syndrome; BCG Vaccine; Child; Child, Preschool; Contraindications; Develop | 1992 |
Tuberculosis chemoprophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Clinical Protocols; Humans; Isoniazid; Predictive Value of Tests | 1992 |
Failure of therapy for tuberculosis in human immunodeficiency virus infection.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Drug Therapy, Combi | 1992 |
[Isoniazide hepatic damage as opposed to prophylactic treatment for tuberculosis].
Topics: Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Tuberculosis | 1992 |
[Chemoprophylaxis of tuberculosis (lecture)].
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; BCG Vaccine; Child; Ethambutol; Humans; Infan | 1992 |
Toxic hepatitis with isoniazid and rifampin. A meta-analysis.
Topics: Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Isoniazid; Meta-Analysis | 1991 |
[Chemotherapy of extrapulmonary tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Rifampin; Tuberculosis | 1991 |
[Therapy of tuberculosis].
Topics: Antitubercular Agents; Contraindications; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; | 1990 |
Acetylator phenotype and short-course chemotherapy for tuberculosis in Papua New Guinea.
Topics: Acetylation; Drug Administration Schedule; Humans; Isoniazid; Papua New Guinea; Peripheral Nervous S | 1989 |
Tuberculosis makes a comeback. Giving and interpreting the Mantoux test.
Topics: Adult; Age Factors; False Negative Reactions; HIV Seropositivity; Humans; Hypersensitivity, Delayed; | 1989 |
Treatment of extrapulmonary tuberculosis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combi | 1989 |
[Which treatment for primary tuberculosis?].
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Pyrazi | 1989 |
Prevention of tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; BCG Vaccine; Child; Developing Countries; Environme | 1989 |
Respiratory pharmacology. Antituberculosis drugs.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cyclosporins; Ethambutol; Humans; Isoniazid; Pyrazinami | 1986 |
Rifampin. No longer just for tuberculosis.
Topics: Adult; Bacterial Infections; Child; Drug Combinations; Humans; Isoniazid; Rifampin; Tuberculosis | 1985 |
[Chemotherapy research on tuberculosis in various countries].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Drug Therapy, Combination; Hospitals, Military; | 1985 |
[Results of chemotherapy in tuberculosis].
Topics: Ambulatory Care; Anti-Bacterial Agents; Antitubercular Agents; Drug Synergism; Ethambutol; Ethionami | 1971 |
Tuberculosis.
Topics: Aminosalicylic Acids; Bronchitis; Cough; Diagnosis, Differential; Ethambutol; Humans; Isoniazid; Mas | 1973 |
[Proceedings: Tuberculosis therapy. Review on today's knowledge, developmental trends and still open problems].
Topics: Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Dose-Response Relationship, Drug; Drug Com | 1973 |
New trends in the chemotherapy of tuberculosis--current aspects.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Ethionamid | 1974 |
[Thiacetazone (Tb-1): recent experimental and clinical data].
Topics: Aminosalicylic Acids; Animals; Cycloserine; Drug Hypersensitivity; Drug Resistance, Microbial; Ethio | 1970 |
Acute forms of tuberculosis.
Topics: Acute Disease; Antitubercular Agents; Child; Diagnosis, Differential; Drug Therapy, Combination; Fem | 1973 |
Modern trends in chemoprophylaxis in tuberculosis.
Topics: Adult; Age Factors; Animals; BCG Vaccine; Chemical and Drug Induced Liver Injury; Child; Humans; Iso | 1973 |
Preventive therapy of tuberculosis.
Topics: Adolescent; Adult; Alcoholism; BCG Vaccine; Chemical and Drug Induced Liver Injury; Child; Clinical | 1974 |
[Pregnancy and tuberculosis].
Topics: Abortion, Therapeutic; Adult; Antitubercular Agents; Birth Rate; Female; Fetal Diseases; Germany, We | 1974 |
Adrenal corticosteroids and tuberculosis. A statement by the Committee on Therapy.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Antitubercular Agents; Drug Hypersensitivity; Drug Sy | 1968 |
Vitamin B6 deficiency following isoniazid therapy.
Topics: Humans; Isoniazid; Nervous System Diseases; Tuberculosis; Vitamin B 6 Deficiency | 1968 |
Avian tuberculosis.
Topics: Adult; Aminosalicylic Acids; Animals; Australia; Bacteriological Techniques; Bird Diseases; Child; E | 1968 |
Studies demonstrating the effectiveness of isoniazid in preventing tuberculosis.
Topics: Clinical Trials as Topic; Humans; Isoniazid; Placebos; Tuberculin Test; Tuberculosis | 1969 |
[Experimental chemotherapy of tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Synergism; Ethambutol; Ethionamide; H | 1969 |
Controlled chemoprophylaxis trials in tuberculosis. A general review.
Topics: Adolescent; Adult; Age Factors; Alaska; Anemia; Child; Child, Preschool; Clinical Trials as Topic; D | 1970 |
[Thiocarlide. Attempt of an evaluation].
Topics: Aminosalicylic Acids; Animals; Bacteria; Drug Resistance, Microbial; Ethionamide; Guinea Pigs; Human | 1969 |
[New drugs in antitubercular therapy].
Topics: Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Humans; Isoniazid; R | 1969 |
Drug-resistant tuberculosis: a review of the world situation.
Topics: Adolescent; Adult; Africa; Aminosalicylic Acids; Asia, Eastern; Canada; Child; Developing Countries; | 1969 |
[Prevention of tuberculosis: vaccination and chemoprophylaxis].
Topics: BCG Vaccine; Child; Humans; Isoniazid; Italy; Tuberculosis; Tuberculosis, Pulmonary | 1968 |
Topics in pharmacogenetics.
Topics: Acyltransferases; Anesthetics; Drug Hypersensitivity; Fever; Gene Frequency; Genetics, Medical; Huma | 1971 |
[New anti-tubercular agents--rifampicin and ethambutol].
Topics: Adolescent; Adult; Aged; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Rifampin; Tubercu | 1971 |
225 trials available for isoniazid and Koch's Disease
| Article | Year |
|---|---|
A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
Topics: Amino Acid Sequence; Animals; Antitubercular Agents; Bacterial Proton-Translocating ATPases; Diarylq | 2005 |
A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcareclinics in South Africa.
Topics: Ambulatory Care Facilities; HIV Infections; Humans; Isoniazid; South Africa; Tuberculosis | 2021 |
Organizational contextual factors that predict success of a quality improvement collaborative approach to enhance integrated HIV-tuberculosis services: a sub-study of the Scaling up TB/HIV Integration trial.
Topics: HIV Infections; Humans; Isoniazid; Quality Improvement; Research Design; South Africa; Tuberculosis | 2021 |
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; HIV Infe | 2021 |
Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children.
Topics: Adolescent; Africa; Antitubercular Agents; Child; Child, Preschool; Drug Administration Schedule; Dr | 2022 |
Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP).
Topics: Adult; Antitubercular Agents; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Humans; | 2022 |
A CD4+ TNF+ monofunctional memory T-cell response to BCG vaccination is associated with Mycobacterium tuberculosis infection in infants exposed to HIV.
Topics: Antitubercular Agents; BCG Vaccine; CD4-Positive T-Lymphocytes; Cytokines; HIV Infections; Humans; I | 2022 |
Cumulative Mycobacterium tuberculosis Infection Incidence (Measured Primarily by Tuberculin Skin Test) Among Infants With Human Immunodeficiency Virus Exposure: Observational Follow-up of an Isoniazid Prophylaxis Trial.
Topics: Antitubercular Agents; Child, Preschool; Follow-Up Studies; HIV; HIV Infections; Humans; Incidence; | 2022 |
Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial.
Topics: Antitubercular Agents; Contraceptive Agents; Drug Administration Schedule; Drug Therapy, Combination | 2022 |
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxac | 2023 |
Effect of patient-delivered household contact tracing and prevention for tuberculosis: A household cluster-randomised trial in Malawi.
Topics: Adolescent; Adult; Child; Child, Preschool; Contact Tracing; Family Characteristics; Humans; Isoniaz | 2022 |
Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial.
Topics: Adult; Antitubercular Agents; Ethiopia; Female; Humans; Isoniazid; Male; Medication Adherence; Tuber | 2022 |
Tuberculosis preventive treatment among individuals with inactive tuberculosis suggested by untreated radiographic abnormalities: a community-based randomized controlled trial.
Topics: Antitubercular Agents; Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosis; Tuber | 2023 |
Prevalence of neurotoxicity symptoms among postpartum women on isoniazid preventive therapy and efavirenz-based treatment for HIV: an exploratory objective of the IMPAACT P1078 randomized trial.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Postpartum Period; Pregnancy; Prev | 2023 |
Isoniazid preventive therapy completion in children under 5 years old who are contacts of tuberculosis cases in Lima, Peru: study protocol for an open-label, cluster-randomized superiority trial.
Topics: Antitubercular Agents; Child, Preschool; Contact Tracing; Humans; Isoniazid; Peru; Randomized Contro | 2023 |
Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.
Topics: Antitubercular Agents; Clofazimine; Drug Therapy, Combination; Humans; Isoniazid; Prothionamide; Pyr | 2023 |
Factors Associated With Discontinuation of Tuberculosis Preventive Treatment: Post Hoc Analysis of 2 Randomized, Controlled Trials.
Topics: Antitubercular Agents; Clinical Protocols; Drug Administration Schedule; Humans; Isoniazid; Rifampin | 2023 |
Optimizing (O) rifapentine-based (RI) regimen and shortening (EN) the treatment of drug-susceptible tuberculosis (T) (ORIENT) using an adaptive seamless design: study protocol of a multicenter randomized controlled trial.
Topics: Clinical Trials, Phase II as Topic; Humans; Isoniazid; Moxifloxacin; Multicenter Studies as Topic; P | 2023 |
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV In | 2023 |
Timing of maternal isoniazid preventive therapy on tuberculosis infection among infants exposed to HIV in low-income and middle-income settings: a secondary analysis of the TB APPRISE trial.
Topics: Antitubercular Agents; BCG Vaccine; Female; HIV Infections; Humans; Infant; Isoniazid; Pregnancy; Tu | 2023 |
Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial.
Topics: Adolescent; Adult; Alcoholism; Biomarkers; Ethanol; Female; HIV Infections; Humans; Isoniazid; Male; | 2023 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
Isoniazid Preventive Therapy in HIV-Infected Pregnant and Postpartum Women.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method | 2019 |
Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: A randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; California; Directly Observed The | 2019 |
CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; HIV Infections; | 2020 |
Preventive tuberculosis treatment effect on QuantiFERON TB-Gold in-tube testing in a high tuberculosis-endemic country: A clinical trial.
Topics: Antigens, Bacterial; Antitubercular Agents; China; Diagnostic Tests, Routine; Endemic Diseases; Fema | 2020 |
Infant TB Infection Prevention Study (iTIPS): a randomised trial protocol evaluating isoniazid to prevent
Topics: Antitubercular Agents; Female; HIV; HIV Infections; Humans; Incidence; Infant; Isoniazid; Kenya; Mal | 2020 |
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
Topics: Adult; Drug Administration Schedule; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; | 2020 |
Twice-Daily Doravirine Overcomes the Interaction Effect from Once-Weekly Rifapentine and Isoniazid in Healthy Volunteers.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Drug Administration Schedule; Drug Inter | 2020 |
A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.
Topics: Antitubercular Agents; HIV; HIV Infections; Humans; Infant; Isoniazid; Kenya; Mycobacterium tubercul | 2021 |
Inference without randomization or ignorability: A stability-controlled quasi-experiment on the prevention of tuberculosis.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Random Allocation; Tuberculosis | 2020 |
Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Arylamine N-Acetyltransferase; B | 2021 |
Individual and Composite Adverse Pregnancy Outcomes in a Randomized Trial on Isoniazid Preventative Therapy Among Women Living With Human Immunodeficiency Virus.
Topics: Adolescent; Child; Female; HIV; HIV Infections; Humans; Infant, Newborn; Isoniazid; Pregnancy; Pregn | 2021 |
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Topics: Adult; Antitubercular Agents; Biomarkers; Drug Administration Schedule; Female; HIV Seronegativity; | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Optimising pyrazinamide for the treatment of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuber | 2021 |
Treatment Outcomes of Isoniazid-Resistant (Rifampicin Susceptible) Tuberculosis Patients in Uzbekistan, 2017-2018.
Topics: Antitubercular Agents; Cohort Studies; Humans; Isoniazid; Prospective Studies; Rifampin; Treatment O | 2021 |
Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Moxifloxacin | 2020 |
Evaluation of a serum-based antigen test for tuberculosis in HIV-exposed infants: a diagnostic accuracy study.
Topics: Antigens, Bacterial; Child; HIV Infections; Humans; Infant; Isoniazid; Mycobacterium tuberculosis; S | 2021 |
The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial.
Topics: Adult; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Motivation; Randomized Controlled T | 2021 |
Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.
Topics: Adult; Antitubercular Agents; Child; Drug Therapy, Combination; Female; HIV Infections; Humans; Ison | 2022 |
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Drug Interactions; Female; HIV Infections; Hum | 2022 |
Impact of isoniazid preventive therapy on the evaluation of long-term effectiveness of infant MVA85A vaccination.
Topics: Antitubercular Agents; Child, Preschool; Double-Blind Method; Female; Follow-Up Studies; Humans; Inc | 2017 |
Screening for active tuberculosis before isoniazid preventive therapy among HIV-infected West African adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte | 2017 |
Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antitubercular Agents; Aspartate Aminotransfera | 2018 |
High Incidence of Tuberculosis Infection in HIV-exposed Children Exiting an Isoniazid Preventive Therapy Trial.
Topics: Antitubercular Agents; Child, Preschool; Clinical Trials as Topic; Double-Blind Method; Female; HIV | 2018 |
Completion of isoniazid preventive therapy among human immunodeficiency virus positive adults in urban Malawi.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antitubercular Agents; CD4 Lymphocyte Count; Female; HIV | 2018 |
Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi.
Topics: Adolescent; Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Kaplan-Meier Es | 2018 |
Bacterial Factors That Predict Relapse after Tuberculosis Therapy.
Topics: Adult; Antitubercular Agents; Area Under Curve; Drug Resistance, Bacterial; Female; Humans; Isoniazi | 2018 |
Clinical effect of lamivudine in treating liver function lesion caused by hepatitis B combined with Anti-TB drugs.
Topics: Adult; Aged; Antitubercular Agents; Antiviral Agents; Drug Therapy, Combination; Female; Hepatitis B | 2018 |
Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.
Topics: Adolescent; Adult; Africa, Western; Aged; Aged, 80 and over; Alkynes; Anti-Retroviral Agents; Antire | 2019 |
Optimization of dosing regimens of isoniazid and rifampicin in children with tuberculosis in India.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Dose-Response | 2019 |
Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial.
Topics: Adult; Antibiotics, Antitubercular; Contact Tracing; Cost-Benefit Analysis; Ethambutol; Family Chara | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2019 |
Pregnancy outcomes in HIV-infected women receiving long-term isoniazid prophylaxis for tuberculosis and antiretroviral therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Analysis of Variance; Antibiotic Prophylaxis; Antitube | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Brazil; F | 2013 |
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltr | 2014 |
Effect of isoniazid therapy for latent TB infection on QuantiFERON-TB gold in-tube responses in adults with positive tuberculin skin test results in a high TB incidence area: a controlled study.
Topics: Adolescent; Adult; Antitubercular Agents; Female; Follow-Up Studies; Humans; Incidence; Interferon-g | 2014 |
A trial of mass isoniazid preventive therapy for tuberculosis control.
Topics: Adult; Antitubercular Agents; Epidemics; Gold; Humans; Incidence; Isoniazid; Male; Mass Screening; M | 2014 |
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Topics: Adult; Alkynes; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Female; Half-Life; | 2014 |
Impact of isoniazid preventive therapy for HIV-infected adults in Rio de Janeiro, Brazil: an epidemiological model.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Brazil; HIV Infections; Humans; Isoniazid | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Topics: Age Factors; Antitubercular Agents; Biomarkers; Biotransformation; Child; Chromatography, High Press | 2014 |
Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Canada; Directly Observed Therapy; Drug Ad | 2014 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Area Under Curve; Disinfection; Drug Antagonism; Drug Syne | 2015 |
Quantiferon-TB Gold: performance for ruling out active tuberculosis in HIV-infected adults with high CD4 count in Côte d'Ivoire, West Africa.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Enzyme-Linked Immunosorbent Assay; Fema | 2014 |
Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial.
Topics: Adolescent; Antitubercular Agents; Body Height; Body Mass Index; Body Weight; Child; Child, Preschoo | 2014 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Chemical and Drug Induced Liver Injury; Double-Blind Method; | 2015 |
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Black People; Coinfection; Cross-Over Studies; | 2014 |
Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; India; I | 2015 |
Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-γ-releasing assay: an exploratory randomized controlled trial.
Topics: Adult; Antitubercular Agents; Female; Humans; Immunocompromised Host; Incidence; Interferon-gamma Re | 2015 |
A randomized trial comparing standard outcomes in two treatment models for substance users with tuberculosis.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Users; Ethambutol; Ethnicity; Female; | 2015 |
Bioequivalence of fixed-dose combination RIN®-150 to each reference drug in loose combination.
Topics: Adult; Antitubercular Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Combination | 2015 |
Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: a posttrial observational analysis.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Female; HIV Infections; Humans; Inciden | 2015 |
Tuberculosis control in South African gold mines: mathematical modeling of a trial of community-wide isoniazid preventive therapy.
Topics: Adult; Antitubercular Agents; Gold; HIV Infections; Humans; Isoniazid; Middle Aged; Mining; Models, | 2015 |
Do clinical decision-support reminders for medical providers improve isoniazid preventative therapy prescription rates among HIV-positive adults? Study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Clinical Protocols; Coinfection; Decision Support Techniques; Drug Prescripti | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopro | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Asympto | 2015 |
Implementation and Operational Research: Cost-Effectiveness of Antiretroviral Therapy and Isoniazid Prophylaxis to Reduce Tuberculosis and Death in People Living With HIV in Botswana.
Topics: Anti-HIV Agents; Botswana; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Tuberculosis | 2015 |
Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care Facilities; Anti-HIV Agents; Antituber | 2016 |
Tackling the unknowns of short-course rifapentine-based treatment for active tuberculosis: a decision analysis.
Topics: Antitubercular Agents; Decision Support Techniques; Ethambutol; Humans; Isoniazid; Markov Chains; Py | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons.
Topics: Adolescent; Adult; Americas; Antitubercular Agents; Asia; Child; Drug-Related Side Effects and Adver | 2016 |
Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
Topics: Adult; Antitubercular Agents; Diabetes Mellitus; Female; Humans; Isoniazid; Male; Middle Aged; Pyraz | 2017 |
Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Double-Blind | 2017 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Completion of isoniazid preventive therapy among HIV-infected patients in Tanzania.
Topics: Adult; Antitubercular Agents; Counseling; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Medi | 2008 |
Prevention of hepatotoxicity due to anti tuberculosis treatment: a novel integrative approach.
Topics: Adult; Antitubercular Agents; Blood Sedimentation; Body Weight; Chemical and Drug Induced Liver Inju | 2008 |
Interferon-gamma release assays during follow-up of tuberculin skin test-positive contacts.
Topics: Antitubercular Agents; Drug Monitoring; Follow-Up Studies; Humans; Immunoassay; Interferon-gamma; Is | 2008 |
Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administratio | 2008 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2009 |
Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; CD4 Lym | 2009 |
Use of isoniazid chemoprophylaxis in renal transplant recipients.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Kidney Transplantation; Male; Prospective S | 2010 |
Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules.
Topics: Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Infant, Newb | 2009 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana Experience, 2004-2006.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agen | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Drug Admi | 2010 |
Patient-centred tuberculosis treatment delivery under programmatic conditions in Tanzania: a cohort study.
Topics: Adult; Antitubercular Agents; Cohort Studies; Directly Observed Therapy; Ethambutol; Humans; Isoniaz | 2009 |
Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin.
Topics: Adult; Antitubercular Agents; Biological Availability; Cross-Over Studies; Delayed-Action Preparatio | 2011 |
Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis.
Topics: Antitubercular Agents; Child; Child Nutrition Disorders; Child, Preschool; Female; Humans; India; Is | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy | 2010 |
Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymph | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Alcohol Drinking; Anti-Retroviral Agents; Antitubercu | 2010 |
Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania.
Topics: Adult; Antibodies, Bacterial; Antibody Formation; Antigens, Bacterial; Antitubercular Agents; BCG Va | 2010 |
Adverse events with isoniazid preventive therapy: experience from a large trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) study.
Topics: Antitubercular Agents; Brazil; Delivery of Health Care, Integrated; Female; HIV Infections; HIV-1; H | 2010 |
The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Child; Child, Prescho | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Antitubercular Agents; Botswana; Double-Blind Method; Drug Administration Schedule; Drug Resi | 2011 |
The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid.
Topics: Administration, Oral; Age Factors; Antitubercular Agents; Arylamine N-Acetyltransferase; Child, Pres | 2012 |
Risk of tuberculosis among contacts of isoniazid-resistant and isoniazid-susceptible cases.
Topics: Adolescent; Adult; Age Distribution; Antitubercular Agents; Child, Preschool; Contact Tracing; Doubl | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
New regimens to prevent tuberculosis in adults with HIV infection.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Cause o | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Double-Blind Method; Drug Resistance, | 2011 |
Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; Huma | 2011 |
Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD4 Lymp | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Three months of rifapentine and isoniazid for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, | 2011 |
Isoniazid pharmacokinetics, pharmacodynamics, and dosing in South African infants.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Double-Blind Method; Female; HIV Infectio | 2012 |
Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemical and Drug Induced Liver Injury | 2013 |
NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
Topics: Adult; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; Asian People; Chemical and Dru | 2013 |
Loss to follow-up among infants in a study of isoniazid prophylaxis (P1041) in South Africa.
Topics: Antitubercular Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Humans; Infan | 2013 |
Efficacy of a six-month versus a 36-month regimen for prevention of tuberculosis in HIV-infected persons in India: a randomized clinical trial.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; HIV Infections; Huma | 2012 |
Infection fighters. Maintenance therapy for TB works.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Isoniazid; Male; Place | 2001 |
Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
Topics: Analysis of Variance; Antibiotics, Antitubercular; Cross-Over Studies; Drug Combinations; Ethambutol | 2002 |
Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis.
Topics: Acculturation; Adolescent; Adolescent Behavior; Antitubercular Agents; California; Counseling; Femal | 2003 |
Increasing Latino adolescents' adherence to treatment for latent tuberculosis infection: a controlled trial.
Topics: Adolescent; Adolescent Behavior; Antitubercular Agents; California; Counseling; Female; Health Servi | 2003 |
Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong.
Topics: Aged; Antitubercular Agents; Drug Administration Schedule; Female; Hong Kong; Humans; Isoniazid; Mal | 2003 |
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Topics: Adolescent; Adult; Antitubercular Agents; Cost Savings; Cost-Benefit Analysis; Costs and Cost Analys | 2004 |
[Treatment of latent tuberculosis among homeless population. Comparison between wo therapeutic approaches].
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Human | 2004 |
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis.
Topics: Acetamides; Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug | 2004 |
Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months.
Topics: Adult; Antitubercular Agents; Costs and Cost Analysis; Drug Administration Schedule; Female; Follow- | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease.
Topics: Acetylation; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Eth | 2004 |
Prospective randomised trial of isoniazid prophylaxis in renal transplant recipient.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Kidney Failure, Chronic; Kidney Transplantation; M | 2004 |
INH preventive therapy among adult HIV-infected patients in Thailand.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Female; Follow | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; CD4 Lymphocyte Count; Directly Observed Therapy; Dru | 2005 |
Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Humans; Incidence; Isoniazid; M | 2005 |
Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Cross-Over Studies; Drug Thera | 2005 |
Role of isoniazid prophylaxis for prevention of tuberculosis in haemopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antitubercular Agents; Child; Child, Preschool; Female; H | 2005 |
Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens.
Topics: Adult; Antigens, Bacterial; Antitubercular Agents; Cells, Cultured; Female; Humans; Interferon-gamma | 2006 |
Lack of weight gain and relapse risk in a large tuberculosis treatment trial.
Topics: Adult; Antitubercular Agents; Body Mass Index; Body Weight; Female; Humans; Isoniazid; Male; Middle | 2006 |
A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Case Management; Female; Humans; Ill-Housed Persons; Isoniazid; Male; | 2006 |
A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Case Management; Female; Humans; Ill-Housed Persons; Isoniazid; Male; | 2006 |
A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Case Management; Female; Humans; Ill-Housed Persons; Isoniazid; Male; | 2006 |
A randomized controlled trial of two treatment programs for homeless adults with latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Case Management; Female; Humans; Ill-Housed Persons; Isoniazid; Male; | 2006 |
Efficacy of isoniazid prophylaxis in renal allograft recipients.
Topics: Antitubercular Agents; Humans; Isoniazid; Kidney Transplantation; Postoperative Complications; Pyrid | 2006 |
Costs and cost-effectiveness of adolescent compliance with treatment for latent tuberculosis infection: results from a randomized trial.
Topics: Adolescent; Antitubercular Agents; Child; Contracts; Cost-Benefit Analysis; Counseling; Female; Heal | 2007 |
Latent variable assessment of outcomes in a nurse-managed intervention to increase latent tuberculosis treatment completion in homeless adults.
Topics: Adolescent; Adult; Antitubercular Agents; Case Management; Comorbidity; Female; Health Knowledge, At | 2007 |
Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFalpha.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Asp | 2007 |
Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention.
Topics: Antitubercular Agents; Brazil; HIV Infections; Humans; Isoniazid; Models, Statistical; Patient Care | 2007 |
[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Age | 2007 |
[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Age | 2007 |
[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Age | 2007 |
[Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Age | 2007 |
[Randomized clinical trial investigating three chemoprophylaxis regimens for latent tuberculosis infection in HIV-infected patients].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; | 2007 |
Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Area Under Curve; Cohort Studies; Drug Interacti | 2007 |
Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chromatography, Liquid; Drug Moni | 2007 |
The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2007 |
Randomised controlled trial of isoniazid preventive therapy in South African adults with advanced HIV disease.
Topics: Adult; Antitubercular Agents; Double-Blind Method; Female; Follow-Up Studies; HIV Infections; Humans | 2007 |
[Effectiveness of prophylaxis against tuberculosis in patients infected with HIV].
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Cohort Studies; Comorbidity; Fe | 2007 |
Mass ambulatory chemotherapy in the treatment of tuberculosis in a predominantly urban community.
Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Hong Kong; Humans; Isoniazid; Outpatient Clinics, | 1967 |
A controlled trial of community-wide isoniazid prophylaxis in Alaska.
Topics: Adolescent; Adult; Alaska; Child; Child, Preschool; Female; Humans; Indians, North American; Inuit; | 1967 |
Chemoprophylaxis: a major adjunct in the prevention of tuberculosis.
Topics: Adult; Child; Humans; Isoniazid; Michigan; Placebos; Pyridoxine; Tuberculosis | 1967 |
The incidence of cancer among participants in controlled, randomized isoniazid preventive therapy trial.
Topics: Adolescent; Adult; Aged; Child; Clinical Trials as Topic; Female; Humans; Isoniazid; Male; Middle Ag | 1980 |
Chemotherapy of tuberculosis for the 1980's.
Topics: Animals; Antitubercular Agents; Clinical Trials as Topic; Humans; Isoniazid; Rifampin; Time Factors; | 1980 |
Tuberculosis treated with rifampicin, ethambutol and isoniazid: Danish tuberculosis trial 1972-1974.
Topics: Adolescent; Adult; Aged; Alcoholism; Clinical Trials as Topic; Denmark; Drug Therapy, Combination; E | 1982 |
Evaluation of the 3-drug combination, Rifater, versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town.
Topics: Antitubercular Agents; Drug Combinations; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; | 1994 |
Note on large, simple, widely representative trials.
Topics: Cross-Sectional Studies; Female; Humans; Isoniazid; Male; Poliomyelitis; Research Design; Tuberculos | 1995 |
Clinically significant drug interactions with antituberculosis agents.
Topics: Absorption; Antitubercular Agents; Biotransformation; Cytochrome P-450 Enzyme System; Drug Interacti | 1994 |
A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients.
Topics: Adult; Double-Blind Method; Female; Humans; Isoniazid; Kidney Transplantation; Male; Middle Aged; Re | 1994 |
[Results of short-term tuberculosis therapy with isoniazid, rifampicin and pyrazinamide].
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Resistance, Microbial; Female; Humans; Isoniaz | 1993 |
Evaluation of the efficacy of health education on the compliance with antituberculosis chemoprophylaxis in school children. A randomized clinical trial.
Topics: Child; Female; Health Education; Humans; Isoniazid; Male; Patient Compliance; Tuberculin Test; Tuber | 1993 |
Effect of isoniazid prophylaxis on incidence of active tuberculosis among Thai HIV-infected individuals.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; Incide | 1996 |
Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters.
Topics: Adult; Aged; Aging; Antitubercular Agents; Female; Homeostasis; Humans; Isoniazid; Male; Middle Aged | 1995 |
Effect of isoniazid chemoprophylaxis on HIV-related mycobacterial disease.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; Female; | 1996 |
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Disease Progr | 1997 |
[Compliance, efficacy and tolerability of the therapeutic regimen recommended by National Consensus on Tuberculosis].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Child; Chi | 1997 |
Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Biological Availability; Diarrh | 1997 |
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinica
Topics: AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antibiotics, Antitubercular; Antituber | 1997 |
A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Female; Follow-Up Studies; Humans; Isoniaz | 1998 |
Comparison of three composite compliance indices in a trial of self-administered preventive therapy for tuberculosis in HIV-infected Ugandan adults. Uganda-Case Western Reserve University Research Collaboration.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care; Factor Analysis, Statistical; Female; | 1998 |
Is a purified protein derivative skin test and subsequent antituberculous chemoprophylaxis really necessary in systemic rheumatic disease patients receiving corticosteroids?
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Confidence Intervals | 1998 |
[Compliance, tolerance and effectiveness of a short chemoprophylaxis regimen for the treatment of tuberculosis].
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Age | 1998 |
Hepatic enzyme abnormalities in children on triple therapy for tuberculosis.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 1999 |
Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Follow-Up Studies; Humans; Incidence; | 1999 |
Tolerability of twice-weekly rifabutin-isoniazid combinations versus daily isoniazid for latent tuberculosis in HIV-infected subjects: a pilot study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Dr | 1999 |
Bioavailability of rifampicin in a separate formulation and fixed dose combination with isoniazid NIH: a case for a fixed dose combination (FDC) for the treatment of tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Chemistry, Pharm | 1999 |
Attentional function in secondary school students receiving isoniazid prophylaxis for tuberculosis infection.
Topics: Adolescent; Analysis of Variance; Attention; Cross-Over Studies; Humans; Isoniazid; Learning Disabil | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health O
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Administ | 2000 |
Isoniazid toxicity in health care workers.
Topics: Adult; Antitubercular Agents; Female; Health Personnel; Humans; Isoniazid; Liver Function Tests; Mal | 1999 |
A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis.
Topics: Adult; Antitubercular Agents; Community Health Workers; Drug Combinations; Female; Humans; Isoniazid | 2000 |
[Evaluation of 2 tuberculosis chemoprophylaxis regimens in patients infected with human immunodeficiency virus. The GECMEI Group].
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Fe | 2000 |
Effect of post-treatment isoniazid on prevention of recurrent tuberculosis in HIV-1-infected individuals: a randomised trial.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Female; H | 2000 |
Incentives vs outreach workers for latent tuberculosis treatment in drug users.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Motiva | 2001 |
[Desensitization therapy for allergic reactions of antituberculous drugs--evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Desensitization, Immunologic; Drug Hypersensi | 2000 |
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 2001 |
Isoniazid does not affect bioavailability of cyclosporine in renal transplant recipients.
Topics: Acetylation; Acetyltransferases; Adolescent; Adult; Antitubercular Agents; Area Under Curve; Biologi | 2000 |
Inhibition of isoniazid-induced expression of Mycobacterium tuberculosis antigen 85 in sputum: potential surrogate marker in tuberculosis chemotherapy trials.
Topics: Acyltransferases; Antibiotics, Antitubercular; Antigens, Bacterial; Antitubercular Agents; Biomarker | 2001 |
Substandard tuberculosis drugs on the global market and their simple detection.
Topics: Antitubercular Agents; Asia; Chromatography, Thin Layer; Colombia; Drug Combinations; Europe, Easter | 2001 |
A randomized, controlled trial of interventions to improve adherence to isoniazid therapy to prevent tuberculosis in injection drug users.
Topics: Adult; Antitubercular Agents; Counseling; Female; Humans; Isoniazid; Male; Middle Aged; Patient Comp | 2001 |
The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
Topics: Antibiotics, Antitubercular; Area Under Curve; Biological Availability; Chromatography, High Pressur | 2001 |
Can guardians supervise TB treatment as well as health workers? A study on adherence during the intensive phase.
Topics: Adult; Ambulatory Care; Antitubercular Agents; Caregivers; Directly Observed Therapy; Ethambutol; Fe | 2001 |
Reintroducing antituberculosis therapy after Stevens-Johnson syndrome in human immunodeficiency virus-infected patients with tuberculosis: role of desensitization.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antitubercular Age | 2001 |
No effect of isoniazid prophylaxis for purified protein derivative-negative HIV-infected adults living in a country with endemic tuberculosis: results of a randomized trial.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Endemic Diseases; H | 2001 |
Risk factors for development of tuberculosis after isoniazid chemoprophylaxis in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemoprevention; Female; Follow | 2002 |
Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail.
Topics: Adult; Antitubercular Agents; Female; Follow-Up Studies; Humans; Isoniazid; Male; Outpatient Clinics | 2002 |
A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
Topics: Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admi | 2002 |
A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users.
Topics: Adult; Analysis of Variance; Antitubercular Agents; Chi-Square Distribution; Directly Observed Thera | 2002 |
Isoniazid chemoprophylaxis. Association with detection and incidence of liver toxicity.
Topics: Adult; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic | 1977 |
An assessment of the possible association of isoniazid with human cancer deaths.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Female; Follow-Up Studies; Humans; Isoniazid; Mal | 1977 |
[Hepatoxic side-effects of rifampicin. A comparative clinical study].
Topics: Alanine Transaminase; Alcoholism; Alkaline Phosphatase; Aspartate Aminotransferases; Chemical and Dr | 1977 |
[A comparison of the therapeutic efficacy of two drug combinations in cases of previously untreated open tuberculosis (author's transl)].
Topics: Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Prothionamide; Streptomycin; Tuberculosis | 1978 |
Tuberculosis prevention project.
Topics: Adult; Counseling; Female; Health Education; Hospitals, Municipal; Humans; Isoniazid; Male; Middle A | 1992 |
Intensive short course chemotherapy for treatment of Greek children with tuberculosis.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combinat | 1992 |
[Influence of health education on compliance with antituberculous chemoprophylaxis in children: a community trial].
Topics: Child; Community Health Services; Cost-Benefit Analysis; Evaluation Studies as Topic; Humans; Isonia | 1990 |
A randomized trial of fully intermittent vs. daily followed by intermittent short course chemotherapy for childhood tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follo | 1990 |
Treatment of extrapulmonary tuberculosis.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Clinical Trials as Topic; Drug Therapy, Combi | 1989 |
[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin].
Topics: Adult; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Ke | 1989 |
Long-term follow-up of a clinical trial of six-month and four-month regimens of chemotherapy in the treatment of pulmonary tuberculosis. Singapore Tuberculosis Service/British Medical Research Council.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Clinical Trials as Topic; Follow-Up Studies; Humans; | 1986 |
Variations in national health care practices and behaviours and their influence on international research.
Topics: Clinical Trials as Topic; Cross-Cultural Comparison; Double-Blind Method; Humans; International Coop | 1985 |
Antituberculous treatment of erythema induratum Bazin.
Topics: Adult; Age Factors; Aged; Aminosalicylic Acids; Female; Follow-Up Studies; Humans; Isoniazid; Leg Ul | 1970 |
[Isoniazid and carcinogenesis].
Topics: Adenoma; Adult; Animals; Carbamates; Carcinoma; Child; Clinical Trials as Topic; Female; Humans; Hyd | 1969 |
Preventive treatment of untreated, nonactive tuberculosis in an Eskimo population.
Topics: Alaska; Bacteriological Techniques; Clinical Trials as Topic; Humans; Inuit; Isoniazid; Placebos; Ra | 1972 |
Effects of antacids on gastrointestinal absorption of isoniazid in rat and man.
Topics: Aluminum Hydroxide; Animals; Antacids; Clinical Trials as Topic; Depression, Chemical; Gastrointesti | 1974 |
Preventive therapy of tuberculosis.
Topics: Adolescent; Adult; Alcoholism; BCG Vaccine; Chemical and Drug Induced Liver Injury; Child; Clinical | 1974 |
[Double blind study of the toxicity of different doses of ethambutol given in an intermittent therapeutic regimen with streptomycin, isoniazide and ethambutol].
Topics: Clinical Trials as Topic; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Placebos; Strept | 1973 |
The effect of isoniazid on transaminase levels.
Topics: Adult; Aspartate Aminotransferases; Female; Humans; Isoniazid; Liver; Liver Function Tests; Male; Mi | 1974 |
Studies demonstrating the effectiveness of isoniazid in preventing tuberculosis.
Topics: Clinical Trials as Topic; Humans; Isoniazid; Placebos; Tuberculin Test; Tuberculosis | 1969 |
Double-blind therapeutic trial of isoniazid in 344 patients with uveitis.
Topics: Clinical Trials as Topic; Humans; Isoniazid; Placebos; Tuberculin Test; Tuberculosis; Uveitis | 1969 |
Controlled chemoprophylaxis trials in tuberculosis. A general review.
Topics: Adolescent; Adult; Age Factors; Alaska; Anemia; Child; Child, Preschool; Clinical Trials as Topic; D | 1970 |
Aspects of the tuberculosis situation in Denmark, especially chemoresistance.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Denmark; Follow-Up Studies; Humans; Isoniazid; Strep | 1969 |
How much isoniazid is needed for prophylaxis?
Topics: Adolescent; Alaska; Child; Clinical Trials as Topic; Follow-Up Studies; Humans; Isoniazid; Placebos; | 1970 |
Clinical applications of ethambutol.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Child, Preschool; Clinical Trials as Topic; Cycloseri | 1969 |
Rifampicin.
Topics: Adenoviridae; Administration, Oral; Animals; Bacteria; Chemical Phenomena; Chemistry; Clinical Trial | 1971 |
The place of BCG vaccine in the management of infants born of tuberculous mothers.
Topics: Adolescent; Adult; BCG Vaccine; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Infant; | 1969 |
Influence of isoniazid on naturally acquired tuberculin allergy and on induction of allergy by BCG vaccination.
Topics: Adolescent; Adult; BCG Vaccine; Child; Female; Humans; Hypersensitivity, Delayed; India; Isoniazid; | 1970 |
Chemoprophylaxis of tuberculosis: when is the benefit worth the risk and cost?
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Costs and Cost Analysis; Denmark; | 1971 |
Isoniazid prophylaxis in contacts of persons with known tuberculosis. Second report.
Topics: Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Communicable Disease Control; | 1965 |
Epidemiological basis of tuberculosis eradication. 4. The isoniazid trial in Greenland.
Topics: Adolescent; Adult; Clinical Trials as Topic; Follow-Up Studies; Greenland; Humans; Isoniazid; Placeb | 1966 |
Carcinogenesis of isoniazid in mice.
Topics: Animals; Carcinogens; Humans; Isoniazid; Lung Neoplasms; Mice; Neoplasms, Experimental; Tuberculosis | 1965 |
5057 other studies available for isoniazid and Koch's Disease
| Article | Year |
|---|---|
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Mul | 2000 |
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Topics: Animals; Antitubercular Agents; Blood; Cell Line; Humans; In Vitro Techniques; Intracellular Membran | 2006 |
Aspirin antagonism in isoniazid treatment of tuberculosis in mice.
Topics: Animals; Antitubercular Agents; Aspirin; Drug Antagonism; Drug Therapy, Combination; Ibuprofen; Ison | 2007 |
Antitubercular nucleosides that inhibit siderophore biosynthesis: SAR of the glycosyl domain.
Topics: Adenosine Triphosphate; Antitubercular Agents; Bacterial Proteins; Cell Wall; Kinetics; Microbial Se | 2006 |
5-Nitrofuran-2-yl derivatives: synthesis and inhibitory activities against growing and dormant mycobacterium species.
Topics: Antitubercular Agents; Combinatorial Chemistry Techniques; Microbial Sensitivity Tests; Mycobacteriu | 2009 |
Design, synthesis and biological evaluation of novel triazole, urea and thiourea derivatives of quinoline against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; ATP Synthetase Complexes; Bacterial Proteins; Cell Survival; Macroph | 2009 |
Novel 4-(morpholin-4-yl)-N'-(arylidene)benzohydrazides: synthesis, antimycobacterial activity and QSAR investigations.
Topics: Antitubercular Agents; Microbial Sensitivity Tests; Morpholines; Mycobacterium tuberculosis; Quantit | 2009 |
Antimycobacterial activity of new 3,5-disubstituted 1,3,4-oxadiazol-2(3H)-one derivatives. Molecular modeling investigations.
Topics: Antitubercular Agents; Bacterial Proteins; Computer Simulation; Cytochrome P-450 Enzyme Inhibitors; | 2009 |
Preparation and antitubercular activities in vitro and in vivo of novel Schiff bases of isoniazid.
Topics: Animals; Antitubercular Agents; Female; Isoniazid; Macrophages; Mice; Mice, Inbred C57BL; Microbial | 2009 |
A facile synthesis and antimycobacterial evaluation of novel spiro-pyrido-pyrrolizines and pyrrolidines.
Topics: Anti-Bacterial Agents; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Mycobact | 2009 |
Salicylanilide carbamates: antitubercular agents active against multidrug-resistant Mycobacterium tuberculosis strains.
Topics: Antitubercular Agents; Carbamates; Cell Line; Cell Proliferation; Humans; Mycobacterium tuberculosis | 2010 |
In vitro antituberculosis activities of ACH-702, a novel isothiazoloquinolone, against quinolone-susceptible and quinolone-resistant isolates.
Topics: Antitubercular Agents; DNA Gyrase; Drug Resistance, Bacterial; Humans; Microbial Sensitivity Tests; | 2010 |
5-Nitro-2,6-dioxohexahydro-4-pyrimidinecarboxamides: synthesis, in vitro antimycobacterial activity, cytotoxicity, and isocitrate lyase inhibition studies.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Chlorocebus aethiops; Com | 2010 |
Isoxazole analogs of curcuminoids with highly potent multidrug-resistant antimycobacterial activity.
Topics: Antitubercular Agents; Curcuma; Curcumin; Humans; Isoxazoles; Microbial Sensitivity Tests; Mycobacte | 2010 |
Schiff bases of indoline-2,3-dione (isatin) derivatives and nalidixic acid carbohydrazide, synthesis, antitubercular activity and pharmacophoric model building.
Topics: Antitubercular Agents; Drug Design; Humans; Hydrazines; Isatin; Models, Molecular; Mycobacterium; Na | 2010 |
Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents.
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Isoniazid; Mycobacterium tuberculosis; NAD; Oxido | 2010 |
Inhibition of mycobacterial replication by pyrimidines possessing various C-5 functionalities and related 2'-deoxynucleoside analogues using in vitro and in vivo models.
Topics: Alkynes; Animals; Antitubercular Agents; Cell Line, Tumor; Deoxycytidine; Deoxyribonucleosides; Huma | 2010 |
Novel dihydropyrimidines as a potential new class of antitubercular agents.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Humans; Inhibitory Concentration 50; Microbial | 2010 |
Novel isatinyl thiosemicarbazones derivatives as potential molecule to combat HIV-TB co-infection.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Cell Line; HIV; HIV Infections; HIV Reverse Transcriptase; I | 2011 |
Identification of novel potential antibiotics for tuberculosis by in silico structure-based drug screening.
Topics: Animals; Anti-Bacterial Agents; Cell Line; Cell Survival; Dogs; Drug Evaluation, Preclinical; Enoyl- | 2011 |
Synthesis and antitubercular evaluation of novel dibenzo[b,d]furan and 9-methyl-9H-carbazole derived hexahydro-2H-pyrano[3,2-c]quinolines via Povarov reaction.
Topics: Antitubercular Agents; Carbazoles; Humans; Imines; Models, Molecular; Mycobacterium tuberculosis; Py | 2011 |
Synthesis of 3-heteroarylthioquinoline derivatives and their in vitro antituberculosis and cytotoxicity studies.
Topics: Animals; Antitubercular Agents; Humans; Mice; Microbial Sensitivity Tests; Models, Molecular; Mycoba | 2011 |
Design, synthesis and docking studies of quinoline-oxazolidinone hybrid molecules and their antitubercular properties.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Catalytic Domain; Drug Design; Enoyl-(Acyl-C | 2011 |
Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.
Topics: Antitubercular Agents; Escherichia coli; Humans; Microbial Sensitivity Tests; Mycobacterium tubercul | 2011 |
Synthesis and in vitro antitubercular evaluation of novel sansanmycin derivatives.
Topics: Antitubercular Agents; China; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oligo | 2011 |
New series of isoniazid hydrazones linked with electron-withdrawing substituents.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Cell Survival; Hep G2 Cells; Humans; Hydrazones; Isoni | 2011 |
Novel 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole derivatives as anti-tubercular agents.
Topics: Antitubercular Agents; Benzothiazoles; Chemistry, Pharmaceutical; Drug Design; Escherichia coli; Hum | 2012 |
Synthesis and evaluation of anti-tubercular and antibacterial activities of new 4-(2,6-dichlorobenzyloxy)phenyl thiazole, oxazole and imidazole derivatives. Part 2.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Humans; Imidazoles; Mi | 2012 |
Design, synthesis of some new (2-aminothiazol-4-yl)methylester derivatives as possible antimicrobial and antitubercular agents.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Crystallography, X-Ray | 2012 |
1,4-diarylpiperazines and analogs as anti-tubercular agents: synthesis and biological evaluation.
Topics: Animals; Antitubercular Agents; Cell Line; Drug Design; Hepatocytes; Humans; Macrophages; Mice; Myco | 2012 |
Novel imidazo[2,1-b][1,3,4]thiadiazole carrying rhodanine-3-acetic acid as potential antitubercular agents.
Topics: Acetates; Antitubercular Agents; Humans; Imidazoles; Microbial Sensitivity Tests; Mycobacterium tube | 2012 |
Anti-mycobacterial activities of some cationic and anionic calix[4]arene derivatives.
Topics: 2,2'-Dipyridyl; Anions; Antitubercular Agents; Calixarenes; Guanidine; Humans; Inhibitory Concentrat | 2012 |
Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Discovery; Female; Isomerism; Mice; Mice, | 2012 |
Green synthesis and anti-infective activities of fluorinated pyrazoline derivatives.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; Green Chemistry | 2012 |
Design and synthesis of biquinolone-isoniazid hybrids as a new class of antitubercular and antimicrobial agents.
Topics: Animals; Anti-Bacterial Agents; Antifungal Agents; Antitubercular Agents; Artemia; Bacteria; Dose-Re | 2013 |
Synthesis and structure-activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Humans; Mycobacterium tuberculosis; Rats; Rats | 2013 |
Studies on substituted benzo[h]quinazolines, benzo[g]indazoles, pyrazoles, 2,6-diarylpyridines as anti-tubercular agents.
Topics: Antitubercular Agents; Cell Line; Humans; Indazoles; Mycobacterium tuberculosis; Pyrazoles; Pyridine | 2013 |
Thiazolopyridine ureas as novel antitubercular agents acting through inhibition of DNA Gyrase B.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; DNA Gyrase; Dose-Response Relationship, Drug | 2013 |
Design, synthesis, and biological evaluation of indole-2-carboxamides: a promising class of antituberculosis agents.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; Humans; Indoles; Mice | 2013 |
Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Microbial Sensitivity Tests; Models, Molecular; M | 2014 |
Rational design and synthesis of novel dibenzo[b,d]furan-1,2,3-triazole conjugates as potent inhibitors of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Benzofurans; Click Chemistry; HEK293 Cells; Humans; Microbial Sensitivity Tes | 2014 |
Design, synthesis, molecular docking and 3D-QSAR studies of potent inhibitors of enoyl-acyl carrier protein reductase as potential antimycobacterial agents.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Design; Humans; Hydrazones; Ligands; Molecular Docki | 2014 |
Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Dose-Response Relationship, Drug; Drug Design; | 2014 |
Design, synthesis and antitubercular evaluation of novel series of N-[4-(piperazin-1-yl)phenyl]cinnamamide derivatives.
Topics: Antitubercular Agents; Cinnamates; Drug Design; Humans; Microbial Sensitivity Tests; Mycobacterium t | 2014 |
1,2,3,4,8,9,10,11-octahydrobenzo[j]phenanthridine-7,12-diones as new leads against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Proliferation; Comet Assay; DNA Damage; Drug Design; Drug Resis | 2014 |
Development of 2-(4-oxoquinazolin-3(4H)-yl)acetamide derivatives as novel enoyl-acyl carrier protein reductase (InhA) inhibitors for the treatment of tuberculosis.
Topics: Acetamides; Animals; Bacterial Proteins; Cell Line; Cell Survival; Dose-Response Relationship, Drug; | 2014 |
Design, synthesis and antimycobacterial activity of various 3-(4-(substitutedsulfonyl)piperazin-1-yl)benzo[d]isoxazole derivatives.
Topics: Animals; Antitubercular Agents; Cell Proliferation; Cells, Cultured; Crystallography, X-Ray; Drug De | 2014 |
Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Benzoxazoles; Cell Line; Humans; Mice; Microbial | 2014 |
Synthesis and antimycobacterial evaluation of 5-alkylamino-N-phenylpyrazine-2-carboxamides.
Topics: Amides; Anti-Bacterial Agents; Antitubercular Agents; Humans; Pyrazinamide; Structure-Activity Relat | 2015 |
Antitubercular activity of quinolizidinyl/pyrrolizidinylalkyliminophenazines.
Topics: Animals; Antitubercular Agents; Cell Line; Cell Survival; Chlorocebus aethiops; Humans; Microbial Se | 2014 |
Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.
Topics: Anti-Bacterial Agents; Antifungal Agents; Bacteria; Bacterial Infections; Benzoates; Fungi; Humans; | 2015 |
Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Topics: Adenosine Triphosphate; Animals; Antitubercular Agents; Male; Mice; Mice, Inbred BALB C; Molecular D | 2015 |
Synthesis and biological evaluation of new imidazo[2,1-b][1,3,4]thiadiazole-benzimidazole derivatives.
Topics: Animals; Antifungal Agents; Antioxidants; Antitubercular Agents; Benzimidazoles; Cell Survival; Chlo | 2015 |
Guanidinium compounds with sub-micromolar activities against Mycobacterium tuberculosis. Synthesis, characterization and biological evaluations.
Topics: Antitubercular Agents; Guanidine; Humans; Models, Molecular; Mycobacterium tuberculosis; Tuberculosi | 2015 |
Pyrazole clubbed triazolo[1,5-a]pyrimidine hybrids as an anti-tubercular agents: Synthesis, in vitro screening and molecular docking study.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Chlorocebus aethiops; Humans; Molecular Docking | 2015 |
Identification of a novel class of quinoline-oxadiazole hybrids as anti-tuberculosis agents.
Topics: Animals; Antitubercular Agents; Cell Survival; Hep G2 Cells; Humans; Microbial Sensitivity Tests; Mi | 2016 |
New direct inhibitors of InhA with antimycobacterial activity based on a tetrahydropyran scaffold.
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Microbial Sensitivity Tests; Models, Molecular; M | 2016 |
Novel morpholinoquinoline nucleus clubbed with pyrazoline scaffolds: Synthesis, antibacterial, antitubercular and antimalarial activities.
Topics: Anti-Infective Agents; Antimalarials; Antitubercular Agents; Bacteria; Bacterial Infections; Fungi; | 2016 |
Synthesis, biological evaluation and molecular docking study of some novel indole and pyridine based 1,3,4-oxadiazole derivatives as potential antitubercular agents.
Topics: Animals; Antitubercular Agents; Cell Line; Humans; Indoles; Microbial Sensitivity Tests; Molecular D | 2016 |
Facile synthesis of 1,3-thiazolidin-4-ones as antitubercular agents.
Topics: Animals; Antitubercular Agents; Cell Line; Combinatorial Chemistry Techniques; Green Chemistry Techn | 2016 |
Investigation of 4-amino-5-alkynylpyrimidine-2(1H)-ones as anti-mycobacterial agents.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Female; Mice | 2016 |
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Design; Female; Hum | 2016 |
Design, development of new synthetic methodology, and biological evaluation of substituted quinolines as new anti-tubercular leads.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Design; HEK293 Cells; Humans; Microbia | 2016 |
Discovery of new chemical entities as potential leads against Mycobacterium tuberculosis.
Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Chlorocebus aethiops; | 2016 |
Discovery of Imidazo[1,2-a]pyridine Ethers and Squaramides as Selective and Potent Inhibitors of Mycobacterial Adenosine Triphosphate (ATP) Synthesis.
Topics: Adenosine Triphosphate; Animals; Antitubercular Agents; Ethers; Humans; Mice; Mice, Inbred BALB C; M | 2017 |
Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Binding Sites; Catalytic | 2017 |
Amphiphilic Indole Derivatives as Antimycobacterial Agents: Structure-Activity Relationships and Membrane Targeting Properties.
Topics: Animals; Antitubercular Agents; Cell Line; Female; Humans; Indoles; Male; Microsomes, Liver; Molecul | 2017 |
In vivo potent BM635 analogue with improved drug-like properties.
Topics: Animals; Antitubercular Agents; Cell Proliferation; Cell Survival; Disease Models, Animal; Dose-Resp | 2018 |
Design, synthesis and antitubercular evaluation of benzothiazinones containing a piperidine moiety.
Topics: Animals; Antitubercular Agents; Drug Design; Female; Humans; Mice, Inbred ICR; Microbial Sensitivity | 2018 |
New lipophilic isoniazid derivatives and their 1,3,4-oxadiazole analogues: Synthesis, antimycobacterial activity and investigation of their mechanism of action.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Hep G2 Cells; Humans; Isoniazid; Microbial Sensit | 2018 |
Overview of the Development of DprE1 Inhibitors for Combating the Menace of Tuberculosis.
Topics: Alcohol Oxidoreductases; Antitubercular Agents; Bacterial Proteins; Drug Development; Humans; Mycoba | 2018 |
Synthesis of carbohydrazides and carboxamides as anti-tubercular agents.
Topics: Antitubercular Agents; Caco-2 Cells; Drug Design; HEK293 Cells; Humans; Hydrazines; Microbial Sensit | 2018 |
Easy-To-Synthesize Spirocyclic Compounds Possess Remarkable in Vivo Activity against Mycobacterium tuberculosis.
Topics: Administration, Intravenous; Administration, Oral; Animals; Antitubercular Agents; Biological Availa | 2018 |
Identification and Profiling of Hydantoins-A Novel Class of Potent Antimycobacterial DprE1 Inhibitors.
Topics: Actinobacteria; Alcohol Oxidoreductases; Antitubercular Agents; Bacterial Proteins; Drug Stability; | 2018 |
Phenolic N-monosubstituted carbamates: Antitubercular and toxicity evaluation of multi-targeting compounds.
Topics: Antitubercular Agents; Carbamates; Hep G2 Cells; Humans; Isocitrate Lyase; Mycobacterium tuberculosi | 2019 |
Identification of benzothiazinones containing an oxime functional moiety as new anti-tuberculosis agents.
Topics: Animals; Antitubercular Agents; Drug Design; Female; Humans; Mice, Inbred ICR; Microbial Sensitivity | 2019 |
Transferrin conjugates of antitubercular drug isoniazid: Synthesis and in vitro efficacy.
Topics: Antitubercular Agents; Drug Stability; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium | 2019 |
Design, synthesis, and evaluation of new 2-(quinoline-4-yloxy)acetamide-based antituberculosis agents.
Topics: Animals; Antitubercular Agents; Cell Survival; Cells, Cultured; Chlorocebus aethiops; Dose-Response | 2020 |
Indole chalcones: Design, synthesis, in vitro and in silico evaluation against Mycobacterium tuberculosis.
Topics: Amino Acid Sequence; Animals; Antitubercular Agents; Cell Line; Cell Survival; Chalcones; Drug Evalu | 2020 |
Synthesis and evaluation of heterocycle structures as potential inhibitors of Mycobacterium tuberculosis UGM.
Topics: 4-Butyrolactone; Antitubercular Agents; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Ind | 2020 |
Anti-tubercular profile of new selenium-menadione conjugates against Mycobacterium tuberculosis H37Rv (ATCC 27294) strain and multidrug-resistant clinical isolates.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Humans; Models, Molecular; Mycobacterium tuber | 2021 |
Synthesis and biological evaluation of anti-tubercular activity of Schiff bases of 2-Amino thiazoles.
Topics: Amination; Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; S | 2020 |
Design and synthesis of 2-(2-isonicotinoylhydrazineylidene)propanamides as InhA inhibitors with high antitubercular activity.
Topics: Amides; Aniline Compounds; Antitubercular Agents; Bacterial Proteins; Cell Survival; Drug Design; Dr | 2021 |
Mycobactin Analogues with Excellent Pharmacokinetic Profile Demonstrate Potent Antitubercular Specific Activity and Exceptional Efflux Pump Inhibition.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Calcium Channel Blockers; Ion Transport; Iron Ch | 2022 |
Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Biological Availability; Mice; Prodrugs; Tuberc | 2022 |
Structure-activity relationship of 2-aminodibenzothiophene pharmacophore and the discovery of aminobenzothiophenes as potent inhibitors of Mycobacterium smegmatis.
Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium smegmatis; Mycobacterium t | 2022 |
Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.
Topics: Amines; Animals; Antitubercular Agents; Benzoxazoles; Chlorocebus aethiops; Microbial Sensitivity Te | 2022 |
Drug screening approach against mycobacterial fatty acyl-AMP ligase FAAL32 renews the interest of the salicylanilide pharmacophore in the fight against tuberculosis.
Topics: Adenosine Monophosphate; Antitubercular Agents; Drug Evaluation, Preclinical; Humans; Mycobacterium | 2022 |
Nitroimidazopyrazinones with Oral Activity against Tuberculosis and Chagas Disease in Mouse Models of Infection.
Topics: Animals; Chagas Disease; Disease Models, Animal; Mice; Mycobacterium tuberculosis; Nitroimidazoles; | 2022 |
Discovery of biphenyls bearing thiobarbiturate fragment by structure-based strategy as Mycobacterium tuberculosis protein tyrosine phosphatase B inhibitors.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Biphenyl Compounds; Enzyme Inhibitors; Mice; Mol | 2022 |
Tuberculosis Preventive Therapy for People With Diabetes Mellitus.
Topics: Diabetes Mellitus; Humans; Isoniazid; Tuberculosis | 2022 |
PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.
Topics: Acetylation; Adult; Aged; Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 CYP | 2021 |
Tuberculosis preventive treatment in people living with HIV-Is the glass half empty or half full?
Topics: Antibiotic Prophylaxis; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis | 2021 |
Low prevalence of isoniazid preventive therapy uptake among HIV-infected patients attending tertiary health facility in Lagos, Southwest Nigeria.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cross-Sectional Studies; | 2021 |
TB in paediatric kidney transplant recipients - A single-centre experience.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Graft Survival; Humans; Incidenc | 2022 |
Using Isoniazid More Safely and More Effectively: The Time Is Now.
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 2021 |
Flow cytometry method for absolute counting and single-cell phenotyping of mycobacteria.
Topics: Colony Count, Microbial; Flow Cytometry; Humans; Immunologic Tests; Isoniazid; Kanamycin; Mycobacter | 2021 |
Tuberculosis screening coverage and isoniazid preventive therapy among people living with HIV at Gambella Hospital, southwest Ethiopia: a retrospective study design.
Topics: Adolescent; Adult; Antitubercular Agents; Ethiopia; HIV Infections; Hospitals; Humans; Isoniazid; Ma | 2021 |
Diagnostic performance of the Abbott RealTime MTB assay for tuberculosis diagnosis in people living with HIV.
Topics: Adult; DNA, Bacterial; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Isoniazid; Male; | 2021 |
A Quality Improvement Intervention to Inform Scale-Up of Integrated HIV-TB Services: Lessons Learned From KwaZulu-Natal, South Africa.
Topics: HIV Infections; Humans; Isoniazid; Quality Improvement; South Africa; Tuberculosis | 2021 |
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study.
Topics: Adult; Amikacin; Australia; Capreomycin; Cross-Sectional Studies; Drug Resistance, Bacterial; Ethion | 2022 |
Evaluation of tuberculosis diagnostic tools, with extending MODS assay use to second line susceptibility testing.
Topics: Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Tuberculosis; Tuberculos | 2021 |
Novel mutations detected from drug resistant Mycobacterium tuberculosis isolated from North East of Thailand.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; DNA, Bacterial; D | 2021 |
Paediatric management of a tuberculosis outbreak in an Irish Direct Provision Centre.
Topics: Adult; Child; Disease Outbreaks; Humans; Isoniazid; Latent Tuberculosis; Retrospective Studies; Tube | 2022 |
Adherence of HIV clinics to guidelines for the delivery of TB screening among people living with HIV/AIDS in Ghana.
Topics: Antitubercular Agents; Cross-Sectional Studies; Ghana; HIV Infections; Humans; Isoniazid; Tuberculos | 2021 |
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study.
Topics: Adult; Antitubercular Agents; Child; Drug Combinations; Ethambutol; Female; Humans; Infant; Isoniazi | 2022 |
Effect of mobile-phone messaging on patient and health-worker knowledge and adherence to the isoniazid preventive therapy guideline in HIV clinics in Southeast, Nigeria.
Topics: Antitubercular Agents; Cell Phone; Guideline Adherence; HIV Infections; Humans; Isoniazid; Nigeria; | 2021 |
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; Rifampin; | 2022 |
Real-life isoniazid and rifampicin plasma concentrations in children: a tool for therapeutic drug monitoring of tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Monitoring; Humans; In | 2021 |
Risk of childhood TB from non-adherence to isoniazid chemoprophylaxis.
Topics: Antitubercular Agents; Chemoprevention; Child; Humans; Isoniazid; Medication Adherence; Tuberculosis | 2021 |
LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Ethambutol; Humans; Is | 2021 |
Safety of latent tuberculosis infection treatment in older patients with immune-mediated inflammatory diseases.
Topics: Aged; Antitubercular Agents; Female; Humans; Isoniazid; Latent Tuberculosis; Middle Aged; Retrospect | 2022 |
The impact of blood transcriptomic biomarker targeted tuberculosis preventive therapy in people living with HIV: a mathematical modelling study.
Topics: Antitubercular Agents; Biomarkers; HIV Infections; Humans; Isoniazid; Mass Screening; Transcriptome; | 2021 |
Novel Assay Platform to Evaluate Intracellular Killing of
Topics: Animals; Antimicrobial Peptides; Antitubercular Agents; Biological Assay; Bronchi; Cell Line; Cell-P | 2021 |
Isoniazid or rifampicin preventive therapy with and without screening for subclinical TB: a modeling analysis.
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Res | 2021 |
Genomic signatures of pre-resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Genome, Bacterial; Genomics; Humans; Is | 2021 |
Thermodynamic integration combined with molecular dynamic simulations to explore the cross-resistance mechanism of isoniazid and ethionamide.
Topics: Bacterial Proteins; Ethionamide; Humans; Isoniazid; Molecular Dynamics Simulation; Mutation; Mycobac | 2022 |
Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Bayes Theorem; Genotype; Humans; Indonesia; Is | 2022 |
Estimating tuberculosis drug resistance amplification rates in high-burden settings.
Topics: Antitubercular Agents; Drug Resistance; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacteriu | 2022 |
Adherence to Isoniazid Preventive Therapy among children living with tuberculosis patients in Delhi, India: An exploratory prospective study.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; India; Isoniazid; Prospective Studies; Tubercu | 2022 |
Influence of NAT2 Genotype and Maturation on Isoniazid Exposure in Low-Birth-Weight and Preterm Infants With or Without Human Immunodeficiency Virus (HIV) Exposure.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Child, Preschool; Genotype; HIV; HIV Infection | 2022 |
[Association between isoniazid induced hepatotoxicity and host N-acetyltransferase 2 polymorphisms].
Topics: Acetyltransferases; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced | 2022 |
Evaluation of diagnostic components and management of childhood pulmonary tuberculosis: a prospective study from Istanbul, Turkey.
Topics: Humans; Isoniazid; Prospective Studies; Tuberculin Test; Tuberculosis; Tuberculosis, Pulmonary; Turk | 2022 |
Improving enrolment for TB preventive treatment.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 2022 |
Prediction of lung exposure to anti-tubercular drugs using plasma pharmacokinetic data: Implications for dose selection.
Topics: Animals; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Lung; Mice; Pyrazinamide; Tuberculosi | 2022 |
Time to start of tuberculosis treatment in penitentiary system of Kyrgyz Republic: A retrospective cohort study.
Topics: Humans; Isoniazid; Kyrgyzstan; Mycobacterium tuberculosis; Prisons; Retrospective Studies; Rifampin; | 2022 |
Molecular insights of hyaluronic acid - ethambutol and hyaluronic acid - isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis.
Topics: Antitubercular Agents; Ethambutol; Humans; Hyaluronic Acid; Isoniazid; Molecular Docking Simulation; | 2023 |
Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Diarylquinolines; Disease Models, Anima | 2022 |
Assessment of the efficacy of clofazimine alone and in combination with primary agents against Mycobacterium tuberculosis in vitro.
Topics: Animals; Antitubercular Agents; Clofazimine; Ethambutol; Humans; Isoniazid; Mice; Mycobacterium tube | 2022 |
Time for Isoniazid Pharmacogenomic-Guided Therapy of Tuberculosis Based on NAT2 Acetylation Profiles in India.
Topics: Acetylation; Antitubercular Agents; Arylamine N-Acetyltransferase; Humans; India; Isoniazid; Pharmac | 2022 |
The Impact of a Knowledge Discovery-Based Psychoanalytic Intervention in the Treatment of Tuberculosis in University Students with Different Doses of Isoniazid.
Topics: Humans; Isoniazid; Knowledge Discovery; Students; Tuberculosis; Universities | 2022 |
Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy.
Topics: Adult; Antitubercular Agents; Brazil; Cohort Studies; HIV Infections; Humans; Isoniazid; Tuberculosi | 2022 |
Lack of reactivation of tuberculosis in patients with psoriasis treated with secukinumab in a real-world setting of latent tuberculosis infection.
Topics: Antibodies, Monoclonal, Humanized; Humans; Isoniazid; Latent Tuberculosis; Psoriasis; Retrospective | 2022 |
Barriers and facilitators for isoniazid preventive therapy (IPT) administration in children under 5 years of age in the Dominican Republic.
Topics: Antitubercular Agents; Child; Child, Preschool; Dominican Republic; HIV Infections; Humans; Isoniazi | 2022 |
Isoniazid-associated pellagra during mass scale-up of tuberculosis preventive therapy: a case-control study.
Topics: Antitubercular Agents; Case-Control Studies; Exanthema; Female; HIV Infections; Humans; Isoniazid; M | 2022 |
Can you treat non-severe tuberculosis with a shorter regimen?
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Treatment Outcome; Tuberculosis | 2022 |
Tuberculosis and isoniazid prophylaxis among adult HIV positive patients on ART in Northwest Ethiopia.
Topics: Adult; Antitubercular Agents; Ethiopia; HIV Infections; HIV Seropositivity; Humans; Incidence; Isoni | 2022 |
Synthesis and Antimycobacterial Evaluation of
Topics: Aminoquinolines; Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacteriu | 2022 |
Association between Mycobacterium tuberculosis genotype and diabetes mellitus/hypertension: a molecular study.
Topics: Cross-Sectional Studies; Diabetes Mellitus; Genotype; Humans; Hypertension; Isoniazid; Mycobacterium | 2022 |
Whole genome sequencing of multidrug-resistant Mycobacterium tuberculosis isolates collected in the Czech Republic, 2005-2020.
Topics: Antitubercular Agents; Czech Republic; Drug Resistance, Multiple, Bacterial; Genotype; Humans; Isoni | 2022 |
Sustained effect of isoniazid preventive therapy among household contacts in Brazil.
Topics: Brazil; Family Characteristics; Humans; Isoniazid; Retrospective Studies; Tuberculin Test; Tuberculo | 2022 |
Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.
Topics: Antitubercular Agents; Cohort Studies; HIV Infections; Humans; Incidence; Isoniazid; Multicenter Stu | 2022 |
Primary psoas tuberculosis abscess with an iliac bone lytic lesion: a case report.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Psoas Abscess; Pyrazinamide; Rifampin; Tube | 2022 |
Diagnostic Accuracy of Therapeutic Drug Monitoring During Tuberculosis Treatment.
Topics: Antitubercular Agents; Drug Monitoring; Ethambutol; HIV Infections; Humans; Isoniazid; Pyrazinamide; | 2022 |
Molecular detection of isoniazid monoresistance improves tuberculosis treatment: A retrospective cohort in France.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; R | 2022 |
Effect of different interventions for latent tuberculosis infections in China: a model-based study.
Topics: Adolescent; Aged; Antitubercular Agents; China; Humans; Incidence; Isoniazid; Latent Tuberculosis; T | 2022 |
Isoniazid preventive therapy and tuberculosis transcriptional signatures in people with HIV.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV Infections; Humans; Isoniazid; Tuberculos | 2022 |
Intelligence Classification Algorithm-Based Drug-Resistant Pulmonary Tuberculosis Computed Tomography Imaging Features and Influencing Factors.
Topics: Adult; Algorithms; Antitubercular Agents; Humans; Intelligence; Isoniazid; Lung; Middle Aged; Rifamp | 2022 |
Synthesis, Molecular Docking, and
Topics: Antitubercular Agents; Ciprofloxacin; Ethanol; Humans; Hydrazones; Isoniazid; Molecular Docking Simu | 2022 |
Enteropathogen spectrum and effect on antimycobacterial pharmacokinetics among children with tuberculosis in rural Tanzania: a prospective cohort study.
Topics: Antitubercular Agents; Child; Cohort Studies; Ethambutol; Female; Humans; Isoniazid; Male; Prospecti | 2022 |
Prevalence and Drug Resistance Pattern of
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; | 2022 |
An effective nano drug delivery and combination therapy for the treatment of Tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Fluoxetine; Humans; Isoniazid | 2022 |
High-Throughput Variant Detection Using a Color-Mixing Strategy.
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; | 2022 |
Designing quinoline-isoniazid hybrids as potent anti-tubercular agents inhibiting mycolic acid biosynthesis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Isoniazid; Mammals; Mycobacterium tuberculosis; | 2022 |
Incidence of TB among kidney transplant recipients in a setting with universal isoniazid prophylaxis.
Topics: Antitubercular Agents; Humans; Incidence; Isoniazid; Kidney Transplantation; Retrospective Studies; | 2022 |
Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally.
Topics: Europe; Humans; Isoniazid; Rifampin; Tuberculosis | 2022 |
Diagnosing osteo-articular tuberculosis and multidrug resistance using real-time polymerase chain reaction and high-resolution melt-curve analysis.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Isoniazid; Microbial Sensitivit | 2023 |
Non-actionable Results, Accuracy, and Effect of First- and Second-line Line Probe Assays for Diagnosing Drug-Resistant Tuberculosis, Including on Smear-Negative Specimens, in a High-Volume Laboratory.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; R | 2023 |
Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs.
Topics: Animals; Antitubercular Agents; Isoniazid; Latent Tuberculosis; Lung; Macaca mulatta; Mycobacterium | 2022 |
The impact of HIV and tuberculosis interventions on South African adult tuberculosis trends, 1990-2019: a mathematical modeling analysis.
Topics: Adult; Bayes Theorem; HIV Infections; Humans; Incidence; Isoniazid; South Africa; Tuberculosis | 2022 |
Altered drug exposures of first-line TB drugs in a moxifloxacin-containing treatment regimen.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Moxifloxacin; Pregnanes; Pyrazi | 2022 |
Promoting tuberculosis preventive therapy in HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis | 2022 |
Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Isoniazid; Li | 2022 |
Drop-offs in the isoniazid preventive therapy cascade among children living with HIV in western Kenya, 2015-2019.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; Isoniazid; Kenya; Tuberculosis | 2022 |
Prevalence and associated factors of tuberculosis among isoniazid users and non-users of HIV patients in Dessie, Ethiopia.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Ethiopia; HIV Infections; Humans; Incidence; | 2022 |
Dual Rifampicin and Isoniazid Mannose-Decorated Lipopolysaccharide Nanospheres for Macrophage- Targeted Lung Delivery.
Topics: Humans; Isoniazid; Lipopolysaccharides; Macrophages; Mannose; Nanoparticles; Nanospheres; Rifampin; | 2023 |
Determinants of stock-outs of first line anti-tuberculosis drugs: the case of public health facilities of Addis Ababa city administration health bureau, Addis Ababa, Ethiopia.
Topics: Antitubercular Agents; Ethiopia; Health Facilities; Humans; Isoniazid; Retrospective Studies; Rifamp | 2022 |
Use of 3HP for TB preventive treatment in prisons.
Topics: Antitubercular Agents; Humans; Isoniazid; Prisons; Rifampin; Tuberculosis | 2022 |
Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010-2016.
Topics: Antitubercular Agents; Canada; Humans; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; R | 2022 |
An evaluation of the isoniazid preventive therapy program performance for under-fives in Kwekwe City, January 2019 - December 2020: a descriptive cross-sectional study.
Topics: Antitubercular Agents; Child; Contact Tracing; Cross-Sectional Studies; HIV Infections; Humans; Ison | 2022 |
Human Kinase IGF1R/IR Inhibitor Linsitinib Controls the In Vitro and Intracellular Growth of
Topics: Adenosine Triphosphate; Anti-Bacterial Agents; Glutamine; Humans; Imidazoles; Isoniazid; Lipids; Myc | 2022 |
Effectiveness and safety of available preventive tuberculosis treatment regimens for children and adolescents: protocol for a systematic review and network meta-analysis.
Topics: Adolescent; Child; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Network Meta-Analysis; Sy | 2022 |
Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
Topics: Antitubercular Agents; Chromatography, Liquid; Cytochrome P-450 CYP2C19; Enzyme Induction; HIV Infec | 2022 |
Bacterial FtsZ inhibition by benzo[
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Imidazoles; Isoniazid; Microbial Sensitivity Test | 2022 |
A world without tuberculosis: moving from imagination to reality.
Topics: Animals; Imagination; Isoniazid; Latent Tuberculosis; Mycobacterium tuberculosis; Tuberculosis | 2022 |
Tuberculosis: Common Questions and Answers.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Latent Tuberculosis; Pyrazinamide; Rifampin; T | 2022 |
Pyrazinamide resistance in rifampicin discordant tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuber | 2022 |
Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis patients on a newly introduced daily dose regimen in South India: A cross-sectional study.
Topics: Antitubercular Agents; Clinical Protocols; Cross-Sectional Studies; Humans; India; Isoniazid; Tuberc | 2022 |
Tuberculosis screening after detection of a case in a paediatric haemato-oncology unit in a low prevalence country.
Topics: Adult; Antitubercular Agents; Child; Humans; Isoniazid; Latent Tuberculosis; Prevalence; Tuberculosi | 2022 |
Drug resistance profile of Mycobacterium kansasii clinical isolates before and after 2-month empirical antimycobacterial treatment.
Topics: Anti-Bacterial Agents; Antitubercular Agents; China; Ethambutol; Humans; Isoniazid; Lung Diseases; M | 2023 |
A Mycobacterium tuberculosis-Infected Patient Who Could Not Tolerate Oral Intake Successfully Treated Using an Intravenous Tedizolid-Containing Regimen.
Topics: Aged; Anti-Bacterial Agents; Antitubercular Agents; Cutaneous Fistula; Ethambutol; Humans; Isoniazid | 2022 |
A facile one-step jet-milling approach for the preparation of proliposomal dry powder for inhalation as effective delivery system for anti-TB therapeutics.
Topics: Administration, Inhalation; Aerosols; Dry Powder Inhalers; Humans; Isoniazid; Liposomes; Particle Si | 2022 |
Anti-Mycobacterial Activity of Flavonoid and Pyrimidine Compounds.
Topics: Antitubercular Agents; Clarithromycin; Cycloserine; Drug Combinations; Flavonoids; Humans; Isoniazid | 2022 |
Isoniazid prophylaxis: highly effective but underutilised to prevent tuberculosis in people living with HIV.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis | 2022 |
Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania.
Topics: Antitubercular Agents; CD4 Lymphocyte Count; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazi | 2022 |
Feasibility, Ease-of-Use, and Operational Characteristics of World Health Organization-Recommended Moderate-Complexity Automated Nucleic Acid Amplification Tests for the Detection of Tuberculosis and Resistance to Rifampicin and Isoniazid.
Topics: Feasibility Studies; Humans; Isoniazid; Mycobacterium tuberculosis; Nucleic Acid Amplification Techn | 2023 |
A test of infection should not be a "standard" for guiding TB preventive therapy in at-risk populations.
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculin Test; Tuberculosis | 2022 |
Development and Optimization of a New UPLC-UV/MS Method through DoE and MLR for Detecting Substandard Drug Products to Treat Tuberculosis.
Topics: Antitubercular Agents; Chromatography, Liquid; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin | 2022 |
[An atypical presentation of tuberculosis].
Topics: Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Microbial Sensitivity Tests; Middle Ag | 2022 |
A high-throughput LC-MS/MS method for simultaneous determination of isoniazid, ethambutol and pyrazinamide in human plasma.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Ethambutol; Hum | 2023 |
Clinical, Microbiological Profile and Treatment Outcomes of Infants with BCG Adenitis: A Retrospective Study.
Topics: BCG Vaccine; Child; Humans; Infant; Isoniazid; Lymphadenitis; Mycobacterium bovis; Retrospective Stu | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Assessment of contextual factors shaping delivery and uptake of isoniazid preventive therapy among people living with HIV in Dar es salaam, Tanzania.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tanzania; Tuberculosis | 2022 |
Using the Food and Drug Administration´s Sentinel System for surveillance of TB infection.
Topics: Antitubercular Agents; Drug Prescriptions; Humans; Isoniazid; Rifampin; Tuberculosis; United States; | 2022 |
Using the Food and Drug Administration´s Sentinel System for surveillance of TB infection.
Topics: Antitubercular Agents; Drug Prescriptions; Humans; Isoniazid; Rifampin; Tuberculosis; United States; | 2022 |
Using the Food and Drug Administration´s Sentinel System for surveillance of TB infection.
Topics: Antitubercular Agents; Drug Prescriptions; Humans; Isoniazid; Rifampin; Tuberculosis; United States; | 2022 |
Using the Food and Drug Administration´s Sentinel System for surveillance of TB infection.
Topics: Antitubercular Agents; Drug Prescriptions; Humans; Isoniazid; Rifampin; Tuberculosis; United States; | 2022 |
Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Humans; Isoniazid; Microbial Sensitivity Tests; | 2023 |
Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Humans; Isoniazid; Microbial Sensitivity Tests; | 2023 |
Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Humans; Isoniazid; Microbial Sensitivity Tests; | 2023 |
Genetic mutations underlying isoniazid-resistant Mycobacterium tuberculosis in Khyber Pakhtunkhwa, Pakistan.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Humans; Isoniazid; Microbial Sensitivity Tests; | 2023 |
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Isoniaz | 2022 |
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Isoniaz | 2022 |
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Isoniaz | 2022 |
Quantitative Analysis of Isoniazid and Its Four Primary Metabolites in Plasma of Tuberculosis Patients Using LC-MS/MS.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Isoniaz | 2022 |
Tuberculosis treatment without rifampin in kidney/kidney-pancreas transplantation: A case series report.
Topics: Adult; Antitubercular Agents; Humans; Immunosuppressive Agents; Isoniazid; Kidney; Middle Aged; Panc | 2022 |
Tuberculosis treatment without rifampin in kidney/kidney-pancreas transplantation: A case series report.
Topics: Adult; Antitubercular Agents; Humans; Immunosuppressive Agents; Isoniazid; Kidney; Middle Aged; Panc | 2022 |
Tuberculosis treatment without rifampin in kidney/kidney-pancreas transplantation: A case series report.
Topics: Adult; Antitubercular Agents; Humans; Immunosuppressive Agents; Isoniazid; Kidney; Middle Aged; Panc | 2022 |
Tuberculosis treatment without rifampin in kidney/kidney-pancreas transplantation: A case series report.
Topics: Adult; Antitubercular Agents; Humans; Immunosuppressive Agents; Isoniazid; Kidney; Middle Aged; Panc | 2022 |
Gallium and indium complexes with isoniazid-derived ligands: Interaction with biomolecules and biological activity against cancer cells and Mycobacterium tuberculosis.
Topics: Antineoplastic Agents; Coordination Complexes; Gallium; Humans; Indium; Isoniazid; Ligands; Male; My | 2023 |
Gallium and indium complexes with isoniazid-derived ligands: Interaction with biomolecules and biological activity against cancer cells and Mycobacterium tuberculosis.
Topics: Antineoplastic Agents; Coordination Complexes; Gallium; Humans; Indium; Isoniazid; Ligands; Male; My | 2023 |
Gallium and indium complexes with isoniazid-derived ligands: Interaction with biomolecules and biological activity against cancer cells and Mycobacterium tuberculosis.
Topics: Antineoplastic Agents; Coordination Complexes; Gallium; Humans; Indium; Isoniazid; Ligands; Male; My | 2023 |
Gallium and indium complexes with isoniazid-derived ligands: Interaction with biomolecules and biological activity against cancer cells and Mycobacterium tuberculosis.
Topics: Antineoplastic Agents; Coordination Complexes; Gallium; Humans; Indium; Isoniazid; Ligands; Male; My | 2023 |
Evaluation Study of xMAP TIER Assay on a Microsphere-Based Platform for Detecting First-Line Anti-Tuberculosis Drug Resistance.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tests; Microspheres; Myc | 2022 |
Ultrasensitive Detection of Multidrug-Resistant
Topics: Antitubercular Agents; DNA, Bacterial; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; Myc | 2022 |
Evaluation of Five User-Friendly Whole Genome Sequencing Software for
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Isoniazid; Microbial Sensitivit | 2022 |
Large-scale genomic analysis of Mycobacterium tuberculosis reveals extent of target and compensatory mutations linked to multi-drug resistant tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Genomics; Humans; Isoniazid; Microbial Sensitivity Tests; | 2023 |
Implementation of an integrated care strategy for child contacts of tuberculosis patients: a quasi-experimental study protocol.
Topics: Child; Child, Preschool; Delivery of Health Care, Integrated; Humans; Isoniazid; Latent Tuberculosis | 2023 |
Prevalence of latent tuberculosis infection and incidence of tuberculin conversion among school contacts older than 5 years in the City of Buenos Aires.
Topics: Adolescent; Child; Humans; Incidence; Isoniazid; Latent Tuberculosis; Prevalence; Tuberculin; Tuberc | 2023 |
Urinary excretion of metformin in diabetic patients with and without tuberculosis.
Topics: Antitubercular Agents; Diabetes Mellitus; Humans; India; Isoniazid; Metformin; Pyrazinamide; Tubercu | 2023 |
An efficient CRISPR interference-based prediction method for synergistic/additive effects of novel combinations of anti-tuberculosis drugs.
Topics: Antitubercular Agents; Clustered Regularly Interspaced Short Palindromic Repeats; Ethambutol; Humans | 2022 |
A host blood transcriptional signature differentiates multi-drug/rifampin-resistant tuberculosis (MDR/RR-TB) from drug susceptible tuberculosis: a pilot study.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2023 |
Genomic Sequencing from Sputum for Tuberculosis Disease Diagnosis, Lineage Determination, and Drug Susceptibility Prediction.
Topics: Antitubercular Agents; Genomics; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuber | 2023 |
The Dysbiosis Triggered by First-Line Tuberculosis Antibiotics Fails to Reduce Their Bioavailability.
Topics: Animals; Antitubercular Agents; Biological Availability; Dysbiosis; Humans; Isoniazid; Mice; Moxiflo | 2023 |
Variation in Treatment of Pediatric Tuberculosis Infection in Different Provider Settings.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Infant; Isoniazid; Latent Tuberculo | 2023 |
[Investigation of Efflux Pump Genes in Resistant Mycobacterium tuberculosis Complex Clinical Isolates Exposed to First Line Antituberculosis Drugs and Verapamil Combination].
Topics: Antitubercular Agents; Bacterial Proteins; DNA, Complementary; Humans; Isoniazid; Microbial Sensitiv | 2023 |
Dynamin-like proteins mediate extracellular vesicle secretion in Mycobacterium tuberculosis.
Topics: Dynamins; Extracellular Vesicles; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 2023 |
Scale-Up of Rifapentine and Isoniazid for Tuberculosis Prevention Among Household Contacts in 2 Urban Centers: An Effectiveness Assessment.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Latent Tuberculosis; Male; Tube | 2023 |
Acquired drug resistance during the turnaround time for drug susceptibility testing impacts outcome of tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2023 |
Anti-tubercular therapy (ATT) induced exfoliative dermatitis-A case series.
Topics: Antitubercular Agents; Dermatitis, Exfoliative; Humans; Isoniazid; Pyrazinamide; Tuberculosis | 2023 |
Is it time for new fixed-dose combinations and revised weight bands for children with drug-susceptible TB?
Topics: Antitubercular Agents; Child; Drug Combinations; Humans; Isoniazid; Tuberculosis | 2023 |
Healthcare workers' knowledge and practice of the South African national tuberculosis management guidelines.
Topics: Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Isoniazid; Male; South Africa; Tuber | 2023 |
Cisatracurium besylate rescues Mycobacterium Tuberculosis-infected macrophages from necroptosis and enhances the bactericidal effect of isoniazid.
Topics: Animals; Anti-Bacterial Agents; Apoptosis; Isoniazid; Macrophages; Mice; Mycobacterium tuberculosis; | 2023 |
The Effect of Inoculum Size on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Culture Media; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium | 2023 |
Molecular and cellular remodeling of HepG2 cells upon treatment with antitubercular drugs.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Hep G2 Cells; Humans; Isoniazid; Pyra | 2023 |
Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use.
Topics: Alcohol Drinking; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Prospective Studies; Tub | 2023 |
Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Contraception, Postcoital; Cytochrome P-450 CY | 2023 |
Isoniazid-N-acylhydrazones as promising compounds for the anti-tuberculosis treatment.
Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacter | 2023 |
Clinicopathological profile of peritoneal tuberculosis and a new scoring model for predicting mortality: an international ID-IRI study.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Liver Cirrhosis; Male; Midd | 2023 |
Antimycobacterial pyridine carboxamides: From design to in vivo activity.
Topics: Aminosalicylic Acid; Animals; Antitubercular Agents; Humans; Isoniazid; Methionine; Mice; Microbial | 2023 |
A physiologically-based pharmacokinetic model for tuberculosis drug disposition at extrapulmonary sites.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis | 2023 |
Estimating the prevalence of poor-quality anti-TB medicines: a neglected risk for global TB control and resistance.
Topics: Antitubercular Agents; Humans; Isoniazid; Prevalence; Rifampin; Tuberculosis | 2023 |
Standardization and validation of a novel UPLC-MS/MS method to quantify first line anti-tuberculosis drugs in plasma and dried blood spots.
Topics: Antitubercular Agents; Bayes Theorem; Chromatography, High Pressure Liquid; Chromatography, Liquid; | 2023 |
[Recommendations for contact tracing for tuberculosis - update 2023].
Topics: Adult; Child; Contact Tracing; Humans; Isoniazid; Rifampin; Tuberculin Test; Tuberculosis | 2023 |
Uncommon but Clinically Significant: Bacillus Calmette-Guerin (BCG) Infection of the Urinary Tract and its Impact on Quality of Life.
Topics: Aged; Aged, 80 and over; BCG Vaccine; Ethambutol; Humans; Isoniazid; Male; Mycobacterium bovis; Qual | 2023 |
Newer TB diagnostics: An update.
Topics: Antibiotics, Antitubercular; Drug Resistance, Bacterial; Humans; Isoniazid; Mycobacterium tuberculos | 2023 |
Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival of
Topics: Animals; Autophagy; Curcumin; Isoniazid; Macrophages; Mice; Mycobacterium tuberculosis; Tuberculosis | 2023 |
Application of a physiologically based pharmacokinetic model to predict isoniazid disposition during pregnancy.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Genotype; Humans; Isoniazid; Phenotype | 2023 |
Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia.
Topics: Amikacin; Antitubercular Agents; Capreomycin; Drug Resistance, Multiple, Bacterial; Ethambutol; Ethi | 2023 |
Community-supported self-administered tuberculosis treatment combined with active tuberculosis screening: a pilot experience in Conakry, Guinea.
Topics: Antitubercular Agents; Child; Child, Preschool; Female; Guinea; Humans; Isoniazid; Male; Tuberculosi | 2023 |
Rv1255c, a dormancy-related transcriptional regulator of TetR family in Mycobacterium tuberculosis, enhances isoniazid tolerance in Mycobacterium smegmatis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacterial Proteins; Catalase; Humans; Isoniazid; Mycob | 2023 |
Protein binding investigation of first-line and second-line antituberculosis drugs.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Levofloxacin; Linezolid; Moxifloxacin; Protein | 2023 |
Compliance level to Tuberculosis prophylaxis in patients undergoing therapy with tumor necrosis factor-alpha inhibitors: a cross-sectional study.
Topics: Adult; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Immunologic Factors; Isoniazi | 2023 |
Prevalence and predictors of tuberculosis among HIV patients who completed isoniazid preventive therapy (IPT) at Reach out Mbuya community health initiative.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV; HIV Infections; HIV Seropositivity; Huma | 2023 |
[Recommendations for Contact Tracing for Tuberculosis - Update 2023].
Topics: Adult; Child; Contact Tracing; Germany; Humans; Isoniazid; Rifampin; Tuberculosis | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Huma | 2023 |
Interactive effect of oral anti-hyperglycaemic or anti-hypertensive drugs on the inhibitory and bactericidal activity of first line anti-TB drugs against M. tuberculosis.
Topics: Antihypertensive Agents; Antitubercular Agents; Diabetes Mellitus; Ethambutol; Humans; Hypertension; | 2023 |
The effect of antenatal isoniazid preventive therapy on birth outcomes in Western Kenya.
Topics: Female; HIV Infections; Humans; Infant, Newborn; Isoniazid; Kenya; Perinatal Death; Pregnancy; Prema | 2023 |
Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.
Topics: Antitubercular Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Isoniazid; Pyra | 2023 |
Encapsulation of Isoniazid-conjugated Phthalocyanine-In-Cyclodextrin-In-Liposomes Using Heating Method.
Topics: Antitubercular Agents; Chemistry, Pharmaceutical; Cyclodextrins; Delayed-Action Preparations; Drug C | 2019 |
Brief Report: High Programmatic Isoniazid Preventive Therapy (IPT) Use in Pregnancy Among HIV-Infected Women.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Kenya; Postpartum Period; P | 2019 |
Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.
Topics: Antitubercular Agents; Clinical Trials as Topic; Humans; Isoniazid; Risk Assessment; Tuberculosis | 2020 |
Antituberculosis drug resistance in isolates of Mycobacterium tuberculosis complex in southeast Spain.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Presch | 2020 |
Factors associated with isoniazid resistant tuberculosis among human immunodeficiency virus positive patients in Swaziland: a case-control study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Case-Control Studies; Eswatini; | 2019 |
High mortality during tuberculosis retreatment at a Ghanaian tertiary center: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Resistance, Multiple, Bacterial; Female; Ghana; H | 2019 |
Determinants of alcohol use among people living with HIV initiating isoniazid preventive therapy in Ethiopia.
Topics: Adult; Alcohol Drinking; Alcoholism; Antitubercular Agents; Catha; Cross-Sectional Studies; Ethiopia | 2019 |
Pancreatic tuberculosis diagnosed by endoscopic ultrasound-guided fine needle aspiration in a 14-year-old adolescent.
Topics: Abdominal Pain; Adolescent; Antitubercular Agents; Cote d'Ivoire; Drug Therapy, Combination; Endosco | 2020 |
A Shorter Regimen for Rifampin-Resistant Tuberculosis.
Topics: Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
A Shorter Regimen for Rifampin-Resistant Tuberculosis.
Topics: Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
A Shorter Regimen for Rifampin-Resistant Tuberculosis. Reply.
Topics: Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. Reply.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
Promoting Tuberculosis Preventive Therapy for People Living with HIV in South Africa: Interventions Hindered by Complicated Clinical Guidelines and Imbalanced Patient-Provider Dynamics.
Topics: Antitubercular Agents; Female; Health Promotion; HIV Infections; Humans; Isoniazid; Male; South Afri | 2020 |
Comparative analysis of the effectiveness of tuberculosis prophylaxis in patients with HIV/AIDS treated with isoniazid.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Pros | 2019 |
Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Brazil; Cross-Sectional Studies; Female; HIV Infectio | 2020 |
Isoniazid preventive therapy: Uptake, incidence of tuberculosis and survival among people living with HIV in Bulawayo, Zimbabwe.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Female; HIV Infections; Humans; | 2019 |
Determinants of serum concentration of first-line anti-tuberculosis drugs from China.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Case-Control Studies; China; Chro | 2019 |
SHORT COMMUNICATION-Pattern of anti-tuberculosis drugs susceptibility in new and previously treated tuberculosis patients and environmental risk factors investigation.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Environment; Female; Humans; Isoniazid; Male; Microb | 2019 |
Development of 'S', 'N' Heterocycles as Antimycobacterials Targeting Fatty Acid Biosynthesis.
Topics: Antitubercular Agents; Bacterial Proteins; Computer Simulation; Drug Design; Fatty Acids; Isoniazid; | 2020 |
Implementation of isoniazid preventive therapy in people living with HIV in Zambia: challenges and lessons.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Female; HIV Infections; Humans; Incidence; Isoniazid; | 2019 |
[Tuberculosis].
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifa | 2019 |
Isoniazid and Rifapentine Treatment Eradicates Persistent
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; L | 2020 |
Polymeric nanobiotics as a novel treatment for mycobacterial infections.
Topics: Animals; Antitubercular Agents; Clofazimine; Delayed-Action Preparations; Disease Models, Animal; Dr | 2019 |
Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis.
Topics: Adult; Alanine Transaminase; Antitubercular Agents; Asian People; ATP-Binding Cassette Transporters; | 2020 |
Clinical findings and treatment of disseminated 'Mycobacterium avium subspecies hominissuis' infection in a domestic cat.
Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Drug Therapy, Combination; Isoniazid; Liver; Lun | 2019 |
NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arylamine N-Acetyltr | 2019 |
Nonparametric Population Pharmacokinetic Modeling of Isoniazid in Colombian Patients With Tuberculosis.
Topics: Adult; Antitubercular Agents; Colombia; Computer Simulation; Female; Humans; Isoniazid; Male; Middle | 2019 |
Impact of Baseline Tuberculin Skin Test and Isoniazid Chemoprophylaxis on Subsequent Quantiferon-TB Gold In-Tube Performance in Young Children Assessed After Tuberculosis Contact in Catalonia.
Topics: Antitubercular Agents; Chemoprevention; Female; Humans; Interferon-gamma Release Tests; Isoniazid; M | 2020 |
Adjunctive Immunotherapeutic Efficacy of N-Formylated Internal Peptide of Mycobacterial Glutamine Synthetase in Mouse Model of Tuberculosis.
Topics: Animals; Bacterial Load; Bacterial Proteins; Disease Models, Animal; Drug Therapy, Combination; Fema | 2020 |
Macrophage-Targeted Isoniazid-Selenium Nanoparticles Promote Antimicrobial Immunity and Synergize Bactericidal Destruction of Tuberculosis Bacilli.
Topics: Anti-Bacterial Agents; Drug Delivery Systems; Humans; Isoniazid; Macrophages; Mycobacterium tubercul | 2020 |
Mycobacterium tuberculosis infection in psoriatic patients treated with biologics: Real-world data from 18 Japanese facilities.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Biological Products; Child; Femal | 2020 |
Clinical Characteristics of Active Tuberculosis Diagnosed After Starting Treatment for Latent Tuberculosis Infection.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Rifampin; Tuberculosis | 2020 |
Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin: Therapeutic assessment in a murine model of tuberculosis infection.
Topics: Administration, Oral; Animals; Antitubercular Agents; Disease Models, Animal; Drug Combinations; Gal | 2020 |
Multicenter evaluation of TB-SPRINT 59-Plex Beamedex®: accuracy and cost analysis.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Costs and Cost Analysis; DNA-Directed RNA Polym | 2019 |
Nonclinical evaluation of IQG-607, an anti-tuberculosis candidate with potential use in combination drug therapy.
Topics: Animals; Anti-Bacterial Agents; Chromosome Aberrations; Cytochrome P-450 Enzyme System; Disease Mode | 2020 |
Rapid and highly sensitive quantification of the anti-tuberculosis agents isoniazid, ethambutol, pyrazinamide, rifampicin and rifabutin in human plasma by UPLC-MS/MS.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Calibration; Chromatography, High Pres | 2020 |
Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.
Topics: Arylamine N-Acetyltransferase; Brazil; Cost-Benefit Analysis; Humans; India; Isoniazid; Pharmacogene | 2020 |
Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
Topics: Adult; Antitubercular Agents; Female; HIV; HIV Infections; Humans; Isoniazid; Male; Pyrazinamide; Tu | 2020 |
To start or to complete? - Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studie | 2020 |
Isoniazid-resistant tuberculosis: A problem we can no longer ignore.
Topics: Antitubercular Agents; Cross-Sectional Studies; Genetic Profile; Humans; Isoniazid; Prevalence; Tube | 2020 |
Incidence of Tuberculosis after Routine IPT (Isoniazid Preventive Therapy) in HIV Infected Patients at a Tertiary Center.
Topics: Antitubercular Agents; HIV Infections; Humans; Incidence; Isoniazid; Tuberculosis | 2020 |
Migrations do not modify Mycobacterium tuberculosis resistance rates: a 20-year retrospective study.
Topics: Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Italy; Male; Microbial Sensitivity Te | 2020 |
Model-Based Assessment of Variability in Isoniazid Pharmacokinetics and Metabolism in Patients Co-Infected With Tuberculosis and HIV: Implications for a Novel Dosing Strategy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Biological Availability; CD4 L | 2020 |
Access and adherence to isoniazid preventive therapy and occurrence of active TB in a cohort of people living with HIV: a retrospective cohort study in Sao Paulo, Brazil.
Topics: Adult; Antitubercular Agents; Brazil; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; Lat | 2020 |
Determination of minimum bactericidal concentration, in single or combination drugs, against
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Drug Synergism; Humans; Isoniazid; Levo | 2020 |
Evaluation of the BD MAX™ MDR-TB assay in a real-world setting for the diagnosis of pulmonary and extra-pulmonary TB.
Topics: Antibiotics, Antitubercular; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Male; Microbial | 2020 |
Translational Model-Informed Approach for Selection of Tuberculosis Drug Combination Regimens in Early Clinical Development.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Load; Clinical Trials, Phase II as Top | 2020 |
Latent tuberculosis infection in children and adolescents in Russia.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Humans; Incidence; Infant; Infant, Newbo | 2020 |
Effectiveness of Isoniazid Preventive Therapy to Reduce Tuberculosis Incidence in the Context of Antiretroviral Therapy.
Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Inc | 2020 |
Incidence and determinants of tuberculosis among HIV-positive individuals in Addis Ababa, Ethiopia: A retrospective cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Disease-Free Survival; Ethio | 2020 |
High-Dose First-Line Treatment Regimen for Recurrent Rifampicin-Susceptible Tuberculosis.
Topics: Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Reply to Decroo
Topics: Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2020 |
Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Mal | 2020 |
Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017.
Topics: Adult; Alberta; Antitubercular Agents; Cohort Studies; Drug Resistance, Bacterial; Emigrants and Imm | 2020 |
Cost-effectiveness of IGRA/QFT-Plus for TB screening of migrants in Oman.
Topics: Cost-Benefit Analysis; Female; Humans; Interferon-gamma Release Tests; Isoniazid; Latent Tuberculosi | 2020 |
Improving coverage and completion rate of isoniazid preventive therapy among eligible HIV patients using quality improvement approaches: a case study of State Hospital, Ijebu Ode, Ogun State, Nigeria.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Delivery of Health Care; HIV Infections; Humans; Is | 2019 |
HIV, Pregnancy, and Isoniazid Preventive Therapy.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Postpartum Period; Pregnancy; Tube | 2020 |
HIV, Pregnancy, and Isoniazid Preventive Therapy. Reply.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Pregnancy; Tuberculosis | 2020 |
Quantitative estimation of isoniazid content in the commercially available and government-supplied formulations.
Topics: Antitubercular Agents; Drug Industry; Government Programs; Humans; India; Isoniazid; Reference Stand | 2020 |
Incidence and predictors of tuberculosis occurrence among adults on antiretroviral therapy at Debre Markos referral hospital, Northwest Ethiopia: retrospective follow-up study.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Age | 2020 |
Evaluation of the Accuracy of 99DOTS, a Novel Cellphone-based Strategy for Monitoring Adherence to Tuberculosis Medications: Comparison of DigitalAdherence Data With Urine Isoniazid Testing.
Topics: Antitubercular Agents; Cell Phone; Humans; Isoniazid; Medication Adherence; Tuberculosis | 2020 |
Drug Conjugation Induced Modulation of Structural and Membrane Interaction Features of Cationic Cell-Permeable Peptides.
Topics: Amino Acid Sequence; Antitubercular Agents; Cell Line, Tumor; Cell-Penetrating Peptides; Drug Carrie | 2020 |
Prevention of tuberculosis in HIV infection with novel drugs.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Isoniazid; Oxazines; Piperazines; Pyridones; | 2020 |
Structural Changes in the Lungs and Liver of Mice with Experimental Tuberculosis Treated with Liposome-Encapsulated Dextrazide.
Topics: Animals; Dextrans; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Rou | 2020 |
Trend analysis of tuberculosis case notifications with scale-up of antiretroviral therapy and roll-out of isoniazid preventive therapy in Zimbabwe, 2000-2018.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis; Zimbabwe | 2020 |
Determinants of isoniazid preventive therapy completion among people living with HIV attending care and treatment clinics from 2013 to 2017 in Dar es Salaam Region, Tanzania. A cross-sectional analytical study.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Age | 2020 |
Accuracy of a reverse dot blot hybridization assay for simultaneous detection of the resistance of four anti-tuberculosis drugs in Mycobacterium tuberculosis isolated from China.
Topics: Antitubercular Agents; China; Drug Resistance, Bacterial; Ethambutol; Humans; Immunoblotting; Isonia | 2020 |
Priorities among HIV-positive individuals for tuberculosis preventive therapies.
Topics: Adult; Antitubercular Agents; Health Personnel; HIV Infections; Humans; Isoniazid; Tuberculosis | 2020 |
Tuberculosis contact investigation and short-course preventive therapy among young children in Africa.
Topics: Adult; Benin; Burkina Faso; Cameroon; Child; Child, Preschool; Contact Tracing; Humans; Isoniazid; T | 2020 |
Use of whole-genome sequencing to predict Mycobacterium tuberculosis drug resistance in Shanghai, China.
Topics: Adult; Amikacin; Antitubercular Agents; China; Drug Resistance, Bacterial; Ethambutol; Humans; Isoni | 2020 |
Advanced Quantification Methods To Improve the 18b Dormancy Model for Assessing the Activity of Tuberculosis Drugs
Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Pharmaceutical Preparations; T | 2020 |
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
Topics: Antitubercular Agents; Drug Monitoring; Humans; Isoniazid; Mycobacterium tuberculosis; Pharmaceutica | 2020 |
No significant influence of diabetic mellitus on isoniazid plasma levels in patients under treatment for tuberculosis.
Topics: Antitubercular Agents; Diabetes Mellitus; Humans; Isoniazid; Patients; Plasma; Rifampin; Tuberculosi | 2020 |
Fully weekly antituberculosis regimen: a proof-of-concept study.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Isoniazid; | 2020 |
Provider attitudes about childhood tuberculosis prevention in Lesotho: a qualitative study.
Topics: Adult; Aged; Attitude of Health Personnel; Child; Female; Health Personnel; Humans; Isoniazid; Lesot | 2020 |
Identification of Substituted Amino Acid Hydrazides as Novel Anti-Tubercular Agents, Using a Scaffold Hopping Approach.
Topics: Amino Acid Substitution; Antitubercular Agents; Cell Proliferation; Humans; Isoniazid; Microbial Sen | 2020 |
A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Female; HIV Infections; Humans; Incidence; Intersec | 2020 |
The social implications of participant choice on adherence to Isonaizid Preventive Therapy (IPT): A follow-up study to high completion rates in Eswatini.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Choice Behavior; Community Health Workers; | 2020 |
Tuberculosis sepsis after tocilizumab treatment.
Topics: Antibodies, Monoclonal, Humanized; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; | 2020 |
Mesenchymal stem cells offer a drug-tolerant and immune-privileged niche to Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cells, Cult | 2020 |
Ocular adverse events in drug sensitive TB patients on daily fixed dose combination anti-TB drugs: A record review study from Kerala, India.
Topics: Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; | 2020 |
Human mesenchymal stem cell based intracellular dormancy model of Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Bone | 2020 |
Compatibility investigation for a new antituberculotic fixed dose combination with an adequate drug delivery.
Topics: Biological Availability; Drug Combinations; Humans; Isoniazid; Tuberculosis | 2020 |
Genome sequencing of Mycobacterium tuberculosis clinical isolates revealed isoniazid resistance mechanisms undetected by conventional molecular methods.
Topics: Antitubercular Agents; Bacterial Outer Membrane; Bacterial Proteins; Catalase; DNA, Bacterial; Genes | 2020 |
Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Mass Index; Chro | 2020 |
Novel isoniazid derivative as promising antituberculosis agent.
Topics: Antitubercular Agents; Cytochrome P-450 Enzyme System; Humans; Isoniazid; Isonicotinic Acids; Macrop | 2020 |
Intestinal microbiota disruption limits the isoniazid mediated clearance of Mycobacterium tuberculosis in mice.
Topics: Animals; CD4-Positive T-Lymphocytes; Disease Models, Animal; Dysbiosis; Female; Gastrointestinal Mic | 2020 |
[6]-Gingerol exhibits potent anti-mycobacterial and immunomodulatory activity against tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Catechols; Chemotherapy, Adjuvant; Disease Models, A | 2020 |
Host sirtuin 2 as an immunotherapeutic target against tuberculosis.
Topics: Animals; Antitubercular Agents; Epigenesis, Genetic; Female; Immunotherapy; Isoniazid; Mice; Mice, I | 2020 |
Primary breast tuberculosis in an HIV-infected patient.
Topics: Adult; Antitubercular Agents; Biopsy; Breast; Ethambutol; Female; HIV Infections; Humans; Isoniazid; | 2020 |
Formulation and Bioequivalence Testing of Fixed-Dose Combination Orally Disintegrating Tablets for the Treatment of Tuberculosis in the Paediatric Population.
Topics: Administration, Oral; Caco-2 Cells; Child; Cross-Over Studies; Humans; Isoniazid; Tablets; Therapeut | 2020 |
Machine learning reveals that Mycobacterium tuberculosis genotypes and anatomic disease site impacts drug resistance and disease transmission among patients with proven extra-pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Drug Resistance, Bacterial; Fem | 2020 |
Preterm Twins Born to a Mother with Miliary Tuberculosis: Importance of Early Recognition and Prompt Response in Infection Control to Manage Congenital Tuberculosis Exposure in a Neonatal Intensive Care Unit.
Topics: Adult; Antitubercular Agents; Contact Tracing; Female; Health Personnel; Humans; Infant, Newborn; In | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Safety and Efficacy of Rifampin or Isoniazid Among People With Mycobacterium tuberculosis Infection and Living With Human Immunodeficiency Virus or Other Health Conditions: Post Hoc Analysis of 2 Randomized Trials.
Topics: Adult; Antitubercular Agents; Drug Administration Schedule; HIV; HIV Infections; Humans; Isoniazid; | 2021 |
Intrapulmonary Pharmacokinetics of First-line Anti-tuberculosis Drugs in Malawian Patients With Tuberculosis.
Topics: Antitubercular Agents; Bayes Theorem; Ethambutol; Humans; Isoniazid; Pyrazinamide; Tuberculosis | 2021 |
Anti-tuberculosis effect of isoniazid scales accurately from zebrafish to humans.
Topics: Animals; Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Tuberculosis; Zebraf | 2020 |
The Effects Study of Isoniazid Conjugated Multi-Wall Carbon Nanotubes Nanofluid on
Topics: Antitubercular Agents; Drug Delivery Systems; Humans; Isoniazid; Microbial Sensitivity Tests; Micros | 2020 |
Anti-tuberculosis site-specific oral delivery system that enhances rifampicin bioavailability in a fixed-dose combination with isoniazid.
Topics: Animals; Antitubercular Agents; Biological Availability; Dogs; Isoniazid; Rifampin; Tuberculosis | 2021 |
Cyclic Peptide [R
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Autophagy; Cytokines; Drug Therapy, Combinatio | 2020 |
Empiric vs screening-based use of isoniazid for tuberculosis prophylaxis: Safety and effectiveness in lung transplant recipients in Saudi Arabia.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Lung; Male; Middle Aged; Prospective Studie | 2021 |
Hemophagocytic syndrome associated with Mycobacterium bovis in a patient with X-SCID: a case report.
Topics: Antibiotics, Antitubercular; High-Throughput Nucleotide Sequencing; Humans; Infant; Interleukin Rece | 2020 |
Tuberculosis drug resistance in Canakkale, Turkey.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Ethambutol; Humans; Isoniazid; Microbial Sensit | 2020 |
Knowledge and adherence to isoniazid preventive therapy among people living with HIV in multilevel health facilities in South-East, Nigeria: baseline findings from a quasi-experimental study.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Female; Health Knowledge, Attitudes, Practice; HIV In | 2020 |
Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.
Topics: Adolescent; Ambulatory Care Facilities; Anti-Retroviral Agents; Antitubercular Agents; Caregivers; C | 2020 |
Active household contact screening for tuberculosis and provision of isoniazid preventive therapy to under-five children in Afghanistan.
Topics: Afghanistan; Antitubercular Agents; Child, Preschool; Contact Tracing; Female; Humans; Isoniazid; Ma | 2020 |
Tuberculous Spondylodiscitis after Lumbar Microdiscectomy.
Topics: Discitis; Diskectomy; Humans; Interferon-gamma Release Tests; Isoniazid; Male; Rifampin; Tuberculin | 2020 |
Dynamics of Extensive Drug Resistance Evolution of Mycobacterium tuberculosis in a Single Patient During 9 Years of Disease and Treatment.
Topics: Antitubercular Agents; Drug Resistance; Drug Resistance, Multiple, Bacterial; Humans; Isoniazid; Mic | 2022 |
Urine Biomarker Assessment of Infant Adherence to Isoniazid Prophylaxis.
Topics: Antitubercular Agents; Biomarkers; Cohort Studies; Female; HIV Infections; Humans; Infant; Isoniazid | 2021 |
Cost-effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Th | 2020 |
Aerodynamic properties and in silico deposition of isoniazid loaded chitosan/thiolated chitosan and hyaluronic acid hybrid nanoplex DPIs as a potential TB treatment.
Topics: Biopolymers; Chitosan; Drug Carriers; Dry Powder Inhalers; Humans; Hyaluronic Acid; Isoniazid; Nanop | 2020 |
Tuberculosis prevention in children: a prospective community-based study in South Africa.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; HIV Infections; Humans; Infan | 2021 |
Tuberculosis in the intensive care unit: alternative treatment regimens and association with mortality.
Topics: Adult; Amikacin; Antibiotics, Antitubercular; APACHE; Brazil; Drug Administration Routes; Drug Admin | 2021 |
Quantification of pyrazinamide, isoniazid, acetyl-isoniazid, and rifampicin by a high-performance liquid chromatography method in human plasma from patients with tuberculosis.
Topics: Adult; Aged; Chromatography, High Pressure Liquid; Female; Humans; Isoniazid; Male; Middle Aged; Pil | 2021 |
Evaluating the integration of tuberculosis screening and contact investigation in tuberculosis clinics in Ethiopia: A mixed method study.
Topics: Adult; Child; Contact Tracing; Ethiopia; Female; Humans; Isoniazid; Male; Mass Screening; Tuberculos | 2020 |
Bacillus Calmette-GuÉrin-Associated Cervical Spondylitis in a 3-Year-Old Immunocompetent Girl.
Topics: Abscess; Antitubercular Agents; BCG Vaccine; Cervical Vertebrae; Child, Preschool; Female; Humans; I | 2020 |
Isoniazid preventive therapy in HIV-infected pregnant and postpartum women in high prevalence of tuberculosis countries: A protocol for systematic review.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Isoniazid; Post | 2020 |
Characteristics and Treatment Outcomes of Isoniazid Mono-Resistant Tuberculosis: A Retrospective Study.
Topics: Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Mutation; Mycobact | 2020 |
Mutations in dnaA and a cryptic interaction site increase drug resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; DNA Replication; DNA-Binding Proteins; Drug Resistance, M | 2020 |
Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis.
Topics: Adult; Antitubercular Agents; Coinfection; Female; HIV Infections; Humans; Isoniazid; Male; Mass Scr | 2020 |
Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Ambulatory Care F | 2020 |
Dual antitubercular drug loaded liposomes for macrophage targeting: development, characterisation,
Topics: Animals; Antitubercular Agents; Cell Line; Drug Delivery Systems; Humans; Isoniazid; Liposomes; Macr | 2021 |
Analysis of the Efficiency of Different Antituberculous Drugs and Approaches to Treat BCG-Induced Granulomatosis in Mice and Abundance and Localization of Mycobacterium tuberculosis in the Liver.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; BCG Vaccine; Dextrans; Diffusion; Drug C | 2020 |
Point-of-Care Ultrasound Image of Intra-Abdominal Lymphadenopathy in Tuberculosis.
Topics: Abdomen; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Lymph Nodes; Lymphadenopathy; | 2020 |
Coverage of isoniazid preventive therapy among people living with HIV; A retrospective cohort study in Tanzania (2012-2016).
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Female; HIV Infec | 2021 |
Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Isoniazid; Latent T | 2021 |
Moving forward through the in silico modeling of tuberculosis: a further step with UISS-TB.
Topics: Antitubercular Agents; Computational Biology; Immune System; Isoniazid; Treatment Outcome; Tuberculo | 2020 |
Predictors of suboptimal adherence to isoniazid preventive therapy among adolescents and children living with HIV.
Topics: Adolescent; Adolescent Behavior; Adult; Age Factors; Caregivers; Child; Child Behavior; Eswatini; Fe | 2020 |
Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids.
Topics: Adult; Antitubercular Agents; Female; Glucocorticoids; Humans; Isoniazid; Male; Middle Aged; Prognos | 2020 |
Implementation of TB preventive therapy in Uganda: effect of an intervention on completion rates.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Tuberculosis; Uganda | 2021 |
Accuracy of molecular drug susceptibility testing amongst tuberculosis patients in Karakalpakstan, Uzbekistan.
Topics: Antibiotics, Antitubercular; Capreomycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Ison | 2021 |
Detection of Mycobacterium tuberculosis complex in pulmonary and extrapulmonary samples with the FluoroType MTBDR assay.
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Isoniazid; Mutation; Mycobacterium tuberculosis; | 2021 |
Integrated TB and HIV care for Mozambican children: temporal trends, site-level determinants of performance, and recommendations for improved TB preventive treatment.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; Incidence; Isoniazid; Mozambique; Retrospectiv | 2021 |
Toward patient-centered tuberculosis preventive treatment: preferences for regimens and formulations in Lima, Peru.
Topics: Antitubercular Agents; Child; Clinical Protocols; Drug Therapy, Combination; Humans; Isoniazid; Pati | 2021 |
Mycobacterium tuberculosis Rv3160c is a TetR-like transcriptional repressor that regulates expression of the putative oxygenase Rv3161c.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Gene Expression; Gene Express | 2021 |
The Outcome of Accidental Bacille Calmette-Guérin Overdose During Routine Neonatal Immunization.
Topics: Accidents; Anti-Bacterial Agents; BCG Vaccine; Drug-Related Side Effects and Adverse Reactions; Huma | 2021 |
Population pharmacokinetic model of isoniazid in patients with tuberculosis in Tunisia.
Topics: Absorption, Physiological; Adolescent; Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; | 2021 |
Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients.
Topics: Ethambutol; Humans; Isoniazid; Lung; Lung Transplantation; Moxifloxacin; Pyrazinamide; Rifamycins; T | 2021 |
Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis.
Topics: Acetylation; Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arylamine N-Acetyltr | 2021 |
A broad spectrum anti-bacterial peptide with an adjunct potential for tuberculosis chemotherapy.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Ethambutol; Female; Humans; Isoniaz | 2021 |
Closing the loop in child TB contact management: completion of TB preventive therapy outcomes in western Kenya.
Topics: Antitubercular Agents; Child; HIV Infections; Humans; Isoniazid; Kenya; Retrospective Studies; Tuber | 2021 |
Development of a population pharmacokinetic model and Bayesian estimators for isoniazid in Tunisian tuberculosis patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Bayes Theorem; Drug Monitoring; Female; Humans; Ison | 2021 |
Phenotypic and genotypic drug sensitivity profiles of Mycobacterium tuberculosis infection and associated factors in northeastern Ethiopia.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Cross-Sectional Studies; Drug Resistance, Bacterial; | 2021 |
Tuberculosis despite latent infection screening and treatment in patients receiving TNF inhibitor therapy.
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Infection; Latent Tuberculosis; Tuberculin Test; Tu | 2021 |
Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Duration of Therapy; Fem | 2021 |
Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).
Topics: Adolescent; Adult; Ambulatory Care Facilities; Antitubercular Agents; Child; Child, Preschool; Femal | 2021 |
Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Drug Resistance, Bacterial; Female; France; Huma | 2021 |
[Research progress of high-dose isoniazid in tuberculosis].
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 2021 |
Inhalable particles containing isoniazid and rifabutin as adjunct therapy for safe, efficacious and relapse-free cure of experimental animal tuberculosis in one month.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Guine | 2021 |
Diagnostic accuracy of the FluoroType MTB and MTBDR VER 2.0 assays for the centralized high-throughput detection of Mycobacterium tuberculosis complex DNA and isoniazid and rifampicin resistance.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Isoniazid; Microbial Sens | 2021 |
Implementation of isoniazid preventive therapy in southern Lima, Peru: an analysis of health center characteristics.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV Infections; Humans; I | 2021 |
Can isoniazid preventive therapy be scaled up rapidly? Lessons learned in Kenya, 2014-2018.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Kenya; Tuberculosis | 2021 |
Isoniazid preventive therapy use among adult people living with HIV in Zimbabwe.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; HIV Infections; Humans; Isoniazid; Tuberculos | 2021 |
Facility and patient barriers in the implementation of isoniazid preventive therapy for people living with HIV attending Care and Treatment Centers, Songea Municipality, Tanzania.
Topics: Adult; Aged; Antitubercular Agents; Cross-Sectional Studies; Female; HIV Infections; Humans; Isoniaz | 2021 |
Drug Resistance of Mouse Somatic Cells to Rifampicin in Experimental Tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Resistance; Isoniazid; Mice; Mycobacterium tuberculosis; Rifamp | 2021 |
Prevalence of latent tuberculosis in patients with hematological neoplasms in a cancer referral hospital in Mexico City.
Topics: Adult; Antitubercular Agents; Cancer Care Facilities; Female; Hematologic Neoplasms; Humans; Isoniaz | 2021 |
Prevalence and outcome of isoniazid-monoresistant tuberculosis at a university hospital in Saudi Arabia.
Topics: Antitubercular Agents; Cross-Sectional Studies; Drug Resistance, Bacterial; Hospitals; Humans; Isoni | 2021 |
Significance of the coexistence of non-codon 315 katG, inhA, and oxyR-ahpC intergenic gene mutations among isoniazid-resistant and multidrug-resistant isolates of Mycobacterium tuberculosis: a report of novel mutations.
Topics: Antitubercular Agents; Bacterial Proteins; DNA, Bacterial; DNA, Intergenic; Humans; Isoniazid; Micro | 2022 |
A high-throughput screening assay based on automated microscopy for monitoring antibiotic susceptibility of Mycobacterium tuberculosis phenotypes.
Topics: Antitubercular Agents; Automation; High-Throughput Screening Assays; Humans; Isoniazid; Linezolid; M | 2021 |
Topics: Cross-Sectional Studies; DNA; Ethiopia; HeLa Cells; HIV Infections; Humans; Hydrogen Peroxide; Isoni | 2021 |
Early and Midterm Outcomes of Endovascular Repair of Tuberculous Infected Native (Mycotic) Aortic Aneurysms.
Topics: Aged; Antitubercular Agents; Aortic Aneurysm; Blood Vessel Prosthesis; Drug-Eluting Stents; Endovasc | 2021 |
Effectiveness of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected adults in programme setting.
Topics: Adult; Antitubercular Agents; HIV Infections; Humans; Incidence; India; Isoniazid; Pilot Projects; P | 2020 |
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal | 2021 |
Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
Topics: Adult; Aged; Antitubercular Agents; Arylamine N-Acetyltransferase; Asian People; Body Weights and Me | 2021 |
The impact of contact evaluation and TB preventive therapy on TB incidence.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Humans; Incidence; Isoniazid; Tuberculosis | 2021 |
A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Models, Statistical; Prognosis; Treatment | 2022 |
Suicide attempt with isoniazid in adolescents receiving tuberculous prophylaxis: three cases.
Topics: Adolescent; Antitubercular Agents; Child; Humans; Isoniazid; Pyridoxine; Seizures; Suicide, Attempte | 2021 |
Effect of serum isoniazid level on treatment outcomes among tuberculosis patients with slow response - A retrospective cohort study.
Topics: Antitubercular Agents; Humans; Isoniazid; Retrospective Studies; Treatment Outcome; Tuberculosis | 2021 |
Impact of Isoniazid Preventive Therapy on Tuberculosis incidence among people living with HIV: A secondary data analysis using Inverse Probability Weighting of individuals attending HIV care and treatment clinics in Tanzania.
Topics: Adolescent; Adult; Child; Child, Preschool; Data Analysis; Female; Follow-Up Studies; HIV Infections | 2021 |
Vikela Ekhaya: A Novel, Community-based, Tuberculosis Contact Management Program in a High Burden Setting.
Topics: Adult; Child; Contact Tracing; HIV Infections; Humans; Isoniazid; Levonorgestrel; Rifampin; Tubercul | 2022 |
The efficacy of isoniazid prophylaxis in renal transplant recipients in a high tuberculosis burden country.
Topics: Antitubercular Agents; Humans; Isoniazid; Kidney Transplantation; Retrospective Studies; Transplant | 2021 |
Brief Report: Yield of Repeat Tuberculin Skin Testing for People Living With HIV in Brazil.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; F | 2021 |
Dual pH-Responsive Macrophage-Targeted Isoniazid Glycoparticles for Intracellular Tuberculosis Therapy.
Topics: Antitubercular Agents; Humans; Hydrogen-Ion Concentration; Isoniazid; Macrophages; Tuberculosis | 2021 |
A novel agar base medium for drug susceptibility testing of
Topics: Agar; Antitubercular Agents; Culture Media; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tes | 2021 |
Luteolin as a potential host-directed immunotherapy adjunct to isoniazid treatment of tuberculosis.
Topics: Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; I | 2021 |
Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization-Recommended Weight Band Doses and Formulations.
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Ethambutol; Female; Humans; Isoniazid; Male; | 2022 |
A peculiarly characterised case of isoniazid-induced pellagra- 2 Ds and a C: a case report.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Constipation; Dementia; Dermatitis; Female; HIV Infec | 2021 |
Tuberculosis Preventive Therapy for People With HIV Infection in High Tuberculosis Burden Settings: How Much Is Enough?
Topics: Antibiotic Prophylaxis; HIV Infections; Humans; Isoniazid; Tuberculosis | 2021 |
Antibiotic prophylaxis for preventing postorthotopic liver transplant tuberculosis: is there a safe alternative to isoniazid?
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Humans; Isoniazid; Liver Transplantation; Tuberculosi | 2017 |
The need for randomised controlled trials of isoniazid monoresistant tuberculosis treatment.
Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 2017 |
A high content microscopy assay to determine drug activity against intracellular Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Discovery; Isoniazid; Macrophages; Mice; Microscopy; Mycobacter | 2017 |
Assessments of serum copper and zinc concentration, and the Cu/Zn ratio determination in patients with multidrug resistant pulmonary tuberculosis (MDR-TB) in Côte d'Ivoire.
Topics: Adolescent; Adult; Antitubercular Agents; Copper; Cote d'Ivoire; Female; Humans; Isoniazid; Male; Mi | 2017 |
Implementing isoniazid preventive therapy in a tuberculosis treatment-experienced cohort on ART.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Incid | 2017 |
Survey of health care worker knowledge about childhood tuberculosis in high-burden centers in Botswana.
Topics: Antitubercular Agents; Botswana; Child; Contact Tracing; Cross-Sectional Studies; Health Knowledge, | 2017 |
[Description of an isoniazid-resistant tuberculosis outbreak in a block of apartments].
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Disease Outbreaks; Female; Humans | 2017 |
Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Breast Feeding; Case-Control Studies; Drug Therapy, C | 2017 |
BCG vaccination-induced suppurative lymphadenitis: four signs to pay attention to.
Topics: Adjuvants, Immunologic; Antibiotics, Antitubercular; Antitubercular Agents; BCG Vaccine; Humans; Iso | 2017 |
Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.
Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; HIV Infections; Humans; Isoniazid; | 2017 |
[Prevalence of Mycobacterium tuberculosis resistance to quinolones and injectables in Colombia, 2012-2013].
Topics: Antitubercular Agents; Colombia; Cross-Sectional Studies; Humans; Isoniazid; Mycobacterium tuberculo | 2017 |
[Characterization of clinical isolates of Mycobacterium tuberculosis from HIV positive individuals in Colombia, 2012].
Topics: Antitubercular Agents; Colombia; HIV Infections; Humans; Isoniazid; Rifampin; Streptomycin; Tubercul | 2017 |
Management of long-term therapy with biological drugs in psoriatic patients with latent tuberculosis infection in real life setting.
Topics: Aged; Antitubercular Agents; Biological Products; Dermatologic Agents; Female; Follow-Up Studies; Hu | 2017 |
Rifamycin action on RNA polymerase in antibiotic-tolerant
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Proteins; DNA-Directed RNA Polymerases | 2017 |
Addressing tuberculosis control in fragile states: Urban DOTS experience in Kabul, Afghanistan, 2009-2015.
Topics: Afghanistan; Antitubercular Agents; Child; Contact Tracing; Directly Observed Therapy; Female; Human | 2017 |
N-acetyltransferase gene polymorphisms & plasma isoniazid concentrations in patients with tuberculosis.
Topics: Adult; Arylamine N-Acetyltransferase; Female; Genotype; Humans; Inactivation, Metabolic; Isoniazid; | 2017 |
Design of Isoniazid Smart Nanogel by Gamma Radiation-Induced Template Polymerization for Biomedical Application.
Topics: Acrylates; Antitubercular Agents; Delayed-Action Preparations; Drug Liberation; Gamma Rays; Gels; Hu | 2017 |
Dual antibiotherapy of tuberculosis mediated by inhalable locust bean gum microparticles.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; Cell Line; Drug Carriers; Galactans; Hum | 2017 |
Cost-Effectiveness of isoniazid preventive therapy among HIV-infected patients clinicaly screened for latent tuberculosis infection in Dar es Salaam, Tanzania: A prospective Cohort study.
Topics: Antitubercular Agents; Cost-Benefit Analysis; HIV Infections; Humans; Isoniazid; Latent Tuberculosis | 2017 |
A 25-Year-Old Woman With a Deceptive Pancreas Cyst: All Is Not as It Appears!
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Endoscopic Ultrasound-Guided Fine Needle As | 2018 |
Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - A retrospective cohort study in Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Female; Humans; Immunocompromised Host; Incidence; Inflammation; | 2018 |
Active Tuberculosis Incidence and Characteristics in Patients Treated with Tumor Necrosis Factor Antagonists According to Latent Tuberculosis Infection.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Female; Humans; Incidence; Interferon-gamma R | 2017 |
Evaluation of the Isoniazid Preventive Therapy Care Cascade Among HIV-Positive Female Sex Workers in Mombasa, Kenya.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Directive | 2017 |
Poncet's disease after the intravesical instillation of Bacillus Calmette-Guérin (BCG): a case report.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adrenal Cortex Hormones; Arthritis, Reactive; | 2017 |
PknB remains an essential and a conserved target for drug development in susceptible and MDR strains of M. Tuberculosis.
Topics: Antitubercular Agents; Base Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Ethambut | 2017 |
An application of competitive reporter monitored amplification (CMA) for rapid detection of single nucleotide polymorphisms (SNPs).
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Genes, Reporter; Humans; Isoniazid; M | 2017 |
Activity of human beta defensin-1 and its motif against active and dormant Mycobacterium tuberculosis.
Topics: Antitubercular Agents; beta-Defensins; Computational Biology; Hemolysis; Humans; Isoniazid; Leukocyt | 2017 |
Food significantly reduces plasma concentrations of first-line anti-tuberculosis drugs.
Topics: Adult; Antitubercular Agents; Fasting; Female; Food; Humans; India; Isoniazid; Male; Middle Aged; Py | 2017 |
Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada.
Topics: Adult; Antitubercular Agents; British Columbia; Drug Resistance, Bacterial; Female; Fluoroquinolones | 2017 |
Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care Facilities; Antitubercular Agents; Com | 2017 |
[Genotyping and drug susceptibility of
Topics: Antitubercular Agents; China; Genotype; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacteriu | 2017 |
High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Eswatini; F | 2017 |
Correlates of isoniazid preventive therapy failure in child household contacts with infectious tuberculosis in high burden settings in Nairobi, Kenya - a cohort study.
Topics: Adolescent; Adult; Antitubercular Agents; Child, Preschool; Family Characteristics; Female; Humans; | 2017 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort | 2017 |
Implementing an isoniazid preventive therapy program for people living with HIV in Thailand.
Topics: Adolescent; Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Thailand; | 2017 |
Identification of a novel class of small compounds with anti-tuberculosis activity by in silico structure-based drug screening.
Topics: Antitubercular Agents; Biotin; Computer Simulation; Drug Design; Isoniazid; Mycobacterium smegmatis; | 2017 |
Programmatic Evaluation of an Algorithm for Intensified Tuberculosis Case Finding and Isoniazid Preventive Therapy for People Living With HIV in Thailand and Vietnam.
Topics: Adolescent; Adult; Algorithms; Antitubercular Agents; Communicable Disease Control; Female; HIV Infe | 2017 |
Follow-up of 1887 patients receiving tumor necrosis-alpha antagonists: Tuberculin skin test conversion and tuberculosis risk.
Topics: Adalimumab; Adult; Antirheumatic Agents; Antitubercular Agents; Connective Tissue Diseases; Female; | 2018 |
Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Biomarkers, Pharmacological; Case-Control Stud | 2017 |
Variants of katG, inhA and nat genes are not associated with mutations in efflux pump genes (mmpL3 and mmpL7) in isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Bacterial Proteins; Bacteriological Techniques | 2017 |
Microbial sensor for drug susceptibility testing of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; R | 2018 |
Anti-mycobacterium tuberculosis activity of polyherbal medicines used for the treatment of tuberculosis in Eastern Cape, South Africa.
Topics: Antitubercular Agents; Drug Contamination; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacte | 2017 |
Isoniazid Monoresistance and Rate of Culture Conversion among Patients in the State of Georgia with Confirmed Tuberculosis, 2009-2014.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Female; Georgia; Humans; | 2018 |
Deregulation of Genes Associated with Alternate Drug Resistance Mechanisms in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Down-Regulation; Drug Resistance, Multiple, Bacterial; Ge | 2018 |
Evaluation of Whole-Genome Sequencing for Mycobacterial Species Identification and Drug Susceptibility Testing in a Clinical Setting: a Large-Scale Prospective Assessment of Performance against Line Probe Assays and Phenotyping.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Isoniazid; Molecular T | 2018 |
Tuberculosis of the tonsil simulating a cancer.
Topics: Adenoids; Adult; Antitubercular Agents; Diagnosis, Differential; Ethambutol; Female; Humans; Isoniaz | 2017 |
Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana.
Topics: Adolescent; Adult; Aged; Clarithromycin; Drug Resistance, Bacterial; Female; Genotype; Ghana; Humans | 2017 |
Isoniazid concentrations in hair and plasma area-under-the-curve exposure among children with tuberculosis.
Topics: Antitubercular Agents; Area Under Curve; Child, Preschool; Humans; Isoniazid; Prospective Studies; T | 2017 |
Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.
Topics: Adult; Alcoholism; Anti-Retroviral Agents; Antitubercular Agents; Brazil; Chemoprevention; Female; H | 2018 |
Optimal doses of rifampicin in the standard drug regimen to shorten tuberculosis treatment duration and reduce relapse by eradicating persistent bacteria.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Thera | 2018 |
50 Years Ago in The Journal of Pediatrics: Isoniazid Prophylaxis in Tuberculin Reactors.
Topics: Child; History, 20th Century; Humans; Interferon-gamma Release Tests; Isoniazid; Pediatrics; Risk Fa | 2018 |
Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.
Topics: Adolescent; Age Factors; Antitubercular Agents; Body Weight; Child; Child, Preschool; Coinfection; D | 2018 |
Completion Rate and Safety of Tuberculosis Infection Treatment With Shorter Regimens.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administ | 2018 |
Completion of the tuberculosis care cascade in a community-based HIV linkage-to-care study in South Africa and Uganda.
Topics: Adolescent; Adult; Community Health Services; Female; HIV Infections; Humans; Isoniazid; Male; South | 2018 |
Multifaceted remodeling by vitamin C boosts sensitivity of Mycobacterium tuberculosis subpopulations to combination treatment by anti-tubercular drugs.
Topics: Antitubercular Agents; Ascorbic Acid; Drug Combinations; Gene Expression Regulation, Bacterial; Huma | 2018 |
Automated broth-based systems versus the MYCOTB plate for antimicrobial susceptibility testing of the Mycobacterium tuberculosis complex: challenges in interpretation.
Topics: Antitubercular Agents; Automation, Laboratory; Ethambutol; Humans; Isoniazid; Microbial Sensitivity | 2018 |
Incidence and determinants of tuberculosis infection among adult patients with HIV attending HIV care in north-east Ethiopia: a retrospective cohort study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Body Mass Index; Di | 2018 |
First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Chromatography, High Pressure | 2018 |
Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Drug Resistance, Bacterial; Humans; Isoniazid; | 2018 |
Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
Topics: Antitubercular Agents; Caffeic Acids; Crystallization; Drug Combinations; Drug Stability; Drug Stora | 2018 |
Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Topics: Adolescent; Adult; Aftercare; Anti-Retroviral Agents; Antitubercular Agents; Coinfection; Directly O | 2018 |
Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
Topics: Antitubercular Agents; Clinical Trials as Topic; Electrocardiography; Ethambutol; Female; Gatifloxac | 2018 |
Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study.
Topics: Adolescent; Adult; Antitubercular Agents; Bayes Theorem; Child; Child, Preschool; Epidemics; HIV Inf | 2018 |
Isoniazid Monoresistance: A Precursor to Multidrug-Resistant Tuberculosis?
Topics: Georgia; Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2018 |
Household point of care CD4 testing and isoniazid preventive therapy initiation in a household TB contact tracing programme in two districts of South Africa.
Topics: Adolescent; Adult; Antitubercular Agents; CD4 Antigens; CD4 Lymphocyte Count; Cluster Analysis; Cont | 2018 |
Evaluation of the efficacy of valproic acid and suberoylanilide hydroxamic acid (vorinostat) in enhancing the effects of first-line tuberculosis drugs against intracellular Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Isoniazid; Macropha | 2018 |
The role of agency in the implementation of Isoniazid Preventive Therapy (IPT): Lessons from oMakoti in uMgungundlovu District, South Africa.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Culture; Female; Gender Identity; Heal | 2018 |
Individualizing Tuberculosis (TB) Treatment: Are TB Programs in High Burden Settings Ready for Prime Time Therapeutic Drug Monitoring?
Topics: Antitubercular Agents; Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampi | 2018 |
Priorities for Decreasing Morbidity and Mortality in Children With Advanced HIV Disease.
Topics: Adolescent; Africa South of the Sahara; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti | 2018 |
Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS/MS: Application to therapeutic drug monitoring.
Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Monitoring; Ethambutol; Humans; Is | 2018 |
ART and lifelong IPT for health care workers with HIV: a priority for infection control.
Topics: Adolescent; Botswana; Health Personnel; HIV; Humans; Infection Control; Isoniazid; Middle Aged; Tube | 2018 |
High rates of exposure to tuberculosis patients among HIV-infected health care workers in Botswana.
Topics: Adult; Antitubercular Agents; Botswana; Cross Infection; Cross-Sectional Studies; Female; Health Per | 2018 |
The effect of partner HIV status on motivation to take antiretroviral and isoniazid preventive therapies: a conjoint analysis.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Counseling; Female; HIV I | 2018 |
Defining the best regimen to treat isoniazid-resistant tuberculosis.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Mycobacterium tuberculosis; Rif | 2018 |
Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.
Topics: Anti-HIV Agents; Antitubercular Agents; Cost-Benefit Analysis; Drug Therapy, Combination; HIV Infect | 2018 |
Urgent Living-Donor Liver Transplantation in a Patient With Concurrent Active Tuberculosis: A Case Report.
Topics: Antitubercular Agents; Humans; Isoniazid; Levofloxacin; Liver Failure; Liver Transplantation; Living | 2018 |
Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Granuloma, Respiratory Tract; Isoniazid; Lung; Matrix Metalloprotein | 2018 |
Protein Binding of First-Line Antituberculosis Drugs.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; | 2018 |
Emergence and selection of isoniazid and rifampin resistance in tuberculosis granulomas.
Topics: Antitubercular Agents; Computer Simulation; Drug Resistance, Bacterial; Drug Resistance, Multiple; G | 2018 |
A Breast Lump in an Elderly Lady - Carcinoma or else ?.
Topics: Aged; Antitubercular Agents; Biopsy, Fine-Needle; Breast; Breast Neoplasms; Ethambutol; Female; Huma | 2016 |
Genetic diversity of Mycobacterium tuberculosis isoniazid monoresistant and multidrug-resistant in Rio Grande do Sul, a tuberculosis high-burden state in Brazil.
Topics: Antitubercular Agents; Bacterial Typing Techniques; Drug Resistance, Bacterial; Drug Resistance, Mul | 2018 |
New and Noteworthy in Tuberculosis Diagnostics and Treatment.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Latent Tuberculosis; Male; | 2018 |
Intrapatient variability in plasma rifampicin & isoniazid in tuberculosis patients.
Topics: Adolescent; Adult; Antitubercular Agents; Humans; India; Isoniazid; Pilot Projects; Prospective Stud | 2018 |
Magnitude of opportunistic diseases and their predictors among adult people living with HIV enrolled in care: national level cross sectional study, Ethiopia.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cross-Se | 2018 |
Significance of catalase-peroxidase (KatG) mutations in mediating isoniazid resistance in clinical strains of Mycobacterium tuberculosis.
Topics: Bacterial Proteins; Catalase; Drug Resistance, Bacterial; Humans; Isoniazid; Models, Molecular; Mole | 2018 |
Anti-Mycobacterium tuberculosis activity of naphthoimidazoles combined with isoniazid and rifampicin.
Topics: Antitubercular Agents; Drug Discovery; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans | 2018 |
Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophages.
Topics: Antitubercular Agents; Autophagy; Diarylquinolines; Host-Pathogen Interactions; Humans; Isoniazid; L | 2018 |
Serious hepatotoxicity following use of isoniazid preventive therapy in HIV patients in Eritrea.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antituber | 2018 |
Structure-based design of some isonicotinic acid hydrazide analogues as potential antitubercular agents.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Design; HEK293 Cells; Humans; Isoniazid; Microbial S | 2018 |
Antimycobacterial susceptibility evaluation of rifampicin and isoniazid benz-hydrazone in biodegradable polymeric nanoparticles against
Topics: A549 Cells; Animals; Antitubercular Agents; Biocompatible Materials; Cell Death; Chromatography, Hig | 2018 |
Cost-utility analysis of high-dose treatment for intermediate-susceptible, dose-dependent tuberculosis patients.
Topics: Antitubercular Agents; Cohort Studies; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug | 2018 |
Burden, spectrum and outcomes of children with tuberculosis diagnosed at a district-level hospital in South Africa.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Coinfection; Comorbidity; Cost of Illnes | 2018 |
Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemoprevention; Child; Female; H | 2018 |
Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Antitubercular Agents; Cell Line; Drug Therapy, Combi | 2018 |
Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.
Topics: Adult; Antitubercular Agents; Brazil; Cost Savings; Directly Observed Therapy; Female; Humans; Isoni | 2018 |
Molecular mechanism of the synergistic activity of ethambutol and isoniazid against
Topics: Antitubercular Agents; Bacterial Proteins; Drug Synergism; Drug Therapy, Combination; Ethambutol; Ge | 2018 |
Therapeutic Drug Monitoring: The Need for Practical Guidance.
Topics: Coinfection; Drug Monitoring; HIV; HIV Infections; Humans; Isoniazid; Rifampin; Sputum; Tuberculosis | 2019 |
Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Genome, Bacterial; Genotype; Humans; | 2018 |
Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Chemoprevention; Disease Transmission, Infecti | 2019 |
Vitamin C and Mycobacterium tuberculosis Persisters.
Topics: Animals; Ascorbic Acid; Isoniazid; Mice; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 2018 |
Reply to Yew et al., "Vitamin C and Mycobacterium tuberculosis Persisters".
Topics: Animals; Ascorbic Acid; Isoniazid; Mice; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 2018 |
Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Ethambutol; F | 2020 |
Transformation Morphisms and Time-to-Extinction Analysis That Map Therapy Duration From Preclinical Models to Patients With Tuberculosis: Translating From Apples to Oranges.
Topics: Antitubercular Agents; Clinical Trials as Topic; Drug Discovery; Drug Evaluation, Preclinical; Etham | 2018 |
Revised Antituberculosis Drug Doses and Hepatotoxicity in HIV Negative Children.
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; | 2019 |
Synergistic Lethality of a Binary Inhibitor of Mycobacterium tuberculosis KasA.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Animals; Antitubercular Agents; Cell Line; Crystallograph | 2018 |
Factors affecting the acceptability of isoniazid preventive therapy among healthcare providers in selected HIV clinics in Nairobi County, Kenya: a qualitative study.
Topics: Ambulatory Care Facilities; Antitubercular Agents; Attitude of Health Personnel; Evaluation Studies | 2018 |
3D-Printed Isoniazid Tablets for the Treatment and Prevention of Tuberculosis-Personalized Dosing and Drug Release.
Topics: Antitubercular Agents; Drug Compounding; Drug Delivery Systems; Drug Liberation; Isoniazid; Printing | 2019 |
Mycobactericidal activity of some micro-encapsulated synthetic Host Defense Peptides (HDP) by expediting the permeation of antibiotic: A new paradigm of drug delivery for tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Membrane Permeability; Drug Delivery Systems; Isoniazid; Mice; | 2019 |
Effect of isoniazid preventive therapy on tuberculosis incidence and associated risk factors among HIV infected adults in Tanzania: a retrospective cohort study.
Topics: Adult; Antitubercular Agents; Chemoprevention; Coinfection; Female; HIV Infections; HIV-1; Humans; I | 2019 |
Advantages of the AdvanSure MDR-TB GenoBlot assay containing disputed rpoB mutation-specific probes in a routine clinical laboratory setting.
Topics: Bacterial Proteins; Diagnostic Tests, Routine; DNA-Directed RNA Polymerases; Drug Resistance, Bacter | 2019 |
Efficacy and tolerability of desensitization in the treatment of delayed drug hypersensitivities to anti-tuberculosis medications.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Desensitization, Immunologic; Drug Hypersensi | 2019 |
Breakthrough tuberculosis disease among people with HIV - Should we be worried? A retrospective longitudinal study.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Coun | 2019 |
Incidence and predictors of LTFU among adults with TB/HIV co-infection in two governmental hospitals, Mekelle, Ethiopia, 2009-2016: survival model approach.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Coinfection; Ethiopia; Female; HIV; HIV Infec | 2019 |
Health system barriers to implementation of TB preventive strategies in South African primary care facilities.
Topics: Adult; Antitubercular Agents; Female; Government Programs; Health Facilities; Health Personnel; Huma | 2019 |
Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
Topics: Adult; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily B; Female; Genotyp | 2019 |
The Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH Study.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Correlation of Data; Female; HIV Infect | 2019 |
Metformin induced autophagy in diabetes mellitus - Tuberculosis co-infection patients: A case study.
Topics: Adult; Antitubercular Agents; Autophagy; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Etham | 2019 |
Rapid direct drug susceptibility testing of
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2019 |
Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries.
Topics: Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Developing Countries; HIV Infections; | 2019 |
Halloysite nanotubes as tools to improve the actual challenge of fixed doses combinations in tuberculosis treatment.
Topics: Caco-2 Cells; Cell Death; Cell Membrane Permeability; Cell Survival; Clay; Drug Liberation; Humans; | 2019 |
Ending Tuberculosis through Prevention.
Topics: HIV; Humans; Isoniazid; Rifampin; Tuberculosis | 2019 |
High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Area Under Curve; Central Nervous | 2019 |
IPT in people living with HIV in Myanmar: a five-fold decrease in incidence of TB disease and all-cause mortality.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Incidence; | 2019 |
High prevalence and incidence of tuberculosis in people living with the HIV in Mandalay, Myanmar, 2011-2017.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Cohort Studies; Female; Follow- | 2019 |
Topics: Adult; Antitubercular Agents; Attitude of Health Personnel; Cross-Sectional Studies; Ethiopia; Femal | 2019 |
Inhibiting the stringent response blocks
Topics: Animals; Bacterial Proteins; Crystallography, X-Ray; DNA Replication; Escherichia coli Proteins; GTP | 2019 |
Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.
Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Europe; Female; Humans; Isoniazid; Male; M | 2019 |
Genetic polymorphisms of long noncoding RNA RP11-37B2.1 associate with susceptibility of tuberculosis and adverse events of antituberculosis drugs in west China.
Topics: Adult; Anemia; Antitubercular Agents; Asian People; Case-Control Studies; China; Female; Genetic Pre | 2019 |
Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Topics: Adolescent; Adult; Aged; Anthropometry; Antibiotics, Antitubercular; Antitubercular Agents; Arylamin | 2019 |
Inflammatory bowel disease and mycobacteria: how much can we trust isoniazid prophylaxis during antitumor necrosis factor therapy?
Topics: Adult; Aged; Antitubercular Agents; Chemoprevention; Female; Humans; Inflammatory Bowel Diseases; In | 2019 |
Outlook for tuberculosis elimination in California: An individual-based stochastic model.
Topics: Algorithms; Antitubercular Agents; Calibration; California; Computer Simulation; Cost-Benefit Analys | 2019 |
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Io | 2019 |
Subtherapeutic Rifampicin Concentration Is Associated With Unfavorable Tuberculosis Treatment Outcomes.
Topics: Antitubercular Agents; Humans; India; Isoniazid; Prospective Studies; Pyrazinamide; Rifampin; Treatm | 2020 |
Fabrication of bioactive rifampicin loaded κ-Car-MA-INH/Nano hydroxyapatite composite for tuberculosis osteomyelitis infected tissue regeneration.
Topics: Animals; Antitubercular Agents; Carrageenan; Cell Line; Drug Delivery Systems; Drug Liberation; Dura | 2019 |
Screening and treatment for tuberculosis in a cohort of unaccompanied minor refugees in Berlin, Germany.
Topics: Adolescent; Berlin; Chemoprevention; Female; Germany; Hepatitis B; Humans; Isoniazid; Latent Tubercu | 2019 |
OxiR specifically responds to isoniazid and regulates isoniazid susceptibility in mycobacteria.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Gene Expression Regulation, B | 2019 |
Evaluation of Thin Layer Agar 7H11 for Direct Susceptibility Testing of Mycobacterium Tuberculosis Complex against Second Line Anti Tuberculosis Drugs on Smear Positive Specimens.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Bacteriolo | 2019 |
Modeling Host-Pathogen Interaction to Elucidate the Metabolic Drug Response of Intracellular
Topics: Adenosine Triphosphatases; Amides; Amino Acids; Antitubercular Agents; Cycloserine; Diarylquinolines | 2019 |
Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study.
Topics: Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Child; Child, Preschool; Female; H | 2019 |
Predictors of isoniazid preventive therapy completion among HIV-infected patients receiving differentiated and non-differentiated HIV care in rural Uganda.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Cross-Sectional Studies; Female; HIV Infections; Huma | 2020 |
Prophylaxis for Tuberculosis in Pregnant Women.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Int | 2019 |
Tuberculosis decline in populations affected by HIV: a retrospective study of 12 countries in the WHO African Region.
Topics: Africa; Anti-Retroviral Agents; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Mycobacter | 2019 |
Rifampin-resistant Tuberculosis in the United States, 1998-2014.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium | 2020 |
Outcome of inadvertent high dose BCG administration in newborns at a tertiary care hospital, Karachi- Case series.
Topics: Antitubercular Agents; BCG Vaccine; Dose-Response Relationship, Drug; Drug Combinations; Female; Hum | 2019 |
Evaluation of in silico designed inhibitors targeting MelF (Rv1936) against Mycobacterium marinum within macrophages.
Topics: Animals; Antitubercular Agents; Cell Line; Drug Synergism; Host-Pathogen Interactions; Humans; Inter | 2019 |
Identification and Characterization of Genetic Determinants of Isoniazid and Rifampicin Resistance in Mycobacterium tuberculosis in Southern India.
Topics: Adult; Allosteric Regulation; Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA | 2019 |
Incidence and predictors of tuberculosis among HIV-positive children at Adama Referral Hospital and Medical College, Oromia, Ethiopia: a retrospective follow-up study.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Coinfection; Ethiopia; Femal | 2019 |
Alternative dosing guidelines to improve outcomes in childhood tuberculosis: a mathematical modelling study.
Topics: Algorithms; Antitubercular Agents; Body Weight; Child Nutrition Disorders; Child, Preschool; Drug Ad | 2019 |
Optimization of a paediatric fixed dose combination mini-tablet and dosing regimen for the first line treatment of tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Humans; Isoniazid; Pyrazinamide; Rifampin; Tablets; Tuberculosi | 2019 |
Change in prevalence and molecular characteristics of isoniazid-resistant tuberculosis over a 10-year period in China.
Topics: Adult; Aged; Antitubercular Agents; Bacterial Proteins; China; Drug Resistance, Bacterial; Female; H | 2019 |
Tuberculosis in Poland in 2017
Topics: Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resi | 2019 |
The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity.
Topics: Adult; Aged; Alleles; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induce | 2013 |
A new tool for monitoring isoniazid preventive therapy.
Topics: Antitubercular Agents; Communicable Disease Control; Epidemics; HIV Infections; Humans; Isoniazid; N | 2013 |
[Primary sinonasal tuberculosis: apropos of a case].
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Maxil | 2013 |
Isoniazid could be used for antibiotic-loaded bone cement for musculoskeletal tuberculosis: an in vitro study.
Topics: Antibiotics, Antitubercular; Bone Cements; Chemistry, Pharmaceutical; Drug Carriers; Isoniazid; Micr | 2013 |
Progress and challenges in childhood tuberculosis.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antitubercular Agents; BCG Vaccine; Child; Child, | 2013 |
High incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapy.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Biological Products; Chemoprevention; Female; Humans | 2013 |
HLA-DRB1*1501 and VDR polymorphisms and survival of Mycobacterium tuberculosis in human macrophages exposed to inhalable microparticles.
Topics: Cell Survival; Drug Delivery Systems; Haplotypes; HLA-DRB1 Chains; Humans; Immunity, Innate; Isoniaz | 2013 |
Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; Cells, Cultured; Colony Count, Microbial | 2013 |
Factors associated with the rapid implementation process of the fixed-dose combination RHZE tuberculosis regimen in Brazil: an ecological study.
Topics: Antitubercular Agents; Brazil; Drug Combinations; Ethambutol; Health Plan Implementation; Humans; In | 2013 |
Exacerbation of latent lupus: is the culprit acid-fast bacilli or antitubercular therapy?
Topics: Adolescent; Antitubercular Agents; Autoimmunity; Epitopes; Female; Humans; Immunosuppression Therapy | 2013 |
For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance.
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis.
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
Isoniazid preventive treatment: predictors of adverse events and treatment completion.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Databases, Factual; Feasibility Studies; Fema | 2013 |
Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
Topics: Acetylation; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, High Press | 2013 |
Detection of and treatment protocol for rifampicin-monoresistant tuberculosis: what is the role of isoniazid?
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Iran; Isoniazid; Microbial Sensitivity Te | 2013 |
Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Proteins; Catalase; Cod | 2013 |
The polyphosphate kinase gene ppk2 is required for Mycobacterium tuberculosis inorganic polyphosphate regulation and virulence.
Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Female; Gene Deletion; Isoni | 2013 |
Impact of a shortage of first-line antituberculosis medication on tuberculosis control - United States, 2012-2013.
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis; United States | 2013 |
High throughput screening of 7-methylpicene-1,2-diol as arylamine N-acetyltransferase (NAT) inhibitor to establish a isoniazid supplement in anti-tubercular therapy.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Chrysenes; High-Throughput Screening Assays; H | 2013 |
Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Chromatography, Liquid; Dr | 2013 |
A qualitative assessment of challenges to tuberculosis management and prevention in Northern Ethiopia.
Topics: Antitubercular Agents; Child; Delivery of Health Care; Dose-Response Relationship, Drug; Ethiopia; F | 2013 |
Comparing cost-effectiveness of standardised tuberculosis treatments given varying drug resistance.
Topics: Blindness; Cost-Benefit Analysis; Decision Trees; Drug Resistance, Bacterial; Ethambutol; Health Car | 2014 |
Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infection using isoniazid for people living with HIV, in upper northern Thailand.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice | 2013 |
[Tuberculosis annual report 2010--(9) Treatment of tuberculosis-2].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Presch | 2013 |
Genetic diversity of Mycobacterium tuberculosis in Peru and exploration of phylogenetic associations with drug resistance.
Topics: Adult; Antitubercular Agents; Directly Observed Therapy; Drug Resistance, Multiple, Bacterial; Femal | 2013 |
Multidrug- and isoniazid-resistant tuberculosis in three high HIV burden African regions.
Topics: Adolescent; Adult; Africa South of the Sahara; Antitubercular Agents; Cross-Sectional Studies; Drug | 2013 |
Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs.
Topics: Antitubercular Agents; Argentina; Bacterial Typing Techniques; DNA, Bacterial; Drug Resistance, Bact | 2013 |
[Acute isoniazid poisoning: seizure in a patient on anti-tuberculosis treatment].
Topics: Acute Disease; Antitubercular Agents; Child, Preschool; Humans; Isoniazid; Male; Seizures; Tuberculo | 2014 |
Treatment response and adverse reactions in older tuberculosis patients with immunocompromising comorbidities.
Topics: Age Factors; Aged; Aged, 80 and over; Antitubercular Agents; Comorbidity; Female; Humans; Immunocomp | 2013 |
Isoniazid-gelatin conjugate microparticles containing rifampicin for the treatment of tuberculosis.
Topics: Administration, Inhalation; Aerosols; Antitubercular Agents; Cell Line; Desiccation; Drug Carriers; | 2013 |
Estimation of content of anti-TB drugs supplied at centres of the Revised National TB Control Programme in Tamil Nadu, India.
Topics: Antitubercular Agents; Cycloserine; Drug Stability; Drug Storage; Drug Therapy, Combination; Ethambu | 2013 |
[Proposal of anti-tuberculosis regimens based on susceptibility to isoniazid and rifampicin].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Clinical | 2013 |
Isoniazid prevention of HIV-associated tuberculosis.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2013 |
Immunotherapeutic efficacy of recombinant Mycobacterium smegmatis expressing Ag85B-ESAT6 fusion protein against persistent tuberculosis infection in mice.
Topics: Acyltransferases; Animals; Antigens, Bacterial; Antitubercular Agents; Bacteria; Bacterial Load; Bac | 2014 |
Elisa protocol for rapid screening of potential anti-tubercular drugs based on antigenic reactivity of mycobacterial ES-31 serine protease - a drug target supported by axenic culture of Mycobacterium tuberculosis H37 Ra strain in the presence of inhibitor
Topics: Antitubercular Agents; Axenic Culture; Bacterial Proteins; Drug Resistance, Microbial; Enzyme-Linked | 2013 |
Drug-resistant tuberculosis in children in Thailand.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Female; Huma | 2013 |
Response to comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis".
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 2013 |
Comment on "Community-wide isoniazid preventive therapy drives drug-resistant tuberculosis: a model-based analysis".
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 2013 |
Transmission of Mycobacterium tuberculosis in a High School and School-Based Supervision of an Isoniazid-Rifapentine Regimen for Preventing Tuberculosis - Colorado, 2011-2012.
Topics: Antitubercular Agents; Capacity Building; Colorado; Communication; Community-Institutional Relations | 2013 |
Fast detection of drug interaction in Mycobacterium tuberculosis by a checkerboard resazurin method.
Topics: Antitubercular Agents; Drug Combinations; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bac | 2013 |
Results of implementation of preventive recommendations for tuberculosis after renal transplantation in an endemic area.
Topics: Adult; Antitubercular Agents; Brazil; Female; Follow-Up Studies; Humans; Incidence; Isoniazid; Kidne | 2013 |
Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Checklist; Coinfection; Ethiopia; Female; | 2013 |
Access channel residues Ser315 and Asp137 in Mycobacterium tuberculosis catalase-peroxidase (KatG) control peroxidatic activation of the pro-drug isoniazid.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Humans; Isoniazid; Models, Molecular; Mycobacte | 2013 |
Eligibility for isoniazid preventive therapy in South African gold mines.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Female; Gold; Humans; Isoniazid; Male; Middle | 2013 |
Risk for tuberculosis in child contacts. Development and validation of a predictive score.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Early Diagn | 2014 |
Sterilization of granulomas is common in active and latent tuberculosis despite within-host variability in bacterial killing.
Topics: Adaptive Immunity; Animals; Disease Progression; Granuloma; Isoniazid; Latent Tuberculosis; Lung; Ma | 2014 |
Point-of-care C-reactive protein testing to facilitate implementation of isoniazid preventive therapy for people living with HIV.
Topics: Adult; Antitubercular Agents; C-Reactive Protein; Clinical Laboratory Techniques; Cohort Studies; Fe | 2014 |
A patient with HIV and tuberculosis with diminished clopidogrel response.
Topics: Antitubercular Agents; Clopidogrel; Drug Interactions; Drug Resistance; HIV Infections; HIV Protease | 2014 |
A silent mutation in mabA confers isoniazid resistance on Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Gene Expression; Humans; Ison | 2014 |
Rifampicin-loaded 'flower-like' polymeric micelles for enhanced oral bioavailability in an extemporaneous liquid fixed-dose combination with isoniazid.
Topics: Administration, Oral; Animals; Antitubercular Agents; Area Under Curve; Biological Availability; Chr | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
Topics: Adult; Antitubercular Agents; Area Under Curve; Case-Control Studies; Chemical and Drug Induced Live | 2014 |
Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis.
Topics: Adolescent; Adult; Aged; Alleles; Antitubercular Agents; Colorimetry; Female; Genotype; Humans; Ison | 2014 |
Tuberculosis case finding and isoniazid preventive therapy among people living with HIV at public health facilities of Addis Ababa, Ethiopia: a cross-sectional facility based study.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Ethiopia; Female; Health Facilities; HIV Infe | 2014 |
Troubles with tuberculosis prevention.
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Mining; Tuberculosis | 2014 |
Isoniazid-induced cerebellitis: a disguised presentation.
Topics: Adult; Antitubercular Agents; Cerebellar Diseases; Cerebellar Nuclei; Diagnosis, Differential; Femal | 2014 |
Tuberculosis screening and isoniazid preventive therapy implementation: a Brazilian experience.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2014 |
Clinical characteristics and treatment outcomes of patients with low- and high-concentration isoniazid-monoresistant tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Male; Middle Aged; Odd | 2014 |
Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.
Topics: Antitubercular Agents; Child; Child, Preschool; Electronic Data Processing; Female; Humans; Infant; | 2014 |
Pharmacokinetics of isoniazid in low-birth-weight and premature infants.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Genotype; Humans; Infant, Low Birth We | 2014 |
Unfinished battle with childhood tuberculosis: is it curable with less drugs and shorter duration?
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Human | 2013 |
Full-gene sequencing analysis of NAT2 and its relationship with isoniazid pharmacokinetics in Venezuelan children with tuberculosis.
Topics: Adolescent; Arylamine N-Acetyltransferase; Child; Child, Preschool; Female; Genetic Predisposition t | 2014 |
Relationship of streptomycin sensitivity of M tuberculosis to the action of hydrazines of isonicotinic acid (rimifon and marsalid).
Topics: Humans; Hydrazines; Isoniazid; Isonicotinic Acids; Mycobacterium tuberculosis; Streptomycin; Tubercu | 1952 |
Isoniazid and neohetramine(R) in delayed treatment of experimental tuberculosis.
Topics: Anti-Allergic Agents; Histamine H1 Antagonists; Isoniazid; Niacin; Nicotinic Acids; Pyrimidines; Tub | 1953 |
[Treatment of the buccal manifestations of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Lupus Vulgaris; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Topoisomerases, Type I; Gene Expression Regulation, B | 2014 |
Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis.
Topics: Bacterial Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Isoniazid; | 2014 |
Concordance between molecular and phenotypic testing of Mycobacterium tuberculosis complex isolates for resistance to rifampin and isoniazid in the United States.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Genotyping Techniques; Humans; Isoniazid; Microbi | 2014 |
Isoniazid preventive therapy use among patients on antiretroviral therapy: a missed opportunity.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; CD4 Lymphocyte Count; Chi-Square Distribution; Coinfe | 2014 |
Determinants of tuberculosis treatment completion among newborns in a high-burden setting.
Topics: Adult; Age Factors; Antitubercular Agents; Caregivers; Chi-Square Distribution; Coinfection; Female; | 2014 |
Extent and origin of resistance to antituberculosis drugs in the Netherlands, 1993 to 2011.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Cluster Analysis; DNA Fingerprinting; Female; | 2014 |
Primary tuberculosis of the glans penis.
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Middle Aged; Penile Diseases; Penis; Pyridoxine; Tre | 2014 |
Trend of microbiologically-confirmed tuberculosis in a low-incidence setting with high immigration rates.
Topics: Adult; Aged; Bacterial Typing Techniques; Emigrants and Immigrants; Europe, Eastern; Extensively Dru | 2014 |
Effectiveness of tuberculosis preventive therapy in gold miners.
Topics: Antitubercular Agents; Gold; Humans; Isoniazid; Mining; Occupational Diseases; Tuberculosis | 2014 |
A trial of mass isoniazid preventive therapy for tuberculosis control.
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Mining; Tuberculosis | 2014 |
A trial of mass isoniazid preventive therapy for tuberculosis control.
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Mining; Tuberculosis | 2014 |
A trial of mass isoniazid preventive therapy for tuberculosis control.
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Mining; Tuberculosis | 2014 |
Tuberculosis in liver transplant recipients: experience of a South Indian liver transplant center.
Topics: Adult; Antitubercular Agents; Case-Control Studies; Databases, Factual; End Stage Liver Disease; Fem | 2014 |
6-year follow-up of 522 HIV-positive individuals screened for Mycobacterium tuberculosis infection in Denmark.
Topics: Cohort Studies; Communicable Disease Control; Denmark; Diagnostic Tests, Routine; Female; Follow-Up | 2014 |
Tuberculin skin test reversion following isoniazid preventive therapy reflects diversity of immune response to primary Mycobacterium tuberculosis infection.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Immune System; In | 2014 |
An unusual cause of breast lump: isolated tuberculosis of the breast.
Topics: Antitubercular Agents; Biopsy, Fine-Needle; Breast Diseases; Ethambutol; Female; Humans; Isoniazid; | 2014 |
Reliability of Mycobacterial Growth Indicator Tube (MGIT) 960 for the detection of isoniazid resistance in a tuberculosis endemic setting.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Indicators and Reagents; Isoniazid; Micro | 2014 |
Cervical lymphadenopathy--pitfalls of blind antitubercular treatment.
Topics: Adolescent; Adult; Antitubercular Agents; Biopsy; Diagnostic Errors; Ethambutol; Female; Histiocytic | 2014 |
Improvement in severe psoriasis associated with isoniazid treatment.
Topics: Aged; Antitubercular Agents; Facial Dermatoses; Humans; Isoniazid; Male; Psoriasis; Tuberculosis | 2014 |
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cell Line; Colony Count, Microbial; Disease Models, | 2014 |
Development and characterization of spray-dried porous nanoaggregates for pulmonary delivery of anti-tubercular drugs.
Topics: Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carrier | 2016 |
N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Asia; Case-Control Studies; Chemical an | 2014 |
Evaluation of Mycobacterium tuberculosis cross-resistance to isoniazid, rifampicin and levofloxacin with their respective structural analogs.
Topics: Antitubercular Agents; Base Sequence; Colorimetry; Drug Resistance, Bacterial; Ethionamide; Fluoroqu | 2014 |
[Surveillance of antituberculosis-drug resistance in Cuba, 2010-2011].
Topics: Antitubercular Agents; Clone Cells; Cuba; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bac | 2014 |
Pros and cons of the tuberculosis drugome approach--an empirical analysis.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Combinations; Drug Resistance, Bacterial; Ethambutol | 2014 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
The association between the ratio of monocytes:lymphocytes at age 3 months and risk of tuberculosis (TB) in the first two years of life.
Topics: Antitubercular Agents; Child, Preschool; Female; HIV Infections; Humans; Infant; Isoniazid; Lymphocy | 2014 |
Molecular epidemiology of tuberculosis in Cambodian children.
Topics: Adolescent; Antitubercular Agents; Cambodia; Child; Child, Preschool; DNA, Bacterial; Drug Resistanc | 2015 |
A model of isoniazid treatment of tuberculosis.
Topics: Cell Wall; Diffusion; Granuloma; Isoniazid; Models, Biological; Mycobacterium tuberculosis; Tubercul | 2014 |
Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antitubercular Agents; Child; Ch | 2014 |
A study of Mycobacterium tuberculosis genotypic diversity & drug resistance mutations in Varanasi, north India.
Topics: DNA, Intergenic; Drug Resistance, Bacterial; Ethambutol; Genetic Variation; Genotype; Humans; India; | 2014 |
Preventing tuberculosis among HIV-infected pregnant women in Lesotho: the case for rolling out active case finding and isoniazid preventive therapy.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Lesotho; Logistic Models; P | 2014 |
Comparing interferon-gamma release assays to tuberculin skin test in Thai children with tuberculosis exposure.
Topics: Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Female; Humans; Interferon-gamma; I | 2014 |
Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population.
Topics: Adult; Animals; Antitubercular Agents; Arylamine N-Acetyltransferase; CHO Cells; Cricetulus; Female; | 2014 |
Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia.
Topics: Adult; Amikacin; Antitubercular Agents; Capreomycin; Cross-Sectional Studies; Drug Resistance, Multi | 2014 |
[Fe(CN)5(isoniazid)](3-): an iron isoniazid complex with redox behavior implicated in tuberculosis therapy.
Topics: Antitubercular Agents; Electron Spin Resonance Spectroscopy; Ferrous Compounds; Humans; Isoniazid; M | 2014 |
Isoniazid preventive treatment in children in two districts of South India: does practice follow policy?
Topics: Adult; Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Cross-Sectional Studies; Fem | 2014 |
Implementation of isoniazid preventive therapy for HIV-infected adults: overstatement of district reports.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; Humans; | 2014 |
Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV.
Topics: Algorithms; Antitubercular Agents; CD4 Lymphocyte Count; Cost-Benefit Analysis; Drug Resistance, Bac | 2014 |
A field evaluation of the Hardy TB MODS Kit™ for the rapid phenotypic diagnosis of tuberculosis and multi-drug resistant tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; P | 2014 |
Exploitation of Mycobacterium tuberculosis reporter strains to probe the impact of vaccination at sites of infection.
Topics: Animals; Antitubercular Agents; Fluorescent Antibody Technique; Genes, Reporter; Host-Pathogen Inter | 2014 |
Rapid in vivo detection of isoniazid-sensitive Mycobacterium tuberculosis by breath test.
Topics: Animals; Bacterial Proteins; Breath Tests; Catalase; Isoniazid; Molecular Structure; Mycobacterium t | 2014 |
Anti-tuberculosis treatments and risk of hepatocellular carcinoma in tuberculosis patients with liver cirrhosis: a population-based case-control study.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Carcinoma, Hepatocellular; Case-Control Studi | 2015 |
Isoniazid-Induced Psychosis with Obsessive-Compulsive Symptoms (Schizo-Obsessive Disorder) in a Female Child.
Topics: Antipsychotic Agents; Antitubercular Agents; Aripiprazole; Child; Female; Humans; Isoniazid; Obsessi | 2015 |
Evaluation of the modified colorimetric resazurin microtiter plate-based antibacterial assay for rapid and reliable tuberculosis drug susceptibility testing.
Topics: Antitubercular Agents; Colorimetry; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tu | 2014 |
Thioridazine for treatment of tuberculosis: promises and pitfalls.
Topics: Animals; Antitubercular Agents; Female; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampi | 2014 |
Differences in clinical features of two immigrant populations with tuberculosis.
Topics: Adult; Antitubercular Agents; Asia; Comorbidity; Crowding; Drug Resistance, Bacterial; Drug Therapy, | 2015 |
Recurrence due to relapse or reinfection with Mycobacterium tuberculosis: a whole-genome sequencing approach in a large, population-based cohort with a high HIV infection prevalence and active follow-up.
Topics: Adult; Antitubercular Agents; Cohort Studies; Female; Follow-Up Studies; Genetic Variation; Genome-W | 2015 |
Investigating gender disparities in the profile and treatment outcomes of tuberculosis in Ebonyi state, Nigeria.
Topics: Adult; Antitubercular Agents; Cohort Studies; Coinfection; Ethambutol; Female; Health Status Dispari | 2015 |
Long-term protection from isoniazid preventive therapy for tuberculosis in HIV-infected patients in a medium-burden tuberculosis setting: the TB/HIV in Rio (THRio) study.
Topics: Adult; Antitubercular Agents; Brazil; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; | 2015 |
Mapping and manipulating the Mycobacterium tuberculosis transcriptome using a transcription factor overexpression-derived regulatory network.
Topics: Cloning, Molecular; Gene Expression Regulation, Bacterial; Gene Regulatory Networks; Humans; Isoniaz | 2014 |
Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Carriers; Female; Guinea Pigs; Humans; | 2014 |
Ursolic Acid Activates Intracellular Killing Effect of Macrophages During Mycobacterium tuberculosis Infection.
Topics: Antitubercular Agents; ATP-Binding Cassette Transporters; Cell Line; Cell Survival; Host-Pathogen In | 2015 |
Molecular epidemiology of tuberculosis in Sicily, Italy: what has changed after a decade?
Topics: Adult; Antibiotics, Antitubercular; Drug Resistance, Bacterial; Ethambutol; Female; Genotype; Humans | 2014 |
Bone marrow mesenchymal stem cells provide an antibiotic-protective niche for persistent viable Mycobacterium tuberculosis that survive antibiotic treatment.
Topics: Adapalene; Animals; Anti-Bacterial Agents; Antitubercular Agents; Bone Marrow; Bone Marrow Cells; Di | 2014 |
A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Calibration; Computer Simulation; Disease Mod | 2015 |
Evaluation of point mutation detection in Mycobacterium tuberculosis with isoniazid resistance using real-time PCR and TaqMan probe assay.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Humans; Isoniazid; Mycobacter | 2015 |
Assessment of tuberculosis infection during treatment with biologic agents in a BCG-vaccinated pediatric population.
Topics: Adolescent; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Female; Follow-Up Studies; | 2016 |
Stress and host immunity amplify Mycobacterium tuberculosis phenotypic heterogeneity and induce nongrowing metabolically active forms.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Gene Expression Profiling; Host-Path | 2015 |
Tuberculosis: which drug regimen and when.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Directly Observed Therapy; Drug Thera | 2015 |
Serum drug concentrations of INH and RMP predict 2-month sputum culture results in tuberculosis patients.
Topics: Adult; Aged; Alberta; Antitubercular Agents; Female; Humans; Isoniazid; Male; Middle Aged; Retrospec | 2015 |
Elevated transaminases are common in children on prophylactic treatment for tuberculosis.
Topics: Adolescent; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Chemopreventio | 2015 |
Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Combi | 2014 |
[Preventive therapy for iatrogenic active tuberculosis in systemic lupus erythematosus patients].
Topics: Antibiotic Prophylaxis; Glucocorticoids; Humans; Iatrogenic Disease; Isoniazid; Lupus Erythematosus, | 2014 |
Antitubercular activity of Ru (II) isoniazid complexes.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Isoniazid; Microbial Sensitivity Tests; Mycoba | 2015 |
Synergy of chemotherapy and immunotherapy revealed by a genome-scale analysis of murine tuberculosis.
Topics: Animals; Antitubercular Agents; Combined Modality Therapy; Disease Models, Animal; Drug Therapy; Gen | 2015 |
Cavitary tuberculosis and tracheal stenosis simulating granulomatosis with polyangiitis.
Topics: Adult; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Granulomatosis with Polyangi | 2015 |
[Spanish Society for Pediatric Infectious Diseases guidelines on tuberculosis in pregnant women and neonates (ii): Prophylaxis and treatment].
Topics: Antitubercular Agents; Female; Humans; Infant, Newborn; Isoniazid; Pregnancy; Pregnancy Complication | 2015 |
Tuberculosis prevention in South Africa.
Topics: Anti-HIV Agents; Antitubercular Agents; HIV Infections; Humans; Incidence; Isoniazid; Models, Theore | 2015 |
Safe and effective treatment for patients with isoniazid drug resistance.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Female; Humans; Isoniazid; Male; Pyra | 2015 |
In reply.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Female; Humans; Isoniazid; Male; Pyra | 2015 |
An interlaboratory quality control programme for the measurement of tuberculosis drugs.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Monitoring; Humans; Immunoassay; Isoniazid | 2015 |
The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Cohort Studies; Disease-Free Survival; Ethiop | 2015 |
The Diagnostic Cascade of Incidental Findings: A Teachable Moment.
Topics: Aged; Antitubercular Agents; Carotid Body Tumor; Chemical and Drug Induced Liver Injury; Female; Hum | 2015 |
High mortality associated with retreatment of tuberculosis in a clinic in Kampala, Uganda: a retrospective study.
Topics: Adult; Antitubercular Agents; Coinfection; Ethambutol; Female; Follow-Up Studies; HIV Infections; Hu | 2015 |
Sustained Benefit of Community-based Tuberculosis Interventions after 30 Years.
Topics: Antitubercular Agents; Chemoprevention; Community Health Services; Directly Observed Therapy; Humans | 2015 |
Preventing tuberculosis transmission at a maternity hospital by targeted screening radiography of migrants.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Disease Transmission, Infectious; Female; Hosp | 2015 |
A clonal outbreak of tuberculosis in a homeless population in the interior of British Columbia, Canada, 2008-2015.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; British Columbia; Contact Tracing; Disease Ou | 2015 |
Is Europe ready to reach tuberculosis elimination? An outbreak report from Southern Italy.
Topics: Adult; Child, Preschool; Communicable Disease Control; Contact Tracing; Disease Outbreaks; Ethambuto | 2015 |
Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.
Topics: Adult; Area Under Curve; Bayes Theorem; Drug Monitoring; Female; Humans; Isoniazid; Male; Middle Age | 2015 |
Discrepancies in Drug Susceptibility Test for Tuberculosis Patients Resulted from the Mixed Infection and the Testing System.
Topics: Bacterial Proteins; Catalase; Drug Resistance, Bacterial; Humans; Isoniazid; Microbial Sensitivity T | 2015 |
Successful living donor liver transplantation of fulminant liver failure due to isoniazid prophylaxis.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Liver Failure, Acute; Liver Transplantation | 2015 |
Comparison of Three Commercial Molecular Assays for Detection of Rifampin and Isoniazid Resistance among Mycobacterium tuberculosis Isolates in a High-HIV-Prevalence Setting.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Genotyping Techniques; HIV Infections; Humans; Is | 2015 |
In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment.
Topics: Animals; Antitubercular Agents; Ethambutol; Isoniazid; Mice; Mice, Inbred BALB C; Microbial Sensitiv | 2015 |
The yield of a tuberculosis household contact investigation in two regions of Ethiopia.
Topics: Antitubercular Agents; Child, Preschool; Contact Tracing; Ethiopia; Humans; Isoniazid; Numbers Neede | 2015 |
Immigrants and tuberculosis in Hong Kong.
Topics: Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Asia, Southeastern; Asia, Western; | 2015 |
Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy.
Topics: AIDS-Related Opportunistic Infections; Anti-Retroviral Agents; Antitubercular Agents; Female; HIV In | 2015 |
pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice.
Topics: Aldehydes; Animals; CHO Cells; Cricetinae; Cricetulus; Disease Models, Animal; Female; Humans; Hydro | 2015 |
Dielectrophoretic characterization of antibiotic-treated Mycobacterium tuberculosis complex cells.
Topics: Animals; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Electrophoresis; Equipment Des | 2015 |
Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.
Topics: Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Benzimidazoles; Cell Divis | 2015 |
Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Drug Resistance, Bacterial; Humans; Isoniazid; | 2015 |
Risk of Disease After Isoniazid Preventive Therapy for Mycobacterium tuberculosis Exposure in Young HIV-uninfected Children.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Cohort Studies; Female; Humans; Infant; Infant, Newbo | 2015 |
Molecular epidemiology study of Mycobacterium tuberculosis and its susceptibility to anti-tuberculosis drugs in Indonesia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Antitubercular Agents; Ethambutol; Female; Genetic V | 2015 |
Interpreting hazard ratios.
Topics: Antitubercular Agents; Data Interpretation, Statistical; HIV Infections; Humans; Isoniazid; Randomiz | 2015 |
Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria.
Topics: Animals; Antitubercular Agents; Cells, Cultured; Ferric Compounds; Humans; Isoniazid; Macrophages; M | 2015 |
Spray-dried particles as pulmonary delivery system of anti-tubercular drugs: design, optimization, in vitro and in vivo evaluation.
Topics: Administration, Inhalation; Alginates; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; De | 2016 |
A Description of Mortality Associated with IPT plus ART Compared to ART Alone among HIV-Infected Individuals in Addis Ababa, Ethiopia: A Cohort Study.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Cohort Studie | 2015 |
High completion of isoniazid preventive therapy among HIV-infected children and adults in Kinshasa, Democratic Republic of Congo.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Child; Child, Preschool; Democratic Republic o | 2015 |
Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?
Topics: Adult; Arylamine N-Acetyltransferase; Genetic Association Studies; Humans; Isoniazid; Male; Polymorp | 2015 |
Implementation and evaluation of an isoniazid preventive therapy pilot program among HIV-infected patients in Vietnam, 2008-2010.
Topics: Adult; AIDS-Related Opportunistic Infections; Algorithms; Antitubercular Agents; Female; Humans; Iso | 2015 |
Evaluation of the isoniazid preventive therapy (IPT) program in Shurugwi District, Midlands Province, Zimbabwe, January 2013 to August 2014.
Topics: Antitubercular Agents; Humans; Isoniazid; Outcome and Process Assessment, Health Care; Program Evalu | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactio | 2015 |
Tuberculosis: pH-Responsive Isoniazid-Loaded Nanoparticles Markedly Improve Tuberculosis Treatment in Mice (Small 38/2015).
Topics: Animals; Hydrogen-Ion Concentration; Isoniazid; Mice; Nanoparticles; Tuberculosis | 2015 |
[The effect of renal replacement therapy on the plasma concentration of antituberculosis drugs].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Kidney Diseases; Male; Mi | 2015 |
Isoniazid exposure and pyridoxine levels in human immunodeficiency virus associated distal sensory neuropathy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Arylamine N-Acetyltransferase; Coinfection; Female; HI | 2015 |
The impact of nutritional state on the duration of sputum positivity of Mycobacterium tuberculosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Biomarkers; Body Mass Index; C-Re | 2015 |
A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
Topics: Adult; Aged; Algorithms; Antitubercular Agents; Arylamine N-Acetyltransferase; Body Weight; Drug Dos | 2015 |
The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children.
Topics: Antitubercular Agents; Body Weight; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; | 2015 |
Childhood tuberculosis in the United States: shifting the focus to prevention.
Topics: Antibiotics, Antitubercular; Child; Humans; Incidence; Interferon-gamma Release Tests; Isoniazid; Ma | 2015 |
In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
Topics: Animals; Antitubercular Agents; Computer Simulation; Drug Resistance, Bacterial; Granuloma; Isoniazi | 2015 |
Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains.
Topics: Acetylcysteine; Antitubercular Agents; Ascorbic Acid; Drug Synergism; Drug Therapy, Combination; Hum | 2016 |
Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Topics: Adult; Aged; Antitubercular Agents; Drug Monitoring; Female; HIV Infections; Humans; Isoniazid; Line | 2015 |
Implementation and Operational Research: Implementation of the WHO 2011 Recommendations for Isoniazid Preventive Therapy (IPT) in Children Living With HIV/AIDS: A Ugandan Experience.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; F | 2016 |
[CLINICAL EFFECTS OF TREATMENT FOR MYCOBACTERIUM TUBERCULOSIS INFECTION IN PATIENTS AT A SPECIALIZED HOSPITAL IN 2011].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Drug Resistance, Bacterial | 2015 |
Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
Topics: Antitubercular Agents; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; Follow | 2016 |
Might isoniazid plasma exposure be a valuable predictor of drug-related hepatotoxicity risk among adult patients with TB?
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antitubercular Agents; Chemical and Drug Induc | 2016 |
Tolerability and Healthcare Utilization in Maintenance Hemodialysis Patients Undergoing Treatment for Tuberculosis-Related Conditions.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Cohort Studies; Emergency Medical Services; F | 2016 |
Implementation and Operational Research: Feasibility of Using Tuberculin Skin Test Screening for Initiation of 36-Month Isoniazid Preventive Therapy in HIV-Infected Patients in Resource-Constrained Settings.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Cohort Studies; Eswatini; Female; HIV Infections; Hum | 2016 |
Monitoring latent tuberculosis infection diagnosis and management in the Netherlands.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Communicable Disease Contro | 2016 |
Clofazimine Contributes Sustained Antimicrobial Activity after Treatment Cessation in a Mouse Model of Tuberculosis Chemotherapy.
Topics: Animals; Antitubercular Agents; Clofazimine; Disease Models, Animal; Drug Combinations; Drug Therapy | 2016 |
Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Chemoprevention; HIV Infections; Humans; Incidence; I | 2016 |
Potential of Casiopeínas® Copper Complexes and Antituberculosis Drug Combination against Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Coordination Complexes; Copper; Drug Resistance, Bacterial; Drug Synergism; E | 2016 |
Editorial Commentary: Do We Have Strategies to Improve the Preventive Treatment of Latent Tuberculosis Infection?
Topics: Antitubercular Agents; Humans; Isoniazid; Latent Tuberculosis; Tuberculosis | 2016 |
Study of mechanism of interaction of truncated isoniazid-nicotinamide adenine dinucleotide adduct against multiple enzymes of Mycobacterium tuberculosis by a computational approach.
Topics: Antitubercular Agents; Bacterial Proteins; Humans; Isoniazid; Molecular Docking Simulation; Mycobact | 2015 |
Efficacy and safety of isoniazid preventive therapy in light of increasing multi-drug resistance in tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Mu | 2015 |
The timing of tuberculosis after isoniazid preventive therapy among gold miners in South Africa: a prospective cohort study.
Topics: Adult; Antitubercular Agents; Cohort Studies; Disease-Free Survival; Drug Resistance, Bacterial; Fem | 2016 |
Why are people living with HIV still dying of tuberculosis?
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Female; Humans; Isoni | 2016 |
The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver I | 2016 |
Sensititre® MYCOTB MIC plate for drug susceptibility testing of Mycobacterium tuberculosis complex isolates.
Topics: Amikacin; Aminosalicylic Acid; Antitubercular Agents; China; Cycloserine; Ethambutol; Humans; Isonia | 2016 |
Mathematical modeling and systems pharmacology of tuberculosis: Isoniazid as a case study.
Topics: Antitubercular Agents; Computer Simulation; Dose-Response Relationship, Drug; Isoniazid; Lung; Model | 2016 |
Different Risk of Tuberculosis and Efficacy of Isoniazid Prophylaxis in Rheumatoid Arthritis Patients with Biologic Therapy: A Nationwide Retrospective Cohort Study in Taiwan.
Topics: Adolescent; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Biological T | 2016 |
Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries.
Topics: Africa; AIDS-Related Opportunistic Infections; Antitubercular Agents; Asia; Caribbean Region; HIV In | 2016 |
School-based Study to Identify and Treat Adolescent Students at Risk for Tuberculosis Infection.
Topics: Adolescent; Antitubercular Agents; Directly Observed Therapy; Drug Combinations; Female; Humans; Iso | 2016 |
Determinants for tuberculosis in HIV-infected adults in Northwest Ethiopia: a multicentre case-control study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Case-Control Studies; CD4 Lymph | 2016 |
Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Topics: Adolescent; Age Factors; Antitubercular Agents; Child; Child, Preschool; Chromatography, Liquid; Coi | 2016 |
Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.
Topics: Adolescent; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool; Drug Admini | 2016 |
Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape.
Topics: Bacterial Proteins; Capreomycin; Drug Resistance, Multiple, Bacterial; Isoniazid; Kanamycin; Microbi | 2016 |
Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families.
Topics: Genotype; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Oxygen; Rifamp | 2016 |
Benefit of treatment of latent tuberculosis infection in individual patients.
Topics: Humans; Isoniazid; Latent Tuberculosis; Tuberculosis | 2016 |
Development and Optimization of Dual Drugs (Isoniazid and Moxiflox-acin) Loaded Functional PLGA Nanoparticles for the Synergistic Treatment of Tuberculosis.
Topics: Anti-Bacterial Agents; Drug Carriers; Drug Liberation; Drug Resistance, Bacterial; Drug Resistance, | 2016 |
Isoniazid hair concentrations in children with tuberculosis: a proof of concept study.
Topics: Antitubercular Agents; Child; Child, Preschool; Chromatography, Liquid; Drug Monitoring; Female; Hai | 2016 |
Longitudinal whole genome analysis of pre and post drug treatment Mycobacterium tuberculosis isolates reveals progressive steps to drug resistance.
Topics: Antitubercular Agents; Bacterial Proteins; Bacterial Toxins; Catalase; DNA Mutational Analysis; Drug | 2016 |
Isoniazid prophylaxis for the prevention of travel associated tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Travel; Tuberculosis | 2016 |
Uptake of Isoniazid Preventive Therapy among Under-Five Children: TB Contact Investigation as an Entry Point.
Topics: Algorithms; Antitubercular Agents; Child, Preschool; Communicable Disease Control; Contact Tracing; | 2016 |
[Concomitant Drug Reaction with Eosinophilia and Systemic Symptom Syndrome from Ethambutol and Autoimmune Hepatitis from Isoniazid].
Topics: Alanine Transaminase; Antitubercular Agents; Cycloserine; Drug Hypersensitivity Syndrome; Drug Thera | 2016 |
A Qualitative Evaluation of the Acceptability of an Interactive Voice Response System to Enhance Adherence to Isoniazid Preventive Therapy Among People Living with HIV in Ethiopia.
Topics: Adult; Cell Phone; Ethiopia; Female; HIV Infections; Humans; Isoniazid; Medication Adherence; Middle | 2017 |
Isoniazid-induced control of Mycobacterium tuberculosis by primary human cells requires interleukin-1 receptor and tumor necrosis factor.
Topics: Antitubercular Agents; Bacterial Proteins; Cells, Cultured; Humans; Interleukin-1beta; Isoniazid; Ma | 2016 |
PharmGKB summary: isoniazid pathway, pharmacokinetics.
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Pharmacogenetics; Tuberculosis | 2016 |
Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.
Topics: Adult; Aged; Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Gene Frequency; Genotype; | 2016 |
Sustained release of isoniazid from polylactide microspheres prepared using solid/oil drug loading method for tuberculosis treatment.
Topics: Animals; Antitubercular Agents; Calorimetry, Differential Scanning; Chromatography, Liquid; Drug Car | 2016 |
Chemotherapeutic Evaluation of Guar Gum Coated Chitosan Nanoparticle Against Experimental Tuberculosis.
Topics: Animals; Antitubercular Agents; Chitosan; Coated Materials, Biocompatible; Delayed-Action Preparatio | 2016 |
Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
Topics: Adult; Antitubercular Agents; Databases, Factual; Drug Administration Schedule; Drug Monitoring; Dru | 2016 |
Isoniazid therapy for Mycobacterium tuberculosis infection in HIV clinics, Los Angeles, California.
Topics: Adult; Ambulatory Care Facilities; Antitubercular Agents; Coinfection; Cross-Sectional Studies; Fema | 2016 |
Design, synthesis, and In vitro antituberculosis activity of 2(5H)-Furanone derivatives.
Topics: Animals; Antitubercular Agents; CHO Cells; Cricetulus; Drug Synergism; Ethambutol; Furans; Humans; I | 2016 |
Rapid identification of the NAT2 genotype in tuberculosis patients by multicolor melting curve analysis.
Topics: Acetylation; Antitubercular Agents; Arylamine N-Acetyltransferase; China; Genotype; Humans; Isoniazi | 2016 |
Pellagra: a rare complication of isoniazid therapy.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Niacin; Pellagra; Risk Factors; Treatment O | 2016 |
Impact of diabetes mellitus on tuberculosis drug resistance in new cases of tuberculosis.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus; Drug Resistance, Bacterial; Female; Humans; Ir | 2016 |
Characteristics of infants exposed to maternal tuberculosis and chemoprophylaxis using 3 months of isoniazid and rifampicin.
Topics: Adolescent; Adult; Antitubercular Agents; Chemoprevention; Drug Therapy, Combination; Female; Humans | 2017 |
Inhalable Particles for "Pincer Therapeutics" Targeting Nitazoxanide as Bactericidal and Host-Directed Agent to Macrophages in a Mouse Model of Tuberculosis.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; Autophagy; Cell Line; Humans; Isoniazid; | 2016 |
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.
Topics: Antitubercular Agents; Area Under Curve; Body Weight; Dose-Response Relationship, Drug; Drug Monitor | 2016 |
Implications of the 2015 World Health Organization isoniazid preventive therapy recommendations on tuberculosis prevention efforts in Namibia.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Health Care Rationi | 2016 |
Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Genotyping Techniques; Humans; | 2016 |
Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutation.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Humans; Isoniazid; Microbial Sensitivity Tests; | 2016 |
The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism.
Topics: Alleles; Antitubercular Agents; Arylamine N-Acetyltransferase; Child; Child, Preschool; Enzyme Activ | 2016 |
Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance.
Topics: Antitubercular Agents; Disease Outbreaks; Drug Resistance, Bacterial; Europe; Genetic Variation; Hum | 2016 |
[IZOPASK®--THE NEW COMBINED ANTITUBERCULAR PREPARATION].
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Drug Combinations; Female; Humans; Intestinal Abs | 2010 |
NAT2 Genotypes in Moroccan Patients with Hepatotoxicity Due to Antituberculosis Drugs.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Arylamine N-Acetyltransferase; Ca | 2016 |
Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study.
Topics: Adult; Antitubercular Agents; Attitude of Health Personnel; Delivery of Health Care; Drug Resistance | 2016 |
Proteomic and morphological changes produced by subinhibitory concentration of isoniazid in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Electrophoresis, Gel, Two-Dimensional; Humans; Isoniazid; | 2016 |
Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Drug Resistance, Bacterial; Humans; Isoniazid; | 2016 |
The genotypic study of Mycobacterium tuberculosis complex resistant to isoniazid: Galicia, Spain (2008-2013).
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Genotype; Genotyping Techniques; Humans; Isoniazi | 2016 |
Fixed-dose combination and therapeutic drug monitoring in tuberculosis: friend or foe?
Topics: Antitubercular Agents; Drug Combinations; Drug Monitoring; Humans; Isoniazid; Pyrazinamide; Rifampin | 2016 |
NAT2 Genotype and Isoniazid Medication in Children.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Child; Child, Preschool; Genotype; Humans; Iso | 2016 |
Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP trial): study protocol for a randomised controlled trial.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; HIV Infections; Ho | 2016 |
ISONIAZID AND RIFAMPIN PHARMACOKINETICS IN TWO ASIAN ELEPHANTS (ELEPHAS MAXIMUS) INFECTED WITH MYCOBACTERIUM TUBERCULOSIS.
Topics: Animals; Antitubercular Agents; Area Under Curve; Elephants; Female; Half-Life; Isoniazid; Male; Myc | 2016 |
Whole Genome Sequence Analysis of a Large Isoniazid-Resistant Tuberculosis Outbreak in London: A Retrospective Observational Study.
Topics: Adult; Child; Disease Outbreaks; DNA, Bacterial; Genome, Bacterial; Humans; Isoniazid; London; Minis | 2016 |
Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models.
Topics: Achievement; Antitubercular Agents; Cause of Death; China; Delivery of Health Care; Forecasting; Goa | 2016 |
Predictors of adherence to isoniazid preventive therapy in people living with HIV in Ethiopia.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Ethiopia; Female; Follow-Up Studies; HIV Infec | 2016 |
NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Topics: Acetylation; Adult; Aged; Antitubercular Agents; Arylamine N-Acetyltransferase; Case-Control Studies | 2016 |
Identifying and Tackling Emergent Vulnerability in Drug-Resistant Mycobacteria.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Drug Synergism; Genome, Bacterial; Humans; Isonia | 2016 |
Surveillance for tuberculosis in a rural community in The Philippines.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Female; Follow-Up Studies; | 2016 |
Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
Topics: Antitubercular Agents; Botswana; Chemoprevention; Drug Resistance, Bacterial; HIV Infections; Humans | 2016 |
Isoniazid clearance is impaired among human immunodeficiency virus/tuberculosis patients with high levels of immune activation.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Genotype; HIV | 2017 |
Tuberculosis treatment outcomes of six and eight month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Drug Therapy, Combination; Ethambutol; Ethiop | 2016 |
Health system challenges: An obstacle to the success of isoniazid preventive therapy.
Topics: Antitubercular Agents; Coinfection; Delivery of Health Care; Disease Management; Female; HIV Infecti | 2016 |
Characterization of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone as a novel inhibitor of methionine aminopeptidases from Mycobacterium tuberculosis.
Topics: Aminopeptidases; Anti-HIV Agents; Antitubercular Agents; Bacterial Proteins; Coinfection; Dose-Respo | 2016 |
CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; Cytoch | 2016 |
Time to review treatment of isoniazid-resistant tuberculosis?
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; R | 2017 |
Tuberculosis presenting as a 'swollen calf'.
Topics: Abscess; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Diagnosis, Different | 2016 |
[First clinical isolate of Mycobacterium tuberculosis exhibiting resistance to rifampicin and sensibility to isoniazid in the Elche´s Health Department-General Hospital(1998-2015)].
Topics: Adult; Antibiotics, Antitubercular; Drug Resistance, Bacterial; Hospitals, General; Humans; Isoniazi | 2017 |
Virulence of Mycobacterium tuberculosis after Acquisition of Isoniazid Resistance: Individual Nature of katG Mutants and the Possible Role of AhpC.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Catalase; Cytokines; Drug Resistance, Bacterial; | 2016 |
Rapid Detection of Mycobacterium tuberculosis Strains Resistant to Isoniazid and/or Rifampicin: Standardization of Multiplex Polymerase Chain Reaction Analysis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Isoniazid; Mycobacterium tuberculosis; Po | 2016 |
Drug-related hepatitis in patients treated with standard anti-tuberculosis chemotherapy over a 30-year period.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Chemical and Drug Induced Liver I | 2016 |
Analysis of discrepant results between the Genotype
Topics: Adult; Aged; Antitubercular Agents; Bacterial Proteins; Catalase; Female; Genotype; Humans; Isoniazi | 2017 |
Effects of isoniazid resistance on TB treatment outcomes under programmatic conditions in a high-TB and -HIV setting: a prospective multicentre study.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; HIV Infections; Humans | 2017 |
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Topics: Anticoagulants; Antidepressive Agents; Antimetabolites, Antineoplastic; Antitubercular Agents; Aryla | 2017 |
Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiretroviral Therapy, Highly Active; Antitubercul | 2017 |
High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China.
Topics: Adult; Chemoprevention; China; Coinfection; Cross-Sectional Studies; Female; HIV Infections; HIV-1; | 2017 |
One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America.
Topics: Adult; Antitubercular Agents; Europe; Europe, Eastern; Female; HIV Infections; Humans; Isoniazid; La | 2017 |
Isoniazid Preventive Therapy among Children Living with Tuberculosis Patients: Is It Working? A Mixed-Method Study from Bhopal, India.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child, Preschool; Communicable Disease Control; Cont | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Anti-TB drug concentrations and drug-associated toxicities among TB/HIV-coinfected patients.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Coinfection; Female; HIV Infec | 2017 |
Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; Chemical and Drug Induced L | 2017 |
"It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Ambulatory Care Facilities; Antitubercular Agents; Cou | 2017 |
Tuberculosis along the continuum of HIV care in a cohort of adolescents living with HIV in Ethiopia.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; Chil | 2017 |
Identifying children with tuberculosis among household contacts in The Gambia.
Topics: Antitubercular Agents; Child; Child, Preschool; Contact Tracing; Drug Resistance, Bacterial; Family | 2017 |
Missed opportunities for screening child contacts of smear-positive tuberculosis in Zambia, a high-prevalence setting.
Topics: Adolescent; Adult; Antitubercular Agents; Contact Tracing; Cross-Sectional Studies; Family Character | 2017 |
Is IPT more effective in high-burden settings? Modelling the effect of tuberculosis incidence on IPT impact.
Topics: Antitubercular Agents; Humans; Incidence; Isoniazid; Sensitivity and Specificity; Tuberculosis; Worl | 2017 |
Pharmacokinetics and pharmacodynamics of isoniazid in patients with intermediate resistance.
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 2017 |
The tuberculosis taboo.
Topics: Antitubercular Agents; Contact Tracing; Drug Therapy, Combination; Global Health; Humans; Isoniazid; | 2017 |
Integrating tuberculosis screening in Kenyan Prevention of Mother-To-Child Transmission programs.
Topics: Adult; Antitubercular Agents; Female; HIV Infections; Humans; Infant; Infectious Disease Transmissio | 2017 |
Barriers to the treatment of childhood tuberculous infection and tuberculosis disease: a qualitative study.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Community Health Workers; Drug Resistanc | 2017 |
HIV care in Yangon, Myanmar; successes, challenges and implications for policy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Posit | 2017 |
First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Monitoring; Female; | 2016 |
Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Codon, Nonsense; DNA, Bacterial; Drug Resistanc | 2008 |
Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients.
Topics: Antitubercular Agents; Arylamine N-Acetyltransferase; Cytochrome P-450 CYP2E1; Genotype; Glutathione | 2008 |
Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex.
Topics: Antitubercular Agents; Bacterial Proteins; Bacterial Typing Techniques; DNA Probes; Drug Resistance, | 2009 |
Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans | 2008 |
Opportunities and challenges for HIV care in overlapping HIV and TB epidemics.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antitubercular Agents; | 2008 |
Evaluation of methods for rapid detection of resistance to isoniazid and rifampin in Mycobacterium tuberculosis isolates collected in the Caribbean.
Topics: Antitubercular Agents; Caribbean Region; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Isoniaz | 2008 |
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Disease Models, Animal; | 2008 |
Update on the treatment of tuberculosis.
Topics: Antitubercular Agents; Comorbidity; Directly Observed Therapy; Disease Progression; Drug Therapy, Co | 2008 |
GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples.
Topics: Antitubercular Agents; Bacteriological Techniques; DNA, Bacterial; Drug Resistance; Genotype; German | 2008 |
Mechanisms of heteroresistance to isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan.
Topics: Antitubercular Agents; Bacterial Typing Techniques; Codon; Drug Resistance, Multiple, Bacterial; Gen | 2009 |
Genetic diversity of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Poland and assessed by spoligotyping.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Typing Techniques; DNA | 2008 |
Isoniazid-monoresistant tuberculosis in the United States, 1993 to 2003.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Confidence Intervals; Drug | 2008 |
Prognostic value of a T-cell-based, interferon-gamma biomarker in children with tuberculosis contact.
Topics: Adolescent; Antitubercular Agents; Biomarkers; Child; Child, Preschool; Contact Tracing; Enzyme-Link | 2008 |
[Effects of prophylaxis on QuantiFERON TB-2G responses among children].
Topics: Adolescent; Adult; Antitubercular Agents; Biomarkers; Child; Contact Tracing; Disease Outbreaks; Enz | 2008 |
Needed: new and better tools to combat latent tuberculosis infection.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Humans; | 2008 |
Study of cloud point extraction and high-performance liquid chromatographic determination of isoniazid based on the formation of isonicotinylhydrazone.
Topics: Analytic Sample Preparation Methods; Antitubercular Agents; Benzaldehydes; Chromatography, High Pres | 2009 |
Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Etanercept; Female; Humans; Immunoglobulin G; Ison | 2009 |
Few HIV patients tested for tuberculosis.
Topics: Antitubercular Agents; Delivery of Health Care, Integrated; HIV Infections; Humans; Internationality | 2008 |
Prevalence of tuberculosis drug resistance in 10 provinces of China.
Topics: Antitubercular Agents; China; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; Isoniazid; M | 2008 |
Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Male; Middle Aged; Myc | 2009 |
Molecular analysis of isoniazid resistance in different genotypes of Mycobacterium tuberculosis isolates from Iran.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Genotype; Humans; Iran; Isoni | 2008 |
Does the implementation of an interferon-gamma release assay in lieu of a tuberculin skin test increase acceptance of preventive therapy for latent tuberculosis among healthcare workers?
Topics: Antitubercular Agents; Health Personnel; Humans; Interferon-gamma; Isoniazid; Mycobacterium tubercul | 2009 |
Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in Kuwait.
Topics: Adult; Aged; Antitubercular Agents; Bacterial Proteins; Codon; DNA, Intergenic; Drug Resistance, Bac | 2009 |
Genotypic detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis strains by DNA sequencing: a randomized trial.
Topics: Adult; Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; DNA, Bacte | 2009 |
Vaccine-induced immunity circumvented by typical Mycobacterium tuberculosis Beijing strains.
Topics: Adult; Antibodies, Bacterial; Antigenic Variation; Antitubercular Agents; BCG Vaccine; China; DNA Tr | 2009 |
Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America.
Topics: Antitubercular Agents; Bacterial Proteins; Bacterial Typing Techniques; Cluster Analysis; DNA Finger | 2009 |
Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results.
Topics: Adult; Antitubercular Agents; Female; Humans; Interferon-gamma; Isoniazid; Lymphocyte Activation; Ma | 2009 |
MenA is a promising drug target for developing novel lead molecules to combat Mycobacterium tuberculosis.
Topics: Alkyl and Aryl Transferases; Bacterial Proteins; Benzophenones; Catalysis; Cell Proliferation; Dimet | 2009 |
First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
Topics: Adolescent; Aged; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Iran; | 2009 |
Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Directly Observed Therapy; Drug Administration Schedul | 2009 |
The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda.
Topics: Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Comorbidity; Female; | 2008 |
Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines.
Topics: Antitubercular Agents; Child, Preschool; Female; Humans; Infant; Isoniazid; Male; Plasma; South Afri | 2009 |
Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Retroviral Agents; Cohort Studies; Drug Monitoring; Drug Th | 2009 |
Effectiveness and safety of a treatment regimen based on isoniazid plus vaccination with Mycobacterium tuberculosis cells' fragments: field-study with naturally Mycobacterium caprae-infected goats.
Topics: Animals; Antigens, Bacterial; Antitubercular Agents; Female; Goats; Interferon-gamma; Isoniazid; Myc | 2009 |
[Primary tuberculosis of the tongue].
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Male; Pyrazinamide; Rifampin; Tongue Diseases; Tube | 2009 |
The cost of intensified case finding and isoniazid preventive therapy for HIV-infected patients in Battambang, Cambodia.
Topics: Antitubercular Agents; Cambodia; Costs and Cost Analysis; HIV Infections; Humans; Isoniazid; Patient | 2009 |
Probing ligand binding modes of Mycobacterium tuberculosis MurC ligase by molecular modeling, dynamics simulation and docking.
Topics: Antitubercular Agents; Binding Sites; Cell Wall; Crystallography, X-Ray; Drug Resistance, Multiple; | 2010 |
In vitro and ex vivo activity of peptide deformylase inhibitors against Mycobacterium tuberculosis H37Rv.
Topics: Amidohydrolases; Animals; Antibiotics, Antitubercular; Dipeptides; Drug Synergism; Drug Therapy, Com | 2009 |
Increase in plasma levels of clozapine after addition of isoniazid.
Topics: Aged; Antipsychotic Agents; Antitubercular Agents; Clozapine; Drug Interactions; Humans; Isoniazid; | 2009 |
Isoniazid in patient plasma may cause a false-positive result on the complement-dependent cytotoxicity test.
Topics: Antigen-Antibody Complex; Antitubercular Agents; Complement System Proteins; Cytotoxicity, Immunolog | 2009 |
A retrospective evaluation of completion rates, total cost, and adverse effects for treatment of latent tuberculosis infection in a public health clinic in central massachusetts.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Female; Humans; Isoniazid; Liver; Male; Massa | 2009 |
Are the effects of isoniazid preventive therapy and highly active antiretroviral therapy additive in preventing HIV-associated tuberculosis?
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antitubercular Agents; | 2009 |
Additive effects of isoniazid preventive therapy and HAART.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antitubercular Agents; | 2009 |
Measurement of plasma levels of isoniazid for dose adjustment in the hemodialysis patients.
Topics: Antitubercular Agents; Comorbidity; Half-Life; Humans; Isoniazid; Kidney Failure, Chronic; Renal Dia | 2009 |
Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; | 2009 |
[Evaluation of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in clinical Mycobacterium tuberculosis complex clinical isolates].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA P | 2009 |
Pyridoxine in pregnant women receiving antituberculous drugs.
Topics: Antitubercular Agents; Female; Humans; Isoniazid; Nervous System Diseases; Pregnancy; Pregnancy Comp | 2009 |
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Humans; Isoniazid; Microbial Sensitiv | 2009 |
Inhalable microparticles containing isoniazid and rifabutin target macrophages and 'stimulate the phagocyte' to achieve high efficacy.
Topics: Administration, Inhalation; Antitubercular Agents; DNA Fragmentation; Humans; Isoniazid; Macrophage | 2009 |
A pyrosequencing method for molecular monitoring of regions in the inhA, ahpC and rpoB genes of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; DNA-Directed RNA Polymerases; DNA, Bacterial; Drug Resist | 2010 |
Incomplete immunological recovery following anti-tuberculosis treatment in HIV-infected individuals with active tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Analysis of Variance; beta 2-Microglobulin; Biomarkers; CD4-Posi | 2009 |
Use of non-invasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity.
Topics: Animals; Antitubercular Agents; Diagnostic Imaging; Disease Models, Animal; Humans; Isoniazid; Lucif | 2009 |
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig.
Topics: Animals; Antitubercular Agents; Drug Resistance, Bacterial; Guinea Pigs; Isoniazid; Lung; Mycobacter | 2009 |
Isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
Topics: Antitubercular Agents; Bacterial Proteins; Bacterial Typing Techniques; Catalase; Cluster Analysis; | 2009 |
Development of a pharmacist-managed latent tuberculosis clinic.
Topics: Adult; Antitubercular Agents; Child; Female; Humans; Isoniazid; Male; Outpatient Clinics, Hospital; | 2009 |
Erring on the side of action: time for HIV programmes to implement isoniazid preventive therapy.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Comorbidity; HIV Infections; Humans; Isoniazid; Publi | 2009 |
Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues.
Topics: Antitubercular Agents; Comorbidity; Drug Resistance, Microbial; Global Health; HIV Infections; Human | 2009 |
Mortality benefit of isoniazid preventive therapy in HIV-positive persons: a simulation study.
Topics: Antitubercular Agents; Comorbidity; HIV Infections; Humans; Isoniazid; Meta-Analysis as Topic; Tuber | 2009 |
Absence of transaminase elevation during concomitant methotrexate and isoniazid therapy.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Cohort Studies; Female; Humans; Isoniazid; | 2009 |
A simple in vitro PK/PD model system to determine time-kill curves of drugs against Mycobacteria.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Dose-Response Relationship, Drug; Drug Resistance, Bacter | 2009 |
Commentary: Reducing HIV-associated tuberculosis in children.
Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Antitubercular Agents; Child; HIV Infections; Humans | 2009 |
Analysis of isoniazid, streptomycin and ethambutol resistance in Mycobacterium tuberculosis isolates from Morocco.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; DNA Mutational Analysis; DNA, Bac | 2009 |
An integrated approach to rapid diagnosis of tuberculosis and multidrug resistance using liquid culture and molecular methods in Russia.
Topics: Bacterial Typing Techniques; Bacteriological Techniques; Communicable Disease Control; Cost-Benefit | 2009 |
Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; B | 2009 |
Evaluation of direct method of drug susceptibility testing of Mycobacterium tuberculosis to rifampicin and isoniazid by nitrate reductase assay in a national reference laboratory.
Topics: Antitubercular Agents; Colorimetry; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tu | 2010 |
Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis.
Topics: Adult; Antitubercular Agents; Early Diagnosis; Female; Follow-Up Studies; Humans; Immunosuppressive | 2010 |
Tuberculosis in asymptomatic HIV-infected adults with abnormal chest radiographs screened for tuberculosis prevention.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Botswana; CD4 Lymphocyte Count; | 2010 |
High level association of mutation in KatG315 with MDR and XDR clinical isolates of Mycobacterium tuberculosis in Belarus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Catalase; Drug Resistance, Multiple, Bacterial; Female; H | 2009 |
[Diagnostic image. A man with a swelling under his jaw].
Topics: Aged; BCG Vaccine; Carcinoma; Humans; Isoniazid; Lymph Nodes; Male; Rifampin; Treatment Outcome; Tub | 2009 |
In vitro synergistic interactions of oleanolic acid in combination with isoniazid, rifampicin or ethambutol against Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Drug Synergism; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tests; M | 2010 |
New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability.
Topics: Antitubercular Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacteri | 2010 |
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Guinea Pigs; Isoniazid; Lung; Mice; | 2010 |
Association of chest radiographic abnormalities with tuberculosis disease in asymptomatic HIV-infected adults.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Botswana; Fem | 2010 |
Pyridoxal-5-phosphate plasma concentrations in children receiving tuberculosis chemotherapy including isoniazid.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Child, Preschool; F | 2010 |
Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects?
Topics: Acetylation; Adolescent; Adult; Antitubercular Agents; Biotransformation; Case-Control Studies; Fema | 2010 |
Expanding the role of the microscopic observation drug susceptibility assay in tuberculosis and HIV management.
Topics: Antitubercular Agents; Bacterial Typing Techniques; HIV Infections; Humans; Isoniazid; Microbial Sen | 2010 |
Microscopic observation drug susceptibility assay for tuberculosis screening before isoniazid preventive therapy in HIV-infected persons.
Topics: Adult; Antitubercular Agents; Bacterial Typing Techniques; Chi-Square Distribution; Drug Resistance, | 2010 |
Drug-susceptibility patterns of Mycobacterium tuberculosis in Mpumalanga province, South Africa: possible guiding design of retreatment regimen.
Topics: Adolescent; Adult; Age Distribution; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercu | 2010 |
Tuberculosis in UK prisoners: a challenge for control.
Topics: Antitubercular Agents; Humans; Isoniazid; Prisoners; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2010 |
[Immunosuppressive therapy and tuberculosis].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Enzyme-L | 2010 |
Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; | 2010 |
Incision infection with Mycobacterium tuberculosis after total hip arthroplasty without any primary tuberculosis focus.
Topics: Arthroplasty, Replacement, Hip; Drug Therapy, Combination; Ethambutol; Female; Hip Dislocation, Cong | 2011 |
Re: Use of isoniazid chemoprophylaxis in renal transplantation.
Topics: Antitubercular Agents; Humans; Isoniazid; Kidney Transplantation; Nervous System; Pyridoxine; Tuberc | 2010 |
Therapeutic potential of peptide deformylase inhibitors against experimental tuberculosis.
Topics: Amidohydrolases; Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Dise | 2010 |
Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome.
Topics: Adult; Antibiotics, Antitubercular; Denmark; Drug Resistance, Bacterial; Female; Humans; Isoniazid; | 2010 |
Development of interstitial pneumonia in a patient with rheumatoid arthritis induced by isoniazid for tuberculosis chemoprophylaxis.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Arthritis, Rheumatoid; Biopsy; Chemical and Drug Ind | 2012 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Granuloma encapsulation is a key factor for containing tuberculosis infection in minipigs.
Topics: Animals; Bacterial Vaccines; Disease Models, Animal; Fibrosis; Granuloma; Immunity, Humoral; Isoniaz | 2010 |
Recording isoniazid preventive therapy delivery to children: operational challenges.
Topics: Adult; Antitubercular Agents; Child, Preschool; Documentation; Family Characteristics; Female; Human | 2010 |
[Resistance rates to major anti-tuberculosis drugs in Mycobacterium tuberculosis strains isolated from seven different regions of Turkey in 2003-2006 period].
Topics: Adult; Antitubercular Agents; Child; Drug Resistance, Multiple, Bacterial; Ethambutol; Female; Human | 2010 |
Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Proteins; Catalase; China; DNA Mutatio | 2010 |
Effectiveness of 3 months of rifampicin and isoniazid chemoprophylaxis for the treatment of latent tuberculosis infection in children.
Topics: Adolescent; Antitubercular Agents; Child; Drug Administration Schedule; Drug Therapy, Combination; E | 2010 |
Unequal distribution of resistance-conferring mutations among Mycobacterium tuberculosis and Mycobacterium africanum strains from Ghana.
Topics: Antitubercular Agents; Bacterial Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Ghana; Humans | 2010 |
Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Carriers; Drug Compounding; Excipients; Female; Gelatin; Isonia | 2011 |
Inconsistent dosing of anti-tuberculosis drugs in Taipei, Taiwan.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Dose-Response Relationship, Drug; Drug Combinations; | 2010 |
[Treatment of tuberculous infection: Where we are?].
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Rifampin; Tuberculosis | 2010 |
Mycobacterium tuberculosis persistence mutants identified by screening in isoniazid-treated mice.
Topics: Animals; Antitubercular Agents; ATP-Binding Cassette Transporters; Bacterial Proteins; Cells, Cultur | 2010 |
Bis dihydropyrimidine: synthesis and antimycobacterial activity.
Topics: Acetoacetates; Antitubercular Agents; Benzenesulfonates; Dapsone; Drug Resistance, Bacterial; Humans | 2011 |
Etanercept in a patient with severe psoriasis and latent viral hepatic disease and latent tuberculosis.
Topics: Antitubercular Agents; Etanercept; Hepatitis B; Humans; Immunoglobulin G; Immunologic Factors; Isoni | 2010 |
The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Pyrazinamide; Rifa | 2010 |
Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Disease Progression; HIV Infections; Humans; Isoniazid | 2010 |
Tuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance, 1995-2009.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Emigrants and Immigrants; Female; Greec | 2010 |
One-tube loop-mediated isothermal amplification combined with restriction endonuclease digestion and ELISA for colorimetric detection of resistance to isoniazid, ethambutol and streptomycin in Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Colorimetry; DNA Restriction Enzymes; DNA, Bacterial; Drug Resistance, Multip | 2010 |
Characterisation of the membrane affinity of an isoniazide peptide conjugate by tensiometry, atomic force microscopy and sum-frequency vibrational spectroscopy, using a phospholipid Langmuir monolayer model.
Topics: Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Cell Membrane Permeability; Epitopes | 2010 |
Human bovine tuberculosis - remains in the differential.
Topics: Adult; Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; Isoniazid; Male; Microbial | 2010 |
Mediastina Tuberculosis mass in a three-month-old boy.
Topics: Adrenal Cortex Hormones; Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combinati | 2010 |
Spoligotype-based comparative population structure analysis of multidrug-resistant and isoniazid-monoresistant Mycobacterium tuberculosis complex clinical isolates in Poland.
Topics: Adult; Aged; Antitubercular Agents; Bacterial Typing Techniques; Cluster Analysis; DNA Fingerprintin | 2010 |
High-resolution melting curve analysis for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Codon; DNA Primers; DNA-Directed RNA Polymerase | 2010 |
[Exposure of a cohort of newborn infants to tuberculosis in a neonatology service].
Topics: Antitubercular Agents; Humans; Infant, Newborn; Infant, Newborn, Diseases; Isoniazid; Nursing Staff, | 2010 |
Acute liver failure due to antitubercular therapy: Strategy for antitubercular treatment before and after liver transplantation.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Disease Progressio | 2010 |
Anterior segment optical coherence tomography findings of presumed intraocular tuberculosis.
Topics: Aged; Anterior Eye Segment; Antitubercular Agents; Cataract Extraction; Corneal Edema; Drug Therapy, | 2011 |
[Epidemiology of the resistance of Mycobacterium tuberculosis to antituberculosis drugs at the main hospital in Dakar, Senegal. A 4-year retrospective study (2000-2003)].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Therapy, Combination; Etha | 2010 |
Interferon-γ release assay for tuberculosis screening of healthcare workers at a Korean tertiary hospital.
Topics: Adult; Antitubercular Agents; Female; Health Personnel; Hospitals; Humans; Immunoassay; Incidence; I | 2010 |
Risk of relapse and failure after retreatment with the Category II regimen in Nepal.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Cohort Studies; Drug Resistance, Bacterial; F | 2010 |
MODS accreditation process for regional reference laboratories in Peru: validation by GenoType® MTBDRplus.
Topics: Accreditation; Antitubercular Agents; Bacteriological Techniques; Humans; Isoniazid; Laboratories; M | 2010 |
[Performances of the assay MTBDRplus(®) in the surveillance of rifampicin resistance in Mycobacterium tuberculosis].
Topics: Antitubercular Agents; Bacterial Proteins; Codon; Data Collection; Djibouti; DNA-Directed RNA Polyme | 2011 |
Isoniazid preventive therapy for HIV-infected people: evidence to support implementation.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Evidence-Based Medicine; HIV Infection | 2010 |
Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; HIV Infections; | 2010 |
'Team up against TB': promoting involvement in Thibela TB, a trial of community-wide tuberculosis preventive therapy.
Topics: Adult; Female; Health Education; Health Promotion; HIV Infections; HIV-1; Humans; Isoniazid; Male; P | 2010 |
Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Delivery of Health Care; Female | 2010 |
Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions.
Topics: Antitubercular Agents; Delivery of Health Care, Integrated; Female; HIV Infections; Humans; Isoniazi | 2010 |
Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; Female; HIV Infe | 2010 |
In silico children and the glass mouse model: clinical trial simulations to identify and individualize optimal isoniazid doses in children with tuberculosis.
Topics: Animals; Antitubercular Agents; Area Under Curve; Cerebrospinal Fluid; Child; Child, Preschool; Comp | 2011 |
Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BAL | 2011 |
Acceptability of treatment of latent tuberculosis infection in newly HIV-infected young women in Uganda.
Topics: Adolescent; Adult; Antitubercular Agents; Cohort Studies; Female; HIV Infections; Humans; Isoniazid; | 2010 |
Direct detection of isoniazid-resistant Mycobacterium tuberculosis in respiratory specimens by multiplex allele-specific polymerase chain reaction.
Topics: Alleles; Amino Acid Substitution; Bacterial Proteins; Catalase; DNA, Bacterial; Drug Resistance, Bac | 2011 |
Comment on: isoniazid and rifampicin resistance-associated mutations in Mycobacterium tuberculosis isolates from Yangon, Myanmar: implications for rapid molecular testing.
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Isoniazid; Microbial Sens | 2011 |
Downregulation of katG expression is associated with isoniazid resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Cell Line; Down-Regulation; Drug Resistance, Ba | 2011 |
Perinatal tuberculosis.
Topics: Antimalarials; Humans; Immunocompromised Host; Infant, Newborn; Isoniazid; Prevalence; Tuberculosis | 2011 |
Genomic stability over 9 years of an isoniazid resistant Mycobacterium tuberculosis outbreak strain in Sweden.
Topics: Disease Outbreaks; Drug Resistance, Bacterial; Genomic Instability; Humans; Isoniazid; Mycobacterium | 2011 |
Mycobacteria infection in incomplete transverse myelitis is refractory to steroids: a pilot study.
Topics: Adult; Aged; Antitubercular Agents; Female; Humans; Isoniazid; Magnetic Resonance Imaging; Male; Met | 2011 |
[Resistance rates of Mycobacterium tuberculosis complex strains isolated from clinical specimens].
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Female; Humans | 2011 |
Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice.
Topics: Animals; Antibiotics, Antitubercular; Bacterial Load; Cyclic Nucleotide Phosphodiesterases, Type 4; | 2011 |
[Susceptibility of M. tuberculosis to antituberculosis drugs as determined by two methods, in Sucre state, Venezuela].
Topics: Antitubercular Agents; Bacterial Proteins; Base Sequence; DNA-Directed RNA Polymerases; Drug Resista | 2010 |
Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.
Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Gene Expression Profiling; Gene Expressi | 2010 |
Comparison of isoniazid monoresistant tuberculosis with drug-susceptible tuberculosis and multidrug-resistant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Drug Resistance, Bacterial; Drug Therapy; Emigrants and Immigran | 2011 |
Genetic variation of Mycobacterium tuberculosis circulating in Kharkiv Oblast, Ukraine.
Topics: Adult; Antitubercular Agents; Bacterial Typing Techniques; DNA, Bacterial; Drug Resistance, Bacteria | 2011 |
Torticollis in mice intravenously infected with Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Autopsy; Aza Compounds; Disease Models, Animal; Drug Therapy, Combin | 2011 |
Mycobacterium tuberculosis spoligotypes and drug susceptibility pattern of isolates from tuberculosis patients in South-Western Uganda.
Topics: Adult; Antitubercular Agents; Female; Genetic Variation; Genotype; HIV Infections; Humans; Isoniazid | 2011 |
Large outbreak of isoniazid-monoresistant tuberculosis in London, 1995 to 2006: case-control study and recommendations.
Topics: Adolescent; Adult; Age Distribution; Aged; Antimalarials; Case-Control Studies; Disease Outbreaks; D | 2011 |
Isoniazid preventive therapy in HIV infection.
Topics: Antitubercular Agents; HIV Infections; Isoniazid; Tuberculosis | 2011 |
Successful treatment with infliximab despite positive tuberculosis ELISpot results in a patient with pityriasis rubra pilaris taking prophylactic isoniazid.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antitubercular Agents; Humans; Infliximab; Isoniaz | 2011 |
Modelling the performance of isoniazid preventive therapy for reducing tuberculosis in HIV endemic settings: the effects of network structure.
Topics: Africa South of the Sahara; Antitubercular Agents; Computer Simulation; Contact Tracing; Endemic Dis | 2011 |
Sensitivity to isoniazid of Mycobacterium bovis BCG strains and BCG disseminated disease isolates.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium bovis; Tubercul | 2011 |
The variable clinical presentation of tuberculosis otitis media and the importance of early detection.
Topics: Adolescent; Adult; Audiometry, Pure-Tone; Early Diagnosis; Ethambutol; Female; Humans; Isoniazid; Ma | 2011 |
Drug susceptibility pattern of Mycobacterium tuberculosis isolates against conventional anti-tuberculosis drugs in Dhaka, Bangladesh.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Bangladesh; Drug Resistance, Bacterial; Drug Resista | 2011 |
Formulation and optimization of alkaline extracted ispaghula husk microparticles of isoniazid - in vitro and in vivo assessment.
Topics: Adhesiveness; Alginates; Animals; Antitubercular Agents; Calorimetry, Differential Scanning; Cross-L | 2011 |
T cell monitoring of chemotherapy in experimental rat tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins | 2011 |
Tuberculosis-associated chronic kidney disease.
Topics: Antitubercular Agents; Ethambutol; Fever; Humans; Isoniazid; Kidney Failure, Chronic; Male; Pyrazina | 2011 |
Polymeric emulsion and crosslink-mediated synthesis of super-stable nanoparticles as sustained-release anti-tuberculosis drug carriers.
Topics: Alginates; Calcium Chloride; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Emulsions | 2011 |
Doctor IPT ignorance contributing to TB epidemic--study.
Topics: Antitubercular Agents; Humans; Isoniazid; South Africa; Tuberculosis | 2011 |
Evaluation of the Genotype® MTBDRplus assay as a tool for drug resistance surveys.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Genotype; Humans; Isoniazid; Microbial Sensitivit | 2011 |
Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms.
Topics: Adult; Algorithms; Area Under Curve; Female; HIV Infections; Humans; Infectious Disease Medicine; In | 2012 |
Changes in the epidemiology of tuberculosis: the influence of international migration flows.
Topics: Adult; Africa; Age Distribution; Aged; Aged, 80 and over; Antitubercular Agents; Comorbidity; Diabet | 2011 |
What is thwarting tuberculosis prevention in high-burden settings?
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Bacterial; Dru | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; H | 2011 |
Operational challenges in managing Isoniazid Preventive Therapy in child contacts: a high-burden setting perspective.
Topics: Adult; Antitubercular Agents; Child, Preschool; Community Health Centers; Female; Humans; Isoniazid; | 2011 |
A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients.
Topics: Adult; Antitubercular Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Isoniazid; Kidney T | 2011 |
A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients.
Topics: Adult; Antitubercular Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Isoniazid; Kidney T | 2011 |
A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients.
Topics: Adult; Antitubercular Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Isoniazid; Kidney T | 2011 |
A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients.
Topics: Adult; Antitubercular Agents; Enzyme-Linked Immunosorbent Assay; Female; Humans; Isoniazid; Kidney T | 2011 |
Tuberculosis in HIV programmes in lower-income countries: practices and risk factors.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Co | 2011 |
Primary nasal tuberculosis-a rare clinical entity.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Epistaxis; Female; Humans; Isoniazid; Nasal | 2011 |
Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa.
Topics: Adult; Aged; Antitubercular Agents; Bacterial Proteins; Catalase; Cohort Studies; Disease Progressio | 2011 |
Quantifying the burden and trends of isoniazid resistant tuberculosis, 1994-2009.
Topics: Adult; Antitubercular Agents; Comorbidity; Directly Observed Therapy; HIV; HIV Infections; Humans; I | 2011 |
[Anti-tuberculosis chemotherapy and management of adverse reactions].
Topics: Aged, 80 and over; Antitubercular Agents; Child; Drug Administration Schedule; Drug Hypersensitivity | 2011 |
Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Chemical and Drug Induced Liver Injury; | 2012 |
Anti-tuberculosis drugs and human polymorphonuclear leukocyte functions.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ethambutol; Flow | 2011 |
Tuberculosis management--time for paradigm shift?
Topics: Antitubercular Agents; Comorbidity; HIV Infections; Humans; Isoniazid; Practice Guidelines as Topic; | 2011 |
Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs.
Topics: Animals; Antitubercular Agents; Bacterial Load; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Ty | 2011 |
Isoniazid metal complex reactivity and insights for a novel anti-tuberculosis drug design.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Design; Drug Resistance, Bacterial; Ferric Compounds | 2012 |
Duration of isoniazid preventive therapy in HIV-infected patients.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2011 |
Duration of isoniazid preventive therapy in HIV-infected patients.
Topics: Antitubercular Agents; Female; HIV Infections; Humans; Isoniazid; Male; Tuberculosis | 2011 |
Plasma drug activity assay for treatment optimization in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Monitoring; Humans; Isoniazid; Microbial Sensitiv | 2011 |
Plasma drug activity assay for treatment optimization in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Monitoring; Humans; Isoniazid; Microbial Sensitiv | 2011 |
Plasma drug activity assay for treatment optimization in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Monitoring; Humans; Isoniazid; Microbial Sensitiv | 2011 |
Plasma drug activity assay for treatment optimization in tuberculosis patients.
Topics: Adult; Antitubercular Agents; Cohort Studies; Drug Monitoring; Humans; Isoniazid; Microbial Sensitiv | 2011 |
Isoniazid prophylaxis against tuberculosis in children.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV Infections; HIV-1; Humans; | 2011 |
Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Burkina Faso; | 2012 |
The prevalence of tuberculosis in recipients of renal transplantation.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Kidney Transplantation; Male; Middle Aged; | 2011 |
[Tuberculosis : diagnostics and prophylaxis].
Topics: Antitubercular Agents; Humans; Immunosuppressive Agents; Isoniazid; Tuberculosis; Tumor Necrosis Fac | 2011 |
Practical preventive therapy for tuberculosis?
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Rifampin; Tuberculosis | 2011 |
Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia.
Topics: Adult; Aged; Antitubercular Agents; Cross-Sectional Studies; Ethiopia; Female; Forecasting; HIV Sero | 2011 |
Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Counseling; Female; Humans; Iso | 2012 |
Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Counseling; Female; Humans; Iso | 2012 |
Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Counseling; Female; Humans; Iso | 2012 |
Loss to follow up from isoniazid preventive therapy among adults attending HIV voluntary counseling and testing sites in Uganda.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Counseling; Female; Humans; Iso | 2012 |
Respirable rifampicin-based microspheres containing isoniazid for tuberculosis treatment.
Topics: Animals; Antitubercular Agents; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Hydrogen-Ion C | 2012 |
Therapeutic drug monitoring in the treatment of tuberculosis patients.
Topics: Adult; Aged; Alcoholism; Antibiotics, Antitubercular; Antitubercular Agents; Chromatography, High Pr | 2012 |
A case of isolated pancreatic tuberculosis mimicking pancreatic carcinoma.
Topics: Aged; Antitubercular Agents; Biopsy, Fine-Needle; Diagnosis, Differential; Drug Therapy, Combination | 2011 |
Drug treatment combined with BCG vaccination reduces disease reactivation in guinea pigs infected with Mycobacterium tuberculosis.
Topics: Animals; BCG Vaccine; Combined Modality Therapy; Female; Granuloma; Guinea Pigs; Isoniazid; Lung; My | 2012 |
Isoniazid preventive therapy for all: are we ready?
Topics: Antitubercular Agents; Evidence-Based Medicine; Humans; Isoniazid; Mass Screening; Practice Guidelin | 2011 |
N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians.
Topics: Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Case-Control Studies; Chemical and Drug | 2011 |
Anti-tuberculosis prophylaxis following renal transplantation: acceptable variations?
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Female; Health Policy; Humans; Incidence; Isoniazid; | 2012 |
Analysis of gene mutations associated with isoniazid, rifampicin and ethambutol resistance among Mycobacterium tuberculosis isolates from Ethiopia.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Bacterial Proteins; Catalase; Child; DNA-Directed RN | 2012 |
New insight into the molecular characterization of isoniazid and rifampicin resistant Mycobacterium tuberculosis strains from Saudi Arabia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bacterial Proteins; Catalase; Cluster Analysis; DNA-Dire | 2012 |
Study on the interaction between isoniazid and bovine serum albumin by fluorescence spectroscopy: the effect of dimethylsulfoxide.
Topics: Animals; Binding Sites; Cattle; Dimethyl Sulfoxide; Isoniazid; Mycobacterium tuberculosis; Protein B | 2012 |
Assessing the utility of three TaqMan probes for the diagnosis of tuberculosis and resistance to rifampin and isoniazid in Veracruz, México.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; Genetic Variation | 2012 |
Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City.
Topics: Adolescent; Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Child; Child, Preschool | 2012 |
Adherence to self-administered tuberculosis treatment in a high HIV-prevalence setting: a cross-sectional survey in Homa Bay, Kenya.
Topics: Cross-Sectional Studies; Humans; Isoniazid; Kenya; Patient Compliance; Self Administration; Surveys | 2012 |
Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Catalase; Drug Resistance, Multiple, Bacterial; | 2012 |
Formulation and characterization of modified release tablets containing isoniazid using swellable polymers.
Topics: Antitubercular Agents; Carboxymethylcellulose Sodium; Chemistry, Pharmaceutical; Delayed-Action Prep | 2011 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BAL | 2012 |
MRI findings of isoniazid-induced central nervous system toxicity in a child.
Topics: Antitubercular Agents; Brain; Central Nervous System; Central Nervous System Diseases; Child; Diffus | 2012 |
Rifapentine and isoniazid for latent tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Rifampin; Tuberculosis | 2012 |
Rifapentine and isoniazid for latent tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Male; Rifampin; Tuberculosis | 2012 |
Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Topics: Adult; Antitubercular Agents; Chi-Square Distribution; Drug Resistance, Bacterial; Drug Therapy, Com | 2012 |
Design, synthesis, and antimycobacterial property of PEG-bis(INH) conjugates.
Topics: Animals; Antitubercular Agents; Cell Line; Drug Design; Female; Humans; Isoniazid; Male; Mice; Mice, | 2012 |
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs.
Topics: Animals; Antitubercular Agents; Female; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Pyrazina | 2012 |
The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis.
Topics: Adult; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Ethambutol; Female; HIV Infe | 2012 |
Should tuberculin skin testing be a prerequisite to prolonged IPT for HIV-infected adults?
Topics: Adult; Antitubercular Agents; HIV Infections; Humans; Infection Control; Isoniazid; Mass Screening; | 2012 |
Survey of isoniazid preventive therapy in South Africa, 2011.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Cross-Sectional Studies; HIV Infection | 2012 |
Serial interferon-gamma release assays after chemoprophylaxis in a tuberculosis outbreak cohort.
Topics: Adult; Antitubercular Agents; Cohort Studies; Disease Outbreaks; Humans; Interferon-gamma Release Te | 2012 |
Rifampicin-resistant Mycobacterium tuberculosis: susceptibility to isoniazid and other anti-tuberculosis drugs.
Topics: Antitubercular Agents; DNA Mutational Analysis; Drug Resistance, Bacterial; Humans; Isoniazid; Micro | 2012 |
Community-based multi-disease prevention campaigns for controlling human immunodeficiency virus-associated tuberculosis.
Topics: Africa South of the Sahara; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular A | 2012 |
Completion of isoniazid preventive therapy and survival in HIV-infected TST-positive adults in Tanzania.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Female; HIV Infections; H | 2012 |
Isoniazid preventive therapy in human immunodeficiency virus infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Coinfection; Female; HIV Infections; H | 2012 |
Impact of isoniazid resistance-conferring mutations on the clinical presentation of isoniazid monoresistant tuberculosis.
Topics: Bacterial Proteins; Catalase; Drug Resistance; Genotype; Humans; Isoniazid; Mycobacterium tuberculos | 2012 |
Hurry up and wait? Accelerating access to the Three I's for HIV-TB.
Topics: Antitubercular Agents; HIV Infections; Humans; Infection Control; Isoniazid; Tuberculin Test; Tuberc | 2012 |
[Retroperitoneal abscess in a patient under BCG treatment cause a bladder cancer].
Topics: Abdominal Abscess; Aged; Antitubercular Agents; BCG Vaccine; Humans; Isoniazid; Lung Neoplasms; Male | 2012 |
Rifampicin for continuation phase tuberculosis treatment in Uganda: a cost-effectiveness analysis.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Isoniazid; Rifampin | 2012 |
Activity of IQG-607, a new orally active compound, in a murine model of Mycobacterium tuberculosis infection.
Topics: Animals; Antitubercular Agents; Bacterial Load; Disease Models, Animal; Drug Evaluation, Preclinical | 2012 |
Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations.
Topics: Antitubercular Agents; Binding Sites; Crystallography, X-Ray; Drug Design; Enoyl-(Acyl-Carrier-Prote | 2012 |
Primary isoniazid resistance in Mycobacterium bovis disease: a prospect of concern.
Topics: Abattoirs; Adult; Agriculture; Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; In | 2012 |
Short-course untargeted isoniazid preventive therapy in South Africa: time to rethink policy?
Topics: Antitubercular Agents; Communicable Disease Control; Epidemics; HIV Infections; Humans; Isoniazid; N | 2012 |
Rapid diagnosis of tuberculosis and multidrug resistance using a MGIT 960 system.
Topics: Antitubercular Agents; Automation; Drug Resistance, Multiple, Bacterial; Humans; Isoniazid; Microbia | 2012 |
Determination of principal genotypic groups among susceptible, MDR and XDR clinical isolates of Mycobacterium tuberculosis in Belarus and Iran.
Topics: Antitubercular Agents; Base Sequence; Codon; DNA, Bacterial; Drug Resistance, Bacterial; Drug Resist | 2012 |
[Resistant tuberculosis: chinese anxieties].
Topics: Antitubercular Agents; Anxiety; Asian People; China; Drug Resistance, Multiple, Bacterial; France; H | 2012 |
Pharmacokinetic/pharmacodynamic parameters and the choice of high-dosage rifamycins.
Topics: Acetylation; Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Dose-Response | 2012 |
[Bilateral tuberculous mastitis nulliparous patient, initially treated as idiopathic granulomatous mastitis].
Topics: Adult; Antitubercular Agents; Diagnostic Errors; Drug Therapy, Combination; Ethambutol; Female; Gran | 2012 |
Evaluation of the impact of interferon-gamma release assays on the management of childhood tuberculosis.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Female; Humans; Infant; | 2012 |
Molecular detection and drug resistance of Mycobacterium tuberculosis complex from cattle at a dairy farm in the Nkonkobe region of South Africa: a pilot study.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Cattle; Cattle Diseases; Dairying; Drug | 2012 |
Characterization of Mycobacterium tuberculosis isolated from cancer patients with suspected tuberculosis infection in Egypt: identification, prevalence, risk factors and resistance pattern.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Bacteriological Techniques; Child; Drug Resistance, | 2012 |
Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide.
Topics: Analysis of Variance; Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Anima | 2012 |
The impact of HIV and ART on recurrent tuberculosis in a sub-Saharan setting.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; CD | 2012 |
Improved consistency in dosing anti-tuberculosis drugs in Taipei, Taiwan.
Topics: Adult; Aged; Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations | 2012 |
Recurrent tuberculosis risk among HIV-infected adults in Tanzania with prior active tuberculosis.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Female; HIV Infections; Humans; Isoniazid; Male; Proporti | 2013 |
Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; D | 2012 |
Description of pediatric tuberculosis evaluated in a referral center in istanbul Turkey.
Topics: Adolescent; BCG Vaccine; Child; Child, Preschool; Female; Humans; Infant; Isoniazid; Male; Mycobacte | 2012 |
Twelve doses for tuberculosis prevention--review of a new evidenced based regimen.
Topics: Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; Drug Therapy, Combin | 2012 |
Pharmacokinetics of anti-tuberculosis drugs in Venezuelan children younger than 16 years of age: supportive evidence for the implementation of revised WHO dosing recommendations.
Topics: Acetyltransferases; Adolescent; Age Factors; Antitubercular Agents; Area Under Curve; Biological Ava | 2012 |
The peeling dermatitis with a peculiar demarcation.
Topics: Adult; Antitubercular Agents; Dietary Proteins; Drug Therapy, Combination; Humans; Isoniazid; Male; | 2013 |
When is an outbreak not an outbreak? Fit, divergent strains of Mycobacterium tuberculosis display independent evolution of drug resistance in a large London outbreak.
Topics: Antitubercular Agents; Disease Outbreaks; Drug Resistance, Bacterial; Genetic Variation; Genotype; H | 2013 |
Prevalence of anti-tuberculosis drug resistance in foreign-born tuberculosis cases in the U.S. and in their countries of origin.
Topics: Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Drug Resistance, Bacterial; | 2012 |
Postoperative spondylodiscitis caused by Mycobacterium bovis BCG: a case study.
Topics: Antitubercular Agents; Discitis; Diskectomy; Epidural Abscess; Humans; Intervertebral Disc Displacem | 2012 |
Evaluation of tuberculosis underreporting in Greece through comparison with anti-tuberculosis drug consumption.
Topics: Antitubercular Agents; Epidemiological Monitoring; Ethambutol; Greece; Humans; Isoniazid; Latent Tub | 2012 |
Study of the rifampin monoresistance mechanism in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Base Sequence; Biological Transport; DNA-Directed RNA Pol | 2013 |
Prolonged isoniazid prevention in HIV-positive children: hepatotoxicity is not a major problem.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemical and Drug Induced Liver Injury | 2013 |
Cost-effectiveness of rifampin for 4 months and isoniazid for 9 months in the treatment of tuberculosis infection.
Topics: Adult; Antitubercular Agents; Contact Tracing; Cost-Benefit Analysis; Female; Humans; Isoniazid; Lat | 2013 |
Notes from the field: national shortage of isoniazid 300 mg tablets.
Topics: Antitubercular Agents; Drug Industry; Humans; Isoniazid; Tablets; Tuberculosis; United States; Unite | 2012 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydrox | 2013 |
Improving screening and chemoprophylaxis among child contacts in India's RNTCP: a pilot study.
Topics: Adolescent; Adult; Antitubercular Agents; Chemoprevention; Child; Child, Preschool; Contact Tracing; | 2013 |
Anti-tuberculosis treatment outcomes in HIV-infected adults exposed to isoniazid preventive therapy in Botswana.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Botswana; Drug Therapy, Combination; Female; HIV Infe | 2013 |
[Influence of isoniazid complex with A-I apolipoprotein on activity of lysosomal enzymes in mice with tuberculous inflammation model].
Topics: Acid Phosphatase; Animals; Antitubercular Agents; Apolipoprotein A-I; Cathepsin D; Drug Combinations | 2012 |
Rapid genotypic detection of rpoB and katG gene mutations in Mycobacterium tuberculosis clinical isolates from Northern India as determined by MAS-PCR.
Topics: Adult; Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; DNA, Bacte | 2013 |
First needle marrow biopsy to diagnose a systemic illness.
Topics: Adult; Anti-Bacterial Agents; Antitubercular Agents; Biopsy, Needle; Bone Marrow; Granuloma; Humans; | 2012 |
Effect of rifampicin & isoniazid on the steady state pharmacokinetics of moxifloxacin.
Topics: Adult; Area Under Curve; Aza Compounds; Chromatography, High Pressure Liquid; Fluoroquinolones; Huma | 2012 |
Variations in the occurrence of the S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Kuwait.
Topics: Antitubercular Agents; Bacterial Proteins; Chromatography, Agarose; DNA Primers; Drug Resistance, Mi | 2002 |
Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Colorimetry; Drug Resistance, Microbial; Humans; Indicators and Reagents; Iso | 2002 |
Antitubercular therapy decreases nitric oxide production in HIV/TB coinfected patients.
Topics: Adult; Antibiotics, Antitubercular; Antitubercular Agents; Biomarkers; CD4 Lymphocyte Count; CD4-Pos | 2002 |
Prevalence of purified protein derivative positivity in human immunodeficiency virus infected individuals in Hong Kong.
Topics: Adult; Aged; BCG Vaccine; Female; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prevalence; | 2002 |
Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans.
Topics: Amino Acid Substitution; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacte | 2002 |
Opportunistic infections.
Topics: AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Drug Therapy, Combinat | 2000 |
Bacteriological conversion in twenty urinary tuberculosis patients treated with ofloxacin, rifampin and isoniazid: a 10-year follow-up study.
Topics: Adult; Aged; Anti-Infective Agents, Urinary; Antitubercular Agents; Drug Therapy, Combination; Femal | 2002 |
Is isoniazid ototoxic in patients undergoing hemodialysis?
Topics: Adult; Aged; Antitubercular Agents; Female; Hearing Loss; Humans; Isoniazid; Kidney Failure, Chronic | 2002 |
Lack of toxicity from concomitant directly observed disulfiram and isoniazid-containing therapy for active tuberculosis.
Topics: Alcohol Deterrents; Alcoholism; Antitubercular Agents; Directly Observed Therapy; Disulfiram; Drug T | 2002 |
Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Female; Follow-Up Studies; Humans; Isoniazid; Liver; Liver Trans | 2002 |
The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.
Topics: 1-Butanol; Adult; Antitubercular Agents; Child; False Negative Reactions; False Positive Reactions; | 2002 |
Prevalence of S315T mutation within the katG gene in isoniazid-resistant clinical Mycobacterium tuberculosis isolates from Dubai and Beirut.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Genotype; Humans; Isoniazid; | 2002 |
Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Dose-Response Relationship, Drug; Drug | 2002 |
Congenital tuberculosis and management of exposures in a neonatal intensive care unit.
Topics: Cross Infection; Hospitals, Urban; Humans; Infant; Infant, Newborn; Intensive Care Units, Neonatal; | 2002 |
Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area.
Topics: Adolescent; Adult; Aged; Child; Female; Humans; Isoniazid; Liver; Liver Transplantation; Longitudina | 2002 |
Cerebral hemorrhage associated with vitamin K deficiency in congenital tuberculosis treated with isoniazid and rifampin.
Topics: Cerebral Hemorrhage; Humans; Infant; Infectious Disease Transmission, Vertical; Isoniazid; Male; Rif | 2002 |
Population pharmacokinetics of antituberculous drugs and treatment of Mycobacterium bovis infection in bongo antelope (Tragelaphus eurycerus isaaci).
Topics: Amikacin; Animals; Antelopes; Antitubercular Agents; Area Under Curve; Ethambutol; Female; Isoniazid | 2002 |
Urine color test to monitor isoniazid compliance: "pissin' in the wind"?
Topics: Antitubercular Agents; Directly Observed Therapy; Humans; Isoniazid; Patient Compliance; Reagent Str | 2003 |
Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Infant; Iso | 2003 |
Treatment of latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Risk Factors; Tuberculin Test; Tuberculosis | 2003 |
Treatment of latent tuberculosis infection.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; R | 2003 |
Anti-tuberculosis 4FDC tablets--mystery to chemistry.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Combinations; Drug Stability; Drug Storage; | 2003 |
Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination.
Topics: Administration, Oral; Antibiotics, Antitubercular; Antitubercular Agents; Chemistry, Pharmaceutical; | 2003 |
A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Drug Combinations; Drug | 2003 |
[Tuberculous otitis media. Report of 3 cases].
Topics: Adult; Aged; Amoxicillin; Antitubercular Agents; Cerebrospinal Fluid Otorrhea; Drug Combinations; Ea | 2003 |
Control of anti-tuberculosis drug resistance in Botswana.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Botswana; Child; Child, Preschool | 2003 |
Evaluation and utilization as a public health tool of a national molecular epidemiological tuberculosis outbreak database within the United Kingdom from 1997 to 2001.
Topics: Antitubercular Agents; Databases, Nucleic Acid; Disease Outbreaks; DNA Fingerprinting; DNA, Bacteria | 2003 |
Longitudinal study of tuberculosis outcomes among immunologically naive Aché natives of Paraguay.
Topics: Adolescent; Adult; Age Distribution; Asian People; BCG Vaccine; Child; Child, Preschool; Dapsone; Di | 2003 |
Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical isolates in Lithuania.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Bacterial Proteins; DNA, Bacterial; Drug Resi | 2003 |
Impact of iron loading on the activity of isoniazid or ethambutol in the treatment of murine tuberculosis.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Interactions; Ethambutol; Female; Iron; | 2003 |
Isoniazid prophylaxis for tuberculosis prevention among HIV infected police officers in Dar es Salaam.
Topics: Adult; Antitubercular Agents; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Iso | 2000 |
Preventing recurrent tuberculosis in high HIV-prevalent areas in sub-Saharan Africa: what are the options for tuberculosis control programmes?
Topics: Africa South of the Sahara; Antiretroviral Therapy, Highly Active; Health Policy; HIV Infections; Hu | 2003 |
Current interest of isoniazid in the chemotherapy of tuberculosis in the light of its in vitro activity.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Iso | 2003 |
TREATMENT of pulmonary tuberculosis with isoniazid; an interim report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.
Topics: Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
ISONIAZID in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Therapeutic value of isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[A new antitubercular medicament: isonicotinyl hydrazine].
Topics: Antitubercular Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Use of isonicotinic acid hydrazide in VA hospitals.
Topics: Hospitals; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First results of isonicotinic acid hydrazide therapy of urinary tuberculosis; preliminary note].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1952 |
[First clinical results obtained with isoniazid in the treatment of pulmonary tuberculosis; preliminary note].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Bacteriological evolution of patients treated with isoniazid; preliminary note].
Topics: Biological Evolution; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Hematological studies in patients treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Tuberculous empyema and isoniazid instilled locally].
Topics: Empyema, Tuberculous; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pul | 1952 |
[Treatment of pulmonary tuberculosis with intrabronchial instillations of isoniazid; preliminary note].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
ISONICOTINIC acid hydrazide.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Preliminary clinical results of the therapy of tuberculosis with isonicotinic acid hydrazide].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[First therapeutic tests of isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Preliminary report on the effect of neoteben (isonicotinic acid hydrazide) on tuberculosis of the skin].
Topics: Isoniazid; Niacin; Nicotinic Acids; Skin; Tuberculosis; Tuberculosis, Cutaneous | 1952 |
[Preliminary report on isonicotinic acid hydrazide (rimifon, neoteben) on the basis of experimental and clinical investigations].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Experiences with isonicotinic acid hydrazide rimifon in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Effect of isoniazid on the program of the tuberculosis association.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Clinical-radiological, hemato-medullary and biological report on isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Adrenal Medulla; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Early results of isonicotinic acid hydrazide therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[On the action of isonicotinic acid hydrazide in the treatment of renale tuberculosis].
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1952 |
[Isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide; new tuberculosis drug].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First experiences with rimifon Roche in experimental tuberculosis of guinea pigs].
Topics: Animals; Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First case of resistence against rimifon].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazides and their application in the treatment of tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
The new drug; isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Isoniazid (isonicotinic acid hydrazide) in the treatment of miliary and meningeal tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, | 1952 |
Isoniazid in experimental tuberculosis of guinea pigs infected with tubercle bacilli resistant to streptomycin and to para-aminosalicylic acid.
Topics: Aminosalicylic Acid; Bacillus; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberc | 1952 |
Hazards of isoniazid therapy in epileptics; report of one case.
Topics: Epilepsy; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Effect of isoniazid on the program of the Tuberculosis Association.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin-paraaminosalicylic acid in pulmonary tuberculosis therapy. I. Report on twelve-week observations on 526 patients.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1952 |
[Antituberculous activity of isonicotinic acid hydrazide (INH)].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in chemotherapy of tuberculosis; preliminary report].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Chemotherapy of tuberculosis. 2. Arrest of tuberculosis by isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Caution necessary in the treatment of renal tuberculosis with isoniazid.
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1952 |
Isoniazid in pulmonary tuberculosis; its use with and without streptomycin.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isoniazid in the control of experimental corneal tuberculosis.
Topics: Cornea; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1952 |
ISONIAZID.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Chemotherapy of tuberculosis with the new drugs, isonicotinic acid hydrazide and its isopropyl derivative].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Early clinical and radiological results of isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide therapy of infantile tuberculosis].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Dosage of isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Hyperplastic perifocal reaction produced by isonicotinic acid hydrazide in experimental tuberculosis in guinea pig].
Topics: Guinea Pigs; Hyperplasia; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First clinical results of isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Laboratory observations with the aid of culture on the treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Laboratories; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Streptomycin and isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Chemotherapy of tuberculosis with rimifon (isonicotinylhydrazine)].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Antioxygens and tuberculosis: mechanism of the action of PAS, TB 1 and isonicotinic acid hydrazide].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis | 1952 |
Laboratory studies of the isonicotinic acid hydrazides in tuberculosis.
Topics: Isomerism; Isoniazid; Laboratories; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosi | 1952 |
[Clinical experience in therapy of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Effect of isonicotinic acid hydrazide in experimental ocular tuberculosis].
Topics: Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1952 |
Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[The experimental antitubercular activity of isonicotinic acid hydrazide].
Topics: Antitubercular Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Further date on isonicotinic acid hydrazide; posology and mechanism of action].
Topics: Isoniazid; Niacin; Nicotinic Acids; Phoeniceae; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isoniazid and its isopropyl derivative in the therapy of tuberculosis in humans: comparative therapeutic and toxicologic properties.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Clinical experiences with isonicotinic acid hydrazide in tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Effects of isonicotinic acid hydrazide in mentally ill patients.
Topics: Isoniazid; Mental Disorders; Mentally Ill Persons; Niacin; Nicotinic Acids; Tuberculosis; Tuberculos | 1953 |
[Acquired resistance of Mycobacterium tuberculosis to isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosi | 1952 |
[Experiences at the Institute Carlo Forlanini with a new chemical preparation in the treatment of tuberculosis; isonicotinic acid hydrazide].
Topics: Academies and Institutes; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Considerations on rapid elision of tuberculous caverns during the treatment with isonicotinic acid hydrazide].
Topics: Caves; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Observations on appearance of new foci or foci which appear as such during the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in extrapulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Use of rimifon in tuberculosis in children (preliminary report)].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Rimifon, streptomycin and renal tuberculosis].
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Renal | 1952 |
[Chemotherapy of tuberculosis; special reference to isonicotinic acid hydrazide].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
ISONICOTINIC acid hydrazide; further experiences by a human guinea-pig.
Topics: Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Results of 20 cases of pulmonary tuberculosis treated with isonicotinic acid hydrazide; suggestions about this drug].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in the treatment of silicotuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Silicotuberculosis; Tuberculosis; Tuberculosis, Pulmo | 1952 |
[Results of isonicotinic acid hydrazide therapy (in certain cases associated with streptomycin) of 70 cases of pulmonary and extra-pulmonary tuberculosis; three months follow-up].
Topics: Follow-Up Studies; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberc | 1952 |
[Failure in the treatment with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isonicotinic acid hydrazide in tuberculosis in man.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Miliary; Tuberculosis, Pulmonary | 1952 |
Development of drug resistance to isoniazid in cases of pulmonary tuberculosis.
Topics: Drug Resistance; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonar | 1952 |
Isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[First experiences with the isonicotinic acid hydrazide preparation Neoteben].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Streptomycin, PAS and rimifon].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1952 |
Isoniazid therapy in pulmonary tuberculosis.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Preliminary results of therapy of tuberculosis with isonicotinic acid hydrazide (rimifon)].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Chemotherapy of tuberculosis. V. Isonicotinic acid hydrazide (neoteben, rimiform, ertuban, bacillin)].
Topics: Dipeptides; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Therapy of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Incidence of bacterial resistance encountered with tuberculosis chemotherapy regimens employing isoniazid alone and in combination with intermittent streptomycin.
Topics: Bacterial Infections; Incidence; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1953 |
[Antituberculous hemagglutination during the treatment with isonicotinic acid hydrazide].
Topics: Hemagglutination; Hemagglutination Tests; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tubercul | 1952 |
[Umbro-Lazial Association for the Control of Tuberculosis; therapy of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in ocular tuberculosis and variations of the pathergic state].
Topics: Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1952 |
CURRENT status of isonicotinic acid hydrazides in the treatment of tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Isonicotinic acid hydrazide in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Studies on streptomycin, isonicotinic acid hydrazide, and associated streptomycin and isonicotinic acid hydrazide in experimental tuberculosis in guinea pigs].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1952 |
[Mechanism of the antituberculous action of isonicotinic acid hydrazide (I. N. H.)].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in chronic cavitary pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Preliminary findings in the application of rimifon in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Prophylaxis of tuberculosis with isonicotinic acid hydrazide in subjects living with patients affected with open tuberculosis].
Topics: Isoniazid; Life; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis; initial results].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isonicotinic acid hydrazide in advanced pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Further experience with the treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide therapy of tuberculosis; immediate results].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Results of first trials with isonicotinic acid hydrazide in several cases of pulmonary tuberculosis at the Sousa Martins Sanatorium].
Topics: Animals; Dolphins; Hospitals; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmon | 1952 |
[Effects of isonicotinic acid hydrazide (neoteben, rimifon) on humoral blood picture in pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Thoracic Cavity; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Report on a three month period of clinical tests of isonicotinic acid hydrazide in pulmonary tuberculosis in adults].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide therapy in selected tuberculosis cases in the McKnight State Sanatorium in Texas].
Topics: Hospitals; Isoniazid; Niacin; Nicotinic Acids; Texas; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[First results with isonicotinic acid hydrazide in laryngopulmonary tuberculosis].
Topics: Character; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Treatment of tuberculous meningitis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[Peripheral blood picture in patients treated with isonicotinic acid hydrazide for pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isonicotinic acid hydrazide in the tuberculous diabetic.
Topics: Diabetes Complications; Diabetes Mellitus; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Certain considerations on the action of isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Observations and study on the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Therapy of pulmonary tuberculosis with isoniazid alone and in combination with streptomycin and with para-amino-salicylic acid.
Topics: Amino Acids; Aminosalicylic Acid; Isoniazid; Salicylic Acid; Streptomycin; Tuberculosis; Tuberculosi | 1952 |
[Isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Our experience with the treatment of pulmonary tuberculosis with the isonicotinic acid hydrazide, rimifon, for three months].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isonicotinic acid hydrazide in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[First clinical observations and results of rimifon].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Intermittent treatment of experimental tuberculosis in mice with isonicotinic acid hydrazide].
Topics: Animals; Isomerism; Isoniazid; Mice; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Protection of guinea pigs infected intradermally with tuberculosis by streptomycin, isonicotinic acid hydrazide and PAS].
Topics: Aminosalicylic Acid; Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuber | 1952 |
[Streptomycin and isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in osteoarticular tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1952 |
[Preliminary anatomo-histological observations on the effects of isonicotinic acid hydrazide in various tuberculous processes].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in experimental tuberculosis in the guinea pig].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Blood coagulation in patients treated with isonicotinic acid hydrazide].
Topics: Blood Coagulation; Hemostatics; Isoniazid; Niacin; Nicotinic Acids; Prothrombin; Tuberculosis | 1952 |
[Therapeutic effect of isonicotinic acid hydrazide on various tuberculous processes in adolescent].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Action of isonicotinic acid hydrazide in experimental ocular tuberculosis].
Topics: Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1952 |
[Chemotherapy of experimental tuberculosis of the guinea pig with isonicotinic acid hydrazide].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Observations on the behavior of the sedimentation rate and of pathergy in tuberculous children treated with isonicotinic acid hydrazide].
Topics: Child; Hematologic Tests; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Behavior of azotemia and chloremia in tuberculous children treated with isonicotinic acid hydrazide].
Topics: Azotemia; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Effect of isonicotinic acid hydrazide on the circulatory apparatus in pulmonary tuberculosis].
Topics: Cardiovascular System; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Action of isonicotinic acid hydrazide on experimental ocular tuberculosis in rabbit].
Topics: Animals; Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Rabbits; Tuberculosis; Tuberculosis, Ocular | 1952 |
[Observations on the course of experimental tuberculosis in the guinea pig treated with isonicotinic acid hydrazide associated with nicotinic acid and B complex vitamins].
Topics: Folic Acid; Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Vitamin B Comp | 1952 |
ISONIAZID in the treatment of pulmonary tuberculosis; second report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.
Topics: Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
STREPTOMYCIN and isoniazid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1953 |
[Study of 130 cases of grave pulmonary tuberculosis treated for a minimum of 3 months with isonicotinic acid hydrazide (Rimifon)].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Histological picture of experimental tuberculosis in guinea pig treated with isonicotinic acid hydrazide].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First clinical observations of the patients treated with rimifon].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Therapy of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Results in isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Effect of isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Effect of isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Rimifon].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Tuberculosis chemotherapy with rimifon (Roche)].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Initial trials with isonicotinic acid derivatives (rimifon) in tuberculosis of the skin].
Topics: Isoniazid; Isonicotinic Acids; Niacin; Nicotinic Acids; Skin; Tuberculosis; Tuberculosis, Cutaneous | 1952 |
SOME medical reports on the use of isoniazid in tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, Miliary | 1953 |
An outbreak of bovine tuberculosis in mink and treatment with rimifon.
Topics: Animal Diseases; Animals; Cattle; Disease Outbreaks; Isoniazid; Mink; Niacin; Nicotinic Acids; Tuber | 1952 |
Isoniazid in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
The use of isoniazid in the treatment of tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[A preliminary report on the use of isonicotinic acid hydrazide in clinical tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First results of the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide in the sanatorium of Bhannès].
Topics: Hospitals; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[First clinical results in the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Clinical experiments with isonicotinic acid hydrazide in the sanatorium of Heybeliada].
Topics: Hospitals; Humans; Isoniazid; Tuberculosis | 1952 |
Isoniazid in the treatment of tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[First clinical observations on patients treated with Rimifon].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, Pulmonary | 1952 |
[On the combined chemotherapy of pulmonary tuberculosis with special reference to the isonicotinic acid hydrazide (Neoteben)].
Topics: Drug Therapy, Combination; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Differences between the effect of isonicotylhydrazide (neoteben, rimifon) in vitro and in guinea pigs].
Topics: Animals; Guinea Pigs; In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic | 1952 |
[First impressions of isonicotinic acid hydrazide therapy of female genital tuberculosis].
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Social Behavior; Tuberculosis; Tuberculo | 1952 |
[Effect of the purity of isonicotinic acid hydrazide in the genesis of secondary phenomena in tuberculosis therapy; preventive note].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Clinical experience with isoniazid in childhood tuberculous meningitis.
Topics: Aminosalicylic Acid; Child; Infant; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; | 1953 |
[Therapy of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Data concerning the function of the reticuloendothelial system in isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Mononuclear Phagocyte System; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Clinical results after three months of isonicotinic acid hydrazide therapy in the Sanatorium of Pineta di Sortenna].
Topics: Hospitals; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Effect of isonicotinic acid hydrazide therapy on the adrenal cortex].
Topics: Adrenal Cortex; Isoniazid; Niacin; Nicotinic Acids; Steroids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide and liver function; value of some colloidal lability tests].
Topics: Digestion; Isoniazid; Liver; Liver Function Tests; Niacin; Nicotinic Acids; Tuberculosis; Tuberculos | 1952 |
[Middlebrook Dubos reaction in pulmonary tuberculosis subjects treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Medullary blood picture in pulmonary tuberculosis subjects treated with isonicotinic acid hydrazide].
Topics: Adrenal Medulla; Bone Marrow; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmon | 1952 |
[Tuberculous meningitis treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[Treatment of cutaneous tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1952 |
[Preliminary trials of rimifon therapy of tuberculosis].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in certain forms of tuberculosis in infants].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[The isoniazids].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1952 |
[Isonicotinic acid hydrazide].
Topics: Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First attempt to treat tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Association of isonicotinic acid hydrazide with streptomycin in tuberculous meningitis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[Isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Notes on isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Clinical results obtained in tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in a case of acute ganglionic tuberculosis].
Topics: Acute Disease; Isoniazid; Lymph Nodes; Tuberculosis; Tuberculosis, Lymph Node | 1952 |
Isonicotinic acid hydrazide; some sensory disturbances during therapy.
Topics: Isoniazid; Neuritis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Preliminary report on isoniazid.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isonicotinic acid hydrazide in pulmonary tuberculosis; review of twenty cases.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Impressions on the first 50 cases of osteoarticular tuberculosis treated with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1952 |
[Therapy of the skin tuberculosis with isonicotinic acid hydrazide].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1952 |
[Isonicotinic acid hydrazide therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Experience at the Institute Carlo Forlanini with isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Academies and Institutes; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Chemotherapy of experimental tuberculosis. VI. Derivatives of isoniazid.
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide in experimental ocular tuberculosis].
Topics: Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1952 |
[Variations of opsonic index in isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide and capillary fragility].
Topics: Capillaries; Capillary Fragility; Cardiovascular System; Isoniazid; Niacin; Nicotinic Acids; Tubercu | 1952 |
[So-called secondary therapeutic effects of isonicotinic acid hydrazide; experimental studies with isonicotinic acid hydrazide resistant bacteria].
Topics: Bacteria; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Our experience in the treatment of infantile tuberculous meningitis with isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1952 |
[Contribution to the study of isonicotinic acid hydrazide therapy of renal tuberculosis].
Topics: Isomerism; Isoniazid; Kidney; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1952 |
[Study of antituberculous synthetics from the standpoint of bacteriostasis in vitro; bacteriostatic activity of isonicotinic acid hydrazide and its antituberculous activity in vivo].
Topics: In Vitro Techniques; Isoniazid; Niacin; Nicotinic Acids; Resins, Plant; Resins, Synthetic; Thiram; T | 1953 |
[Therapy of skin tuberculosis with isonicotinic acid hydrazide].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Isonicotinic acid hydrazide in therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Experience at the Instuto C. Forlanine on the new antituberculosis chemotherapeutic preparation: isonicotinic acid hydrazide].
Topics: Antitubercular Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Distribution and excretion of radioactive isoniazid in tuberculous patients.
Topics: Body Fluids; Isoniazid; Nicotinic Acids; Radioactivity; Tuberculosis | 1953 |
Toxic hepatitis with jaundice occuring in a patient treated with isoniazid.
Topics: Chemical and Drug Induced Liver Injury; Hepatitis; Hepatitis A; Isoniazid; Jaundice; Niacin; Nicotin | 1953 |
Pyricidin (isoniazid) in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Effect of isoniazid on tuberculous lesions of the kidneys.
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1953 |
Isoniazid in the treatment of female genital tuberculosis.
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, Female Genit | 1953 |
Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Variations of the Thorn index caused by isonicotinic acid hydrazide].
Topics: Adrenal Cortex; Adrenal Cortex Function Tests; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculo | 1952 |
[The effects of isonicotinic acid hydrazide on experimental tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Experiences in the treatment of tuberculous empyema with isonicotinic acid hydrazide].
Topics: Empyema, Tuberculous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Early results in cases of three patients with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Properties of isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
ISONICOTINIC acid hydrazide; further experiences.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Certain considerations on isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Effect of isonicotinic acid hydrazide therapy of tuberculosis on peripheral eosinophils].
Topics: Eosinophils; Humans; Isomerism; Isoniazid; Leukocyte Count; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Isoniazid in experimental tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis; preliminary report of the Veterans Administration-Army-Navy cooperative study.
Topics: Isoniazid; Military Personnel; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary; Unite | 1952 |
Effect of isoniazid on the program of official health agencies.
Topics: Health; Isoniazid; Niacin; Nicotinic Acids; Organizations; Tuberculosis | 1952 |
Effect of isoniazid on the program of the tuberculosis association.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[The effect of isonicotinic acid hydrazide on experimental tuberculosis in guinea pig].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Tissue reaction in pulmonary tuberculosis during isonicotinic acid hydrazide therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Results obtained in 89 hospitalized patients by isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Patients; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Purpura and meningeal reaction in two pulmonary tuberculosis patients treated with isonicotinic acid hydrazide].
Topics: IgA Vasculitis; Isoniazid; Niacin; Nicotinic Acids; Purpura; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide therapy of miliary tuberculosis, tuberculous meningitis and malignant primary infections].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, | 1952 |
[Effect of isonicotinic acid hydrazide in ineffective pneumothorax due to persistent insufflated caverns].
Topics: Caves; Insufflation; Isoniazid; Niacin; Nicotinic Acids; Pneumothorax; Pneumothorax, Artificial; Tub | 1952 |
[Isonicotinic hydrazide (rimifon) in therapy of advanced tuberculosis].
Topics: Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Preliminary report on the use of isonicotinic acid hydrazide (rimifon) in the treatment of bone and joint tuberculosis.
Topics: Bone and Bones; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1953 |
[Effect of isonicotinic acid hydrazide on BCG culture].
Topics: Humans; Isoniazid; Mycobacterium bovis; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tubercu | 1952 |
[High dose isonicotinic acid hydrazide in therapy of tuberculous meningitis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[Early results of the treatment of tuberculosis in adults with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Rimifon in the treatment of tuberculosis].
Topics: Collapse Therapy; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide therapy of lymph node and hilar tuberculosis].
Topics: Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Lymph Node | 1952 |
[Experiences with antituberculotic isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[Isonicotinic acid hydrazide in therapy of miliary and meningeal tuberculosis in child].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1952 |
[Bacteriological action of intravenous isoniazid in the treatment of renal tuberculosis].
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1952 |
Peripheral neuropathy due to isoniazid; report of two cases.
Topics: Disease; Isoniazid; Niacin; Nicotinic Acids; Peripheral Nerves; Peripheral Nervous System Diseases; | 1953 |
[Experiences with isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1952 |
[Isonicotinic acid hydrazide in tuberculous meningitis; two months experience at the Centro Streptomicina di Bologna].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[First results of isonicotinic acid hydrazide therapy of tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Preliminary results of the treatment of tuberculosis in children with isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Middlebrook-Dubos reaction in tuberculosis in a child during isonicotinic acid hydrazide therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Variation of blood lipases in tuberculosis in children during isonicotinic acid hydrazide therapy].
Topics: Blood; Child; Humans; Infant; Isomerism; Isoniazid; Lipase; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Therapeutic action of isonicotinic acid hydrazide in specific extrapulmonary and epipulmonary forms of tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Experience with isonicotinic acid hydrazide in the treatment of tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Considerations on first results in the treatment of pulmonary tuberculosis in children with isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1952 |
[Hemoptysis complicating isonicotinic acid hydrazide therapy].
Topics: Hemoptysis; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Clinical studies on isonicotinic acid hydrazide].
Topics: Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Results of isonicotinic acid hydrazide therapy of 97 cases of tuberculosis in a sanatorium].
Topics: Hospitals; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Impressions on the effect of isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Social Behavior; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[First research on sub-occipital or intraspinal injection of isonicotinic acid hydrazide in animals and man and first impressions on the activity of the preparation in tuberculous meningitis and primary tuberculosis in children].
Topics: Child; Infant; Injections, Spinal; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, M | 1952 |
[Contribution to the clinical-radiological study of the use of isonicotinic acid hydrazide].
Topics: Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Radiology; Tuberculosis | 1952 |
[In vivo studies of effect of isonicotinic acid hydrazide on tubercle bacilli].
Topics: Bacillus; Isoniazid; Lacticaseibacillus casei; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isoniazid in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Effect of isonicotinic acid hydrazide on the development of experimental tuberculosis in guinea pigs].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Present results of tuberculosis therapy by isonicotinic acid hydrazide in children (Nicozyd)].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Observations on a case of pulmonary tuberculosis treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Use of isonicotinic acid hydrazide in bronchial tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Use of isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in the treatment of tuberculous meningitis and peritonitis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Peritonitis; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[Use of PAS with isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Tuberculin sensitivity in the course of treatment with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Observations on the treatment of pulmonary tuberculosis with rimifon].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide; preliminary results in 50 patients].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Dramatic cure of secondary lingual tuberculosis and unchanged pulmonary and general picture in the treatment with isonicotinic acid hydrazide].
Topics: Isoniazid; Lupus Vulgaris; Niacin; Nicotinic Acids; Tongue Diseases; Tuberculosis; Tuberculosis, Pul | 1953 |
[Orientation on the antituberculotic rimifon].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Results of the treatment of pulmonary tuberculosis with phthivazide; preliminary communication].
Topics: Communication; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isoniazid therapy of tuberculosis in a surgical service].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1953 |
[Results in the treatment of tuberculous meningitis in children and in adolescents with isonicotinic acid hydrazide associated with streptomycin-methylic antigen].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Treatment of a case of meningeal tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1952 |
[Six months experience with the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Toxic psychosis due to overdosage of isonicotinic acid hydrazide.
Topics: Humans; Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychoses, Substance-Induced; Psychoti | 1953 |
[Experience with isonicotinic acid hydrazide; results of 6 months of treatment].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Studies on the effect of isonicotinic acid hydrazide in 44 cases of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Therapy of tuberculous lupus with isonicotinic acid hydrazide].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Treatment of tuberculous lupus with isonicotinic acid hydrazide].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[First experiences with isonicotinic acid hydrazide in cutaneous tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Up to date experiences with neoteben (isonicotinic acid hydrazide) in skin tuberculosis].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide for six months in a sanatorium].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberc | 1953 |
Isoniazid and streptomycin in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1953 |
[Isoniazid in the treatment of sixty-two cases of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Failure of isonicotinic acid hydrazide therapy in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Half year experience in the application of isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Preliminary results of isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Ioniazide (isonicotinic acid hydrazide) therapy in Finnish sanatoria].
Topics: Hospitals; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Therapeutic effects of rimifon on the experimental eye tuberculosis of the rabbit].
Topics: Animals; Eye; Humans; Isoniazid; Niacin; Nicotinic Acids; Rabbits; Tuberculosis; Tuberculosis, Ocula | 1953 |
[Treatment of genitourinary tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1953 |
Treatment of advanced caseouspneumonic tuberculosis with isonicotinic acid hydrazides.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isonicotinic acid hydrazide in excisional surgery of the tuberculous lung.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pulmonary Surgical Procedures; Tuberculosis; Tuberculosis, Pulmo | 1953 |
Chronic pulmonary tuberculosis complicated by Hodgkin's disease and treated with isoniazid and streptomycin: autopsy findings in a case.
Topics: Autopsy; Hodgkin Disease; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; | 1953 |
[First remote results of isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Possible hemoptoic effect of isonicotinic acid hydrazide].
Topics: Hemoptysis; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Stimulation of the development of Mycobacterium tuberculosis in subjects of prolonged isonicotinic acid hydrazide therapy].
Topics: Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonar | 1953 |
[Treatment of pulmonary tuberculosis with isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Effect of isonicotinic acid hydrazide therapy of tuberculosis on changes of blood proteins on colloidal lability test].
Topics: Blood Proteins; Isoniazid; Liver Function Tests; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis | 1953 |
Neural toxicity in tuberculous patients treated with isoniazid (isonicotinic acid hydrazide).
Topics: Isoniazid; Nervous System; Niacin; Nicotinic Acids; Peripheral Nerves; Tuberculosis | 1953 |
[Our first results in treatment of pulmonary tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results obtained in 60 tuberculotics treated with isonicotinic acid hydrazide with or without streptomycin and with or without collapse therapy].
Topics: Collapse Therapy; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulm | 1953 |
Effective therapeutic dose of isoniazid for experimental tuberculosis of guinea pigs.
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide and its relation to tuberculin skin reactions and to tuberculous allergy].
Topics: Humans; Hypersensitivity; Immune System Diseases; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tu | 1953 |
[Behavior of the index of Velez and of the nuclear value in tuberculotics with reference to treatment with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Leukocytes; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Anatomo-histological study of subjects treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Effect of isonicotinic acid hydrazide therapy and streptomycin therapy on the colliquative power of caseous substance; experimental research on tuberculous guinea-pigs].
Topics: Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1953 |
[Treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[First impressions of the application of sodium methanesulfonate of isonicotinic acid hydrazide (T 170) in pulmonary tuberculosis].
Topics: Isoniazid; Mesylates; Niacin; Nicotinic Acids; Sodium; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Large doses of isoniazid in the treatment of tuberculous meningitis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
Anti-tubercular activity of isoniazid, isonicotinic acid hydrazide, (nydrazid).
Topics: Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Effect of isonicotinic acid hydrazide in the treatment of renal tuberculosis].
Topics: Isomerism; Isoniazid; Kidney; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1953 |
Streptomycin, PAS and isoniazid in renal tuberculosis.
Topics: Aminosalicylic Acid; Isoniazid; Kidney; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tubercu | 1953 |
[Effect of isonicotinic acid hydrazide in experimental tuberculosis in mice].
Topics: Animals; Isomerism; Isoniazid; Mice; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of tuberculous meningitis with large doses of isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Isonicotinic acid hydrazide in pulmonary tuberculosis in childhood and adolescence].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Electrocardiographic findings in tuberculosis and in normal children during isonicotinic acid hydrazide therapy].
Topics: Child; Electrocardiography; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
A study on therapeutic evaluation of isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; North Carolina; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[On isonicotinic acid hydrazide therapy of tuberculosis in puberty].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Puberty; Sexual Maturation; Tuberculosis; | 1953 |
[Treatment of surgical tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[First results with isonicotinic acid hydrazide in cutaneous tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
Drug fever due to administration of isoniazid.
Topics: Fever; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Control study of comparative efficacy of isoniazid, streptomycin-isoniazid, and streptomycin; para-aminosalicylic acid in pulmonary tuberculosis therapy. IV. Report on forty-week observations on 583 patients with streptomycin susceptible infections.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1953 |
Antagonism of isoniazid and streptomycin in experimental infection of mice with M. tuberculosis H37Rv.
Topics: Animals; Isoniazid; Mice; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Streptomycin; Tubercu | 1953 |
Isoniazid serum concentrations and total hemoglobin and methemoglobin values in tuberculous patients on two dosage regimens of isoniazid therapy.
Topics: Hemoglobins; Isoniazid; Methemoglobin; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonar | 1953 |
The control of experimental mouse tuberculosis by the intermittent administration of streptomycin, viomycin, isoniazid, and streptomycylidene isonicotinyl hydrazine.
Topics: Animals; Isomerism; Isoniazid; Mice; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Viomycin | 1953 |
Toxicity of isoniazid.
Topics: Isoniazid; Neuritis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Tuberculostatic effect of isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[The clinical results of isonicotinic acid hydrazide therapy in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical studies on the treatment of tuberculosis with a new isonicotinic acid hydrazide preparation; glutizine].
Topics: Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Alternate streptomycin and isonicotinic acid hydrazide therapy of tuberculous meningitis in the Centro di Bologna].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Isonicotinic acid hydrazide in intraspinal therapy of spinal block in tuberculous meningitis].
Topics: Anesthesia, Spinal; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Menin | 1953 |
[Study of 130 cases of grave pulmonary tuberculosis treated with rimifon for at least three months].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in treatment of childhood tuberculosis].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1953 |
[Meningeal tuberculosis with special reference to its therapy with streptomycin and isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Control of tuberculosis and isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical and roentgenological observations in isonicotinic acid hydrazide-bacillin treatment].
Topics: Dipeptides; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results of the treatment of genito-urinary tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1953 |
[First half-year experiences with isonicotinic acid hydrazide therapy of cutaneous tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Rimifon, streptomycin and renal tuberculosis].
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Renal | 1953 |
[Isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
The in vitro and in vivo activity of isoniazid on M. tuberculosis.
Topics: In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Therapeutic assays of the Skin and Cancer Unit of the New York University Hospital. VIII. Isonicotinylhydrazine (rimifon) in the treatment of tuberculosis cutis, some other granulomatous processes and miscellaneous dermatoses of doubtful cause.
Topics: Hospitals, University; Isoniazid; Neoplasms; New York; Niacin; Nicotinic Acids; Skin Diseases; Tuber | 1953 |
Observations and experiences with isonicotinic acid hydrazide (INH).
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
EMERGENCE of bacterial resistance in pulmonary tuberculosis under treatment with isoniazid, streptomycin plus P.A.S. and streptomycin plus isoniazid.
Topics: Aminosalicylic Acid; Bacterial Infections; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic | 1953 |
[Preliminary observations on forty-six rimifon treatments at the Sanatorium Saint-Georges de Mont-Joli].
Topics: Hospitals; Humans; Isoniazid; Saints; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[The action of isoniazid in lupus erythematosus without any tuberculous etiology].
Topics: Folic Acid; Isomerism; Isoniazid; Lupus Erythematosus, Systemic; Niacin; Nicotinic Acids; Tuberculos | 1953 |
[Treatment of tuberculous meningitis with intramuscular and intraspinal streptomycin and with intravenous PAS, addition of isonicotinic acid hydrazide].
Topics: Administration, Intravenous; Aminosalicylic Acid; Injections, Intramuscular; Isoniazid; Niacin; Nico | 1953 |
[Critical evaluation of the isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide. II. Clinical report, side effects].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Early results of isonicotinic acid hydrazide in experimental genital tuberculosis in guinea pigs].
Topics: Female; Guinea Pigs; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, | 1953 |
[Isonicotinic acid hydrazide in some forms of tuberculosis of the skin and mucous membranes].
Topics: Administration, Cutaneous; Humans; Isoniazid; Lupus Vulgaris; Mucous Membrane; Niacin; Nicotinic Aci | 1953 |
[Isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Miliary; Tuberculosis, Pulmo | 1953 |
[Isonicotinic acid hydrazide in exudative pleuritis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pleurisy; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical results of 3 months of isonicotinic acid hydrazide therapy].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Significance of some clinical and laboratory findings during isonicotinic acid hydrazide therapy].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Behavior of the blood protein picture in tuberculous subjects treated with isonicotinic acid hydrazide].
Topics: Blood Proteins; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Remote results of streptomycin and PAS therapy of pulmonary caverns; comparison with early results of isonicotinic acid hydrazide].
Topics: Aminosalicylic Acid; Caves; Humans; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; | 1953 |
[Report on isonicotinic acid hydrazide therapy of 70 cases of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide and hemorrhages in tuberculosis].
Topics: Hemorrhage; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Effect of isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in infantile tuberculosis].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tu | 1953 |
[Changes in tuberculin allergy during isonicotinic acid hydrazide therapy].
Topics: Drug Hypersensitivity; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tuberculosis; Tubercu | 1953 |
[Effect of isonicotinic acid hydrazide on hemogenic test in tuberculous and normal subjects].
Topics: Blood; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in exsudative pleuritis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pleurisy; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Blood and bone marrow picture in subjects of pulmonary tuberculosis during isonicotinic acid hydrazide therapy].
Topics: Blood; Bone Marrow; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonar | 1953 |
[Isonicotinic acid hydrazide therapy of infantile tuberculosis].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide therapy of meningeal and miliary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, | 1953 |
Observations on the effect of isoniazid in acute and chronic tuberculous pulmonary lesions.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Effect of isonicotinic acid hydrazide on tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Relation between allergic reactivity and the clinical and radiological picture in a group of patients treated with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Radiology; Tuberculin; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Properties of isonicotinic acid hydrazide; resistant strains of Mycobacterium tuberculosis during the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosi | 1953 |
[Effect of isonicotinic acid hydrazide on the hemopoietic system in children].
Topics: Hematopoiesis; Hematopoietic System; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, | 1953 |
[Isoniazid in phthisiology; immediate results and therapeutic combinations].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results of the treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Treatment of cutaneous tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Preliminary report on the results of isoniazid treatment in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Local isonicotinic acid hydrazide therapy of lymphatic cold abscess].
Topics: Abscess; Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Lymph Node | 1953 |
[The significance of the recent lesion factor in the effectiveness of pulmonary tuberculosis therapy with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[The action of isonicotinic acid hydrazide in tuberculous meningitis and in miliary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, | 1953 |
A large-scale trial of isoniazid in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Meningeal tuberculosis and isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1953 |
[Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Our clinical impressions of isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Studies on action of isonicotinic acid hydrazide in pulmonary tuberculosis; six-month follow-up].
Topics: Follow-Up Studies; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Twelve months of the treatment of tuberculous meningitis and of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, | 1953 |
[Influence of isonicotinic acid hydrazide on the development of experimental tuberculosis in the guinea pig].
Topics: Guinea Pigs; Isomerism; Isoniazid; Leadership; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of 414 cases of pulmonary tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Tuberculous meningitis in children and isoniazid; report of 30 cases].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Tuberculostatic effect of isonicotinic acid hydrazide in tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Development of resistance of Mycobacterium tuberculosis in pulmonary tuberculosis during isoniazid therapy].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosi | 1953 |
[Isoniazid in the treatment of various forms of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[First results of isoniazid therapy at the Station de Passy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Effect of isoniazid tuberculosis; biological and clinical tolerance].
Topics: Drug Tolerance; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results of isonicotinic acid hydrazide therapy; report of 160 cases].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Considerations on the treatment of pulmonary tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Therapeutic results in the treatment of pulmonary tuberculosis and of tuberculous meningitis with isoniazid in the military hospital in Vannes].
Topics: Hospitals, Military; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meni | 1953 |
[Chronic tuberculosis and isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isoniazid and tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Studies on combined therapy of experimental tuberculosis in guinea pig with isoniazid, streptomycin and PAS; tuberculosis due to streptomycin sensitivity Mycobacterium tuberculosis].
Topics: Aminosalicylic Acid; Guinea Pigs; Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotini | 1953 |
[Development of sensitivity to isonicotinic acid isomers in pulmonary tuberculosis treated with isoniazid].
Topics: Isomerism; Isoniazid; Isonicotinic Acids; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmo | 1953 |
[Antithyroid action of paraaminosalicylic acid and isonicotinic acid hydrazide].
Topics: Aminosalicylic Acid; Hyperthyroidism; Hypothyroidism; Isoniazid; Niacin; Nicotinic Acids; Thyroid Gl | 1953 |
[First differential findings in the course of tuberculous meningitis treated with streptomycin in conjunction with isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tu | 1953 |
[Chemical and biologic titration of isonicotinic acid hydrazide in the cerebrospinal fluid of children affected and cured of tuberculous meningitis].
Topics: Biological Products; Cerebrospinal Fluid; Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicot | 1953 |
[The action of isoniazid on pulmonary tuberculosis; review of 100 cases].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in the treatment of tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isoniazid perfusions].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical and histological observations on the treatment of tuberculous lupus with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Lupus Vulgaris; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Tuberculosis and isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
ISONIAZID in the treatment of pulmonary tuberculosis; a summary of the second report of the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council.
Topics: Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide and tuberculous meningitis].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1953 |
[Isonicotinic acid hydrazide therapy in cases of bronchial tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isoniazid in the treatment of tuberculous meningitis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide and tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Preliminary experiences with rimifon therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in cutaneous tuberculosis; preliminary report].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Our experiences with isonicotinic acid hydrazide in surgery of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical observations in isonicotinic acid hydrazide therapy of pulmonary tuberculosis with nicozide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical experiences in the treatment of skin tuberculosis with isonicotinic acid hydrazide].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Fundus oculi and isonicotinic acid hydrazide].
Topics: Eye; Fundus Oculi; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Mening | 1953 |
Observations on the clinical results of isonicotinic acid hydrazide therapy in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Lupus planus tuberculosus of the face treated with isonicotinic acid hydrazide].
Topics: Face; Isoniazid; Lupus Vulgaris; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Side-effects in isoniazid therapy of tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1953 |
Isoniazid in combined chemotherapy of experimental tuberculosis in mice.
Topics: Animals; Drug Therapy, Combination; Isoniazid; Mice; Niacin; Nicotinic Acids; Streptomycin; Tubercul | 1953 |
Peripheral neuropathy in tuberculosis patients treated with isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Peripheral Nerves; Peripheral Nervous System Diseases; Tuberculo | 1953 |
Clinical evaluation of isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of primary tuberculosis in early infancy by antibiotics and particularly by isoniazid].
Topics: Anti-Bacterial Agents; Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tube | 1953 |
[Therapy of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Research on the effect of isonicotinic acid hydrazide on experimental ocular tuberculosis].
Topics: Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1953 |
[Isonicotinic acid hydrazide therapy of various eye diseases].
Topics: Eye; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1953 |
[Isonicotinic acid hydrazide in the treatment of cutaneous tuberculosis: preliminary report].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
Isoniazid in childhood tuberculosis.
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Clinical and morphological findings in the treatment of urogenital tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, Female Genital; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Respiratory function in patients treated with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Respiration; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[New Russian chemotherapeutic preparation against tuberculosis, phthivazide].
Topics: Ethnicity; Humans; Isoniazid; Language; Niacin; Nicotinic Acids; Russia; Tuberculosis | 1953 |
Cylinder plate assay and some studies of isonicotinic acid hydrazide with M. tuberculosis 607.
Topics: Animals; Gastropoda; Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Rese | 1953 |
Isonicotinyl hydrazine in the treatment of pulmonary tuberculosis in children; a preliminary report.
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isonicotinic acid hydrazide (isoniazid) in the treatment of tuberculosis.
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Experiences with isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
The effect of streptomycin and isoniazid on miliary tuberculosis and tuberculous meningitis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal; Tuberculosi | 1953 |
[Results of isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Use of isonicotinic acid hydrazide in chronic pulmonary tuberculosis; results and side-effects].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isoniazid in pulmonary tuberculosis, with special reference to X-ray findings after four and six months' treatment.
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary; X-Rays | 1953 |
[Current problems in new drug therapy of cutaneous tuberculosis, including isonicotinic acid hydrazide].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculo | 1953 |
[Use of isonicotinic acid hydrazide in tuberculous and non tuberculous dermatoses].
Topics: Isoniazid; Niacin; Nicotinic Acids; Skin Diseases; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Isonicotinic acid hydrazide in therapy of complicated tracheo-bronchial adenopathy].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results of endarticular therapy with isonicotinylhydrazide in tuberculous arthrosynovitis of the knee].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1953 |
[A year of isonicotinic acid hydrazide treatment in early and chronic pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results of rimifon therapy of extrapulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Preliminary results of isonicotinic acid hydrazide therapy of osseous tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1953 |
[Successful isoniazid therapy of tumorous peritoneal tuberculosis].
Topics: Disease; Isoniazid; Niacin; Nicotinic Acids; Peritoneal Diseases; Peritoneal Neoplasms; Peritoneum; | 1953 |
[Report on the use of isonicotinic acid hydrazide for nine months].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[A year's results in tuberculosis therapy with isonicotinic acid hydrazide; observations and comments].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Experimental and clinical study of a new tuberculosis chemotherapeutic agent (glucuronolactone of isonicotinic acid hydrazide)].
Topics: Glucuronates; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Considerations on the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Resistance to isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide therapy of pseudo-tumoral laryngeal tuberculosis].
Topics: Isoniazid; Laryngeal Neoplasms; Larynx; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Larynge | 1953 |
[Isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Comparative clinical results of the combination of isonicotinic acid hydrazide and PAS in pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Tuberculin inactivation by rimifon].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Successful rimifon therapy in a case of Besnier-Boeck-Schaumann disease and tuberculosis of the sternoclavicular joint].
Topics: Isoniazid; Niacin; Nicotinic Acids; Sarcoidosis; Sternoclavicular Joint; Tuberculosis; Tuberculosis, | 1953 |
[Mycobacterium tuberculosis resistant to rimifon in a patient hitherto untreated with isoniazid; probable bovine origin].
Topics: Animals; Cattle; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Probability; Tuberc | 1953 |
[Peroral effect of isonicotinic acid hydrazide on experimental tuberculosis in guinea pigs].
Topics: Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide as a new chemotherapeutic agent against tuberculosis].
Topics: Antineoplastic Agents; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[On the synergism of isonicotinic acid hydrazide and lactoflavin].
Topics: Drug Interactions; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Riboflavin; Tuberculosis | 1953 |
[Experiences with isonicotinic acid hydrazide therapy of pulmonary tuberculosis in adult].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isoniazid (nydrazid) in treatment of cutaneous diseases; Cutaneous tuberculosis, leprosy, sarcoidosis, and miscellaneous dermatoses.
Topics: Isoniazid; Leprosy; Niacin; Nicotinic Acids; Sarcoidosis; Skin Diseases; Tuberculosis; Tuberculosis, | 1953 |
[Three cases of Pott's disease with abscess, treated by combination of isonicotinic acid hydrazide and streptomycin].
Topics: Abscess; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Spinal | 1953 |
[Clinical experiences with combined parenteral streptomycin-isoniazid therapy (SN 3) in tuberculosis in children and adolescents].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1953 |
[Histologic study of the tuberculous ureter before treatment with streptomycin and isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Urogenital; Ureter | 1953 |
[Fate of caseous matter artificially introduced into guinea pigs treated with isonicotinic acid hydrazide].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Effect of isonicotinic acid hydrazide on pulmonary tuberculous caverns].
Topics: Caves; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results of the treatment of tuberculosis in children with isoniazid].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Studies on bacteriostatic and bactericidal effect of streptomycin, PAS, TB1 and rimifon during therapy of tuberculosis].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Thiose | 1953 |
[Critical evaluation of isoniazid in the treatment of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinico-bacteriological contribution to isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
ISONIAZID in combination with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; fifth report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.
Topics: Aminosalicylic Acid; Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tubercul | 1953 |
[Clinical and bacteriological study of 90 cases of grave pulmonary tuberculosis treated with isonicotinic acid hydrazide (Rimifon) for three months and longer].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Experiences with rimifon in therapy of cutaneous tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Isoniazid (INH) therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Chemotherapy of tuberculosis with isonicotinic acid hydrazide derivatives].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Treatment of skin tuberculosis with rimifon and neoteben].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Isonicotinic acid hydrazide; clinical and experimental tests].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Combined streptomycin and isoniazid therapy of tuberculous meningitis].
Topics: Anti-Bacterial Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tu | 1953 |
CONTROL study of isoniazid: factors influencing the response of pulmonary tuberculosis to chemotherapy; a United States Public Health Service cooperative investigation.
Topics: Isoniazid; Niacin; Nicotinic Acids; Public Health; Tuberculosis; Tuberculosis, Pulmonary; United Sta | 1953 |
Isonicotinic acid hydrazide (rimifon) in the treatment of tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide in recent pulmonary tuberculosis at first hospitalization].
Topics: Hospitalization; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Results of the treatment of pulmonary tuberculosis with oral isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isoniazid and meningeal tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Combination treatment of tuberculosis; PAS-isoniazid perfusions].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[The sanatorium and urinary tuberculosis; surveillance of medical treatment, verification of results; first trial of STA-PAS and rimifon mixture].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Urogenital | 1953 |
[Results of application of phthivazide in tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Treatment of tuberculous meningitis with isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
Treatment of tuberculous meningitis with streptomycin and isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1953 |
C.S.F.--isoniazid levels in tuberculous meningitis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Cervical lymph node tuberculosis and osteoarticular tuberculosis; possible bovine etiology; result of isoniazid therapy].
Topics: Animals; Cattle; Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Bovine | 1953 |
Isonicotinic acid hydrazide in pulmonary tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical observations during therapy with isonicotinic acid hydrazide (neotoben and rimifon); and a contribution to its biological effectiveness].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Use of isonicotinic acid hydrazide in therapy of tuberculous lymphadenitis].
Topics: Isomerism; Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Lymph Node | 1953 |
[Isonicotinic acid hydrazide in the treatment of cutaneous tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Behavior of the glycemic rate in patients with genital tuberculosis, treated with isonicotinic acid hydrazide].
Topics: Blood Glucose; Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Femal | 1953 |
[Isonicotinic acid hydrazide therapy of extrapulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide therapy of a case of lymph node tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Lymph Node; Tuberculosis, Miliary | 1953 |
[Isoniazid in hematogenous tuberculous disseminations (granulias); results of treatment in five cases].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Miliary | 1953 |
[Comments on 130 cases of pulmonary tuberculosis treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[In vitro and in vivo antituberculous action of isonicotinic acid hydrazide (isoniazide)].
Topics: Humans; In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tubercu | 1953 |
[Intradermal streptomycin and isoniazid associated therapy of experimental tuberculosis in guinea pigs. I. Streptomycin-resistant tuberculosis].
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, | 1953 |
[Appearance of giant and regressive bullae during antibiotic therapy with special reference to isoniazid therapy of diffuse tuberculous lesions of the lung].
Topics: Anti-Bacterial Agents; Blister; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tubercu | 1953 |
[Blood coagulability changes in subjects treated with isonicotinic acid hydrazide].
Topics: Blood Coagulation; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Relation between schizophrenia and tuberculosis in therapy with a new anti-tuberculous chemical agent: isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Rorschach Test; Schizophrenia; Tuberculosis; Tuberculosis, Pulmo | 1953 |
[Isonicotinic acid hydrazide in tuberculosis in mental patients; neuropsychiatric findings].
Topics: Isoniazid; Mental Disorders; Mentally Ill Persons; Niacin; Nicotinic Acids; Tuberculosis; Tuberculos | 1953 |
[Endobronchial administration of aqueous solution of isonicotinic acid hydrazide in local therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical and bacteriological study of 90 sever cases of pulmonary tuberculosis treated by isoniazid for three months or more].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Therapy of pulmonary tuberculosis in adults with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[The tuberculostatic isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
A study of the effects of isoniazid on the emotions of tuberculous patients.
Topics: Emotions; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Isoniazid and isoniazid; para-aminosalicylic acid in the treatment of tuberculous sinuses and fistulas.
Topics: Aminosalicylic Acid; Fistula; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoa | 1953 |
The effect of combined therapy with isoniazid and streptomycin on experimental tuberculosis of guinea pigs.
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1953 |
Susceptibility to isoniazid and pathogenicity of tubercle bacilli.
Topics: Bacillus; Humans; Isoniazid; Lacticaseibacillus casei; Mycobacterium tuberculosis; Niacin; Nicotinic | 1953 |
Tuberculous meningitis treated with ACTH and isoniazid; a comparison with intrathecal streptomycin.
Topics: Adrenocorticotropic Hormone; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculos | 1953 |
[Tuberculous serofibrinous pleurisy; treatment with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pleurisy; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Diffusion of endorachideal isoniazid in total spinal block in tuberculous meningitis].
Topics: Anesthesia, Spinal; Diffusion; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Menin | 1953 |
[Combined isoniazid and streptomycin in therapy of osteoarticular tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Osteoarticular | 1953 |
The treatment of pulmonary tuberculosis with isonicotinic acid hydrazide.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Treatment of 10 cases of pulmonary tuberculosis in Africans with isoniazid.
Topics: Black People; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Two cases of pulmonary tuberculosis treated with combined dihydrostreptomycin and isoniazid (redutyl)].
Topics: Dihydrostreptomycin Sulfate; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculos | 1953 |
ISONIAZID in pulmonary tuberculosis; report on a trial conducted under the auspices of the Medical Research Council of Ireland.
Topics: Biomedical Research; Ireland; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmon | 1953 |
Isonicotinic acid hydrazide and para-aminosalicylic acid in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
The use of isoniazid as a prophylactic antibacterial agent in pulmonary resection for tuberculosis; preliminary report.
Topics: Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Pulmonary Surgical Procedures; Tuberculos | 1953 |
[Intravenous administration as a means of reinforcing the action of isonicotinic acid hydrazide; other hydrazides; cyanazide].
Topics: Acetates; Administration, Intravenous; Hydrazines; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Results of the treatment of pulmonary tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Five cases of jaundice in tuberculosis treated with isonicotinic acid hydrazide].
Topics: Isoniazid; Jaundice; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Improvement of tuberculous meningitis with isoniazid therapy].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Isonicotinic acid hydrazide in the therapy of tuberculous serositis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Serositis; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Two cases of meningeal tuberculosis treated exclusively with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Therapeutic action of isonicotinic acid hydrazide on infantile tuberculosis].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Clinical considerations regarding the use of isonicotinic acid hydrazide in infantile tuberculosis].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Clinical observations during treatment with INH neoteben and rimifon; with a contribution on its biologic mechanism].
Topics: Biological Products; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Effects of isoniazid on patients with tuberculosis and mental illness.
Topics: Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[New method of associated streptomycin-isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Resistance acquired by the Koch bacillus during isoniazid therapy of pulmonary tuberculosis].
Topics: Bacillus; Humans; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tube | 1953 |
[Results of the combined therapy with rimifon, streptomycin and paraaminosalicylic acid in tuberculosis].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1953 |
[Personal results in treatment of meningeal tuberculosis by streptomycin-isoniazid combination].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Isoniazid in treatment of tuberculosis of the female genitalia].
Topics: Female; Genitalia, Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, F | 1953 |
[Elimination of a large tuberculous cavern by isonicotinic acid hydrazide therapy].
Topics: Biological Transport; Caves; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmona | 1953 |
[Results in the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide; report of 200 cases in dispensaries].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Treatment of pulmonary tuberculosis with isoniazid; experience with 450 patients].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Posology of isonicotinic acid hydrazide in tuberculous meningoencephalitis in relation to the method of administration and cerebrospinal fluid concentration of the drug].
Topics: Bacteriology; Cerebrospinal Fluid; Isoniazid; Meningoencephalitis; Niacin; Nicotinic Acids; Tubercul | 1953 |
[Use of oral and aerosol isonicotinic acid hydrazide in some cases of cavitary tuberculosis].
Topics: Aerosols; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Tuberculosis of the gingiva rapidly cured with small doses of isonicotinic acid hydrazide].
Topics: Disease; Gingiva; Gingival Diseases; Isomerism; Isoniazid; Lupus Vulgaris; Niacin; Nicotinic Acids; | 1953 |
[Recent data on isonicotinic acid hydrazide therapy of pulmonary tuberculosis; importance of associated antibiotic therapy].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Experimental and clinical anti-tuberculous activity of a compound of stable salt of dihydrostreptomycin and isonicotinic acid hydrazide].
Topics: Dihydrostreptomycin Sulfate; Isoniazid; Niacin; Nicotinic Acids; Sodium Chloride, Dietary; Streptomy | 1953 |
Nydrazid, isoniazid, in treatment of tuberculous mental defectives.
Topics: Intellectual Disability; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, | 1953 |
[Tuberculous purulent pleurisy cured with isonicotinic acid hydrazide].
Topics: Empyema, Tuberculous; Isoniazid; Niacin; Nicotinic Acids; Pleurisy; Tuberculosis; Tuberculosis, Pulm | 1953 |
PROGRESS report on therapeutic and toxic effects of combinations of isoniazid, streptomycin, and para-aminosalicylic acid; United States Public Health Service cooperative investigation of antimicrobial therapy of tuberculosis.
Topics: Aminosalicylic Acid; Anti-Infective Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Research | 1954 |
Tuberculous meningitis treatment with streptomycin, para-aminosalicylic acid and promizole, isoniazid and streptomycin, and isoniazid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Sulfones; Thiazole | 1954 |
Streptomycin and PAS vs. streptomycin, PAS and isoniazid in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1954 |
[Death in a case of epilepsy with pulmonary tuberculosis treated with isonicotinic acid hydrazide].
Topics: Epilepsy; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary; Urologic Diseas | 1953 |
[Examination of the function of labyrinth in tuberculous meningitis treated with isoniazid].
Topics: Ear, Inner; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Treatment of tuberculosis meningitis by streptomycin-isoniazid combination in the Clinica Pediatrica di Bologna: methods, results and considerations].
Topics: Diagnosis, Differential; Isoniazid; Niacin; Nicotinic Acids; Pleurisy; Respiration Disorders; Strept | 1953 |
[Course of tuberculous meningitis treated with streptomycin and isonicotinic acid hydrazide by spinal, oral and parenteral administration].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tu | 1953 |
[Development of thrombopenic purpura in a tuberculous subject during isonicotinic acid hydrazide treatment].
Topics: Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Purpura; Purpura, Thrombocytopenic; Tuberculosis; T | 1953 |
[Combined therapy of meningeal tuberculosis with isonicotinic acid hydrazide and paraaminosalicylic acid].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Psychotherapy, Multiple; Strepto | 1953 |
[Clinical experience with isoniazid in therapy of ocular tuberculosis].
Topics: Eye; Head; Humans; Isoniazid; Muscles; Tuberculosis; Tuberculosis, Ocular | 1953 |
[Isoniazid therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide in the treatment of cutaneous tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
Isoniazid therapy in cutaneous tuberculosis and sarcoidosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Sarcoidosis; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
[Statistical study of various disorders caused by isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Clinical experience obtained with isoniazid in hospital practice].
Topics: Aminosalicylic Acid; Hospitals; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1953 |
[High dosage of isonicotinic acid hydrazide by oral route in tuberculous meningitis; assessment of the present state of the therapy of this disease].
Topics: Administration, Oral; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Men | 1953 |
[Isonicotinic acid hydrazide and specific adnexitis].
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvic Inflammatory Disease; Pelvis; Tuberculosi | 1953 |
[Isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Indications and applications of isonicotinic acid hydrazide in the therapy of tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Research on the action of isonicotinic acid hydrazide].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Research; Tuberculosis | 1953 |
[Indications and applications of isonicotinic acid hydrazide in tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide in cavitary pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Indications and applications of isonicotinic acid hydrazide in the treatment of extrapleural tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide in the treatment of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[The electrophoretic curve in tuberculosis with psychosis during isonicotinic acid hydrazide therapy].
Topics: Blood Proteins; Electrophoresis; Humans; Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psych | 1953 |
[Results in isoniazid treatment of chronic pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Effect of isonicotinic acid hydrazide therapy on tuberculin allergy in tuberculosis in adults and children].
Topics: Drug Hypersensitivity; Immune System Phenomena; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tube | 1953 |
[Treatment of tuberculous meningitis with streptomycin associated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Anatomo-pathologic picture of tuberculosis treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Antimycobacterial properties of a new derivative of isoniazid.
Topics: Anti-Bacterial Agents; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Tuberculous meningitis treated with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Initial isonicotinic acid hydrazide resistance and its evolution in subjects previously treated or not treated with other antibiotics].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Isoniazid; Mycobacterium tuberculosis; Niacin; N | 1953 |
[Results obtained in 216 tuberculous treated with isonicotinic acid hydrazide in hospitals and sanitoria of Algeria].
Topics: Algeria; Hospitals; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Six month results of isoniazid therapy of 45 cases of pulmonary tuberculosis in women].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Studies in experimental ocular tuberculosis. XVII. Effect of isoniazid in the normal, nonimmune rabbit.
Topics: Animals; Eye; Isoniazid; Niacin; Nicotinic Acids; Rabbits; Tuberculosis; Tuberculosis, Ocular | 1954 |
Clinical and bacteriological studies on isonicotinic acid hydrazine (rimifon); 36 patients with pulmonary tuberculosis treated for three months and observed for six.
Topics: Hydrazines; Isoniazid; Isonicotinic Acids; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulm | 1953 |
[Hemorrhages and coagulation disorders in pulmonary tuberculosis treated with isoniazid].
Topics: Blood Coagulation; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[The therapeutic effects of isonicotinic acid hydrazide (INH) in tuberculosis induced in the guinea pig by inoculation of the central nervous system with Mycobacterium tuberculosis].
Topics: Central Nervous System; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; | 1953 |
[Sensitivity and resistance of Mycobacterium tuberculosis var. hominis to isoniazid; studies on 322 strains isolated in tuberculous patients and action in vitro of antibiotic associations].
Topics: Anti-Bacterial Agents; Humans; In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Niacin; N | 1953 |
[Isonicotinic acid hydrazide in therapy of meningeal tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Blood protein modifications in tuberculosis treated with isonicotinic acid hydrazide].
Topics: Blood Proteins; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Laboratory and clinical studies on isoniazid in the treatment of tuberculosis; a review of 16 months' experience].
Topics: Biomedical Research; Isoniazid; Laboratories; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Experiences with isonicotinic acid hydrazide on the basis of clinical material from children sanatoria].
Topics: Child; Hospitals; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Chemotherapy of surgical tuberculosis with special reference to isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Therapy of tuberculosis of upper respiratory tract, especially, laryngeal tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Larynx; Larynx, Artificial; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Laryngea | 1953 |
[Concentration of isonicotinic acid hydrazide in cerebrospinal fluid in tuberculous meningitis during therapy with hydrazide, alone and with glutamic acid].
Topics: Anti-Bacterial Agents; Cerebrospinal Fluid; Glutamates; Glutamic Acid; Isomerism; Isoniazid; Niacin; | 1953 |
[Side effects of combined isoniazid and streptomycin in therapy of pulmonary tuberculosis].
Topics: Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, | 1954 |
[Isonicotinic acid hydrazide in the treatment of tuberculous meningitis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Resumption of streptomycin treatment after the use of isonicotinic acid hydrazide in streptomycin-resistant subjects].
Topics: Isoniazid; Streptomycin; Tuberculosis | 1953 |
[Clinical results obtained in the Sanatorio di Chieti by isonicotinic acid hydrazide therapy during the period April-August 1952].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Present results of the treatment of meningeal tuberculosis in the child with streptomycin, PAS and isoniazid at l'Hôpital des Enfants A. Kyriskou, Athènes].
Topics: Aminosalicylic Acid; Child; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tub | 1953 |
Isoniazid and iproniazid in tuberculosis.
Topics: Iproniazid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
Therapeutic effect of isonicotinic acid hydrazide; the experimental tuberculosis of guinea pigs with special reference to prolonged observations after termination of treatment.
Topics: Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
The effect of isoniazid on guinea-pigs previously vaccinated with B.C.G. and infected with strains of mycobacterium tuberculosis already showing varying resistance to this drug.
Topics: BCG Vaccine; Guinea Pigs; Isoniazid; Mycobacterium bovis; Mycobacterium tuberculosis; Niacin; Nicoti | 1954 |
[Effect of isonicotinic acid hydrazide on morphology and biology of Mycobacterium tuberculosis, on saprophytic bacteria, and on experimental tuberculosis in laboratory animals].
Topics: Animals; Animals, Laboratory; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberc | 1953 |
[Diabetic metabolic disorders occurring during thiosemicarbazone and isoniazid therapy].
Topics: Diabetes Mellitus; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosi | 1953 |
[Side-effects in overdosage of isonicotinic acid hydrazide].
Topics: Central Nervous System; Drug Overdose; Isoniazid; Nervous System; Niacin; Nicotinic Acids; Tuberculo | 1953 |
[Therapy of tuberculous meningitis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
[Early results of the treatment of tuberculosis in children with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Periodic disease in a lobectomized pulmonary tuberculosis patient having received 600 grams of streptomycin and Friedmann's treatment: rimifon therapy].
Topics: Familial Mediterranean Fever; Fever; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; | 1953 |
[Isonicotinic acid hydrazide in the treatment of cutaneous tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[A year of treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[One year of isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[New investigations on antituberculous properties of sodium methanesulfonate and of isonicotinic acid hydrazide].
Topics: Isoniazid; Mesylates; Methane; Sodium; Tuberculosis | 1953 |
[Potassium iodide and methyl antigen in chronic pulmonary tuberculosis; variation of the number of radiologic and bacilloscopic improvements according to the method of treatment by streptomycin and isoniazid].
Topics: Iodides; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Potassium Iodide; Streptomy | 1953 |
[Clinical study of a derivative of isoniazid: G 605].
Topics: Hydrazines; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Aerosol therapy (PAS and isoniazid) in the treatment of pulmonary tuberculosis].
Topics: Aerosols; Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmo | 1953 |
[Combined therapy: pneumoperitoneum, isoniazid and PAS in cavitary pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pneumoperitoneum; Pneumoperitoneum, Artific | 1953 |
[Case of extensive tuberculous ulcer cured with isonicotinic acid hydrazide].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
[Rimifon level and rimifon resistance].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
On treatment of pulmonary tuberculosis with isonicotinic acid hydrazide (INAH).
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Combined effect of isonicotinic acid hydrazide and streptomycin on experimental tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1953 |
[Effect of isoniazid on experimental tuberculosis in guinea pig].
Topics: Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Treatment of genital tuberculosis with isonicotinic acid hydrazide].
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Female Genital; Tube | 1953 |
The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis.
Topics: Iproniazid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
A controlled study of isoniazid and iproniazid.
Topics: Aminosalicylic Acid; Iproniazid; Isoniazid; Niacin; Nicotinic Acids; Research Design; Streptomycin; | 1953 |
Distribution of C14 labeled isoniazid in sensitive and resistant tubercle bacilli and in infected and uninfected tissues in tuberculous patients.
Topics: Bacillus; Isoniazid; Lacticaseibacillus casei; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
The value of isoniazid in the treatment of tuberculous meningitis: a preliminary report.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1953 |
The use of the rabbit eye to study tuberculosis: the effect of adrenocorticotropin, growth hormone, and a combination of isonicotinic acid hydrazide with streptomycin upon the course of the disease.
Topics: Adrenocorticotropic Hormone; Animals; Growth Hormone; Human Growth Hormone; Isoniazid; Niacin; Nicot | 1953 |
Control study of isoniazid, a United States Public Health Service cooperative investigation.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; United States; United States Public Hea | 1953 |
[Paper electrophoretic studies in the treatment of pulmonary tuberculosis with isoniazid].
Topics: Electrophoresis; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Thrombopenic purpura in isonicotinic acid hydrazide medication].
Topics: Isoniazid; Niacin; Nicotinic Acids; Purpura; Purpura, Thrombocytopenic; Tuberculosis; Tuberculosis, | 1953 |
[Serum protein reaction in tuberculous meningitis and tuberculosis in children treated with isonicotinic acid hydrazide].
Topics: Blood Proteins; Child; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Menin | 1953 |
[A year of isoniazid therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Controls during and after isoniazid therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Experimental studies with isoniazid and other hydrazide derivatives].
Topics: Aminosalicylic Acids; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Toxicity of isonicotinic acid hydrazides in pulmonary tuberculosis; toxicity of isoniazid and iproniazid used alone and in combination with streptomycin or p-aminosalicylic acid.
Topics: Aminosalicylic Acid; Iproniazid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberc | 1954 |
Isoniazid in tuberculous uveitis.
Topics: Eye; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular; Uveitis | 1954 |
Pyrazinamide-isoniazid in tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1954 |
Observations on the combined use of pyrazinamide (Aldinamide) and isoniazid in the treatment of pulmonary tuberculosis; a clinical study.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Agranulocytosis caused by isonicotinic acid hydrazide].
Topics: Agranulocytosis; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Gastroin | 1953 |
[Isonicotinic acid hydrazide in therapy of tuberculosis].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1953 |
[Research on effects of isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Research; Tuberculosis | 1953 |
[Isoniazid in the light of laboratory findings].
Topics: Humans; Isoniazid; Light; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Report on isoniazid to the Eleventh Italian Congress on Tuberculosis].
Topics: Ethnicity; Humans; Isoniazid; Language; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[On isoniazid therapy of tuberculosis in adults].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Biologic effects of isoniazid].
Topics: Biological Products; Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tube | 1953 |
[Isoniazid therapy of tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1953 |
[Clinical observations on isonicotinic acid hydrazide therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Combined antibiotic therapy and chemotherapy of pulmonary tuberculosis with special reference to dihydrostreptomycin, paratebin and isoniazid].
Topics: Anti-Bacterial Agents; Dihydrostreptomycin Sulfate; Isoniazid; Niacin; Nicotinic Acids; Penicillins; | 1953 |
[Isoniazid; experiences in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[The therapeutic effects of isonicotinic acid hydrazide and certain of its derivatives on tuberculosis induced in the rabbit by injection of Mycobacterium tuberculosis var. hominis into the central nervous system].
Topics: Animals; Central Nervous System; Injections; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotini | 1953 |
[Additional results in the therapy of skin and urogenital tuberculosis with isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous; Tuberculosis, Female Geni | 1953 |
[Intrathecal administration of isoniazid-streptomycin in tuberculous meningitis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tu | 1954 |
Preliminary report on the serial EEGs of pulmonary tuberculous patients treated with isoniazid.
Topics: Electroencephalography; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Recommencement of the pulmonary function in tuberculosis after isonicotinic acid hydrazide therapy].
Topics: Isoniazid; Niacin; Nicotinic Acids; Respiratory Physiological Phenomena; Tuberculosis | 1953 |
[Cases of angio-paralytic hemorrhagic diathesis during isonicotinic acid hydrazide therapy].
Topics: Hemorrhagic Disorders; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide using continuous and shock methods].
Topics: Isoniazid; Niacin; Nicotinic Acids; Shock; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Manifestations of isonicotinic acid hydrazide overdosage in children].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Psychoses, Substance-Induced; Psychotic D | 1953 |
RECIPE: streptomycin, PAS and isoniazid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1954 |
[Development of resistance in administration of isonicotinic acid hydrazide alone and in combination].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide using Wrocław shock method].
Topics: Isoniazid; Niacin; Nicotinic Acids; Shock; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Treatment of tuberculosis with rimifon].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Treatment of experimental tuberculosis (H37Rv) with a combination of isoniazid and streptomycin].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[Personal experiences in therapy of pulmonary tuberculosis with isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
[Rimifon and rimifon associated with streptomycin in experimental tuberculosis in guinea pigs].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1953 |
[PAS and isoniazid therapy of miliary tuberculosis with meningitis; case report].
Topics: Aminosalicylic Acid; Isoniazid; Meningitis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Men | 1953 |
Isoniazid in the home treatment of tuberculous patients.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Laboratory studies with isoniazid.
Topics: Humans; Isoniazid; Laboratories; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Tuberculous meningitis and miliary tuberculosis; case with combined therapy of isoniazid, dihydrostreptomycin and PAS].
Topics: Aminosalicylic Acid; Dihydrostreptomycin Sulfate; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; | 1954 |
[Experience with the treatment of tuberculous meningitis in children since introduction of isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1954 |
An investigation of some psychological effects accompanying isoniazid therapy on tuberculous patients.
Topics: Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
Tuberculin reactions of tuberculous patients on isoniazid therapy; a preliminary report.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tuberculin Test; Tuberculosis | 1954 |
[Isoniazid and its psychological effects].
Topics: Depression; Feeding and Eating Disorders; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; | 1954 |
[Laryngeal tuberculosis and rimifon].
Topics: Isoniazid; Larynx; Larynx, Artificial; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Laryngea | 1954 |
[The treatment of meningeal tuberculosis in children with rimifon (isonicotinylhydrazin)].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1954 |
[Application of streptomycin and isonicotinic acid hydrazide in osteoarticular tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[Treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The present status of isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Isoniazid in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
A controlled study of isoniazid and iproniazid.
Topics: Iproniazid; Isoniazid; Niacin; Nicotinic Acids; Research Design; Tuberculosis; Tuberculosis, Pulmona | 1954 |
[Treatment of pulmonary tuberculosis with Hansen's disease by streptomycin-isoniazid injections].
Topics: Isoniazid; Leprosy; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The effect of medium constituents on the inhibition of growth of M. tuberculosis by isoniazid.
Topics: Culture Media; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Surface-Active Agents | 1954 |
The effect of medium constituents on the inhibition of growth of M. tuberculosis by isoniazid.
Topics: Culture Media; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Effect of isonicotinic acid hydrazide in certain eye diseases].
Topics: Eye; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1953 |
[Treatment of cutaneous tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
[Combined therapy of the pulmonary tuberculosis with streptomycin, PAS and isoniazid].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1953 |
Isonicotinic acid hydrazide compounds in the therapy of pulmonary tuberculosis.
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The present status of isoniazid in the treatment of tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Striae cutis atrophicae in connection with endocrine disorders in the treatment of tuberculosis with isonicotinic acid hydrazide; clinical aspects and pathogenesis. I].
Topics: Endocrine System Diseases; Isoniazid; Niacin; Nicotinic Acids; Skin Diseases; Tuberculosis; Tubercul | 1954 |
[Isonicotinic acid hydrazide combined with streptomycin and PAS in therapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tubercu | 1954 |
[Behavior of erythrocyte sedimentation rate and the reticulocyte curve in pulmonary tuberculosis patients treated with isonicotinic acid hydrazide].
Topics: Aged; Blood Sedimentation; Erythrocytes; Humans; Isoniazid; Niacin; Nicotinic Acids; Reticulocytes; | 1954 |
[Adrenal cortex function examined by Thorn test in subjects of various forms of pulmonary tuberculosis before and after isonicotinic acid hydrazide therapy].
Topics: Adrenal Cortex; Adrenal Cortex Function Tests; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculo | 1954 |
[Isoniazid therapy of silicosis with tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Silicosis; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Biological method of determination of isonicotinic acid hydrazide in cerebrospinal fluid].
Topics: Cerebrospinal Fluid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Tuberculosis and adrenal cortex. III. Urinary excretion of 17-ketosteroids and 11-hydroxysteroids after isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: 17-Ketosteroids; Adrenal Cortex; Hydroxysteroids; Isoniazid; Niacin; Nicotinic Acids; Steroids; Tube | 1953 |
[Allergometric modifications during isonicotinic acid hydrazide-streptomycin therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[Velez index in tuberculosis treated by isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Combination of various antituberculous drugs with isoniazid and its effects on hydrazide resistance].
Topics: Aminosalicylic Acid; Antitubercular Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberc | 1954 |
[Results of combined streptomycin and isonicotinic acid hydrazide in therapy of meningeal tuberculosis].
Topics: Anti-Bacterial Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tu | 1953 |
[Late course of chronic cavitary pulmonary tuberculosis treated with isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1953 |
Management of primary tuberculosis in infancy: isoniazid in the prevention of complications.
Topics: Child; Disease Management; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tubercu | 1953 |
A new method for determining the growth rate of M. tuberculosis and its application to the study of the toxic effect of streptomycin and isonicotinic hydrazide acid on tubercle bacilli.
Topics: Animals; Bacillus; Gram-Positive Bacteria; Insecta; Isoniazid; Lacticaseibacillus casei; Mycobacteri | 1954 |
Isoniazid (isonicotinic acid hydrazide) in skin tuberculosis; preliminary report of sixteen cases.
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
[Study on the effect of isonicotinic acid hydrazide and p-aminosalicylic acid on experimental tuberculosis in guinea pigs].
Topics: Aminosalicylic Acid; Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
The use of the rabbit eye as a tissue to study tuberculosis. IV. Effect of therapy with streptomycin-isoniazid and with growth hormone (STH) upon the course of the infection.
Topics: Animals; Growth Hormone; Isoniazid; Niacin; Nicotinic Acids; Rabbits; Streptomycin; Tuberculosis; Tu | 1954 |
Cystlike cavities with isoniazid therapy in pulmonary tuberculosis.
Topics: Dental Caries; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Isoniazid therapy of tuberculous patients as a preparation for pulmonary resection.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pulmonary Surgical Procedures; Tuberculosis; Tuberculosis, Pulmo | 1954 |
The clinical effect of isoniazid and iproniazid in the treatment of pulmonary tuberculosis.
Topics: Iproniazid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Experimental and clinical experiences with isonicotinic acid hydrazide therapy of cutaneous tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
[Experimental studies on combined effect of isoniazid and streptomycin].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[Effect of isonicotinic acid hydrazide in tuberculosis of the urinary tract].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Urogenital; Urinary Tract; Urogenita | 1953 |
[The electrophoretic blood protein fractions in tuberculosis of children treated with isonicotinic acid hydrazide].
Topics: Blood Protein Electrophoresis; Blood Proteins; Child; Electrophoresis; Infant; Isoniazid; Niacin; Ni | 1954 |
[Blood picture and blood protein picture after chemotherapy, especially after isoniazid therapy of tuberculosis].
Topics: Blood; Blood Proteins; Humans; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Electron-microscopical examinations of sputum for tubercle bacilli after rimifon therapy].
Topics: Bacillus; Electrons; Isoniazid; Microscopy; Microscopy, Electron; Mycobacterium tuberculosis; Niacin | 1954 |
[Isonicotinic acid hydrazide in the treatment of utero-anexal tuberculosis].
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Female Genital; Urin | 1953 |
Isoniazid and weight gain: a pilot investigation.
Topics: Body Weight; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary; Weight Gain | 1954 |
Isoniazid in treatment of bone and joint tuberculosis; a review of 20 cases.
Topics: Bone and Bones; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[Mechanism of cure of tuberculous caverns during the treatment with isonicotinic acid hydrazide].
Topics: Caves; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Clinical observations on the use of isoniazid in tuberculosis.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Sulfones; Tubercul | 1954 |
Treatment of pulmonary tuberculosis with isoniazid and iproniazide.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Management of isoniazid intolerance.
Topics: Disease Management; Gastrointestinal Diseases; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tub | 1954 |
Isoniazid and streptomycin in tuberculous meningitis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Six observations of primary infection of tracheobronchial lymph nodes appeared or worsened during treatment with streptomycin and isonicotinic acid hydrazide for meningitis and miliary tuberculosis].
Topics: Isoniazid; Lymph Nodes; Meningitis; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosi | 1954 |
[100 Cases of different forms of pulmonary tuberculosis treated with isoniazid alone; radiologic findings].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Lessons of 15 months treatment of pulmonary tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Some cases of purpura appearing during isonicotinic acid hydrazide therapy].
Topics: Humans; IgA Vasculitis; Isoniazid; Niacin; Nicotinic Acids; Purpura; Tuberculosis; Tuberculosis, Pul | 1954 |
[Biological foundation for the paused administration schedule of isoniazid].
Topics: Clinical Protocols; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Isonicotinic acid hydrazide therapy of female genital tuberculosis].
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, Female Genit | 1954 |
[Combined isonicotinic acid hydrazide and streptomycin in therapy of meningeal tuberculosis].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, | 1954 |
[Experiences of six years with the combined treatment of tuberculosis with bacteriostatics (conteben, isoniazid, streptomycin) and specific substances (tebeprotin, phthioic acid phosphatide)].
Topics: Fatty Acids; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Phospholipids; Streptom | 1954 |
Isoniazid neuropathy; report of a case with a review of twenty-five patients under treatment.
Topics: Isoniazid; Nervous System; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Streptomycin-PAS-isoniazid combination in treatment of tuberculous meningitis].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1954 |
[Aggravation in tuberculosis treated with rimifon].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Results of isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Remote results of the treatment of chronic tuberculosis in guinea pigs with isoniazid administered daily and every three days].
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Study of the diffusion of isonicotinic acid hydrazide in the body fluids: application to the treatment of tuberculous meningitis].
Topics: Body Fluids; Diffusion; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Streptomycin, isoniazid and psychiatric disorders].
Topics: Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychotherapy; Streptomycin; Tuberculosis | 1954 |
Management of tuberculous meningitis with isoniazid, streptomycin, and PAS.
Topics: Aminosalicylic Acid; Disease Management; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin | 1954 |
[Bacteriological negativity and persistent lesions in tuberculous patients treated with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Modification of allergic reactions during isonicotinic acid hydrazide therapy of various forms of pulmonary tuberculosis].
Topics: Hypersensitivity; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Peripheral blood picture in pulmonary tuberculosis treated with isoniazid].
Topics: Blood; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Some observations on the results of high isoniazid dosage in pulmonary tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Local treatment of the tuberculous empyema with isonicotinic acid hydrazide].
Topics: Empyema, Tuberculous; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pul | 1954 |
[Hemorrhagic diathesis as a side-effect of isoniazid therapy].
Topics: Hemorrhagic Disorders; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Toxic, outbreak and course of a psychosis caused by isoniazid therapy].
Topics: Disease Outbreaks; Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychoses, Substance-Induce | 1954 |
[Radiologic opacity typical of a spontaneously regressed tuberculoma in the course of primary infection, in an Eskimo child under treatment with rimifon and streptomycin].
Topics: Child; Humans; Inuit; Isoniazid; Radiography; Streptomycin; Tuberculoma; Tuberculosis; Tuberculosis, | 1954 |
[Problems of rimifon treatment in joint and bone tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[Neurological complications of isoniazid therapy of tuberculosis].
Topics: Isoniazid; Nervous System; Neuritis; Niacin; Nicotinic Acids; Seizures; Tuberculosis | 1954 |
[Clinical experiences in therapy of tuberculosis with isonicotinic acid hydrazide. II..].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Isoniazid and psyche].
Topics: Electroconvulsive Therapy; Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychotherapy; Tube | 1954 |
[Results of treating pulmonary tuberculosis with the combination of isonicotinic acid hydrazide and streptomycin].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The virulence of isoniazid resistant tubercle bacilli, recovered from patients during treatment.
Topics: Bacillus; Gram-Positive Bacteria; Isoniazid; Lacticaseibacillus casei; Mycobacterium tuberculosis; N | 1954 |
The continuous and concurrent use of streptomycin, para-aminosalicylic acid, isoniazid plus early surgery in the treatment of tuberculosis.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[Isoniazid in experimental tuberculosis in rabbits].
Topics: Animals; Isoniazid; Lagomorpha; Niacin; Nicotinic Acids; Rabbits; Tuberculosis | 1954 |
[Results of the therapy of 70 pulmonary tuberculosis patients with isoniazid alone and with streptomycin and PAS].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1953 |
[Neuro-psychic disturbances and epileptic seizures in the course of isoniazid therapy; electro-encephalographic control].
Topics: Electroencephalography; Epilepsy; Isoniazid; Niacin; Nicotinic Acids; Psychoses, Substance-Induced; | 1953 |
[Some cases of extrapulmonary tuberculosis treated by isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
Paranoid state during therapy with isoniazid in pulmonary.
Topics: Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychoses, Substance-Induced; Psychotic Disord | 1954 |
[Striae cutis atrophicae in connection with endocrine disorders in the treatment of tuberculosis with isoniazid; clinical aspects and pathogenesis. II..].
Topics: Endocrine System Diseases; Isoniazid; Niacin; Nicotinic Acids; Skin Diseases; Tuberculosis; Tubercul | 1954 |
[Vascular effects of isonicotinic acid hydrazide; case reports].
Topics: Female; Hemorrhage; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, | 1954 |
[Early results of large doses of isoniazid in therapy of pulmonary tuberculosis in children].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Blood and bone marrow modifications in isoniazid therapy of tuberculosis].
Topics: Blood; Bone Marrow; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Tuberculous meningitis in children: 30 cases treated with isoniazid].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1954 |
[Isonicotinic acid hydrazide in primary pulmonary tuberculosis: preliminary communication].
Topics: Communication; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Osteoarticular tuberculosis treated with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[Results of treatment of ulcerocaseous pulmonary tuberculosis by combination of streptomycin, isoniazid and PAS, administered at least six months].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1954 |
[Osteoarticular tuberculosis and isoniazid alone or in combination; results in 555 cases treated in specialized sanatoriums].
Topics: Aminosalicylic Acid; Hospitals; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1954 |
The effect of a subtherapeutic dose of streptomycin combined with a low dose of isoniazid on experimental tuberculosis in guinea-pigs.
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[Isonicotinic acid hydrazide therapy of tuberculosis. I. Effect of isolated isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Tests at the Forlanini Institute of combined antibiotic therapy of early forms of pulmonary tuberculosis, with special reference to combined streptomycin-isoniazid].
Topics: Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, | 1953 |
[New observations on chemical casectomy produced by isonicotinic acid hydrazide and evolution of cases during two years].
Topics: Biological Evolution; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Neural toxicity in tubercular patients treated with isonicotinic acid hydrazide.
Topics: Isoniazid; Nervous System; Niacin; Nicotinic Acids; Physiological Phenomena; Tuberculosis | 1953 |
Isoniazid resistance in patients with pulmonary tuberculosis treated on isoniazid alone.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Culture media for tubercle bacilli during chemotherapy with isoniazid.
Topics: Bacillus; Culture Media; Hemoglobins; Isoniazid; Niacin; Nicotinic Acids; Serum Albumin; Tuberculosi | 1954 |
[The effects of isoniazid on chronic cavernous pulmonary tuberculosis compared with conteben].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Thioacetazone; Thiosemicarbazones; Tuberculosis; Tube | 1954 |
Isoniazid in treatment of tuberculosis in childhood.
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[First results of the therapy of tuberculosis with isoniazid glucuronolactone].
Topics: Glucuronates; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
Treatment of experimental ocular tuberculosis with isoniazid.
Topics: Eye; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1954 |
Early ambulatory treatment of pulmonary tuberculosis with isoniazid.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.
Topics: Isoniazid; Neuritis; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The course of pulmonary tuberculosis during long-term single-drug (isoniazid) therapy.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Laboratory diagnostic procedures employed on sputum specimens from ambulatory tuberculous patients treated with isoniazid.
Topics: Bacteriology; Diagnostic Tests, Routine; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Ac | 1954 |
[Isoniazid resistance in various clinical pictures].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Comparative experimental studies on the action of isoniazid and streptomycin on established tuberculous foci].
Topics: Humans; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[The blood proteins in normal and tuberculotic guinea pigs before and after rimifon treatment].
Topics: Animals; Blood Proteins; Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[On isoniazid therapy and its side-effects].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Treatment of chronic experimental tuberculosis in guinea pigs with isoniazid daily and every third day].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[A year's therapy with isoniazid; bacteriological resistance and therapeutic results].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Effect of isonicotinic acid hydrazide on immunity responses of rabbits infected with Koch bacilli].
Topics: Animals; Immune System Phenomena; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Ra | 1954 |
A study on therapeutic evaluation of isoniazid in treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The treatment of tuberculous meningitis in infants with streptomycin and isonicotinic acid hydrazide (isoniazid); a preliminary report of six patients under the age of two years treated without intrathecal medication.
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tu | 1954 |
Effect of isonicotinic acid hydrazide in tuberculous and nontuberculous schizophrenics.
Topics: Isoniazid; Niacin; Nicotinic Acids; Schizophrenia; Tuberculosis | 1954 |
Primary tuberculosis in African children and the value of isoniazid in treatment.
Topics: Black People; Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Treatment of 102 cases of tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Effect of various methods of the treatment with isonicotinic acid hydrazide and with streptomycin on tuberculosis in guinea pigs].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
Isonicotinic acid hydrazid; isoniazid in the treatment of tuberculosis cutis.
Topics: Isomerism; Isoniazid; Isonicotinic Acids; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutan | 1954 |
[Results obtained by isoniazid therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Functional modifications of the reticuloendothelial system caused by isonicotinic acid hydrazide and the value of tissue extract therapy].
Topics: Cell- and Tissue-Based Therapy; Humans; Isoniazid; Mononuclear Phagocyte System; Niacin; Nicotinic A | 1953 |
[Effectiveness of isoniazid in therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Follow-up after one year of isoniazid and PAS-dihydrostreptomycin therapy of pulmonary tuberculosis; a brief orientation].
Topics: Aminosalicylic Acid; Dihydrostreptomycin Sulfate; Follow-Up Studies; Isomerism; Isoniazid; Niacin; N | 1954 |
[Unusual reaction of cerebrospinal fluid cells in a case of tuberculous meningitis treated by oral administration of isoniazid neoteben)].
Topics: Administration, Oral; Cerebrospinal Fluid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculos | 1954 |
[The effect of isonicotinic acid hydrazide and streptomycin on experimental tuberculosis induced by hydrazide and streptomycin-resistant strains].
Topics: Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
The chemotherapy of pulmonary tuberculosis with pyrazinamide used alone and in combination with streptomycin, para-aminosalicylic acid, or isoniazid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tube | 1954 |
Studies on the use of high dose of isoniazid. I. Toxicity studies.
Topics: Isoniazid; Neuritis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The amount of pyridine nucleotides (coenzymes I and II) in blood in experimental tuberculosis before and during isoniazid treatment.
Topics: Coenzymes; Isomerism; Isoniazid; NAD; Niacin; Nicotinic Acids; Nucleotides; Tuberculosis | 1954 |
Effect of isoniazid upon the emotions and the serial electroencephalograms of tuberculous patients.
Topics: Electroencephalography; Emotions; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
Peripheral neuritis in tuberculous patients treated with isoniazid.
Topics: Isoniazid; Neuritis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
United States Public Health service cooperative investigation of antimicrobial therapy of tuberculosis, V. Report on thirty-two-week observations on combinations of isoniazid, streptomycin, and para-aminosalicylic acid.
Topics: Aminosalicylic Acid; Anti-Infective Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomy | 1954 |
The immunizing properties of an isoniazid-resistant mutant of the Vallée strain of M. tuberculosis as compared with BCG; observations in the mouse and guinea pig.
Topics: Animals; BCG Vaccine; Guinea Pigs; Isoniazid; Mice; Mycobacterium bovis; Mycobacterium tuberculosis; | 1954 |
Regression of tuberculous lesions in guinea pigs infected with isoniazid-resistant tubercle bacilli.
Topics: Animals; Bacillus; Gram-Positive Bacteria; Guinea Pigs; Isoniazid; Lacticaseibacillus casei; Mycobac | 1954 |
[Hypersensitive reactions in isoniazid therapy of tuberculous meningitis].
Topics: Central Nervous System; Child; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; | 1954 |
Isoniazid in the treatment of miliary tuberculosis in children.
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Miliary | 1954 |
[Effect of isonicotinic acid hydrazide in experimental meningeal tuberculosis in rabbits].
Topics: Animals; Isomerism; Isoniazid; Lagomorpha; Niacin; Nicotinic Acids; Rabbits; Tuberculosis; Tuberculo | 1954 |
Isonicotinic acid hydrazide in the treatment of tuberculous tenosynovitis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tenosynovitis; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[Therapy of male genital tuberculosis; results of combined isoniazid and streptomycin treatment].
Topics: Anti-Bacterial Agents; Genitalia, Male; Humans; Isoniazid; Male; Niacin; Nicotinic Acids; Streptomyc | 1954 |
[Preliminary results in isoniazid and streptomycin therapy of extensive hematogenous dissemination of tuberculosis].
Topics: Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, Miliary; Tuberculosis, | 1954 |
[Experience with isoniazid in therapy of skin tuberculosis].
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
Roentgenologic changes of the lung associated with isoniazid therapy in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
INTERIM report on the clinical trials of isonicotinic acid hydrazide. II.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
Comparison of the effect of streptomycin plus p-aminosalicylic acid and streptomycin plus isoniazid on tuberculous lesions of the kidneys.
Topics: Aminosalicylic Acid; Isoniazid; Kidney; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tubercu | 1954 |
[Clinical and experimental effects indicating the use of isonicotinic acid hydrazide in tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Results with isoniazid in renal tuberculosis].
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1954 |
[Isonicotinic acid hydrazide in tuberculosis associated with diabetes mellitus; effect on glucose metabolism and on course of tuberculosis].
Topics: Diabetes Complications; Glucose; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculo | 1954 |
[Treatment for tuberculous empyema with isonicotinic acid hydrazide].
Topics: Empyema, Tuberculous; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pul | 1954 |
[Possibility of closure of pulmonary tuberculous cavitation by isoniazid therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Liver function tests: effects of isonicotinic acid hydrazide therapy of tuberculosis].
Topics: Isomerism; Isoniazid; Liver; Liver Function Tests; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Effects of isonicotinic acid hydrazide on experimental tuberculosis in guinea pig].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Action of isonicotinic acid hydrazide on hematopoiesis].
Topics: Hematopoiesis; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1953 |
[Isonicotinic acid hydrazide in the treatment of tuberculosis of the female genitals].
Topics: Female; Genitalia, Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, F | 1954 |
[Treatment of certain forms of tuberculosis in children with isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Isonicotinic acid hydrazide in the treatment of osteoarticular tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[First results of the use of isoniazid, streptomycin, PAS, with and without association of collapse in therapy in pulmonary tuberculosis in a group of Indian and Eskimo male adults and children].
Topics: Aminosalicylic Acid; Humans; Inuit; Isoniazid; Niacin; Nicotinic Acids; Shock; Streptomycin; Tubercu | 1954 |
[Experience with isoniazid in urogenital tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Urogenital | 1954 |
Streptomycin and isoniazid in treatment of erythema induratum (Bazin's disease).
Topics: Administration, Cutaneous; Erythema Induratum; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tub | 1954 |
Psychiatric and neurological side-effects of isoniazid and iproniazid.
Topics: Disease; Iproniazid; Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychotic Disorders; Seiz | 1954 |
Schizophreniclike psychotic reactions with administration of isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Psychotic Disorders; Schizophrenia; Tuberculosis | 1954 |
Experimental tuberculous meningitis in guinea pigs: results of treatment with isoniazid, iproniazid, streptomycin, and isoniazid-streptomycin.
Topics: Guinea Pigs; Iproniazid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; | 1954 |
Pyrazinamide-isoniazid in tuberculosis. I. Results in 58 patients with pulmonary lesions one year after the start of therapy.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
The distribution of C14 labeled isoniazid in normal and infected guinea pigs.
Topics: Animals; Guinea Pigs; Isomerism; Isoniazid; Nicotinic Acids; Tuberculosis | 1954 |
[Isonicotinic acid hydrazide in nasal tuberculosis].
Topics: Isoniazid; Lupus Vulgaris; Niacin; Nicotinic Acids; Respiratory Tract Infections; Tuberculosis | 1954 |
Bacterial resistance to isoniazid and marsilid in treatment of pulmonary tuberculosis; results of trials.
Topics: Bacterial Infections; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; | 1954 |
Streptomycin and isoniazid in acute miliary tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Miliary | 1954 |
[Isoniazid therapy of osteoarticular tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[Clinical report on a new chemo-antibiotic combination in therapy of tuberculosis: streptomycin-PAS-isoniazid].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberc | 1954 |
Treatment of tuberculous meningitis with isonicotinic acid hydrazides.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Results of isonicotinic acid hydrazide therapy of choroiditis].
Topics: Choroiditis; Eye; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1954 |
[Results of isonicotinic acid hydrazide therapy of scleritis].
Topics: Eye; Humans; Isoniazid; Niacin; Nicotinic Acids; Scleritis; Tuberculosis; Tuberculosis, Ocular | 1954 |
Isoniazid and P. A. S. in chronic pulmonary tuberculosis: a warning.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, P | 1954 |
[Treatment of tuberculous meningitis in children with special reference to streptomycin-isoniazid therapy in general admin. with isoniazid in local administration].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tu | 1954 |
[Combined antibiotic therapy of pulmonary tuberculosis in the Forlanini Institute with special reference to streptomycin-isoniazid therapy].
Topics: Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, | 1954 |
[Clinical results of isoniazid in the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Combined streptomycin, dihydrostreptomycin and sodium methanesulfonate of isoniazid in therapy of pulmonary tuberculosis].
Topics: Anti-Bacterial Agents; Dihydrostreptomycin Sulfate; Humans; Isoniazid; Mesylates; Niacin; Nicotinic | 1954 |
[Bronchial tuberculosis as possible complication of isonicotinic acid hydrazide therapy of tuberculous pulmonary caverns; clinical study].
Topics: Caves; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Isonicotinic acid hydrazide and glucide metabolism].
Topics: Carbohydrate Metabolism; Carbohydrates; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tu | 1954 |
[Experimental and clinical electrocardiographic study and sphygmomanometirc observations during treatment with isonicotinic acid hydrazide].
Topics: Biomedical Research; Blood Pressure; Electrocardiography; Isoniazid; Niacin; Nicotinic Acids; Tuberc | 1954 |
[Manifestations of intolerance in an eight-year-old girl treated with isonicotinic acid hydrazide].
Topics: Child; Hypersensitivity; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Contribution to isoniazid therapy of tuberculosis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Peroral chemotherapy of pulmonary tuberculosis; experience with a combination of heterocyclic thiosemicarbazone and isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Clinical and radiologic development of two cases of caseous bronchopneumonia treated with a combination of streptomycin, isoniazid and paraaminosalicylic acid].
Topics: Aminosalicylic Acid; Bronchopneumonia; Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Ra | 1954 |
[Comparative results of the treatment of tuberculous meningitis with streptomycin and PAS and with streptomycin and isonicotinic acid hydrazide].
Topics: Aminosalicylic Acid; Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomy | 1954 |
[Isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Results of three months of combined streptomycin, PAS and isoniazid therapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberc | 1954 |
[Treatment of pulmonary tuberculosis by isonicotinyl isopropyl hydrazine].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Excellent results of isoniazid therapy of a case of peritoneal tuberculosis with pulmonary tuberculosis].
Topics: Disease; Isoniazid; Niacin; Nicotinic Acids; Peritoneal Diseases; Peritoneum; Peritonitis, Tuberculo | 1954 |
[Prognosis and therapy of meningeal tuberculosis in children since the use of isoniazid].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Prognosis; Tuberculosis; Tuberculosis, Me | 1954 |
Isonicotinic acid hydrazide hypersensitivity with pyrexial reaction; report of a case.
Topics: Hypersensitivity; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Adrenal cortical function during isoniazid therapy for pulmonary tuberculosis.
Topics: Adrenal Cortex; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Tuberculous pneumonia due to organisms resistant to streptomycin and isoniazid.
Topics: Aminosalicylic Acid; Bacteriology; Humans; Isoniazid; Niacin; Nicotinic Acids; Pneumonia; Streptomyc | 1954 |
Clinical evaluation of isoniazid.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Isonicotinic acid hydrazide therapy against pulmonary tuberculosis; studies in the light of a control series.
Topics: Isoniazid; Light; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Early and remote results of isoniazid on experimental tuberculosis in guinea pigs; anatomo-histological and bacteriological study].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Experimental reproduction of the phenomenon of intestinal congestion following isoniazid therapy].
Topics: Disease; Humans; Intestinal Diseases; Intestines; Isoniazid; Reproduction; Tuberculosis | 1954 |
[Frequency and degree of isoniazid resistance of Koch bacilli isolated from the organs of tuberculous patients treated with isoniazid].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Effect of the somatotropic hormone, cortisone and desoxycorticosterone combined with isoniazid on experimental tuberculosis in guinea pigs].
Topics: Animals; Cortisone; Desoxycorticosterone; Growth Hormone; Guinea Pigs; Human Growth Hormone; Isoniaz | 1954 |
[Peripheral blood picture in tuberculous patients after more than a year of isoniazid therapy].
Topics: Blood; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Edematigenic effect of isoniazid on the tuberculous lung; anatomo-pathological study].
Topics: Edema; Isoniazid; Niacin; Nicotinic Acids; Pneumonia; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Combined streptomycin and isoniazid in therapy of tuberculous meningitis in children].
Topics: Anti-Bacterial Agents; Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tube | 1954 |
[Changes in capillary resistance by isoniazid].
Topics: Capillaries; Capillary Resistance; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tubercu | 1954 |
[18 Months of clinical experience with isoniazid in pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Clinical study of the effect of isoniazid on the carbohydrate metabolism tuberculous diabetics].
Topics: Carbohydrate Metabolism; Carbohydrates; Diabetes Complications; Diabetes Mellitus; Humans; Isoniazid | 1954 |
[Results of a first follow-up study of pulmonary tuberculosis patients treated with isoniazid].
Topics: Follow-Up Studies; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmon | 1954 |
The use of oxytetracycline in preventing or delaying isoniazid resistance in pulmonary tuberculosis; a report to the Research Committee of the Tuberculosis Society of Scotland.
Topics: Isoniazid; Niacin; Nicotinic Acids; Oxytetracycline; Research; Scotland; Tuberculosis; Tuberculosis | 1954 |
[Two cases of toxic manifestations in the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Kidney; Niacin; Nicotinic Acids; Seizures; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
A rapid colorimetric method for the determination of isonicotinic acid hydrazide in blood plasma. II. Application to blood plasma from human tuberculosis patients.
Topics: Blood; Colorimetry; Isoniazid; Niacin; Nicotinic Acids; Plasma; Tuberculosis | 1954 |
[The fate of isoniazid-resistant tubercle bacilli in tuberculous patients].
Topics: Bacillus; Bacteriology; Humans; Isoniazid; Lung; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis | 1954 |
[Isoniazid therapy of primary tuberculosis].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Additional experiences in isoniazid therapy of pulmonary tuberculosis in adolescence].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Isoniazid therapy of extrapulmonary tuberculosis in infant].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Blood protein picture in immunobiochemical response of tuberculosis treated with isonicotinic acid hydrazide].
Topics: Blood Proteins; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Various aspects of liver function during isoniazid therapy of tuberculosis].
Topics: Isoniazid; Liver; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Studies in experimental ocular tuberculosis. XVII. The effect of isoniazid in the normal, nonimmune rabbit.
Topics: Animals; Eye; Isoniazid; Niacin; Nicotinic Acids; Rabbits; Tuberculosis; Tuberculosis, Ocular | 1953 |
The influence of pyrazinamide-isoniazid on M. tuberculosis in animals and man.
Topics: Isomerism; Isoniazid; Leadership; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Pyrazinamide; | 1954 |
Medical treatment of tuberculosis: streptomycin, isoniazid, and para-aminosalicylic acid in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1954 |
[Isoniazid and isoniazid combined with PAS in therapy of pulmonary tuberculosis; clinical and bacteriologic studies].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Report on the treatment of pulmonary tuberculosis with the isoniazid methanesulfonate].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Treatment of tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Relapses after isoniazid treatment].
Topics: Aminosalicylic Acid; Collapse Therapy; Isoniazid; Niacin; Nicotinic Acids; Recurrence; Thiosemicarba | 1954 |
[Associated effect of streptomycin and isonicotinic acid hydrazide on experimental tuberculosis, in guinea pigs].
Topics: Guinea Pigs; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1954 |
[Use of isoniazid in tuberculous meningitis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Supposed mechanism of weight-increasing effect of isonicotinic acid hydrazide].
Topics: Body Weight; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Treatment of tuberculosis of the lymph nodes with isoniazid].
Topics: Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Lymph Node | 1954 |
[Electrophoretic serum studies in the treatment of infantile tuberculosis with high isoniazid dosage].
Topics: Blood Proteins; Electrophoresis; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Men | 1954 |
[Early results of isonicotinic acid hydrazide of the most severe forms of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Effect of two isoniazid derivatives and PAS hydrazide on isoniazid susceptible and resistant tubercle bacilli.
Topics: Aminosalicylic Acids; Bacillus; Hydrazines; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic | 1954 |
[Synergistic action of isoniazid and PAS in the treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulm | 1954 |
[Effectiveness of phthivazide therapy on tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
CHANGES in isoniazid resistance of tubercle bacilli after cessation of treatment; report by the Laboratory Subcommittee of the Tuberculosis Chemotherapy Trials Committee, Medical Research Council; M.R.C. isoniazid trial: Report No. 6.
Topics: Bacillus; Biomedical Research; Gram-Positive Bacteria; Humans; Isoniazid; Mycobacterium tuberculosis | 1954 |
[Effects of isoniazid on blood circulation].
Topics: Blood Circulation; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmon | 1954 |
[Possible biological cure of experimental tuberculosis by isoniazid].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Culture failure and isoniazid therapy].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Velez sign in female genital tuberculosis during isoniazid and dihydrostreptomycin sulfate therapy].
Topics: Dihydrostreptomycin Sulfate; Female; Humans; Isoniazid; Leukocyte Count; Niacin; Nicotinic Acids; St | 1954 |
[Isoniazid treatment of experimental tuberculosis in guinea pigs following prolonged administration of the same drug].
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Behavior of granulocytic peroxidases during isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Granulocytes; Isoniazid; Niacin; Nicotinic Acids; Oxidoreductases; Peroxidases; Tuberculosis; Tuberc | 1954 |
[Isoniazid in the treatment of diabetic tuberculosis].
Topics: Diabetes Complications; Diabetes Mellitus; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Late results with isoniazid (rimifon) in experimental tuberculous meningitis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
VARIOUS combinations of isoniazid with streptomycin or with P.A.S. in the treatment of pulmonary tuberculosis; seventh report to the Medical Research Council by their Tuberculosis Chemotherapy Trials Committee.
Topics: Aminosalicylic Acid; Biomedical Research; Dermatologic Agents; Isoniazid; Niacin; Nicotinic Acids; S | 1955 |
Experiences in the management of long-standing chronic cases of pulmonary tuberculosis treated with isoniazid for one year.
Topics: Disease Management; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Isoniazids versus streptomycin.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Experimental studies on the treatment of bone and joint tuberculosis with dihydrostreptomycin and isonicotinic acid hydrazide.
Topics: Bone and Bones; Dihydrostreptomycin Sulfate; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuber | 1955 |
[Isonicotinic acid hydrazide and pulmonary tuberculosis; clinico-radiological and immunobiochemical study].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Spinal block (Froin's syndrome) in tuberculous meningitis; favorable therapeutic effect of isoniazid].
Topics: Cerebrospinal Fluid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Combined treatment of cavitary pulmonary tuberculosis with isoniazid and intravenous infusions of PAS].
Topics: Aminosalicylic Acid; Infusions, Intravenous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuber | 1954 |
The prevalence of streptomycin- and isoniazid-resistant strains of Mycobacterium tuberculosis in patients with newly discovered and untreated active pulmonary tuberculosis.
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Prevalence; Streptomycin; Tu | 1955 |
The effect of tibion and isonicotinic acid hydrazide on the morphology of miliary tubercles.
Topics: Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Miliary | 1955 |
The topical application of isonicotinic acid hydrazide in tuberculosis of the skin.
Topics: Isoniazid; Niacin; Nicotinic Acids; Skin; Tuberculosis; Tuberculosis, Cutaneous | 1955 |
Observations on the effect of isoniazid and streptomycin on tubercles in a transparent chamber in the rabbit's ear.
Topics: Animals; Isoniazid; Niacin; Nicotinic Acids; Rabbits; Streptomycin; Tuberculosis | 1955 |
[First trails of combined isoniazid and PAS in tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Isoniazid in the treatment of tuberculosis; our experience].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
EXPERIMENTS with isoniazid as a preventive measure against tuberculosis.
Topics: Biomedical Research; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Evolution towards a polycystic aspect of the lesions of a bronchogenic seeding under the influence of isoniazid therapy].
Topics: Biological Evolution; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Combined isoniazid and PAS therapy in experimental tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Prolonged antibiotic therapy of pulmonary tuberculosis with isoniazid combined with streptomycin or PAS; indications for pneumothorax].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pneumotho | 1955 |
[Effect of isonicotinic acid hydrazide on tuberculous patients with mental disorders].
Topics: Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Isoniazid in the treatment of infantile tuberculosis].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1955 |
[Clinical experience with a new isoniazid derivative].
Topics: Hydrazines; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Intralumbar isonicotinic acid hydrazide in the treatment of tuberculous meningitis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Effect of isonicotinic acid hydrazide in experimental mouse tuberculosis].
Topics: Animals; Isomerism; Isoniazid; Mice; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
Isoniazid and ocular tuberculosis; an evaluation of experimental and clinical studies.
Topics: Eye; Head; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1955 |
Comparative studies on the effect of dihydrostreptomycin and isoniazid on immunized and non-immunized red mice (Clethrionomys G. glareolus schreb.) following intravenous challenge with bovine tubercle bacilli.
Topics: Animals; Arvicolinae; BCG Vaccine; Cattle; Dihydrostreptomycin Sulfate; Immunization; Isoniazid; Myc | 1955 |
[Course of experimental tuberculous infection in guinea pigs by strains sensitive and resistant in relation to combined streptomycin-isoniazid treatment of various doses].
Topics: Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1955 |
[Clinical and experimental studies on the therapy of cutaneous tuberculosis with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1955 |
[Peculiarities in the histological picture of cutaneous tuberculosis after treatment with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1955 |
Urinary complications occurring during isoniazid treatment.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary; Urologic Diseases | 1955 |
[Combined streptomycin and isonicotinic acid hydrazide in the treatment of some specific localized diseases (glandular, articular, osseous, intraabdominal)].
Topics: Anti-Bacterial Agents; Isoniazid; Streptomycin; Tuberculosis | 1955 |
[Intralaryngeal instillations of isonicotinic acid hydrazide in the treatment of tuberculous cavities].
Topics: Dental Caries; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Effect of isonicotinic acid hydrazide associated with para-aminosalicylic acid on experimental tuberculosis in guinea pigs].
Topics: Aminosalicylic Acid; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Therapy of tuberculous of oral cavity, pharynx and larynx with isonicotinic acid hydrazide].
Topics: Isoniazid; Larynx; Mouth; Mouth Diseases; Niacin; Nicotinic Acids; Pharyngeal Diseases; Pharynx; Tub | 1955 |
[Psychoses caused by isoniazid].
Topics: Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychoses, Substance-Induced; Psychotic Disord | 1955 |
[Effect of isonicotinic acid hydrazide and of vitamin C on experimental tuberculosis].
Topics: Ascorbic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Behavior of blood coagulation in tuberculous children treated with isoniazid. I].
Topics: Blood Coagulation; Child; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1955 |
[Changed induced by vitamin E in blood coagulation in tuberculous children treated with isoniazid. II].
Topics: Blood Coagulation; Child; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1955 |
[An isonicotinic-acid-hydrazide treated case of urogenital tuberculosis with bacilli non-pathogenetic to guinea pigs].
Topics: Bacillus; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; | 1955 |
[Use of tuberculin for excitation in the treatment of tuberculosis with streptomycin and with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculin; Tuberculosis | 1955 |
Fatal tuberculous meningitis developing during isoniazid-streptomycin therapy.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal; Tuberculosi | 1955 |
[Mental disorders in the course of tubercular meningitis treated with isoniazid].
Topics: Humans; Isoniazid; Mental Disorders; Tuberculosis; Tuberculosis, Meningeal | 1955 |
The effect of streptomycin, isonicotinic acid hydrazide (isoniazid) and streptomycin plus isoniazid in ocular tuberculosis in animals.
Topics: Eye; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Ocular | 1955 |
Clinical trial of P.A.S. salt of isoniazid in treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acids; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Hepatitis following isoniazid.
Topics: Hepatitis; Hepatitis A; Isoniazid; Jaundice; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1955 |
Conventional therapy versus the continuous and concurrent use of streptomycin, isoniazid, and para-aminosalicylic acid plus early surgery in the treatment of tuberculosis.
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Isonia | 1955 |
Report of a case of miliary tuberculosis and tuberculous meningitis treated with isoniazid.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, | 1955 |
[Bullous images in tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Radiography; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[The relation of excretory isoniazid levels to therapeutic results].
Topics: Body Fluids; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Urine | 1955 |
[Hemorrhagic thrombopenia caused by isoniazid].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Purpura; Purpura, Thrombocytopenic; Thrombocytopenia; Tu | 1955 |
[Experience with streptomycin and isonicotinic acid hydrazide therapy of tuberculous meningitis during the two-year period 1953-54].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1955 |
[Indication of purely peroral isoniazid treatment of tuberculous meningitis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1955 |
[Evaluation of isoniazid in the treatment of infantile tuberculosis].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Results of isoniazid in psychiatry; clinical study].
Topics: Isoniazid; Mental Disorders; Niacin; Nicotinic Acids; Psychiatry; Tuberculosis; Tuberculosis, Pulmon | 1955 |
Pyrazinamide-isoniazid in tuberculosis. III. Observations with reduced dosage of pyrazinamide.
Topics: Clinical Protocols; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pu | 1955 |
[Sensitivity of Mycobacterium tuberculosis to isonicotinic acid hydrazide and bactericidal effect of Wrocław shock method].
Topics: Anti-Bacterial Agents; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
The effect of cortisone alone and in combination with isoniazid in experimental corneal tuberculosis in mice.
Topics: Adrenal Glands; Animals; Cortisone; Eye; Isoniazid; Mice; Niacin; Nicotinic Acids; Tuberculosis; Tub | 1955 |
Isoniazid in pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Combined isoniazid and glutamic acid; study of their clinical use].
Topics: Anti-Bacterial Agents; Glutamates; Glutamic Acid; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberc | 1955 |
[Manifestations of intoxication in therapy with isonicotinic acid hydrazide].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1955 |
[Isonicotinic acid hydrazide in various types of tuberculosis of the skin and mucosa].
Topics: Isoniazid; Mucous Membrane; Niacin; Nicotinic Acids; Skin; Tuberculosis; Tuberculosis, Cutaneous | 1953 |
Prevention of experimental tuberculosis with isoniazid.
Topics: Biomedical Research; Humans; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
Streptomycin, isoniazid, and para-aminosalicylic acid in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1956 |
[Isoniazid in ocular tuberculosis].
Topics: Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1955 |
[Phagocytosis in tuberculous patients before and after isoniazid alone or combined with streptomycin].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Phagocytosis; Streptomycin; Tuberculosis; Tuberculosis, | 1955 |
Experimental infective pneumoconiosis. III. Coal-mine dust and isoniazid-resistant tubercle bacilli of moderate virulence.
Topics: Bacillus; Coal; Dust; Humans; Isoniazid; Lung; Mining; Pneumoconiosis; Tuberculosis; Tuberculosis, P | 1955 |
Experimental infective pneumoconiosis. IV. Massive pulmonary fibrosis produced by coal-mine dust and isoniazid-resistant tubercle bacilli of low virulence.
Topics: Bacillus; Coal; Dust; Isoniazid; Mining; Pneumoconiosis; Pulmonary Fibrosis; Tuberculosis; Tuberculo | 1955 |
[Peripheral nerve disorders in pulmonary tuberculosis patients treated with isoniazid and its derivatives].
Topics: Disease; Isoniazid; Niacin; Nicotinic Acids; Peripheral Nerves; Peripheral Nervous System Diseases; | 1955 |
[Results of isonicotinic acid hydrazide therapy of osteoarticular tuberculosis and of its complications in children].
Topics: Child; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoartic | 1955 |
[Peripheral blood picture in the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Blood; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Observations on the treatment of laryngeal tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Larynx; Larynx, Artificial; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Laryngea | 1955 |
Isonicotinic acid hydrazide and streptomycin in the treatment of pulmonary tuberculosis.
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Isoniazid in cutaneous tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1955 |
[Use of isonicotinic acid hydrazide by inhalatory route].
Topics: Aerosols; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Eosinophilic pulmonary infiltration in the course of isoniazid treatment].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pulmonary Eosinophilia; Tuberculosis; Tuberculosis, Meningeal | 1955 |
[Vesiculose caverns appearing during treatment of pulmonary tuberculosis with isoniazid].
Topics: Caves; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Tuberculous meningitis in children treated with isoniazid, streptomycin, and PAS.
Topics: Aminosalicylic Acid; Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomy | 1956 |
[Results and experience in combined streptomycin-isonicotinic acid hydrazide treatment of meningeal tuberculosis in childhood].
Topics: Child; Combined Modality Therapy; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Str | 1955 |
[Isoniazid and PAS in the treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulm | 1955 |
Treatment of renal tuberculosis with triple-drug therapy; use of a combination of streptomycin, isoniazid, and sodium aminosalicylic acid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Kidney; Niacin; Nicotinic Acids; Sodium; Streptomycin; Tu | 1956 |
[Fundamental experiments on combined effects of three anti-tuberculous agents, streptomycin, PAS and isoniazid. I. Studies mainly on the course of the resistance development of M. tuberculosis serially transferred in the cultural environment of three drug
Topics: Aminosalicylic Acid; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Streptomycin; T | 1955 |
[Three years of experience with combined isoniazid and PAS therapy of pulmonary tuberculosis; caustic study].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Caustics; Humans; Isoniazid; Niacin; Nicotinic Acids; Tu | 1955 |
[Combined streptomycin, isonicotinic acid hydrazide and hydrocortisone by intraspinal route in the treatment of tuberculous meningitis].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Anti-Bacterial Agents; Hydrocortisone; Isoniazid; Niacin; N | 1955 |
[Method of isoniazid therapy, dosage and bacteriostatic concentration in the blood].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Effectivity of combined isoniazid-PAS preparations].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Results of isoniazid treatment in the presence of resistant Mycobacterium strains].
Topics: Isoniazid; Mycobacterium; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Laboratory infection with Mycobacterium tuberculosis which showed reduced sensitivity toward streptomycin and isoniazid].
Topics: Humans; Isomerism; Isoniazid; Laboratory Infection; Mycobacterium tuberculosis; Niacin; Nicotinic Ac | 1956 |
[Treatment of two cases of meningeal tuberculosis with isoniazid alone without intrathecal intervention].
Topics: Isomerism; Isoniazid; Lung Diseases; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1955 |
[Neurological complications following isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isoniazid; Nervous System; Nervous System Diseases; Niacin; Nicotinic Acids; Tuberculosis; Tuberculo | 1956 |
[Long-term results of intracavitary treatment with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Recovery of tuberculous cavities treated with antibiotics (isoniazid) with preservation of their lumen, chemical casectomy].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Treatment of uveal tuberculosis with isonicotinic acid hydrazide].
Topics: Eye; Head; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1955 |
[Treatment of pulmonary tuberculosis with isoniazid combined with PAS].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Isoniazid- and streptomycin resistance of Mycobacterium tuberculosis in tuberculous lesions of the lung treated with resection after chemotherapy. I. Frequency of resistance in chemotherapy with prolonged action; study of 285 cases].
Topics: Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tubercul | 1955 |
[Rimifon in complex therapy of tuberculous meningitis in children].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1955 |
Attenuation of highly isoniazid-resistant tubercle bacilli.
Topics: Bacillus; Gram-Positive Bacteria; Isoniazid; Lacticaseibacillus casei; Mycobacterium bovis; Mycobact | 1955 |
[The value of ammonia determination in isoniazid treatment].
Topics: Ammonia; Blood; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1955 |
[Further experience in the treatment of pulmonary tuberculosis of adult type in puberty with isonicotinic acid hydrazides].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Puberty; Sexual Maturation; Tuberculosis; Tuberculosi | 1955 |
[Our experience since the introduction of isoniazid (INH) into the treatment of tuberculous meningitis (April 1952 till December 21, 1953)].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1955 |
[Treatment of extrapulmonary tuberculosis in children with isoniazid].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Isoniazid (INH) therapy of primary tuberculosis].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pu | 1955 |
[Some unusual secondary effects of isonicotinic acid hydrazide on the digestive organs].
Topics: Digestive System; Flavonoids; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Vitamins | 1955 |
[Comparative research on the results of ambulatory treatment of pulmonary tuberculosis with conteben/pasalon, respectively isonicotinic acid hydrazide].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Thioacetazone; Thiosemicarbazones; Tubercul | 1955 |
Isoniazid in the treatment of cutaneous tuberculosis.
Topics: Administration, Cutaneous; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1955 |
[Variations of the tuberculin allergy reactivity in tuberculosis patients treated with repeated cycles of isoniazid therapy].
Topics: Humans; Hypersensitivity; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tuberculin Test | 1955 |
[Urinary corticoids and ketosteroids in patients with tuberculosis in relation to isoniazid therapy].
Topics: Adrenal Cortex; Adrenal Cortex Hormones; Isoniazid; Ketosteroids; Niacin; Nicotinic Acids; Steroids; | 1955 |
[Tuberculous subchronic pancreatitis cured by isoniazid therapy].
Topics: Disease; Isoniazid; Niacin; Nicotinic Acids; Pancreas; Pancreatic Diseases; Pancreatitis; Tuberculos | 1955 |
[Observations on a streptomycin-isoniazid (streptotibin) combination in treatment of pulmonary tuberculosis].
Topics: Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Significance of isonicotinic acid hydrazide in the treatment of female genital tuberculosis].
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, Female Genit | 1955 |
PROPHYLACTIC isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
[Polyneuritis caused by isoniazid].
Topics: Isoniazid; Neuritis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Treatment of various forms of tuberculosis in children with a streptomycin-isoniazid combination].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1956 |
[Striking change in the composition of bone marrow cells of tuberculous children and the behavior of peripheral blood after prolonged treatment with isonicotinic acid hydrazide (the Hungarian preparation, isonicid K. Gy.) in massive doses].
Topics: Blood Circulation; Bone Marrow; Bone Marrow Cells; Child; Humans; Infant; Isoniazid; Niacin; Nicotin | 1955 |
[Clinical observations on action of isonicotinic acid hydrazide in laryngeal tuberculosis].
Topics: Humans; Isoniazid; Larynx; Larynx, Artificial; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, | 1955 |
[Results of treatment of tuberculous meningitis in children since the use of isoniazid].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1955 |
[An epidemic of epileptic seizures in a sanatorium environment; possible role of alcoholism and isoniazid].
Topics: Alcoholism; Epilepsy; Hospitals, Special; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; | 1955 |
[Rectal administration of isoniazid-eucaliptol in therapy of pulmonary tuberculosis].
Topics: Administration, Rectal; Eucalyptus; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tub | 1955 |
[Water and electrolyte metabolism in pulmonary tuberculosis before and after treatment with isonicotinic acid hydrazide. I].
Topics: Electrolytes; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary; Wat | 1955 |
[Treatment of pulmonary tuberculosis in its various clinical forms with streptomycin, para-aminosalicylic acid (PAS), thiosemicarbazone (TB1) and isoniazid].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Thiosemicarbazones; Tuberculo | 1955 |
[Isoniazid therapy in chronic fibro-cavernous pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Combination of streptomycin, PAS and isoniazid in the treatment of cavitary and bacillary pulmonary tuberculosis; immediate results].
Topics: Aminosalicylic Acid; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Streptomycin; T | 1955 |
[Presentation of a monkey on the 17th day of inoculation with 50 milligrams of isoniazid-resistant Koch bacilli].
Topics: Animals; Haplorhini; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
A pathologic and bacteriologic study of cavitary pulmonary tuberculosis treated with streptomycin and isoniazid.
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
Pyrazinamide-isoniazid: comparison with isoniazid-para-aminosalicylic acid in active pulmonary tuberculosis with the choice of regimens determined by chance.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Pyrimidines; Tuberculosis; Tu | 1956 |
The relationship between the catalase activity, hydrogen peroxide sensitivity, and isoniazid resistance of mycobacteria.
Topics: Catalase; Hydrogen Peroxide; Isoniazid; Mycobacterium; Mycobacterium bovis; Mycobacterium tuberculos | 1956 |
The effect of the anti-isoniazid substance produced by mycobacteria on the chemotherapeutic activity of isoniazid in vivo.
Topics: Humans; Isoniazid; Mycobacterium; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
Tuberculous meningitis developing in the course of isoniazid therapy.
Topics: Child; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; | 1956 |
[First results in the treatment of tuberculous meningitis with the use of pyrazinamide and the first studies on its action on isoniazid-resistant strains].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Pyrimidines; Tuberculosis; Tuberculosis | 1956 |
[Current status of therapy of tuberculosis of the mucous membranes of the ENT area, a comparative evaluation of new drugs, streptomycin, PAS, TB1 and isonicotinic acid hydrazide].
Topics: Aminosalicylic Acid; Disease; Isoniazid; Mouth Diseases; Mucous Membrane; Niacin; Nicotinic Acids; P | 1955 |
[A case of contralateral pneumothorax following intracavitary administration of isoniazid in patients with mediastinal hernia].
Topics: Hernia; Isoniazid; Niacin; Nicotinic Acids; Pneumothorax; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Isoniazid in tuberculosis of the skin.
Topics: Isoniazid; Niacin; Nicotinic Acids; Skin; Tuberculosis; Tuberculosis, Cutaneous | 1955 |
Effects of isonicotinic acid hydrazides on mental status of tuberculous patients.
Topics: Isoniazid; Niacin; Nicotinic Acids; Psychoses, Substance-Induced; Psychotic Disorders; Tuberculosis; | 1956 |
The effect of isonicotinic acid hydrazide on the oxidative metabolism of Mycobacterium tuberculosis var. bovis B.C.G.
Topics: Cell Respiration; Isoniazid; Mycobacterium bovis; Mycobacterium tuberculosis; Niacin; Nicotinic Acid | 1956 |
[About isoniazid resistance].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Results obtained in the treatment of pulmonary tuberculosis with isoniazid calcium methanesulfonate].
Topics: Calcium, Dietary; Isoniazid; Mesylates; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmona | 1956 |
[Results obtained in the treatment of pulmonary tuberculosis with isoniazid calcium methanesulfonate].
Topics: Calcium, Dietary; Isoniazid; Mesylates; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmona | 1956 |
[Meningeal tuberculosis resistant from the first to streptomycin and to isoniazid with a rapid fatal outcome].
Topics: Fatal Outcome; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculos | 1956 |
[Bacteriological survey of pulmonary tuberculosis treated with isoniazid, alone and in combination].
Topics: Data Collection; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Acute tuberculous meningitis during isoniazid treatment].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1956 |
[Difficulties in the type differentiation of M. tuberculosis due to the influence of isoniazid].
Topics: Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
Tuberculous adenitis; twenty-three cases treated with isoniazid alone.
Topics: Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Lymph Node | 1956 |
[Recent studies on histological variations and the course of infection and reinfection with tuberculosis caused by isoniazid-resistant strains with attenuated virulence].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Virulence | 1955 |
[Clinical experience with dipasic and isoniazid-PAS compounds in therapy of tuberculosis].
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulm | 1956 |
The effect of isoniazid in experimental corneal tuberculosis.
Topics: Cornea; Eye; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1956 |
[First trials with a combined preparation of PAS and isoniazid in urinary tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal | 1955 |
[Delayed action of isoniazid on old pulmonary tuberculosis: report on new cases].
Topics: Delayed-Action Preparations; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculos | 1956 |
[Ambulatory treatment of various forms of pulmonary tuberculosis with streptomycin and isonicotinic acid hydrazide combination].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Does isoniazid change the prognosis of primary infection in its pulmonary lymph node form?].
Topics: Aminosalicylic Acid; Child; Communicable Diseases; Humans; Infant; Isoniazid; Lymph Nodes; Niacin; N | 1955 |
[Treatment of diseases occurring in the course of tuberculous meningitis with streptomycin and isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1956 |
Treatment of pulmonary tuberculosis on a combined regimen of para-amino-salicylic acid, streptomycin and isonicotinic acid hydrazide.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Salicylic Acid; Streptomycin; Tuberculosis; | 1956 |
[Results isoniazid treatment of meningeal tuberculosis in Charles Nicolle Hospital].
Topics: Hospitals; Humans; Isoniazid; Niacin; Nicotinic Acids; Treatment Outcome; Tuberculosis; Tuberculosis | 1956 |
[Isoniazid treatment of pulmonary tuberculosis as seen in electrophoretic blood protein determination].
Topics: Blood Protein Electrophoresis; Blood Proteins; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tub | 1956 |
[Clinical experience with an isoniazid-thiosemicarbazone combination in pulmonary tuberculosis in adults].
Topics: Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
Further observations on the prevalence of streptomycin- and isoniazid-resistant strains of Mycobacterium tuberculosis in patients with newly discovered and untreated active pulmonary tuberculosis.
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Prevalence; Streptomycin; Tu | 1956 |
Pathogenicity of isoniazid-resistant tubercle bacilli and prophylaxis of tuberculosis in children.
Topics: Bacillus; Isoniazid; Lacticaseibacillus casei; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; | 1956 |
Some observations on the utility of simian pulmonary tuberculosis in defining the therapeutic potentialities of isoniazid.
Topics: Humans; Isoniazid; Lung; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Biological dynamism of tuberculous processes in relation to streptomycin and isoniazid therapy].
Topics: Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Animal experimental research on intermittent chemotherapy and prevention of tuberculosis. II. Results of biweekly administration of isoniazid in various dosages in simultaneous experimentation on guinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
[A case of primary tuberculosis caused by isoniazid resistant Mycobacterium tuberculosis with weakened virulence].
Topics: Child; Humans; Infant; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; | 1956 |
[Treatment of acute experimental tuberculosis in guinea pigs with isoniazid, daily and every third day].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
[Clinical observations on the course of tuberculosis in isoniazid-resistant patients].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1956 |
[Clinical experiences in the treatment of pulmonary tuberculosis with a thiosemicarbazone-isoniazid combination].
Topics: Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
Acute pancreatitis following administration of isonicotinic acid hydrazide; report of a case.
Topics: Diabetes Complications; Isoniazid; Niacin; Nicotinic Acids; Pancreatitis; Tuberculosis | 1956 |
[Remarkable effect of cortisone on functional signs in a case of tuberculosis in infant].
Topics: Child; Cortisone; Humans; Infant; Isoniazid; Lung; Physical Examination; Streptomycin; Tuberculosis; | 1956 |
[Remarkable effect of cortisone on functional signs in a case of tuberculosis in infant].
Topics: Child; Cortisone; Humans; Infant; Isoniazid; Lung; Physical Examination; Streptomycin; Tuberculosis; | 1956 |
[Remarkable effect of cortisone on functional signs in a case of tuberculosis in infant].
Topics: Child; Cortisone; Humans; Infant; Isoniazid; Lung; Physical Examination; Streptomycin; Tuberculosis; | 1956 |
[Remarkable effect of cortisone on functional signs in a case of tuberculosis in infant].
Topics: Child; Cortisone; Humans; Infant; Isoniazid; Lung; Physical Examination; Streptomycin; Tuberculosis; | 1956 |
[Incidence of resistance of Koch bacillus to antibiotics during primary infection].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacillus; Child; Communicab | 1956 |
[Incidence of resistance of Koch bacillus to antibiotics during primary infection].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacillus; Child; Communicab | 1956 |
[Incidence of resistance of Koch bacillus to antibiotics during primary infection].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacillus; Child; Communicab | 1956 |
[Incidence of resistance of Koch bacillus to antibiotics during primary infection].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacillus; Child; Communicab | 1956 |
[Tuberculous meningitis in children and its treatment].
Topics: Aminosalicylic Acid; Cerebrospinal Fluid; Child; Humans; Isoniazid; Streptomycin; Tuberculosis; Tube | 1956 |
[Tuberculous meningitis in children and its treatment].
Topics: Aminosalicylic Acid; Cerebrospinal Fluid; Child; Humans; Isoniazid; Streptomycin; Tuberculosis; Tube | 1956 |
[Tuberculous meningitis in children and its treatment].
Topics: Aminosalicylic Acid; Cerebrospinal Fluid; Child; Humans; Isoniazid; Streptomycin; Tuberculosis; Tube | 1956 |
[Tuberculous meningitis in children and its treatment].
Topics: Aminosalicylic Acid; Cerebrospinal Fluid; Child; Humans; Isoniazid; Streptomycin; Tuberculosis; Tube | 1956 |
[Examination of resected lung preparations. I. The effect of isoniazid treatment on isoniazid resistance and virulence destruction of Mycobacteria tuberculosis; bacteriologic examination].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virulence | 1956 |
[Examination of resected lung preparations. I. The effect of isoniazid treatment on isoniazid resistance and virulence destruction of Mycobacteria tuberculosis; bacteriologic examination].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virulence | 1956 |
[Examination of resected lung preparations. I. The effect of isoniazid treatment on isoniazid resistance and virulence destruction of Mycobacteria tuberculosis; bacteriologic examination].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virulence | 1956 |
[Examination of resected lung preparations. I. The effect of isoniazid treatment on isoniazid resistance and virulence destruction of Mycobacteria tuberculosis; bacteriologic examination].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virulence | 1956 |
[Radiological aspects of experimental tuberculosis in rabbits before and after treatment with dihydrostreptomycin, sulfoniazid and the neutral salts of streptomycin and dihydrostreptomycin with sulfoniazid].
Topics: Animals; Dihydrostreptomycin Sulfate; Hydrogen-Ion Concentration; Isoniazid; Rabbits; Radiology; Sal | 1956 |
[Radiological aspects of experimental tuberculosis in rabbits before and after treatment with dihydrostreptomycin, sulfoniazid and the neutral salts of streptomycin and dihydrostreptomycin with sulfoniazid].
Topics: Animals; Dihydrostreptomycin Sulfate; Hydrogen-Ion Concentration; Isoniazid; Rabbits; Radiology; Sal | 1956 |
[Radiological aspects of experimental tuberculosis in rabbits before and after treatment with dihydrostreptomycin, sulfoniazid and the neutral salts of streptomycin and dihydrostreptomycin with sulfoniazid].
Topics: Animals; Dihydrostreptomycin Sulfate; Hydrogen-Ion Concentration; Isoniazid; Rabbits; Radiology; Sal | 1956 |
[Radiological aspects of experimental tuberculosis in rabbits before and after treatment with dihydrostreptomycin, sulfoniazid and the neutral salts of streptomycin and dihydrostreptomycin with sulfoniazid].
Topics: Animals; Dihydrostreptomycin Sulfate; Hydrogen-Ion Concentration; Isoniazid; Rabbits; Radiology; Sal | 1956 |
[Indications and results of prolonged bronchoclysis in pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Indications and results of prolonged bronchoclysis in pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Indications and results of prolonged bronchoclysis in pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Indications and results of prolonged bronchoclysis in pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Combined anti-inflammatory and antituberculous chemotherapy in one medication; clinical and therapeutic study].
Topics: Aminopyrine; Anti-Inflammatory Agents; Isoniazid; Phenylbutazone; Tuberculosis; Tuberculosis, Pulmon | 1956 |
[Combined anti-inflammatory and antituberculous chemotherapy in one medication; clinical and therapeutic study].
Topics: Aminopyrine; Anti-Inflammatory Agents; Isoniazid; Phenylbutazone; Tuberculosis; Tuberculosis, Pulmon | 1956 |
[Combined anti-inflammatory and antituberculous chemotherapy in one medication; clinical and therapeutic study].
Topics: Aminopyrine; Anti-Inflammatory Agents; Isoniazid; Phenylbutazone; Tuberculosis; Tuberculosis, Pulmon | 1956 |
[Combined anti-inflammatory and antituberculous chemotherapy in one medication; clinical and therapeutic study].
Topics: Aminopyrine; Anti-Inflammatory Agents; Isoniazid; Phenylbutazone; Tuberculosis; Tuberculosis, Pulmon | 1956 |
The relationship of neuropathy to the treatment of tuberculosis with isoniazid.
Topics: Humans; Isoniazid; Nervous System Diseases; Tuberculosis | 1956 |
The relationship of neuropathy to the treatment of tuberculosis with isoniazid.
Topics: Humans; Isoniazid; Nervous System Diseases; Tuberculosis | 1956 |
The relationship of neuropathy to the treatment of tuberculosis with isoniazid.
Topics: Humans; Isoniazid; Nervous System Diseases; Tuberculosis | 1956 |
The relationship of neuropathy to the treatment of tuberculosis with isoniazid.
Topics: Humans; Isoniazid; Nervous System Diseases; Tuberculosis | 1956 |
[The course of experimental tuberculosis in guinea pigs nursed by mothers treated with isonicotinic acid hydrazide].
Topics: Guinea Pigs; Isoniazid; Mothers; Tuberculosis | 1956 |
[The course of experimental tuberculosis in guinea pigs nursed by mothers treated with isonicotinic acid hydrazide].
Topics: Guinea Pigs; Isoniazid; Mothers; Tuberculosis | 1956 |
[The course of experimental tuberculosis in guinea pigs nursed by mothers treated with isonicotinic acid hydrazide].
Topics: Guinea Pigs; Isoniazid; Mothers; Tuberculosis | 1956 |
[The course of experimental tuberculosis in guinea pigs nursed by mothers treated with isonicotinic acid hydrazide].
Topics: Guinea Pigs; Isoniazid; Mothers; Tuberculosis | 1956 |
[Involution of primary adenopathy in guinea pigs infected with isoniazid-resistant Koch's bacilli and previously vaccinated with killed and diffused bacteria and in non-vaccinated guinea pigs].
Topics: Animals; Bacteria; Guinea Pigs; Isoniazid; Lymphatic Diseases; Mycobacterium tuberculosis; Tuberculo | 1956 |
[Involution of primary adenopathy in guinea pigs infected with isoniazid-resistant Koch's bacilli and previously vaccinated with killed and diffused bacteria and in non-vaccinated guinea pigs].
Topics: Animals; Bacteria; Guinea Pigs; Isoniazid; Lymphatic Diseases; Mycobacterium tuberculosis; Tuberculo | 1956 |
[Involution of primary adenopathy in guinea pigs infected with isoniazid-resistant Koch's bacilli and previously vaccinated with killed and diffused bacteria and in non-vaccinated guinea pigs].
Topics: Animals; Bacteria; Guinea Pigs; Isoniazid; Lymphatic Diseases; Mycobacterium tuberculosis; Tuberculo | 1956 |
[Involution of primary adenopathy in guinea pigs infected with isoniazid-resistant Koch's bacilli and previously vaccinated with killed and diffused bacteria and in non-vaccinated guinea pigs].
Topics: Animals; Bacteria; Guinea Pigs; Isoniazid; Lymphatic Diseases; Mycobacterium tuberculosis; Tuberculo | 1956 |
[Case of intestinal perforation during isonicotinic acid hydrazide therapy in patient with intestinal tuberculosis].
Topics: Humans; Intestinal Perforation; Isoniazid; Peritonitis; Peritonitis, Tuberculous; Tuberculosis; Tube | 1956 |
[Case of intestinal perforation during isonicotinic acid hydrazide therapy in patient with intestinal tuberculosis].
Topics: Humans; Intestinal Perforation; Isoniazid; Peritonitis; Peritonitis, Tuberculous; Tuberculosis; Tube | 1956 |
[Case of intestinal perforation during isonicotinic acid hydrazide therapy in patient with intestinal tuberculosis].
Topics: Humans; Intestinal Perforation; Isoniazid; Peritonitis; Peritonitis, Tuberculous; Tuberculosis; Tube | 1956 |
[Case of intestinal perforation during isonicotinic acid hydrazide therapy in patient with intestinal tuberculosis].
Topics: Humans; Intestinal Perforation; Isoniazid; Peritonitis; Peritonitis, Tuberculous; Tuberculosis; Tube | 1956 |
[Osmotic resistance of leukocytes in tuberculous children treated with isoniazid].
Topics: Biochemical Phenomena; Child; Humans; Isoniazid; Leukocytes; Osmosis; Tuberculosis | 1956 |
[Osmotic resistance of leukocytes in tuberculous children treated with isoniazid].
Topics: Biochemical Phenomena; Child; Humans; Isoniazid; Leukocytes; Osmosis; Tuberculosis | 1956 |
[Osmotic resistance of leukocytes in tuberculous children treated with isoniazid].
Topics: Biochemical Phenomena; Child; Humans; Isoniazid; Leukocytes; Osmosis; Tuberculosis | 1956 |
[Osmotic resistance of leukocytes in tuberculous children treated with isoniazid].
Topics: Biochemical Phenomena; Child; Humans; Isoniazid; Leukocytes; Osmosis; Tuberculosis | 1956 |
[Combined ACTH-antibiotic therapy in various forms of chronic tuberculous empyema].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Anti-Bacterial Agents; Empyema, Tuberculous; Isoni | 1956 |
[Combined ACTH-antibiotic therapy in various forms of chronic tuberculous empyema].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Anti-Bacterial Agents; Empyema, Tuberculous; Isoni | 1956 |
[Combined ACTH-antibiotic therapy in various forms of chronic tuberculous empyema].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Anti-Bacterial Agents; Empyema, Tuberculous; Isoni | 1956 |
[Combined ACTH-antibiotic therapy in various forms of chronic tuberculous empyema].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Anti-Bacterial Agents; Empyema, Tuberculous; Isoni | 1956 |
[Behavior of various serological tests in tuberculotics treated with PAS and PAS plus isoniazid by intravenous perfusions].
Topics: Aminosalicylic Acid; Blood; Humans; Isoniazid; Serologic Tests; Tuberculosis; Tuberculosis, Pulmonar | 1956 |
[Behavior of various serological tests in tuberculotics treated with PAS and PAS plus isoniazid by intravenous perfusions].
Topics: Aminosalicylic Acid; Blood; Humans; Isoniazid; Serologic Tests; Tuberculosis; Tuberculosis, Pulmonar | 1956 |
[Behavior of various serological tests in tuberculotics treated with PAS and PAS plus isoniazid by intravenous perfusions].
Topics: Aminosalicylic Acid; Blood; Humans; Isoniazid; Serologic Tests; Tuberculosis; Tuberculosis, Pulmonar | 1956 |
[Behavior of various serological tests in tuberculotics treated with PAS and PAS plus isoniazid by intravenous perfusions].
Topics: Aminosalicylic Acid; Blood; Humans; Isoniazid; Serologic Tests; Tuberculosis; Tuberculosis, Pulmonar | 1956 |
The results of combined drug therapy and early fusion in bone tuberculosis.
Topics: Aminosalicylic Acid; Drug Therapy, Combination; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, | 1957 |
The results of combined drug therapy and early fusion in bone tuberculosis.
Topics: Aminosalicylic Acid; Drug Therapy, Combination; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, | 1957 |
The results of combined drug therapy and early fusion in bone tuberculosis.
Topics: Aminosalicylic Acid; Drug Therapy, Combination; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, | 1957 |
The results of combined drug therapy and early fusion in bone tuberculosis.
Topics: Aminosalicylic Acid; Drug Therapy, Combination; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, | 1957 |
[Isoniazid in experimental tuberculosis].
Topics: Isoniazid; Tuberculosis | 1956 |
[Isoniazid in experimental tuberculosis].
Topics: Isoniazid; Tuberculosis | 1956 |
[Isoniazid in experimental tuberculosis].
Topics: Isoniazid; Tuberculosis | 1956 |
[Isoniazid in experimental tuberculosis].
Topics: Isoniazid; Tuberculosis | 1956 |
[Hormone therapy with antibiotics in the treatment of meningeal tuberculosis in child].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Dermatologic Agents; Humans; Hydrocortiso | 1956 |
[Hormone therapy with antibiotics in the treatment of meningeal tuberculosis in child].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Dermatologic Agents; Humans; Hydrocortiso | 1956 |
[Hormone therapy with antibiotics in the treatment of meningeal tuberculosis in child].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Dermatologic Agents; Humans; Hydrocortiso | 1956 |
[Hormone therapy with antibiotics in the treatment of meningeal tuberculosis in child].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Dermatologic Agents; Humans; Hydrocortiso | 1956 |
Anti-tuberculous drugs.
Topics: Aminosalicylic Acid; Isoniazid; Streptomycin; Tuberculosis | 1957 |
Anti-tuberculous drugs.
Topics: Aminosalicylic Acid; Isoniazid; Streptomycin; Tuberculosis | 1957 |
Anti-tuberculous drugs.
Topics: Aminosalicylic Acid; Isoniazid; Streptomycin; Tuberculosis | 1957 |
Anti-tuberculous drugs.
Topics: Aminosalicylic Acid; Isoniazid; Streptomycin; Tuberculosis | 1957 |
[Action on the tuberculous pulmonary, lymphatic and osseous processes of a medication combining anti-inflammatory and antituberculous chemotherapy].
Topics: Anti-Inflammatory Agents; Bone and Bones; Humans; Isoniazid; Phenylbutazone; Tuberculosis | 1956 |
[Action on the tuberculous pulmonary, lymphatic and osseous processes of a medication combining anti-inflammatory and antituberculous chemotherapy].
Topics: Anti-Inflammatory Agents; Bone and Bones; Humans; Isoniazid; Phenylbutazone; Tuberculosis | 1956 |
[Action on the tuberculous pulmonary, lymphatic and osseous processes of a medication combining anti-inflammatory and antituberculous chemotherapy].
Topics: Anti-Inflammatory Agents; Bone and Bones; Humans; Isoniazid; Phenylbutazone; Tuberculosis | 1956 |
[Action on the tuberculous pulmonary, lymphatic and osseous processes of a medication combining anti-inflammatory and antituberculous chemotherapy].
Topics: Anti-Inflammatory Agents; Bone and Bones; Humans; Isoniazid; Phenylbutazone; Tuberculosis | 1956 |
[Sensitivity to antituberculous drugs of bacillary strains from initial tuberculosis in children].
Topics: Aminosalicylic Acid; Antitubercular Agents; Bacillus; Humans; Isoniazid; Lacticaseibacillus casei; M | 1956 |
[Sensitivity to antituberculous drugs of bacillary strains from initial tuberculosis in children].
Topics: Aminosalicylic Acid; Antitubercular Agents; Bacillus; Humans; Isoniazid; Lacticaseibacillus casei; M | 1956 |
[Sensitivity to antituberculous drugs of bacillary strains from initial tuberculosis in children].
Topics: Aminosalicylic Acid; Antitubercular Agents; Bacillus; Humans; Isoniazid; Lacticaseibacillus casei; M | 1956 |
[Sensitivity to antituberculous drugs of bacillary strains from initial tuberculosis in children].
Topics: Aminosalicylic Acid; Antitubercular Agents; Bacillus; Humans; Isoniazid; Lacticaseibacillus casei; M | 1956 |
[Indirect appraisal of the contagiosity of isoniazid-treated pulmonary tuberculosis patients by study of contamination methods in primary tuberculosis of children].
Topics: Child; Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Indirect appraisal of the contagiosity of isoniazid-treated pulmonary tuberculosis patients by study of contamination methods in primary tuberculosis of children].
Topics: Child; Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Indirect appraisal of the contagiosity of isoniazid-treated pulmonary tuberculosis patients by study of contamination methods in primary tuberculosis of children].
Topics: Child; Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Indirect appraisal of the contagiosity of isoniazid-treated pulmonary tuberculosis patients by study of contamination methods in primary tuberculosis of children].
Topics: Child; Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Pseudotumoral tuberculous hemiplegia without pulmonary lesion; cure by antibiotic therapy].
Topics: Anti-Bacterial Agents; Child; Hemiplegia; Humans; Infant; Isoniazid; Streptomycin; Tuberculosis; Tub | 1956 |
[Pseudotumoral tuberculous hemiplegia without pulmonary lesion; cure by antibiotic therapy].
Topics: Anti-Bacterial Agents; Child; Hemiplegia; Humans; Infant; Isoniazid; Streptomycin; Tuberculosis; Tub | 1956 |
[Pseudotumoral tuberculous hemiplegia without pulmonary lesion; cure by antibiotic therapy].
Topics: Anti-Bacterial Agents; Child; Hemiplegia; Humans; Infant; Isoniazid; Streptomycin; Tuberculosis; Tub | 1956 |
[Pseudotumoral tuberculous hemiplegia without pulmonary lesion; cure by antibiotic therapy].
Topics: Anti-Bacterial Agents; Child; Hemiplegia; Humans; Infant; Isoniazid; Streptomycin; Tuberculosis; Tub | 1956 |
[Giant, pseudocystic cells and current treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Giant Cells; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Giant, pseudocystic cells and current treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Giant Cells; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Giant, pseudocystic cells and current treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Giant Cells; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Giant, pseudocystic cells and current treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Giant Cells; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Three cases of alcoholic polyneuritis combined with pulmonary tuberculosis; favorable effect of isoniazid therapy on polyneuritis].
Topics: Alcoholic Neuropathy; Alcoholism; Humans; Isoniazid; Neuritis; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Three cases of alcoholic polyneuritis combined with pulmonary tuberculosis; favorable effect of isoniazid therapy on polyneuritis].
Topics: Alcoholic Neuropathy; Alcoholism; Humans; Isoniazid; Neuritis; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Three cases of alcoholic polyneuritis combined with pulmonary tuberculosis; favorable effect of isoniazid therapy on polyneuritis].
Topics: Alcoholic Neuropathy; Alcoholism; Humans; Isoniazid; Neuritis; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Three cases of alcoholic polyneuritis combined with pulmonary tuberculosis; favorable effect of isoniazid therapy on polyneuritis].
Topics: Alcoholic Neuropathy; Alcoholism; Humans; Isoniazid; Neuritis; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
The use of corticosteroids in combination with isonicotinic acid hydrazide in the treatment of advanced bilateral progressive cavitary pulmonary tuberculosis; second report with discussion.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Humans; Isoniazid; Prednisone; Tuberculosis; Tuberculosis, | 1956 |
The use of corticosteroids in combination with isonicotinic acid hydrazide in the treatment of advanced bilateral progressive cavitary pulmonary tuberculosis; second report with discussion.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Humans; Isoniazid; Prednisone; Tuberculosis; Tuberculosis, | 1956 |
The use of corticosteroids in combination with isonicotinic acid hydrazide in the treatment of advanced bilateral progressive cavitary pulmonary tuberculosis; second report with discussion.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Humans; Isoniazid; Prednisone; Tuberculosis; Tuberculosis, | 1956 |
The use of corticosteroids in combination with isonicotinic acid hydrazide in the treatment of advanced bilateral progressive cavitary pulmonary tuberculosis; second report with discussion.
Topics: Adrenal Cortex Hormones; Glucocorticoids; Humans; Isoniazid; Prednisone; Tuberculosis; Tuberculosis, | 1956 |
[Contribution to the long term treatment of urogenital tuberculosis with the combination preparation tebafen].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Urogenit | 1956 |
[Contribution to the long term treatment of urogenital tuberculosis with the combination preparation tebafen].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Urogenit | 1956 |
[Contribution to the long term treatment of urogenital tuberculosis with the combination preparation tebafen].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Urogenit | 1956 |
[Contribution to the long term treatment of urogenital tuberculosis with the combination preparation tebafen].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Urogenit | 1956 |
[Reinfection with isoniazid-resistant Mycobacteria tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidrug-Resistant | 1956 |
[Reinfection with isoniazid-resistant Mycobacteria tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidrug-Resistant | 1956 |
[Reinfection with isoniazid-resistant Mycobacteria tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidrug-Resistant | 1956 |
[Reinfection with isoniazid-resistant Mycobacteria tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidrug-Resistant | 1956 |
[Combination tuberculostatic drug therapy in osteoarticular tuberculosis especially in extra and intrafocal surgery].
Topics: Drug Therapy, Combination; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Osteoarticul | 1956 |
[Combination tuberculostatic drug therapy in osteoarticular tuberculosis especially in extra and intrafocal surgery].
Topics: Drug Therapy, Combination; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Osteoarticul | 1956 |
[Combination tuberculostatic drug therapy in osteoarticular tuberculosis especially in extra and intrafocal surgery].
Topics: Drug Therapy, Combination; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Osteoarticul | 1956 |
[Combination tuberculostatic drug therapy in osteoarticular tuberculosis especially in extra and intrafocal surgery].
Topics: Drug Therapy, Combination; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Osteoarticul | 1956 |
Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients.
Topics: Bacillus; Catalase; Gram-Positive Bacteria; Isoniazid; Oxidation-Reduction; Tuberculosis | 1957 |
Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients.
Topics: Bacillus; Catalase; Gram-Positive Bacteria; Isoniazid; Oxidation-Reduction; Tuberculosis | 1957 |
Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients.
Topics: Bacillus; Catalase; Gram-Positive Bacteria; Isoniazid; Oxidation-Reduction; Tuberculosis | 1957 |
Serum isoniazid levels and catalase activities of tubercle bacilli from isoniazid-treated patients.
Topics: Bacillus; Catalase; Gram-Positive Bacteria; Isoniazid; Oxidation-Reduction; Tuberculosis | 1957 |
[Observations on massive dose isoniazid therapy in adolescent tuberculosis].
Topics: Adolescent; Humans; Isoniazid; Tuberculosis | 1956 |
[Observations on massive dose isoniazid therapy in adolescent tuberculosis].
Topics: Adolescent; Humans; Isoniazid; Tuberculosis | 1956 |
[Observations on massive dose isoniazid therapy in adolescent tuberculosis].
Topics: Adolescent; Humans; Isoniazid; Tuberculosis | 1956 |
[Observations on massive dose isoniazid therapy in adolescent tuberculosis].
Topics: Adolescent; Humans; Isoniazid; Tuberculosis | 1956 |
[Tuberculous super-infection in humans].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Tuberculous super-infection in humans].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Tuberculous super-infection in humans].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Tuberculous super-infection in humans].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Does isonicotinic acid hydrazide prevent or permanently cure experimental tuberculosis?].
Topics: Humans; Isoniazid; Tuberculosis | 1956 |
[Does isonicotinic acid hydrazide prevent or permanently cure experimental tuberculosis?].
Topics: Humans; Isoniazid; Tuberculosis | 1956 |
[Does isonicotinic acid hydrazide prevent or permanently cure experimental tuberculosis?].
Topics: Humans; Isoniazid; Tuberculosis | 1956 |
[Does isonicotinic acid hydrazide prevent or permanently cure experimental tuberculosis?].
Topics: Humans; Isoniazid; Tuberculosis | 1956 |
[Preoperative intrabronchial administration of isoniazid in surgery of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Pulmonary Surgical Procedures; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Preoperative intrabronchial administration of isoniazid in surgery of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Pulmonary Surgical Procedures; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Preoperative intrabronchial administration of isoniazid in surgery of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Pulmonary Surgical Procedures; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Preoperative intrabronchial administration of isoniazid in surgery of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Pulmonary Surgical Procedures; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
On the role of isoniazid in the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Tuberculosis | 1956 |
On the role of isoniazid in the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Tuberculosis | 1956 |
On the role of isoniazid in the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Tuberculosis | 1956 |
On the role of isoniazid in the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Tuberculosis | 1956 |
Isoniazid salt of para-aminosalicylic acid in the treatment of tuberculosis; a preliminary report.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Sodium Chloride; Sodium Chloride, Dietary; Tuberculosis | 1956 |
Isoniazid salt of para-aminosalicylic acid in the treatment of tuberculosis; a preliminary report.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Sodium Chloride; Sodium Chloride, Dietary; Tuberculosis | 1956 |
Isoniazid salt of para-aminosalicylic acid in the treatment of tuberculosis; a preliminary report.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Sodium Chloride; Sodium Chloride, Dietary; Tuberculosis | 1956 |
Isoniazid salt of para-aminosalicylic acid in the treatment of tuberculosis; a preliminary report.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Sodium Chloride; Sodium Chloride, Dietary; Tuberculosis | 1956 |
[Experimental basis and practical possibility of application in man of the new method of antituberculous chemoprophylaxis by means of isoniazid].
Topics: Chemoprevention; Humans; Isoniazid; Male; Tuberculosis | 1956 |
[Experimental basis and practical possibility of application in man of the new method of antituberculous chemoprophylaxis by means of isoniazid].
Topics: Chemoprevention; Humans; Isoniazid; Male; Tuberculosis | 1956 |
[Experimental basis and practical possibility of application in man of the new method of antituberculous chemoprophylaxis by means of isoniazid].
Topics: Chemoprevention; Humans; Isoniazid; Male; Tuberculosis | 1956 |
[Experimental basis and practical possibility of application in man of the new method of antituberculous chemoprophylaxis by means of isoniazid].
Topics: Chemoprevention; Humans; Isoniazid; Male; Tuberculosis | 1956 |
[Experimental tuberculosis in guinea pigs under the influence of tuberculostatic agents].
Topics: Animals; Antitubercular Agents; Guinea Pigs; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Experimental tuberculosis in guinea pigs under the influence of tuberculostatic agents].
Topics: Animals; Antitubercular Agents; Guinea Pigs; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Experimental tuberculosis in guinea pigs under the influence of tuberculostatic agents].
Topics: Animals; Antitubercular Agents; Guinea Pigs; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Experimental tuberculosis in guinea pigs under the influence of tuberculostatic agents].
Topics: Animals; Antitubercular Agents; Guinea Pigs; Isoniazid; Streptomycin; Tuberculosis | 1956 |
Dermatoses in patients receiving chemotherapy for systemic tuberculosis.
Topics: Drug Eruptions; Humans; Isoniazid; Skin Diseases; Streptomycin; Tuberculosis | 1957 |
Dermatoses in patients receiving chemotherapy for systemic tuberculosis.
Topics: Drug Eruptions; Humans; Isoniazid; Skin Diseases; Streptomycin; Tuberculosis | 1957 |
Dermatoses in patients receiving chemotherapy for systemic tuberculosis.
Topics: Drug Eruptions; Humans; Isoniazid; Skin Diseases; Streptomycin; Tuberculosis | 1957 |
Dermatoses in patients receiving chemotherapy for systemic tuberculosis.
Topics: Drug Eruptions; Humans; Isoniazid; Skin Diseases; Streptomycin; Tuberculosis | 1957 |
[Comparative study of the results of tuberculostatic agents with and without prednisolone in therapy of common phthisis].
Topics: Aminosalicylic Acid; Antitubercular Agents; Humans; Isoniazid; Prednisolone; Streptomycin; Tuberculo | 1956 |
[Comparative study of the results of tuberculostatic agents with and without prednisolone in therapy of common phthisis].
Topics: Aminosalicylic Acid; Antitubercular Agents; Humans; Isoniazid; Prednisolone; Streptomycin; Tuberculo | 1956 |
[Comparative study of the results of tuberculostatic agents with and without prednisolone in therapy of common phthisis].
Topics: Aminosalicylic Acid; Antitubercular Agents; Humans; Isoniazid; Prednisolone; Streptomycin; Tuberculo | 1956 |
[Comparative study of the results of tuberculostatic agents with and without prednisolone in therapy of common phthisis].
Topics: Aminosalicylic Acid; Antitubercular Agents; Humans; Isoniazid; Prednisolone; Streptomycin; Tuberculo | 1956 |
The course of experimental tuberculosis inhibited by isoniazid.
Topics: Isoniazid; Tuberculosis | 1957 |
Cycloserine alone and in combination with other drugs in experimental guinea pig tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Guinea Pigs; Isoniazid; Niacin; Nic | 1957 |
[Virulence of tuberculosis bacilli resistant to isoniazid].
Topics: Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virulence | 1955 |
[Study of 88 strains of tuberculosis bacilli isolated from 113 specimens from pleuropulmonary tuberculosis lesions].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tuberculosis | 1955 |
[Action of isonicothydrazone of m-sulfobenzaldehyde (G 605) on experimental tuberculosis in guinea pigs. I. After inoculation of tubercle bacilli sensitive to streptomycin and isoniazid and oral treatment].
Topics: Administration, Oral; Animals; Bacillus; Guinea Pigs; Isoniazid; Lacticaseibacillus casei; Streptomy | 1955 |
[Simultaneous administration of large doses of tuberculin and isoniazid in the treatment of experimental tuberculosis in guinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Tuberculin; Tuberculosis | 1955 |
[The influence of chemotherapy and exercise on experimental tuberculosis].
Topics: Exercise; Isoniazid; Streptomycin; Tuberculosis | 1956 |
[Clinical experiences with pyrazinamide].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Streptomycin; Tuberculosis; T | 1956 |
[Further observations on pyrazinamide].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Isoniazid; Pyrazinamide; Tu | 1956 |
[Further contributions to the study of experimental tuberculosis of the skeleton].
Topics: Isoniazid; Musculoskeletal System; Skeleton; Streptomycin; Tuberculosis; Tuberculosis, Osteoarticula | 1956 |
[Ambulant chemotherapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Experimental studies on the effects of chemotherapy on virulence of tubercle bacteria].
Topics: Bacteria; Isoniazid; Tuberculosis; Virulence | 1957 |
[Chemoprophylaxis against tuberculosis].
Topics: Antibiotic Prophylaxis; Chemoprevention; Humans; Isoniazid; Tuberculosis | 1956 |
Cycloserine combined with other antituberculous agents in the treatment of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Dermatologic Agents; Humans; Isonia | 1957 |
The effect of isoniazid therapy on pyridoxine metabolism in children.
Topics: Biochemical Phenomena; Child; Humans; Infant; Isoniazid; Pyridoxine; Tuberculosis; Tuberculosis, Pul | 1957 |
The influence of streptovaricin used alone and with isoniazid in an experimental tuberculous infection in animals, and some clinical observations.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Isoniazid; Leaders | 1957 |
[Diagnostic value of the inoculation of guinea pigs with pathological matter containing isoniazid-resistant tubercle bacilli].
Topics: Bacillus; Guinea Pigs; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Experimental studies on the effects of isoniazid at the Naples School of Phthisiology].
Topics: Isoniazid; Schools; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Directions for protection against tuberculosis following from promotion and performance of assistance given at the Naples School of Phthisiology; the role of chemotherapeutic prophylaxis and of vaccination].
Topics: BCG Vaccine; Humans; Isoniazid; Mycobacterium bovis; Schools; Tuberculosis; Vaccination | 1956 |
Pyrazinamide together with oxytetracycline in patients with tubercle bacilli resistant to streptomycin, PAS and isoniazid.
Topics: Aminosalicylic Acid; Bacillus; Isoniazid; Lacticaseibacillus casei; Niacin; Nicotinic Acids; Oxytetr | 1957 |
[Treatment of meningeal tuberculosis without intraspinal treatment].
Topics: Dihydrostreptomycin Sulfate; Humans; Isoniazid; Prednisone; Tuberculosis; Tuberculosis, Meningeal | 1956 |
[Chemical prophylaxis in the campaign against tuberculosis; initial clinical results].
Topics: Humans; Isoniazid; Tuberculosis | 1956 |
Response of tuberculosis to intensive combined four drug therapy.
Topics: Aminosalicylic Acid; Dihydrostreptomycin Sulfate; Humans; Isoniazid; Streptomycin; Tuberculosis | 1957 |
[Studies on the types of chemotherapy in tuberculosis. I. The preceding INH treatment, followed by streptomycin-PAS therapy to relatively early cavities].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis | 1957 |
[Transmission of Mycobacteria tuberculosis from patient to patient].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1956 |
[Note on complications imputable to the use of isoniazid in tuberculous children].
Topics: Child; Humans; Isoniazid; Psychology, Child; Tuberculosis | 1956 |
The anti-tuberculosis activity of sulfoniazide.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Immediate results of larusan therapy in tuberculosis of the upper respiratory tract and oral cavity].
Topics: Humans; Isoniazid; Larynx; Mouth; Mouth Diseases; Tuberculosis; Tuberculosis, Laryngeal | 1956 |
[Effect of two modern tuberculostatic drugs on the virulence of Mycobacterium tuberculosis].
Topics: Dihydrostreptomycin Sulfate; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virulence | 1957 |
[New concepts on the resistance to anti-tuberculous drugs].
Topics: Aminosalicylic Acid; Isoniazid; Tuberculosis | 1957 |
[Late positivization of cultures of tuberculosis bacilli; its relation to isoniazid resistance].
Topics: Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1956 |
[Exacerbation and resistance to isonicotinic acid hydrazide in patients with pulmonary tuberculosis treated by antibacterial drugs combined with corticotherapy].
Topics: Anti-Bacterial Agents; Cortisone; Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1956 |
[Hypercorticism & other endocrine disorders in tuberculous meningitis].
Topics: Adrenocortical Hyperfunction; Cushing Syndrome; Endocrine System Diseases; Humans; Isoniazid; Tuberc | 1957 |
[Effects of isoniazid in the tuberculous lymph node localizations in guinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Lymph Nodes; Tuberculosis; Tuberculosis, Lymph Node | 1956 |
[Phagocytosis in the course of tuberculosis. II. Behavior of phagocytosis as compared with M. tuberculosis in tuberculosis treated with antibiotics & chemotherapy].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Humans; Isoniazid; Mycobacterium tuberculosis; P | 1956 |
[Combination of pyrazinamide & isoniazid in experimental tuberculosis in guinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1956 |
[Experimental infection with a combination of sensitive & isoniazid-resistant M. tuberculosis in a healthy & BCG-prevaccinated guinea pig].
Topics: BCG Vaccine; Guinea Pigs; Isoniazid; Mycobacterium bovis; Tuberculosis; Tuberculosis, Multidrug-Resi | 1956 |
[Time instability of isoniazid resistance in M. tuberculosis in vitro & in vivo].
Topics: Biochemical Phenomena; Humans; In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Tuberculo | 1956 |
[Tuberculostatic effect and tolerability of N-acetyl-D-glucosaminylisonicotinic acid hydrazide].
Topics: Anti-Bacterial Agents; Glucosamine; Isoniazid; Tuberculosis | 1957 |
[Animal experiments for intermittent chemotherapy and prevention of tuberculosis. III. Prophylactic studies with isoniazid in massive infection of guinea pigs].
Topics: Animal Experimentation; Animals; Biomedical Research; Guinea Pigs; Isoniazid; Tuberculosis | 1957 |
[Relation between catalase inactivation, decrease in isoniazid sensitivity and virulence in guinea pigs; studies on freshly isolated tuberculosis bacterium strains with differentiable, although total, isoniazid resistance].
Topics: Animals; Biochemical Phenomena; Catalase; Cell Differentiation; Guinea Pigs; Isoniazid; Mycobacteriu | 1957 |
[Preliminary experiences in treatment of tuberculosis with the combination preparation nicoteben comp].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Isoniazid; Methotrexate; P | 1957 |
Endocrine function during treatment of pulmonary tuberculosis with INH.
Topics: Adrenal Cortex; Isoniazid; Steroids; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Combined isoniazid-heterocyclic thiosemicarbazone treatment of tuberculosis].
Topics: Combined Modality Therapy; Humans; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculo | 1957 |
[The mode of action of streptomycin and isoniazid as seen from model tests with killed tubercle bacilli].
Topics: Bacillus; Humans; Isoniazid; Streptomycin; Tuberculosis | 1957 |
[Effect of isoniazid and several p-benzoquinone compounds on experimental tuberculosis in mice].
Topics: Animals; Benzoquinones; Isoniazid; Mice; Muscle Relaxants, Central; Tuberculosis | 1956 |
The diffusion of antibiotics in tuberculous lesions of the lung.
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Tuberculosis as a possible aetiological factor in mental disorder, and the place of isoniazid in treatment; with five illustrative case reports.
Topics: Humans; Isoniazid; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders; Tuberculosis | 1957 |
[Local isoniazid therapy of tuberculous pleural empyema].
Topics: Empyema, Tuberculous; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Contamination by isoniazid-resistant Koch's bacilli resistant Mycobacterium tuberculosis].
Topics: Drug Contamination; Isoniazid; Mycobacterium; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis | 1957 |
Pyrazinamide-isoniazid in patients with previous isoniazid therapy.
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
INHA-PAS in the screening test.
Topics: Aminosalicylic Acid; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Bacteriological observations in orthopedic tuberculosis treated by combined streptomycin and isoniazid therapy.
Topics: Anti-Bacterial Agents; Humans; Isoniazid; Streptomycin; Tuberculosis | 1957 |
The treatment of certain forms of tuberculosis with a combination of prednisone (or hydrocortisone) and antibiotics.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Humans; Hydrocortisone; Iso | 1957 |
Diagnosis and antimicrobial therapy of primary tuberculosis in children.
Topics: Aminosalicylic Acid; Anti-Infective Agents; Isoniazid; Tuberculosis | 1957 |
[The fundamental pathologic finding and its modification by chemotherapy in experimental tuberculosis. II. On the therapeutic effect of various anti-tuberculous compounds containing several benzothiazole derivatives].
Topics: Benzothiazoles; Isoniazid; Streptomycin; Thiazoles; Tuberculosis | 1957 |
[Treatment of primary tuberculosis in children].
Topics: Aminosalicylic Acid; Isoniazid; Tuberculosis | 1957 |
[Possibility of obtaining a prevention & lasting cure in experimental tuberculosis in animals with the use of nicotinic acid hydrazide].
Topics: Biomedical Research; Hydrazines; Isoniazid; Nicotinic Acids; Tuberculosis | 1957 |
[Importance of drug resistance during medical treatment of tuberculosis].
Topics: Drug Resistance; Humans; Isoniazid; Streptomycin; Tuberculosis | 1957 |
[Comparative appreciation of morphological reactions during tuberculosis therapy with antibiotics and chemical preparations in man and in experience].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Isonia | 1957 |
[Experimental study of the use of isoniazid combined with other antibacterial preparations].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Streptomycin; Tuberculosis | 1957 |
[Isoniazid alone in therapy of primary tuberculosis in infants and small children; evaluation of its results in 23 cases].
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis | 1957 |
Effect of certain aromatic amines on serum isoniazid concentrations in tuberculous patients.
Topics: Amines; Humans; Isoniazid; Organic Chemicals; Tuberculosis | 1957 |
[Hemo-sensitive activity of aqueous extracts of BCG sensitive or resistant to isoniazid; antigenic power of these strains].
Topics: Humans; Isoniazid; Mycobacterium bovis; Mycobacterium tuberculosis; Tuberculosis | 1956 |
[Experimental infection and re-infection with isoniazid-resistant Mycobacterium tuberculosis].
Topics: Isoniazid; Mycobacterium; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistan | 1957 |
[Experimental studies on intermittent chemotherapy & chemo-prophylaxis of tuberculosis. IV. Guinea pig experiments on prophylaxis of a minimal infection with intermittent isoniazid administration].
Topics: Guinea Pigs; Isoniazid; Tuberculosis | 1957 |
[Treatment of pulmonary tuberculosis with high alternating dosage of pyrazinamide and isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Clinical trials of a preparation of pyrizinamide and isoniazid base].
Topics: Alkalies; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Chemotherapy of pulmonary tuberculosis with special reference to new results of resistance & virulence research].
Topics: Aminosalicylic Acid; Isoniazid; Research; Streptomycin; Thiosemicarbazones; Tuberculosis; Tuberculos | 1957 |
[Clinical aspects of early diagnosis of synovial articular tuberculosis with special reference to recent insights into the effects of tuberculostatics].
Topics: Early Diagnosis; Humans; Isoniazid; Joints; Streptomycin; Tuberculosis | 1957 |
[Aphasia & right brachial monoplegia during miliary tuberculosis without meningeal involvement in a 3 year old child; recovery with a combination of metacortandracine & antibiotics].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Aphasia; Arm; Child; Hemiplegia; Humans; Infant; | 1957 |
[Comparison of immediate results of isoniazid and metazid therapy of tuberculous patients in sanatoria].
Topics: Hospitals; Isoniazid; Tuberculosis | 1957 |
[Successful isoniazid therapy of two patients with a severe form of lupus tuberculosis complicated by elephantiasic edema].
Topics: Administration, Cutaneous; Edema; Humans; Isoniazid; Tuberculosis; Tuberculosis, Cutaneous | 1957 |
Tuberculosis prophylaxis trials in preview.
Topics: Biomedical Research; Humans; Isoniazid; Tuberculosis | 1957 |
[Effect of BCG on virulent tuberculous infection of guinea pigs treated by isoniazid and streptomycin].
Topics: Animals; BCG Vaccine; Guinea Pigs; Isoniazid; Mycobacterium bovis; Streptomycin; Tuberculosis; Vacci | 1957 |
[Clinical evaluation of 31 cases of pulmonary tuberculosis with isoniazid-resistant bacilli in adults].
Topics: Adult; Bacillus; Humans; Isoniazid; Lacticaseibacillus casei; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Future of one hundred cavitary tuberculosis case declared cured by exclusive and prolonged antibiotic therapy].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Streptomycin; Tuberculosis | 1957 |
[Tuberculous bacilli in bone tuberculosis subjected to antibiotics; therapeutic considerations].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacillus; Gram-Positive Bac | 1957 |
Chemotherapy of tuberculosis. I. Antituberculous activity of verazide and related hydrazones.
Topics: Antitubercular Agents; Humans; Hydrazones; Isoniazid; Tuberculosis | 1957 |
Chemotherapy of tuberculosis. II. Some observations on the pharmacology of verazide.
Topics: Antitubercular Agents; Isoniazid; Tuberculosis | 1957 |
Sensitization to P.A.S., streptomycin, and isoniazid.
Topics: Hypersensitivity; Immune System Diseases; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmo | 1957 |
The rising incidence of isoniazid resistance: its clinical significance.
Topics: Incidence; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Effect of a combination of antituberculous drugs and cortisone on experimental tuberculous meningitis in rabbits].
Topics: Animals; Antitubercular Agents; Cortisone; Humans; Isoniazid; Rabbits; Tuberculosis; Tuberculosis, M | 1957 |
[Experiences with isoniazid-PAS in the treatment of cavernous and exsudative pulmonary tuberculoses in children and adolescents].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Antibacterial isoniazid loading as a test of tubercular activity].
Topics: Anti-Bacterial Agents; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Pyrazinamide-isoniazid mixture in the treatment of chronic pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Therapy of tuberculous meningitis in infants].
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1957 |
[Modern therapy of cutaneous tuberculosis].
Topics: Administration, Cutaneous; Humans; Isoniazid; Tuberculosis; Tuberculosis, Cutaneous; Vitamin D; Vita | 1957 |
[Chemoprophylaxis of tuberculosis].
Topics: Antibiotic Prophylaxis; Chemoprevention; Humans; Isoniazid; Tuberculosis | 1957 |
[Chemoprophylaxis of tuberculosis].
Topics: Biomedical Research; Chemoprevention; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Direct demonstration of heterogenicity of tuberculosis bacillus strains to isoniazid].
Topics: Bacillus; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1957 |
Treatment of tuberculous meningitis with a combination of isonicotinic acid hydrazides, streptomycin and para-aminosalicylic acid.
Topics: Aminosalicylic Acid; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1957 |
[First results in the cure of pulmonary tuberculosis obtained with the combination of nicotinic aldehyde thiosemicarbazone & isoniazid].
Topics: Aldehydes; Isoniazid; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Effect of isoniazid in 10/mg/kg dosage in tuberculosis of the lymph nodes].
Topics: Isoniazid; Lymph Nodes; Tuberculosis; Tuberculosis, Lymph Node | 1957 |
Cyanacethydrazide therapy in pulmonary tuberculosis.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Comparative efficacy of the concurrent use of pyrazinamide and isoniazid with that of other forms of therapy in the treatment of pulmonary tuberculosis.
Topics: Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
The case for the use of isoniazid alone in the treatment of pulmonary tuberculosis in East Africa.
Topics: Africa, Eastern; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Eczematous complications in treatment of tuberculosis; eruptions resulting from combined aminosalicylic acid, dihydrostreptomycin, and isoniazid therapy.
Topics: Aminosalicylic Acid; Dihydrostreptomycin Sulfate; Eczema; Exanthema; Humans; Isoniazid; Tuberculosis | 1957 |
Quantitative studies on human urinary metabolites of tryptophan as affected by isoniazid and deoxypyridoxine.
Topics: Body Fluids; Humans; Isoniazid; Tryptophan; Tuberculosis; Tuberculosis, Pulmonary; Vitamin B 6 | 1957 |
[Antituberculotic effect of isoniazid derivatives in animal experiments].
Topics: Animal Experimentation; Animals; Isoniazid; Tuberculosis | 1957 |
The effects of early isoniazid treatment in experimental guinea pig tuberculosis.
Topics: Guinea Pigs; Isoniazid; Tuberculosis | 1957 |
Atypical histologic aspects of pulmonary tuberculosis as related to attenuation or loss of pathogenicity of isoniazid-resistant strains of M. tuberculosis.
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Pulmonary; Virulence | 1957 |
[Effect of oral administration of isoniazid resistant BCG on experimental tuberculosis infection in rabbits].
Topics: Administration, Oral; Animals; Isoniazid; Mycobacterium bovis; Rabbits; Tuberculosis; Vaccination; V | 1957 |
[PIRAZINAMIDE-ISONIAZID combined therapy for pulmonary tuberculosis; original treatment in cases with unified background factors. I].
Topics: Fibrinogen; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Fundamental pathological findings and their modification by chemotherapy in experimental tuberculosis. VI. Influence on the histological findings of tuberculous liver and lung of guinea pigs].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Liver; Lung; Streptomycin; Tuberculosis | 1957 |
[Research on tuberculosis in mice. VII. Effect & resistance of isonicotinic acid hydrazide methanesulfonate].
Topics: Animals; Isoniazid; Mesylates; Mice; Research; Tuberculosis | 1957 |
[Experiences with the use of isoniazid in tuberculous meningitis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1957 |
[Treatment of blindness associated with tuberculous meningitis].
Topics: Blindness; Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1957 |
[Pyrazinamide & pyrazinamide with isoniazid in pulmonary tuberculosis; comparison with other chemotherapeuticantibiotic combinations].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[A case of Still-Chauffard disease in a boy with tuberculous hilar adenopathy treated with isoniazid & cortisone].
Topics: Arthritis; Arthritis, Rheumatoid; Child; Cortisone; Humans; Infant; Isoniazid; Lymph Nodes; Tubercul | 1957 |
[Cyanacetic acid hydrazide associated with dihydrostreptomycin in the treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acids; Dihydrostreptomycin Sulfate; Humans; Hydrazines; Isoniazid; Tuberculosis; Tube | 1957 |
[Cortisone and derivatives in therapy of pulmonary tuberculosis; case reports].
Topics: Anti-Bacterial Agents; Cortisone; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Failures in tuberculosis therapy and supplementary antibiotic therapy].
Topics: Anti-Bacterial Agents; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Clinical implications of isoniazid blood levels in pulmonary tuberculosis.
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Duration of results in chemotherapy of pulmonary tuberculosis, with special consideration of isoniazid].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Continuous clinical & bacteriological studies on results of prolonged isoniazid & PAS therapy of pulmonary tuberculosis].
Topics: Biomedical Research; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Treatment of tuberculous otitis media by means of antibiotics & isonicotinic acid hydrazid].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Humans; Isoniazid; Isonicotinic Acids; Otitis Me | 1957 |
The relative merits of isoniazid and other therapeutic agents in the treatment of tuberculous meningitis in children: a five-year follow-up.
Topics: Child; Follow-Up Studies; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1957 |
[Results of repeated simultaneous studies on the resistance of Mycobacterium tuberculosis to streptomycin and isoniazid].
Topics: Biochemical Phenomena; Humans; Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tuberculosis | 1957 |
[Concentration of phthivazid in the blood, urine, and pathological foci during inhalation therapy].
Topics: Body Fluids; Isoniazid; Respiratory Therapy; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Studies on larusan in experimental tuberculosis].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1957 |
Prophylactic effects of isoniazid on primary tuberculosis in children; a preliminary report.
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Ineffectiveness of isoniazid in modifying the phenomenon of microbial persistence.
Topics: Isoniazid; Tuberculosis | 1957 |
[Experimental research on reinfections with isoniazid-resistant bacilli].
Topics: Bacillus; Isoniazid; Lacticaseibacillus casei; Tuberculosis | 1957 |
The antituberculous activity of ethyl thiolesters with particular reference to diethyl dithiolisophthalate.
Topics: Animals; Benzoates; Isoniazid; Mice; Streptomycin; Sulfhydryl Compounds; Tuberculosis | 1957 |
Isonicotinoyl hydrazine derivatives and their activity against Mycobacterium tuberculosis in the mouse.
Topics: Animals; Hydrazines; Isoniazid; Mice; Mycobacterium tuberculosis; Tuberculosis | 1957 |
[Studies on the metabolic fate and mechanism of antituberculous activity of derivatives of isonicotinic acid hydrazide. II. The antituberculous activity of derivatives of isonicotinic acid hydrazide].
Topics: Isoniazid; Tuberculosis | 1957 |
[Isonicotinic acid hydrazide as a therapeutic & prognostic means in renal tuberculosis].
Topics: Humans; Isoniazid; Kidney; Prognosis; Tuberculosis; Tuberculosis, Renal | 1957 |
[Treatment of tuberculosis with an INH-thiosemicarbazone preparation].
Topics: Isoniazid; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Treatment of nasal ozena with isonicotinic acid hydrazide; tuberculous etiopathogenesis of ozena].
Topics: Atrophy; Humans; Isoniazid; Nose; Rhinitis; Rhinitis, Atrophic; Skin Diseases; Tuberculosis | 1957 |
[Relations between clinical and bacteriological findings in isoniazid-resistance].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Tests of combined isoniazid and heterocyclic thiosemicarbazone therapy].
Topics: Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Importance of the tuberculin reaction in sanatoria for tuberculous children & adolescents].
Topics: Hospitals; Immune System Phenomena; Isoniazid; Streptomycin; Tuberculin; Tuberculin Test; Tuberculos | 1957 |
[Frequency of tubercle bacilli strains with decreased sensitivity for isoniazid in non-treated tuberculosis in adults & children from 1953 to 1956].
Topics: Adult; Adult Children; Bacillus; Gram-Positive Bacteria; Humans; Hypesthesia; Isoniazid; Lacticaseib | 1957 |
[Comparative effects of combined and continuous streptomycin-PAS and streptomycin-PAS-isoniazid therapy on closure of tuberculous caverns].
Topics: Caves; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
Possible superinfection with isoniazid-resistant tubercle bacilli.
Topics: Bacillus; Gram-Positive Bacteria; Isoniazid; Lacticaseibacillus casei; Medical Records; Superinfecti | 1958 |
[Treatment of experimental tuberculosis in guinea pigs with varying doses of isoniazid].
Topics: Animals; Guinea Pigs; Isoniazid; Tuberculosis | 1957 |
Antituberculous chemoprophylaxis with isoniazid preliminary note.
Topics: Chemoprevention; Child; Humans; Infant; Isoniazid; Tuberculosis | 1958 |
[Combined pyrazinamide and isoniazid in therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Appearance of gynecomastia in pulmonary tuberculosis patients during isoniazid therapy].
Topics: Gynecomastia; Humans; Isoniazid; Male; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Problem of treatment of pulmonary tuberculosis with stroke doses of isoniazid].
Topics: Isoniazid; Stroke; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Experimental studies of anti-tuberculous effect of phthivaside].
Topics: Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1957 |
[Treatment of ocular tuberculosis with saluzid].
Topics: Eye; Head; Humans; Isoniazid; Tuberculosis; Tuberculosis, Ocular | 1957 |
[Clinical importance of isoniazid resistance].
Topics: Humans; Isoniazid; Tuberculosis | 1957 |
Cystic cavities in pulmonary tuberculosis treated with isoniazid.
Topics: Dental Caries; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
Drug-susceptibility testing in tuberculosis; a method using diluted bacterial suspensions for the indirect test.
Topics: Aminosalicylic Acid; Diagnosis, Differential; Humans; Isoniazid; Mycobacterium tuberculosis; Peptic | 1958 |
Further experience with single-drug (isoniazid) therapy in chronic pulmonary tuberculosis; initial therapy with high-dose isoniazid.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Histological studies of the early parenchymal reactions of guinea pigs inoculated with isoniazid-resistant Mycobacterium tuberculosis in crudely and finely dispersed suspension].
Topics: Animals; Guinea Pigs; Isoniazid; Mycobacterium; Mycobacterium tuberculosis; Tuberculosis; Tuberculos | 1957 |
[Experimental findings on acquired tropism in guinea pigs inoculated with isoniazid-resistant bacilli].
Topics: Animals; Bacillus; BCG Vaccine; Gram-Positive Bacteria; Guinea Pigs; Isoniazid; Lacticaseibacillus c | 1957 |
[Behavior of leukocyte osmotic resistance in tuberculous patients treated with isoniazid].
Topics: Isoniazid; Leukocytes; Osmosis; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Cyanacetic acid hydrazide in experimental tuberculosis in mice].
Topics: Animals; Hydrazines; Isoniazid; Mice; Tuberculosis | 1957 |
A preliminary report on the safety and therapeutic activity of a salizid INH derivative.
Topics: Isoniazid; Neuritis; Safety; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
Cycloserine-isoniazid combination therapy in virgin cases of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Dermatologic Agents; Isoniazid; Tub | 1958 |
[Effect of cyanacetic acid hydrazide in anti-tuberculosis therapy on indices of organic resistance; clinico-functional studies].
Topics: Blood Sedimentation; Hydrazines; Isoniazid; Oxygen; Phagocytosis; Tuberculosis; Tuberculosis, Pulmon | 1957 |
[Effect of isoniazid therapy of tuberculosis on blood coagulation; clinico-functional study].
Topics: Blood Coagulation; Humans; Isoniazid; Tuberculosis | 1957 |
[On the so-called chemoprevention of tuberculosis by isoniazid].
Topics: Antibiotic Prophylaxis; Chemoprevention; Humans; Isoniazid; Tuberculosis | 1957 |
[Hearing in patients of meningeal tuberculosis treated with streptomycin, isoniazid and PAS].
Topics: Hearing; Hearing Disorders; Hearing Tests; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meni | 1957 |
[Recent work on the para-aminosalicylic salt of isoniazid].
Topics: Isoniazid; Sodium Chloride, Dietary; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
A case of pulmonary tuberculosis due to isoniazid-resistant, guinea-pig attenuated, Myco. tuberculosis.
Topics: Guinea Pigs; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Weakining of virulence of Mycobacteria tuberculosis induced by isoniazid treatment and significance of such strains for tuberculosis in men].
Topics: Humans; Isoniazid; Male; Mycobacterium tuberculosis; Tuberculosis; Virulence | 1957 |
[Results of prolonged treatment with isoniazid].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Recent tuberculostatic drugs, isoniazid derivatives and combinations in experiments with animals].
Topics: Animals; Isoniazid; Tuberculosis | 1957 |
[Experimental research on chemotherapy and chemoprophylaxis of tuberculosis. V. Testing of virulence and resistance of cultures from tissue of guinea pigs treated with isoniazid].
Topics: Animals; Chemoprevention; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virulenc | 1957 |
Hinconstarch in genito-urinary tuberculosis.
Topics: Isoniazid; Starch; Thiosemicarbazones; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1958 |
Hinconstarch in genitourinary tuberculosis; preliminary report.
Topics: Isoniazid; Starch; Thiosemicarbazones; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1958 |
[Clinical results of the treatment of pulmonary tuberculosis with combination isoniazid & T40; frequency of appearance of isoniazid resistant tubercle bacilli].
Topics: Bacillus; Isoniazid; Lacticaseibacillus casei; Salicylates; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Studies of the combination of isoniazid with a heterocyclic thiosemicarbazone].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Thiosemicarbazones; Tuberculosis | 1957 |
[Treatment of children with isoniazid and PAS during the early period of primary tuberculous infection].
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis | 1957 |
[Deaths from tuberculosis since the advent of isoniazid].
Topics: Death; Humans; Isoniazid; Tuberculosis | 1958 |
[Early results in the treatment of pulmonary tuberculosis with a combination of d-cycloserine & isoniazid in a Sino-Vietnamese environment].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Dermatologic Agents; Isoniazid; Tub | 1957 |
[Isoniazid & hyaluronidase aerosol in bronchial tuberculosis].
Topics: Aerosols; Humans; Hyaluronoglucosaminidase; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Excretion of isoniazid in renal tuberculosis & its resorption by the bladder mucosa].
Topics: Humans; Isoniazid; Kidney; Mucous Membrane; Tuberculosis; Tuberculosis, Renal; Urinary Bladder | 1957 |
[Effects of Staub-Traugott's glucose tolerance test on blood surgar in tuberculotic children treated with isoniazid].
Topics: Blood Glucose; Catabolite Repression; Child; Glucose; Glucose Tolerance Test; Humans; Infant; Isonia | 1957 |
[Allergic edema due to isoniazid therapy of pulmonary tuberculosis].
Topics: Edema; Immune System Diseases; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
[Ultrasonic aerosols in medicine; comparative blood level determination after inhalation & peroral administration of isoniazid in pulmonary tuberculosis].
Topics: Aerosols; Humans; Isoniazid; Medicine; Tuberculosis; Tuberculosis, Pulmonary; Ultrasonics | 1957 |
The effect of chemotherapy on the leukocytic sensitivity to tuberculin in guinea pigs experimentally infected with Mycobacterium tuberculosis H37RV.
Topics: Animals; Guinea Pigs; Immune System Phenomena; Isoniazid; Leukocytes; Mycobacterium tuberculosis; St | 1958 |
Sputkm conversion and the metabolism of isoniazid.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Chromoblastomycosis cured in a tuberculous patient during isoniazid therapy].
Topics: Blastomycosis; Chromoblastomycosis; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1957 |
The influence of ethyl-sulphone (S.N.44) and isoniazid (IHN) on chronic re-infection experimental tuberculosis of guinea-pigs.
Topics: Guinea Pigs; Isoniazid; Leadership; Sulfones; Tuberculosis | 1958 |
[Effects of small doses of streptomycin & isoniazid administered by intradermal route in experimental tuberculosts].
Topics: Humans; Injections, Intradermal; Isoniazid; Streptomycin; Tuberculosis | 1958 |
[Thorn test in tuberculosis in childhood before and during isoniazid treatment].
Topics: Adrenal Cortex; Adrenal Cortex Function Tests; Child; Humans; Infant; Isoniazid; Plant Structures; T | 1958 |
[Animal experimental studies on an intermittent chemotherapy and prophylaxis of tuberculosis. VI. Infection immunity of guinea pigs in a tuberculosis treated prophylactically with isoniazid].
Topics: Animal Experimentation; Animals; Guinea Pigs; Immunity; Isoniazid; Tuberculosis | 1958 |
[Chemotherapy of acute experimental tuberculosis in guinea pigs by intramuscular cycloserine-isoniazid].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Guinea Pigs; Isoniazid; Tu | 1958 |
Pathogenicity of isoniazid-resistant tubercle bacilli.
Topics: Bacillus; Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary; Virulence | 1958 |
[Effects of corticotherapy on experimental tuberculosis due to isoniazid-resistant bacilli in guinea pigs].
Topics: Animals; Bacillus; Gram-Positive Bacteria; Guinea Pigs; Isoniazid; Lacticaseibacillus casei; Prednis | 1957 |
[Use of hyaluronidase to enhance effectiveness of isonicotinic acid hydrazide after intrabronchial instillation].
Topics: Hyaluronoglucosaminidase; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Comparison of the early results of treatment of infiltrative & fibronodular pulmonary tuberculosis with massive doses of isoniazid alone & with pneumothorax].
Topics: Humans; Isoniazid; Lung; Pneumothorax; Pneumothorax, Artificial; Tuberculosis; Tuberculosis, Pulmona | 1958 |
Metal chelates and antitubercular activity. IV. Isonicotinyl hydrazide.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Isoniazid; Metals; Tuberculosis | 1958 |
Tuberculous meningitis occurring during isoniazid therapy.
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, Miliary | 1958 |
[The attitude of tubercle bacilli in sputum, especially on the smear-positive & culture-negative cases. III. The influence of anti-tuberculous agents contained in sputum on culture for tubercle bacilli].
Topics: Aminosalicylic Acid; Bacillus; Humans; Isoniazid; Mycobacterium tuberculosis; Sputum; Streptomycin; | 1958 |
[A. Omodei Zorini's new method of chemoprophylaxis of tuberculosis with isoniazid].
Topics: Chemoprevention; Humans; Isoniazid; Tuberculosis | 1957 |
[Are there tubercular and non-tubercular clinical conditions in which tuberculosis prevention with isoniazid is to be recommended].
Topics: Antibiotic Prophylaxis; Humans; Isoniazid; Tuberculosis | 1957 |
[Isoniazid in prevention of bovine tuberculosis].
Topics: Animals; Biomedical Research; Cattle; Isoniazid; Tuberculosis; Tuberculosis, Bovine | 1957 |
[Chemoprophylaxis of tuberculosis with isoniazid in dispensary practice].
Topics: Antibiotic Prophylaxis; Chemoprevention; Humans; Isoniazid; Tuberculosis | 1957 |
[Chemotherapy of pulmonary tuberculosis with nicoteben-compositum].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Clinical contribution to chemotherapy of pulmonary tuberculosis with reference to isoniazid and PAS].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Several cases of primary tuberculosis in children treated with isoniazid & heterocyclic thiosemicarbazone].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tubercu | 1958 |
[Clinical importance of isoniazid resistance].
Topics: Humans; Isoniazid; Tuberculosis | 1958 |
[Inactivation of isonicotinic acid hydrazide].
Topics: Isoniazid; Tuberculosis | 1958 |
Seromucoid (serum mucoprotein) values in patients undergoing hinconstarch therapy.
Topics: Blood Proteins; Fungi; Isoniazid; Mucoproteins; Orosomucoid; Starch; Thiosemicarbazones; Tuberculosi | 1958 |
[Radiological records of the results of combined pyrazinamide-streptomycin-isoniazid therapy].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Radiology; Streptomycin; Tuberculosis; Tuberculosi | 1958 |
[Liver damage in isoniazid treatment of cutaneous tuberculosis].
Topics: Humans; Isoniazid; Liver Diseases; Tuberculosis; Tuberculosis, Cutaneous | 1958 |
[Incidence of isoniazid therapy of urogenital tuberculosis on laboratory tests].
Topics: Humans; Incidence; Isoniazid; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1958 |
[The effect of isonicotinic acid hydrazide (INAH) on cavities and caseous lesions, especially the effect on caseous material].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
Concentrations of active isoniazid in serum and cerebrospinal fluid of patients with tuberculosis treated with isoniazid.
Topics: Humans; Isoniazid; Tuberculosis | 1958 |
[Clinical results of combined phenylbutazone & isoniazid therapy in pulmonary tuberculosis].
Topics: Isoniazid; Phenylbutazone; Psychotherapy, Multiple; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Method of antituberculosis chemoprophylaxis with isoniazid].
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Chemoprevention; Humans; Isoniazid; Tuberculosis | 1957 |
[Chemotherapeutic properties of methazid in experimental tuberculosis (generalized tuberculosis and tuberculous meningitis)].
Topics: Acute Disease; Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, Miliary | 1958 |
[Biological properties of phthivazid resistant tuberculosis strains].
Topics: Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1958 |
[Treatment of cutaneous tuberculosis with small doses of phthivazid].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Cutaneous | 1958 |
[Saluzid in the treatment of meningeal tuberculosis in children].
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1958 |
[The problem of the so-called viable and non-viable mycobacteria tuberculosis in experimental tuberculosis in guinea pigs treated with large single doses of streptomycin, isoniazid and their combinations].
Topics: Animals; Guinea Pigs; Isoniazid; Nontuberculous Mycobacteria; Streptomycin; Tuberculosis | 1958 |
[Experience with INH-PAS combination in ophthalmology].
Topics: Humans; Isoniazid; Ophthalmology; Tuberculosis; Tuberculosis, Ocular | 1958 |
Chemotherapy of tuberculosis. III. Verazide in the treatment of pulmonary tuberculosis.
Topics: Antitubercular Agents; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Four cases of lichen planus during streptomycin, PAS and isoniazid therapy].
Topics: Isoniazid; Lichen Planus; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
The treatment of pulmonary tuberculosis with prolonged streptomycin, sodium P-aminosalicylate and isoniazid.
Topics: Aminosalicylic Acid; Humans; Isoniazid; Sodium; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
Isoniazid treatment of early ambulant cases of pulmonary tuberculosis.
Topics: Early Ambulation; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Blood and cerebrospinal fluid levels of isoniazid in tuberculous meningitis in children].
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1958 |
The treatment of tuberculosis of the endometrium; a comparison of streptomycin and PAS with streptomycin and isoniazid.
Topics: Endometrium; Female; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Female Genital | 1958 |
[Studies on the changes of the daily amount of tubercle bacilli present in sputum and its resistance against drugs, when patients have been treated with anti-tuberculous agents. I. Combined therapy with pyrazinamide and isonicotinic acid hydrazide].
Topics: Bacillus; Humans; Isoniazid; Lung; Pyrazinamide; Sputum; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Experimental studies on the mode of action of pyrazinamide. I. The relation with isoniazid].
Topics: Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis | 1958 |
[Pyrazinamide-isoniazid combination in treatment of bone tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Osteoarticular | 1958 |
[Protracted triple drug treatment of urogenital tuberculosis (isoniazid with PAS & streptomycin)].
Topics: Dental Care; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Urogenital; Urogenital Sys | 1958 |
Current therapeutics. CXXVI. Isoniazid and related drugs.
Topics: Isoniazid; Tuberculosis | 1958 |
[Interrelation of isonicotinic acid & cyan-acetic acid hydrazides in reference to their tuberculostatic effect].
Topics: Acetates; Cyanides; Isoniazid; Tuberculosis | 1957 |
Psychotic reactions due to anti-tuberculous drugs.
Topics: Humans; Isoniazid; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders; Streptomycin | 1958 |
Massive-dose isoniazid with pyridoxine in chronic pulmonary tuberculosis.
Topics: Humans; Isoniazid; Pyridoxine; Tuberculosis; Tuberculosis, Pulmonary; Vitamin B 6 | 1958 |
The treatment of pulmonary tuberculosis with isoniazid and reduced dose of p-aminosalicylic acid.
Topics: Aminosalicylic Acid; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Isoniazid chemoprophylaxis with concomitant BCG in Espírito Santo].
Topics: BCG Vaccine; Chemoprevention; Humans; Isoniazid; Mycobacterium bovis; Tuberculosis; Vaccination | 1958 |
[Isoniazid chemotherapy and chemoprophylaxis of tuberculosis].
Topics: Chemoprevention; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Large doses of isoniazid in therapy of pulmonary buberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary; Vitamin B 6 | 1958 |
[Isoniazid resistance, its effect on the prognosis and therapy in adolescents].
Topics: Isoniazid; Prognosis; Tuberculosis | 1958 |
[Endocrine disorders caused by tuberculostatics, especially isoniazid].
Topics: Endocrine System Diseases; Isoniazid; Tuberculosis | 1958 |
Studies of the PAS salt of isoniazid in the treatment of tuberculosis.
Topics: Isoniazid; Sodium Chloride; Sodium Chloride, Dietary; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
Clinical use of a single daily dose of para-aminosalicylic acid in association with isoniazid.
Topics: Aminosalicylic Acid; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
An evaluation of chemotherapy in pulmonary tuberculosis. I. High doses of isoniazid with PAS and pyridoxine.
Topics: Isoniazid; Pyridoxine; Tuberculosis; Tuberculosis, Pulmonary; Vitamin B 6 | 1958 |
An evaluation of chemotherapy in pulmonary tuberculosis. II. Daily streptomycin plus high doses of isoniazid with PAS and pyridoxine.
Topics: Isoniazid; Pyridoxine; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary; Vitamin B 6 | 1958 |
Metabolism of isoniazid by Mycobacterium tuberculosis BCG with reference to current theories of the mode of action.
Topics: Isoniazid; Mycobacterium bovis; Mycobacterium tuberculosis; Tuberculosis | 1958 |
[Experimental studies on the effect of certain anti-tuberculous drugs on carboxylase activity in vitro].
Topics: Aminosalicylic Acid; Carboxy-Lyases; In Vitro Techniques; Isoniazid; Lyases; Tuberculosis | 1958 |
Streptomycin and isoniazid in experimental guinea pig tuberculosis infected with kanamycin resistant tubercle bacilli.
Topics: Bacillus; Guinea Pigs; Isoniazid; Kanamycin; Lacticaseibacillus casei; Streptomycin; Tuberculosis | 1958 |
[Studies on the changes of the daily amount of tubercle bacilli present in sputum and its resistance against drugs, when patients have been treated with anti-tuberculous agents. III. Combined therapy with streptomycin, PAS and isoniazid].
Topics: Bacillus; Humans; Isoniazid; Sputum; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Changes in morphology and mode of development of tubercle bacilli and other mycobacteria caused by anti-tuberculous agents. IV. The survival and the recovery of growth of cells after treatment with streptomycin or isoniazid].
Topics: Bacillus; Humans; Isoniazid; Mycobacterium; Mycobacterium tuberculosis; Streptomycin; Tuberculosis | 1958 |
[Simultaneous intravenous administration of PAS, isoniazid and streptomycin in the area of tuberculosis therapy].
Topics: Administration, Intravenous; Isoniazid; Streptomycin; Tuberculosis | 1958 |
Preliminary observations on the development of atypical (chromogenic) variants of the H37Rv strain of M. tuberculosis under the influence of streptomycin and isoniazid in vitro.
Topics: In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tuberculosis | 1958 |
[Initial sensitivity to streptomycin & isoniazid of Mycobacterium tuberculosis isolated from patients with primary pulmonary tuberculosis not yet treated].
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Behavior of antituberculous hemagglutinins, electroretic gamma globulins & blood proteins in rabbits treated with isoniazid & placed in various experimental conditions].
Topics: Agammaglobulinemia; Animals; Blood Proteins; gamma-Globulins; Hemagglutination; Hemagglutination Tes | 1958 |
[Experimental research on the manner of renewal of tuberculous infections of the lymph nodes of guinea pigs treated with isoniazid].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Lymph Nodes; Tuberculosis; Tuberculosis, Lymph Node | 1958 |
[Symptomatic psychoses in (silico-) tuberculosis treated with chemotherapy].
Topics: Humans; Isoniazid; Psychoses, Substance-Induced; Psychotic Disorders; Tuberculosis | 1958 |
[Animal experimental studies on an intermittent chemotherapy and prevention of tuberculosis. VII. Success of continuous and intermittent doses of isoniazid and the triple combination isoniazid, streptomycin, PAS in a therapeutic test in guinea pigs].
Topics: Animal Experimentation; Animals; Guinea Pigs; Isoniazid; Streptomycin; Tuberculosis | 1958 |
[Research on resected lung preparations. II. Relation between isoniazid treatment, biology of causative agent & structure of tuberculous foci].
Topics: Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Methods of testing chemotherapeutic and antibiotic substances in experimental tuberculosis in mice].
Topics: Animals; Anti-Bacterial Agents; Isoniazid; Mice; Streptomycin; Tuberculosis | 1958 |
[The correct way to use combined antituberculosis drugs; on alpha-ethylisonicotinic acid thioamide, a new antituberculosis drug active against isoniazid-resistant bacteria].
Topics: Antitubercular Agents; Bacteria; Humans; Isoniazid; Niacin; Nicotinic Acids; Thioamides; Tuberculosi | 1958 |
[The influence of isoniazid administration on experimental tuberculosis of guinea pigs previously vaccinated with BCG].
Topics: Animals; BCG Vaccine; Guinea Pigs; Isoniazid; Mycobacterium bovis; Tuberculosis; Vaccination | 1958 |
[The action of streptomycin and isoniazid on tuberculous caverns].
Topics: Caves; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Comparative evaluation of immediate results following tubazide and phthivazide therapy of pulmonary tuberculosis in a sanatorium; preliminary communication].
Topics: Communication; Hospitals; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Maleinic acid hydrazid & maleinic acid phenylhydrazid, 2 new antituberculotics].
Topics: Isoniazid; Pyrimidines; Tuberculosis | 1958 |
[A molecular combination of isoniazid and PAS in therapy of tuberculosis].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Intolerance to anti-tuberculosis preparations PAS, isonicotinic acid hydrazide and streptomycin].
Topics: Aminosalicylic Acid; Humans; Hypersensitivity; Immune System Diseases; Isoniazid; Streptomycin; Tube | 1958 |
[Toxic side-effects of antibacterial therapy of tuberculosis and methods of their prevention].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Biomedical Research; Humans; Isoniazid; Streptomycin; Tu | 1958 |
[Indication for and duration of simple oral isoniazid therapy of tuberculous meningitis in children with special reference to the incidence of exacerbations or relapses and the clinical aspects of resistence problems].
Topics: Child; Humans; Incidence; Infant; Isoniazid; Recurrence; Tuberculosis; Tuberculosis, Meningeal | 1958 |
[Epidemiological significance of isoniazid resistance in open tuberculosis].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Isoniazid & recurrence of tuberculosis in diabetics].
Topics: Diabetes Complications; Diabetes Mellitus; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Sensitivity of tuberculous bacillus to streptomycin, isoniazid & para-aminosalicylic acid in 1,879 patients].
Topics: Aminosalicylic Acid; Bacillus; Isoniazid; Streptomycin; Tuberculosis | 1958 |
[Sensitivity of tuberculous bacillus to streptomycin & isoniazid in 243 cases of meningitis].
Topics: Animals; Bacillus; Insecta; Isoniazid; Meningitis; Streptomycin; Tuberculosis; Tuberculosis, Meninge | 1958 |
Report on the use of isoniazid and cycloserine in 84 cases of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Dermatologic Agents; Isoniazid; Tub | 1959 |
Acquired resistance and isoniazid medication.
Topics: Humans; Isoniazid; Tuberculosis | 1959 |
Pyrazinamide in low dosage in combination with isoniazid or paraaminosalicylic acid in the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, P | 1959 |
[Therapeutic effect of combined isoniazid-streptovaricin on experimental tuberculosis of the guinea pig].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Guinea Pigs; Isoniazid; Streptovaricin; Tubercul | 1958 |
[Animal experiments on intermittent chemotherapy and the prevention of tuberculosis. VIII. Tissue bacterial counts in minimally-infected guinea pigs during preventive treatment with isoniazid].
Topics: Animal Experimentation; Animals; Bacterial Load; Guinea Pigs; Isoniazid; Tuberculosis | 1958 |
[Clinical significance of the dynamics of development of isoniazid resistance].
Topics: Biochemical Phenomena; Humans; Isoniazid; Tuberculosis | 1958 |
[Secondary sensitivity to isoniazid].
Topics: Humans; Isoniazid; Tuberculosis | 1958 |
[Problems connected with combination therapy of pulmonary tuberculosis; bacteriological results of monotherapy with isoniazid & combination therapy with isoniazid & streptomycin].
Topics: Combined Modality Therapy; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Poisoning & side-effects produced by isoniazid].
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis | 1958 |
[Behavior of the clinical and serum protein picture in tuberculous patients treated with a heavy metal derivative of isoniazid].
Topics: Blood Proteins; Cobalt; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Clinical study of the use of isonicotinoylhydrazones combined with isonicotinic acid hydrazide in therapy of pulmonary tuberculosis].
Topics: Biomedical Research; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Sulfoniazid, a new anti-tuberculosis chemotherapeutic agent; clinical tests].
Topics: Antineoplastic Agents; Humans; Isoniazid; Tuberculosis | 1958 |
[Studies on INH resistant BCG bacillus].
Topics: Bacillus; Humans; Isoniazid; Mycobacterium bovis; Mycobacterium tuberculosis; Tuberculosis | 1958 |
[Experimental tuberculosis in the guinea pig by intracerebral inoculation of Koch's bacilli isolated from patients treated & not treated with isoniazid].
Topics: Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Vaccination | 1958 |
[Statistical data on the behavior of tuberculosis in children treated in the Pediatric Clinic in the twoyear periods of 1945-46 (pre-antibiotic period), 1950-51 (advent of streptomycin) and 1955-56 (advent of isoniazid)].
Topics: Anti-Bacterial Agents; Child; Humans; Infant; Isoniazid; Streptomycin; Tuberculosis | 1958 |
[Long-term evaluation of isoniazid-PAS in the therapy of pulmonary & extrapulmonary tuberculosis; report on 489 patients from 2 to 72 years of age].
Topics: Humans; Isoniazid; Tuberculosis | 1958 |
Preliminary observations on the induced development of atypical (chromogenic) variants of the H37Rv strain of M. tuberculosis under the influence of streptomycin & isoniazid.
Topics: Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tuberculosis | 1958 |
[Effects of antituberculous drugs on the secretory capacity of a tuberculous kidney].
Topics: Aminosalicylic Acid; Antitubercular Agents; Humans; Isoniazid; Kidney; Streptomycin; Tuberculosis; T | 1958 |
[Experiences with oral BCG therapy in chronic erythema and cutaneous tuberculosis; preliminary report].
Topics: BCG Vaccine; Erythema; Humans; Isoniazid; Mycobacterium bovis; Tuberculosis; Tuberculosis, Cutaneous | 1958 |
[Isonicotinylhydrazone of furyl-2-methyl ketone].
Topics: Furans; Humans; Isoniazid; Ketones; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[First clinical results of an isoniazid derivative (isonicotinylhydrazone of furyl-2-methyl ketone) in pulmonary tuberculosis].
Topics: Furans; Humans; Isoniazid; Ketones; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Preventive chemotherapy of tuberculosis by isoniazid].
Topics: Biomedical Research; Chemoprevention; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1958 |
[Clinical significance of isoniazid resistance in tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis | 1958 |
Experimental reinfection in arrested guinea pig tuberculosis and its behavior under isoniazid therapy.
Topics: Guinea Pigs; Humans; Isoniazid; Tuberculosis | 1959 |
Association between carcinoma of the bladder and pulmonary tuberculosis: evaluation of PAS and INH as carcinogenic agents.
Topics: Aminosalicylic Acid; Carcinogens; Carcinoma; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonar | 1959 |
[Studies on the resistant BCG strain to isonicotinic acid hydrazid (INH). III. Immunogenicity of resistant BCG strain to INH].
Topics: Isoniazid; Isonicotinic Acids; Mycobacterium bovis; Mycobacterium tuberculosis; Tuberculosis | 1959 |
[Intolerance phenomena observed in therapy of tuberculosis with isoniazid & PAS & means of diminishing their effects].
Topics: Isoniazid; Tuberculosis | 1959 |
[Isoniazid chemoprophylaxis & tuberculosis immunity: an experimental study].
Topics: Chemoprevention; Immunity; Isoniazid; Tuberculosis | 1959 |
[Isoniazid load test for evaluation of tuberculous activity; clinical findings].
Topics: Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Concentration of phthivazide in blood, urine and renal tissue in renal tuberculosis].
Topics: Body Fluids; Humans; Isoniazid; Kidney; Tuberculosis; Tuberculosis, Renal | 1959 |
[Antituberculous activity of crotonylidene-isoniazid].
Topics: Isoniazid; Tuberculosis | 1959 |
COMPARATIVE trial of isoniazid in combination with sulphone or PAS in the treatment of acute pulmonary tuberculosis in East Africans; a co-operative investigation in East African hospitals and laboratories with the collaboration of the British Medical Res
Topics: Biomedical Research; Cooperative Behavior; Humans; Isoniazid; Sulfones; Tuberculosis; Tuberculosis, | 1959 |
The use of pyrazinamide plus isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Combined treatment of pulmonary tuberculosis with isoniazid, streptomycin & elpimed & their effect on formation of resistance].
Topics: Combined Modality Therapy; Humans; Immunization, Passive; Isoniazid; Serum; Streptomycin; Tuberculos | 1959 |
[Treatment of skeletal tuberculosis with isoniazid & rehabilitation].
Topics: Isoniazid; Musculoskeletal System; Tuberculosis; Tuberculosis, Osteoarticular | 1959 |
[7 Years of isoniazid therapy].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Cutaneous | 1959 |
Chemotherapy of tuberculosis. IV. Stability of hydrazones of isoniazid in biologic fluids.
Topics: Biological Products; Body Fluids; Feces; Hydrazones; Isoniazid; Tuberculosis | 1959 |
The effect of isoniazid upon the growth of tubercle bacilli from pulmonary lesions.
Topics: Bacillus; Isoniazid; Lacticaseibacillus casei; Physiological Phenomena; Tuberculosis; Tuberculosis, | 1959 |
Catalase and peroxidase activities of isoniazid-susceptible and -resistant strains of M. tuberculosis; relationship between the results of a test for enzymes and those of the indirect drug-susceptibility test.
Topics: Catalase; Humans; Isoniazid; Mycobacterium tuberculosis; Oxidoreductases; Tuberculosis | 1959 |
Toxic psychosis due to isoniazid; report of three cases with studies of patterns of isoniazid inactivation in the serum.
Topics: Isoniazid; Mental Disorders; Psychoses, Substance-Induced; Psychotic Disorders; Tuberculosis; Tuberc | 1959 |
[Effects of isoniazid on immunity acquired by rabbits previously vaccinated with killed M. tuberculosis].
Topics: Animals; Isoniazid; Mycobacterium tuberculosis; Rabbits; Tuberculosis | 1958 |
[Blood protein & electrophoretic picture of rabbits vaccinated with formol-treated Mycobacterium tuberculosis bovis & subsequently treated with isoniazid].
Topics: Animals; Blood Protein Electrophoresis; Blood Proteins; Formaldehyde; Isoniazid; Mycobacterium; Myco | 1958 |
[Nicotinic acid associated with isoniazid in the treatment of experimental ocular tuberculosis].
Topics: Eye; Head; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1958 |
[Studies on the effect of INH on experimental tuberculosis of guinea pig in relation to biologically active blood concentration of the drug. 1].
Topics: Guinea Pigs; Isoniazid; Tuberculosis | 1959 |
[Study of liver function in children during prolonged isoniazid therapy].
Topics: Child; Humans; Infant; Isoniazid; Liver; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Tests of liver function during pyrazinamide therapy].
Topics: Child; Humans; Infant; Isoniazid; Liver; Niacin; Nicotinic Acids; Pyrazinamide; Tuberculosis; Tuberc | 1959 |
[Use of isoniazid para-aminosalicylate in treatment of urogenital tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Humans; Isoniazid; Tuberculosis; Tuberculosis, Urogenit | 1959 |
Chemotherapy of tuberculosis; antituberculous activity of isonicotinoyl-3.4-diethoxybenzal hydrazone (No. 284).
Topics: Humans; Hydrazones; Isoniazid; Tuberculosis | 1959 |
Isoniazid in a probable role in tuberculosis control.
Topics: Isoniazid; Probability; Tuberculosis | 1959 |
The effect of treatment with a large dose of isoniazid on an established tuberculous infection in mice.
Topics: Animals; Isoniazid; Mice; Mycobacterium bovis; Tuberculosis | 1959 |
[Cycloserine and isoniazid combination in therapy of chronic pulmonary tuberculosis].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Dermatologic Agents; Isoniazid; Tub | 1959 |
[Observations on the treatment of pulmonary tuberculosis with sulfoniazid].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Effect of cortisone derivatives on pleural & meningeal permeability to isoniazid].
Topics: Cortisone; Isoniazid; Permeability; Pleura; Prednisone; Tuberculosis; Tuberculosis, Meningeal; Tuber | 1959 |
Cycloserine-isoniazid in the ambulatory treatment of active tuberculosis after failure of previous chemotherapy.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Cycloserine; Dermatologic Agents; Isoniazid; Tub | 1959 |
Isoniazid and para-aminosalicylic acid toxicity in 513 cases: a study including high doses of INH and gastrointestinal intolerance to PAS.
Topics: Aminosalicylic Acid; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Combined drug treatment of tuberculosis. I. Prevention of emergence of mutant populations of tubercle bacilli resistant to both streptomycin and isoniazid in vitro.
Topics: Bacillus; Biomedical Research; Gram-Positive Bacteria; Humans; In Vitro Techniques; Isoniazid; Mycob | 1959 |
Combined drug treatment of tuberculosis. II. Studies of antimicrobially-active isoniazid and streptomycin serum levels in adult tuberculous patients.
Topics: Adult; Combined Modality Therapy; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmo | 1959 |
A COMPANION for isoniazid.
Topics: Friends; Isoniazid; Sexual Partners; Tuberculosis | 1959 |
[The effectiveness of metazid in the treatment of various clinical forms of tuberculosis in children].
Topics: Antihypertensive Agents; Child; Infant; Isoniazid; Tuberculosis | 1960 |
Observations on cycloserineisoniazid in pulmonary tuberculosis.
Topics: Cycloserine; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Cortisone and tuberculin as adjuvants to streptomycin and isoniazid in the chemotherapy of experimental tuberculosis in the guinea pig.
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Cortisone; Guinea Pigs; Isoniazid; Streptomycin; Tu | 1961 |
The antitubercular activity of 3-acetylthiopropylene sulphide and 3-(2-furoylthio) propylene sulphide.
Topics: Animals; Antitubercular Agents; Isoniazid; Mice; Mycobacterium tuberculosis; Streptomycin; Sulfides; | 1960 |
The effects of prednisolone, INAH, and a combination of the two on experimental tuberculous cavities in the guinea-pig. 3.
Topics: Guinea Pigs; Isoniazid; Lung; Prednisolone; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Effects of prednisolone and or isoniazid on experimental pulmonary cavitary tuberculosis in guinea pigs. I].
Topics: Animals; Guinea Pigs; Isoniazid; Lung; Prednisolone; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Studies on tuberculosis bacilli resistant to isoniazid. III. Pathogenic potency for man].
Topics: Humans; Isoniazid; Male; Mycobacterium tuberculosis; Tuberculosis | 1960 |
[The effectiveness of metazid in the treatment of patients with tuberculosis of the lungs].
Topics: Antihypertensive Agents; Isoniazid; Tuberculosis | 1960 |
[Treatment of tuberculous meningitis with the p-amino-salicylate of isoniazid (Dipasic)].
Topics: Aminosalicylic Acids; Humans; Isoniazid; Salicylates; Tuberculosis; Tuberculosis, Meningeal | 1960 |
Tuberculous Addison's disease. A case apparently cured by chemotherapy.
Topics: Addison Disease; Adrenal Insufficiency; Humans; Hypoadrenocorticism, Familial; Isoniazid; Medical Re | 1961 |
[On the treatment of freshly diagnosed active pulmonary tuberculosis with special reference to gluronazide].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Clinico-biological observations on the use of verazide in the therapy of pulmonary tuberculosis].
Topics: Antitubercular Agents; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Toxicity of cycloserine combined with isoniazid in the treatment of tuberculosis in children.
Topics: Child; Cycloserine; Humans; Infant; Isoniazid; Tuberculosis | 1961 |
Report on the use of cycloserine and isoniazid in twenty-seven cases of pulmonary tuberculosis in psychotic patients.
Topics: Cycloserine; Isoniazid; Mental Disorders; Psychotic Disorders; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[The distribution of isoniazid in the organs of the guinea pig. Research with labeled INH].
Topics: Guinea Pigs; Isoniazid; Research; Tuberculosis | 1960 |
[Accidents induced by isoniazid during prolonged treatments of tuberculosis in children. I. Clinical study. II. Interpretation. III. Biological results].
Topics: Accidents; Brain; Brain Diseases; Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Meni | 1960 |
[A study of the effect of metazid in experimental conditions in tuberculosis].
Topics: Antihypertensive Agents; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1960 |
Critical evaluation of a recent trial of isoniazid prophylaxis.
Topics: Antibiotic Prophylaxis; Humans; Isoniazid; Tuberculosis | 1961 |
[On the therapeutic use of sulfoniazid in tuberculosis].
Topics: Humans; Isoniazid; Kidney; Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis, Renal | 1961 |
[Results of the use of metazid in the treatment of tuberculosis in children].
Topics: Antihypertensive Agents; Child; Infant; Isoniazid; Tuberculosis | 1960 |
[Treatment of tuberculosis with massive doses of isoniazid in combination with streptomycin or PAS].
Topics: Antitubercular Agents; Isoniazid; Streptomycin; Tuberculosis | 1961 |
[On the problem of the effect of therapeutic administration of phthivazide on vitamin B6 and nicotinic acid in patients with tuberculosis of the lungs].
Topics: Biochemical Phenomena; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Vitamin B 6 | 1960 |
[On excretion in the urine of the products of transformation of the hydrazide of isonicotinic acid, phtivazid and metazid in patients with tuberculosis of the lungs].
Topics: Antihypertensive Agents; Body Fluids; Humans; Isoniazid; Isonicotinic Acids; Tuberculosis; Tuberculo | 1960 |
[Inactivation of the hydrazide of isonicotinic acid and its derivatives phtivazid and metazid in the body of various types of animals].
Topics: Anti-Bacterial Agents; Antihypertensive Agents; Isoniazid; Isonicotinic Acids; Tuberculosis | 1960 |
Retreatment of pulmonary tuberculosis. Experiences with various combinations of pyrazinamide, cycloserine, and kanamycin in patients excreting tubercle bacilli resistant to both streptomycin and isoniazid.
Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Humans; Isoniazid; Kanamycin; Pyrazinamide; Retreatmen | 1960 |
The differential diagnosis of toxic depression in pulmonary tuberculosis.
Topics: Depression; Depressive Disorder; Diagnosis, Differential; Humans; Isoniazid; Tuberculosis; Tuberculo | 1960 |
[Clinical experiences with nicoteben treatment of 578 patients with pulmonary tuberculosis].
Topics: Isoniazid; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Results of metazid treatment of tuberculosis in children].
Topics: Antihypertensive Agents; Child; Infant; Isoniazid; Tuberculosis | 1960 |
[The differentiation between isoniazid-inactivating and normally catabolizing patients by means of a simple test].
Topics: Cell Differentiation; Isoniazid; Tuberculosis | 1961 |
The immediate effectiveness of isoniazid chemoprophylaxis as determined by the tuberculin test. A five-year study including 5,555 Navajo and Pueblo children from birth to 15 years of age and the use of isonicotinic acid hydrazide in the prevention of tube
Topics: Antibiotic Prophylaxis; Chemoprevention; Child; Humans; Immune System Phenomena; Infant; Isoniazid; | 1960 |
[Studies on tuberculosis bacilli resistant to isoniazid. I. Introduction and behavior in vitro].
Topics: Humans; In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1960 |
[Studies on tuberculosis bacilli resistant to isoniazid. II. Pathogenic potency for the guinea pig].
Topics: Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1960 |
[Isoniazid chemoprophylaxis and antituberculosis immunity].
Topics: Antitubercular Agents; Chemoprevention; Immunity; Isoniazid; Tuberculosis | 1960 |
Progress in the second and third years of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate.
Topics: Aged; Chronic Disease; Drug Therapy, Combination; Follow-Up Studies; Hospitals; Humans; India; Isoni | 1961 |
Peripheral neuritis due to isoniazid.
Topics: Africa, Eastern; Folic Acid; Humans; India; Isoniazid; Neuritis; Peripheral Nervous System Diseases; | 1960 |
INH prophylaxis and treatment in bovines.
Topics: Animals; Biomedical Research; Cattle; Isoniazid; Tuberculosis; Tuberculosis, Bovine | 1961 |
Prophylactic isoniazid in nurses in a tuberculosis hospital.
Topics: Hospitals, Chronic Disease; Humans; Isoniazid; Nurses; Nursing; Occupational Diseases; Tuberculosis; | 1960 |
[Determination of urinary phthivazid as a control method in chemotherapy of tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Urinary Tract | 1961 |
Comparative study of isoniazid versus no chemotherapy in the prevention of relapse of chronic cavitary tuberculosis.
Topics: Biomedical Research; Chronic Disease; Isoniazid; Recurrence; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Study of isoniazid-resistant tubercle bacilli. II. Comparison between virulence in guinea pigs and mice].
Topics: Animals; Bacillus; Guinea Pigs; Isoniazid; Mice; Tuberculosis; Virulence | 1961 |
The antituberculosis activity of isoniazid in combination with sulfisoxazole (gantrisin). II. The effect of isoniazid in combination with sulfisoxazole on the experimental tuberculosis in guinea pigs and mice.
Topics: Animals; Antitubercular Agents; Guinea Pigs; Isoniazid; Mice; Sulfanilamide; Sulfanilamides; Sulfiso | 1960 |
[Studies on the virulence of tubercle bacilli to mice, with special reference to INH-resistant strains].
Topics: Animals; Bacillus; Isoniazid; Mice; Tuberculosis; Virulence | 1961 |
An increased effect with increased dosage of isoniazid in experimental tuberculosis.
Topics: Isoniazid; Tuberculosis | 1960 |
[Treatment of pulmonary tuberculosis with high dosage of isoniazid derivative (Na-methansulfonate-IHMS) combined with PAS. The results of primary treatment of infiltrative caseous lesions].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Antitubercular "chemoprophylaxis" by means of isoniazid. The situation in Italy.
Topics: Antitubercular Agents; Chemoprevention; Humans; Isoniazid; Italy; Tuberculosis | 1961 |
[First clinical observation on the use of the isonicotinoylhydrazone of 2-furyl methyl ketone in osteoarticular tuberculosis].
Topics: Acetone; Antineoplastic Agents; Isoniazid; Tuberculosis; Tuberculosis, Osteoarticular | 1961 |
[Test for evaluation of the protective power of isoniazid using strain H37 RV tubercle bacilli labeled with C-14].
Topics: Bacillus; Gram-Positive Bacteria; Isoniazid; Lacticaseibacillus casei; Tuberculosis | 1960 |
Drugs other than streptomycin, para-aminosalicylic acid, and isoniazid in the surgical treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Antitubercular Agents; Isoniazid; Pulmonary Surgical Procedures; Streptomycin; | 1961 |
Characteristics of mycobacterial populations found in the sputum of tuberculous patients after prolonged isoniazid therapy.
Topics: Humans; Isoniazid; Sputum; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Chem otherpeutic properties of metazid in experimental tuberculosis. (Generalized tuberculosis and tuberculous meningitis)].
Topics: Acute Disease; Antihypertensive Agents; Isoniazid; Tuberculosis; Tuberculosis, Meningeal; Tuberculos | 1960 |
[On metabolism of isonicotinic acid hydrazide (INH) and alpha-keto acids in tuberculous diabetics].
Topics: Diabetes Mellitus; Glutarates; Humans; Isoniazid; Keto Acids; Tuberculosis | 1960 |
[Isoniazid, ultrasonics-aerosol in the treatment of pulmonary tuberculosis].
Topics: Aerosols; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary; Ultrasonic Therapy; Ultrasonics | 1961 |
[Comparative study between detection of catalases according to Middlebrook's method, isoniazid resistance and the biological test in guinea pigs for the determination of the virulence of Koch's bacillus].
Topics: Animals; Bacillus; Catalase; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Virul | 1961 |
[Influence of the inhibition of the growth of Koch's bacilli by the serum of tuberculous patients on the exactitude of the results of determination of active isoniazid].
Topics: Biological Phenomena; Isoniazid; Leadership; Mycobacterium tuberculosis; Physiological Phenomena; Tu | 1960 |
[Comparison of pathological processes after intranasal and subcutaneous infection of guinea pigs. II. Isonicotinic acid hydrazide (INH) resistant strains of Mycobacterium tuberculosis].
Topics: Administration, Intranasal; Animals; Guinea Pigs; Humans; Isoniazid; Mycobacterium tuberculosis; Tub | 1960 |
[Comparative experimental observations in vivo on the antitubercular activity of isoniazid, of kanamycin and of their association].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Isoniazid; Kanamycin; Tub | 1960 |
Serum isoniazid concentrations in Japanese tuberculosis patients and the effect of the simultaneous administration of PAS.
Topics: Aminosalicylic Acid; Asian People; Humans; Isoniazid; Tuberculosis | 1960 |
Multiplication of Mycobacterium tuberculosis in the cornea and its modification by immunity and by isoniazid.
Topics: Cornea; Isoniazid; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Ocular | 1960 |
Retreatment of tuberculous patients: an experience with the combined use of high doses of isoniazid, pyrazinamide and cycloserine.
Topics: Cycloserine; Isoniazid; Pyrazinamide; Retreatment; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Initial chemotherapy in pulmonary tuberculosis: daily streptomycin with high isoniazid dosage in previously untreated cases.
Topics: Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Treatment of pulmonary tuberculosis with PAS, isoniazid and streptomycin by venous infusions. Hematic concentrations and clinical results].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[The association of nicotinaldehyde thiosemicarbazone and isoniazid in the treatment of pulmonary tuberculosis in adults].
Topics: Aldehydes; Isoniazid; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmo | 1959 |
[Clinical experiences with Iso-Benzacyl in childhood tuberculosis].
Topics: Aminosalicylic Acids; Child; Infant; Isoniazid; Tuberculosis | 1961 |
[Studies on the amino acid in urine of tuberculous patients and on the variation due to administration of isoniazid and vitamin B6].
Topics: Amino Acids; Isoniazid; Tuberculosis; Vitamin B 6 | 1960 |
Effect of cortisone plus antituberculosis agents on tuberculous pneumonia in guinea pigs.
Topics: Animals; Antitubercular Agents; Cortisone; Guinea Pigs; Isoniazid; Lung; Pneumonia; Streptomycin; Tu | 1961 |
Isoniazid medication in tuberculin reactors of all ages: a new pattern in prophylaxis of childhood tuberculosis. A preliminary report.
Topics: Child; Humans; Immune System Phenomena; Infant; Isoniazid; Tuberculin; Tuberculin Test; Tuberculosis | 1961 |
[The therapy of cutaneous tuberculosis with INH (rimifon) from 1952 to 1959 at the Dermatologische Klinik Zuerich].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Cutaneous | 1960 |
[On the use of metazid in the treatment of tuberculous meningitis].
Topics: Antihypertensive Agents; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1960 |
[Studies on double or triple resistance of Mycobacterium tuberculosis. 1. The rate of appearance of double or triple resistance, and the effect of drugs on the appearance of this resistance].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1960 |
[A study on the immunogenity of isonicotinic acid hydrazid-resistant tuberculous bacillus].
Topics: Animals; Bacillus; Humans; Insecta; Isoniazid; Isonicotinic Acids; Mycobacterium tuberculosis; Tuber | 1961 |
[The effect of phthivazide on the blood coagulation factor in tuberculosis patients with hemoptysis and hemorrhage].
Topics: Blood Coagulation; Blood Coagulation Factors; Hemoptysis; Hemorrhage; Humans; Isoniazid; Tuberculosi | 1960 |
The influence of chemoprophylaxis on immunity in experimental tuberculosis.
Topics: Chemoprevention; Immunity; Isoniazid; Leadership; Tuberculosis | 1960 |
[The use of metazid in the treatment of tuberculosis of the lungs].
Topics: Antihypertensive Agents; Isoniazid; Tuberculosis | 1960 |
[Active I.N.H. in the serum and liver function test resuls. Study of 60 subjects].
Topics: Humans; Isoniazid; Liver Function Tests; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[The bacteriostatic antitubercular activity of the blood and cerebrospinal fluid in experimental animals during peroral administration of metazid].
Topics: Animals; Antihypertensive Agents; Antitubercular Agents; Isoniazid; Tuberculosis | 1960 |
[A comparative study of the hydrazide of isonicotinic acid and its derivatives in experimental tuberculosis].
Topics: Anti-Bacterial Agents; Isoniazid; Isonicotinic Acids; Tuberculosis | 1960 |
[The use of metazid in tuberculosis in infants].
Topics: Antihypertensive Agents; Child; Humans; Infant; Isoniazid; Tuberculosis | 1960 |
High dose isoniazid in original and retreatment chemotherapy for pulmonary tuberculosis: clinical, electrophoretic, and bacteriological studies.
Topics: Electrophoresis; Isoniazid; Retreatment; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Effect of hydrazides of aspartic and glutamic acids on tubercle bacilli. III. Effect of aspartic acid hydrazide on the course of experimental tuberculosis in guinea pigs and its comparison with the effect of isonicotinic acid hydrazide].
Topics: Animals; Anti-Bacterial Agents; Aspartic Acid; Bacillus; Glutamates; Guinea Pigs; Isoniazid; Lactica | 1961 |
[The antibacterial action in vivo of a single therapeutic dose of isoniazid in mice infected with Mycobacterium tuberculosis labeled with radiocarbon C-14].
Topics: Animals; Anti-Bacterial Agents; Isoniazid; Mice; Mycobacterium tuberculosis; Tuberculosis | 1960 |
[The future of tuberculous patients treated with isoniazid every three days].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Experience in the use of metazid in tuberculosis of the lungs].
Topics: Antihypertensive Agents; Isoniazid; Tuberculosis | 1960 |
Control study of biologically active isoniazid in serum of children with primary tuberculosis.
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Isoniazid prophylaxis of tuberculous infection in mice.
Topics: Animals; Isoniazid; Mice; Tuberculosis | 1961 |
[Effects of prednisolone and/or isoniazid on experimental pulmonary cavitary tuberculosis in guinea pigs. II].
Topics: Animals; Guinea Pigs; Isoniazid; Lung; Prednisolone; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Endobronchial instillation of isonicotinic acid hydrazide in chronic cavitary pulmonary tuberculosis.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Effect of combined chemotherapy with streptomycin, isoniazid and sulfisoxazole on experimental tuberculosis in mice].
Topics: Animals; Drug Therapy, Combination; Isoniazid; Mice; Streptomycin; Sulfanilamide; Sulfanilamides; Su | 1961 |
[Individual differences in the pattern of resistance development of tubercle bacilli to streptomycin, PAS and isoniazid in tuberculous patients].
Topics: Antitubercular Agents; Bacillus; Individuality; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, | 1960 |
[Corticoids in the treatment of pulmonary tuberculosis. Animal experimental studies. II. The effect of prednisolone on guinea pig tuberculosis treated with isonicotinic acid and streptomycin].
Topics: Adrenal Cortex Hormones; Animals; Guinea Pigs; Isoniazid; Isonicotinic Acids; Lung; Prednisolone; St | 1961 |
Isoniazid and 4-aminobenzoic acid in the treatment of murine tuberculosis.
Topics: 4-Aminobenzoic Acid; Animals; Isoniazid; Mice; Tuberculosis | 1961 |
[Anti-tuberculous properties of ethyl acetoacetate isonicotinoylhydrazone (T-428)].
Topics: Acetoacetates; Isoniazid; Tuberculosis | 1960 |
Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of chemotherapy at home or in sanatorium, and influence of further chemotherapy on the relapse rate.
Topics: Aged; Aminosalicylic Acid; Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Follow | 1960 |
[Importance of the treatment of severe tuberculous primary infection with combined isoniazid and ethioniamide (Th 1314). Role of avitaminosis PP in the origin of therapeutic complications. Possibilities of prevention].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Avitaminosis; Ethionamide; Isoniazid; Niacin; Nicotini | 1961 |
A short-term clinical trial with a combination of INH and PAS in the treatment of tuberculosis in infants and children.
Topics: Aminosalicylic Acid; Child; Humans; Infant; Isoniazid; Tuberculosis | 1961 |
The treatment of pulmonary tuberculosis with isoniazid and sulfadimethoxine: a controlled study.
Topics: Isoniazid; Research Design; Sulfadimethoxine; Sulfanilamide; Sulfanilamides; Sulfonamides; Tuberculo | 1961 |
[Effects of working conditions on chemotherapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Occupational Medicine; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Initial tuberculous infection due to drug-resistant organisms. With a review of the world literature on initial infection due to isoniazid-resistant tubercle bacilli.
Topics: Bacillus; Bacteria; Child; Humans; Infant; Isoniazid; Tuberculosis | 1961 |
Long-term consequences of isoniazid alone as initial therapy.
Topics: Isoniazid; Tuberculosis | 1961 |
[Results of treatment in tuberculous meningitis].
Topics: Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1960 |
[Chemoprophylaxis of tuberculosis].
Topics: Biomedical Research; Chemoprevention; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Ineffectiveness of nicotinamide and isoniazid in the treatment of pulmonary tuberculosis.
Topics: Isoniazid; Niacin; Niacinamide; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[The use of combined nicotinaldehydo-thiosemicarba one and isonicotinic acid hydrazide (GT3) in infantile tuberculosis. Our experience].
Topics: Child; Infant; Isoniazid; Thiosemicarbazones; Tuberculosis | 1959 |
A comparison between the behavior of Eskimos and non-Eskimos to the administration of isoniazid.
Topics: Disease; Humans; Inuit; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Exclusive INH prolonged therapy of tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis | 1960 |
[Animal experimental studies on an intermittent chemotherapy and prevention of tuberculosis. Part 9. Studies on guinea pigs in prevention of a minimal infection with continuous and intermittent doses of isoniazid].
Topics: Animal Experimentation; Animals; Biomedical Research; Guinea Pigs; Isoniazid; Tuberculosis | 1959 |
[Experimental animal studies on an intermittent chemotherapy and prophylaxis of tuberculosis. Part 10. The success of continuous and intermittent administration of INH and the combination INH-streptomycin in tuberculosis in mice].
Topics: Animals; Animals, Laboratory; Isoniazid; Mice; Research; Streptomycin; Tuberculosis | 1960 |
[The experimental bases of chemoprophylaxis of tuberculosis by isonicotinic acid hydrazide (INH)].
Topics: Antibiotic Prophylaxis; Chemoprevention; Isoniazid; Tuberculosis | 1960 |
Bacterial resistance to streptomycin, PAS and isoniazid in untreated patients with symptomatic pulmonary tuberculosis in Ashanti.
Topics: Aminosalicylic Acid; Bacterial Infections; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulm | 1960 |
The initiation of chemotherapy in pulmonary tuberculosis in West Africans. Hospital and ambulant treatment compared using streptomycyclidine-isonicotinic acid hydrazide.
Topics: Hospitals; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Treatment of pulmonary tuberculosis. Massive doses of isoniazid].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
An evaluation of chemotherapy in pulmonary tuberculosis. High doses of isoniazid and PAS versus daily streptomycin with high doses of isoniazid and PAS.
Topics: Aminosalicylic Acid; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Chemoprophylaxis of complications of tuberculosis in children and adolescents].
Topics: Adolescent; Chemoprevention; Child; Humans; Infant; Isoniazid; Tuberculosis | 1960 |
Primary tuberculosis and converters and the rationale of treatment.
Topics: Humans; Isoniazid; Tuberculosis | 1960 |
[Evaluation of properties of pathogenic INH-resistant tubercle bacilli after intradermal infection of guinea pigs].
Topics: Animals; Bacillus; Gram-Positive Bacteria; Guinea Pigs; Isoniazid; Lacticaseibacillus casei; Tubercu | 1960 |
[The course of tuberculous processes in guinea pigs after the infection with tubercle bacilli resistant to the effect of isonicotinic acid hydrazide (INH)].
Topics: Animals; Bacillus; Gram-Positive Bacteria; Guinea Pigs; Isoniazid; Lacticaseibacillus casei; Tubercu | 1960 |
Pyrazinamide-isoniazid treated tuberculous patients: a five year follow-up.
Topics: Follow-Up Studies; Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Studies of bacillary populations in experimental tuberculosis of mice treated by isoniazid.
Topics: Animals; Bacillus; Isoniazid; Lacticaseibacillus casei; Mice; Tuberculosis | 1960 |
[On various side-effects of isonicotinic acid hydrazide].
Topics: Female; Humans; Isoniazid; Pelvis; Tuberculosis; Tuberculosis, Female Genital; Urinary Tract | 1959 |
[Distribution of isoniazide and bacteriologic findings in the context of pathologic materials of tubercular processes].
Topics: Humans; Isoniazid; Tuberculosis | 1959 |
[Experimental research on the acquisition of antitubercular immunity induced by exogenous bacteria administration repeated during chemoprophylactic treatment with INH].
Topics: Antitubercular Agents; Bacteria; Isoniazid; Tuberculosis | 1959 |
Safe high dosage isoniazid therapy.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary; Vitamin B 6 | 1959 |
[The isonicotonylhydrazone of the furyl-2-methyl ketone in the treatment of female genital tuberculosis].
Topics: Female; Humans; Isoniazid; Ketones; Pelvis; Tuberculosis; Tuberculosis, Female Genital | 1960 |
Infection of children by strains of tubercle bacilli initially resistant to streptomycin or to isoniazid.
Topics: Bacillus; Child; Gram-Positive Bacteria; Humans; Infant; Isoniazid; Lacticaseibacillus casei; Strept | 1959 |
Streptovaricin and isoniazid in the treatment of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Isoniazid; Streptovaricin; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Phenylbutazone and isoniazid in pulmonary tuberculosis.
Topics: Isoniazid; Phenylbutazone; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Clinical usefulness of riboflavin-tagged isoniazid for self-medication in tuberculous patients.
Topics: Isoniazid; Riboflavin; Self Medication; Tuberculosis | 1960 |
A clinical evaluation of thiocarbanidin and isoniazid in the treatment of pulmonary tuberculosis.
Topics: Antitubercular Agents; Isoniazid; Thiourea; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Prophylactic isoniazid: protection of infants in a tuberculosis hospital.
Topics: Child; Hospitals, Chronic Disease; Humans; Infant; Isoniazid; Tuberculosis | 1959 |
[Treatment of tuberculosis on a combined regimen of x-ray and anti-tuberculous drugs. Report 2. An animal experiment as to the effectiveness of a combined regimen of x-ray, streptomycin (SM), isonicotinic acid hydrazide (INH) and/or para-aminosalicylic ac
Topics: Aminosalicylic Acid; Animal Experimentation; Animals; Humans; Isoniazid; Radiotherapy; Streptomycin; | 1959 |
Treatment of tuberculous meningitis.
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1959 |
[Our therapeutic results in genital tuberculosis].
Topics: Aminosalicylic Acid; Isoniazid; Pelvis; Streptomycin; Tuberculosis; Tuberculosis, Female Genital; Tu | 1959 |
[Gonadotropin excretion in pulmonary tuberculosis in men before and during isoniazid treatment].
Topics: Body Fluids; Gonadotropins; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Use of a new drug combination in therapy of tuberculosis].
Topics: Drug Combinations; Isoniazid; Thiosemicarbazones; Tuberculosis | 1960 |
Mass chemoprophylaxis of tuberculosis. The acceptability and untoward side effects of isoniazid in a control study in Greenland.
Topics: Antibiotic Prophylaxis; Chemoprevention; Greenland; Humans; Isoniazid; Tuberculosis | 1960 |
[The inactivation of isoniazid in the rat. Its effects on the results of the chemotherapy of tuberculosis in that species].
Topics: Animals; Isoniazid; Rats; Tuberculosis | 1960 |
[The action of small doses of isoniazid administered by the intradermal route in experimental tuberculosis. Note II. On the subsequent fate of guinea pigs and on their resistance to a second experimental infection].
Topics: Animals; Biochemical Phenomena; Guinea Pigs; Isoniazid; Tuberculosis | 1959 |
[The new antitubercular drugs derived from isoniazid].
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 1960 |
[Action of kanamycin alone and associated with isoniazid in experimental tuberculosis induced by streptomycin-resistant bacteria].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacteria; Isoniazid; Kanamycin; Streptomycin; Tu | 1960 |
Chemotherapeutic studies on INH derivatives & other compounds in experimental tuberculosis.
Topics: Isoniazid; Tuberculosis | 1961 |
A comparison of isoniazid-cycloserine with isoniazid-PAS in the therapy of cavitary pulmonary tuberculosis. X. A report of the Veterans Administration-Armed Forces cooperative study.
Topics: Biomedical Research; Cycloserine; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary; United S | 1960 |
[Experimental tuberculous meningitis in guinea pigs. 3. The effect of the administration of SM or INH alone and of SM. INH and PAS in combination].
Topics: Aminosalicylic Acid; Guinea Pigs; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Menin | 1959 |
[On the correlation of the guinea pig test, the catalase-peroxidase test and INH-resistance of the tuberculosis bacillus].
Topics: Bacillus; Catalase; Coloring Agents; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Oxidoreduct | 1960 |
A retrospective study of cases of pulmonary tuberculosis developing drug resistance.
Topics: Drug Resistance; Isoniazid; Retrospective Studies; Streptomycin; Tuberculosis; Tuberculosis, Multidr | 1960 |
[Combination of a heterocycline thiosemicarbazone and isoniazid in the therapy of extrapulmonary tuberculosis].
Topics: Isoniazid; Thiosemicarbazones; Tuberculosis | 1960 |
The accumulation of isoniazid in tissues, and the course of experimental tuberculosis.
Topics: Animals; Hypersensitivity; Immune System Diseases; Isoniazid; Rats; Tuberculosis | 1960 |
[The chemoprophylaxis of pulmonary tuberculosis. What must one think of it?].
Topics: Chemoprevention; Humans; Isoniazid; Thinking; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Further observations on the isoniazid-resistance, catalase activity, and virulence of M. tuberculosis.
Topics: Catalase; Humans; Isoniazid; Mycobacterium tuberculosis; Oxidation-Reduction; Tuberculosis; Virulenc | 1960 |
[On the chemotherapeutic combined therapy of tuberculosis in childhood (with special reference to nicoteben)].
Topics: Child; Infant; Isoniazid; Psychotherapy, Multiple; Thiosemicarbazones; Tuberculosis | 1960 |
[Effect of isonicotinic acid hydrazide on early experimental tuberculosis of the epididymis in rabbits].
Topics: Animals; Epididymis; Genitalia, Male; Humans; Isoniazid; Lagomorpha; Male; Rabbits; Tuberculosis; Tu | 1959 |
Evaluation of cycloserine with high dosage of isoniazid in chronic treatment-failure pulmonary tuberculosis.
Topics: Cycloserine; Isoniazid; Treatment Failure; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
[Trial of treatment of recent pulmonary tuberculosis patients by isoniazid in massive doses (15 mg kg) without pyridoxine].
Topics: Isoniazid; Pyridoxine; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Unusual reactions to anti-tuberculous chemotherapy.
Topics: Hepatitis; Hepatitis A; Humans; Isoniazid; Pyrazinamide; Tuberculosis; Uric Acid | 1960 |
[Intrathecal hydrocortisone and isoniazid treatment of tuberculous meningitis].
Topics: Hydrocortisone; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1960 |
[Results of treatment of abdominal tuberculosis with antibiotics].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Antibiotics, Antitubercular; Isoniazid; Thiosemicarbazon | 1960 |
[Streptomycin, phthivasid and their combination in the treatment of experimental osteoarticular tuberculosis induced in rabbits by streptomycin sensitive and resistant Mycobacterium tuberculosis].
Topics: Animals; Isoniazid; Mycobacterium tuberculosis; Rabbits; Streptomycin; Tuberculosis; Tuberculosis, O | 1959 |
SEQUENTIAL use of paired combinations of isoniazid, streptomycin, para-aminosalicylic acid, and pyrazinamide. A United States Public Health Service tuberculosis therapy trial.
Topics: Aminosalicylic Acid; Antitubercular Agents; Isoniazid; Pyrazinamide; Streptomycin; Tuberculosis; Uni | 1959 |
[Diagnosis and clinical aspects of urogenital tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Streptomyces; Thiosemicarbazones; Tuberculosis | 1962 |
[Loss of consciousness with relapse during treatment with Rimifon].
Topics: Child; Chronic Disease; Coma; Consciousness; Humans; Infant; Isoniazid; Recurrence; Tuberculosis; Tu | 1961 |
[Further experiments on the use of INH chemoprophylaxis in bovine tuberculosis].
Topics: Animals; Biomedical Research; Cattle; Chemoprevention; Isoniazid; Tuberculosis; Tuberculosis, Bovine | 1961 |
[Prevention of tuberculosis with BCG and isoniazid, alone and in combination, in animal and man].
Topics: Animals; Antibiotic Prophylaxis; BCG Vaccine; Humans; Isoniazid; Male; Mycobacterium bovis; Tubercul | 1962 |
Treatment of tuberculous meningitis.
Topics: Hydrocortisone; Isoniazid; Prednisone; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1962 |
Effect of isoniazid prophylaxis in experimental tuberculosis in guinea pigs. Action of isoniazid in vivo.
Topics: Animals; Guinea Pigs; Isoniazid; Tuberculosis | 1962 |
Intermittent isoniazid therapy for mice.
Topics: Animals; Isoniazid; Lung; Mice; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
The prophylaxis of tuberculosis: a new concept.
Topics: Antibiotic Prophylaxis; Humans; Isoniazid; Tuberculosis | 1962 |
[Crotonylidene--isoniazid in tuberculosis in children. Study of 50 treated cases].
Topics: Child; Humans; Isoniazid; Tuberculosis | 1962 |
[Antitubercular chemioprophylaxis according to the Omodei Zorini method as consolidation therapy in students of the Centro "B.E.F. Vigorelli"].
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Humans; Isoniazid; Students; Tuberculosis | 1961 |
Chemoprophylaxis with isoniazid against aerogenic tuberculous infection in the guinea pig.
Topics: Chemoprevention; Guinea Pigs; Isoniazid; Tuberculosis | 1962 |
[Endobronchial treatment of caverns in the lungs].
Topics: Caves; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
Study methods for checking regularity of isoniazid self-medication in tuberculosis patients.
Topics: Antitubercular Agents; Isoniazid; Self Medication; Tuberculosis | 1962 |
Response of patients infected with isoniazid-resistant tubercle bacilli to treatment with isoniazid plus PAS or isoniazid alone.
Topics: Bacillus; Humans; India; Isoniazid; Sputum; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Tuberculosis morbidity in a controlled trial of the prophylactic use of isoniazid among household contacts.
Topics: Humans; Isoniazid; Morbidity; Safe Sex; Tuberculosis | 1962 |
The chemotherapy and epidemiology of tuberculosis. Some findings of general applicability from the tuberculosis Chemotherapy Centre, Madras.
Topics: Aminosalicylic Acid; Health Facilities; India; Isoniazid; Tuberculosis | 1962 |
Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis.
Topics: Antitubercular Agents; Biological Assay; Female; Hospitalization; Humans; India; Isoniazid; Male; Re | 1961 |
Rate of inactivation of isoniazid in South Indian patients with pulmonary tuberculosis. 3. Serum concentrations of isoniazid produced by three regimens of isoniazid alone and one of isoniazid plus PAS.
Topics: Humans; India; Isoniazid; Microbial Sensitivity Tests; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Pyrazole preparations in the therapy of the a specific inflammatory component of female genital tuberculosis].
Topics: Female; Humans; Isoniazid; Pelvic Inflammatory Disease; Pelvis; Phenylbutazone; Pyrazoles; Streptomy | 1962 |
[The effect of combined streptomycin pantothenate and INH therapy on the otovestibular system in chronic pulmonary tuberculosis patients].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary; Vestibule, Labyrinth | 1962 |
Combined streptomycin and thiacetazone in the treatment of pulmonary tuberculosis resistant to isoniazid and PAS.
Topics: Anti-Bacterial Agents; Isoniazid; Streptomycin; Thioacetazone; Thiosemicarbazones; Tuberculosis; Tub | 1961 |
Treatment of experimental murine tuberculosis with different combinations of isoniazid/streptomycin followed by isoniazid alone.
Topics: Animals; Isoniazid; Mice; Streptomycin; Tuberculosis | 1962 |
[The treatment of experimental tuberculosis in mice by the association of isoniazid and ethionamide in different doses. Application of the results to clinical posology].
Topics: Animals; Antitubercular Agents; Ethionamide; Isoniazid; Mice; Tuberculosis | 1961 |
[Observations on the behavior of some biological indices in pulmonary tuberculosis patients during treatment with microdoses of streptomycin and isoniazid by intradermal route].
Topics: Injections, Intradermal; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
The effect of crotonylidene isonicotinic acid hydrazone (CIH) and mesityl oxide hydrazone (MIH) in experimental tuberculosis.
Topics: Antitubercular Agents; Hexanones; Hydrazines; Hydrazones; Isoniazid; Isonicotinic Acids; Tuberculosi | 1962 |
[Effect of therapy of pulmonary tuberculosis with a combination of Neoiscotin and Erycon].
Topics: Isoniazid; Sulfanilamide; Sulfanilamides; Sulfonamides; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Preliminary study of the therapeutic effects of a single weekly high dose of isoniazid on twenty-nine patients with active pulmonary tuberculosis.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Corticoids in the treatment of lung tuberculosis. Animal experimental studies. VI. Comparative studies on the fine morphological structures of experimentally induced tubercle under prednisolone-streptomycin or isonicotinic acid hydrazidestreptomycin and
Topics: Adrenal Cortex Hormones; Animals; Guinea Pigs; Isoniazid; Isonicotinic Acids; Prednisolone; Streptom | 1962 |
[A study of the effect of saluzid on the metabolism of phosphorus compounds in the liver during experimental tuberculosis with the aid of radioactive phosphorus].
Topics: Isoniazid; Liver; Phosphorus; Phosphorus Compounds; Phosphorus, Dietary; Tuberculosis | 1962 |
Study of eosinophilia in pulmonary tuberculosis during antibiotic and chemotherapy.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Eosinophilia; Isoniazid; Streptomy | 1962 |
[Experimental study on airborne infection with tubercle bacilli, especially infection with the isoniazid-resistant strain and the relation of BCG immunity].
Topics: Bacillus; BCG Vaccine; Isoniazid; Mycobacterium bovis; Tuberculosis; Vaccination | 1961 |
[Studies on the virulence of isoniazid-resistant tubercle bacilli. On the difference in virulence in airborne infection and intravenous infection].
Topics: Bacillus; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary; Virulence | 1961 |
[The problem of rapid inactivation of phthivazid in the body of patients with tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis | 1961 |
Studies on the inactivation of isonicotinyl acid hydrazide in normal subjects and tuberculous patients.
Topics: Anti-Bacterial Agents; Humans; Isoniazid; Tuberculosis | 1962 |
[Studies on the stability of INH and the kinetics of inactivation of Bacterium tuberculosis by INH].
Topics: Humans; Isoniazid; Kinetics; Mycobacterium tuberculosis; Tuberculosis | 1962 |
Ethionamide in re-treatment of eleven patients with pulmonary tuberculosis.
Topics: Ethionamide; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[On the combination of vaccine and chemoprophylaxis in tuberculosis].
Topics: BCG Vaccine; Chemoprevention; Humans; Isoniazid; Mycobacterium bovis; Tuberculosis; Vaccination; Vac | 1961 |
The virulence in the guinea-pig of isoniazid-sensitive tubercle bacilli isolated from South Indian patients before treatment and after three months of chemotherapy.
Topics: Bacillus; Guinea Pigs; Hospitalization; Humans; India; Isoniazid; Mycobacterium tuberculosis; Resear | 1961 |
[On results of the use of INH-sulfisomezole (especially in relation to the surgical treatment of pulmonary tuberculosis)].
Topics: Isoniazid; Sulfamethoxazole; Sulfanilamide; Sulfanilamides; Sulfonamides; Tuberculosis; Tuberculosis | 1961 |
[On ambulant therapy of pulmonary tuberculosis in the aged].
Topics: Aged; Aged, 80 and over; Aminosalicylic Acid; Exercise Therapy; Humans; Isoniazid; Streptomycin; Tub | 1962 |
[Pathohistological changes in tuberculosis of the skin during the process of treatment with phtivazid].
Topics: Administration, Cutaneous; Humans; Isoniazid; Skin; Tuberculosis; Tuberculosis, Cutaneous | 1962 |
[Corticoids in the treatment of pulmonary tuberculosis. III. Comparative studies on the different course of vaccination tuberculosis in guinea pigs during prednisolone or isonicotinic acid hydrazide-streptomycin and isonicotinic acid hydrazidestreptomycin
Topics: Adrenal Cortex Hormones; Animals; Guinea Pigs; Humans; Isoniazid; Isonicotinic Acids; Prednisolone; | 1962 |
Prelimianry observations on the increase in isoniazid resistance of M. tuberculosis H37RV after exposure to an extract of tuberculous tissue.
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1962 |
Progress in the second year of patients with quiescent pulmonary tuberculosis after a year of domiciliary chemotherapy, and influence of further chemotherapy on the relapse rate.
Topics: Aminosalicylic Acid; Chronic Disease; Humans; India; Isoniazid; Recurrence; Tuberculosis; Tuberculos | 1961 |
[Chemioprophylaxis by INH and BCG vaccination].
Topics: Antibiotic Prophylaxis; BCG Vaccine; Humans; Isoniazid; Mycobacterium bovis; Tuberculosis; Vaccinati | 1962 |
[Treatment of isoniazid-resistant tuberculosis].
Topics: Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Tubercul | 1962 |
[Identification of the sources of contagion in various cases of primary tuberculosis resistance].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
The present status of the treatment of tuberculosis of the central nervous system.
Topics: Central Nervous System; Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1963 |
[Comparative results of INH therapy in large doses and routine doses in 160 cases of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
A randomized study of the effects of corticosteroid therapy on healing of pulmonary tuberculosis as judged by clinical, roentgenographic, and physiologic measurements.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Prednisolone; Strepto | 1963 |
[Comparison of hospital treatment and ambulant therapy in patients receiving chemotherapy for the first time].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[On results of examination of drug resistant tubercle bacilli in the sputum before chemotherapy of tuberculosis. 2].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Drug Resistance; Drug Resistance, Microbial; Hu | 1962 |
[Preventive action of drugs prophylaxis in virulent superinfection appearing during isoniazid treatment].
Topics: Humans; Isoniazid; Superinfection; Tuberculosis | 1962 |
The prevention by drug prophylaxis of superinfections in experimental tuberculosis.
Topics: Humans; Infections; Isoniazid; Superinfection; Tuberculosis | 1962 |
[The chemotherapy of renal tuberculosis: statistical observation].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Kanamycin; Kidney; Streptomycin; Sulfa | 1963 |
[Studies on the metabolism of phosphate compounds in experimental pulmonary tuberculosis and the effect of various kinds of antitubercular agents].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Isoniazid; Phosphates; Streptomyci | 1963 |
[Various problems regarding ambulant chemotherapy].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulm | 1962 |
[Streptomycin, dihydrostreptomycin, P.A.S. and isoniazid. Intolerance in the treatment of pulmonary tuberculosis].
Topics: Antitubercular Agents; Dihydrostreptomycin Sulfate; Drug Tolerance; Humans; Isoniazid; Streptomycin; | 1962 |
Chemotherapy of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculos | 1962 |
[Treatment with 1st-line drugs (streptomycin, INH and PAS) in pulmonary tuberculotics without previous treatment. (Preliminary report)].
Topics: Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Residual cerebrospinal hyperalbumin in tuberculous meningitis in adults since the use of isoniazid].
Topics: Adult; Albumins; Cerebrospinal Fluid Proteins; Humans; Isoniazid; Tuberculosis; Tuberculosis, Mening | 1962 |
[INH metabolism and the course of tuberculosis in diabetics].
Topics: Diabetes Mellitus; Humans; Isoniazid; Tuberculosis | 1963 |
[Bronchial tuberculosis since the use of isoniazid].
Topics: Bronchial Diseases; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
The tate of patients with drug-resistant tubercle bacilli and pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Bacillus; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionami | 1962 |
[Antitubercular activity of the calcium methansulfonate of isonicotinic acid hydrazide].
Topics: Antitubercular Agents; Calcium, Dietary; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
The use of chemotherapy as a prophylactic measure in tuberculosis.
Topics: Humans; Isoniazid; Tuberculosis | 1963 |
Catalase of bacilli and of the host.
Topics: Bacillus; Catalase; Gram-Positive Bacteria; Isoniazid; Lacticaseibacillus casei; Liver; Mycobacteriu | 1963 |
[Isolated chromogenic chemoresistant strains of M. tuberculosis (H37 Rv)].
Topics: Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1962 |
[On the effect of antitubercular preparations on thiamine metabolism in pulmonary tuberculosis patients].
Topics: Antitubercular Agents; Humans; Isoniazid; Lung; Thiamine; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
Initial resistance to isoniazid para-aminosal-icylic acid and streptomycin in two areas in Kenya.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Humans; Ison | 1962 |
[Content of phthivazid in the cerebrospinal fluid in tuberculous meningitis in children].
Topics: Cerebrospinal Fluid; Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1963 |
Local treatment of prostatic tuberculosis with a streptomycin gel.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Dihydrostreptomycin Sulfate; Gelatin; Humans; Isoniazid; | 1963 |
[Failure of ambulatory drug treatment for tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[The importance of medical treatment of pulmonary tuberculosis from a new viewpoint].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Dihydrostreptomycin Sulfate; Ethionamide; Ip | 1962 |
Development of drug resistance to isoniazid during desensitization: a report of two cases.
Topics: Drug Resistance; Drug Resistance, Microbial; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
The action of bromosalicylhydroxamic acid (T40) on the biological level of INH and on the emergence of INH-resistant bacilli in combined treatment of tuberculosis.
Topics: Bacillus; Drug Resistance; Drug Resistance, Microbial; Humans; Hydroxamic Acids; Isoniazid; Salicyli | 1962 |
[Corticosteroid treatment of primary tuberculosis].
Topics: Adrenal Cortex Hormones; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary; Viomycin | 1963 |
An evaluation of surveillance methods for self-medication with isoniazid and para-aminosalicylic acid in tuberculous patients.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Research Design; Self Medication; Tube | 1963 |
[Ambulant treatment or hospitalization. An investigation of ambulant chemotherapy].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Hospitalization; Humans; Isoniazid; Streptomycin; Tubercu | 1962 |
[The problem of primary drug resistance and tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; S | 1963 |
The treatment of patients harbouring tubercle bacilli resistant to isoniazid, streptomycin and PAS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Drug Resistance; Drug Resistance, Microbial; Et | 1962 |
[Isoniazid-ethioniamide combination in the treatment of tuberculous meningitis. Superiority of administration by venous route].
Topics: Ethionamide; Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal; Veins | 1962 |
[Association of isoniazid and ethionamide in the treatment of tuberculous meningitis. (Superiority of intravenous administration)].
Topics: Administration, Intravenous; Ethionamide; Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1962 |
[Utilization of isonicotylhydrazide p-aminosalicylate (Rd 328) in high doses in the treatment of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
Ambulatory chemotherapy in a developing country: clinical and epidemiological studies.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Developing Countries; Epidemiologic Studies; Isoniazid; T | 1963 |
[The reaction of neutrophil blood cell as an indication of infectious and drug allergy].
Topics: Communicable Diseases; Drug Hypersensitivity; Humans; Isoniazid; Leukocytes; Neutrophils; Streptomyc | 1962 |
[Drug resistance in patients with pulmonary tuberculosis converted to positive during the course of original treatment and its clinical course].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; S | 1962 |
[Results in the comparison of ambulant therapy and hospitalization].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Hospitalization; Humans; Isoniazid; Streptomycin; Tubercu | 1962 |
[Results of enzyme diagnosis in the therapy of tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Clinical Enzyme Tests; Hydrazines; | 1962 |
[Effect of phthivazid on anti-tubercular immunity and on the level of its development].
Topics: Humans; Isoniazid; Tuberculosis | 1963 |
Ambulant treatment of spinal tuberculosis.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Spinal Fusion; Streptomycin; Tuberculo | 1963 |
[Action of experimental tuberculosis and isoniazid on the mammary gland of the adult male guinea pig].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Mammary Glands, Animal; Mammary Glands, Human; Tuberculosis | 1962 |
[On initially resistant tuberculous bacilli].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Drug Resistance; Drug Resistance, Microbial; Is | 1963 |
[Resistance and survival of bacilli in relapses of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Drug Resistance; Drug Resistance, Microbial; Hu | 1963 |
[Biological effects of repeated subminimal charges of isoniazid-resistant Mycobacterium tuberculosis on the immunologic allergic state. (Experimental investigations). I].
Topics: Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mycobacterium; Mycobacterium tuberculosis; T | 1962 |
[Biological effects of repeated subminimal charges of isoniazid-resistant Mycobacterium tuberculosis on the immunologic allergic state. (Experimental investigations). II].
Topics: Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mycobacterium; Mycobacterium tuberculosis; T | 1962 |
The treatment of pulmonary tuberculosis amongst Africans in Bulawayo. III. Criteria of selection for out-patient status.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Outpatients; Tuberculosis; Tuberculosis, Pulmo | 1963 |
Hypersensitivity to drugs in the treatment of tuberculosis. Rapid desensitization using cortisone acetate.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cortisone; Drug Hypersensitivity; Humans; Hypersensitivit | 1962 |
[Reappraisal of a combination of chemotherapy and irritation treatment in pulmonary tuberculosis].
Topics: Humans; Isoniazid; Lung; Radiotherapy; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[The possible influence of primary resistance on tuberculosis morbidity in adolescent school children].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; M | 1962 |
[Comparative study of different therapeutic procedures in the treatment of pulmonary tuberculotics with bacilli resistant to isoniazid and streptomycin].
Topics: Bacillus; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Lacticaseibacillus casei; | 1962 |
[Even ambulatory INH therapy is problematical].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
The fate of the patient with isoniazid-resistant tuberculosis.
Topics: Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Tuberculosis; Tuberculosis, Multidru | 1962 |
[Pyrazinamide in association with streptomycin, PAS and isoniazid in the therapy of pulmonary tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Pyrazinamide; Streptomycin; Tuberculos | 1962 |
[On the virulence of bacilli highly resistant to INH. Observations for 1 year after airborne infection].
Topics: Bacillus; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis | 1963 |
[Evaluation of different methods of treatment of tuberculous meningitis in children and their effect on the character of further complications].
Topics: Antitubercular Agents; Child; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1963 |
[Tuberculosis in diabetes mellitus].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Diabetes Mellitus; Isoniazid; Tuberculosis | 1962 |
[Combination of INH and nicotinoylaldehyde thiosemicarbazone in the therapy of tuberculosis in children].
Topics: Child; Humans; Isoniazid; Thiosemicarbazones; Tuberculosis | 1962 |
[Comparative study of phthivazid and tubazid metabolism in the body of tuberculosis patients].
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 1962 |
A detailed survey of one hundred cases of pulmonary tuberculosis on domiciliary treatment in the Nyeri District of Kenya.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Kenya; Outpatient Clinics, Hospital; O | 1963 |
The operative treatment of pulmonary tuberculosis in conjunction with specific drugs. Results from the years 1949 to 1955.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Pneumonectomy; Streptomycin; Thoracoplasty; Tu | 1962 |
Preliminary experiments on the use of "the air-tight cultivation method" in determining blood levels of drugs during the chemotherapy of tuberculosis.
Topics: Bacteriological Techniques; Blood Chemical Analysis; Humans; Isoniazid; Mycobacterium tuberculosis; | 1963 |
[Limits of ambulant therapy from the standpoint of hospital treatment].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulm | 1962 |
[Value of anti-tubercular treatment in Addison's disease. Where must the onset of this disease be placed and when must it be treated?].
Topics: Addison Disease; Adrenal Insufficiency; Humans; Hypoadrenocorticism, Familial; Isoniazid; Streptomyc | 1963 |
[The effect of irregular use of antitubercular medication by outpatients on the effectiveness of subsequent sanatorial therapy].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Isoniazid; Outpatients; Streptomyc | 1962 |
[Combined chemotherapy in mouse tuberculosis. Synergistic effect of phenothiazine derivatives with isoniazid. Evaluation with the bacterial count method].
Topics: Animals; Bacterial Load; Drug Therapy, Combination; Isoniazid; Mice; Phenazines; Phenothiazines; Tub | 1963 |
[Considerations on the current treatment of osteoarticular tuberculosis].
Topics: Humans; Isoniazid; Orthopedic Procedures; Orthopedics; Streptomycin; Tuberculosis; Tuberculosis, Ost | 1963 |
[Results of 5-year long-term ambulant INH therapy].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[Tuberculostatics, combination and change of medication].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Streptomyces; Thiosemicarbazones; Tuberculosis | 1962 |
[Directions for the treatment of children with primary pulmonary and hilar lymph node tuberculosis].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Isoniazid; Lymph Nodes; Streptomycin; Tube | 1963 |
Further developments in human and bovine anti-tuberculosis chemoprophylaxis with isoniazid in Italy.
Topics: Animals; Cattle; Chemoprevention; Humans; Isoniazid; Italy; Tuberculosis; Tuberculosis, Bovine | 1963 |
The prognosis of tuberculous meningitis in the isoniazid era.
Topics: Isoniazid; Prognosis; Tuberculosis; Tuberculosis, Meningeal | 1961 |
Chemoprophylaxis of tuberculosis.
Topics: Biomedical Research; Chemoprevention; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Combined treatment of lupus tuberculosus patients with phtivazid, streptomycin and vitamin D-2].
Topics: Administration, Cutaneous; Combined Modality Therapy; Ergocalciferols; Isoniazid; Streptomycin; Tube | 1963 |
[Tuberculous osteoarticular diseases treated with Dipasic].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Tuberculosis; Tuberculosis, Osteoartic | 1963 |
[The choice of drug to be combined with INH in the initial drug therapy of tuberculosis patients].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Streptomycin; Thiosemicarbazones; Tuberculosis | 1962 |
[Recovery results in primary INH resistance].
Topics: Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonar | 1963 |
On corticosteroid therapy in tuberculosis.
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Drug Resistance; Drug Resistance, Microbial; I | 1961 |
Unclassified mycobacteria isolated from human suspect tuberculosis cases in New-foundland: preliminary studies on fifteen strains.
Topics: Guinea Pigs; Humans; Isoniazid; Mycobacterium; Mycobacterium tuberculosis; Streptomycin; Tuberculosi | 1963 |
[The review of medical treatment of pulmonary tuberculosis].
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
Isoniazid prophylaxis in an undeveloped area.
Topics: Humans; Isoniazid; Tuberculosis | 1962 |
[Considerations on a case of asymptomatic hyperplastic tuberculosis of the cecum as an incidental finding during an appendectomy for typical acute appendicitis. Recovery following medical treatment].
Topics: Appendectomy; Appendicitis; Cecal Diseases; Cecum; Humans; Incidental Findings; Isoniazid; Tuberculo | 1962 |
The present status of the treatment of pulmonary tuberculosis.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Humans; Isoniazid; Streptomycin; T | 1963 |
[Various biological tests on several groups of subjects with tuberculosis subjected respectively to monotherapy with isoniazid, viomycin, pyrazinamide, cycloserine, ethioniamide and kanamycin].
Topics: Cycloserine; Ethionamide; Isoniazid; Kanamycin; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary; | 1962 |
[Comparative effects of prednisone and dexamethasone (associated with bacteriostatics) in the clinical course and plasma parameters in pulmonary tuberculosis patients].
Topics: Blood Chemical Analysis; Dexamethasone; Isoniazid; Plasma; Prednisone; Streptomycin; Tuberculosis; T | 1962 |
[Organization of tuberculosis chemoprophylaxis in Belorussian SSR].
Topics: Antitubercular Agents; Chemoprevention; Humans; Isoniazid; Organizations; Republic of Belarus; Tuber | 1963 |
Prevalence and early attack rate of tuberculosis among close family contacts of tuberculous patients in South India under domiciliary treatment with isoniazid plus PAS or isoniazid alone.
Topics: Aminosalicylic Acid; Child; Hospitals; Humans; Incidence; India; Isoniazid; Prevalence; Tuberculosis | 1961 |
JAUNDICE DUE TO ETHIONAMIDE.
Topics: Ethionamide; Geriatrics; Isoniazid; Jaundice; Streptomycin; Toxicology; Tuberculosis; Tuberculosis, | 1963 |
CRYPTOCOCCAL MENINGO-ENCEPHALITIS.
Topics: Amphotericin B; Cryptococcosis; Encephalitis; Humans; Isoniazid; Meningoencephalitis; Streptomycin; | 1963 |
[ON THERAPY DURING EMPLOYMENT IN PULMONARY TUBERCULOSIS IN THE AGED, WITH SPECIAL REFERENCE TO CASES WHERE TREATMENT WAS INEFFECTIVE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Employment; Geriatrics; Hospitalization; Humans; Isoniazi | 1963 |
DRUG THERAPY FOR TUBERCULOUS PATIENTS OUTSIDE THE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Hypersensitivity; Drug Resistance; Drug | 1963 |
A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS.
Topics: Hospitals; Hospitals, Psychiatric; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
PRIMARY CUTANEOUS TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculo | 1963 |
EFFECT OF KANAMYCIN ON GENITOURINARY TUBERCULOSIS: RESULTS WITH A LOW-DOSAGE REGIMEN.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Eruptions; Hearing Disorders; | 1963 |
[THE PROBLEM OF INFECTION WITH DRUG-RESISTANT MICROORGANISMS-TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; J | 1963 |
[RESULTS OF TREATMENT FOR PULMONARY TUBERCULOSIS WITH PRIMARY DRUG RESISTANCE IN OUR SANATORIUM].
Topics: Bacteriological Techniques; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Japan; Kanamycin | 1963 |
[RECURRENCE FOLLOWING CONSERVATIVE THERAPEUTIC PROCEDURES FOR BACILLARY PULMONARY TUBERCULOSIS IN ELDERLY PATIENTS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Isoniazid; Mycobacterium tuberculo | 1963 |
FRACTIONIZATION OF 17-KETOSTEROIDS IN URINE OF PATIENTS TREATED WITH ISONIAZID.
Topics: 17-Ketosteroids; Androsterone; Chromatography; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmon | 1963 |
CATALASE ACTIVITY OF MYCOBACTERIUM TUBERCULOSIS AND PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Catalase; Drug Resistance; Drug Resistance, Microbial; Is | 1963 |
THE ANTITUBERCULOSIS ISONIAZID CHEMOPROPHYLAXIS ON HUMANS AND CATTLE.
Topics: Animals; Antitubercular Agents; BCG Vaccine; Cattle; Chemoprevention; Drug Resistance; Drug Resistan | 1963 |
[SHORT-TERM HOSPITALIZATION IN THE TREATMENT OF ADULT PULMONARY TUBERCULOSIS IN MOROCCO. ITS CAUSES, ITS FORMS, ITS IMMEDIATE RESULTS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Hospitalization; Humans; Isoniazid; Morocco; Radiography, | 1963 |
PROPHYLACTIC TREATMENT OF TUBERCULOSIS.
Topics: Adolescent; BCG Vaccine; Child; Communicable Disease Control; Humans; Infant; Isoniazid; Mycobacteri | 1963 |
[EXPERIMENTAL OBSERVATION ON COMPLEX ANTIBACTERIAL THERAPY IN TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Anti-Bacterial Agents; Guinea Pigs; Insulin; Iso | 1963 |
[SELECTION OF KOCH BACILLI GENETICALLY RESISTANT TO ISONIAZID AND STREPTOMYCIN. OTHER ADVERSE PHENOMENA APPEARING IN THE COURSE OF TREATMENT WITH ISONIAZ AND STREPTOMYCIN].
Topics: Catalase; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mycobacterium tuberculosis; Pharma | 1963 |
[PRELIMINARY REPORT ON CLINICAL FINDINGS ON THE COMBINED TREATMENT OF PULMONARY TUBERCULOSIS WITH ISOXYL, A NEW TUBERCULOSTATIC].
Topics: Antitubercular Agents; Combined Modality Therapy; Cycloserine; Humans; Isoniazid; Oxytetracycline; P | 1963 |
[THE ANTITUBERCULOSIS CHEMOPROPHYLAXIS BY ISONIAZID IN HUMANS AND CATTLE].
Topics: Animals; Antitubercular Agents; BCG Vaccine; Cattle; Chemoprevention; Drug Resistance; Drug Resistan | 1963 |
[CHEMOPROPHYLAXIS. I].
Topics: BCG Vaccine; Chemoprevention; Child; Humans; Isoniazid; Mycobacterium bovis; Tuberculosis; Vaccinati | 1963 |
[THE FOCUS OF INOCULATION IN GUINEA PIGS DURING TREATMENT WITH MORFOZINAMIDE. (INFECTION WITH STRAINS SENSITIVE AND RESISTANT TO CHEMOTHERAPY AND ANTIBIOTICS].
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance; | 1963 |
[METHOD FOR EVALUATING THE STRENGTH OF SYNTHETIC ANTIBIOTICS IN THE BLOOD SERUM DURING CHEMOTHERAPY OF TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antit | 1963 |
TREATMENT OF SKIN TUBERCULOSIS.
Topics: Administration, Cutaneous; Humans; Isoniazid; Tuberculosis; Tuberculosis, Cutaneous | 1963 |
[CONTROLLED TUBERCULOSTATIC THERAPY IN PREVIOUSLY UNTREATED TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulm | 1963 |
ISCHIO-FEMORAL ARTHRODESIS FOR TUBERCULOSIS OF THE HIP.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Arthrodesis; Child; Femur; Femur Head; Hip; H | 1963 |
COMBINED DRUG THERAPY OF PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy, Combination; Isoniazid; Streptomycin; Tuber | 1963 |
SOME OBSERVATIONS IN RELATION TO PROPERDIN SYSTEM. III. RELATION BETWEEN SERUM PROPERDIN LEVEL AND ANTI-TUBERCULOUS DRUG THERAPY IN HUMAN PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Chemical Analysis; Isoniazid; Liver; Properdin; Str | 1963 |
[DISTRIBUTION OF INH LABELED WITH RADIOACTIVE ISOTOPE C-14 IN NORMAL AND TUBERCULOUS GUINEA PIGS].
Topics: Animals; Carbon Isotopes; Guinea Pigs; Isoniazid; Metabolism; Radioisotopes; Research; Tuberculosis | 1962 |
[TREATMENT OF PULMONARY TUBERCULOSIS WITH LARGE DOSES OF INH].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[TESTING FOR ACTIVE INH IN THE CEREBROSPINAL FLUID AND BLOOD OF PATIENTS WITH TUBERCULOUS MENINGOENCEPHALITIS. (PRELIMINARY COMMUNICATION)].
Topics: Blood Chemical Analysis; Cerebrospinal Fluid; Isoniazid; Meningoencephalitis; Tuberculosis; Tubercul | 1963 |
[RESULTS OF THE TREATMENT OF RECENT PULMONARY TUBERCULOSIS WITH LARGE DOSES OF INH].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
HAS CHEMOTHERAPY REDUCED THE INCIDENCE OF GENITOURINARY TUBERCULOSIS?A COMPARISON BASED ON NECROPSY MATERIAL FROM BELLEVUE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Incidence; Isoniazid; Morbidity; Mortality | 1963 |
[LEUCOCYTE FUNCTIONS IN PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Carbon; Isoniazid; Leukocyte Count | 1962 |
MODERN DRUG TREATMENT OF MYCOBACTERIAL DISEASES.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri | 1963 |
PROGRAM AIMED AT ERADICATION OF TUBERCULOSIS.
Topics: Adolescent; Black People; Child; Communicable Disease Control; Geriatrics; Humans; Infant; Isoniazid | 1963 |
[EFFECT OF PROLONGED USE OF PHTHIVAZID ON THIAMINE METABOLISM IN EXPERIMENTAL TUBERCULOSIS].
Topics: Animals; Isoniazid; Lagomorpha; Metabolism; Rabbits; Research; Thiamine; Thiamine Deficiency; Tuberc | 1963 |
[ON THE EFFECTIVENESS OF THE CONSERVATIVE TREATMENT OF PRIMARY TUBERCULOUS OSTITIS IN CHILDREN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Isoniazid; Osteitis; Streptomycin; Tubercu | 1963 |
TOXICITY IN NEWLY DIAGNOSED CASES OF PULMONARY TUBERCULOSIS TREATED WITH ETHIONAMIDE.
Topics: Ethionamide; Isoniazid; Streptomycin; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[RESULTS OF PRELIMINARY ANTIMICROBIAL THERAPY WITH CLASSICAL DRUGS IN RECENT PULMONARY TUBERCULOSIS IN ADOLESCENTS AND ADULTS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Humans; Isoniazid; Str | 1962 |
[EFFECT OF CORTISONE ON THE PENETRATION OF INH LABELED WITH CARBON C-14 INTO ORGANS OF NORMAL AND TUBERCULOUS GUINEA PIGS].
Topics: Carbon; Carbon Isotopes; Carbon Radioisotopes; Cortisone; Guinea Pigs; Isoniazid; Metabolism; Pharma | 1963 |
[DRUGRESISTANCE OF TUBERCLE BACILLI CULTURED FROM TISSUE SAMPLES TAKEN DURING SURGERY OF PATIENTS WITH OSTEOARTICULAR TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Drug Resistance; Drug Resistance, Microbial; Hu | 1963 |
[RELAPSES IN TUBERCULOUS ENCEPHALITIS AND MENINGOENCEPHALITIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Brain Diseases; Child; Encephalitis; Humans; Isoniazid; M | 1962 |
TREATMENT OF RENAL TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drainage; Humans; Isoniazid; Kidney; Mortality; Nephrecto | 1963 |
VIRULENCE IN THE GUINEA-PIG, SUSCEPTIBILITY TO HYDROGEN PEROXIDE, AND CATALASE ACTIVITY OF ISONIAZID-SENSITIVE TUBERCLE BACILLI FROM SOUTH INDIAN AND BRITISH PATIENTS.
Topics: Animals; Bacillus; Catalase; Drug Resistance; Drug Resistance, Microbial; England; Guinea Pigs; Hydr | 1963 |
[CHEMOPROPHYLAXIS OF TUBERCULOSIS IN THE CZECHOSLOVAKIAN SOCIALISTIC REPUBLIC].
Topics: Chemoprevention; Child; Czechoslovakia; Humans; Isoniazid; Preventive Medicine; Research; Socialism; | 1963 |
[THE COMPARATIVE EFFECT OF INH, PHTHIVAZID AND METAZID ON VITAMIN B-6 EXCRETION IN TUBERCULOSIS PATIENTS].
Topics: Antitubercular Agents; Body Fluids; Humans; Isoniazid; Pharmacology; Pyridoxine; Tuberculosis; Urine | 1963 |
PULMONARY ALVEOLAR MICROLITHIASIS IN A CHILD OF THIRTEEN YEARS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Calcification, Physiologic; Calcinosis; Calcu | 1963 |
[ATYPICAL TUBERCULOUS INFECTION OF THE BRAIN].
Topics: Brain; Brain Diseases; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meningeal | 1963 |
[OUR EXPERIENCES WITH DIATHYMOSULFONE + ISONIAZID TREATMENT IN VARIOUS FORMS OF TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Isoniazid; Lymph Nodes; Pneumonia; | 1963 |
SIDE EFFECTS OF AN ANTITUBERCULOUS FIVE-DRUG REGIMEN: ETHIONAMIDE, CYCLOSERINE, PYRAZINAMIDE, VIOMYCIN AND ISONIAZID.
Topics: Amyloidosis; Antitubercular Agents; Cycloserine; Deafness; Drug Hypersensitivity; Duodenal Ulcer; Et | 1963 |
[TUBERCULOSIS PREVENTION].
Topics: BCG Vaccine; Chile; Communicable Disease Control; Humans; Isoniazid; Mass Chest X-Ray; Mycobacterium | 1963 |
[TREATMENT OF INFANTILE TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; Child; Chile; Humans; Infant; Infant, Newbor | 1963 |
RATIONALE OF ECONOMY ON THE DIET IN TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Diet; Diet Therapy; Isoniazid; Streptomycin; Tuberculosis | 1963 |
[THE PROBLEM OF CHRONIC TUBERCULOSIS. ROUND TABLE].
Topics: Isoniazid; Statistics as Topic; Streptomycin; Tuberculosis; Uruguay | 1963 |
TUBERCULOSIS OF THE PERICARDIUM. A LONG-TERM ANALYSIS OF FORTY-FOUR PROVED CASES.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Black People; Blood Circulation Time; Cardiac Surgical Pr | 1964 |
A CASE OF TUBERCULOUS MENINGITIS DEVELOPED DURING THE COURSE OF CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS.
Topics: Antitubercular Agents; Cerebrospinal Fluid; Humans; Isoniazid; Prednisone; Tuberculosis; Tuberculosi | 1963 |
COLLATERAL SUSCEPTIBILITY OF ISONIAZID-RESISTANT TUBERCLE BACILLI TO NITROFURANS.
Topics: Bacillus; Drug Resistance; Drug Resistance, Microbial; Furazolidone; Humans; Isoniazid; Lacticaseiba | 1963 |
SURGICAL TREATMENT OF POTT'S PARAPLEGIA.
Topics: Abscess; Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Paraplegia; Radiography; | 1963 |
OBSERVATIONS ON THE TREATMENT OF TUBERCULOSIS OF URINARY TRACT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Nephrectomy; Streptomycin; Thiosemicar | 1963 |
[EXPERIENCE WITH A NONSPECIFIC ANTIINFLAMMATORY AGENT IN PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents; Cycloserine; Drug Resistance; D | 1963 |
A CLINICAL STUDY OF ISONIAZID INACTIVATION.
Topics: Administration, Oral; Biomedical Research; Blood; Half-Life; Humans; Isoniazid; Metabolism; Pharmaco | 1963 |
[BCG VACCINATION AND PREVENTIVE INH].
Topics: BCG Vaccine; Child; Humans; Infant; Isoniazid; Mycobacterium bovis; Tuberculin Test; Tuberculosis; V | 1963 |
[THERAPEUTIC RESULTS IN 180 ALCOHOLIC PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Adrenocorticotropic Hormone; Alcoholism; Aminosalicylic Acid; Aminosalicylic Acids; Empyema; Empyema | 1963 |
[PREVENTION OF DRUG RESISTANCE FREQUENTLY OCCURRING IN AGED TUBERCULOSIS PATIENTS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Geriatrics; | 1963 |
ORAL OUT-PATIENT CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN WEST AFRICANS.
Topics: Africa; Africa, Western; Aminosalicylic Acid; Aminosalicylic Acids; Body Weight; Drug Resistance; Dr | 1963 |
COMPARATIVE STUDIES IN ISONIAZID AND ACETYLISONIAZID CONCENTRATIONS IN AQUEOUS HUMOUR AND SERUM.
Topics: Aqueous Humor; Blood Chemical Analysis; Chorioretinitis; Chromatography; Eye; Glaucoma; Humans; Ison | 1963 |
[SHOULD PRIMARY TUBERCULOSIS BE TREATED?].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Infant; Infant, Newborn; Isoniazid; Predni | 1963 |
[ON SOME CHANGES OF THE BLOOD CELL COMPOSITION IN ADULT TUBERCULOSIS PATIENTS].
Topics: Adult; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Hypersensitivity; Eosi | 1963 |
EFFECTS OF MEASLES, GAMMA-GLOBULIN-MODIFIED MEASLES AND VACCINE MEASLES ON THE TUBERCULIN TEST.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; gamma-Globulins; Isoniazid; Measles; Measles Vacci | 1964 |
[TREATMENT WITH FIRST LINE DRUGS (S.M.), (I.N.H.) AND (P.A.S.) IN PATIENTS WITH PULMONARY TUBERCULOSIS NEVER TREATED BEFORE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; S | 1963 |
DRUG RESISTANT MYCOBACTERIAL INFECTION AND ITS RESPONSE TO TREATMENT.
Topics: Cycloserine; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium; Mycobact | 1963 |
[PROLONGED CLINICAL AND ROENTGENOLOGICAL FOLLOW-UP OF CHILDREN WITH 1ST SIGNS OF TUBERCULIN ALLERGY].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Follow-Up Studies; Humans; Hypersensit | 1963 |
[RENAL TUBERCULOSIS IN CHILDREN AND ADOLESCENTS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Isoniazid; Kidney; Nephrectomy | 1963 |
THE PREVENTION OF TUBERCULOSIS.
Topics: BCG Vaccine; Biomedical Research; Child; Humans; Infant; Infant, Newborn; Isoniazid; Mycobacterium b | 1963 |
[ON THE ETIOLOGY AND TREATMENT OF ERYTHEMA NODOSUM].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Ascorbic Acid; Erythema Nodosum; Humans; Isoniazid; Mitra | 1963 |
TUBERCULOUS MENINGITIS: PATHOLOGICAL OBSERVATIONS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cerebrovascular Circulation; Dihydrostreptomycin Sulfate; | 1963 |
[PULMONARY TUBERCULOSIS AND METACORTICOID DIABETES].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Dexamethasone; Diabetes Mellitus; Diet; Diet Therapy; Gou | 1963 |
PRIMARY TUBERCULOSIS OF THE CONJUNCTIVA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Child; Conjunctiva; Conjuncti | 1964 |
[THE ACTION OF CORTICOIDS IN TUBERCULOSIS].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Carbon Isotopes; Cortisone; Guinea Pigs; Isoni | 1963 |
[THERAPEUTIC ACTIVITY AND TOLERANCE TO SOME COMBINED ANTIBIOTICS IN TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Blood Chemi | 1963 |
[APROPOS OF 70 TUBERCULOUS MOSLEMS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; France; Isoniazid; Lung; Pneumonectomy; Pneum | 1963 |
[SOURCES OF ERROR IN THE DETERMINATION OF DRUG RESISTANCE OF TUBERCULOSIS BACTERIA].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance, Microbial; Isoniazid; Mycobacterium tube | 1963 |
[CONTRIBUTIONS TO A NEW METHOD OF EVALUATING EARLY THERAPEUTIC RESULTS IN PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Hungary; Isoniazid; Pneumonectomy; Statistics as Topic; S | 1963 |
[EVALUATION OF OUR CASES OF UROGENITAL TUBERCULOSIS DURING THE PAST 5 AND ONE HALF YEARS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Female; Humans; Hungary; Isoniazid; Kidney; Male; Nephrec | 1963 |
[RESEARCH ON LUNG RESECTION PREPARATION. 3. RELATIONS BETWEEN GERM BIOLOGY, GERM NUMBERS AND FOCAL STRUCTURE AFTER INH TREATMENT].
Topics: Humans; Isoniazid; Lung; Mycobacterium tuberculosis; Pathology; Pneumonectomy; Tuberculosis; Tubercu | 1963 |
[CLINICAL VALUE OF THE DETERMINATION OF THE ACTIVE INH LEVEL BY THE VERTICAL DIFFUSION METHOD IN TUBERCULOUS PATIENTS].
Topics: Blood Chemical Analysis; Diffusion; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[BACTERIOLOGICAL STUDIES ON PULMONARY TUBERCULOSIS IN THE AGED].
Topics: Bacteriological Techniques; Catalase; Drug Resistance; Drug Resistance, Microbial; Geriatrics; Human | 1963 |
[EXPERIMENTS IN THE TREATMENT OF EXPERIMENTAL TUBERCULOSIS IN GUINEA PIGS WITH 4,4'-DIISOAMYLOXYTHIOCARBANILIDE (ISOXYL)].
Topics: Antitubercular Agents; Guinea Pigs; Isoniazid; Japan; Kanamycin; Pathology; Phenylthiourea; Streptom | 1963 |
[COMPARATIVE THERAPEUTIC STUDIES IN EXUDATIVE PLEURISY].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Blood Sedimentation; Humans; Iso | 1963 |
RECENT ADVANCES IN TREATMENT OF ORGAN TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Child; Cycloserine; Ethionamide; I | 1964 |
[THERAPY OF CERVICAL LYMPH NODE TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Humans; Isoniazid; Lymph Node Exci | 1963 |
[OUR EXPERIENCES WITH CORTISONE IN THE MANAGEMENT OF RENAL TUBERCULOSIS].
Topics: Cortisone; Humans; Isoniazid; Kidney; Nephrectomy; Prednisolone; Streptomycin; Tuberculosis; Tubercu | 1963 |
[ON THE ETIOPATHOGENESIS OF THE BULLOUS FORMATIONS OF THE TUBERCULAR LUNG].
Topics: Autoantibodies; Isoniazid; Pathology; Pulmonary Emphysema; Toxicology; Tuberculosis; Tuberculosis, P | 1963 |
[URINARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Statistics as Topic; Streptomycin; Surgical Pr | 1963 |
[THE FURTHER COURSE OF PATIENTS WITH PHLYCTENULES. A 1-5 YEAR OBSERVATION PERIOD].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Corneal Ulcer; Eye Manifestations; Iso | 1963 |
[STUDIES ON COMBINED INH-ETHIONAMIDE TREATMENT OF PULMONARY TUBERCULOSIS WITH LOW ETHIONAMIDE DOSAGE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Ethionamide; Humans; Isoniazid; Sputum; Streptomycin; Tub | 1963 |
[DOES THE CHILD REALLY HAVE TUBERCULOSIS?].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; Child; Diagnosis; Humans; Infant; Isoniazid; | 1963 |
(CHEMOTHERAPEUTIC ORIGINAL AND RE-TREATMENT OF PULMONARY TUBERCULOSIS.)
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethionamide; Isoniazi | 1963 |
COMBINED TREATMENT OF PULMONARY TUBERCULOSIS WITH GLYCYRRHIZIN AND INH.
Topics: Combined Modality Therapy; Glycyrrhiza; Glycyrrhizic Acid; Humans; Isoniazid; Tuberculosis; Tubercul | 1963 |
[THE FATE OF OUR PATIENTS WITH INFECTIOUS CAVERNOUS PROCESSES REGISTERED MORE THAN 6 YEARS AGO].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Outpatient Clinics, Hospital; Radiography, Tho | 1963 |
TREATMENT AND CURRENT STATUS OF TUBERCULOUS PERITONITIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Black People; Humans; Isoniazid; Peritoneum; Peritonitis, | 1963 |
A COMPARISON OF THE VIRULENCE IN THE GUINEA-PIG OF TUBERCLE BACILLI FROM THAI AND BRITISH PATIENTS.
Topics: Animals; Autopsy; Bacillus; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; India; Isoniaz | 1963 |
[CURRENT CLINICAL ASPECTS AND TREATMENT OF INTESTINAL TUBERCULOSIS].
Topics: Appendectomy; Crohn Disease; Diagnosis; Diagnosis, Differential; Enteritis; Granuloma; Humans; Isoni | 1963 |
[STUDIES ON THE RELATIONSHIP BETWEEN THE INH-RESISTANCE, CATALASE ACTIVITY AND VIRULENCE OF SOME STRAINS OF MYCOBACTERIUM TUBERCULOSIS AVIUM].
Topics: Animals; Catalase; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Metabolism; Mycobacterium | 1963 |
[BACTERIOLOGICAL RESULTS OF CHEMOTHERAPY OF PRIMARY PULMONARY TUBERCULOSIS IN SCHOOL CHILDREN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Isoniazid; Poland; Statistics as Topic; Streptomyc | 1963 |
[HYPERSENSITIVITY REACTIONS IN TREATMENT WITH BASIC ANTIBACTERIAL DRUGS].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Corti | 1963 |
[DYNAMICS OF THE COEFFICIENT OF SUBOXIDATION OF URINE IN PATIENTS WITH CUTANEOUS TUBERCULOSIS DURING TUBAZID THERAPY].
Topics: Administration, Cutaneous; Body Fluids; Chlorides; Humans; Isoniazid; Nitrogen; Oxidation-Reduction; | 1963 |
[DETERMINATION OF XANTHURENIC ACID AFTER THE TRYPTOPHAN LOADING TEST IN PULMONARY TUBERCULOTICS TREATED WITH ISONIAZID].
Topics: Blood Chemical Analysis; Humans; Isoniazid; Metabolism; Tryptophan; Tuberculosis; Tuberculosis, Pulm | 1963 |
[CASE OF PULMONARY TUBERCULOSIS MISDIAGNOSED AS LUNG METASTASIS OF MALIGNANT CHORIOCARCINOMA].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Choriocarcinoma; Diagnosis, Differ | 1963 |
[PULMONARY TUBERCULOSIS MISDIAGNOSED AS OTHER DISEASES].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Diagnosis, Differenti | 1963 |
A CONTROLLED CLINICAL TRIAL OF ISONIAZID AND HETEROCYCLIC THIOSEMICARBAZONE COMPARED WITH ISONIAZID AND PAS IN PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Diabetes Insipidus; Drug Hype | 1963 |
CHEMOTHERAPY FOR PATIENTS WITH CULTURES RESISTANT TO STREPTOMYCIN, ISONIAZID AND PAS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Czechoslovakia; Drug Resistance; Drug Resist | 1963 |
THE VIRULENCE IN THE GUINEA-PIG OF TUBERCLE BACILLI FROM PATIENTS WITH PULMONARY TUBERCULOSIS IN HONG KONG.
Topics: Bacillus; Bacteriological Techniques; China; Drug Resistance; Drug Resistance, Microbial; Guinea Pig | 1963 |
THE LATE RESULTS OF CHEMOTHERAPY IN PNEUMOCONIOSIS COMPLICATED BY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Isoniazid; Mycobacterium tube | 1963 |
BLOOD CONCENTRATIONS OF PAS PRODUCED BY A MIXTURE OF PAS AND THE PHENYL ESTER OF PAS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Chemical Analysis; Isoniazid; Silicotuberculosis; S | 1963 |
MYCOBACTERIA: LABORATORY METHODS FOR TESTING DRUG SENSITIVITY AND RESISTANCE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Humans | 1963 |
[DIRECT ANTIBIOTIC TREATMENT OF TUBERCULOUS CAVERNS DURING DRAINAGE AND CAVERNOTOMY].
Topics: Anti-Bacterial Agents; Caves; Drainage; Isoniazid; Neomycin; Streptomycin; Tuberculosis; Tuberculosi | 1963 |
[TUBERCULOUS MENINGITIS. DIAGNOSTIC ASPECTS. EXTRATHECAL TREATMENT EXCLUSIVELY. CURE].
Topics: Cerebrospinal Fluid; Clinical Laboratory Techniques; Cycloserine; Dihydrostreptomycin Sulfate; Isoni | 1963 |
[ON LOCAL THERAPY OF TUBERCULOUS EPIDIDYMITIS].
Topics: Epididymis; Epididymitis; Humans; Isoniazid; Male; Tuberculosis; Tuberculosis, Male Genital | 1963 |
[717 DIRECT APPROACHES IN FOCI OF POTT'S DISEASE].
Topics: Humans; Isoniazid; Kyphosis; Musculoskeletal System; Paraplegia; Pathology; Postoperative Complicati | 1963 |
AMINO ACIDS ACTIVATION IN TUBERCULOSIS BACILLI OF VARIOUS ANTIBACILLAR DRUGS SENSIVITY.
Topics: Aminoacylation; Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbi | 1963 |
[RESULTS OF 8 DIFFERENT ANTITUBERCULAR TREATMENTS. FIRST KNOWN PULMONARY ATTACK IN 495 PATIENTS].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Humans; I | 1963 |
[FATE OF A GROUP OF PATIENTS PRESENTING TUBERCULOUS SEROFIBRINOUS PLEURISY].
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibiotics, Antitubercular; Child; Geri | 1963 |
[THE OUTCOME OF PLEURISY IN YOUNG ADULTS TREATED AT THE PREVENTORIUM SEEN AFTER A RECESSION OF 2 AND 9 YEARS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Pleurisy; Statistics as To | 1963 |
[THE RISK OF TUBERCULOSIS IN THE PLEURISY PATIENT SINCE 1940].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Human | 1963 |
[APROPOS OF THE FUNCTIONAL OUTCOME OF PLEURISY PATIENTS].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Exercise Therapy; Humans; Isoniazid; Pleurisy; | 1963 |
[EXPERIENCE WITH AMBULATORY TREATMENT OF PATIENTS RECOVERING FROM MENINGEAL TUBERCULOSIS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Convalescence; Humans; Isoniazid; Outpatient | 1963 |
[CLINICAL PICTURE AND TREATMENT OF PULMONARY TUBERCULOSIS IN PATIENTS WITH CONGENITAL HEART DEFECT].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Angiocardiography; Cardiac Surgical Procedure | 1963 |
[COURSE OF DISSEMINATED PULMONARY TUBERCULOSIS IN ANTIBACTERIAL TREATMENT].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Humans; Isoniazid; Pneumoperitoneu | 1963 |
[ULTRASONICS IN COMBINED TREATMENT OF DESTRUCTIVE PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bronchography; Isoniazid; Pleurisy | 1963 |
[TREATMENT OF MENINGEAL TUBERCULOSIS IN PREGNANT WOMEN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cesarean Section; Communicable Diseases; Cortisone; Femal | 1963 |
[APROPOS OF RESIDUAL THIN-WALLED CAVITIES].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Bronchography; Isoniazid; Ra | 1963 |
[TOXICO-ALLERGIC SEROUS MENINGITIS AND ERYTHEMA NODOSUM IN A CHILD SUFFERING FROM TUBERCULOUS BRONCHOADENITIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cerebrospinal Fluid; Child; Diagnosis, Differential; Eryt | 1963 |
[ON FUNCTIONAL HEPATIC CHANGES IN PULMONARY TUBERCULOSIS PATIENTS TREATED WITH ANTIBACTERIAL PREPARATIONS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Blood Proteins; Blood Sedimentatio | 1963 |
[OUR HOSPITAL TREATMENT OF SEVERE PULMONARY TUBERCULOSIS].
Topics: Humans; Hyaluronoglucosaminidase; Isoniazid; Respiratory Therapy; Tuberculosis; Tuberculosis, Pulmon | 1963 |
THE TUBERCULOSIS OUTPATIENTS DEFECTION FROM THERAPY.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Outpatients; Tuberculosis; Urine | 1964 |
[ANTIMYCOBACTERIAL ACTIVITY OF ISOXYL. II. EXPERIMENTS WITH GUINEA PIGS AND RABBITS].
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Guinea Pigs; Isoniazid; Mycobacterium bovis; | 1964 |
SEARCH FOR ANTAGONISTIC ACTIONOMYCETAE IN HUNGARIAN SOILS. IV. ANTI-TUBERCULOUS ACTIVITY OF STREPTOMYCES FERMENTATION LIQUIDS.
Topics: Actinomycetales; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Drug Res | 1963 |
A MILD FORM OF TUBERCULOUS MENINGITIS.
Topics: Bacteriological Techniques; Biopsy; Cerebrospinal Fluid; Diagnosis; Isoniazid; Lymph Nodes; Streptom | 1964 |
[EFFECT OF INH AND SM THERAPY OF EXPERIMENTAL TUBERCULOSIS CAUSED BY STRAINS WITH A LOW INH-RESISTANCE].
Topics: Animals; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Research; Streptomycin | 1963 |
[MULTIPLE SENSITIZATION TO ANTIBACTERIAL DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anaphylaxis; Anti-Bacterial Agents; Caffeine; Drug Erupti | 1963 |
[RESISTANCE OF TUBERCLE BACILLI TO STREPTOMYCIN, ISONICOTINIC ACID HYDRAZIDE AND P-AMINOSALICYLIC ACID IN VITRO AND IN VIVO].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Drug Resistance; Drug Resistance, Microbial; Gu | 1963 |
[STUDY OF THE EFFECTIVENESS OF CHEMOTHERAPY OF TUBERCULOSIS ACCORDING TO THE PLAN PROPOSED BY THE INTERNATIONAL ANTITUBERCULOSIS SOCIETY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Communicable Disease Control; Huma | 1963 |
[CLINICAL SIGNIFICANCE OF DRUG RESISTANCE IN TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; S | 1963 |
[ON THE INCIDENCE OF PRIMARY DRUG RESISTANCE IN PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; Incidence; Isoniazi | 1963 |
[EFFECTIVENESS OF TREATING PATIENTS WITH TUBERCULOSIS OF THE LUNGS EXCRETING MYCOBACTERIUM TUBERCULOSIS WITH VARING DEGREES OF DRUG RESISTANCE].
Topics: Antitubercular Agents; Biological Transport; Culture Media; Drug Resistance; Drug Resistance, Microb | 1963 |
[BACTERIOLOGICAL ASPECTS OF PROBLEMS IN THE CHEMOTHERAPY OF TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Child; Empyema; Humans; Isoniazid; | 1963 |
[HEALING PROCESSES IN EXPERIMENTAL TUBERCULOSIS DURING THE USE OF PREPARATIONS OF THE 2D GROUP].
Topics: Animals; Antitubercular Agents; Guinea Pigs; Histological Techniques; Isoniazid; Lagomorpha; Liver G | 1963 |
[ON THE POSSIBILITY OF A THERAPEUTIC EFFECT OF PHTHIVAZID ON EXPERIMENTAL TUBERCULOSIS CAUSED BY A RESISTANT STRAIN].
Topics: Animals; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Lymphadenitis; Patholo | 1963 |
[EFFECT OF DRUG RESISTANCE ON THE COURSE OF THE TUBERCULOUS PROCESS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; S | 1963 |
[SPONTANEOUS MEDIASTINAL EMPHYSEMA (HAMMAN'S SYNDROME)].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Asthma; Bronchoscopy; Humans; Iatrogenic Disease; Isoniaz | 1963 |
[MYXEDEMA IN THE COURSE OF ANTITUBERCULOSIS THERAPY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Argentina; Isoniazid; Myxedema; St | 1963 |
RAPID CLEARING IN HEMATOGENOUS PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Black People; Humans; Hydrocortisone; Isoniazid; Predniso | 1964 |
[STUDY OF THE SENSITIVITY OF TUBERCLE BACILLI TO THE CLASSICAL ANTIBIOTICS DURING ROUTINE DETECTION OF TUBERCULOSIS IN A PARIS PLANT].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Bacil | 1963 |
[BACTERIAL SENSITIVITY TO ANTIMICROBIAL AGENTS IN PULMONARY TUBERCULOSIS. II. THERAPEUTIC RESULTS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Drug Resistance; Drug Resistance, | 1963 |
[CONSIDERATIONS ON THE USE OF LIQUID HYDRAZIDE IN AEROSOL FORM AS THE SOLE MEDICATION AND AS AN ADJUVANT TO 1ST-LINE TUBERCULOSTATIC AGENTS BY ORAL ROUTE, IN THE TREATMENT OF PULMONARY AND LARYNGEAL TUBERCULOSIS. EXPERIENCE WITH 31 CASES].
Topics: Aerosols; Antitubercular Agents; Humans; Isoniazid; Penicillins; Radiography, Thoracic; Streptomycin | 1963 |
[ON THE SUBJECT OF SURGICAL TREATMENT OF PATIENTS AFFLICTED WITH PULMONARY TUBERCULOSIS AND RESISTANT TO THE MAJOR ANTIBIOTICS. THE ROLE OF KANAMYCIN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cyclo | 1963 |
[THE COMBINATION INH AND ISONICOTINYLADEHYDE-THIOSEMICARBAZONE IN THE TREATMENT OF TUBERCULOSIS IN CHILDHOOD].
Topics: Aldehydes; Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Infant; Isoniazid; Niacin; Nico | 1963 |
[TUBERCULOSTATIC ACTIVITY FROM THE ASSOCIATION I.N.H. RO-4-4393-6(SULFAMIDIC COMPOUND OF THERAPEUTIC ACTIVITY OF LONGER THAN 120 HOURS IN THE BLOOD). PRELIMINARY REPORT].
Topics: Child; Humans; Infant; Isoniazid; Pharmacology; Radiography; Sulfadimethoxine; Sulfadoxine; Toxicolo | 1963 |
[SYSTEMATIC DETERMINATION OF ACTIVE ISONIAZID IN THE BLOOD SERUM. (DATA FROM A SERIES OF 1,000 PATIENTS)].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biometry; Blood Chemical Analysis; Isoniazid; Serum; Stat | 1963 |
[THE FATE OF 306 TUBERCULOUS CAVERNS TREATED BY CHEMOTHERAPY. II. REMOTE RESULTS (5 TO 9 YEAR FOLLOW-UP)].
Topics: Caves; Follow-Up Studies; Humans; Isoniazid; Lung; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
[CLINICAL STUDY OF 323 CASES OF TUBERCULOSIS DUE TO ISONIAZID-RESISTANT BACILLI].
Topics: Bacillus; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Tuberculosis; Tuberculosis, Pulmon | 1963 |
[THE EFFECTIVENESS OF TREATMENT WITH COMBINED ISONIAZID AND PARA-AMINOSALICYLIC ACID (PAS) AND WITH ISONIAZID AND PARA-AMINOBENZOIC ACID (PABA) IN EXPERIMENTAL TUBERCULOSIS IN GUINEA PIGS].
Topics: 4-Aminobenzoic Acid; Aminosalicylic Acid; Aminosalicylic Acids; Animals; Guinea Pigs; Humans; Isonia | 1963 |
[A CASE OF AN UNUSUALLY SEVERE SENSITIZATION TO ANTIBACTERIAL DRUGS].
Topics: Adolescent; Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agent | 1963 |
[SOME CLINICAL ASPECTS OF DRUG RESISTANCE OF TUBERCLE BACILLI ISOLATED FROM PATIENTS WITH FIBRO-CAVERNOUS TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Culture Media; Drug Resistance; Drug Resistance | 1963 |
NONTHROMBOPENIC PURPURA RESULTING FRON SENSITIVITY TO ISONIAZID.
Topics: IgA Vasculitis; Isoniazid; Purpura; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
THE LACK OF EFFECT OF ISONIAZID ON THE BLOOD AMMONIA CONCENTRATION.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Ammonia; Blood Chemical Analysis; Isoniazid; Liver Cirrho | 1964 |
THE GUINEA PIG VIRULENCE OF INDIAN TUBERCLE BACILLI.
Topics: Animals; Bacillus; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; India; Isoniazid; Mycob | 1964 |
IMMUNOLOGIC RELATIONSHIPS BETWEEN TYPICAL AND ATYPICAL MYCOBACTERIA AS STUDIED BY MEANS OF THE MOUSE PROTECTION TEST.
Topics: Animals; BCG Vaccine; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium; M | 1964 |
CHOROIDAL TUBERCLES. A CLUE TO HEMATOGENOUS TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Black People; Choroid; Humans; I | 1964 |
[ON MAMMARY TUBERCULOSIS AND ITS PRESENT TREATMENT].
Topics: Aging; Aminosalicylic Acid; Aminosalicylic Acids; Breast Diseases; Humans; Isoniazid; Mastectomy; St | 1963 |
SOME PROBLEMS IN THE MANAGEMENT OF TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; | 1964 |
D-CYCLOSERINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS RESISTANT TO THE STANDARD DRUGS: A STUDY OF 116 CASES.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
[EXPERIENCES WITH LUNG RESECTION IN TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anesthetics; Bronchoscopy; Collapse Therapy; Electrocardi | 1963 |
[CURRENT TREATMENT OF TUBERCULOUS CAVITATION. STUDY OF 237 CASES TREATED IN THE SANATORIUM].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Lung; Pneumonectomy; Streptomycin; Thoracoplas | 1963 |
TUBERCULOSIS OF THE MIDDLE EAR.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Deafness; Ear, Middle; Fenestration, Labyrint | 1964 |
CULTIVATION OF ACID-FAST ORGANISMS FROM TUBERCULOUS PATIENTS AFTER PROLONGED AND INTENSIVE TREATMENT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Humans; Isoniazid; Mycobacter | 1964 |
CONGENITAL DEFECTS AMONG CHILDREN BORN TO WOMEN UNDER SUPERVISION OR TREATMENT FOR PULMONARY TUBERCULOSIS.
Topics: Abnormalities, Drug-Induced; Aminosalicylic Acid; Aminosalicylic Acids; Communicable Diseases; Conge | 1964 |
[INTOLERANCE PHENOMENA IN ISONIAZID USE].
Topics: Diabetes Mellitus; Diarrhea; Drug Hypersensitivity; Isoniazid; Toxicology; Tuberculosis; Tuberculosi | 1963 |
CONCOMITANT BRONCHOGENIC CARCINOMA AND TUBERCULOSIS OF THE LUNG OCCURRING IN A SOLITARY COIN LESION.
Topics: Carcinoma, Bronchogenic; Humans; Isoniazid; Lung; Pathology; Pneumonectomy; Radiography, Thoracic; S | 1964 |
[ASSOCIATED EFFECT OF ISONICOTINIC ACID HYDRAZIDE (INH) AND OF SOME DRUGS INFLUENCING THE MACRO-ORGANISM IN EXPERIMENTAL TUBERCULOSIS].
Topics: Anabolic Agents; Growth Hormone; Insulin; Isoniazid; Methandrostenolone; Mice; Pharmacology; Researc | 1963 |
[ANTITUBERCULAR EFFECTS OF ETHYL ACETOACETATE ISONICOTINOYLHYDRAZONE (T-428) ADMINISTERED JOINTLY WITH ULTRACORTENOL AND SOMATOTROPIN].
Topics: Acetoacetates; Growth Hormone; Guinea Pigs; Isoniazid; Levobunolol; Pharmacology; Prednisolone; Rese | 1963 |
[RECENT EXPERIMENTAL REPORTS IN THE ROLE OF CHEMOPROPHYLAXIS WITH THE AID OF INH AND THE RESISTANCE OF THE ANIMAL ORGANISM].
Topics: Animals; BCG Vaccine; Cattle; Chemoprevention; Immunity; Isoniazid; Mycobacterium bovis; Pharmacolog | 1963 |
[RECENT DATA ON CHEMOPROPHYLAXIS WITH THE AID OF INH IN ITALY].
Topics: Chemoprevention; Child; Communicable Disease Control; Humans; Infant; Isoniazid; Italy; Tuberculosis | 1963 |
[APROPOS OF GUIDES FOR THE PREVENTIVE THERAPY OF NEWBORN INFANTS INFECTED WITH TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; Infant; Infant, Newborn; Infant, Newborn, | 1963 |
[SIDE-EFFECTS IN TUBERCULOSIS TREATMENT WITH CLASSICAL ANTIBACTERIAL DRUGS].
Topics: Alcoholism; Anti-Bacterial Agents; Diarrhea; Drug Hypersensitivity; Feeding and Eating Disorders; He | 1963 |
[VARIATIONS OF BLOOD SODIUM, POTASSIUM AND CALCIUM IN PULMONARY TUBERCULOSIS PATIENTS TREATED WITH ISONICOTINIC ACID HYDRAZIDE].
Topics: Blood Chemical Analysis; Calcium; Calcium, Dietary; Humans; Isoniazid; Potassium; Sodium; Sodium, Di | 1963 |
[EFFECT OF ANTIBACTERIAL DRUGS ON THE LEVEL OF 11-HYDROXYSTEROIDS IN THE BLOOD SERUM IN PULMONARY TUBERCULOSIS PATIENTS. (PRELIMINARY COMMUNICATION)].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Blood Che | 1963 |
[EFFECT OF INH ON TUBERCULIN ALLERGY IN BCG-VACCINATED CHILDREN].
Topics: BCG Vaccine; Child; Drug Hypersensitivity; Humans; Infant; Isoniazid; Mycobacterium bovis; Tuberculi | 1963 |
[EXPERIMENTAL TUBERCULOSIS IN RATS].
Topics: Animals; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mycobacterium; Mycobacterium bovis; | 1963 |
[STUDIES ON THE VALUE OF ISONICOTINIC ACID HYDRAZIDE IN PREVENTING CATTLE TUBERCULOSIS].
Topics: Animals; Cattle; Isoniazid; Research; Tuberculosis; Tuberculosis, Bovine | 1963 |
[ON BACTERIAL SENSITIVITY TO ANTIMICROBIAL AGENTS IN PULMONARY TUBERCULOSIS. ON THE MICROBIAL TESTS. I].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Drug Resistance; Drug Resistance, | 1963 |
[ON BACTERIAL SENSITIVITY TO ANTIMICROBIAL AGENTS IN PULMONARY TUBERCULOSIS. THERAPEUTIC RESULTS. II].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Drug Resistance; Drug Resistance, | 1963 |
[ANTIMICROBIAL SCREEN IN PHTHISIOLOGICAL SURGERY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Collapse Th | 1963 |
BROCK-SUCKOW POLYPOSIS OF THE COLON (OBLITERATIVE ARTERIOLARSCLEROSIS OF THE COLON?).
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Arteriosclerosis Obliterans; Biopsy; Black People; Coloni | 1964 |
[APROPOS OF SILICO-TUBERCULOSIS THERAPY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Isoniazid; Silicotuberculosis; Streptomycin; | 1963 |
["PERSISTANCE" OF THE "SENSITIVE" KOCH BACILLI. CLINICO-EXPERIMENTAL STUDY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Biomedical Research; Dihydrostreptomycin Su | 1963 |
[SIGNIFICANCE OF CORTICOID THERAPY FOR TUBERCULOUS MENINGITIS].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Cortisone; Humans; Injections; I | 1963 |
[ATYPICAL OSSEOUS TUBERCULOSIS, CRANIAL AND DORSAL].
Topics: Bacteriology; Benzoates; Cervical Vertebrae; Child; Isoniazid; Lymph Nodes; Radiography; Ribs; Skull | 1963 |
VARIATIONS IN MYCOBACTERIA RELATED INTIMATELY OR REMOTELY TO THE DISEASE TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; M | 1964 |
[OUR EXPERIENCE WITH STEROIDS IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Bacteriology; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Methylprednisolone; Radiograph | 1963 |
[CYCLOSERINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS. OBSERVATIONS IN 45 PATIENTS].
Topics: Bacteriology; Cycloserine; Isoniazid; Radiography, Thoracic; Sputum; Toxicology; Tuberculosis; Tuber | 1963 |
[BACTERIOLOGICAL STUDY OF 20 SPECIMENS OF RESECTION FOR PULMONARY TUBERCULOSIS IN PATIENTS TREATED WITH CHEMIANTIBIOTICS. (WITH ANATOMIC REFERENCES)].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Bacteriology; Drug Resist | 1963 |
[TUBERCULOUS MENINGITIS. TREATMENT IN CHILDREN WITH CYCLOSERINE AND HYDRAZIDE].
Topics: Cerebrospinal Fluid; Child; Cycloserine; Humans; Infant; Isoniazid; Lymph Nodes; Mexico; Pharmacolog | 1963 |
[VITAMIN B DEFICIENCIES IN PULMONARY TUBERCULOUS PATIENTS TREATED BY ANTIBACILLARY MEDICATIONS].
Topics: Aspartate Aminotransferases; Clinical Enzyme Tests; Dermatology; Diagnosis; Gynecomastia; Humans; Is | 1963 |
[THE RESULTS OBTAINED WITH THE COMBINATION OF PYRAZINAMIDE AND ISONIAZID IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Humans; Isoniazid; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary | 1963 |
CLINICOPATHOLOGICAL STUDY OF RESECTED TUBERCULOUS LUNGS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Humans; India; Isoniazid; Lung; Pathol | 1964 |
[PSYCHOLOGICAL SEQUELAE AND MENTAL DEVELOPMENT FOLLOWING TUBERCULOUS MENINGITIS].
Topics: Adolescent; Child; Deafness; Hearing Loss; Humans; Intelligence; Isoniazid; Psychology, Adolescent; | 1963 |
SPECIFICITY OF THE ISONIAZID DROP TEST FOR CONTROL OF DOMICILIARY TREATMENT OF TUBERCULOSIS.
Topics: Antitubercular Agents; Body Fluids; Chemistry Techniques, Analytical; Chloramines; Cyanides; Double- | 1964 |
TUBERCULOSIS IN CHILDHOOD, THE CHANGING PATTERN.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; Child; Drug Resistance; Drug Res | 1964 |
[THE FREQUENCY OF APPEARANCE AND MICROBIOLOGICAL CLASSIFICATION OF ATYPICAL ACID-FAST BACILLI CULTURED FROM PATIENT MATERIAL].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Catalase; Classification; Dru | 1964 |
[QUANTITATIVE EVALUATION OF THE VIRULENCE OF STREPTOMYCIN AND ISONICOTINIC ACID HYDRAZIDE RESISTANT TUBERCLE BACILLI].
Topics: Animals; Bacillus; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Lacticaseiba | 1964 |
[TREATMENT OF THE TUBERCULOUS AND DIABETIC WITH CHLORPROPAMIDE].
Topics: Chlorpropamide; Diabetes Mellitus; Geriatrics; Isoniazid; Streptomycin; Toxicology; Tuberculosis; Tu | 1964 |
[BASIC CONCEPTS FOR THE DIAGNOSIS, PROPHYLAXIS AND TREATMENT OF T.B.C].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Argentina; BCG Vaccine; Diagnosis; Epidemiology; Isoniazi | 1964 |
ATYPICAL PULMONARY TUBERCULOSIS CAUSED BY UNCLASSIFIED MYCOBACTERIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Black People; Humans; Isoniazid; Mycobacterium Infections | 1964 |
ACTIVITY IN RADIOGRAPHICALLY UNCHANGED TUBERCULOUS LESIONS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Radiography, Thoracic; Tuberculosis; Tuberculo | 1964 |
A CONTINUING STUDY OF PRIMARY DRUG RESISTANCE IN TUBERCULOSIS IN A VETERAN POPULATION WITHIN THE UNITED STATES. I.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Isoniazid; M | 1964 |
STUDIES ON THE EARLY CHANGES OF TION IN VITRO OF PERITONEAL EXUDATE CELLS FROM GUINEA PIGS AT DIFFERENT LEVELS AFTER INFECTION WITH MYCOBACTERIUM TUBERCULOSIS.
Topics: Animals; BCG Vaccine; Exudates and Transudates; Guinea Pigs; In Vitro Techniques; Isoniazid; Leukocy | 1964 |
SKIN RASH, HEPATITIS, AND HEMOLYTIC ANEMIA CAUSED BY PARA-AMINOSALICYLIC ACID.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anemia; Anemia, Hemolytic; Chemical and Drug Induced Live | 1964 |
[LOCAL ANTIBIOTIC THERAPY OF TUBERCULOUS LESIONS. TREATMENT OF COMMON PULMONARY TUBERCULOSIS BY AEROSOL ANTIBIOTICS AND SPREADING FACTORS].
Topics: Aerosols; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercu | 1964 |
PATHOGENICITY OF ATTENUATED AND AVIRULENT TUBERCLE BACILLI: THEIR IMPLICATION AS VACCINATING AGENTS IN HUMANS.
Topics: Animals; Bacillus; Catalase; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; La | 1964 |
OBSTRUCTIVE JAUNDICE DUE TO TUBERCULOUS HEPATIC LYMPH GLANDS.
Topics: Alkaline Phosphatase; Aminosalicylic Acid; Aminosalicylic Acids; Bilirubin; Blood Chemical Analysis; | 1964 |
[STUDY OF ISONIAZID-RESISTANT MYCOBACTERIA BY MEANS OF RADIOISOTOPES (C-14)].
Topics: Animals; Autoradiography; Carbon Isotopes; Drug Resistance; Drug Resistance, Microbial; Isoniazid; L | 1964 |
[MAGNANTYL IN PNEUMO-PHTHISIOLOGY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Deficiency Diseases; Ethionamide; Fishes; Humans | 1964 |
ETHIONAMIDE AND ISONIAZID IN PREVIOUSLY UNTREATED CASES OF PULMONARY TUBERCULOSIS.
Topics: Ethionamide; Isoniazid; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
TREATMENT OF PROGRESSIVE PRIMARY TUBERCULOSIS WITH ISONIAZID ALONE.
Topics: Child; Infant; Infant, Newborn; Isoniazid; South Africa; Statistics as Topic; Tuberculosis; Tubercul | 1964 |
ISONIAZID TREATMENT OF BOVINE TUBERCULOSIS.
Topics: Animals; Cattle; Humans; Isoniazid; South Africa; Tuberculin Test; Tuberculosis; Tuberculosis, Bovin | 1964 |
[THE NUMBER OF PATIENTS WITH CHRONIC FIBROUS-CAVERNOUS PULMONARY TUBERCULOSIS AND THEIR TREATMENT UNDER DISPENSARY CONDITIONS].
Topics: Antitubercular Agents; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Statistics as | 1963 |
[OSTEOARTICULAR TUBERCULOSIS: ITS RELATIONS TO PLEUROPULMONARY ANTECEDENTS].
Topics: Humans; Isoniazid; Italy; Physiology; Statistics as Topic; Tuberculosis; Tuberculosis, Osteoarticula | 1963 |
[PRESENT STATUS OF TUBERCULOSIS AMONG THE INHABITANTS OF THE AMAMI ISLANDS. 3. RESULTS OF BACTERIOLOGICAL EXAMINATION].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Epidemiology | 1963 |
[THE STATUS OF TUBERCULOSIS IN JAPAN].
Topics: BCG Vaccine; Humans; Isoniazid; Japan; Mass Screening; Mycobacterium bovis; Tuberculosis; Tuberculos | 1963 |
[CONSERVATIVE TREATMENT OF PULMONARY TUBERCULOSIS DIFFICULT TO CURE IN ELDERLY PATIENTS UNFIT FOR SURGERY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Ethionamide; Geriatrics; Isoniazid; Japan; K | 1963 |
[MYELOPROLIFERATIVE SYNDROMES AND TUBERCULOSIS. SEARCH FOR THE MEANS TO ARRIVE AT A DIFFERENTIAL DIAGNOSIS].
Topics: Blood Cell Count; Blood Platelets; Bone Marrow Examination; Diagnosis, Differential; Female; Humans; | 1964 |
[TREATMENT OF TUBERCULOSIS AND DIABETES BECOMING SIMILAR].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Diabetes Mellitus; Ethionamide; Isoniazid; P | 1964 |
[POLYVALENT ANTIBIOTHERAPY OF TUBERCULOSIS IN COAL MINERS. COMPARATIVE RESULTS IN "NEW" CASES AND THOSE WITH SUCCESSIVE TREATMENT].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Coal; Coal Mining; Humans; Isoniazid; Silicotuberculosis; | 1964 |
[SOME DATA ON THE CHEMOTHERAPEUTIC PROPERTIES OF FLORIMYCIN (VIOMYCIN)].
Topics: Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mycobacterium tuberculosis; Pharmacology; Re | 1963 |
CLINICAL ASPECTS, MEDICAL AND SURGICAL, IN THE MANAGEMENT OF BATTEY-TYPE PULMONARY DISEASE.
Topics: Bronchiectasis; Calcification, Physiologic; Drug Resistance; Drug Resistance, Microbial; Epidemiolog | 1964 |
[THE LEVEL OF FREE INH IN THE BLOOD SERUM DURING ITS SIMULTANEOUS ADMINISTRATION WITH 5-BROMOSALICYLOHYDROXAMIC ACID (T4O)].
Topics: Antitubercular Agents; Blood Chemical Analysis; Humans; Hydroxamic Acids; Isoniazid; Serum; Tubercul | 1964 |
[1-YEAR RESULTS OF ANTIBACTERIAL THERAPY OF RECENTLY DISCOVERED CAVERNOUS PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Drug Resistance; Drug Resistance, | 1964 |
[1-YEAR RESULTS OF ANTIBACTERIAL THERAPY OF RECENTLY DISCOVERED CAVERNOUS PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Drug Resistance; Drug Resistance, | 1964 |
[TRIPLE SCHEMA IN THE TREATMENT OF TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Hypersensitivity; Drug Resistance; Drug Resistance, | 1964 |
[LABORATORY CONTROL FOR THE REGULATION OF THE USE OF PAS AND PHTIVAZID FOR PATIENTS WITH TUBERCULOSIS IN AMBULATORY CONDITIONS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Outpatient Clinics, Hospital; Streptom | 1964 |
[PREVALENCE OF BACTERIAL RESISTANCE AT THE KOCH PAVILLION].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Epidemiology | 1964 |
[RECENT DATA TO THE ORIGIN OF THE NARROWING OF THE INTER-VERTEBRAL SPACE].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Casts, Surgical; Child; Humans; Isoniazid; Ky | 1964 |
[ATYPICAL MYCOBACTERIA OF HUMAN ORIGIN. (REPORT OF 2 CASES)].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Cerebrospinal Fluid; Drug Resistance; Drug | 1964 |
THE EFFECT OF SYSTEMATIC ADMINISTRATION OF INH ON PRIMARY TUBERCULOSIS IN CHILDHOOD. PRESENTATION OF A "5-YEAR TRIAL".
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Child; France; Humans; I | 1963 |
ANTIMICROBIAL THERAPY OF PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Cycloserine; Dihydrostreptomycin S | 1963 |
[OSSEOUS TUBERCULOSIS IN INFANCY. MULTIPLE CYSTIC FORM].
Topics: Ascorbic Acid; Bone Cysts; Child; Humans; Infant; Isoniazid; Penicillins; Prognosis; Radiography; St | 1964 |
[D-CYCLOSERINE IN THE TREATMENT OF PULMONARY TUBERCULOSIS. (ARE TUBERCULOSTATICS OF THE 2D GROUP NECESSARY?].
Topics: Cycloserine; Isoniazid; Mycobacterium bovis; Streptomycin; Thiosemicarbazones; Tuberculosis; Tubercu | 1964 |
[THERAPY OF PULMONARY TUBERCULOSIS BY THE ADMINISTRATION OF HIGH DOSES OF INH].
Topics: Blood Chemical Analysis; Humans; Isoniazid; Sputum; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
[ON THE TREATMENT OF DIFFERENT TYPES OF RHEUMATIC DISEASES IN PULMONARY TUBERCULOSIS AND LUNG TUMORS].
Topics: Agranulocytosis; Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Leukopenia; Lung; Lung Neopla | 1964 |
[THE IMMEDIATE RESULTS OF CONSERVATIVE TREATMENT OF SPINAL TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Penicillins; Streptomycin; Tuberculosi | 1963 |
[THE EFFECTIVENESS OF LONG-TERM ANTIBACTERIAL THERAPY OF PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Isoniazid; Streptomycin; Tuberculo | 1963 |
[CLINICO-RADIOLOGICAL RESULTS WITH CORTICO-ANTIBIOTIC THERAPY COMBINED WITH ACTH IN A CASE STUDY OF YOUNG SUBJECTS WITH PULMONARY TUBERCULOSIS].
Topics: Adolescent; Adrenocorticotropic Hormone; Anti-Bacterial Agents; Biomedical Research; Cortisone; Huma | 1964 |
"NO TRUCE FOR TUBERCULOSIS".
Topics: Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; Isoniazid; Mycobacterium bovis; Streptomycin | 1964 |
INCIDENCE AND MANAGEMENT OF TUBERCULOUS STRICTURES OF THE URINARY TRACT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Constriction, Pathologic; Humans; Hydronephrosis; Inciden | 1964 |
PULMONARY RESECTION AS TREATMENT FOR HAEMORRHAGE IN TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Blood Transfusion; Hemorrhage; Iso | 1964 |
[COMBINED PROTECTION OF CHILDREN LIVING IN AN ENVIRONMENT INFECTED WITH TUBERCULOSIS].
Topics: Adolescent; BCG Vaccine; Child; Communicable Disease Control; Erythema Nodosum; Hungary; Infant; Iso | 1964 |
[THE EFFECTIVENESS OF PROLONGED ANTIBACTERIAL THERAPY OF RECENT FORMS OF PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Biometry; Isoniazid; Lithuania; St | 1964 |
[PROGNOSIS IN INFILTRATIVE FORMS OF PULMONARY TUBERCULOSIS AND METHODS OF THEIR THERAPY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Prognosis; Radiography, Thoracic; Tube | 1964 |
[FF-725 AND TUBERCULOSTATICS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Ethionamide; Gastroenterology; Isoniazid; Muscle Relaxant | 1964 |
SINGLE DAILY DOSE REGIMEN OF ISONIAZID AND PAS IN THE TREATMENT OF PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Drug Tolerance; Isoniazid; Sputum; Statisti | 1964 |
[CONSTANT FIGHT AGAINST TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; Child; Communicable Disease Control; Humans; | 1964 |
[THERAPEUTIC EFFECTS OF A METABOLITE OF PHENYLBUTAZONE (G 27202) IN PRIMARY SEROSITIS].
Topics: Aminopyrine; Blood Sedimentation; Humans; Isoniazid; Neoplasms; Oxyphenbutazone; Peritonitis; Perito | 1964 |
[THE MEDICAL TREATMENT OF COMMON PULMONARY TUBERCULOSIS IN THE ADULT].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Ethionamide; Is | 1964 |
[LOCAL ANTIBIOTIC THERAPY OF PULMONARY TUBERCULOSIS LESIONS (INTRABRONCHIAL INSTILLATIONS)].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Ethionamide; Isoniazid; Kanamycin; | 1964 |
[SUICIDE AFTER PROLONGED USE OF CYCLOSERINE].
Topics: Cycloserine; Depression; Depressive Disorder; Ethionamide; Isoniazid; Pyridoxine; Suicide; Toxicolog | 1964 |
GENITO-URINARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Epididymitis; Hospitalization; Humans; Isoniazid; Male; N | 1964 |
[THE USE OF ANTIBACILLARY DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
[2 CASES OF POLYARTHRITIS OF DIFFICULT DIAGNOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Arthritis; Arthritis, Rheumatoid; Diagnosis, Differential | 1964 |
PROLONGED STREPTOMYCIN AND ISONIAZID FOR PULMONARY TUBERCULOSIS.
Topics: Deafness; Isoniazid; Pantothenic Acid; Psychoses, Substance-Induced; Psychotic Disorders; Statistics | 1964 |
[SIDE-EFFECTS OF ANTIBACTERIAL PREPARATIONS IN PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Cycloserine; Drug Eruptions; Drug | 1963 |
[EXPERIENCE IN TUBERCULOSIS CONTROL WORK].
Topics: Adolescent; Armenia; BCG Vaccine; Child; Humans; Isoniazid; Mycobacterium bovis; Preventive Medicine | 1964 |
[STUDY OF THE ABSORPTION, BLOOD CONCENTRATION AND EXCRETION IN THE URINE OF THE BULGARIAN ANTITUBERCULAR PREPARATION INHA-17].
Topics: Antitubercular Agents; Blood Chemical Analysis; Body Fluids; Humans; Isoniazid; Metabolism; Tubercul | 1964 |
[THE CHEMOPROPHYLAXIS OF TUBERCULOSIS IN CHILDREN AND ADOLESCENTS IN TUBERCULOUS INFECTION FOCI].
Topics: Adolescent; Biometry; Chemoprevention; Child; Focal Infection; Humans; Isoniazid; Preventive Medicin | 1964 |
[A CASE OF TUBERCULOUS OTITIS IN A 3-MONTH-OLD INFANT].
Topics: BCG Vaccine; Child; Humans; Infant; Isoniazid; Mycobacterium bovis; Otitis; Streptomycin; Tuberculos | 1963 |
[PREGNANCY AND LABOR IN CHRONIC ADRENAL INSUFFICIENCY].
Topics: Addison Disease; Adrenal Insufficiency; Cortisone; Drug Therapy; Female; Humans; Hypoadrenocorticism | 1963 |
[METHOD OF VISUAL COLORIMETRY FOR THE DETERMINATION OF THE INACTIVATION OF ISONIAZID PREPARATIONS IN PATIENTS WITH TUBERCULOSIS].
Topics: Body Fluids; Colorimetry; Humans; Isoniazid; Tuberculosis; Urine | 1963 |
[CONSERVATIVE AND SURGICAL TREATMENT OF TUBERCULOUS SYNOVITIS IN ADULTS].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Chloramphenicol; Drug Therap | 1963 |
[SURGICAL TREATMENT OF TUBERCULOUS OSTEITIS IN THE REGION OF THE HIP AND KNEE JOINTS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Casts, Surgical; Child; Drug Therapy; Hip; Hu | 1963 |
[CONSERVATIVE AND SURGICAL TREATMENT OF PATIENTS WITH TUBERCULOSIS OF THE HIP JOINT IN THE PREARTHRITIC STAGE].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Casts, Surgical; Child; Drug Therapy; Femur; | 1963 |
[TOXIC EFFECT OF CYCLOSERINE].
Topics: Alanine Transaminase; Aminosalicylic Acid; Aminosalicylic Acids; Aspartate Aminotransferases; Centra | 1963 |
[EFFECT OF GLUTAMIC ACID ON THE METABOLISM OF PHOSPHOROUS COMPOUNDS IN THE BLOOD AND BRAIN IN EXPERIMENTAL TUBERCULOSIS].
Topics: Adenosine Triphosphate; Animals; Blood; Brain; Coenzymes; Glutamates; Glutamic Acid; Guinea Pigs; Is | 1963 |
[USE OF PYRIDOXINE IN THE TREATMENT OF SIDE EFFECTS OF ANTITUBERCULAR AGENTS].
Topics: Antitubercular Agents; Cycloserine; Depression; Drug Therapy; Eye Manifestations; Isoniazid; Paresth | 1963 |
[TRACHEOSTOMY IN THE SURGERY OF THE SEVERE TUBERCULOUS PATIENT. ITS PREVIOUS INDICATION].
Topics: Acid-Base Equilibrium; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mortality; Ox | 1964 |
[EFFECTIVENESS OF ANTIBACTERIAL TREATMENT OF TUBERCULOUS PATIENTS WITH AND WITHOUT ASSOCIATED HORMONAL PREPARATIONS].
Topics: Adrenocorticotropic Hormone; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Corti | 1963 |
[USE OF CHEMOPROPHYLACTIC METHODS WITH TUBERCULOUS "CONTACTS" IN THE REPUBLIC].
Topics: Carrier State; Communicable Disease Control; Family; Isoniazid; Lithuania; Tuberculosis | 1964 |
NO TRUCE FOR TUBERCULOSIS. 1. A STATEMENT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; International Cooperation; Isoniazid; Mycoba | 1964 |
[MINIMAL TUBERCULOUS ENTEROPERITONITIS].
Topics: BCG Vaccine; Humans; Isoniazid; Mycobacterium bovis; Peritoneum; Peritonitis, Tuberculous; Streptomy | 1964 |
[ON CASES OF HIGHLY VIRULENT AND NORMALLY VIRULENT BOVINE PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Antitubercular Agents; Cattle; Isoniazid; Lymph | 1964 |
[BACILLI COUNT--A DIRECTIVE FOR TUBERCULOSTATIC THERAPY].
Topics: Antitubercular Agents; Bacillus; Bacteriological Techniques; Culture Media; Humans; Isoniazid; Mycob | 1964 |
A SPUTUM SURVEY OF CASES OF PULMONARY TUBERCULOSIS TWO TO THREE YEARS AFTER STARTING TREATMENT IN A RURAL AREA IN KENYA.
Topics: Child; Drug Resistance; Drug Resistance, Microbial; Health Surveys; Humans; Infant; Isoniazid; Kenya | 1964 |
[NEW COMBINATIONS OF ANTITUBERCULAR AGENTS IN THE TREATMENT OF RENAL TUBERCULOSIS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; | 1964 |
[CLINICAL DATA ON CHRONIC RECURRENT PANCREATIC NECROSIS].
Topics: Alcoholism; Cycloserine; Isoniazid; Pancreatic Diseases; Pancreatitis; Pneumonectomy; Streptomycin; | 1964 |
[RESEARCH ON THE BEHAVIOR OF TUBERCULIN ALLERGY DURING TREATMENT WITH RIFAMYCIN SV].
Topics: Animals; Biomedical Research; Guinea Pigs; Hypersensitivity; Isoniazid; Pharmacology; Research; Rifa | 1964 |
[ON THE CLINICAL ASPECTS AND SURGICAL TREATMENT OF TUBERCULOSIS SUBCUTANEA FISTULOSA].
Topics: Administration, Cutaneous; Ascorbic Acid; Aspirin; Biopsy; Diathermy; Humans; Isoniazid; Male; Patho | 1964 |
[ASSOCIATION OF PULMONARY TUBERCULOSIS AND DIABETES MELLITUS].
Topics: Diabetes Mellitus; Humans; Hypoglycemic Agents; Insulin; Insulin, Long-Acting; Isoniazid; Kanamycin; | 1964 |
SOME OBSERVATIONS IN RELATION TO THE PROPERDIN SYSTEM. V. COMPARATIVE STUDIES ON SERUM PROTEIN PATTERN OF HUMAN PULMONARY TUBERCULOSIS PATIENTS UNDER CONVENTIONAL ANTI-TUBERCULAR THERAPY.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Protein Electrophoresis; Blood Proteins; Chromatogr | 1963 |
ACQUIRED ESOPHAGOBRONCHIAL FISTULA OF INFECTIOUS ORIGIN.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Biopsy; Bronchial Fistula; Bronchi | 1964 |
ANTITUBERCULOSIS ACTIVITY OF DEXTRO-2,2'-(ETHYLENEDIIMINO)-DI-1-BUTANOL (ETHAMBUTOL) (I).
Topics: 1-Butanol; Antitubercular Agents; Culture Media; Drug Resistance; Drug Resistance, Microbial; Ethamb | 1964 |
EFFECTIVENESS OF CAPREOMYCIN AGAINST EXPERIMENTAL TUBERCULOSIS OF MICE AND GUINEA PIGS.
Topics: Antitubercular Agents; Capreomycin; Guinea Pigs; Isoniazid; Kanamycin; Mice; Mycobacterium bovis; Ph | 1964 |
[THE TREATMENT OF TUBERCULOSIS WITH 2ND LINE DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cyclo | 1964 |
[ANTIMICROBIAL TREATMENT OF TUBERCULOSIS WITH SUBSIDIARY DRUGS. 2ND LINE DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Antitubercular Agents; Bacteriolog | 1964 |
[INFORMATION ON A NEW TECHNIQUE FOR ANTITUBERCULOSIS THERAPY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Audiometry; Drug Resistance; Drug | 1964 |
BACILLUS CALMETTE GUERIN. A NEGLECTED BUT USEFUL AGENT.
Topics: Bacillus; BCG Vaccine; Drug Therapy; Humans; Indians, North American; Isoniazid; Mycobacterium bovis | 1964 |
QUANTITATIVE AND QUALITATIVE DETERMINATIONS OF CATALASE ACTIVITY IN MYCOBACTERIA.
Topics: Catalase; Chemistry Techniques, Analytical; Drug Resistance; Drug Resistance, Microbial; Hydrogen Pe | 1964 |
[QUANTIFICATION OF XANTHURENIC ACID IN THE URINE OF TUBERCULOSIS PATIENTS UNDERGOING TREATMENT WITH ISONIAZID].
Topics: Body Fluids; Isoniazid; Metabolism; Tryptophan; Tuberculosis; Tuberculosis, Pulmonary; Urine; Vitami | 1964 |
RECOVERABILITY OF ACID-FAST BACILLI FROM RESECTED PULMONARY TUBERCULOUS LESIONS AS RELATED TO THE DURATION OF PREOPERATIVE ANTITUBERCULOUS DRUG THERAPY.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacteriological Techniques; Humans | 1964 |
PULMONARY TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Child; Cycloserine; Drug Resista | 1964 |
PULMONARY ASPERGILLOSIS. A CASE REPORT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Aspergillosis; Humans; Isoniazid; Lung Diseases, Fungal; | 1964 |
PULMONARY TUBERCULOSIS IN GUINEA PIGS BY TRANS-TRACHEAL INOCULATION.
Topics: Animals; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Lung; Mortality; Mycob | 1964 |
LIPOID PNEUMONIA: REVIEW OF LITERATURE WITH A CASE REPORT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Diagnosis, Differential; Humans; Isoniazid; Lipids | 1964 |
[SOME CONSIDERATIONS ON THE RESISTANCE OF KOCH BACILLI TO ANTIBIOTICS AND ON ITS PRACTICAL IMPORTANCE].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance; Drug Res | 1964 |
[CORTISONE IN THE TREATMENT OF UROGENITAL TUBERCULOSIS. II (RESULTS)].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Cortisone; Humans; Isoniazid; Pr | 1964 |
FURTHER EXPERIMENTS ON LONG-TERM CHEMOTHERAPY OF ADVANCED MURINE TUBERCULOSIS, WITH EMPHASIS ON INTERMITTENT REGIMES.
Topics: Animals; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mice; Pathology; Research; Streptom | 1964 |
A STUDY OF THE INFLUENCE OF THE ISONIAZID INACTIVATOR PHENOTYPE ON REVERSION IN GENITO-URINARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Genetics, Medical; Geriatrics; Isoniazid; M | 1964 |
A CONTROLLED COMPARISON OF STREPTOMYCIN PLUS PYRAZINAMIDE AND STREPTOMYCIN PLUS PAS IN THE RETREATMENT OF PATIENTS EXCRETING ISONIAZID-RESISTANT ORGANISMS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriology; Biomedical Research; Drug Resistance; Drug | 1964 |
TREATMENT OF PATIENTS WITH CULTURES RESISTANT TO THE PRIMARY ANTI-TUBERCULOSIS DRUGS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacteriological Techniques; Biomed | 1964 |
[ON THE EVALUATION OF THE ACTIVITY OF FEMALE GENITAL TUBERCULOSIS TREATED BY DRUGS ON THE BASIS OF A HISTOPATHOLOGIC AND BACTERIOLOGICAL EXAMINATION OF SURGICALLY REMOVED OVIDUCTS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Bacteriological Techniques; Fallopian Tubes; Fem | 1964 |
DANISH PATIENTS WITH LUNG INFECTIONS CAUSED BY M. AVIUM AND ATYPICAL MYCOBACTERIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Denmark; Humans; Isoniazid; Lung Diseases; M | 1964 |
THE EFFICACY OF KILLED ANTITUBERCULOUS VACCINES IN RELATION TO THE MORPHOLOGICAL INTEGRITY OF THE SUSPENDED BACILLARY CELLS.
Topics: Adolescent; Bacillus; BCG Vaccine; Child; Humans; Infant; Infant, Newborn; Isoniazid; Mycobacterium | 1964 |
[EVOLUTIVE ASPECTS OF RENAL TUBERCULOSIS AFTER CHEMIOANTIBIOTIC THERAPY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Isoniazid; Kidney; Nephrectomy; Pathology; Pyridoxine; St | 1964 |
[LUNG TUBERCULOMAS].
Topics: Adolescent; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Bronchoscopy; | 1963 |
A STUDY ON PROBLEMS OF RESISTANCE. 2. INVESTIGATIONS INTO THE EMERGENCE OF RESISTANCE OF TUBERCLE BACILLI TO ISONIAZID.
Topics: Bacillus; Culture Media; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Lacticaseibacillus | 1964 |
[EXPERIMENTAL DATA CONCERNING THE DEVELOPMENT OF ANTITUBERCULOUS IMMUNITY UNDER THE ACTION OF TUBERCULOSTATICS].
Topics: BCG Vaccine; Guinea Pigs; Immunity; Isoniazid; Mycobacterium bovis; Pharmacology; Research; Tubercul | 1963 |
[CURRENT PROBLEMS IN THE ANTITUBERCULOSIS CAMPAIGN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Humans; Isoniazid; Italy; Morbidit | 1964 |
MONOTHERAPY WITH 4-4'DIISOAMYLOXYTHIO-CARBANILIDE (ISOXYL).
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Biomedical Research; Blood Sedimen | 1964 |
THE TOLERANCE OF ISONIAZID IN ONE DAILY DOSE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Tolerance; Isoniazid; Neuritis; Pyridoxine; Streptom | 1964 |
THE SIGNIFICANCE OF LIVER NEEDLE BIOPSY IN THE DIAGNOSIS OF TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biopsy; Biopsy, Needle; Communicable Diseases; Diagnosis; | 1964 |
[APROPOS OF ETHIONAMIDE JAUNDICE].
Topics: Alanine Transaminase; Alcoholism; Aminosalicylic Acid; Aminosalicylic Acids; Aspartate Aminotransfer | 1964 |
[TRIAL OF OXYPHENBUTAZONE, NEW ANTI-INFLAMMATORY TREATMENT OF PULMONARY AND PLEURAL TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Cell Count; Blood Glucose; Blood Sedimentation; Ema | 1964 |
[D.A.T.C. IN PULMONARY TUBERCULOSIS IN NON-TREATED PATIENTS].
Topics: Antitubercular Agents; Argentina; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Ph | 1964 |
CORTISONE THERAPY FOR EXUDATIVE TUBERCULOUS PLEURISY IN THE LIGHT OF A FOLLOW-UP STUDY.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Sedimentation; Body Temperature; Cortisone; Finland | 1964 |
[APROPOS OF THE TREATMENT OF A CASE OF TUBERCULOUS OPTO-CHIASMATIC ARACHNOIDITIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Arachnoid; Arachnoiditis; Humans; Isoniazid; Optic Chiasm | 1964 |
[CLINICAL TRIAL OF A NEW TYPE OF TUBERCULIN (PREPARED WITH KOCH BACILLI RESISTANT TO ISONIAZID].
Topics: Biomedical Research; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium t | 1964 |
[TREATMENT TRIALS IN PULMONARY TUBERCULOSIS COMBINING ISONIAZID, ADMINISTERED 2 TIMES A WEEK, AND A THIOCARBANILIDE IN DAILY FORM].
Topics: Anilides; Antitubercular Agents; Biomedical Research; Drug Resistance; Drug Resistance, Microbial; I | 1964 |
THE CLINICAL SIGNIFICANCE OF LOW DEGREES OF DRUG RESISTANCE IN PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Drug Resistance; Drug Resista | 1964 |
THE SEQUELAE OF TUBERCULOUS MENINGITIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Child Behavior Disorders; Cortisone; D | 1964 |
ACUTE DERMATOMYOSITIS PRESENTING WITH PULMONARY MANIFESTATIONS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Chickenpox; Child; Clinical Enzyme Tests; Cortisone; Derm | 1964 |
CERVICAL ADENITIS IN CHILDREN DUE TO HUMAN AND UNCLASSIFIED MYCOBACTERIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Black People; Child; Drug The | 1964 |
A STUDY ON PRIMARILY DRUG-RESISTANT STRAINS OF TUBERCLE BACILLI IN SHANGHAI. THE INCIDENCE AND VIRULENCE OF THE RESISTANT BACILLI.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Bacteriological Techniques; China; Drug Resista | 1964 |
[URETHRO-PROSTATO-RECTAL FISTULA, FOLLOWING A TUBERCULOUS ABSCESS OF THE PROSTATE. SURGICAL TREATMENT UNDER STREPTOMYCIN-RIMIFON TREATMENT. RECOVERY IN A MONTH, MAINTAINED FOR 6 YEARS].
Topics: Abscess; Fistula; Humans; Isoniazid; Male; Prostatitis; Rectal Fistula; Streptomycin; Surgical Proce | 1964 |
STUDIES ON DRUG-RESISTANT TUBERCLE BACILLI IN EXPERIMENTAL TUBERCULOSIS. I. DEVELOPMENT OF INH-RESISTANT TUBERCLE BACILLI IN EXPERIMENTAL MURINE TUBERCULOSIS.
Topics: Animals; Bacillus; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Lacticaseibacillus casei; | 1963 |
SKELETAL TUBERCULOSIS--1963.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biopsy; Child; Florida; Geriatrics; Isoniazid; Pyridoxine | 1964 |
[ANTITUBERCULOUS ACTIVITY OF DEXTRO-2,2'-(ETHYLENEDIIMINO)-DI-1-BUTANOL (ETHAMBUTOL). (II) COMBINED EFFECT OF ETHAMBUTOL AND ISONIAZID].
Topics: 1-Butanol; Animals; Antitubercular Agents; Drug Resistance; Drug Resistance, Microbial; Ethambutol; | 1964 |
[EXPERIMENTAL STUDIES ON EFFECT OF COMBINED USE OF 1314TH AND INH TO INH-RESISTANT TUBERCLE BACILLI. 2. COMBINATION EFFECT IN THE EXPERIMENTAL TUBERCULOSIS OF MICE].
Topics: Animals; Bacillus; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Isoniazid; Mice; Pathol | 1964 |
[DETERMINATION OF THE CLINICAL RECOVERY OF TUBERCULOSIS OF THE LUNGS IN ADULTS].
Topics: Adult; Humans; Isoniazid; Physiological Phenomena; Radiography, Thoracic; Tuberculin Test; Tuberculo | 1964 |
[EFFECTIVENESS OF ANTIBACTERIAL THERAPY IN PATIENTS WITH TUBERCULOSIS OF THE LUNGS DURING THE PRESENCE OF PRIMARY DRUG RESISTANCE OF MYCOBACTERIA TUBERCULOSIS].
Topics: Anti-Bacterial Agents; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium | 1964 |
[PHTHIVAZID THERAPY OF EXPERIMENTAL TUBERCULOSIS CAUSED BY PHTHIVAZID-RESISTANT MYCOBACTERIA TUBERCULOSIS].
Topics: Animals; Drug Resistance; Drug Resistance, Microbial; Guinea Pigs; Hyperplasia; Hypertrophy; Isoniaz | 1964 |
[VIRULENCE OF PHTHIVAZID-RESISTANT AND CATALASE-NEGATIVE STRAINS OF MYCOBACTERIA TUBERCULOSIS FOR GUINEA PIGS FOLLOWING INTRATESTICULAR INFECTION].
Topics: Animals; Catalase; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; R | 1964 |
[STATUS OF THE CARDIOVASCULAR SYSTEM IN AGED PATIENTS WITH PULMONARY TUBERCULOSIS DURING ANTIBACTERIAL TREATMENT].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Blood Pressure; Cardiovascular Diseases; Cardiovascula | 1964 |
[THE EFFECTIVENESS OF ANTIBACTERIAL TREATMENT IN TUBERCULOUS SPONDYLITIS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Child; Drug Therapy; H | 1964 |
[HISTOAUTORADIOGRAPHIC STUDY OF THE DISTRIBUTION OF PHTHIVAZID LABELLED WITH RADIOACTIVE CARBON IN THE LUNG, LIVER AND SPLEEN].
Topics: Animals; Autoradiography; Carbon; Carbon Isotopes; Histocytochemistry; Histology; Isoniazid; Liver; | 1964 |
[DETERMINATION OF TUBERCULOUS ACTIVITY IN CHILDREN DURING EARLY CHEMOTHERAPY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Drug Therapy; Infant; Isoniazid; Tuberculin Test; | 1964 |
[ON SIDE EFFECTS IN THE TREATMENT OF TUBERCULOSIS WITH VARIOUS ISONICOTINIC ACID DERIVATIVES].
Topics: Drug Therapy; Isoniazid; Isonicotinic Acids; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
[IMMEDIATE AND REMOTE RESULTS OF ANTIBACTERIAL TREATMENT OF PULMONARY TUBERCULOSIS IN MIDDLE-AGED AND ELDERLY PATIENTS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Drug Therapy; Geriatrics; Isoniazi | 1964 |
[DETECTION AND TREATMENT OF TUBERCULOUS MENINGITIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood-Brain Barrier; Cerebrospinal Fluid; Clinical Labora | 1964 |
[COMPLICATIONS OF TUBERCULOSIS TREATMENT BY ANTIBIOTICS].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Ethionamide; Isoniazid; Toxicology; Tuberculosis | 1964 |
[HEMORRHAGIC PURPURA IN THE COURSE AND CHEMO-ANTIBIOTIC THERAPY OF PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Geriatrics; Isoniazid; Purpura; St | 1963 |
A CLINICAL EVALUATION OF THE ROLE OF CORTICOSTEROIDS IN THE MANAGEMENT OF RESISTANT CASES OF PULMONARY TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Humans; Iso | 1964 |
FURTHER OBSERVATIONS ON THE KANAMYCIN RESISTANCE IN TUBERCULOUS PATIENTS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Cycloserine; Drug Resistance, Microb | 1964 |
[HISTOAUTORADIOGRAPHIC STUDY OF THE DISTRIBUTION OF PHTHIVAZID LABELLED WITH RADIOACTIVE CARBON IN THE LUNG, LIVER AND SPLEEN].
Topics: Animals; Autoradiography; Carbon; Carbon Isotopes; Histocytochemistry; Histology; Isoniazid; Liver; | 1964 |
RELAPSE IN TREATED CASES OF PULMONARY TUBERCULOSIS. II. SIX-YEAR FOLLOW-UP OF 109 PATIENTS DISCHARGED FROM THE HOSPITAL WITH MEDICAL APPROVAL, 1955-1956.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Collapse Therapy; Follow-Up Studies; Isoniazid; Pneumonec | 1964 |
TUBERCULOUS OSTEOMYELITIS OF THE MANDIBLE; REPORT OF A CASE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Drug Therapy; Isoniazid; Lymph Nodes; Mandible; Os | 1964 |
[DRUG TREATMENT OF RENAL TUBERCULOSIS].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloseri | 1964 |
PULMONARY TUBERCULOSIS IN RETROSPECT AND PROSPECT.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; History; His | 1964 |
[ETHYLACETYLACETATE ISONICOTINOYLHYDRAZONE (PREPARATION T-428) IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Isoniazid; Streptomycin; Tuberculosis; Tube | 1964 |
[CLINICAL EXPERIENCE WITH D.A.T.C].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance; Drug Resistance, | 1964 |
[TREATMENT OF PULMONARY TUBERCULOSIS WITH SUBSIDIARY DRUGS].
Topics: Antitubercular Agents; Humans; Isoniazid; Phenylthiourea; Streptomycin; Toxicology; Tuberculosis; Tu | 1964 |
[CLINICAL MANIFESTATIONS AND TREATMENT OF EARLY STAGES OF PRIMARY TUBERCULOSIS IN CHILDREN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bronchitis; Child; Drug Therapy; Erythema Nodosum; Humans | 1964 |
[TUBERCULIN AS AN ADDITIONAL FACTOR IN THE HEALING PROCESS IN TUBERCULOSIS].
Topics: Guinea Pigs; Isoniazid; Mycobacterium bovis; Pathology; Pharmacology; Research; Tuberculin; Tubercul | 1964 |
[HISTOCHEMICAL STUDY OF SUCCINIC DEHYDROGENASE IN TUBERCULOSIS].
Topics: Animals; Histocytochemistry; Isoniazid; Liver; Lung; Mycobacterium bovis; Pathology; Pharmacology; R | 1964 |
MAJOR SURGERY FOR PULMONARY TUBERCULOSIS: FINAL REPORT.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Bronchial Diseases; Disability Evaluation; Em | 1964 |
[QUANTITATIVE CONTROL OF URINARY INH IN AMBULATORY PATIENTS].
Topics: Drug Therapy; Humans; Isoniazid; Outpatient Clinics, Hospital; Tuberculosis; Urinary Tract; Urine | 1964 |
[POISONING WITH THERAPEUTIC DOSES OF ISONICOTINIC ACID HYDRAZIDE AND TRECATOR IN A 9-YEAR-OLD CHILD].
Topics: Child; Ethionamide; Isoniazid; Lymph Nodes; Toxicology; Tuberculosis; Tuberculosis, Lymph Node; Tube | 1964 |
[CASES OF TUBERCULOSIS OF THE PENIS ASSOCIATED WITH SPECIFIC CHANGES IN THE KIDNEYS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Humans; Isoniazid; Kidney; Male; Penis; Streptomycin; Sur | 1964 |
[TUBERCULOUS EXSUDATIVE PLEURISY IN ADVANCED AGE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Cell Count; Calcium; Geriatrics; Humans; Isoniazid; | 1964 |
[COMBINATION OF ETHIONAMIDE AND P-AMINOSALICYLIC ACID IN THE TREATMENT OF PULMONARY TUBERCULOSIS WITH GERMS RESISTANT TO ISONIAZID AND STREPTOMYCIN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Ethionamide; | 1963 |
[INDICATIONS AND UTILITY OF INTRATHECAL AND INTRAVENTRICULAR TREATMENT IN THE THERAPY OF TUBERCULAR MENINGITIS].
Topics: Child; Chlorpromazine; Humans; Injections; Injections, Spinal; Isoniazid; Prednisolone; Pyrazinamide | 1963 |
TREATMENT OF TUBERCULOSIS OF THE KNEE.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Drug Therapy; Ethionamide; Humans; Iso | 1964 |
[ON THE PROBLEM OF PRIMARY RESISTANCE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Clinical Laboratory Techniques; Drug Resistance; Drug Res | 1964 |
[INH THERAPY IN INH RESISTANCE].
Topics: Antitubercular Agents; Clinical Laboratory Techniques; Drug Resistance; Drug Resistance, Microbial; | 1964 |
HEMOLYTIC ANEMIA DUE TO AMINOSALICYLIC ACID. ANEMIA WITH METHEMOGLOBINEMIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anemia; Anemia, Hemolytic; Child; Diseases in Twins; Gluc | 1964 |
[DIAGNOSTIC AND THERAPEUTIC PROBLEMS OF OPEN CAVERN HEALING].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Caves; Clinical Laboratory Techniques; Drug Therapy; Ison | 1963 |
[EXPERIENCES IN THE TREATMENT OF VIRAL HEPATITIS IN TUBERCULOUS PATIENTS].
Topics: Adrenal Cortex Hormones; Communicable Diseases; Cycloserine; Drug Therapy; Hepatitis; Hepatitis A; I | 1963 |
ANAPHYLACTIC REACTION CAUSED BY INTRAMUSCULAR INJECTION OF LYOPHILIZED ALPHA-CHYMOTRYPSIN.
Topics: Aminophylline; Aminosalicylic Acid; Aminosalicylic Acids; Anaphylaxis; Betamethasone; Chymotrypsin; | 1964 |
[REMOTE RESULTS OF DRUG-INDUCED CAVITY CLOSURE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Isoniazid; Pneumonectomy; Pneumothorax; Pne | 1964 |
[ON THE PROBLEM OF DOSAGE IN INH THERAPY].
Topics: Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Humans; Isoniazid; Tuberculosis | 1964 |
MULTIPLE DEFICIENCY STATE ASSOCIATED WITH ISONIAZID THERAPY.
Topics: Anxiety; Depression; Ethionamide; Feeding and Eating Disorders; Isoniazid; Mental Disorders; Niacin; | 1964 |
[CLINICAL ASPECTS OF INFANTILE TUBERCULOSIS].
Topics: BCG Vaccine; Child; Chile; Diagnosis; Humans; Isoniazid; Mycobacterium bovis; Preventive Medicine; T | 1964 |
[THERAPEUTIC OUTLINE FOR THE TUBERCULOUS PATIENT].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Isoniazid; Streptomycin; Tuberculosis; Tube | 1964 |
[CHEMO-ANTIBIOTIC THERAPY OF TUBERCULOSIS IN DIABETICS AND ITS REPERCUSSIONS ON GLUCIDE METABOLISM].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Blood Glucose; Carbohydrate Metabo | 1964 |
[EVOLUTION OF THE TREATMENT OF OSTEO-ARTICULAR TUBERCULOSIS AFTER ANTIBIOCHEMOTHERAPY].
Topics: Adolescent; Humans; Isoniazid; Orthopedics; Surgical Procedures, Operative; Tomography; Tomography, | 1964 |
[BRONCHIAL INSTILLATIONS OF CHEMOANTIBIOTICS IN THE TREATMENT OF TUBERCULOUS CAVITIES].
Topics: Adolescent; Bronchi; Dosage Forms; Drug Therapy; Humans; Isoniazid; Radiography, Thoracic; Streptomy | 1964 |
[DIFFUSE BULLOUS DYSTROPHY OF THE TUBERCULOUS LUNG, ISONIAZID AND ADRENAL HYPERCORTICISM].
Topics: 17-Ketosteroids; Adolescent; Adrenocortical Hyperfunction; Isoniazid; Radiography, Thoracic; Toxicol | 1964 |
[OUR EXPERIENCE WITH OSTEOARTICULAR TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Arthrodesis; Humans; Isoniazid; Streptomycin; Surgical Pr | 1964 |
[ADRENAL HYPERFUNCTION IN ISONICOTINIC ACID HYDRAZIDE THERAPY].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adrenocortical Hyperfunction; Drug Therapy; | 1964 |
[CLINICO-ROENTGENOLOGICAL AND PATHOMORPHOLOGICAL CHARACTERISTICS OF CURED CAVERNS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Caves; Drug Therapy; Isoniazid; Lung; Pathology; Pneumone | 1964 |
[AEROSOL THERAPY WITH THE USE OF 3 ANTITUBERCULAR AND ANTISPASMODIC PREPARATIONS IN THE TREATMENT OF PULMONARY TUBERCULOSIS].
Topics: Aerosols; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Therapy; Ephedrine; | 1964 |
[TREATMENT OF BRONCHIAL TUBERCULOSIS WITH CORTISONE AEROSOLS].
Topics: Aerosols; Bronchial Diseases; Cortisone; Drug Therapy; Humans; Isoniazid; Respiratory Therapy; Strep | 1964 |
[ANTITUBERCULAR DRUGS. XIV. ISONICOTINOYLHYDRAZONES OF SOME PHENYLGLYOXYLIC ACIDS].
Topics: Antitubercular Agents; Chemistry, Pharmaceutical; Glyoxylates; Isoniazid; Mandelic Acids; Mice; Myco | 1964 |
[EFFECTS OF HIGH-ENERGY IONIZING RADIATIONS ON THE TUBERCLE BACILLUS. (1ST RESEARCH SERIES)].
Topics: Animals; Bacillus; Drug Resistance, Microbial; Guinea Pigs; Insecta; Isoniazid; Mycobacterium tuberc | 1964 |
[CLINICAL TRIAL OF 3 TYPES OF ORAL TREATMENT OF PULMONARY TUBERCULOSIS. (ISONIAZID+ETHIONAMIDE, ISONIAZID + PAS, ISONIAZID ALONE)].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Clinical Laboratory Techniques; Drug | 1964 |
TREATMENT OF INTESTINAL TUBERCULOSIS.
Topics: Drug Therapy; Gastroenterostomy; Humans; Isoniazid; Radiography; Streptomycin; Surgical Procedures, | 1964 |
EXPERIENCE WITH ENDOBRONCHIAL MEDICATION.
Topics: Bronchi; Bronchoscopy; Catheterization; Cough; Humans; Isoniazid; Lung; Reflex; Streptomycin; Tuberc | 1964 |
[PATHOMORPHOLOGICAL INDICES OF IMMUNOREACTIVE CHARACTERISTICS OF THE ORGANISM DURING ANTIBACTERIAL THERAPY OF TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Child; Drug Therapy; Isoniazid; Mo | 1964 |
ALTERNATING REGIMENS OF STREPTOMYCIN-PYAZINAMIDE, ISONIAZID-PARA-AMINOSALICYLIC ACID AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Drug Therapy | 1964 |
[CHEMOPROPHYLAXIS IN THE FIGHT AGAINST TUBERCULOSIS IN CHILDHOOD; GENERAL NORMS FOR ITS APPLICATION IN THE PROVINCE OF SEVILLE].
Topics: Adolescent; Chemoprevention; Child; Drug Therapy; Epidemiology; Humans; Infant; Infant, Newborn; Iso | 1964 |
THE CASE OF THE LILT OF LOVE'S LULLABY.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Isoniazid; Love; Social Conditi | 1964 |
[CLINICAL MEDITATIONS ON "BACTERIAL RESISTANCE" IN CHEMO-ANTIBIOTIC THERAPY OF PULMONARY TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacterial Infections; Drug Resista | 1964 |
[CURRENT DEVELOPMENT OF TUBERCULOUS SEROFIBRINOUS PLEURISY IN YOUNG ADULTS. STUDY OF 143 CASES EXAMINED AND FOLLOWED UP FROM 1954 TO 1962].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Exercise Therapy; | 1964 |
[CASE OF ENCEPHALOMYELORADICULONEURITIS FOLLOWING DIARRHEA].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Diarrhea; Drug Therapy; Encephalitis; Isoniazid; Kanamyci | 1964 |
[INCIDENCE AND DETERMINATION OF PHENOMENA OF BLOCKAGE IN RELATION TO ORIGINAL PROCESSES OF PULMONARY TUBERCULOSIS AND THEIR THERAPEUTIC TREATMENT].
Topics: Collapse Therapy; Humans; Incidence; Isoniazid; Italy; Statistics as Topic; Streptomycin; Thoracopla | 1964 |
EPIDEMIOLOGY AND CLINICAL COURSE OF 41 PATIENTS TREATED FOR PULMONARY DISEASE DUE TO UNCLASSIFIED MYCOBACTERIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Epidemiology; Humans; Isoniazid; Lung Diseases; Mycobacte | 1964 |
TREATMENT FOR TUBERCULOSIS OF THE SPINE. ANTI-TUBERCULOSIS DRUGS IN CONJUNCTION WITH RADICAL OPERATION AND SHORT HOSPITALIZATION WITH NO ENFORCED RECUMBENCY OR IMMOBILIZATION.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Child; Convalescence; Disability E | 1964 |
ON THE EFFECT EXERTED BY FIRST-LINE TUBERCULOSIS MEDICINES ON THE FOETUS.
Topics: Abnormalities, Drug-Induced; Aminosalicylic Acid; Aminosalicylic Acids; Fetus; Isoniazid; Pregnancy; | 1964 |
PRIMARY DRUG RESISTANCE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Child; Drug Resistance; Drug | 1964 |
ADRENAL CORTICOSTEROIDS IN LIFE-THREATENING PULMONARY TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Cachexia; Drug Therapy; Hydrocor | 1964 |
THE RESULTS OF DIFFERENT METHODS OF CHEMOTHERAPY IN THE TREATMENT OF PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; China; Drug Therapy; Isoniazid; Sputum; Statistics as Top | 1964 |
INJECTIONS ARE NO LONGER NECESSARY IN THE TREATMENT OF RENAL TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Cycloserine; Drug Therapy; Ethionami | 1964 |
ANNUAL CHANGE OF DRUG RESISTANCE CASES VIEWED THROUGH A JAPANESE NATIONAL SANATORIUM.
Topics: Dihydrostreptomycin Sulfate; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Humans; Ison | 1964 |
EFFECTS OF DIFFERENT CONCENTRATIONS OF ISONIAZID ON TUBERCLE BACILLI IN GUINEA PIGS.
Topics: Animals; Bacillus; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Lacticaseibacillus casei; Myc | 1964 |
[EXOPHTHALMIC FORM OF GANGOLPHE'S LACUNAR CRANIAL TUBERCULOSIS].
Topics: Black People; Child; Drug Therapy; Exophthalmos; Humans; Isoniazid; Radiography; Skull; Streptomycin | 1964 |
THE CHILD WITH A POSITIVE MANTOUX TEST.
Topics: Child; Drug Therapy; Humans; Infant; Isoniazid; Tuberculin Test; Tuberculosis | 1964 |
INFECTION OF MICE WITH MYCOBACTERIUM TUBERCULOSIS, STRAIN H37RA.
Topics: Animals; Isoniazid; Lung; Mice; Mycobacterium bovis; Mycobacterium tuberculosis; Pharmacology; Pyraz | 1964 |
[EFFECTIVENESS OF CHEMOTHERAPY IN PATIENTS WITH PULMONARY TUBERCULOSIS WITH VARIOUS COMBINATIONS AND SEQUENCE OF DRUGS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Dermatologic Agents; Drug Therapy; Isoniazid; Streptomyci | 1964 |
BILATERAL PULMONARY RESECTION FOR TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Brain; Brain Damage, Chronic; Drug T | 1964 |
[ON SOME PROBLEMS OF TUBERCULOSIS PREVENTION].
Topics: BCG Vaccine; Communicable Disease Control; Humans; Isoniazid; Mass Chest X-Ray; Mycobacterium bovis; | 1964 |
THE CLINICAL SIGNIFICANCE OF PRIMARY DRUG RESISTANCE IN TUBERCULOSIS AS JUDGED IN A MILITARY POPULATION, 1960-1963.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Drug Therapy | 1964 |
ETHIONAMIDE-INDUCED HEPATITIS. A REVIEW WITH A REPORT OF AN ADDITIONAL CASE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biopsy; Chemical and Drug Induced Liver Injury; Cycloseri | 1964 |
AN UNUSUAL URINARY FISTULA.
Topics: Abscess; Aminosalicylic Acid; Aminosalicylic Acids; Calcinosis; Escherichia coli Infections; Humans; | 1964 |
[FIRST EXPERIMENT OF ANTITUBERCULAR CHEMOPROPHYLAXIS WITH ISONIAZID ACCORDING TO THE OMODEI-ZORINI METHOD IN A GROUP OF ARABO-LIBIC CHILDREN OF CIRENAICA EXPOSED TO CONTAGIOUS FAMILIAL TUBERCULOSIS].
Topics: Antitubercular Agents; Chemoprevention; Child; Communicable Disease Control; Humans; Isoniazid; Liby | 1964 |
THE EFFECT OF MEASLES, GAMMA GLOBULIN MODIFIED MEASLES, AND ATTENUATED MEASLES VACCINE ON THE COURSE OF TREATED TUBERCULOSIS IN CHILDREN.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Child; Drug Therapy; gamma-Globulins | 1965 |
[ENZYMATIC STUDY OF THE LIVER IN PULMONARY TUBERCULOSIS. RESEARCH ON A POSSIBLE HEPATOTOXIC EFFECT OF ANTIBACTERIAL MEDICATIONS].
Topics: Alanine Transaminase; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Aspartate Am | 1964 |
STUDIES WITH A NEW ANTITUBERCULOSIS DRUG.
Topics: Antitubercular Agents; Biomedical Research; Drug Therapy; Ethionamide; Humans; Isoniazid; Streptomyc | 1964 |
CHEMOTHERAPY OF PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Hypersensitivity; Drug Resistance; Drug | 1964 |
PREGNANCY AND PULMONARY TUBERCULOSIS: OBSERVATIONS ON THE DOMICILIARY MANAGEMENT OF 238 PATIENTS IN INDIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Female; Home Care Services; Humans; India; | 1964 |
UNUSUAL LATE SEQUELAE OF TUBERCULOUS MENINGITIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Brain Diseases; Calcinosis; Drug Therapy; Epi | 1964 |
THE BLOOD LEVELS OF ISONIAZID AND PAS WHEN GIVEN TOGETHER AS ADEGRATE GRANULES.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Blood Chemical Analysis; Dosage Forms; Geriat | 1964 |
PAS SERUM CONCENTRATIONS OBTAINED WITH AN ADEGRATE GRANULE PREPARATION OF PAS AND ISONIAZID.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Chemical Analysis; Dosage Forms; Geriatrics; Isonia | 1964 |
[COMPARATIVE DATA ON PHTHIVAZID AND METHAZID INACTIVATION IN THE BODY OF TUBERCULOSIS PATIENTS].
Topics: Blood; Body Fluids; Drug Therapy; Humans; Isoniazid; Metabolism; Tuberculosis; Urine | 1964 |
[PRIMARY TUBERCULOUS ULCER ON THE FOOT OF A 3-YEAR-OLD CHILD].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Drug Therapy; Foot Diseases; Isoniazid; Tuberculos | 1964 |
THE PROBLEM AND MANAGEMENT OF DRUG-RESISTANT CASES OF PULMONARY TUBERCULOSIS IN KENYA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance; Drug Resistance, | 1964 |
POTT'S DISEASE TREATED WITHOUT SPINAL FUSION.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Therapy; Humans; Isoniazid; P | 1964 |
RE-TREATMENT OF DRUG-RESISTANT PULMONARY TUBERCULOSIS AT BATTEY STATE HOSPITAL.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1964 |
PRIMARY DRUG RESISTANCE AND PULMONARY TUBERCULOSIS. EMERGENCE OF PRIMARY DRUG RESISTANCE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Finland; Iso | 1964 |
A PRELIMINARY REPORT ON A NEW ANTITUBERCULOUS DRUG 4-AMINO-2-HYDROXY-PHENYL-1, 3, 4,-OXADIAZOL-2-OL WS 127.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Biomedical Research; Blood; Cyclos | 1964 |
SPUTUM CONVERSION IN CHRONIC TUBERCULOSIS WITH POLYRESISTANT BACILLI.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacillus; Cycloserine; Dihydrostre | 1964 |
INDICATIONS FOR THE PROPHYLACTIC USE OF ISONIAZID.
Topics: California; Drug Therapy; Humans; Isoniazid; Preventive Medicine; Radiography, Thoracic; Safe Sex; S | 1964 |
A CASE OF RED CELL APLASIA OCCURRING AS A RESULT OF ANTITUBERCULOUS THERAPY.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anemia; Anemia, Aplastic; Blood Cell Count; Bone Marrow C | 1964 |
TUBERCULOSIS IN THE GURKHAS OF NEPAL.
Topics: Asia, Western; Asian People; Communicable Disease Control; Drug Therapy; Isoniazid; Military Medicin | 1964 |
RESULTS OF CHEMOTHERAPY AND PARTIAL LUNG RESECTION FOR PULMONARY TUBERCULOSIS IN GURKHA SOLDIERS: A FIVE YEAR FOLLOW UP.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Asia, Western; Asian People; Drug Therapy; Follow-Up Stud | 1964 |
[EFFECT OF INH AND ACTH ON EXPERIMENTAL EXUDATIVE TUBERCULOSIS].
Topics: Adrenocorticotropic Hormone; Guinea Pigs; Isoniazid; Pharmacology; Research; Tuberculosis | 1964 |
[ON PRIMARY DRUG RESISTANCE OF MYCOBACTERIUM TUBERCULOSIS IN PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Humans; Isoniazid; Mycobacterium tubercul | 1964 |
[CHANGES IN THE SENSITIVITY TO CHEMOTHERAPY OF MYCOBACTERIUM TUBERCULOSIS IN ANIMAL ORGANISMS].
Topics: Animals; Cycloserine; Drug Resistance; Drug Resistance, Microbial; Ethionamide; Isoniazid; Kanamycin | 1964 |
[ON RELATION OF THE PHTHIVAZID RESISTANCE TO THE CATALASE ACTIVITY OF ACID-FAST MYCOBACTERIA].
Topics: Animals; Catalase; Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mycobacterium; Mycobacter | 1964 |
[TREATMENT OF TUBERCULOUS PATIENTS EXPECTORATING, MYCOBACTERIUM TUBERCULOSIS RESISTANT TO ANTIBIOTICS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anti-Bacterial Agents; Antibiotics, Antitubercular; Cyclo | 1964 |
ECTOPIC PREGNANCY ASSOCIATED WITH ACTIVE PELVIC TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Female; Humans; Isoniazid; Pathology; Pelvi | 1964 |
ANTITUBERCULOUS DRUGS AND SIDEROBLASTIC ANAEMIA.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Anemia; Anemia, Hypochromic; Anemia, Siderobl | 1965 |
[FIRST EXPERIENCES IN THE USE OF RIFAMYCIN SV ASSOCIATED WITH PAS USING THE METHOD OF VENOUS PERFUSION. CLINICAL CONTRIBUTION].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Humans; Infusions, Parenteral; Isoniazid; R | 1964 |
[TUBERCULOUS MENINGITIS WITH RESISTANT KOCH BACILLI; RECOVERY OWING TO CYCLOSERINE-PYRAZINAMIDE COMBINATION].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance | 1964 |
PRACTICAL ASPECTS OF TUBERCULOSIS PROPHYLAXIS.
Topics: Antibiotic Prophylaxis; Biomedical Research; Child; Communicable Disease Control; Drug Therapy; Huma | 1964 |
[TUBERCULIN REACTION IN CALFS AFTER VACCINATION WITH BCG VACCINES BOTH SENSITIVE AND RESISTANT TO STREPTOMYCIN AND ISONICOTINIC ACID HYDRAZIDE AND AFTER INFECTION WITH BOVINE BACILLUS DURING INH PREVENTIVE TREATMENT].
Topics: Animals; Bacillus; BCG Vaccine; Cattle; Drug Resistance; Drug Resistance, Microbial; Immune System P | 1964 |
[COMPARISON OF TUBERCULIN REACTION OF CHILDREN VACCINATED WITH BCG (MOREAU) VACCINE AND BCG VACCINE SENSITIVE AND RESISTANT TO INH AND STREPTOMYCIN].
Topics: BCG Vaccine; Child; Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium bo | 1964 |
PHLYCTENULAR KERATOCONJUNCTIVITIS AMONG ESKIMOS IN SOUTHWESTERN ALASKA. II. ISONIAZID PROPHYLAXIS.
Topics: Adolescent; Alaska; Biomedical Research; Child; Corneal Opacity; Drug Therapy; Humans; Infant; Infan | 1965 |
PRIMARY DRUG RESISTANCE: A CONTINUING STUDY OF DRUG RESISTANCE IN TUBERCULOSIS IN A VETERAN POPULATION WITHIN THE UNITED STATES. 3. THE RESISTANCE OF MYCOBACTEIA OTHER THAN MYCOBACTERIUM TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance; Drug Resistance, Microbial; Epidemiology | 1965 |
[CHEMOPROPHYLAXIS OF PRIMARY TUBERCULOSIS IN CHILDREN AND ADOLESCENTS IN FRANCE: AN EPIDEMIOLOGICAL STUDY OF CASES RECRUITED FROM 1948 TO 1958 AND FOLLOWED UP TO 1963].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Chemoprevention; Child; Drug Therapy; Epidemi | 1964 |
[BACTERIOLOGICAL FINDINGS IN SUBJECTS AFFECTED BY CHRONIC PULMONARY TUBERCULOSIS (FINDINGS ON PATIENTS HOSPITALIZED IN THE ISTITUTO "C. FORLANINI" IN THE 3 YEAR PERIOD 1960-62)].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Cycloserine; Drug Resistance; | 1964 |
TREATMENT OF TUBERCULOUS PLEURAL EFFUSION WITH LOCAL INSTILLATION OF HYDROCORTISONE.
Topics: Drug Therapy; Humans; Hydrocortisone; Isoniazid; Pleura; Pleural Effusion; Streptomycin; Tuberculosi | 1965 |
[RESISTANCE TO TUBERCULOSIS TREATMENT: SUGGESTED CONTROLS ON THE OUTCOME].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Isoniazid; Streptomycin; Tuberculosis | 1965 |
[CHEMOTHERAPY IN EARLY STAGES OF PRIMARY INFECTION AND IN THE PREVENTION OF INFECTION OF CHILDREN EXPOSED TO TUBERCULOSIS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; Child; Communicable Disease Cont | 1964 |
[FREQUENCY OF DRUG RESISTANCE AND ITS EFFECT ON THE COURSE OF OSTEOARTICULAR TUBERCULOSIS].
Topics: Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Isoniazid; Streptomycin; Tuberculosis; Tu | 1964 |
[EXPERIMENTAL STUDY OF THE HEALING MECHANISM OF TUBERCULOUS CAVERNS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Caves; Dogs; Electroencephalography; Isoniazid; Lung; Ner | 1964 |
[ON THE EFFECT OF PHTHIVAZID ON IMMUNOGENESIS IN VACCINATION AGAINST DIPHTHERIA AND WHOOPING COUGH IN CHILDREN WITH MANIFESTATIONS OF PRIMARY TUBERCULOSIS].
Topics: Antibodies; Child; Diphtheria; Diphtheria Toxoid; Drug Therapy; Humans; Isoniazid; Pertussis Vaccine | 1964 |
[THE REASON FOR OUR DISAPPOINTMENTS IN THE ANTITUBERCULOSIS CAMPAIGN].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; BCG Vaccine; Communicable Disease | 1964 |
[PRACTICAL PROBLEMS POSED BY RESISTANCE OF THE KOCH BACILLUS TO STREPTOMYCIN AND ISONIAZID].
Topics: Bacillus; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Isoniazid; Mycobacterium tuberc | 1965 |
[PROPHYLAXIS WITH ISONIAZID DURING PREGNANCY AND PUERPERIUM TO PREVENT THE REACTIVATION OF INACTIVE TUBERCULAR FOCI].
Topics: Communicable Diseases; Drug Therapy; Female; Humans; Isoniazid; Postpartum Period; Pregnancy; Pregna | 1964 |
ISONIAZID-INDUCED ENCEPHALOPATHY.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Brain Diseases; Diagnosis, Differential; Drug Therapy; Is | 1965 |
DISSEMINATED INFECTION CAUSED BY BATTEY TYPE MYCOBACTERIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Child; Culture Media; Diagnosis, Differential; Drug Thera | 1965 |
[STUDY OF AMBULATORY TREATMENT OF PULMONARY TUBERCULOSIS WITH THE COMBINATION OF 1906 CIBA (DPT) AND INH].
Topics: Drug Therapy; Isoniazid; Phenylthiourea; Thiourea; Toxicology; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
THE EPIDEMIOLOGIC BONUS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; BCG Vaccine; Drug Therapy; Epidemiology; Isoniazid; Mycob | 1965 |
FURTHER OBSERVATIONS ON THE LACK OF EFFECT OF ISONIAZID ON THE BLOOD AMMONIA CONCENTRATION.
Topics: Ammonia; Blood Chemical Analysis; Hemochromatosis; Heparin; Isoniazid; Liver Cirrhosis; Oxalates; Ph | 1965 |
U. S. VETERANS ADMINISTRATION-ARMED FORCES COOPERATIVE STUDY ON THE CHEMOTHERAPY OF TUBERCULOSIS. XII. RESULTS OF TREATMENT IN MILIARY TUBERCULOSIS: A FOLLOW-UP STUDY OF 570 ADULT PATIENTS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Follow-Up Studies; Geriatrics; Isoniazid; M | 1965 |
DRUG RESISTANCE IN PULMONARY TUBERCULOSIS; TREATMENT WITH ETHIONAMIDE IN VARIOUS DRUG COMBINATIONS.
Topics: Cycloserine; Drug Combinations; Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Drug Tole | 1965 |
PHARMACOKINETICS AND THE DOSE OF ISONIAZID AND P-AMINOSALICYLIC ACID IN THE TREATMENT OF TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Blood Chemical Analysis; Drug Therapy; Isoniazid; Kinetic | 1964 |
TREATMENT OF PULMONARY TUBERCULOSIS. A COMPARATIVE STUDY WITH A NEW DRUG.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Biomedical Research; Child; Drug Therapy; Hum | 1965 |
PRIMARY DRUG RESISTANCE: A CONTINUING STUDY OF TUBERCLE BACILLI IN A VETERAN POPULATION WITHIN THE UNITED STATES. IV. FACTORS INFLUENCING THE OBSERVED FREQUENCY OF RESISTANCE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacillus; Bacteriological Techniques; Drug Resistance; Dr | 1965 |
EFFECT OF ISONIAZID UPON THE REACTIVATION OF INACTIVE TUBERCULOSIS; FINAL REPORT.
Topics: Biomedical Research; Biometry; Drug Therapy; Isoniazid; Statistics as Topic; Tuberculosis | 1965 |
SPECIFIC DRUG THERAPY IN PULMONARY TUBERCULOSIS: ILLUSTRATED BY CLINICAL, RADIOLOGICAL, BACTERIOLOGICAL AND PATHOLOGICAL OBSERVATIONS IN RESECTED PATIENTS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Drug Resistance; Drug Resista | 1964 |
TUBERCULOSIS OF THE GENITAL ORGANS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Female; Genitalia; Humans; Isoniazid; Strep | 1965 |
[12 YEARS OF CHEMOTHERAPY WITH ISONIAZID. THE CHANGE IN INDICATIONS AND USE].
Topics: Drug Therapy; Humans; Isoniazid; Tuberculosis | 1965 |
CHEMOTHERAPY OF TUBERCULOSIS.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Classific | 1964 |
[THE ROLE OF THE ISONIAZID-BCG COMBINATION IN THE PREVENTION OF TUBERCULOSIS].
Topics: Adolescent; BCG Vaccine; Brazil; Child; Communicable Disease Control; Drug Therapy; Isoniazid; Mycob | 1964 |
UNITED STATES PUBLIC HEALTH SERVICE TRIALS OF ISONIAZID PROPHYLAXIS.
Topics: Alaska; Biomedical Research; Child; Communicable Disease Control; Drug Therapy; Humans; Isoniazid; P | 1964 |
THE RESULTS OF THE CHEMOPROPHYLACTIC TRIAL IN GREENLAND DURING THE FIRST FOUR YEARS.
Topics: Biometry; Communicable Disease Control; Drug Therapy; Greenland; Humans; Inuit; Isoniazid; Statistic | 1964 |
[ENDOCRINE-METABOLIC COMPLICATIONS OF ANTIBACTERIAL CHEMOTHERAPY. ISONIAZID AND CUSHING'S SYNDROME].
Topics: Anti-Bacterial Agents; Cushing Syndrome; Drug Therapy; Isoniazid; Toxicology; Tuberculosis; Tubercul | 1964 |
[EFFECTIVENESS OF THE TREATMENT OF PULMONARY TUBERCULOSIS WITH ANTITUBERCULAR AGENTS IN DIFFERENT CONDITIONS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Biometry; Drug Therapy; Isoniazid; | 1964 |
[REGIMEN OF CHEMOTHERAPY IN RELATION TO THE ECONOMIC RESOURCES OF THE DEVELOPING COUNTRY].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Developing Countries; Drug Therapy; Economics; Health Res | 1964 |
DOMICILIARY CHEMOTHERAPY FOR PULMONARY TUBERCULOSIS IN DEVELOPING COUNTRIES (BASED ON EXPERIENCE IN NIGERIA).
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Developing Countries; Drug Therapy; Economics; Isoniazid; | 1964 |
CHEMOTHERAPY OF PULMONARY TUBERCULOSIS WITH COAL-WORKERS PNEUMOCONIOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Anthracosis; Coal; Drug Therapy; Isoniazid; Silicotubercu | 1964 |
[CLINICAL PICTURE AND THERAPY OF EARLY MANIFESTATION OF TUBERCULOSIS IN SILICOTICS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Diagnosis; Drug Therapy; Isoniazid; Silicotuberculosis; S | 1964 |
[THE TREATMENT OF PNEUMOCONIO-TUBERCULOSIS IN COAL MINERS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Coal; Drug Therapy; France; Isoniazid; Silicotuberculosis | 1964 |
[THE PROBLEM OF CHEMOPROPHYLAXIS AND THE RESULTS OF LARGE SCALE EXPERIMENTS].
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Chemoprevention; Child; Communicable Disease | 1964 |
NEWER EXPERIMENTAL DATA ON CHEMOPROPHYLAXIS, WITH SPECIAL REGARD TO THE INFLUENCE OF TREATMENT ON ACQUIRED IMMUNITY.
Topics: Adaptive Immunity; Chemoprevention; Child; Communicable Disease Control; Drug Therapy; Isoniazid; Tu | 1964 |
CHEMOPROPHYLAXIS OF TUBERCULOSIS FOR ADULTS IN JAPAN.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Chemoprevention; Communicable Disease Control; Drug Thera | 1964 |
[CONSIDERATIONS ON THE APPLICATION OF ANTITUBERCULAR CHEMOPROPHYLAXIS IN RUMANIA].
Topics: Antitubercular Agents; Chemoprevention; Child; Communicable Disease Control; Drug Therapy; Isoniazid | 1964 |
THE EXTERNAL MANIFESTATIONS OF OCULAR TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Bacteriological Techniques; Child; Conjunctiva; Diagnosis | 1964 |
DIAGNOSIS AND TREATMENT OF ERYTHEMA INDURATUM (BAZIN).
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Diagnosis, Differential; Drug Therapy; Erythema Induratum | 1965 |
[INVOLUTION OF CAVERNOUS PULMONARY TUBERCULOSIS IN DOGS AFTER CHEMOTHERAPY].
Topics: Dogs; Isoniazid; Lung; Pathology; Pharmacology; Radiography; Research; Streptomycin; Tuberculosis; T | 1964 |
[EXPERIMENTAL STUDIES ON THE EFFECT OF SO-CALLED SECONDARY ANTITUBERCULOSIS DRUGS. (1). COMBINATION EFFECTS OF SM-INH-PAS, SM-INH-TH AND KM-TH-CS ON EXPERIMENTAL TUBERCULOSIS IN MICE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Antitubercular Agents; Isoniazid; Mice; Pharmaco | 1964 |
RENAL CALCIFICATION IN GENITO-URINARY TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Isoniazid; Nephrectomy; Nephrocalcinosis; P | 1965 |
[ON THE PROBLEM OF LIVER DAMAGE IN TUBERCULOSIS IN CHILDHOOD].
Topics: Adolescent; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Therapy; Hepa | 1965 |
[RELATIONSHIP BETWEEN CANCER AND TUBERCULOSIS. 2). A RETARDING EFFECT OF BCG INOCULATION FOR TUMOR INDUCTION IN MICE WITH INH OR URETHANE-4 NQO INJECTIONS].
Topics: Animals; Antitubercular Agents; BCG Vaccine; Isoniazid; Lung Neoplasms; Mice; Mycobacterium bovis; N | 1964 |
[QUANTITATIVE RESISTANCE DETERMINATION WITH MICROBIAL COUNTING METHODS].
Topics: Drug Resistance; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Sputum; | 1965 |
[DETERMINATION OF THE RESISTANCE OF TUBERCULOSIS BACTERIA IN THE SERIAL DILUTION TEST AND IN THE VERTICAL DIFFUSION TEST].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Resistance; Drug Resistance, Microbial; | 1965 |
[FEVER FROM UNKNOWN CAUSE].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Diagnosis, Differential; Endoscopy; Fever; Humans; Isonia | 1965 |
THE VIRULENCE OF TUBERCLE BACILLI FROM PATIENTS WITH PULMONARY TUBERCULOSIS IN INDIA AND OTHER COUNTRIES.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Bacillus; Guinea Pigs; India; Isoniazid; Mycobac | 1964 |
[THE TRYPTOPHAN TEST: TECHNIC AND RESULTS IN NONTUBERCULOUS PATIENTS AND IN TUBERCULOUS PATIENTS NOT TREATED WITH ISONIAZID (FOR AT LEAST A YEAR)].
Topics: Body Fluids; Clinical Laboratory Techniques; Drug Therapy; Humans; Isoniazid; Laboratories; Metaboli | 1965 |
[ON RENAL TUBERCULOSIS].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Humans; Isoniazid; Thiosemicarbazones; Tube | 1965 |
DISSEMINATED TUBERCULOSIS OF BONE: REPORT OF TWO CASES.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Diagnosis, Differential; Drug Therapy; Geriatrics; Isonia | 1965 |
CHEMOTHERAPY OF TUBERCULOSIS: A BACTERIOLOGIST'S VIEWPOINT.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Bacteriol | 1965 |
EXTERNAL BILIARY FISTULA, WITH PORTAL HYPERTENSION, DUE TO MULTIPLE TUBERCULOUS ABSCESSES OF THE LIVER.
Topics: Abscess; Aminosalicylic Acid; Aminosalicylic Acids; Biliary Fistula; Drainage; Drug Therapy; Gastroi | 1965 |
PRELIMINARY REPORT ON THIACETAZONE WITH ISONIAZID FOR MASS-TREATMENT OF PULMONARY TUBERCULOSIS.
Topics: Drug Therapy; Humans; Isoniazid; Thioacetazone; Thiosemicarbazones; Toxicology; Tuberculosis; Tuberc | 1965 |
TUBERCULOSIS OF THE MASTOID; (A CASE REPORT OF POSSIBLE KOCH'S PHENOMENON).
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Cresols; Drug Therapy; Ear Canal; Ear, Middle | 1965 |
[ON PARTICIPATION OF THE SANITARY-EPIDEMIOLOGICAL SERVICE IN TUBERCULOSIS CONTROL].
Topics: Communicable Disease Control; Drug Therapy; Humans; Isoniazid; Mass Chest X-Ray; Statistics as Topic | 1964 |
THE USE OF ETHIONAMIDE IN COMBINED DRUG REGIMENS IN THE RE-TREATMENT OF ISONIAZID-RESISTANT PULMONARY TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resi | 1965 |
[FAMILIAL CONTAMINATION DUE TO PULMONARY TUBERCULOSIS CARRIERS OF ISONIAZID-RESISTANT BACILLI].
Topics: Bacillus; Carrier State; Epidemiology; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1964 |
[VITAMIN METABOLISM AND 17-KETOSTEROID EXCRETION IN PATIENTS WITH CUTANEOUS TUBERCULOSIS TREATED WITH TUBAZID].
Topics: 17-Ketosteroids; Administration, Cutaneous; Body Fluids; Humans; Isoniazid; Tuberculosis; Tuberculos | 1965 |
CHEMOTHERAPY OF TUBERCULOSIS.
Topics: Carcinogens; Drug Therapy; Isoniazid; Lung Neoplasms; Mice; Neoplasms; Toxicology; Tuberculosis; Tub | 1965 |
[ANTITUBERCULAR TREATMENTS OF VERY SHORT DURATION IN MICE. I. METHOD OF STUDY AND COMPARISON WITH ANTIBACTERIAL DRUGS].
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Isoniazid; Mice; Mortality; Pharmacology; Res | 1965 |
[THE TRYPTOPHAN TEST IN TUBERCULOTICS TREATED WITH ISONIAZID AND A COMBINATION OF ISONIAZID AND PYRIDOXINE].
Topics: Drug Therapy; Humans; Isoniazid; Pyridoxine; Tryptophan; Tuberculosis; Tuberculosis, Pulmonary | 1965 |
U. S. VETERANS ADMINISTRATION-ARMED FORCES COOPERATIVE STUDY ON THE CHEMOTHERAPY OF TUBERCULOSIS.13. TUBERCULOUS MENINGITIS IN ADULTS, WITH SPECIAL REFERENCE TO SURVIVAL, NEUROLOGIC RESIDUALS, AND WORK STATUS.
Topics: Adult; Antitubercular Agents; Black People; Brain; Brain Damage, Chronic; Drug Therapy; Hemiplegia; | 1965 |
A FIELD EXPERIENCE OF MASS PERCUTANEOUS BCG INOCULATION AS AN IMMUNIZING AND DIAGNOSTIC PROCEDURE: FOLLOWING-UP PHASE.
Topics: BCG Vaccine; Black People; Drug Therapy; Humans; Isoniazid; Mass Screening; Mycobacterium bovis; Rad | 1965 |
TUBERCULOSIS IN WESTERN SAMOA AND TOKELAU ISLANDS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Child; Drug Therapy; Geriatrics; Humans; Inde | 1965 |
TUBERCULOSIS ABSCESS OF THE LIVER.
Topics: Abscess; Aminosalicylic Acid; Aminosalicylic Acids; Biopsy; Cholecystitis; Diagnosis, Differential; | 1965 |
PREVENTION OF TUBERCULOSIS AND REVERSAL OF TUBERCULIN REACTION IN GUINEA PIGS.
Topics: Animals; Biomedical Research; Guinea Pigs; Immune System Phenomena; Isoniazid; Pharmacology; Researc | 1965 |
INJECTIONS ARE NO LONGER NECESSARY IN THE TREATMENT OF RENAL TUBERCULOSIS.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Cycloserine; Drug Therapy; Ethionamide; Isoniazid; Kidney | 1965 |
[EXPERIMENTAL STUDIES ON THE DEVELOPMENT OF DRUG RESISTANCE IN VIVO. I. STUDIES ON THE DEVELOPMENT OF HYDRAZID (INH) AND STREPTOMYCIN (SM) RESISTANCE ON EXPERIMENTAL TUBERCULOSIS IN MICE].
Topics: Drug Resistance; Drug Resistance, Microbial; Isoniazid; Mice; Research; Streptomycin; Tuberculosis | 1965 |
[TREATMENT OF PRIMARY TUBERCULOUS INFECTION OF THE INFANT WITH RECTAL ETHIONAMIDE IN ASSOCIATION WITH ORAL ISONIAZID].
Topics: Child; Drug Therapy; Ethionamide; Humans; Infant; Isoniazid; Tuberculosis | 1965 |
[THE EARLY TREATMENT OF PULMONARY TUBERCULOSIS: EXPERIMENTAL STUDY].
Topics: Animals; Isoniazid; Lagomorpha; Lung; Pharmacology; Rabbits; Research; Streptomycin; Tuberculosis; T | 1964 |
[CONTRIBUTION TO A QUICK DIFFERENTIATION OF THE INDIVIDUAL ISONIAZID METABOLISM].
Topics: Cell Differentiation; Isoniazid; Metabolism; Tuberculosis | 1964 |
[ISONIAZID TREATMENT IN CASES OF ISONIAZID RESISTANCE].
Topics: Drug Resistance; Drug Resistance, Microbial; Drug Therapy; Isoniazid; Tuberculosis; Tuberculosis, Pu | 1964 |
[LEVEL OF BIOLOGICALLY-ACTIVE INH IN THE BLOOD SERUM OF TUBERCULOUS CHILDREN].
Topics: Blood; Child; Humans; Isoniazid; Serum; Tuberculosis | 1964 |
[TRYPTOPHAN STRESS AND INH METABOLISM IN THE TUBERCULOSIS DIABETIC].
Topics: Diabetes Mellitus; Drug Therapy; Humans; Isoniazid; Mental Disorders; Toxicology; Tryptophan; Tuberc | 1964 |
GENITAL TUBERCULOSIS IN THE FEMALE.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Australia; Diagnosis; Drug Therapy; Geriatrics; Isoniazid | 1965 |
TUBERCULOUS AORTITIS: SURGICAL RESECTION OF RUPTURED ABDOMINAL FALSE ANEURYSM.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Aneurysm; Aneurysm, False; Aneurysm, Infected; Aorta; Aor | 1965 |
[TEBAFEN IN THE TREATMENT OF TUBERCULOSIS IN CHILDREN].
Topics: Child; Drug Therapy; Humans; Infant; Isoniazid; Toxicology; Tuberculosis | 1965 |
[THE EFFECT OF CHEMOPROPHYLAXIS WITH PHTHIVAZID ON INFECTIVITY AND MORBIDITY OF CHILDREN AND ADOLESCENTS FROM TUBERCULOUS FOCI].
Topics: Adolescent; Chemoprevention; Child; Communicable Disease Control; Humans; Isoniazid; Morbidity; Tube | 1964 |
PATHOLOGICAL FINDINGS IN A TUBERCULOUS BABOON.
Topics: Animals; Drug Therapy; Isoniazid; Lung; Monkey Diseases; Papio; Pathology; Radiography, Thoracic; Tu | 1965 |
[RESISTANCE OF M. TUBERCULOSIS TO STREPTOMYCIN AND PHTHIVAZID AND INCIDENCE OF POSTOPERATIVE COMPLICATIONS IN PATIENTS WITH PULMONARY TUBERCULOSIS].
Topics: Antitubercular Agents; Drug Resistance; Drug Resistance, Microbial; Humans; Incidence; Isoniazid; My | 1964 |
[ROLE OF PYRIDOXINE IN EXPERIMENTAL CHEMOTHERAPY OF TUBERCULOSIS].
Topics: Isoniazid; Mice; Pyridoxine; Research; Tuberculosis | 1964 |
A CONTROLLED CLINICAL TRIAL OF ETHIONAMIDE, CYCLOSERINE AND PYRAZINAMIDE IN PREVIOUSLY TREATED PATIENTS WITH PULMONARY TUBERCULOSIS.
Topics: Cycloserine; Drug Therapy; Ethionamide; Isoniazid; Pyrazinamide; Radiography, Thoracic; Streptomycin | 1965 |
A CONTROLLED TRIAL OF ISONIAZID AND 4-4 DIISOAMYLOXYTHIOSEMICARBANILIDE COMPARED WITH ISONIAZID AND PAS AND ISONIAZID, STREPTOMYCIN AND PAS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Therapy; Geriatri | 1965 |
[THE CURRENT POSITION OF CULTURE AND ANIMAL TESTS IN THE DIAGNOSIS OF TUBERCULOSIS. II. THE SIGNIFICANCE OF ISONIAZID RESISTANCE AND BACTERIAL COUNT].
Topics: Bacterial Load; Bacteriological Techniques; Diagnosis; Drug Resistance; Drug Resistance, Microbial; | 1964 |
DISSOCIANTS OF M. TUBERCULOSIS AND ATYPICAL MYCOBACTERIA.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Bacteriological Techniques; Bacteriophage Typing | 1965 |
[ON THE EFFECTS OF TRASYLOL ON EXPERIMENTAL TUBERCULOSIS IN RABBITS].
Topics: Aprotinin; Isoniazid; Pharmacology; Rabbits; Research; Trypsin Inhibitors; Tuberculosis | 1964 |
ISONIAZID PROPHYLAXIS IN GENERAL PRACTICE.
Topics: Communicable Disease Control; General Practice; Humans; Isoniazid; Toxicology; Tuberculosis | 1965 |
SOME DIFFICULTIES IN THE TREATMENT OF TUBERCULOUS ALCOHOLICS.
Topics: Alcoholics; Alcoholism; Aminosalicylic Acid; Aminosalicylic Acids; Drug Therapy; Humans; Isoniazid; | 1965 |
CHEMOTHERAPY OF PULMONARY TUBERCULOSIS IN ADULTS: THE CHOICE OF DRUGS IN RELATION TO DRUG SUSCEPTIBILITY. A STATEMENT OF THE COMMITTEE ON THERAPY.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance; Drug Resistance, | 1965 |
SERUM IRON, COPPER, IRON-BINDING CAPACITY AND MARROW HEMOSIDERIN IN PULMONARY TUBERCULOSIS.
Topics: Adolescent; Aminosalicylic Acid; Aminosalicylic Acids; Blood; Blood Chemical Analysis; Blood Sedimen | 1965 |
[ON THE CONCEPT OF RESISTANCE IN RELATION TO DECREASED SENSITIVITY OF MYCOBACTERIA TUBERCULOSIS TO ISONIAZID].
Topics: Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium tuberculosis; Research; Tuberculosis | 1965 |
[REPERCUSSIONS OF EXPERIMENTAL TUBERCULOSIS ON MAMMARY GLANDS, THE TESTES AND THE ADRENAL GLANDS].
Topics: Adrenal Glands; Animals; Guinea Pigs; Humans; Inferior Colliculi; Isoniazid; Male; Mammary Glands, A | 1965 |
NICOTINAMIDE-ADENINE DINUCLEOTIDE-GLYCOHYDROLASE ACTIVITY IN EXPERIMENTAL TUBERCULOSIS.
Topics: Animals; Biochemical Phenomena; Biochemistry; Chloromercuribenzoates; Enzyme Inhibitors; Ethylmaleim | 1965 |
[The problem of endocrine disorders during isoniazid treatment].
Topics: Cushing Syndrome; Endocrine System Diseases; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuber | 1954 |
[Case report on the injurious side-effects of isoniazid].
Topics: Gastrointestinal Hemorrhage; Hemorrhage; Isoniazid; Niacin; Nicotinic Acids; Stomach; Stomach Diseas | 1954 |
[Blood iron level in isoniazid therapy of pulmonary tuberculosis].
Topics: Blood; Humans; Iron; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Modifications of tuberculous lesions in patients treated with isoniazid.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
Observations on the pathogenicity of isoniazid-resistant mutants of tubercle bacilli for tuberculous patients.
Topics: Animals; Bacillus; Gram-Positive Bacteria; Humans; Insecta; Isoniazid; Lacticaseibacillus casei; Myc | 1955 |
[Effects of streptomycin, PAS and isoniazid on tuberculin allergy in experimental tuberculosis in guinea pigs].
Topics: Aminosalicylic Acid; Drug Hypersensitivity; Guinea Pigs; Humans; Isomerism; Isoniazid; Niacin; Nicot | 1954 |
[Studies on the isonicotinylhydrazide methansulfonate (NA-salt) 1. Acute toxicity and tuberculostatic effects in vitro and in vivo].
Topics: In Vitro Techniques; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
Optic atrophy after administration of isoniazid with P.A.S.
Topics: Disease; Isoniazid; Niacin; Nicotinic Acids; Optic Atrophy; Optic Nerve; Optic Nerve Diseases; Tuber | 1955 |
[Acute hemorrhagic thrombocytopenic purpura caused by isoniazid in a primary tuberculous infection starting in the tonsils].
Topics: Disease; Isoniazid; Niacin; Nicotinic Acids; Palatine Tonsil; Pharyngeal Diseases; Purpura; Purpura, | 1955 |
[Possible survival factors in guinea pigs innoculated with Mycobacterium tuberculosis obtained from patients treated with isoniazid].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberc | 1954 |
[Our experience in treatment of meningeal tuberculosis with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1954 |
[Treatment of tuberculous meningitis and isoniazid].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1955 |
[Allergometric variations during antibacterial therapy with isoniazid associated with PAS].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculo | 1954 |
[Case of possible primary isoniazid resistance].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Our opinion on the importance of isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Increasing frequency of resistance to isoniazid in patients arriving at the sanatorium].
Topics: Hospitals; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosi | 1954 |
[Treatment of pulmonary tuberculosis with high doses of isoniazid; report on 100 cases].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[Results of three months of combined isoniazid and PAS therapy of pulmonary tuberculosis; comparison with isoniazid therapy alone and with combined isoniazid, streptomycin and PAS].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberc | 1954 |
[Use of subcontinuous isoniazid and hyaluronidase aerosols in very grave pulmonary tuberculosis; a year and a half of tests].
Topics: Aerosols; Hyaluronoglucosaminidase; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, | 1954 |
Chemotherapy of miliary and meningeal tuberculosis; progress report on isoniazid.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Research Report; Streptomycin; T | 1955 |
[A rare accident in the isoniazid treatment of tuberculous meningitis in a child].
Topics: Accidents; Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1954 |
Topical isoniazid-streptomycin aerosol in the treatment of pulmonary tuberculosis.
Topics: Aerosols; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Treatment of tuberculosis with intermittent streptomycin and isoniazid.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1955 |
[Effects of isonicotinic acid hydrazide on the lysozyme activity of blood in tuberculosis].
Topics: Anti-Infective Agents, Local; Blood; Dermatologic Agents; Humans; Isoniazid; Muramidase; Niacin; Nic | 1954 |
Isoniazid treatment of pulmonary tuberculosis in out-patients: a clinical trial.
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Outpatients; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Isoniazid by the intrathecal route in the therapy of tuberculous meningitis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1955 |
The treatment of primary tuberculosis in children; results of a controlled study using isoniazid.
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
Two years' experience with isonicotinic acid hydrazide.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis | 1955 |
[Effect of varying doses of isoniazid on advanced experimental tuberculosis in the mouse; effect of massive doses].
Topics: Animals; Isoniazid; Mice; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
[Treatment of cervical lymph node tuberculosis with isonicotinic acid hydrazide and thiosemicarbazone combination].
Topics: Isoniazid; Lymph Nodes; Niacin; Nicotinic Acids; Thiosemicarbazones; Tuberculosis; Tuberculosis, Lym | 1955 |
[The treatment of infantile tuberculosis with isoniazid].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Streptomycin, thiosemicarbazone, PAS and isoniazid in therapy of tuberculous meningitis in children].
Topics: Child; Drug Therapy; Humans; Infant; Isoniazid; Lymph Nodes; Streptomycin; Thiosemicarbazones; Tuber | 1955 |
[Anatomical and histological research on the development of experimental tuberculosis in the guinea pig treated with isoniazid].
Topics: Guinea Pigs; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1954 |
Isoniazid in the treatment of primary pulmonary tuberculosis.
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Virulence for the guinea pig of Koch bacilli isolated from tuberculous patients treated with isoniazid].
Topics: Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Virulence | 1954 |
Tuberculin hypersensitivity in tuberculous infants treated with isoniazid.
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculin; Tuberculin Test; Tuberculosis | 1955 |
[PAS-isoniazid and PAS-streptomycin combined therapy, a comparison of two case series].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Research Design; Streptomycin; Tuberculosis | 1955 |
[Observations on the treatment of surgical tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoarticular | 1954 |
[Current status of tuberculosis therapy with isoniazid].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
Attenuation of isoniazid-resistant mutants of tubercle bacilli and host hypersensitivity to tuberculin.
Topics: Bacillus; Gram-Positive Bacteria; Hypersensitivity; Isoniazid; Lacticaseibacillus casei; Mycobacteri | 1955 |
[Therapeutic value of alternative application of streptomycin and isoniazid in meningeal tuberculosis in children].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, | 1954 |
[Therapeutic effect of isonicotinic acid hydrazide in the urological field and first results of perirenalureteral infusion of antibiotics].
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[The effects of tuberculostatics on the carbohydrates metabolism, demonstrated by the sample of isonicotinic acid hydrazide].
Topics: Carbohydrate Metabolism; Carbohydrates; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tu | 1955 |
[The use of isonicotinic acid hydrazide in skin tuberculosis and other skin diseases].
Topics: Isoniazid; Niacin; Nicotinic Acids; Skin Diseases; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
[Sensitivity and resistance of Mycobacterium tuberculosis before and during isoniazid therapy].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosi | 1953 |
[Herpes zoster as a results of isonicotinic acid hydrazide; contribution to the enurotropictoxic effects of INH].
Topics: Herpes Zoster; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
[The treatment of pulmonary tuberculosis of the adult type in puberty with isonicotinic acid hydrazide (INH)].
Topics: Adolescent; Disease; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Puberty; Sexual Maturation; Tube | 1954 |
[Preliminary clinical results of isoniazid therapy].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1954 |
Isoniazid in tuberculous peritonitis of childhood.
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Peritonitis; Peritonitis, Tuberculous; Tu | 1955 |
Isoniazid in single and multiple drug regimens in the treatment of pulmonary tuberculosis of recent origin.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1955 |
[Isonicotinic acid hydrazide in the therapy of female genital tuberculosis].
Topics: Female; Humans; Isoniazid; Niacin; Nicotinic Acids; Pelvis; Tuberculosis; Tuberculosis, Female Genit | 1954 |
[Therapeutic effect of isonicotinic acid hydrazide (INH) in cutaneous tuberculosis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous | 1954 |
[Therapy of eye tubercolosis with isoniazid].
Topics: Eye; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1955 |
[Therapeutic use of isoniazid in ophthalmology; preliminary report].
Topics: Eye; Eye Diseases; Isoniazid; Niacin; Nicotinic Acids; Ophthalmology; Tuberculosis; Tuberculosis, Oc | 1955 |
[Circulatory changes in human tuberculosis treated with isonicotinic acid hydrazide].
Topics: Blood Circulation; Cardiovascular Physiological Phenomena; Isomerism; Isoniazid; Niacin; Nicotinic A | 1954 |
[Therapy of tuberculosis of the kidneys and of the urogenital system with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Renal; Tuberculosis, Urogenital; Uro | 1954 |
[The question of side effects intrathecal and oral isoniazid treatment in children].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, | 1955 |
[Influence of the reduction capacity of isoniazid on the results of the Hagedorn-Jensen reaction in cerebrospinal fluid in tuberculous meningitis].
Topics: Cerebrospinal Fluid; Isomerism; Isoniazid; Leadership; Niacin; Nicotinic Acids; Tuberculosis; Tuberc | 1955 |
[Isoniazid as preferred drug in therapy of tuberculosis in children].
Topics: Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Treatment of ocular tuberculosis with isoniazid].
Topics: Eye; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocular | 1955 |
[Cellular changes in the bone marrow and in the peripheral blood in tuberculosis in children following prolonged application of massive doses of isoniazid].
Topics: Blood; Bone Marrow; Child; Humans; Infant; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Prolonged administration of isoniazid as anti-infectious therapy in tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
A comparison of the efficacy of iproniazid (marsilid) and isoniazid (rimifon) in the treatment of bone and joint tuberculosis.
Topics: Bone and Bones; Iproniazid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Osteoart | 1955 |
[Development of resistance of Mycobacterium tuberculosis to isonicotinic acid hydrazide during the treatment of pulmonary tuberculosis].
Topics: Isomerism; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosi | 1954 |
[Comparative results of continuous treatment of ulcero-nodular tuberculosis for 10 months with isoniazid-PAS and with isoniazidstreptomycin].
Topics: Aminosalicylic Acid; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tuberculosis, P | 1955 |
ISONIAZID (INH), PAS and streptomycin in pulmonary tuberculosis; a control study on 443 cases.
Topics: Aminosalicylic Acid; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomycin; Tuberculosis; Tube | 1955 |
Intrapleural administration of isoniazid in tuberculous empyema; concentration in serum and pleural fluid.
Topics: Blood; Empyema, Tuberculous; Exudates and Transudates; Isoniazid; Niacin; Nicotinic Acids; Tuberculo | 1955 |
[Results of treatment of meningeal tuberculosis in children since the use of isoniazid].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1955 |
[Variations of blood proteins in evaluation of therapeutic effects of isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Blood Proteins; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
[Transfer of isonicotinic acid hydrazide from mother to fetus].
Topics: Child; Female; Fetus; Infant; Isoniazid; Mothers; Niacin; Nicotinic Acids; Placenta; Pregnancy; Stre | 1955 |
[Dangers in the treatment of tuberculosis with isoniazid].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[Isoniazid in the treatment of meningeal tuberculosis].
Topics: Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Me | 1955 |
[Massive doses of intraspinal isoniazid in tuberculous meningitis].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1955 |
[Results of treatment of meningeal tuberculosis in children since the use of isoniazid].
Topics: Aminosalicylic Acid; Child; Humans; Infant; Isomerism; Isoniazid; Niacin; Nicotinic Acids; Streptomy | 1955 |
[The fate of isoniazid-resistant tubercle bacilli in tuberculous patients].
Topics: Bacillus; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
[The question of isoniazid binding to blood proteins].
Topics: Blood Proteins; Electrophoresis; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pul | 1955 |
[Passage of isonicotinic acid hydrazide from mother to newborn; determination of isoniazid in milk, maternal blood and follicular blood].
Topics: Blood; Female; Humans; Isoniazid; Milk, Human; Mothers; Nicotinic Acids; Placenta; Pregnancy; Tuberc | 1955 |
[Some apparently unusual secondary effects of isonicotinic acid hydrazide on the digestive tract].
Topics: Colitis; Constipation; Gastrointestinal Tract; Humans; Isoniazid; Niacin; Nicotinic Acids; Peptic Ul | 1955 |
[Treatment of meningeal tuberculosis by isoniazid in adequate doses; two and a half years of experience].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1955 |
The treatment of pulmonary tuberculosis with iproniazid (1-isonicotinyl-2-isopropyl hydrazine) and isoniazid (isonicotinyl hydrazine).
Topics: Hydrazines; Iproniazid; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1955 |
The clinical significance of positive cultures and of isoniazid-resistant tubercle bacilli during the treatment of pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council.
Topics: Bacillus; Biomedical Research; Gram-Positive Bacteria; Isoniazid; Mycobacterium tuberculosis; Niacin | 1955 |
[Side effects of isoniazid in the treatment of tuberculous patients].
Topics: Isomerism; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1955 |
Isoniazid therapy of primary tuberculosis in children.
Topics: Isoniazid; Tuberculosis | 1960 |
[The contagiosity of adult pulmonary tuberculotics treated by isoniazid. Recent control by the study of 140 cases of primary tuberculosis in children observed in 1957 and 1958].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[On the effect of INH metabolism on the therapy of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[On the therapy of skin tuberculosis with INH and INH derivatives].
Topics: Administration, Cutaneous; Humans; Isoniazid; Tuberculosis; Tuberculosis, Cutaneous | 1959 |
The effect of rubeola on tuberculosis under antimicrobial therapy. I. Primary pulmonary tuberculosis treated with isoniazid.
Topics: Anti-Infective Agents; Child; Infant; Isoniazid; Measles; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
The effect of rubeola on tuberculosis under antimicrobial therapy. II. Tuberculous meningitis treated with isoniazid, streptomycin and paraaminosalicylic acid.
Topics: Aminosalicylic Acid; Anti-Infective Agents; Antitubercular Agents; Child; Humans; Infant; Isoniazid; | 1959 |
[On the treatment of childhood forms of tuberculosis with tebafen (GT3)].
Topics: Child; Humans; Infant; Isoniazid; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Isorilone in chronic pulmonary tuberculosis.
Topics: Isoniazid; Sulfanilamide; Sulfanilamides; Sulfonamides; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Activity of niamid tuberculosis and cross resistance to isonizid.
Topics: Iproniazid; Isoniazid; Mycobacterium tuberculosis; Nialamide; Tuberculosis | 1960 |
[The histopathology of regressive tuberculosis in the guinea pig after infection with isoniazidresistant mycobacteria].
Topics: Guinea Pigs; Isoniazid; Mycobacterium; Tuberculosis | 1960 |
[The enzymatic modifications of isoniazid-resistant tuberculous bacilli].
Topics: Bacillus; Enzymes; Gram-Positive Bacteria; Isoniazid; Lacticaseibacillus casei; Mycobacterium tuberc | 1959 |
[The influence of isoniazid and adrenal cortex hormones on the serum polysaccharides in tuberculosis in childhood].
Topics: Adrenal Cortex Hormones; Child; Humans; Infant; Isoniazid; Leadership; Polysaccharides; Tuberculosis | 1960 |
Results of therapy with thiocarbanidin used with isoniazid or streptomycin.
Topics: Antitubercular Agents; Isoniazid; Streptomycin; Thiourea; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Neurotoxic manifestations in a tuberculous patient during treatment with large doses of isoniazid].
Topics: Central Nervous System Depressants; Humans; Isoniazid; Nervous System; Neurotoxicity Syndromes; Tube | 1959 |
Cycloserine-isoniazid in the treatment of chronic, resistant pulmonary tuberculosis.
Topics: Cycloserine; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Dosages of isoniazid and streptomycin for routine chemotherapy of tuberculosis.
Topics: Isoniazid; Streptomycin; Tuberculosis | 1960 |
Usefulness of a combined isoniazid, para-aminosalicylic acid and pyridoxine preparation.
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Isoniazid; Pyridoxine; Tuberculosis; Tuberculosis, Pulmo | 1959 |
The pathogenicity for guinea pigs of isoniazidresistant tubercle bacilli isolated from patients on a high-dose isoniazid regimen.
Topics: Animals; Bacillus; Gram-Positive Bacteria; Guinea Pigs; Isoniazid; Lacticaseibacillus casei; Tubercu | 1960 |
[Behavior of blood catalase in tuberculous patients treated with INH. (Communication II)].
Topics: Catalase; Humans; Isoniazid; Tuberculosis | 1960 |
[Antitubercular chemoprophylaxis with Omodel Zorini's method in silicotic patients].
Topics: Antitubercular Agents; Chemoprevention; Humans; Isoniazid; Silicosis; Tuberculosis; Tuberculosis, Pu | 1960 |
Streptovaricin and isoniazid in the treatment of pulmonary tuberculosis.
Topics: Anti-Bacterial Agents; Isoniazid; Streptovaricin; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Psychological side-effects during long-term ambulatory chemotherapy with isoniazid and PAS.
Topics: Aminosalicylic Acid; Isoniazid; Tuberculosis | 1959 |
[Present status in Italy of antitubercular "chemioprophylaxis" by means of isoniazid].
Topics: Humans; Isoniazid; Italy; Tuberculosis | 1959 |
[The chemoprophylaxis of tuberculosis by means of isoniazid in Italy at the present time].
Topics: Antibiotic Prophylaxis; Chemoprevention; Humans; Isoniazid; Italy; Tuberculosis | 1960 |
Isonlazid prevents tuberculous meningitis.
Topics: Biomedical Research; Humans; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1960 |
[Experiences with transthoracic injections of isonized in tuberculous lung cavities].
Topics: Injections; Isoniazid; Tuberculosis | 1959 |
The prevalence of bacterial resistance to isoniazid and to PAS in patients with acute pulmonary tuberculosis presenting for treatment in East Africa.
Topics: Acute Disease; Africa, Eastern; Aminosalicylic Acid; Bacterial Infections; Isoniazid; Prevalence; Tu | 1960 |
Comparison of isoniazid alone with isoniazid--PAS in the original chemotherapy of noncavitary pulmonary tuberculosis. Results from the Veterans Administration-Armed Forces co-operative study on the chemotherapy of tuberculosis.
Topics: Aminosalicylic Acid; Humans; Isoniazid; Military Personnel; Tuberculosis; Tuberculosis, Pulmonary; U | 1959 |
Tuberculous meningitis since the introduction of isoniazid.
Topics: Antitubercular Agents; Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1960 |
Tuberculosis chemoprophylaxis.
Topics: Antibiotic Prophylaxis; Chemoprevention; Isoniazid; Tuberculosis | 1960 |
Follow-up investigation of eleven cases of miliary tuberculosis and tuberculous meningitis.
Topics: Aminosalicylic Acid; Follow-Up Studies; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Meninge | 1959 |
[On the pathogenic power of isoniazid-resistant tuberculous bacilli].
Topics: Bacillus; Gram-Positive Bacteria; Isoniazid; Lacticaseibacillus casei; Mycobacterium tuberculosis; T | 1959 |
[Isoniazid in experimental tuberculous charce of guinea pig skin].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Cutaneous | 1959 |
[Is it necessary to apply large doses of isoniazid in the treatment of tuberculosis in children?].
Topics: Isoniazid; Tuberculosis | 1960 |
Cycloserine and isoniazid in childhood tuberculous infections.
Topics: Child; Cycloserine; Infant; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Treatment of pulmonary tuberculosis with cycloserine and isoniazid: a preliminary report.
Topics: Cycloserine; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
Pulmonary tuberculosis treated with high doses of INH plus glutamic acid.
Topics: Glutamates; Glutamic Acid; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Serum transaminase in tuberculotic children after prolonged treatment with isonicotinic acid hydrazide].
Topics: Child; Humans; Infant; Isoniazid; Transaminases; Tuberculosis | 1959 |
Oxytetracycline and isoniazid combination as original treatment of pulmonary tuberculosis.
Topics: Isoniazid; Oxytetracycline; Tuberculosis; Tuberculosis, Pulmonary | 1960 |
[Experimental studies on the effects of past immunization with BCG on the power of antitubercular drugs to arrest the onset of tuberculosis].
Topics: Antitubercular Agents; Humans; Immunization; Isoniazid; Mycobacterium bovis; Tuberculosis | 1959 |
[The use of sulfoniazide in forms of pulmonary tuberculosis in childhood].
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1959 |
Decrease of bacteriotropic activity of isoniazid on M. tuberculosis in the presence of anthranilic acid.
Topics: Health Services; Isoniazid; Mycobacterium tuberculosis; ortho-Aminobenzoates; Tuberculosis | 1960 |
Drug resistance in out-patients treated with sodium PAS and isoniazid cachets.
Topics: Aminosalicylic Acid; Drug Resistance; Isoniazid; Outpatients; Sodium; Sodium, Dietary; Tuberculosis; | 1959 |
Case reports of the Massachusetts General Hospital. Case 42-1961.
Topics: Hospitals, General; Isoniazid; Liver; Massachusetts; Medical Records; Peptic Ulcer Hemorrhage; Tuber | 1961 |
Morphological study of the chemotherapeutic effect on the experimental pulmonary tuberculosis of rabbits.
Topics: Animals; Isoniazid; Lagomorpha; Lung; Rabbits; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
The open-negative tuberculous patient.
Topics: Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
Peroxidase activity and INH resistance in M. tuberculosis.
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Oxidation-Reduction; Oxidoreductases; Tuberculosis | 1962 |
[Amyloid goiter with increased thyroid function in a patient with pulmonary tuberculosis].
Topics: Goiter; Humans; Hyperthyroidism; Isoniazid; Medical Records; Streptomycin; Tuberculosis; Tuberculosi | 1962 |
[Experience with "Elpimed" as an adjuvant in streptomycin and isoniazid therapy of pulmonary tuberculosis].
Topics: Adjuvants, Immunologic; Adjuvants, Pharmaceutic; Blood; Immunization, Passive; Isoniazid; Streptomyc | 1961 |
Effect of isoniazid upon the reactivation of inactive tuberculosis. Preliminary report.
Topics: Humans; Isoniazid; Tuberculosis | 1962 |
[The effect of early treatment with isoniazid on the protective effect against reinfection in the mouse].
Topics: Animals; Isoniazid; Mice; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Reversible pyridoxine-sensitive symptomatic sideroachrestic anemia during isoniazid therapy of caseous lymph node tuberculosis with exudative pleurisy].
Topics: Anemia; Humans; Isoniazid; Lymph Nodes; Medical Records; Pleurisy; Pyridoxine; Tuberculosis; Tubercu | 1962 |
[Study on infection with drug resistant tubercle bacilli from patients among the already tuberculin-positive persons without tuberculous lesions in a workshop].
Topics: Aminosalicylic Acid; Bacillus; Humans; Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tubercul | 1962 |
[A study on the distribution of the plasma concentration of active INH pulmonary tuberculous patients].
Topics: Humans; Isoniazid; Tuberculosis | 1962 |
[Histochemical studies on fibrosis in cases of tuberculosis luposa of the skin treated with isonicotinic acid hydrazide].
Topics: Administration, Cutaneous; Humans; Isoniazid; Skin; Tuberculosis; Tuberculosis, Cutaneous | 1961 |
[The effect of isoniazid on glycide metabolism. II. The blood level of pyruvic acid and alpha-ketoglutaric acid in tuberculous patients after a single administration of isoniazid].
Topics: Epoxy Compounds; Isoniazid; Keto Acids; Ketoglutaric Acids; Propanols; Pyruvates; Pyruvic Acid; Tube | 1962 |
[The effect of isoniazid on glucide metabolism. IV. Excretion of pyruvic acid and alpha-ketoglutaric acid after isoniazid administration in tuberculous children and adults].
Topics: Biological Transport; Body Fluids; Humans; Isoniazid; Keto Acids; Ketoglutaric Acids; Pyruvates; Pyr | 1962 |
[Modern chemotherapy of pulmonary tuberculosis (a summary of WHO & NTA statements)].
Topics: Aminosalicylic Acid; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Concentration of free isoniazid in the blood of pulmonary tuberculosis patients].
Topics: Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
Isoniazid in primary tuberculosis in infancy. A controlled clinical trial.
Topics: Child; Humans; Infant; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Studies on the antitubercular action of N-acetyl-D-glucosaminyl-isonicotinic acid hydrazide (AG-INH)].
Topics: Antitubercular Agents; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Phthivazid polyneuritis in tuberculous patients].
Topics: Humans; Isoniazid; Neuritis; Tuberculosis | 1962 |
[Comparative studies on chemotherapeutic activities of isonicotinic acid hydrazide and its derivatives in experimental tuberculosis].
Topics: Isoniazid; Tuberculosis | 1961 |
[Spontaneous development of primary tuberculosis and its changes under the influence of chemotherapy].
Topics: Aminosalicylic Acid; Child; Infant; Isoniazid; Leadership; Tuberculosis | 1961 |
[Pulmonary resections in tuberculosis. The use of isoniazid, ethioniamide, streptomycin and cycloserine].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Isoniazid; Pneumonectomy; Pulmonary Surgica | 1961 |
[Experimental studies on the penetration of anti-tuberculous agents into the ocular tissues. II. Penetration of INAH].
Topics: Anti-Anxiety Agents; Eye; Eye Injuries, Penetrating; Isoniazid; Tuberculosis | 1961 |
[The protective action of isoniazid in tubercular infections studied by the auto-radiographic technic].
Topics: Autoradiography; Isoniazid; Tuberculosis | 1961 |
[Relation between protection by BCG vaccination and the antibacterial action of isoniazid in tubercular infections obtained in mice by means of mycobacteria labeled with C-14 radiocarbon].
Topics: Animals; Anti-Bacterial Agents; BCG Vaccine; Isoniazid; Mice; Mycobacterium; Mycobacterium bovis; Tu | 1961 |
[Treatment of genital tuberculosis].
Topics: Aminosalicylic Acids; Female; Humans; Isoniazid; Tuberculosis; Tuberculosis, Female Genital; Tubercu | 1961 |
[Effects of combined treatment with thiasin-INH and thiasin-INH and SM or KM on tuberculous diseases of the eye].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Combined Modality Therapy; Eye; Humans; Isoniazid; Str | 1961 |
Preventive effects of isoniazid in the treatment of primary tuberculosis in children.
Topics: Child; Infant; Isoniazid; Tuberculosis | 1961 |
The effect of isoniazid prophylaxis on tuberculosis morbidity among household contacts of previously known cases of tuberculosis.
Topics: Family Characteristics; Humans; Isoniazid; Morbidity; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[Combined therapy of massive doses of isoniazid, pyrazinamide, and sulfisoxazole for patients with pulmonary tuberculosis resistant to streptomycin, paraaminosalicylic acid, and isoniazid].
Topics: Aminosalicylic Acid; Humans; Isoniazid; Psychotherapy, Multiple; Pyrazinamide; Streptomycin; Sulfani | 1961 |
[Reparative processes in the lungs in primary tuberculosis in children treated with antibacterial preparations].
Topics: Aminosalicylic Acid; Anti-Bacterial Agents; Child; Infant; Isoniazid; Streptomycin; Tuberculosis; Tu | 1961 |
Standards of therapy for tuberculosis, 1962.
Topics: Chemoprevention; Humans; Isoniazid; Lung; Pulmonary Surgical Procedures; Time Factors; Tuberculosis; | 1962 |
[Sulfadimethoxine and INH combined therapy. Basc principles and clinical aspects].
Topics: Isoniazid; Psychotherapy, Multiple; Sulfadimethoxine; Sulfanilamide; Sulfanilamides; Sulfonamides; T | 1962 |
[Therapeutic results obtained in tuberculous meningitis in adults since the use of INH].
Topics: Isoniazid; Tuberculosis; Tuberculosis, Meningeal | 1962 |
The course of pulmonary tuberculosis in patients excreting organisms which have acquired resistance. Response to continued treatment for a second year with isoniazid alone or with isoniazid plus PAS.
Topics: 4-Aminobenzoic Acid; Guinea Pigs; Humans; India; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. 3. Virulence related to pretreatment status of disease and to response to chemotherapy.
Topics: Aged; Antitubercular Agents; Bacillus; Guinea Pigs; Humans; India; Isoniazid; Tuberculosis; Tubercul | 1961 |
The role of diet in the treatment of pulmonary tuberculosis. An evaluation in a controlled chemotherapy study in home and sanatorium patients in South India.
Topics: Antitubercular Agents; Body Weight; Diet; Disease Management; Humans; India; Isoniazid; Nutrition As | 1961 |
[Effect of phthivazid on the secretary function of the stomach in normal dogs and those infected with tuberculosis].
Topics: Animals; Dogs; Isoniazid; Stomach; Tuberculosis | 1961 |
Multiplication of Mycobacterium tuberculosis in the lungs and its modification by immunity and by isoniazid.
Topics: Isoniazid; Lung; Mycobacterium tuberculosis; Tuberculin; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Cycloserine-viomycin association in the treatment of pulmonary tuberculosis caused by isoniazid- and streptomycin-resistant bacilli (first results)].
Topics: Bacillus; Cycloserine; Humans; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary; Viomy | 1961 |
[Cycloserine-viomycin combination in the treatment of pulmonary tuberculosis caused by isoniazid and streptomycin resistant bacilli. (1st results)].
Topics: Bacillus; Cycloserine; Isoniazid; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary; Viomycin | 1961 |
[Gastric resection and pulmonary tuberculosis. X. Isoniazid chemioprophylaxis according to the Omodei Zorini method in gastric-resected and non-resected gastroduodenal ulcer patients].
Topics: Gastrectomy; Humans; Isoniazid; Peptic Ulcer; Tuberculosis; Tuberculosis, Pulmonary | 1961 |
[Importance of the determination of the bacteriostatically active concentration of phtivazid in the blood for chemotherapy of patients with tuberculosis].
Topics: Humans; Isoniazid; Thiram; Tuberculosis | 1962 |
[Combined therapy with INH and TB 1 for pulmonary tuberculosis].
Topics: Isoniazid; Psychotherapy, Multiple; Thiosemicarbazones; Tuberculosis; Tuberculosis, Pulmonary | 1962 |
[On the problem of simultaneous application of the tuberculostatic INH and vitamin B6 in tuberculosis therapy with reference to some results of examination].
Topics: Humans; Isoniazid; Tuberculosis; Vitamin B 6 | 1962 |
Efficacy of secondary isoniazid preventive therapy among HIV-infected Southern Africans: time to change policy?
Topics: Adult; Age Distribution; Antitubercular Agents; Black People; CD4 Lymphocyte Count; Cohort Studies; | 2003 |
Question from the clinician: tuberculosis prophylaxis.
Topics: Adolescent; Antitubercular Agents; BCG Vaccine; Female; Humans; Isoniazid; Tuberculosis | 2003 |
Detection of katG Ser315Thr substitution in respiratory specimens from patients with isoniazid-resistant Mycobacterium tuberculosis using PCR-RFLP.
Topics: Bacterial Proteins; Bronchoalveolar Lavage; Catalase; Drug Resistance, Multiple, Bacterial; Humans; | 2003 |
Isoniazid resistance among tuberculosis patients by birth cohort in Germany.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Drug Resist | 2003 |
Frequency and antibiotic susceptibility pattern of mycobacterial isolates from extra-pulmonary tuberculosis cases.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Ethambutol; Humans; Is | 2003 |
Rapid colorimetric method for testing susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin in liquid cultures.
Topics: Antitubercular Agents; Colorimetry; Drug Resistance, Bacterial; Humans; Isoniazid; Microbial Sensiti | 2003 |
Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis.
Topics: Administration, Inhalation; Aerosols; Animals; Antibiotics, Antitubercular; Antitubercular Agents; A | 2003 |
Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Disease Models, Animal; Drug Resistance, Bacteri | 2003 |
Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis.
Topics: Administration, Oral; Animals; Antitubercular Agents; Delayed-Action Preparations; Drug Carriers; Dr | 2003 |
High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors.
Topics: Adult; Aged; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Chemical and Drug I | 2003 |
Mycobacterium tuberculosis infection following allogeneic peripheral blood stem cell transplantation.
Topics: Adult; Anemia, Aplastic; Antitubercular Agents; Drug Therapy, Combination; Humans; Immunocompromised | 2003 |
Urine color testing and isoniazid monitoring.
Topics: Antitubercular Agents; Humans; Isoniazid; Patient Compliance; Reagent Kits, Diagnostic; Tuberculosis | 2003 |
Typing of Mycobacterium tuberculosis strains resistant to rifampicin and isoniazid by molecular biological methods.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Typing Techniques; Codon; DNA; Drug Re | 2003 |
Effect of drug resistance on the generation of secondary cases of tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Confidence Intervals; DNA | 2003 |
Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; HIV; HIV Infectio | 2003 |
Malabsorption of rifampin and isoniazid in HIV-infected patients with and without tuberculosis.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; HIV Infections; Humans; Intestinal Absorption; Isoni | 2004 |
Evaluation of the fully automated Bactec MGIT 960 system for the susceptibility testing of Mycobacterium tuberculosis to first-line drugs: a multicenter study.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; Isoniazid; Microbia | 2004 |
[Septic loosening of a Wagner revision stem provoked by Mycobacterium tuberculosis].
Topics: Acetabulum; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Arthroplasty, Replacement, Hip | 2003 |
Pancytopenia due to extensive hemophagocytosis following anti-tubercular treatment.
Topics: Adult; Antitubercular Agents; Biopsy, Needle; Bone Marrow; Hepatomegaly; Histiocytosis; Humans; Ison | 2004 |
Chemotherapy of experimental tuberculosis. V. Isonicotinic acid hydrazide (nydrazid) and related compounds.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Antituberculous properties of hydrazines of isonicotinic acid (rimifon, marsilid).
Topics: Hydrazines; Isoniazid; Isonicotinic Acids; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Hydrazine derivatives of isonicotinic acid (rimifon marsilid) in the treatment of active progressive caseous-pneumonic tuberculosis; a preliminary report.
Topics: Hydrazines; Isoniazid; Isonicotinic Acids; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulm | 1952 |
ISONICOTINIC acid hydrazide.
Topics: Isoniazid; Tuberculosis | 1952 |
[First results of isonicotinic acid hydrazide therapy of tuberculosis at the Institute C. Forlanini].
Topics: Academies and Institutes; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
CURRENT status of isonicotinic acid hydrazide in the treatment of tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
The development of drug resistance of M. tuberculosis to isonicotinic acid hydrazide.
Topics: Drug Resistance; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Chemotherapy of genitourinary tuberculosis with isonicotinic acid hydrazide; preliminary observations.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1952 |
The use of isonicotinyl hydrazines in the treatment of tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Potential danger of isoniazid resistance through failure to use multiple chemotherapy in treatment of tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Isonicotinic acid hydrazide in (INAH) in tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
CURRENT status of isonicotinic acid hydrazide in the treatment of tuberculosis.
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
ISONIAZID in pulmonary tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isonicotinic acid hydrazide in the treatment of tuberculous meningitis in children.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal | 1952 |
Isonicotinic Acid Hydrazide and its derivatives in tuberculosis: an evaluation of the side-effects in relation to peripheral circulation; preliminary report.
Topics: Blood Circulation; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Isoniazid and its derivatives in tuberculosis--the sympatholytic side effects in relation to peripheral circulation; a preliminary report.
Topics: Blood Circulation; Isoniazid; Niacin; Nicotinic Acids; Sympatholytics; Tuberculosis | 1952 |
Tuberculosis of the genitourinary tract treated with isonicotinic acid hydrazide an interval report.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Urogenital; Urogenital System | 1952 |
[Present state of the treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
ISONICOTINIC acid hydrazide in the treatment of tuberculosis.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First observations on the therapeutic value of isonicotinic acid hydrazide in tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[New synthetic drug in the treatment of tuberculosis; isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Present state of the treatment of tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide as a new drug in the treatment of tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[New drugs in the treatment of tuberculosis; isonicotinic acid hydrazides].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Effect of isonicotinic acid hydrazide on intracutaneous infection caused by streptomycin-sensitive and streptomycin-resistant Koch Bacilli in guinea pigs].
Topics: Guinea Pigs; Injections, Intradermal; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids | 1952 |
[Early changes in cutaneous allergy in tubercular subjects treated with isonicotinic acid hydrazide].
Topics: Dermatitis, Atopic; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
ISONICOTINIC acid hydrazide.
Topics: Fistula; Isoniazid; Niacin; Nicotinic Acids; Trachea; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Isonicotinic acid hydrazide and tuberculosis; a provisional assessment.
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide in treatment of tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Preliminary therapeutic experiences with isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Preliminary notes on value of isonicotinic acid hydrazide in the treatment of tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Observations on 8 cases of pulmonary tuberculosis treated with isonicotinic acid hydrazide during 30 days].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Rapid therapeutic action of isonicotinic acid hydrazide in grave oropharyngo-laryngeal tuberculosis].
Topics: Isoniazid; Larynx; Larynx, Artificial; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Laryngea | 1952 |
[Preliminary results of the treatment of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Case of intestinal tuberculosis treated with isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Gastrointestinal; Tuberculosis, Lymp | 1952 |
[Resistance, of Mycobacterium tuberculosis to isonicotinic acid hydrazide in the treatment of cavitary pulmonary tuberculosis].
Topics: Biochemical Phenomena; Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis; | 1952 |
[Therapy of tuberculosis with neoteben (isonicotinic acid hydrazide)].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First impressions of use of isonicotinic acid hydrazide in pulmonary tuberculosis bedridden subjects in the Rasori Sanatorium].
Topics: Isoniazid; Nervous System Diseases; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
ISONIAZID trials.
Topics: Isoniazid; Mycobacterium tuberculosis; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Rimifon Roche, a new tuberculostatic drug].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First clinical report on therapeutic use of isonicotinic acid hydrazide in human tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[First clinical results of treatment of 50 cases of pulmonary tuberculosis with isonicotinic acid hydrazide].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[First clinico-radiological report on the effect of isonicotinic acid hydrazide in pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Use of isonicotinic acid hydrazide in collapse therapy and exeresis in pulmonary tuberculosis].
Topics: Collapse Therapy; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Effect of isonicotinic acid hydrazide in tubercular laryngitis and bronchitis].
Topics: Bronchitis; Humans; Isoniazid; Laryngitis; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Lary | 1952 |
[Chemotherapy of tuberculosis: isonicotinic acid hydrazide and combined chemical and antibiotic therapy of experimental ocular tuberculosis].
Topics: Anti-Bacterial Agents; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Ocula | 1952 |
[First anatomo-pathological report on the effect of isonicotinic acid hydrazide in experimental tuberculosis in guinea pigs].
Topics: Guinea Pigs; Humans; Isoniazid; Tuberculosis | 1952 |
[A case of acute miliary tuberculosis treated with isonicotinic acid hydrazide].
Topics: Acute Disease; Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Miliary | 1952 |
[Complications and incidents in isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Laboratory data on several tubercular subjects during isonicotinic acid hydrazide therapy].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[First clinical tests of isonicotinic acid hydrazide in the Sanatoria of the Piedmont].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide in antitubercular therapy abroad].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Opinion of Italian clinicians and phthisiologists concerning the therapeutic uses of isonicotinic acid hydrazide].
Topics: Humans; Isoniazid; Language; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Suboccipital or spinal infection of isonicotinic acid hydrazide in animals and humans and first report on the activity of the drug in tubercular meningitis and primary pulmonary tuberculosis in children].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Meningeal; Tuberculosis, Pulmonary | 1952 |
[Isonicotinic acid hydrazide].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Protective effect of isonicotinic acid hydrazide in experimental tuberculosis in guinea pig].
Topics: Guinea Pigs; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
Effect of isonicotinic acid hydrazide (isoniazid) on survival time of mice infected with tubercle bacilli resistant to the drug in vitro.
Topics: Animals; Bacillus; In Vitro Techniques; Isoniazid; Lacticaseibacillus casei; Mice; Niacin; Nicotinic | 1952 |
[Rimifon in the therapy of tuberculosis; first clinical observations].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Comparison of early therapeutic results of pulmonary tuberculosis with rimifon].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
[Preliminary experiences with rimifon in cutaneous and genital tuberculosis].
Topics: Humans; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Cutaneous; Tuberculosis, Uro | 1952 |
[A new synthetic antituberculosis drug: isonicotinic acid hydrazide].
Topics: Antitubercular Agents; Isoniazid; Niacin; Nicotinic Acids; Tuberculosis | 1952 |
[Isonicotinic acid hydrazide therapy of pulmonary tuberculosis].
Topics: Isoniazid; Niacin; Nicotinic Acids; Tuberculosis; Tuberculosis, Pulmonary | 1952 |
Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes.
Topics: Antitubercular Agents; Developing Countries; Drug Resistance, Bacterial; Female; Humans; Isoniazid; | 2004 |
[Cardiac tamponade with paroxysmal atrial flutter controlled by antituberculous therapy].
Topics: Aged; Aged, 80 and over; Antitubercular Agents; Atrial Flutter; Cardiac Tamponade; Drainage; Drug Ad | 2004 |
Identification of a Mycobacterium tuberculosis strain with stable, low-level resistance to isoniazid.
Topics: Antimalarials; DNA, Bacterial; Drug Resistance, Bacterial; Humans; Isoniazid; Microbial Sensitivity | 2004 |
Molecular epidemiology unmasks the tubercle bacillus: new techniques reveal new aspects of virulence.
Topics: Antitubercular Agents; Disease Outbreaks; Humans; Isoniazid; London; Molecular Epidemiology; Mycobac | 2004 |
Incorporation of isoniazid into liposomes with different lipid composition.
Topics: Antitubercular Agents; Humans; Isoniazid; Liposomes; Mycobacterium tuberculosis; Phospholipids; Tube | 2004 |
Contribution of AGC to ACC and other mutations at codon 315 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis isolates from the Middle East.
Topics: Antitubercular Agents; Bacterial Proteins; Bacterial Typing Techniques; Catalase; Codon; Deoxyribonu | 2004 |
Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Biological Availability; Drug Combinati | 2004 |
Feasibility and reliability of health-related quality of life measurements among tuberculosis patients.
Topics: Adult; Antitubercular Agents; Emigration and Immigration; Female; Health Status; Humans; Isoniazid; | 2004 |
Completing tuberculosis prophylaxis in jail: targeting treatment and comparison of rifampin/pyrazinamide with isoniazid regimens.
Topics: Antitubercular Agents; Carrier State; Drug Administration Schedule; Drug Therapy, Combination; Femal | 2004 |
Drug resistance trends among previously treated tuberculosis patients in a national registry in Peru, 1994-2001.
Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Ethambutol; Humans; Isoniazid; Peru; Py | 2004 |
Twelfth nerve palsy due to a retropharyngeal tuberculous abscess.
Topics: Antitubercular Agents; Child; Drainage; Humans; Hypoglossal Nerve Diseases; Isoniazid; Magnetic Reso | 2004 |
Antituberculosis drugs and hepatotoxicity.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Humans; Is | 2004 |
[Current aspects of laryngeal tuberculosis].
Topics: Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Laryngeal Disease | 2004 |
Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis clinical strains isolated in the Philippines.
Topics: Amino Acid Substitution; Antitubercular Agents; Bacterial Proteins; Catalase; DNA Fingerprinting; DN | 2004 |
Long-term outcome of isoniazid prophylaxis against tuberculosis in Chinese renal transplant recipients.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; China; Female; Humans; Isoniazid; Kidney Trans | 2004 |
Transmission of isoniazid-resistant tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Isoniazid; Mycobacterium tuberculosis; Sa | 2004 |
Purification and characterization of Mycobacterium tuberculosis KatG, KatG(S315T), and Mycobacterium bovis KatG(R463L).
Topics: Amino Acid Substitution; Bacterial Proteins; Catalase; Drug Resistance, Bacterial; Isoniazid; Kineti | 2004 |
Lung specific stealth liposomes as antitubercular drug carriers in guinea pigs.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Carriers; Drug Therapy, Combinatio | 2004 |
Isoniazid and hypoglycaemia in a premature infant.
Topics: Antibiotics, Antitubercular; Female; Humans; Hypoglycemia; Infant, Newborn; Infant, Premature; Infan | 2004 |
Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis.
Topics: Aerosols; Animals; Antitubercular Agents; Area Under Curve; Blood Proteins; Cell Line; Chromatograph | 2004 |
Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil.
Topics: Antitubercular Agents; Brazil; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Isoniaz | 2004 |
Moxifloxacin treatment of tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Fluoroquinolon | 2004 |
[Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; DNA, Bacterial; | 2004 |
Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Antibiotics, Antitubercular; Chemical and Drug Induced Liv | 2004 |
Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Topics: Adolescent; Adult; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced Liver Injury; D | 2004 |
Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy.
Topics: alpha-Defensins; Animals; Anti-Infective Agents; Antitubercular Agents; Cell Line; Disease Models, A | 2004 |
Forgotten but not gone.
Topics: Antitubercular Agents; Drug Administration Schedule; Humans; Isoniazid; Tuberculosis; Tuberculosis, | 2004 |
[Extensive subacute ulcerative tuberculosis of the labial and jugal mucosa treated by isonicotinic acid hydrazide].
Topics: Isoniazid; Lupus Vulgaris; Mouth Diseases; Mouth Mucosa; Mucous Membrane; Niacin; Nicotinic Acids; T | 1953 |
[Histobacteriological research on lymphatic tuberculosis of guinea pigs treated with repeated cycles of isoniazid therapy].
Topics: Animals; Guinea Pigs; Humans; Isoniazid; Lymph Nodes; Lymphatic Vessels; Tuberculosis; Tuberculosis, | 1959 |
New guidelines about latent tuberculosis infection in children and adolescents: a welcome advancement.
Topics: Adolescent; Antitubercular Agents; Child; Humans; Isoniazid; Mycobacterium tuberculosis; Practice Gu | 2004 |
Aortobifemoral graft infection with Mycobacterium tuberculosis: treatment with abscess drainage, debridement, and long-term administration of antibiotic agents.
Topics: Abdominal Abscess; Antitubercular Agents; Aorta, Abdominal; Blood Vessel Prosthesis Implantation; De | 2004 |
[The resistance rates of Mycobacterium tuberculosis strains to antituberculosis drugs: evaluation of two years' data in Aegean region, Turkey].
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Ethambutol; Humans; Isoniazid; Mycobacterium tube | 2004 |
Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; DNA Primers; DNA, Bacte | 2004 |
Tuberculosis in Australia: bacteriologically confirmed cases and drug resistance, 2002: a report of the Australian Mycobacterium Reference Laboratory Network.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Australia; Bronchoscopy; Child; C | 2003 |
Childhood turberculosis: reflections from the front line.
Topics: Antitubercular Agents; Chemoprevention; Child; Community Health Planning; Female; Humans; Infant; Is | 2004 |
In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis.
Topics: Acylation; Animals; Antitubercular Agents; Culture Media; Female; Isoniazid; Mice; Microbial Sensiti | 2003 |
Rapid, simple in vivo screen for new drugs active against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Drug Evaluation, Preclinical; Female; Is | 2004 |
[Use of dissolved ozone in the treatment of experimental tuberculosis in mice].
Topics: Animals; Drug Therapy, Combination; Injections, Intraperitoneal; Isoniazid; Mice; Mice, Inbred BALB | 2004 |
Reduction of clinical tuberculosis in HIV-infected males with isoniazid prophylaxis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Chemoprevention; Humans; Incide | 2002 |
Distribution of the Beijing family genotypes of Mycobacterium tuberculosis in Taiwan.
Topics: Adolescent; Adult; Age Distribution; Aged; Antitubercular Agents; Bacterial Typing Techniques; Drug | 2005 |
Screening and treatment of latent tuberculosis among healthcare workers at low, moderate, and high risk for tuberculosis exposure: a cost-effectiveness analysis.
Topics: Antitubercular Agents; Cost-Benefit Analysis; Decision Trees; Health Personnel; Humans; Isoniazid; M | 2004 |
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.
Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Cell Line; Diamines; | 2005 |
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th | 2005 |
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th | 2005 |
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th | 2005 |
Immunotherapy with fragmented Mycobacterium tuberculosis cells increases the effectiveness of chemotherapy against a chronical infection in a murine model of tuberculosis.
Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Colony Count, Microbial; Combined Modality Th | 2005 |
Studies on the 4-benzoylpyridine-3-carboxamide entity as a fragment model of the Isoniazid-NAD adduct.
Topics: Crystallography, X-Ray; Humans; Isoniazid; Molecular Conformation; Molecular Structure; NAD; Niacin; | 2005 |
Isoniazid-related fulminant hepatic failure in a child: assessment of the native liver's early regeneration after auxiliary partial orthotopic liver transplantation.
Topics: Antitubercular Agents; Child; Hepatic Artery; Humans; Isoniazid; Liver; Liver Failure, Acute; Liver | 2005 |
Population pharmacokinetics of isoniazid in the treatment of Mycobacterium tuberculosis among Asian and African elephants (Elephas maximus and Loxodonta africana).
Topics: Administration, Oral; Administration, Rectal; Animals; Antitubercular Agents; Area Under Curve; Elep | 2005 |
Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Pr | 2005 |
Optimal latent TB control methods.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Tubercu | 2005 |
Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.
Topics: Adult; Antibiotic Prophylaxis; Antitubercular Agents; Azathioprine; Endemic Diseases; Female; Glucoc | 2005 |
Susceptibility testing of Mycobacterium tuberculosis: comparison of the BACTEC TB-460 method and flow cytometric assay with the proportion method.
Topics: Antitubercular Agents; Ethambutol; Flow Cytometry; Humans; Isoniazid; Microbial Sensitivity Tests; M | 2005 |
[Risk of acquisition of RFP resistance out of INH resistant RFP susceptible tuberculosis].
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Resistance, Bacterial; Female; Humans; I | 2005 |
Self-report INH adherence measures were reliable and valid in Latino adolescents with latent tuberculosis infection.
Topics: Adolescent; Adolescent Behavior; Antitubercular Agents; Disclosure; Female; Hispanic or Latino; Huma | 2005 |
Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis.
Topics: Administration, Inhalation; Animals; Antitubercular Agents; Area Under Curve; Biological Availabilit | 2005 |
[Medicine and television: a diagnosis history].
Topics: Adult; Antitubercular Agents; Cholestasis, Intrahepatic; Diagnostic Errors; Hepatitis B; Hepatitis C | 2005 |
Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; F | 2005 |
[Molecular and genetic characterization of rifampicin- and/or izoniazid-resistent strains of M. tuberculosis, isolated in Novosibirsk and Tomsk regions].
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Genome, Bacterial; Humans; Isoniazid; Minisatelli | 2005 |
Multiple Pappenheimer bodies.
Topics: Alcoholism; Antitubercular Agents; Emergencies; Erythrocyte Inclusions; Folic Acid Deficiency; Human | 2005 |
Cost-effectiveness of isoniazid chemoprevention in close contacts.
Topics: Adolescent; Adult; Antitubercular Agents; Carrier State; Chemoprevention; Contact Tracing; Cost-Bene | 2005 |
Identifiability, stratification and minimum variance estimation of causal effects.
Topics: Computer Simulation; Data Interpretation, Statistical; Humans; Isoniazid; Mycobacterium tuberculosis | 2005 |
Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Ciprofloxacin; Clarithrom | 2005 |
Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis.
Topics: Aerosols; Alginates; Animals; Antitubercular Agents; Drug Carriers; Drug Evaluation, Preclinical; Fe | 2005 |
Molecular characterization of isoniazid-resistant Mycobacterium tuberculosis isolates collected in Australia.
Topics: Algorithms; Alleles; Antitubercular Agents; Australia; Cluster Analysis; Codon; DNA, Bacterial; Drug | 2005 |
Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis?
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Liver Failure, Acute; Liver Transplantation; Male; | 2005 |
Incidence of TB in inmates with latent TB infection: 5-year follow-up.
Topics: Adult; Antitubercular Agents; Female; Follow-Up Studies; Humans; Incidence; Isoniazid; Male; Patient | 2005 |
Optic neuritis with concurrent etanercept and isoniazid therapy.
Topics: Antitubercular Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Etanercept; Humans; Immunog | 2005 |
Concurrence of granular cell tumor and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bronchoscopy; Ethambutol; Granular Cell Tumor; Humans; Isoniazid; Lung; Male; | 2005 |
Susceptibility pattern and epidemiology of Mycobacterium tuberculosis in a Saudi Arabian hospital: a 15-year study from 1989 to 2003.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Child; Child, Preschool; Ethambut | 2005 |
Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Topics: Africa, Southern; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Anti-Retroviral Agen | 2006 |
Isoniazid and food interactions: --fish, cheese, and wine.
Topics: Antitubercular Agents; Cheese; Fish Products; Food-Drug Interactions; Humans; Isoniazid; Risk Factor | 2005 |
An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in tuberculous ward.
Topics: Adult; Aged; Aged, 80 and over; Antitubercular Agents; Diagnosis, Differential; Disease Outbreaks; F | 2005 |
Assessment of age-related isoniazid hepatotoxicity during treatment of latent tuberculosis infection.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; | 2006 |
Screening for tuberculosis in the study of the living renal donor in a developing country.
Topics: Adolescent; Adult; Antitubercular Agents; Developing Countries; Female; Humans; Isoniazid; Kidney Tr | 2006 |
Physician adherence to isoniazid preventive therapy guidelines for HIV-infected patients in Thailand.
Topics: Antitubercular Agents; Guideline Adherence; HIV Infections; Humans; Isoniazid; Practice Guidelines a | 2005 |
Evaluation of the CombiChip Mycobacteria Drug-Resistance detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Codon; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Bacterial; G | 2006 |
Tuberculosis prevention for non-US-born pregnant women.
Topics: Adult; Antitubercular Agents; Emigration and Immigration; Female; Humans; Isoniazid; Practice Patter | 2006 |
In closely monitored patients, adherence in the first month predicts completion of therapy for latent tuberculosis infection.
Topics: Adult; Antitubercular Agents; Carrier State; Cohort Studies; Directly Observed Therapy; Drug Adminis | 2005 |
Adverse drug reactions observed during DOTS.
Topics: Adolescent; Adult; Antitubercular Agents; Directly Observed Therapy; Drug Administration Schedule; D | 2004 |
[Efficiency of preventive chemotherapy in children and adolescents from the bacterial isolation foci of tuberculous infection].
Topics: Adolescent; Anti-Bacterial Agents; Antitubercular Agents; Child; Drug Resistance, Bacterial; Female; | 2006 |
Mycobacterium tuberculosis in a Saudi Arabian hospital.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Saudi Ar | 2006 |
Rapid detection of specific gene mutations associated with isoniazid or rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; DNA, Bacterial; D | 2006 |
[Isoniazid-induced visual hallucinosis].
Topics: Adult; Antitubercular Agents; Female; Hallucinations; Humans; Isoniazid; Tuberculosis | 2006 |
The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation.
Topics: Adult; Antitubercular Agents; Cohort Studies; Directly Observed Therapy; Drug Resistance, Bacterial; | 2006 |
Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.
Topics: Adult; Antitubercular Agents; Area Under Curve; Cohort Studies; Ethambutol; Female; Humans; Isoniazi | 2006 |
Passive serum therapy with polyclonal antibodies against Mycobacterium tuberculosis protects against post-chemotherapy relapse of tuberculosis infection in SCID mice.
Topics: Animals; Antibodies, Bacterial; Antitubercular Agents; Disease Models, Animal; Female; Humans; Immun | 2006 |
Exposure to tuberculosis among newborns in a nursery: decision analysis for initiation of prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Antibiotic Prophylaxis; Antitubercular Agents; Decision Support | 2006 |
Predicting non-completion of treatment for latent tuberculous infection: a prospective survey.
Topics: Adult; Antitubercular Agents; Female; Humans; Incidence; Isoniazid; Male; Massachusetts; Patient Com | 2006 |
Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates.
Topics: Amino Acid Substitution; Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polym | 2006 |
Mutations prevalent among rifampin- and isoniazid-resistant Mycobacterium tuberculosis isolates from a hospital in Vietnam.
Topics: Amino Acid Substitution; Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polym | 2006 |
Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; DNA, Bacterial; Drug Resistance, Multiple, Bacte | 2006 |
Mixed infection and clonal representativeness of a single sputum sample in tuberculosis patients from a penitentiary hospital in Georgia.
Topics: Adult; Antitubercular Agents; DNA Fingerprinting; Drug Resistance, Bacterial; Georgia (Republic); Ho | 2006 |
Molecular characterization of mutation associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis isolates.
Topics: Adolescent; Adult; Antitubercular Agents; Bacterial Proteins; Catalase; Codon; Drug Resistance, Mult | 2006 |
Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders.
Topics: Adolescent; Adult; Antitubercular Agents; CD3 Complex; CD56 Antigen; Drug Resistance; Female; Flow C | 2006 |
Anti-tuberculosis drug inducd hepatitis - a Sri Lankan experience.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Female; Hum | 2006 |
The history of tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; BCG Vaccine; Europe; History, 18th Century; History, 1 | 2006 |
Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study.
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Female; Humans; Isoniazid; Ma | 2006 |
Predominance of multi-drug-resistant LAM and Beijing family strains among Mycobacterium tuberculosis isolates recovered from prison inmates in Tula Region, Russia.
Topics: Adult; Antibiotics, Antitubercular; Bacterial Typing Techniques; DNA Transposable Elements; Drug Res | 2006 |
Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; DNA, Bacterial; Drug Resistance, Multiple, Bact | 2006 |
Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; Drug Resistance, | 2006 |
Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis.
Topics: Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Ag | 2006 |
Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis.
Topics: Antibiotics, Antitubercular; Bacteriological Techniques; Drug Resistance, Multiple, Bacterial; Human | 2006 |
Isoniazid prophylaxis in end-stage renal disease.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Humans; Isoniazid; Kidney Failure, Chronic; Mycobacte | 2006 |
Preventing latent tuberculosis among HIV-infected patients: efficacious and effective, yet inefficient?
Topics: AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; Cohort Studies | 2007 |
[Liver damage in treatment of latent tuberculous infection by isoniazid].
Topics: Adolescent; Adult; Antitubercular Agents; Asian People; Chemical and Drug Induced Liver Injury; Chil | 2006 |
Optic neuritis and bitemporal hemianopsia associated with isoniazid treatment in end-stage renal failure.
Topics: Adult; Antitubercular Agents; Combined Modality Therapy; Drug Therapy, Combination; Ethambutol; Hemi | 2006 |
Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Colony Count, Microbial; Dose-Response Relation | 2007 |
Tuberculosis in resource poor countries.
Topics: Anti-Retroviral Agents; Antitubercular Agents; Developing Countries; Health Services Accessibility; | 2007 |
Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study.
Topics: Adult; Antibiotic Prophylaxis; Antigens, Bacterial; Epitopes; Female; Humans; Isoniazid; Longitudina | 2007 |
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Topics: Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Ce | 2007 |
Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Drug Resista | 2007 |
[Adverse effect other than liver dysfunction in treatment of latent tuberculous infection by isoniazid].
Topics: Adolescent; Adult; Antitubercular Agents; Central Nervous System Diseases; Chemical and Drug Induced | 2007 |
[Treatment results of rifampicin (RFP) resistant isoniazid (INH) susceptible tuberculosis, a hospital based study].
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Drug Administration Schedule; Drug | 2007 |
Community-wide INH treatment of latent TB infection in a BCG-vaccinated population: experience in rural Taiwan.
Topics: Antitubercular Agents; Humans; Isoniazid; Rural Population; Taiwan; Tuberculin Test; Tuberculosis | 2007 |
[Case report: tuberculosis of parotid gland].
Topics: Adult; Antitubercular Agents; Biopsy; Diagnosis, Differential; Ethambutol; Humans; Isoniazid; Lymph | 2007 |
Molecular characteristics of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis isolates from the Russian Federation.
Topics: Antitubercular Agents; Codon; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; | 2007 |
Antimycobacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea compounds endowed with high activity toward multidrug-resistant Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Cell Survival; Chlorocebus aethiops; Drug Resistance, Multiple, Bact | 2007 |
Persistence, not resistance, is the cause of loss of isoniazid effect.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Isoniazid; Models, Biological; Mycobacter | 2007 |
Isoniazid activity is terminated by bacterial persistence.
Topics: Antitubercular Agents; Drug Resistance, Bacterial; Humans; Isoniazid; Models, Biological; Mycobacter | 2007 |
Tuberculin skin test positivity in pediatric allogeneic BMT recipients and donors in Turkey.
Topics: Adolescent; Antitubercular Agents; Bone Marrow Transplantation; Child; Child, Preschool; Diagnosis, | 2007 |
Cost-effectiveness of interferon-gamma release assay screening for latent tuberculosis infection treatment in Germany.
Topics: Adult; Antitubercular Agents; Carrier State; Cost-Benefit Analysis; False Positive Reactions; Female | 2007 |
Short-course regimens for latent tuberculosis: what is ready for prime time?
Topics: Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Tuberc | 2007 |
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolin | 2007 |
Drug resistance in tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Resistance, Multiple, Bacterial; H | 2007 |
Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; DNA-Directed RNA Polymerases; DNA, Bacterial; D | 2007 |
Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Mi | 2007 |
[Comparative study of bactec MGIT 960 AST and conventional proportion method using Ogawa medium for the drug susceptibility testing of Mycobacterium tuberculosis to isoniazid].
Topics: Antitubercular Agents; Culture Media; Drug Resistance, Bacterial; Humans; Isoniazid; Japan; Microbia | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Brazil; CD4 Lymphocyte Count; Female; Follow-U | 2007 |
Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period.
Topics: Adolescent; Adult; Alanine Transaminase; Antitubercular Agents; Aspartate Aminotransferases; Comorbi | 2007 |
Patient choice promotes adherence in preventive treatment for latent tuberculosis.
Topics: Adolescent; Adult; Age Factors; Antibiotics, Antitubercular; Antineoplastic Agents; Attitude to Heal | 2007 |
Predictors of adherence to latent tuberculosis infection therapy in Latino immigrants.
Topics: Adolescent; Adult; Analysis of Variance; Antitubercular Agents; Bolivia; Community Health Nursing; D | 2007 |
Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity.
Topics: Antitubercular Agents; Apoptosis; Caspase 3; Cell Line; Flow Cytometry; Humans; Isoniazid; Mycobacte | 2007 |
Isoniazid-related hepatic failure in children: a survey of liver transplantation centers.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Female; Follow-Up Studies; Hospitals, Pe | 2007 |
Hepatitis C virus infection and isoniazid hepatotoxicity.
Topics: Antitubercular Agents; Hepatitis C; Humans; Isoniazid; Liver; Prognosis; Risk Factors; Substance-Rel | 2007 |
Urine levels of rifampicin & isoniazid in asymptomatic HIV-positive individuals.
Topics: Adult; Antitubercular Agents; CD4-Positive T-Lymphocytes; Drug Administration Schedule; Drug Resista | 2007 |
Adverse drug reactions associated with first-line anti-tuberculosis drug regimens.
Topics: Antitubercular Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Isoniazid; Pyrazinam | 2007 |
Edith Maas Lincoln and the treatment of latent tuberculous infection.
Topics: Antitubercular Agents; Child; History, 20th Century; Humans; Isoniazid; New York City; Pediatrics; P | 2007 |
Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic.
Topics: Adult; Antirheumatic Agents; Antitubercular Agents; Arthritis, Rheumatoid; Chemical and Drug Induced | 2008 |
Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis.
Topics: Antitubercular Agents; Dermatomyositis; Female; Humans; Immunoglobulins, Intravenous; Immunologic Fa | 2007 |
[Use of a mini-sequencing test, followed by the MALDI-TOF mass-spectrometric analysis to evaluate rifampicin and izoniazid resistance in Mycobacterium tuberculosis circulating in the Russian Federation].
Topics: Antitubercular Agents; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Isoniazid; Myco | 2007 |
Lack of correlation between embB mutation and ethambutol MIC in Mycobacterium tuberculosis clinical isolates from China.
Topics: Antitubercular Agents; Bacterial Proteins; China; Drug Resistance, Bacterial; Ethambutol; Humans; Is | 2007 |
Evaluation of the Arkansas method of urine testing for isoniazid in South Africa.
Topics: Adult; Antitubercular Agents; Cross-Sectional Studies; Humans; Isoniazid; Male; Middle Aged; Patient | 2007 |
Evaluation of a semi-automated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa.
Topics: Antitubercular Agents; Biological Assay; Genes, Reporter; Humans; Isoniazid; Luciferases; Microbial | 2008 |
Molecular analysis of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from India.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Amino Acid Substitution; Bacterial Proteins; Catalase; DN | 2008 |
Anti-tuberculosis drug susceptibility testing of Mycobacterium bovis BCG Tokyo strain.
Topics: Antitubercular Agents; BCG Vaccine; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tests; Myco | 2007 |
Severe sporotrichoid fish tank granuloma following infliximab therapy.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antitubercular Agents; Environmental Exposure; Gra | 2007 |
The tuberculosis prodrug isoniazid bound to activating peroxidases.
Topics: Antitubercular Agents; Ascorbate Peroxidases; Bacterial Proteins; Binding Sites; Catalase; Crystallo | 2008 |
Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Hum | 2008 |
Tuberculosis peritonitis.
Topics: Aged; Antitubercular Agents; Dominican Republic; Ethambutol; Humans; Isoniazid; Male; Mycobacterium | 2007 |
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; | 2007 |
Transfer of isoniazid from circulation to breast milk in lactating women on chronic therapy for tuberculosis.
Topics: Adolescent; Adult; Female; Humans; Isoniazid; Lactation; Milk, Human; Tuberculosis | 2008 |
Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis.
Topics: Animals; Female; Gene Expression Regulation, Bacterial; Genes, Bacterial; Humans; Isoniazid; Mice; M | 2008 |
Pure red blood cell aplasia and isoniazid use.
Topics: Aged; Antitubercular Agents; Female; Humans; Isoniazid; Red-Cell Aplasia, Pure; Tuberculosis | 2007 |
[Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Hepatitis, Chronic; Humans; I | 2008 |
Molecular characterisation of isoniazid-resistant Mycobacterium tuberculosis isolated from new cases in Lagunes region (Côte d'Ivoire).
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; Cote d'Ivoire; DNA Mutational Analysis; DNA, Ba | 2008 |
Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests.
Topics: Acetylation; Adult; Antitubercular Agents; Arylamine N-Acetyltransferase; Case-Control Studies; Chem | 2008 |
[A case of excellent response to efalizumab. Experience in the University Hospital of Salamanca].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antitubercular Agents; Biological Product | 2008 |
Antimycobacterial activity of novel N-(substituted)-2-isonicotinoylhydrazinocarbothioamide endowed with high activity towards isoniazid resistant tuberculosis.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Drug Resistance, Bacterial; Female; Isoniazid; | 2009 |
Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Topics: Adult; Aged; Antitubercular Agents; Case-Control Studies; Chemical and Drug Induced Liver Injury; Dr | 2008 |
An ounce of tuberculosis prevention.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Patient Compliance; Rifampin; | 2008 |
Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Biomarkers; Dose-Response Relationship, Drug; Female; Humans; In | 2008 |
Modeling the joint epidemics of TB and HIV in a South African township.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Comorbidity; Condoms; Disease Notifica | 2008 |
Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibiotic Prophylaxis; Antitubercular Agents; Comorbidity; Fe | 2008 |
[Resistance effect to the para-amino-salicylic acid and the isoniazid phenyl-para-amino-salicylate].
Topics: Aged; Aminosalicylic Acids; Drug Tolerance; Female; Humans; Isoniazid; Male; Middle Aged; Tuberculos | 1966 |
Reversion of recently acquired tuberculin reactivity during isoniazid prophylaxis.
Topics: Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1967 |
Experience with isoniazid prophylaxis in a large city health department.
Topics: Community Health Services; Humans; Isoniazid; Massachusetts; Tuberculosis | 1967 |
Isoniazid therapy in relation to later occurrence of cancer in adults and in infants.
Topics: Adult; Aged; Aging; Carcinogens; Child; Child, Preschool; Female; Fetal Death; Fetal Diseases; Human | 1967 |
Metabolism in infection: ATP-Pi32 exchange of kidney mitochondria of tuberculous guinea pigs.
Topics: Adenosine Triphosphate; Animals; Dinitrophenols; Guinea Pigs; Isoniazid; Kidney; Male; Mitochondria; | 1967 |
Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model.
Topics: Animals; Drug Synergism; Ethionamide; Isoniazid; Mice; Models, Theoretical; Streptomycin; Tuberculos | 1967 |
Non-pulmonary tuberculosis in the west of Scotland, 1963-65.
Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Female; Humans; Isoniazid; Male; Scotland; Strepto | 1967 |
Tuberculin skin testing in San Francisco schools, 1956-1966: an epidemiologic analysis.
Topics: Asian People; BCG Vaccine; Black or African American; California; Child; Community Health Services; | 1967 |
[Effect of 4-chloroanilid of 5-chlorosalicylic acid on experimental tuberculosis in guinea pigs].
Topics: Anilides; Animals; Guinea Pigs; Isoniazid; Salicylates; Streptomycin; Tuberculosis | 1967 |
Chemoprophylaxis of tuberculosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Humans; Isoniazid; Tuberculosis | 1967 |
Diagnostic and prognostic significance of the quantitative tuberculin tests. The influence of subclinical infections with atypical mycobacteria.
Topics: Adolescent; Adult; Animals; Antigens; BCG Vaccine; Child; Female; Guinea Pigs; Humans; Isoniazid; Ma | 1967 |
Prophylactic use of isoniazid.
Topics: Humans; Isoniazid; Tuberculosis | 1967 |
Determination of isonicotinic acid hydrazide in blood serum.
Topics: Cycloserine; Humans; Indicators and Reagents; Isoniazid; Pyrazinamide; Spectrophotometry; Tuberculos | 1967 |
Influence of isoniazid therapy on the course of tuberculosis in a rhesus monkey.
Topics: Animals; Isoniazid; Monkey Diseases; Tuberculin Test; Tuberculosis | 1967 |
Chemoprophylaxis for tuberculosis.
Topics: BCG Vaccine; Child; Humans; Isoniazid; Tuberculosis | 1967 |
Tuberculosis in chronic renal failure.
Topics: Ethambutol; Humans; Isoniazid; Kidney Failure, Chronic; Mycobacterium avium; Rifampin; Tuberculosis | 1980 |
Isoniazid hepatotoxicity and acetylation during tuberculosis chemoprophylaxis.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; gamma-Glu | 1980 |
Antituberculous drugs in pregnancy.
Topics: Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Pregnancy; Pregnancy Complications, In | 1981 |
Potentiating action of rifampicin and isoniazid against Leishmania mexicana amazonensis.
Topics: Brazil; Drug Synergism; Humans; Isoniazid; Leishmania; Leishmaniasis; Male; Rifampin; Tuberculosis | 1981 |
Adverse drug reaction to sunset-yellow in rifampicin-isoniazid tablet.
Topics: Azo Compounds; Excipients; Female; Gastrointestinal Diseases; Humans; Isoniazid; Middle Aged; Rifamp | 1982 |
Chromosome-damaging action of isoniazid and thiacetazone on human lymphocyte cultures in vivo.
Topics: Adolescent; Adult; Cells, Cultured; Chromosomes, Human; Drug Combinations; Humans; Isoniazid; Lympho | 1981 |
[Effect of kinin system inhibitors and stimulants on the course of tuberculosis and the healing processes in an experiment].
Topics: Animals; Aprotinin; Drug Combinations; Drug Evaluation, Preclinical; Guinea Pigs; Isoniazid; Kininog | 1983 |
Virulence in the guinea pig of M. tuberculosis strains isolated from untreated patients in nine American countries.
Topics: Americas; Animals; Drug Resistance, Microbial; Guinea Pigs; Hydrogen Peroxide; Isoniazid; Male; Myco | 1983 |
Tuberculosis in hospital.
Topics: Adult; BCG Vaccine; Child; Cross Infection; Disease Outbreaks; Female; Humans; Infant; Infant, Newbo | 1984 |
Genetic effects of drug interaction in tuberculosis patients and their fate.
Topics: Aminosalicylic Acid; Antitubercular Agents; Cells, Cultured; Chromosome Aberrations; Crossing Over, | 1984 |
Guidelines for short-course tuberculosis chemotherapy. U.S. Department of Health, Education, and Welfare, Public Health Service, Center for Disease Control Atlanta, Ga.
Topics: Centers for Disease Control and Prevention, U.S.; Drug Administration Schedule; Ethambutol; Humans; | 1980 |
[Activity of rifampicin administered daily and intermittently on experimental tuberculosis in mice].
Topics: Animals; Drug Administration Schedule; Female; Isoniazid; Mice; Rifampin; Time Factors; Tuberculosis | 1983 |
[Sodium metabisulfite inhibition of the reaction between isoniazid and streptomycin in solution].
Topics: Animals; Chemical Phenomena; Chemistry; Drug Combinations; Excipients; Isoniazid; Mice; Mycobacteriu | 1983 |
[Effect of parmidin on the course of tuberculosis under isoniazid therapy].
Topics: Animals; Carbamates; Drug Evaluation, Preclinical; Drug Therapy, Combination; Isoniazid; Kinins; Myc | 1984 |
Chronic isoniazid poisoning. Case report and recommendations for usage of the drug.
Topics: Child; Epilepsies, Partial; Humans; Isoniazid; Male; Pyridoxine; Self Administration; Tuberculosis | 1983 |
Interstate outbreak of drug-resistant tuberculosis involving children--California, Montana, Nevada, Utah.
Topics: Adolescent; Adult; California; Child; Child, Preschool; Disease Outbreaks; Drug Resistance, Microbia | 1983 |
[Chemoprophylaxis against tuberculosis].
Topics: Cost-Benefit Analysis; Humans; Isoniazid; Norway; Tuberculosis | 1983 |
Disseminated tuberculosis in a renal transplant recipient: presentation as an anterior mediastinal mass.
Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Humans; Isoniazid; Kidney Transplantation; Ma | 1983 |
[Resistance of the Koch bacillus to antibacillary agents in the Department of the Lower Rhine].
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Male; Microbial Sensitivity Tes | 1983 |
[Resistance to antitubercular drugs in Chile].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Immunity; Isoniazid; Mycobacterium tuberc | 1984 |
The usefulness of phage typing Mycobacterium tuberculosis isolates.
Topics: Adolescent; Adult; Aged; Animal Diseases; Animals; Bacteriophage Typing; Child; Child, Preschool; Di | 1984 |
Effect of chemotherapy on suppressor T cells in BCG-infected mice.
Topics: Animals; Drug Combinations; Isoniazid; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Mice; | 1980 |
[Recommendations of the French Language Society of Pneumology: The treatment of tuberculosis in France].
Topics: Follow-Up Studies; France; Humans; Isoniazid; Tuberculosis | 1984 |
Preventive therapy for tuberculous infection: an intervention in need of improvement.
Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Isoniazid; Tuberculosis | 1984 |
Tuberculosis in Cuba.
Topics: Adolescent; Adult; Aged; Ambulatory Care; BCG Vaccine; Child; Child, Preschool; Cuba; Drug Therapy, | 1984 |
Preliminary observations on short-course chemotherapy in tuberculous serositis.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Py | 1984 |
Health care of Indochinese refugees.
Topics: Cambodia; Hepatitis B; Humans; Isoniazid; Laos; Parasitic Diseases; Refugees; Tuberculosis; United S | 1984 |
Management of tuberculosis in elderly persons.
Topics: Aged; Antitubercular Agents; Ethambutol; Female; Humans; Isoniazid; Rifampin; Streptomycin; Tubercul | 1984 |
Nurse, your Mantoux is positive.
Topics: Adolescent; Adult; Cross Infection; Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1984 |
Prevention of tuberculosis with isoniazid.
Topics: Humans; Isoniazid; Radiography; Recurrence; Time Factors; Tuberculosis | 1983 |
[Use of isoniazid derivatives synthesized using carbohydrate-type monomeric matrices as a base in experimental tuberculosis].
Topics: Animals; Antitubercular Agents; Female; Guinea Pigs; Isoniazid; Male; Mice; Tuberculosis | 1983 |
[Adjusting or not adjusting isoniazid dosage?].
Topics: Acetylation; Adult; Aged; Antitubercular Agents; Drug Therapy, Combination; Female; Half-Life; Human | 1983 |
[Activity of intermittently administered rifampicin and cyclopentyl rifamycin (or DL473) on experimental tuberculosis in the mouse].
Topics: Animals; DNA-Directed RNA Polymerases; Drug Therapy, Combination; Female; Isoniazid; Mice; Pyrazinam | 1983 |
[Treatment modalities applied to tuberculosis patients in a French department. Hautes-Pyrénées, 1973 to 1980].
Topics: Ambulatory Care; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Ethionamide; Hospital | 1983 |
[Short-term chemotherapy for juvenile tuberculosis].
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female | 1983 |
An overview of tuberculosis in the 1980s.
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Patie | 1983 |
Tuberculoid granuloma of the pharynx.
Topics: Adult; Female; Granuloma; Humans; Isoniazid; Pharyngeal Diseases; Rifampin; Tuberculosis | 1984 |
Chemoprophylaxis against tuberculosis.
Topics: Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1984 |
The first infant to survive a generalized BCG infection.
Topics: Antibodies, Bacterial; B-Lymphocytes; Child, Preschool; Humans; Infant; Isoniazid; Lymphocyte Activa | 1982 |
[Effect of different isoniazid concentrations on the Mycobacterium tuberculosis variant highly resistant to the preparation].
Topics: Animals; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Genetic Variation; Guinea Pig | 1980 |
The efficacy of short-course chemotherapy for tuberculosis.
Topics: Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Tuberculosis | 1980 |
Choice of preventive treatment for isoniazid-resistant tuberculous infection. Use of decision analysis and the Delphi technique.
Topics: Adolescent; Child; Child, Preschool; Cost-Benefit Analysis; Decision Making; Delphi Technique; Drug | 1980 |
The contribution of hydrogen peroxide resistance to virulence of Mycobacterium tuberculosis during the first six days after intravenous infection of normal and BCG-vaccinated guinea-pigs.
Topics: Animals; BCG Vaccine; Drug Resistance, Microbial; Female; Guinea Pigs; Hydrogen Peroxide; Isoniazid; | 1981 |
Prophylactic treatment of tuberculosis.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Mycobacterium tubercul | 1981 |
Drug resistance among Indochinese refugees with tuberculosis.
Topics: Asia, Southeastern; California; Drug Resistance, Microbial; Humans; Isoniazid; Refugees; Streptomyci | 1981 |
Clinical applications of the radioimmunoassay of secretory tuberculoprotein.
Topics: Bacterial Proteins; Humans; Isoniazid; Mycobacterium tuberculosis; Radioimmunoassay; Sputum; Tubercu | 1981 |
Resistance to rifampicin and isoniazid in strains of Mycobacterium tuberculosis.
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Species Specifi | 1981 |
Experimental investigations on the significance of different environmental and immunological factors on the disposition to tuberculous infection.
Topics: Animals; Avitaminosis; BCG Vaccine; Guinea Pigs; Isoniazid; Mice; Mycobacterium tuberculosis; Protei | 1982 |
The prevalence of tuberculosis and drug resistance among Haitians.
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Resistanc | 1982 |
[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)].
Topics: Animals; Antibiotics, Antitubercular; Drug Therapy, Combination; Female; Humans; Isoniazid; Lung; Mi | 1982 |
Present chemotherapy for tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Mycobacterium tube | 1982 |
Antituberculous agents. Isoniazid, rifampin, streptomycin, ethambutol, and pyrazinamide.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1983 |
Acetylator phenotypes in Papua New Guinea.
Topics: Acetylation; Gene Frequency; Humans; Isoniazid; Papua New Guinea; Phenotype; Polymorphism, Genetic; | 1983 |
Intradermal BCG vaccination complications--analysis of 51 cases.
Topics: Abscess; Adolescent; BCG Vaccine; Child; Child, Preschool; Female; Humans; Infant; Injections, Intra | 1983 |
Calcium metabolism during rifampicin and isoniazid therapy.
Topics: Calcium Metabolism Disorders; Drug Therapy, Combination; Female; Humans; Isoniazid; Rifampin; Tuberc | 1983 |
[Possibilities of using Nootropyl in the treatment of tuberculosis].
Topics: Adult; Alcoholism; Animals; Chemical and Drug Induced Liver Injury; Female; Hepatitis, Alcoholic; Hu | 1983 |
Two-step tuberculin testing in a veterans domiciliary population.
Topics: Adult; Aged; Costs and Cost Analysis; Female; Hospitals, Veterans; Humans; Immunization, Secondary; | 1983 |
Therapy of tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Child; Humans; Isoniazid; Rifampin; Streptomycin; Tuberculosis; | 1983 |
BCG vaccine and isoniazid prophylaxis.
Topics: Adult; BCG Vaccine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Isoniazid; Tuberculosis; Vac | 1983 |
[Treatment of tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Rifampin; Streptomy | 1982 |
[The effect of a combination of INH, Rifadin and Miambutol in generalized tuberculosis].
Topics: Animals; Drug Combinations; Ethambutol; Guinea Pigs; Isoniazid; Rifamycins; Tuberculosis | 1981 |
BCG versus isoniazid in the prevention of tuberculosis.
Topics: BCG Vaccine; Humans; Immunization Schedule; Isoniazid; Puerto Rico; Tuberculosis; Vaccination | 1980 |
Isoniazid (INH) cystitis.
Topics: Adult; Cystitis; Humans; Isoniazid; Male; Tuberculosis | 1980 |
Circulating immune complexes in tuberculosis.
Topics: Adolescent; Adult; Aged; Antigen-Antibody Complex; Child; Child, Preschool; Complement Activating En | 1981 |
Chemotherapy of respiratory disease.
Topics: Aminosalicylic Acid; Asthma; Cystic Fibrosis; Developing Countries; History, 20th Century; Humans; I | 1980 |
Clinicopathologic correlations of tuberculosis in large zoo mammals.
Topics: Animals; Animals, Zoo; Artiodactyla; Elephants; Enzyme-Linked Immunosorbent Assay; Hypersensitivity, | 1981 |
[Antibacterian activity modifications of serum isoniazid when using it with rifampicin (author's transl)].
Topics: Acetylation; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Mycobacterium; Rifampi | 1982 |
Isoniazid and the nursing mother.
Topics: Breast Feeding; Developing Countries; Female; Humans; Isoniazid; Tuberculosis | 1982 |
[Clinically primary tuberculosis of the tongue].
Topics: Ethambutol; Humans; Isoniazid; Lung; Male; Middle Aged; Mouth Mucosa; Radiography; Rifampin; Tongue | 1982 |
Adverse drug reactions in TB therapy: risks and recommendations.
Topics: Adult; Age Factors; Aged; Antitubercular Agents; Aspartate Aminotransferases; Chemical and Drug Indu | 1982 |
Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis.
Topics: Adolescent; Adult; Calcium; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; | 1982 |
[Hepatotoxicity of the tuberculostatic combination INH+RMP+EMB in relation to drug metabolism in the liver].
Topics: Acetylation; Antitubercular Agents; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; | 1982 |
Maternal plasma concentration of pyridoxal phosphate during pregnancy: adequacy of vitamin B6 supplementation during isoniazid therapy.
Topics: Female; Humans; Isoniazid; Pregnancy; Pregnancy Complications; Pregnancy Complications, Infectious; | 1982 |
[Report of a meeting of the Therapy of Tuberculosis Task Force, East Germany].
Topics: Drug Therapy, Combination; Humans; Isoniazid; Streptomycin; Tuberculosis | 1982 |
Modern treatment of tuberculosis.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combi | 1982 |
Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis.
Topics: Calcium; Drug Therapy, Combination; Humans; Isoniazid; Rifampin; Tuberculosis | 1982 |
[Effectiveness of antibacterial preparations incorporated into liposomes in the treatment of experimental tuberculosis].
Topics: Animals; Antitubercular Agents; Female; Isoniazid; Liposomes; Mice; Mice, Inbred BALB C; Rats; Strep | 1982 |
The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women.
Topics: Adolescent; Adult; Ethambutol; Ethinyl Estradiol; Female; Humans; Isoniazid; Kinetics; Norethindrone | 1980 |
Elimination kinetics of isoniazid in the newborn infant.
Topics: Female; Humans; Infant, Newborn; Isoniazid; Kinetics; Maternal-Fetal Exchange; Pregnancy; Pregnancy | 1981 |
Laryngeal tuberculosis: a hazard to the otolaryngologist.
Topics: Adult; Diagnosis, Differential; Ethambutol; Female; Humans; Isoniazid; Laryngeal Neoplasms; Male; Mi | 1980 |
Should young adults with a positive tuberculin test take isoniazid?
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Risk; Tuberculin Test; | 1981 |
Evaluating isoniazid preventive therapy: the need for more data.
Topics: Chemical and Drug Induced Liver Injury; Isoniazid; Tuberculosis | 1981 |
Current concept of short-term chemotherapy of tuberculosis.
Topics: Drug Combinations; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Time Factors; Tuberculosis | 1981 |
Single high-dose pyridoxine treatment for isoniazid overdose.
Topics: Acidosis; Adolescent; Adult; Bicarbonates; Coma; Female; Humans; Isoniazid; Male; Pyridoxine; Seizur | 1981 |
Chemoprophylaxis for tuberculosis.
Topics: Adolescent; Adult; Aged; Child; Humans; Isoniazid; Middle Aged; Tuberculin Test; Tuberculosis | 1981 |
Isoniazid prophylaxis.
Topics: Adult; Age Factors; Humans; Isoniazid; Tuberculosis | 1981 |
Isoniazid prophylaxis in new immigrants.
Topics: Emigration and Immigration; Humans; Isoniazid; Tuberculosis | 1981 |
[Hepatotoxicity of the rifampicin-isoniazid combination in children].
Topics: Chemical and Drug Induced Liver Injury; Child, Preschool; Humans; Isoniazid; Liver; Male; Parotid Di | 1981 |
[Levamisole treatment of experimental tuberculosis].
Topics: Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Guinea Pigs; Isoniazid; Levamisole | 1981 |
[Effect of levamisole on the immunological reactivity of mice infected with tuberculosis].
Topics: Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Immunity; Isoniazid; Levamisole; L | 1981 |
Antibacterial activity of DL 473, a new semisynthetic rifamycin derivative.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Bacterial Infections; Dose-Response Relationship, Drug; Is | 1981 |
[Hepatotoxicity caused by isoniazid].
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Liver Function Tests; Male | 1981 |
Isoniazid-induced liver disease.
Topics: Adult; Age Factors; Chemical and Drug Induced Liver Injury; Diagnosis, Differential; Hepatitis, Vira | 1981 |
Tuberculosis in patients with end-stage renal disease.
Topics: Adult; Aged; Ethambutol; Female; Humans; Immunity, Cellular; Isoniazid; Kidney Failure, Chronic; Mal | 1980 |
Tuberculosis in the elderly: treating the "white plague".
Topics: Adolescent; Adult; Age Factors; Aged; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, | 1980 |
[Dynamics of the experimental tuberculous process under the influence of nerobol].
Topics: Anabolic Agents; Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Guinea Pigs; Ison | 1980 |
Tuberculosis in the 1980's.
Topics: Humans; Isoniazid; Tuberculosis | 1980 |
Tuberculosis in the 1980's.
Topics: Humans; Isoniazid; Transaminases; Tuberculosis | 1980 |
American Thoracic Society. Medical Section of the American Lung Association. Guidelines for short-course tuberculosis chemotherapy.
Topics: Adult; Child; Humans; Isoniazid; Rifampin; Tuberculosis | 1980 |
A service program of antituberculosis chemotherapy with five drugs for four months in the treatment of drug addicts and prisoners with pulmonary tuberculosis in Hong Kong. Hong Kong Chest Service/British Medical Research Council.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Ethambutol; Heroin | 1980 |
Treatment of tuberculosis during pregnancy.
Topics: Ethambutol; Female; Humans; Isoniazid; Pregnancy; Pregnancy Complications, Infectious; Tuberculosis | 1980 |
Tuberculosis of the breast.
Topics: Adult; Aged; Antitubercular Agents; Combined Modality Therapy; Ethambutol; Female; Follow-Up Studies | 1995 |
Importance of surveillance mycobacterial cultures after liver transplantation.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Eth | 1995 |
Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis.
Topics: Acetaminophen; Adult; Capreomycin; Ciprofloxacin; Drug Combinations; Drug Overdose; Ethambutol; Fema | 1994 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Dose-Response Relationship, Drug; Female; Flu | 1995 |
IgA antihistone antibodies in isoniazid-treated tuberculosis patients.
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Child; Chromatin; Female; Histones; Humans; Immuno | 1995 |
Isoniazid prophylactic therapy for tuberculosis in HIV-seropositive patients--a least-cost analysis.
Topics: Ambulatory Care; Computer Simulation; Cost of Illness; Costs and Cost Analysis; Feasibility Studies; | 1995 |
[Travels and medical problems of the asylum seeker in Switzerland].
Topics: Adult; Ambulatory Care; Angola; Humans; Isoniazid; Male; Refugees; Switzerland; Tuberculin Test; Tub | 1995 |
An economic evaluation of alternative programme designs for tuberculosis control in rural Uganda.
Topics: Ambulatory Care; Cost of Illness; Cost-Benefit Analysis; Drug Packaging; Guidelines as Topic; Humans | 1995 |
Drugs for tuberculosis.
Topics: Adult; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; Hum | 1995 |
Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis.
Topics: Animals; Bacterial Proteins; Catalase; DNA Mutational Analysis; DNA, Bacterial; Drug Resistance, Mic | 1995 |
New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains.
Topics: Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Multiple; E | 1995 |
Tuberculosis drug resistance in the Western Cape.
Topics: Adolescent; Adult; Aged; Drug Resistance, Multiple; Ethambutol; Female; Humans; Isoniazid; Male; Mid | 1995 |
Increased recurrence of tuberculosis in HIV-1-infected patients in Kenya.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitu | 1993 |
Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis.
Topics: Adolescent; AIDS-Related Opportunistic Infections; BCG Vaccine; Child; Child, Preschool; Drug Therap | 1993 |
[Tuberculous dacryocystitis].
Topics: Acute Disease; Child, Preschool; Dacryocystitis; Dacryocystorhinostomy; Humans; Isoniazid; Male; Myc | 1995 |
Drug therapy of bacillus Calmette-Guérin sepsis.
Topics: Animals; Body Weight; Cycloserine; Drug Combinations; Isoniazid; Mice; Mice, Inbred C3H; Mycobacteri | 1995 |
Community infection ratio as indicator for tuberculosis control.
Topics: BCG Vaccine; Child; Community-Acquired Infections; Humans; Isoniazid; Peru; Tuberculin Test; Tubercu | 1995 |
Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
Topics: AIDS-Related Opportunistic Infections; Cost-Benefit Analysis; Counseling; Female; Humans; Isoniazid; | 1995 |
Chemoprophylaxis in tuberculosis and HIV infection.
Topics: AIDS-Related Opportunistic Infections; Developing Countries; Drug Costs; Humans; Isoniazid; Preventi | 1995 |
Treating tuberculosis with one combination drug.
Topics: Antitubercular Agents; Drug Combinations; Ethambutol; Humans; Isoniazid; Patient Compliance; Pyrazin | 1994 |
Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model.
Topics: Animals; Antibiotics, Antitubercular; Drug Therapy, Combination; Female; Isoniazid; Mice; Pyrazinami | 1994 |
Effectiveness of rifabutin alone or in combination with isoniazid in preventive therapy of mouse tuberculosis.
Topics: Animals; BCG Vaccine; Drug Therapy, Combination; Female; Isoniazid; Mice; Microbial Sensitivity Test | 1994 |
Empiric antituberculosis treatment: benefits for earlier diagnosis and treatment of tuberculosis.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Body Weight; Drug Administratio | 1994 |
Tuberculosis in human immunodeficiency virus-exposed or -infected United States children.
Topics: Adult; Child; Child, Preschool; Drug Resistance, Multiple; HIV Infections; Humans; Infant; Isoniazid | 1994 |
Comment: Isoniazid-induced psychosis.
Topics: Humans; Isoniazid; Male; Middle Aged; Psychoses, Substance-Induced; Tuberculosis | 1994 |
[Treatment and prevention of main infections associated with HIV].
Topics: Adrenal Cortex Hormones; Amphotericin B; Controlled Clinical Trials as Topic; Cryptococcosis; Flucon | 1994 |
Isoniazid and acetylisoniazid kinetics in serum and urine in pulmonary primary complex with intermittent regimen.
Topics: Adolescent; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fe | 1994 |
Tuberculosis and HIV infection.
Topics: Africa; AIDS-Related Opportunistic Infections; Drug Resistance, Microbial; HIV Infections; Humans; I | 1994 |
Preventive therapy of tuberculosis with rifapentine in immunocompetent and nude mice.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Drug Therapy, Combination; Female; Immun | 1994 |
Early bactericidal activity as a method of assessment of drugs for the treatment of tuberculosis.
Topics: Anti-Infective Agents; Ciprofloxacin; Drug Evaluation, Preclinical; Isoniazid; Microbial Sensitivity | 1994 |
[Effect of tuberculin on the clinical course and healing processes in experimental tuberculosis].
Topics: Animals; Drug Therapy, Combination; Guinea Pigs; Injections, Subcutaneous; Isoniazid; Models, Biolog | 1994 |
Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Child; Clinical Pro | 1994 |
[Human immunodeficiency virus infection and tuberculosis: who should receive chemoprophylaxis?].
Topics: Global Health; HIV Infections; Humans; Isoniazid; Tuberculosis | 1994 |
[Decision regarding chemoprophylaxis with isoniazid in patients using parenteral drugs and infected with HIV].
Topics: Decision Support Techniques; Decision Trees; HIV Infections; Humans; Isoniazid; Substance Abuse, Int | 1994 |
From the Food and Drug Administration.
Topics: Antitubercular Agents; Blood Donors; Drug Approval; Drug Combinations; Electromagnetic Phenomena; Eq | 1994 |
[Antitubercular chemoprevention: hepatotoxicity and therapeutic compliance].
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransf | 1993 |
Tuberculosis in liver transplant patients.
Topics: Adult; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Isoniazid; Liver Transplant | 1994 |
Acute hepatic failure in seven patients after prophylaxis and therapy with antituberculous agents. Successful treatment with orthotopic liver transplantation.
Topics: Adult; Aged; Antitubercular Agents; Child; Female; Humans; Incidence; Isoniazid; Liver Failure, Acut | 1994 |
Isoniazid-induced acute pancreatitis.
Topics: Acute Disease; Adult; Humans; Isoniazid; Male; Pancreatitis; Tuberculosis | 1994 |
Rifampin-resistant Mycobacterium kansasii.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Antitubercular Agents; Ciprofloxacin; Clinical Protocols; | 1994 |
Prevalence of tuberculosis and the use of isoniazid prophylaxis in anergic HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Clonal Anergy; Humans; Isoniazid; Longitudinal Studies; Preva | 1994 |
Transmission of tuberculosis.
Topics: Adult; Humans; Isoniazid; Tuberculosis | 1994 |
Risk for developing tuberculosis among anergic patients infected with HIV.
Topics: Adult; CD4-Positive T-Lymphocytes; Female; HIV Infections; Humans; Hypersensitivity, Delayed; Immune | 1993 |
Tuberculosis and HIV infection.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cuba; Emigration and Immi | 1993 |
Transmission of multidrug-resistant Mycobacterium tuberculosis among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis.
Topics: AIDS-Related Opportunistic Infections; Cross Infection; DNA, Bacterial; Drug Resistance; Hospitals, | 1993 |
[Role of phenotype in liver function in adolescents with change of the tuberculin reaction during chemoprophylaxis].
Topics: Adolescent; Body Composition; Humans; Isoniazid; Liver; Liver Function Tests; Phenotype; Tuberculin | 1993 |
[Cephalosporins as possible methods of etiotropic therapy of tuberculosis].
Topics: Animals; Cefazolin; Cefotaxime; Cells, Cultured; Cephalosporins; Culture Media; Drug Therapy, Combin | 1993 |
Short course chemotherapy for tuberculosis in children.
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Dose-Response Relations | 1993 |
Factors affecting compliance with preventive treatment for tuberculosis at Mistassini Lake, Quebec, Canada.
Topics: Adult; Alcohol Drinking; Culture; Female; Health Knowledge, Attitudes, Practice; Humans; Indians, No | 1994 |
Isoniazid toxicity: a survey of pyridoxine availability.
Topics: Data Collection; Drug Overdose; Humans; Isoniazid; Pharmacy Service, Hospital; Pyridoxine; Tuberculo | 1994 |
Experimental chemotherapy of tuberculosis using single dose treatment with isoniazid in biodegradable polymers.
Topics: Animals; Biological Availability; Drug Carriers; Drug Implants; Isoniazid; Lactic Acid; Liver; Male; | 1994 |
Screening of physicians for tuberculosis.
Topics: Adult; Aftercare; Aged; Female; Hospital Bed Capacity, 500 and over; Humans; Infection Control; Ison | 1994 |
[Preventive antituberculosis chemotherapy in 250 patients of the antituberculosis outpatient clinic in Lausanne].
Topics: Adolescent; Adult; Child; Drug Administration Schedule; Emigration and Immigration; Female; Humans; | 1994 |
Tuberculosis preventive therapy in HIV-infected individuals.
Topics: AIDS-Related Opportunistic Infections; HIV Infections; Humans; Isoniazid; Mass Screening; Tuberculos | 1994 |
[Tuberculosis of the parotid gland].
Topics: Demyelinating Diseases; Electromyography; Facial Nerve; Facial Paralysis; Female; Functional Lateral | 1993 |
Reducing occupational transmission of tuberculosis to health care workers.
Topics: Centers for Disease Control and Prevention, U.S.; Health Occupations; Humans; Infection Control; Inf | 1993 |
[Hepatic toxicity of antitubercular agents. Role of different drugs. 199 cases].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Child; Child, Pr | 1993 |
Turning intermittent regimens into daily regimens using blister-packs. An exploration in murine tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Administration Schedule; Drug Packaging; Drug Therapy, Combinat | 1993 |
A prospective study of the risk of tuberculosis among HIV-infected patients.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Cohort Studies; Female; Follow-Up Studies; Human | 1993 |
Prevention of infections in patients with neoplastic disease: use of a historical model for developmental strategies.
Topics: Humans; Immunocompromised Host; Infection Control; Isoniazid; Models, Biological; Neoplasms; Tubercu | 1993 |
Unveiling a tuberculosis drug target.
Topics: Drug Resistance, Microbial; Genes, Bacterial; Humans; Isoniazid; Mycobacterium tuberculosis; Mycolic | 1994 |
Phenytoin toxicity due to rifampicin induced hepatic dysfunction.
Topics: Chemical and Drug Induced Liver Injury; Child; Drug Interactions; Epilepsy; Female; Humans; Isoniazi | 1993 |
[Tuberculosis in children and adolescents in orphanage and boarding schools and optimization of its prevention].
Topics: Adolescent; Age Factors; BCG Vaccine; Child; Child, Institutionalized; Child, Preschool; Follow-Up S | 1993 |
Isoniazid induced encephalopathy in dialysis patients.
Topics: Adult; Confusion; Female; Humans; Isoniazid; Kidney Failure, Chronic; Middle Aged; Pyridoxine; Renal | 1993 |
Isoniazid and rifampin therapy for tuberculosis: what patients need to know.
Topics: Drug Interactions; Food; Humans; Isoniazid; Patient Education as Topic; Rifampin; Tuberculosis | 1993 |
Severe isoniazid-associated hepatitis--New York, 1991-1993.
Topics: Acute Disease; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; F | 1993 |
From the Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambut | 1993 |
From the Centers for Disease Control and Prevention. Severe isoniazid-associated hepatitis--New York, 1991-1993.
Topics: Acute Disease; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; F | 1993 |
[INH preventive therapy in Chiba Prefecture--before and after the renewal of the guideline].
Topics: Adolescent; Adult; BCG Vaccine; Child; Child, Preschool; Humans; Infant; Isoniazid; Japan; Tuberculi | 1993 |
[Analysis of drug sensitivity of M. tuberculosis strains isolated from patients treated for tuberculosis in 1982-1991].
Topics: Adult; Child; Ethambutol; Female; Humans; Isoniazid; Male; Microbial Sensitivity Tests; Mycobacteriu | 1993 |
Low prevalence of positive tuberculin tests in homo-/bisexual white men from Seattle: implications for anergy testing.
Topics: Adult; Bisexuality; Comorbidity; False Negative Reactions; HIV Infections; Homosexuality; Humans; Im | 1993 |
Current status of mycobacterial testing in clinical laboratories. Results of a questionnaire completed by participants in the College of American Pathologists Mycobacteriology E survey.
Topics: Bacteriological Techniques; Drug Resistance, Microbial; Humans; Isoniazid; Laboratories; Microbial S | 1993 |
Tuberculosis, past, present and future.
Topics: Drug Resistance, Microbial; England; History, 19th Century; History, 20th Century; Humans; Isoniazid | 1993 |
Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City.
Topics: Base Sequence; Catalase; DNA, Bacterial; Drug Resistance; Gene Deletion; Genes, Bacterial; Humans; I | 1993 |
The emergence of drug-resistant tuberculosis in New York City.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antitubercular Agents; Centers for Disease Co | 1993 |
CDC recommends four-drug treatment of tuberculosis in multidrug-resistant era.
Topics: Adult; Centers for Disease Control and Prevention, U.S.; Child; Drug Therapy; Drug Therapy, Combinat | 1993 |
Results of screening for tuberculosis in foreign-born persons applying for adjustment of immigration status.
Topics: Adolescent; Adult; Aged; Colorado; Emigration and Immigration; Humans; Isoniazid; Mass Screening; Mi | 1993 |
Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambut | 1993 |
[Indications for chemoprophylaxis of tuberculosis. Arguments for].
Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Child; Child, Preschool | 1993 |
[Is antitubercular chemoprophylaxis useful--a controversy].
Topics: Drug Costs; Humans; Isoniazid; Tuberculosis | 1993 |
[Preventive chemotherapy for tuberculous infection. Arguments against].
Topics: Diagnostic Errors; Humans; Isoniazid; Liver; Patient Compliance; Tuberculin Test; Tuberculosis | 1993 |
Drug resistance of Mycobacterium tuberculosis in Karachi, Pakistan.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Female; Humans; Isoniazid; Male; Mycobacterium tu | 1993 |
Acute and long-term efficacy of antituberculous treatment in HIV-seropositive patients with tuberculosis: a study of 36 cases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antitubercular Agents; Bisexuality; CD4-CD8 Ratio; | 1993 |
[Tuberculosis treatment in 1992].
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Humans; Isoniazid; P | 1993 |
Chemoprophylaxis for tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; | 1993 |
Statement of the Tuberculosis Committee of the Infectious Diseases Society of America.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Resistance, Microbial; Drug | 1993 |
[Are microbiological studies necessary before starting tuberculosis chemoprophylaxis?].
Topics: Adolescent; Adult; Antitubercular Agents; Humans; Isoniazid; Mycobacterium tuberculosis; Polymorphis | 1995 |
[Morphological features of tissue reactions in combined treatment of experimental tuberculosis induced by xenobiotics].
Topics: Animals; Drug Therapy, Combination; Guinea Pigs; Isoniazid; Polycyclic Compounds; Sodium Glutamate; | 1995 |
Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance.
Topics: Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Base Sequence; Catalase; DNA, Bacter | 1996 |
Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Catalase; DNA, Bacterial; Drug Resistance, Microbial; Gen | 1995 |
Antituberculosis activity of clarithromycin.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antitubercular Agents; Clarithromycin; | 1995 |
Investigation into typical and atypical tuberculin sensitivity in the Royal Netherlands Army, resulting in a more rational indication for isoniazid prophylaxis.
Topics: Adult; Antigens; Antigens, Bacterial; Antitubercular Agents; False Positive Reactions; Humans; Hyper | 1995 |
Acceptance of isoniazid preventive therapy by health care workers after tuberculin skin test conversion.
Topics: Adult; Chemoprevention; Female; Georgia; Humans; Infectious Disease Transmission, Patient-to-Profess | 1996 |
Phenytoin toxicity due to concomitant antituberculosis therapy.
Topics: Acetylation; Anticonvulsants; Antitubercular Agents; Drug Interactions; Humans; Isoniazid; Middle Ag | 1995 |
The high incidence of tuberculosis among renal transplant recipients in India.
Topics: Adult; Antitubercular Agents; Ethambutol; Female; Follow-Up Studies; Humans; Incidence; India; Isoni | 1996 |
Active tuberculosis in HIV-infected injecting drug users from a low-rate tuberculosis area.
Topics: Antitubercular Agents; Connecticut; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Is | 1996 |
Management of primary chest wall tuberculosis.
Topics: Abscess; Adult; Antibiotics, Antitubercular; Antitubercular Agents; Combined Modality Therapy; Debri | 1995 |
Isoniazid preventive therapy.
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 1996 |
Is INH alone enough for prophylaxis.
Topics: Antitubercular Agents; Child; Humans; India; Isoniazid; Tuberculosis | 1995 |
Isoniazid safety.
Topics: Aged; Drug Utilization; Humans; Isoniazid; Tuberculosis | 1996 |
Benefits of isoniazid preventive therapy.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Life Expectancy; Male; Tuberculosis | 1996 |
[Efficacy and tolerance of the treatment of tuberculosis in the aged].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antitubercular; Antitubercular Agents; Dru | 1996 |
Alternatives to INH chemoprophylaxis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemoprevention; Child; Child, Preschool; Drug R | 1995 |
Hepatotoxic effects of tuberculosis therapy. A practical approach to a tricky management problem.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Humans; | 1996 |
[Oxidative metabolism changes in respiratory tract cells of guinea pigs during natural development of experimental tuberculosis and under specific chemotherapy].
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Bronchoalveolar Lavage Fluid; Catalase; | 1996 |
[Immunotropic activity of antimicrobial agents used in tuberculosis].
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Cefotaxime; Cephalospo | 1996 |
Clinical manifestations of tuberculosis in renal transplant patients.
Topics: Adult; Antitubercular Agents; Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Hu | 1996 |
Remission of hypercalciuria in patients with tuberculosis after treatment.
Topics: Adult; Calcitriol; Calcium; Female; Humans; Isoniazid; Male; Parathyroid Hormone; Remission Inductio | 1996 |
[A health system that does not live up to expectations. A primary health care team attempt at an integrated approach to a case].
Topics: Alcoholism; Angina Pectoris; Antitubercular Agents; Diagnosis, Differential; Humans; Isoniazid; Live | 1996 |
Directly observed preventive therapy. Turning the tide against tuberculosis.
Topics: Adolescent; Cohort Studies; Female; Humans; Isoniazid; Male; New York City; Patient Compliance; Prev | 1996 |
Evaluation of inhA gene and catalase-peroxidase gene among isoniazid-sensitive and resistant Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Bacterial Proteins; Base Sequence; Drug Resistance, Microbial; Gene Deletion; | 1996 |
Hypoglycaemia in convalescent tuberculous children.
Topics: Antitubercular Agents; Child, Preschool; Fatal Outcome; Female; Humans; Hypoglycemia; Isoniazid; Moz | 1996 |
Whither the roles of rifater and rifamate?
Topics: Antitubercular Agents; Drug Combinations; Humans; Isoniazid; Pyrazinamide; Rifampin; Trimethoprim; T | 1996 |
A comparative study of tuberculin skin test reactivity between asymptomatic HIV-1 seropositive subjects and healthy volunteers.
Topics: Adult; Antitubercular Agents; Female; HIV Seropositivity; HIV-1; Humans; Isoniazid; Male; Thailand; | 1995 |
[Primary nasal tuberculosis].
Topics: Antitubercular Agents; Eosinophils; Female; Humans; Isoniazid; Middle Aged; Nasal Cavity; Tuberculos | 1996 |
Diagnostic and therapeutic challenges.
Topics: Aged; Antitubercular Agents; Choroid Diseases; Cicatrix; Humans; Isoniazid; Male; Retinal Detachment | 1996 |
[Effect of a complex preparation of isoniazide on mononuclear cells in tuberculous granuloma].
Topics: Animals; Antitubercular Agents; BCG Vaccine; Granuloma; Isoniazid; Mice; Mice, Inbred BALB C; Micros | 1996 |
Impact on USAF tuberculosis detection and control program given a low facility tuberculosis prevalence rate.
Topics: Antitubercular Agents; Bayes Theorem; Communicable Disease Control; Costs and Cost Analysis; False P | 1996 |
Isoniazid-related fatal hepatitis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child | 1996 |
Mycobacterial tenosynovitis of the flexor tendons of the hand. A report of five cases.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Carpal Tunnel Syndrome; Combined Mo | 1996 |
Tuberculosis in Siberia: 2. Diagnosis, chemoprophylaxis and treatment.
Topics: Adult; Antitubercular Agents; Child; Drug Therapy, Combination; Humans; Isoniazid; Pneumonectomy; Ra | 1996 |
Prevalence of tuberculosis infection among primary school-entry children in Sydney.
Topics: BCG Vaccine; Child; Emigration and Immigration; Humans; Isoniazid; New South Wales; Prevalence; Tube | 1996 |
KatG sequence deletion is not the major cause of isoniazid resistance in Japanese and Yemeni Mycobacterium tuberculosis isolates.
Topics: Bacterial Proteins; Base Sequence; DNA, Bacterial; Drug Resistance, Microbial; Drug Resistance, Mult | 1995 |
Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a murine model.
Topics: Animals; Antibiotics, Antitubercular; Colony Count, Microbial; Drug Therapy, Combination; Female; Is | 1996 |
In vitro bactericidal and in vivo therapeutic activities of a new rifamycin derivative, KRM-1648, against Mycobacterium tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Dose-Response Relationship, Drug; Drug | 1996 |
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide.
Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Culture Media; Drug Combinations; Drug Inte | 1996 |
Antituberculosis activities of clofazimine and its new analogs B4154 and B4157.
Topics: Animals; Antitubercular Agents; Cell Line; Clofazimine; Drug Resistance, Multiple; Female; Isoniazid | 1996 |
Focal tuberculosis of the liver with local hemorrhage in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Ethambutol; Granuloma; Histocytochemistry; Homosexuality, | 1996 |
Prophylaxis of mycobacterial infections in immunocompromised patients.
Topics: Algorithms; Antitubercular Agents; Humans; Immunocompromised Host; Isoniazid; Mycobacterium avium-in | 1996 |
[Cytokine production during the development and correction of an immunodeficiency in experimental tuberculosis].
Topics: Adjuvants, Immunologic; Animals; Antitubercular Agents; Concanavalin A; Drug Evaluation, Preclinical | 1996 |
Erythema induratum of Bazin.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Erythema Induratum; Female; Humans; Immunohistochemi | 1996 |
Four-drug initial therapy for TB is standard treatment.
Topics: Aminosalicylic Acid; Drug Therapy, Combination; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomy | 1996 |
[Isoniazid acetylation, its relation to genetic and environmental altitude factors].
Topics: Acetylation; Adolescent; Adult; Aged; Altitude; Antitubercular Agents; Arylamine N-Acetyltransferase | 1987 |
Status epilepticus due to accidental overdose of isoniazid in an infant.
Topics: Drug Overdose; Female; Humans; Infant; Isoniazid; Status Epilepticus; Tuberculosis | 1996 |
Presence of katG gene in resistant Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Catalase; Drug Resistance, Microbial; Gene Deletion; Humans; Isoniazid; Micro | 1996 |
Tuberculosis control programme guidelines--treatment regimens.
Topics: Antitubercular Agents; Body Weight; Dose-Response Relationship, Drug; Drug Combinations; Ethambutol; | 1996 |
Psychotic disorder associated with isoniazid.
Topics: Adult; Antitubercular Agents; Humans; Isoniazid; Male; Psychoses, Substance-Induced; Tuberculosis | 1996 |
Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects.
Topics: Adult; Antibiotics, Antitubercular; Drug Interactions; Ethambutol; Female; Histocompatibility Testin | 1996 |
Tuberculosis and renal transplantation.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Follow-Up Studies; Humans; Ison | 1996 |
Coadministration of isoniazid and antidepressant drugs.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents; Comorbidity; Depressive Disorder; Drug Interactions; | 1996 |
[HIV infection, tuberculosis and tuberculin test in Switzerland. The Swiss HIV Cohort Study].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; CD4 Lymphocyte Count; Cohort St | 1996 |
Autopsy findings in HIV-1-infected adults in Kenya.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Autopsy; Female; HIV Infections | 1997 |
Osteomalacia during rifampicin and isoniazid therapy is rare in Hong Kong.
Topics: Antitubercular Agents; Hong Kong; Hospitals, Teaching; Humans; Isoniazid; Osteomalacia; Rifampin; Tu | 1996 |
[Tuberculosis of the middle ear: a rare extrapulmonary manifestation].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diagnosis, Differential; Ear Diseases; Ear, Midd | 1996 |
[Antitubercular activity of lomefloxacin in an experiment].
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Disease Models, Animal; Dose-Response Relatio | 1996 |
Analysis of the oxyR-ahpC region in isoniazid-resistant and -susceptible Mycobacterium tuberculosis complex organisms recovered from diseased humans and animals in diverse localities.
Topics: Animals; Antitubercular Agents; Blotting, Western; Catalase; Codon; DNA, Bacterial; Drug Resistance, | 1997 |
Isoniazid hepatotoxicity in renal transplant recipients.
Topics: Adult; Antitubercular Agents; Aspartate Aminotransferases; Female; Humans; Isoniazid; Kidney Transpl | 1997 |
Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice.
Topics: Alanine Transaminase; Alkaline Phosphatase; Amylopectin; Animals; Antitubercular Agents; Bilirubin; | 1997 |
Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Follow-Up S | 1997 |
Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Dose-Response Relationship, Drug; Isoni | 1997 |
Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analysis; Humans; Isoniaz | 1997 |
Impact of tuberculosis control measures and crowding on the incidence of tuberculous infection in Maryland prisons.
Topics: Adult; Cohort Studies; Crowding; HIV Infections; Humans; Incidence; Isoniazid; Longitudinal Studies; | 1997 |
Surgical treatment of bacillus Calmette Guérin lymphadenitis.
Topics: Antitubercular Agents; Austria; BCG Vaccine; Female; Humans; Infant, Newborn; Isoniazid; Male; Micro | 1997 |
Current recommendations for empiric therapy for tuberculosis.
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Kentucky; Tuberculosis | 1997 |
[Changes of isoniazid concentrations in guinea pig blood and organs after various routes of drug administration].
Topics: Animals; Antitubercular Agents; Drug Administration Routes; Guinea Pigs; Isoniazid; Liver; Lung; Ref | 1997 |
[Antibacterial effectiveness of long-acting isoniazid in the experiment].
Topics: Animals; Antitubercular Agents; Cattle; Delayed-Action Preparations; Disease Models, Animal; Isoniaz | 1997 |
Administration of anti-tuberculosis drugs through patient empowerment.
Topics: Adult; Antitubercular Agents; Chi-Square Distribution; Drug Therapy, Combination; Female; Hospitals, | 1997 |
A case of acute deterioration in asthma symptoms induced by isoniazid prophylaxis.
Topics: Acute Disease; Antitubercular Agents; Asthma; Child; Humans; Isoniazid; Male; Peak Expiratory Flow R | 1997 |
Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Clonal Anergy; HIV Infections; Humans; | 1997 |
Lack of clinical significance for the common arginine-to-leucine substitution at codon 463 of the katG gene in isoniazid-resistant Mycobacterium tuberculosis in Singapore.
Topics: Antitubercular Agents; Arginine; Bacterial Proteins; Drug Resistance, Microbial; Humans; Isoniazid; | 1997 |
[A case of tuberculous abscess in the chest wall close to the thickening pleural lesion following tuberculous pleuritis].
Topics: Abscess; Adult; Antitubercular Agents; Female; Humans; Isoniazid; Rifampin; Thoracic Diseases; Tuber | 1997 |
Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus-associated tuberculosis.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; DNA-Directed RNA Polymerases; DNA, Bac | 1997 |
Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: a risk-benefit and cost-effectiveness analysis.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; D | 1997 |
Outbreak of drug-resistant tuberculosis with second-generation transmission in a high school in California.
Topics: Adolescent; California; Cohort Studies; Disease Outbreaks; Drug Resistance, Multiple; Ethambutol; Et | 1997 |
Short-course chemoprophylaxis evaluated in gold miners with chronic silicosis.
Topics: Antitubercular Agents; Gold; Humans; Isoniazid; Mining; Patient Compliance; Pyrazinamide; Rifampin; | 1997 |
Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bacteriological Techniques; Coloring Agents; Cul | 1998 |
[Immunologic memory induced by Mycobacterium bovis in the inbred mice].
Topics: Animals; Antitubercular Agents; Female; Fluorescent Antibody Technique, Direct; Immunologic Memory; | 1997 |
[Tuberculosis of the breast].
Topics: Abscess; Aged; Antibiotics, Antitubercular; Antitubercular Agents; Breast Diseases; Female; Follow-U | 1997 |
Isoniazid dose adjustment in a pediatric population.
Topics: Adolescent; Antitubercular Agents; Child; Child, Preschool; Chromatography, High Pressure Liquid; Dr | 1998 |
Screening for tuberculosis in jail and clinic follow-up after release.
Topics: Adult; Antitubercular Agents; Follow-Up Studies; Humans; Isoniazid; Male; Mass Screening; Patient Co | 1998 |
[Tuberculosis in hemodialysis].
Topics: Adolescent; Adult; Antibiotics, Antitubercular; Female; Humans; Isoniazid; Male; Middle Aged; Pyrazi | 1997 |
Iatrogenic liver failure, transplantation, and prisoners.
Topics: Adult; Antitubercular Agents; Ethics Consultation; Ethics, Medical; Humans; Iatrogenic Disease; Ison | 1997 |
[HPLC study of blood isoniazid in patients with tuberculosis in Tunisia: significance and therapeutic results].
Topics: Acetylation; Aged; Antitubercular Agents; Chromatography, High Pressure Liquid; Humans; Isoniazid; M | 1995 |
Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice.
Topics: Amikacin; Animals; Clarithromycin; Drug Therapy, Combination; Humans; Isoniazid; Lung; Mice; Mycobac | 1998 |
Physician compliance with national tuberculosis treatment guidelines: a university hospital study.
Topics: Antitubercular Agents; Cerebrospinal Fluid; Drug Administration Schedule; Drug Therapy, Combination; | 1998 |
Expression of katG in Mycobacterium tuberculosis is associated with its growth and persistence in mice and guinea pigs.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Chronic Disease; Codon; Colony Count, Microbial; | 1998 |
Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Chi-Square Distribution; Child; Drug Therapy, Co | 1998 |
Effectiveness of a nosocomial tuberculosis control program at an urban teaching hospital.
Topics: Adult; Antitubercular Agents; California; Cross Infection; Hospitals, Teaching; Hospitals, Urban; Hu | 1998 |
Tuberculosis in children and adolescents: California, 1985 to 1995.
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; California; Child; Child, Preschool; Drug Res | 1998 |
Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
Topics: Antitubercular Agents; Cross-Sectional Studies; Drug Resistance, Microbial; Ethambutol; Global Healt | 1998 |
Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.
Topics: 3-Oxoacyl-(Acyl-Carrier-Protein) Synthase; Acyl Carrier Protein; Amino Acid Sequence; Antitubercular | 1998 |
Monitored isoniazid prophylaxis for low-risk tuberculin reactors.
Topics: Antitubercular Agents; Decision Support Techniques; Humans; Isoniazid; Risk Factors; Tuberculin Test | 1998 |
Isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Developing Countries; Drug Therapy, Co | 1998 |
Commentary: making tuberculosis treatment available for all.
Topics: Ambulatory Care; Aminosalicylic Acid; Antitubercular Agents; Drug Therapy, Combination; Health Servi | 1998 |
Monitoring compliance with antituberculous treatment by detection of isoniazid in urine.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Patient Co | 1997 |
Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Packaging; Electronics; Female; Humans; Isoniazid; Ma | 1998 |
Cost-effectiveness of directly observed chemoprophylaxis of tuberculosis among drug users at high risk for tuberculosis.
Topics: Antibiotic Prophylaxis; Antitubercular Agents; Cost-Benefit Analysis; Female; Humans; Isoniazid; Mal | 1998 |
Tuberculosis after renal transplantation: experience of one Turkish centre.
Topics: Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Kid | 1998 |
Does AIDS impair the absorption of antituberculosis agents?
Topics: Absorption; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antitubercular Agents; Biological | 1998 |
Acute mental changes in a 68-year-old man with bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Confusion; Hematuria; | 1998 |
Peptide-specific T cell response to Mycobacterium tuberculosis: clinical spectrum, compartmentalization, and effect of chemotherapy.
Topics: Adolescent; Adult; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; BCG Vaccine; Cell | 1998 |
Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Humans; Isoniazid; Mutagenesi | 1998 |
Prevention of tuberculosis in HIV-1.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Drug Resistance, Microbial; HIV-1; Hum | 1998 |
Compliance with anti-tuberculosis preventive therapy among 6-year-old children.
Topics: Antitubercular Agents; Child; Humans; Isoniazid; New South Wales; Patient Compliance; Prospective St | 1998 |
[Multi-organ tuberculosis in a child: diagnosis and therapeutic problems].
Topics: Antitubercular Agents; Child, Preschool; Fatal Outcome; Humans; Isoniazid; Male; Rifampin; Tuberculo | 1998 |
Significance of ahpC promoter mutations for the prediction of isoniazid resistance in Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Bacterial Proteins; Base Sequence; Codon; DNA, Bacterial; Drug Resistance, Mi | 1998 |
Short-term tuberculosis prophylaxis is effective in persons with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Humans; Isoniazid; Patient Compliance; | 1998 |
Evaluation of once-weekly therapy for tuberculosis using isoniazid plus rifamycins in the mouse aerosol infection model.
Topics: Aerosols; Animals; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; F | 1998 |
Preventive therapy for tuberculosis in HIV-infected persons: analysis of policy options based on tuberculin status and CD4+ cell count. Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA).
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analysis; Humans; Isoniaz | 1998 |
Antisense RNA to ahpC, an oxidative stress defence gene involved in isoniazid resistance, indicates that AhpC of Mycobacterium bovis has virulence properties.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Benzene Derivatives; Cell Division; Drug Resista | 1998 |
Action of metronidazole in combination with isoniazid & rifampicin on persisting organisms in experimental murine tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Metronidazole; Mice; M | 1998 |
Purified protein derivative testing and tuberculosis preventive therapy for HIV-infected patients in New York City.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Female; Humans; Isoniazid; Male | 1998 |
Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Female; Humans; Immunosuppr | 1998 |
Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
Topics: AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Antitubercular Agents; Chemical | 1998 |
[Efficacy of a short 6 month therapeutic coursefor HIV infected tuberculosis patients in Abidjan, Côte d'Ivoire].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antitubercular Agents; Cohort Studies; Cote d | 1998 |
Tuberculosis of the pyriform fossa--a rare entity.
Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Therapy, Combination; Ethambutol; Humans | 1998 |
A tuberculin screening and isoniazid preventive therapy program in an inner-city population.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Female; HIV Seropositivity; | 1999 |
[Tuberculosis among hemodialysis patients in Dakar, apropos of 2 cases].
Topics: Adolescent; Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Hallucinations; Hum | 1998 |
Lymphocyte transformation test for the evaluation of adverse effects of antituberculous drugs.
Topics: Adult; Anaphylaxis; Anti-Bacterial Agents; Antitubercular Agents; Bromodeoxyuridine; Cells, Cultured | 1999 |
Isoniazid and nonalcoholic steatohepatitis.
Topics: Adult; Antitubercular Agents; Fatty Liver; Female; Humans; Isoniazid; Liver; Tuberculosis | 1999 |
Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Femal | 1999 |
Preventing tuberculosis among HIV-infected persons: a survey of physicians' knowledge and practices.
Topics: AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Agents; California; Ch | 1999 |
Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Decision Support Techniques; Developing Countries; HIV In | 1999 |
The geographic distribution of tuberculosis and pyridoxine supply in Ontario.
Topics: Antitubercular Agents; Drug Overdose; Health Services Needs and Demand; Humans; Injections, Intraven | 1995 |
[What does tuberculosis prophylaxis bring in HIV infections?].
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Humans; Isoniazid; Placebos; Ra | 1999 |
BCG vaccination with antitubercular therapy.
Topics: Antitubercular Agents; BCG Vaccine; Humans; Immunization Schedule; Infant, Newborn; Isoniazid; Tuber | 1998 |
CDC clarifies when to retest staff shown positive by Aplisol TB test.
Topics: Centers for Disease Control and Prevention, U.S.; Humans; Isoniazid; Personnel, Hospital; Tuberculin | 1982 |
Twice-weekly, directly observed treatment for HIV-infected and uninfected tuberculosis patients: cohort study in rural South Africa.
Topics: Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studies; Drug Therapy, C | 1999 |
Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide.
Topics: Administration, Oral; Analysis of Variance; Animals; Antitubercular Agents; Biocompatible Materials; | 1999 |
A report on home visiting practices conducted in remote districts of Nepal in an NGO-run tuberculosis control programme.
Topics: Antitubercular Agents; Cohort Studies; Communicable Disease Control; Disease Outbreaks; Evaluation S | 1999 |
Therapy of tuberculosis in mice by DNA vaccination.
Topics: Animals; Antigens, Bacterial; Antitubercular Agents; Bacterial Proteins; Chaperonin 60; Chaperonins; | 1999 |
Reply: Treatment of tuberculosis in HIV-infected patients.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Drug Therapy, Combination; HIV Infections; Human | 1999 |
Reactivation of latent tuberculosis: variations on the Cornell murine model.
Topics: Animals; Antitubercular Agents; Dexamethasone; Disease Models, Animal; Genetic Variation; Glucocorti | 1999 |
A novel approach to monitoring adherence to preventive therapy for tuberculosis in adolescence.
Topics: Adolescent; Antitubercular Agents; Drug Monitoring; Drug Therapy, Computer-Assisted; Humans; Isoniaz | 1999 |
Culture-independent prediction of isoniazid resistance in Mycobacterium tuberculosis by katG gene analysis directly from sputum samples.
Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Humans; Isoniazid; Mutation; | 1999 |
Analysis of rifapentine for preventive therapy in the Cornell mouse model of latent tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models | 1999 |
Evaluation of rifapentine in long-term treatment regimens for tuberculosis in mice.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, C | 1999 |
Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; AIDS-Related Opportunistic Infections; Antitubercular Ag | 1999 |
Evaluation of reverse transcription-PCR and a bacteriophage-based assay for rapid phenotypic detection of rifampin resistance in clinical isolates of Mycobacterium tuberculosis.
Topics: Antibiotics, Antitubercular; Base Sequence; DNA Primers; Drug Resistance, Microbial; Drug Resistance | 1999 |
Evaluation of a bacteriophage-based assay (phage amplified biologically assay) as a rapid screen for resistance to isoniazid, ethambutol, streptomycin, pyrazinamide, and ciprofloxacin among clinical isolates of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Ciprofloxacin; Drug Resistance, Microbial; Ethambutol; Evaluation Studies as | 1999 |
Effectiveness of isoniazid chemoprophylaxis for HIV-infected drug users at high risk for active tuberculosis.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antibiotic Prophylaxis; Antitubercular Age | 1999 |
Tuberculosis prevention questionnaire: common practices among pulmonary medicine and infectious disease specialists in Puerto Rico.
Topics: Antitubercular Agents; Attitude of Health Personnel; Humans; Internal Medicine; Isoniazid; Occupatio | 1999 |
Tuberculosis prophylaxis for the chronically dialysed patient--yes or no?
Topics: Humans; Isoniazid; Renal Dialysis; Skin Tests; Tuberculosis | 1999 |
Tuberculosis in renal transplant recipients.
Topics: Adult; Female; Humans; Isoniazid; Kidney Transplantation; Liver; Male; Middle Aged; Retrospective St | 1999 |
High-dose isoniazid therapy for isoniazid-resistant murine Mycobacterium tuberculosis infection.
Topics: Animals; Antitubercular Agents; Culture Media; Dose-Response Relationship, Drug; Drug Resistance, Mi | 1999 |
Preventive therapy against tuberculosis in people living with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Counseling; Feasibility Studies; Globa | 1999 |
Investigation of tuberculosis contacts in a nonhospital pneumology practice.
Topics: Adolescent; Adult; Age Distribution; Aged; Ambulatory Care Facilities; Antitubercular Agents; Chemop | 1999 |
Unusual clinical manifestation of tuberculosis in a renal transplant recipient.
Topics: Adult; Antitubercular Agents; Ethambutol; Fatal Outcome; Female; Humans; Isoniazid; Kidney Transplan | 1999 |
Rapid, efficient detection and drug susceptibility testing of Mycobacterium tuberculosis in sputum by microscopic observation of broth cultures. The Tuberculosis Working Group in Peru.
Topics: Antitubercular Agents; Bacterial Typing Techniques; Costs and Cost Analysis; Drug Resistance, Microb | 2000 |
Tuberculosis chemoprophylaxis using a liquid isoniazid-methadone admixture for drug users in methadone maintenance.
Topics: Antitubercular Agents; Cohort Studies; Drug Combinations; Female; Humans; Isoniazid; Male; Methadone | 1999 |
Acute isoniazid neurotoxicity during preventive therapy.
Topics: Acute Disease; Adolescent; Antitubercular Agents; Coma; Conscious Sedation; Electroencephalography; | 2000 |
[Molecular mechanisms of mycobacterium tuberculosis strains resistance to rifampicin and isoniazid].
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Bacterial Proteins; Colony Count, Microbial; DNA | 2000 |
DOTS in Haiti.
Topics: Antitubercular Agents; Communicable Disease Control; Haiti; Humans; Isoniazid; Mycobacterium tubercu | 2000 |
Tuberculosis in patients with systemic lupus erythematosus.
Topics: Antitubercular Agents; Humans; Isoniazid; Lupus Erythematosus, Systemic; Tuberculosis | 1999 |
Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Drug Administr | 2000 |
Identification and management of tuberculosis.
Topics: Adult; Algorithms; Antitubercular Agents; Child; HIV Infections; Humans; Isoniazid; Patient Complian | 2000 |
Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.
Topics: Antitubercular Agents; Humans; Isoniazid; Rifampin; Tuberculin Test; Tuberculosis | 2000 |
The cost-effectiveness of evidence-based guidelines and practice for screening and prevention of tuberculosis.
Topics: Antitubercular Agents; Contact Tracing; Cost of Illness; Cost-Benefit Analysis; Drug Costs; Evidence | 2000 |
Health care workers and tuberculosis.
Topics: Antitubercular Agents; Australia; BCG Vaccine; Cross Infection; Health Personnel; Humans; Infection | 2000 |
Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Mas | 2000 |
Trends in antituberculosis drug resistance in Karonga District, Malawi, 1986-1998.
Topics: Adult; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; HIV Seropositivity; Hu | 2000 |
Results from 8 yrs of susceptibility testing of clinical Mycobacterium tuberculosis isolates in Denmark.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Denmark; Female; Humans; In | 2000 |
The treatment of WHO Category 1 tuberculosis with 2HRZE/6HE is indeed defensible.
Topics: Antitubercular Agents; Drug Resistance; Drug Therapy, Combination; Humans; Isoniazid; Randomized Con | 2000 |
More on the question of optimal chemotherapy in the presence of isoniazid resistance.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; End | 2000 |
Recall of isoniazid used for antimicrobial susceptibility testing for tuberculosis.
Topics: Antitubercular Agents; Drug and Narcotic Control; Humans; Isoniazid; Microbial Sensitivity Tests; My | 2000 |
Primary and acquired resistance of Mycobacterium tuberculosis in Western Mexico.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Isoniazid; Mex | 2000 |
Evaluation of rifalazil in a combination treatment regimen as an alternative to isoniazid-rifampin therapy in a mouse tuberculosis model.
Topics: Animals; Antitubercular Agents; Colony-Forming Units Assay; Disease Models, Animal; Drug Therapy, Co | 2000 |
Second episode of tuberculosis in an HIV-infected child: relapse or reinfection?
Topics: AIDS-Related Opportunistic Infections; Amoxicillin-Potassium Clavulanate Combination; Antibiotics, A | 2000 |
From the Centers for Disease Control and Prevention. Missed opportunities for prevention of tuberculosis among persons with HIV infection--selected locations, United States, 1996-1997.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Mas | 2000 |
From the Centers for Disease Control and Prevention. Recall of isoniazid used for antimicrobial susceptibility testing for tuberculosis.
Topics: Antitubercular Agents; Drug and Narcotic Control; Humans; Isoniazid; Microbial Sensitivity Tests; My | 2000 |
Mycobacterium tuberculosis infections after renal transplantation.
Topics: Adolescent; Adult; Antibiotic Prophylaxis; Antitubercular Agents; Female; Humans; Incidence; Isoniaz | 2000 |
Treatment of tuberculosis: a well-standardised protocol.
Topics: Adult; Child; Clinical Protocols; Ethambutol; France; Humans; Isoniazid; Pyrazinamide; Rifampin; Tim | 2000 |
[Desensitization therapy for antituberculous drugs].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Desensitization, Immunologic; Fem | 2000 |
Mutations at amino acid position 315 of the katG gene are associated with high-level resistance to isoniazid, other drug resistance, and successful transmission of Mycobacterium tuberculosis in the Netherlands.
Topics: Antitubercular Agents; Bacterial Proteins; DNA Transposable Elements; Drug Resistance, Microbial; Dr | 2000 |
Tuberculous abscess of the graft in a renal transplant recipient after chronic rejection: case report.
Topics: Abscess; Adult; Antitubercular Agents; Chronic Disease; Drug Therapy, Combination; Ethambutol; Femal | 2000 |
Tuberculosis after renal transplantation.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Follow-Up Studies; Huma | 2000 |
Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Biocompatible Materials; Drug Combinati | 2001 |
[Cost effectiveness analysis of isoniazid preventive therapy to the contacts of tuberculosis patients under Japanese settings].
Topics: Adult; Aged; Antitubercular Agents; Chemoprevention; Cost-Benefit Analysis; Disease Transmission, In | 2000 |
Sources of variation in studies of the early bactericidal activity of antituberculosis drugs.
Topics: Anti-Infective Agents; Antitubercular Agents; Hong Kong; Humans; Isoniazid; Microbial Sensitivity Te | 2001 |
Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis.
Topics: Animals; Antitubercular Agents; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Female | 2001 |
Guidelines for preventing the transmission of tuberculosis in Canadian Health Care Facilities and other institutional settings.
Topics: Antitubercular Agents; Canada; Disease Transmission, Infectious; Health Facility Administration; Hum | 1996 |
Contralateral pleural effusion during chemotherapy for tuberculous pleural effusion.
Topics: Adult; Antitubercular Agents; Drug Therapy, Combination; Female; Humans; Isoniazid; Pleural Effusion | 2000 |
Isonex prophylaxis in cases of SLE on immunosuppressive therapy.
Topics: Antitubercular Agents; Humans; Immunocompromised Host; Immunosuppressive Agents; Isoniazid; Lupus Er | 2000 |
Can a nine-month regimen be used to treat isoniazid resistant tuberculosis diagnosed after standard treatment is started?
Topics: Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Microbial; Female | 2001 |
TB prevention in HIV clinics in New York City.
Topics: Adult; Antitubercular Agents; Disease Progression; Female; HIV Infections; Humans; Incidence; Isonia | 2001 |
Connatal tuberculosis in an extremely low birth weight infant: case report and management of exposure to tuberculosis in a neonatal intensive care unit.
Topics: Antitubercular Agents; Female; Humans; Infant, Newborn; Infant, Very Low Birth Weight; Infection Con | 2001 |
The susceptibility of Mycobacterium tuberculosis to isoniazid and the Arg-->Leu mutation at codon 463 of katG are not associated.
Topics: Antitubercular Agents; Arginine; Bacterial Proteins; Codon; Drug Resistance, Microbial; Humans; Ison | 2001 |
Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Female; Humans; Isoniazid; Male; Micr | 2001 |
Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.
Topics: Administration, Oral; Animals; Antibiotics, Antitubercular; Chemistry, Pharmaceutical; Colony Count, | 2001 |
Isoniazid TB prophylaxis effective in drug users with HIV.
Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; HIV Infections; Humans; Isoniazid; Sub | 1996 |
Tuberculosis in farmworkers.
Topics: Antitubercular Agents; HIV Infections; Humans; Isoniazid; Medical History Taking; Risk Factors; Tube | 1996 |
CPCRA researchers present OI studies at Vancouver.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antifung | 1996 |
CDC changing position on anergy testing, therapy. Centers for Disease Control and Prevention.
Topics: Antitubercular Agents; Clinical Protocols; HIV Seropositivity; Humans; Isoniazid; Risk Factors; Tube | 1997 |
Medical advances with international impact.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antitubercular | 1998 |
New TB therapy works for HIV-positive patients.
Topics: Antitubercular Agents; Clinical Trials as Topic; Disease Progression; HIV Infections; Humans; Isonia | 1998 |
Short course preventive therapy for tuberculosis is successful in HIV-infected patients.
Topics: AIDS-Related Opportunistic Infections; Clinical Trials as Topic; Drug Administration Schedule; Drug | 1998 |
N-Acetyltransferase2 genotype correlated with isoniazid acetylation in Japanese tuberculous patients.
Topics: Acetylation; Adult; Aged; Antitubercular Agents; Arylamine N-Acetyltransferase; Female; Genotype; Hu | 2001 |
Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Capsules; Disease Models, Animal; Drug | 2001 |
Regulation of catalase-peroxidase (KatG) expression, isoniazid sensitivity and virulence by furA of Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Bacterial Proteins; Base Sequence; Drug Resistance, Microbial; Gene | 2001 |
Acute pancreatitis induced by isoniazid in the treatment of tuberculosis.
Topics: Acute Disease; Adult; Antitubercular Agents; Humans; Isoniazid; Male; Pancreatitis; Tuberculosis | 2001 |
Tuberculous otitis media -- a diagnostic dilemma.
Topics: Adult; Antitubercular Agents; Diagnosis, Differential; Drug Therapy, Combination; Ear Diseases; Faci | 2001 |
Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen.
Topics: Animals; Antibody Formation; Antimalarials; BCG Vaccine; Disease Models, Animal; Fibrosis; Humans; I | 2001 |
Cost-effectiveness of tuberculosis screening and observed preventive therapy for active drug injectors at a syringe-exchange program.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cost-Benefit Analys | 2001 |
Treatment of tuberculosis in Haiti.
Topics: Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Haiti; H | 2001 |
Adverse reaction to antimycobacterials administered as a combination tablet with no reaction to the same drugs in isolation.
Topics: Adult; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; Huma | 2001 |
[Molecular medicine and treatment of tuberculosis].
Topics: Adjuvants, Immunologic; Animals; Antibiotics, Antitubercular; Antitubercular Agents; BCG Vaccine; Fe | 2001 |
Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular A | 2001 |
Revised treatment and testing guidelines for latent tuberculosis infection.
Topics: Adolescent; Antitubercular Agents; Centers for Disease Control and Prevention, U.S.; Child; Child, P | 2000 |
Management of tuberculosis.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Humans; Isoniazid; Patient Compliance; Rifampin; | 2001 |
Compliance to treatment of latent tuberculosis infection in a region of Israel.
Topics: Adolescent; Antitubercular Agents; Child; Communicable Disease Control; Ethiopia; Female; Humans; Is | 2002 |
A 23-year-old with refractory seizures following an isoniazid overdose.
Topics: Adult; Anticonvulsants; Drug Overdose; Follow-Up Studies; Humans; Isoniazid; Male; Recurrence; Risk | 2002 |
Tuberculosis presenting as immune thrombocytopenic purpura.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Autoimmune Diseases; Drug Therapy, Combination; Ethamb | 2002 |
Suicidal psychosis secondary to isoniazid.
Topics: Adolescent; Antitubercular Agents; Female; Hallucinations; Humans; Isoniazid; Psychoses, Substance-I | 2002 |
Urine testing to monitor adherence to TB preventive therapy.
Topics: Adolescent; Antitubercular Agents; Female; Hispanic or Latino; Humans; Isoniazid; Male; Patient Comp | 2002 |
Sample survey of drug-resistant tuberculosis in Henan, China, 1996.
Topics: Adult; Aged; China; Data Collection; Drug Resistance, Bacterial; Ethambutol; Female; Humans; Isoniaz | 2002 |
In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Drug | 2002 |
Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral | 2002 |
Operational assessment of isoniazid prophylaxis in a community AIDS service organisation in Uganda.
Topics: Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Antitubercular Agents; Cohort Studie | 2002 |
[Latent tuberculosis infection: diagnosis and treatment].
Topics: Antitubercular Agents; BCG Vaccine; Humans; Isoniazid; Predictive Value of Tests; Pyrazinamide; Rifa | 2002 |
Tuberculosis preventative treatment also prevented diarrhoea in HIV-infected patients in Zambia.
Topics: Antibiotics, Antitubercular; Antitubercular Agents; Diarrhea; Drug Therapy, Combination; Follow-Up S | 2002 |
Noncompliance with tuberculosis treatment by patients at a tuberculosis and AIDS reference hospital in midwestern Brazil.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Antitubercular Agents; Brazil; Child; C | 2002 |
Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child | 2002 |
Tuberculosis of the pancreas diagnosed with needle aspiration.
Topics: Adult; Biopsy, Needle; Diagnosis, Differential; Ethambutol; Humans; Isoniazid; Male; Pancreas; Pancr | 2002 |
Isoniazid-induced acute hepatitis and acute pancreatitis in a patient during chemoprophylaxis.
Topics: Acute Disease; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Female; Humans; | 2002 |
European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections. Tuberculosis.
Topics: Humans; Isoniazid; Kidney Transplantation; Liver; Rifampin; Tuberculin Test; Tuberculosis | 2002 |
Tuberculosis in the 1980s: a case for short-course chemotherapy.
Topics: Animals; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ethamb | 1979 |
Letter: Short-course triple chemotherapy for tuberculosis.
Topics: Adult; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Peritonitis, Tubercu | 1975 |
Side effects of drugs used to treat tuberculosis.
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Capreomycin; Chemical and Drug Induced Liver I | 1975 |
[Anticonvulsant drugs and liver damage (Author's transl)].
Topics: Adult; Anticonvulsants; Antitubercular Agents; Autopsy; Chemical and Drug Induced Liver Injury; Chol | 1975 |
The treatment of tuberculosis.
Topics: Aminosalicylic Acids; Capreomycin; Ethambutol; Ethionamide; Humans; Isoniazid; Prothionamide; Pyrazi | 1975 |
[Sensitivity of 628 isolated mycobacteria to the antibacterial agents used in ambulatory treatment in the Senegal].
Topics: Drug Resistance, Microbial; Ethionamide; Isoniazid; Microbial Sensitivity Tests; Mycobacterium; Sene | 1975 |
Tuberculosis in Tanzania: a national sampling survey of drug resistance and other factors.
Topics: Adolescent; Adult; Aminosalicylic Acids; Child; Child, Preschool; Drug Resistance, Microbial; Female | 1975 |
Controlling the spread of leprosy--some observations on.
Topics: Allied Health Personnel; Antitubercular Agents; Dapsone; Drug Resistance, Microbial; Drug Therapy, C | 1976 |
[Microbiologic method of separate determination of protein-bound and non-protein-bound active INH fraction in the blood of tuberculosis patients during treatment with isoniazid].
Topics: Adult; Aged; Biological Assay; Blood Proteins; Female; Humans; Isoniazid; Male; Middle Aged; Protein | 1977 |
[Report of a study tour in India (author's transl)].
Topics: BCG Vaccine; Communicable Disease Control; Education, Medical, Graduate; Epidemiologic Methods; Huma | 1978 |
Thiacetazone toxicity in the treatment of tuberculosis patients in Nigeria.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Dizziness; Drug Combinations; Drug Eruptions; Drug | 1978 |
Tuberculosis in Kenya: a second national sampling survey of drug resistance and other factors, and a comparison with the prevalence data from the first national sampling survey. An East African and British Medical Research Council Co-operative Investigati
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Developing Countries; Drug Resistance, Micr | 1978 |
Comparison of various measures of sensitivity of M. tuberculosis to ethambutol.
Topics: Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacteriu | 1978 |
[The bacteriological principles of tuberculosis treatments].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Humans; Isoniazid; Microbial Sensitivity Tests; M | 1979 |
The cost of antituberculous drug regimens.
Topics: Antitubercular Agents; Biological Availability; Drug Administration Schedule; Drug Therapy; Humans; | 1979 |
[Short term chemotherapy of tuberculosis. Bactericidal mechanisms in short term chemotherapy].
Topics: Animals; Antitubercular Agents; Guinea Pigs; Humans; Isoniazid; Mice; Mycobacterium tuberculosis; Ri | 1978 |
A radioimmunoassay for isoniazid.
Topics: Acetylation; Aminosalicylic Acids; Cross Reactions; Humans; Isoniazid; Isonicotinic Acids; Niacinami | 1975 |
Tuberculosis after corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Adult; Aged; Airway Obstruction; Arthritis, Rheumatoid; Dermatitis, Exfolia | 1976 |
[Chemoprophylaxis and chemoprevention of tuberculosis].
Topics: Female; Humans; Isoniazid; Male; Tuberculosis; Vaccination | 1977 |
[Surveillance and complications of antituberculosis chemotherapy].
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Drug Hypersensitivity | 1979 |
[Treatment of tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Rifampin; Streptomy | 1978 |
Preventive treatment of tuberculous infection.
Topics: Humans; Isoniazid; Tuberculosis; United States | 1977 |
[Tasks and possibilities in the near future of consultation bureaus for the prevention of tuberculosis].
Topics: Community Health Services; Ethambutol; History, 20th Century; Humans; Isoniazid; Netherlands; Rifamp | 1978 |
[Effect of cyclophosphamide on experimental tuberculosis in mice].
Topics: Acute Disease; Animals; BCG Vaccine; Chronic Disease; Cyclophosphamide; Disease Models, Animal; Ison | 1978 |
An immunohematologic complication of isoniazid.
Topics: Adult; Antibody Formation; Antibody Specificity; Antigen-Antibody Complex; Antigens; Cell Membrane; | 1978 |
[Antitubercular chemoprophylaxis after 20 years of its world-wide application].
Topics: Animals; BCG Vaccine; Cattle; Cortisone; Drug Therapy; Guinea Pigs; History, 20th Century; Hospitals | 1979 |
Tuberculosis in renal transplant patients.
Topics: Humans; Immunosuppressive Agents; Isoniazid; Kidney Transplantation; Postoperative Complications; Ri | 1979 |
Adverse reactions to isoniazid on ingestion of fish with a high histamine content.
Topics: Adolescent; Adult; Amine Oxidase (Copper-Containing); Animals; Drug Interactions; Female; Fishes; Fo | 1977 |
Treatment of tuberculosis in alcoholic patients.
Topics: Alcoholism; Hospitalization; Humans; Isoniazid; Long-Term Care; Patient Compliance; Rifampin; Social | 1977 |
[Effect of acridine compounds on stopping the development of drug resistance in Mycobacterium tuberculosis (an experimental study)].
Topics: Acridines; Animals; Drug Evaluation, Preclinical; Drug Resistance, Microbial; Drug Therapy, Combinat | 1977 |
Drug resistant tuberculosis in a large southern California hospital.
Topics: Aminosalicylic Acid; Antitubercular Agents; California; Drug Resistance, Microbial; Ethambutol; Huma | 1977 |
[Studies on the relationship between the proliferation rate of infecting tubercle bacilli and the effectiveness of chemotherapy. II. Observations in various types of infection experiment (author's transl)].
Topics: Animals; Isoniazid; Mice; Mycobacterium bovis; Mycobacterium tuberculosis; Tuberculosis | 1977 |
Drug dependence, a possible new risk factor for tuberculosis disease.
Topics: Humans; Isoniazid; New York City; Risk; Substance-Related Disorders; Tuberculosis | 1979 |
Abdominal tuberculosis in childhood.
Topics: Abdomen; Adolescent; Aminosalicylic Acid; Child; Child, Preschool; Female; Humans; Infant; Isoniazid | 1979 |
[Chemoprevention of tuberculosis].
Topics: Humans; Isoniazid; Time Factors; Tuberculin Test; Tuberculosis | 1979 |
[Indications, dosage and combinations of the major antitubercular drugs].
Topics: Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Rifampin; Tuberculosis | 1979 |
Tuberculosis in patients on regular haemodialysis.
Topics: Humans; Isoniazid; Kidney Failure, Chronic; Renal Dialysis; Streptomycin; Tuberculosis | 1979 |
Tuberculosis in Kenya: follow-up of the second (1974) national sampling survey and a comparison with the follow-up data from the first (1964) national sampling survey. An East African and British Medical Research Council co-operative investigation.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Developing Countries; Drug Resistance, Microbial; | 1979 |
The effect of high doses of isoniazid on biosynthesis of albunin in experimental tuberculosis.
Topics: Albumins; Animals; Guinea Pigs; Isoniazid; Serum Albumin; Tuberculosis | 1979 |
Isoniazid exposure in relation to cancer incidence and mortality in a cohort of tuberculosis patients.
Topics: Adolescent; Adult; Canada; Carcinogens; Female; Follow-Up Studies; Humans; Isoniazid; Lung Neoplasms | 1979 |
Resistance of tubercle bacilli: a brief review in relation to a recent study in Ethiopia.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Drug Resistance, Microbial; Ethiopia; Humans; Isoniazid; | 1979 |
[Indications for chemoprophylaxis in tuberculosis in BCG-vaccinated children].
Topics: BCG Vaccine; Canada; Child; Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1979 |
[The importance of estimating the individual acetylation rate in modern tuberculosis treatment].
Topics: Acetylation; Humans; Isoniazid; Tuberculosis | 1979 |
Histamine poisoning in tuberculosis patients on ingestion of tropical fish.
Topics: Adult; Aged; Animals; Female; Fishes; Foodborne Diseases; Histamine; Humans; Isoniazid; Male; Middle | 1978 |
Histamine intoxication with isoniazid and a species of fish.
Topics: Adult; Animals; Drug Interactions; Fishes; Histamine; Humans; Hypersensitivity, Immediate; Isoniazid | 1978 |
Interaction of isoniazid and warfarin.
Topics: Adult; Drug Interactions; Hemorrhage; Humans; Intracranial Embolism and Thrombosis; Isoniazid; Male; | 1977 |
[Comparison between SM daily and twice weekly treatment in the regimen of SM, INH and PAS--particularly considering the degree of drug resistance (Report 2) (author's transl)].
Topics: Adult; Aminosalicylic Acid; Aminosalicylic Acids; Drug Administration Schedule; Drug Resistance, Mic | 1977 |
Evaluation of tuberculosis control measures. The 2nd Basil Dormer Lecture, 1977.
Topics: Adult; Antitubercular Agents; BCG Vaccine; Child; Drug Therapy, Combination; Humans; Infant, Newborn | 1977 |
Tuberculosis and alcoholism. A partial solution through detection.
Topics: Alabama; Alcoholism; Ethambutol; Female; Humans; Isoniazid; Male; Mass Screening; Streptomycin; Tube | 1978 |
Clinical treatment of tuberculosis in rural Africa.
Topics: Ambulatory Care; Child; Democratic Republic of the Congo; Drug Administration Schedule; Ethambutol; | 1978 |
Diseases of the respiratory system: tuberculosis.
Topics: Adrenal Cortex Hormones; Antitubercular Agents; Drug Combinations; Ethambutol; Humans; Isoniazid; Pa | 1978 |
[Value of lymphography within the framework of complex diagnosis of fever of unknown origin].
Topics: Diagnosis, Differential; Fever of Unknown Origin; Focal Infection; Hodgkin Disease; Humans; Isoniazi | 1978 |
Treatment of tuberculosis.
Topics: Attitude of Health Personnel; Humans; Isoniazid; Rifampin; Tuberculosis | 1978 |
Clinical and immunologic studies of disseminated BCG infection.
Topics: Adult; BCG Vaccine; Bone Marrow Diseases; Female; Fever; Granuloma; Humans; Isoniazid; Liver Disease | 1978 |
A correlated study of the cytogenetic effect of Isoniazid (INH) on cell systems of mammals and man conducted by thirteen laboratories. Introductory remarks.
Topics: Cell Division; Chromosomes; Humans; Isoniazid; Tuberculosis | 1978 |
[Comparative studies on therapeutic effect of rifampicin and isoniazid on experimental mouse tuberculosis (author's transl)].
Topics: Animals; Drug Evaluation, Preclinical; Isoniazid; Male; Mice; Rifampin; Tuberculosis | 1978 |
[An attempt to work out highly efficient short-course regimens by model experiments in mouse tuberculosis (author's transl)].
Topics: Animals; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Isoniazid; Mice; Rifam | 1978 |
Clinical and epidemiological aspects of myocobacterial infection in Western Germany.
Topics: Adult; Aged; Airway Obstruction; Aspergillosis; Carrier State; Dapsone; Female; Germany, West; Human | 1978 |
Uncontolled ruminations on modern controlled trials.
Topics: BCG Vaccine; Child; Humans; Isoniazid; Tuberculosis; United Kingdom; United States | 1978 |
The hepatic toxicity of isoniazid among rapid and slow acetylators of the drug.
Topics: Acetylation; Asian People; Biotransformation; Chemical and Drug Induced Liver Injury; Humans; Isonia | 1978 |
[Tuberculosis chemoprophylaxis in students with strongly positive tuberculin reactions].
Topics: Adolescent; Adult; Drug Hypersensitivity; Female; Humans; Isoniazid; Male; Students; Tuberculin Test | 1978 |
[Chemotherapeutic activity of isonicotinoyl hydrazide of phosphonacetic acid in experimental tuberculosis].
Topics: Animals; Drug Evaluation; Guinea Pigs; Isoniazid; Tuberculosis; Tuberculosis, Hepatic; Tuberculosis, | 1978 |
Isoniazid inactivators.
Topics: Acetylation; Humans; Isoniazid; Tuberculosis | 1978 |
[Tuberculosis of hematopoietic organs in the child. 2 cases with pulmonary involvement].
Topics: Adolescent; Child, Preschool; Drug Tolerance; Ethambutol; Female; Humans; Isoniazid; Male; Prognosis | 1978 |
The epidemiology of tuberculosis in physicians.
Topics: Adult; Age Factors; Female; Humans; Immunization; Isoniazid; Male; Middle Aged; Occupational Disease | 1979 |
Treatment of tuberculosis.
Topics: Antitubercular Agents; Chemical and Drug Induced Liver Injury; Costs and Cost Analysis; Drug Hyperse | 1979 |
The use of in-vitro and in-vivo experiments with Mycobacterium tuberculosis in helping to plan chemotherapy regimens.
Topics: Animals; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Ethambutol; Guine | 1975 |
Tuberculous meningitis in children during the isoniazid era.
Topics: Adolescent; Adult; Aminosalicylic Acids; Child; Child, Preschool; Cranial Nerves; Electroencephalogr | 1975 |
Tuberculosis: the new challenge to the practicing clinician.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Resistance, Microbial; Emigration and Immigra | 1975 |
Emergence of rifampin-resistant Mycobacterium tuberculosis in Massachusetts.
Topics: Drug Resistance, Microbial; Female; Humans; In Vitro Techniques; Isoniazid; Male; Massachusetts; Mid | 1976 |
Letter: Tuberculosis and isoniazid in steroid-treated asthmatic patients.
Topics: Adrenal Cortex Hormones; Asthma; Humans; Isoniazid; Long-Term Care; Risk; Tuberculin Test; Tuberculo | 1976 |
[Use of isoniazid with nitrofuran and 5-NHQ derivatives in experimental tuberculosis].
Topics: Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Guinea Pigs; Hydroxyquinolines; Is | 1976 |
Bactericidal activity in vitro and in the guinea-pig of isoniazid, rifampicin and ethambutol.
Topics: Animals; Drug Therapy, Combination; Ethambutol; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; | 1976 |
[Hepatotoxic effect of isoniazid (clinical, genetic and metabolic aspects)].
Topics: Acetylation; Acetyltransferases; Alleles; Animals; Genotype; Humans; Isoniazid; Liver; Middle Aged; | 1977 |
[Tuberculosis of the middle and external ear; a report of two cases (author's transl)].
Topics: Adult; Deafness; Ear Diseases; Ear, External; Ear, Middle; Female; Gentamicins; Humans; Isoniazid; M | 1977 |
Isoniazid with corticosteroids in patients infected with Mycobacterium tuberculosis.
Topics: Adrenal Cortex Hormones; Humans; Isoniazid; Tuberculosis | 1977 |
[Studies on tuberactinomycin-N. Report 3. Comparison of the effects of TUM-N and INH on experimental mouse tuberculosis (author's transl)].
Topics: Animals; Antibiotics, Antitubercular; Drug Evaluation, Preclinical; Enviomycin; Isoniazid; Mice; Tub | 1977 |
Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.
Topics: Acetylation; Chemistry, Organic; Humans; Isoniazid; Kinetics; Organic Chemistry Phenomena; Phenotype | 1977 |
Isoniazid chemoprophylaxis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Tuberculosis | 1977 |
Tuberculosis.
Topics: Ethambutol; Humans; Isoniazid; Rifampin; Streptomycin; Tuberculosis | 1977 |
[Toxic hepatitis caused by rifampin and isoniazid in treatment of tuberculosis (author's transl)].
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Diagnosis, Differential; Female; H | 1977 |
Febrile reactions to INH.
Topics: Female; Fever; Humans; Isoniazid; Middle Aged; Tuberculosis | 1977 |
Antituberculous effect of histidine.
Topics: Animals; Antitubercular Agents; Guinea Pigs; Histidine; Isoniazid; Male; Streptomycin; Tuberculosis | 1977 |
[INH and rifampicin dosage at the beginning of tuberculosis treatment].
Topics: Drug Tolerance; Ethambutol; Humans; Isoniazid; Rifampin; Tuberculosis | 1977 |
[Experimental studies on the effective regimens of antituberculous drugs in the treatment of tuberculosis. II. Long-term chemotherapy in mice by daily and intermittent administration with changing drug combination (author's transl)].
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Isoniazid; Mice; Rifampin; Tu | 1977 |
[Modification during treatment of the rate of acetylation of isoniazide clinically or biologically detectable hepatic damage (author's transl)].
Topics: Acetylation; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Liver; Male; Optic Neuritis; | 1977 |
Preventing tuberculosis.
Topics: Humans; Isoniazid; Tuberculin Test; Tuberculosis; Tuberculosis, Pulmonary | 1977 |
Antituberculosis agents: isoniazid, rifampin, streptomycin, ethambutol.
Topics: Antibiotics, Antitubercular; Ethambutol; Humans; Isoniazid; Rifampin; Streptomycin; Tuberculosis | 1977 |
When we give prophylactic INH.
Topics: Humans; Isoniazid; Tuberculosis | 1976 |
Editorial: The XXIIrd International Tuberculosis Conference.
Topics: Antitubercular Agents; BCG Vaccine; Drug Administration Schedule; Evaluation Studies as Topic; Human | 1976 |
[Experiences with INHG-Na in the triple-drug-therapy of extrapulmonal tuberculoses (author's transl)].
Topics: Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Tuberculosis; Tuberculosis, Lymph Node; | 1976 |
Tuberculosis management in the mid-1970s.
Topics: Ambulatory Care; Antitubercular Agents; Drug Resistance; Drug Therapy, Combination; Ethambutol; Huma | 1976 |
Letter: Tuberculosis management.
Topics: Humans; Indians, North American; Isoniazid; Tuberculosis | 1976 |
[Effect of the prolonged use of streptomycin as well as streptomycin in combination with tubazid on the bioelectrical activity of the brain in experimental tuberculosis].
Topics: Alpha Rhythm; Animals; Brain; Chronic Disease; Cortical Synchronization; Drug Combinations; Electroe | 1976 |
Editorial: Tuberculosis in corticosteroid-treated asthmatics.
Topics: Adrenal Cortex Hormones; Asthma; Humans; Isoniazid; Tuberculosis | 1976 |
[Effect of combinations of trace elements and vitamins in inositol metabolism and the morphohistochemical indices in the isoniazid treatment of experimental tuberculosis].
Topics: Animals; Copper; Drug Therapy, Combination; Inositol; Isoniazid; Liver; Male; Rabbits; Trace Element | 1976 |
Isoniazid acetylator status of Black South African tuberculosis patients.
Topics: Acetylation; Adolescent; Adult; Aged; Aminosalicylic Acids; Black People; Half-Life; Humans; Isoniaz | 1976 |
Chemoprophylaxis of respiratory infections.
Topics: Antiviral Agents; BCG Vaccine; Bronchitis; Humans; Isoniazid; Respiratory Tract Infections; Tetracyc | 1976 |
[Experimental comparison of the tuberculostatic activities of INH, INHG and INHG-Na (author's transl)].
Topics: Administration, Oral; Animals; Female; Guinea Pigs; Humans; Injections, Intravenous; Isoniazid; Kine | 1976 |
[Frequency, diagnosis, and course of hepatotoxic side effects of Rifampicin (author's transl)].
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Chemical and Drug Induced L | 1976 |
New concepts in diagnosis and treatment of tuberculosis. Part II: current trends in treatment and management.
Topics: Humans; Isoniazid; Rifampin; Streptomycin; Tuberculosis | 1976 |
A slow-release preparation of isoniazid: therapeutic efficacy and adverse side-effects.
Topics: Delayed-Action Preparations; Drug Therapy, Combination; Humans; India; Isoniazid; Streptomycin; Tube | 1976 |
Clinical experience of acceptability of slow release matrix isoniazid.
Topics: Delayed-Action Preparations; Drug Therapy, Combination; Humans; Isoniazid; Streptomycin; Tuberculosi | 1976 |
Treating tuberculosis infection.
Topics: Humans; Isoniazid; Tuberculosis | 1975 |
Orificial tuberculosis of the lip.
Topics: Adult; Biopsy; Ethambutol; Humans; Isoniazid; Lip Diseases; Male; Mouth Mucosa; Pyridoxine; Radiogra | 1975 |
Acetylation rates and monthly liver function tests during one year of isoniazid preventive therapy.
Topics: Acetylation; Adult; Aged; Antibodies, Antinuclear; Aspartate Aminotransferases; Bilirubin; Chemical | 1975 |
[Current aspects in treatment of tuberculosis].
Topics: Adult; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Rifampin; Streptomycin; Tube | 1976 |
Chemoprophylaxis for the prevention of tuberculosis in the immunosuppressed renal allograft recipient.
Topics: Adrenal Cortex Hormones; Humans; Immunosuppression Therapy; Isoniazid; Kidney Transplantation; Trans | 1975 |
Letter: Massive use of chemoprophylaxis against tuberculosis.
Topics: BCG Vaccine; Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1975 |
[Letter: Preventive chemotherapy of tuberculosis].
Topics: Humans; Isoniazid; Tuberculosis | 1975 |
[New aspects of tuberculosis therapy].
Topics: Contraceptives, Oral; Ethambutol; Female; Humans; Isoniazid; Menstruation; Methods; Pulmonary Heart | 1975 |
Intentional isoniazid overdosage among southwestern American Indians.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Arizona; Child; Drug Administration Schedule; | 1975 |
The competing risks of tuberculosis and hepatitis for adult tuberculin reactors.
Topics: Adult; Age Factors; Alabama; Chemical and Drug Induced Liver Injury; Female; Georgia; Humans; Isonia | 1975 |
Letter: Isoniazid and the liver.
Topics: Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Liver; Liver | 1975 |
Guidelines on tuberculosis control programs for hospital employees.
Topics: Administration, Oral; BCG Vaccine; Cross Infection; Humans; Isoniazid; Methods; Occupational Disease | 1975 |
[Survey over drug therapy of tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Humans; Isoniazid; Streptomycin; Tuberculosis | 1975 |
Monitoring preventive therapy patients for liver disease as well as compliance.
Topics: Chemical and Drug Induced Liver Injury; Health Services; Humans; Isoniazid; Mass Screening; Medical | 1975 |
Isoniazid-associated hepatitis in 114 patients.
Topics: Age Factors; Alanine Transaminase; Alkaline Phosphatase; Asian People; Aspartate Aminotransferases; | 1975 |
[EEG studies in children on long-term therapy with hydrazide (INH)].
Topics: Adolescent; Age Factors; Brain; Child; Child, Preschool; Electroencephalography; Female; Humans; Inf | 1975 |
Tuberculosis. Chemoprophylaxis and treatment.
Topics: Chemical and Drug Induced Liver Injury; Drug Resistance, Microbial; Drug Therapy, Combination; Etham | 1975 |
Letter: World anaesthesiology congress, Mexico city.
Topics: Black People; Humans; Isoniazid; South Africa; Tuberculosis | 1975 |
Topics in tuberculosis.
Topics: Ambulatory Care; Female; Humans; Isoniazid; Maryland; Patient Care Planning; Pregnancy; Rifampin; Tu | 1975 |
Letter: Isoniazid and cancer risks.
Topics: Carcinogens; Humans; Isoniazid; Tuberculosis | 1975 |
Drug resistance in tuberculosis.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Family Practice; Humans; Isoniazid; Tuberculosis | 1975 |
Proceedings: Latest results of East African/British Medical Research Council short course chemotherapy studies.
Topics: Drug Evaluation; Humans; Isoniazid; Pyrazinamide; Recurrence; Rifampin; Streptomycin; Tuberculosis | 1975 |
Proceedings: On the medical use of isoniazid.
Topics: Humans; Isoniazid; Tuberculosis | 1975 |
The emergence of the cooperative clinical trial.
Topics: Drug Evaluation; Female; Humans; International Cooperation; Isoniazid; Penicillins; Pregnancy; Resea | 1975 |
Letter: Isoniazid metabolism in black patients.
Topics: Black People; Humans; India; Isoniazid; Phenotype; South Africa; Tuberculosis; White People | 1975 |
Letter: The competing risks of tuberculosis and hepatitis for adult tuberculin reactors.
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Tuberculosis | 1975 |
Rifampicin in clinical use.
Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Drug Therapy, Combination; England; Humans; Isonia | 1975 |
[Isoprodian in combination with ethambutol and rifampicin in the treatment of tuberculosis (author's transl)].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethamb | 1975 |
[Treatment of tuberculosis].
Topics: Aminosalicylic Acids; Ethambutol; Humans; Isoniazid; Rifampin; Streptomycin; Tuberculosis | 1975 |
[Effect of splenin on protein-synthetising function of the liver during treatment of experimental tuberculosis with large doses of isoniazid].
Topics: Albumins; Animals; Cattle; Drug Therapy, Combination; Female; Guinea Pigs; Isoniazid; Liver; Male; S | 1975 |
[In favor of an adapted isoniazid posology].
Topics: Drug Therapy, Combination; Humans; Isoniazid; Tuberculosis | 1975 |
Some bacteriologic aspects of the epidemiology of pulmonary and extrapulmonary tuberculosis.
Topics: Adult; Aminosalicylic Acids; Catalase; Drug Resistance, Microbial; Female; Humans; Isoniazid; Male; | 1976 |
[Acute isoniazid poisoning].
Topics: Adult; Body Weight; Female; Humans; Isoniazid; Male; Poisoning; Tuberculosis | 1976 |
[Is prophylactic administration of isoniazide still justified?].
Topics: Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Liver; Tuberculosis | 1976 |
Rationale for chemotherapy of tuberculosis and current recommendations.
Topics: Antitubercular Agents; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Mycobacteriu | 1992 |
An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Air Movements; Case-Control Studies; Cluster Analysis; Cr | 1992 |
Irrational speech occurring in the course of anti-tuberculous therapy--possibly caused by isoniazid.
Topics: Child; Female; Humans; Isoniazid; Speech Disorders; Tuberculosis | 1992 |
Case holding in patients with tuberculosis in Botswana.
Topics: Botswana; Drug Therapy, Combination; Humans; Isoniazid; National Health Programs; Patient Compliance | 1992 |
Is there a place for prophylaxis against tuberculosis following renal transplantation?
Topics: Adolescent; Adult; Azathioprine; Child; Cyclosporine; Female; Follow-Up Studies; Humans; Isoniazid; | 1992 |
[Active tuberculosis in children who received INH chemoprophylaxis].
Topics: Adolescent; Child; Child, Preschool; Humans; Infant; Isoniazid; Tuberculosis | 1992 |
Isoniazid-associated hepatitis deaths: a review of available information.
Topics: Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Risk Factors; Tuberculosis | 1992 |
Isoniazid-associated hepatitis deaths: a review of available information.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Risk Factors; Tuberculosis | 1992 |
Tuberculosis in Australia.
Topics: Adult; Asia; Emigration and Immigration; Humans; Isoniazid; Tuberculosis; Victoria | 1992 |
Clinical application of the polymerase chain reaction for a rapid diagnosis of Mycobacterium tuberculosis infection.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Base Sequence; DNA, Bacterial; Drug Therap | 1992 |
Culture-positive tuberculosis in Western Australia.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Resistance, Microbial; Emigration and Immigra | 1992 |
The benefits of isoniazid chemoprophylaxis and risk factors for tuberculosis among Oglala Sioux Indians.
Topics: Adult; Case-Control Studies; Diabetes Complications; Female; Humans; Indians, North American; Isonia | 1992 |
Failure of the 12 months course of antituberculous chemoprophylaxis in HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Isoniazid; Male; Mycobacterium tuberculos | 1992 |
[Cold tuberculous retropharyngeal abscess].
Topics: Abscess; Brachial Plexus Neuritis; Deglutition Disorders; Drug Therapy, Combination; Ethambutol; Fem | 1992 |
[PPD and chemoprophylaxis in diabetes mellitus].
Topics: Adult; Aged; Aged, 80 and over; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus | 1992 |
Pancreatic tuberculosis following renal transplantation.
Topics: Ethambutol; Female; Humans; Immunosuppression Therapy; Isoniazid; Kidney Failure, Chronic; Kidney Tr | 1992 |
[Chemoprophylaxis of tuberculosis: compliance to treatment in the pediatric population].
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Infant; Isoniazid; Male; Patient Compliance; Sp | 1992 |
HIV infection: the dominant new face of tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Humans; Isoniazid; Risk Factors; Tuberculosis | 1992 |
Tuberculosis in the 1990's: resurgence, regimens, and resources.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Child; Drug Administration Schedule; Drug Interacti | 1992 |
Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
Topics: Animals; Colony Count, Microbial; Drug Combinations; Female; Isoniazid; Mice; Mycobacterium tubercul | 1992 |
Transmission of multidrug-resistant tuberculosis among immunocompromised persons in a correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |
From the Centers for Disease Control. Transmission of multidrug-resistant tuberculosis among immunocompromised persons, correctional system--New York, 1991.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; HIV Seropositivity; Huma | 1992 |
Primary and acquired drug resistance in adult black patients with tuberculosis in South Africa: results of a continuous national drug resistance surveillance programme involvement.
Topics: Black or African American; Black People; Drug Resistance, Microbial; Ethambutol; Ethionamide; Female | 1992 |
HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; CD4-Positive T-Lymphocytes; Drug Resist | 1991 |
Tuberculosis in children: treatment evaluation and results in a 5 year cohort of children with tuberculosis in Turiani Hospital, Tanzania.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Drug Combinations; Drug Therapy, Combination; H | 1991 |
Primary vaginal tuberculosis after vaginal carcinoma.
Topics: Aged; Carcinoma, Squamous Cell; Female; Humans; Isoniazid; Male; Middle Aged; Mycobacterium tubercul | 1992 |
Drugs for tuberculosis.
Topics: Adult; Antitubercular Agents; Child; Drug Administration Schedule; Humans; Isoniazid; Tuberculosis | 1992 |
Tuberculosis screening and indications for preventive therapy.
Topics: BCG Vaccine; Child; Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1992 |
Mycobacterium bovis (BCG) vaccination. Progressive disease in a patient asymptomatically infected with the human immunodeficiency virus.
Topics: Adult; BCG Vaccine; Ethambutol; HIV Infections; Humans; Isoniazid; Male; Mycobacterium bovis; Rifamp | 1992 |
Decision analysis for isoniazid chemoprophylaxis.
Topics: Adult; Age Factors; Aged; Decision Trees; Humans; Isoniazid; Middle Aged; Tuberculosis | 1991 |
Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children.
Topics: Ascorbic Acid; Child; Chromatography, High Pressure Liquid; Drug Stability; Humans; Isoniazid; Pyraz | 1991 |
AIDS and tuberculosis in Spain. A report of 140 cases.
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Ethambutol; Female; Humans; Incidence | 1991 |
[The role of phenotypic factors in predicting the effectiveness of pharmacological prevention of tuberculosis in children].
Topics: Child; Child, Preschool; Dermatoglyphics; Drug Resistance; Female; Humans; Isoniazid; Male; Phenotyp | 1991 |
Pyridoxine supplementation with isonex: is it necessary?
Topics: Drug Therapy, Combination; Humans; Isoniazid; Pyridoxine; Tuberculosis | 1991 |
[Tuberculosis of the larynx, oral cavity and pharynx].
Topics: Adult; Diagnosis, Differential; Drug Therapy, Combination; Endoscopy; Ethambutol; Humans; Isoniazid; | 1991 |
Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Drug Administration Schedule; Drug Therapy, Combination; | 1991 |
Memory T cell-mediated resistance to Mycobacterium tuberculosis infection in innately susceptible and resistant mice.
Topics: Animals; Cyclophosphamide; Immunity, Cellular; Immunization, Passive; Immunologic Memory; Immunother | 1991 |
Hepatotoxicity of rifampin and isoniazid. Is it all drug-induced hepatitis?
Topics: Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Hepatitis A; Hepatitis B; H | 1991 |
Preventive therapy for tuberculosis in Maryland.
Topics: Adolescent; Adult; Asia; Child; Child, Preschool; Female; Humans; Infant; Isoniazid; Male; Maryland; | 1991 |
Decision analysis, public health policy, and isoniazid chemoprophylaxis for young adult tuberculin skin reactors.
Topics: Adult; Chemical and Drug Induced Liver Injury; Female; Health Policy; Humans; Isoniazid; Male; Survi | 1991 |
The isoniazid debate.
Topics: Adult; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Male; Models, Biological; Tubercul | 1991 |
[Hiv infection and tuberculosis. Recommendations of the German Central Committee for the Control of Tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; HIV Infections; Humans; Isoniazid; Records; Tuberc | 1991 |
Sustained release of isoniazid in vivo from a single implant of a biodegradable polymer.
Topics: Biocompatible Materials; Delayed-Action Preparations; Drug Implants; Humans; Isoniazid; Lactic Acid; | 1991 |
Relapse of tuberculosis in a patient with the acquired immunodeficiency syndrome despite 12 months of antituberculous therapy and continuation of isoniazid.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antitubercular Agents; Humans; Isoniazid; Male; Recurrenc | 1991 |
Testing international students for tuberculosis.
Topics: Adolescent; Adult; Humans; Illinois; International Educational Exchange; Isoniazid; Liver Function T | 1991 |
Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Decision Trees; HIV Infections; HIV Seropositivity; H | 1991 |
[Infection prophylaxis in patients with hematological malignancies (II)--Successful prophylaxis of tuberculosis with isoniazid].
Topics: Adolescent; Adult; Aged; Female; Humans; Isoniazid; Leukemia; Lymphoma; Male; Middle Aged; Retrospec | 1991 |
[Drug therapy of intractable Mycobacterium infections].
Topics: Antibiotics, Antitubercular; Drug Therapy, Combination; Ethambutol; Humans; Isoniazid; Mycobacterium | 1990 |
A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Aspartate Aminotransferases; Cost-Benefit Analysis; | 1990 |
The use of preventive therapy for tuberculous infection in the United States. Recommendations of the Advisory Committee for Elimination of Tuberculosis.
Topics: Adult; Child; Drug Administration Schedule; Humans; Isoniazid; Patient Education as Topic; Risk Fact | 1990 |
Drug resistance trends in Mycobacterium tuberculosis: Blackburn 1985-89.
Topics: Antitubercular Agents; Drug Resistance, Microbial; England; Humans; India; Isoniazid; Longitudinal S | 1990 |
[Tuberculosis: a disease that is difficult to eradicate. Description of a case].
Topics: Acquired Immunodeficiency Syndrome; Antitubercular Agents; Diagnosis, Differential; Ethambutol; Fema | 1990 |
Central nervous system tuberculosis in children: a review of 30 cases.
Topics: Brain Diseases; Child, Preschool; Drug Resistance, Microbial; Ethnicity; Female; Humans; Hydrocephal | 1990 |
Cerebellar syndrome caused by isoniazid.
Topics: Aged; Cerebellar Diseases; Female; Humans; Isoniazid; Kidney Failure, Chronic; Pyrazinamide; Pyridox | 1990 |
Drug combinations and the bioavailability of rifampicin.
Topics: Antitubercular Agents; Biological Availability; Drug Combinations; Humans; Isoniazid; Pyrazinamide; | 1990 |
[Drugs used in tuberculosis and leprosy].
Topics: Administration, Oral; Antibiotics, Antitubercular; Clofazimine; Dapsone; Humans; Injections, Intramu | 1990 |
Therapeutic priorities of Canadian internists.
Topics: Attitude of Health Personnel; Canada; Cardiovascular Diseases; Cholestyramine Resin; Humans; Hyperch | 1990 |
Tuberculosis infection in urban adolescents: results of a school-based testing program.
Topics: Adolescent; Boston; Ethnicity; Female; Haiti; Humans; Isoniazid; Male; Mass Screening; Prevalence; T | 1990 |
[Chemoprophylaxis of tuberculosis].
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Humans; Infant; Isoniazid; Rifamp | 1990 |
Tuberculosis control and the AIDS epidemic in developing countries.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Developing Countries; Diagnosis, Different | 1990 |
[Detection of a pathological cutaneous reaction to tuberculin in an adolescent].
Topics: Adolescent; Antitubercular Agents; BCG Vaccine; Drug Therapy, Combination; Humans; Isoniazid; Physic | 1990 |
Screening for tuberculosis in nursing homes.
Topics: Aged; Female; Homes for the Aged; Humans; Isoniazid; Male; Mass Screening; Nursing Homes; Radiograph | 1990 |
Salivary levels of isoniazid and rifampicin in tuberculous patients.
Topics: Adolescent; Adult; Female; Humans; Isoniazid; Male; Middle Aged; Rifampin; Saliva; Tuberculosis; Tub | 1990 |
Monitoring therapy for tuberculosis.
Topics: Child; Child, Preschool; Humans; Isoniazid; Monitoring, Physiologic; Patient Compliance; Time Factor | 1990 |
Failure of tuberculosis chemotherapy in a human immunodeficiency virus-infected patient.
Topics: Adult; HIV Infections; Humans; Isoniazid; Male; Rifampin; Tuberculosis | 1990 |
Cost savings from alternative treatments for tuberculosis.
Topics: Ambulatory Care; Antitubercular Agents; Botswana; Cost-Benefit Analysis; Ethambutol; Humans; Isoniaz | 1986 |
Drug resistance of Mycobacterium tuberculosis isolated from treated patients in Pakistan.
Topics: Adolescent; Adult; Aminosalicylic Acid; Antitubercular Agents; Drug Resistance, Microbial; Ethambuto | 1989 |
Problems of tuberculosis treatment in Thailand.
Topics: Dose-Response Relationship, Drug; Drug Combinations; Drug Evaluation; Female; Humans; Isoniazid; Mal | 1989 |
Influence of BCG-induced immunity on the bactericidal activity of isoniazid and rifampicin in experimental tuberculosis of the mouse and guinea-pig.
Topics: Animals; BCG Vaccine; Guinea Pigs; Immunity; Isoniazid; Mice; Mycobacterium tuberculosis; Rifampin; | 1989 |
Prevention and control of tuberculosis in correctional institutions: recommendations of the Advisory Committee for the Elimination of Tuberculosis.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Crowding; Disease Outbreaks; Humans; Isoniazi | 1989 |
Relapses after stopping chemotherapy for experimental tuberculosis in genetically resistant and susceptible strains of mice.
Topics: Animals; Anti-Bacterial Agents; Disease Susceptibility; Drug Therapy, Combination; Female; Immunity, | 1989 |
Annual tuberculin skin testing of employees at a university hospital: a cost-benefit analysis.
Topics: Age Factors; Cost-Benefit Analysis; Florida; Hospitals, Psychiatric; Hospitals, Teaching; Hospitals, | 1989 |
[The etiopathogenetic treatment of experimental tuberculosis using preparations with immunomodulating action].
Topics: Adjuvants, Immunologic; Animals; Drug Evaluation, Preclinical; Drug Therapy, Combination; Guinea Pig | 1989 |
Primary and acquired drug resistance in Mycobacterium tuberculosis strains in western region of Libyan Arab Jamahiriya.
Topics: Drug Resistance, Microbial; Ethambutol; Female; Humans; Isoniazid; Libya; Male; Mycobacterium tuberc | 1989 |
Aging and immunity to tuberculosis: prolonged survival of old mice infected with Mycobacterium tuberculosis by adoptive immunization with memory-immune T lymphocytes.
Topics: Aging; Animals; Female; Immunization, Passive; Immunologic Memory; Isoniazid; Mice; Mice, Inbred C57 | 1989 |
Psychosis and anti-tuberculosis therapy.
Topics: Adult; GABA Antagonists; Humans; Isoniazid; Psychoses, Substance-Induced; Tuberculosis | 1989 |
Combination chemotherapy with ciprofloxacin for infection with Mycobacterium tuberculosis in mouse models.
Topics: Animals; Ciprofloxacin; Disease Models, Animal; Drug Therapy, Combination; Isoniazid; Male; Mice; Ri | 1989 |
[Tuberculosis in children in 1989].
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Age Factors; Anti-Bacterial Agents; BCG Vaccine; Chi | 1989 |
Incidence of hepatotoxicity in children receiving isoniazid chemoprophylaxis.
Topics: Adolescent; Alanine Transaminase; Aspartate Aminotransferases; Child; Child, Preschool; Female; Huma | 1989 |
[Tuberculous ulcer of the tongue: clinical case].
Topics: Adult; Female; Humans; Isoniazid; Pyrazinamide; Rifampin; Tongue Diseases; Tuberculosis; Tuberculosi | 1989 |
[Pharmacologic prevention of tuberculosis (instruction)].
Topics: Adolescent; Adult; Age Factors; Calcium Gluconate; Carrier State; Child; Child, Preschool; Humans; I | 1989 |
Systemic bacillus Calmette-Guérin infection, 'BCGitis', in patients treated by intravesical bacillus Calmette-Guérin therapy for bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Humans; Isoniazid; Ma | 1989 |
[Recommendations for the therapy of tuberculosis. (Position: December, 1988)].
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1989 |
Less is more: short-course preventive therapy of tuberculosis.
Topics: Animals; Humans; Isoniazid; Mice; Rifampin; Tuberculosis | 1989 |
Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide.
Topics: Animals; BCG Vaccine; Colony Count, Microbial; Drug Administration Schedule; Drug Therapy, Combinati | 1989 |
Compliance with isoniazid prophylaxis in jail.
Topics: Adolescent; Adult; Education; Housing; Humans; Isoniazid; Male; Patient Compliance; Patient Educatio | 1989 |
Isoniazid-induced valproic-acid toxicity, or vice versa.
Topics: Adolescent; Drug Interactions; Epilepsy; Female; Humans; Isoniazid; Tuberculosis; Valproic Acid | 1987 |
[Routine use of 6-month antitubercular treatment in 300 patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Drug Therapy, Combination; Drug T | 1986 |
Isoniazid, rifampin, and hepatotoxicity.
Topics: Acetylation; Asian; Chemical and Drug Induced Liver Injury; Drug Combinations; Drug Interactions; Hu | 1986 |
The role of host factors for the chemotherapy of BCG infection in inbred strains of mice.
Topics: Animals; Cyclosporins; Immunity; Isoniazid; Mice; Mice, Inbred Strains; Mycobacterium bovis; Rifampi | 1988 |
Decision analysis for chest clinicians.
Topics: Decision Support Techniques; Humans; Isoniazid; Lung Diseases; Lung Neoplasms; Neoplasm Staging; Pub | 1988 |
Preventive therapy with isoniazid. Cost-effectiveness of different durations of therapy.
Topics: Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Drug Administration Schedule; Follow- | 1986 |
Supplement on future research in tuberculosis. Prospects and priorities for elimination. Endorsement of the American Thoracic Society Board of Directors in March 1986.
Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Disease Su | 1986 |
Recombinant interferon-gamma and chemotherapy with isoniazid and rifampicin in experimental murine tuberculosis.
Topics: Animals; Drug Therapy, Combination; Interferon-gamma; Isoniazid; Lung; Mice; Mice, Inbred BALB C; My | 1986 |
Drug-resistant tuberculosis in Sierra Leone.
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Microbial Sensitiv | 1986 |
[Theoretical basis for the treatment of tuberculosis].
Topics: Antitubercular Agents; Drug Resistance; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Tub | 1986 |
Tuberculosis of the soft palate: an unusual presentation of oral tuberculosis.
Topics: Adult; Diagnosis, Differential; Humans; Isoniazid; Male; Palate, Soft; Tuberculosis; Tuberculosis, O | 1987 |
Tuberculosis control in the military population: apathy revisited.
Topics: Adult; Disease Outbreaks; Female; Humans; Isoniazid; Male; Military Personnel; Naval Medicine; Tuber | 1987 |
The first joint THELEP-Sasakawa Memorial Health Foundation workshop on experimental chemotherapy of leprosy.
Topics: Dapsone; Drug Resistance, Microbial; Humans; Isoniazid; Leprosy; Mycobacterium leprae; Mycobacterium | 1987 |
Characteristics and specificity of acquired immunologic memory to Mycobacterium tuberculosis infection.
Topics: Animals; Cyclophosphamide; Hypersensitivity, Delayed; Immunity, Cellular; Immunization, Passive; Imm | 1988 |
Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan.
Topics: Antitubercular Agents; China; Ethambutol; Humans; Isoniazid; Mycobacterium tuberculosis; Osmolar Con | 1988 |
[Prospective study of the primary resistance of the tuberculosis bacillus to antibiotics. Methods and results].
Topics: Algeria; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Prospective Stud | 1988 |
Decision analysis for isoniazid preventive therapy: take it or leave it?
Topics: Humans; Isoniazid; Tuberculosis | 1988 |
Isoniazid for the tuberculin reactor: take it or leave it.
Topics: Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1988 |
Isoniazid for the tuberculin reactor: take it or leave.
Topics: Decision Making; Humans; Isoniazid; Models, Theoretical; Tuberculin Test; Tuberculosis | 1988 |
[Effectiveness of the combined use of antihypoxic agents and antioxidants in tuberculosis].
Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Hydroxybutyrates; Hypoxia; Isoniazid; Lipid Peroxid | 1988 |
Single dose kinetics of rifampicin and isoniazid in well-nourished and malnourished patients of tuberculosis.
Topics: Acetylation; Adult; Female; Half-Life; Humans; Isoniazid; Male; Middle Aged; Nutrition Disorders; Ph | 1988 |
Isoniazid for the tuberculin reactor: take it or leave it.
Topics: Adult; Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Decision Support Techniques; | 1988 |
Multidrug chemotherapy of tuberculosis in rhesus monkeys.
Topics: Animals; Antitubercular Agents; Disease Outbreaks; Drug Therapy, Combination; Ethambutol; Female; Is | 1988 |
[The sense of prophylactic treatment of tuberculosis].
Topics: Humans; Isoniazid; Primary Prevention; Risk Factors; Time Factors; Tuberculosis | 1988 |
Antimycobacterial activities in vitro and in vivo and pharmacokinetics of dihydromycoplanecin A.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Chemical Phen | 1988 |
Intentional isoniazid overdosage in young Southeast Asian refugee women.
Topics: Adolescent; Adult; Cambodia; Female; Humans; Isoniazid; Refugees; Suicide, Attempted; Tuberculosis; | 1988 |
Drugs for tuberculosis.
Topics: Adult; Aged; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Drug Administrati | 1988 |
Tuberculosis in a cohort of Southeast Asian Refugees. A five-year surveillance study.
Topics: Age Factors; Asia, Southeastern; Drug Resistance, Microbial; Humans; Isoniazid; Population Surveilla | 1988 |
Preventive treatment for tuberculosis in elderly persons.
Topics: Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Humans; Isoniazid; Middle Aged; Tub | 1988 |
[Therapeutic properties of a prolonged-action preparation of isoniazid].
Topics: Animals; Delayed-Action Preparations; Drug Evaluation, Preclinical; Guinea Pigs; Isoniazid; Lethal D | 1988 |
A more simple, rapid and sensitive fluorimetric method for the determination of isoniazid and acetylisoniazid in serum. Application for acetylator phenotyping.
Topics: Acetonitriles; Acetylation; Blood Proteins; Humans; Isoniazid; Phenotype; Spectrometry, Fluorescence | 1988 |
Incidence of isoniazid-induced antinuclear antibodies in patients of tuberculosis.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Female; Humans; Isoniazid; Male; Middle Aged; Prospectiv | 1987 |
Prevalence of antinuclear antibodies in isoniazid treated patients.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Female; Humans; Isoniazid; Male; Middle Aged; Tuberculos | 1987 |
American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children.
Topics: Adult; Age Factors; Blood Cell Count; Blood Urea Nitrogen; Child; Creatinine; Drug Administration Sc | 1986 |
Report of the joint leprosy-tuberculosis project in Paraguay.
Topics: Dapsone; Drug Combinations; Drug Therapy, Combination; Humans; Isoniazid; Leprostatic Agents; Lepros | 1986 |
[Basic experiment on the action of isobutol in tuberculosis].
Topics: Animals; Antitubercular Agents; Drug Combinations; Ethambutol; Female; Isoniazid; Male; Mice; Microb | 1986 |
Tuberculosis chemoprophylaxis in compromised host.
Topics: Humans; Immunosuppression Therapy; Isoniazid; Tuberculosis | 1987 |
Discounting, isoniazid, and tuberculosis.
Topics: Age Factors; Humans; Isoniazid; Life Expectancy; Tuberculosis | 1987 |
Isoniazid prophylaxis.
Topics: Age Factors; Humans; Isoniazid; Risk; Tuberculosis | 1987 |
[Demonstration of a correlation between the degree of pigmentation and the power of inactivation of isoniazid in man].
Topics: Eye Color; Hair; Humans; Iris; Isoniazid; Pigmentation; Skin Pigmentation; Tuberculosis | 1987 |
Reduced incidence of tuberculosis by prophylactic chemotherapy in subjects showing strong reactions to tuberculin testing.
Topics: Adolescent; Child; Child, Preschool; Drug Therapy, Combination; England; Humans; India; Infant; Infa | 1987 |
Antituberculous agents.
Topics: Antitubercular Agents; Ethambutol; Humans; Isoniazid; Pyrazinamide; Rifampin; Streptomycin; Tubercul | 1987 |
[Correction of the toxic effect of isoniazid preparations].
Topics: Animals; Guinea Pigs; Isoniazid; Succinates; Succinic Acid; Tuberculosis | 1987 |
Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons.
Topics: Aged; Aged, 80 and over; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Male; Mi | 1987 |
A case-control study to evaluate the effectiveness of mass neonatal BCG vaccination among Canadian Indians.
Topics: Adolescent; BCG Vaccine; Child; Child, Preschool; Female; Health Policy; Humans; Indians, North Amer | 1986 |
Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin.
Topics: Acetylation; Chemical and Drug Induced Liver Injury; Drug Combinations; Humans; Hydrazines; Isoniazi | 1986 |
The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis.
Topics: Acetylation; Adolescent; Adult; Biological Availability; Drug Combinations; Humans; Isoniazid; Middl | 1986 |
Hepatic mixed function oxidase induction during rifampicin/isoniazid therapy in Indian vegetarians.
Topics: Antipyrine; Diet, Vegetarian; Drug Therapy, Combination; Enzyme Induction; Female; Half-Life; Humans | 1986 |
The benefits of evaluating close associates of child tuberculin reactors from a high prevalence group.
Topics: Adolescent; Adult; California; Child; Child, Preschool; Emigration and Immigration; Epidemiologic Me | 1986 |
The age threshold for isoniazid chemoprophylaxis. A decision analysis for low-risk tuberculin reactors.
Topics: Adolescent; Adult; Age Factors; Aged; Chemical and Drug Induced Liver Injury; Child; Humans; Isoniaz | 1986 |
Prevention of tuberculosis among tuberculin reactors: maximizing benefits, minimizing risks.
Topics: Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1986 |
Hepatic toxicity in South Indian patients during treatment of tuberculosis with short-course regimens containing isoniazid, rifampicin and pyrazinamide.
Topics: Adolescent; Adult; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Child; Child, Pres | 1986 |
Delayed tuberculin boosting in the older population.
Topics: Adult; False Positive Reactions; Humans; Isoniazid; Middle Aged; Tuberculin Test; Tuberculosis | 1986 |
The age threshold for isoniazid chemotherapy.
Topics: Humans; Isoniazid; Risk; Statistics as Topic; Tuberculosis | 1987 |
[Efficacy of immunotropic drugs in experimental tuberculosis].
Topics: Animals; Drug Therapy, Combination; Guinea Pigs; Isoniazid; Levamisole; Mice; Thymus Hormones; Tuber | 1985 |
Isoniazid-induced pure red cell aplasia.
Topics: Aged; Bone Marrow; Drug Therapy, Combination; Humans; Isoniazid; Male; Middle Aged; Red-Cell Aplasia | 1985 |
[The latest topics concerning pyrazinamide].
Topics: Adolescent; Adult; Animals; Child; Drug Resistance, Microbial; Drug Synergism; Female; Humans; Isoni | 1985 |
Childhood tuberculosis in North Carolina: a study of the opportunities for intervention in the transmission of tuberculosis to children.
Topics: Adolescent; Child; Child, Preschool; Epidemiologic Methods; Humans; Infant; Isoniazid; Medical Recor | 1986 |
Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Drug Administration Schedule; Female; Humans; Isonia | 1986 |
Isoniazid chemoprophylaxis.
Topics: Drug Administration Schedule; Humans; Isoniazid; Tuberculosis | 1986 |
Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees.
Topics: Adolescent; Adult; Asia, Southeastern; Asian; Child; Drug Resistance, Microbial; Female; Humans; Iso | 1986 |
Tuberculosis control practices in major metropolitan health departments in the United States. 3. Standard of practice in 1984.
Topics: Adolescent; Adult; Child; Drug Therapy; Drug Therapy, Combination; Ethambutol; Health Facilities; He | 1985 |
Preventive treatment of tuberculosis.
Topics: Adult; Age Factors; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Costs and Cost | 1985 |
Tuberculosis screening.
Topics: Adult; Female; Humans; Isoniazid; Male; New York City; Tuberculin Test; Tuberculosis | 1985 |
[Sarcoidosis with destruction of joints].
Topics: Female; Finger Joint; Fingers; Humans; Isoniazid; Middle Aged; Nose; Prednisone; Pyridoxine; Sarcoid | 1985 |
Epidemic tuberculosis in a nursing home: a retrospective cohort study.
Topics: Adult; Age Factors; Aged; Arkansas; Cross Infection; Female; Humans; Isoniazid; Male; Medical Record | 1985 |
Should the dose of antituberculosis drugs be reduced in patients with liver disease?
Topics: Humans; Isoniazid; Liver Diseases; Rifampin; Tuberculosis | 1985 |
[Tuberculosis: some current problems].
Topics: Belgium; Humans; Isoniazid; Rifampin; Tuberculosis | 1985 |
Severe fetal deformities associated with ingestion of excessive isoniazid in early pregnancy.
Topics: Abnormalities, Drug-Induced; Abnormalities, Multiple; Adolescent; Female; Humans; Isoniazid; Pregnan | 1985 |
Risk of tuberculous infection among house staff in an urban teaching hospital.
Topics: Attitude of Health Personnel; Cooperative Behavior; Cross Infection; Florida; Hospitals, Teaching; H | 1985 |
Use of streptomycin and isoniazid during a tuberculosis epizootic in a rhesus and cynomolgus breeding colony.
Topics: Animals; Costs and Cost Analysis; Disease Outbreaks; Isoniazid; Liver; Macaca; Macaca fascicularis; | 1985 |
[Immunologic reactivity and healing reactions in animals with experimental tuberculosis as affected by chemotherapy].
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Guinea Pigs; Isoniazid; Rifampin; Strepto | 1985 |
[Use of ultrasonic inhalation of antibacterial preparations in the complex treatment of children and adolescents with tuberculosis of the organs of respiration].
Topics: Adolescent; Child; Humans; Isoniazid; Respiratory Therapy; Respiratory Tract Infections; Tuberculosi | 1985 |
Tuberculosis in Tanzania--a national survey of newly notified cases. Tanzanian/British Medical Research Council Collaborative Study.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Resistance, Microbial; Female; Follow-Up Studies; H | 1985 |
Tuberculosis in an Indochinese refugee camp: epidemiology, management and therapeutic results.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; Female | 1985 |
Clinical experience with short-course chemotherapy in patients with tubercular pleural effusion and lymphadenitis.
Topics: Adolescent; Adult; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Lymphadenitis; | 1985 |
Sarcoidosis of the larynx in a child.
Topics: Adolescent; Diagnosis, Differential; Epiglottis; Female; Humans; Isoniazid; Laryngeal Diseases; Lary | 1985 |
Strategies to improve compliance with therapy.
Topics: Humans; Isoniazid; Life Style; Patient Compliance; Time Factors; Tuberculosis | 1985 |
Characteristics of African M. tuberculosis.
Topics: Adolescent; Adult; Aminosalicylic Acids; Child; Child, Preschool; Drug Resistance, Microbial; Female | 1970 |
A new approach to the study of non-acid-fast mycobacteria.
Topics: Animals; Bacteriological Techniques; Cricetinae; Guinea Pigs; Humans; Isoniazid; Lung; Methods; Mice | 1970 |
Control of tuberculosis.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Thioacetazone; Tuberculosis | 1971 |
The choice of systemic antimicrobial drugs.
Topics: Ampicillin; Anti-Infective Agents; Carbenicillin; Ethambutol; Gentamicins; Humans; Infant; Infant, N | 1971 |
Laboratory aspects of intermittent drug therapy.
Topics: Animals; Ethionamide; Growth; Guinea Pigs; Humans; Isoniazid; Rifampin; Streptomycin; Thioacetazone; | 1971 |
[Characteristics of drug-induced hepatitis in patients with tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Ethionamide; Hu | 1972 |
Antinuclear antibodies in patients on anticonvulsant therapy.
Topics: Adolescent; Adult; Aged; Antibodies, Antinuclear; Anticonvulsants; Carbamazepine; Cell Nucleus; Comp | 1972 |
Initial treatment of tuberculosis with streptomycin and isoniazid combined with either aminosalyl or rifampicin.
Topics: Alcoholism; Aminosalicylic Acids; Bilirubin; Dihydrostreptomycin Sulfate; Humans; Isoniazid; Rifampi | 1973 |
Editorial: Antituberculosis chemotherapy: a resume of the rationale.
Topics: Drug Resistance, Microbial; Drug Therapy, Combination; Humans; India; Isoniazid; Self Medication; Th | 1973 |
[Proceedings: Ambulatory chemotherapy of tuberculosis in Finland (organization)].
Topics: Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Ethambutol; Ethionamide; | 1973 |
Letter: The story of tuberculosis.
Topics: Developing Countries; Humans; Isoniazid; Tuberculosis | 1973 |
Letter: Self-administration of isoniazid and thiacetazone studied by medication monitoring.
Topics: Ambulatory Care; Evaluation Studies as Topic; Humans; Isoniazid; Malawi; Medication Systems; Monitor | 1974 |
Thiacetazone and INH in tuberculosis. Synchronised peak concentration drug administration for greater action.
Topics: Humans; Isoniazid; Thioacetazone; Time Factors; Tuberculosis | 1973 |
[Drug therapy of tuberculosis].
Topics: Amides; Aminosalicylic Acids; Antitubercular Agents; Capreomycin; Drug Therapy, Combination; Ethambu | 1974 |
[The tuberculosis problem in Botswana].
Topics: BCG Vaccine; Botswana; Carrier State; Complementary Therapies; Disease Reservoirs; Drug Combinations | 1974 |
Letter: Rifampicin and cortisone replacement therapy.
Topics: Addison Disease; Aged; Cortisone; Drug Interactions; Female; Humans; Isoniazid; Recurrence; Rifampin | 1974 |
Binding of rifampicin by human plasma proteins.
Topics: Adult; Aged; Aminosalicylic Acids; Blood Proteins; Carbon Radioisotopes; Chromatography, Thin Layer; | 1974 |
Rheumatic symptoms during tuberculosis therapy. A manifestation of isoniazid toxicity?
Topics: Adult; Aged; Aminosalicylic Acids; Female; Humans; Isoniazid; Male; Middle Aged; Reflex Sympathetic | 1965 |
Possible induction of antinuclear antibodies by isoniazid.
Topics: Antibody Formation; Autoantibodies; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Iso | 1966 |
Agranulocytosis during unithiben therapy. (A case report).
Topics: Adult; Agranulocytosis; Female; Humans; India; Isoniazid; Thioacetazone; Thiosemicarbazones; Tubercu | 1965 |
Tuberculosis and pneumoconiosis.
Topics: Aminosalicylic Acids; Coal Mining; Humans; Isoniazid; Middle Aged; Pneumoconiosis; Streptomycin; Tub | 1967 |
Chemoprophylaxis against tuberculosis.
Topics: Adult; Child; Child, Preschool; Female; Humans; Infant; Isoniazid; Male; Pregnancy; Tuberculin Test; | 1967 |
Advances in the treatment of tuberculosis.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Humans; Infant; Isoniazid; Middle Aged; Thioacetaz | 1967 |
[Algodystrophy of chemotherapeutic origin. Pseudorheumatism due to isoniazid, ethionamide, phenobarbital and radioactive iodine].
Topics: Adult; Aged; Ethionamide; Female; Humans; Iodine Isotopes; Isoniazid; Male; Middle Aged; Phenobarbit | 1967 |
[Determination of the degree of inactivation of preparations of isonicotinic acid hydrazides in tuberculous patients].
Topics: Humans; Isoniazid; Tuberculosis | 1966 |
[Bacteriological development in the triple combination antituberculosis treatment].
Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Humans; Isoniazid; Streptomycin; Thioacetazone; Tu | 1966 |
Treatment of tuberculosis overseas.
Topics: Africa, Eastern; Isoniazid; Streptomycin; Thioacetazone; Tuberculosis | 1967 |
Prophylaxis against tuberculosis.
Topics: Adolescent; Humans; Isoniazid; Male; Tuberculosis | 1967 |
Efficacy and cost of commonly used chemotherapy regimens.
Topics: Aminosalicylic Acids; Antitubercular Agents; Community Health Services; Costs and Cost Analysis; Fee | 1968 |
Side effects and toxicity to thiacetazone and isoniazid: findings in a Hong Kong Tuberculosis Treatment Service-British Medical Research Council investigation.
Topics: Anemia; Hong Kong; Humans; Isoniazid; Jaundice; Male; Nausea; Neurologic Manifestations; Skin Manife | 1968 |
Side effects and toxicity in the combined regimen of thiacetazone and isoniazid in Morocco.
Topics: Adult; Drug Synergism; Female; Humans; Isoniazid; Male; Morocco; Thioacetazone; Tuberculosis | 1968 |
In vitro and in vivo studies to assess the suitability of antituberculous drugs for use in intermittent chemotherapy regimens.
Topics: Animals; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Guinea Pigs; In Vitro Techniqu | 1968 |
Tuberculosis in Kenya: a national sampling survey of drug resistance and other factors.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Child; Child, Preschool; Drug Resistance, Microbial; | 1968 |
Drugs for tuberculosis.
Topics: Aminosalicylic Acids; Costs and Cost Analysis; Cycloserine; Drug Synergism; Ethambutol; Ethionamide; | 1968 |
[Effect of hypothyroidism on the course of experimental tuberculosis. I. Infection with tubercle bacilli resistant to INH].
Topics: Animals; Antithyroid Agents; Drug Resistance, Microbial; Guinea Pigs; Hypothyroidism; Isoniazid; Lym | 1968 |
[Effect of hypothyreoisis on the experimental tuberculosis. II. Infection with tubercle bacilli susceptible to INH].
Topics: Animals; Antithyroid Agents; Guinea Pigs; Hypothyroidism; Isoniazid; Mycobacterium tuberculosis; Tub | 1968 |
Anti-tuberculosis chemotherapy in Australia.
Topics: Aminosalicylic Acids; Antitubercular Agents; Australia; Humans; Isoniazid; Thioacetazone; Tuberculos | 1968 |
[On the method of determining the degree of inactivation of tubazid in tuberculosis patients].
Topics: Female; Humans; Isoniazid; Male; Methods; Tuberculosis | 1967 |
In vitro and in vivo studies to assess the suitability of anti-tuberculous drugs for use in intermittent chemotherapy regimens.
Topics: Animals; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Guinea Pigs; In Vitro Techniqu | 1968 |
The ethionamide sensitivity of East African strains of Mycobacterium tuberculosis resistant to thiacetazone.
Topics: Africa, Eastern; Bacteriological Techniques; Drug Resistance, Microbial; Ethionamide; Humans; In Vit | 1969 |
The suitability of new drugs for intermittent chemotherapy of tuberculosis. An experimental study.
Topics: Animals; Ethambutol; Ethionamide; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Rifampin; Stre | 1969 |
Comparative activity of sisomicin against mycobacteria in vitro and against Mycobacterium tuberculosis in mice.
Topics: Amino Sugars; Animals; Anti-Bacterial Agents; Female; Gentamicins; Glycosides; Isoniazid; Mice; Myco | 1973 |
[Serological and pathomorphological aspects of the autoimmunization process in experimental tuberculosis in guinea pigs exposed to fractionated gamma-irradition and treated with isoniazid].
Topics: Animals; Autoantibodies; Guinea Pigs; Immunity; Isoniazid; Mycobacterium tuberculosis; Radiation Eff | 1972 |
Toxicologic and pharmacologic aspects of rifampin.
Topics: Administration, Oral; Drug Interactions; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacteriu | 1973 |
A survey of mycobacterial isolates from the Randwick Chest Hospital, Sydney, in an 18-month period, 1970 to 1971.
Topics: Adult; Aged; Aminosalicylic Acids; Australia; Ethambutol; Female; Humans; Isoniazid; Male; Microbial | 1973 |
[Studies on the development of drug-resistant tubercle bacilli in experimental animal tuberculosis].
Topics: Animals; Drug Resistance, Microbial; Female; Guinea Pigs; Isoniazid; Mice; Microbial Sensitivity Tes | 1973 |
Preventive treatment of tuberculin-negative contacts.
Topics: Aminosalicylic Acids; Antitubercular Agents; BCG Vaccine; Child; Female; Humans; Infant; Isoniazid; | 1973 |
Endobronchial tuberculosis.
Topics: Aged; Bronchial Diseases; Bronchoscopy; Ethambutol; Female; Humans; Isoniazid; Mycobacterium tubercu | 1973 |
Studies on the treatment of experimental tuberculosis of the guinea pig with intermittent doses of isoniazid.
Topics: Animals; Guinea Pigs; Half-Life; Isoniazid; Mycobacterium tuberculosis; Spleen; Time Factors; Tuberc | 1973 |
[Results of daily-oral therapy with ethambutol and isoniazid in tuberculosis (author's transl)].
Topics: Administration, Oral; Adolescent; Adult; Child; Drug Therapy, Combination; Ethambutol; Humans; Isoni | 1973 |
Tuberculosis in Acukland.
Topics: Adult; Age Factors; Aged; Antitubercular Agents; Drug Resistance, Microbial; Drug Therapy, Combinati | 1973 |
The effect of chemotherapy for tuberculosis on immunity to tuberculosis.
Topics: Animals; BCG Vaccine; Drug Resistance, Microbial; Female; Immunity, Maternally-Acquired; Immunizatio | 1974 |
Tuberculosis in a family day-care home. Report of an outbreak and recommendations for prevention.
Topics: Air Microbiology; Aminosalicylic Acids; Child; Child Day Care Centers; Child, Preschool; Disease Out | 1974 |
[Signes of adaptation under long-term combined antituberculous therapy (author's transl)].
Topics: Adaptation, Physiological; Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Humans; Iso | 1974 |
Primary drug-resistant Mycobacterium tuberculosis isolated in Massachusetts in 1972.
Topics: Adolescent; Adult; Aged; Alcoholism; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, M | 1974 |
Immunological memory in tuberculosis. I. Influence of persisting viable organisms.
Topics: Animals; BCG Vaccine; Cortisone; Female; Hypersensitivity, Delayed; Immunity, Maternally-Acquired; I | 1974 |
[Effectiveness, during the 1st year, of 3 treatment durations].
Topics: Drug Evaluation; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Time Fac | 1974 |
[Experience with cooperative antituberculous work of a santiary-epidemiologic station and a dispensary].
Topics: Adolescent; Adult; Ambulatory Care; BCG Vaccine; Child; Child, Preschool; Community Health Services; | 1966 |
[Algodystrophy associated with antitubercular chemotherapy: 22 cases].
Topics: Adult; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Female; Humans; Isoniazid; Male; | 1969 |
Electron-microscopic study of mesosome structures in Mycobacterium tuberculosis strains isolated from patients with different susceptibility toward isoniazid and streptomycin.
Topics: Humans; Isoniazid; Microscopy, Electron; Mycobacterium tuberculosis; Streptomycin; Tuberculosis | 1970 |
[Results of outpatient treatment of tuberculous patients in a rural area of the Moldavian SSR].
Topics: Adolescent; Adult; Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Ethion | 1974 |
[Facial paralysis caused by tubercular otitis. Current therapeutic possibilities].
Topics: Adult; Ethambutol; Facial Paralysis; Female; Humans; Isoniazid; Male; Otitis; Rifampin; Tuberculosis | 1974 |
Actions of isoniazid on NADH dehydrogenase activity of kidney of tuberculous guinea pigs.
Topics: Animals; Guinea Pigs; In Vitro Techniques; Isoniazid; Kidney; NAD; Oxidoreductases; Tuberculosis | 1966 |
Bacteriology of tuberculosis with special reference to kanamycin and related drugs.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethionamide; H | 1966 |
Subcellular distribution of nicotinamide adenine dinucleotidase in the spleen of tuberculous guinea pigs and tuberculous guinea pigs treated with isoniazid.
Topics: Animals; Cell Nucleus; Centrifugation; Enzymes; Guinea Pigs; Isoniazid; Male; Microsomes; Mitochondr | 1967 |
Effect of isoniazid on preservation of nicotinamide dinucleotide in animal cells.
Topics: Alcohol Oxidoreductases; Animals; Carcinoma, Ehrlich Tumor; Isoniazid; Liver; Lung; Mice; NAD; Nucle | 1967 |
Pathways of glucose utilization in kidney homogenates of tuberculous and isoniazid-treated tuberculous guinea pigs. (Preliminary report).
Topics: Animals; Carbon Isotopes; Glucose; Glucose-6-Phosphatase; Glucosephosphate Dehydrogenase; Guinea Pig | 1967 |
[Isoniazid-pyridoxine combination in the treatment of tuberculosis].
Topics: Humans; Isoniazid; Pyridoxine; Tuberculosis | 1967 |
Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. II. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with SM- and INH-resistant Schacht strain.
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Etham | 1967 |
Biochemical study on the host response to tuberculous infection. IV. Influences of isoniazid, streptomycin, nicotinamide, and cortisone.
Topics: Animals; Cortisone; Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium tuberculosis; N-Glyco | 1968 |
[Actual tuberculosis therapy. An attempt to simplify and to determine a schedule of tuberculosis chemotherapy].
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Synergism; Ethambutol; Ethionamide; H | 1969 |
[How to oversee the treatment of tuberculosis?].
Topics: Antitubercular Agents; Ethambutol; Ethionamide; Follow-Up Studies; Humans; Isoniazid; Long-Term Care | 1970 |
[Significance of isoniazid for the therapy of experimental infection with total INH- and SM- resistant human tuberculosis bacteria in the mice].
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; Injections, Int | 1970 |
[Jaundice and rifampicin].
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Humans; Imipramine; Isoniazid; Jaundice; Liver | 1971 |
[Drug sensitivity of atypical Mycobacteria isolated from patients to antitubercular agents of the first and second order].
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Depression, Chemical; Drug Resistance, Mic | 1971 |
[Advances and principles in tuberculostatic therapy].
Topics: Adult; Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Ethambu | 1971 |
Serum levels of vitamin B 6 in hypercholesterolemic rhesus monkeys on prophylactic isoniazid.
Topics: Administration, Oral; Animals; Biological Assay; Diet, Atherogenic; Haplorhini; Hypercholesterolemia | 1971 |
On the epidemiology of tuberculosis in some selected countries. Highlights and prospects for control and eradication. II.
Topics: Adolescent; Aftercare; Antitubercular Agents; BCG Vaccine; Child; Comprehensive Health Care; Coopera | 1971 |
Twice weekly tuberculosis chemotherapy.
Topics: Absenteeism; Administration, Oral; Adult; Aged; Colorado; Community Health Services; Ethambutol; Eva | 1973 |
Treatment of tuberculosis today in Nebraska.
Topics: Aminosalicylic Acids; Antitubercular Agents; Cycloserine; Drug Hypersensitivity; Ethambutol; Ethiona | 1973 |
[Liver tolerance of antitubercular treatment including rifampicin. Study on 214 cases].
Topics: Adult; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Drug Hypersensitivity; Drug Tolerance | 1973 |
[Cold thoracic abscess due to Histoplasma duboisii. Treatment using rifampicin].
Topics: Abscess; Adult; Diagnosis, Differential; Ethambutol; Fluorescent Antibody Technique; Histoplasma; Hi | 1973 |
New antituberculosis drugs and concepts of prophylaxis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Arthritis; Chemical and Drug Induced Liver Injury; Chil | 1974 |
[The liver and rifampicin].
Topics: Bilirubin; Biopsy; Chemical and Drug Induced Liver Injury; Drug Interactions; Ethambutol; Humans; Is | 1973 |
[Use of a isoniozid-rifompicin drug hepatotoxicity screening technic in tuberculosis therapy].
Topics: Adult; Bilirubin; Chemical and Drug Induced Liver Injury; Clinical Enzyme Tests; Dose-Response Relat | 1974 |
Isocitric dehydrogenase and nicotinamide adenine dinucleotidase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Topics: Animals; Guinea Pigs; Isocitrate Dehydrogenase; Isoniazid; Kidney; Male; NAD; NADP; Nucleotidases; T | 1967 |
[Survey of the tuberculosis problem in the Nordic countries. Are BCG vaccination and mass screening necessary?].
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; BCG Vaccine; Ethambutol; Female; Humans; Iceland; Inf | 1974 |
Chemoprophylaxis against tuberculosis.
Topics: Adult; BCG Vaccine; Chemical and Drug Induced Liver Injury; Child; Greenland; Humans; Isoniazid; Jap | 1974 |
Intermittent chemotherapy for adults with tuberculosis.
Topics: Administration, Oral; Adult; Drug Resistance, Microbial; Ethambutol; Humans; Injections, Intramuscul | 1974 |
Preventive therapy of tuberculous infection.
Topics: Administration, Oral; Adult; Age Factors; Chemical and Drug Induced Liver Injury; Child; Humans; Iso | 1974 |
Isoniazid prophylaxis and deaths in Baltimore, 1972.
Topics: Adult; Aged; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Liver; Liver Disease | 1974 |
Letter: Chemoprophylaxis against tuberculosis.
Topics: Breast Feeding; Developing Countries; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Is | 1974 |
[The effects of antituberculosis drugs on the pharmacokinetics of digitoxin (author's transl)].
Topics: Administration, Oral; Adult; Antitubercular Agents; Digitoxin; Drug Therapy, Combination; Ethambutol | 1974 |
Tuberculosis--new thoughts on an old disease.
Topics: Adolescent; Adult; Aged; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Hu | 1974 |
[Hematopoietic tuberculosis].
Topics: Bone Marrow; Bone Marrow Examination; Cholestasis; Erythema; Ethambutol; Humans; Isoniazid; Leukopen | 1974 |
[Combined application of mycobacteriophages and tubazid in experimental tuberculosis].
Topics: Animals; Guinea Pigs; In Vitro Techniques; Injections, Intravenous; Isoniazid; Mice; Mice, Inbred St | 1974 |
[Diphenylhydantoin poisoning due to diphenylhydantoin-isoniazid interaction].
Topics: Adult; Cognition Disorders; Drug Interactions; Epilepsy; Fatigue; Humans; Isoniazid; Male; Middle Ag | 1974 |
Letter: Treatment of tuberculosis in children.
Topics: Adult; Black People; Humans; Isoniazid; Male; South Africa; Tuberculosis | 1974 |
BCG vaccination and chemoprophylaxis in the control of tuberculosis.
Topics: Adolescent; Adult; Age Factors; BCG Vaccine; Child; Evaluation Studies as Topic; Humans; Infant; Iso | 1974 |
Practical policies in the control of tuberculosis in Hong Kong.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; BCG Vaccine; Child; Child, Preschool; Female; Hong Ko | 1974 |
[The combined effect of histones and antibiotics. Treatment of experimental tuberculosis in guinea pigs and white mice with tubazid combined with histones].
Topics: Animals; Antitubercular Agents; Cattle; Drug Therapy, Combination; Guinea Pigs; Histones; Isoniazid; | 1974 |
The impact of rifampicin on the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Costs and Cost Analysis; Drug Therapy, Combination; Ethambutol; Humans; Isonia | 1974 |
Letter: Isoniazid and cancer risks.
Topics: Animals; Child; Child, Preschool; Humans; Isoniazid; Male; Neoplasms; Tuberculosis; Urinary Bladder | 1974 |
[Proceedings: Current status and perspectives of tuberculosis chemotherapy in Algeria].
Topics: Algeria; Ambulatory Care; Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; H | 1973 |
Hemorrhagic disease associated with inhibitors of fibrin cross-linkage.
Topics: Aged; Aminosalicylic Acids; Antibodies; Antigen-Antibody Reactions; Binding Sites; Binding, Competit | 1972 |
Editorial: The prevention of tuberculosis.
Topics: Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Female; Humans; Isoniazid; Liver; P | 1974 |
[Changes in the factors influencing the epidemiology of tuberculosis].
Topics: Child; Humans; Hungary; Isoniazid; Mass Chest X-Ray; Tuberculosis; Tuberculosis, Pulmonary | 1973 |
Results of 20 years of tuberculosis control in Alaska.
Topics: Adolescent; Adult; Alaska; Ambulatory Care; Aminosalicylic Acids; BCG Vaccine; Child; Child, Prescho | 1973 |
Late prognosis of children born into tuberculous households. The effect of isolation and simultaneous BCG-vaccination.
Topics: Adolescent; Adult; Age Factors; BCG Vaccine; Birth Weight; Child; Child Health Services; Child, Pres | 1972 |
Tuberculosis in the United States today.
Topics: Adolescent; Adult; Aged; Child; Humans; Isoniazid; Middle Aged; Tuberculosis; Tuberculosis, Pulmonar | 1973 |
Letter: Massive use of chemoprophylaxis against tuberculosis.
Topics: BCG Vaccine; Child; Humans; Isoniazid; Tuberculosis; Tuberculosis, Pulmonary | 1974 |
Simplification of isoniazid phenotyping procedure to promote its application in the chemotherapy of tuberculosis.
Topics: Acetates; Humans; Isoniazid; Methods; Pharmacogenetics; Phenotype; Tuberculosis | 1973 |
[Comparative study of hepatic bilirubin and paranitrophenol glucuronyl transferase activity. 3. Effect of rifampicin alone or associated with streptomycin and isoniazid in man].
Topics: Bilirubin; Enzyme Induction; Glucuronates; Humans; Isoniazid; Liver; Liver Function Tests; Microscop | 1973 |
Intermittent rifampicin treatment in experimental tuberculosis.
Topics: Administration, Oral; Agglutination Tests; Animals; Antibodies, Bacterial; Blood Bactericidal Activi | 1973 |
Letter: Isoniazid hepatotoxicity.
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Glomerulonephritis; Humans; Isoniazid; | 1973 |
The John Barnwell lecture: Improving existing methods of control of tuberculosis: A prime challenge to the experimentalist.
Topics: Animals; Antitubercular Agents; BCG Vaccine; Biopsy; Disease Models, Animal; Drug Resistance, Microb | 1972 |
Isoniazid inactivation in tuberculous patients: a comparative study by vertical diffusion and tube dilution methods.
Topics: Depression, Chemical; Humans; Immunodiffusion; Isoniazid; Methods; Tuberculosis | 1972 |
[Critical concentration for definition of rifampicin resistance of tubercle bacilli].
Topics: Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacteriu | 1972 |
Undiagnosed tuberculosis in a general hospital.
Topics: Adult; Age Factors; Aged; Aminosalicylic Acids; Biopsy; Body Weight; Bone Marrow; Ethambutol; Fatigu | 1972 |
[The risk of tuberculosis in a milieu exposed to constant superinfection with INH-sensitive and INH-resistant tubercle bacilli].
Topics: Drug Resistance, Microbial; Environmental Exposure; Humans; Isoniazid; Mycobacterium tuberculosis; R | 1972 |
[Rifampicine in tuberculosis. Peculiarity of its experimental activity and new therapeutic prospects].
Topics: Animals; Drug Resistance, Microbial; Humans; Isoniazid; Mice; Microbial Sensitivity Tests; Mutation; | 1972 |
Generalized seizures following isoniazid therapy for tuberculosis in a patient with uremia.
Topics: Aged; Animals; Cerebral Cortex; Colon; Epididymis; Granuloma; Guinea Pigs; Humans; Hypertension; Iso | 1972 |
An epidemiologic account of tuberculosis transmitted from man to monkey.
Topics: Adult; Animals; Cross Infection; Ethambutol; Female; Haplorhini; Humans; Isoniazid; Macaca; Male; Py | 1972 |
[Chemoprevention and preventive chemotherapy of tuberculosis].
Topics: Costs and Cost Analysis; Follow-Up Studies; Germany, West; Humans; Isoniazid; Long-Term Care; Tuberc | 1973 |
Isoniazid chemoprophylaxis.
Topics: Humans; Isoniazid; Tuberculosis; United States; United States Public Health Service | 1972 |
[Treatment of tuberculosis in childhood].
Topics: Antitubercular Agents; Child; Ethambutol; Humans; Isoniazid; Rifampin; Streptomycin; Tuberculosis | 1972 |
Regional lymphadenitis following BCG vaccination (BCGitis). Clinical comments based upon 25 instances among 1295 childhood vaccinees.
Topics: Abscess; Age Factors; Axilla; BCG Vaccine; Child, Preschool; Female; Humans; Infant; Isoniazid; Lymp | 1972 |
[Modern view on drug therapy of tuberculosis].
Topics: Ethambutol; Humans; Isoniazid; Rifampin; Tuberculosis | 1972 |
Isoniazid-associated hepatitis. A study of five cases.
Topics: Adult; Biopsy; Chemical and Drug Induced Liver Injury; Female; Hepatitis B Antigens; Humans; Isoniaz | 1972 |
The Australian rifampicin trial.
Topics: Adult; Aged; Costs and Cost Analysis; Drug Resistance, Microbial; Ethambutol; Female; Follow-Up Stud | 1972 |
[Modification of the classical chemotherapy by the use of ethambutol].
Topics: Adult; Aged; Drug Synergism; Ethambutol; Female; Humans; Isoniazid; Male; Methods; Middle Aged; Stre | 1972 |
[Therapy of tuberculosis].
Topics: Antitubercular Agents; Drug Combinations; Ethambutol; Humans; Isoniazid; Rifampin; Tuberculosis | 1972 |
[Scrofulous lichen following BCG vaccination].
Topics: BCG Vaccine; Diagnosis, Differential; Female; Humans; Infant; Isoniazid; Lichen Planus; Prednisolone | 1972 |
Experimental tuberculosis with African strains of various drug-resistance.
Topics: Africa; Animals; Catalase; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Liver; Lung; Lymph No | 1972 |
Tuberculosis complicated by pregnancy.
Topics: Adolescent; Adult; Aminosalicylic Acids; Anesthesia, General; Cross Infection; Delivery, Obstetric; | 1973 |
[Treatment of experimental tuberculosis in guinea pigs by continuous and intermittent regimen with special reference to ethambutol and rifampicin].
Topics: Animals; Drug Synergism; Ethambutol; Guinea Pigs; Isoniazid; Methods; Rifampin; Tuberculosis | 1973 |
Multiple puncture tuberculin reactions. A rubber model to facilitate uniform interpretation.
Topics: BCG Vaccine; Child; Child, Preschool; Cross Reactions; Humans; Infant, Newborn; Isoniazid; Models, S | 1973 |
Isoniazid acetylator phenotyping of Amharas in Ethiopia.
Topics: Acetylation; Adolescent; Adult; Black People; Ethiopia; Ethnicity; Humans; Isoniazid; Male; Middle A | 1973 |
Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis.
Topics: Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Black or African American | 1973 |
Validity of serum glutamic oxalacetic transaminase determinations in isoniazid recipients.
Topics: Aspartate Aminotransferases; Autoanalysis; Chemical and Drug Induced Liver Injury; Clinical Enzyme T | 1973 |
TB talk 1973.
Topics: Alabama; Humans; Isoniazid; Tuberculosis | 1973 |
Simplified screening test for phenotyping of isoniazid inactivators.
Topics: Acetylation; Administration, Oral; Colorimetry; Drug Antagonism; Humans; Isoniazid; Mass Screening; | 1973 |
Isoniazid dosage in patients with renal failure.
Topics: Acetylation; Adult; Aged; Creatinine; Female; Half-Life; Humans; Isoniazid; Kidney; Kidney Failure, | 1973 |
Fetal hepatic necrosis in a woman receiving chemoprophylaxis with isoniazid.
Topics: Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Autopsy; Chemical and Drug Induced Liver Inju | 1973 |
A pharmacy outpatient monitoring program providing primary medical care to selected patients.
Topics: Isoniazid; Monitoring, Physiologic; Outpatient Clinics, Hospital; Peer Review; Pharmacists; Pharmacy | 1973 |
[Two cases of auricular tuberculosis with facial paralysis].
Topics: Adolescent; Adult; Ear Diseases; Facial Paralysis; Female; Humans; Isoniazid; Labyrinth Diseases; Ri | 1973 |
Isoniazid hepatitis: backlash of progress.
Topics: Aged; Biopsy, Needle; Chemical and Drug Induced Liver Injury; Cholangitis; Drug Hypersensitivity; Fe | 1973 |
Isoniazid hepatitis.
Topics: Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Chemical and Drug Induced | 1973 |
Twice weekly chemotherapy for tuberculosis.
Topics: Ambulatory Care; Antitubercular Agents; Humans; Indians, North American; Isoniazid; Methods; Pyridox | 1973 |
Tuberculin conversion in junior and senior medical students at the University of Iowa.
Topics: BCG Vaccine; Humans; Iowa; Isoniazid; Radiography; Students, Medical; Surveys and Questionnaires; Ti | 1973 |
Comparative blood levels and metabolism of INH and an INH-matrix preparation in fast and slow inactivators.
Topics: Acetates; Adolescent; Delayed-Action Preparations; Female; Humans; Isoniazid; Male; Phenotype; Time | 1973 |
Ambulatory tuberculosis chemotherapy on an Indian reservation.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Arizona; Child; Female; Hospitalization; Humans; Indians, | 1973 |
[Excretion and concentration of tubazid, PAS and their metabolites in patients with tuberculosis and different functional conditions of kidneys].
Topics: Aminosalicylic Acids; Humans; Isoniazid; Kidney; Tuberculosis; Tuberculosis, Pulmonary; Tuberculosis | 1973 |
[Rifampicin in the treatment of tuberculosis].
Topics: Administration, Oral; Aminosalicylic Acids; Chemical and Drug Induced Liver Injury; Drug Hypersensit | 1973 |
[Current problems of maximum INH chemotherapy of tuberculosis].
Topics: Adult; Animals; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Humans; Injections, In | 1973 |
Further studies on the pharmacology of a slow-release matrix preparation of isoniazid (Smith and Nephew HS 82) of potential use in the intermittent treatment of tuberculosis.
Topics: Adult; Aged; Body Weight; Delayed-Action Preparations; Humans; Hydrazines; Isoniazid; Middle Aged; S | 1973 |
The determination of the acetylator phenotype of tuberculosis patients in Czechoslovakia using sulphadimidine.
Topics: Acetylation; Czechoslovakia; Delayed-Action Preparations; Humans; Isoniazid; Metabolic Clearance Rat | 1973 |
[Probable genetic loading of the population with "INH" (Isonicotinic hydrazide) (author's transl)].
Topics: Adolescent; Adult; Age Factors; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; G | 1973 |
[Toxicity of isoniazid].
Topics: Brain Edema; Humans; Isoniazid; Nausea; Photosensitivity Disorders; Tuberculosis; Vomiting | 1973 |
[Modern treatment of tuberculosis].
Topics: Antitubercular Agents; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Recur | 1973 |
Chemoprophylaxis against tuberculosis in Britain. A memorandum from the Jont Tuberculosis Committee of the British Thoracic and Tuberculosis Association.
Topics: Emigration and Immigration; Epidemiologic Methods; Humans; Isoniazid; Tuberculin Test; Tuberculosis; | 1973 |
[Thiamine metabolism in experimental animals during treatment of tuberculosis with tubazid and PASA].
Topics: Adrenal Glands; Aminosalicylic Acids; Animals; Brain; Feces; Guinea Pigs; Isoniazid; Kidney; Liver; | 1973 |
Letter: Is tuberculosis preventable?
Topics: BCG Vaccine; Humans; Isoniazid; Tuberculosis | 1974 |
Letter: Isoniazid hepatitis.
Topics: Adolescent; Chemical and Drug Induced Liver Injury; Child; Humans; Isoniazid; Liver; Male; Tuberculo | 1974 |
Automated tuberculosis surveillance and control.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Cell Count; Carrier State; Computers; Costs | 1974 |
Editorial: Rifampin in the treatment of tuberculosis.
Topics: Canada; Drug Therapy, Combination; Emigration and Immigration; Ethambutol; Humans; Isoniazid; Rifamp | 1974 |
Letter: Stop isoniazid prophylaxis.
Topics: Adolescent; Adult; Humans; Isoniazid; Tuberculosis; United States | 1974 |
Upper respiratory tract tuberculosis. Sixteen cases in a general hospital.
Topics: Aged; Diagnosis, Differential; Epiglottis; Esophageal Neoplasms; Hospitals, General; Humans; Ileocec | 1974 |
Hyperuricemia induced by ethambutol.
Topics: Allopurinol; Creatinine; Diuretics; Ethambutol; Ethanol; Gout; Humans; Isoniazid; Lactates; Pyrazina | 1974 |
Sensitivity to rifampicin: incidence, mechanism, and prevention.
Topics: Antibodies; Antibody Formation; Binding Sites, Antibody; Biological Assay; Cell Membrane; Coombs Tes | 1974 |
[Detection of the effects of the rifampin-isoniazid combination on the human liver].
Topics: Chemical and Drug Induced Liver Injury; Drug Combinations; Drug Interactions; Female; Humans; Isonia | 1974 |
[Jaundice and rifampicin. Critical study].
Topics: Antigen-Antibody Reactions; Chemical and Drug Induced Liver Injury; Drug Interactions; Female; Human | 1974 |
[Intermittent drug therapy of tuberculosis: study of the problems involved and summary of the progress made recently in Canada].
Topics: Ambulatory Care; Canada; Drug Therapy, Combination; Ethnicity; Humans; Inuit; Isoniazid; Streptomyci | 1974 |
Mycobacterium tuberculosis infection of the middle ear.
Topics: Adult; Drug Therapy, Combination; Ethambutol; Female; Humans; Isoniazid; Male; Otitis Media; Pyridox | 1974 |
[Ethambutol induced severe optic neuritis].
Topics: Adult; Aged; Chelating Agents; Drug Interactions; Electroretinography; Ethambutol; Ethanol; Evoked P | 1974 |
[Treatment of primary tuberculosis].
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Antibody Formation; Antitubercular Agents; BCG Va | 1974 |
Letter: Isoniazid prophylaxis.
Topics: Adolescent; Adult; Humans; Isoniazid; Tuberculosis | 1974 |
Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid.
Topics: Adult; Aged; Aminosalicylic Acids; Biological Assay; Drug Interactions; Female; Half-Life; Humans; I | 1974 |
Tuberculosis of the nose and paranasal sinuses.
Topics: Female; Humans; Isoniazid; Maxillary Sinus; Middle Aged; Nasal Mucosa; Nasal Polyps; Nose Diseases; | 1974 |
[Chemoprophylaxis and chemoprevention].
Topics: Adolescent; Adult; BCG Vaccine; Child; Child, Preschool; Humans; Infant; Isoniazid; Tuberculosis; Tu | 1966 |
[Various experimental diseases induced in guinea pigs by the historical Institut Pasteur BCG strain and by the B-1 positive catalase strain. Study of the viability of the inoculated bacteria].
Topics: Animals; Bacteriological Techniques; Catalase; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; M | 1968 |
Long-lasting antituberculous activity of derivatives of 2-styrylquinoline.
Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Isoniazid; Mice; Mycobacterium; Mycobact | 1970 |
[Effect of phthivazid and isoniazid on the macro- and microorganisms in tubercular infections].
Topics: Animals; Isoniazid; Liver; Lung; Mycobacterium bovis; Pyridoxine; Rabbits; RNA; Spleen; Tuberculosis | 1970 |
[Bacteriostatic action of Tubazid with intermittent administration].
Topics: Animals; Isoniazid; Mice; Mycobacterium bovis; Tuberculosis | 1970 |
[Specific allergy and its immunologic significance in infection of guinea pigs with hydrazide sensitive and resistant causative agents of tuberculosis].
Topics: Animals; Guinea Pigs; Hypersensitivity, Delayed; Isoniazid; Mycobacterium bovis; Species Specificity | 1970 |
[Tuberculosis and tuberculosis prevention through changing times].
Topics: BCG Vaccine; History, 19th Century; History, 20th Century; Humans; Isoniazid; Streptomycin; Tubercul | 1970 |
[Practicing physicians and the chemoprophylaxis of tuberculosis].
Topics: Animals; Child; Child, Preschool; Guinea Pigs; Haplorhini; Humans; Infant; Isoniazid; Rats; Tubercul | 1965 |
Experimental basis for the chemotherapy of tuberculosis.
Topics: Animals; Antitubercular Agents; In Vitro Techniques; Isoniazid; Mice; Mycobacterium tuberculosis; St | 1965 |
Succinic dehydrogenase in experimental tuberculosis: influence of isoniazid on metabolic damage.
Topics: Animals; Guinea Pigs; In Vitro Techniques; Isoniazid; Kidney; Male; Succinate Dehydrogenase; Tubercu | 1966 |
Isoniazid prophylaxis in experimental tuberculosis. Comparison of single versus multiple daily doses.
Topics: Animals; Female; Follow-Up Studies; Guinea Pigs; Isoniazid; Male; Mycobacterium tuberculosis; Tuberc | 1966 |
Primary drug resistance: a continuing study of drug resistance in tuberculosis in a veteran population within the United States. V. September 1963 to September 1965.
Topics: Adult; Aminosalicylic Acids; Drug Resistance, Microbial; Hospitals, Veterans; Humans; In Vitro Techn | 1966 |
The future control of tuberculosis.
Topics: Animals; BCG Vaccine; Cattle; Communicable Disease Control; Dogs; England; Ethnology; Guinea Pigs; H | 1967 |
August Weismann and the genetics of tuberculosis.
Topics: Body Constitution; Genetics; Germany; History, 19th Century; History, 20th Century; Humans; Isoniazi | 1967 |
Effect of ultraviolet irradiation on the acid-fastness of drug-resistant mutants of tubercle bacilli, with special reference to the virulence of isoniazid-resistant strains.
Topics: Aminosalicylic Acids; Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Mutation; Mycobac | 1968 |
[Bacteriostatic concentrations in the blood of tuberculosis patients after fractional and single dose administration of the primary antitubercular drugs].
Topics: Adult; Aminosalicylic Acids; Antitubercular Agents; Blood; Female; Humans; Isoniazid; Male; Middle A | 1968 |
Comparisons between the effects of isoniazid in a single daily dose and in divided daily doses.
Topics: Animals; Isoniazid; Mice; Mycobacterium tuberculosis; Tuberculosis | 1967 |
[Problems of therapeutic management of patients with pulmonary tuberculosis excreting tuberculous mycobacteria resistent to streptomycin and phthivazid].
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Pneumoperitoneum, Artific | 1966 |
[The modifications of the thymus in the course of experimental tuberculosis in the mouse].
Topics: Animals; Bacteriological Techniques; Cell Division; Cortisone; Ethionamide; Female; Isoniazid; Lymph | 1968 |
Activity of rifampicin in experimental tuberculosis of the guinea pig.
Topics: Animals; Antitubercular Agents; Guinea Pigs; Isoniazid; Lung Diseases; Lymph Nodes; Mycobacterium tu | 1967 |
Experiments on long-term intermittent chemotherapy in advanced tuberculosis in mice.
Topics: Animals; Drug Resistance, Microbial; Drug Synergism; Isoniazid; Mice; Mycobacterium tuberculosis; St | 1968 |
[Antibacterial effect of Soliutizon].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Mice; Mycobacterium tuberculosis; Thios | 1966 |
Quantitative tests with old tuberculin in sanatorium practice.
Topics: Adolescent; Adult; Aminosalicylic Acids; Antigen-Antibody Reactions; Female; Humans; Isoniazid; Male | 1968 |
[Significance of decalcification in the treatment of tuberculosis. 8. Studies on the effect of decalcification on the course of tuberculosis caused by INH-resistant bacilli].
Topics: Animals; Calcium; Drug Resistance, Microbial; Edetic Acid; Guinea Pigs; Isoniazid; Tuberculosis | 1968 |
[Bacteriological diagnosis of tuberculosis in an antituberculosis dispensary].
Topics: Ambulatory Care; Aminosalicylic Acids; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium | 1968 |
[Treatment of guinea pigs infected with a mixture of drug resistant and drug sensitive mycobacterium tuberculosis].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Isonicotinic Acids; Mycobacterium tuber | 1968 |
[Comments on the current state of experimental chemotherapy of tuberculosis].
Topics: Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Chronic Disease; Drug Resistance | 1967 |
Chemotherapy of tuberculosis. I. Typical Mycobacterium tuberculosis--primary drugs.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tuberculosis | 1968 |
[Clinical significance of resistance of Mycobacterium tuberculosis to chemoantibiotics].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Mice; Mycobacterium tuberculosis; Strep | 1967 |
Rifampin--a major new chemotherapeutic agent for the treatment of tuberculosis.
Topics: Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Mycobacterium; Mycobacterium tuberculosis | 1969 |
[Experimental tuberculosis produced by phthivazid-resistant mutants of the culture H 37 Rv].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Methods; Mutation; Mycobacterium tuberc | 1967 |
[On the bactericidal activity in vivo of Rifampicin alone or associated with isoniazid].
Topics: Animals; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Rifampin; Spleen; Tuberculosis | 1967 |
Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis.
Topics: Animals; Ethambutol; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Spleen; Time Factors; Tuber | 1968 |
[Study of the virulence of human strains of Koch bacillus isolated in Dakar and Western Africa].
Topics: Africa, Western; Animals; Drug Resistance, Microbial; Guinea Pigs; Humans; Injections; Isoniazid; Ly | 1968 |
[Effect of acridine compounds on the development of drug resistance to antitubercular agents of Mycobacterium of avian type].
Topics: Acridines; Anti-Bacterial Agents; Drug Resistance, Microbial; Humans; Isoniazid; Kanamycin; Mycobact | 1969 |
The treatment of renal tuberculosis.
Topics: Aminosalicylic Acids; Cycloserine; Drug Resistance, Microbial; Female; Humans; Isoniazid; Mycobacter | 1969 |
Effect of prophylactic isoniazid on early developing experimental tuberculosis in Macaca mulatta.
Topics: Animals; Female; Haplorhini; Isoniazid; Male; Mycobacterium tuberculosis; Tuberculin Test; Tuberculo | 1969 |
[Drug therapy of tuberculosis. Advanced training and working conference at the Central Hospital Gauting of the State Insurance Company of Upper Bavaria on Nov. 9, 1968].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Ethionamide; Germany, West; Hospitals | 1969 |
[On the problem of the inactivation of antibacterial drugs and drug resistance of disease agents].
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1969 |
[Experimental evaluation of the antimycobacterial activity of rifampicin].
Topics: Animals; Drug Synergism; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Rifampin; Streptomycin; | 1968 |
Rifampicin in daily and intermittent treatment of experimental murine tuberculosis, with emphasis on late results.
Topics: Animals; Ethambutol; Ethionamide; Follow-Up Studies; Isoniazid; Lung; Mice; Mycobacterium tuberculos | 1969 |
Rifampicin in treatment of experimental tuberculosis in mice.
Topics: Animals; Drug Synergism; Isoniazid; Lung; Male; Mice; Mycobacterium tuberculosis; Rifampin; Spleen; | 1969 |
[Antitubercular effect of capreomycin in vitro].
Topics: Anti-Bacterial Agents; Antitubercular Agents; Clinical Laboratory Techniques; Diffusion; Drug Resist | 1969 |
Rifampicin activity "in vitro" and in established tuberculosis in mice.
Topics: Animals; Drug Resistance, Microbial; Drug Synergism; In Vitro Techniques; Isoniazid; Mice; Mycobacte | 1969 |
[Incidence and significance of positive fluorescent bacilloscopy associated with negative cultures during treatment based on isoniazid or rifomycin in tubercular patients treated in the sanatorium].
Topics: Drug Synergism; Hospitals, Special; Humans; Isoniazid; Microbial Sensitivity Tests; Microscopy, Fluo | 1969 |
[Rifomycin in treatment of tuberculosis with polyresistant mycobacteria: clinical and laboratory observations].
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Rifampin; Streptomycin; T | 1969 |
[Results of treatment of experimental tuberculosis in guinea pigs with isoniazid or with isoniazid combined with ethambutol, either in continous or in intermittent regimen].
Topics: Animals; Drug Resistance, Microbial; Drug Synergism; Ethambutol; Fatty Liver; Guinea Pigs; Isoniazid | 1970 |
[On the comparative effectiveness of rifampicin and INI treatment in guinea pigs inoculated with repeated microdoses of bacilli].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Mycobacterium tuberculosis; Rifampin; T | 1968 |
[Action of dinitrophenol on mouse tuberculous infection after isoniazid chemoprophylaxis].
Topics: Animals; Dinitrophenols; Ethionamide; Female; Isoniazid; Lung; Male; Mycobacterium tuberculosis; Tim | 1970 |
Isoniazid-resistant strains of M. tuberculosis.
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculos | 1970 |
Isoniazid-resistant strains of M. tuberculosis.
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1970 |
[Mycobacterial resistance in Lower Franconia].
Topics: Antitubercular Agents; Chronic Disease; Drug Resistance, Microbial; Germany, West; Humans; Isoniazid | 1970 |
Introduction to a formal theory of the dosage regimen calculation in intermittent chemotherapy of tuberculosis.
Topics: Antitubercular Agents; Humans; Isoniazid; Microbial Sensitivity Tests; Models, Theoretical; Mycobact | 1970 |
[Effect of drug resistance of Mycobacterium tuberculosis on the therapeutic results of a drug to which sensitivity is retained(experimental data)].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Liver; Lung; Lymph Nodes; Mycobacterium | 1970 |
Unusual cold abscesses.
Topics: Abscess; Adolescent; Adult; Aminosalicylic Acids; Drainage; Female; Humans; Isoniazid; Male; Mycobac | 1970 |
Antimicrobial activity of the leprostatic drug 3-(p-chloranilino)-10-(p-chlorphenyl-2,10-dihydro-2-(isopropylimino)-phenazine (G 30'320, B. 663).
Topics: Animals; Antitubercular Agents; Aspergillosis; Candidiasis; Chloroquine; Cricetinae; Disease Models, | 1970 |
What is drug resistance?
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Microbial Sensitivity Tests; Mutation; Mycobacterium | 1969 |
[Importance of the inactivation of tubazid in the complex therapy of patients with pulmonary tuberculosis].
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculosis | 1970 |
[Role of psychotherapy in a group of adolescents with tuberculosis].
Topics: Adolescent; Adult; Female; France; Humans; Isoniazid; Long-Term Care; Male; Mental Disorders; Psycho | 1970 |
[Some aspects of tuberculosis at puberty].
Topics: Adolescent; Drug Resistance, Microbial; Female; Humans; Isoniazid; Male; Mycobacterium tuberculosis; | 1970 |
Primary drug-resistant tuberculosis. Report of an outbreak.
Topics: Adolescent; Adult; Aminosalicylic Acids; Child; Child, Preschool; Disease Outbreaks; Drug Resistance | 1970 |
[Effect of the addition of the 3rd agent on the combined therapy with ethionamide and kanamycin in tuberculosis in the mice].
Topics: Animals; Cycloserine; Drug Resistance, Microbial; Endopeptidases; Ethambutol; Ethionamide; Isoniazid | 1970 |
[Chromogenic mycobacteria cultures from lesions of animal tuberculosis].
Topics: Abattoirs; Aminosalicylic Acids; Animals; Bacteriological Techniques; Catalase; Cattle; Chickens; Cu | 1970 |
[Inhibition of isoniazid activity in the presence of chloroquinum diphosphoricum].
Topics: Animals; Body Weight; Chloroquine; Depression, Chemical; Drug Antagonism; Isoniazid; Mice; Mycobacte | 1970 |
Suitability of rifampicin for intermittent administration in the treatment of tuberculosis.
Topics: Analysis of Variance; Animals; Drug Resistance, Microbial; Guinea Pigs; Isoniazid; Mycobacterium tub | 1970 |
Rifampicin in the treatment of experimental tuberculosis in mice: sterilization of tubercle bacilli in the tissues.
Topics: Animals; Cortisone; Drug Synergism; Isoniazid; Lung; Male; Mice; Mycobacterium tuberculosis; Rifampi | 1970 |
Isoniazid treatment for tuberculosis.
Topics: Adult; Chemical and Drug Induced Liver Injury; Child; Drug Resistance, Microbial; Humans; Isoniazid; | 1971 |
Drug-resistant tuberculosis.
Topics: Child; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Streptomycin; Tube | 1971 |
[Durable character of the sterilization of experimental tuberculosis in mice by rifampicin-isoniazid association: cortisone test].
Topics: Animals; Cortisone; Drug Synergism; Isoniazid; Mice; Mycobacterium tuberculosis; Rifampin; Streptomy | 1970 |
Rifampin: characteristics and role in the chemotherapy of tuberculosis.
Topics: Animals; Haplorhini; Humans; Isoniazid; Mice; Mycobacterium tuberculosis; Research; Rifampin; Tuberc | 1971 |
Planning models for tuberculosis control programs.
Topics: Adult; BCG Vaccine; Child; Costs and Cost Analysis; Female; Health Expenditures; Humans; Infant, New | 1971 |
[Discrepancy between drug resistance of mycobacterium tuberculosis determined in vitro and in vivo].
Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Guinea Pigs; In Vitro Techniques; Isonia | 1971 |
[Primary isoniazid resistance in tuberculous children of West Berlin].
Topics: Berlin; Child; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tuberculosis; Tuberculos | 1971 |
[Mycobacterium tuberculosis resistant drugs and their effect on guinea pigs inoculated with a mixture of sensitive and resistant M. tuberculosis].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Humans; Isoniazid; Mycobacterium tuberculosis; Spu | 1971 |
Rifampicin in experimental investigations on mice.
Topics: Animals; Drug Combinations; Drug Resistance, Microbial; Evaluation Studies as Topic; Injections, Sub | 1970 |
[Activity of rifampicin on experimental tuberculosis in mice. The development of resistance to rifampicin. Therapeutic effects of combinations of different drugs with rifampicin].
Topics: Animals; Drug Combinations; Drug Resistance, Microbial; Ethambutol; Ethionamide; Evaluation Studies | 1970 |
Experimental and clinical studies on the antituberculous activity of rifampicin alone or combined with other drugs.
Topics: Administration, Oral; Adolescent; Adult; Aminosalicylic Acids; Animals; Culture Media; Drug Combinat | 1970 |
[Catalase activity of drug-resistant Mycobacterium tuberculosis strains].
Topics: Catalase; Depression, Chemical; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium tubercu | 1971 |
Limits in tuberculosis chemotherapy as revealed by experimental study in mice.
Topics: Animals; BCG Vaccine; Drug Resistance, Microbial; Isoniazid; Kanamycin; Lung; Male; Mice; Mycobacter | 1971 |
[Studies on the effects of antituberculosis agents against tubercle bacilli in the resting state, using streptomycin-dependent strain (18-b). II. Studies in vivo].
Topics: Animals; Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Isoniazid; Kanamycin; Male; | 1971 |
[Correlation of lipid fractions, toxicity and virulence of M. tuberculosis isolated from patients treated with antibacterial preparations].
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Drug Resistance, Microbial; Guinea Pigs; Human | 1971 |
Mode of action of antituberculous agents and ultrastructure of mycobacteria.
Topics: Animals; Antitubercular Agents; Cycloserine; Ethambutol; Isoniazid; Kanamycin; Mice; Microscopy, Ele | 1971 |
[Incidence of the bovine bacillus in human tuberculosis at Algiers in 1969].
Topics: Animals; Cattle; Drug Resistance, Microbial; Humans; Isoniazid; Mycobacterium bovis; Mycobacterium t | 1970 |
INH prophylaxis.
Topics: Adolescent; Adult; Aspartate Aminotransferases; Child; Humans; Isoniazid; Time Factors; Tuberculosis | 1972 |
INH for children.
Topics: Adult; Child; Humans; Isoniazid; Tuberculosis | 1972 |
The new approach to tuberculosis.
Topics: Ambulatory Care; BCG Vaccine; Comprehensive Health Care; Forecasting; Hospitals, Special; Humans; Im | 1972 |
Isoniazid chemoprophylaxis of tuberculosis.
Topics: Adult; Animals; Child; Guinea Pigs; Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1972 |
Tuberculosis chemotherapy.
Topics: Humans; Isoniazid; Pyridoxine; Tuberculosis | 1972 |
Tuberculin testing and chemoprophylaxis in tuberculosis: recommendations of the Colorado Trudeau Society.
Topics: Adolescent; Humans; Infant; Isoniazid; Methods; Tuberculin Test; Tuberculosis; Tuberculosis, Pulmona | 1972 |
What needs to be done to eradicate tuberculosis.
Topics: Child; Economics, Medical; Humans; Isoniazid; Tuberculosis | 1972 |
Para-aminosalicylic acid-induced malabsorption.
Topics: Aminosalicylic Acids; Carotenoids; Celiac Disease; Cholesterol; Feces; Folic Acid; Folic Acid Defici | 1972 |
[Tuberculosis therapy today].
Topics: Antitubercular Agents; Drug Synergism; Female; Hospitals, Special; Humans; Isoniazid; Male; Steroids | 1972 |
Primary drug-resistant tuberculosis in Vietnam veterans 1967 to 1970.
Topics: Aminosalicylic Acids; Antineoplastic Agents; Drug Resistance, Microbial; Humans; Isoniazid; Male; Mi | 1972 |
[Intramuscular administration of tubazid and streptomycin in a single injection during treatment of tuberculosis].
Topics: Adolescent; Adult; Drug Synergism; Humans; Injections, Intramuscular; Isoniazid; Middle Aged; Strept | 1972 |
Tuberculosis in South Vietnam.
Topics: Adolescent; Child; Child, Preschool; Hospitals; Humans; Infant; Isoniazid; Outpatient Clinics, Hospi | 1972 |
Isoniazid toxicity. A prospective study in secondary chemoprophylaxis.
Topics: Adult; Aged; Anorexia Nervosa; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; | 1972 |
Isoniazid-associated hepatitis. Report of an outbreak.
Topics: Adult; Aged; Aspartate Aminotransferases; Autopsy; Bilirubin; Biopsy; Chemical and Drug Induced Live | 1972 |
Failure to demonstrate transformation of lymphocytes of patients with isoniazid-associated hepatitis.
Topics: Aspartate Aminotransferases; Autoradiography; Cells, Cultured; Chemical and Drug Induced Liver Injur | 1972 |
Chemoprophylaxis in tuberculous infection.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Child; Female; Gastrectomy; Humans; Immunosuppressiv | 1972 |
Superficial abscess formation: an unusual presenting feature of tuberculosis.
Topics: Abscess; Adiposis Dolorosa; Adolescent; Adult; Aminosalicylic Acids; Blood Cell Count; Blood Sedimen | 1971 |
Feasibility of a chemoprophylaxis trial in India against tuberculosis.
Topics: Humans; India; Isoniazid; Tuberculosis | 1971 |
Use of isoniazid.
Topics: Humans; Isoniazid; Tuberculosis | 1971 |
Isoniazid hepatotoxicity--fact of fantasy.
Topics: Bilirubin; Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Jaundice; Liver; Male; | 1971 |
Primary tuberculosis otitis media.
Topics: Anti-Bacterial Agents; Ear; Ear Diseases; Female; Humans; Isoniazid; Middle Aged; Myringoplasty; Oti | 1971 |
A rationale for tuberculosis control.
Topics: Adolescent; Adult; Aged; Alabama; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; | 1971 |
[Studies on atypical mycobacteria. X. Experimental approach to the etiology of atypical mycobacteriosis].
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Cycloserine; Drug Resistance, Microbial; Etham | 1971 |
Isoniazid prophylaxis and BCG vaccination in the control of tuberculosis. High-risk groups.
Topics: Adolescent; Adult; BCG Vaccine; Child; Female; Humans; Isoniazid; Male; Military Personnel; Personne | 1971 |
Safety of INH chemoprophylaxis in aviation personnel.
Topics: Adult; Aerospace Medicine; Alanine Transaminase; Aspartate Aminotransferases; Electroencephalography | 1971 |
[Primary tuberculous otitis media].
Topics: Humans; Isoniazid; Otitis Media; Streptomycin; Thebaine; Tuberculosis | 1971 |
[Combined action of histones and anibacterial agents in vitro and in vivo--potentiation of the effect of tubazide].
Topics: Animals; Cattle; Drug Synergism; Guinea Pigs; Histones; Isoniazid; Lethal Dose 50; Mice; Thymus Glan | 1971 |
[Current place of chemoprophylaxis in tuberculosis control].
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Child; Child, Preschool; Humans; Isoniazid; Middle A | 1971 |
[Cancer and tuberculosis].
Topics: Adult; Age Factors; Aged; Carcinoma; Carcinoma, Basal Cell; Denmark; Female; Humans; Isoniazid; Lung | 1971 |
[Effect of INH on coronary arteries and heart action in experimental tuberculosis].
Topics: Animals; Arteries; Coronary Circulation; Coronary Vessels; Female; Guinea Pigs; Heart; Heart Rate; I | 1971 |
[Pseudoneurasthenia and EEG chenges due to vitamin B 6 deficiency during INH therapy].
Topics: Adult; Affective Symptoms; Antitubercular Agents; Carboxy-Lyases; Depression; Electroencephalography | 1971 |
[Use of complex compounds of copper and cobalt trace elements with vitamins during isoniazid treatment of experimental tuberculosis].
Topics: Animals; Cobalt; Copper; Drug Interactions; Isoniazid; Male; Rabbits; Trace Elements; Tuberculosis; | 1971 |
[Problems of tuberculosis treatment in the African context].
Topics: Africa; Aminosalicylic Acids; Antitubercular Agents; Economics, Medical; Humans; Isoniazid; Streptom | 1971 |
The effect of pyrazinamide, rifampicin and cycloserine on the blood levels and urinary excretion of isoniazid.
Topics: Cycloserine; Humans; Isoniazid; Pyrazinamide; Rifampin; Tuberculosis | 1971 |
Potentially serious side-effects of high-dose twice-weekly rifampicin.
Topics: Acute Kidney Injury; Adolescent; Adult; Antibodies; Child; Complement Fixation Tests; Epistaxis; Fem | 1971 |
Tuberculosis case-finding in the seventies.
Topics: Costs and Cost Analysis; Female; Humans; Isoniazid; Mass Chest X-Ray; Pregnancy; Prenatal Care; Resp | 1971 |
Screening for prevention of isoniazid-associated liver disease.
Topics: Chemical and Drug Induced Liver Injury; Female; Humans; Isoniazid; Liver; Male; Mass Screening; Surv | 1971 |
Drugs for tuberculosis.
Topics: Aminosalicylic Acids; Isoniazid; Nursing; Streptomycin; Tuberculosis | 1966 |
Effect of isoniazid on tuberculosis in guinea pigs.
Topics: Animals; Female; Guinea Pigs; Injections, Subcutaneous; Isoniazid; Male; Tuberculin Test; Tuberculos | 1967 |
It's happening in Yolo County.
Topics: California; Isoniazid; Nursing; Tuberculosis | 1968 |
Isoniazid prophylaxis. For the few--or the many?
Topics: Isoniazid; Nursing; Tuberculosis; United States | 1968 |
[Drug therapy and drug resistance in the treatment of tuberculosis].
Topics: Aminosalicylic Acids; Drug Resistance, Microbial; Isoniazid; Nursing; Streptomycin; Tuberculosis | 1968 |
[I.N.H. prophylaxis].
Topics: Isoniazid; Netherlands; Nursing; Tuberculosis | 1968 |
International co-operation in tuberculosis research.
Topics: Antitubercular Agents; BCG Vaccine; Humans; International Cooperation; Isoniazid; Mass Chest X-Ray; | 1968 |
The role of the metabolism of p-aminosalicylic acid (PAS) in the treatment of tuberculosis. Interaction with the metabolism of isonicotinic acid hydrazide (INH) and the synthesis of cholesterol.
Topics: Aminosalicylic Acids; Autoradiography; Cholesterol; Humans; Isoniazid; Tuberculosis | 1969 |
Guilty. Who?
Topics: Child; Female; Humans; Isoniazid; Male; Ohio; School Health Services; Tuberculosis | 1970 |
[The fight against tuberculosis. Changes in norms and objectives].
Topics: Adolescent; Antitubercular Agents; BCG Vaccine; Child; Child, Preschool; Female; Hospitals, General; | 1969 |
Genetic variations in the acetylation of isoniazid and other drugs.
Topics: Adult; Aminobenzoates; Aminosalicylic Acids; Asian People; Black People; Body Weight; Depression; Fe | 1968 |
Drug-resistant pulmonary tuberculosis in Norway. Preliminary report.
Topics: Aminosalicylic Acids; Humans; Isoniazid; Norway; Streptomycin; Tuberculosis; Tuberculosis, Pulmonary | 1969 |
[Isoniazide induced fibrosing arthropathy ("Algodystrophy")].
Topics: Adult; Female; Humans; Isoniazid; Male; Middle Aged; Reflex Sympathetic Dystrophy; Tuberculosis; Tub | 1969 |
Clinical effect of cycloserine on cavity-size, frequency of improvement with remarks on control of side effects.
Topics: Aminosalicylic Acids; Cycloserine; Epilepsy; Humans; Isoniazid; Streptomycin; Tuberculosis | 1970 |
Clinical experience with cycloserine in Hungary.
Topics: Adolescent; Adult; Chronic Disease; Cycloserine; Drug Resistance, Microbial; Humans; Isoniazid; Midd | 1970 |
Tolerance to cycloserine.
Topics: Adult; Aged; Aminosalicylic Acids; Cycloserine; Drug Tolerance; Ethionamide; Female; Humans; Isoniaz | 1970 |
Experimental studies on host-parasite equilibrium in tuberculous infection, in relation to vaccination and chemotherapy.
Topics: Animals; BCG Vaccine; Guinea Pigs; Isoniazid; Kanamycin; Male; Mice; Mycobacterium; Streptomycin; Tu | 1966 |
[Place and task of preventive chemotherapy in the framework of tuberculosis control].
Topics: Child, Preschool; Humans; Infant; Infant, Newborn; Isoniazid; Placebos; Tuberculin Test; Tuberculosi | 1965 |
Experimental studies on therapeutic effects of various combinations of antituberculosis drugs. I. Comparison of various regimens in treatment of experimental mouse tuberculosis infected with drug-susceptible mycobacteria.
Topics: Aminosalicylic Acids; Animals; Antitubercular Agents; Cycloserine; Ethambutol; Ethionamide; Isoniazi | 1967 |
[On the metabolism of isoniazid in the body: the problem of rapid inactivation].
Topics: Female; Humans; Isoniazid; Male; Tuberculosis | 1967 |
Infants of tuberculous mothers: further thoughts.
Topics: BCG Vaccine; Child; Humans; Infant, Newborn; Isoniazid; Tuberculin Test; Tuberculosis; Tuberculosis, | 1968 |
Diagnosis and treatment: approaches to newborn infants of tuberculous mothers.
Topics: BCG Vaccine; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Isoniazid; Male; Pregnancy; | 1968 |
[Tuberculin sensitivity and isoniazid prophylaxis].
Topics: Adolescent; Adult; Age Factors; Child; Humans; Infant; Isoniazid; Netherlands; Time Factors; Tubercu | 1968 |
Newborn infants of tuberculous mothers, further comment.
Topics: Female; Humans; Infant; Isoniazid; Maternal-Fetal Exchange; Pregnancy; Pregnancy Complications, Infe | 1969 |
Isoniazid prophylaxis in a slum area.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Humans; Isoniazid; Male; Middle Aged; Pove | 1969 |
The treatment of tuberculosis in children.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; BCG Vaccine; Child; Humans; Isoniazid; Streptomycin; | 1969 |
[Activity of Rifampicin associated with other drugs on experimental tuberculosis in guinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Rifampin; Streptomycin; Tuberculosis | 1967 |
The paradox of BCG.
Topics: Adult; BCG Vaccine; Humans; Infant; Isoniazid; Tuberculin Test; Tuberculosis; Tuberculosis, Pulmonar | 1969 |
[Chemotherapy and chemoprophylaxis in children's sanatorial antituberculous institutions].
Topics: Aminosalicylic Acids; Child, Preschool; Hospitals, Special; Humans; Isoniazid; Schools, Nursery; Tub | 1969 |
Rheumatism and chemotherapy of tuberculosis.
Topics: Humans; Isoniazid; Rheumatic Diseases; Tuberculosis | 1970 |
Feasibility of a chemoprophylaxis trial in India against tuberculosis. A pilot study.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Humans; India; Isoniazid; Male; Middle Age | 1970 |
Interpretation of the multiple puncture tuberculin reaction.
Topics: Adult; Antibody Specificity; BCG Vaccine; Child; Cross Reactions; Humans; Isoniazid; School Health S | 1970 |
[Prevention of tuberculosis among children born into families infected with tuberculosis].
Topics: Breast Feeding; Female; Humans; Infant, Newborn; Infant, Newborn, Diseases; Isoniazid; Male; Methods | 1970 |
Isoniazid acetylation rates (phenotypes) of patients being treated for tuberculosis.
Topics: Humans; Isoniazid; Phenotype; Tuberculosis; Tuberculosis, Pulmonary | 1971 |
Inactivation of isoniazid by condensation in a syrup preparation.
Topics: Adult; Child, Preschool; Chromatography, Paper; Drug Compounding; Drug Incompatibility; Humans; Ison | 1971 |
An experimental attempt of intensified chemotherapy with rifampicin combined with other drugs.
Topics: Administration, Oral; Animals; Drug Synergism; Ethambutol; Ethionamide; Female; Isoniazid; Mice; Mic | 1971 |
Rifampicin.
Topics: Bronchitis; Chronic Disease; Drug Resistance, Microbial; Drug Synergism; Economics, Medical; Ethambu | 1969 |
Use of BCG is defeatist.
Topics: BCG Vaccine; Humans; Idaho; Isoniazid; Tuberculin Test; Tuberculosis | 1969 |
Retreatment of tuberculosis patients with combined drug therapy.
Topics: Brazil; Cycloserine; Drug Resistance, Microbial; Ethionamide; Humans; Isoniazid; Pyrazinamide; Tuber | 1969 |
[Effect of sodium para-aminosalicylate on the concentration of isoniazid (tubazid) in the blood of patients with tuberculosis].
Topics: Aminosalicylic Acids; Drug Synergism; Humans; Isoniazid; Tuberculosis | 1969 |
Antibodies to nucleoprotein and to hydrazide-altered soluble nucleoprotein in tuberculous patients receiving isoniazid.
Topics: Adult; Age Factors; Animals; Antigens; Autoantibodies; Cattle; Child; Complement Fixation Tests; DNA | 1969 |
[Level of isoniazid labeled with C-14 in the tissue of animals infected with tuberculosis administered insulin].
Topics: Animals; Carbon Isotopes; Diabetes Mellitus; Female; Guinea Pigs; Insulin; Isoniazid; Male; Tubercul | 1969 |
Primary drug resistance in Australia in 1968.
Topics: Aspirin; Australia; Drug Resistance, Microbial; Humans; Isoniazid; Streptomycin; Tuberculosis | 1969 |
[Basophilic serological test in side effects of antituberculous drugs of the first series].
Topics: Aminosalicylic Acids; Basophils; Drug Hypersensitivity; Humans; Isoniazid; Streptomycin; Tuberculosi | 1969 |
[Bacteriostatic concentration of tubazid in experimental tuberculosis].
Topics: Animals; Guinea Pigs; Isoniazid; Tuberculosis | 1969 |
[Rifomycin in continuous and intermittent combined treatment of experimental tuberculosis in mice].
Topics: Animals; Drug Synergism; Isoniazid; Mice; Rifampin; Streptomycin; Tuberculosis | 1969 |
The management of hypersensitivity reactions to antituberculosis drugs.
Topics: Adult; Aged; Aminosalicylic Acids; Desensitization, Immunologic; Drug Hypersensitivity; Female; Huma | 1969 |
[Allergic and immunologic indices in chemoprophylaxis of experimental tuberculosis].
Topics: Animals; Antibodies; Antigens; Antitubercular Agents; Guinea Pigs; Isoniazid; Skin Tests; Tuberculin | 1969 |
Serum levels, urinary excretion, and side-effects of cycloserine in the presence of isoniazid and p-aminosalicylic acid.
Topics: Adult; Aged; Aminosalicylic Acids; Biological Assay; Bordetella; Cycloserine; Drug Synergism; Female | 1969 |
[Comparative therapeutic value of tubazid and phthivazid].
Topics: Adult; Aged; Humans; Isoniazid; Middle Aged; Tuberculosis | 1969 |
[Liver function in tuberculosis treated with pyrazinamide, cycloserine, ethionamide and isoniazid].
Topics: Antitubercular Agents; Cycloserine; Ethionamide; Humans; Isoniazid; Liver; Pyrazinamide; Tuberculosi | 1969 |
Problems of treatment of drug resistance in the developing countries.
Topics: Africa; Aminosalicylic Acids; Antitubercular Agents; Costs and Cost Analysis; Developing Countries; | 1969 |
[Attempt at intermittent chemotherapeutic treatment of patients with bacilli resistant to streptomycin and isoniazid (cooperative survey by the antitubercular services of Marrakech, Meknes, Tangiers)].
Topics: Cycloserine; Drug Resistance, Microbial; Drug Synergism; Ethionamide; Humans; Isoniazid; Morocco; Py | 1969 |
[Rifampicin and isoniazid in the intermittent treatment of experimental tuberculosis in guinea-pigs].
Topics: Animals; Drug Synergism; Guinea Pigs; Isoniazid; Rifampin; Tuberculin Test; Tuberculosis | 1969 |
International Union Against Tuberculosis, Committee of Prophylaxis.
Topics: BCG Vaccine; Europe; Humans; Isoniazid; Tuberculosis | 1969 |
BCG.
Topics: BCG Vaccine; Humans; Isoniazid; Tuberculosis; United States | 1970 |
The diagnostic and prognostic value of the second strength dose of PPD (5.0 micrograms). Its use in detecting pseudoconverters from blood transfusions and from the booster effect of previous tuberculin tests.
Topics: Adult; Blood Transfusion; Diagnosis, Differential; Female; Humans; Immunity, Maternally-Acquired; Is | 1970 |
[Progress in the treatment of tuberculosis. Isoniazid plus rifomycin plus myambutol equals standard therapy].
Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Drug Synergism; Ethambutol; | 1970 |
Chemoprophylaxis of tuberculosis.
Topics: Adult; Female; Humans; Isoniazid; Pregnancy; Pregnancy Complications, Infectious; Tuberculin Test; T | 1970 |
Diphenylhydantoin intoxication. A complication of isoniazid therapy.
Topics: Adolescent; Adult; Animals; Biotransformation; Cats; Epilepsy; Female; Humans; Isoniazid; Male; Midd | 1970 |
[Effect of proflavin on the chemotherapeutic activity of isoniazid and streptomycin in albino mice with experimental tuberculosis].
Topics: Acridines; Animals; Drug Synergism; Isoniazid; Mice; Streptomycin; Tuberculosis | 1970 |
A study of ethambutol as a supplement to standard triple-drug regimen.
Topics: Aminosalicylic Acids; Ethambutol; Humans; Isoniazid; Sputum; Streptomycin; Tuberculosis | 1970 |
[Isoniazid monotherapy?].
Topics: Humans; Isoniazid; Tuberculosis | 1970 |
[Adverse effects of drugs in tuberculous patients. Allergic reactions due to isoniazid and hydantoins or disulfiram].
Topics: Alcoholism; Disulfiram; Drug Hypersensitivity; Drug Synergism; Epilepsy; Humans; Hydantoins; Isoniaz | 1970 |
Chemoprophylaxis of tuberculosis.
Topics: Humans; Isoniazid; Skin Tests; Tuberculosis | 1970 |
Chemoprophylaxis of tuberculosis.
Topics: Humans; Isoniazid; Skin Tests; Tuberculosis | 1970 |
Chemoprophylaxis of tuberculosis.
Topics: Alaska; Humans; Isoniazid; Poisoning; Pyridoxine; Tuberculosis | 1970 |
Long-term corticosteroid treatment.
Topics: Glucocorticoids; Humans; Isoniazid; Prednisone; Time Factors; Tuberculin Test; Tuberculosis | 1970 |
Rifampin, new hope in the fight against tuberculosis.
Topics: Humans; Isoniazid; Rifampin; Tuberculosis | 1970 |
Tuberculosis of the upper respiratory tract.
Topics: Adult; Female; Humans; Isoniazid; Male; Middle Aged; Prognosis; Respiratory Tract Infections; Salicy | 1970 |
Nasopharyngeal tuberculosis.
Topics: Aminosalicylic Acids; Audiometry; Deafness; Female; Humans; Isoniazid; Middle Aged; Nasopharyngeal D | 1970 |
The action of rifampin alone and in combination with other antituberculous drugs.
Topics: Drug Resistance, Microbial; Drug Synergism; Ethambutol; Isoniazid; Rifampin; Streptomycin; Tuberculo | 1970 |
Inactivation of isoniazid (INH) in Swedish tuberculous patients before and during treatment with para-aminosalicylic acid (PAS).
Topics: Administration, Oral; Aminosalicylic Acids; Drug Synergism; Isoniazid; Tuberculosis | 1970 |
[Relapse and chemotherapy in experimental mouse tuberculosis].
Topics: Animals; Disease Models, Animal; Isoniazid; Lung; Male; Mice; Spleen; Streptomycin; Tuberculosis | 1970 |
A program for tuberculosis control in the schools.
Topics: Adolescent; Child; Humans; Isoniazid; Pennsylvania; Records; School Health Services; Tuberculin Test | 1970 |
It's time for BCG vaccine.
Topics: BCG Vaccine; Humans; Isoniazid; Tuberculin Test; Tuberculosis; Tuberculosis, Pulmonary; United State | 1970 |
[Modern chemotherapy of tuberculosis].
Topics: Adolescent; Adult; Age Factors; Antitubercular Agents; Berlin; Child; Child, Preschool; Drug Resista | 1970 |
[Pharmacogenetic and interaction-model with some usual antitubercular agents].
Topics: Aminosalicylic Acids; Humans; Isoniazid; Rifampin; Tuberculosis | 1970 |
[Comparative value of tubazid, larusan and preparation INKh-17].
Topics: Antitubercular Agents; Humans; Isoniazid; Tuberculosis | 1970 |
[Use of vitamins during tubazid treatment of experimental tuberculosis in white mice].
Topics: Animals; Female; Isoniazid; Mice; Tuberculosis; Vitamins | 1970 |
[New drugs in the treatment of primary tuberculosis].
Topics: Aminosalicylic Acids; Child; Child, Preschool; Ethambutol; Female; France; Humans; Isoniazid; Male; | 1970 |
[Research on the protective action of rifampicin administered intermittently in experimental tuberculosis in guinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Rifampin; Tuberculosis | 1970 |
Tuberculin skin-test conversion in Vietnam. 1969 annual skin-test reports of Navy and Marine Corps.
Topics: Humans; Isoniazid; Male; Naval Medicine; Tuberculin Test; Tuberculosis; United States; Vietnam | 1970 |
Which children in the United States should receive BCG vaccination?
Topics: BCG Vaccine; Canada; Child; Child, Preschool; Disease Outbreaks; District of Columbia; Europe; Human | 1970 |
[Intracranial tuberculosis: yesterday and today].
Topics: Adolescent; Age Factors; Aminosalicylic Acids; Brain Diseases; Child; Female; Humans; India; Isoniaz | 1970 |
[Population screening and chemoprophylaxis in tuberculosis].
Topics: BCG Vaccine; Humans; Isoniazid; Mass Chest X-Ray; Tuberculosis | 1970 |
[Current views on drug treatment of tuberculosis].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Antitubercular Agents; Ethambu | 1970 |
[Change in isoniazid-H3 concentration in the blood and tissues in relation to dosage and mode of administration].
Topics: Animals; Female; Guinea Pigs; Isoniazid; Rats; Tritium; Tuberculosis | 1970 |
Intermittent chemotherapy in the Northern Territory of Australia.
Topics: Aminosalicylic Acids; Antitubercular Agents; Australia; Humans; Isoniazid; Native Hawaiian or Other | 1970 |
Jaundice associated with rifampicin.
Topics: Aged; Alkaline Phosphatase; Chemical and Drug Induced Liver Injury; Drug Synergism; Female; Humans; | 1970 |
Risk of infection.
Topics: Aminosalicylic Acids; Hospitalization; Humans; India; Isoniazid; Tuberculosis | 1970 |
[Bacteriostatic activity of the blood in tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Blood Bactericidal Activity; Drug Resistance, Microbial | 1970 |
[A new and powerful anti-tubercular drug: rifampicin].
Topics: Drug Resistance, Microbial; Drug Synergism; Drug Tolerance; Ethambutol; Humans; Infusions, Parentera | 1970 |
[Jaundice epidemiology in 1,974 hospitalized tubercular patients, treated or untreated by rifampicin].
Topics: Drug Synergism; Humans; Isoniazid; Jaundice; Rifampin; Tuberculosis; Tuberculosis, Hepatic | 1970 |
[Effect of isoniazid on pyridoxine (vitamin B6) metabolism in children. Experimental study].
Topics: Acids; Animals; Central Nervous System Diseases; Child; Child, Preschool; Cycloserine; Drug Synergis | 1970 |
[A new and powerful anti-tubercular drug: rifampicin].
Topics: Drug Resistance, Microbial; Drug Synergism; Drug Tolerance; Ethambutol; Humans; Infusions, Parentera | 1970 |
[Antituberculosis treatment with pasiniazide (isoniazide p-aminosalicylate): experimental and clinical aspects].
Topics: Aminosalicylic Acids; Humans; Isoniazid; Salts; Tuberculosis | 1970 |
[Concentration of isoniazid-H3 in the blood and tissues of experimental animals].
Topics: Animals; Female; Guinea Pigs; Isoniazid; Liver; Lung; Rats; Time Factors; Tritium; Tuberculosis | 1970 |
Rifampicin, isoniazid, ethambutol, ethionamide, and streptomycin in murine tuberculosis: comparative chemotherapeutic studies.
Topics: Administration, Oral; Animals; Drug Combinations; Ethambutol; Ethionamide; Evaluation Studies as Top | 1970 |
Consequences of the development of new antituberculous drugs for the treatment of tuberculosis.
Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Combinations; Drug Resistance, Microbial; Ethambut | 1970 |
[Morphological changes in the liver of guinea pigs with minor tubercular changes treated for a prolonged period with streptomycin, phthivazid and PASK].
Topics: Aminosalicylic Acids; Animals; Guinea Pigs; Isoniazid; Liver; Streptomycin; Tuberculosis | 1970 |
Clinical experiences with thiocarlide (Isoxyl) in combination therapy of freshly evaluated tuberculosis.
Topics: Aminosalicylic Acids; Drug Combinations; Drug Synergism; Ethionamide; Female; Humans; Isoniazid; Mal | 1970 |
Experimental therapy with rifampicin.
Topics: Animals; Drug Combinations; Drug Resistance, Microbial; Ethambutol; Ethionamide; Isoniazid; Mice; My | 1970 |
[Standard therapy of tuberculosis].
Topics: Antitubercular Agents; Body Weight; Drug-Related Side Effects and Adverse Reactions; Ethambutol; Hum | 1971 |
[Symposium: chemotherapy including new antitubercular agents].
Topics: Aminosalicylic Acids; Antitubercular Agents; Ethambutol; Humans; Isoniazid; Rifampin; Streptomycin; | 1971 |
[Changing picture of tuberculosis during a decade].
Topics: Adult; Age Factors; Aged; Aminosalicylic Acids; Drug Resistance, Microbial; Ethambutol; Female; Huma | 1971 |
The combination of rifampicin and other antituberculous agents in chronic murine tuberculosis.
Topics: Animals; Cell Count; Chronic Disease; Disease Models, Animal; Drug Synergism; Ethambutol; Ethionamid | 1971 |
[The rational basis for the treatment of tuberculosis].
Topics: Antitubercular Agents; Drug Resistance, Microbial; Ethambutol; Humans; Isoniazid; Microbial Sensitiv | 1971 |
Isoniazid prophylaxis re-examined.
Topics: Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; Humans; Isoniazid; Tuberculin Test | 1971 |
Free drugs for the treatment of tuberculosis.
Topics: Financing, Government; Humans; Isoniazid; Massachusetts; Outpatient Clinics, Hospital; Tuberculosis | 1971 |
The effects of chemotherapy on iron, folate, and vitamin B 12 metabolism in tuberculosis.
Topics: Acrylates; Adolescent; Adult; Aged; Aminosalicylic Acids; Anemia; Anemia, Hypochromic; Anemia, Macro | 1971 |
Experimental investigations on the influence of isoniazid on the coronary flow and on the activity of the heart.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Coronary Vessels; Female; Guinea Pigs; Heart; Heart Ra | 1971 |
"Control of tuberculosis" up-to-date.
Topics: Aminosalicylic Acids; Ethambutol; Humans; Isoniazid; Rifampin; Tuberculosis | 1971 |
[Experimental study of rifampicin and ethambutol].
Topics: Animals; Blood Bactericidal Activity; Ethambutol; Guinea Pigs; Humans; In Vitro Techniques; Isoniazi | 1971 |
[Influence of thyroid gland hypofunction on the course of experimental tuberculosis with hydrazide-resistant bacilli].
Topics: Animals; Drug Resistance, Microbial; Guinea Pigs; Hypothyroidism; Isoniazid; Lung; Lymph Nodes; Sple | 1967 |
[Short-term, primary INH-prevention with high doses in mininally infected quinea pigs].
Topics: Animals; Guinea Pigs; Isoniazid; Tuberculosis | 1967 |
Active systemic lesions in cases of suspected ocular tuberculosis.
Topics: Adolescent; Adult; Female; Humans; Isoniazid; Male; Streptomycin; Tuberculosis; Tuberculosis, Ocular | 1967 |
[Primary tuberculous infection (study of 42 cases)].
Topics: Adolescent; Brazil; Child; Child, Preschool; Humans; Infant; Isoniazid; Tuberculosis | 1967 |
[Intensive intravenous isoniazid therapy. Record of 5 years].
Topics: Adolescent; Adult; Humans; Injections, Intravenous; Isoniazid; Male; Middle Aged; Tuberculosis | 1967 |
[Clinical experiences with INH-isoxyl therapy of primary tuberculosis].
Topics: Antitubercular Agents; Child; Child, Preschool; Drug Synergism; Humans; Infant; Isoniazid; Phenylthi | 1967 |
[Significance of chemoprophylaxis in children and adolescents with high sensitivity to tuberculin].
Topics: Adolescent; Aminosalicylic Acids; Antitubercular Agents; Child; Humans; Isoniazid; Tuberculin Test; | 1967 |
[Histochemical study of alkaline and acid phosphatase in prolonged therapy of tuberculosis].
Topics: Acid Phosphatase; Alkaline Phosphatase; Aminosalicylic Acids; Animals; Histocytochemistry; Isoniazid | 1967 |
[Harmful effects of isoniazid on the fetus and infants].
Topics: Brain Diseases; Child, Preschool; Female; Fetal Diseases; Fetus; Humans; Infant; Infant, Newborn; In | 1967 |
Rifampicin: a new rifamycin. II. Laboratory studies on the antituberculous activity and preliminary clinical observations.
Topics: Adolescent; Adult; Aminosalicylic Acids; Animals; Guinea Pigs; Humans; Isoniazid; Mice; Middle Aged; | 1967 |
Isoniazid prophylaxis in tuberculin reactors.
Topics: Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1968 |
Chemoprophylaxis for the prevention of tuberculosis.
Topics: Humans; Isoniazid; Motivation; Tuberculin Test; Tuberculosis | 1968 |
Problems in the control of tuberculosis.
Topics: BCG Vaccine; Humans; Isoniazid; Tuberculosis | 1968 |
Incidence of drug hypersensitivity in the chemotherapy of tuberculosis.
Topics: Adolescent; Adult; Age Factors; Aged; Aminosalicylic Acids; Blood Sedimentation; Drug Hypersensitivi | 1968 |
Relationships between chemotherapeutic activity and blood concentration of rifampin in murine tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Isoniazid; Mice; Rodent Diseases; Tuberculosi | 1968 |
Chemoprophylaxis for the prevention of tuberculosis: a report of the Ad Hoc Committee on chemoprophylaxis.
Topics: Humans; Isoniazid; Tuberculosis | 1968 |
Isoniazid prophylaxis.
Topics: Humans; Isoniazid; Tuberculin Test; Tuberculosis | 1968 |
Intermittent chemotherapy in murine tuberculosis.
Topics: Animals; Guinea Pigs; Isoniazid; Mice; Streptomycin; Time Factors; Tuberculosis | 1968 |
[Electrophoretic pattern of the blood serum proteins in experimental tuberculosis].
Topics: Animals; Blood Protein Electrophoresis; Fibrinogen; Guinea Pigs; Isoniazid; Serum Albumin; Serum Glo | 1968 |
Three basic characteristics of the tuberculin reaction to be observed in the prophylactic treatment of positive reactors.
Topics: Antibody Formation; Antitubercular Agents; Humans; Isoniazid; Skin; Tuberculin Test; Tuberculosis | 1968 |
The Mississippi program of chemoprophylaxis for the prevention of tuberculosis.
Topics: Adolescent; Adult; Humans; Isoniazid; Medical Assistance; Mississippi; Regional Medical Programs; Tu | 1968 |
[On the possibility of using polymers for experimentally prolonging the action of tubazid].
Topics: Animals; Delayed-Action Preparations; Female; Guinea Pigs; Isoniazid; Mice; Polymers; Tuberculosis | 1968 |
Chemoprophylaxis of tuberculosis.
Topics: Adult; Antitubercular Agents; Female; Humans; Isoniazid; Male; Tuberculosis; Tuberculosis, Urogenita | 1968 |
[New combinations of drugs for the treatment of drug-resistant tuberculosis].
Topics: Aminosalicylic Acids; Antitubercular Agents; Drug Resistance, Microbial; Ethionamide; Humans; Isonia | 1968 |
[Isolated unilateral maxillary sinus tuberculosis].
Topics: Adult; Aminosalicylic Acids; Humans; Isoniazid; Male; Maxillary Sinus; Mucous Membrane; Postoperativ | 1968 |
[Remote results of antitubercular chemoprophylaxis and its present applications].
Topics: Adolescent; Adult; Age Factors; BCG Vaccine; Child; Child, Preschool; Humans; Isoniazid; Time Factor | 1968 |
[Intermittent rifomycin therapy of experimental tuberculosis in guinea pigs].
Topics: Animals; Body Weight; Drug Synergism; Ethambutol; Guinea Pigs; Isoniazid; Rifampin; Tuberculosis | 1968 |
[Intermittent ethambutol therapy of experimental tuberculosis in guinea pigs].
Topics: Animals; Body Weight; Drug Synergism; Ethambutol; Guinea Pigs; Isoniazid; Tuberculosis | 1968 |
[Report on the scientific and didactic activity at the Clinica Tisiologica of Rome University, the research center and the Ospedale Sanatoriale Carlo Forlanini of INPS during 1967].
Topics: Hospitals, Teaching; Humans; Isoniazid; Italy; Lung Neoplasms; Nuclear Medicine; Research; Tuberculo | 1968 |
Avian tuberculosis.
Topics: Aminosalicylic Acids; Animal Diseases; Animals; Bird Diseases; Birds; Cattle; Child, Preschool; Eryt | 1968 |
[Thiamine metabolism in children with tuberculosis during therapy with streptomycin, phthivazid and PAS].
Topics: Adolescent; Aminosalicylic Acids; Child; Child, Preschool; Female; Humans; Infant; Isoniazid; Male; | 1968 |
Tuberculosis prevention is stressed by SBH.
Topics: Humans; Isoniazid; Mississippi; Tuberculosis | 1969 |
Tuberculosis, isoniazid and corticosteroids.
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Isoniazid; Prednisone; Tuberculosis; Tuberculosis, P | 1969 |
Possible interaction between disulfiram and isoniazid.
Topics: Adult; Alcoholism; Brain; Brain Chemistry; Disulfiram; Dopamine; Drug Synergism; Humans; Isoniazid; | 1969 |
Tuberculosis prophylaxis.
Topics: Adolescent; Adult; Aged; BCG Vaccine; Child; Female; Humans; Isoniazid; Male; Middle Aged; School He | 1969 |
[Effect of INH on metabolism of pyridoxine on tuberculosis in rats. II].
Topics: Animals; Drug Tolerance; Hydrocortisone; Isoniazid; Pyridoxine; Rats; Tuberculosis; Vitamin B 6 Defi | 1969 |
Intermittent chemotherapy for tuberculosis. A statement by the committee on therapy.
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Streptomycin; Tuberculosis | 1969 |
[Comparative study of therapeutic effect and side actions of 1314 TH and 1321 TH in the initial therapy of tuberculosis].
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Ethionamide; Female; Humans; Isoniazid; Isonicotinic | 1969 |
[Isolated tuberculosis of the gallbladder].
Topics: Cholecystectomy; Cholelithiasis; Female; Gallbladder Diseases; Humans; Isoniazid; Middle Aged; Tuber | 1969 |
Hemolytic anemia with positive Coombs' test. Association with isoniazid therapy.
Topics: Anemia, Hemolytic, Autoimmune; Child, Preschool; Coombs Test; Humans; Isoniazid; Male; Tuberculosis | 1969 |
Prophylaxis of tuberculosis after gastrectomy.
Topics: Isoniazid; Tuberculosis | 1969 |
Intermittent combination therapy with INH and thiambutosine (CIBA-1906) in tuberculous mice.
Topics: Animals; Antitubercular Agents; Isoniazid; Mice; Streptomycin; Thiourea; Tuberculosis | 1965 |
[Inactivation of isonicotinic acid hydrazides in the organism of patients and drug resistance of Mycobacterium tuberculosis].
Topics: Drug Resistance, Microbial; Humans; Isoniazid; Tuberculosis | 1965 |
[Concentration and tolerance of INH and PAS in single daily doses. (Preliminary report)].
Topics: Aminosalicylic Acids; Isoniazid; Tuberculosis | 1965 |
[Blood and urinary concentration measurements in intracavity INH application. A contribution to the testing of resorption conditions in the cavity wall].
Topics: Absorption; Adult; Aged; Blood; Female; Humans; Isoniazid; Male; Middle Aged; Tuberculosis; Urine | 1965 |
[Experimental therapy of tuberculosis with tuberculostatically inactive peptides].
Topics: Aminosalicylic Acids; Animals; Isoniazid; Mice; Peptides; Rabbits; Tuberculosis | 1965 |
[Chemoprophylaxis and early chemotherapy of experimental primary tuberculous infections].
Topics: Aminosalicylic Acids; Animals; Guinea Pigs; Isoniazid; Tuberculosis | 1965 |
[Intermittent method for the treatment of experimental tuberculosis with streptomycin only and streptomycin combined with methazid].
Topics: Animals; Drug Synergism; Guinea Pigs; Isoniazid; Streptomycin; Tuberculosis | 1965 |
[Apropos of the inactivation of phthivazid, tubazid and methazid in the organism of tuberculous patients].
Topics: Humans; Isoniazid; Tuberculosis | 1965 |
[Tuberculosis problems as seen from the viewpoint of chemotherapy].
Topics: Animals; Antitubercular Agents; BCG Vaccine; Humans; Isoniazid; Japan; Mice; Mortality; Prognosis; T | 1965 |
[Experimental studies on the effects of INH treatment on the morphologic dynamics of tuberculosis in animals vaccinated with BCG].
Topics: Animals; BCG Vaccine; Guinea Pigs; Isoniazid; Tuberculosis | 1965 |
[Observations and studies on the joint effects of alcohol and D-cycloserine].
Topics: Adult; Animals; Cycloserine; Drug Synergism; Ethanol; Humans; Isoniazid; Male; Mice; Middle Aged; Tu | 1965 |
Toleration and absorption of sodium para-aminosalicylate and para-aminosalicylic acid (neopasalate). Comparison with other forms of para-aminosalicylic acid.
Topics: Aminosalicylic Acids; Blood Chemical Analysis; Drug Tolerance; Humans; Intestinal Absorption; Isonia | 1966 |
[Dosage and serum levels of isoniazid in tuberculosis patients].
Topics: Blood; Humans; In Vitro Techniques; Isoniazid; Tuberculosis | 1966 |
[Effect of insulin on therapeutic activity of isoniazid in experimental tuberculosis of guinea pigs].
Topics: Animals; Guinea Pigs; In Vitro Techniques; Insulin; Isoniazid; Tuberculosis | 1966 |
Depression of prahydroxylation of diphenylhydantoin by antituberculosis chemotherapy.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anticonvulsants; Ataxia; Cycloserine; Drug Incompatib | 1966 |
[Studies on plasma histamine in experimental tuberculosis. I. Transition of the histamine levels in tuberculous and BCG-immune rabbits].
Topics: Animals; BCG Vaccine; Histamine; Isoniazid; Rabbits; Streptomycin; Tuberculin Test; Tuberculosis | 1966 |
Serum transaminase levels during treatment with isoniazid, streptomycin and PAS.
Topics: Adolescent; Alanine Transaminase; Aminosalicylic Acids; Drug Hypersensitivity; Female; Humans; Isoni | 1966 |
Folate deficiency during antituberculous (PAS-INH) medication.
Topics: Adult; Aminosalicylic Acids; Blood Cell Count; Bone Marrow Examination; Female; Folic Acid Deficienc | 1966 |
[Basic studies on the treatment of liver dysfunction. I. Report by the Basic Study Group, Joint Study Unit on the Economic Therapy, Medical Affairs Bureau, Ministry of Health and Welfare].
Topics: Ammonia; Animals; Humans; Isoniazid; Liver Diseases; Rabbits; Tuberculosis | 1966 |
[Study of the treatment of liver damage due to several causes in tuberculosis, using ornithine-aspartate].
Topics: Aspartic Acid; Blood Transfusion; Female; Hepatitis; Hepatitis B; Humans; Isoniazid; Male; Ornithine | 1966 |
Chemoprophylaxis.
Topics: Isoniazid; Male; Tuberculosis | 1966 |
"Active" tuberculosis contacts a guide in tuberculosis control.
Topics: Adolescent; Adult; Aged; Child, Preschool; Humans; Isoniazid; Middle Aged; Tuberculin Test; Tubercul | 1966 |
[Results of antibacterial therapy of tuberculosis using the intermittent and continuous methods].
Topics: Aminosalicylic Acids; Animals; Female; Isoniazid; Male; Mice; Tuberculosis | 1966 |
[Collateral effects of isonicotinic acid hydrazide].
Topics: Blood Coagulation Disorders; Drug Hypersensitivity; Humans; Isoniazid; Liver Diseases; Nervous Syste | 1966 |